<SEC-DOCUMENT>0001714899-21-000054.txt : 20210505
<SEC-HEADER>0001714899-21-000054.hdr.sgml : 20210505
<ACCEPTANCE-DATETIME>20210505083122
ACCESSION NUMBER:		0001714899-21-000054
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		64
CONFORMED PERIOD OF REPORT:	20210331
FILED AS OF DATE:		20210505
DATE AS OF CHANGE:		20210505

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Denali Therapeutics Inc.
		CENTRAL INDEX KEY:			0001714899
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				463872213
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38311
		FILM NUMBER:		21891301

	BUSINESS ADDRESS:	
		STREET 1:		161 OYSTER POINT BLVD.
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
		BUSINESS PHONE:		(650) 866-8548

	MAIL ADDRESS:	
		STREET 1:		161 OYSTER POINT BLVD.
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>dnli-20210331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2021 Workiva--><!--r:be7bc6f9-6af9-45b5-b822-49fcbbf3ecfb,g:6a95e0ad-15c9-4fb8-a5d1-2bfd737ebde3,d:5ae1cfc88aa4492caf56e9d4ac91e096--><html xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dnli="http://www.denalitherapeutics.com/20210331" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>dnli-20210331</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80L2ZyYWc6ZDMyN2EyZDg2ZGRiNDdkOGIwZjY5YmE4ODk3NjEzYjYvdGFibGU6NmIxMGVlNDA4ZmRiNDFkZGIwZWU2YmY0ZTQ3M2JmMjAvdGFibGVyYW5nZTo2YjEwZWU0MDhmZGI0MWRkYjBlZTZiZjRlNDczYmYyMF8xMi0xLTEtMS0w_c285fbf9-ff4b-49da-b295-07899dd0cdbc">2021</ix:nonNumeric><ix:nonNumeric contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80L2ZyYWc6ZDMyN2EyZDg2ZGRiNDdkOGIwZjY5YmE4ODk3NjEzYjYvdGFibGU6NmIxMGVlNDA4ZmRiNDFkZGIwZWU2YmY0ZTQ3M2JmMjAvdGFibGVyYW5nZTo2YjEwZWU0MDhmZGI0MWRkYjBlZTZiZjRlNDczYmYyMF8xMy0xLTEtMS0w_f9ce3166-90bf-4e5e-9ea9-64386b6fb57e">Q1</ix:nonNumeric><ix:nonNumeric contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80L2ZyYWc6ZDMyN2EyZDg2ZGRiNDdkOGIwZjY5YmE4ODk3NjEzYjYvdGFibGU6NmIxMGVlNDA4ZmRiNDFkZGIwZWU2YmY0ZTQ3M2JmMjAvdGFibGVyYW5nZTo2YjEwZWU0MDhmZGI0MWRkYjBlZTZiZjRlNDczYmYyMF8xNC0xLTEtMS0w_1b290a87-e9e7-445d-aa9b-dc3518eb779d">false</ix:nonNumeric><ix:nonNumeric contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80L2ZyYWc6ZDMyN2EyZDg2ZGRiNDdkOGIwZjY5YmE4ODk3NjEzYjYvdGV4dHJlZ2lvbjpkMzI3YTJkODZkZGI0N2Q4YjBmNjliYTg4OTc2MTNiNl84MQ_84cc81af-1c0f-407e-9626-f5fe6d308354">0001714899</ix:nonNumeric><ix:nonNumeric contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80L2ZyYWc6ZDMyN2EyZDg2ZGRiNDdkOGIwZjY5YmE4ODk3NjEzYjYvdGV4dHJlZ2lvbjpkMzI3YTJkODZkZGI0N2Q4YjBmNjliYTg4OTc2MTNiNl84Mg_73a2e1e3-8d7e-48bf-99e0-c77e73d8a361">--12-31</ix:nonNumeric><ix:nonFraction unitRef="usd" contextRef="i67ac6e40ada9472996476ac5ea5bcbc7_I20201231" decimals="-3" name="us-gaap:DerivativeLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xMDgwL2ZyYWc6NTBhMGUzMzE1YWQ3NGZjMThhODBjOTMxNzY4MmM0YTkvdGV4dHJlZ2lvbjo1MGEwZTMzMTVhZDc0ZmMxOGE4MGM5MzE3NjgyYzRhOV80Mzk4MDQ2NTExOTg5_cff67f9f-587c-43b7-a204-854bdbcc49fb">0</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="i90752bb1d6844732a5f7754270148e69_I20210331" decimals="-3" name="us-gaap:DerivativeAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xMDgwL2ZyYWc6NTBhMGUzMzE1YWQ3NGZjMThhODBjOTMxNzY4MmM0YTkvdGV4dHJlZ2lvbjo1MGEwZTMzMTVhZDc0ZmMxOGE4MGM5MzE3NjgyYzRhOV80Mzk4MDQ2NTExOTky_4eca0241-284f-4f69-a9d1-7ce710d6bb81">0</ix:nonFraction><ix:nonNumeric contextRef="ia961be148e584fd4a2a57cc1b21dced2_D20200805-20200805" name="dnli:CollaborativeArrangementTermNumberOfBusinessDaysIfEffectiveDateCriteriaMet" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfNTMxNA_6ca82b29-adf5-4704-b8b5-513bcd955ad5">P30D</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="dnli-20210331.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="id5f8b6da332f4721952346e234823fd7_I20210426"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i9953f50a7fd74f7d8438f304f136a07b_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idb7ca9f362da46eab3a29bbbecbda977_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="ia34dfea6b8734d64abf707c28256801c_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b1694c4d5a44ff2b0218864ff3535bb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1182c403bed14f779ebd3c5cf55f280c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3e68706d6d7742388257b82fc7c16d8d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibe96d84e0a5e425bab91f9c7441e0d1d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3cc86f0bf14143f4ae8b3600808a8b8e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i512d7365f8ba4cffa29eb6d1a746e90d_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8f89be0032cd49c2b7c0a19693e48b5c_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8017a7d7e9414d9cac2f173a2d4a39dc_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6881ec9f4b804f8bb0b380a22e0d14bc_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iab67b1cb96b04f5eae11176694e59a6b_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8faf25a1f5264f7bbd65f096a2d9a464_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2d9b04bba6cb45aab3777466d4b29061_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if9deb2734a184a7cbde40db4324e7d19_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia3061e69973345b0a814850b46a1e70d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7fc2ea20a15f4358958ac2de513cbedf_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4f05e20d565c4dec84e3cf8ab862dd61_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id36b0e599cb3498a8671e8c185763bc9_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia63b42181ffa4fb5aa0692f27bc204e4_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i481b7d29f5714b2c9591d38d45fb69a2_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc9c2fd3102f4601910401b0065ccdee_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5462764077c54d46b830279d94f82af0_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e6a5f965fc64fdc84e37350364784a2_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6acc176d0fde4b30bb04303aefe4c09c_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if9160027ce4c429abb35b07016b25738_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8288b3c6af7a4ceca6f0c97aa25994dc_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i29b65d7585ff41c5843594c6319bdb90_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>dnli:Segment</xbrli:measure></xbrli:unit><xbrli:context id="i6c67df6d9d254626b9391157cc6763f4_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa61d3a997f64111a4b23a96b7fe5b8a_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ida70779bab1a408eab2c0f807c7c2184_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a012763ca204bf7ac713bfc5a5fe5bb_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia57c5b507b6a47618a967591bf368bff_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if3f854bad0dd4fcab527216138601aaa_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i66e037a80d03458791ec3572ec41d1cb_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie652e808c1f147618ebb4562358ce95a_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie5f979a4d5d94f0ead845cf6e9d26c7e_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8efa8793ba8f446f8ffd529b619bbbfd_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i78246248a32444d0b6f9cc3c2d85efd5_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaab08a4f99ff4ba2950d1437d42c90b2_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6b542a8ed7164ce7a3f01a3325375861_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i588c2440f58644e8a6a0c3b8856f304b_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic52a660c9ba0416c80ca6df7c8fb50dc_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf0336c48b2a4b5f93669576fb24b804_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i67d5388ca1f140b0b751939b213807d3_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie9c36eef19a84e07bdddd763d415a7f7_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b241ffdc9c94e2082b8b85ebca483df_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i000addedaff44daba745c02655b81159_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i131f1b1eb6604026a5c42366001ad668_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dnli:LongTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i79306ba88f4140a183b8a8b4b6135daa_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dnli:LongTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib0c77906277e4e39847898b3e7673e51_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dnli:LongTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia06ecd5d4e7943cfb188e226606891fc_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dnli:LongTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i19b242abfd1e4002a024557986c6d987_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dnli:LongTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i99a26d4be72a42eb865297d52d41de8b_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dnli:LongTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9dbd5d046d3244ef870fa23ff49cb036_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dnli:LongTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie4aa0eddd0fb49eda4c41fc2a826b8c1_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dnli:LongTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i50be2f68d7ea46f1a2d7e733b2391ac5_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0881221dc0304651bd4cc951315603f9_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i057152fc2b0d48c0969e0b03ae05f47f_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie0489620584748b8a18511d5315c484d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iacef9d3f91dd40d0a87a4c4a0d2b6fb2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i216c3025b0124b688dd2fd43fb4468fb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib663c99903ea42359657773d88880b3a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4680cafe26584c1f86d850c496eda36c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a690a2144264f4f8dfff3d5dfce6fe6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i239e913cbb1a4a0389051b486d08f75a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if25b3a1f38994654bc19ed04aca9372f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idc5b52a3db1b4f8baed84d10ed64492c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i86c3ea8f2f1f49c4a026b6bc52858668_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i908a382fdfd44406be1c76e156800e93_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i72798f9b723345d7b2945778149039ab_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i118d49e34100478aad6bb4134c3b2aaa_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i178051c344504d07985f78aa8cc32492_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id3593591cc6b4645bcbbae5e79b647d6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9286f708ff8349709d22f68a1a329272_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ided63883ce3647bc936cd798e72ea186_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0e93f92b75c548efb9c7fbf7491b4063_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idb6cdf24410f45c282312f8166a766ff_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic16516c243df4551a83161ad3c5c0f09_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i25d88de0f197490fb779e1e3071f901e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b60ffb67bd147c3a56d06666f6ff77c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibfac6e99e22f43c68f58fb5907948edb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idf6e2668dddb49d2ac374501483e7bf9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i215ae1ee50d14e92a7ea23ab3f943a5d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dnli:LongTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4026f6a97f4340d6a98d226ab3c04c12_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dnli:LongTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec8ba588c80d4f4191cc54f76a956ff0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dnli:LongTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i57f0286f0cdd41afb93b20cd06df11c7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dnli:LongTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i480dc0971b7d403fad3d95c1932c7534_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dnli:LongTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifa86ad4908bc434aa3c51f66f9a60281_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dnli:LongTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic4170e2296ad4137872fb9951088b913_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dnli:LongTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6da17c1dcc0c448cbd20f8ec3a5656d1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dnli:LongTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0b67e7dddea84ea5bd2068d25930c3f0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i71c0a54ceaf448c7b9d4d9c1d534b5cc_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2db26540968047c2b760e6148893f1f0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5c991a09175c4907972778fd5a54038d_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dnli:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i58c971960b254076bc5ebc8a3a3a5a34_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dnli:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5abb55cd5abc4ef4a6963ecc132bb1be_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dnli:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i382bf15544d0451c8ad0005fe504ecc1_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dnli:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c72ee3da1524776845e9b5ae9946eee_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dnli:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i89fb6181d11a43d88db96cf5f175becc_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dnli:LongTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad80279b43b74b3fbb24392412ebf8d4_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dnli:LongTermMarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id97fb3aa68ae491e9d798fe7cf3f01b6_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dnli:LongTermMarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="security"><xbrli:measure>dnli:security</xbrli:measure></xbrli:unit><xbrli:context id="ia965935f3dfc41e9898218d34d2db66f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dnli:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3607ed8ca137404691d4a18591291e6d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dnli:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0fd58d29aa7f4494bf30f6d59ca72c8c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dnli:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieb9f9878977d4bee8003a43bbd55fbf7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dnli:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i86be035a34fe478ea00df2e76fba4dc9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dnli:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i74d3c7dbdd71495c8557f07cac6cd34d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dnli:LongTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icc4f3f2e913840ec946d6ab82f45dc71_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dnli:LongTermMarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iac0bb6ea773e4895b9939e783cbf93a7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dnli:LongTermMarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="derivative_instrument"><xbrli:measure>dnli:derivative_instrument</xbrli:measure></xbrli:unit><xbrli:context id="i5e5ef3c57c01481ab32c18cba94f5fe4_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dnli:ForeignExchangeForwardEurosMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="eur"><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unit><xbrli:context id="id84a031bb1374baa8de940b07c3dff05_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dnli:ForeignExchangeForwardBritishPoundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="gbp"><xbrli:measure>iso4217:GBP</xbrli:measure></xbrli:unit><xbrli:context id="ibf15d1cb21ae4c5b886c0aea82e7d1f3_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d51a225b0e74a329c75163f5353da38_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dnli:ForeignExchangeForwardEurosMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i83e8165a75164bcd89f57c0c00451316_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dnli:ForeignExchangeForwardBritishPoundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idcf71a3762844d5ebc7aaa02a121c837_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3e3538bcdaba49b4bc9b8ff9d89ef4b8_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2d55a3178b03487c9c5028f18060a482_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i67ac6e40ada9472996476ac5ea5bcbc7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i90752bb1d6844732a5f7754270148e69_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="program"><xbrli:measure>dnli:program</xbrli:measure></xbrli:unit><xbrli:context id="id19e1b668ad54ff0a1bcaaf50d236bcd_I20200805"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dnli:ProvisionalCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dnli:TransportVehicleTechnologyPlatformUnnamedProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:BiogenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if6dd4f0c67444b1194ee0a12b060c2e7_I20200805"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dnli:ProvisionalCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:BiogenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dnli:TransportVehicleTechnologyProgramRightOfFirstNegotiationProgramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i708f730074a74563a853bf7ef8f740fe_D20200805-20200805"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dnli:ProvisionalCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:BiogenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-05</xbrli:startDate><xbrli:endDate>2020-08-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3bf8c8eaa53e41d5a068b18edae5519f_I20200805"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dnli:ProvisionalCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:BiogenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i19ba65d441e94cbda7c97a7dedf0b14c_I20200805"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dnli:ProvisionalCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id5c33ba7e2874d50a83a5008b6ae7852_I20200805"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dnli:ProvisionalCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id978123c42ea48179c72134ceea46ba2_I20200805"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dnli:ProvisionalCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">dnli:BiogenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a30e11a54f94b2ebb02e2da6fe5446f_I20200805"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dnli:ProvisionalCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib106d7ba52674677b8cb2ac5693422b7_I20200805"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dnli:ProvisionalCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dnli:TransportVehicleTechnologyPlatformPreclinicalProgramsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:BiogenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia961be148e584fd4a2a57cc1b21dced2_D20200805-20200805"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dnli:ProvisionalCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dnli:TransportVehicleTechnologyPlatformPreclinicalProgramsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:BiogenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-05</xbrli:startDate><xbrli:endDate>2020-08-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3df519c68317420e8222a86148ab6e41_I20200805"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dnli:ProvisionalCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dnli:TransportVehicleTechnologyPlatformRightOfFirstNegotiationProgramsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:BiogenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id16d8e434fba4f8ca86744e3c63d5d95_D20200805-20200805"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dnli:ProvisionalCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dnli:TransportVehicleTechnologyPlatformRightOfFirstNegotiationProgramsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:BiogenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-05</xbrli:startDate><xbrli:endDate>2020-08-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f469ca238db4f19ade2b0c2f5542d55_D20200922-20200922"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dnli:ProvisionalCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:BiogenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">dnli:SharePurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-22</xbrli:startDate><xbrli:endDate>2020-09-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i53d1846478874ac7a03801cbb5049533_I20200922"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dnli:ProvisionalCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:BiogenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">dnli:SharePurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3d221276fee544dc91f74c0f2b96de94_I20201006"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dnli:ROFNAndOptionAgreementCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:BiogenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia59d27ad521d4576896de358cda1e1a8_D20201006-20201031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dnli:BiogenCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:BiogenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-06</xbrli:startDate><xbrli:endDate>2020-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i22fa845ccdd543acb615ea629ab5344c_D20201006-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dnli:BiogenCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:BiogenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-06</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2934421e8d7b4a55a318b2d3d6102fed_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:BiogenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i611b2655965e42dfbda911bc7c9ee9c8_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dnli:ROFNAndOptionAgreementCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:BiogenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0f8d7006122c478b92ae9f39d8d1b0e5_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dnli:OptionResearchServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dnli:BiogenCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:BiogenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if1065b142ae843249dfdfee04de24a66_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dnli:BiogenCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:BiogenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5dd55e97d29845d79435cc613548f911_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dnli:BiogenCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:BiogenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0013ce3d1a8247a08d873ceee1cdf67a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dnli:BiogenCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:BiogenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="milestone"><xbrli:measure>dnli:milestone</xbrli:measure></xbrli:unit><xbrli:context id="i37367f9356d64fd3928fdd776c7f31a8_D20181101-20181130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:SanofiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-11-01</xbrli:startDate><xbrli:endDate>2018-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic6d24297d8d84d17b99d57fe8ee7d6f5_I20181130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:SanofiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i69a8709612b349b38ac7bf012d3e0fd3_I20181130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:SanofiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dnli:CNSProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="indication"><xbrli:measure>dnli:indication</xbrli:measure></xbrli:unit><xbrli:context id="i32ecdc0092f641bd9100243e5a27d217_I20181130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa8b5535fbd846a4bd38c3e3b7f756a4_I20181130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:SanofiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dnli:PeripheralProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6ea2228697dd4aaba41a39520dc51665_I20181130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">dnli:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iae801c2eda2b4f468e16600312d29411_I20181130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i46ab6c65582f4d8bab7e57d6dd6f7588_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:SanofiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dnli:MilestoneTriggeredAndRetainedActivitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c01d0c60cd542c4a229d6789938312a_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:SanofiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dnli:MilestoneTriggeredAndRetainedActivitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i71f6e4875572417586577b9989db412c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dnli:AlzheimersDiseaseServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i261cc6d074024d72a8c693a4ea9e24fa_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dnli:AlzheimersDiseaseServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i85da405a68d44147816b407c550dd77b_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:SanofiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib2c5d3daea2b469eb42d1e130f45621f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:SanofiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8e78aebb6758499aa9b578b8b7365ab9_D20181001-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:SanofiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dnli:MilestoneTriggeredMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieb8b43e946ab4a5e983647ccb9581dc3_D20181001-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:SanofiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf62192d651f44fa9a8f0990d46c3286_D20180223-20180223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-02-23</xbrli:startDate><xbrli:endDate>2018-02-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e206bb2a68d468195031df47711679a_D20180223-20180223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-02-23</xbrli:startDate><xbrli:endDate>2018-02-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i629da488ba924dfc9f4eb9daeb937953_I20180223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-02-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="target"><xbrli:measure>dnli:target</xbrli:measure></xbrli:unit><xbrli:context id="idf9de44243d0448abccdf83151ea9bfa_I20180223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-02-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9261bc8472184e6fa1082e8c5405a625_D20180223-20180223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">dnli:SharePurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-02-23</xbrli:startDate><xbrli:endDate>2018-02-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e0b33f51ccf452bae9b4c3f0109b86d_I20180223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">dnli:SharePurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-02-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8319328706f24bcdb7bf7f3fc0782056_D20180223-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-02-23</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8fd4f33cc0454770bb9522977f4298cc_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b343adcffb94181bcbdfcb6161d5aba_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a890b5264394316bc209b1df064b85d_D20210301-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dnli:CollaborativeArrangementATVTREM2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if1c8a3c07b01480bb07bf6e10da36189_D20210101-20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dnli:CollaborativeArrangementPTVPGRNMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i82572c2ba407421ab1eeaea4cc017b83_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dnli:CollaborativeArrangementPTVPGRNMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if1fffa1219a047f0a51060aeafb58951_D20180101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dnli:MilestoneTriggeredMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i98a0ba98854b4bb8ac86be212e357b16_D20180101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i643ec7e1d2a3451c9d8905efbcdbf48c_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dnli:TakedaCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff0f9b13d274493e8564765eb94360ae_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dnli:TakedaCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie9ccfab524d04954920c80a3c7ac6796_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dnli:SanofiCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dnli:RetainedActivitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if81ccf0b3968466bb8ad747c00401a8d_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dnli:SanofiCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dnli:RetainedActivitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifcf20312d910402ab56471a2d6469134_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dnli:SanofiCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dnli:AlzheimersDiseaseServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc2536462b694f07b028b19e58c564fe_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dnli:SanofiCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dnli:AlzheimersDiseaseServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieb7e2edd7c3c4ff1a01d715afc57516e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dnli:SanofiCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i18c380c88187451c9ad16eccfc6df52c_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dnli:SanofiCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic480049fe58042bdb36bf14a067dcfc0_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dnli:OptionServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dnli:BiogenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a7cd8e57f5f494c9a40a6b2b090b922_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dnli:OptionServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dnli:BiogenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifedff44484c341d28f698f572ac47df9_D20160601-20160630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:GenentechIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-06-01</xbrli:startDate><xbrli:endDate>2016-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i14b16f9e96df4c0a9e50dca2366b9336_D20160601-20160630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:GenentechIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">dnli:ClinicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-06-01</xbrli:startDate><xbrli:endDate>2016-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i692ffa74a5584f1cbfe4713804c9f8bc_D20160601-20160630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:GenentechIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">dnli:RegulatoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-06-01</xbrli:startDate><xbrli:endDate>2016-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i80495385ed674ae8925cf688501ec409_D20160601-20160630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">dnli:CommercialMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:GenentechIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-06-01</xbrli:startDate><xbrli:endDate>2016-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id8ddb142f82e43fa84f4fd4d9e8cbf3d_I20201005"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:GenentechIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">dnli:BiogenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id263c00fb24f43c9874f4e5f5bcb3bc4_D20160601-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:GenentechIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dnli:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-06-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab3d75662fac47f5a5b91e0c391e1ad9_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:GenentechIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dnli:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i90ec159768884d8a91ddd3533160d98c_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:GenentechIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dnli:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:context id="i7fec5584f40f4e2589bf51cfb5be2fa0_D20180502-20180502"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">dnli:HeadquartersLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-02</xbrli:startDate><xbrli:endDate>2018-05-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie37401f4fa5441f69f346d3a02b8b078_I20180502"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">dnli:HeadquartersLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-05-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i99207688a3a04bb6b263d1f44c4431cb_D20180502-20180502"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">dnli:HeadquartersLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-02</xbrli:startDate><xbrli:endDate>2018-05-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic993dcf5385f4b81b82f62d1d7c425ad_D20180502-20180502"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">dnli:HeadquartersLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-02</xbrli:startDate><xbrli:endDate>2018-05-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8bf8a6f92025417783902a1461338b26_I20180502"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-05-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6456f8216b9a4588b93f1a1da733ca1d_D20180502-20180502"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">dnli:HeadquartersLeaseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">dnli:LandlordFundedTenantImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-02</xbrli:startDate><xbrli:endDate>2018-05-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib5b9d59cd718474d84fa120208dacc38_I20181031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">dnli:NewPremisesSubleaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5883d19040b14361a685e33448d24167_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">dnli:DMSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i71996497ebce4b2c8c7d7e4cd228fb94_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">dnli:DMSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i450a57d93cb84950a947b2c09bd3ca2d_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">dnli:DMSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8e1a3ef913c04a4dbb9618e565378ec6_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">dnli:DMSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i84ba3b58bcce4a4c9748d2ca212f024c_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i884b579d788c483eb3a9ee088d3e5d89_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id3763ebb47a74e7aa55cdc9ec33e6ba1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if9c544fa84d346779359fdcd69c81fe6_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa1dc7a3953b414298ab33929383425a_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic95a24eb031142ffb8fea378c4c16539_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie9e73e4cbcdf45859b5ab6fdf05d2397_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if224ee1d3e1d40cda888c5569a5ca491_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie960cec998d6496380dc4b23cade2ada_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1bfd917477b04985b275e7880a6800ee_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">dnli:EmployeeAndNonEmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieb96c5c2a58b43ecb70f4570ae6501d5_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">dnli:EmployeeAndNonEmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i14d03db975fe42b1b25891a5de38963a_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">dnli:RestrictedSharesSubjectToFutureVestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaab0bf674ec742169a75f1ba80135e68_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">dnli:RestrictedSharesSubjectToFutureVestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xOS9mcmFnOjU2Y2EwZjE3OWFiNTQ3M2VhZGFlZDM5NjQxYjQ1NzhkL3RhYmxlOmRhMmJiMjEyNGYyZDQyODY4OTE3MTc5NWI4YmJmOThmL3RhYmxlcmFuZ2U6ZGEyYmIyMTI0ZjJkNDI4Njg5MTcxNzk1YjhiYmY5OGZfNy0xLTEtMS0w_ff2936cd-371c-41a6-961e-a0ff4d0036c6" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xOS9mcmFnOjU2Y2EwZjE3OWFiNTQ3M2VhZGFlZDM5NjQxYjQ1NzhkL3RleHRyZWdpb246NTZjYTBmMTc5YWI1NDczZWFkYWVkMzk2NDFiNDU3OGRfNDM5ODA0NjUxMTg1Ng_76fefc42-6d2b-4030-95d8-128d6d256c4f" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xOS9mcmFnOjU2Y2EwZjE3OWFiNTQ3M2VhZGFlZDM5NjQxYjQ1NzhkL3RhYmxlOmRhMmJiMjEyNGYyZDQyODY4OTE3MTc5NWI4YmJmOThmL3RhYmxlcmFuZ2U6ZGEyYmIyMTI0ZjJkNDI4Njg5MTcxNzk1YjhiYmY5OGZfMy0xLTEtMS0w_3e600fff-1d7a-4a97-8ad7-909f7d61a045" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xOS9mcmFnOjU2Y2EwZjE3OWFiNTQ3M2VhZGFlZDM5NjQxYjQ1NzhkL3RleHRyZWdpb246NTZjYTBmMTc5YWI1NDczZWFkYWVkMzk2NDFiNDU3OGRfNDM5ODA0NjUxMTg1NQ_863ec15a-a62e-4021-bc98-1a2980c27a3f" order="1"></ix:relationship></ix:resources></ix:header></div><div id="i5ae1cfc88aa4492caf56e9d4ac91e096_1"></div><div style="min-height:45pt;width:100%"><div style="margin-top:4pt"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5ae1cfc88aa4492caf56e9d4ac91e096_7">Table of Contents</a></span></div></div><div style="margin-bottom:2pt;text-align:center"><span><br/></span></div><div style="margin-bottom:2pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.643%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.413%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.644%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:2pt;margin-top:8pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xL2ZyYWc6NTljZGFhMGY5N2ZkNDFhNDg5MDgwNDc2MDljYTRlYmEvdGV4dHJlZ2lvbjo1OWNkYWEwZjk3ZmQ0MWE0ODkwODA0NzYwOWNhNGViYV84Nw_dda14b06-9f53-4057-8539-5c2dda4ead20">10-Q</ix:nonNumeric></span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.643%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.413%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.644%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Mark One)</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.315%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.485%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331" format="ixt-sec:boolballotbox" name="dei:DocumentQuarterlyReport" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xL2ZyYWc6NTljZGFhMGY5N2ZkNDFhNDg5MDgwNDc2MDljYTRlYmEvdGFibGU6M2EyNGNkM2M0MTZjNDk3YTg2YWNlMGY3M2I5MzE3ZTEvdGFibGVyYW5nZTozYTI0Y2QzYzQxNmM0OTdhODZhY2UwZjczYjkzMTdlMV8wLTAtMS0xLTA_7d28d03b-7fa6-4758-b7d7-b5eb110d483b">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES&#160;EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:2pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xL2ZyYWc6NTljZGFhMGY5N2ZkNDFhNDg5MDgwNDc2MDljYTRlYmEvdGV4dHJlZ2lvbjo1OWNkYWEwZjk3ZmQ0MWE0ODkwODA0NzYwOWNhNGViYV8xMzY_295c6713-8359-4632-bfe0-d779bac6d035">March 31, 2021</ix:nonNumeric> </span></div><div style="text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">OR</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.315%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.485%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xL2ZyYWc6NTljZGFhMGY5N2ZkNDFhNDg5MDgwNDc2MDljYTRlYmEvdGFibGU6NzYwOWMwYTg4N2NmNGZhYmFiNDQ4ZGZkNzBjYjM0YmEvdGFibGVyYW5nZTo3NjA5YzBhODg3Y2Y0ZmFiYWI0NDhkZmQ3MGNiMzRiYV8wLTAtMS0xLTA_901ba6f0-b175-4ec4-b296-0769683d6f74">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-bottom:2pt;margin-top:2pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the transition period from&#160;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;to&#160;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="margin-bottom:4pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Commission File Number: <ix:nonNumeric contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xL2ZyYWc6NTljZGFhMGY5N2ZkNDFhNDg5MDgwNDc2MDljYTRlYmEvdGV4dHJlZ2lvbjo1OWNkYWEwZjk3ZmQ0MWE0ODkwODA0NzYwOWNhNGViYV8yNDU_118f9ef8-4041-4a4f-bc5b-c004223b41d2">001-38311</ix:nonNumeric></span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.643%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.413%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.644%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xL2ZyYWc6NTljZGFhMGY5N2ZkNDFhNDg5MDgwNDc2MDljYTRlYmEvdGV4dHJlZ2lvbjo1OWNkYWEwZjk3ZmQ0MWE0ODkwODA0NzYwOWNhNGViYV8yNTA_6d459f57-666a-4376-8994-ae00298ddc09">Denali Therapeutics Inc.</ix:nonNumeric></span></div><div style="margin-bottom:6pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.643%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.413%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.644%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.522%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.748%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xL2ZyYWc6NTljZGFhMGY5N2ZkNDFhNDg5MDgwNDc2MDljYTRlYmEvdGFibGU6Y2Y5OTU0NmMxYjIyNDhmZGFiMzE2YmI5MTFkOTkwNTYvdGFibGVyYW5nZTpjZjk5NTQ2YzFiMjI0OGZkYWIzMTZiYjkxMWQ5OTA1Nl8wLTAtMS0xLTA_8bb26ff5-2fc8-4093-85ad-898e19054255">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xL2ZyYWc6NTljZGFhMGY5N2ZkNDFhNDg5MDgwNDc2MDljYTRlYmEvdGFibGU6Y2Y5OTU0NmMxYjIyNDhmZGFiMzE2YmI5MTFkOTkwNTYvdGFibGVyYW5nZTpjZjk5NTQ2YzFiMjI0OGZkYWIzMTZiYjkxMWQ5OTA1Nl8wLTItMS0xLTA_fd890157-9459-478b-a9b3-842c4e3a89d6">46-3872213</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(State or other jurisdiction of</span></div><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">incorporation or organization)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(I.R.S. Employer</span></div><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Identification No.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xL2ZyYWc6NTljZGFhMGY5N2ZkNDFhNDg5MDgwNDc2MDljYTRlYmEvdGFibGU6Y2Y5OTU0NmMxYjIyNDhmZGFiMzE2YmI5MTFkOTkwNTYvdGFibGVyYW5nZTpjZjk5NTQ2YzFiMjI0OGZkYWIzMTZiYjkxMWQ5OTA1Nl8zLTAtMS0xLTAvdGV4dHJlZ2lvbjphNzZkZjNlMTdjYzU0NGI3YTQzYTIyZjM5YmE3NzM4MV81_6bb06cfa-d3d1-431e-bc64-94ce78cc6581">161 Oyster Point Blvd</ix:nonNumeric>.</span></div><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xL2ZyYWc6NTljZGFhMGY5N2ZkNDFhNDg5MDgwNDc2MDljYTRlYmEvdGFibGU6Y2Y5OTU0NmMxYjIyNDhmZGFiMzE2YmI5MTFkOTkwNTYvdGFibGVyYW5nZTpjZjk5NTQ2YzFiMjI0OGZkYWIzMTZiYjkxMWQ5OTA1Nl8zLTAtMS0xLTAvdGV4dHJlZ2lvbjphNzZkZjNlMTdjYzU0NGI3YTQzYTIyZjM5YmE3NzM4MV85_8ca787dc-0dde-4e23-b460-00394677530f">South San Francisco</ix:nonNumeric>, <ix:nonNumeric contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xL2ZyYWc6NTljZGFhMGY5N2ZkNDFhNDg5MDgwNDc2MDljYTRlYmEvdGFibGU6Y2Y5OTU0NmMxYjIyNDhmZGFiMzE2YmI5MTFkOTkwNTYvdGFibGVyYW5nZTpjZjk5NTQ2YzFiMjI0OGZkYWIzMTZiYjkxMWQ5OTA1Nl8zLTAtMS0xLTAvdGV4dHJlZ2lvbjphNzZkZjNlMTdjYzU0NGI3YTQzYTIyZjM5YmE3NzM4MV8xMw_e356a33e-1d1b-4ce7-8aa4-0ff7bae8c354">CA</ix:nonNumeric>, <ix:nonNumeric contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xL2ZyYWc6NTljZGFhMGY5N2ZkNDFhNDg5MDgwNDc2MDljYTRlYmEvdGFibGU6Y2Y5OTU0NmMxYjIyNDhmZGFiMzE2YmI5MTFkOTkwNTYvdGFibGVyYW5nZTpjZjk5NTQ2YzFiMjI0OGZkYWIzMTZiYjkxMWQ5OTA1Nl8zLTAtMS0xLTAvdGV4dHJlZ2lvbjphNzZkZjNlMTdjYzU0NGI3YTQzYTIyZjM5YmE3NzM4MV8xNw_fe1a224e-9f98-4a11-bb0b-ba79aeb62682">94080</ix:nonNumeric></span></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Address of principal executive offices and zip code)</span></td></tr></table></div><div style="margin-top:4pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xL2ZyYWc6NTljZGFhMGY5N2ZkNDFhNDg5MDgwNDc2MDljYTRlYmEvdGV4dHJlZ2lvbjo1OWNkYWEwZjk3ZmQ0MWE0ODkwODA0NzYwOWNhNGViYV8zMTQ_9f22157e-5422-4209-bd16-627e334337e8">650</ix:nonNumeric>) <ix:nonNumeric contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xL2ZyYWc6NTljZGFhMGY5N2ZkNDFhNDg5MDgwNDc2MDljYTRlYmEvdGV4dHJlZ2lvbjo1OWNkYWEwZjk3ZmQ0MWE0ODkwODA0NzYwOWNhNGViYV8zMTg_789e8b4a-1c69-48f0-aafa-70f223a3720d">866-8548</ix:nonNumeric></span></div><div style="text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="margin-bottom:6pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">_______________________________________</span></div><div style="margin-bottom:4pt;margin-top:4pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.337%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.391%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.972%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trading Symbol</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xL2ZyYWc6NTljZGFhMGY5N2ZkNDFhNDg5MDgwNDc2MDljYTRlYmEvdGFibGU6NGM2YzEwZWUyZmEwNGMwNjk4MTRlMGNkYTg0OWYxMzIvdGFibGVyYW5nZTo0YzZjMTBlZTJmYTA0YzA2OTgxNGUwY2RhODQ5ZjEzMl8xLTAtMS0xLTA_738252b8-9e65-4e9e-a8af-53b15fc6ac9b">Common Stock, par value $0.01 per share</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xL2ZyYWc6NTljZGFhMGY5N2ZkNDFhNDg5MDgwNDc2MDljYTRlYmEvdGFibGU6NGM2YzEwZWUyZmEwNGMwNjk4MTRlMGNkYTg0OWYxMzIvdGFibGVyYW5nZTo0YzZjMTBlZTJmYTA0YzA2OTgxNGUwY2RhODQ5ZjEzMl8xLTEtMS0xLTA_f722b37a-b755-4d4c-848b-3a389d2ea4c5">DNLI</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xL2ZyYWc6NTljZGFhMGY5N2ZkNDFhNDg5MDgwNDc2MDljYTRlYmEvdGFibGU6NGM2YzEwZWUyZmEwNGMwNjk4MTRlMGNkYTg0OWYxMzIvdGFibGVyYW5nZTo0YzZjMTBlZTJmYTA0YzA2OTgxNGUwY2RhODQ5ZjEzMl8xLTItMS0xLTA_f1926460-3056-46a3-a812-5ea7095cc322">NASDAQ Global Select Market</ix:nonNumeric></span></td></tr><tr style="height:9pt"><td colspan="9" style="border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:4pt;margin-top:4pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xL2ZyYWc6NTljZGFhMGY5N2ZkNDFhNDg5MDgwNDc2MDljYTRlYmEvdGV4dHJlZ2lvbjo1OWNkYWEwZjk3ZmQ0MWE0ODkwODA0NzYwOWNhNGViYV84MjQ_bd14d090-58b9-47f4-a61a-1fb355a01aa5">Yes</ix:nonNumeric>&#160;&#160;<ix:nonNumeric contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331" format="ixt:booleanfalse" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xL2ZyYWc6NTljZGFhMGY5N2ZkNDFhNDg5MDgwNDc2MDljYTRlYmEvdGV4dHJlZ2lvbjo1OWNkYWEwZjk3ZmQ0MWE0ODkwODA0NzYwOWNhNGViYV84Mjg_e65f2035-c37f-4947-9679-44d6dd34c861">&#9746;</ix:nonNumeric>&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="background-color:#ffffff;color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-bottom:4pt;margin-top:4pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(&#167;232.405 of this chapter) during t</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">he preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xL2ZyYWc6NTljZGFhMGY5N2ZkNDFhNDg5MDgwNDc2MDljYTRlYmEvdGV4dHJlZ2lvbjo1OWNkYWEwZjk3ZmQ0MWE0ODkwODA0NzYwOWNhNGViYV8xMTUz_bed8d6fd-3bb9-4aa2-9861-0598020aaf81">Yes</ix:nonNumeric>&#160;&#160;<ix:nonNumeric contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331" format="ixt:booleanfalse" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xL2ZyYWc6NTljZGFhMGY5N2ZkNDFhNDg5MDgwNDc2MDljYTRlYmEvdGV4dHJlZ2lvbjo1OWNkYWEwZjk3ZmQ0MWE0ODkwODA0NzYwOWNhNGViYV8xMTU3_e65f2035-c37f-4947-9679-44d6dd34c861">&#9746;</ix:nonNumeric>&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="background-color:#ffffff;color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-bottom:4pt;margin-top:4pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and "emerging growth company" in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:16.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:57.369%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.665%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.180%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xL2ZyYWc6NTljZGFhMGY5N2ZkNDFhNDg5MDgwNDc2MDljYTRlYmEvdGFibGU6YzNhNzM0YzBkMmNmNDMwNjkzYTU3MjNkNWRjYzBjZTMvdGFibGVyYW5nZTpjM2E3MzRjMGQyY2Y0MzA2OTNhNTcyM2Q1ZGNjMGNlM18xLTAtMS0xLTA_6e4a08c1-b51c-481c-b437-fa799d3f948f">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xL2ZyYWc6NTljZGFhMGY5N2ZkNDFhNDg5MDgwNDc2MDljYTRlYmEvdGFibGU6YzNhNzM0YzBkMmNmNDMwNjkzYTU3MjNkNWRjYzBjZTMvdGFibGVyYW5nZTpjM2E3MzRjMGQyY2Y0MzA2OTNhNTcyM2Q1ZGNjMGNlM18zLTMtMS0xLTA_abc7b0a9-11f9-4aec-993b-c581e6b0caad">&#9744;</ix:nonNumeric></span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xL2ZyYWc6NTljZGFhMGY5N2ZkNDFhNDg5MDgwNDc2MDljYTRlYmEvdGFibGU6YzNhNzM0YzBkMmNmNDMwNjkzYTU3MjNkNWRjYzBjZTMvdGFibGVyYW5nZTpjM2E3MzRjMGQyY2Y0MzA2OTNhNTcyM2Q1ZGNjMGNlM181LTMtMS0xLTA_4e84023e-c0a1-4fda-81f9-417389b6cf55">&#9744;</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:4pt;margin-top:4pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  &#9744;</span></div><div style="margin-bottom:4pt;margin-top:4pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;&#9744;&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="background-color:#ffffff;color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331" format="ixt:booleanfalse" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xL2ZyYWc6NTljZGFhMGY5N2ZkNDFhNDg5MDgwNDc2MDljYTRlYmEvdGV4dHJlZ2lvbjo1OWNkYWEwZjk3ZmQ0MWE0ODkwODA0NzYwOWNhNGViYV8xOTA0_e65f2035-c37f-4947-9679-44d6dd34c861">&#9746;</ix:nonNumeric></span></div><div style="margin-bottom:8pt;margin-top:4pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The number of outstanding shares of the registrant&#8217;s common stock as of April&#160;26, 2021</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> was <ix:nonFraction unitRef="shares" contextRef="id5f8b6da332f4721952346e234823fd7_I20210426" decimals="INF" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xL2ZyYWc6NTljZGFhMGY5N2ZkNDFhNDg5MDgwNDc2MDljYTRlYmEvdGV4dHJlZ2lvbjo1OWNkYWEwZjk3ZmQ0MWE0ODkwODA0NzYwOWNhNGViYV8xOTg2_e3a4da4a-bc1e-4657-ba35-922abec33ec4">121,192,210</ix:nonFraction>.</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i5ae1cfc88aa4492caf56e9d4ac91e096_7"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div style="text-align:center;text-indent:25pt"><span><br/></span></div><div style="text-align:center;text-indent:25pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.034%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:80.470%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.196%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i5ae1cfc88aa4492caf56e9d4ac91e096_10">PART I. FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Page</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Item&#160;1.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5ae1cfc88aa4492caf56e9d4ac91e096_13">Financial Statements (Unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5ae1cfc88aa4492caf56e9d4ac91e096_13">3</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5ae1cfc88aa4492caf56e9d4ac91e096_16">Condensed Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5ae1cfc88aa4492caf56e9d4ac91e096_16">3</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5ae1cfc88aa4492caf56e9d4ac91e096_19">Condensed Consolidated Statements of Operations and Comprehensive Loss</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5ae1cfc88aa4492caf56e9d4ac91e096_19">4</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5ae1cfc88aa4492caf56e9d4ac91e096_22">Condensed Consolidated Statements of Stockholders&#8217; Equity</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5ae1cfc88aa4492caf56e9d4ac91e096_22">5</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5ae1cfc88aa4492caf56e9d4ac91e096_25">Condensed Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5ae1cfc88aa4492caf56e9d4ac91e096_25">6</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5ae1cfc88aa4492caf56e9d4ac91e096_28">Notes to Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5ae1cfc88aa4492caf56e9d4ac91e096_28">7</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Item&#160;2.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5ae1cfc88aa4492caf56e9d4ac91e096_70">Management's Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5ae1cfc88aa4492caf56e9d4ac91e096_70">29</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Item&#160;3.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5ae1cfc88aa4492caf56e9d4ac91e096_97">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5ae1cfc88aa4492caf56e9d4ac91e096_97">43</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Item&#160;4.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5ae1cfc88aa4492caf56e9d4ac91e096_100">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5ae1cfc88aa4492caf56e9d4ac91e096_100">44</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i5ae1cfc88aa4492caf56e9d4ac91e096_103">PART II. OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Item&#160;1.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5ae1cfc88aa4492caf56e9d4ac91e096_106">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5ae1cfc88aa4492caf56e9d4ac91e096_106">45</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Item&#160;1A.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5ae1cfc88aa4492caf56e9d4ac91e096_109">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5ae1cfc88aa4492caf56e9d4ac91e096_109">45</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Item&#160;2.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5ae1cfc88aa4492caf56e9d4ac91e096_133">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5ae1cfc88aa4492caf56e9d4ac91e096_133">112</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Item&#160;3.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5ae1cfc88aa4492caf56e9d4ac91e096_136">Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5ae1cfc88aa4492caf56e9d4ac91e096_136">112</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Item&#160;4.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5ae1cfc88aa4492caf56e9d4ac91e096_139">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5ae1cfc88aa4492caf56e9d4ac91e096_139">112</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Item&#160;5.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5ae1cfc88aa4492caf56e9d4ac91e096_142">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5ae1cfc88aa4492caf56e9d4ac91e096_142">112</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Item&#160;6.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5ae1cfc88aa4492caf56e9d4ac91e096_145">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5ae1cfc88aa4492caf56e9d4ac91e096_145">113</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5ae1cfc88aa4492caf56e9d4ac91e096_148">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5ae1cfc88aa4492caf56e9d4ac91e096_148">114</a></span></div></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i5ae1cfc88aa4492caf56e9d4ac91e096_10"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:4pt"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5ae1cfc88aa4492caf56e9d4ac91e096_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5ae1cfc88aa4492caf56e9d4ac91e096_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I. FINANCIAL INFORMATION</span></div><div id="i5ae1cfc88aa4492caf56e9d4ac91e096_13"></div><div style="margin-top:8pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1.&#160;&#160;&#160;&#160;  FINANCIAL STATEMENTS</span></div><div id="i5ae1cfc88aa4492caf56e9d4ac91e096_16"></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Denali Therapeutics Inc.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Balance Sheets</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except share amounts)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.483%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.848%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9953f50a7fd74f7d8438f304f136a07b_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfMy0xLTEtMS0w_cf2c1560-21db-46b4-af90-2524a9ab29e3">435,321</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb7ca9f362da46eab3a29bbbecbda977_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfMy0zLTEtMS0w_2bc400f5-57ae-47d3-956e-8f06773f1d89">507,144</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Short-term marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9953f50a7fd74f7d8438f304f136a07b_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:MarketableSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfNC0xLTEtMS0w_7ec45a3e-9913-449e-968b-3c423abeda05">977,827</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb7ca9f362da46eab3a29bbbecbda977_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:MarketableSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfNC0zLTEtMS0w_69bbc470-32dd-4049-aa61-33a4e170cc57">962,553</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost sharing reimbursements due from related party</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9953f50a7fd74f7d8438f304f136a07b_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DueFromRelatedPartiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfNS0xLTEtMS0yOQ_dfb839e4-93d4-417d-936e-c44609276613">2,511</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb7ca9f362da46eab3a29bbbecbda977_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DueFromRelatedPartiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfNS0zLTEtMS0zMg_46bf291d-2875-4296-8ded-7e94e1131b4f">5,674</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9953f50a7fd74f7d8438f304f136a07b_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfNS0xLTEtMS0w_b189563b-6713-4be9-b698-541f36fd346e">15,963</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb7ca9f362da46eab3a29bbbecbda977_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfNS0zLTEtMS0w_8c03cf21-ad6c-4ceb-b53d-8f6be09c6f3e">20,284</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9953f50a7fd74f7d8438f304f136a07b_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfNi0xLTEtMS0w_c0465fd8-4553-4d41-beb7-c2c9269f7d61">1,431,622</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb7ca9f362da46eab3a29bbbecbda977_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfNi0zLTEtMS0w_ee1aede5-77b6-4466-a75a-f23c60366525">1,495,655</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term marketable securities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9953f50a7fd74f7d8438f304f136a07b_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:MarketableSecuritiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfNy0xLTEtMS0w_b42339a2-7c5d-46ff-9f49-889d14d52f0e">38,885</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb7ca9f362da46eab3a29bbbecbda977_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:MarketableSecuritiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfNy0zLTEtMS0w_c8b152b4-7c0a-47ef-8f80-fa0eba55ae2e">32,699</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9953f50a7fd74f7d8438f304f136a07b_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfOC0xLTEtMS0w_4f253388-f359-4d0d-8fbe-5be1b40dec27">41,376</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb7ca9f362da46eab3a29bbbecbda977_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfOC0zLTEtMS0w_4b345a88-d882-4e32-bb3a-954354529ec9">40,846</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease right-of-use asset</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9953f50a7fd74f7d8438f304f136a07b_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfOS0xLTEtMS0w_6118d93f-40c5-41d9-8ff4-5d2073899e64">32,236</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb7ca9f362da46eab3a29bbbecbda977_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfOS0zLTEtMS0w_ad728fde-e0fd-4b3a-a9a6-6ee612157613">32,618</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9953f50a7fd74f7d8438f304f136a07b_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfMTAtMS0xLTEtMA_51ad5d9a-a38b-43f5-bb34-4c4b2c6f73a5">3,739</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb7ca9f362da46eab3a29bbbecbda977_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfMTAtMy0xLTEtMA_3d524367-c6a0-48b2-b17c-8a664b18f4af">2,462</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9953f50a7fd74f7d8438f304f136a07b_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfMTEtMS0xLTEtMA_f3485074-bbe3-4f49-8966-a0143a353639">1,547,858</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb7ca9f362da46eab3a29bbbecbda977_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfMTEtMy0xLTEtMA_2653eab9-9f25-492e-92e3-c995cbec6fd5">1,604,280</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liabilities and stockholders' equity </span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9953f50a7fd74f7d8438f304f136a07b_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfMTQtMS0xLTEtMA_afaef670-96b8-46d6-915f-c91fa6ab6527">1,626</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb7ca9f362da46eab3a29bbbecbda977_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfMTQtMy0xLTEtMA_50829d99-05da-4043-901f-aea46d786674">1,071</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9953f50a7fd74f7d8438f304f136a07b_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfMTUtMS0xLTEtMA_ea0a9aec-0893-49f2-b9b9-54c8034971b3">4,963</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb7ca9f362da46eab3a29bbbecbda977_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfMTUtMy0xLTEtMA_a45fad14-8703-4461-afbf-c41cea76f6f4">20,503</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued clinical costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9953f50a7fd74f7d8438f304f136a07b_I20210331" decimals="-3" format="ixt:numdotdecimal" name="dnli:AccruedClinicalCostsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfMTYtMS0xLTEtMA_cd5a6ff5-9746-447d-b7a2-b9d9371285f8">5,049</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb7ca9f362da46eab3a29bbbecbda977_I20201231" decimals="-3" format="ixt:numdotdecimal" name="dnli:AccruedClinicalCostsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfMTYtMy0xLTEtMA_4374a1f4-b914-4c25-9fbd-f7dc8fa12cd6">6,497</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued manufacturing costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9953f50a7fd74f7d8438f304f136a07b_I20210331" decimals="-3" format="ixt:numdotdecimal" name="dnli:OtherAccruedManufacturingCostsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfMTgtMS0xLTEtNDI5MA_75387d3c-50b3-48a0-a3fe-0cb57b5ab4a1">13,342</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb7ca9f362da46eab3a29bbbecbda977_I20201231" decimals="-3" format="ixt:numdotdecimal" name="dnli:OtherAccruedManufacturingCostsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfMTgtMy0xLTEtNDI5NQ_b334af1d-7fc5-4e18-bba0-9a35686bc876">7,140</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other accruals and other current liabilities </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9953f50a7fd74f7d8438f304f136a07b_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfMTctMS0xLTEtMA_c76e12d5-b3a4-462d-b936-fc0916602058">8,299</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb7ca9f362da46eab3a29bbbecbda977_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfMTctMy0xLTEtMA_e0f51f21-7d02-4e13-a5ff-88e55615ad4c">8,315</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease liability, current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9953f50a7fd74f7d8438f304f136a07b_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfMTgtMS0xLTEtMA_888da52f-004e-452f-8eaa-d54e3b38fd0d">4,876</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb7ca9f362da46eab3a29bbbecbda977_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfMTgtMy0xLTEtMA_d4099fe6-77e8-4c88-a82b-acca3aa88070">4,690</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Related party contract liability, current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9953f50a7fd74f7d8438f304f136a07b_I20210331" decimals="-3" format="ixt:numdotdecimal" name="dnli:ContractWithCustomerLiabilityFromRelatedPartiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfMTktMS0xLTEtMA_502bdc51-5159-4e07-beff-afca67ffec04">3,569</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb7ca9f362da46eab3a29bbbecbda977_I20201231" decimals="-3" format="ixt:numdotdecimal" name="dnli:ContractWithCustomerLiabilityFromRelatedPartiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfMTktMy0xLTEtMA_7cb426f6-72d5-4645-b309-4ad8006d1976">3,569</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contract liabilities, current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9953f50a7fd74f7d8438f304f136a07b_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfMjAtMS0xLTEtMA_402647a5-7184-4860-ab27-fc580bc33acd">12,886</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb7ca9f362da46eab3a29bbbecbda977_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfMjAtMy0xLTEtMA_a19229a2-24c5-4745-abb4-6b4e7b656078">19,914</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9953f50a7fd74f7d8438f304f136a07b_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfMjEtMS0xLTEtMA_215ecb06-716e-44ac-8d82-2f445907589d">54,610</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb7ca9f362da46eab3a29bbbecbda977_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfMjEtMy0xLTEtMA_9ccd6d19-8260-4bf5-be06-f63da7fe0abd">71,699</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Related party contract liability, less current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9953f50a7fd74f7d8438f304f136a07b_I20210331" decimals="-3" format="ixt:numdotdecimal" name="dnli:ContractWithCustomerLiabilityFromRelatedPartiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfMjMtMS0xLTEtMTg3_7bca2cee-ced0-4a39-b8de-ea7bdf8e7f1f">292,956</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb7ca9f362da46eab3a29bbbecbda977_I20201231" decimals="-3" format="ixt:numdotdecimal" name="dnli:ContractWithCustomerLiabilityFromRelatedPartiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfMjMtMy0xLTEtMTkw_ea80a8c6-6408-45d4-b0fc-860fe734567c">293,849</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contract liabilities, less current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9953f50a7fd74f7d8438f304f136a07b_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfMjItMS0xLTEtMA_91c6b1f3-abdb-4871-91a5-7b50ab7ca582">31,322</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb7ca9f362da46eab3a29bbbecbda977_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfMjItMy0xLTEtMA_e53d01bd-80c5-44a5-85b6-cd1bd2869a83">23,325</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease liability, less current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9953f50a7fd74f7d8438f304f136a07b_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfMjMtMS0xLTEtMA_344e1538-c378-483b-9479-7a8ff5442ea9">62,916</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb7ca9f362da46eab3a29bbbecbda977_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfMjMtMy0xLTEtMA_99809f63-4f2f-4edc-8d93-825ee48742c4">64,175</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other non-current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9953f50a7fd74f7d8438f304f136a07b_I20210331" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfMjQtMS0xLTEtMA_b883eb70-6861-44e5-85ed-e0e9616d307b">701</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb7ca9f362da46eab3a29bbbecbda977_I20201231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfMjQtMy0xLTEtMA_78290355-244a-40f9-ba48-cece21349431">701</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9953f50a7fd74f7d8438f304f136a07b_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfMjUtMS0xLTEtMA_769851a8-860c-492e-955c-80ad73b86329">442,505</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb7ca9f362da46eab3a29bbbecbda977_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfMjUtMy0xLTEtMA_8629e210-d1cd-4405-9218-c131db9fe813">453,749</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commitments and contingencies (Note 7)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i9953f50a7fd74f7d8438f304f136a07b_I20210331" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfMjYtMS0xLTEtMA_966d8431-1811-4510-a067-b740c5f0c9af"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="idb7ca9f362da46eab3a29bbbecbda977_I20201231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfMjYtMy0xLTEtMA_85cb7e15-484b-418f-b012-caacc107e788"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stockholders' equity:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:23.98pt;text-indent:-12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Convertible preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="idb7ca9f362da46eab3a29bbbecbda977_I20201231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfMjgtMC0xLTEtMC90ZXh0cmVnaW9uOjBiNTgyZDk3ZTM1NDRlYzI4YWFhYThlZDA1NGIyYzJmXzM0_0de80b99-b915-4170-be94-842d700d7cf7"><ix:nonFraction unitRef="usdPerShare" contextRef="i9953f50a7fd74f7d8438f304f136a07b_I20210331" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfMjgtMC0xLTEtMC90ZXh0cmVnaW9uOjBiNTgyZDk3ZTM1NDRlYzI4YWFhYThlZDA1NGIyYzJmXzM0_52fab557-3428-4853-8885-678739d9b64a">0.01</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i9953f50a7fd74f7d8438f304f136a07b_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfMjgtMC0xLTEtMC90ZXh0cmVnaW9uOjBiNTgyZDk3ZTM1NDRlYzI4YWFhYThlZDA1NGIyYzJmXzQ4_3b7b92d2-7209-4a89-b9fa-fd9e3dadceaf"><ix:nonFraction unitRef="shares" contextRef="idb7ca9f362da46eab3a29bbbecbda977_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfMjgtMC0xLTEtMC90ZXh0cmVnaW9uOjBiNTgyZDk3ZTM1NDRlYzI4YWFhYThlZDA1NGIyYzJmXzQ4_6cf3240e-7f83-4936-8e8b-31a977baa77a">40,000,000</ix:nonFraction></ix:nonFraction> shares authorized as of March 31, 2021 and December 31, 2020; <ix:nonFraction unitRef="shares" contextRef="idb7ca9f362da46eab3a29bbbecbda977_I20201231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfMjgtMC0xLTEtMC90ZXh0cmVnaW9uOjBiNTgyZDk3ZTM1NDRlYzI4YWFhYThlZDA1NGIyYzJmXzg2_1db05b09-2ed6-4abe-99af-ce315f9e14dc"><ix:nonFraction unitRef="shares" contextRef="i9953f50a7fd74f7d8438f304f136a07b_I20210331" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfMjgtMC0xLTEtMC90ZXh0cmVnaW9uOjBiNTgyZDk3ZTM1NDRlYzI4YWFhYThlZDA1NGIyYzJmXzg2_3d303cfc-a517-4f5c-b3c3-95ef14ee40f5"><ix:nonFraction unitRef="shares" contextRef="idb7ca9f362da46eab3a29bbbecbda977_I20201231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfMjgtMC0xLTEtMC90ZXh0cmVnaW9uOjBiNTgyZDk3ZTM1NDRlYzI4YWFhYThlZDA1NGIyYzJmXzg2_78ea2491-810a-4e4c-94d7-0f6c56a8ed88"><ix:nonFraction unitRef="shares" contextRef="i9953f50a7fd74f7d8438f304f136a07b_I20210331" decimals="INF" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfMjgtMC0xLTEtMC90ZXh0cmVnaW9uOjBiNTgyZDk3ZTM1NDRlYzI4YWFhYThlZDA1NGIyYzJmXzg2_da5352cf-ea6a-4c5d-8f37-c40c6661814e">0</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding as of March 31, 2021 and December 31, 2020</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9953f50a7fd74f7d8438f304f136a07b_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfMjgtMS0xLTEtMA_8660419c-27ed-4964-8744-30298c8c9243">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb7ca9f362da46eab3a29bbbecbda977_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfMjgtMy0xLTEtMA_e9e129b4-1f14-4555-858f-35489f61c8f8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:23.98pt;text-indent:-12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i9953f50a7fd74f7d8438f304f136a07b_I20210331" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfMjktMC0xLTEtMC90ZXh0cmVnaW9uOjA1YWQxNDc2NTMxYjQxNGI5YWRiODFkY2E3ZDA2ZjdlXzE4_c6b744d0-0f7c-47b5-af59-55cc091119ba"><ix:nonFraction unitRef="usdPerShare" contextRef="idb7ca9f362da46eab3a29bbbecbda977_I20201231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfMjktMC0xLTEtMC90ZXh0cmVnaW9uOjA1YWQxNDc2NTMxYjQxNGI5YWRiODFkY2E3ZDA2ZjdlXzE4_ead3099c-ce64-4346-b649-3227dd69b40b">0.01</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i9953f50a7fd74f7d8438f304f136a07b_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfMjktMC0xLTEtMC90ZXh0cmVnaW9uOjA1YWQxNDc2NTMxYjQxNGI5YWRiODFkY2E3ZDA2ZjdlXzMy_a584d5b6-fc12-4301-a196-3708adbf459d"><ix:nonFraction unitRef="shares" contextRef="idb7ca9f362da46eab3a29bbbecbda977_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfMjktMC0xLTEtMC90ZXh0cmVnaW9uOjA1YWQxNDc2NTMxYjQxNGI5YWRiODFkY2E3ZDA2ZjdlXzMy_c3a276ff-b81f-4eb7-a1cb-1d684df1d243">400,000,000</ix:nonFraction></ix:nonFraction> shares authorized as of March 31, 2021 and December 31, 2020; <ix:nonFraction unitRef="shares" contextRef="i9953f50a7fd74f7d8438f304f136a07b_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfMjktMC0xLTEtMC90ZXh0cmVnaW9uOjA1YWQxNDc2NTMxYjQxNGI5YWRiODFkY2E3ZDA2ZjdlXzcw_2c20251f-19e7-4a9a-93b1-8180cd471426"><ix:nonFraction unitRef="shares" contextRef="i9953f50a7fd74f7d8438f304f136a07b_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfMjktMC0xLTEtMC90ZXh0cmVnaW9uOjA1YWQxNDc2NTMxYjQxNGI5YWRiODFkY2E3ZDA2ZjdlXzcw_958a8067-a014-40ea-916a-ff88d2100daa">121,147,432</ix:nonFraction></ix:nonFraction> shares and <ix:nonFraction unitRef="shares" contextRef="idb7ca9f362da46eab3a29bbbecbda977_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfMjktMC0xLTEtMC90ZXh0cmVnaW9uOjA1YWQxNDc2NTMxYjQxNGI5YWRiODFkY2E3ZDA2ZjdlXzg0_1531b96d-4511-4f2b-84fc-0a2d2228f650"><ix:nonFraction unitRef="shares" contextRef="idb7ca9f362da46eab3a29bbbecbda977_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfMjktMC0xLTEtMC90ZXh0cmVnaW9uOjA1YWQxNDc2NTMxYjQxNGI5YWRiODFkY2E3ZDA2ZjdlXzg0_90e808c3-66f6-4de7-91b7-8dcd1c4edbea">120,531,333</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of March 31, 2021 and December 31, 2020, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9953f50a7fd74f7d8438f304f136a07b_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfMjktMS0xLTEtMA_536cd9a9-ae3b-41c9-b346-d35fe7041294">1,537</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb7ca9f362da46eab3a29bbbecbda977_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfMjktMy0xLTEtMA_cdb8ab95-2880-4804-906a-5a3412a69f07">1,531</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9953f50a7fd74f7d8438f304f136a07b_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfMzAtMS0xLTEtMA_1205d558-077a-49a9-ae2f-dacf40a49e5e">1,528,504</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb7ca9f362da46eab3a29bbbecbda977_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfMzAtMy0xLTEtMA_7662ee9e-168c-4656-8566-ea5ac6635dfb">1,503,660</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9953f50a7fd74f7d8438f304f136a07b_I20210331" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfMzEtMS0xLTEtMA_94fa2d18-0246-4338-923a-c933028b31ba">232</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb7ca9f362da46eab3a29bbbecbda977_I20201231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfMzEtMy0xLTEtMA_8cf25565-e3e9-4d02-907e-a1d91d768900">245</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9953f50a7fd74f7d8438f304f136a07b_I20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfMzItMS0xLTEtMA_fc03c30b-7641-4497-b3b6-3850e0e54ec5">424,456</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb7ca9f362da46eab3a29bbbecbda977_I20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfMzItMy0xLTEtMA_80ef1818-2be4-43cb-984a-8136dd1a153d">354,415</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total stockholders' equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9953f50a7fd74f7d8438f304f136a07b_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfMzMtMS0xLTEtMA_fb858ec3-7669-439a-96a8-3fda49aa5003">1,105,353</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb7ca9f362da46eab3a29bbbecbda977_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfMzMtMy0xLTEtMA_3c92eba2-b0a0-41f2-875e-7517e3c7292f">1,150,531</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9953f50a7fd74f7d8438f304f136a07b_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfMzQtMS0xLTEtMA_75953f67-c8fd-462c-884a-336c6884f19a">1,547,858</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb7ca9f362da46eab3a29bbbecbda977_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfMzQtMy0xLTEtMA_9426620e-7a07-4f70-a3a9-912b1ef87bed">1,604,280</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to unaudited condensed consolidated financial statements.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="i5ae1cfc88aa4492caf56e9d4ac91e096_19"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5ae1cfc88aa4492caf56e9d4ac91e096_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Denali Therapeutics Inc.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Operations and Comprehensive Loss</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except share and per share amounts)</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.553%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.252%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.254%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Collaboration revenue:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Collaboration revenue from customers</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xOS9mcmFnOjU2Y2EwZjE3OWFiNTQ3M2VhZGFlZDM5NjQxYjQ1NzhkL3RhYmxlOmRhMmJiMjEyNGYyZDQyODY4OTE3MTc5NWI4YmJmOThmL3RhYmxlcmFuZ2U6ZGEyYmIyMTI0ZjJkNDI4Njg5MTcxNzk1YjhiYmY5OGZfMy0xLTEtMS0w_3e600fff-1d7a-4a97-8ad7-909f7d61a045">7,922</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia34dfea6b8734d64abf707c28256801c_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xOS9mcmFnOjU2Y2EwZjE3OWFiNTQ3M2VhZGFlZDM5NjQxYjQ1NzhkL3RhYmxlOmRhMmJiMjEyNGYyZDQyODY4OTE3MTc5NWI4YmJmOThmL3RhYmxlcmFuZ2U6ZGEyYmIyMTI0ZjJkNDI4Njg5MTcxNzk1YjhiYmY5OGZfMy0zLTEtMS0w_2085c283-6abe-41cb-87a7-f1af23aba47a">3,552</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other collaboration revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xOS9mcmFnOjU2Y2EwZjE3OWFiNTQ3M2VhZGFlZDM5NjQxYjQ1NzhkL3RhYmxlOmRhMmJiMjEyNGYyZDQyODY4OTE3MTc5NWI4YmJmOThmL3RhYmxlcmFuZ2U6ZGEyYmIyMTI0ZjJkNDI4Njg5MTcxNzk1YjhiYmY5OGZfNC0xLTEtMS0w_6002fe5d-5bf8-40f0-96e0-21910e296057">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia34dfea6b8734d64abf707c28256801c_D20200101-20200331" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xOS9mcmFnOjU2Y2EwZjE3OWFiNTQ3M2VhZGFlZDM5NjQxYjQ1NzhkL3RhYmxlOmRhMmJiMjEyNGYyZDQyODY4OTE3MTc5NWI4YmJmOThmL3RhYmxlcmFuZ2U6ZGEyYmIyMTI0ZjJkNDI4Njg5MTcxNzk1YjhiYmY5OGZfNC0zLTEtMS0w_74f4c8f7-1de4-42e4-8be5-2fe3f3cd424a">52</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total collaboration revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xOS9mcmFnOjU2Y2EwZjE3OWFiNTQ3M2VhZGFlZDM5NjQxYjQ1NzhkL3RhYmxlOmRhMmJiMjEyNGYyZDQyODY4OTE3MTc5NWI4YmJmOThmL3RhYmxlcmFuZ2U6ZGEyYmIyMTI0ZjJkNDI4Njg5MTcxNzk1YjhiYmY5OGZfNS0xLTEtMS0w_fe256c91-bf8c-445a-af17-dec1b46f116e">7,923</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia34dfea6b8734d64abf707c28256801c_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xOS9mcmFnOjU2Y2EwZjE3OWFiNTQ3M2VhZGFlZDM5NjQxYjQ1NzhkL3RhYmxlOmRhMmJiMjEyNGYyZDQyODY4OTE3MTc5NWI4YmJmOThmL3RhYmxlcmFuZ2U6ZGEyYmIyMTI0ZjJkNDI4Njg5MTcxNzk1YjhiYmY5OGZfNS0zLTEtMS0w_27e5d189-1e49-4a97-b56a-d4557f58e3a4">3,604</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xOS9mcmFnOjU2Y2EwZjE3OWFiNTQ3M2VhZGFlZDM5NjQxYjQ1NzhkL3RhYmxlOmRhMmJiMjEyNGYyZDQyODY4OTE3MTc5NWI4YmJmOThmL3RhYmxlcmFuZ2U6ZGEyYmIyMTI0ZjJkNDI4Njg5MTcxNzk1YjhiYmY5OGZfNy0xLTEtMS0w_ff2936cd-371c-41a6-961e-a0ff4d0036c6">60,207</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia34dfea6b8734d64abf707c28256801c_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xOS9mcmFnOjU2Y2EwZjE3OWFiNTQ3M2VhZGFlZDM5NjQxYjQ1NzhkL3RhYmxlOmRhMmJiMjEyNGYyZDQyODY4OTE3MTc5NWI4YmJmOThmL3RhYmxlcmFuZ2U6ZGEyYmIyMTI0ZjJkNDI4Njg5MTcxNzk1YjhiYmY5OGZfNy0zLTEtMS0w_c27c224f-10c1-4e6b-a179-07afb5d152de">51,016</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xOS9mcmFnOjU2Y2EwZjE3OWFiNTQ3M2VhZGFlZDM5NjQxYjQ1NzhkL3RhYmxlOmRhMmJiMjEyNGYyZDQyODY4OTE3MTc5NWI4YmJmOThmL3RhYmxlcmFuZ2U6ZGEyYmIyMTI0ZjJkNDI4Njg5MTcxNzk1YjhiYmY5OGZfOC0xLTEtMS0w_a14038a1-5245-4bcf-b692-b36663e277ee">18,936</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia34dfea6b8734d64abf707c28256801c_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xOS9mcmFnOjU2Y2EwZjE3OWFiNTQ3M2VhZGFlZDM5NjQxYjQ1NzhkL3RhYmxlOmRhMmJiMjEyNGYyZDQyODY4OTE3MTc5NWI4YmJmOThmL3RhYmxlcmFuZ2U6ZGEyYmIyMTI0ZjJkNDI4Njg5MTcxNzk1YjhiYmY5OGZfOC0zLTEtMS0w_18cfc9ef-460f-4db6-835d-18140332c88a">12,555</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xOS9mcmFnOjU2Y2EwZjE3OWFiNTQ3M2VhZGFlZDM5NjQxYjQ1NzhkL3RhYmxlOmRhMmJiMjEyNGYyZDQyODY4OTE3MTc5NWI4YmJmOThmL3RhYmxlcmFuZ2U6ZGEyYmIyMTI0ZjJkNDI4Njg5MTcxNzk1YjhiYmY5OGZfOS0xLTEtMS0w_68fe63c2-ecbc-442b-bb5e-ed250b39c11e">79,143</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia34dfea6b8734d64abf707c28256801c_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xOS9mcmFnOjU2Y2EwZjE3OWFiNTQ3M2VhZGFlZDM5NjQxYjQ1NzhkL3RhYmxlOmRhMmJiMjEyNGYyZDQyODY4OTE3MTc5NWI4YmJmOThmL3RhYmxlcmFuZ2U6ZGEyYmIyMTI0ZjJkNDI4Njg5MTcxNzk1YjhiYmY5OGZfOS0zLTEtMS0w_cd636a98-a2c0-4181-9c15-65cc79134649">63,571</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xOS9mcmFnOjU2Y2EwZjE3OWFiNTQ3M2VhZGFlZDM5NjQxYjQ1NzhkL3RhYmxlOmRhMmJiMjEyNGYyZDQyODY4OTE3MTc5NWI4YmJmOThmL3RhYmxlcmFuZ2U6ZGEyYmIyMTI0ZjJkNDI4Njg5MTcxNzk1YjhiYmY5OGZfMTAtMS0xLTEtMA_a686a84b-0be9-441e-a313-0aa0445e342c">71,220</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia34dfea6b8734d64abf707c28256801c_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xOS9mcmFnOjU2Y2EwZjE3OWFiNTQ3M2VhZGFlZDM5NjQxYjQ1NzhkL3RhYmxlOmRhMmJiMjEyNGYyZDQyODY4OTE3MTc5NWI4YmJmOThmL3RhYmxlcmFuZ2U6ZGEyYmIyMTI0ZjJkNDI4Njg5MTcxNzk1YjhiYmY5OGZfMTAtMy0xLTEtMA_ea306577-d562-4247-8b37-345d41ad5f52">59,967</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest and other income, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xOS9mcmFnOjU2Y2EwZjE3OWFiNTQ3M2VhZGFlZDM5NjQxYjQ1NzhkL3RhYmxlOmRhMmJiMjEyNGYyZDQyODY4OTE3MTc5NWI4YmJmOThmL3RhYmxlcmFuZ2U6ZGEyYmIyMTI0ZjJkNDI4Njg5MTcxNzk1YjhiYmY5OGZfMTEtMS0xLTEtMA_9b23a34f-69e8-42cd-bddb-8e12a8e694a2">1,179</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia34dfea6b8734d64abf707c28256801c_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xOS9mcmFnOjU2Y2EwZjE3OWFiNTQ3M2VhZGFlZDM5NjQxYjQ1NzhkL3RhYmxlOmRhMmJiMjEyNGYyZDQyODY4OTE3MTc5NWI4YmJmOThmL3RhYmxlcmFuZ2U6ZGEyYmIyMTI0ZjJkNDI4Njg5MTcxNzk1YjhiYmY5OGZfMTEtMy0xLTEtMA_5a94b413-9e43-4d2b-ae6c-3a12ff99ee5c">3,069</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xOS9mcmFnOjU2Y2EwZjE3OWFiNTQ3M2VhZGFlZDM5NjQxYjQ1NzhkL3RhYmxlOmRhMmJiMjEyNGYyZDQyODY4OTE3MTc5NWI4YmJmOThmL3RhYmxlcmFuZ2U6ZGEyYmIyMTI0ZjJkNDI4Njg5MTcxNzk1YjhiYmY5OGZfMTItMS0xLTEtMA_c46605d8-080e-4c4a-b534-3915bc7973d9">70,041</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia34dfea6b8734d64abf707c28256801c_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xOS9mcmFnOjU2Y2EwZjE3OWFiNTQ3M2VhZGFlZDM5NjQxYjQ1NzhkL3RhYmxlOmRhMmJiMjEyNGYyZDQyODY4OTE3MTc5NWI4YmJmOThmL3RhYmxlcmFuZ2U6ZGEyYmIyMTI0ZjJkNDI4Njg5MTcxNzk1YjhiYmY5OGZfMTItMy0xLTEtMA_4ce84b76-9908-43f7-b079-d1f4bc916888">56,898</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax benefit </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xOS9mcmFnOjU2Y2EwZjE3OWFiNTQ3M2VhZGFlZDM5NjQxYjQ1NzhkL3RhYmxlOmRhMmJiMjEyNGYyZDQyODY4OTE3MTc5NWI4YmJmOThmL3RhYmxlcmFuZ2U6ZGEyYmIyMTI0ZjJkNDI4Njg5MTcxNzk1YjhiYmY5OGZfMTMtMS0xLTEtMA_15c3de78-bcae-43df-9cb7-3fe47321b9eb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia34dfea6b8734d64abf707c28256801c_D20200101-20200331" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xOS9mcmFnOjU2Y2EwZjE3OWFiNTQ3M2VhZGFlZDM5NjQxYjQ1NzhkL3RhYmxlOmRhMmJiMjEyNGYyZDQyODY4OTE3MTc5NWI4YmJmOThmL3RhYmxlcmFuZ2U6ZGEyYmIyMTI0ZjJkNDI4Njg5MTcxNzk1YjhiYmY5OGZfMTMtMy0xLTEtMA_a6e8bc46-0a48-41a0-b960-43b58cd50555">135</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xOS9mcmFnOjU2Y2EwZjE3OWFiNTQ3M2VhZGFlZDM5NjQxYjQ1NzhkL3RhYmxlOmRhMmJiMjEyNGYyZDQyODY4OTE3MTc5NWI4YmJmOThmL3RhYmxlcmFuZ2U6ZGEyYmIyMTI0ZjJkNDI4Njg5MTcxNzk1YjhiYmY5OGZfMTQtMS0xLTEtMA_925af861-1450-4332-a251-593607c17747">70,041</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia34dfea6b8734d64abf707c28256801c_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xOS9mcmFnOjU2Y2EwZjE3OWFiNTQ3M2VhZGFlZDM5NjQxYjQ1NzhkL3RhYmxlOmRhMmJiMjEyNGYyZDQyODY4OTE3MTc5NWI4YmJmOThmL3RhYmxlcmFuZ2U6ZGEyYmIyMTI0ZjJkNDI4Njg5MTcxNzk1YjhiYmY5OGZfMTQtMy0xLTEtMA_d4610458-faa9-4bc5-8b64-8acc566f5d80">56,763</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.98pt;text-align:left;text-indent:-12pt;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net unrealized gain on marketable securities, net of tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xOS9mcmFnOjU2Y2EwZjE3OWFiNTQ3M2VhZGFlZDM5NjQxYjQ1NzhkL3RhYmxlOmRhMmJiMjEyNGYyZDQyODY4OTE3MTc5NWI4YmJmOThmL3RhYmxlcmFuZ2U6ZGEyYmIyMTI0ZjJkNDI4Njg5MTcxNzk1YjhiYmY5OGZfMTYtMS0xLTEtMA_a5ddb717-ea6a-42a0-ae1f-cb558de7f4a5">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia34dfea6b8734d64abf707c28256801c_D20200101-20200331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xOS9mcmFnOjU2Y2EwZjE3OWFiNTQ3M2VhZGFlZDM5NjQxYjQ1NzhkL3RhYmxlOmRhMmJiMjEyNGYyZDQyODY4OTE3MTc5NWI4YmJmOThmL3RhYmxlcmFuZ2U6ZGEyYmIyMTI0ZjJkNDI4Njg5MTcxNzk1YjhiYmY5OGZfMTYtMy0xLTEtMA_15a85b23-bd9d-4075-a833-991696e4f166">485</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Comprehensive loss</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xOS9mcmFnOjU2Y2EwZjE3OWFiNTQ3M2VhZGFlZDM5NjQxYjQ1NzhkL3RhYmxlOmRhMmJiMjEyNGYyZDQyODY4OTE3MTc5NWI4YmJmOThmL3RhYmxlcmFuZ2U6ZGEyYmIyMTI0ZjJkNDI4Njg5MTcxNzk1YjhiYmY5OGZfMTctMS0xLTEtMA_76cbf43a-4ba4-4ebe-9e1c-b469e5eee71a">70,028</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia34dfea6b8734d64abf707c28256801c_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xOS9mcmFnOjU2Y2EwZjE3OWFiNTQ3M2VhZGFlZDM5NjQxYjQ1NzhkL3RhYmxlOmRhMmJiMjEyNGYyZDQyODY4OTE3MTc5NWI4YmJmOThmL3RhYmxlcmFuZ2U6ZGEyYmIyMTI0ZjJkNDI4Njg5MTcxNzk1YjhiYmY5OGZfMTctMy0xLTEtMA_46534ffc-c202-4d48-bc05-f3488f2689bc">56,278</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss per share, basic and diluted</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xOS9mcmFnOjU2Y2EwZjE3OWFiNTQ3M2VhZGFlZDM5NjQxYjQ1NzhkL3RhYmxlOmRhMmJiMjEyNGYyZDQyODY4OTE3MTc5NWI4YmJmOThmL3RhYmxlcmFuZ2U6ZGEyYmIyMTI0ZjJkNDI4Njg5MTcxNzk1YjhiYmY5OGZfMTgtMS0xLTEtMA_286d7405-7acb-44ad-94db-dd208f2207f0"><ix:nonFraction unitRef="usdPerShare" contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xOS9mcmFnOjU2Y2EwZjE3OWFiNTQ3M2VhZGFlZDM5NjQxYjQ1NzhkL3RhYmxlOmRhMmJiMjEyNGYyZDQyODY4OTE3MTc5NWI4YmJmOThmL3RhYmxlcmFuZ2U6ZGEyYmIyMTI0ZjJkNDI4Njg5MTcxNzk1YjhiYmY5OGZfMTgtMS0xLTEtMA_abf84322-713d-4b1e-b7a1-75fa05c608e1">0.58</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ia34dfea6b8734d64abf707c28256801c_D20200101-20200331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xOS9mcmFnOjU2Y2EwZjE3OWFiNTQ3M2VhZGFlZDM5NjQxYjQ1NzhkL3RhYmxlOmRhMmJiMjEyNGYyZDQyODY4OTE3MTc5NWI4YmJmOThmL3RhYmxlcmFuZ2U6ZGEyYmIyMTI0ZjJkNDI4Njg5MTcxNzk1YjhiYmY5OGZfMTgtMy0xLTEtMA_70df80d6-01e9-4040-911c-1a0f05e2ce26"><ix:nonFraction unitRef="usdPerShare" contextRef="ia34dfea6b8734d64abf707c28256801c_D20200101-20200331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xOS9mcmFnOjU2Y2EwZjE3OWFiNTQ3M2VhZGFlZDM5NjQxYjQ1NzhkL3RhYmxlOmRhMmJiMjEyNGYyZDQyODY4OTE3MTc5NWI4YmJmOThmL3RhYmxlcmFuZ2U6ZGEyYmIyMTI0ZjJkNDI4Njg5MTcxNzk1YjhiYmY5OGZfMTgtMy0xLTEtMA_dc268d5b-0f05-402e-98db-5b05b75d01a9">0.55</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted average number of shares outstanding, basic and diluted</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xOS9mcmFnOjU2Y2EwZjE3OWFiNTQ3M2VhZGFlZDM5NjQxYjQ1NzhkL3RhYmxlOmRhMmJiMjEyNGYyZDQyODY4OTE3MTc5NWI4YmJmOThmL3RhYmxlcmFuZ2U6ZGEyYmIyMTI0ZjJkNDI4Njg5MTcxNzk1YjhiYmY5OGZfMTktMS0xLTEtMA_3f570753-c7b7-490a-8f0b-cc526cba4531"><ix:nonFraction unitRef="shares" contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xOS9mcmFnOjU2Y2EwZjE3OWFiNTQ3M2VhZGFlZDM5NjQxYjQ1NzhkL3RhYmxlOmRhMmJiMjEyNGYyZDQyODY4OTE3MTc5NWI4YmJmOThmL3RhYmxlcmFuZ2U6ZGEyYmIyMTI0ZjJkNDI4Njg5MTcxNzk1YjhiYmY5OGZfMTktMS0xLTEtMA_75e87f16-ec01-4604-a3eb-b793f78036d7">120,884,665</ix:nonFraction></ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia34dfea6b8734d64abf707c28256801c_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xOS9mcmFnOjU2Y2EwZjE3OWFiNTQ3M2VhZGFlZDM5NjQxYjQ1NzhkL3RhYmxlOmRhMmJiMjEyNGYyZDQyODY4OTE3MTc5NWI4YmJmOThmL3RhYmxlcmFuZ2U6ZGEyYmIyMTI0ZjJkNDI4Njg5MTcxNzk1YjhiYmY5OGZfMTktMy0xLTEtMA_60e45f11-b1b1-447f-82a1-2f62e5730233"><ix:nonFraction unitRef="shares" contextRef="ia34dfea6b8734d64abf707c28256801c_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xOS9mcmFnOjU2Y2EwZjE3OWFiNTQ3M2VhZGFlZDM5NjQxYjQ1NzhkL3RhYmxlOmRhMmJiMjEyNGYyZDQyODY4OTE3MTc5NWI4YmJmOThmL3RhYmxlcmFuZ2U6ZGEyYmIyMTI0ZjJkNDI4Njg5MTcxNzk1YjhiYmY5OGZfMTktMy0xLTEtMA_e71a2566-eeac-462d-9166-3e90685e0b2d">102,419,718</ix:nonFraction></ix:nonFraction></span></td></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:120%">__________________________________________________</span></div><div style="margin-top:4pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10.69pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xOS9mcmFnOjU2Y2EwZjE3OWFiNTQ3M2VhZGFlZDM5NjQxYjQ1NzhkL3RleHRyZWdpb246NTZjYTBmMTc5YWI1NDczZWFkYWVkMzk2NDFiNDU3OGRfNDM5ODA0NjUxMTg1NQ_863ec15a-a62e-4021-bc98-1a2980c27a3f" footnoteRole="http://www.xbrl.org/2003/role/footnote">Includes related party collaboration revenue from customer of $<ix:nonFraction unitRef="usd" contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromRelatedParties" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xOS9mcmFnOjU2Y2EwZjE3OWFiNTQ3M2VhZGFlZDM5NjQxYjQ1NzhkL3RleHRyZWdpb246NTZjYTBmMTc5YWI1NDczZWFkYWVkMzk2NDFiNDU3OGRfMTA5OTUxMTYyODI0OA_dc54ec58-a372-45cb-be75-971226cedec6">0.9</ix:nonFraction>&#160;million for the three months ended March 31, 2021.</ix:footnote></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10.69pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xOS9mcmFnOjU2Y2EwZjE3OWFiNTQ3M2VhZGFlZDM5NjQxYjQ1NzhkL3RleHRyZWdpb246NTZjYTBmMTc5YWI1NDczZWFkYWVkMzk2NDFiNDU3OGRfNDM5ODA0NjUxMTg1Ng_76fefc42-6d2b-4030-95d8-128d6d256c4f" footnoteRole="http://www.xbrl.org/2003/role/footnote">Includes an offset to expense from related party cost reimbursement of $<ix:nonFraction unitRef="usd" contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="dnli:ResearchAndDevelopmentExpenseOffsetFromRelatedPartyCostReimbursement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xOS9mcmFnOjU2Y2EwZjE3OWFiNTQ3M2VhZGFlZDM5NjQxYjQ1NzhkL3RleHRyZWdpb246NTZjYTBmMTc5YWI1NDczZWFkYWVkMzk2NDFiNDU3OGRfMTA5OTUxMTYyODI2MA_dbb3c119-6678-4bf7-9532-ca97b065d2a9">2.5</ix:nonFraction>&#160;million for the three months ended March 31, 2021.</ix:footnote></span></div><div style="text-align:center;text-indent:4.5pt"><span><br/></span></div><div style="margin-top:12pt;text-align:center;text-indent:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to unaudited condensed consolidated financial statements.</span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center;text-indent:27pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="i5ae1cfc88aa4492caf56e9d4ac91e096_22"></div><hr style="page-break-after:always"/><div style="min-height:29.25pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5ae1cfc88aa4492caf56e9d4ac91e096_7">Table of Contents</a></span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Denali Therapeutics Inc.</span></div><div style="margin-top:6pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Stockholders&#8217; Equity</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-bottom:8pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except share amounts)</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:27.906%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:9.156%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.752%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.996%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.919%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.723%"></td><td style="width:0.1%"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional Paid-in Capital</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Income (Loss)</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Deficit</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Stockholders' Equity</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6b1694c4d5a44ff2b0218864ff3535bb_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yMi9mcmFnOjY1NDQ3MWYzNDY0OTRiYmRiMTQ3ZWJmZjQ0ZjE5NDAzL3RhYmxlOjFlNDMxNWRlMDJjZDRjYTE5OGYyZjc0Y2RiYTlkOGJlL3RhYmxlcmFuZ2U6MWU0MzE1ZGUwMmNkNGNhMTk4ZjJmNzRjZGJhOWQ4YmVfMi02LTEtMS0w_29248d0a-8ef0-4c9a-8a9e-83a5070f137c">120,531,333</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b1694c4d5a44ff2b0218864ff3535bb_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yMi9mcmFnOjY1NDQ3MWYzNDY0OTRiYmRiMTQ3ZWJmZjQ0ZjE5NDAzL3RhYmxlOjFlNDMxNWRlMDJjZDRjYTE5OGYyZjc0Y2RiYTlkOGJlL3RhYmxlcmFuZ2U6MWU0MzE1ZGUwMmNkNGNhMTk4ZjJmNzRjZGJhOWQ4YmVfMi04LTEtMS0w_ccd89bfd-c35a-4106-bbec-1c2d39c4a05e">1,531</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1182c403bed14f779ebd3c5cf55f280c_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yMi9mcmFnOjY1NDQ3MWYzNDY0OTRiYmRiMTQ3ZWJmZjQ0ZjE5NDAzL3RhYmxlOjFlNDMxNWRlMDJjZDRjYTE5OGYyZjc0Y2RiYTlkOGJlL3RhYmxlcmFuZ2U6MWU0MzE1ZGUwMmNkNGNhMTk4ZjJmNzRjZGJhOWQ4YmVfMi0xMC0xLTEtMA_f36d8d23-65c7-41d5-ac64-15ec81a366fb">1,503,660</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e68706d6d7742388257b82fc7c16d8d_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yMi9mcmFnOjY1NDQ3MWYzNDY0OTRiYmRiMTQ3ZWJmZjQ0ZjE5NDAzL3RhYmxlOjFlNDMxNWRlMDJjZDRjYTE5OGYyZjc0Y2RiYTlkOGJlL3RhYmxlcmFuZ2U6MWU0MzE1ZGUwMmNkNGNhMTk4ZjJmNzRjZGJhOWQ4YmVfMi0xMi0xLTEtMA_6facecc0-e60b-4203-ae8f-161f1f03a340">245</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibe96d84e0a5e425bab91f9c7441e0d1d_I20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yMi9mcmFnOjY1NDQ3MWYzNDY0OTRiYmRiMTQ3ZWJmZjQ0ZjE5NDAzL3RhYmxlOjFlNDMxNWRlMDJjZDRjYTE5OGYyZjc0Y2RiYTlkOGJlL3RhYmxlcmFuZ2U6MWU0MzE1ZGUwMmNkNGNhMTk4ZjJmNzRjZGJhOWQ4YmVfMi0xNC0xLTEtMA_b8f6176c-98bf-4290-ad16-085106a238e6">354,415</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb7ca9f362da46eab3a29bbbecbda977_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yMi9mcmFnOjY1NDQ3MWYzNDY0OTRiYmRiMTQ3ZWJmZjQ0ZjE5NDAzL3RhYmxlOjFlNDMxNWRlMDJjZDRjYTE5OGYyZjc0Y2RiYTlkOGJlL3RhYmxlcmFuZ2U6MWU0MzE1ZGUwMmNkNGNhMTk4ZjJmNzRjZGJhOWQ4YmVfMi0xNi0xLTEtMA_9f66c4a8-1655-4c37-851a-107f26938f1e">1,150,531</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:23.98pt;text-indent:-12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuances under equity incentive plans</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3cc86f0bf14143f4ae8b3600808a8b8e_D20210101-20210331" decimals="INF" format="ixt:numdotdecimal" name="dnli:StockIssuedDuringPeriodSharesEquityIncentivePlan" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yMi9mcmFnOjY1NDQ3MWYzNDY0OTRiYmRiMTQ3ZWJmZjQ0ZjE5NDAzL3RhYmxlOjFlNDMxNWRlMDJjZDRjYTE5OGYyZjc0Y2RiYTlkOGJlL3RhYmxlcmFuZ2U6MWU0MzE1ZGUwMmNkNGNhMTk4ZjJmNzRjZGJhOWQ4YmVfNS02LTEtMS0w_bfa9de0b-d9e6-4e34-811e-c3ab3cce402b">334,634</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cc86f0bf14143f4ae8b3600808a8b8e_D20210101-20210331" decimals="-3" name="dnli:StockIssuedDuringPeriodValueEquityIncentivePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yMi9mcmFnOjY1NDQ3MWYzNDY0OTRiYmRiMTQ3ZWJmZjQ0ZjE5NDAzL3RhYmxlOjFlNDMxNWRlMDJjZDRjYTE5OGYyZjc0Y2RiYTlkOGJlL3RhYmxlcmFuZ2U6MWU0MzE1ZGUwMmNkNGNhMTk4ZjJmNzRjZGJhOWQ4YmVfNS04LTEtMS0w_4b81b4ed-5514-4d4d-bb7f-b87d7ae9ef29">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i512d7365f8ba4cffa29eb6d1a746e90d_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="dnli:StockIssuedDuringPeriodValueEquityIncentivePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yMi9mcmFnOjY1NDQ3MWYzNDY0OTRiYmRiMTQ3ZWJmZjQ0ZjE5NDAzL3RhYmxlOjFlNDMxNWRlMDJjZDRjYTE5OGYyZjc0Y2RiYTlkOGJlL3RhYmxlcmFuZ2U6MWU0MzE1ZGUwMmNkNGNhMTk4ZjJmNzRjZGJhOWQ4YmVfNS0xMC0xLTEtMA_9165fba1-9803-4e07-8372-a7af6db5879a">3,819</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="dnli:StockIssuedDuringPeriodValueEquityIncentivePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yMi9mcmFnOjY1NDQ3MWYzNDY0OTRiYmRiMTQ3ZWJmZjQ0ZjE5NDAzL3RhYmxlOjFlNDMxNWRlMDJjZDRjYTE5OGYyZjc0Y2RiYTlkOGJlL3RhYmxlcmFuZ2U6MWU0MzE1ZGUwMmNkNGNhMTk4ZjJmNzRjZGJhOWQ4YmVfNS0xNi0xLTEtMA_32042ec5-5bd9-4391-b078-0aa72070b021">3,822</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:23.98pt;text-indent:-12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vesting of restricted stock units</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3cc86f0bf14143f4ae8b3600808a8b8e_D20210101-20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yMi9mcmFnOjY1NDQ3MWYzNDY0OTRiYmRiMTQ3ZWJmZjQ0ZjE5NDAzL3RhYmxlOjFlNDMxNWRlMDJjZDRjYTE5OGYyZjc0Y2RiYTlkOGJlL3RhYmxlcmFuZ2U6MWU0MzE1ZGUwMmNkNGNhMTk4ZjJmNzRjZGJhOWQ4YmVfNi02LTEtMS0w_067a147e-cd9e-44b3-b13b-356e1a7e2239">281,465</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cc86f0bf14143f4ae8b3600808a8b8e_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yMi9mcmFnOjY1NDQ3MWYzNDY0OTRiYmRiMTQ3ZWJmZjQ0ZjE5NDAzL3RhYmxlOjFlNDMxNWRlMDJjZDRjYTE5OGYyZjc0Y2RiYTlkOGJlL3RhYmxlcmFuZ2U6MWU0MzE1ZGUwMmNkNGNhMTk4ZjJmNzRjZGJhOWQ4YmVfNi04LTEtMS0w_87754892-d034-4068-90d8-e2a06160d9d3">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i512d7365f8ba4cffa29eb6d1a746e90d_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yMi9mcmFnOjY1NDQ3MWYzNDY0OTRiYmRiMTQ3ZWJmZjQ0ZjE5NDAzL3RhYmxlOjFlNDMxNWRlMDJjZDRjYTE5OGYyZjc0Y2RiYTlkOGJlL3RhYmxlcmFuZ2U6MWU0MzE1ZGUwMmNkNGNhMTk4ZjJmNzRjZGJhOWQ4YmVfNi0xMC0xLTEtMA_a26a767f-18aa-4b91-bf43-fc854f8ca96b">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yMi9mcmFnOjY1NDQ3MWYzNDY0OTRiYmRiMTQ3ZWJmZjQ0ZjE5NDAzL3RhYmxlOjFlNDMxNWRlMDJjZDRjYTE5OGYyZjc0Y2RiYTlkOGJlL3RhYmxlcmFuZ2U6MWU0MzE1ZGUwMmNkNGNhMTk4ZjJmNzRjZGJhOWQ4YmVfNi0xNi0xLTEtMA_d5c50f63-8fd9-4215-b0ff-004b302c1e76">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:23.98pt;text-indent:-12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i512d7365f8ba4cffa29eb6d1a746e90d_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yMi9mcmFnOjY1NDQ3MWYzNDY0OTRiYmRiMTQ3ZWJmZjQ0ZjE5NDAzL3RhYmxlOjFlNDMxNWRlMDJjZDRjYTE5OGYyZjc0Y2RiYTlkOGJlL3RhYmxlcmFuZ2U6MWU0MzE1ZGUwMmNkNGNhMTk4ZjJmNzRjZGJhOWQ4YmVfNy0xMC0xLTEtMA_562891cf-9f89-4c15-9182-69cd5e3deb23">21,028</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yMi9mcmFnOjY1NDQ3MWYzNDY0OTRiYmRiMTQ3ZWJmZjQ0ZjE5NDAzL3RhYmxlOjFlNDMxNWRlMDJjZDRjYTE5OGYyZjc0Y2RiYTlkOGJlL3RhYmxlcmFuZ2U6MWU0MzE1ZGUwMmNkNGNhMTk4ZjJmNzRjZGJhOWQ4YmVfNy0xNi0xLTEtMA_ffe52130-b5da-46dd-a2d5-7833a69c6435">21,028</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:23.98pt;text-indent:-12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8f89be0032cd49c2b7c0a19693e48b5c_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yMi9mcmFnOjY1NDQ3MWYzNDY0OTRiYmRiMTQ3ZWJmZjQ0ZjE5NDAzL3RhYmxlOjFlNDMxNWRlMDJjZDRjYTE5OGYyZjc0Y2RiYTlkOGJlL3RhYmxlcmFuZ2U6MWU0MzE1ZGUwMmNkNGNhMTk4ZjJmNzRjZGJhOWQ4YmVfOC0xNC0xLTEtMA_0ec6960f-4f01-4a43-8e9f-56b053631b96">70,041</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yMi9mcmFnOjY1NDQ3MWYzNDY0OTRiYmRiMTQ3ZWJmZjQ0ZjE5NDAzL3RhYmxlOjFlNDMxNWRlMDJjZDRjYTE5OGYyZjc0Y2RiYTlkOGJlL3RhYmxlcmFuZ2U6MWU0MzE1ZGUwMmNkNGNhMTk4ZjJmNzRjZGJhOWQ4YmVfOC0xNi0xLTEtMA_45e86b11-6b09-47c5-b7f4-cb3cde0f5f6b">70,041</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.98pt;text-align:left;text-indent:-12pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8017a7d7e9414d9cac2f173a2d4a39dc_D20210101-20210331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yMi9mcmFnOjY1NDQ3MWYzNDY0OTRiYmRiMTQ3ZWJmZjQ0ZjE5NDAzL3RhYmxlOjFlNDMxNWRlMDJjZDRjYTE5OGYyZjc0Y2RiYTlkOGJlL3RhYmxlcmFuZ2U6MWU0MzE1ZGUwMmNkNGNhMTk4ZjJmNzRjZGJhOWQ4YmVfOS0xMi0xLTEtMA_4b217e53-0425-4fe0-8e4c-9a059e41c569">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yMi9mcmFnOjY1NDQ3MWYzNDY0OTRiYmRiMTQ3ZWJmZjQ0ZjE5NDAzL3RhYmxlOjFlNDMxNWRlMDJjZDRjYTE5OGYyZjc0Y2RiYTlkOGJlL3RhYmxlcmFuZ2U6MWU0MzE1ZGUwMmNkNGNhMTk4ZjJmNzRjZGJhOWQ4YmVfOS0xNi0xLTEtMA_893039b3-684d-4c9a-b7fe-7e854b0eec5e">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at March 31, 2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6881ec9f4b804f8bb0b380a22e0d14bc_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yMi9mcmFnOjY1NDQ3MWYzNDY0OTRiYmRiMTQ3ZWJmZjQ0ZjE5NDAzL3RhYmxlOjFlNDMxNWRlMDJjZDRjYTE5OGYyZjc0Y2RiYTlkOGJlL3RhYmxlcmFuZ2U6MWU0MzE1ZGUwMmNkNGNhMTk4ZjJmNzRjZGJhOWQ4YmVfMTAtNi0xLTEtMA_e5fcf46c-c85b-4efb-96e8-101e262ef6f7">121,147,432</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6881ec9f4b804f8bb0b380a22e0d14bc_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yMi9mcmFnOjY1NDQ3MWYzNDY0OTRiYmRiMTQ3ZWJmZjQ0ZjE5NDAzL3RhYmxlOjFlNDMxNWRlMDJjZDRjYTE5OGYyZjc0Y2RiYTlkOGJlL3RhYmxlcmFuZ2U6MWU0MzE1ZGUwMmNkNGNhMTk4ZjJmNzRjZGJhOWQ4YmVfMTAtOC0xLTEtMA_1bb9ec45-a6ad-4df1-ad78-610bd957170f">1,537</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab67b1cb96b04f5eae11176694e59a6b_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yMi9mcmFnOjY1NDQ3MWYzNDY0OTRiYmRiMTQ3ZWJmZjQ0ZjE5NDAzL3RhYmxlOjFlNDMxNWRlMDJjZDRjYTE5OGYyZjc0Y2RiYTlkOGJlL3RhYmxlcmFuZ2U6MWU0MzE1ZGUwMmNkNGNhMTk4ZjJmNzRjZGJhOWQ4YmVfMTAtMTAtMS0xLTA_0c263fb2-00ff-4fa1-83f4-852165509dbe">1,528,504</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8faf25a1f5264f7bbd65f096a2d9a464_I20210331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yMi9mcmFnOjY1NDQ3MWYzNDY0OTRiYmRiMTQ3ZWJmZjQ0ZjE5NDAzL3RhYmxlOjFlNDMxNWRlMDJjZDRjYTE5OGYyZjc0Y2RiYTlkOGJlL3RhYmxlcmFuZ2U6MWU0MzE1ZGUwMmNkNGNhMTk4ZjJmNzRjZGJhOWQ4YmVfMTAtMTItMS0xLTA_cbf83a62-bb9c-4f5b-a37f-f77f29b0845b">232</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2d9b04bba6cb45aab3777466d4b29061_I20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yMi9mcmFnOjY1NDQ3MWYzNDY0OTRiYmRiMTQ3ZWJmZjQ0ZjE5NDAzL3RhYmxlOjFlNDMxNWRlMDJjZDRjYTE5OGYyZjc0Y2RiYTlkOGJlL3RhYmxlcmFuZ2U6MWU0MzE1ZGUwMmNkNGNhMTk4ZjJmNzRjZGJhOWQ4YmVfMTAtMTQtMS0xLTA_ca464809-6370-46a1-a996-51d4ff062d60">424,456</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9953f50a7fd74f7d8438f304f136a07b_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yMi9mcmFnOjY1NDQ3MWYzNDY0OTRiYmRiMTQ3ZWJmZjQ0ZjE5NDAzL3RhYmxlOjFlNDMxNWRlMDJjZDRjYTE5OGYyZjc0Y2RiYTlkOGJlL3RhYmxlcmFuZ2U6MWU0MzE1ZGUwMmNkNGNhMTk4ZjJmNzRjZGJhOWQ4YmVfMTAtMTYtMS0xLTA_618de84b-219d-47a8-ac92-f085bc1b721c">1,105,353</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December 31, 2019</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if9deb2734a184a7cbde40db4324e7d19_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yMi9mcmFnOjY1NDQ3MWYzNDY0OTRiYmRiMTQ3ZWJmZjQ0ZjE5NDAzL3RhYmxlOjFlNDMxNWRlMDJjZDRjYTE5OGYyZjc0Y2RiYTlkOGJlL3RhYmxlcmFuZ2U6MWU0MzE1ZGUwMmNkNGNhMTk4ZjJmNzRjZGJhOWQ4YmVfMjEtNi0xLTEtMA_b22abb3b-ea23-40c8-8618-d24b4b08ceff">96,189,935</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9deb2734a184a7cbde40db4324e7d19_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yMi9mcmFnOjY1NDQ3MWYzNDY0OTRiYmRiMTQ3ZWJmZjQ0ZjE5NDAzL3RhYmxlOjFlNDMxNWRlMDJjZDRjYTE5OGYyZjc0Y2RiYTlkOGJlL3RhYmxlcmFuZ2U6MWU0MzE1ZGUwMmNkNGNhMTk4ZjJmNzRjZGJhOWQ4YmVfMjEtOC0xLTEtMA_1dd51a71-88ba-4042-83d9-cbda382a0017">1,288</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3061e69973345b0a814850b46a1e70d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yMi9mcmFnOjY1NDQ3MWYzNDY0OTRiYmRiMTQ3ZWJmZjQ0ZjE5NDAzL3RhYmxlOjFlNDMxNWRlMDJjZDRjYTE5OGYyZjc0Y2RiYTlkOGJlL3RhYmxlcmFuZ2U6MWU0MzE1ZGUwMmNkNGNhMTk4ZjJmNzRjZGJhOWQ4YmVfMjEtMTAtMS0xLTA_de9f6877-4b44-4c9b-9747-8b49777c4c75">818,803</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fc2ea20a15f4358958ac2de513cbedf_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yMi9mcmFnOjY1NDQ3MWYzNDY0OTRiYmRiMTQ3ZWJmZjQ0ZjE5NDAzL3RhYmxlOjFlNDMxNWRlMDJjZDRjYTE5OGYyZjc0Y2RiYTlkOGJlL3RhYmxlcmFuZ2U6MWU0MzE1ZGUwMmNkNGNhMTk4ZjJmNzRjZGJhOWQ4YmVfMjEtMTItMS0xLTA_613a03e7-db8a-43bd-b8a6-d256d7fafeff">350</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4f05e20d565c4dec84e3cf8ab862dd61_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yMi9mcmFnOjY1NDQ3MWYzNDY0OTRiYmRiMTQ3ZWJmZjQ0ZjE5NDAzL3RhYmxlOjFlNDMxNWRlMDJjZDRjYTE5OGYyZjc0Y2RiYTlkOGJlL3RhYmxlcmFuZ2U6MWU0MzE1ZGUwMmNkNGNhMTk4ZjJmNzRjZGJhOWQ4YmVfMjEtMTQtMS0xLTA_5a54e031-d00b-418c-ad60-d570923c3b31">425,551</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id36b0e599cb3498a8671e8c185763bc9_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yMi9mcmFnOjY1NDQ3MWYzNDY0OTRiYmRiMTQ3ZWJmZjQ0ZjE5NDAzL3RhYmxlOjFlNDMxNWRlMDJjZDRjYTE5OGYyZjc0Y2RiYTlkOGJlL3RhYmxlcmFuZ2U6MWU0MzE1ZGUwMmNkNGNhMTk4ZjJmNzRjZGJhOWQ4YmVfMjEtMTYtMS0xLTA_8bf3624f-9f66-4ded-acc4-cf9fc504472b">394,890</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:24pt;text-indent:-12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock in follow-on offering, net of issuance costs of $<ix:nonFraction unitRef="usd" contextRef="ia63b42181ffa4fb5aa0692f27bc204e4_D20200101-20200331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yMi9mcmFnOjY1NDQ3MWYzNDY0OTRiYmRiMTQ3ZWJmZjQ0ZjE5NDAzL3RhYmxlOjFlNDMxNWRlMDJjZDRjYTE5OGYyZjc0Y2RiYTlkOGJlL3RhYmxlcmFuZ2U6MWU0MzE1ZGUwMmNkNGNhMTk4ZjJmNzRjZGJhOWQ4YmVfMTItMC0xLTEtOTYvdGV4dHJlZ2lvbjphMTNmZDhmYjMwOWM0YjY5YmMxZTAzYmUyMzU3MGFiNF8xMDk5NTExNjI3ODYw_e3299929-72b3-42c9-977f-f368290ddb79">632</ix:nonFraction></span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia63b42181ffa4fb5aa0692f27bc204e4_D20200101-20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yMi9mcmFnOjY1NDQ3MWYzNDY0OTRiYmRiMTQ3ZWJmZjQ0ZjE5NDAzL3RhYmxlOjFlNDMxNWRlMDJjZDRjYTE5OGYyZjc0Y2RiYTlkOGJlL3RhYmxlcmFuZ2U6MWU0MzE1ZGUwMmNkNGNhMTk4ZjJmNzRjZGJhOWQ4YmVfMTItNi0xLTEtOTA_7014afcd-d930-462f-8f65-7b5150501fe6">9,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia63b42181ffa4fb5aa0692f27bc204e4_D20200101-20200331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yMi9mcmFnOjY1NDQ3MWYzNDY0OTRiYmRiMTQ3ZWJmZjQ0ZjE5NDAzL3RhYmxlOjFlNDMxNWRlMDJjZDRjYTE5OGYyZjc0Y2RiYTlkOGJlL3RhYmxlcmFuZ2U6MWU0MzE1ZGUwMmNkNGNhMTk4ZjJmNzRjZGJhOWQ4YmVfMTItOC0xLTEtOTk_bce0cddf-296e-42ee-b40d-f20c5df924bd">90</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i481b7d29f5714b2c9591d38d45fb69a2_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yMi9mcmFnOjY1NDQ3MWYzNDY0OTRiYmRiMTQ3ZWJmZjQ0ZjE5NDAzL3RhYmxlOjFlNDMxNWRlMDJjZDRjYTE5OGYyZjc0Y2RiYTlkOGJlL3RhYmxlcmFuZ2U6MWU0MzE1ZGUwMmNkNGNhMTk4ZjJmNzRjZGJhOWQ4YmVfMTItMTAtMS0xLTEwMw_27ee5563-fdbd-4d16-b76a-3eff1adeed83">193,858</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia34dfea6b8734d64abf707c28256801c_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yMi9mcmFnOjY1NDQ3MWYzNDY0OTRiYmRiMTQ3ZWJmZjQ0ZjE5NDAzL3RhYmxlOjFlNDMxNWRlMDJjZDRjYTE5OGYyZjc0Y2RiYTlkOGJlL3RhYmxlcmFuZ2U6MWU0MzE1ZGUwMmNkNGNhMTk4ZjJmNzRjZGJhOWQ4YmVfMTItMTYtMS0xLTExNg_e6cab4cc-4f62-460e-94a7-5c604b536e3a">193,948</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:23.98pt;text-indent:-12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuances under equity incentive plans</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia63b42181ffa4fb5aa0692f27bc204e4_D20200101-20200331" decimals="INF" format="ixt:numdotdecimal" name="dnli:StockIssuedDuringPeriodSharesEquityIncentivePlan" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yMi9mcmFnOjY1NDQ3MWYzNDY0OTRiYmRiMTQ3ZWJmZjQ0ZjE5NDAzL3RhYmxlOjFlNDMxNWRlMDJjZDRjYTE5OGYyZjc0Y2RiYTlkOGJlL3RhYmxlcmFuZ2U6MWU0MzE1ZGUwMmNkNGNhMTk4ZjJmNzRjZGJhOWQ4YmVfMjItNi0xLTEtMA_12b466d1-02ac-4cd2-9471-1347e5de26a0">259,569</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia63b42181ffa4fb5aa0692f27bc204e4_D20200101-20200331" decimals="-3" name="dnli:StockIssuedDuringPeriodValueEquityIncentivePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yMi9mcmFnOjY1NDQ3MWYzNDY0OTRiYmRiMTQ3ZWJmZjQ0ZjE5NDAzL3RhYmxlOjFlNDMxNWRlMDJjZDRjYTE5OGYyZjc0Y2RiYTlkOGJlL3RhYmxlcmFuZ2U6MWU0MzE1ZGUwMmNkNGNhMTk4ZjJmNzRjZGJhOWQ4YmVfMjItOC0xLTEtMA_abc9de20-4327-4cc6-9464-16003f71f938">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i481b7d29f5714b2c9591d38d45fb69a2_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="dnli:StockIssuedDuringPeriodValueEquityIncentivePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yMi9mcmFnOjY1NDQ3MWYzNDY0OTRiYmRiMTQ3ZWJmZjQ0ZjE5NDAzL3RhYmxlOjFlNDMxNWRlMDJjZDRjYTE5OGYyZjc0Y2RiYTlkOGJlL3RhYmxlcmFuZ2U6MWU0MzE1ZGUwMmNkNGNhMTk4ZjJmNzRjZGJhOWQ4YmVfMjItMTAtMS0xLTA_bf2af1b7-384d-4f8e-b9dd-4fa6bb11daca">1,963</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia34dfea6b8734d64abf707c28256801c_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="dnli:StockIssuedDuringPeriodValueEquityIncentivePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yMi9mcmFnOjY1NDQ3MWYzNDY0OTRiYmRiMTQ3ZWJmZjQ0ZjE5NDAzL3RhYmxlOjFlNDMxNWRlMDJjZDRjYTE5OGYyZjc0Y2RiYTlkOGJlL3RhYmxlcmFuZ2U6MWU0MzE1ZGUwMmNkNGNhMTk4ZjJmNzRjZGJhOWQ4YmVfMjItMTYtMS0xLTA_a64a45ff-ab25-40c4-b9d1-283e0536929a">1,966</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.98pt;text-align:left;text-indent:-12pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vesting of restricted stock units</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia63b42181ffa4fb5aa0692f27bc204e4_D20200101-20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yMi9mcmFnOjY1NDQ3MWYzNDY0OTRiYmRiMTQ3ZWJmZjQ0ZjE5NDAzL3RhYmxlOjFlNDMxNWRlMDJjZDRjYTE5OGYyZjc0Y2RiYTlkOGJlL3RhYmxlcmFuZ2U6MWU0MzE1ZGUwMmNkNGNhMTk4ZjJmNzRjZGJhOWQ4YmVfMjQtNi0xLTEtMA_99f809a2-9254-429b-8b7e-5b8b24d0f316">91,839</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia63b42181ffa4fb5aa0692f27bc204e4_D20200101-20200331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yMi9mcmFnOjY1NDQ3MWYzNDY0OTRiYmRiMTQ3ZWJmZjQ0ZjE5NDAzL3RhYmxlOjFlNDMxNWRlMDJjZDRjYTE5OGYyZjc0Y2RiYTlkOGJlL3RhYmxlcmFuZ2U6MWU0MzE1ZGUwMmNkNGNhMTk4ZjJmNzRjZGJhOWQ4YmVfMjQtOC0xLTEtMA_1461024e-26f9-4825-ac7b-e37753bafee4">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i481b7d29f5714b2c9591d38d45fb69a2_D20200101-20200331" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yMi9mcmFnOjY1NDQ3MWYzNDY0OTRiYmRiMTQ3ZWJmZjQ0ZjE5NDAzL3RhYmxlOjFlNDMxNWRlMDJjZDRjYTE5OGYyZjc0Y2RiYTlkOGJlL3RhYmxlcmFuZ2U6MWU0MzE1ZGUwMmNkNGNhMTk4ZjJmNzRjZGJhOWQ4YmVfMjQtMTAtMS0xLTA_dd804ac5-dc37-4773-b072-8023c6d86a92">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia34dfea6b8734d64abf707c28256801c_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yMi9mcmFnOjY1NDQ3MWYzNDY0OTRiYmRiMTQ3ZWJmZjQ0ZjE5NDAzL3RhYmxlOjFlNDMxNWRlMDJjZDRjYTE5OGYyZjc0Y2RiYTlkOGJlL3RhYmxlcmFuZ2U6MWU0MzE1ZGUwMmNkNGNhMTk4ZjJmNzRjZGJhOWQ4YmVfMjQtMTYtMS0xLTA_a88dabe0-d28b-4d5c-839e-ec348164d7a1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:23.98pt;text-indent:-12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i481b7d29f5714b2c9591d38d45fb69a2_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yMi9mcmFnOjY1NDQ3MWYzNDY0OTRiYmRiMTQ3ZWJmZjQ0ZjE5NDAzL3RhYmxlOjFlNDMxNWRlMDJjZDRjYTE5OGYyZjc0Y2RiYTlkOGJlL3RhYmxlcmFuZ2U6MWU0MzE1ZGUwMmNkNGNhMTk4ZjJmNzRjZGJhOWQ4YmVfMjUtMTAtMS0xLTA_3e9b02fd-61ac-4af5-b836-fc3011ba6777">10,785</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia34dfea6b8734d64abf707c28256801c_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yMi9mcmFnOjY1NDQ3MWYzNDY0OTRiYmRiMTQ3ZWJmZjQ0ZjE5NDAzL3RhYmxlOjFlNDMxNWRlMDJjZDRjYTE5OGYyZjc0Y2RiYTlkOGJlL3RhYmxlcmFuZ2U6MWU0MzE1ZGUwMmNkNGNhMTk4ZjJmNzRjZGJhOWQ4YmVfMjUtMTYtMS0xLTA_e6b943bf-1622-456b-9275-b8b65e430886">10,785</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:23.98pt;text-indent:-12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idc9c2fd3102f4601910401b0065ccdee_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yMi9mcmFnOjY1NDQ3MWYzNDY0OTRiYmRiMTQ3ZWJmZjQ0ZjE5NDAzL3RhYmxlOjFlNDMxNWRlMDJjZDRjYTE5OGYyZjc0Y2RiYTlkOGJlL3RhYmxlcmFuZ2U6MWU0MzE1ZGUwMmNkNGNhMTk4ZjJmNzRjZGJhOWQ4YmVfMjYtMTQtMS0xLTA_83dccb88-bbac-46ac-a99a-395247c15806">56,763</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia34dfea6b8734d64abf707c28256801c_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yMi9mcmFnOjY1NDQ3MWYzNDY0OTRiYmRiMTQ3ZWJmZjQ0ZjE5NDAzL3RhYmxlOjFlNDMxNWRlMDJjZDRjYTE5OGYyZjc0Y2RiYTlkOGJlL3RhYmxlcmFuZ2U6MWU0MzE1ZGUwMmNkNGNhMTk4ZjJmNzRjZGJhOWQ4YmVfMjYtMTYtMS0xLTA_5e2be81f-d640-4b8b-8c9d-5967fc9d36d8">56,763</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:23.98pt;text-indent:-12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5462764077c54d46b830279d94f82af0_D20200101-20200331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yMi9mcmFnOjY1NDQ3MWYzNDY0OTRiYmRiMTQ3ZWJmZjQ0ZjE5NDAzL3RhYmxlOjFlNDMxNWRlMDJjZDRjYTE5OGYyZjc0Y2RiYTlkOGJlL3RhYmxlcmFuZ2U6MWU0MzE1ZGUwMmNkNGNhMTk4ZjJmNzRjZGJhOWQ4YmVfMjctMTItMS0xLTA_57344729-b204-4f57-8894-4950cae9a27b">485</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia34dfea6b8734d64abf707c28256801c_D20200101-20200331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yMi9mcmFnOjY1NDQ3MWYzNDY0OTRiYmRiMTQ3ZWJmZjQ0ZjE5NDAzL3RhYmxlOjFlNDMxNWRlMDJjZDRjYTE5OGYyZjc0Y2RiYTlkOGJlL3RhYmxlcmFuZ2U6MWU0MzE1ZGUwMmNkNGNhMTk4ZjJmNzRjZGJhOWQ4YmVfMjctMTYtMS0xLTA_56649749-e264-4478-9438-7f4d9d61e585">485</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at March 31, 2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9e6a5f965fc64fdc84e37350364784a2_I20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yMi9mcmFnOjY1NDQ3MWYzNDY0OTRiYmRiMTQ3ZWJmZjQ0ZjE5NDAzL3RhYmxlOjFlNDMxNWRlMDJjZDRjYTE5OGYyZjc0Y2RiYTlkOGJlL3RhYmxlcmFuZ2U6MWU0MzE1ZGUwMmNkNGNhMTk4ZjJmNzRjZGJhOWQ4YmVfMjgtNi0xLTEtMA_9709761b-c127-460b-a982-57471be7fbe7">105,541,343</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e6a5f965fc64fdc84e37350364784a2_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yMi9mcmFnOjY1NDQ3MWYzNDY0OTRiYmRiMTQ3ZWJmZjQ0ZjE5NDAzL3RhYmxlOjFlNDMxNWRlMDJjZDRjYTE5OGYyZjc0Y2RiYTlkOGJlL3RhYmxlcmFuZ2U6MWU0MzE1ZGUwMmNkNGNhMTk4ZjJmNzRjZGJhOWQ4YmVfMjgtOC0xLTEtMA_0d6bb11a-352c-41a1-8517-665b66c9b9b2">1,382</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6acc176d0fde4b30bb04303aefe4c09c_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yMi9mcmFnOjY1NDQ3MWYzNDY0OTRiYmRiMTQ3ZWJmZjQ0ZjE5NDAzL3RhYmxlOjFlNDMxNWRlMDJjZDRjYTE5OGYyZjc0Y2RiYTlkOGJlL3RhYmxlcmFuZ2U6MWU0MzE1ZGUwMmNkNGNhMTk4ZjJmNzRjZGJhOWQ4YmVfMjgtMTAtMS0xLTA_4b2f283a-9bcf-4e9a-8246-7f7fba7c794e">1,025,408</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9160027ce4c429abb35b07016b25738_I20200331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yMi9mcmFnOjY1NDQ3MWYzNDY0OTRiYmRiMTQ3ZWJmZjQ0ZjE5NDAzL3RhYmxlOjFlNDMxNWRlMDJjZDRjYTE5OGYyZjc0Y2RiYTlkOGJlL3RhYmxlcmFuZ2U6MWU0MzE1ZGUwMmNkNGNhMTk4ZjJmNzRjZGJhOWQ4YmVfMjgtMTItMS0xLTA_4fe4ee48-261a-4d59-b9bb-f933bf2da640">835</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8288b3c6af7a4ceca6f0c97aa25994dc_I20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yMi9mcmFnOjY1NDQ3MWYzNDY0OTRiYmRiMTQ3ZWJmZjQ0ZjE5NDAzL3RhYmxlOjFlNDMxNWRlMDJjZDRjYTE5OGYyZjc0Y2RiYTlkOGJlL3RhYmxlcmFuZ2U6MWU0MzE1ZGUwMmNkNGNhMTk4ZjJmNzRjZGJhOWQ4YmVfMjgtMTQtMS0xLTA_b5a8b40d-b3d9-421f-a67a-64b4d3d5cfaa">482,314</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29b65d7585ff41c5843594c6319bdb90_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yMi9mcmFnOjY1NDQ3MWYzNDY0OTRiYmRiMTQ3ZWJmZjQ0ZjE5NDAzL3RhYmxlOjFlNDMxNWRlMDJjZDRjYTE5OGYyZjc0Y2RiYTlkOGJlL3RhYmxlcmFuZ2U6MWU0MzE1ZGUwMmNkNGNhMTk4ZjJmNzRjZGJhOWQ4YmVfMjgtMTYtMS0xLTA_9ed75f2d-0b38-414e-952a-9b879dc3817d">545,311</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to unaudited condensed consolidated financial statements.</span></div><div style="height:29.25pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="i5ae1cfc88aa4492caf56e9d4ac91e096_25"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5ae1cfc88aa4492caf56e9d4ac91e096_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Denali Therapeutics Inc.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Cash Flows</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands)</span></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.137%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.921%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.722%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating activities</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yNS9mcmFnOjYzZmYxMmI2NTFjMTRhMTRhNWZkYmE3ODczNzg3M2U5L3RhYmxlOmFiYWYwYmNlMzAxMjRmNTk4ZTE0MzdlNTRjMDY4NzZiL3RhYmxlcmFuZ2U6YWJhZjBiY2UzMDEyNGY1OThlMTQzN2U1NGMwNjg3NmJfMy0xLTEtMS0w_c003414c-99e6-4a43-ba1c-b6500d9fb0a6">70,041</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia34dfea6b8734d64abf707c28256801c_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yNS9mcmFnOjYzZmYxMmI2NTFjMTRhMTRhNWZkYmE3ODczNzg3M2U5L3RhYmxlOmFiYWYwYmNlMzAxMjRmNTk4ZTE0MzdlNTRjMDY4NzZiL3RhYmxlcmFuZ2U6YWJhZjBiY2UzMDEyNGY1OThlMTQzN2U1NGMwNjg3NmJfMy0zLTEtMS0w_b7ef8aee-2b36-4581-9646-0a25cb652c1b">56,763</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yNS9mcmFnOjYzZmYxMmI2NTFjMTRhMTRhNWZkYmE3ODczNzg3M2U5L3RhYmxlOmFiYWYwYmNlMzAxMjRmNTk4ZTE0MzdlNTRjMDY4NzZiL3RhYmxlcmFuZ2U6YWJhZjBiY2UzMDEyNGY1OThlMTQzN2U1NGMwNjg3NmJfNS0xLTEtMS0w_56d9cbee-e344-46d9-aee6-395011e1ceda">2,108</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia34dfea6b8734d64abf707c28256801c_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yNS9mcmFnOjYzZmYxMmI2NTFjMTRhMTRhNWZkYmE3ODczNzg3M2U5L3RhYmxlOmFiYWYwYmNlMzAxMjRmNTk4ZTE0MzdlNTRjMDY4NzZiL3RhYmxlcmFuZ2U6YWJhZjBiY2UzMDEyNGY1OThlMTQzN2U1NGMwNjg3NmJfNS0zLTEtMS0w_2489ca1f-bacb-49f3-b162-6ea80e633290">2,109</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock&#8211;based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yNS9mcmFnOjYzZmYxMmI2NTFjMTRhMTRhNWZkYmE3ODczNzg3M2U5L3RhYmxlOmFiYWYwYmNlMzAxMjRmNTk4ZTE0MzdlNTRjMDY4NzZiL3RhYmxlcmFuZ2U6YWJhZjBiY2UzMDEyNGY1OThlMTQzN2U1NGMwNjg3NmJfNi0xLTEtMS0w_80dd0011-a8ae-4f28-af66-98cc2d1ccd28">21,028</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia34dfea6b8734d64abf707c28256801c_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yNS9mcmFnOjYzZmYxMmI2NTFjMTRhMTRhNWZkYmE3ODczNzg3M2U5L3RhYmxlOmFiYWYwYmNlMzAxMjRmNTk4ZTE0MzdlNTRjMDY4NzZiL3RhYmxlcmFuZ2U6YWJhZjBiY2UzMDEyNGY1OThlMTQzN2U1NGMwNjg3NmJfNi0zLTEtMS0w_f010e005-2a39-4458-86df-96fdc8a56b9d">10,785</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net amortization of discounts on marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yNS9mcmFnOjYzZmYxMmI2NTFjMTRhMTRhNWZkYmE3ODczNzg3M2U5L3RhYmxlOmFiYWYwYmNlMzAxMjRmNTk4ZTE0MzdlNTRjMDY4NzZiL3RhYmxlcmFuZ2U6YWJhZjBiY2UzMDEyNGY1OThlMTQzN2U1NGMwNjg3NmJfNy0xLTEtMS0w_4520b146-a55e-47b8-8d13-ae11d9f5ad3a">1,161</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia34dfea6b8734d64abf707c28256801c_D20200101-20200331" decimals="-3" name="us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yNS9mcmFnOjYzZmYxMmI2NTFjMTRhMTRhNWZkYmE3ODczNzg3M2U5L3RhYmxlOmFiYWYwYmNlMzAxMjRmNTk4ZTE0MzdlNTRjMDY4NzZiL3RhYmxlcmFuZ2U6YWJhZjBiY2UzMDEyNGY1OThlMTQzN2U1NGMwNjg3NmJfNy0zLTEtMS0w_6d04180c-cffc-48a2-8e24-24a561658362">607</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-cash adjustment to operating lease expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331" decimals="-3" name="dnli:IncreaseDecreaseInNonCashOperatingLeaseExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yNS9mcmFnOjYzZmYxMmI2NTFjMTRhMTRhNWZkYmE3ODczNzg3M2U5L3RhYmxlOmFiYWYwYmNlMzAxMjRmNTk4ZTE0MzdlNTRjMDY4NzZiL3RhYmxlcmFuZ2U6YWJhZjBiY2UzMDEyNGY1OThlMTQzN2U1NGMwNjg3NmJfOC0xLTEtMS0w_2f3f83bf-e6a6-4128-b118-df1ac32ccb6b">691</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia34dfea6b8734d64abf707c28256801c_D20200101-20200331" decimals="-3" name="dnli:IncreaseDecreaseInNonCashOperatingLeaseExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yNS9mcmFnOjYzZmYxMmI2NTFjMTRhMTRhNWZkYmE3ODczNzg3M2U5L3RhYmxlOmFiYWYwYmNlMzAxMjRmNTk4ZTE0MzdlNTRjMDY4NzZiL3RhYmxlcmFuZ2U6YWJhZjBiY2UzMDEyNGY1OThlMTQzN2U1NGMwNjg3NmJfOC0zLTEtMS0w_d8bd4c81-1fd2-441c-9139-210d08f06fb5">321</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other non-cash items</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331" decimals="-3" name="us-gaap:OtherNoncashIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yNS9mcmFnOjYzZmYxMmI2NTFjMTRhMTRhNWZkYmE3ODczNzg3M2U5L3RhYmxlOmFiYWYwYmNlMzAxMjRmNTk4ZTE0MzdlNTRjMDY4NzZiL3RhYmxlcmFuZ2U6YWJhZjBiY2UzMDEyNGY1OThlMTQzN2U1NGMwNjg3NmJfMTAtMS0xLTEtMA_67cb7910-ed93-483c-b21a-ea38d0fb0b94">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia34dfea6b8734d64abf707c28256801c_D20200101-20200331" decimals="-3" name="us-gaap:OtherNoncashIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yNS9mcmFnOjYzZmYxMmI2NTFjMTRhMTRhNWZkYmE3ODczNzg3M2U5L3RhYmxlOmFiYWYwYmNlMzAxMjRmNTk4ZTE0MzdlNTRjMDY4NzZiL3RhYmxlcmFuZ2U6YWJhZjBiY2UzMDEyNGY1OThlMTQzN2U1NGMwNjg3NmJfMTAtMy0xLTEtMA_f1243fbf-2160-4163-85a3-b3aa55d866ec">53</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yNS9mcmFnOjYzZmYxMmI2NTFjMTRhMTRhNWZkYmE3ODczNzg3M2U5L3RhYmxlOmFiYWYwYmNlMzAxMjRmNTk4ZTE0MzdlNTRjMDY4NzZiL3RhYmxlcmFuZ2U6YWJhZjBiY2UzMDEyNGY1OThlMTQzN2U1NGMwNjg3NmJfMTItMS0xLTEtMA_5515a98c-e033-4308-b76c-f606d649b411">6,301</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia34dfea6b8734d64abf707c28256801c_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yNS9mcmFnOjYzZmYxMmI2NTFjMTRhMTRhNWZkYmE3ODczNzg3M2U5L3RhYmxlOmFiYWYwYmNlMzAxMjRmNTk4ZTE0MzdlNTRjMDY4NzZiL3RhYmxlcmFuZ2U6YWJhZjBiY2UzMDEyNGY1OThlMTQzN2U1NGMwNjg3NmJfMTItMy0xLTEtMA_f22aa879-d579-4ed4-b034-e53191557066">2,454</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yNS9mcmFnOjYzZmYxMmI2NTFjMTRhMTRhNWZkYmE3ODczNzg3M2U5L3RhYmxlOmFiYWYwYmNlMzAxMjRmNTk4ZTE0MzdlNTRjMDY4NzZiL3RhYmxlcmFuZ2U6YWJhZjBiY2UzMDEyNGY1OThlMTQzN2U1NGMwNjg3NmJfMTMtMS0xLTEtMA_22a0d43c-19ba-4b0c-8317-30e496f31bfc">623</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia34dfea6b8734d64abf707c28256801c_D20200101-20200331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yNS9mcmFnOjYzZmYxMmI2NTFjMTRhMTRhNWZkYmE3ODczNzg3M2U5L3RhYmxlOmFiYWYwYmNlMzAxMjRmNTk4ZTE0MzdlNTRjMDY4NzZiL3RhYmxlcmFuZ2U6YWJhZjBiY2UzMDEyNGY1OThlMTQzN2U1NGMwNjg3NmJfMTMtMy0xLTEtMA_679e7037-f054-49aa-b036-e8e12cb75e84">292</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accruals and other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yNS9mcmFnOjYzZmYxMmI2NTFjMTRhMTRhNWZkYmE3ODczNzg3M2U5L3RhYmxlOmFiYWYwYmNlMzAxMjRmNTk4ZTE0MzdlNTRjMDY4NzZiL3RhYmxlcmFuZ2U6YWJhZjBiY2UzMDEyNGY1OThlMTQzN2U1NGMwNjg3NmJfMTQtMS0xLTEtMA_e55b43d4-5dfe-43aa-ac3e-1204290eaa5b">10,804</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia34dfea6b8734d64abf707c28256801c_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yNS9mcmFnOjYzZmYxMmI2NTFjMTRhMTRhNWZkYmE3ODczNzg3M2U5L3RhYmxlOmFiYWYwYmNlMzAxMjRmNTk4ZTE0MzdlNTRjMDY4NzZiL3RhYmxlcmFuZ2U6YWJhZjBiY2UzMDEyNGY1OThlMTQzN2U1NGMwNjg3NmJfMTQtMy0xLTEtMA_f66c39bf-c953-45e0-ba33-2c81c9aa0eb0">3,827</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contract liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331" decimals="-3" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yNS9mcmFnOjYzZmYxMmI2NTFjMTRhMTRhNWZkYmE3ODczNzg3M2U5L3RhYmxlOmFiYWYwYmNlMzAxMjRmNTk4ZTE0MzdlNTRjMDY4NzZiL3RhYmxlcmFuZ2U6YWJhZjBiY2UzMDEyNGY1OThlMTQzN2U1NGMwNjg3NmJfMTUtMS0xLTEtMA_4a6fe491-0091-4adb-9e25-df2302d287fe">969</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia34dfea6b8734d64abf707c28256801c_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yNS9mcmFnOjYzZmYxMmI2NTFjMTRhMTRhNWZkYmE3ODczNzg3M2U5L3RhYmxlOmFiYWYwYmNlMzAxMjRmNTk4ZTE0MzdlNTRjMDY4NzZiL3RhYmxlcmFuZ2U6YWJhZjBiY2UzMDEyNGY1OThlMTQzN2U1NGMwNjg3NmJfMTUtMy0xLTEtMA_721a68ae-5562-4616-8f39-4b30479e464d">3,069</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Related party contract liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331" decimals="-3" sign="-" name="dnli:IncreaseDecreaseInContractWithCustomerLiabilityRelatedParties" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yNS9mcmFnOjYzZmYxMmI2NTFjMTRhMTRhNWZkYmE3ODczNzg3M2U5L3RhYmxlOmFiYWYwYmNlMzAxMjRmNTk4ZTE0MzdlNTRjMDY4NzZiL3RhYmxlcmFuZ2U6YWJhZjBiY2UzMDEyNGY1OThlMTQzN2U1NGMwNjg3NmJfMTYtMS0xLTEtMA_03dc03e6-43bd-4f14-adf7-e359a54117a6">892</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia34dfea6b8734d64abf707c28256801c_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="dnli:IncreaseDecreaseInContractWithCustomerLiabilityRelatedParties" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yNS9mcmFnOjYzZmYxMmI2NTFjMTRhMTRhNWZkYmE3ODczNzg3M2U5L3RhYmxlOmFiYWYwYmNlMzAxMjRmNTk4ZTE0MzdlNTRjMDY4NzZiL3RhYmxlcmFuZ2U6YWJhZjBiY2UzMDEyNGY1OThlMTQzN2U1NGMwNjg3NmJfMTYtMy0xLTEtMA_c7ed04d0-b19b-4d98-ac0d-377b46dde9a2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yNS9mcmFnOjYzZmYxMmI2NTFjMTRhMTRhNWZkYmE3ODczNzg3M2U5L3RhYmxlOmFiYWYwYmNlMzAxMjRmNTk4ZTE0MzdlNTRjMDY4NzZiL3RhYmxlcmFuZ2U6YWJhZjBiY2UzMDEyNGY1OThlMTQzN2U1NGMwNjg3NmJfMTktMS0xLTEtMA_1e9588b9-8b97-4bbe-ad23-361e76c60fff">50,240</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia34dfea6b8734d64abf707c28256801c_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yNS9mcmFnOjYzZmYxMmI2NTFjMTRhMTRhNWZkYmE3ODczNzg3M2U5L3RhYmxlOmFiYWYwYmNlMzAxMjRmNTk4ZTE0MzdlNTRjMDY4NzZiL3RhYmxlcmFuZ2U6YWJhZjBiY2UzMDEyNGY1OThlMTQzN2U1NGMwNjg3NmJfMTktMy0xLTEtMA_0ddbae32-1e3f-4253-a3c7-ba689d8dbf47">54,492</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Investing activities</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases of marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yNS9mcmFnOjYzZmYxMmI2NTFjMTRhMTRhNWZkYmE3ODczNzg3M2U5L3RhYmxlOmFiYWYwYmNlMzAxMjRmNTk4ZTE0MzdlNTRjMDY4NzZiL3RhYmxlcmFuZ2U6YWJhZjBiY2UzMDEyNGY1OThlMTQzN2U1NGMwNjg3NmJfMjEtMS0xLTEtMA_f310c4d4-0f42-4992-8278-a8b94dc2d843">463,105</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia34dfea6b8734d64abf707c28256801c_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yNS9mcmFnOjYzZmYxMmI2NTFjMTRhMTRhNWZkYmE3ODczNzg3M2U5L3RhYmxlOmFiYWYwYmNlMzAxMjRmNTk4ZTE0MzdlNTRjMDY4NzZiL3RhYmxlcmFuZ2U6YWJhZjBiY2UzMDEyNGY1OThlMTQzN2U1NGMwNjg3NmJfMjEtMy0xLTEtMA_5a75f9fe-fcb3-4eec-825d-25360c7ab4e7">153,155</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yNS9mcmFnOjYzZmYxMmI2NTFjMTRhMTRhNWZkYmE3ODczNzg3M2U5L3RhYmxlOmFiYWYwYmNlMzAxMjRmNTk4ZTE0MzdlNTRjMDY4NzZiL3RhYmxlcmFuZ2U6YWJhZjBiY2UzMDEyNGY1OThlMTQzN2U1NGMwNjg3NmJfMjItMS0xLTEtMA_b4384297-5983-46d6-b5d1-4a7f38cf9a42">2,800</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia34dfea6b8734d64abf707c28256801c_D20200101-20200331" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yNS9mcmFnOjYzZmYxMmI2NTFjMTRhMTRhNWZkYmE3ODczNzg3M2U5L3RhYmxlOmFiYWYwYmNlMzAxMjRmNTk4ZTE0MzdlNTRjMDY4NzZiL3RhYmxlcmFuZ2U6YWJhZjBiY2UzMDEyNGY1OThlMTQzN2U1NGMwNjg3NmJfMjItMy0xLTEtMA_63d441b3-07d9-4eff-a8bc-3f3f734050f3">879</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Maturities and sales of marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yNS9mcmFnOjYzZmYxMmI2NTFjMTRhMTRhNWZkYmE3ODczNzg3M2U5L3RhYmxlOmFiYWYwYmNlMzAxMjRmNTk4ZTE0MzdlNTRjMDY4NzZiL3RhYmxlcmFuZ2U6YWJhZjBiY2UzMDEyNGY1OThlMTQzN2U1NGMwNjg3NmJfMjMtMS0xLTEtMA_262aece3-4f2f-46c9-afe0-192a72e51f25">440,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia34dfea6b8734d64abf707c28256801c_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yNS9mcmFnOjYzZmYxMmI2NTFjMTRhMTRhNWZkYmE3ODczNzg3M2U5L3RhYmxlOmFiYWYwYmNlMzAxMjRmNTk4ZTE0MzdlNTRjMDY4NzZiL3RhYmxlcmFuZ2U6YWJhZjBiY2UzMDEyNGY1OThlMTQzN2U1NGMwNjg3NmJfMjMtMy0xLTEtMA_e0d3853c-69dc-47b4-be95-080a853c4b43">140,701</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yNS9mcmFnOjYzZmYxMmI2NTFjMTRhMTRhNWZkYmE3ODczNzg3M2U5L3RhYmxlOmFiYWYwYmNlMzAxMjRmNTk4ZTE0MzdlNTRjMDY4NzZiL3RhYmxlcmFuZ2U6YWJhZjBiY2UzMDEyNGY1OThlMTQzN2U1NGMwNjg3NmJfMjQtMS0xLTEtMA_d3256b20-18ed-47d9-88ed-43e6e09e17a9">25,405</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia34dfea6b8734d64abf707c28256801c_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yNS9mcmFnOjYzZmYxMmI2NTFjMTRhMTRhNWZkYmE3ODczNzg3M2U5L3RhYmxlOmFiYWYwYmNlMzAxMjRmNTk4ZTE0MzdlNTRjMDY4NzZiL3RhYmxlcmFuZ2U6YWJhZjBiY2UzMDEyNGY1OThlMTQzN2U1NGMwNjg3NmJfMjQtMy0xLTEtMA_7bcc352b-6d9e-4752-97da-81f1fa9992ed">13,333</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Financing activities</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from public offering of common stock, net of issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yNS9mcmFnOjYzZmYxMmI2NTFjMTRhMTRhNWZkYmE3ODczNzg3M2U5L3RhYmxlOmFiYWYwYmNlMzAxMjRmNTk4ZTE0MzdlNTRjMDY4NzZiL3RhYmxlcmFuZ2U6YWJhZjBiY2UzMDEyNGY1OThlMTQzN2U1NGMwNjg3NmJfMjctMS0xLTEtMA_e19876e2-fd80-46c7-b1b1-84c97aa47beb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia34dfea6b8734d64abf707c28256801c_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yNS9mcmFnOjYzZmYxMmI2NTFjMTRhMTRhNWZkYmE3ODczNzg3M2U5L3RhYmxlOmFiYWYwYmNlMzAxMjRmNTk4ZTE0MzdlNTRjMDY4NzZiL3RhYmxlcmFuZ2U6YWJhZjBiY2UzMDEyNGY1OThlMTQzN2U1NGMwNjg3NmJfMjctMy0xLTEtMA_24b36591-d040-4523-a3a7-aea60d7f7465">193,948</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from exercise of awards under equity incentive plans</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yNS9mcmFnOjYzZmYxMmI2NTFjMTRhMTRhNWZkYmE3ODczNzg3M2U5L3RhYmxlOmFiYWYwYmNlMzAxMjRmNTk4ZTE0MzdlNTRjMDY4NzZiL3RhYmxlcmFuZ2U6YWJhZjBiY2UzMDEyNGY1OThlMTQzN2U1NGMwNjg3NmJfMjktMS0xLTEtMA_3a7c6b6e-3989-4056-9e5c-0ba651f46d2a">3,822</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia34dfea6b8734d64abf707c28256801c_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yNS9mcmFnOjYzZmYxMmI2NTFjMTRhMTRhNWZkYmE3ODczNzg3M2U5L3RhYmxlOmFiYWYwYmNlMzAxMjRmNTk4ZTE0MzdlNTRjMDY4NzZiL3RhYmxlcmFuZ2U6YWJhZjBiY2UzMDEyNGY1OThlMTQzN2U1NGMwNjg3NmJfMjktMy0xLTEtMA_b2e4eae4-28ae-41ce-abbc-9fcf63f6c33e">1,965</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yNS9mcmFnOjYzZmYxMmI2NTFjMTRhMTRhNWZkYmE3ODczNzg3M2U5L3RhYmxlOmFiYWYwYmNlMzAxMjRmNTk4ZTE0MzdlNTRjMDY4NzZiL3RhYmxlcmFuZ2U6YWJhZjBiY2UzMDEyNGY1OThlMTQzN2U1NGMwNjg3NmJfMzAtMS0xLTEtMA_96558033-18e5-436a-9c0d-1e6433a025c3">3,822</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia34dfea6b8734d64abf707c28256801c_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yNS9mcmFnOjYzZmYxMmI2NTFjMTRhMTRhNWZkYmE3ODczNzg3M2U5L3RhYmxlOmFiYWYwYmNlMzAxMjRmNTk4ZTE0MzdlNTRjMDY4NzZiL3RhYmxlcmFuZ2U6YWJhZjBiY2UzMDEyNGY1OThlMTQzN2U1NGMwNjg3NmJfMzAtMy0xLTEtMA_e89bdc6d-f33f-4302-b631-fcbc1da35c66">195,913</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net increase (decrease) in cash, cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yNS9mcmFnOjYzZmYxMmI2NTFjMTRhMTRhNWZkYmE3ODczNzg3M2U5L3RhYmxlOmFiYWYwYmNlMzAxMjRmNTk4ZTE0MzdlNTRjMDY4NzZiL3RhYmxlcmFuZ2U6YWJhZjBiY2UzMDEyNGY1OThlMTQzN2U1NGMwNjg3NmJfMzEtMS0xLTEtMA_c872649c-5c78-43f9-a10e-293c5df6140d">71,823</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia34dfea6b8734d64abf707c28256801c_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yNS9mcmFnOjYzZmYxMmI2NTFjMTRhMTRhNWZkYmE3ODczNzg3M2U5L3RhYmxlOmFiYWYwYmNlMzAxMjRmNTk4ZTE0MzdlNTRjMDY4NzZiL3RhYmxlcmFuZ2U6YWJhZjBiY2UzMDEyNGY1OThlMTQzN2U1NGMwNjg3NmJfMzEtMy0xLTEtMA_0ea1dcd8-795d-4a05-a868-b65c13908e56">128,088</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash at beginning of period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb7ca9f362da46eab3a29bbbecbda977_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yNS9mcmFnOjYzZmYxMmI2NTFjMTRhMTRhNWZkYmE3ODczNzg3M2U5L3RhYmxlOmFiYWYwYmNlMzAxMjRmNTk4ZTE0MzdlNTRjMDY4NzZiL3RhYmxlcmFuZ2U6YWJhZjBiY2UzMDEyNGY1OThlMTQzN2U1NGMwNjg3NmJfMzItMS0xLTEtMA_df0eb480-d1de-42d9-ac1f-5504f325b467">508,644</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id36b0e599cb3498a8671e8c185763bc9_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yNS9mcmFnOjYzZmYxMmI2NTFjMTRhMTRhNWZkYmE3ODczNzg3M2U5L3RhYmxlOmFiYWYwYmNlMzAxMjRmNTk4ZTE0MzdlNTRjMDY4NzZiL3RhYmxlcmFuZ2U6YWJhZjBiY2UzMDEyNGY1OThlMTQzN2U1NGMwNjg3NmJfMzItMy0xLTEtMA_aa5eb411-b790-40ca-ab86-7e76aa487d72">80,949</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash at end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9953f50a7fd74f7d8438f304f136a07b_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yNS9mcmFnOjYzZmYxMmI2NTFjMTRhMTRhNWZkYmE3ODczNzg3M2U5L3RhYmxlOmFiYWYwYmNlMzAxMjRmNTk4ZTE0MzdlNTRjMDY4NzZiL3RhYmxlcmFuZ2U6YWJhZjBiY2UzMDEyNGY1OThlMTQzN2U1NGMwNjg3NmJfMzMtMS0xLTEtMA_a7489d21-6f99-43c5-8793-cf7cef681011">436,821</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29b65d7585ff41c5843594c6319bdb90_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yNS9mcmFnOjYzZmYxMmI2NTFjMTRhMTRhNWZkYmE3ODczNzg3M2U5L3RhYmxlOmFiYWYwYmNlMzAxMjRmNTk4ZTE0MzdlNTRjMDY4NzZiL3RhYmxlcmFuZ2U6YWJhZjBiY2UzMDEyNGY1OThlMTQzN2U1NGMwNjg3NmJfMzMtMy0xLTEtMA_d1e708a6-bc5e-4292-98c0-bd157d061502">209,037</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to unaudited condensed consolidated financial statements.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="i5ae1cfc88aa4492caf56e9d4ac91e096_28"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5ae1cfc88aa4492caf56e9d4ac91e096_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Denali Therapeutics Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div id="i5ae1cfc88aa4492caf56e9d4ac91e096_31"></div><div style="margin-top:18pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zMS9mcmFnOjcwYWY3MzdmZGVkYjQzOWFhZjJiY2E2NmEyMGIyYjViL3RleHRyZWdpb246NzBhZjczN2ZkZWRiNDM5YWFmMmJjYTY2YTIwYjJiNWJfMjExNzI_4a372001-274d-4e69-86fb-761ca02d9ebe" continuedAt="i4b5979f8495a4363aa09fa8a07ecd84c" escape="true">Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="i4b5979f8495a4363aa09fa8a07ecd84c" continuedAt="ie553e1c77a864e5aa89c4329c6754eae"><ix:nonNumeric contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331" name="dnli:OrganizationAndDescriptionOfBusinessPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zMS9mcmFnOjcwYWY3MzdmZGVkYjQzOWFhZjJiY2E2NmEyMGIyYjViL3RleHRyZWdpb246NzBhZjczN2ZkZWRiNDM5YWFmMmJjYTY2YTIwYjJiNWJfMjExODQ_718b0516-3973-49bc-be8c-e4e3b81d23ec" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Organization and Description of Business</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Denali Therapeutics Inc. ("Denali" or the &#8220;Company&#8221;) is a biopharmaceutical company, incorporated in Delaware, that discovers and develops therapeutics to defeat neurodegenerative diseases. The Company is headquartered in South San Francisco, California.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zMS9mcmFnOjcwYWY3MzdmZGVkYjQzOWFhZjJiY2E2NmEyMGIyYjViL3RleHRyZWdpb246NzBhZjczN2ZkZWRiNDM5YWFmMmJjYTY2YTIwYjJiNWJfMjExNzQ_1741a799-1835-4519-bd82-d7fa0eadd4be" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) for interim financial information and the instructions to Form 10-Q and Article 10 of SEC Regulation S-X for interim financial information. </span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These unaudited condensed consolidated financial statements and notes should be read in conjunction with the audited consolidated financial statements and notes thereto contained in the Annual Report on Form 10-K for the year ended December 31, 2020, as filed with the Securities and Exchange Commission on February&#160;26, 2021 (the "2020 Annual Report on Form 10-K"). The Condensed Consolidated Balance Sheet as of December 31, 2020 was derived from the audited annual consolidated financial statements as of and for the period then ended. Certain information and footnote disclosures typically included in the Company's annual consolidated financial statements have been condensed or omitted. The accompanying unaudited condensed consolidated financial statements reflect all adjustments that, in the opinion of management, are necessary for a fair statement of the results of the interim periods presented. All such adjustments are of a normal recurring nature except for the impacts of adopting new accounting standards, if any, discussed below. These interim financial results are not necessarily indicative of results expected for the full fiscal year or for any subsequent interim period.</span></div></ix:nonNumeric><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended&#160;March 31, 2021, except as discussed below in the section titled "Recently Adopted Accounting Pronouncement," there were no material changes to the Company's significant accounting and financial reporting policies from those reflected in the 2020 Annual Report on Form 10-K. For further information with regard to the Company&#8217;s Significant Accounting Policies, please refer to Note 1, "Significant Accounting Policies," to the Company&#8217;s Consolidated Financial Statements included in the 2020 Annual Report on Form 10-K.</span></div><ix:nonNumeric contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zMS9mcmFnOjcwYWY3MzdmZGVkYjQzOWFhZjJiY2E2NmEyMGIyYjViL3RleHRyZWdpb246NzBhZjczN2ZkZWRiNDM5YWFmMmJjYTY2YTIwYjJiNWJfMjExNzk_88a5a3e2-749f-49e5-9b07-49f81e3bf379" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. All intercompany balances and transactions have been eliminated in consolidation.&#160;For the Company and its subsidiary, the functional currency has been determined to be U.S. dollars. Monetary assets and liabilities denominated in foreign currency are remeasured at period-end exchange rates. Non-monetary assets and liabilities denominated in foreign currencies are remeasured at historical rates. Foreign currency transaction gains and losses resulting from remeasurement are recognized in interest and other income, net in the Condensed Consolidated Statements of Operations and Comprehensive Loss.</span></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5ae1cfc88aa4492caf56e9d4ac91e096_7">Table of Contents</a></span></div></div><ix:continuation id="ie553e1c77a864e5aa89c4329c6754eae" continuedAt="i06601ce194d8418caa5fd7ff20b3d493"><ix:nonNumeric contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zMS9mcmFnOjcwYWY3MzdmZGVkYjQzOWFhZjJiY2E2NmEyMGIyYjViL3RleHRyZWdpb246NzBhZjczN2ZkZWRiNDM5YWFmMmJjYTY2YTIwYjJiNWJfMjExODk_59fc7666-d667-41ef-a976-8d3b7a53dff4" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires the Company to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, as well as the reported amounts of expenses during the reporting period. Actual results could differ from those estimates, and such differences could be material to the Condensed Consolidated Balance Sheets and Statements of Operations and Comprehensive Loss.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331" name="us-gaap:ConcentrationRiskCreditRisk" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zMS9mcmFnOjcwYWY3MzdmZGVkYjQzOWFhZjJiY2E2NmEyMGIyYjViL3RleHRyZWdpb246NzBhZjczN2ZkZWRiNDM5YWFmMmJjYTY2YTIwYjJiNWJfMjExNzU_7c446b49-6414-4000-b973-850bd8279ce2" continuedAt="i8e83822e738943bea2d692a52b156945" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk and Other Risks and Uncertainties</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents, marketable securities and forward foreign currency exchange contracts. Substantially all of the Company&#8217;s cash and cash equivalents are deposited in accounts with financial institutions that management believes are of high credit quality. Such deposits have and will continue to exceed federally insured limits. The Company maintains its cash with accredited financial institutions and accordingly, such funds are subject to minimal credit risk. </span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s investment policy limits investments to certain types of securities issued by the U.S. government, its agencies and institutions with investment-grade credit ratings and places restrictions on maturities and concentration by type and issuer. The Company is exposed to credit risk in the event of a default by the financial institutions holding its cash, cash equivalents and marketable securities and issuers of marketable securities to the extent recorded on the Condensed Consolidated Balance Sheets. As of March 31, 2021 and December 31, 2020, the Company had no off balance sheet concentrations of credit risk. </span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is exposed to counterparty credit risk on all of its derivative financial instruments. The Company has established and maintains strict counterparty credit guidelines and enters into hedges only with financial institutions that are investment grade or better to minimize the Company&#8217;s exposure to potential defaults. The Company does not require collateral to be pledged under these agreements.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to a number of risks similar to other early-stage biopharmaceutical companies, including, but not limited to, the need to obtain adequate additional funding, possible failure of current or future preclinical testing or clinical trials, its reliance on third parties to conduct its clinical trials, the need to obtain regulatory and marketing approvals for its product candidates, competitors developing new technological innovations, the need to successfully commercialize and gain market acceptance of the Company&#8217;s product candidates, its right to develop and commercialize its product candidates pursuant to the terms and conditions of the licenses granted to the Company, protection of proprietary technology, the ability to make milestone, royalty or other payments due under any license or collaboration agreements, and the need to secure and maintain adequate manufacturing arrangements with third parties. If the Company does not successfully commercialize or partner any of its product candidates, it will be unable to generate product revenue or achieve profitability.</span></div></ix:nonNumeric><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i8e83822e738943bea2d692a52b156945">The COVID-19 pandemic has caused increased risk and uncertainty for the Company. Credit risk associated with investments in securities may increase if any institution with which the Company has an investment is significantly impacted by the COVID-19 pandemic.</ix:continuation> As of March 31, 2021, the Company has not realized any losses on its cash deposits or investments. COVID-19 may impact the timelines and progress of the Company's preclinical activities and clinical trials, and may impact its ability to raise capital in the near term. </span></div><ix:nonNumeric contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zMS9mcmFnOjcwYWY3MzdmZGVkYjQzOWFhZjJiY2E2NmEyMGIyYjViL3RleHRyZWdpb246NzBhZjczN2ZkZWRiNDM5YWFmMmJjYTY2YTIwYjJiNWJfMjExNzY_b2e1a7d4-7bcb-4ecf-a47c-c342a16addfe" escape="true"><div style="margin-bottom:8pt;margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segments</span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has <ix:nonFraction unitRef="segment" contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zMS9mcmFnOjcwYWY3MzdmZGVkYjQzOWFhZjJiY2E2NmEyMGIyYjViL3RleHRyZWdpb246NzBhZjczN2ZkZWRiNDM5YWFmMmJjYTY2YTIwYjJiNWJfNzA1Nw_260e2b5a-e37b-4c53-ae40-d9063c93dcfb">one</ix:nonFraction> operating segment. The Company&#8217;s chief operating decision maker, its Chief Executive Officer, manages the Company&#8217;s operations on a consolidated basis for the purposes of allocating resources.</span></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5ae1cfc88aa4492caf56e9d4ac91e096_7">Table of Contents</a></span></div></div><ix:continuation id="i06601ce194d8418caa5fd7ff20b3d493" continuedAt="iae29b596c1bd4d78bccdc64111f9a392"><ix:nonNumeric contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zMS9mcmFnOjcwYWY3MzdmZGVkYjQzOWFhZjJiY2E2NmEyMGIyYjViL3RleHRyZWdpb246NzBhZjczN2ZkZWRiNDM5YWFmMmJjYTY2YTIwYjJiNWJfMjExNzc_210a644a-c2cd-4abf-b4b1-4118c47e0d3a" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents and Restricted Cash</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly liquid investments with original maturities of 90 days or less at the date of purchase to be cash and cash equivalents. Cash equivalents are reported at fair value.</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents, and restricted cash reported within the Condensed Consolidated Statements of Cash Flows is composed of Cash and Cash equivalents reported in the Condensed Consolidated Balance Sheets and $<ix:nonFraction unitRef="usd" contextRef="i29b65d7585ff41c5843594c6319bdb90_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zMS9mcmFnOjcwYWY3MzdmZGVkYjQzOWFhZjJiY2E2NmEyMGIyYjViL3RleHRyZWdpb246NzBhZjczN2ZkZWRiNDM5YWFmMmJjYTY2YTIwYjJiNWJfMTA5OTUxMTY0OTMzNA_76cae682-cf72-4a01-adb8-712b24110fb3">1.5</ix:nonFraction> million of restricted cash for the letter of credit for the Company&#8217;s headquarters building lease, which is included&#160;within other&#160;non-current&#160;assets&#160;in the Condensed Consolidated Balance Sheets.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331" name="us-gaap:MarketableSecuritiesPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zMS9mcmFnOjcwYWY3MzdmZGVkYjQzOWFhZjJiY2E2NmEyMGIyYjViL3RleHRyZWdpb246NzBhZjczN2ZkZWRiNDM5YWFmMmJjYTY2YTIwYjJiNWJfMjExOTM_cb415140-0d8b-494e-9aa5-75c05d5494e0" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Marketable Securities</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company generally invests its excess cash in money market funds and investment grade short to intermediate-term fixed income securities. Such investments are included in cash and cash equivalents, short-term marketable securities, or long-term marketable securities on the Condensed Consolidated Balance Sheets, are considered available-for-sale, and reported at fair value with net unrealized gains and losses included as a component of stockholders&#8217; equity. </span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company classifies investments in securities with remaining maturities of less than one year, or where its intent is to use the investments to fund current operations or to make them available for current operations, as short-term investments. The Company classifies investments in securities with remaining maturities of over one year as long-term investments. The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity, which is included in interest and other income, net in the Condensed Consolidated Statements of Operations and Comprehensive Loss. Realized gains and losses and declines in value determined to be due to credit losses on marketable securities, if any, are included in interest and other income, net.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company periodically evaluates the need for an allowance for credit losses. This evaluation includes consideration of several qualitative and quantitative factors, including whether it has plans to sell the security, whether it is more likely than not it will be required to sell any marketable securities before recovery of its amortized cost basis, and if the entity has the ability and intent to hold the security to maturity, and the portion of any unrealized loss that is the result of a credit loss. Factors considered in making these evaluations include quoted market prices, recent financial results and operating trends, implied values from any recent transactions or offers of investee securities, credit quality of debt instrument issuers, expected cash flows from securities, other publicly available information that may affect the value of the marketable security, duration and severity of the decline in value, and the Company's strategy and intentions for holding the marketable security.</span></div></ix:nonNumeric><div style="margin-bottom:10pt;margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331" name="us-gaap:ReceivablesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zMS9mcmFnOjcwYWY3MzdmZGVkYjQzOWFhZjJiY2E2NmEyMGIyYjViL3RleHRyZWdpb246NzBhZjczN2ZkZWRiNDM5YWFmMmJjYTY2YTIwYjJiNWJfMjExODE_1319f765-a6e5-408f-965e-51affba14cf1" continuedAt="i01ae9b7087bd439ea4f77cf2e19c1b73" escape="true">Accounts Receivable</ix:nonNumeric></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i01ae9b7087bd439ea4f77cf2e19c1b73">Accounts receivable are included within prepaid expenses and other current assets on the Condensed Consolidated Balance Sheets. The accounts receivable balance represents amounts receivable from the Company's collaboration partners, net of an allowance for credit losses, if required.</ix:continuation> </span></div><div style="margin-bottom:10pt;margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331" name="us-gaap:DerivativesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zMS9mcmFnOjcwYWY3MzdmZGVkYjQzOWFhZjJiY2E2NmEyMGIyYjViL3RleHRyZWdpb246NzBhZjczN2ZkZWRiNDM5YWFmMmJjYTY2YTIwYjJiNWJfMjExODI_5ea009d2-e7fe-4878-8d9b-9d64cdf8a461" continuedAt="i2bd3d4e30eb94e5d8969d0799c8571fe" escape="true">Derivatives and Hedging Activities</ix:nonNumeric></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i2bd3d4e30eb94e5d8969d0799c8571fe">The Company measures its derivative instruments at fair value, and accounts for them as either assets or liabilities included within Prepaid expenses and other current assets and Other accruals and other current liabilities, respectively, on the Condensed Consolidated Balance Sheets. Derivatives are adjusted to fair value through interest and other income, net in the Condensed Consolidated Statements of Operations and Comprehensive Loss.</ix:continuation> </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5ae1cfc88aa4492caf56e9d4ac91e096_7">Table of Contents</a></span></div></div><ix:continuation id="iae29b596c1bd4d78bccdc64111f9a392" continuedAt="i70d514904acc49b9aedc8ed6b35048dc"><ix:nonNumeric contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331" name="us-gaap:LesseeLeasesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zMS9mcmFnOjcwYWY3MzdmZGVkYjQzOWFhZjJiY2E2NmEyMGIyYjViL3RleHRyZWdpb246NzBhZjczN2ZkZWRiNDM5YWFmMmJjYTY2YTIwYjJiNWJfMjExOTQ_590956bd-ac26-442e-8ed1-e53bd8fd497a" continuedAt="i2163fa279dc4408daf979bd5ce987849" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases real estate, and certain equipment for use in its operations. A determination is made as to whether an arrangement is a lease at inception. A right-of-use (&#8220;ROU&#8221;) asset an</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d operating lease liability is recognized for identified operating leases in the Condensed Consolidated Balance Sheets. The changes in operating lease ROU assets and operating lease liabilities are presented net within non-cash adjustment to operating lease expense in the Condensed Consolidated Statements of Cash Flows. Certain amounts for the three months ended March 31, 2020 were reclassified to conform to the current period presentation.</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ROU assets represent the Company&#8217;s right to use the underlying asset for the lease term and lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the lease commencement date based on the present value of lease payments due over the lease term, with the ROU assets adjusted for lease incentives received. When determining the present value of lease payments, the Company uses its incremental borrowing rate on the date of lease commencement, or the rate implicit in the lease, if known. The Company does not assume renewals in its determination of the lease term unless the renewals are deemed by management to be reasonably certain at lease inception.</span></div></ix:nonNumeric><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i2163fa279dc4408daf979bd5ce987849">Leases with an initial term of 12 months or less are not recorded on the balance sheet, unless they include an option to purchase the underlying asset that the Company is reasonably certain to exercise. The Company recognizes lease expenses on a straight-line basis over the lease term. The Company has leases with lease and non-lease components, which the Company has elected to account for as a single lease component.</ix:continuation> </span></div><ix:nonNumeric contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331" name="us-gaap:RevenueRecognitionPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zMS9mcmFnOjcwYWY3MzdmZGVkYjQzOWFhZjJiY2E2NmEyMGIyYjViL3RleHRyZWdpb246NzBhZjczN2ZkZWRiNDM5YWFmMmJjYTY2YTIwYjJiNWJfMjExODU_2be1adce-789d-46b0-b8f9-6490cf5fbcd4" continuedAt="i931a84ee77614173a95926a7a6002ae7" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License and Collaboration Revenue</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company analyzes its collaboration arrangements to assess whether they are within the scope of ASC&#160;808,&#160;Collaborative Arrangements&#160;(&#8220;ASC&#160;808&#8221;) to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities.&#160;This assessment is performed throughout the life of the arrangement based on changes in the responsibilities of all parties in the arrangement.&#160;For collaboration arrangements within the scope of ASC&#160;808&#160;that contain multiple elements, the Company first determines which elements of the collaboration are deemed to be within the scope of ASC&#160;808&#160;and those that are more reflective of a vendor-customer relationship and, therefore, within the scope of Topic 606. For elements of collaboration arrangements that are accounted for pursuant to ASC&#160;808, an appropriate recognition method is determined and applied consistently, generally by analogy to Topic 606.&#160;The accounting treatment pursuant to Topic 606 is outlined below. </span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The terms of licensing and collaboration agreements entered into typically include payment of one or more of the following: non-refundable, up-front license fees; development, regulatory and commercial milestone payments; payments for manufacturing supply and research and development services and royalties on net sales of licensed products. Each of these payments results in license, collaboration and other revenue, except for revenues from royalties on net sales of licensed products, which are classified as royalty revenue. The core principle of Topic 606 is to recognize revenue when promised goods or services are transferred to customers in an amount that reflects the consideration that is expected to be received in exchange for those goods or services. The Company may also receive reimbursement or make payments to a collaboration partner to satisfy cost sharing requirements. These payments are accounted for pursuant to ASC 808 and are recorded as an offset or increase to research and development expenses, respectively.</span></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5ae1cfc88aa4492caf56e9d4ac91e096_7">Table of Contents</a></span></div></div><ix:continuation id="i70d514904acc49b9aedc8ed6b35048dc" continuedAt="i7f71fdb9fc034597aaebf48ab6bde845"><ix:continuation id="i931a84ee77614173a95926a7a6002ae7"><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under each of its agreements, the Company performs the following steps: (i)&#160;identification of the promised goods or services in the contract; (ii)&#160;determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii)&#160;measurement of the transaction price, including the constraint on variable consideration; (iv)&#160;allocation of the transaction price to the performance obligations based on estimated selling prices; and (v)&#160;recognition of revenue when (or as) the Company satisfies each performance obligation.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts received prior to satisfying the revenue recognition criteria are recorded as contract liabilities in the Company&#8217;s Condensed Consolidated Balance Sheets. If the related performance obligation is expected to be satisfied within the next twelve months this will be classified in current liabilities. Amounts recognized as revenue prior to the Company having an unconditional right (other than a right that is conditioned only on the passage of time) to receipt are recorded as contract assets in the Company's Condensed Consolidated Balance Sheets. If the Company expects to have an unconditional right to receive the consideration in the next twelve months, this will be classified in current assets. A net contract asset or liability is presented for each contract with a customer. </span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At contract inception, the Company assesses the goods or services promised in a contract with a customer and identifies those distinct goods and services that represent a performance obligation. A promised good or service may not be identified as a performance obligation if it is immaterial in the context of the contract with the customer, if it is not separately identifiable from other promises in the contract (either because it is not capable of being separated or because it is not separable in the context of the contract), or if the promised good or service does not provide the customer with a material right. </span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers the terms of the contract to determine the transaction price. The transaction price is the amount of consideration to which the Company expects to be entitled in exchange for transferring promised goods or services to a customer. The consideration promised in a contract with a customer may include fixed amounts, variable amounts, or both. Variable consideration will only be included in the transaction price when it is not considered constrained, which is when it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur. </span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If it is determined that multiple performance obligations exist, the transaction price is allocated at the inception of the agreement to all identified performance obligations based on the relative standalone selling prices ("SSP").&#160;The relative SSP for each deliverable is estimated using external sourced evidence if it is available. If external sourced evidence is not available, the Company uses its best estimate of the SSP for the deliverable. </span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue is recognized when, or as, the Company satisfies a performance obligation by transferring a promised good or service to a customer. An asset is transferred when, or as, the customer obtains control of that asset, which for a service is considered to be as the services are received and used. The Company recognizes revenue over time by measuring the progress toward complete satisfaction of the relevant performance obligation using an appropriate input or output method based on the nature of the service promised to the customer. </span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After contract inception, the transaction price is reassessed at every period end and updated for changes such as resolution of uncertain events. Any change in the transaction price is allocated to the performance obligations on the same basis as at contract inception, or to a single performance obligation as applicable. </span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management may be required to exercise considerable judgment in estimating revenue to be recognized. Judgment is required in identifying performance obligations, estimating the transaction price, estimating the SSP of identified performance obligations, which may include forecasted revenue, development timelines, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success, and estimating the progress towards satisfaction of performance obligations.</span></div></ix:continuation></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5ae1cfc88aa4492caf56e9d4ac91e096_7">Table of Contents</a></span></div></div><ix:continuation id="i7f71fdb9fc034597aaebf48ab6bde845"><ix:nonNumeric contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zMS9mcmFnOjcwYWY3MzdmZGVkYjQzOWFhZjJiY2E2NmEyMGIyYjViL3RleHRyZWdpb246NzBhZjczN2ZkZWRiNDM5YWFmMmJjYTY2YTIwYjJiNWJfMjExODY_f8762b42-bee9-49c3-a680-0b97417a9687" escape="true"><div style="margin-bottom:10pt;margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Loss</span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss is composed of net loss and certain changes in stockholders&#8217; equity that are excluded from net loss, primarily unrealized gains or losses on the Company&#8217;s marketable securities.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zMS9mcmFnOjcwYWY3MzdmZGVkYjQzOWFhZjJiY2E2NmEyMGIyYjViL3RleHRyZWdpb246NzBhZjczN2ZkZWRiNDM5YWFmMmJjYTY2YTIwYjJiNWJfMjExODc_8656fc48-af86-429b-9892-2ea382d2a511" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss per Share</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding during the period, without consideration for common stock equivalents. Diluted net loss per share is the same as basic net loss per share, since the effects of potentially dilutive securities are antidilutive given the net loss for each period presented.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zMS9mcmFnOjcwYWY3MzdmZGVkYjQzOWFhZjJiY2E2NmEyMGIyYjViL3RleHRyZWdpb246NzBhZjczN2ZkZWRiNDM5YWFmMmJjYTY2YTIwYjJiNWJfMjExNzg_b0cbd047-97ba-4eb1-877f-cedb84b826f8" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncement</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the Financial Accounting Standards Board ("FASB") issued ASU No. 2019-12</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">, Income Taxes (Topic 740) Simplifying the Accounting for Income Taxes. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASU No. 2019-12 modifies ASC 740 to simplify several aspects of accounting for income taxes, including eliminating certain exceptions to the guidance in ASC 740 related to the approach for intraperiod tax allocation. The guidance is effective for fiscal years beginning after December 15, 2020 and interim periods within those fiscal years, with early adoption permitted, and is required to be adopted prospectively, with the exception of certain specific amendments, which were not applicable to the Company. The Company adopted this standard as of January 1, 2021 using a prospective approach. Adoption of the standard did not have a material impact on its Condensed Consolidated Financial Statements.</span></div></ix:nonNumeric></ix:continuation><div id="i5ae1cfc88aa4492caf56e9d4ac91e096_34"></div><div style="margin-top:18pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RleHRyZWdpb246NDdjNjg5ZGVlNzBkNGM0Mjk2MTA5OWRlNzNkYTQwZjBfNzA2_2de11114-12e5-4036-99b1-b6d44d6fef7b" continuedAt="i5e007ec5ad3642ac9d5745d70fcf014a" escape="true">Fair Value Measurements</ix:nonNumeric></span></div><ix:continuation id="i5e007ec5ad3642ac9d5745d70fcf014a" continuedAt="id682624fb39444268ef50e1c6765a2f8"><ix:nonNumeric contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RleHRyZWdpb246NDdjNjg5ZGVlNzBkNGM0Mjk2MTA5OWRlNzNkYTQwZjBfNzA3_4b1d70a0-4c0e-403a-8078-dcb5a3a4fcaf" continuedAt="if6812bba0ea54b9da8302f34c458866a" escape="true"><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities measured at fair value at each balance sheet date are as follows (in thousands):</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.214%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.723%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c67df6d9d254626b9391157cc6763f4_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjg5MmUxMTZkYjQxODQxYjg5YjBhYjEzMzNjN2M5OTc1L3RhYmxlcmFuZ2U6ODkyZTExNmRiNDE4NDFiODliMGFiMTMzM2M3Yzk5NzVfNC0xLTEtMS0w_cfcb0398-c0de-4710-8c96-8c79d135e524">426,770</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa61d3a997f64111a4b23a96b7fe5b8a_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjg5MmUxMTZkYjQxODQxYjg5YjBhYjEzMzNjN2M5OTc1L3RhYmxlcmFuZ2U6ODkyZTExNmRiNDE4NDFiODliMGFiMTMzM2M3Yzk5NzVfNC0zLTEtMS0w_338069ed-a53c-4121-ad63-c6618767e348">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida70779bab1a408eab2c0f807c7c2184_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjg5MmUxMTZkYjQxODQxYjg5YjBhYjEzMzNjN2M5OTc1L3RhYmxlcmFuZ2U6ODkyZTExNmRiNDE4NDFiODliMGFiMTMzM2M3Yzk5NzVfNC01LTEtMS0w_ac110731-2553-48c9-8040-d40a54c93f77">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a012763ca204bf7ac713bfc5a5fe5bb_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjg5MmUxMTZkYjQxODQxYjg5YjBhYjEzMzNjN2M5OTc1L3RhYmxlcmFuZ2U6ODkyZTExNmRiNDE4NDFiODliMGFiMTMzM2M3Yzk5NzVfNC03LTEtMS0w_e7434ae7-e217-435b-a0a4-4a45fd45efd0">426,770</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Short-term marketable securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. government treasuries</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia57c5b507b6a47618a967591bf368bff_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjg5MmUxMTZkYjQxODQxYjg5YjBhYjEzMzNjN2M5OTc1L3RhYmxlcmFuZ2U6ODkyZTExNmRiNDE4NDFiODliMGFiMTMzM2M3Yzk5NzVfOC0xLTEtMS0w_5d1008b7-f46e-4026-b75d-95b6ef79da2e">870,756</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3f854bad0dd4fcab527216138601aaa_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjg5MmUxMTZkYjQxODQxYjg5YjBhYjEzMzNjN2M5OTc1L3RhYmxlcmFuZ2U6ODkyZTExNmRiNDE4NDFiODliMGFiMTMzM2M3Yzk5NzVfOC0zLTEtMS0w_e509ff8e-fda7-40b1-8782-34781d4b5dc9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66e037a80d03458791ec3572ec41d1cb_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjg5MmUxMTZkYjQxODQxYjg5YjBhYjEzMzNjN2M5OTc1L3RhYmxlcmFuZ2U6ODkyZTExNmRiNDE4NDFiODliMGFiMTMzM2M3Yzk5NzVfOC01LTEtMS0w_d3d7c722-da83-45f5-baf9-f0f7874de141">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie652e808c1f147618ebb4562358ce95a_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjg5MmUxMTZkYjQxODQxYjg5YjBhYjEzMzNjN2M5OTc1L3RhYmxlcmFuZ2U6ODkyZTExNmRiNDE4NDFiODliMGFiMTMzM2M3Yzk5NzVfOC03LTEtMS0w_5fca6d31-9035-4cd8-8b0a-898aa2b418a2">870,756</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. government agency securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5f979a4d5d94f0ead845cf6e9d26c7e_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjg5MmUxMTZkYjQxODQxYjg5YjBhYjEzMzNjN2M5OTc1L3RhYmxlcmFuZ2U6ODkyZTExNmRiNDE4NDFiODliMGFiMTMzM2M3Yzk5NzVfOS0xLTEtMS0w_0e1ae674-dbc7-465f-89a9-de73542afae3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8efa8793ba8f446f8ffd529b619bbbfd_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjg5MmUxMTZkYjQxODQxYjg5YjBhYjEzMzNjN2M5OTc1L3RhYmxlcmFuZ2U6ODkyZTExNmRiNDE4NDFiODliMGFiMTMzM2M3Yzk5NzVfOS0zLTEtMS0w_3c575f5a-6c80-4410-b542-bc1646e2e308">20,136</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78246248a32444d0b6f9cc3c2d85efd5_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjg5MmUxMTZkYjQxODQxYjg5YjBhYjEzMzNjN2M5OTc1L3RhYmxlcmFuZ2U6ODkyZTExNmRiNDE4NDFiODliMGFiMTMzM2M3Yzk5NzVfOS01LTEtMS0w_56ff84e3-8dfa-4296-9453-b1f5a3f8f947">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaab08a4f99ff4ba2950d1437d42c90b2_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjg5MmUxMTZkYjQxODQxYjg5YjBhYjEzMzNjN2M5OTc1L3RhYmxlcmFuZ2U6ODkyZTExNmRiNDE4NDFiODliMGFiMTMzM2M3Yzk5NzVfOS03LTEtMS0w_46ae85f9-b271-46bb-8f1e-b0d1fe7fd9d9">20,136</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b542a8ed7164ce7a3f01a3325375861_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjg5MmUxMTZkYjQxODQxYjg5YjBhYjEzMzNjN2M5OTc1L3RhYmxlcmFuZ2U6ODkyZTExNmRiNDE4NDFiODliMGFiMTMzM2M3Yzk5NzVfMTAtMS0xLTEtMA_1d0bff01-9d19-47b4-85e3-97d7b43c47aa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i588c2440f58644e8a6a0c3b8856f304b_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjg5MmUxMTZkYjQxODQxYjg5YjBhYjEzMzNjN2M5OTc1L3RhYmxlcmFuZ2U6ODkyZTExNmRiNDE4NDFiODliMGFiMTMzM2M3Yzk5NzVfMTAtMy0xLTEtMA_18d785ee-e8ac-4108-a178-4f36d3b68c80">15,729</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic52a660c9ba0416c80ca6df7c8fb50dc_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjg5MmUxMTZkYjQxODQxYjg5YjBhYjEzMzNjN2M5OTc1L3RhYmxlcmFuZ2U6ODkyZTExNmRiNDE4NDFiODliMGFiMTMzM2M3Yzk5NzVfMTAtNS0xLTEtMA_a12bc185-e5d7-4c35-82c4-b1dc4e7803dd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf0336c48b2a4b5f93669576fb24b804_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjg5MmUxMTZkYjQxODQxYjg5YjBhYjEzMzNjN2M5OTc1L3RhYmxlcmFuZ2U6ODkyZTExNmRiNDE4NDFiODliMGFiMTMzM2M3Yzk5NzVfMTAtNy0xLTEtMA_9a319374-a0c5-4971-b6fd-6df27a496d61">15,729</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67d5388ca1f140b0b751939b213807d3_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjg5MmUxMTZkYjQxODQxYjg5YjBhYjEzMzNjN2M5OTc1L3RhYmxlcmFuZ2U6ODkyZTExNmRiNDE4NDFiODliMGFiMTMzM2M3Yzk5NzVfMTEtMS0xLTEtMA_0a35630f-638b-4a72-b1f9-95773163341e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9c36eef19a84e07bdddd763d415a7f7_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjg5MmUxMTZkYjQxODQxYjg5YjBhYjEzMzNjN2M5OTc1L3RhYmxlcmFuZ2U6ODkyZTExNmRiNDE4NDFiODliMGFiMTMzM2M3Yzk5NzVfMTEtMy0xLTEtMA_fa03f653-1159-46a1-a39a-1d59f726cd96">71,206</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b241ffdc9c94e2082b8b85ebca483df_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjg5MmUxMTZkYjQxODQxYjg5YjBhYjEzMzNjN2M5OTc1L3RhYmxlcmFuZ2U6ODkyZTExNmRiNDE4NDFiODliMGFiMTMzM2M3Yzk5NzVfMTEtNS0xLTEtMA_e28b401a-5137-453d-9ebe-006dfc03565e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i000addedaff44daba745c02655b81159_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjg5MmUxMTZkYjQxODQxYjg5YjBhYjEzMzNjN2M5OTc1L3RhYmxlcmFuZ2U6ODkyZTExNmRiNDE4NDFiODliMGFiMTMzM2M3Yzk5NzVfMTEtNy0xLTEtMA_686431c4-1c4d-46f2-a0ce-fb2bf42ea9d4">71,206</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. government treasuries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i131f1b1eb6604026a5c42366001ad668_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjg5MmUxMTZkYjQxODQxYjg5YjBhYjEzMzNjN2M5OTc1L3RhYmxlcmFuZ2U6ODkyZTExNmRiNDE4NDFiODliMGFiMTMzM2M3Yzk5NzVfMTMtMS0xLTEtMA_8da36e13-50f5-4f33-9723-05575fee6115">4,050</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79306ba88f4140a183b8a8b4b6135daa_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjg5MmUxMTZkYjQxODQxYjg5YjBhYjEzMzNjN2M5OTc1L3RhYmxlcmFuZ2U6ODkyZTExNmRiNDE4NDFiODliMGFiMTMzM2M3Yzk5NzVfMTMtMy0xLTEtMA_d2084932-1a6f-4356-99f0-fef0f7f0fb13">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0c77906277e4e39847898b3e7673e51_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjg5MmUxMTZkYjQxODQxYjg5YjBhYjEzMzNjN2M5OTc1L3RhYmxlcmFuZ2U6ODkyZTExNmRiNDE4NDFiODliMGFiMTMzM2M3Yzk5NzVfMTMtNS0xLTEtMA_d12b247b-5dfd-4817-8c1f-d3e109288255">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia06ecd5d4e7943cfb188e226606891fc_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjg5MmUxMTZkYjQxODQxYjg5YjBhYjEzMzNjN2M5OTc1L3RhYmxlcmFuZ2U6ODkyZTExNmRiNDE4NDFiODliMGFiMTMzM2M3Yzk5NzVfMTMtNy0xLTEtMA_70aa7c63-9033-48aa-b844-addd6f32e502">4,050</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19b242abfd1e4002a024557986c6d987_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjg5MmUxMTZkYjQxODQxYjg5YjBhYjEzMzNjN2M5OTc1L3RhYmxlcmFuZ2U6ODkyZTExNmRiNDE4NDFiODliMGFiMTMzM2M3Yzk5NzVfMTUtMS0xLTEtMA_948fec35-dc02-4aa1-8d1b-e3d9d02e7cb5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99a26d4be72a42eb865297d52d41de8b_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjg5MmUxMTZkYjQxODQxYjg5YjBhYjEzMzNjN2M5OTc1L3RhYmxlcmFuZ2U6ODkyZTExNmRiNDE4NDFiODliMGFiMTMzM2M3Yzk5NzVfMTUtMy0xLTEtMA_cc4cb9b4-5e11-4726-9757-cee2267cb113">34,835</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dbd5d046d3244ef870fa23ff49cb036_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjg5MmUxMTZkYjQxODQxYjg5YjBhYjEzMzNjN2M5OTc1L3RhYmxlcmFuZ2U6ODkyZTExNmRiNDE4NDFiODliMGFiMTMzM2M3Yzk5NzVfMTUtNS0xLTEtMA_4a75baba-068d-44e0-874a-9144a2193463">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4aa0eddd0fb49eda4c41fc2a826b8c1_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjg5MmUxMTZkYjQxODQxYjg5YjBhYjEzMzNjN2M5OTc1L3RhYmxlcmFuZ2U6ODkyZTExNmRiNDE4NDFiODliMGFiMTMzM2M3Yzk5NzVfMTUtNy0xLTEtMA_8fc2dbb4-a49d-493f-8ad3-a0208ff30552">34,835</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency derivative contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50be2f68d7ea46f1a2d7e733b2391ac5_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:DerivativeAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjg5MmUxMTZkYjQxODQxYjg5YjBhYjEzMzNjN2M5OTc1L3RhYmxlcmFuZ2U6ODkyZTExNmRiNDE4NDFiODliMGFiMTMzM2M3Yzk5NzVfMTYtMS0xLTEtMA_d69c6b15-b09f-46cb-abf1-ed2cd144e043">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0881221dc0304651bd4cc951315603f9_I20210331" decimals="-3" name="us-gaap:DerivativeAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjg5MmUxMTZkYjQxODQxYjg5YjBhYjEzMzNjN2M5OTc1L3RhYmxlcmFuZ2U6ODkyZTExNmRiNDE4NDFiODliMGFiMTMzM2M3Yzk5NzVfMTYtMy0xLTEtMA_7a9aa900-d923-4936-8764-1d3af8230965">45</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i057152fc2b0d48c0969e0b03ae05f47f_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:DerivativeAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjg5MmUxMTZkYjQxODQxYjg5YjBhYjEzMzNjN2M5OTc1L3RhYmxlcmFuZ2U6ODkyZTExNmRiNDE4NDFiODliMGFiMTMzM2M3Yzk5NzVfMTYtNS0xLTEtMA_d77d8de3-dbb5-4dde-8d9f-aeea75fc0d16">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9953f50a7fd74f7d8438f304f136a07b_I20210331" decimals="-3" name="us-gaap:DerivativeAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjg5MmUxMTZkYjQxODQxYjg5YjBhYjEzMzNjN2M5OTc1L3RhYmxlcmFuZ2U6ODkyZTExNmRiNDE4NDFiODliMGFiMTMzM2M3Yzk5NzVfMTYtNy0xLTEtMA_f4ff5d70-25b2-42ec-b798-b0956f08a963">45</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50be2f68d7ea46f1a2d7e733b2391ac5_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjg5MmUxMTZkYjQxODQxYjg5YjBhYjEzMzNjN2M5OTc1L3RhYmxlcmFuZ2U6ODkyZTExNmRiNDE4NDFiODliMGFiMTMzM2M3Yzk5NzVfMTctMS0xLTEtMA_746fc484-e4c9-45e8-8a65-339b5795348e">1,301,576</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0881221dc0304651bd4cc951315603f9_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjg5MmUxMTZkYjQxODQxYjg5YjBhYjEzMzNjN2M5OTc1L3RhYmxlcmFuZ2U6ODkyZTExNmRiNDE4NDFiODliMGFiMTMzM2M3Yzk5NzVfMTctMy0xLTEtMA_b279aced-4f17-42a6-b3ce-299fc03fb05e">141,951</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i057152fc2b0d48c0969e0b03ae05f47f_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjg5MmUxMTZkYjQxODQxYjg5YjBhYjEzMzNjN2M5OTc1L3RhYmxlcmFuZ2U6ODkyZTExNmRiNDE4NDFiODliMGFiMTMzM2M3Yzk5NzVfMTctNS0xLTEtMA_2de0da63-61c6-4951-9867-58dfb17e278c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9953f50a7fd74f7d8438f304f136a07b_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjg5MmUxMTZkYjQxODQxYjg5YjBhYjEzMzNjN2M5OTc1L3RhYmxlcmFuZ2U6ODkyZTExNmRiNDE4NDFiODliMGFiMTMzM2M3Yzk5NzVfMTctNy0xLTEtMA_46ba566e-23df-4c9c-a618-5041f4430c83">1,443,527</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency derivative contracts</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50be2f68d7ea46f1a2d7e733b2391ac5_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:DerivativeLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjg5MmUxMTZkYjQxODQxYjg5YjBhYjEzMzNjN2M5OTc1L3RhYmxlcmFuZ2U6ODkyZTExNmRiNDE4NDFiODliMGFiMTMzM2M3Yzk5NzVfMTktMS0xLTEtMA_8ae0959b-d949-4ecc-b2f5-819ade9efb96">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0881221dc0304651bd4cc951315603f9_I20210331" decimals="-3" name="us-gaap:DerivativeLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjg5MmUxMTZkYjQxODQxYjg5YjBhYjEzMzNjN2M5OTc1L3RhYmxlcmFuZ2U6ODkyZTExNmRiNDE4NDFiODliMGFiMTMzM2M3Yzk5NzVfMTktMy0xLTEtMA_7fc819cd-a98b-4960-ba5d-f94ef96cf62e">176</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i057152fc2b0d48c0969e0b03ae05f47f_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:DerivativeLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjg5MmUxMTZkYjQxODQxYjg5YjBhYjEzMzNjN2M5OTc1L3RhYmxlcmFuZ2U6ODkyZTExNmRiNDE4NDFiODliMGFiMTMzM2M3Yzk5NzVfMTktNS0xLTEtMA_9d1e2954-9f0f-45bf-baf7-f5920d888e1a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9953f50a7fd74f7d8438f304f136a07b_I20210331" decimals="-3" name="us-gaap:DerivativeLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjg5MmUxMTZkYjQxODQxYjg5YjBhYjEzMzNjN2M5OTc1L3RhYmxlcmFuZ2U6ODkyZTExNmRiNDE4NDFiODliMGFiMTMzM2M3Yzk5NzVfMTktNy0xLTEtMA_b8014c3f-7f56-41f6-bfd8-e78b534d99fb">176</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50be2f68d7ea46f1a2d7e733b2391ac5_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjg5MmUxMTZkYjQxODQxYjg5YjBhYjEzMzNjN2M5OTc1L3RhYmxlcmFuZ2U6ODkyZTExNmRiNDE4NDFiODliMGFiMTMzM2M3Yzk5NzVfMjAtMS0xLTEtMA_46b9de95-0a02-4c82-82b1-09dbf9a04910">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0881221dc0304651bd4cc951315603f9_I20210331" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjg5MmUxMTZkYjQxODQxYjg5YjBhYjEzMzNjN2M5OTc1L3RhYmxlcmFuZ2U6ODkyZTExNmRiNDE4NDFiODliMGFiMTMzM2M3Yzk5NzVfMjAtMy0xLTEtMA_db802700-3009-4797-be5f-54cb783567f9">176</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i057152fc2b0d48c0969e0b03ae05f47f_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjg5MmUxMTZkYjQxODQxYjg5YjBhYjEzMzNjN2M5OTc1L3RhYmxlcmFuZ2U6ODkyZTExNmRiNDE4NDFiODliMGFiMTMzM2M3Yzk5NzVfMjAtNS0xLTEtMA_fda7ec28-bdf7-4c97-8a79-fb9d69d1e01b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9953f50a7fd74f7d8438f304f136a07b_I20210331" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjg5MmUxMTZkYjQxODQxYjg5YjBhYjEzMzNjN2M5OTc1L3RhYmxlcmFuZ2U6ODkyZTExNmRiNDE4NDFiODliMGFiMTMzM2M3Yzk5NzVfMjAtNy0xLTEtMA_14195799-6b8a-43ed-8efa-7e9af96cd5b4">176</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-align:center"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5ae1cfc88aa4492caf56e9d4ac91e096_7">Table of Contents</a></span></div></div><ix:continuation id="id682624fb39444268ef50e1c6765a2f8"><div style="margin-bottom:6pt"><ix:continuation id="if6812bba0ea54b9da8302f34c458866a"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.053%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.884%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0489620584748b8a18511d5315c484d_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjIwYmEwMjk4ZDEyNDQ3MTRiMjk2NjkyNzRhNDZjOWQ2L3RhYmxlcmFuZ2U6MjBiYTAyOThkMTI0NDcxNGIyOTY2OTI3NGE0NmM5ZDZfNC0xLTEtMS0w_8df3c7a9-f289-4bfd-803a-b64d7b76165b">335,284</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iacef9d3f91dd40d0a87a4c4a0d2b6fb2_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjIwYmEwMjk4ZDEyNDQ3MTRiMjk2NjkyNzRhNDZjOWQ2L3RhYmxlcmFuZ2U6MjBiYTAyOThkMTI0NDcxNGIyOTY2OTI3NGE0NmM5ZDZfNC0zLTEtMS0w_d4d3d2a4-d84e-40cc-a00c-b84038d451a1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i216c3025b0124b688dd2fd43fb4468fb_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjIwYmEwMjk4ZDEyNDQ3MTRiMjk2NjkyNzRhNDZjOWQ2L3RhYmxlcmFuZ2U6MjBiYTAyOThkMTI0NDcxNGIyOTY2OTI3NGE0NmM5ZDZfNC01LTEtMS0w_9595e233-c039-4911-a91a-0b74d4f103ff">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib663c99903ea42359657773d88880b3a_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjIwYmEwMjk4ZDEyNDQ3MTRiMjk2NjkyNzRhNDZjOWQ2L3RhYmxlcmFuZ2U6MjBiYTAyOThkMTI0NDcxNGIyOTY2OTI3NGE0NmM5ZDZfNC03LTEtMS0w_028b7cb6-30c1-47d6-83a2-6c38b05685a1">335,284</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. government treasuries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4680cafe26584c1f86d850c496eda36c_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjIwYmEwMjk4ZDEyNDQ3MTRiMjk2NjkyNzRhNDZjOWQ2L3RhYmxlcmFuZ2U6MjBiYTAyOThkMTI0NDcxNGIyOTY2OTI3NGE0NmM5ZDZfNS0xLTEtMS0w_55a1521e-2348-404a-b45f-e681cbfd5715">149,997</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a690a2144264f4f8dfff3d5dfce6fe6_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjIwYmEwMjk4ZDEyNDQ3MTRiMjk2NjkyNzRhNDZjOWQ2L3RhYmxlcmFuZ2U6MjBiYTAyOThkMTI0NDcxNGIyOTY2OTI3NGE0NmM5ZDZfNS0zLTEtMS0w_a9ef62ff-b505-4a82-9f27-8271d48bb5b8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i239e913cbb1a4a0389051b486d08f75a_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjIwYmEwMjk4ZDEyNDQ3MTRiMjk2NjkyNzRhNDZjOWQ2L3RhYmxlcmFuZ2U6MjBiYTAyOThkMTI0NDcxNGIyOTY2OTI3NGE0NmM5ZDZfNS01LTEtMS0w_3166aecf-10fd-47e2-a1ce-bc96b2c3240b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if25b3a1f38994654bc19ed04aca9372f_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjIwYmEwMjk4ZDEyNDQ3MTRiMjk2NjkyNzRhNDZjOWQ2L3RhYmxlcmFuZ2U6MjBiYTAyOThkMTI0NDcxNGIyOTY2OTI3NGE0NmM5ZDZfNS03LTEtMS0w_ebb4c3ac-2787-4e55-b248-c1d4dc38ca4b">149,997</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Short-term marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. government treasuries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc5b52a3db1b4f8baed84d10ed64492c_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjIwYmEwMjk4ZDEyNDQ3MTRiMjk2NjkyNzRhNDZjOWQ2L3RhYmxlcmFuZ2U6MjBiYTAyOThkMTI0NDcxNGIyOTY2OTI3NGE0NmM5ZDZfNy0xLTEtMS0w_96b36df7-0b78-4100-98d0-ea97fe2f83f9">878,938</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86c3ea8f2f1f49c4a026b6bc52858668_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjIwYmEwMjk4ZDEyNDQ3MTRiMjk2NjkyNzRhNDZjOWQ2L3RhYmxlcmFuZ2U6MjBiYTAyOThkMTI0NDcxNGIyOTY2OTI3NGE0NmM5ZDZfNy0zLTEtMS0w_4b6aa9b7-4e53-4a83-ac22-c8cecca32f35">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i908a382fdfd44406be1c76e156800e93_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjIwYmEwMjk4ZDEyNDQ3MTRiMjk2NjkyNzRhNDZjOWQ2L3RhYmxlcmFuZ2U6MjBiYTAyOThkMTI0NDcxNGIyOTY2OTI3NGE0NmM5ZDZfNy01LTEtMS0w_40b2e6f7-50cb-46d6-9cbd-10619343c7c7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72798f9b723345d7b2945778149039ab_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjIwYmEwMjk4ZDEyNDQ3MTRiMjk2NjkyNzRhNDZjOWQ2L3RhYmxlcmFuZ2U6MjBiYTAyOThkMTI0NDcxNGIyOTY2OTI3NGE0NmM5ZDZfNy03LTEtMS0w_6c8a643b-a124-4dc8-bab4-4b4c6cbd96f9">878,938</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. government agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i118d49e34100478aad6bb4134c3b2aaa_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjIwYmEwMjk4ZDEyNDQ3MTRiMjk2NjkyNzRhNDZjOWQ2L3RhYmxlcmFuZ2U6MjBiYTAyOThkMTI0NDcxNGIyOTY2OTI3NGE0NmM5ZDZfOC0xLTEtMS0w_e81c639b-6617-4294-9de5-9c5ba06c739f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i178051c344504d07985f78aa8cc32492_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjIwYmEwMjk4ZDEyNDQ3MTRiMjk2NjkyNzRhNDZjOWQ2L3RhYmxlcmFuZ2U6MjBiYTAyOThkMTI0NDcxNGIyOTY2OTI3NGE0NmM5ZDZfOC0zLTEtMS0w_a18c8097-c484-4eec-8420-f369d6297428">25,217</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3593591cc6b4645bcbbae5e79b647d6_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjIwYmEwMjk4ZDEyNDQ3MTRiMjk2NjkyNzRhNDZjOWQ2L3RhYmxlcmFuZ2U6MjBiYTAyOThkMTI0NDcxNGIyOTY2OTI3NGE0NmM5ZDZfOC01LTEtMS0w_c95173a1-b335-4c64-bef4-2c0dc8a19db2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9286f708ff8349709d22f68a1a329272_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjIwYmEwMjk4ZDEyNDQ3MTRiMjk2NjkyNzRhNDZjOWQ2L3RhYmxlcmFuZ2U6MjBiYTAyOThkMTI0NDcxNGIyOTY2OTI3NGE0NmM5ZDZfOC03LTEtMS0w_128b4016-c3bc-466c-9545-1c06e30d1cf5">25,217</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ided63883ce3647bc936cd798e72ea186_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjIwYmEwMjk4ZDEyNDQ3MTRiMjk2NjkyNzRhNDZjOWQ2L3RhYmxlcmFuZ2U6MjBiYTAyOThkMTI0NDcxNGIyOTY2OTI3NGE0NmM5ZDZfOS0xLTEtMS0w_6b06e93a-fa30-4ed0-89c6-5956679aa0c2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e93f92b75c548efb9c7fbf7491b4063_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjIwYmEwMjk4ZDEyNDQ3MTRiMjk2NjkyNzRhNDZjOWQ2L3RhYmxlcmFuZ2U6MjBiYTAyOThkMTI0NDcxNGIyOTY2OTI3NGE0NmM5ZDZfOS0zLTEtMS0w_46eb873f-0f99-4449-826a-6f75fd4167b0">27,180</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb6cdf24410f45c282312f8166a766ff_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjIwYmEwMjk4ZDEyNDQ3MTRiMjk2NjkyNzRhNDZjOWQ2L3RhYmxlcmFuZ2U6MjBiYTAyOThkMTI0NDcxNGIyOTY2OTI3NGE0NmM5ZDZfOS01LTEtMS0w_8f50b06d-3a50-431b-a940-b900f72b159c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic16516c243df4551a83161ad3c5c0f09_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjIwYmEwMjk4ZDEyNDQ3MTRiMjk2NjkyNzRhNDZjOWQ2L3RhYmxlcmFuZ2U6MjBiYTAyOThkMTI0NDcxNGIyOTY2OTI3NGE0NmM5ZDZfOS03LTEtMS0w_71da31fb-acf8-4246-b267-ca37e257aa56">27,180</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25d88de0f197490fb779e1e3071f901e_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjIwYmEwMjk4ZDEyNDQ3MTRiMjk2NjkyNzRhNDZjOWQ2L3RhYmxlcmFuZ2U6MjBiYTAyOThkMTI0NDcxNGIyOTY2OTI3NGE0NmM5ZDZfMTAtMS0xLTEtMA_0fd322aa-06fd-4f75-94a8-9ac8ec1c9d3a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b60ffb67bd147c3a56d06666f6ff77c_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjIwYmEwMjk4ZDEyNDQ3MTRiMjk2NjkyNzRhNDZjOWQ2L3RhYmxlcmFuZ2U6MjBiYTAyOThkMTI0NDcxNGIyOTY2OTI3NGE0NmM5ZDZfMTAtMy0xLTEtMA_56b3f254-e093-4404-a1f4-38e20aa66f82">31,218</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfac6e99e22f43c68f58fb5907948edb_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjIwYmEwMjk4ZDEyNDQ3MTRiMjk2NjkyNzRhNDZjOWQ2L3RhYmxlcmFuZ2U6MjBiYTAyOThkMTI0NDcxNGIyOTY2OTI3NGE0NmM5ZDZfMTAtNS0xLTEtMA_b9f421f6-f2f1-413a-9035-2e473189fee4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf6e2668dddb49d2ac374501483e7bf9_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjIwYmEwMjk4ZDEyNDQ3MTRiMjk2NjkyNzRhNDZjOWQ2L3RhYmxlcmFuZ2U6MjBiYTAyOThkMTI0NDcxNGIyOTY2OTI3NGE0NmM5ZDZfMTAtNy0xLTEtMA_8cba09fe-5555-4834-a994-a6d64c3495fe">31,218</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term marketable securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. government treasuries</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i215ae1ee50d14e92a7ea23ab3f943a5d_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjIwYmEwMjk4ZDEyNDQ3MTRiMjk2NjkyNzRhNDZjOWQ2L3RhYmxlcmFuZ2U6MjBiYTAyOThkMTI0NDcxNGIyOTY2OTI3NGE0NmM5ZDZfMTItMS0xLTEtMA_5a7f0dae-fbb5-4bb0-992a-6adc0c14ec84">2,561</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4026f6a97f4340d6a98d226ab3c04c12_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjIwYmEwMjk4ZDEyNDQ3MTRiMjk2NjkyNzRhNDZjOWQ2L3RhYmxlcmFuZ2U6MjBiYTAyOThkMTI0NDcxNGIyOTY2OTI3NGE0NmM5ZDZfMTItMy0xLTEtMA_efa70157-85f0-40dc-8c4e-1cb0f3a4dad3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec8ba588c80d4f4191cc54f76a956ff0_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjIwYmEwMjk4ZDEyNDQ3MTRiMjk2NjkyNzRhNDZjOWQ2L3RhYmxlcmFuZ2U6MjBiYTAyOThkMTI0NDcxNGIyOTY2OTI3NGE0NmM5ZDZfMTItNS0xLTEtMA_80fc19de-37fb-4706-bb6f-0311e33886d7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57f0286f0cdd41afb93b20cd06df11c7_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjIwYmEwMjk4ZDEyNDQ3MTRiMjk2NjkyNzRhNDZjOWQ2L3RhYmxlcmFuZ2U6MjBiYTAyOThkMTI0NDcxNGIyOTY2OTI3NGE0NmM5ZDZfMTItNy0xLTEtMA_68d1d7db-4d36-44fe-8c3b-2200fd39e0a3">2,561</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i480dc0971b7d403fad3d95c1932c7534_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjIwYmEwMjk4ZDEyNDQ3MTRiMjk2NjkyNzRhNDZjOWQ2L3RhYmxlcmFuZ2U6MjBiYTAyOThkMTI0NDcxNGIyOTY2OTI3NGE0NmM5ZDZfMTMtMS0xLTEtMA_6828a0e3-3f5b-403c-b730-0da9d39d6dd7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa86ad4908bc434aa3c51f66f9a60281_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjIwYmEwMjk4ZDEyNDQ3MTRiMjk2NjkyNzRhNDZjOWQ2L3RhYmxlcmFuZ2U6MjBiYTAyOThkMTI0NDcxNGIyOTY2OTI3NGE0NmM5ZDZfMTMtMy0xLTEtMA_c2fac36f-5123-484d-9d86-f19aaaad3d64">30,138</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4170e2296ad4137872fb9951088b913_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjIwYmEwMjk4ZDEyNDQ3MTRiMjk2NjkyNzRhNDZjOWQ2L3RhYmxlcmFuZ2U6MjBiYTAyOThkMTI0NDcxNGIyOTY2OTI3NGE0NmM5ZDZfMTMtNS0xLTEtMA_8dd39fe9-0e24-4451-ba38-0f86b579d736">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6da17c1dcc0c448cbd20f8ec3a5656d1_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjIwYmEwMjk4ZDEyNDQ3MTRiMjk2NjkyNzRhNDZjOWQ2L3RhYmxlcmFuZ2U6MjBiYTAyOThkMTI0NDcxNGIyOTY2OTI3NGE0NmM5ZDZfMTMtNy0xLTEtMA_b09a0e18-0e51-4f0d-a6f6-267b99c75594">30,138</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency derivative contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b67e7dddea84ea5bd2068d25930c3f0_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:DerivativeAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjIwYmEwMjk4ZDEyNDQ3MTRiMjk2NjkyNzRhNDZjOWQ2L3RhYmxlcmFuZ2U6MjBiYTAyOThkMTI0NDcxNGIyOTY2OTI3NGE0NmM5ZDZfMTQtMS0xLTEtMA_18bb0888-2521-4ddc-afad-59633f6d9d2c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71c0a54ceaf448c7b9d4d9c1d534b5cc_I20201231" decimals="-3" name="us-gaap:DerivativeAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjIwYmEwMjk4ZDEyNDQ3MTRiMjk2NjkyNzRhNDZjOWQ2L3RhYmxlcmFuZ2U6MjBiYTAyOThkMTI0NDcxNGIyOTY2OTI3NGE0NmM5ZDZfMTQtMy0xLTEtMA_c26cf1e4-8146-4579-b4ba-dcf0816dd115">185</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2db26540968047c2b760e6148893f1f0_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:DerivativeAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjIwYmEwMjk4ZDEyNDQ3MTRiMjk2NjkyNzRhNDZjOWQ2L3RhYmxlcmFuZ2U6MjBiYTAyOThkMTI0NDcxNGIyOTY2OTI3NGE0NmM5ZDZfMTQtNS0xLTEtMA_7abfd15e-3d72-4f41-a6b4-de76a178aaaa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb7ca9f362da46eab3a29bbbecbda977_I20201231" decimals="-3" name="us-gaap:DerivativeAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjIwYmEwMjk4ZDEyNDQ3MTRiMjk2NjkyNzRhNDZjOWQ2L3RhYmxlcmFuZ2U6MjBiYTAyOThkMTI0NDcxNGIyOTY2OTI3NGE0NmM5ZDZfMTQtNy0xLTEtMA_ea59584f-af8f-40eb-b19e-64593506ec4d">185</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b67e7dddea84ea5bd2068d25930c3f0_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjIwYmEwMjk4ZDEyNDQ3MTRiMjk2NjkyNzRhNDZjOWQ2L3RhYmxlcmFuZ2U6MjBiYTAyOThkMTI0NDcxNGIyOTY2OTI3NGE0NmM5ZDZfMTUtMS0xLTEtMA_f9796c26-96f9-49e6-a32f-4297dc1e16bc">1,366,780</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71c0a54ceaf448c7b9d4d9c1d534b5cc_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjIwYmEwMjk4ZDEyNDQ3MTRiMjk2NjkyNzRhNDZjOWQ2L3RhYmxlcmFuZ2U6MjBiYTAyOThkMTI0NDcxNGIyOTY2OTI3NGE0NmM5ZDZfMTUtMy0xLTEtMA_57b98d1c-9d16-4f3a-94b0-6c0c1908ed6f">113,938</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2db26540968047c2b760e6148893f1f0_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjIwYmEwMjk4ZDEyNDQ3MTRiMjk2NjkyNzRhNDZjOWQ2L3RhYmxlcmFuZ2U6MjBiYTAyOThkMTI0NDcxNGIyOTY2OTI3NGE0NmM5ZDZfMTUtNS0xLTEtMA_bbcd8ae6-8dd6-460f-9a55-cb1bb6a43a95">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb7ca9f362da46eab3a29bbbecbda977_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjIwYmEwMjk4ZDEyNDQ3MTRiMjk2NjkyNzRhNDZjOWQ2L3RhYmxlcmFuZ2U6MjBiYTAyOThkMTI0NDcxNGIyOTY2OTI3NGE0NmM5ZDZfMTUtNy0xLTEtMA_66665f51-1c08-4cbe-88c4-7e1a3431969a">1,480,718</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liabilities:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency derivative contracts</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b67e7dddea84ea5bd2068d25930c3f0_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:DerivativeLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjIwYmEwMjk4ZDEyNDQ3MTRiMjk2NjkyNzRhNDZjOWQ2L3RhYmxlcmFuZ2U6MjBiYTAyOThkMTI0NDcxNGIyOTY2OTI3NGE0NmM5ZDZfMTctMS0xLTEtMA_1e1e226f-47fd-4471-b265-1f483d73cb1d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71c0a54ceaf448c7b9d4d9c1d534b5cc_I20201231" decimals="-3" name="us-gaap:DerivativeLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjIwYmEwMjk4ZDEyNDQ3MTRiMjk2NjkyNzRhNDZjOWQ2L3RhYmxlcmFuZ2U6MjBiYTAyOThkMTI0NDcxNGIyOTY2OTI3NGE0NmM5ZDZfMTctMy0xLTEtMA_70360605-57d2-495a-8234-1e001bbca4fb">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2db26540968047c2b760e6148893f1f0_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:DerivativeLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjIwYmEwMjk4ZDEyNDQ3MTRiMjk2NjkyNzRhNDZjOWQ2L3RhYmxlcmFuZ2U6MjBiYTAyOThkMTI0NDcxNGIyOTY2OTI3NGE0NmM5ZDZfMTctNS0xLTEtMA_a577d26e-248d-4ada-9466-b1c4ce4532b8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb7ca9f362da46eab3a29bbbecbda977_I20201231" decimals="-3" name="us-gaap:DerivativeLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjIwYmEwMjk4ZDEyNDQ3MTRiMjk2NjkyNzRhNDZjOWQ2L3RhYmxlcmFuZ2U6MjBiYTAyOThkMTI0NDcxNGIyOTY2OTI3NGE0NmM5ZDZfMTctNy0xLTEtMA_30748d42-b37c-4157-9c7e-22f759f7524b">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b67e7dddea84ea5bd2068d25930c3f0_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjIwYmEwMjk4ZDEyNDQ3MTRiMjk2NjkyNzRhNDZjOWQ2L3RhYmxlcmFuZ2U6MjBiYTAyOThkMTI0NDcxNGIyOTY2OTI3NGE0NmM5ZDZfMTgtMS0xLTEtMA_223fa935-25c6-4792-ba49-450885f135c5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71c0a54ceaf448c7b9d4d9c1d534b5cc_I20201231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjIwYmEwMjk4ZDEyNDQ3MTRiMjk2NjkyNzRhNDZjOWQ2L3RhYmxlcmFuZ2U6MjBiYTAyOThkMTI0NDcxNGIyOTY2OTI3NGE0NmM5ZDZfMTgtMy0xLTEtMA_06689b59-a98b-4b38-8afd-52cdde0f3809">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2db26540968047c2b760e6148893f1f0_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjIwYmEwMjk4ZDEyNDQ3MTRiMjk2NjkyNzRhNDZjOWQ2L3RhYmxlcmFuZ2U6MjBiYTAyOThkMTI0NDcxNGIyOTY2OTI3NGE0NmM5ZDZfMTgtNS0xLTEtMA_f9df74b8-0b97-4a3b-8eda-a27da5a6247a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb7ca9f362da46eab3a29bbbecbda977_I20201231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjIwYmEwMjk4ZDEyNDQ3MTRiMjk2NjkyNzRhNDZjOWQ2L3RhYmxlcmFuZ2U6MjBiYTAyOThkMTI0NDcxNGIyOTY2OTI3NGE0NmM5ZDZfMTgtNy0xLTEtMA_8e80dc48-f93b-46e0-8ab6-6f4357d5627b">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of prepaid expenses and other current assets, accounts payable and accrued liabilities approximate their fair values due to their short-term maturities.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s Level&#160;2 securities are valued using third-party pricing sources. The pricing services utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company has not transferred any assets or liabilities between the fair value measurement levels.</span></div></ix:continuation><div id="i5ae1cfc88aa4492caf56e9d4ac91e096_37"></div><div style="margin-top:18pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331" name="us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RleHRyZWdpb246MjFlN2QzYmNkYTljNDAwMzgwZjEzZmJmZjY4YzA4NTRfMjczNQ_0201c45f-8bf2-4b07-bb51-db9a7ed160a8" continuedAt="id21fe29faf644312aa8d1aaf1455475a" escape="true">Marketable Securities</ix:nonNumeric></span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="id21fe29faf644312aa8d1aaf1455475a" continuedAt="i24e97f9602044061ba73c2f1942232bf">All marketable securities were considered&#160;available-for-sale&#160;at March 31, 2021 and December 31, 2020. On a recurring basis, the Company records its marketable securities at fair value using Level 1 or Level 2 inputs as discussed in Note 2, "Fair Value Measurements". <ix:nonNumeric contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331" name="us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RleHRyZWdpb246MjFlN2QzYmNkYTljNDAwMzgwZjEzZmJmZjY4YzA4NTRfMjczMQ_cc4ceb8b-581c-499a-bfc1-b88b30c73ab8" continuedAt="i19e81f3d540749dcb9ac45d03721eea1" escape="true">The amortized cost, gross unrealized holding gains or losses, and fair value of the Company&#8217;s marketable securities by major security type at each balance sheet date are summarized in the tables below (in thousands):</ix:nonNumeric></ix:continuation></span></div><div style="text-indent:27pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5ae1cfc88aa4492caf56e9d4ac91e096_7">Table of Contents</a></span></div></div><ix:continuation id="i24e97f9602044061ba73c2f1942232bf"><ix:continuation id="i19e81f3d540749dcb9ac45d03721eea1"><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.085%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.002%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.002%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.002%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.006%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Holding Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Holding Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Short-term marketable securities:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. government treasuries</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c991a09175c4907972778fd5a54038d_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RhYmxlOjhjMjY2ZGU1NDdhOTQ2ODM4YmIxZGYzMjdjMTY2YmU3L3RhYmxlcmFuZ2U6OGMyNjZkZTU0N2E5NDY4MzhiYjFkZjMyN2MxNjZiZTdfMy0xLTEtMS0w_24b67c7b-3724-4d7c-bd9c-606e1fd9e184">870,674</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c991a09175c4907972778fd5a54038d_I20210331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RhYmxlOjhjMjY2ZGU1NDdhOTQ2ODM4YmIxZGYzMjdjMTY2YmU3L3RhYmxlcmFuZ2U6OGMyNjZkZTU0N2E5NDY4MzhiYjFkZjMyN2MxNjZiZTdfMy0zLTEtMS0w_5a600c62-ccd4-4f10-bbef-5fbceb38484e">90</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5c991a09175c4907972778fd5a54038d_I20210331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RhYmxlOjhjMjY2ZGU1NDdhOTQ2ODM4YmIxZGYzMjdjMTY2YmU3L3RhYmxlcmFuZ2U6OGMyNjZkZTU0N2E5NDY4MzhiYjFkZjMyN2MxNjZiZTdfMy01LTEtMS0w_142fcb05-8627-4c8c-a9c5-5bb10a3e79bd">8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c991a09175c4907972778fd5a54038d_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RhYmxlOjhjMjY2ZGU1NDdhOTQ2ODM4YmIxZGYzMjdjMTY2YmU3L3RhYmxlcmFuZ2U6OGMyNjZkZTU0N2E5NDY4MzhiYjFkZjMyN2MxNjZiZTdfMy03LTEtMS0w_03c1da61-0207-40ea-93b8-58c0d6c2049b">870,756</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. government agency securities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58c971960b254076bc5ebc8a3a3a5a34_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RhYmxlOjhjMjY2ZGU1NDdhOTQ2ODM4YmIxZGYzMjdjMTY2YmU3L3RhYmxlcmFuZ2U6OGMyNjZkZTU0N2E5NDY4MzhiYjFkZjMyN2MxNjZiZTdfNC0xLTEtMS0w_278cc404-49ab-43dd-9139-5df8d868ae01">20,126</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58c971960b254076bc5ebc8a3a3a5a34_I20210331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RhYmxlOjhjMjY2ZGU1NDdhOTQ2ODM4YmIxZGYzMjdjMTY2YmU3L3RhYmxlcmFuZ2U6OGMyNjZkZTU0N2E5NDY4MzhiYjFkZjMyN2MxNjZiZTdfNC0zLTEtMS0w_62f6e81a-4f9f-4215-ba7a-872c4d6cc5bb">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58c971960b254076bc5ebc8a3a3a5a34_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RhYmxlOjhjMjY2ZGU1NDdhOTQ2ODM4YmIxZGYzMjdjMTY2YmU3L3RhYmxlcmFuZ2U6OGMyNjZkZTU0N2E5NDY4MzhiYjFkZjMyN2MxNjZiZTdfNC01LTEtMS0w_58a3ddcc-0427-4393-b881-95ace9665d92">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58c971960b254076bc5ebc8a3a3a5a34_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RhYmxlOjhjMjY2ZGU1NDdhOTQ2ODM4YmIxZGYzMjdjMTY2YmU3L3RhYmxlcmFuZ2U6OGMyNjZkZTU0N2E5NDY4MzhiYjFkZjMyN2MxNjZiZTdfNC03LTEtMS0w_5c94fef5-2505-4751-adc4-0a683c618977">20,136</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5abb55cd5abc4ef4a6963ecc132bb1be_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RhYmxlOjhjMjY2ZGU1NDdhOTQ2ODM4YmIxZGYzMjdjMTY2YmU3L3RhYmxlcmFuZ2U6OGMyNjZkZTU0N2E5NDY4MzhiYjFkZjMyN2MxNjZiZTdfNS0xLTEtMS0w_7765d5a6-baef-4bdc-84dd-0e375dcc48d4">15,684</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5abb55cd5abc4ef4a6963ecc132bb1be_I20210331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RhYmxlOjhjMjY2ZGU1NDdhOTQ2ODM4YmIxZGYzMjdjMTY2YmU3L3RhYmxlcmFuZ2U6OGMyNjZkZTU0N2E5NDY4MzhiYjFkZjMyN2MxNjZiZTdfNS0zLTEtMS0w_7a8d57f3-0ed6-402d-ac4d-f5289e457966">48</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5abb55cd5abc4ef4a6963ecc132bb1be_I20210331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RhYmxlOjhjMjY2ZGU1NDdhOTQ2ODM4YmIxZGYzMjdjMTY2YmU3L3RhYmxlcmFuZ2U6OGMyNjZkZTU0N2E5NDY4MzhiYjFkZjMyN2MxNjZiZTdfNS01LTEtMS0w_3e29f035-b2e4-48b9-bf61-a3a4359cdf9f">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5abb55cd5abc4ef4a6963ecc132bb1be_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RhYmxlOjhjMjY2ZGU1NDdhOTQ2ODM4YmIxZGYzMjdjMTY2YmU3L3RhYmxlcmFuZ2U6OGMyNjZkZTU0N2E5NDY4MzhiYjFkZjMyN2MxNjZiZTdfNS03LTEtMS0w_9135baef-3040-4310-83c1-0b6739cc6554">15,729</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i382bf15544d0451c8ad0005fe504ecc1_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RhYmxlOjhjMjY2ZGU1NDdhOTQ2ODM4YmIxZGYzMjdjMTY2YmU3L3RhYmxlcmFuZ2U6OGMyNjZkZTU0N2E5NDY4MzhiYjFkZjMyN2MxNjZiZTdfNi0xLTEtMS0w_605ea546-6a09-4b50-af0b-27852b28c9eb">71,206</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i382bf15544d0451c8ad0005fe504ecc1_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RhYmxlOjhjMjY2ZGU1NDdhOTQ2ODM4YmIxZGYzMjdjMTY2YmU3L3RhYmxlcmFuZ2U6OGMyNjZkZTU0N2E5NDY4MzhiYjFkZjMyN2MxNjZiZTdfNi0zLTEtMS0w_f39965c3-80f6-40c5-aeaa-7b7cad5f6d85">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i382bf15544d0451c8ad0005fe504ecc1_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RhYmxlOjhjMjY2ZGU1NDdhOTQ2ODM4YmIxZGYzMjdjMTY2YmU3L3RhYmxlcmFuZ2U6OGMyNjZkZTU0N2E5NDY4MzhiYjFkZjMyN2MxNjZiZTdfNi01LTEtMS0w_e9e2c23d-ad3e-45bb-b850-ab4c125593b6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i382bf15544d0451c8ad0005fe504ecc1_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RhYmxlOjhjMjY2ZGU1NDdhOTQ2ODM4YmIxZGYzMjdjMTY2YmU3L3RhYmxlcmFuZ2U6OGMyNjZkZTU0N2E5NDY4MzhiYjFkZjMyN2MxNjZiZTdfNi03LTEtMS0w_54ce129a-c6de-4f42-b982-7b2fad6005d9">71,206</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total short-term marketable securities</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c72ee3da1524776845e9b5ae9946eee_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RhYmxlOjhjMjY2ZGU1NDdhOTQ2ODM4YmIxZGYzMjdjMTY2YmU3L3RhYmxlcmFuZ2U6OGMyNjZkZTU0N2E5NDY4MzhiYjFkZjMyN2MxNjZiZTdfNy0xLTEtMS0w_7ebc8885-71b5-4967-aad0-8e07c87a55df">977,690</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c72ee3da1524776845e9b5ae9946eee_I20210331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RhYmxlOjhjMjY2ZGU1NDdhOTQ2ODM4YmIxZGYzMjdjMTY2YmU3L3RhYmxlcmFuZ2U6OGMyNjZkZTU0N2E5NDY4MzhiYjFkZjMyN2MxNjZiZTdfNy0zLTEtMS0w_71927f3e-1cee-43d8-ae6e-7a7a251a5ce1">148</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c72ee3da1524776845e9b5ae9946eee_I20210331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RhYmxlOjhjMjY2ZGU1NDdhOTQ2ODM4YmIxZGYzMjdjMTY2YmU3L3RhYmxlcmFuZ2U6OGMyNjZkZTU0N2E5NDY4MzhiYjFkZjMyN2MxNjZiZTdfNy01LTEtMS0w_6a0bdf0b-8eda-4cba-a62d-6eefcfa51b9f">11</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c72ee3da1524776845e9b5ae9946eee_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RhYmxlOjhjMjY2ZGU1NDdhOTQ2ODM4YmIxZGYzMjdjMTY2YmU3L3RhYmxlcmFuZ2U6OGMyNjZkZTU0N2E5NDY4MzhiYjFkZjMyN2MxNjZiZTdfNy03LTEtMS0w_68526601-ba8a-4ba0-922a-642ba1e10374">977,827</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term marketable securities:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. government treasuries</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89fb6181d11a43d88db96cf5f175becc_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RhYmxlOjhjMjY2ZGU1NDdhOTQ2ODM4YmIxZGYzMjdjMTY2YmU3L3RhYmxlcmFuZ2U6OGMyNjZkZTU0N2E5NDY4MzhiYjFkZjMyN2MxNjZiZTdfOS0xLTEtMS0w_5ff8e70c-3f83-4071-9fc6-04a17b6a042d">4,049</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89fb6181d11a43d88db96cf5f175becc_I20210331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RhYmxlOjhjMjY2ZGU1NDdhOTQ2ODM4YmIxZGYzMjdjMTY2YmU3L3RhYmxlcmFuZ2U6OGMyNjZkZTU0N2E5NDY4MzhiYjFkZjMyN2MxNjZiZTdfOS0zLTEtMS0w_ed299bf1-2623-4400-8dff-5c533bb94566">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89fb6181d11a43d88db96cf5f175becc_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RhYmxlOjhjMjY2ZGU1NDdhOTQ2ODM4YmIxZGYzMjdjMTY2YmU3L3RhYmxlcmFuZ2U6OGMyNjZkZTU0N2E5NDY4MzhiYjFkZjMyN2MxNjZiZTdfOS01LTEtMS0w_3097c93f-0d3f-476f-bea1-60fd75e8ba35">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89fb6181d11a43d88db96cf5f175becc_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RhYmxlOjhjMjY2ZGU1NDdhOTQ2ODM4YmIxZGYzMjdjMTY2YmU3L3RhYmxlcmFuZ2U6OGMyNjZkZTU0N2E5NDY4MzhiYjFkZjMyN2MxNjZiZTdfOS03LTEtMS0w_eec4817b-931e-44e5-9a19-aef9fd61ac60">4,050</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad80279b43b74b3fbb24392412ebf8d4_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RhYmxlOjhjMjY2ZGU1NDdhOTQ2ODM4YmIxZGYzMjdjMTY2YmU3L3RhYmxlcmFuZ2U6OGMyNjZkZTU0N2E5NDY4MzhiYjFkZjMyN2MxNjZiZTdfMTEtMS0xLTEtMA_5d3ae2ec-9b83-4b89-a2fc-e7a3c9de2820">34,854</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad80279b43b74b3fbb24392412ebf8d4_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RhYmxlOjhjMjY2ZGU1NDdhOTQ2ODM4YmIxZGYzMjdjMTY2YmU3L3RhYmxlcmFuZ2U6OGMyNjZkZTU0N2E5NDY4MzhiYjFkZjMyN2MxNjZiZTdfMTEtMy0xLTEtMA_dbb3994b-aeb5-4643-8e51-5be15ec3e7c0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iad80279b43b74b3fbb24392412ebf8d4_I20210331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RhYmxlOjhjMjY2ZGU1NDdhOTQ2ODM4YmIxZGYzMjdjMTY2YmU3L3RhYmxlcmFuZ2U6OGMyNjZkZTU0N2E5NDY4MzhiYjFkZjMyN2MxNjZiZTdfMTEtNS0xLTEtMA_7afbac0b-aae5-4c65-84fa-07725617d817">19</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad80279b43b74b3fbb24392412ebf8d4_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RhYmxlOjhjMjY2ZGU1NDdhOTQ2ODM4YmIxZGYzMjdjMTY2YmU3L3RhYmxlcmFuZ2U6OGMyNjZkZTU0N2E5NDY4MzhiYjFkZjMyN2MxNjZiZTdfMTEtNy0xLTEtMA_f8d4e75c-5541-4d18-97b2-a512317d774a">34,835</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total long-term marketable securities</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id97fb3aa68ae491e9d798fe7cf3f01b6_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RhYmxlOjhjMjY2ZGU1NDdhOTQ2ODM4YmIxZGYzMjdjMTY2YmU3L3RhYmxlcmFuZ2U6OGMyNjZkZTU0N2E5NDY4MzhiYjFkZjMyN2MxNjZiZTdfMTItMS0xLTEtMA_5ac2c7ff-e496-4c9d-b6c5-a67f9d8e10cb">38,903</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id97fb3aa68ae491e9d798fe7cf3f01b6_I20210331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RhYmxlOjhjMjY2ZGU1NDdhOTQ2ODM4YmIxZGYzMjdjMTY2YmU3L3RhYmxlcmFuZ2U6OGMyNjZkZTU0N2E5NDY4MzhiYjFkZjMyN2MxNjZiZTdfMTItMy0xLTEtMA_6deaa75a-da2c-41cc-842e-538068f9e1b2">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id97fb3aa68ae491e9d798fe7cf3f01b6_I20210331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RhYmxlOjhjMjY2ZGU1NDdhOTQ2ODM4YmIxZGYzMjdjMTY2YmU3L3RhYmxlcmFuZ2U6OGMyNjZkZTU0N2E5NDY4MzhiYjFkZjMyN2MxNjZiZTdfMTItNS0xLTEtMA_80b4f6ef-826a-45df-9220-77f0bc436761">19</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id97fb3aa68ae491e9d798fe7cf3f01b6_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RhYmxlOjhjMjY2ZGU1NDdhOTQ2ODM4YmIxZGYzMjdjMTY2YmU3L3RhYmxlcmFuZ2U6OGMyNjZkZTU0N2E5NDY4MzhiYjFkZjMyN2MxNjZiZTdfMTItNy0xLTEtMA_4920cf81-8df7-41f6-bd30-b647a083f8ad">38,885</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9953f50a7fd74f7d8438f304f136a07b_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RhYmxlOjhjMjY2ZGU1NDdhOTQ2ODM4YmIxZGYzMjdjMTY2YmU3L3RhYmxlcmFuZ2U6OGMyNjZkZTU0N2E5NDY4MzhiYjFkZjMyN2MxNjZiZTdfMTMtMS0xLTEtMA_b63bea75-fa2c-48fd-b3f5-20415950beda">1,016,593</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9953f50a7fd74f7d8438f304f136a07b_I20210331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RhYmxlOjhjMjY2ZGU1NDdhOTQ2ODM4YmIxZGYzMjdjMTY2YmU3L3RhYmxlcmFuZ2U6OGMyNjZkZTU0N2E5NDY4MzhiYjFkZjMyN2MxNjZiZTdfMTMtMy0xLTEtMA_11c07772-b694-448d-81c9-da3668994bf5">149</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9953f50a7fd74f7d8438f304f136a07b_I20210331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RhYmxlOjhjMjY2ZGU1NDdhOTQ2ODM4YmIxZGYzMjdjMTY2YmU3L3RhYmxlcmFuZ2U6OGMyNjZkZTU0N2E5NDY4MzhiYjFkZjMyN2MxNjZiZTdfMTMtNS0xLTEtMA_9cfce900-4301-4797-a5ee-d9e142b5735d">30</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9953f50a7fd74f7d8438f304f136a07b_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RhYmxlOjhjMjY2ZGU1NDdhOTQ2ODM4YmIxZGYzMjdjMTY2YmU3L3RhYmxlcmFuZ2U6OGMyNjZkZTU0N2E5NDY4MzhiYjFkZjMyN2MxNjZiZTdfMTMtNy0xLTEtMA_107ed197-f7a5-464b-a3c4-59f55d3acd5a">1,016,712</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:120%">__________________________________________________</span></div><div style="margin-top:4pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10.69pt">Unrealized holding losses on <ix:nonFraction unitRef="security" contextRef="i5c991a09175c4907972778fd5a54038d_I20210331" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RleHRyZWdpb246MjFlN2QzYmNkYTljNDAwMzgwZjEzZmJmZjY4YzA4NTRfODk2_83a2bc83-67b6-454c-a6c7-af8e614c1460">3</ix:nonFraction> securities with an aggregate fair value of $<ix:nonFraction unitRef="usd" contextRef="i5c991a09175c4907972778fd5a54038d_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RleHRyZWdpb246MjFlN2QzYmNkYTljNDAwMzgwZjEzZmJmZjY4YzA4NTRfOTQy_a798ff3f-1c38-43c0-a94b-f9c7fc2c4c8d">126.4</ix:nonFraction> million.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10.69pt">Unrealized holding losses on <ix:nonFraction unitRef="security" contextRef="i5abb55cd5abc4ef4a6963ecc132bb1be_I20210331" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RleHRyZWdpb246MjFlN2QzYmNkYTljNDAwMzgwZjEzZmJmZjY4YzA4NTRfMTA5OTUxMTYzMzU5OA_3d1315f5-2abb-405b-90de-d44d66ce3f54">4</ix:nonFraction> securities with an aggregate fair value of $<ix:nonFraction unitRef="usd" contextRef="i5abb55cd5abc4ef4a6963ecc132bb1be_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RleHRyZWdpb246MjFlN2QzYmNkYTljNDAwMzgwZjEzZmJmZjY4YzA4NTRfMTA5OTUxMTYzMzU4OA_47abea4c-7f44-436f-88e5-8fb9db1290eb">7.1</ix:nonFraction> million.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10.69pt">Unrealized holding losses on <ix:nonFraction unitRef="security" contextRef="iad80279b43b74b3fbb24392412ebf8d4_I20210331" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RleHRyZWdpb246MjFlN2QzYmNkYTljNDAwMzgwZjEzZmJmZjY4YzA4NTRfMTA5OTUxMTYzMzc1Ng_f2ebcbd2-832e-4a0c-acde-da2f983445ac">4</ix:nonFraction> securities with an aggregate fair value of $<ix:nonFraction unitRef="usd" contextRef="iad80279b43b74b3fbb24392412ebf8d4_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RleHRyZWdpb246MjFlN2QzYmNkYTljNDAwMzgwZjEzZmJmZjY4YzA4NTRfMTA5OTUxMTYzMzc0Ng_ddd50aa4-0abf-424b-b06d-19afbc62d20b">34.8</ix:nonFraction> million.</span></div><div><span><br/></span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.085%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.002%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.002%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.002%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.006%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Holding Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Holding Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Short-term marketable securities:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. government treasuries</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia965935f3dfc41e9898218d34d2db66f_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RhYmxlOmEwMWVjYjY1YzA5MzQyODJiZTVkZmMzNTdjNTU0MjM3L3RhYmxlcmFuZ2U6YTAxZWNiNjVjMDkzNDI4MmJlNWRmYzM1N2M1NTQyMzdfMy0xLTEtMS0w_0f8469b1-6739-4915-afb2-0a1ced612ae3">878,906</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia965935f3dfc41e9898218d34d2db66f_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RhYmxlOmEwMWVjYjY1YzA5MzQyODJiZTVkZmMzNTdjNTU0MjM3L3RhYmxlcmFuZ2U6YTAxZWNiNjVjMDkzNDI4MmJlNWRmYzM1N2M1NTQyMzdfMy0zLTEtMS0w_520f65bd-6226-4c0e-a306-4b7f9821a213">44</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia965935f3dfc41e9898218d34d2db66f_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RhYmxlOmEwMWVjYjY1YzA5MzQyODJiZTVkZmMzNTdjNTU0MjM3L3RhYmxlcmFuZ2U6YTAxZWNiNjVjMDkzNDI4MmJlNWRmYzM1N2M1NTQyMzdfMy01LTEtMS0w_4d92535d-a201-4b4b-bd13-fb32f4ea3442">12</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia965935f3dfc41e9898218d34d2db66f_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RhYmxlOmEwMWVjYjY1YzA5MzQyODJiZTVkZmMzNTdjNTU0MjM3L3RhYmxlcmFuZ2U6YTAxZWNiNjVjMDkzNDI4MmJlNWRmYzM1N2M1NTQyMzdfMy03LTEtMS0w_e91879cc-7985-41f1-b0ba-144800f08221">878,938</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. government agency securities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3607ed8ca137404691d4a18591291e6d_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RhYmxlOmEwMWVjYjY1YzA5MzQyODJiZTVkZmMzNTdjNTU0MjM3L3RhYmxlcmFuZ2U6YTAxZWNiNjVjMDkzNDI4MmJlNWRmYzM1N2M1NTQyMzdfNC0xLTEtMS0w_04d30223-057d-4f94-a4df-3624f01662b1">25,214</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3607ed8ca137404691d4a18591291e6d_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RhYmxlOmEwMWVjYjY1YzA5MzQyODJiZTVkZmMzNTdjNTU0MjM3L3RhYmxlcmFuZ2U6YTAxZWNiNjVjMDkzNDI4MmJlNWRmYzM1N2M1NTQyMzdfNC0zLTEtMS0w_22735b54-96e4-4de0-8238-be68c65f0ffa">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3607ed8ca137404691d4a18591291e6d_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RhYmxlOmEwMWVjYjY1YzA5MzQyODJiZTVkZmMzNTdjNTU0MjM3L3RhYmxlcmFuZ2U6YTAxZWNiNjVjMDkzNDI4MmJlNWRmYzM1N2M1NTQyMzdfNC01LTEtMS0w_a1dcb1b4-0e5b-4499-964c-534f20746340">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3607ed8ca137404691d4a18591291e6d_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RhYmxlOmEwMWVjYjY1YzA5MzQyODJiZTVkZmMzNTdjNTU0MjM3L3RhYmxlcmFuZ2U6YTAxZWNiNjVjMDkzNDI4MmJlNWRmYzM1N2M1NTQyMzdfNC03LTEtMS0w_c8c1cad6-9361-4aa8-8e8e-da0381fec05c">25,217</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fd58d29aa7f4494bf30f6d59ca72c8c_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RhYmxlOmEwMWVjYjY1YzA5MzQyODJiZTVkZmMzNTdjNTU0MjM3L3RhYmxlcmFuZ2U6YTAxZWNiNjVjMDkzNDI4MmJlNWRmYzM1N2M1NTQyMzdfNS0xLTEtMS0w_a77790da-537f-4e06-a818-0f4c0c90190a">27,101</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fd58d29aa7f4494bf30f6d59ca72c8c_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RhYmxlOmEwMWVjYjY1YzA5MzQyODJiZTVkZmMzNTdjNTU0MjM3L3RhYmxlcmFuZ2U6YTAxZWNiNjVjMDkzNDI4MmJlNWRmYzM1N2M1NTQyMzdfNS0zLTEtMS0w_cc2d4aff-7138-43f0-b928-5fb38afdb903">79</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fd58d29aa7f4494bf30f6d59ca72c8c_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RhYmxlOmEwMWVjYjY1YzA5MzQyODJiZTVkZmMzNTdjNTU0MjM3L3RhYmxlcmFuZ2U6YTAxZWNiNjVjMDkzNDI4MmJlNWRmYzM1N2M1NTQyMzdfNS01LTEtMS0w_f0f51293-818d-4fb6-be50-3b231a765da5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fd58d29aa7f4494bf30f6d59ca72c8c_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RhYmxlOmEwMWVjYjY1YzA5MzQyODJiZTVkZmMzNTdjNTU0MjM3L3RhYmxlcmFuZ2U6YTAxZWNiNjVjMDkzNDI4MmJlNWRmYzM1N2M1NTQyMzdfNS03LTEtMS0w_51bd8a1c-cb4b-43cd-8703-f7794e680f1f">27,180</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb9f9878977d4bee8003a43bbd55fbf7_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RhYmxlOmEwMWVjYjY1YzA5MzQyODJiZTVkZmMzNTdjNTU0MjM3L3RhYmxlcmFuZ2U6YTAxZWNiNjVjMDkzNDI4MmJlNWRmYzM1N2M1NTQyMzdfNi0xLTEtMS0w_97e7f8b1-2d14-41e6-8bcb-0bb8774d6cb8">31,218</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb9f9878977d4bee8003a43bbd55fbf7_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RhYmxlOmEwMWVjYjY1YzA5MzQyODJiZTVkZmMzNTdjNTU0MjM3L3RhYmxlcmFuZ2U6YTAxZWNiNjVjMDkzNDI4MmJlNWRmYzM1N2M1NTQyMzdfNi0zLTEtMS0w_6f633f50-65cc-4582-a70d-6a14a6447191">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb9f9878977d4bee8003a43bbd55fbf7_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RhYmxlOmEwMWVjYjY1YzA5MzQyODJiZTVkZmMzNTdjNTU0MjM3L3RhYmxlcmFuZ2U6YTAxZWNiNjVjMDkzNDI4MmJlNWRmYzM1N2M1NTQyMzdfNi01LTEtMS0w_d1778b8e-71fa-42a6-926f-b58f34b4ba68">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb9f9878977d4bee8003a43bbd55fbf7_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RhYmxlOmEwMWVjYjY1YzA5MzQyODJiZTVkZmMzNTdjNTU0MjM3L3RhYmxlcmFuZ2U6YTAxZWNiNjVjMDkzNDI4MmJlNWRmYzM1N2M1NTQyMzdfNi03LTEtMS0w_503cc52a-3b01-4106-a89b-a06ec3a8f8b3">31,218</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total short-term marketable securities</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86be035a34fe478ea00df2e76fba4dc9_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RhYmxlOmEwMWVjYjY1YzA5MzQyODJiZTVkZmMzNTdjNTU0MjM3L3RhYmxlcmFuZ2U6YTAxZWNiNjVjMDkzNDI4MmJlNWRmYzM1N2M1NTQyMzdfNy0xLTEtMS0w_3dcf7ecc-1005-4346-8524-485d3ec45689">962,439</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86be035a34fe478ea00df2e76fba4dc9_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RhYmxlOmEwMWVjYjY1YzA5MzQyODJiZTVkZmMzNTdjNTU0MjM3L3RhYmxlcmFuZ2U6YTAxZWNiNjVjMDkzNDI4MmJlNWRmYzM1N2M1NTQyMzdfNy0zLTEtMS0w_00f708b1-ee71-4d44-9d91-2e7404e9225e">128</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i86be035a34fe478ea00df2e76fba4dc9_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RhYmxlOmEwMWVjYjY1YzA5MzQyODJiZTVkZmMzNTdjNTU0MjM3L3RhYmxlcmFuZ2U6YTAxZWNiNjVjMDkzNDI4MmJlNWRmYzM1N2M1NTQyMzdfNy01LTEtMS0w_9e253df8-a07a-463a-93f3-2f2a15cca77d">14</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86be035a34fe478ea00df2e76fba4dc9_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RhYmxlOmEwMWVjYjY1YzA5MzQyODJiZTVkZmMzNTdjNTU0MjM3L3RhYmxlcmFuZ2U6YTAxZWNiNjVjMDkzNDI4MmJlNWRmYzM1N2M1NTQyMzdfNy03LTEtMS0w_32e180d9-99e6-4264-ad01-7d68774cc624">962,553</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term marketable securities:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. government treasuries</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74d3c7dbdd71495c8557f07cac6cd34d_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RhYmxlOmEwMWVjYjY1YzA5MzQyODJiZTVkZmMzNTdjNTU0MjM3L3RhYmxlcmFuZ2U6YTAxZWNiNjVjMDkzNDI4MmJlNWRmYzM1N2M1NTQyMzdfOS0xLTEtMS0w_ea7058ee-fb3d-4c97-87c6-0ea80a3e2194">2,561</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74d3c7dbdd71495c8557f07cac6cd34d_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RhYmxlOmEwMWVjYjY1YzA5MzQyODJiZTVkZmMzNTdjNTU0MjM3L3RhYmxlcmFuZ2U6YTAxZWNiNjVjMDkzNDI4MmJlNWRmYzM1N2M1NTQyMzdfOS0zLTEtMS0w_31f311de-fd42-41ae-b0a8-1fa172d82c78">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74d3c7dbdd71495c8557f07cac6cd34d_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RhYmxlOmEwMWVjYjY1YzA5MzQyODJiZTVkZmMzNTdjNTU0MjM3L3RhYmxlcmFuZ2U6YTAxZWNiNjVjMDkzNDI4MmJlNWRmYzM1N2M1NTQyMzdfOS01LTEtMS0w_d1ce3487-9bd4-4cf7-ac22-26bbe0a5323c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74d3c7dbdd71495c8557f07cac6cd34d_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RhYmxlOmEwMWVjYjY1YzA5MzQyODJiZTVkZmMzNTdjNTU0MjM3L3RhYmxlcmFuZ2U6YTAxZWNiNjVjMDkzNDI4MmJlNWRmYzM1N2M1NTQyMzdfOS03LTEtMS0w_f38d8907-0013-4538-8847-a1f27199d8d8">2,561</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc4f3f2e913840ec946d6ab82f45dc71_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RhYmxlOmEwMWVjYjY1YzA5MzQyODJiZTVkZmMzNTdjNTU0MjM3L3RhYmxlcmFuZ2U6YTAxZWNiNjVjMDkzNDI4MmJlNWRmYzM1N2M1NTQyMzdfMTEtMS0xLTEtMA_ea437638-cefb-43f9-a951-edd653017fe3">30,147</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc4f3f2e913840ec946d6ab82f45dc71_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RhYmxlOmEwMWVjYjY1YzA5MzQyODJiZTVkZmMzNTdjNTU0MjM3L3RhYmxlcmFuZ2U6YTAxZWNiNjVjMDkzNDI4MmJlNWRmYzM1N2M1NTQyMzdfMTEtMy0xLTEtMA_703f8c1f-1a73-49a2-a603-de1103c8fe9c">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icc4f3f2e913840ec946d6ab82f45dc71_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RhYmxlOmEwMWVjYjY1YzA5MzQyODJiZTVkZmMzNTdjNTU0MjM3L3RhYmxlcmFuZ2U6YTAxZWNiNjVjMDkzNDI4MmJlNWRmYzM1N2M1NTQyMzdfMTEtNS0xLTEtMA_93572e91-67d2-49d8-ac52-01029837f279">11</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc4f3f2e913840ec946d6ab82f45dc71_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RhYmxlOmEwMWVjYjY1YzA5MzQyODJiZTVkZmMzNTdjNTU0MjM3L3RhYmxlcmFuZ2U6YTAxZWNiNjVjMDkzNDI4MmJlNWRmYzM1N2M1NTQyMzdfMTEtNy0xLTEtMA_d53f687f-9f95-42a4-a30b-37b4a752ba6f">30,138</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total long-term marketable securities</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac0bb6ea773e4895b9939e783cbf93a7_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RhYmxlOmEwMWVjYjY1YzA5MzQyODJiZTVkZmMzNTdjNTU0MjM3L3RhYmxlcmFuZ2U6YTAxZWNiNjVjMDkzNDI4MmJlNWRmYzM1N2M1NTQyMzdfMTItMS0xLTEtMA_0da1b19b-7f39-4289-af29-238a3a7c684e">32,708</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac0bb6ea773e4895b9939e783cbf93a7_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RhYmxlOmEwMWVjYjY1YzA5MzQyODJiZTVkZmMzNTdjNTU0MjM3L3RhYmxlcmFuZ2U6YTAxZWNiNjVjMDkzNDI4MmJlNWRmYzM1N2M1NTQyMzdfMTItMy0xLTEtMA_68bfef65-caaf-41cf-9c5d-a21f018b762a">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iac0bb6ea773e4895b9939e783cbf93a7_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RhYmxlOmEwMWVjYjY1YzA5MzQyODJiZTVkZmMzNTdjNTU0MjM3L3RhYmxlcmFuZ2U6YTAxZWNiNjVjMDkzNDI4MmJlNWRmYzM1N2M1NTQyMzdfMTItNS0xLTEtMA_a63ccd6e-e8f5-4d1c-a3ba-0c6c232b3db3">11</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac0bb6ea773e4895b9939e783cbf93a7_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RhYmxlOmEwMWVjYjY1YzA5MzQyODJiZTVkZmMzNTdjNTU0MjM3L3RhYmxlcmFuZ2U6YTAxZWNiNjVjMDkzNDI4MmJlNWRmYzM1N2M1NTQyMzdfMTItNy0xLTEtMA_5e2e4925-2789-44d7-815f-5e54547667f3">32,699</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb7ca9f362da46eab3a29bbbecbda977_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RhYmxlOmEwMWVjYjY1YzA5MzQyODJiZTVkZmMzNTdjNTU0MjM3L3RhYmxlcmFuZ2U6YTAxZWNiNjVjMDkzNDI4MmJlNWRmYzM1N2M1NTQyMzdfMTMtMS0xLTEtMA_119ffa24-a1cd-42a1-a879-f1e4897356b1">995,147</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb7ca9f362da46eab3a29bbbecbda977_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RhYmxlOmEwMWVjYjY1YzA5MzQyODJiZTVkZmMzNTdjNTU0MjM3L3RhYmxlcmFuZ2U6YTAxZWNiNjVjMDkzNDI4MmJlNWRmYzM1N2M1NTQyMzdfMTMtMy0xLTEtMA_d7ee7b48-5210-4660-8ce5-2f78bc721921">130</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb7ca9f362da46eab3a29bbbecbda977_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RhYmxlOmEwMWVjYjY1YzA5MzQyODJiZTVkZmMzNTdjNTU0MjM3L3RhYmxlcmFuZ2U6YTAxZWNiNjVjMDkzNDI4MmJlNWRmYzM1N2M1NTQyMzdfMTMtNS0xLTEtMA_1d0007b0-416f-4cbe-88af-2c0563fbc6e0">25</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb7ca9f362da46eab3a29bbbecbda977_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RhYmxlOmEwMWVjYjY1YzA5MzQyODJiZTVkZmMzNTdjNTU0MjM3L3RhYmxlcmFuZ2U6YTAxZWNiNjVjMDkzNDI4MmJlNWRmYzM1N2M1NTQyMzdfMTMtNy0xLTEtMA_c797fd9e-269c-4775-bd22-b3bd3232147b">995,252</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:120%">__________________________________________________</span></div><div style="margin-top:4pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10.69pt">Unrealized holding losses on <ix:nonFraction unitRef="security" contextRef="ia965935f3dfc41e9898218d34d2db66f_I20201231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RleHRyZWdpb246MjFlN2QzYmNkYTljNDAwMzgwZjEzZmJmZjY4YzA4NTRfMTA5OTUxMTYzMTIzNQ_c7d1f524-8af1-454f-bead-effd656944f2">19</ix:nonFraction> securities with an aggregate fair value of $<ix:nonFraction unitRef="usd" contextRef="ia965935f3dfc41e9898218d34d2db66f_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RleHRyZWdpb246MjFlN2QzYmNkYTljNDAwMzgwZjEzZmJmZjY4YzA4NTRfMTA5OTUxMTYzMTI1OQ_a9563279-1c15-4ca4-a3a9-0b081249f300">369.9</ix:nonFraction> million.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10.69pt">Unrealized holding losses on <ix:nonFraction unitRef="security" contextRef="i3607ed8ca137404691d4a18591291e6d_I20201231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RleHRyZWdpb246MjFlN2QzYmNkYTljNDAwMzgwZjEzZmJmZjY4YzA4NTRfMTA5OTUxMTYzMTI2OQ_3516e64f-e74e-46b3-8c59-7370d7c7e744">2</ix:nonFraction> securities with an aggregate fair value of $<ix:nonFraction unitRef="usd" contextRef="i3607ed8ca137404691d4a18591291e6d_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RleHRyZWdpb246MjFlN2QzYmNkYTljNDAwMzgwZjEzZmJmZjY4YzA4NTRfMTA5OTUxMTYzMTI5Mw_f58f4889-901f-422a-9642-5750537fcb0f">10.1</ix:nonFraction> million.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10.69pt">Unrealized holding losses on <ix:nonFraction unitRef="security" contextRef="icc4f3f2e913840ec946d6ab82f45dc71_I20201231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RleHRyZWdpb246MjFlN2QzYmNkYTljNDAwMzgwZjEzZmJmZjY4YzA4NTRfMTA5OTUxMTYzMTMwNg_3749bc50-bf21-4070-92a1-9580ed5cf601">1</ix:nonFraction> security with an aggregate fair value of $<ix:nonFraction unitRef="usd" contextRef="icc4f3f2e913840ec946d6ab82f45dc71_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RleHRyZWdpb246MjFlN2QzYmNkYTljNDAwMzgwZjEzZmJmZjY4YzA4NTRfMTA5OTUxMTYzMTMzMA_48f7c94a-44e5-408e-bfe8-42a5136336d5">20.1</ix:nonFraction> million.</span></div></ix:continuation><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> As of March 31, 2021 and December 31, 2020, some of the Company's marketable securities were in an unrealized loss position. The Company has <ix:nonFraction unitRef="usd" contextRef="idb7ca9f362da46eab3a29bbbecbda977_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RleHRyZWdpb246MjFlN2QzYmNkYTljNDAwMzgwZjEzZmJmZjY4YzA4NTRfMTYyOA_1b2cff37-4c0d-4cfe-b884-86e6d2493515"><ix:nonFraction unitRef="usd" contextRef="i9953f50a7fd74f7d8438f304f136a07b_I20210331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RleHRyZWdpb246MjFlN2QzYmNkYTljNDAwMzgwZjEzZmJmZjY4YzA4NTRfMTYyOA_a28060ef-e17c-4ccd-a94c-10a1a16e3e4e">no</ix:nonFraction></ix:nonFraction>t recognized an allowance for credit losses as of March 31, 2021 or December 31, 2020. The Company determined that it had the ability and intent to hold all marketable securities that have been in a continuous loss position until maturity or recovery. Further, these marketable securities were initially, and continue to be, held with investment grade, high credit quality institutions. All marketable securities with unrealized losses as of each balance sheet date have been in a loss position for less than twelve months or the loss is not material.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded unrealized gains on marketable securities in other comprehensive income for the three months ended March 31, 2020. As a result, the Company recorded a tax benefit of $<ix:nonFraction unitRef="usd" contextRef="ia34dfea6b8734d64abf707c28256801c_D20200101-20200331" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RleHRyZWdpb246MjFlN2QzYmNkYTljNDAwMzgwZjEzZmJmZjY4YzA4NTRfMjM1NA_090b023e-02f0-4365-804a-f9cd097d2a0c"><ix:nonFraction unitRef="usd" contextRef="ia34dfea6b8734d64abf707c28256801c_D20200101-20200331" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RleHRyZWdpb246MjFlN2QzYmNkYTljNDAwMzgwZjEzZmJmZjY4YzA4NTRfMjM1NA_6f8a118a-2172-49e3-a8e0-b6212117bda3">0.1</ix:nonFraction></ix:nonFraction>&#160;million for the three months ended March 31, 2020 on the Condensed Consolidated Statements of Operations and Comprehensive Loss and a corresponding tax charge in other comprehensive income. </span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of the Company&#8217;s marketable securities have an effective maturity of less than <ix:nonNumeric contextRef="i9953f50a7fd74f7d8438f304f136a07b_I20210331" format="ixt-sec:durwordsen" name="us-gaap:DebtSecuritiesAvailableForSaleTerm" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RleHRyZWdpb246MjFlN2QzYmNkYTljNDAwMzgwZjEzZmJmZjY4YzA4NTRfMjcyNw_7ef42a61-e760-4ad7-97d2-22a03be7f1ed">two years</ix:nonNumeric>.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><div id="i5ae1cfc88aa4492caf56e9d4ac91e096_40"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5ae1cfc88aa4492caf56e9d4ac91e096_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331" name="us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80MC9mcmFnOmM4NDBhMmRhOTM0YzQ4YjBhNzkzOTczMWU0YTVkMzQ0L3RleHRyZWdpb246Yzg0MGEyZGE5MzRjNDhiMGE3OTM5NzMxZTRhNWQzNDRfMTQxNg_b2c276a9-222e-4622-9891-537bc926b275" continuedAt="i32969bf341e9400e8159ddd32b0a464c" escape="true">Derivative Financial Instruments</ix:nonNumeric></span></div><ix:continuation id="i32969bf341e9400e8159ddd32b0a464c"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foreign Currency Exchange Rate Exposure</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses forward foreign currency exchange contracts to hedge certain operational exposures resulting from potential changes in foreign currency exchange rates. Such exposures result from portions of the Company&#8217;s forecasted cash flows being denominated in currencies other than the U.S. dollar, primarily the Euro and British Pound. The derivative instruments the Company uses to hedge this exposure are not designated as cash flow hedges, and as a result, changes in their fair value are recorded in interest and other income, net, on the Company's Condensed Consolidated Statements of Operations and Comprehensive Loss.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of forward foreign currency exchange contracts are estimated using current exchange rates and interest rates and take into consideration the current creditworthiness of the counterparties. Information regarding the specific instruments used by the Company to hedge its exposure to foreign currency exchange rate fluctuations is provided below.</span></div><ix:nonNumeric contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331" name="us-gaap:ScheduleOfDerivativeInstrumentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80MC9mcmFnOmM4NDBhMmRhOTM0YzQ4YjBhNzkzOTczMWU0YTVkMzQ0L3RleHRyZWdpb246Yzg0MGEyZGE5MzRjNDhiMGE3OTM5NzMxZTRhNWQzNDRfMTQxOA_c1a7dde2-8d48-4b6b-8515-4a9075d24f85" escape="true"><div style="margin-bottom:10pt;margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s forward foreign currency exchange contracts outstanding as of March 31, 2021 and December 31, 2020, respectively (notional amounts in thousands):</span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:27.265%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.252%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.778%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.902%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign Exchange Contracts</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Contracts</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Notional</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount in Foreign Currency</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maturity</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Euros </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="derivative_instrument" contextRef="i5e5ef3c57c01481ab32c18cba94f5fe4_I20210331" decimals="INF" name="us-gaap:DerivativeNumberOfInstrumentsHeld" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80MC9mcmFnOmM4NDBhMmRhOTM0YzQ4YjBhNzkzOTczMWU0YTVkMzQ0L3RhYmxlOjA4MDUwZTQ1N2VjYzQ3NjBiODQ0MzhhNDNjNTViNzEzL3RhYmxlcmFuZ2U6MDgwNTBlNDU3ZWNjNDc2MGI4NDQzOGE0M2M1NWI3MTNfMS0yLTEtMS0w_564f2b01-d4c7-4bda-a7d5-cbd5d0674661">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="i5e5ef3c57c01481ab32c18cba94f5fe4_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80MC9mcmFnOmM4NDBhMmRhOTM0YzQ4YjBhNzkzOTczMWU0YTVkMzQ0L3RhYmxlOjA4MDUwZTQ1N2VjYzQ3NjBiODQ0MzhhNDNjNTViNzEzL3RhYmxlcmFuZ2U6MDgwNTBlNDU3ZWNjNDc2MGI4NDQzOGE0M2M1NWI3MTNfMS00LTEtMS0w_31cad5bb-720c-471c-bc97-e528be6032c7">4,305</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Apr 2021- Mar 2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">British Pounds </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="derivative_instrument" contextRef="id84a031bb1374baa8de940b07c3dff05_I20210331" decimals="INF" name="us-gaap:DerivativeNumberOfInstrumentsHeld" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80MC9mcmFnOmM4NDBhMmRhOTM0YzQ4YjBhNzkzOTczMWU0YTVkMzQ0L3RhYmxlOjA4MDUwZTQ1N2VjYzQ3NjBiODQ0MzhhNDNjNTViNzEzL3RhYmxlcmFuZ2U6MDgwNTBlNDU3ZWNjNDc2MGI4NDQzOGE0M2M1NWI3MTNfMi0yLTEtMS0w_55a8c5ae-e61b-4293-b0b5-b0d152dc7b45">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="gbp" contextRef="id84a031bb1374baa8de940b07c3dff05_I20210331" decimals="-3" name="us-gaap:DerivativeNotionalAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80MC9mcmFnOmM4NDBhMmRhOTM0YzQ4YjBhNzkzOTczMWU0YTVkMzQ0L3RhYmxlOjA4MDUwZTQ1N2VjYzQ3NjBiODQ0MzhhNDNjNTViNzEzL3RhYmxlcmFuZ2U6MDgwNTBlNDU3ZWNjNDc2MGI4NDQzOGE0M2M1NWI3MTNfMi00LTEtMS0w_4e96f6f9-df1e-4585-90f8-36c0dddfddce">963</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Apr 2021- Nov 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total at March 31, 2021</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="derivative_instrument" contextRef="ibf15d1cb21ae4c5b886c0aea82e7d1f3_I20210331" decimals="INF" name="us-gaap:DerivativeNumberOfInstrumentsHeld" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80MC9mcmFnOmM4NDBhMmRhOTM0YzQ4YjBhNzkzOTczMWU0YTVkMzQ0L3RhYmxlOjA4MDUwZTQ1N2VjYzQ3NjBiODQ0MzhhNDNjNTViNzEzL3RhYmxlcmFuZ2U6MDgwNTBlNDU3ZWNjNDc2MGI4NDQzOGE0M2M1NWI3MTNfNC0yLTEtMS0w_9b396e25-980c-4124-8c88-67ebd9044f78">37</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Euros </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="derivative_instrument" contextRef="i8d51a225b0e74a329c75163f5353da38_I20201231" decimals="INF" name="us-gaap:DerivativeNumberOfInstrumentsHeld" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80MC9mcmFnOmM4NDBhMmRhOTM0YzQ4YjBhNzkzOTczMWU0YTVkMzQ0L3RhYmxlOjA4MDUwZTQ1N2VjYzQ3NjBiODQ0MzhhNDNjNTViNzEzL3RhYmxlcmFuZ2U6MDgwNTBlNDU3ZWNjNDc2MGI4NDQzOGE0M2M1NWI3MTNfNS0yLTEtMS0w_de871a70-3192-4874-90b2-81b73639ec5a">26</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="i8d51a225b0e74a329c75163f5353da38_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80MC9mcmFnOmM4NDBhMmRhOTM0YzQ4YjBhNzkzOTczMWU0YTVkMzQ0L3RhYmxlOjA4MDUwZTQ1N2VjYzQ3NjBiODQ0MzhhNDNjNTViNzEzL3RhYmxlcmFuZ2U6MDgwNTBlNDU3ZWNjNDc2MGI4NDQzOGE0M2M1NWI3MTNfNS00LTEtMS0w_715bfb02-4c58-40a5-b286-2ace8ccf487c">3,855</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Jan 2021 - Nov 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">British Pounds </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="derivative_instrument" contextRef="i83e8165a75164bcd89f57c0c00451316_I20201231" decimals="INF" name="us-gaap:DerivativeNumberOfInstrumentsHeld" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80MC9mcmFnOmM4NDBhMmRhOTM0YzQ4YjBhNzkzOTczMWU0YTVkMzQ0L3RhYmxlOjA4MDUwZTQ1N2VjYzQ3NjBiODQ0MzhhNDNjNTViNzEzL3RhYmxlcmFuZ2U6MDgwNTBlNDU3ZWNjNDc2MGI4NDQzOGE0M2M1NWI3MTNfNi0yLTEtMS0w_c67cd388-c335-463f-9655-5b59eb69fe32">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="gbp" contextRef="i83e8165a75164bcd89f57c0c00451316_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80MC9mcmFnOmM4NDBhMmRhOTM0YzQ4YjBhNzkzOTczMWU0YTVkMzQ0L3RhYmxlOjA4MDUwZTQ1N2VjYzQ3NjBiODQ0MzhhNDNjNTViNzEzL3RhYmxlcmFuZ2U6MDgwNTBlNDU3ZWNjNDc2MGI4NDQzOGE0M2M1NWI3MTNfNi00LTEtMS0w_c9df10d8-a2bd-4edb-8b98-24e566f1ecb3">2,658</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Jan 2021 - Nov 2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total at December 31, 2020</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="derivative_instrument" contextRef="idcf71a3762844d5ebc7aaa02a121c837_I20201231" decimals="INF" name="us-gaap:DerivativeNumberOfInstrumentsHeld" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80MC9mcmFnOmM4NDBhMmRhOTM0YzQ4YjBhNzkzOTczMWU0YTVkMzQ0L3RhYmxlOjA4MDUwZTQ1N2VjYzQ3NjBiODQ0MzhhNDNjNTViNzEzL3RhYmxlcmFuZ2U6MDgwNTBlNDU3ZWNjNDc2MGI4NDQzOGE0M2M1NWI3MTNfOC0yLTEtMS0w_a8bd1382-6142-4f75-a1e2-0799ffd2b032">47</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:120%">_________________________________________________</span></div><div style="margin-top:4pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;padding-left:11.65pt;position:relative;top:-2.8pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The notional amount represents the net amount of foreign currency that will be received upon maturity of the forward contracts.</span></div></ix:nonNumeric><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A derivative liability balance of $<ix:nonFraction unitRef="usd" contextRef="i3e3538bcdaba49b4bc9b8ff9d89ef4b8_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80MC9mcmFnOmM4NDBhMmRhOTM0YzQ4YjBhNzkzOTczMWU0YTVkMzQ0L3RleHRyZWdpb246Yzg0MGEyZGE5MzRjNDhiMGE3OTM5NzMxZTRhNWQzNDRfMTA5OTUxMTYzMTM2Ng_ab5dc2e7-df30-40b7-ac21-f4c6b591a994">0.2</ix:nonFraction> million is recorded on the Condensed Consolidated Balance Sheets as of March 31, 2021 and an immaterial derivative liability balance is recorded on the Condensed Consolidated Balance Sheets as of December 31, 2020. An immaterial derivative asset balance is recorded in prepaid expenses and other current assets on the Condensed Consolidated Balance Sheets as of March 31, 2021 and a derivative asset balance of $<ix:nonFraction unitRef="usd" contextRef="i2d55a3178b03487c9c5028f18060a482_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80MC9mcmFnOmM4NDBhMmRhOTM0YzQ4YjBhNzkzOTczMWU0YTVkMzQ0L3RleHRyZWdpb246Yzg0MGEyZGE5MzRjNDhiMGE3OTM5NzMxZTRhNWQzNDRfMTA5OTUxMTYzMTMwMA_9d74a06f-4349-4b7f-9247-ca26bc4a340d">0.2</ix:nonFraction> million is recorded in prepaid expenses and other current assets on the Condensed Consolidated Balance Sheets as of December 31, 2020. A net loss of $<ix:nonFraction unitRef="usd" contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80MC9mcmFnOmM4NDBhMmRhOTM0YzQ4YjBhNzkzOTczMWU0YTVkMzQ0L3RleHRyZWdpb246Yzg0MGEyZGE5MzRjNDhiMGE3OTM5NzMxZTRhNWQzNDRfMTA5OTUxMTYzMTEwOA_1556ac27-b6b9-4437-81fb-095edb3c4cfc"><ix:nonFraction unitRef="usd" contextRef="ia34dfea6b8734d64abf707c28256801c_D20200101-20200331" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80MC9mcmFnOmM4NDBhMmRhOTM0YzQ4YjBhNzkzOTczMWU0YTVkMzQ0L3RleHRyZWdpb246Yzg0MGEyZGE5MzRjNDhiMGE3OTM5NzMxZTRhNWQzNDRfMTA5OTUxMTYzMTEwOA_21f2f906-649c-4bb6-9cc6-01766ccee4be">0.2</ix:nonFraction></ix:nonFraction> million associated with the Company's derivative instruments is recognized in interest and other income, net on the Condensed Consolidated Statements of Operations and Comprehensive Loss for each of the three months ended March 31, 2021 and March 31, 2020.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><div id="i5ae1cfc88aa4492caf56e9d4ac91e096_46"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5ae1cfc88aa4492caf56e9d4ac91e096_7">Table of Contents</a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMjkyNjk_9230ab11-45f7-4493-970c-c8dc1c1d2c31" continuedAt="i542131a3b9174e90a9af192e04792e1b" escape="true">Collaboration Agreements</ix:nonNumeric></span></div><ix:continuation id="i542131a3b9174e90a9af192e04792e1b" continuedAt="ib6ea2339fe6949d7ac4404f37c4057c4"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Biogen</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Provisional Biogen Collaboration Agreement and Common Stock Purchase Agreement</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August&#160;5, 2020, the Company entered into a binding Provisional Collaboration and License Agreement (&#8220;Provisional Biogen Collaboration Agreement&#8221;) with Biogen Inc.&#8217;s subsidiaries, Biogen MA Inc. (&#8220;BIMA&#8221;) and Biogen International GmbH (&#8220;BIG&#8221;) (BIMA and BIG, collectively, &#8220;Biogen&#8221;) pursuant to which the Company granted Biogen a license to co-develop and co-commercialize Denali&#8217;s small molecule LRRK2 inhibitor program (the &#8220;LRRK2 Program&#8221;), an option in respect of each of (i) the Company&#8217;s amyloid beta program utilizing the Company's Transport Vehicle ("TV") technology platform to cross the blood-brain barrier ("BBB") and (ii) <ix:nonFraction unitRef="program" contextRef="id19e1b668ad54ff0a1bcaaf50d236bcd_I20200805" decimals="INF" format="ixt-sec:numwordsen" name="dnli:CollaborativeArrangementNumberOfPrograms" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfNzM0_8c081a07-3db8-4840-8288-c1a6d3713aaf">one</ix:nonFraction> other unnamed program also utilizing the Company's TV technology platform (the &#8220;Option Programs&#8221;), and a right of first negotiation with respect to <ix:nonFraction unitRef="program" contextRef="if6dd4f0c67444b1194ee0a12b060c2e7_I20200805" decimals="INF" format="ixt-sec:numwordsen" name="dnli:CollaborativeArrangementNumberOfAdditionalProgramsIfCircumstancesMet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfODg1_9759b9a2-1fa4-4b06-8c28-c2fbb7e61a32">two</ix:nonFraction> additional unnamed programs for indications within Alzheimer&#8217;s disease, Parkinson&#8217;s disease, amyotrophic lateral sclerosis ("ALS") or multiple sclerosis utilizing the Company's TV technology platform (the &#8220;ROFN Programs&#8221;) should the Company decide to seek a collaboration with a third party for such programs. The Provisional Biogen Collaboration Agreement was a binding agreement, which became effective on the closing of the Common Stock Purchase Agreement ("SPA"), as described further below. The Provisional Biogen Collaboration Agreement expired in October 2020 upon the execution of a Definitive LRRK2 Collaboration and License Agreement (&#8220;LRRK2 Agreement&#8221;) with Biogen on October&#160;4, 2020 and a Right of First Negotiation, Option and License Agreement (the &#8220;ROFN and Option Agreement&#8221;) on October&#160;6, 2020 (collectively, the "Biogen Collaboration Agreement").</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Provisional Biogen Collaboration Agreement, Biogen was obligated to pay the Company a $<ix:nonFraction unitRef="usd" contextRef="i708f730074a74563a853bf7ef8f740fe_D20200805-20200805" decimals="-5" format="ixt:numdotdecimal" name="dnli:CollaborativeArrangementUpfrontPaymentToBeReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMTg0Nw_d7d9154c-df56-4928-86fb-32608f7db76f">560.0</ix:nonFraction> million upfront payment, payable upon execution of the Biogen Collaboration Agreement, which occurred in October 2020. With respect to the LRRK2 Program, Biogen is required to make milestone payments up to approximately $<ix:nonFraction unitRef="usd" contextRef="i3bf8c8eaa53e41d5a068b18edae5519f_I20200805" decimals="-6" format="ixt:numdotdecimal" name="dnli:AggregateDevelopmentFirstCommercialSaleAndNetSalesBasedMilestonePayments" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMjA2Mw_bbe8bb1a-b743-4cb7-b592-ad56f6881522">1.125</ix:nonFraction> billion upon achievement of certain development and sales milestone events. Such milestone payments include $<ix:nonFraction unitRef="usd" contextRef="i3bf8c8eaa53e41d5a068b18edae5519f_I20200805" decimals="-5" format="ixt:numdotdecimal" name="dnli:DevelopmentMilestonePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMjE2MQ_8cc50dec-9c24-42d8-b0f6-b94d91b15ee6">375.0</ix:nonFraction>&#160;million in development, $<ix:nonFraction unitRef="usd" contextRef="i3bf8c8eaa53e41d5a068b18edae5519f_I20200805" decimals="-5" format="ixt:numdotdecimal" name="dnli:FirstCommercialSaleMilestonePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMjE4MA_de3fdff6-53e5-48ec-9da8-87f8d1270c0c">375.0</ix:nonFraction>&#160;million upon first commercial sale, and $<ix:nonFraction unitRef="usd" contextRef="i3bf8c8eaa53e41d5a068b18edae5519f_I20200805" decimals="-5" format="ixt:numdotdecimal" name="dnli:NetSalesBasedMilestonePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMjIxNQ_4656a46f-7c1f-435e-b90a-0ace5afddc1e">375.0</ix:nonFraction>&#160;million in net sales-based milestones. The Company will share <ix:nonFraction unitRef="number" contextRef="i19ba65d441e94cbda7c97a7dedf0b14c_I20200805" decimals="INF" name="dnli:CollaborativeAgreementAgreedShareOfCommercialProfitLoss" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMTA5OTUxMTcwMjcyOQ_b09efb0d-9365-461b-b68e-a1bcac36950d">50</ix:nonFraction>% of the profits and losses with Biogen for LRRK2 Products in the United States, and <ix:nonFraction unitRef="number" contextRef="id5c33ba7e2874d50a83a5008b6ae7852_I20200805" decimals="INF" name="dnli:CollaborativeAgreementAgreedShareOfCommercialProfitLoss" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMjM1OA_17c03de2-34d9-4730-b254-f2d89235b9d5">40</ix:nonFraction>% of such profits and losses in China. The Company will be entitled to receive royalties in the high teens to low twenties percentages on net sales for LRRK2 Products outside of the United States and China.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Provisional Biogen Collaboration Agreement, Denali conducted and controlled LRRK2 clinical development through the effective date of the Biogen Collaboration Agreement. Subsequently, the Company and Biogen are jointly developing LRRK2 Products pursuant to a clinical development plan set forth within the LRRK2 Agreement. The parties share responsibility and costs for global development of LRRK2 Products pursuant to a mutually agreed development plan and budget ("LRRK2 Development Activities"), with Biogen funding <ix:nonFraction unitRef="number" contextRef="id978123c42ea48179c72134ceea46ba2_I20200805" decimals="INF" name="dnli:CollaborativeAgreementFundedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMzA5NA_fc009065-b01d-42f2-9259-997fbecb83e2">60</ix:nonFraction>% and the Company funding <ix:nonFraction unitRef="number" contextRef="i8a30e11a54f94b2ebb02e2da6fe5446f_I20200805" decimals="INF" name="dnli:CollaborativeAgreementFundedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMzEyMQ_2ffb4be0-e5af-4f46-b9cf-7f5a84f6617d">40</ix:nonFraction>% of such costs.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may opt out of development cost sharing worldwide and upon such election, from any further profit-sharing from the LRRK2 Program. The Company also has the right to opt-out of the profit sharing arrangement for the LRRK2 Program or for only those LRRK2 Products that do not penetrate the BBB (&#8220;Peripheral LRRK2 Products&#8221;), in each of the United States and China. After such an opt out, the Company will no longer be obligated to share in the development and commercialization costs for, or be entitled to share in the applicable revenues from, such LRRK2 Program (or from the Peripheral LRRK2 Products) for such country, as applicable. If the Company chooses to exercise its opt out rights, the Company will be entitled to receive tiered royalties on net sales of the applicable LRRK2 Program in the relevant country (or countries). The royalty rates for the applicable LRRK2 Program will be a percentage in the high teens to low twenties, but may increase to the mid-twenties if the Company has met certain co-funding thresholds or there has been a first commercial sale at the time of the Company's election.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5ae1cfc88aa4492caf56e9d4ac91e096_7">Table of Contents</a></span></div></div><ix:continuation id="ib6ea2339fe6949d7ac4404f37c4057c4" continuedAt="ib255da9973434f5e8d06328b335a86ee"><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the LRRK2 Program, Biogen received an exclusive option to license <ix:nonFraction unitRef="program" contextRef="ib106d7ba52674677b8cb2ac5693422b7_I20200805" decimals="INF" format="ixt-sec:numwordsen" name="dnli:CollaborativeArrangementNumberOfPrograms" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfNDY2Mw_89b10637-642e-4e11-bfc7-7ea3abeae7b9">two</ix:nonFraction> preclinical programs enabled by the Company's TV technology platform, which platform aims to improve brain uptake of biotherapeutics, including its Antibody Transport Vehicle ("ATV"): Abeta program ("ATV-enabled anti-amyloid beta program") and a second program utilizing the Company's TV technology for an unnamed target ("TV program"), excluding small molecules, Adeno-associated viruses ("AAV") and oligonucleotides. Biogen&#8217;s option may be exercised up to initiation of investigational new drug ("IND")-enabling studies for each program and continues for each program until a specified period of time after delivery of an option data package, or <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfNTMxNA_6ca82b29-adf5-4704-b8b5-513bcd955ad5">thirty</span> business days after the 5th anniversary of the effective date of the Provisional Biogen Collaboration Agreement, whichever is earlier.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, Biogen will have the right of first negotiation ("ROFN") on <ix:nonFraction unitRef="program" contextRef="i3df519c68317420e8222a86148ab6e41_I20200805" decimals="INF" format="ixt-sec:numwordsen" name="dnli:CollaborativeArrangementNumberOfAdditionalProgramsIfCircumstancesMet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfNTUyMQ_a962cc6c-85a4-499f-a60f-9dcde6ca4b2a">two</ix:nonFraction> additional TV-enabled therapeutics within Alzheimer&#8217;s disease, Parkinson&#8217;s disease, ALS or multiple sclerosis should the Company decide to seek a collaboration with a third party for such programs, but this does not include any of the Company&#8217;s small molecule, AAV or oligonucleotide programs. The ROFN period continues until <ix:nonNumeric contextRef="id16d8e434fba4f8ca86744e3c63d5d95_D20200805-20200805" format="ixt-sec:durwordsen" name="dnli:CollaborativeArrangementRightOfFirstNegotiationTermPeriodAfterEffectiveDateOfAgreementIfCircumstancesMet" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfNTg1Mg_bdc38ba6-ddfa-4cec-a3f0-9975ffa48c8b">seven years</ix:nonNumeric> after the effective date of the Provisional Biogen Collaboration Agreement or the date on which the Company has offered Biogen <ix:nonFraction unitRef="program" contextRef="i3df519c68317420e8222a86148ab6e41_I20200805" decimals="INF" format="ixt-sec:numwordsen" name="dnli:CollaborativeArrangementRightOfFirstNegotiationPeriodTermAdditionalProgramCriteria" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfNTk4Mg_8ecb7806-7f37-476c-905f-b47001931bae">two</ix:nonFraction> ROFN Programs, and for which Biogen has agreed to trigger a ROFN for such program, whichever is earlier. However, if the Company does not execute an agreement with a third party with respect to a particular ROFN Program offered to Biogen within a specified amount of time, Biogen will have <ix:nonFraction unitRef="program" contextRef="i3df519c68317420e8222a86148ab6e41_I20200805" decimals="INF" format="ixt-sec:numwordsen" name="dnli:CollaborativeArrangementNumberOfAdditionalProgramsNoThirdPartyAgreementExecutedIfCircumstancesMet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfNjIwNw_b744b707-394a-47f1-88ac-7ed079ece811">one</ix:nonFraction> additional right to exercise the ROFN again with respect to such ROFN Program.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Provisional Biogen Collaboration Agreement, the Company entered into a common stock purchase agreement (the "Stock Purchase Agreement") with BIMA on August&#160;5, 2020, pursuant to which the Company agreed to issue and sell, and BIMA agreed to purchase, <ix:nonFraction unitRef="shares" contextRef="i3f469ca238db4f19ade2b0c2f5542d55_D20200922-20200922" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfNjU1MA_265734d2-834c-42b9-8e23-6153ab21eb73">13,310,243</ix:nonFraction> shares of the Company&#8217;s common stock (the &#8220;Shares&#8221;) for an aggregate purchase price of $<ix:nonFraction unitRef="usd" contextRef="i3f469ca238db4f19ade2b0c2f5542d55_D20200922-20200922" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfNjY0MA_3fdba689-a8a9-498a-bc7f-695785769f6c">465.0</ix:nonFraction> million pursuant to the terms and conditions thereof. Since the shares of common stock owned by Biogen as of March 31, 2021 represent more than 10% of the voting interest of the Company, Biogen is considered a related party as defined in ASC 850. Management determined that it was appropriate to account for the Provisional Biogen Collaboration Agreement and the SPA as one arrangement because they were entered into at the same time with interrelated financial terms.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September&#160;22, 2020, the Company closed the sale of the Shares to BIMA pursuant to the Stock Purchase Agreement. The estimated fair market value of the Shares issued to BIMA was $<ix:nonFraction unitRef="usd" contextRef="i53d1846478874ac7a03801cbb5049533_I20200922" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CommonStocksIncludingAdditionalPaidInCapital" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfNzI1Ng_8a7157a4-90e1-44a7-adc5-5fa30e5729cc">420.1</ix:nonFraction>&#160;million, based on the closing stock price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i53d1846478874ac7a03801cbb5049533_I20200922" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfNzI5Ng_1de955ee-4888-4cce-8a60-18efd3a69f82">35.87</ix:nonFraction> on the date of issuance adjusted by a discount for lack of marketability due to certain holding period restrictions, which was valued using an option pricing model. This stock issuance resulted in a $<ix:nonFraction unitRef="usd" contextRef="i3f469ca238db4f19ade2b0c2f5542d55_D20200922-20200922" decimals="-5" format="ixt:numdotdecimal" name="dnli:SaleOfStockConsiderationPremiumReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfNzQ5OA_3ce619e8-0db7-4a21-9411-f51f1fa2a39f">44.9</ix:nonFraction>&#160;million premium paid to the Company above the estimated fair value of the Company's common stock (the "Stock Premium"), which forms part of the transaction price for the Biogen Collaboration Agreement. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Biogen Collaboration Agreement</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company entered into the LRRK2 Agreement with Biogen on October&#160;4, 2020 and the ROFN and Option Agreement on October&#160;6, 2020. Collectively these are known as the Biogen Collaboration Agreement, the material terms of which are consistent with, and supersede, the Provisional Biogen Collaboration Agreement discussed above. </span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the ROFN and Option Agreement, with respect to the options granted by the Company to Biogen, Biogen is obligated to pay to the Company an aggregate of up to $<ix:nonFraction unitRef="usd" contextRef="i3d221276fee544dc91f74c0f2b96de94_I20201006" decimals="INF" format="ixt:numdotdecimal" name="dnli:CollaborativeArrangementOptionExerciseAndDevelopmentMilestonePaymentsToBeReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMTE4NDU_bc529328-792e-41b5-ad4e-465055c21251">270.0</ix:nonFraction>&#160;million in option exercise and development milestone payments, up to $<ix:nonFraction unitRef="usd" contextRef="i3d221276fee544dc91f74c0f2b96de94_I20201006" decimals="INF" format="ixt:numdotdecimal" name="dnli:CollaborativeArrangementFirstCommercialSaleMilestonePaymentsToBeReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMTE5MDk_2f7c1e35-8324-485e-837c-f3fafb9acb6d">325.0</ix:nonFraction>&#160;million upon first commercial sale, and up to $<ix:nonFraction unitRef="usd" contextRef="i3d221276fee544dc91f74c0f2b96de94_I20201006" decimals="INF" format="ixt:numdotdecimal" name="dnli:CollaborativeArrangementNetSalesBasedMilestonePaymentsToBeReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMTE5NTA_46911fa5-5e2d-4ac5-9208-cf4c187a6138">290.0</ix:nonFraction>&#160;million of net sales-based milestone payments, following the achievement of certain prespecified milestone events and if Biogen exercises both of its options. Furthermore, Biogen is obligated to pay to the Company royalties in the mid-single digit to mid-teens percentages, depending on the program for which Biogen exercises its option and upon the achievement of certain sales thresholds.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, the Company received upfront payments totaling $<ix:nonFraction unitRef="usd" contextRef="ia59d27ad521d4576896de358cda1e1a8_D20201006-20201031" decimals="-5" format="ixt:numdotdecimal" name="dnli:UpfrontPayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMTI0MDA_482d71c3-d373-4175-890b-77877f155f80">560.0</ix:nonFraction>&#160;million pursuant to the Biogen Collaboration Agreement. </span></div></ix:continuation><div style="text-indent:27pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5ae1cfc88aa4492caf56e9d4ac91e096_7">Table of Contents</a></span></div></div><ix:continuation id="ib255da9973434f5e8d06328b335a86ee" continuedAt="i1d1a6da9538c41cb9ece8112e3ff9c05"><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Biogen Collaboration Agreement is considered a contract modification to the Provisional Biogen Collaboration Agreement and was accounted for as a termination of the provisional agreement and commencement of a new contract.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company identified the following distinct performance obligations associated with the Biogen Collaboration Agreement that had not yet been delivered under the original contract: the LRRK2 Program license, the research services for the ATV:Abeta and TV programs (&#8220;Option Research Services&#8221;) which include option joint steering committee ("JSC") participation, and a material right for an option under the ROFN and Option Agreement. Further, the LRRK2 Development Activities which includes LRRK2 JSC and joint development committee (&#8220;JDC&#8221;) participation was identified as a unit of account under ASC 808. The LRRK2 Development Activities, JSC and JDC participation are considered to be a single unit of account since the development activities are highly interrelated with the JSC and JDC involvement and these are not distinct in the context of the contract. Further, the same was considered to be true for the option research services and option JSC participation performance obligation.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes that the Biogen Collaboration Agreement is a collaboration arrangement as defined in ASC 808, Collaborative Arrangements. The Company also believes that Biogen meets the definition of a customer as defined in ASC 606, Revenue From Contracts With Customers for all of the performance obligations identified at inception except for the LRRK2 Development Activities. Since ASC 808 does not address recognition and measurement, the Company looked to other accounting literature for guidance where the performance obligation does not fall under ASC 606, and determined that for the interim LRRK2 development activities subject to cost sharing provisions, the guidance in ASC 730, Research and Development should be applied.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The transaction price at inception included fixed consideration consisting of the upfront fee of $<ix:nonFraction unitRef="usd" contextRef="ia59d27ad521d4576896de358cda1e1a8_D20201006-20201031" decimals="-5" format="ixt:numdotdecimal" name="dnli:UpfrontPayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMTY0OTI2NzQ4MjgzOA_11beab15-ae94-4654-b610-103ad279428d">560.0</ix:nonFraction>&#160;million and the $<ix:nonFraction unitRef="usd" contextRef="i3f469ca238db4f19ade2b0c2f5542d55_D20200922-20200922" decimals="-5" format="ixt:numdotdecimal" name="dnli:SaleOfStockConsiderationPremiumReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMTY0OTI2NzQ4Mjg1NA_96e9daf0-3fcb-4ede-ba0e-78a1cc1b1e0f">44.9</ix:nonFraction>&#160;million premium on the sale of common stock. All potential future milestones and other payments were considered constrained at the inception of the Biogen Collaboration Agreement since the Company could not conclude it was probable that a significant reversal in the amount recognized would not occur. From inception of the Biogen Collaboration Agreement through March 31, 2021, there was <ix:nonFraction unitRef="usd" contextRef="i22fa845ccdd543acb615ea629ab5344c_D20201006-20210331" decimals="INF" format="ixt-sec:numwordsen" name="dnli:CollaborationAgreementTransactionPriceIncreaseDecrease" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMTY0OTI2NzQ4Mjg4OA_2977e961-2cc5-4e16-a203-80c6d60bd024">no</ix:nonFraction> change to the transaction price.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The respective standalone value for each of the performance obligations was determined by applying the SSP method and the transaction price was allocated based on the relative SSP method with revenue recognition timing to be determined either by delivery, resolution of an option, or the provision of services.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company used an adjusted market assessment approach to estimate the selling price for the LRRK2 Program license, an expected cost plus margin approach for estimating the Option Research Services and estimated the intrinsic value of the material right for the option, taking into account the likelihood that an option would be exercised. The LRRK2 Program license was delivered on or around the effective date of the Biogen Collaboration Agreement and the revenue allocated to this performance obligation was recognized during the year ended December 31, 2020. The Option Research Services are expected to be delivered over time as the services are performed, with revenue being recognized over time based on costs incurred to perform the services, since the level of costs incurred over time is thought to best reflect the transfer of services to Biogen. Revenue allocated to the material right for an option under the ROFN and Option Agreement is deferred as a contract liability until the option opt in period ends, expiration or ROFN and Option Agreement termination. The LRRK2 Development Activities cost sharing reimbursements or expenses will be recognized over time as earned or incurred, since this is believed to directly correlate to the value of the services performed.</span></div></ix:continuation><div style="text-indent:27pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5ae1cfc88aa4492caf56e9d4ac91e096_7">Table of Contents</a></span></div></div><ix:continuation id="i1d1a6da9538c41cb9ece8112e3ff9c05" continuedAt="i568f227f72ff475cb6993f62c98954be"><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A related party contract liability of $<ix:nonFraction unitRef="usd" contextRef="i2934421e8d7b4a55a318b2d3d6102fed_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMTY0OTI2NzQ4MjkyNQ_f7a6bb5b-1036-4d5d-9c12-a068a5f1f715">296.5</ix:nonFraction> million was recorded on the Consolidated Balance Sheet as of March 31, 2021. Approximately $<ix:nonFraction unitRef="usd" contextRef="i611b2655965e42dfbda911bc7c9ee9c8_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMTY0OTI2NzQ4Mjk0NQ_56a23032-f5f1-42bf-9f03-bdfbd65f680f">288.9</ix:nonFraction>&#160;million of this contract liability relates to the revenue allocated to the material right for an option under the ROFN and Option Agreement which is being deferred until resolution of the option which is expected to be several years from the balance sheet date, and $<ix:nonFraction unitRef="usd" contextRef="i0f8d7006122c478b92ae9f39d8d1b0e5_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMTY0OTI2NzQ4Mjk5OQ_98b1fb1d-9961-4887-804b-6d5e9564c713">7.6</ix:nonFraction>&#160;million of this contract liability relates to the portion of the Option Research Services performance obligation yet to be satisfied, with such amount to be recognized over the estimated period of the services, which is expected to be several years. The Company recorded $<ix:nonFraction unitRef="usd" contextRef="if1065b142ae843249dfdfee04de24a66_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="dnli:ResearchAndDevelopmentExpenseOffsetFromRelatedPartyCostReimbursement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMTY0OTI2NzQ4MzA1Nw_8815c5a8-7431-4fb4-b758-d7f29c8a81a4">2.5</ix:nonFraction>&#160;million of cost sharing reimbursements for LRRK2 Development Activities as an offset to research and development expenses in the Consolidated Statement of Operations and Comprehensive Income for the three months ended March 31, 2021. </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">cost sharing reimbursements due from Biogen</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the Condensed Consolidated Balance Sheet as of March 31, 2021 and December 31, 2020 of $<ix:nonFraction unitRef="usd" contextRef="i5dd55e97d29845d79435cc613548f911_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DueFromRelatedPartiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMjc0ODc3OTEzNzMxNg_a1d93721-0f41-438e-813a-7166a947cb28">2.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i0013ce3d1a8247a08d873ceee1cdf67a_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DueFromRelatedPartiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMjc0ODc3OTE0MTU5Mg_b8d851a6-0126-400c-8266-32dd81c1c941">5.7</ix:nonFraction>&#160;million, respectively.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In assessing the Biogen Collaboration Agreement, management exercised considerable judgment in estimating revenue to be recognized, specifically related to estimating the discount for lack of marketability associated with the stock issuance, determining the separate performance obligations under the Biogen Collaboration Agreement, and estimating the standalone selling price of those performance obligations. </span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2021, the Company had <ix:nonFraction unitRef="milestone" contextRef="i5dd55e97d29845d79435cc613548f911_I20210331" decimals="INF" format="ixt-sec:numwordsen" name="dnli:CollaborativeArrangementNumberOfMilestonesAchieved" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMTY0OTI2NzQ3Njc3MA_ad3c8e2a-8c61-4977-b2d2-c4984aa3e516">no</ix:nonFraction>t achieved any milestones or recorded any product sales under the Biogen Collaboration Agreement. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sanofi </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, the Company entered into a Collaboration and License Agreement ("Sanofi Collaboration Agreement") with Genzyme Corporation, a wholly owned subsidiary of Sanofi S.A. ("Sanofi") pursuant to which certain small molecule CNS and peripheral </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">receptor interacting serine/threonine protein kinase 1 ("</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RIPK1") inhibitors contributed by Sanofi and by the Company will be developed and commercialized. The Sanofi Collaboration Agreement became effective in November 2018 at which time Sanofi paid the Company an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i37367f9356d64fd3928fdd776c7f31a8_D20181101-20181130" decimals="-5" format="ixt:numdotdecimal" name="dnli:UpfrontPayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMTMxODI_efb028c8-9f1b-4ff2-b565-579b4906f5d4">125.0</ix:nonFraction> million. Under the Sanofi Collaboration Agreement, the Company is eligible to receive milestone payments from Sanofi up to approximately $<ix:nonFraction unitRef="usd" contextRef="ic6d24297d8d84d17b99d57fe8ee7d6f5_I20181130" decimals="-8" format="ixt:numdotdecimal" name="dnli:AggregateClinicalRegulatoryAndSalesMilestonePayment" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMTMzMTQ_1f43aee6-d0ef-44a0-a176-3eb88f78bc7a">1.1</ix:nonFraction> billion upon achievement of certain clinical, regulatory and sales milestone events. Such milestone payments include $<ix:nonFraction unitRef="usd" contextRef="i69a8709612b349b38ac7bf012d3e0fd3_I20181130" decimals="-5" format="ixt:numdotdecimal" name="dnli:ClinicalMilestonePayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMTM0MjY_92cae6b0-e305-4f1a-88da-ce1fedba5e1a">215.0</ix:nonFraction> million in clinical milestone payments and $<ix:nonFraction unitRef="usd" contextRef="i69a8709612b349b38ac7bf012d3e0fd3_I20181130" decimals="-5" format="ixt:numdotdecimal" name="dnli:RegulatoryMilestonePayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMTM0NjQ_e2c528a0-26b3-48ff-b173-8419aed2cb16">385.0</ix:nonFraction> million in regulatory milestone payments for CNS Products, as defined, that are developed and approved in the United States, by the European Medicines Agency ("EMA") and in Japan for <ix:nonFraction unitRef="indication" contextRef="i32ecdc0092f641bd9100243e5a27d217_I20181130" decimals="INF" format="ixt-sec:numwordsen" name="dnli:NumberOfIndications" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMTM2NDI_485544c9-9aa4-407f-9bd6-707c01dc9f3c">three</ix:nonFraction> indications, including Alzheimer's disease. These milestones also include $<ix:nonFraction unitRef="usd" contextRef="iaa8b5535fbd846a4bd38c3e3b7f756a4_I20181130" decimals="-5" format="ixt:numdotdecimal" name="dnli:ClinicalMilestonePayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMTM3MTk_9a6f05d1-c4be-4032-9b04-c1ec9ea7bbab">120.0</ix:nonFraction> million in clinical milestone payments, $<ix:nonFraction unitRef="usd" contextRef="iaa8b5535fbd846a4bd38c3e3b7f756a4_I20181130" decimals="-5" format="ixt:numdotdecimal" name="dnli:RegulatoryMilestonePayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMTM3NTQ_4c828007-05ab-4473-9185-a285b1f2ef20">175.0</ix:nonFraction> million in regulatory milestone payments and $<ix:nonFraction unitRef="usd" contextRef="iaa8b5535fbd846a4bd38c3e3b7f756a4_I20181130" decimals="-5" format="ixt:numdotdecimal" name="dnli:CommercialMilestonePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMTM3OTQ_625693ee-964e-45df-a526-b24dc46ef509">200.0</ix:nonFraction> million in commercial milestone payments for Peripheral Products, as defined, that are developed and approved in the United States, by the EMA and Japan for <ix:nonFraction unitRef="indication" contextRef="i32ecdc0092f641bd9100243e5a27d217_I20181130" decimals="INF" format="ixt-sec:numwordsen" name="dnli:NumberOfIndications" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMTM5NDY_b7ad2622-d35e-410e-9fea-f31ac4bcf05f">three</ix:nonFraction> indications. </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company will share profits and losses equally with Sanofi for CNS Products sold in the United States and China, and receive variable royalties on net sales for CNS Products sold outside of the United States and China and for Peripheral Products sold worldwide.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and Sanofi will jointly develop CNS Products pursuant to a global development plan. The Company will be responsible, at its own cost, for conducting Phase 1 and Phase 2 trials for CNS Products in Alzheimer&#8217;s disease and any activities required to support such clinical trials and specific for Alzheimer's disease ("Denali CNS Development Activities"). The Company conducted, at Sanofi&#8217;s cost, a Phase 1b trial for the initial lead CNS penetrant RIPK1 inhibitor, DNL747 (SAR443060), in ALS. In June 2020, the Company announced that clinical activities on DNL747 would be paused and efforts focused on the development of the backup preclinical candidate, DNL788 (SAR443820). Other than with the Denali CNS Development Activities, Sanofi is responsible, at its cost, for all other Phase 1 and Phase 2 trials for CNS Products, including for ALS and multiple sclerosis. Sanofi will lead the conduct of all Phase 3 and later stage development trials for CNS Products, with Sanofi and the Company funding <ix:nonFraction unitRef="number" contextRef="i6ea2228697dd4aaba41a39520dc51665_I20181130" decimals="INF" name="dnli:CollaborativeAgreementFundedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMTUxMjU_09e8dd58-eb79-4bb4-b936-5a6dbfb64d7e">70</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="iae801c2eda2b4f468e16600312d29411_I20181130" decimals="INF" name="dnli:CollaborativeAgreementFundedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMTUxMzI_90913293-d0d6-4f51-b189-8126d5f0478e">30</ix:nonFraction>% of such costs, respectively. Sanofi will also lead the commercialization activities globally for CNS Products, subject to certain options that the Company has to conduct co-commercialization activities with respect to each CNS Product in the United States and China. </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5ae1cfc88aa4492caf56e9d4ac91e096_7">Table of Contents</a></span></div></div><ix:continuation id="i568f227f72ff475cb6993f62c98954be" continuedAt="i160abaec0849453fb1d3a8cea497a002"><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sanofi will be responsible, at its cost, for conducting activities relating to the development and commercialization of all Peripheral Products. Denali will be entitled to receive tiered royalties in the low- to mid- teen percentages on net sales of Peripheral Products.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company identified the following distinct performance obligations associated with the Sanofi Collaboration Agreement upon inception: the CNS program license, the Peripheral program license, the Phase 1 and Phase 2 trials for CNS Products for Alzheimer&#8217;s disease ("Alzheimer's Disease Services"), and the Phase 1b trial for DNL747 for ALS and associated activities ("Retained Activities"). </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes that the Sanofi Collaboration Agreement is a collaboration arrangement as defined in ASC 808, Collaborative Arrangements. The Company also believes that Sanofi meets the definition of a customer as defined in ASC 606, Revenue From Contracts With Customers for three of the performance obligations identified at inception, but does not meet the definition of a customer for the Alzheimer's Disease Services. Further, Sanofi does not meet the definition of a customer for all Phase 3 and later stage development trials for CNS Products led by Sanofi for which the Company will fund <ix:nonFraction unitRef="number" contextRef="iae801c2eda2b4f468e16600312d29411_I20181130" decimals="INF" name="dnli:CollaborativeAgreementFundedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMTY2NDE_90913293-d0d6-4f51-b189-8126d5f0478e">30</ix:nonFraction>% of total costs. Since ASC 808 does not address recognition and measurement, the Company looked to other accounting literature for guidance where the performance obligation does not fall under ASC 606, and determined that for the Alzheimer's Disease Services, the guidance in ASC 606 should be analogized for the recognition, measurement and reporting of this performance obligation, and for the cost sharing provisions, the Company determined that the guidance in ASC 730, Research and Development should be applied. </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The transaction price at inception included upfront fixed consideration of $<ix:nonFraction unitRef="usd" contextRef="i37367f9356d64fd3928fdd776c7f31a8_D20181101-20181130" decimals="-5" format="ixt:numdotdecimal" name="dnli:UpfrontPayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMTcyMzc_efb028c8-9f1b-4ff2-b565-579b4906f5d4">125.0</ix:nonFraction> million. All potential future milestones and other payments were considered constrained at the inception of the Sanofi Collaboration Agreement since the Company could not conclude it was probable that a significant reversal in the amount recognized would not occur. The transaction price did <ix:nonFraction unitRef="usd" contextRef="i46ab6c65582f4d8bab7e57d6dd6f7588_D20210101-20210331" decimals="INF" format="ixt-sec:numwordsen" name="dnli:CollaborationAgreementTransactionPriceIncrease" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfNDM5ODA0NjU4NDg5NQ_d354a7fd-d25f-40e6-9eba-8fe52942a0cd">no</ix:nonFraction>t increase in the three months ended March 31, 2021, and increased by $<ix:nonFraction unitRef="usd" contextRef="i1c01d0c60cd542c4a229d6789938312a_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="dnli:CollaborationAgreementTransactionPriceIncrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMTY0OTI2NzQ4MzY4Mg_a9aca8f9-dce0-4f77-b575-c550b54486d2">0.5</ix:nonFraction> million for the three months ended March 31, 2020 related to costs incurred for Retained Activities that were no longer constrained. </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The respective standalone value for each of the performance obligations was determined by applying the SSP method and the transaction price allocated based on the relative SSP method with revenue recognition timing to be determined either by delivery or the provision of services.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company used an adjusted market assessment approach to estimate the selling price for the program licenses, and an expected cost plus margin approach for estimating the Alzheimer&#8217;s Disease Services and the Retained Activities. The program licenses and existing know-how were delivered on the effective date of the Sanofi Collaboration Agreement. The Alzheimer&#8217;s Disease Services and the Retained Activities were expected to be delivered over time as the services are performed. For the Alzheimer's Disease Services, revenue is being recognized over time using the input method, based on costs incurred to perform the services, since the level of costs incurred over time is thought to best reflect the transfer of services to Sanofi. For the Retained Activities, revenue is being recognized over time using the output method, based on amounts invoiced to Sanofi, since this is believed to directly correlate to the value of the services performed.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A contract liability of $<ix:nonFraction unitRef="usd" contextRef="i71f6e4875572417586577b9989db412c_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueRemainingPerformanceObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMTk0MjA_6c59c130-eab2-48ce-aa2e-c3c9a7edf738"><ix:nonFraction unitRef="usd" contextRef="i261cc6d074024d72a8c693a4ea9e24fa_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueRemainingPerformanceObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMTk0MjA_ac70b266-b13e-42f1-b970-adf6fd2c20e1">3.4</ix:nonFraction></ix:nonFraction> million was recorded on the Condensed Consolidated Balance Sheets as of March 31, 2021 and December 31, 2020. This contract liability relates to the portion of the Alzheimer's Disease Services performance obligation yet to</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> be satisfied, with such amounts to be recognized over the estimated period of the services, which is expected to be several years. The Company recorded <ix:nonFraction unitRef="usd" contextRef="i85da405a68d44147816b407c550dd77b_I20210331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:AccountsReceivableNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfNDM5ODA0NjU4NDkwMw_2e0883eb-a50f-4dce-9fc2-eb5aa80660fb">no</ix:nonFraction> receivable associated with the Sanofi Collaboration Agreement on the Condensed Consolidated Balance Sheets as of March 31, 2021, and a receivable of $<ix:nonFraction unitRef="usd" contextRef="ib2c5d3daea2b469eb42d1e130f45621f_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMjc0ODc3OTE0MTkyMw_66db8f95-6834-4431-af9d-239bb457239c">44,303</ix:nonFraction> as of December 31, 2020. </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In assessing the Sanofi Collaboration Agreement, management is required to exercise considerable judgment in estimating revenue to be recognized. Managem</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ent applies judgment in determining the separate performance obligations, in estimating the selling price, in determining when control was transferred to Sanofi for the licenses, and in estimating total future costs when using the input method.  </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through March 31, 2021, the Company has received milestone payments of </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="i8e78aebb6758499aa9b578b8b7365ab9_D20181001-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMjAzOTY_23662527-52aa-4997-827d-495bcc45f7aa">10.0</ix:nonFraction> million</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and has <ix:nonFraction unitRef="usd" contextRef="ieb8b43e946ab4a5e983647ccb9581dc3_D20181001-20210331" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMjA0MDc_b5335f63-36c8-4f97-9c64-c383c703eefb">no</ix:nonFraction>t recorded any product sales under the Sanofi Collaboration Agreement.</span><span style="color:#ee2724;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5ae1cfc88aa4492caf56e9d4ac91e096_7">Table of Contents</a></span></div></div><ix:continuation id="i160abaec0849453fb1d3a8cea497a002" continuedAt="i965f5def5acc464aae4c3e171306e405"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Takeda </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2018, the Company entered into a Collaboration and Option Agreement ("Takeda Collaboration Agreement") with Takeda Pharmaceutical Company Limited ("Takeda"), pursuant to which the Company granted Takeda an option to develop and commercialize, jointly with the Company, certain biologic products that are enabled by the Company's BBB delivery technology and intended for the treatment of neurodegenerative disorders. The programs were the Company&#8217;s ATV:BACE1/Tau and ATV:TREM2 and PTV:PGRN programs. The Takeda Collaboration Agreement became effective in February 2018, at which time Takeda paid the Company an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="iaf62192d651f44fa9a8f0990d46c3286_D20180223-20180223" decimals="-5" format="ixt:numdotdecimal" name="dnli:UpfrontPayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMjExNDE_d219599e-ab85-4a3d-86d9-b9b4b5dc9313">40.0</ix:nonFraction> million. Takeda may pay up to an aggregate of $<ix:nonFraction unitRef="usd" contextRef="i2e206bb2a68d468195031df47711679a_D20180223-20180223" decimals="-5" format="ixt:numdotdecimal" name="dnli:PreclinicalMilestonePaymentPerProgram" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMjExODI_be7141f9-1c70-4fde-aaaa-5247f01d2abe">25.0</ix:nonFraction> million with respect to each of the <ix:nonFraction unitRef="program" contextRef="i629da488ba924dfc9f4eb9daeb937953_I20180223" decimals="INF" format="ixt-sec:numwordsen" name="dnli:NumberOfPrograms" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMjEyMTM_f7a4cdc2-e358-4ed1-8773-130ad3625087">three</ix:nonFraction> programs directed to a target and based upon the achievement of certain preclinical milestone events, up to $<ix:nonFraction unitRef="usd" contextRef="i2e206bb2a68d468195031df47711679a_D20180223-20180223" decimals="-5" format="ixt:numdotdecimal" name="dnli:AggregatePreclinicalMilestonePayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMjEzMjQ_3d5fa34b-b408-4957-a328-4ed57e6642e7">75.0</ix:nonFraction> million in total, $<ix:nonFraction unitRef="usd" contextRef="iaf62192d651f44fa9a8f0990d46c3286_D20180223-20180223" decimals="-5" format="ixt:numdotdecimal" name="dnli:PreclinicalMilestonePaymentReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMjEzMzc_b370c370-0522-492f-ba37-9b54d94736f9">5.0</ix:nonFraction> million of which was paid upon the Takeda Collaboration Agreement becoming effective. In February 2019, the agreement was amended to replace the ATV:BACE1/Tau program with the ATV:Tau program. The amendment did not have a material impact to the condensed consolidated financial statements.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Takeda Collaboration Agreement and unless otherwise agreed jointly between both parties, the Company will be responsible, at its cost, for conducting activities relating to pre-IND&#160;development of biologic products directed to the <ix:nonFraction unitRef="target" contextRef="i629da488ba924dfc9f4eb9daeb937953_I20180223" decimals="INF" format="ixt-sec:numwordsen" name="dnli:NumberOfTargets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMjE4ODA_df16c7b6-d1a2-4c53-9ded-dd7de2c7559d">three</ix:nonFraction> identified targets and enabled by its BBB delivery technology targeting TfR during the applicable research period. The period through which the option can be exercised continues for each target until the first biologic product directed to the relevant target is&#160;IND-ready&#160;or approximately <ix:nonNumeric contextRef="iaf62192d651f44fa9a8f0990d46c3286_D20180223-20180223" format="ixt-sec:durwordsen" name="dnli:TargetOptionPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMjIxNzI_caa9e489-8485-4ebe-9edf-320de5a035f6">five years</ix:nonNumeric> after selection of the target, whichever is earlier.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If Takeda exercises its option with respect to a particular target, then Takeda will have the right to develop and commercialize, jointly with the Company, a specified number of biologic products enabled by its BBB delivery technology that were developed during the research period and which are directed to the relevant target. The Company will grant to Takeda a&#160;co-exclusive&#160;license under the intellectual property the Company controls related to those biologic products.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Takeda is obligated to pay the Company a $<ix:nonFraction unitRef="usd" contextRef="i629da488ba924dfc9f4eb9daeb937953_I20180223" decimals="-5" format="ixt:numdotdecimal" name="dnli:OptionFeesPerProgram" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMjI3NDM_2e8392be-f4fc-45d3-b96f-5e2d212947d8">5.0</ix:nonFraction> million option fee for each target for which Takeda exercises its option, up to $<ix:nonFraction unitRef="usd" contextRef="idf9de44243d0448abccdf83151ea9bfa_I20180223" decimals="-5" format="ixt:numdotdecimal" name="dnli:AggregateOptionExerciseFee" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMjI4MTg_c15ca5c0-a42b-4b8c-acc9-bb6f4f52d2ce">15.0</ix:nonFraction> million in total.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, if Takeda exercises its option for all <ix:nonFraction unitRef="program" contextRef="i629da488ba924dfc9f4eb9daeb937953_I20180223" decimals="INF" format="ixt-sec:numwordsen" name="dnli:NumberOfPrograms" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMjI4ODM_c2622e74-4dce-4212-ae93-1e51800f25b8">three</ix:nonFraction> collaboration programs, Takeda may be obligated to pay the Company up to an aggregate of $<ix:nonFraction unitRef="usd" contextRef="idf9de44243d0448abccdf83151ea9bfa_I20180223" decimals="-5" format="ixt:numdotdecimal" name="dnli:AggregateDevelopmentMilestonePayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMjI5NzU_e651b80a-01bd-4d11-8bbd-107277751a52">407.5</ix:nonFraction> million upon achievement of certain clinical milestone events and up to an aggregate of $<ix:nonFraction unitRef="usd" contextRef="idf9de44243d0448abccdf83151ea9bfa_I20180223" decimals="-5" format="ixt:numdotdecimal" name="dnli:RegulatoryMilestonePayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMjMwNTg_5d3cb8b0-ae27-4ab0-94e9-055b37f0eee4">300.0</ix:nonFraction> million in regulatory milestone events relating to receipt of regulatory approval in the United States, certain European countries and Japan. Takeda may also be obligated to pay the Company up to $<ix:nonFraction unitRef="usd" contextRef="idf9de44243d0448abccdf83151ea9bfa_I20180223" decimals="-5" format="ixt:numdotdecimal" name="dnli:CommercialMilestonesPerProgram" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMjMyNDk_7d849092-a96f-4e95-9aea-7936e91402c6">75.0</ix:nonFraction> million per biologic product upon achievement of a certain sales-based milestone, or an aggregate of $<ix:nonFraction unitRef="usd" contextRef="idf9de44243d0448abccdf83151ea9bfa_I20180223" decimals="-5" format="ixt:numdotdecimal" name="dnli:AggregateCommercialMilestones" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMjMzNDU_d1adac58-d4da-4bbc-a063-19a68cb7cf38">225.0</ix:nonFraction> million if one biologic product from each program achieves this milestone.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If Takeda exercises its option for a particular target, the Company and Takeda will share equally in the development and commercialization costs, and, if applicable, the profits, for each collaboration program.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the terms of the Takeda Collaboration Agreement, the Company entered into a common stock purchase agreement (the "Stock Purchase Agreement") with Takeda on January&#160;3, 2018, pursuant to which Takeda purchased <ix:nonFraction unitRef="shares" contextRef="i9261bc8472184e6fa1082e8c5405a625_D20180223-20180223" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMjM4MzM_6a79ac7f-6c42-4213-9d63-0d77c7914304">4,214,559</ix:nonFraction> shares of the Company's common stock (the "Shares") for an aggregate purchase price of $<ix:nonFraction unitRef="usd" contextRef="i9261bc8472184e6fa1082e8c5405a625_D20180223-20180223" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMjM5MjM_ec977466-879b-4c69-94f1-7da092d78f67">110.0</ix:nonFraction> million. The sale of the Shares closed on February&#160;23, 2018. The fair market value of the common stock sold to Takeda was $<ix:nonFraction unitRef="usd" contextRef="i9e0b33f51ccf452bae9b4c3f0109b86d_I20180223" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CommonStocksIncludingAdditionalPaidInCapital" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMjQwMjU_77a85470-3320-46af-aeda-746dd094967f">94.4</ix:nonFraction> million, based on the closing stock price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i9e0b33f51ccf452bae9b4c3f0109b86d_I20180223" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMjQwNjU_944408c1-4b71-494a-bccf-7c5c98b715ab">22.40</ix:nonFraction> on the date of issuance, resulting in&#160;a $<ix:nonFraction unitRef="usd" contextRef="i9261bc8472184e6fa1082e8c5405a625_D20180223-20180223" decimals="-5" format="ixt:numdotdecimal" name="dnli:SaleOfStockConsiderationPremiumReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMjQxMDg_f79aad69-1963-45c0-8a5d-bf5c3cb1e1a5">15.6</ix:nonFraction> million premium paid to the Company above the fair value of the Company's common stock which was credited to contract liability in the Company's Condensed Consolidated Balance Sheets.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes that the Takeda Collaboration Agreement is a collaboration arrangement as defined in ASC&#160;808, Collaborative Arrangements.&#160;Further, during the research period, the Company believes that the arrangement is a contract with a customer as defined in ASC 606,&#160;Revenue From Contracts With Customers</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Takeda Collaboration Agreement and the Stock Purchase Agreement are being accounted for as one arrangement because they were entered into at the same time with interrelated financial terms.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5ae1cfc88aa4492caf56e9d4ac91e096_7">Table of Contents</a></span></div></div><ix:continuation id="i965f5def5acc464aae4c3e171306e405" continuedAt="i25ac40ca27714750a9ff187656230955"><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company identified performance obligations during the research period consisting of the license, the development options, and joint steering committee ("JSC") participation together with the research services for each collaboration program. The license rights, JSC involvement, option and research services are considered to be a single performance obligation for each program since the research services are highly interrelated with the option and JSC involvement and will significantly modify the license. The performance obligations under each of the <ix:nonFraction unitRef="program" contextRef="i629da488ba924dfc9f4eb9daeb937953_I20180223" decimals="INF" format="ixt-sec:numwordsen" name="dnli:NumberOfPrograms" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfNDM5ODA0NjU4NDkxOQ_e868046d-5115-40f5-a981-a9e01dce3a57">three</ix:nonFraction> programs are separate since the activities and risks under the programs are distinct. </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that all other goods or services which are contingent upon Takeda exercising its option for each program were not considered performance obligations at the inception of the Takeda Collaboration Agreement.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The transaction price at inception included fixed consideration consisting of the upfront fee of $<ix:nonFraction unitRef="usd" contextRef="iaf62192d651f44fa9a8f0990d46c3286_D20180223-20180223" decimals="-5" format="ixt:numdotdecimal" name="dnli:UpfrontPayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMjU3NDA_d219599e-ab85-4a3d-86d9-b9b4b5dc9313">40.0</ix:nonFraction> million, the $<ix:nonFraction unitRef="usd" contextRef="i9261bc8472184e6fa1082e8c5405a625_D20180223-20180223" decimals="-5" format="ixt:numdotdecimal" name="dnli:SaleOfStockConsiderationPremiumReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMjU3NDg_f79aad69-1963-45c0-8a5d-bf5c3cb1e1a5">15.6</ix:nonFraction> million premium on the sale of common stock, and the </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">first preclinical milestone payment of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="iaf62192d651f44fa9a8f0990d46c3286_D20180223-20180223" decimals="-5" format="ixt:numdotdecimal" name="dnli:PreclinicalMilestonePaymentReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMjU4MzU_b370c370-0522-492f-ba37-9b54d94736f9">5.0</ix:nonFraction> million. It also included variable consideration of $<ix:nonFraction unitRef="usd" contextRef="iaf62192d651f44fa9a8f0990d46c3286_D20180223-20180223" decimals="-5" format="ixt:numdotdecimal" name="dnli:VariableConsiderationFutureConsideration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMjU4ODI_a62399d7-c0c5-4c4f-ad7d-34f0aab2b100">26.0</ix:nonFraction> million relating to future milestones that were not constrained, and have since all been met and received. </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The remaining $<ix:nonFraction unitRef="usd" contextRef="i629da488ba924dfc9f4eb9daeb937953_I20180223" decimals="-5" format="ixt:numdotdecimal" name="dnli:ConstrainedVariableConsideration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMjYwNDQ_84edd3f0-f9f7-4992-ad24-31739e9bb22a">44.0</ix:nonFraction> million of preclinical milestones were considered constrained at the inception of the Takeda Collaboration Agreement since the Company could not conclude it is probable that a significant reversal in the amount recognized will not occur. Additionally, cost and profit-sharing income, and the development and commercial milestones as outlined above, have not been considered given Takeda has not exercised its options for the development and commercial phases for any program. <ix:nonFraction unitRef="usd" contextRef="i8319328706f24bcdb7bf7f3fc0782056_D20180223-20210331" decimals="INF" format="ixt-sec:numwordsen" name="dnli:CollaborationAgreementTransactionPriceIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMjY1MTU_8b571d16-0eba-4a7c-ad52-5652c37c2260">No</ix:nonFraction> change in the transaction price has been recorded since inception. This will be reassessed at each reporting period. </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The transaction price has been ascribed in its entirety to the <ix:nonFraction unitRef="program" contextRef="i629da488ba924dfc9f4eb9daeb937953_I20180223" decimals="INF" format="ixt-sec:numwordsen" name="dnli:RevenueNumberOfPerformanceObligations" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMjY2OTk_6e69572c-e35a-4cad-8cef-000d1cada667">three</ix:nonFraction> performance obligations identified in the research term of the Takeda Collaboration Agreement.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue is recognized when, or as, the Company satisfies its performance obligations by transferring the promised services to Takeda. Revenue is being recognized over time using the input method, based on costs incurred to perform the research services, since the level of costs incurred over time is thought to best reflect the transfer of services to Takeda. There were no material changes in estimates during the three months ended March 31, 2021 or March 31, 2020.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A contract liability of $<ix:nonFraction unitRef="usd" contextRef="i8fd4f33cc0454770bb9522977f4298cc_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMjcyNTA_30d92d1f-e5a2-4f2b-b690-481a9f487acb">40.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i1b343adcffb94181bcbdfcb6161d5aba_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMjcyNTc_c83d1492-e1fe-4090-b9a3-2437ce971bc2">39.8</ix:nonFraction> million was recorded on the Condensed Consolidated Balance Sheets as of March 31, 2021 and December 31, 2020, respectively. This contract liability relates to the <ix:nonFraction unitRef="program" contextRef="i629da488ba924dfc9f4eb9daeb937953_I20180223" decimals="INF" format="ixt-sec:numwordsen" name="dnli:RevenueNumberOfPerformanceObligations" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMjczODg_6e69572c-e35a-4cad-8cef-000d1cada667">three</ix:nonFraction> performance obligations identified, with such amounts to be recognized over the estimated period of the pre-IND research services, which is expected to be several years. In December 2020 and January 2021, GLP toxicology studies were initiated for PTV:PGRN and ATV:TREM2, respectively, triggering the second preclinical milestone payments of $<ix:nonFraction unitRef="usd" contextRef="i6a890b5264394316bc209b1df064b85d_D20210301-20210331" decimals="-5" format="ixt:numdotdecimal" name="dnli:PreclinicalMilestonePaymentReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMTY0OTI2NzQ4Njg0Nw_44989ff8-a2d8-4bc6-a840-cef1495503a6"><ix:nonFraction unitRef="usd" contextRef="if1c8a3c07b01480bb07bf6e10da36189_D20210101-20210131" decimals="-5" format="ixt:numdotdecimal" name="dnli:PreclinicalMilestonePaymentReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMTY0OTI2NzQ4Njg0Nw_97340907-c24a-4744-83d1-7ab9fc81aa7a">8.0</ix:nonFraction></ix:nonFraction> million for each program, which were received in January and March 2021, respectively. There was <ix:nonFraction unitRef="usd" contextRef="i8fd4f33cc0454770bb9522977f4298cc_I20210331" decimals="INF" format="ixt-sec:numwordsen" name="dnli:PreclinicalMilestonePaymentEarnedNotYetReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMTA5OTUxMTY5OTgxMg_739a8546-e787-420f-965a-8dbc6077b36f">no</ix:nonFraction> receivable as of March 31, 2021 and a receivable of $<ix:nonFraction unitRef="usd" contextRef="i82572c2ba407421ab1eeaea4cc017b83_I20201231" decimals="-5" format="ixt:numdotdecimal" name="dnli:PreclinicalMilestonePaymentEarnedNotYetReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMTA5OTUxMTY5OTc4NA_abbce44a-742a-4357-9391-a4e7bdb78322">8.0</ix:nonFraction> million for the PTV:PGRN milestone as of December 31, 2020. </span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In assessing the Takeda Collaboration Agreement, management is required to exercise considerable judgment in estimating revenue to be recognized. Management applies judgment in determining the separate performance obligations in the research period and estimating total future costs when using the input method. There is some increase in the judgment required in estimating the timing of future costs due to the COVID-19 pandemic. This is because it is challenging to predict the duration and extent of the impact of the COVID-19 pandemic on the third-party service providers assisting with the Company's ATV:Tau, ATV:TREM2 and PTV:PGRN programs. This may impact the split between current and non-current contract liability on the Condensed Consolidated Balance Sheets in the future. </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through March 31, 2021, the Company had received $<ix:nonFraction unitRef="usd" contextRef="if1fffa1219a047f0a51060aeafb58951_D20180101-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMjg4MTk_a8fb3cc8-1e27-4c32-8278-fb3a9e3005e8">31.0</ix:nonFraction> million in preclinical milestone payments from Takeda which are included in the transaction price described above, and had <ix:nonFraction unitRef="usd" contextRef="i98a0ba98854b4bb8ac86be212e357b16_D20180101-20210331" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMjg4NzY_4549cf22-bc37-4e6f-a2bb-33e5a3bf66e1">no</ix:nonFraction>t recorded any product sales under the Takeda Collaboration Agreement. </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5ae1cfc88aa4492caf56e9d4ac91e096_7">Table of Contents</a></span></div></div><ix:continuation id="i25ac40ca27714750a9ff187656230955" continuedAt="i9febd1103b894143b4dbbb25eb32e355"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration Revenue</span></div><ix:nonNumeric contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMjkyNzI_42c87e89-f77a-4909-a099-244724dc0def" continuedAt="ifdf3f63764d14b2193f168b5332c2ef5" escape="true"><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue disaggregated by collaboration agreement and performance obligation is as follows (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.432%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.073%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.921%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.074%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Takeda Collaboration Agreement</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i643ec7e1d2a3451c9d8905efbcdbf48c_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RhYmxlOmJhNWVhZTk2NGVkODRkNjg4MTRmOGU2NTNiZDUxNDY4L3RhYmxlcmFuZ2U6YmE1ZWFlOTY0ZWQ4NGQ2ODgxNGY4ZTY1M2JkNTE0NjhfMi0xLTEtMS0w_44f95404-6768-4319-b4f0-82805ccf0a70">7,030</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff0f9b13d274493e8564765eb94360ae_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RhYmxlOmJhNWVhZTk2NGVkODRkNjg4MTRmOGU2NTNiZDUxNDY4L3RhYmxlcmFuZ2U6YmE1ZWFlOTY0ZWQ4NGQ2ODgxNGY4ZTY1M2JkNTE0NjhfMi0zLTEtMS0w_9335c3c3-7538-43a0-a10e-98cad965912c">3,018</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sanofi Collaboration Agreement</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Retained Activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9ccfab524d04954920c80a3c7ac6796_D20210101-20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RhYmxlOmJhNWVhZTk2NGVkODRkNjg4MTRmOGU2NTNiZDUxNDY4L3RhYmxlcmFuZ2U6YmE1ZWFlOTY0ZWQ4NGQ2ODgxNGY4ZTY1M2JkNTE0NjhfNi0xLTEtMS0w_16cc4a9d-e072-467d-a951-bb1871b51404">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if81ccf0b3968466bb8ad747c00401a8d_D20200101-20200331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RhYmxlOmJhNWVhZTk2NGVkODRkNjg4MTRmOGU2NTNiZDUxNDY4L3RhYmxlcmFuZ2U6YmE1ZWFlOTY0ZWQ4NGQ2ODgxNGY4ZTY1M2JkNTE0NjhfNi0zLTEtMS0w_ea0cc034-7d2d-4069-a84e-b76c95e41e0e">534</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Alzheimer's Disease Services</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifcf20312d910402ab56471a2d6469134_D20210101-20210331" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RhYmxlOmJhNWVhZTk2NGVkODRkNjg4MTRmOGU2NTNiZDUxNDY4L3RhYmxlcmFuZ2U6YmE1ZWFlOTY0ZWQ4NGQ2ODgxNGY4ZTY1M2JkNTE0NjhfNy0xLTEtMS0w_33ad5500-10d7-40d3-81a0-c1daa5bb15ed">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc2536462b694f07b028b19e58c564fe_D20200101-20200331" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RhYmxlOmJhNWVhZTk2NGVkODRkNjg4MTRmOGU2NTNiZDUxNDY4L3RhYmxlcmFuZ2U6YmE1ZWFlOTY0ZWQ4NGQ2ODgxNGY4ZTY1M2JkNTE0NjhfNy0zLTEtMS0w_eaa6f727-3e90-4ca2-aaf5-92aa6a5a73cd">52</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Sanofi Collaboration Revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb7e2edd7c3c4ff1a01d715afc57516e_D20210101-20210331" decimals="-3" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RhYmxlOmJhNWVhZTk2NGVkODRkNjg4MTRmOGU2NTNiZDUxNDY4L3RhYmxlcmFuZ2U6YmE1ZWFlOTY0ZWQ4NGQ2ODgxNGY4ZTY1M2JkNTE0NjhfOC0xLTEtMS0w_f3886546-f1ba-4b58-b35b-e1e915070c0f">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18c380c88187451c9ad16eccfc6df52c_D20200101-20200331" decimals="-3" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RhYmxlOmJhNWVhZTk2NGVkODRkNjg4MTRmOGU2NTNiZDUxNDY4L3RhYmxlcmFuZ2U6YmE1ZWFlOTY0ZWQ4NGQ2ODgxNGY4ZTY1M2JkNTE0NjhfOC0zLTEtMS0w_f66e1f59-9ebd-491b-ade7-d02d4cb9541a">586</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen Collaboration Agreement</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Option Research Services</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic480049fe58042bdb36bf14a067dcfc0_D20210101-20210331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RhYmxlOmJhNWVhZTk2NGVkODRkNjg4MTRmOGU2NTNiZDUxNDY4L3RhYmxlcmFuZ2U6YmE1ZWFlOTY0ZWQ4NGQ2ODgxNGY4ZTY1M2JkNTE0NjhfMTItMS0xLTEtMA_c1b90fd6-a239-4e2c-be96-94b5bdda9f19">892</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a7cd8e57f5f494c9a40a6b2b090b922_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RhYmxlOmJhNWVhZTk2NGVkODRkNjg4MTRmOGU2NTNiZDUxNDY4L3RhYmxlcmFuZ2U6YmE1ZWFlOTY0ZWQ4NGQ2ODgxNGY4ZTY1M2JkNTE0NjhfMTItMy0xLTEtMA_87fc787b-99b4-4d67-a705-92de9955ba41">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Collaboration Revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RhYmxlOmJhNWVhZTk2NGVkODRkNjg4MTRmOGU2NTNiZDUxNDY4L3RhYmxlcmFuZ2U6YmE1ZWFlOTY0ZWQ4NGQ2ODgxNGY4ZTY1M2JkNTE0NjhfMTQtMS0xLTEtMA_826e519d-3ef8-4da1-a8e7-0a100576bf9f">7,923</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia34dfea6b8734d64abf707c28256801c_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RhYmxlOmJhNWVhZTk2NGVkODRkNjg4MTRmOGU2NTNiZDUxNDY4L3RhYmxlcmFuZ2U6YmE1ZWFlOTY0ZWQ4NGQ2ODgxNGY4ZTY1M2JkNTE0NjhfMTQtMy0xLTEtMA_e7438866-4b62-4a5e-beac-befa5a06c847">3,604</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:120%">_________________________________________________</span></div><div style="margin-top:4pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10.69pt">$<ix:nonFraction unitRef="usd" contextRef="i643ec7e1d2a3451c9d8905efbcdbf48c_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMTY0OTI2NzQ5MTY4MA_1fef7022-14b7-43c5-ab13-4d5c76695935">5.7</ix:nonFraction>&#160;million of revenue for the three months ended March 31, 2021 and all of revenue for the three months ended March 31, 2020 was included in the contract liability balance at the beginning of the period. </span></div></ix:nonNumeric></ix:continuation><div style="margin-top:4pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:continuation id="i9febd1103b894143b4dbbb25eb32e355" continuedAt="i92a3c3bc1909454fb75b6ea0a12d0e42"><ix:continuation id="ifdf3f63764d14b2193f168b5332c2ef5" continuedAt="ic0c0d286157d411cbdde8e501de22b2a">(2)</ix:continuation></ix:continuation></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10.69pt"><ix:continuation id="i92a3c3bc1909454fb75b6ea0a12d0e42"><ix:continuation id="ic0c0d286157d411cbdde8e501de22b2a">Revenue for the three months ended March 31, 2021 and March 31, 2020, where applicable, represent amounts that were included in the contract liability balance at the beginning of the respective period.</ix:continuation></ix:continuation> </span></div><div id="i5ae1cfc88aa4492caf56e9d4ac91e096_52"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331" name="dnli:LicenseAgreementTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81Mi9mcmFnOjczMGQxNTRlYTk5YzRhNmRhY2I4ZGE4ZTFhMDAxMWNjL3RleHRyZWdpb246NzMwZDE1NGVhOTljNGE2ZGFjYjhkYThlMWEwMDExY2NfMTUxMw_af315cdd-4b49-45b2-8725-1f98b0c44afc" continuedAt="if1589fe5cb57490ca4ffd036bfeb6d9a" escape="true">License Agreements</ix:nonNumeric></span></div><ix:continuation id="if1589fe5cb57490ca4ffd036bfeb6d9a"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Genentech</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Company entered into an Exclusive License Agreement with Genentech, Inc. (&#8220;Genentech&#8221;). The agreement gives the Company access to Genentech&#8217;s LRRK2 inhibitor small molecule program for Parkinson&#8217;s disease. Under the agreement, Genentech granted the Company (i)&#160;an exclusive, worldwide, sublicensable license under Genentech&#8217;s rights to certain patents and patent applications directed to small molecule compounds which bind to and inhibit LRRK2 and (ii)&#160;a&#160;non-exclusive,&#160;worldwide, sublicensable license to certain related&#160;know-how,&#160;in each case, to develop and commercialize certain compounds and licensed products incorporating any such compound. </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may owe Genentech milestone payments upon the achievement of certain development, regulatory, and commercial milestones, up to a maximum of $<ix:nonFraction unitRef="usd" contextRef="ifedff44484c341d28f698f572ac47df9_D20160601-20160630" decimals="INF" format="ixt:numdotdecimal" name="dnli:LicenseAgreementMilestonePaymentUponAchievementOfClinicalAndRegulatoryMilestones" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81Mi9mcmFnOjczMGQxNTRlYTk5YzRhNmRhY2I4ZGE4ZTFhMDAxMWNjL3RleHRyZWdpb246NzMwZDE1NGVhOTljNGE2ZGFjYjhkYThlMWEwMDExY2NfODUx_0b918179-567b-458a-ae71-7e5fd070aa19">315.0</ix:nonFraction> million in the aggregate. These milestones include up to $<ix:nonFraction unitRef="usd" contextRef="i14b16f9e96df4c0a9e50dca2366b9336_D20160601-20160630" decimals="INF" format="ixt:numdotdecimal" name="dnli:LicenseAgreementMilestonePaymentUponAchievementOfClinicalAndRegulatoryMilestones" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81Mi9mcmFnOjczMGQxNTRlYTk5YzRhNmRhY2I4ZGE4ZTFhMDAxMWNjL3RleHRyZWdpb246NzMwZDE1NGVhOTljNGE2ZGFjYjhkYThlMWEwMDExY2NfOTAz_8957a5ae-9975-494f-9d08-a9d185acf16d">37.5</ix:nonFraction> million in clinical milestone payments, $<ix:nonFraction unitRef="usd" contextRef="i692ffa74a5584f1cbfe4713804c9f8bc_D20160601-20160630" decimals="INF" format="ixt:numdotdecimal" name="dnli:LicenseAgreementMilestonePaymentUponAchievementOfClinicalAndRegulatoryMilestones" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81Mi9mcmFnOjczMGQxNTRlYTk5YzRhNmRhY2I4ZGE4ZTFhMDAxMWNjL3RleHRyZWdpb246NzMwZDE1NGVhOTljNGE2ZGFjYjhkYThlMWEwMDExY2NfOTM4_6a9470b9-e516-40fe-82ca-77ea9f499400">102.5</ix:nonFraction> million in regulatory milestone payments and $<ix:nonFraction unitRef="usd" contextRef="i80495385ed674ae8925cf688501ec409_D20160601-20160630" decimals="INF" format="ixt:numdotdecimal" name="dnli:LicenseAgreementMilestonePaymentUponAchievementOfClinicalAndRegulatoryMilestones" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81Mi9mcmFnOjczMGQxNTRlYTk5YzRhNmRhY2I4ZGE4ZTFhMDAxMWNjL3RleHRyZWdpb246NzMwZDE1NGVhOTljNGE2ZGFjYjhkYThlMWEwMDExY2NfOTc4_7f748972-2685-4382-b166-57b80733fe1e">175.0</ix:nonFraction> million in commercial milestone payments. In addition, the Company may owe royalties on net sales of licensed products ranging from low to high single-digit percentages. Under the terms of our LRRK2 Agreement with Biogen, Biogen is responsible for <ix:nonFraction unitRef="number" contextRef="id8ddb142f82e43fa84f4fd4d9e8cbf3d_I20201005" decimals="INF" name="dnli:LicenseAgreementMilestonePaymentObligationResponsibilityPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81Mi9mcmFnOjczMGQxNTRlYTk5YzRhNmRhY2I4ZGE4ZTFhMDAxMWNjL3RleHRyZWdpb246NzMwZDE1NGVhOTljNGE2ZGFjYjhkYThlMWEwMDExY2NfMTE4Mw_d2ce3eb5-ea36-4512-83ab-d2831dea2833">50</ix:nonFraction>% of any payment obligation to Genentech under this agreement accruing after October&#160;4, 2020.</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, the Company has paid Genentech $<ix:nonFraction unitRef="usd" contextRef="id263c00fb24f43c9874f4e5f5bcb3bc4_D20160601-20210331" decimals="-5" format="ixt:numdotdecimal" name="dnli:UpfrontFeesPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81Mi9mcmFnOjczMGQxNTRlYTk5YzRhNmRhY2I4ZGE4ZTFhMDAxMWNjL3RleHRyZWdpb246NzMwZDE1NGVhOTljNGE2ZGFjYjhkYThlMWEwMDExY2NfMTI4Nw_aa855c32-522e-4bf0-babf-a548eb0ccc39">12.5</ix:nonFraction>&#160;million in the aggregate, including an upfront fee, a technology transfer fee and a clinical milestone payment, all of which was recorded as research and development expense as incurred. <ix:nonFraction unitRef="usd" contextRef="iab3d75662fac47f5a5b91e0c391e1ad9_D20200101-20200331" decimals="INF" format="ixt-sec:numwordsen" name="dnli:UpfrontFeesPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81Mi9mcmFnOjczMGQxNTRlYTk5YzRhNmRhY2I4ZGE4ZTFhMDAxMWNjL3RleHRyZWdpb246NzMwZDE1NGVhOTljNGE2ZGFjYjhkYThlMWEwMDExY2NfMTQ2OQ_a75cadbe-1ac1-42af-b09d-00e4c8c53b4d"><ix:nonFraction unitRef="usd" contextRef="i90ec159768884d8a91ddd3533160d98c_D20210101-20210331" decimals="INF" format="ixt-sec:numwordsen" name="dnli:UpfrontFeesPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81Mi9mcmFnOjczMGQxNTRlYTk5YzRhNmRhY2I4ZGE4ZTFhMDAxMWNjL3RleHRyZWdpb246NzMwZDE1NGVhOTljNGE2ZGFjYjhkYThlMWEwMDExY2NfMTQ2OQ_df627736-1d66-4ee6-b41c-d0c4eee90faa">No</ix:nonFraction></ix:nonFraction> expenses were recorded in the three months ended March 31, 2021 or 2020.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><div id="i5ae1cfc88aa4492caf56e9d4ac91e096_55"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5ae1cfc88aa4492caf56e9d4ac91e096_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81NS9mcmFnOjFlY2VlN2YxM2M0ZTQ0NWQ4ZjMwODVkYjQ4NzdkZmUxL3RleHRyZWdpb246MWVjZWU3ZjEzYzRlNDQ1ZDhmMzA4NWRiNDg3N2RmZTFfNzk1Nw_864bcc9a-7453-44c4-b02b-dfd3c62b9c52" continuedAt="i4b24acffd19b4c368f5c17cc7f5c128b" escape="true">Commitments and Contingencies </ix:nonNumeric></span></div><ix:continuation id="i4b24acffd19b4c368f5c17cc7f5c128b" continuedAt="i5c0bb5aeeecf4f0dba56cb6dd713f60b"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lease Obligations</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2018, the Company entered into an amendment to its operating lease for its former corporate headquarters in South San Francisco (the "Headquarters Lease Amendment") to relocate and expand its headquarters to <ix:nonFraction unitRef="sqft" contextRef="i7fec5584f40f4e2589bf51cfb5be2fa0_D20180502-20180502" decimals="-1" format="ixt:numdotdecimal" name="dnli:OperatingLeasesAreaUnderLease" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81NS9mcmFnOjFlY2VlN2YxM2M0ZTQ0NWQ4ZjMwODVkYjQ4NzdkZmUxL3RleHRyZWdpb246MWVjZWU3ZjEzYzRlNDQ1ZDhmMzA4NWRiNDg3N2RmZTFfMjY2_ba4b0b7b-eb05-49d4-9873-3df792de18ee">148,020</ix:nonFraction> rentable square feet in a building in South San Francisco, California (the "New Premises"). The Headquarters Lease Amendment has a contractual term of <ix:nonNumeric contextRef="ie37401f4fa5441f69f346d3a02b8b078_I20180502" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81NS9mcmFnOjFlY2VlN2YxM2M0ZTQ0NWQ4ZjMwODVkYjQ4NzdkZmUxL3RleHRyZWdpb246MWVjZWU3ZjEzYzRlNDQ1ZDhmMzA4NWRiNDg3N2RmZTFfNDIw_c767fa9c-e45f-46a8-8267-f87f76cafd0f">ten years</ix:nonNumeric> from the legal commencement date, which was April&#160;1, 2019, when the building was ready for occupancy. For accounting purposes, the lease commencement date was determined to be August&#160;1, 2018, which was the date at which the Company was deemed to have obtained control over the property. The Company has an option to extend the lease term for a period of <ix:nonNumeric contextRef="ie37401f4fa5441f69f346d3a02b8b078_I20180502" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81NS9mcmFnOjFlY2VlN2YxM2M0ZTQ0NWQ4ZjMwODVkYjQ4NzdkZmUxL3RleHRyZWdpb246MWVjZWU3ZjEzYzRlNDQ1ZDhmMzA4NWRiNDg3N2RmZTFfNzU0_75c7dee2-5fc0-4a1c-bddb-0c4177a2ee32">ten years</ix:nonNumeric> by giving the landlord written notice of the election to exercise the option at least <ix:nonNumeric contextRef="i99207688a3a04bb6b263d1f44c4431cb_D20180502-20180502" format="ixt-sec:durwordsen" name="dnli:LesseeOperatingLeaseRenewalNoticePeriod" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81NS9mcmFnOjFlY2VlN2YxM2M0ZTQ0NWQ4ZjMwODVkYjQ4NzdkZmUxL3RleHRyZWdpb246MWVjZWU3ZjEzYzRlNDQ1ZDhmMzA4NWRiNDg3N2RmZTFfODQz_cc7ea482-f59f-4145-8275-06645a30f285">nine months</ix:nonNumeric>, but not more than <ix:nonNumeric contextRef="ic993dcf5385f4b81b82f62d1d7c425ad_D20180502-20180502" format="ixt-sec:durwordsen" name="dnli:LesseeOperatingLeaseRenewalNoticePeriod" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81NS9mcmFnOjFlY2VlN2YxM2M0ZTQ0NWQ4ZjMwODVkYjQ4NzdkZmUxL3RleHRyZWdpb246MWVjZWU3ZjEzYzRlNDQ1ZDhmMzA4NWRiNDg3N2RmZTFfNzk1OQ_b38427ce-3704-41b8-b101-898e0ecf2e97">twelve months</ix:nonNumeric>, prior to the expiration of the Headquarters Lease Amendment lease term. The Company determined that this renewal was not reasonably certain at lease inception. The remaining lease term was <ix:nonNumeric contextRef="i9953f50a7fd74f7d8438f304f136a07b_I20210331" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81NS9mcmFnOjFlY2VlN2YxM2M0ZTQ0NWQ4ZjMwODVkYjQ4NzdkZmUxL3RleHRyZWdpb246MWVjZWU3ZjEzYzRlNDQ1ZDhmMzA4NWRiNDg3N2RmZTFfMjc0ODc3OTA4MTU3OQ_619833fc-898b-4fdb-824e-77ee86ec2274">8.1</ix:nonNumeric> years at March 31, 2021.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Headquarters Lease Amendment provides for monthly base rent amounts escalating over the term of the lease. In addition, the Headquarters Lease Amendment provided a tenant improvement allowance ("TIA") of up to $<ix:nonFraction unitRef="usd" contextRef="i8bf8a6f92025417783902a1461338b26_I20180502" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LeaseholdImprovementsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81NS9mcmFnOjFlY2VlN2YxM2M0ZTQ0NWQ4ZjMwODVkYjQ4NzdkZmUxL3RleHRyZWdpb246MWVjZWU3ZjEzYzRlNDQ1ZDhmMzA4NWRiNDg3N2RmZTFfMTI0Mw_a38b80f0-d5a0-4558-8afd-485f4f15e12b">25.9</ix:nonFraction> million, which was fully utilized, of which $<ix:nonFraction unitRef="usd" contextRef="i6456f8216b9a4588b93f1a1da733ca1d_D20180502-20180502" decimals="-5" format="ixt:numdotdecimal" name="dnli:TenantImprovementAllowanceRepayableAsRent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81NS9mcmFnOjFlY2VlN2YxM2M0ZTQ0NWQ4ZjMwODVkYjQ4NzdkZmUxL3RleHRyZWdpb246MWVjZWU3ZjEzYzRlNDQ1ZDhmMzA4NWRiNDg3N2RmZTFfMTI4Mg_6098e8c2-f6a0-4195-9fc9-a532a68dc79a">4.4</ix:nonFraction> million will be repaid to the landlord in the form of additional monthly rent. This is recorded as leasehold improvement assets and an offset to the lease ROU asset on the Condensed Consolidated Balance Sheets as of March 31, 2021 and December 31, 2020. The Company is also required to pay the operating expenses for the New Premises, such as taxes and insurance, which are treated as variable lease payments.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management exercised judgment in applying the requirements of ASC 842, including the determination as to whether certain contracts contain a lease and for the Headquarters Lease Amendment, the discount rate used to determine the measurement of the lease liability. As the implicit rate of the Headquarters Lease Amendment was not known, the Company estimated a <ix:nonFraction unitRef="number" contextRef="i9953f50a7fd74f7d8438f304f136a07b_I20210331" decimals="2" name="us-gaap:LesseeOperatingLeaseDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81NS9mcmFnOjFlY2VlN2YxM2M0ZTQ0NWQ4ZjMwODVkYjQ4NzdkZmUxL3RleHRyZWdpb246MWVjZWU3ZjEzYzRlNDQ1ZDhmMzA4NWRiNDg3N2RmZTFfMjAyMQ_5281cd4e-7da6-4cc1-96ac-4302794b1cbd">9.0</ix:nonFraction>% discount rate, which was management&#8217;s estimate of the Company&#8217;s incremental borrowing rate. To estimate the incremental borrowing rate, management considered observable debt yields of comparable market instruments, as well as benchmarks within the Headquarters Lease Amendment that may be indicative of the rate implicit in the lease. </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total operating lease costs, including variable and short-term lease costs, were $<ix:nonFraction unitRef="usd" contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81NS9mcmFnOjFlY2VlN2YxM2M0ZTQ0NWQ4ZjMwODVkYjQ4NzdkZmUxL3RleHRyZWdpb246MWVjZWU3ZjEzYzRlNDQ1ZDhmMzA4NWRiNDg3N2RmZTFfMjQ0MQ_11749fea-2646-44fc-944a-45a540f0e27b">2.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ia34dfea6b8734d64abf707c28256801c_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81NS9mcmFnOjFlY2VlN2YxM2M0ZTQ0NWQ4ZjMwODVkYjQ4NzdkZmUxL3RleHRyZWdpb246MWVjZWU3ZjEzYzRlNDQ1ZDhmMzA4NWRiNDg3N2RmZTFfMjQ4NA_b065956b-05b3-4a9e-86e6-719ac041acae">2.6</ix:nonFraction> million for the three months ended March 31, 2021 and 2020, respectively. Cash paid for amounts included in the measurement of lease liabilities for the three months ended</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> March 31, 2021 and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 31, 2020</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of $<ix:nonFraction unitRef="usd" contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81NS9mcmFnOjFlY2VlN2YxM2M0ZTQ0NWQ4ZjMwODVkYjQ4NzdkZmUxL3RleHRyZWdpb246MWVjZWU3ZjEzYzRlNDQ1ZDhmMzA4NWRiNDg3N2RmZTFfMzA3MQ_57758fdf-c18d-4a98-be4f-457edad93ff8">2.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ia34dfea6b8734d64abf707c28256801c_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81NS9mcmFnOjFlY2VlN2YxM2M0ZTQ0NWQ4ZjMwODVkYjQ4NzdkZmUxL3RleHRyZWdpb246MWVjZWU3ZjEzYzRlNDQ1ZDhmMzA4NWRiNDg3N2RmZTFfMzA3OA_d4f19a75-db32-462f-8c79-8e769ed35246">2.2</ix:nonFraction> million, respectively, was included in net cash used in operating activities in the Company's Condensed Consolidated Statements of Cash Flows.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5ae1cfc88aa4492caf56e9d4ac91e096_7">Table of Contents</a></span></div></div><ix:continuation id="i5c0bb5aeeecf4f0dba56cb6dd713f60b" continuedAt="i8b9e66d94ef34317929d2e9a87c091a5"><ix:nonNumeric contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81NS9mcmFnOjFlY2VlN2YxM2M0ZTQ0NWQ4ZjMwODVkYjQ4NzdkZmUxL3RleHRyZWdpb246MWVjZWU3ZjEzYzRlNDQ1ZDhmMzA4NWRiNDg3N2RmZTFfNzk2MQ_7c382dea-6e7d-40c0-ad3f-da1c474c2243" escape="true"><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles the undiscounted cash flows for the next five years and total of the remaining years to the operating lease liabilities recorded in the Condensed Consolidated Balance Sheet as of March 31, 2021 (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.867%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.162%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.671%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021 (nine months)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9953f50a7fd74f7d8438f304f136a07b_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81NS9mcmFnOjFlY2VlN2YxM2M0ZTQ0NWQ4ZjMwODVkYjQ4NzdkZmUxL3RhYmxlOjVkYTNlZTI3NTBjYzRjNWE4NzQ4Mjc3OTE2MGFlNTlmL3RhYmxlcmFuZ2U6NWRhM2VlMjc1MGNjNGM1YTg3NDgyNzc5MTYwYWU1OWZfMS0yLTEtMS0w_b123fa54-549c-47c8-a0a8-d6c6d87b0425">7,855</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9953f50a7fd74f7d8438f304f136a07b_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81NS9mcmFnOjFlY2VlN2YxM2M0ZTQ0NWQ4ZjMwODVkYjQ4NzdkZmUxL3RhYmxlOjVkYTNlZTI3NTBjYzRjNWE4NzQ4Mjc3OTE2MGFlNTlmL3RhYmxlcmFuZ2U6NWRhM2VlMjc1MGNjNGM1YTg3NDgyNzc5MTYwYWU1OWZfMi0yLTEtMS0w_6f172162-ef83-4974-93bd-d1af6efc240d">10,731</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9953f50a7fd74f7d8438f304f136a07b_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81NS9mcmFnOjFlY2VlN2YxM2M0ZTQ0NWQ4ZjMwODVkYjQ4NzdkZmUxL3RhYmxlOjVkYTNlZTI3NTBjYzRjNWE4NzQ4Mjc3OTE2MGFlNTlmL3RhYmxlcmFuZ2U6NWRhM2VlMjc1MGNjNGM1YTg3NDgyNzc5MTYwYWU1OWZfMy0yLTEtMS0w_e393d73b-439a-4060-b33b-696c3070839c">11,083</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9953f50a7fd74f7d8438f304f136a07b_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81NS9mcmFnOjFlY2VlN2YxM2M0ZTQ0NWQ4ZjMwODVkYjQ4NzdkZmUxL3RhYmxlOjVkYTNlZTI3NTBjYzRjNWE4NzQ4Mjc3OTE2MGFlNTlmL3RhYmxlcmFuZ2U6NWRhM2VlMjc1MGNjNGM1YTg3NDgyNzc5MTYwYWU1OWZfNC0yLTEtMS0w_ff7d8556-defd-4c61-a3a1-56f6ad7d1025">11,447</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9953f50a7fd74f7d8438f304f136a07b_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81NS9mcmFnOjFlY2VlN2YxM2M0ZTQ0NWQ4ZjMwODVkYjQ4NzdkZmUxL3RhYmxlOjVkYTNlZTI3NTBjYzRjNWE4NzQ4Mjc3OTE2MGFlNTlmL3RhYmxlcmFuZ2U6NWRhM2VlMjc1MGNjNGM1YTg3NDgyNzc5MTYwYWU1OWZfNS0yLTEtMS0w_5da1812f-f103-4df2-af14-7250282d4730">11,824</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9953f50a7fd74f7d8438f304f136a07b_I20210331" decimals="-3" format="ixt:numdotdecimal" name="dnli:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81NS9mcmFnOjFlY2VlN2YxM2M0ZTQ0NWQ4ZjMwODVkYjQ4NzdkZmUxL3RhYmxlOjVkYTNlZTI3NTBjYzRjNWE4NzQ4Mjc3OTE2MGFlNTlmL3RhYmxlcmFuZ2U6NWRhM2VlMjc1MGNjNGM1YTg3NDgyNzc5MTYwYWU1OWZfNi0yLTEtMS0w_8e3928eb-87c2-47b7-ab40-487bfa6ad412">42,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total undiscounted lease payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9953f50a7fd74f7d8438f304f136a07b_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81NS9mcmFnOjFlY2VlN2YxM2M0ZTQ0NWQ4ZjMwODVkYjQ4NzdkZmUxL3RhYmxlOjVkYTNlZTI3NTBjYzRjNWE4NzQ4Mjc3OTE2MGFlNTlmL3RhYmxlcmFuZ2U6NWRhM2VlMjc1MGNjNGM1YTg3NDgyNzc5MTYwYWU1OWZfNy0yLTEtMS0w_f4db27ee-31fa-479f-9fab-40d92fbfe810">95,190</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Present value adjustment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9953f50a7fd74f7d8438f304f136a07b_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81NS9mcmFnOjFlY2VlN2YxM2M0ZTQ0NWQ4ZjMwODVkYjQ4NzdkZmUxL3RhYmxlOjVkYTNlZTI3NTBjYzRjNWE4NzQ4Mjc3OTE2MGFlNTlmL3RhYmxlcmFuZ2U6NWRhM2VlMjc1MGNjNGM1YTg3NDgyNzc5MTYwYWU1OWZfOC0yLTEtMS0w_14072796-c03e-49ff-b15c-541435938e90">27,398</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9953f50a7fd74f7d8438f304f136a07b_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81NS9mcmFnOjFlY2VlN2YxM2M0ZTQ0NWQ4ZjMwODVkYjQ4NzdkZmUxL3RhYmxlOjVkYTNlZTI3NTBjYzRjNWE4NzQ4Mjc3OTE2MGFlNTlmL3RhYmxlcmFuZ2U6NWRhM2VlMjc1MGNjNGM1YTg3NDgyNzc5MTYwYWU1OWZfOS0yLTEtMS0w_01882ac7-385d-4b65-826b-6ba410c6161b">67,792</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, the Company entered into a sublease agreement ("Sublease Agreement") to sublease approximately <ix:nonFraction unitRef="sqft" contextRef="ib5b9d59cd718474d84fa120208dacc38_I20181031" decimals="0" format="ixt:numdotdecimal" name="dnli:OperatingLeasesSubleaseNetRentableArea" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81NS9mcmFnOjFlY2VlN2YxM2M0ZTQ0NWQ4ZjMwODVkYjQ4NzdkZmUxL3RleHRyZWdpb246MWVjZWU3ZjEzYzRlNDQ1ZDhmMzA4NWRiNDg3N2RmZTFfMzU1MA_723c5f46-a9d7-471d-945d-0ad137829c4d">36,835</ix:nonFraction> rentable square feet of space in its New Premises. The Sublease Agreement has a term of <ix:nonNumeric contextRef="ib5b9d59cd718474d84fa120208dacc38_I20181031" format="ixt-sec:durwordsen" name="us-gaap:LessorOperatingLeaseTermOfContract" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81NS9mcmFnOjFlY2VlN2YxM2M0ZTQ0NWQ4ZjMwODVkYjQ4NzdkZmUxL3RleHRyZWdpb246MWVjZWU3ZjEzYzRlNDQ1ZDhmMzA4NWRiNDg3N2RmZTFfMzY0MQ_eb03f648-89dc-429a-8115-359988796ba6">five years</ix:nonNumeric> from the commencement date of April&#160;12, 2019 and provides for the Company to receive monthly base rent amounts escalating over the term of the lease. The Company also passes through a portion of the operating expenses, such as taxes and insurance for the New Premises to the sublessee, which are treated as variable sublease income. Total sublease income, including rent and variable sublease cost reimbursements, was $<ix:nonFraction unitRef="usd" contextRef="ia34dfea6b8734d64abf707c28256801c_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SubleaseIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81NS9mcmFnOjFlY2VlN2YxM2M0ZTQ0NWQ4ZjMwODVkYjQ4NzdkZmUxL3RleHRyZWdpb246MWVjZWU3ZjEzYzRlNDQ1ZDhmMzA4NWRiNDg3N2RmZTFfNDA5NA_0349fec2-786a-43c6-a03d-b914d40718d4"><ix:nonFraction unitRef="usd" contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SubleaseIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81NS9mcmFnOjFlY2VlN2YxM2M0ZTQ0NWQ4ZjMwODVkYjQ4NzdkZmUxL3RleHRyZWdpb246MWVjZWU3ZjEzYzRlNDQ1ZDhmMzA4NWRiNDg3N2RmZTFfNDA5NA_cebf51e7-7a42-4846-b0aa-0249eed3a07c">0.9</ix:nonFraction></ix:nonFraction> million for both the three months ended March 31, 2021 and 2020.</span></div><ix:nonNumeric contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331" name="us-gaap:LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81NS9mcmFnOjFlY2VlN2YxM2M0ZTQ0NWQ4ZjMwODVkYjQ4NzdkZmUxL3RleHRyZWdpb246MWVjZWU3ZjEzYzRlNDQ1ZDhmMzA4NWRiNDg3N2RmZTFfNzk1Ng_0554304d-1caa-4fc6-807a-7672ee2eea76" escape="true"><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table details the future undiscounted cash inflows relating to the Sublease Agreement as of March 31, 2021 (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.867%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.162%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.671%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021 (nine months)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9953f50a7fd74f7d8438f304f136a07b_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81NS9mcmFnOjFlY2VlN2YxM2M0ZTQ0NWQ4ZjMwODVkYjQ4NzdkZmUxL3RhYmxlOjg3MzhjNWJkNzlmZDQ0ZDE5ZGE4MjYyOGEwNTgyZmZiL3RhYmxlcmFuZ2U6ODczOGM1YmQ3OWZkNDRkMTlkYTgyNjI4YTA1ODJmZmJfMS0yLTEtMS0w_33e8b20a-fac0-4dfc-aac8-4d7a82b6f774">2,209</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9953f50a7fd74f7d8438f304f136a07b_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81NS9mcmFnOjFlY2VlN2YxM2M0ZTQ0NWQ4ZjMwODVkYjQ4NzdkZmUxL3RhYmxlOjg3MzhjNWJkNzlmZDQ0ZDE5ZGE4MjYyOGEwNTgyZmZiL3RhYmxlcmFuZ2U6ODczOGM1YmQ3OWZkNDRkMTlkYTgyNjI4YTA1ODJmZmJfMi0yLTEtMS0w_c1fbf029-1188-44f7-8e21-41cc4f4b8a70">3,009</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9953f50a7fd74f7d8438f304f136a07b_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LessorOperatingLeasePaymentsToBeReceivedTwoYears" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81NS9mcmFnOjFlY2VlN2YxM2M0ZTQ0NWQ4ZjMwODVkYjQ4NzdkZmUxL3RhYmxlOjg3MzhjNWJkNzlmZDQ0ZDE5ZGE4MjYyOGEwNTgyZmZiL3RhYmxlcmFuZ2U6ODczOGM1YmQ3OWZkNDRkMTlkYTgyNjI4YTA1ODJmZmJfMy0yLTEtMS0w_3276d202-4177-43a7-b2a8-213b9cab5b7f">3,096</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9953f50a7fd74f7d8438f304f136a07b_I20210331" decimals="-3" name="us-gaap:LessorOperatingLeasePaymentsToBeReceivedThreeYears" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81NS9mcmFnOjFlY2VlN2YxM2M0ZTQ0NWQ4ZjMwODVkYjQ4NzdkZmUxL3RhYmxlOjg3MzhjNWJkNzlmZDQ0ZDE5ZGE4MjYyOGEwNTgyZmZiL3RhYmxlcmFuZ2U6ODczOGM1YmQ3OWZkNDRkMTlkYTgyNjI4YTA1ODJmZmJfNC0yLTEtMS0w_917e5b0e-e809-4b20-be17-211d1a8dcaa1">876</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total undiscounted sublease receipts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9953f50a7fd74f7d8438f304f136a07b_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LessorOperatingLeasePaymentsToBeReceived" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81NS9mcmFnOjFlY2VlN2YxM2M0ZTQ0NWQ4ZjMwODVkYjQ4NzdkZmUxL3RhYmxlOjg3MzhjNWJkNzlmZDQ0ZDE5ZGE4MjYyOGEwNTgyZmZiL3RhYmxlcmFuZ2U6ODczOGM1YmQ3OWZkNDRkMTlkYTgyNjI4YTA1ODJmZmJfNy0yLTEtMS0w_39f8adc9-e85e-43d4-97f9-a5e05be06a66">9,190</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Indemnification</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, the Company may provide indemnifications of varying scope and terms to vendors, lessors, business partners, board members, officers, and other parties with respect to certain matters, including, but not limited to, losses arising out of breach of such agreements, services to be provided by the Company, negligence or willful misconduct of the Company, violations of law by the Company, or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with directors and certain officers and employees that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors, officers or employees. No demands have been made upon the Company to provide indemnification under such agreements, and thus, there are no claims that the Company is aware of that could have a material effect on the Company&#8217;s Condensed Consolidated Balance Sheets, Condensed Consolidated Statements of Operations and Comprehensive Loss, or Condensed Consolidated Statements of Cash Flows.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5ae1cfc88aa4492caf56e9d4ac91e096_7">Table of Contents</a></span></div></div><ix:continuation id="i8b9e66d94ef34317929d2e9a87c091a5" continuedAt="i754c7fe862c946df9a2a925936d36e81"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Commitments</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective September 2017, the Company entered into a Development and Manufacturing Services Agreement as amended (&#8220;DMSA&#8221;) with Lonza Sales AG (&#8220;Lonza&#8221;) for the development and manufacture of biologic products. Under the DMSA, the Company will execute purchase orders based on project plans authorizing Lonza to provide development and manufacturing services with respect to certain of the Company's antibody and enzyme products, and will pay for the services provided and batches delivered in accordance with the DMSA and project plan. </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier terminated, the DMSA will expire on September&#160;6, 2022.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2021 and December 31, 2020, the Company had open purchase orders for biological product development and manufacturing costs totaling $<ix:nonFraction unitRef="usd" contextRef="i5883d19040b14361a685e33448d24167_I20210331" decimals="-5" format="ixt:numdotdecimal" name="dnli:PurchaseOrderExecuted" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81NS9mcmFnOjFlY2VlN2YxM2M0ZTQ0NWQ4ZjMwODVkYjQ4NzdkZmUxL3RleHRyZWdpb246MWVjZWU3ZjEzYzRlNDQ1ZDhmMzA4NWRiNDg3N2RmZTFfNjE3Mg_85c2640c-9164-4563-9f98-23e1db68deb8">33.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i71996497ebce4b2c8c7d7e4cd228fb94_I20201231" decimals="-5" format="ixt:numdotdecimal" name="dnli:PurchaseOrderExecuted" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81NS9mcmFnOjFlY2VlN2YxM2M0ZTQ0NWQ4ZjMwODVkYjQ4NzdkZmUxL3RleHRyZWdpb246MWVjZWU3ZjEzYzRlNDQ1ZDhmMzA4NWRiNDg3N2RmZTFfNjE3OQ_3e09d178-3892-4e10-816c-51bd3a0f8f87">33.0</ix:nonFraction> million, respectively. The activities under these purchase orders are expected to be completed by February 2028. As of March 31, 2021 and December 31, 2020, the Company had total non-cancellable purchase commitments under the DMSA of $<ix:nonFraction unitRef="usd" contextRef="i5883d19040b14361a685e33448d24167_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PurchaseObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81NS9mcmFnOjFlY2VlN2YxM2M0ZTQ0NWQ4ZjMwODVkYjQ4NzdkZmUxL3RleHRyZWdpb246MWVjZWU3ZjEzYzRlNDQ1ZDhmMzA4NWRiNDg3N2RmZTFfNjM3MA_75de225a-685d-4efb-b3fe-7386107ec861">28.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i71996497ebce4b2c8c7d7e4cd228fb94_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PurchaseObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81NS9mcmFnOjFlY2VlN2YxM2M0ZTQ0NWQ4ZjMwODVkYjQ4NzdkZmUxL3RleHRyZWdpb246MWVjZWU3ZjEzYzRlNDQ1ZDhmMzA4NWRiNDg3N2RmZTFfNjM3Nw_9d1a90c5-751d-46c8-9022-8394b6ca8009">27.1</ix:nonFraction> million, respectively, under the DMSA.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2021 and 2020, the Company incurred costs of $<ix:nonFraction unitRef="usd" contextRef="i450a57d93cb84950a947b2c09bd3ca2d_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CostsIncurredDevelopmentCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81NS9mcmFnOjFlY2VlN2YxM2M0ZTQ0NWQ4ZjMwODVkYjQ4NzdkZmUxL3RleHRyZWdpb246MWVjZWU3ZjEzYzRlNDQ1ZDhmMzA4NWRiNDg3N2RmZTFfNjQ1MA_5874e967-f59a-4995-b434-cddfaba5add3">5.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i8e1a3ef913c04a4dbb9618e565378ec6_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CostsIncurredDevelopmentCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81NS9mcmFnOjFlY2VlN2YxM2M0ZTQ0NWQ4ZjMwODVkYjQ4NzdkZmUxL3RleHRyZWdpb246MWVjZWU3ZjEzYzRlNDQ1ZDhmMzA4NWRiNDg3N2RmZTFfNjQ1Nw_a4607852-35ca-4048-84ed-59f99398a237">1.0</ix:nonFraction>&#160;million, respectively, and made payments of $<ix:nonFraction unitRef="usd" contextRef="i450a57d93cb84950a947b2c09bd3ca2d_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="dnli:PaymentsForManufacturingCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81NS9mcmFnOjFlY2VlN2YxM2M0ZTQ0NWQ4ZjMwODVkYjQ4NzdkZmUxL3RleHRyZWdpb246MWVjZWU3ZjEzYzRlNDQ1ZDhmMzA4NWRiNDg3N2RmZTFfNjQ5Ng_ee1e2a72-0fd6-4fab-9dba-6fbded72cf3e">0.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i8e1a3ef913c04a4dbb9618e565378ec6_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="dnli:PaymentsForManufacturingCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81NS9mcmFnOjFlY2VlN2YxM2M0ZTQ0NWQ4ZjMwODVkYjQ4NzdkZmUxL3RleHRyZWdpb246MWVjZWU3ZjEzYzRlNDQ1ZDhmMzA4NWRiNDg3N2RmZTFfNjUwMw_f91b47b2-ab0d-42f7-adff-3782d5d742bf">3.2</ix:nonFraction> million, respectively, for the development and manufacturing services rendered under the DMSA. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingencies</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company may be involved in lawsuits, arbitration, claims, investigations and proceedings consisting of intellectual property, employment and other matters which arise in the ordinary course of business. The Company records accruals for loss contingencies to the extent that the Company concludes that it is probable that a liability has been incurred and the amount of the related loss can be reasonably estimated. </span></div></ix:continuation><div style="margin-top:10pt;text-indent:27pt"><ix:continuation id="i754c7fe862c946df9a2a925936d36e81" continuedAt="i0095b5bc54274a6da762e4e28b650744"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 10, 2020, the Company and all Directors were named in a shareholder derivative action filed in the Delaware Court of Chancery challenging the compensation paid to the Company's Directors since the </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">initial public offering ("IPO")</span></ix:continuation><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i0095b5bc54274a6da762e4e28b650744"> in December 2017. On January&#160;13, 2021, the parties to the derivative action entered into a settlement agreement, the terms of which were disclosed in a Form 8-K filed on February&#160;5, 2021. The settlement agreement was approved by the Court on April 16, 2021. Amounts owed by the Company pursuant to the settlement agreement are not material to the Company.</ix:continuation> </span></div><div id="i5ae1cfc88aa4492caf56e9d4ac91e096_58"></div><div style="margin-top:18pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81OC9mcmFnOjdiZjczNTljOWJmNTQ1Yjg4ODEzMGFlMmU4YzMwMjA2L3RleHRyZWdpb246N2JmNzM1OWM5YmY1NDViODg4MTMwYWUyZThjMzAyMDZfODY1_1ab153d3-d32a-4984-9221-bb5fde041dbc" continuedAt="i5f5088f86f5d4ecdb67cc116b0995b6c" escape="true">Stock-Based Awards</ix:nonNumeric></span></div><ix:continuation id="i5f5088f86f5d4ecdb67cc116b0995b6c" continuedAt="i29450f84fde04f7ba7416390bf2301af"><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has issued stock-based awards from various equity incentive and stock purchase plans, as more fully described in Note 10, "Stock-Based Awards" to the consolidated financial statements in the Company's 2020 Annual Report on Form 10-K.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Option Activity</span></div><ix:nonNumeric contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81OC9mcmFnOjdiZjczNTljOWJmNTQ1Yjg4ODEzMGFlMmU4YzMwMjA2L3RleHRyZWdpb246N2JmNzM1OWM5YmY1NDViODg4MTMwYWUyZThjMzAyMDZfODYw_fc346972-ad63-46bb-8297-14f5f37b94e1" escape="true"><div style="margin-bottom:10pt;margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity for the three months ended March 31, 2021:</span></div><div style="margin-bottom:10pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.226%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.335%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.338%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Options</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercise&#160;Price</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idb7ca9f362da46eab3a29bbbecbda977_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81OC9mcmFnOjdiZjczNTljOWJmNTQ1Yjg4ODEzMGFlMmU4YzMwMjA2L3RhYmxlOjE3ZTA3ZTI3OTg3NDQwZjc4OTBhMjgyOWFjNGUwYmI1L3RhYmxlcmFuZ2U6MTdlMDdlMjc5ODc0NDBmNzg5MGEyODI5YWM0ZTBiYjVfMS0xLTEtMS0w_c974e1d6-f2bd-491d-a369-dd4ce5f25121">12,959,926</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="idb7ca9f362da46eab3a29bbbecbda977_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81OC9mcmFnOjdiZjczNTljOWJmNTQ1Yjg4ODEzMGFlMmU4YzMwMjA2L3RhYmxlOjE3ZTA3ZTI3OTg3NDQwZjc4OTBhMjgyOWFjNGUwYmI1L3RhYmxlcmFuZ2U6MTdlMDdlMjc5ODc0NDBmNzg5MGEyODI5YWM0ZTBiYjVfMS0zLTEtMS0w_6b5c5f16-0c4d-4f52-a416-ffb13aafce55">16.31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81OC9mcmFnOjdiZjczNTljOWJmNTQ1Yjg4ODEzMGFlMmU4YzMwMjA2L3RhYmxlOjE3ZTA3ZTI3OTg3NDQwZjc4OTBhMjgyOWFjNGUwYmI1L3RhYmxlcmFuZ2U6MTdlMDdlMjc5ODc0NDBmNzg5MGEyODI5YWM0ZTBiYjVfMi0xLTEtMS0w_a06cf805-6f08-4b2b-84a9-3369d36f8e03">1,639,041</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81OC9mcmFnOjdiZjczNTljOWJmNTQ1Yjg4ODEzMGFlMmU4YzMwMjA2L3RhYmxlOjE3ZTA3ZTI3OTg3NDQwZjc4OTBhMjgyOWFjNGUwYmI1L3RhYmxlcmFuZ2U6MTdlMDdlMjc5ODc0NDBmNzg5MGEyODI5YWM0ZTBiYjVfMi0zLTEtMS0w_ce922683-eb0f-474a-a7c0-17c282ba4106">75.52</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercised</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81OC9mcmFnOjdiZjczNTljOWJmNTQ1Yjg4ODEzMGFlMmU4YzMwMjA2L3RhYmxlOjE3ZTA3ZTI3OTg3NDQwZjc4OTBhMjgyOWFjNGUwYmI1L3RhYmxlcmFuZ2U6MTdlMDdlMjc5ODc0NDBmNzg5MGEyODI5YWM0ZTBiYjVfMy0xLTEtMS0w_81712c26-dc9d-4bf6-8d25-284f9d7c3871">334,634</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81OC9mcmFnOjdiZjczNTljOWJmNTQ1Yjg4ODEzMGFlMmU4YzMwMjA2L3RhYmxlOjE3ZTA3ZTI3OTg3NDQwZjc4OTBhMjgyOWFjNGUwYmI1L3RhYmxlcmFuZ2U6MTdlMDdlMjc5ODc0NDBmNzg5MGEyODI5YWM0ZTBiYjVfMy0zLTEtMS0w_f3ce35c0-f5f2-45e1-af8c-2ec1e7423061">11.42</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81OC9mcmFnOjdiZjczNTljOWJmNTQ1Yjg4ODEzMGFlMmU4YzMwMjA2L3RhYmxlOjE3ZTA3ZTI3OTg3NDQwZjc4OTBhMjgyOWFjNGUwYmI1L3RhYmxlcmFuZ2U6MTdlMDdlMjc5ODc0NDBmNzg5MGEyODI5YWM0ZTBiYjVfNC0xLTEtMS0w_5436917f-b152-4d03-a3f6-04d35beb39fc">34,056</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81OC9mcmFnOjdiZjczNTljOWJmNTQ1Yjg4ODEzMGFlMmU4YzMwMjA2L3RhYmxlOjE3ZTA3ZTI3OTg3NDQwZjc4OTBhMjgyOWFjNGUwYmI1L3RhYmxlcmFuZ2U6MTdlMDdlMjc5ODc0NDBmNzg5MGEyODI5YWM0ZTBiYjVfNC0zLTEtMS0w_dbee7aad-c490-4eef-a39c-66a2b871a896">26.77</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at March 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9953f50a7fd74f7d8438f304f136a07b_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81OC9mcmFnOjdiZjczNTljOWJmNTQ1Yjg4ODEzMGFlMmU4YzMwMjA2L3RhYmxlOjE3ZTA3ZTI3OTg3NDQwZjc4OTBhMjgyOWFjNGUwYmI1L3RhYmxlcmFuZ2U6MTdlMDdlMjc5ODc0NDBmNzg5MGEyODI5YWM0ZTBiYjVfNS0xLTEtMS0w_fe706335-b987-4dea-800a-b4d8f6e6dab1">14,230,277</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9953f50a7fd74f7d8438f304f136a07b_I20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81OC9mcmFnOjdiZjczNTljOWJmNTQ1Yjg4ODEzMGFlMmU4YzMwMjA2L3RhYmxlOjE3ZTA3ZTI3OTg3NDQwZjc4OTBhMjgyOWFjNGUwYmI1L3RhYmxlcmFuZ2U6MTdlMDdlMjc5ODc0NDBmNzg5MGEyODI5YWM0ZTBiYjVfNS0zLTEtMS0w_fa0ad58b-4946-4d28-b546-33e8d8b20bbc">23.22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;text-indent:-12pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested and expected to vest at March 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9953f50a7fd74f7d8438f304f136a07b_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81OC9mcmFnOjdiZjczNTljOWJmNTQ1Yjg4ODEzMGFlMmU4YzMwMjA2L3RhYmxlOjE3ZTA3ZTI3OTg3NDQwZjc4OTBhMjgyOWFjNGUwYmI1L3RhYmxlcmFuZ2U6MTdlMDdlMjc5ODc0NDBmNzg5MGEyODI5YWM0ZTBiYjVfNi0xLTEtMS0w_7bd5a38f-32a8-426b-8baf-c6d18efe9238">13,357,914</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9953f50a7fd74f7d8438f304f136a07b_I20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81OC9mcmFnOjdiZjczNTljOWJmNTQ1Yjg4ODEzMGFlMmU4YzMwMjA2L3RhYmxlOjE3ZTA3ZTI3OTg3NDQwZjc4OTBhMjgyOWFjNGUwYmI1L3RhYmxlcmFuZ2U6MTdlMDdlMjc5ODc0NDBmNzg5MGEyODI5YWM0ZTBiYjVfNi0zLTEtMS0w_05d77876-18e4-4891-b3c9-bb6aec770fd6">24.69</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercisable at March 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9953f50a7fd74f7d8438f304f136a07b_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81OC9mcmFnOjdiZjczNTljOWJmNTQ1Yjg4ODEzMGFlMmU4YzMwMjA2L3RhYmxlOjE3ZTA3ZTI3OTg3NDQwZjc4OTBhMjgyOWFjNGUwYmI1L3RhYmxlcmFuZ2U6MTdlMDdlMjc5ODc0NDBmNzg5MGEyODI5YWM0ZTBiYjVfNy0xLTEtMS0w_62caa6d6-4402-43d7-b50c-ad8b5679a5bf">7,013,040</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9953f50a7fd74f7d8438f304f136a07b_I20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81OC9mcmFnOjdiZjczNTljOWJmNTQ1Yjg4ODEzMGFlMmU4YzMwMjA2L3RhYmxlOjE3ZTA3ZTI3OTg3NDQwZjc4OTBhMjgyOWFjNGUwYmI1L3RhYmxlcmFuZ2U6MTdlMDdlMjc5ODc0NDBmNzg5MGEyODI5YWM0ZTBiYjVfNy0zLTEtMS0w_620a1a84-3830-4344-a882-acd18617532c">14.01</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5ae1cfc88aa4492caf56e9d4ac91e096_7">Table of Contents</a></span></div></div><ix:continuation id="i29450f84fde04f7ba7416390bf2301af"><ix:nonNumeric contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81OC9mcmFnOjdiZjczNTljOWJmNTQ1Yjg4ODEzMGFlMmU4YzMwMjA2L3RleHRyZWdpb246N2JmNzM1OWM5YmY1NDViODg4MTMwYWUyZThjMzAyMDZfODYy_0f9f464e-50a4-42bf-93b4-ecddc304a6cd" escape="true"><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of stock options granted to employees were calculated using the Black-Scholes option-pricing model using the following assumptions:</span></div><div style="margin-top:18pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.226%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.335%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.338%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected term (in years)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i84ba3b58bcce4a4c9748d2ca212f024c_D20210101-20210331" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81OC9mcmFnOjdiZjczNTljOWJmNTQ1Yjg4ODEzMGFlMmU4YzMwMjA2L3RhYmxlOjdlNDk0MjEzNGU4NDRkMjlhMjMzNWM4NzM5OWJjZjUzL3RhYmxlcmFuZ2U6N2U0OTQyMTM0ZTg0NGQyOWEyMzM1Yzg3Mzk5YmNmNTNfMi0xLTEtMS0wL3RleHRyZWdpb246NjU1MDZjNTIxYjZmNGRmNDg1NTYwYTc3NTA4MzdhZDhfMTA5OTUxMTYyNzgwNg_4a2a0861-4f2f-46da-97fb-ad557cc7f380">6.08</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i884b579d788c483eb3a9ee088d3e5d89_D20200101-20200331" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81OC9mcmFnOjdiZjczNTljOWJmNTQ1Yjg4ODEzMGFlMmU4YzMwMjA2L3RhYmxlOjdlNDk0MjEzNGU4NDRkMjlhMjMzNWM4NzM5OWJjZjUzL3RhYmxlcmFuZ2U6N2U0OTQyMTM0ZTg0NGQyOWEyMzM1Yzg3Mzk5YmNmNTNfMi0zLTEtMS0wL3RleHRyZWdpb246MTZhNWU3MWJiYTQ5NGQxNTllMTRjOTg1NTRjODJhMDhfMTA5OTUxMTYyNzgxNA_cae915fa-e553-4ff7-a4ab-73448ab73546">6.08</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Volatility</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i84ba3b58bcce4a4c9748d2ca212f024c_D20210101-20210331" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81OC9mcmFnOjdiZjczNTljOWJmNTQ1Yjg4ODEzMGFlMmU4YzMwMjA2L3RhYmxlOjdlNDk0MjEzNGU4NDRkMjlhMjMzNWM4NzM5OWJjZjUzL3RhYmxlcmFuZ2U6N2U0OTQyMTM0ZTg0NGQyOWEyMzM1Yzg3Mzk5YmNmNTNfMy0xLTEtMS0wL3RleHRyZWdpb246ODFkOWU1MTU0NmZhNDBkNGJkM2VlNjBiNWVkYjZiYTNfNA_0e2ca703-51e8-43e9-89aa-0dead8f563bf">62.2</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i84ba3b58bcce4a4c9748d2ca212f024c_D20210101-20210331" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81OC9mcmFnOjdiZjczNTljOWJmNTQ1Yjg4ODEzMGFlMmU4YzMwMjA2L3RhYmxlOjdlNDk0MjEzNGU4NDRkMjlhMjMzNWM4NzM5OWJjZjUzL3RhYmxlcmFuZ2U6N2U0OTQyMTM0ZTg0NGQyOWEyMzM1Yzg3Mzk5YmNmNTNfMy0xLTEtMS0wL3RleHRyZWdpb246ODFkOWU1MTU0NmZhNDBkNGJkM2VlNjBiNWVkYjZiYTNfOQ_13a8d433-41af-4aed-9d43-9cadcea36e7e">63.4</ix:nonFraction>%</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i884b579d788c483eb3a9ee088d3e5d89_D20200101-20200331" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81OC9mcmFnOjdiZjczNTljOWJmNTQ1Yjg4ODEzMGFlMmU4YzMwMjA2L3RhYmxlOjdlNDk0MjEzNGU4NDRkMjlhMjMzNWM4NzM5OWJjZjUzL3RhYmxlcmFuZ2U6N2U0OTQyMTM0ZTg0NGQyOWEyMzM1Yzg3Mzk5YmNmNTNfMy0zLTEtMS0wL3RleHRyZWdpb246NDExMDE3ZTMxMTJiNGExZmIxYzA4YTZjZDA3NWNjNjdfNA_da5e755f-ab70-4231-ab99-df55c7c0ac6e">65.2</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i884b579d788c483eb3a9ee088d3e5d89_D20200101-20200331" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81OC9mcmFnOjdiZjczNTljOWJmNTQ1Yjg4ODEzMGFlMmU4YzMwMjA2L3RhYmxlOjdlNDk0MjEzNGU4NDRkMjlhMjMzNWM4NzM5OWJjZjUzL3RhYmxlcmFuZ2U6N2U0OTQyMTM0ZTg0NGQyOWEyMzM1Yzg3Mzk5YmNmNTNfMy0zLTEtMS0wL3RleHRyZWdpb246NDExMDE3ZTMxMTJiNGExZmIxYzA4YTZjZDA3NWNjNjdfOQ_2f9afb32-f6e9-4a4b-ada3-79b1b7f455e5">65.6</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Risk-free interest rate</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i84ba3b58bcce4a4c9748d2ca212f024c_D20210101-20210331" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81OC9mcmFnOjdiZjczNTljOWJmNTQ1Yjg4ODEzMGFlMmU4YzMwMjA2L3RhYmxlOjdlNDk0MjEzNGU4NDRkMjlhMjMzNWM4NzM5OWJjZjUzL3RhYmxlcmFuZ2U6N2U0OTQyMTM0ZTg0NGQyOWEyMzM1Yzg3Mzk5YmNmNTNfNC0xLTEtMS0wL3RleHRyZWdpb246ZWRmOThhMTZkOWNkNGY5NWE2YjIwMDQzNDU5MTI5ZDFfNA_e563eb64-a01b-495b-8a1d-8ab44840247d">0.5</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i84ba3b58bcce4a4c9748d2ca212f024c_D20210101-20210331" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81OC9mcmFnOjdiZjczNTljOWJmNTQ1Yjg4ODEzMGFlMmU4YzMwMjA2L3RhYmxlOjdlNDk0MjEzNGU4NDRkMjlhMjMzNWM4NzM5OWJjZjUzL3RhYmxlcmFuZ2U6N2U0OTQyMTM0ZTg0NGQyOWEyMzM1Yzg3Mzk5YmNmNTNfNC0xLTEtMS0wL3RleHRyZWdpb246ZWRmOThhMTZkOWNkNGY5NWE2YjIwMDQzNDU5MTI5ZDFfOQ_b6af21a4-f98e-4faa-a342-12258919d39b">1.0</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i884b579d788c483eb3a9ee088d3e5d89_D20200101-20200331" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81OC9mcmFnOjdiZjczNTljOWJmNTQ1Yjg4ODEzMGFlMmU4YzMwMjA2L3RhYmxlOjdlNDk0MjEzNGU4NDRkMjlhMjMzNWM4NzM5OWJjZjUzL3RhYmxlcmFuZ2U6N2U0OTQyMTM0ZTg0NGQyOWEyMzM1Yzg3Mzk5YmNmNTNfNC0zLTEtMS0wL3RleHRyZWdpb246YjkxOGVjNWQ4ZTI2NGQ2YzlmN2M0OTRhMmMzMjc5YTRfNA_0be29516-8b58-4d0a-a274-ab7b050fc801">0.7</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i884b579d788c483eb3a9ee088d3e5d89_D20200101-20200331" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81OC9mcmFnOjdiZjczNTljOWJmNTQ1Yjg4ODEzMGFlMmU4YzMwMjA2L3RhYmxlOjdlNDk0MjEzNGU4NDRkMjlhMjMzNWM4NzM5OWJjZjUzL3RhYmxlcmFuZ2U6N2U0OTQyMTM0ZTg0NGQyOWEyMzM1Yzg3Mzk5YmNmNTNfNC0zLTEtMS0wL3RleHRyZWdpb246YjkxOGVjNWQ4ZTI2NGQ2YzlmN2M0OTRhMmMzMjc5YTRfOQ_be97122a-45eb-4f5c-8dfe-aa61fd042439">1.7</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividend yield</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i84ba3b58bcce4a4c9748d2ca212f024c_D20210101-20210331" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81OC9mcmFnOjdiZjczNTljOWJmNTQ1Yjg4ODEzMGFlMmU4YzMwMjA2L3RhYmxlOjdlNDk0MjEzNGU4NDRkMjlhMjMzNWM4NzM5OWJjZjUzL3RhYmxlcmFuZ2U6N2U0OTQyMTM0ZTg0NGQyOWEyMzM1Yzg3Mzk5YmNmNTNfNS0xLTEtMS0w_e03868cf-eb5f-4a64-8149-10d8af24aa9d">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i884b579d788c483eb3a9ee088d3e5d89_D20200101-20200331" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81OC9mcmFnOjdiZjczNTljOWJmNTQ1Yjg4ODEzMGFlMmU4YzMwMjA2L3RhYmxlOjdlNDk0MjEzNGU4NDRkMjlhMjMzNWM4NzM5OWJjZjUzL3RhYmxlcmFuZ2U6N2U0OTQyMTM0ZTg0NGQyOWEyMzM1Yzg3Mzk5YmNmNTNfNS0zLTEtMS0w_b2a77764-45f3-4f98-8ebf-b1b6042bd329">&#8212;</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Activity</span></div><ix:nonNumeric contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331" name="us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81OC9mcmFnOjdiZjczNTljOWJmNTQ1Yjg4ODEzMGFlMmU4YzMwMjA2L3RleHRyZWdpb246N2JmNzM1OWM5YmY1NDViODg4MTMwYWUyZThjMzAyMDZfODYz_26ec0b5d-8adc-4fd5-908d-30959bb27284" escape="true"><div style="margin-bottom:10pt;margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes restricted stock unit ("RSU") activity for the three months ended March 31, 2021:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.226%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.335%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.338%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of RSU shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Fair Value at Date of Grant per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unvested at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id3763ebb47a74e7aa55cdc9ec33e6ba1_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81OC9mcmFnOjdiZjczNTljOWJmNTQ1Yjg4ODEzMGFlMmU4YzMwMjA2L3RhYmxlOmRkNTgxOWU1NDVhODQ1NzM5Njc0Y2U2Y2ExODkzNjdlL3RhYmxlcmFuZ2U6ZGQ1ODE5ZTU0NWE4NDU3Mzk2NzRjZTZjYTE4OTM2N2VfMS0xLTEtMS0w_481e1fb5-a1d7-4a6d-811d-aa6c204c678d">2,301,679</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id3763ebb47a74e7aa55cdc9ec33e6ba1_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81OC9mcmFnOjdiZjczNTljOWJmNTQ1Yjg4ODEzMGFlMmU4YzMwMjA2L3RhYmxlOmRkNTgxOWU1NDVhODQ1NzM5Njc0Y2U2Y2ExODkzNjdlL3RhYmxlcmFuZ2U6ZGQ1ODE5ZTU0NWE4NDU3Mzk2NzRjZTZjYTE4OTM2N2VfMS0zLTEtMS0w_c13a8a32-4808-4c8b-8c5d-147419d0e4ee">27.08</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if9c544fa84d346779359fdcd69c81fe6_D20210101-20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81OC9mcmFnOjdiZjczNTljOWJmNTQ1Yjg4ODEzMGFlMmU4YzMwMjA2L3RhYmxlOmRkNTgxOWU1NDVhODQ1NzM5Njc0Y2U2Y2ExODkzNjdlL3RhYmxlcmFuZ2U6ZGQ1ODE5ZTU0NWE4NDU3Mzk2NzRjZTZjYTE4OTM2N2VfMi0xLTEtMS0w_28c1f0a7-f9fc-446a-8dcb-64423bf1c311">696,270</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if9c544fa84d346779359fdcd69c81fe6_D20210101-20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81OC9mcmFnOjdiZjczNTljOWJmNTQ1Yjg4ODEzMGFlMmU4YzMwMjA2L3RhYmxlOmRkNTgxOWU1NDVhODQ1NzM5Njc0Y2U2Y2ExODkzNjdlL3RhYmxlcmFuZ2U6ZGQ1ODE5ZTU0NWE4NDU3Mzk2NzRjZTZjYTE4OTM2N2VfMi0zLTEtMS0w_767bae70-c366-4411-8640-4ce9881ec839">76.33</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested and released</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="if9c544fa84d346779359fdcd69c81fe6_D20210101-20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81OC9mcmFnOjdiZjczNTljOWJmNTQ1Yjg4ODEzMGFlMmU4YzMwMjA2L3RhYmxlOmRkNTgxOWU1NDVhODQ1NzM5Njc0Y2U2Y2ExODkzNjdlL3RhYmxlcmFuZ2U6ZGQ1ODE5ZTU0NWE4NDU3Mzk2NzRjZTZjYTE4OTM2N2VfMy0xLTEtMS0w_20aaeef1-b8d5-41e4-a8f8-9fb5f78bdc38">281,465</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if9c544fa84d346779359fdcd69c81fe6_D20210101-20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81OC9mcmFnOjdiZjczNTljOWJmNTQ1Yjg4ODEzMGFlMmU4YzMwMjA2L3RhYmxlOmRkNTgxOWU1NDVhODQ1NzM5Njc0Y2U2Y2ExODkzNjdlL3RhYmxlcmFuZ2U6ZGQ1ODE5ZTU0NWE4NDU3Mzk2NzRjZTZjYTE4OTM2N2VfMy0zLTEtMS0w_b9660d2c-0363-4224-8368-ddcadba1711f">22.73</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="if9c544fa84d346779359fdcd69c81fe6_D20210101-20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81OC9mcmFnOjdiZjczNTljOWJmNTQ1Yjg4ODEzMGFlMmU4YzMwMjA2L3RhYmxlOmRkNTgxOWU1NDVhODQ1NzM5Njc0Y2U2Y2ExODkzNjdlL3RhYmxlcmFuZ2U6ZGQ1ODE5ZTU0NWE4NDU3Mzk2NzRjZTZjYTE4OTM2N2VfNC0xLTEtMS0w_610835c8-850c-4353-b236-74a51f68ca7c">17,377</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if9c544fa84d346779359fdcd69c81fe6_D20210101-20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81OC9mcmFnOjdiZjczNTljOWJmNTQ1Yjg4ODEzMGFlMmU4YzMwMjA2L3RhYmxlOmRkNTgxOWU1NDVhODQ1NzM5Njc0Y2U2Y2ExODkzNjdlL3RhYmxlcmFuZ2U6ZGQ1ODE5ZTU0NWE4NDU3Mzk2NzRjZTZjYTE4OTM2N2VfNC0zLTEtMS0w_b0f82f9d-272d-45e2-b3b6-8f3551d996cf">61.97</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unvested at March 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifa1dc7a3953b414298ab33929383425a_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81OC9mcmFnOjdiZjczNTljOWJmNTQ1Yjg4ODEzMGFlMmU4YzMwMjA2L3RhYmxlOmRkNTgxOWU1NDVhODQ1NzM5Njc0Y2U2Y2ExODkzNjdlL3RhYmxlcmFuZ2U6ZGQ1ODE5ZTU0NWE4NDU3Mzk2NzRjZTZjYTE4OTM2N2VfNS0xLTEtMS0w_32728e3d-2dd9-4e9b-8e4e-32aa45abc90b">2,699,107</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ifa1dc7a3953b414298ab33929383425a_I20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81OC9mcmFnOjdiZjczNTljOWJmNTQ1Yjg4ODEzMGFlMmU4YzMwMjA2L3RhYmxlOmRkNTgxOWU1NDVhODQ1NzM5Njc0Y2U2Y2ExODkzNjdlL3RhYmxlcmFuZ2U6ZGQ1ODE5ZTU0NWE4NDU3Mzk2NzRjZTZjYTE4OTM2N2VfNS0zLTEtMS0w_66a23e32-b5d2-4bdd-8f61-ebb35eacbeb8">40.24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected to vest at March 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifa1dc7a3953b414298ab33929383425a_I20210331" decimals="INF" format="ixt:numdotdecimal" name="dnli:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81OC9mcmFnOjdiZjczNTljOWJmNTQ1Yjg4ODEzMGFlMmU4YzMwMjA2L3RhYmxlOmRkNTgxOWU1NDVhODQ1NzM5Njc0Y2U2Y2ExODkzNjdlL3RhYmxlcmFuZ2U6ZGQ1ODE5ZTU0NWE4NDU3Mzk2NzRjZTZjYTE4OTM2N2VfNi0xLTEtMS0w_85b64720-fd78-42b8-8019-b58f1f7a16dc">2,699,107</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ifa1dc7a3953b414298ab33929383425a_I20210331" decimals="2" name="dnli:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueExpectedToVest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81OC9mcmFnOjdiZjczNTljOWJmNTQ1Yjg4ODEzMGFlMmU4YzMwMjA2L3RhYmxlOmRkNTgxOWU1NDVhODQ1NzM5Njc0Y2U2Y2ExODkzNjdlL3RhYmxlcmFuZ2U6ZGQ1ODE5ZTU0NWE4NDU3Mzk2NzRjZTZjYTE4OTM2N2VfNi0zLTEtMS0w_d6165589-e9c2-4b7d-9ca5-1f8c4995407f">40.24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-indent:27pt"><span><br/></span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation Expense</span></div><ix:nonNumeric contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81OC9mcmFnOjdiZjczNTljOWJmNTQ1Yjg4ODEzMGFlMmU4YzMwMjA2L3RleHRyZWdpb246N2JmNzM1OWM5YmY1NDViODg4MTMwYWUyZThjMzAyMDZfODY0_a139acf5-537a-48bb-a907-04bed518ce21" escape="true"><div style="margin-bottom:10pt;margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s results of operations include expenses relating to stock-based compensation as follows (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.778%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.060%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.061%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic95a24eb031142ffb8fea378c4c16539_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81OC9mcmFnOjdiZjczNTljOWJmNTQ1Yjg4ODEzMGFlMmU4YzMwMjA2L3RhYmxlOjUzOGYwY2E5MjYxMTRiNGFhYTk4YzE3ODQxNTY1MjAwL3RhYmxlcmFuZ2U6NTM4ZjBjYTkyNjExNGI0YWFhOThjMTc4NDE1NjUyMDBfMi0xLTEtMS0w_ed0758ae-0b8b-4627-b38e-19dcd21fc24a">12,314</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9e73e4cbcdf45859b5ab6fdf05d2397_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81OC9mcmFnOjdiZjczNTljOWJmNTQ1Yjg4ODEzMGFlMmU4YzMwMjA2L3RhYmxlOjUzOGYwY2E5MjYxMTRiNGFhYTk4YzE3ODQxNTY1MjAwL3RhYmxlcmFuZ2U6NTM4ZjBjYTkyNjExNGI0YWFhOThjMTc4NDE1NjUyMDBfMi0zLTEtMS0w_0d73ef83-b4a7-4336-b2a5-90bdbf9442a6">6,054</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">General and administrative</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if224ee1d3e1d40cda888c5569a5ca491_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81OC9mcmFnOjdiZjczNTljOWJmNTQ1Yjg4ODEzMGFlMmU4YzMwMjA2L3RhYmxlOjUzOGYwY2E5MjYxMTRiNGFhYTk4YzE3ODQxNTY1MjAwL3RhYmxlcmFuZ2U6NTM4ZjBjYTkyNjExNGI0YWFhOThjMTc4NDE1NjUyMDBfMy0xLTEtMS0w_b3ae7855-a0ce-4966-a423-8f850fcb9fb0">8,714</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie960cec998d6496380dc4b23cade2ada_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81OC9mcmFnOjdiZjczNTljOWJmNTQ1Yjg4ODEzMGFlMmU4YzMwMjA2L3RhYmxlOjUzOGYwY2E5MjYxMTRiNGFhYTk4YzE3ODQxNTY1MjAwL3RhYmxlcmFuZ2U6NTM4ZjBjYTkyNjExNGI0YWFhOThjMTc4NDE1NjUyMDBfMy0zLTEtMS0w_c3dc7388-0572-4cd3-ae42-8b3260dc254b">4,731</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81OC9mcmFnOjdiZjczNTljOWJmNTQ1Yjg4ODEzMGFlMmU4YzMwMjA2L3RhYmxlOjUzOGYwY2E5MjYxMTRiNGFhYTk4YzE3ODQxNTY1MjAwL3RhYmxlcmFuZ2U6NTM4ZjBjYTkyNjExNGI0YWFhOThjMTc4NDE1NjUyMDBfNC0xLTEtMS0w_bfe9ec00-9ee3-45cb-af1e-224fc5a8633a">21,028</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia34dfea6b8734d64abf707c28256801c_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81OC9mcmFnOjdiZjczNTljOWJmNTQ1Yjg4ODEzMGFlMmU4YzMwMjA2L3RhYmxlOjUzOGYwY2E5MjYxMTRiNGFhYTk4YzE3ODQxNTY1MjAwL3RhYmxlcmFuZ2U6NTM4ZjBjYTkyNjExNGI0YWFhOThjMTc4NDE1NjUyMDBfNC0zLTEtMS0w_2d1152b2-4466-45e2-9011-784adbacbe4a">10,785</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:1pt;font-weight:400;line-height:120%">1</span></div><div id="i5ae1cfc88aa4492caf56e9d4ac91e096_61"></div><div style="margin-top:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9.&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl82MS9mcmFnOjZkNzY2NWQ3YTZlZTRlOGNiZTEyZDlhYjE3ZDg1ODRjL3RleHRyZWdpb246NmQ3NjY1ZDdhNmVlNGU4Y2JlMTJkOWFiMTdkODU4NGNfNDI5_542bf52c-d513-41d7-8bf0-7ff5da753633" continuedAt="i51f3d52582744977bfa7096734b2f4f2" escape="true">Net Loss Per Share</ix:nonNumeric></span></div><ix:continuation id="i51f3d52582744977bfa7096734b2f4f2"><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since the Company was in a loss position for all periods presented, basic net loss per share is the same as diluted net loss per share for all periods as the inclusion of all potential shares of common stock outstanding would have been anti-dilutive. </span></div><div style="text-indent:25pt"><span><br/></span></div><ix:nonNumeric contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl82MS9mcmFnOjZkNzY2NWQ3YTZlZTRlOGNiZTEyZDlhYjE3ZDg1ODRjL3RleHRyZWdpb246NmQ3NjY1ZDdhNmVlNGU4Y2JlMTJkOWFiMTdkODU4NGNfNDI4_806b40ca-5b5c-4551-80d7-4b8e04d3df0f" escape="true"><div style="margin-bottom:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potentially dilutive securities that were not included in the diluted per share calculations because they would be anti-dilutive were as follows:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.778%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.060%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.061%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Options issued and outstanding and ESPP shares issuable</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1bfd917477b04985b275e7880a6800ee_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl82MS9mcmFnOjZkNzY2NWQ3YTZlZTRlOGNiZTEyZDlhYjE3ZDg1ODRjL3RhYmxlOjQ3NDk0ZTQyZGRhNTRmOGVhZmU5MDMwYzdjZTg0NjU1L3RhYmxlcmFuZ2U6NDc0OTRlNDJkZGE1NGY4ZWFmZTkwMzBjN2NlODQ2NTVfMi0xLTEtMS0w_1d3d2ca3-d726-49d1-b540-a6f29553edb2">14,323,256</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ieb96c5c2a58b43ecb70f4570ae6501d5_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl82MS9mcmFnOjZkNzY2NWQ3YTZlZTRlOGNiZTEyZDlhYjE3ZDg1ODRjL3RhYmxlOjQ3NDk0ZTQyZGRhNTRmOGVhZmU5MDMwYzdjZTg0NjU1L3RhYmxlcmFuZ2U6NDc0OTRlNDJkZGE1NGY4ZWFmZTkwMzBjN2NlODQ2NTVfMi0zLTEtMS0w_7c1623a7-336e-4a42-8253-2ff7781a4452">14,530,378</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted shares subject to future vesting</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i14d03db975fe42b1b25891a5de38963a_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl82MS9mcmFnOjZkNzY2NWQ3YTZlZTRlOGNiZTEyZDlhYjE3ZDg1ODRjL3RhYmxlOjQ3NDk0ZTQyZGRhNTRmOGVhZmU5MDMwYzdjZTg0NjU1L3RhYmxlcmFuZ2U6NDc0OTRlNDJkZGE1NGY4ZWFmZTkwMzBjN2NlODQ2NTVfMy0xLTEtMS0w_07a6b5a0-d676-468e-9100-146701d987ba">2,699,107</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iaab0bf674ec742169a75f1ba80135e68_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl82MS9mcmFnOjZkNzY2NWQ3YTZlZTRlOGNiZTEyZDlhYjE3ZDg1ODRjL3RhYmxlOjQ3NDk0ZTQyZGRhNTRmOGVhZmU5MDMwYzdjZTg0NjU1L3RhYmxlcmFuZ2U6NDc0OTRlNDJkZGE1NGY4ZWFmZTkwMzBjN2NlODQ2NTVfMy0zLTEtMS0w_3688ce7b-24bb-40c1-a203-16ee6c70b11f">1,637,984</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl82MS9mcmFnOjZkNzY2NWQ3YTZlZTRlOGNiZTEyZDlhYjE3ZDg1ODRjL3RhYmxlOjQ3NDk0ZTQyZGRhNTRmOGVhZmU5MDMwYzdjZTg0NjU1L3RhYmxlcmFuZ2U6NDc0OTRlNDJkZGE1NGY4ZWFmZTkwMzBjN2NlODQ2NTVfNS0xLTEtMS0w_5e4f87dc-d8c4-4d28-a1f3-c54fa9f55f69">17,022,363</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia34dfea6b8734d64abf707c28256801c_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl82MS9mcmFnOjZkNzY2NWQ3YTZlZTRlOGNiZTEyZDlhYjE3ZDg1ODRjL3RhYmxlOjQ3NDk0ZTQyZGRhNTRmOGVhZmU5MDMwYzdjZTg0NjU1L3RhYmxlcmFuZ2U6NDc0OTRlNDJkZGE1NGY4ZWFmZTkwMzBjN2NlODQ2NTVfNS0zLTEtMS0w_9f259a15-1c13-4148-9ac2-781a8da27642">16,168,362</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><div id="i5ae1cfc88aa4492caf56e9d4ac91e096_64"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5ae1cfc88aa4492caf56e9d4ac91e096_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl82NC9mcmFnOjRhNWM3YTAyYTcxZDQxNGRhODRhMTk3ZTZmODJhNmNhL3RleHRyZWdpb246NGE1YzdhMDJhNzFkNDE0ZGE4NGExOTdlNmY4MmE2Y2FfMjYw_06cc89d6-42c3-4235-9290-a61c984e0605" continuedAt="i8d13f9bee6a04db9a9cba126af996227" escape="true">Related Party Transactions</ix:nonNumeric></span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i8d13f9bee6a04db9a9cba126af996227">On September 22, 2020, upon becoming an owner of record of more than 10% of the voting interest in the Company, Biogen became a related party under ASC 850. Refer to Note 5, "Collaboration Agreements" for further information.</ix:continuation></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><div id="i5ae1cfc88aa4492caf56e9d4ac91e096_70"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5ae1cfc88aa4492caf56e9d4ac91e096_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2.  MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div id="i5ae1cfc88aa4492caf56e9d4ac91e096_73"></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following discussion and analysis of our financial condition and results of operations should be read together with our condensed consolidated financial statements and the related notes to those statements included elsewhere in this Quarterly Report on Form 10-Q</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">. This discussion and analysis and other parts of this report contain forward-looking statements based upon current beliefs, plans and expectations related to future events and our future financial performance that involve risks, uncertainties and assumptions, such as statements regarding our intentions, plans, objectives, expectations, forecasts and projections. Our actual results and the timing of selected events coul</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">d differ materially from those anticipated in these forward-looking statements as a result of several factors, including those set forth under the section titled &#8220;Risk Factors&#8221; included in this Quarterly Report on Form 10-Q.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Forward-looking statements include, but are not limited to, statements about:</span></div><div><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10pt">the success, cost and timing of our development activities, preclinical studies and clinical trials, including the enrollment in such trials, and in particular the development of our blood-brain barrier (&#8220;BBB&#8221;) platform technology, programs and biomarkers;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10pt">the extent to which any dosing limitations that we have been subject to, and/or may be subject to in the future, may affect the success of our product candidates;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10pt">the impact of preclinical findings on our ability to achieve exposures of our product candidates that allow us to explore a robust pharmacodynamic range of these candidates in humans;</span></div><div style="padding-left:13.5pt;text-indent:4.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10pt">expectations regarding the transaction with Biogen, including all financial aspects of the collaboration and equity investment, the potential benefits and results of the transaction;</span></div><div style="padding-left:13.5pt;text-indent:4.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10pt">the expected potential benefits and potential revenue resulting from strategic collaborations with third parties and our ability to attract collaborators with development, regulatory and commercialization expertise;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10pt">the timing or likelihood of regulatory filings and approvals;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10pt">our ability to obtain and maintain regulatory approval of our product candidates, and any related restrictions, limitations and/or warnings in the label of any approved product candidate;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10pt">the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and technology;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10pt">the terms and conditions of licenses granted to us and our ability to license and/or acquire additional intellectual property relating to our product candidates and BBB platform technology;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10pt">our ability to obtain funding for our operations, including funding necessary to develop and commercialize our current and potential future product candidates;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10pt">our plans and ability to establish sales, marketing and distribution infrastructure to commercialize any product candidates for which we obtain approval;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10pt">future agreements with third parties in connection with the commercialization of our product candidates;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10pt">the size and growth potential of the markets for our product candidates, if approved for commercial use, and our ability to serve those markets;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10pt">the rate and degree of market acceptance of our product candidates;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5ae1cfc88aa4492caf56e9d4ac91e096_7">Table of Contents</a></span></div></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10pt">existing regulations and regulatory developments in the United States and foreign countries; </span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10pt">potential claims relating to our intellectual property and third-party intellectual property;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10pt">our ability to contract with third-party suppliers and manufacturers and their ability to perform adequately;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10pt">our potential plans and ability to develop our own manufacturing facilities;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10pt">the pricing and reimbursement of our product candidates, if approved and commercialized;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10pt">the success of competing products or platform technologies that are or may become available;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10pt">our ability to attract and retain key managerial, scientific and medical personnel;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10pt">the accuracy of our estimates regarding expenses, future revenue, capital requirements and needs for additional financing;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10pt">our ability to enhance operational, financial and information management systems;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10pt">our financial performance; and</span></div><div style="padding-left:13.5pt;text-indent:4.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10pt">our expectations regarding the impact of the COVID -19 pandemic on our business.</span></div><div style="padding-left:13.5pt;text-indent:4.5pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">These forward-looking statements are subject to a number of risks, uncertainties, and assumptions, including those described in &#8220;Risk Factors&#8221;. In some cases, you can identify these statements by terms such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expects,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; &#8220;would&#8221; or the negative of those terms, and similar expressions that convey uncertainty of future events or outcomes. These forward-looking statements reflect our beliefs and views with respect to future events and are based on estimates and assumptions as of the date of this Quarterly Report on Form 10-Q and are subject to risks and uncertainties. We discuss many of these risks in greater detail in the section entitled &#8220;Risk Factors&#8221; included in Part II, Item 1A and elsewhere in this report. Moreover, we operate in a very competitive and rapidly changing environment. New risks emerge from time to time. It is not possible to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. Given these uncertainties, you should not place undue reliance on these forward-looking statements. We qualify all of the forward-looking statements in this Quarterly Report on Form 10-Q by these cautionary statements. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in any forward-looking statements, whether as a result of new information, future events or otherwise.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5ae1cfc88aa4492caf56e9d4ac91e096_7">Table of Contents</a></span></div></div><div style="margin-top:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our goal is to discover, develop and deliver therapeutics to defeat degeneration.</span></div><div style="text-indent:25pt"><span><br/></span></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our strategy is guided by three overarching principles that we believe will significantly increase the probability of success and will accelerate the timing to bring effective therapeutics to patients with neurodegenerative diseases:</span></div><div style="text-indent:25pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Genetic Pathway Potential</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: We select our therapeutic targets and disease pathways based on genes that, when mutated, cause, or are major risk factors for, neurodegenerative diseases. We refer to these genes as degenogenes;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Engineering Brain Delivery</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: We engineer our product candidates to cross the BBB and act directly in the brain; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Biomarker-Driven Development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: We discover, develop and utilize biomarkers to select the right patient population and demonstrate target engagement, pathway engagement and impact on disease progression of our product candidates.</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:13.5pt;text-indent:4.5pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By executing this strategy with a team of experienced and passionately dedicated scientists and drug developers, we believe we can succeed in a field that has seen limited progress over the past several decades. We have a focused yet diversified portfolio with five clinical programs and more than fifteen programs in the preclinical development stage.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have also developed a proprietary BBB platform technology, our transport vehicle ("TV"), which enables multiple modality-based platforms to deliver a wide range of large-molecule therapeutics across the BBB, including enzymes, antibodies, proteins and oligonucleotides. This technology is designed to engage specific BBB transport receptors, which are ubiquitously expressed in brain capillaries and facilitate transport of proteins into the brain. We are currently optimizing and broadening this platform technology. </span></div><div><span><br/></span></div><div style="margin-bottom:10pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ou</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">r five clinic</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">al-stage programs are: </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our leucine-rich repeat kinase 2 ("LRRK2") inhibitor program, in collaboration with Biogen, to address Parkinson&#8217;s disease;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our eukaryotic initiation factor 2 B ("EIF2B") activator program to address diseases such as amyotrophic lateral sclerosis ("ALS") and frontotemporal dementia ("FTD");</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ETV:IDS program, our lead brain-penetrant enzyme replacement therapy ("ERT"), enabled by our enzyme transport vehicle ("ETV"), which is designed to restore iduronate 2-sulfatase ("IDS"), and reduce glycosaminoglycans, both peripherally and in the brain, in patients with mucopolysaccharidosis II ("MPS II", or "Hunter syndrome");</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our receptor interacting serine/threonine protein kinase 1 ("RIPK1") inhibitor program, partnered with Sanofi, to address neurological diseases such as Alzheimer's disease and ALS as well as multiple sclerosis ("MS"); and</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a second non-CNS penetrant RIPK1 inhibitor, partnered with Sanofi, to address peripheral inflammatory diseases such as cutaneous lupus erythematosus ("CLE").</span></div><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5ae1cfc88aa4492caf56e9d4ac91e096_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes key information about our clinical stage programs:</span></div><div style="margin-bottom:10pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:16.688%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.252%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.303%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.288%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Program</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Product Candidate(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Clinical Phase</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Indication(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operational Control</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">LRRK2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">DNL151 (BIIB122)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Ph 1 and Ph 1b complete</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Parkinson's disease</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Joint with Biogen</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ETV:IDS</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">DNL310</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Ph1/2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Hunter syndrome (MPS II)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Denali</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">EIF2B</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">DNL343</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Ph 1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ALS and FTD</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Denali</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">RIPK1 (Peripheral)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">DNL758 (SAR443122) </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Ph 1b complete</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Systemic inflammatory diseases</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sanofi</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">RIPK1 (CNS)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">DNL788 (SAR443820) </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Ph 1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Neurological diseases</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sanofi</span></td></tr></table></div><div style="margin-bottom:10pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To complement our internal capabilities, we have entered into arrangements with biopharmaceutical companies, patient-focused data companies, numerous leading academic institutions and foundations to gain access to new product candidates, enable and accelerate the development of our existing programs and deepen our scientific understanding of certain areas of biology. We currently rely on third-party contract manufacturers to manufacture and supply our preclinical and clinical materials to be used during the development of our product candidates. We currently do not need commercial manufacturing capacity.</span></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since we commenced operations, we have devoted substantially all of our resources to discovering, acquiring and developing product candidates, building our BBB platform technology and assembling our core capabilities in understanding key neurodegenerative disease pathways.</span></div><div style="text-indent:25pt"><span><br/></span></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Key operational and financing milestones in 2021 to date include:</span></div><div style="padding-left:13.5pt;text-indent:4.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">In December 2020 and January 2021, GLP toxicology studies were initiated for PTV:PGRN (DNL593) and ATV:TREM2 (DNL919), respectively, triggering the second preclinical milestone payments under the Takeda Collaboration Agreement of $8.0 million for each program. The milestone payment for PTV:PGRN was received in January 2021 and ATV:TREM2 was received in March 2021;</span></div><div style="padding-left:13.5pt;text-indent:4.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">In January 2021, we announced completion of the DNL151 (BIIB122) Phase 1b study in Parkinson&#8217;s patients. In March 2021, we completed our Phase 1 study of DNL151 (BIIB122). In May 2021, we presented results from both studies at the International Association of Parkinsonism and Related Disorders Virtual Congress held on May 1-4. DNL151 (BIIB122) was generally well tolerated, and target engagement and pathway engagement biomarker goals were met. We plan, together with our collaboration partner Biogen, to initiate late-stage clinical development of DNL151 (BIIB122) in patients with Parkinson's disease by year-end 2021.</span></div><div style="padding-left:13.5pt;text-indent:4.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">In January 2021, following achievement of human biomarker proof of concept with DNL310 for Hunter syndrome, we announced the addition of five new brain-penetrant ERT programs in our ETV portfolio including: (1) ETV:GBA for Gaucher disease and Parkinson&#8217;s disease; (2) ETV:GAA for Pompe disease; (3) ETV:IDUA for MPS I; (4) ETV:NAGLU for MPS IIIB; and (5) ETV:ARSA for metachromatic leukodystrophy ("MLD");</span></div><div style="padding-left:13.5pt;text-indent:4.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">In February 2021, we announced Sanofi's decision, upon completion of a Phase 1b study in hospitalized adult patients with severe COVID-19 lung disease, to cease further development of DNL758 (SAR443122) in COVID-19 based on the rapidly evolving landscape of treatment and prevention options for COVID-19. Although the study did not meet its primary endpoint, DNL758 (SAR443122) was generally well tolerated and did generate positive signals of relevant biological effect. Sanofi plans to commence dosing in a Phase 2 study of DNL758 (SAR443122) in CLE patients in the first half of 2021; </span></div><div style="padding-left:13.5pt;text-indent:4.5pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5ae1cfc88aa4492caf56e9d4ac91e096_7">Table of Contents</a></span></div></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">In February 2021, we reported three-month data from Cohort A (n=5) in a Phase 1/2 study of DNL310 in patients with Hunter syndrome. The data showed that DNL310 treatment resulted in normalization of glycosaminoglycan ("GAG") levels in cerebrospinal fluid and a safety and tolerability profile consistent with standard of care ERT. In March 2021, we announced that the U.S. Food and Drug Administration ("FDA") granted Fast Track designation to DNL310 for the treatment of patients with Hunter syndrome. Denali plans to report six-month data from Cohort A in mid-2021; </span></div><div style="padding-left:13.5pt;text-indent:4.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">In May 2021, we announced that based on interim data from the ongoing Phase 1 single- and multiple-ascending-dose study of DNL343 in healthy volunteers, safety and pathway engagement biomarker goals of the study were met. A maximum tolerated dose was not reached and an additional multiple dose cohort has been added to the study to further explore the therapeutic window. Based on these data, we plan to initiate a Phase 1b study in patients with ALS in the second half of 2021; and</span></div><div style="padding-left:13.5pt;text-indent:4.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">To address risks posed by the COVID-19 pandemic, we have implemented policies that enable some of our employees to work remotely. For all on-site personnel, we have implemented several safety protocols, including regular, mandatory COVID-19 testing procedures, compliance measures for social distancing, and use of personal protective equipment. After initial COVID-19 pandemic shutdown restrictions were put into place in March 2020, we experienced a pause in patient recruitment in several clinical trials. Recruitment has since resumed for all affected clinical trials.</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have any products approved for sale and have not generated any product revenue since our inception. We have funded our operations primarily from the issuance and sale of convertible preferred stock, the sale of common stock in public offerings, and payments received from our collaboration agreements with Takeda, Sanofi and Biogen.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred significant operating losses to date and expect to continue to incur operating losses for the foreseeable future. Our ability to generate product revenue will depend on the successful development and eventual commercialization of one or more of our product candida</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">tes. Our net losses</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> wer</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e $70.0 million and $56.8 million for the three months ended March 31, 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2020,</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> respectively. As of March 31, 2021, we had an accumulated deficit o</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">f $424.5 million. We e</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">xpect to continue to incur significant expenses and operating losses as we advance our current clinical stage programs through healthy volunteer and patient trials; broaden and improve our BBB platform technology; acquire, discover, validate and develop additional product candidates; obtain, maintain, protect and enforce our intellectual property portfolio; and hire additional personnel.</span></div><div id="i5ae1cfc88aa4492caf56e9d4ac91e096_76"></div><div style="margin-top:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Components of Operating Results </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration Revenue</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have not generated any revenue from product sales and do not expect to generate any revenue from product sales for the foreseeable future. All revenue recognized to date has been collaboration and license revenue from our collaboration agreements with Takeda, Sanofi and Biogen.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the future, we will continue to recognize revenue from the Takeda Collaboration Agreement, Sanofi Collaboration Agreement, and Biogen Collaboration Agreement, and may generate revenue from product sales or milestones, royalties and cost reimbursement from other collaboration agreements, strategic alliances and licensing arrangements. We expect that our revenue will fluctuate from quarter-to-quarter and year-to-year as a result of the timing and amount of license fees, milestones, reimbursement of costs incurred and other payments and product sales, to the extent any are successfully commercialized. If we fail to complete the development of our product candidates in a timely manner or obtain regulatory approval for them, our ability to generate future revenue, and our results of operations and financial position, would be materially adversely affected.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5ae1cfc88aa4492caf56e9d4ac91e096_7">Table of Contents</a></span></div></div><div style="margin-top:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Expenses</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development</span></div><div style="text-indent:25pt"><span><br/></span></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development activities account for a significant portion of our operating expenses. We record research and development expenses as incurred. Research and development expenses incurred by us for the discovery and development of our product candidates and BBB platform technology include:</span></div><div style="text-indent:25pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:27pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">external research and development expenses, including:</span></div><div style="padding-left:24.75pt;padding-right:24.75pt;text-align:center;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.94pt">expenses incurred under arrangements with third parties, such as contract research organizations ("CROs"), preclinical testing organizations, contract development and manufacturing organizations ("CDMOs"), academic and non-profit institutions and consultants;</span></div><div style="padding-left:18pt;padding-right:18pt;text-align:center"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.94pt">expenses to acquire technologies to be used in research and development that have not reached technological feasibility and have no alternative future use;</span></div><div style="padding-left:18pt;padding-right:18pt;text-align:center"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.94pt">fees related to our license and collaboration agreements;</span></div><div style="padding-left:24.75pt;padding-right:24.75pt;text-align:center;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:27pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">personnel related expenses, including salaries, benefits and stock-based compensation expense; and</span></div><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:27pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">other expenses, which include direct and allocated expenses for laboratory, facilities and other costs.</span></div><div style="padding-left:36pt;text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A portion of our research and development expenses are direct external expenses, which we track on a program-specific basis once a program has commenced late-stage IND-enabling studies.</span></div><div style="text-indent:25pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Program expenses include expenses associated with our most advanced product candidates and the discovery and development of backup or next-generation molecules. We also track external expenses associated with our TV platform. These expenses include those incurred by us relating to our Takeda Collaboration Agreement, Sanofi Collaboration Agreement a</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nd Biogen Collaboration Agreement. Al</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">l external costs associated with earlier stage programs, or that benefit the entire portfolio, are tracked as a group. We do not track personnel or other operating expenses incurred for our research and development programs on a program-specific basis. These expenses primarily relate to salaries and benefits, stock-based compensation, facility expenses including rent and depreciation, and lab consumables.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Where we share costs with our collaboration partners, such as in our Biogen Collaboration Agreement, research and development expenses may include cost sharing reimbursements from or payments to our partner, respectively.</span></div><div style="text-indent:25pt"><span><br/></span></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> It is challenging to predict the nature, timing and estimated long-range costs of the efforts that will be necessary to complete the development of, and obtain regulatory approval for, any of our product candidates. This is made more challenging by events outside of our control, such as the recent COVID-19 pandemic. We are also unable to predict when, if ever, material net cash inflows will commence from sales or licensing of our product candidates. This is due to the numerous risks and uncertainties associated with drug development, including the uncertainty of:</span></div><div style="text-indent:25pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">our ability to add and retain key research and development personnel;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">our ability to establish an appropriate safety profile with IND-enabling toxicology studies;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">our ability to successfully develop, obtain regulatory approval for, and then successfully commercialize, our product candidates;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">our successful enrollment in and completion of clinical trials;</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5ae1cfc88aa4492caf56e9d4ac91e096_7">Table of Contents</a></span></div></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the costs associated with the development of any additional product candidates we identify in-house or acquire through collaborations;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">our ability to discover, develop and utilize biomarkers to demonstrate target engagement, pathway engagement and the impact on disease progression of our molecules;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">our ability to establish agreements with third-party manufacturers for clinical supply for our clinical trials and commercial manufacturing, if our product candidates are approved;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the terms and timing of any collaboration, license or other arrangement, including the terms and timing of any milestone payments thereunder;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">our ability to obtain and maintain patent, trade secret and other intellectual property protection and regulatory exclusivity for our product candidates if and when approved;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">our receipt of marketing approvals from applicable regulatory authorities;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">our ability to commercialize products, if and when approved, whether alone or in collaboration with others; and</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the continued acceptable safety profiles of the product candidates following approval.</span></div><div style="padding-left:36pt;text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A change in any of these variables with respect to the development of any of our product candidates would significantly change the costs, timing and viability associated with the development of that product candidate. We expect our research and development expenses to increase at least over the next several years as we continue to implement our business strategy, advance our current programs, expand our research and development efforts, seek regulatory approvals for any product candidates that successfully complete clinical trials, access and develop additional product candidates and incur expenses associated with hiring additional personnel to support our research and development efforts. In addition, product candidates in later stages of clinical development generally incur higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and Administrative</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses include personnel-related expenses, such as salaries, benefits, travel and stock-based compensation expense, expenses for outside professional services and allocated expenses. Outside professional services consist of legal, accounting and audit services and other consulting fees. Allocated expenses consist of rent, depreciation and other expenses related to our office and research and development facility not otherwise included in research and development expenses. We expect to increase our administrative headcount as we advance our product candidates through clinical development, which will increase our general and administrative expenses.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest and Other Income, Net </span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest and other income, net</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, consists pr</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">imarily of interest income and investment income earned on our cash, cash equivalents, and marketable securities, gains and losses on foreign currency hedges, and sublease income.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><div id="i5ae1cfc88aa4492caf56e9d4ac91e096_79"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5ae1cfc88aa4492caf56e9d4ac91e096_7">Table of Contents</a></span></div></div><div style="margin-top:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">three months ended</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> March 31, 2021 and 2020 </span></div><div style="text-indent:25pt"><span><br/></span></div><div style="margin-bottom:10pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the significant components of our results of operations (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.124%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.162%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.921%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.797%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.368%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Collaboration revenue:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Collaboration revenue from customers</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,922&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,552&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,370&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other collaboration revenue</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(51)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(98)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:60pt;text-indent:-12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total collaboration revenue</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,923&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,604&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,319&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expenses:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60,207&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51,016&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,191&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">General and administrative</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,936&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,555&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,381&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:60pt;text-indent:-12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total operating expenses</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">79,143&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">63,571&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,572&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(71,220)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(59,967)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11,253)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest and other income, net</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,179&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,069&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,890)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(62)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(70,041)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(56,898)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13,143)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax benefit </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">135&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(135)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(70,041)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(56,763)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13,278)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:120%">__________________________________________________</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">* &#160;&#160;&#160;&#160;Percentage is not meaningful.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaboration revenue. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration revenue was $7.9 million and $3.6 million for the three months ended March 31, 2021 and 2020, respectively. The increase in collaboration revenue of $4.3 million for the three months ended March 31, 2021 compared to the three months ended March 31, 2020 was due to an increase in revenue from our collaboration with Takeda of $4.0 million driven by increased costs incurred in the underlying partnered programs, and revenue of $0.9 million from our collaboration with Biogen, partially offset by a decrease of $0.6 million in revenue from our collaboration with Sanofi driven by the termination of revenue for retained activities which have been transferred to Sanofi.</span></div><div style="text-indent:27pt"><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development expen</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ses. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses were $60.2 million and $51.0 million for the three months ended March 31, 2021 and 2020, respectively.</span></div><div style="text-indent:25pt"><span><br/></span></div><div style="margin-bottom:10pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our research and development expenses by program and category (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.938%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.061%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">LRRK2 program external expenses</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,376&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,592&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">EIF2B program external expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,340&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,312&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ETV:IDS program external expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,886&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,138&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TV platform and other program external expenses</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,483&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,724&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other external research and development expenses</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,479&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,392&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Personnel-related expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27,767&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,871&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other unallocated research and development expenses</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,387&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,987&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost sharing reimbursements from related party</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,511)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total research and development expenses</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60,207&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51,016&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:120%">__________________________________________________</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10.69pt">Personnel-related expenses include stock-based compensation expense of $12.3 million and $6.1 million for the three months ended March 31, 2021 and 2020, respectively, reflecting an increase of $6.2 million.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10.69pt">Cost sharing reimbursements from Biogen during the three months ended March 31, 2021 for LRRK2 program external expenses, and LRRK2 program internal expenses which are included within Personnel-related expenses.</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5ae1cfc88aa4492caf56e9d4ac91e096_7">Table of Contents</a></span></div></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in research and development expenses of approximately $9.2 million for three months ended March 31, 2021 and 2020, respectively, was primarily attributable to the following:</span></div><div style="margin-top:10pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">An increase of $8.9 million in personnel-related expenses, consisting of a $2.7 million increase in salaries and related expenses attributable to an increase in our research and development headcount, and a $6.2 million increase in stock-based compensation expense primarily attributable to additional equity award grants and our increasing market price; </span></div><div style="margin-top:10pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">$4.8 million of increased TV platform and other program external expenses, reflecting our increased investment in our pipeline, including the progress in our PTV:PGRN and ATV:TREM2 programs as well our continued investment in developing a robust pipeline; </span></div><div style="margin-top:10pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Increases of $3.0 million and $3.7 million in EIF2B and ETV:IDS program external expenses, respectively, reflecting the progress of these programs in clinical trials during 2021; and</span></div><div style="margin-top:10pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">$0.4 million of increased other unallocated research and development expenses, which is primarily due to an increase in facilities-related expenses of $0.6 million including depreciation expense and certain costs associated with COVID-19 safety protocols and an increase in lab consumable expenses of $0.1 million, partially offset by a $0.3 million decrease in other general costs, primarily due to a decrease in travel related expenses attributable to our research and development departments due to the COVID-19 pandemic.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These increases were partially offset by a decrease of $7.2 million in the LRRK2 program external expenses primarily due to completion of the phase 1 and 1b trials of DNL151 (BIIB122), cost sharing reimbursements from Biogen of $2.5&#160;million, and a $1.9 million decrease in other external research and development expenses.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and administrative expenses. </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses were </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$18.9 million and $12.6 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three months ended March 31, 2021 and 2020, respectively.</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">increase</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$6.3 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was primarily attributable </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to the following:</span></div><div style="margin-top:10pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">$4.8 million of increased personnel-related expenses, driven by higher general and administrative headcount and stock-based compensation expense associated with additional equity award grants and our increasing market price;</span></div><div style="margin-top:10pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">$0.7 million of increased legal and other professional services expenses, primarily due to accounting and tax fees associated with assessment of the Biogen Collaboration Agreement;</span></div><div style="margin-top:10pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">$0.6 million of increased other general costs, including insurance, tax and IT related expenses; and</span></div><div style="margin-top:10pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">$0.2 million of increased facilities related expenses, including depreciation expense and certain costs associated with COVID-19 safety protocols.</span></div><div style="text-indent:27pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest and other income, net. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest and other income, net was $1.2 million and $3.1 million for the three months ended March 31, 2021 and 2020, respectively. The decrease of $1.9 million was primarily due to decreased interest income earned on our investments due to declining interest rates.</span></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income tax benefit. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax benefit was $0.1 million for the three months ended March 31, 2020 due to the tax benefit associated with an unrealized gain on marketable securities in other comprehensive income. There was no income tax benefit for the three months ended March 31, 2021. </span></div><div style="margin-bottom:10pt;margin-top:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">three months ended</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> March 31, 2020 and 2019</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to &#8220;Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8212;Results of Operations&#8221; in our Form 10-Q for the three months ended </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 31, 2020</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for a discussion of the results of operations for the three months ended </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 31, 2020 compared to the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three months ended March 31, 2019.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><div id="i5ae1cfc88aa4492caf56e9d4ac91e096_82"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5ae1cfc88aa4492caf56e9d4ac91e096_7">Table of Contents</a></span></div></div><div style="margin-top:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sources of Liquidity</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We fund our operations primarily with the proceeds from the sale of common stock in public offerings and payments received from our collaboration agreements with Takeda, Sanofi, and Biogen. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020, we sold 9.0 million shares of common stock (inclusive of shares sold pursuant to an overallotment option granted to the underwriters in connection with the offering) through an underwritten public offering at a price of $23.00 per share for aggregate net proceeds of approximately $193.9 million.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Takeda Collaboration Agreement, we have received $71.0 million related to upfront and milestone payments through </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 31, 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Further, under the associated Stock Purchase Agreement we received </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$110.0 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in February 2018 for the sale and issuance of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,214,559</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> shares of our common stock.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Sanofi Collaboration Agreement, </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we received an upfront payment of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$125.0 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in November 2018 and a milestone payment of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$10.0 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in August 2019, which was triggered by the commencement of a DNL758 (SAR443122) Phase 1 clinical trial in healthy volunteers. W</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e have received</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">further payments of $13.7 million for performance of Retained Activities through March 31, 2021.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the common stock purchase agreement between us and BIMA (the "Biogen Stock Purchase Agreement"), we received $465.0 million in September 2020 for the sale and issuance of 13,310,243 shares of our common stock. In October 2020, we received $560.0&#160;million from Biogen </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in upfront payments associated with the Biogen Collaboration Agreement. We have received cost sharing reimbursements of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$9.3 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> from Biogen </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">through March 31, 2021.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 31, 2021, we had cash, cash equivalents and marketable securities in the amount of $1.45 billion.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Future Funding Requirements</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have not generated any product revenue. We do not expect to generate any product revenue unless and until we obtain regulatory approval of and commercialize any of our product candidates, and we do not know when, or if, either will occur.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to continue to incur significant losses for the foreseeable future, and we expect the losses to increase as we expand our research and development activities and continue the development of, and seek regulatory approvals for, our product candidates, and begin to commercialize any approved products. Further, we expect general and administrative expenses to increase as we continue to incur additional costs associated with supporting our growing operations. We are subject to all of the risks typically related to the development of new product candidates, and we may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect our business. We anticipate that we will need substantial additional funding in connection with our continuing operations. </span></div><div style="text-indent:27pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5ae1cfc88aa4492caf56e9d4ac91e096_7">Table of Contents</a></span></div></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Until we can generate a sufficient amount of revenue from the commercialization of our product candidates or from our existing collaboration agreements, or future agreements with other third parties, if ever, we expect to finance our future cash needs through public or private equity or debt financings. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional capital may not be available on reasonable terms, if at all. If we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we may have to significantly delay, scale back or discontinue the development or commercialization of one or more of our product candidates. If we raise additional funds through the issuance of additional debt or equity securities, it could result in dilution to our existing stockholders, increased fixed payment obligations and the existence of securities with rights that may be senior to those of our common stock. If we incur indebtedness, we could become subject to covenants that would restrict our operations and potentially impair our competitiveness, such as limitations on our ability to incur additional debt, limitations on our ability to acquire, sell or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. Additionally, any future collaborations we enter into with third parties may provide capital in the near term but limit our potential cash flow and revenue in the future. Any of the foregoing could significantly harm our business, financial condition and prospects.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception, we have incurred significant losses and negative cash flows from operations. We have an accumulated deficit of $424.5 million through March 31, 2021. We expect to incur substantial additional losses in the future as we conduct and expand our research and development activities. We believe that our existing cash, cash equivalents and marketable securities will be sufficient to enable us to fund our projected operations through at least the 12 months following the filling date of this Form 10-Q. We have based this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we currently expect. Our future funding requirements will depend on many factors, including:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the timing and progress of preclinical and clinical development activities;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the number and scope of preclinical and clinical programs we decide to pursue;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the progress of the development efforts of third parties with whom we have entered into license and collaboration agreements;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">our ability to maintain our current research and development programs and to establish new research and development, license or collaboration arrangements;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">our ability and success in securing manufacturing relationships with third parties or in establishing and operating a manufacturing facility;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the costs involved in prosecuting, defending and enforcing patent claims and other intellectual property claims;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the cost and timing of regulatory approvals;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">our efforts to enhance operational, financial and information management systems and hire additional personnel, including personnel to support development of our product candidates; and</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the costs and ongoing investments to in-license and/or acquire additional technologies.</span></div><div style="padding-left:36pt;text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A change in the outcome of any of these or other variables with respect to the development of any of our product candidates could significantly change the costs and timing associated with the development of that product candidate. Furthermore, our operating plans may change in the future, and we may need additional funds to meet operational needs and capital requirements associated with such operating plans.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5ae1cfc88aa4492caf56e9d4ac91e096_7">Table of Contents</a></span></div></div><div style="margin-top:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows</span></div><div><span><br/></span></div><div style="margin-bottom:10pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth a summary of the primary sources and uses of cash for each of the periods presented below (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.534%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.536%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(50,240)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(54,492)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(25,405)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13,333)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,822&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">195,913&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net increase (decrease) in cash, cash equivalents and restricted cash</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(71,823)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">128,088&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Cash Used In Operating Activities </span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2021, cash used in operating activities was $50.2 million, which consisted of a net loss of $70.0 million, adjusted by non-cash items primarily related to stock-based compensation and depreciation, net amortization of discounts on marketable securities and non-cash rent expenses. Cash used in operating activities was also driven by changes in our operating assets and liabilities, including a decrease to Accruals and other current liabilities attributable to the payout of the bonus accrual in the three months ended March 31, 2021. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Cash Used In Investing Activities </span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2021, cash used in investing activities was $25.4 million, which consisted of $463.1 million of purchases of marketable securities and $2.8 million of capital expenditures to purchase property and equipment, partially offset by $440.5 million in proceeds from the maturity of marketable securities.</span></div><div style="margin-top:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Cash Provided By Financing Activities </span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2021, cash provided by financing activities was $3.8 million in proceeds from the exercise of options to purchase common stock.</span></div><div style="margin-top:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Discussion of the three months ended March 31, 2020</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to &#8220;Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8212;Liquidity and Capital Resources&#8221; in our Form 10-Q for the three months ended </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 31, 2020</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for a discussion of the cash flows for that period.</span></div><div id="i5ae1cfc88aa4492caf56e9d4ac91e096_85"></div><div style="margin-top:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Off-Balance Sheet Arrangements</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not entered into any off-balance sheet arrangements. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><div id="i5ae1cfc88aa4492caf56e9d4ac91e096_88"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5ae1cfc88aa4492caf56e9d4ac91e096_7">Table of Contents</a></span></div></div><div style="margin-top:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual Obligations and Commitments</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2018, we entered into an amendment to our operating lease for our former corporate headquarters in South San Francisco (the "Headquarters Lease Amendment") to relocate and expand our headquarters to 148,020 rentable square feet in a building in South San Francisco, California (the "New Premises"). The Headquarters Lease Amendment has a contractual term of ten years from the legal commencement date, which was April&#160;1, 2019 when the building was ready for occupancy. For accounting purposes, the lease commencement date was determined to be August&#160;1, 2018, which was the date at which we were deemed to have obtained control over the property. We have an option to extend the lease term for a period of ten years by giving the landlord written notice of the election to exercise the option at least nine months, but not more than twelve months, prior to the expiration of the Headquarters Lease Amendment lease term. We determined that this renewal was not reasonably certain at lease inception.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Headquarters Lease Amendment provides for monthly base rent amounts escalating over the term of the lease. In addition, the Headquarters Lease Amendment provided a tenant improvement allowance ("TIA") of up to $25.9 million, which was fully utilized, of which $4.4 million will be repaid to the landlord in the form of additional monthly rent. This is recorded as leasehold improvement assets and an offset to the lease ROU asset on the Consolidated Balance Sheets as of March 31, 2021 and December 31, 2020. We are also required to pay the operating expenses for the New Premises, such as taxes and insurance, which are treated as variable lease payments.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective September 2017, we entered into a Development and Manufacturing Services Agreement, as amended ("DMSA") with Lonza Sales AG ("Lonza") for the development and manufacture of biologic products. Under the DMSA, we will execute purchase orders based on project plans authorizing Lonza to provide development and manufacturing services with respect to certain of our antibody and enzyme products, and will pay for the services provided and batches delivered in accordance with the DMSA and project plan. Unless earlier terminated, the DMSA will expire on September&#160;6, 2022. </span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2021 and December 31, 2020, we had open purchase orders for biological product development and manufacturing costs totaling $33.4 million and $33.0 million, respectively. The activities under these purchase orders are expected to be completed by February 2028. As of March 31, 2021 and December 31, 2020, we had total non-refundable purchase commitments of $28.5 million and $27.1 million, respectively, under the DMSA.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2021 and 2020, we incurred costs of $5.2 million and $1.0&#160;million, and made payments of $0.7 million and $3.2 million, respectively, for the development and manufacturing services rendered under the DMSA. </span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than those detailed above, there have been no other material changes from the contractual obligations and commitments previously disclosed in our Annual Report on Form 10-K for the year ended December 31, 2020, as filed with the SEC on February&#160;26, 2021.</span></div><div id="i5ae1cfc88aa4492caf56e9d4ac91e096_91"></div><div style="margin-top:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Significant Judgments and Estimates</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This discussion and analysis of our financial condition and results of operations is based on our condensed consolidated financial statements, which have been prepared in accordance with </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. GAAP</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The preparation of these condensed consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, as well as the reported revenues recognized and expenses incurred during the reporting periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. </span></div><div style="text-indent:25pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5ae1cfc88aa4492caf56e9d4ac91e096_7">Table of Contents</a></span></div></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes to our critical accounting policies and estimates during the three months ended </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 31, 2021</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> from those described in &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; included in our Annual Report on Form 10-K for the year ended December 31, 2020, as filed with the SEC on </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;26, 2021</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div id="i5ae1cfc88aa4492caf56e9d4ac91e096_94"></div><div style="margin-top:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div><span><br/></span></div><div style="margin-bottom:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except as described in Note 1 to the Condensed Consolidated Financial Statements under the heading "Recently Adopted Accounting Pronouncement," there have been no new accounting pronouncements or changes to accounting pronouncements during the&#160;three months ended&#160;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 31, 2021</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as compared to the recent accounting pronouncements described in our&#160;Annual Report on Form 10-K for the year ended December 31, 2020, as filed with the SEC on February&#160;26, 2021, that are of significance or potential significance to us.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><div id="i5ae1cfc88aa4492caf56e9d4ac91e096_97"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:4pt"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5ae1cfc88aa4492caf56e9d4ac91e096_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3. &#160;&#160;&#160;&#160;QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK </span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to market risks in the ordinary course of our business, primarily related to interest rate and foreign currency sensitivities.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Interest Rate Sensitivity</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to market risk related to changes in interest rates. We had cash, cash equivalents and marketable securities of $1.45 billion as of March 31, 2021, which consisted primarily of money market funds and marketable securities, largely composed of investment grade, short to intermediate term fixed income securities.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The primary objective of our investment activities is to preserve capital to fund our operations. We also seek to maximize income from our investments without assuming significant risk. To achieve our objectives, we maintain a portfolio of investments in a variety of securities of high credit quality and short-term duration, according to our board-approved investment policy. Our investments are subject to interest rate risk and could fall in value if market interest rates increase. A hypothetical 10% relative change in interest rates during any of the periods presented would not have had a material impact on our condensed consolidated financial statements.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foreign Currency Sensitivity</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of our transactions occur in U.S. dollars. However, we do have certain transactions that are denominated in currencies other than the U.S. dollar, primarily the Euro and British Pound, and we therefore are subject to foreign exchange risk. The fluctuation in the value of the U.S. dollar against other currencies affects the reported amounts of expenses, assets and liabilities primarily associated with a limited number of preclinical, clinical and manufacturing activities. </span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We seek to mitigate the impact of changes in currency exchange rates on cash flows from certain foreign currency denominated operating expenses by entering into forward foreign currency exchange contracts. Generally, the market risks of these contracts are offset by the corresponding gains and losses on the transactions being hedged.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not use derivative financial instruments for speculative trading purposes, nor do we hedge foreign currency exchange rate exposure in a manner that entirely offsets the effects of changes in foreign currency exchange rates. The counterparties to these forward foreign currency exchange contracts are creditworthy multinational commercial banks, which minimizes the risk of counterparty nonperformance. We regularly review our hedging program and may, as part of this review, make changes to the program.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2021, we had open forward foreign currency exchange contracts with notional amounts of $6.5 million. A hypothetical 10% strengthening in foreign currency compared with the U.S. dollar at March 31, 2021 would have resulted in an increase in the value received over the remaining life of these contracts of approximately $0.7 million and, if realized, would positively affect earnings during the remaining life of the contracts. This analysis does not consider the impact of the hypothetical changes in foreign currency rates would have on the forecasted transactions that these foreign currency sensitive instruments were designated to offset.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><div id="i5ae1cfc88aa4492caf56e9d4ac91e096_100"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:4pt"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5ae1cfc88aa4492caf56e9d4ac91e096_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4. &#160;&#160;&#160;&#160;CONTROLS AND PROCEDURES</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 31, 2021</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, management, with the participation of our Chief Executive Officer and Chief Financial Officer, performed an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act. Our disclosure controls and procedures are designed to ensure that information required to be disclosed in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms, and that such information is accumulated and communicated to our management, including the Chief Executive Officer and the Chief Financial Officer, to allow timely decisions regarding required disclosures.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objective and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on this evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 31, 2021</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the design and operation of our disclosure controls and procedures were effective at a reasonable assurance level.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was no change in our internal control over financial reporting identified in connection with the evaluation required by Rule 13a-15(d) and 15d-15(d) of the Exchange Act that occurred during the quarter ended </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 31, 2021</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></div><div id="i5ae1cfc88aa4492caf56e9d4ac91e096_103"></div><div style="margin-top:18pt;text-align:center"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5ae1cfc88aa4492caf56e9d4ac91e096_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II. OTHER INFORMATION</span></div><div id="i5ae1cfc88aa4492caf56e9d4ac91e096_106"></div><div style="margin-bottom:10pt;margin-top:18pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;LEGAL PROCEEDINGS</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may become involved in litigation or other legal proceedings. We are not currently a party to any litigation or legal proceedings that, in the opinion of our management, are likely to have a material adverse effect on our business. Regardless of outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 10, 2020, we and all directors were named in a shareholder derivative action filed in the Delaware Court of Chancery challenging the compensation we paid to our directors since the IPO in December 2017. On January 13, 2021, the parties to the derivative action entered into a settlement agreement, the terms of which were disclosed in a Form 8-K filed on February 5, 2021. The settlement agreement was approved by the Court on April 16, 2021. Amounts owed by us pursuant to the settlement agreement are not material to us.</span></div><div id="i5ae1cfc88aa4492caf56e9d4ac91e096_109"></div><div style="margin-top:18pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1A. &#160;&#160;&#160;&#160;RISK FACTORS </span></div><div style="padding-left:72pt;text-indent:-72pt"><span><br/></span></div><div style="margin-bottom:10pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing in our common stock involves a high degree of risk. You should carefully consider the risks described below, as well as the other information in t</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">his Quarterly Report on Form 10-Q, incl</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">uding our financial statements and the related notes and the section titled &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.&#8221; The occurrence of any of the events or developments described below could harm our business, financial condition, results of operations and growth prospects. In such an event, the market price of our common stock could decline and you may lose all or part of your investment. Additional risks and uncertainties not presently known to us or that we currently deem immaterial also may impair our business operations and the market price of our common stock. The risk factors set forth below are substantially the same as the risk factors included in our Annual Report on Form 10-K filed with the Securities and Exchange Commission on February&#160;26, 2021.</span></div><div style="margin-bottom:10pt;text-indent:27pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><div id="i5ae1cfc88aa4492caf56e9d4ac91e096_1056"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:4pt"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5ae1cfc88aa4492caf56e9d4ac91e096_7">Table of Contents</a></span></div></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risk Factor Summary</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The summary of risks below provides an overview of the principal risks we are exposed to. These risks are described more fully in the section entitled &#8220;Risk Factors&#8221; in this Form 10-Q. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risks Related to Our Business, Financial Condition and Capital Requirements</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are in the early stages of clinical drug development and have a very limited operating history and no products approved for commercial sale.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have incurred significant net losses since our inception and anticipate that we will continue to incur net losses for the foreseeable future.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A pandemic, epidemic or outbreak of an infectious disease, such as COVID-19, or the perception of its effects, may materially and adversely affect our business, operations and financial condition.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Drug development is a highly uncertain undertaking. We have never generated any revenue from product sales, and may never do so.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Due to the significant resources required for the development of our programs, and depending on our ability to access capital, we must prioritize development of certain product candidates. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risks Related to the Discovery, Development and Commercialization of Our Product Candidates</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are heavily dependent on the successful development of our BBB technology and the programs currently in our pipeline, which are in the early stages of development. There&#8217;s no assurance that any of our product candidates will receive regulatory approval.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may not be successful in our efforts to continue to create a pipeline of product candidates or to develop commercially successful products.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have concentrated a substantial portion of our efforts on the treatment of neurodegenerative diseases, a field that has seen limited success in drug development. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may encounter substantial delays in our clinical trials, or may not be able to conduct or complete our clinical trials on the timelines we expect, if at all.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may encounter difficulties enrolling and/or retaining patients in our clinical trials, and our clinical development activities could thereby be delayed or otherwise adversely affected.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our clinical trials may fail to demonstrate evidence of the safety and efficacy of our product candidates, which would delay or limit the scope of regulatory approval and commercialization.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We face significant competition and there is a possibility that our competitors may achieve regulatory approval before us or develop therapies that are safer or more effective than ours.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The manufacture of our product candidates, particularly those that utilize our BBB platform technology, is complex and we may encounter difficulties in production. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we are unable to establish sales and marketing capabilities or enter into agreements with third parties, we may not be successful in commercializing product candidates if and when they are approved.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our product candidates.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risks Related to Regulatory Approval and Other Legal Compliance Matters</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The regulatory approval processes of the FDA, EMA and comparable foreign regulatory authorities are lengthy and inherently unpredictable. If we are ultimately unable to obtain regulatory approval for our product candidates, we will be unable to generate product revenue.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may in the future conduct clinical trials outside the United States, and the FDA, EMA and applicable foreign regulatory authorities may not accept data from such trials.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Healthcare legislative measures aimed at reducing healthcare costs may have a material adverse effect on our business and results of operations.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our business is subject to complex and evolving U.S. and foreign laws and regulations, information security policies and contractual obligations relating to privacy and data protection.</span></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risks Related to Our Reliance on Third Parties</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:4pt"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5ae1cfc88aa4492caf56e9d4ac91e096_7">Table of Contents</a></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We expect to depend on collaborations with third parties for the research, development and commercialization of certain product candidates. If any such collaborations are not successful, we may not be able to realize the market potential of those product candidates.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We expect to rely on third parties to conduct our clinical trials and some aspects of our research and preclinical testing, and those third parties may not perform satisfactorily.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We contract with third parties for the manufacture of materials for our research programs, preclinical studies and clinical trials. This reliance on third parties may increase the risk that we will not have sufficient quantities of such materials or product candidates.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We depend on third-party suppliers for key raw materials used in our manufacturing, and the loss of these suppliers or their inability to supply us with adequate materials could harm our business.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risks Related to Our Intellectual Property</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we are unable to obtain and maintain patent protection for our product candidates or our BBB technology, our competitors could develop and commercialize products or technology similar or identical to ours, and adversely affect our ability to commercialize any product candidates.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If any of our owned or in-licensed patent applications do not issue as patents in any jurisdiction, we may not be able to compete effectively.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our rights to develop and commercialize our BBB technology and product candidates are subject to the terms of licenses granted to us by others or licenses granted by us to others.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may not be able to protect our intellectual property throughout the world.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Changes in U.S. patent law could impair our ability to protect our products.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Issued patents covering our BBB technology, product candidates and other technologies could be found invalid or unenforceable if challenged.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may be subject to claims challenging the inventorship of our intellectual property.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we are unable to protect the confidentiality of our trade secrets, our business would be harmed.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may not be successful in obtaining, through acquisitions, in-licenses or otherwise, necessary rights to our BBB platform technology, product candidates or other technologies.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may be subject to claims that our employees, consultants, or advisors have wrongfully used or disclosed alleged trade secrets of their current or former employers.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Third party intellectual property claims against us, our licensors or our collaborators may delay the development our BBB platform technology, product candidates and other technologies.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risks Related to Our Operations</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we are not successful in attracting, motivating and retaining highly qualified personnel, we may not be able to successfully implement our business strategy.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have engaged in and may in the future engage in acquisitions or strategic partnerships, which may increase our capital requirements, dilute our stockholders, or cause us to incur debt or assume contingent liabilities.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our internal computer systems, or those used by our collaborators, CROs or other contractors, may fail or suffer security breaches that could compromise the confidentiality, integrity, and availability of such systems and data and expose us to liability.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our business is subject to risks associated with international operations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risks Related to Ownership of Our Common Stock</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The market price of our common stock has been and may continue to be volatile, which could result in substantial losses for investors.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If securities analysts do not publish research or reports about our business or if they publish negative evaluations of our stock, the price of our stock and trading volume could decline.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Raising additional capital may cause dilution to our existing stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Delaware law and provisions in our charter documents might prevent a change in control of our company or changes in our management, depressing the trading price of our common stock.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our amended and restated certificate of incorporation provides exclusive forums for disputes between us and our stockholders, limiting their ability to obtain a favorable judicial forum.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><div id="i5ae1cfc88aa4492caf56e9d4ac91e096_112"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:4pt"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5ae1cfc88aa4492caf56e9d4ac91e096_7">Table of Contents</a></span></div></div><div style="margin-top:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Business, Financial Condition and Capital Requirements</span></div><div style="margin-top:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are in the early stages of clinical drug development and have a very limited operating history and no products approved for commercial sale, which may make it difficult to evaluate our current business and predict our future success and viability.</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are an early clinical-stage biopharmaceutical company with a very limited operating history, focused on developing therapeutics for neurodegenerative diseases, including Alzheimer&#8217;s disease, Parkinson&#8217;s disease and ALS. We commenced operations in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">May 2015</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, have no products approved for commercial sale and have not generated any revenue from product sales. Drug development is a highly uncertain undertaking</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and involves a substantial degree of risk. We are in Phase 1, 1b or 1/2 clinical trials for our LRRK2, EIF2B, ETV:IDS and RIPK1 programs and have not initiated clinical trials for any of our other current product candidates. To date, we have not initiated or completed a pivotal clinical trial, obtained marketing approval for any product candidat</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">es, manufactured a commercial scale product, or arranged for a third party to do so on our behalf, or conducted sales and marketing activities necessary for successful product commercialization. Our short operating history as a company makes any assessment of our future success and viability subject to significant uncertainty. We will encounter risks and difficulties frequently experienced by early-stage biopharmaceutical companies in rapidly evolving fields, and we have not yet demonstrated an ability to successfully overcome such risks and difficulties. If we do not address these risks and difficulties successfully, our business will suffer.</span></div><div style="margin-top:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have incurred significant net losses since our inception and anticipate that we will continue to incur net losses for the foreseeable future.</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred significant net losses since our inception, including net losses of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$70.0 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$56.8 million for the three months ended </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 31, 2021 and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2020</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, respectively. As of March 31, 2021, we had an accumulated deficit of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$424.5 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have invested significant financial resources in research and development activities, including for our preclinical and clinical product candidates and our TV platform. We do not expect to generate revenue from product sales for several years, if at all. The amount of our future net losses will depend, in part, on the level of our future expenditures and revenue. Moreover, our net losses may fluctuate significantly from quarter to quarter and year to year, such that a period-to-period comparison of our results of operations may not be a good indication of our future performance.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to continue to incur significant expenses and increasingly higher operating losses for the foreseeable future. We anticipate that our expenses will increase substantially if and as we:</span></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">continue our research and discovery activities;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">progress our current and any future product candidates through preclinical and clinical development;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">initiate and conduct additional preclinical, clinical or other studies for our product candidates;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">work with our contract manufacturers to scale up the manufacturing processes for our product candidates or, in the future, establish and operate a manufacturing facility;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">change or add additional contract manufacturers or suppliers;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">seek regulatory approvals and marketing authorizations for our product candidates;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">establish sales, marketing and distribution infrastructure to commercialize any products for which we obtain approval;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">acquire or in-license product candidates, intellectual property and technologies;</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:4pt"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5ae1cfc88aa4492caf56e9d4ac91e096_7">Table of Contents</a></span></div></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">make milestone, royalty or other payments due under any license or collaboration agreements;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">obtain, maintain, protect and enforce our intellectual property portfolio, including intellectual property obtained through license agreements;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">attract, hire and retain qualified personnel;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">provide additional internal infrastructure to support our continued research and development operations and any planned commercialization efforts in the future;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">experience any delays or encounter other issues related to our operations;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">meet the requirements and demands of being a public company; and</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">defend against any product liability claims or other lawsuits related to our products.</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our prior losses and expected future losses have had and will continue to have an adverse effect on our stockholders&#8217; equity and working capital. In any particular quarter or quarters, our operating results could be below the expectations of securities analysts or investors, which could cause our stock price to decline.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">A pandemic, epidemic or outbreak of an infectious disease, such as COVID-19, or the perception of its effects, may materially and adversely affect our business, operations and financial condition.</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Public health outbreaks, such as epidemics or pandemics involving infectious or contagious diseases, such as COVID-19, may significantly disrupt our business. Such outbreaks pose the risk that we or our employees, contractors, suppliers, and other partners may be prevented from conducting business activities for an indefinite period of time due to the spread of the disease, due to shutdowns that may be requested or mandated by federal, state and local governmental authorities or certain employers, or due to the economic consequences associated with the pandemic. Business disruptions could include disruptions or restrictions on our ability to travel, as well as temporary closures of our facilities and the facilities of our partners, clinical trial sites, service providers, suppliers or contract manufacturers. While it is not possible at this time to estimate the overall impact that the COVID-19 pandemic could have on our business, the continued rapid spread of COVID-19, both across the United States and throughout much of the world, and the measures taken by the governments of countries and local authorities affected has disrupted and could delay the initiation of new clinical trials, the progress of our ongoing clinical trials, and could disrupt and delay our preclinical activities, and potentially the manufacture or shipment of both drug substance and finished drug product of our product candidates for preclinical testing and clinical trials and adversely impact our business, financial condition or operating results.</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, as a result of the COVID-19 pandemic the state of California, where our corporate offices are located, has issued orders limiting activities to varying levels, including at the most restrictive level, an order for all residents to remain at home, except for the performance of essential activities, which include biomedical research. We have implemented policies that enable some of our employees to work remotely, and such policies may continue for an indefinite period. We have also implemented various safety protocols for all on-site personnel, including regular, mandatory COVID-19 testing procedures and compliance measures for social distancing and use of personal protective equipment. Our priority is to protect the health and safety of our employees, community, partners and clinical trial participants, while working to ensure the sustainability of our business operations as this unprecedented situation continues to evolve. We continue to evaluate the impact COVID-19 may have on our ability to effectively conduct our business operations as planned, and work with healthcare providers supporting our clinical studies to mitigate risk to patients while taking into account regulatory, institutional, and government guidance and policies, but there can be no assurance that we will be able to avoid part or all of any impact from the spread of COVID-19 or its consequences. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:4pt"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5ae1cfc88aa4492caf56e9d4ac91e096_7">Table of Contents</a></span></div></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the COVID-19 pandemic continues to spread around the globe, we have experienced and may continue to experience disruptions that could severely impact our business, preclinical programs and clinical trials, including:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays or difficulties in enrolling patients in our clinical trials, particularly elderly subjects, who are at a higher risk of severe illness or death from COVID-19, which can be further complicated by the presence of comorbidities that are often present in subjects with neurodegenerative diseases;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">difficulties interpreting data from our clinical trials due to the possible effects of COVID-19 on subjects enrolled in our clinical trials that contract COVID-19;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays or difficulties in clinical site initiation, including difficulties in recruiting clinical site investigators and clinical site staff;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">diversion of healthcare resources away from the conduct of clinical trials, including the diversion of hospitals serving as our clinical trial sites and hospital staff supporting the conduct of clinical trials;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">interruption of key clinical trial activities, such as clinical trial site monitoring, due to limitations on travel imposed or recommended by federal or state governments, employers and others; limitations in resources that would otherwise be focused on the conduct of our business or our clinical trials, including because of sickness or the desire to avoid contact with large groups of people or as a result of government-imposed &#8220;shelter in place&#8221; or similar working restrictions;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in receiving approval from local regulatory authorities to initiate our planned clinical trials;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">interruption of, or delays in receiving, supplies of our product candidates from our contract manufacturing organizations due to staffing shortages, production slowdowns or stoppages and disruptions in delivery systems, as well as delays in clinical sites receiving the supplies and materials needed to conduct our clinical trials;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays or difficulties in furthering our preclinical and clinical programs, due to interruptions or limitations in our third party service providers&#8217; business operations;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">interruption in global shipping that may affect the transport of clinical trial materials, such as investigational drug product used in our clinical trials;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in clinical trial site procedures and requirements as well as regulatory requirements for conducting clinical trials during the COVID-19 pandemic which may require us to change the ways in which our clinical trials are conducted, implement additional procedures and policies, or to discontinue the clinical trials altogether, or which may result in unexpected costs and delays;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays or interruptions in the operations of or necessary interactions with the U.S. Food and Drug Administration ("FDA") or other regulators, ethics committees and other important agencies and contractors due to limitations in employee resources or forced furlough of government or contractor personnel, which may impact review and approval timelines and result in unexpected costs and delays; </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">refusal of the FDA to accept data from clinical trials in affected geographies outside the United States; </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limitations on employee resources that would otherwise be focused on the conduct of our nonclinical studies and clinical trials, either because of sickness of employees and their families or the desire of employees to avoid contact with large groups of people; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">negative impact on our ability to raise capital.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:4pt"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5ae1cfc88aa4492caf56e9d4ac91e096_7">Table of Contents</a></span></div></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have clinical trial sites for our clinical studies in the United States and Europe, certain of which have been affected by the COVID-19 pandemic due to prioritization of hospital resources toward the COVID-19 outbreak, travel or quarantine restrictions imposed by federal, state or local governments, and the inability to access sites for initiation and patient monitoring and enrollment. Healthcare facilities and offices may be required to focus limited resources on non-clinical trial matters, including treatment of COVID-19 patients, and may not be available, in whole or in part, for clinical trial services related to our clinical trials. As a result, patient screening, new patient enrollment, monitoring and data collection may be affected. We experienced a pause in enrollment in our DNL151 (BIIB122) Phase 1 and Phase 1b trials, our DNL343 Phase 1 trial, and our ETV:IDS program observational biomarker study. In all cases, recruitment resumed within several months. However, further pauses or delays could occur depending on the progression of the pandemic. The completion of ongoing trials could be delayed as a result. </span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may be required to develop and implement additional clinical trial policies and procedures designed to help protect subjects from the COVID-19 virus. For example, in March 2020, the FDA issued a guidance, which the FDA subsequently updated, on conducting clinical trials during the pandemic, which describes a number of considerations for sponsors of clinical trials impacted by the pandemic, including the requirement to include in the clinical trial report contingency measures implemented to manage the clinical trial, and any disruption of the clinical trial as a result of the COVID-19 pandemic; a list of all subjects affected by the COVID-19-pandemic related study disruption by unique subject identifier and by investigational site and a description of how the individual&#8217;s participation was altered; and analyses and corresponding discussions that address the impact of implemented contingency measures (e.g., participant discontinuation from investigational product and/or study, alternative procedures used to collect critical safety and/or efficacy data) on the safety and efficacy results reported for the clinical trial. In June 2020, FDA also issued a guidance on good manufacturing practice considerations for responding to COVID-19 infection in employees in drug and biologic products manufacturing, including recommendations for manufacturing controls to prevent contamination of the products.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some third-party manufacturers that supply us materials for product candidates or other materials necessary to manufacture product to conduct preclinical tests and clinical trials are located in countries affected by COVID-19, and we may experience delays in advancing these tests and trials, if our third-party manufacturers experience disruptions such as temporary closures or suspension of services. The spread of an infectious disease, including COVID-19, may also result in the inability of our suppliers to deliver components or raw materials on a timely basis or at all. Currently, we do not expect delays to our clinical trials due to manufacturing or supply-chain issues, and we believe we have sufficient drug supplies to complete ongoing trials as well as additional drug substance supplies expected to be sufficient to support planned clinical trials well into 2021. Furthermore, the spread of the virus may affect the operations of key governmental agencies, such as the FDA, which may delay the development of our product candidates. Such events may result in a period of business disruption, and in reduced operations, or doctors and medical providers may be unwilling to participate in our clinical trials, any of which could materially affect our business, operations and financial condition.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic continues to rapidly evolve. The extent to which COVID-19 impacts our business will depend on future developments, which are highly uncertain and cannot be predicted, such as the ultimate geographic spread of the disease, the duration of the pandemic, travel restrictions and social distancing in the United States and other countries, business closures or business disruptions and the effectiveness of actions taken in the United States and other countries to contain and treat the disease and to address its impact, including on financial markets or otherwise. While the extent of the impact of the COVID-19 pandemic on our business and financial results is uncertain, a continued and prolonged public health crisis could have a material negative impact on our business, operations and financial condition.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent the COVID-19 pandemic adversely affects our business, operations and financial condition, it may also have the effect of heightening many of the risks described in this &#8220;Risk Factors&#8221; section.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:4pt"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5ae1cfc88aa4492caf56e9d4ac91e096_7">Table of Contents</a></span></div></div><div style="margin-top:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Drug development is a highly uncertain undertaking and involves a substantial degree of risk. We have never generated any revenue from product sales, and we may never generate product revenue or be profitable.</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have no products approved for commercial sale and have not generated any revenue from product sales. To obtain revenue from the sales of our product candidates that are significant or large enough to achieve pr</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ofitability, we must succeed, either alone or with third parties, in developing, obtaining regulatory approval for, manufacturing and marketing therapies with significant commercial success.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to generate revenue and achieve profitability depends significantly on many factors, including:</span></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">successfully completing research and preclinical and clinical development of our product candidates;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">obtaining regulatory approvals and marketing authorizations for product candidates for which we successfully complete clinical development and clinical trials;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">developing a sustainable and scalable manufacturing process for our product candidates, including those that utilize our TV platform, as well as establishing and maintaining commercially viable supply relationships with third parties that can provide adequate products and services to support clinical activities and commercial demand of our product candidates;</span></div><div style="padding-left:24.75pt;padding-right:24.75pt;text-align:center;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">identifying, assessing, acquiring and/or developing new product candidates;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">negotiating favorable terms in any collaboration, licensing or other arrangements into which we may enter;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">launching and successfully commercializing product candidates for which we obtain regulatory and marketing approval, either by collaborating with a partner or, if launched independently, by establishing a sales, marketing and distribution infrastructure;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">obtaining and maintaining an adequate price for our product candidates, both in the United States and in foreign countries where our products are commercialized;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">obtaining adequate reimbursement for our product candidates from payors;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">obtaining market acceptance of our product candidates as viable treatment options;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">addressing any competing technological and market developments;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">maintaining, protecting, expanding and enforcing our portfolio of intellectual property rights, including patents, trade secrets and know-how; and</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">attracting, hiring and retaining qualified personnel.</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the numerous risks and uncertainties associated with drug development, we are unable to predict the timing or amount of our expenses, or when we will be able to generate any meaningful revenue or achieve or maintain profitability, if ever. In addition, our expenses could increase beyond our current expectations if we are required by the FDA, or foreign regulatory agencies, to perform studies in addition to those that we currently anticipate, or if there are any delays in any of our or our future collaborators&#8217; clinical trials or the development of any of our product candidates. Even if one or more of our product candidates is approved for commercial sale, we anticipate incurring significant costs associated with commercializing any approved product candidate and ongoing compliance efforts.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:4pt"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5ae1cfc88aa4492caf56e9d4ac91e096_7">Table of Contents</a></span></div></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we are able to generate revenue from the sale of any approved products, we may not become profitable and may need to obtain additional funding to continue operations. Revenue from the sale of any product candidate for which regulatory approval is obtained will be dependent, in part, upon the size of the markets in the territories for which we gain regulatory approval, the accepted price for the product, the ability to get reimbursement at any price and whether we own the commercial rights for that territory. If the number of addressable patients is not as significant as we anticipate, the indication approved by regulatory authorities is narrower than we expect, or the reasonably accepted population for treatment is narrowed by competition, physician choice or treatment guidelines, we may not generate significant revenue from sales of such products, even if approved. Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our failure to become and remain profitable would decrease the value of our company and could impair our ability to raise capital, expand our business, maintain our research and development efforts, diversify our pipeline of product candidates or continue our operations and cause a decline in the value of our common stock, all or any of which may adversely affect our viability.</span></div><div style="margin-top:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to obtain additional financing, we may be unable to complete the development and, if approved, commercialization of our product candidates.</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations have required substantial amounts of cash since inception. We currently fund our operations primarily with </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the proceeds from our follow-on offering completed in January 2020, and payments received from our Takeda Collaboration Agreement, Sanofi Collaboration Agreement and Biogen Collaboration Agreement. We currently have five clinical-stage programs, DNL151 (BIIB122), DNL343, DNL310, DNL758 (SAR443122) and DNL788 (SAR443820), and have several other product candidates in preclinical development, as well as early-stage research projects. Developing our product candidates is expensive, and we expect to continue to spend substa</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ntial amounts as we fund our early-stage research projects, and continue to advance our programs through preclinical and clinical development. Even if we are successful in developing our product candidates, obtaining regulatory approvals and launching and commercializing any product candidate will require substantial additional funding.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2021, we had $1.45&#160;billion in cash, cash equivalents and marketable securities. We believe that our existing cash, cash equivalents and marketable securities will be sufficient to fund our projected operations through at least the next 12 months. Our estimate as to how long we expect our existing cash, cash equivalents and marketable securities to be available to fund our operations is based on assumptions that may be proved inaccurate, and we could use our available capital resources sooner than we currently expect. In addition, changing circumstances may cause us to increase our spending significantly faster than we currently anticipate, and we may need to spend more money than currently expected because of circumstances beyond our control. We may need to raise additional funds sooner than we anticipate if we choose to expand more rapidly than we presently anticipate.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will require additional capital for the further development and, if approved, commercialization of our product candidates. Additional capital may not be available when we need it, on terms acceptable to us or at all. We have no committed source of additional capital. If adequate capital is not available to us on a timely basis, we may be required to significantly delay, scale back or discontinue our research and development programs or the commercialization of any product candidates, if approved, or be unable to continue or expand our operations or otherwise capitalize on our business opportunities, as desired, which could materially affect our business, financial condition, results of operations, growth prospects and cause the price of our common stock to decline.</span></div><div style="margin-top:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Due to the significant resources required for the development of our programs, and depending on our ability to access capital, we must prioritize development of certain product candidates. Moreover, we may expend our limited resources on programs that do not yield a successful product candidate and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.</span></div><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:4pt"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5ae1cfc88aa4492caf56e9d4ac91e096_7">Table of Contents</a></span></div></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a diversified portfolio</span><span style="background-color:#ffffff;color:#ee2724;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">with more than fifteen programs. These programs require significant capital investment. Our programs are at various stages of research, discovery, preclinical and early clinical development. We seek to maintain a process of prioritization and resource allocation to maintain an optimal balance between aggressively advancing lead programs and ensuring replenishment of our portfolio. We regularly review the programs in our portfolio, and terminate those programs which do not meet our development criteria, which we have done a number of times in the past. </span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the significant resources required for the development of our programs, we must focus our programs on specific diseases and disease pathways and decide which product candidates to pursue and advance and the amount of resources to allocate to each. Our decisions concerning the allocation of research, development, collaboration, management and financial resources toward particular product candidates or therapeutic areas may not lead to the development of any viable commercial product and may divert resources away from better opportunities. Similarly, our potential decisions to delay, terminate or collaborate with third parties in respect of certain programs may subsequently also prove to be suboptimal and could cause us to miss valuable opportunities. If we make incorrect determinations regarding the viability or market potential of any of our programs or product candidates or misread trends in the biopharmaceutical industry, in particular for neurodegenerative diseases, our business, financial condition, results of operations and growth prospects could be materially adversely affected. As a result, we may fail to capitalize on viable commercial products or profitable market opportunities, be required to forego or delay pursuit of opportunities with other product candidates or other diseases and disease pathways that may later prove to have greater commercial potential than those we choose to pursue, or relinquish valuable rights to such product candidates through collaboration, licensing or other royalty arrangements in cases in which it would have been advantageous for us to invest additional resources to retain sole development and commercialization rights.</span></div><div id="i5ae1cfc88aa4492caf56e9d4ac91e096_115"></div><div style="margin-top:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to the Discovery, Development and Commercialization of Our Product Candidates</span></div><div style="margin-top:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and development of biopharmaceutical products is inherently risky.&#160;We are heavily dependent on the successful development of our BBB platform technology and the programs currently in our pipeline, which are in the early stages of preclinical and clinical development. We cannot give any assurance that any of our product candidates will receive regulatory, including marketing approval, which is necessary before they can be commercialized.</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are at an early stage of development of the product candidates currently in our programs and are further developing our BBB platform technology. To date, we have invested substantially all of our efforts and financial resources to identify, acquire intellectual property for, and develop our BBB platform technology and our programs, including conducting preclinical studies and early-stage clinical trials, and providing general and administrative support for these operations. Our future success is dependent on our ability to successfully develop, obtain regulatory approval for, and then successfully commercialize our product candidates, and we may fail to do so for many reasons, including the following:</span></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">our product candidates may not successfully complete preclinical studies or clinical trials;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">our drug delivery platform technology designed to deliver large molecule therapeutics across the BBB may not be clinically viable;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">a product candidate may on further study be shown to have harmful side effects or other characteristics that indicate it is unlikely to be effective or otherwise does not meet applicable regulatory criteria;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">our competitors may develop therapeutics that render our product candidates obsolete or less attractive;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">our competitors may develop platform technologies to deliver large molecule therapeutics across the BBB that render our platform technology obsolete or less attractive;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:4pt"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5ae1cfc88aa4492caf56e9d4ac91e096_7">Table of Contents</a></span></div></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the product candidates and BBB platform technology that we develop may not be sufficiently covered by intellectual property for which we hold exclusive rights;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the product candidates and BBB platform technology that we develop may be covered by third parties&#8217; patents or other intellectual property or exclusive rights;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the market for a product candidate may change so that the continued development of that product candidate is no longer reasonable or commercially attractive;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">a product candidate may not be capable of being produced in commercial quantities at an acceptable cost, or at all;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">if a product candidate obtains regulatory approval, we may be unable to establish sales and marketing capabilities, or successfully market such approved product candidate, to gain market acceptance; and</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">a product candidate may not be accepted as safe and effective by patients, the medical community or third-party payors, if applicable.</span></div><div style="padding-left:36pt;text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of these events occur, we may be forced to abandon our development efforts for a program or programs, which would have a material adverse effect on our business and could potentially cause us to cease operations.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not be successful in our efforts to further develop our BBB platform technology and current product candidates. We are not permitted to market or promote any of our product candidates before we receive regulatory approval from the FDA or comparable foreign regulatory authorities, and we may never receive such regulatory approval for any of our product candidates. Each of our product candidates is in the early stages of development and will require significant additional clinical development, management of preclinical, clinical, and manufacturing activities, regulatory approval, adequate manufacturing supply, a commercial organization, and significant marketing efforts before we generate any revenue from product sales, if at all.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have never completed a clinical development program. We have previously discontinued the development of certain molecules prior to completion of preclinical development because we did not believe they </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">met our criteria for potential clinical success. None of our product candidates have advanced into late-stage development or a pivotal clinical trial and it may be years before any such trial is initiated, if at all. Further, we canno</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">t be certain that any of our product candidates will be successful in clinical trials. For instance, in 2016, we initiated a Phase 1 clinical trial in a former RIPK1 inhibitor product candidate, DNL104, which we subsequently discontinued based on liver test abnormalities in some clinical trial healthy volunteer participants. Further, in June 2020, together with our collaboration partner Sanofi, we paused clinical activities with DNL747 to accelerate development of DNL788 (SAR443820), in part due to DNL747 preclinical chronic toxicity studies. We may in the future advance product candidates into clinical trials and terminate such trials prior to their completion.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:4pt"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5ae1cfc88aa4492caf56e9d4ac91e096_7">Table of Contents</a></span></div></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of our product candidates successfully complete clinical trials, we generally plan to seek regulatory approval to market our product candidates in the United States, the European Union ("EU"), and in additional foreign countries where we believe there is a viable commercial opportunity. We have never commenced, compiled or submitted an application seeking regulatory approval to market any product candidate. We may never receive regulatory approval to market any product candidates even if such product candidates successfully complete clinical trials, which would adversely affect our viability. To obtain regulatory approval in countries outside the United States, we must comply with numerous and varying regulatory requirements of such other countries regarding safety, efficacy or potency, purity, chemistry, manufacturing and controls, clinical trials, commercial sales, pricing, and distribution of our product candidates. We may also rely on our collaborators or partners to conduct the required activities to support an application for regulatory approval, and to seek approval, for one or more of our product candidates. We cannot be sure that our collaborators or partners will conduct these activities or do so within the time frame we desire. Even if we (or our collaborators or partners) are successful in obtaining approval in one jurisdiction, we cannot ensure that we will obtain approval in any other jurisdictions. If we are unable to obtain approval for our product candidates in multiple jurisdictions, our revenue, business, financial condition, results of operations and growth prospects could be negatively affected.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we receive regulatory approval to market any of our product candidates, whether for the treatment of neurodegenerative diseases or other diseases, we cannot assure you that any such product candidate will be successfully commercialized, widely accepted in the marketplace or more effective than other commercially available alternatives.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investment in biopharmaceutical product development involves significant risk that any product candidate will fail to demonstrate adequate efficacy or potency, or an acceptable safety profile, gain regulatory approval, and become commercially viable. We cannot provide any assurance that we will be able to successfully advance any of our product candidates through the development process or, if approved, successfully commercialize any of our product candidates.</span></div><div style="margin-top:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be successful in our efforts to continue to create a pipeline of product candidates or to develop commercially successful products. If we fail to successfully identify and develop additional product candidates, our commercial opportunity may be limited.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">One of our strategies is to identify and pursue clinical development of additional product candidates. We curren</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">tly have several programs </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the research, discovery and preclinical stages of development. Identifying, developing, obtaining regulatory approval and commercializing additional product candidates for the treatment of neurodegenerative diseases will require substantial additional funding and is prone to the risks of failure inherent in drug development. We cannot provide you any assurance that we will be able to successfully identify or acquire additional product candidates, advance any of these additional product candidates through the development process, successfully commercialize any such additional product candidates, if approved, or assemble sufficient resources to identify, acquire, develop or, if approved, commercialize additional product candidates. If we are unable to successfully identify, acquire, develop and commercialize additional product candidates, our commercial opportunity may be limited.</span></div><div style="margin-top:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have concentrated a substantial portion of our research and development efforts on the treatment of neurodegenerative diseases, a field that has seen limited success in drug development. Further, our product candidates are based on new approaches and novel technology, which makes it difficult to predict the time and cost of product candidate development and subsequently obtaining regulatory approval.</span></div><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:4pt"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5ae1cfc88aa4492caf56e9d4ac91e096_7">Table of Contents</a></span></div></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have focused our research and development efforts on addressing neurodegenerative diseases. Collectively, efforts by biopharmaceutical companies in the field of neurodegenerative diseases have seen limited success in drug development. There are few effective therapeutic options available for patients with Alzheimer&#8217;s disease, Parkinson&#8217;s disease, ALS and other neurodegenerative diseases. Our future success is highly dependent on the successful development of our BBB platform technology and our product candidates for treating neurodegenerative diseases. Developing and, if approved, commercializing our product candidates for treatment of neurodegenerative diseases subjects us to a number of challenges, including engineering product candidates to cross the BBB to enable optimal concentration of the therapeutic in the brain and obtaining regulatory approval from the FDA and other regulatory authorities who have only a limited set of precedents to rely on.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our approach to the treatment of neurodegenerative diseases aims to identify and select targets with a genetic link to neurodegenerative diseases, identify and develop molecules that engage the intended target, identify and develop biomarkers, which are biological molecules found in blood, other bodily fluids or tissues that are signs of a normal or abnormal process or of a condition or disease, to select the right patient population and demonstrate target engagement, pathway engagement and impact on disease progression of our molecules, and engineer our molecules to cross the BBB and act directly in the brain. This strategy may not prove to be successful. We may not be able to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">discover, develop and utilize biomarkers to demonstrate target engagement, pathway engagement and the impact on disease progression of our molecules. </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot be sure that our approach will yield satisfactory therapeutic products that are safe and effective, scalable, or profitable. Moreover, public perception of drug safety issues, including adoption of new therapeutics or novel approaches to treatment, may adversely influence the willingness of subjects to participate in clinical trials, or if approved, of physicians to subscribe to novel treatments.</span></div><div style="margin-top:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may encounter substantial delays in our clinical trials, or may not be able to conduct or complete our clinical trials on the timelines we expect, if at all.</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical testing is expensive, time consuming, and subject to uncertainty. We cannot guarantee that any clinical trials will be conducted as planned or completed on schedule, if at all. We cannot be sure that submission of an investigational new drug application ("IND"), or a clinical trial application ("CTA"), will result in the FDA or European Medicines Agency ("EMA"), as applicable, allowing clinical trials to begin in a timely manner, if at all. Moreover, even if these trials begin, issues may arise that could suspend or terminate such clinical trials. A failure of one or more clinical trials can occur at any stage of testing, and our future clinical trials may not be successful. Events that may prevent successful or timely initiation or completion of clinical trials include:</span></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">inability to generate sufficient preclinical, toxicology, or other&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;or&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;data to support the initiation or continuation of clinical trials;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">delays in confirming target engagement, patient selection or other relevant biomarkers to be utilized in preclinical and clinical product candidate development;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">delays in reaching a consensus with regulatory agencies on trial design;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">delays in reaching agreement on acceptable terms with prospective CROs and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and clinical trial sites;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">delays in identifying, recruiting and training suitable clinical investigators;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">delays in obtaining required Institutional Review Board ("IRB") approval at each clinical trial site;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:4pt"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5ae1cfc88aa4492caf56e9d4ac91e096_7">Table of Contents</a></span></div></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">imposition of a temporary or permanent clinical hold by regulatory agencies for a number of reasons, including after review of an IND or amendment, CTA or amendment, or equivalent application or amendment; as a result of a new safety finding that presents unreasonable risk to clinical trial participants; a negative finding from an inspection of our clinical trial operations or trial sites; developments on trials conducted by competitors for related technology that raises FDA or EMA concerns about risk to patients of the technology broadly; or if the FDA or EMA finds that the investigational protocol or plan is clearly deficient to meet its stated objectives;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">delays in identifying, recruiting and enrolling suitable patients to participate in our clinical trials, and delays caused by patients withdrawing from clinical trials or failing to return for post-treatment follow-up;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">difficulty collaborating with patient groups and investigators;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">failure by our CROs, other third parties, or us to adhere to clinical trial requirements;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">failure to perform in accordance with the FDA&#8217;s or any other regulatory authority&#8217;s current good clinical practices ("cGCPs") requirements, or applicable EMA or other regulatory guidelines in other countries;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">occurrence of adverse events associated with the product candidate that are viewed to outweigh its potential benefits;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">changes in regulatory requirements and guidance that require amending or submitting new clinical protocols;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">changes in the standard of care on which a clinical development plan was based, which may require new or additional trials;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the cost of clinical trials of our product candidates being greater than we anticipate;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">clinical trials of our product candidates producing negative or inconclusive results, which may result in our deciding, or regulators requiring us, to conduct additional clinical trials or abandon product development programs;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">transfer of manufacturing processes from our academic collaborators to larger-scale facilities operated by a CDMO or by us, and delays or failure by our CDMOs or us to make any necessary changes to such manufacturing process; </span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">delays in manufacturing, testing, releasing, validating, or importing/exporting sufficient stable quantities of our product candidates for use in clinical trials or the inability to do any of the foregoing; and</span></div><div style="padding-left:13.5pt;text-indent:4.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">delays associated with the COVID-19 global pandemic.</span></div><div style="padding-left:36pt;text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any inability to successfully initiate or complete clinical trials could result in additional costs to us or impair our ability to generate revenue. In addition, if we make manufacturing or formulation changes to our product candidates, we may be required to or we may elect to conduct additional studies to bridge our modified product candidates to earlier versions. Clinical trial delays could also shorten any periods during which our products have patent protection and may allow our competitors to bring products to market before we do, which could impair our ability to successfully commercialize our product candidates and may harm our business and results of operations.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:4pt"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5ae1cfc88aa4492caf56e9d4ac91e096_7">Table of Contents</a></span></div></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We could also encounter delays if a clinical trial is suspended or terminated by us, by the data safety monitoring board for such trial or by the FDA, EMA or any other regulatory authority, or if the IRBs of the institutions in which such trials are being conducted suspend or terminate the participation of their clinical investigators and sites subject to their review. Such authorities may suspend or terminate a clinical trial due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA, EMA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a product candidate, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DNL201, a former LRRK2 inhibitor product candidate, completed a Phase 1b clinical trial in Parkinson's disease patients with and without the genetic LRRK2 mutation. This program was previously subject to a partial clinical hold due to preclinical toxicity data. The partial clinical hold was removed in December 2017 based on additional clinical and preclinical data provided to the FDA. In our completed Phase 1b clinical trial of DNL201 in patients with Parkinson&#8217;s disease, there was one SAE considered unrelated to drug, and at the high dose, there was one severe AE (headache) leading to dose reduction and one study withdrawal (headache and nausea). Our clinical-stage product candidates are DNL151 (BIIB122) for Parkinson's disease, DNL343 for ALS and FTD, DNL310 for Hunter syndrome, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DNL758 (SAR443122) for system inflammatory diseases and DNL788 (SAR443820) for neurological diseases</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In the nonclinical safety studies for these product candidates, toxicities were observed at high doses in rat and/or cynomolgus monkey above doses and exposures that will be tested in the clinic. We cannot assure you that DNL151 (BIIB122), DNL343, DNL310, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DNL758 (SAR443122) and DNL788 (SAR443820), </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or our other product candidates will not be subject to new, partial or full clinical holds in the future.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may in the future advance product candidates into clinical trials and terminate such trials prior to their completion, such as we did for DNL104, which could adversely affect our business. Further, after the commencement of clinical trials, we may pause the advancement of lead molecules in favor of a backup molecule with a superior safety or efficacy profile, such as we did in our RIPK1 program, switching our focus from DNL747 to DNL788 (SAR443820).</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Delays in the completion of any clinical trial of our product candidates will increase our costs, slow down our product candidate development and approval process and delay or potentially jeopardize our ability to commence product sales and generate revenue. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates.</span></div><div style="margin-top:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may encounter difficulties enrolling and/or retaining patients in our clinical trials, and our clinical development activities could thereby be delayed or otherwise adversely affected.</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The timely completion of clinical trials in accordance with their protocols depends, among other things, on our ability to enroll a sufficient number of patients who remain in the trial until its conclusion. We may experience difficulties in patient enrollment and retention in our clinical trials for a variety of reasons, including:</span></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">inability or delay in enrollment of patients due to a variety of reasons, including outbreaks and public health crises, such as the COVID-19 global pandemic;</span></div><div style="padding-left:13.5pt;text-indent:4.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the size and nature of the patient population;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the patient eligibility criteria defined in the protocol, including biomarker-driven identification and/or certain highly-specific criteria related to stage of disease progression, which may limit the patient populations eligible for our clinical trials to a greater extent than competing clinical trials for the same indication that do not have biomarker-driven patient eligibility criteria;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the size of the study population required for analysis of the trial&#8217;s primary endpoints;</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:4pt"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5ae1cfc88aa4492caf56e9d4ac91e096_7">Table of Contents</a></span></div></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the proximity of patients to a trial site;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the design of the trial;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">our ability to recruit clinical trial investigators with the appropriate competencies and experience;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">competing clinical trials for similar therapies or targeting patient populations meeting our patient eligibility criteria;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">clinicians&#8217; and patients&#8217; perceptions as to the potential advantages and side effects of the product candidate being studied in relation to other available therapies and product candidates;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">our ability to obtain and maintain patient consents; and</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the risk that patients enrolled in clinical trials will not complete such trials, for any reason, including the risk of higher drop-out rates if participants become infected with the COVID-19 virus or other infectious diseases that impact their participation in our trials.</span></div><div style="padding-left:13.5pt;text-indent:4.5pt"><span><br/></span></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our inability to enroll and retain a sufficient number of patients for our clinical trials would result in significant delays or may require us to abandon one or more clinical trials altogether. Enrollment delays in our clinical trials may result in increased development costs for our product candidates and jeopardize our ability to obtain marketing approval for the sale of our product candidates. Furthermore, even if we are able to enroll a sufficient number of patients for our clinical trials, we may have difficulty maintaining participation in our clinical trials through the treatment and any follow-up periods, which could delay or negatively impact the anticipated readouts from our clinical trials, delay our regulatory submissions, and increase the costs of the clinical trials.</span></div><div style="margin-top:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our clinical trials may reveal significant adverse events, toxicities, or other side effects and may fail to demonstrate substantial evidence of the safety and efficacy or potency of our product candidates, which would prevent, delay or limit the scope of regulatory approval and commercialization.</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before obtaining regulatory approvals for the commercial sale of any of our product candidates, we must demonstrate through lengthy, complex and expensive preclinical studies and clinical trials that our product candidates are both safe and effective for use in each target indication. For those product candidates that are subject to regulation as biological drug products, we will need to demonstrate that they are safe, pure, and potent for use in their target indications. Each product candidate must demonstrate an adequate risk versus benefit profile in its intended patient population and for its intended use.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:4pt"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5ae1cfc88aa4492caf56e9d4ac91e096_7">Table of Contents</a></span></div></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical trial process. The results of preclinical studies of our product candidates may not be predictive of the results of early-stage or later-stage clinical trials, and results of early clinical trials of our product candidates may not be predictive of the results of later-stage clinical trials. The results of clinical trials in one set of patients or disease indications may not be predictive of those obtained in another. In some instances, there can be significant variability in safety or efficacy or potency results between different clinical trials of the same product candidate due to numerous factors, including changes in trial procedures set forth in protocols, differences in the size and type of the patient populations, changes in and adherence to the dosing regimen and other clinical trial protocols and the rate of dropout among clinical trial participants. Open-label extension studies may also extend the timing and increase the cost of clinical development substantially. Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy or potency profile despite having progressed through preclinical studies and initial clinical trials. A number of companies in the biopharmaceutical industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy or potency or unacceptable safety issues, notwithstanding promising results in earlier trials. This is particularly true in neurodegenerative diseases, where failure rates historically have been higher than in many other disease areas. Most product candidates that begin clinical trials are never approved by regulatory authorities for commercialization.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have limited experience in designing clinical trials and may be unable to design and execute a clinical trial to support marketing approval. We cannot be certain that our current clinical trials or any other future clinical trials will be successful. Additionally, any safety concerns observed in any one of our clinical trials in our targeted indications could limit the prospects for regulatory approval of our product candidates in those and other indications, which could have a material adverse effect on our business, financial condition, results of operations and growth prospects.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, even if such clinical trials are successfully completed, we cannot guarantee that the FDA or foreign regulatory authorities will interpret the results as we do, or that the product candidates will be approved for the currently proposed indications, and more trials could be required before we submit our product candidates for approval. To the extent that the results of the trials are not satisfactory to the FDA or foreign regulatory authorities for support of a marketing application, we may be required to expend significant resources, which may not be available to us, to conduct additional trials in support of potential approval of our product candidates. Even if regulatory approval is secured for any of our product candidates, the terms of such approval, such as requiring us to narrow our indications to smaller subset of patient population, may limit the scope and use of our product candidate, which may also limit its commercial potential.</span></div><div style="margin-top:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interim, topline and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available, and are subject to audit and verification procedures that could result in material changes in the final data.</span></div><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:4pt"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5ae1cfc88aa4492caf56e9d4ac91e096_7">Table of Contents</a></span></div></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may publicly disclose preliminary, interim or topline data from our nonclinical studies and clinical trials. These interim updates are based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the particular study or trial. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the topline results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Topline data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, topline data should be viewed with caution until the final data are available. In addition, we may report interim analyses of only certain endpoints rather than all endpoints. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Adverse changes between interim data and final data could significantly harm our business and prospects. Further, additional disclosure of interim data by us or by our competitors in the future could result in volatility in the price of our common stock.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate and our company in general. In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is typically selected from a more extensive amount of available information. You or others may not agree with what we determine is the material or otherwise appropriate information to include in our disclosure, and any information we determine not to disclose may ultimately be deemed significant with respect to future decisions, conclusions, views, activities or otherwise regarding a particular product candidate or our business. If the preliminary or topline data that we report differ from late, final or actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize our product candidates may be harmed, which could harm our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:18pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face significant competition in an environment of rapid technological and scientific change, and there is a possibility that our competitors may achieve regulatory approval before us or develop therapies that are safer, more advanced or more effective than ours, which may negatively impact our ability to successfully market or commercialize any product candidates we may develop and ultimately harm our financial condition.</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The development and commercialization of new drug products is highly competitive. Moreover, the neurodegenerative field is characterized by strong and increasing competition, and a strong emphasis on intellectual property. We may face competition with respect to any product candidates that we seek to develop or commercialize in the future from major pharmaceutical companies, specialty pharmaceutical companies, and biotechnology companies worldwide. Potential competitors also include academic institutions, government agencies, and other public and private research organizations that conduct research, seek patent protection, and establish collaborative arrangements for research, development, manufacturing, and commercialization.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are a number of large pharmaceutical and biotechnology companies that are currently pursuing the development of products for the treatment of the neurodegenerative disease indications for which we have research programs, including Alzheimer&#8217;s disease, Parkinson&#8217;s disease and ALS. Companies that we are aware are developing therapeutics in the neurodegenerative disease area include companies with significant financial resources, such as AbbVie, Alector, AstraZeneca, Biogen, Bristol-Myers Squibb, Eli Lilly, E-Scape Bio, GlaxoSmithKline, Ionis, JCR Pharmaceuticals, Johnson&#160;&amp; Johnson, Novartis, Prevail Therapeutics, Roche, Sanofi and Takeda. In addition to competition from other companies targeting neurodegenerative indications, any products we may develop may also face competition from other types of therapies, such as gene-editing therapies.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:4pt"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5ae1cfc88aa4492caf56e9d4ac91e096_7">Table of Contents</a></span></div></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our current or potential competitors, either alone or with their strategic partners, have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals, and marketing approved products than we do. Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient, or are less expensive than any products that we may develop. Furthermore, currently approved products could be discovered to have application for treatment of neurodegenerative disease indications, which could give such products significant regulatory and market timing advantages over any of our product candidates. Our competitors also may obtain FDA, EMA or other regulatory approval for their products more rapidly than we may obtain approval for ours and may obtain orphan product exclusivity from the FDA for indications our product candidates are targeting, which could result in our competitors establishing a strong market position before we are able to enter the market. Additionally, products or technologies developed by our competitors may render our potential product candidates uneconomical or obsolete, and we may not be successful in marketing any product candidates we may develop against competitors.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we could face litigation or other proceedings with respect to the scope, ownership, validity and/or enforceability of our patents relating to our competitors&#8217; products and our competitors may allege that our products infringe, misappropriate or otherwise violate their intellectual property. The availability of our competitors&#8217; products could limit the demand, and the price we are able to charge, for any products that we may develop and commercialize. See &#8220;Risks Related to Our Intellectual Property.&#8221;</span></div><div style="margin-top:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The manufacture of our product candidates, particularly those that utilize our BBB platform technology, is complex and we may encounter difficulties in production. If we or any of our third-party manufacturers encounter such difficulties, or fail to meet rigorously enforced regulatory standards, our ability to provide supply of our product candidates for clinical trials or our products for patients, if approved, could be delayed or stopped, or we may be unable to maintain a commercially viable cost structure.</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The processes involved in manufacturing our drug and biological product candidates, particularly those that utilize our BBB platform technology, are complex, expensive, highly regulated and subject to multiple risks. Additionally, the manufacture of biologics involves complex processes, including developing cells or cell systems to produce the biologic, growing large quantities of such cells, and harvesting and purifying the biologic produced by them. As a result, the cost to manufacture a biologic is generally far higher than traditional small molecule chemical compounds, and the biologics manufacturing process is less reliable and is difficult to reproduce. Manufacturing biologics is highly susceptible to product loss due to contamination, equipment failure, improper installation or operation of equipment, vendor or operator error, inconsistency in yields, variability in product characteristics and difficulties in scaling the production process. Even minor deviations from normal manufacturing processes could result in reduced production yields, product defects and other supply disruptions. Further, as product candidates are developed through preclinical studies to late-stage clinical trials towards approval and commercialization, it is common that various aspects of the development program, such as manufacturing methods, are altered along the way in an effort to optimize processes and results. Such changes carry the risk that they will not achieve these intended objectives, and any of these changes could cause our product candidates to perform differently and affect the results of planned clinical trials or other future clinical trials.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:4pt"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5ae1cfc88aa4492caf56e9d4ac91e096_7">Table of Contents</a></span></div></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to conduct clinical trials of our product candidates, or supply commercial products, if approved, we will need to manufacture them in small and large quantities. Our manufacturing partners may be unable to successfully increase the manufacturing capacity for any of our product candidates in a timely or cost-effective manner, or at all. In addition, quality issues may arise during scale-up activities. If our manufacturing partners are unable to successfully scale up the manufacture of our product candidates in sufficient quality and quantity, the development, testing and clinical trials of that product candidate may be delayed or become infeasible, and regulatory approval or commercial launch of any resulting product may be delayed or not obtained, which could significantly harm our business. The same risks would apply to our internal manufacturing facilities and capabilities, which we are actively working towards building. In addition, building internal manufacturing capacity carries significant risks in terms of being able to plan, design and execute on a complex project to build manufacturing facilities in a timely and cost-efficient manner, and our efforts to scale our internal manufacturing capabilities may not succeed.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the manufacturing process, including any material modifications in the manufacturing process for any products that we may develop is subject to FDA, EMA and foreign regulatory authority approval processes, and continuous oversight, and we will need to contract with manufacturers who can meet all applicable FDA, EMA and foreign regulatory authority requirements, including complying with current good manufacturing practices ("cGMPs"), on an ongoing basis. If we or our third-party manufacturers are unable to reliably produce products to specifications acceptable to the FDA, EMA or other regulatory authorities, we may not obtain or maintain the approvals we need to commercialize such products. Even if we obtain regulatory approval for any of our product candidates, there is no assurance that either we or our CDMOs will be able to manufacture the approved product to specifications acceptable to the FDA, EMA or other regulatory authorities, to produce it in sufficient quantities to meet the requirements for the potential launch of the product, or to meet potential future demand. Any of these challenges could delay completion of clinical trials, require bridging clinical trials or the repetition of one or more clinical trials, increase clinical trial costs, delay approval of our product candidate, impair commercialization efforts, increase our cost of goods, and have an adverse effect on our business, financial condition, results of operations and growth prospects.</span></div><div style="margin-top:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If, in the future, we are unable to establish sales and marketing capabilities or enter into agreements with third parties to sell and market any product candidates we may develop, we may not be successful in commercializing those product candidates if and when they are approved.</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have a sales or marketing infrastructure and have no experience in the sale, marketing, or distribution of pharmaceutical products. To achieve commercial success for any approved product for which we retain sales and marketing responsibilities, we must either develop a sales and marketing organization or outsource these functions to third parties. In the future, we may choose to build a focused sales, marketing, and commercial support infrastructure to sell, or participate in sales activities with our collaborators for, some of our product candidates if and when they are approved.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are risks involved with both establishing our own commercial capabilities and entering into arrangements with third parties to perform these services. For example, recruiting and training a sales force or reimbursement specialists is expensive and time consuming and could delay any product launch. If the commercial launch of a product candidate for which we recruit a sales force and establish marketing and other commercialization capabilities is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses. This may be costly, and our investment would be lost if we cannot retain or reposition our commercialization personnel.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Factors that may inhibit our efforts to commercialize any approved product on our own include:</span></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">our inability to recruit and retain adequate numbers of effective sales, marketing, reimbursement, customer service, medical affairs, and other support personnel;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the inability of sales personnel to obtain access to physicians or persuade adequate numbers of physicians to prescribe any future approved products;</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:4pt"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5ae1cfc88aa4492caf56e9d4ac91e096_7">Table of Contents</a></span></div></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the inability of reimbursement professionals to negotiate arrangements for formulary access, reimbursement, and other acceptance by payors;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the inability to price our products at a sufficient price point to ensure an adequate and attractive level of profitability;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">restricted or closed distribution channels that make it difficult to distribute our products to segments of the patient population;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the lack of complementary products to be offered by sales personnel, which may put us at a competitive disadvantage relative to companies with more extensive product lines; and</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">unforeseen costs and expenses associated with creating an independent commercialization organization.</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we enter into arrangements with third parties to perform sales, marketing, commercial support, and distribution services, our product revenue or the profitability of product revenue may be lower than if we were to market and sell any products we may develop ourselves. In addition, we may not be successful in entering into arrangements with third parties to commercialize our product candidates or may be unable to do so on terms that are favorable to us. We may have little control over such third parties, and any of them may fail to devote the necessary resources and attention to sell and market our products effectively. If we do not establish commercialization capabilities successfully, either on our own or in collaboration with third parties, we will not be successful in commercializing our product candidates if approved.</span></div><div style="margin-top:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if any product candidates we develop receive marketing approval, they may fail to achieve the degree of market acceptance by physicians, patients, healthcare payors, and others in the medical community necessary for commercial success.</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The commercial success of any of our product candidates will depend upon its degree of market acceptance by physicians, patients, third-party payors, and others in the medical community. Even if any product candidates we may develop receive marketing approval, they may nonetheless fail to gain sufficient market acceptance by physicians, patients, healthcare payors, and others in the medical community. The degree of market acceptance of any product candidates we may develop, if approved for commercial sale, will depend on a number of factors, including:</span></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the efficacy or potency and safety of such product candidates as demonstrated in pivotal clinical trials and published in peer-reviewed journals;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the potential and perceived advantages compared to alternative treatments;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the ability to offer our products for sale at competitive prices;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the ability to offer appropriate patient access programs, such as co-pay assistance;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the extent to which physicians recommend our products to their patients;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">convenience and ease of dosing and administration compared to alternative treatments;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the clinical indications for which the product candidate is approved by FDA, EMA or other regulatory agencies;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">product labeling or product insert requirements of the FDA, EMA or other comparable foreign regulatory authorities, including any limitations, contraindications or warnings contained in a product&#8217;s approved labeling;</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:4pt"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5ae1cfc88aa4492caf56e9d4ac91e096_7">Table of Contents</a></span></div></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">restrictions on how the product is distributed;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the timing of market introduction of competitive products;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">publicity concerning our products or competing products and treatments;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the strength of marketing and distribution support;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">sufficient third-party coverage or reimbursement; and</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the prevalence and severity of any side effects.</span></div><div style="padding-left:36pt;text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any product candidates we develop do not achieve an adequate level of acceptance, we may not generate significant product revenue, and we may not become profitable.</span></div><div style="margin-top:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if we are able to commercialize any product candidates, such products may become subject to unfavorable pricing regulations, third-party reimbursement practices, or healthcare reform initiatives, which would harm our business.</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The regulations that govern marketing approvals, pricing, and reimbursement for new drugs vary widely from country to country. In the United States, recently enacted legislation may significantly change the approval requirements in ways that could involve additional costs and cause delays in obtaining approvals. Some countries require approval of the sale price of a drug before it can be marketed. In many countries, the pricing review period begins after marketing or product licensing approval is granted. In some foreign markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. As a result, we might obtain marketing approval for a product in a particular country, but then be subject to price regulations that delay our commercial launch of the product, possibly for lengthy time periods, and negatively impact the revenue we are able to generate from the sale of the product in that country. Adverse pricing limitations may hinder our ability to recoup our investment in one or more product candidates, even if any product candidates we may develop obtain marketing approval.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:4pt"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5ae1cfc88aa4492caf56e9d4ac91e096_7">Table of Contents</a></span></div></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to successfully commercialize any products that we may develop also will depend in part on the extent to which reimbursement for these products and related treatments will be available from government health administration authorities, private health insurers, and other organizations. Government authorities and third-party payors, such as private health insurers and health maintenance organizations, decide which medications they will pay for and establish reimbursement levels. A primary trend in the U.S. healthcare industry and elsewhere is cost containment. Government authorities and third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. Government authorities currently impose mandatory discounts for certain patient groups, such as Medicare, Medicaid and Veterans Affairs ("VA"), hospitals, and may seek to increase such discounts at any time. Future regulation may negatively impact the price of our products, if approved. Increasingly, third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products. We cannot be sure that reimbursement will be available for any product candidate that we commercialize and, if reimbursement is available, the level of reimbursement. Reimbursement may impact the demand for, or the price of, any product candidate for which we obtain marketing approval. In order to get reimbursement, physicians may need to show that patients have superior treatment outcomes with our products compared to standard of care drugs, including lower-priced generic versions of standard of care drugs. If reimbursement is not available or is available only to limited levels, we may not be able to successfully commercialize any product candidate for which we obtain marketing approval. In the United States, no uniform policy of coverage and reimbursement for products exists among third-party payors and coverage and reimbursement levels for products can differ significantly from payor to payor. As a result, the coverage determination process is often a time consuming and costly process that may require us to provide scientific and clinical support for the use of our products to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There may be significant delays in obtaining reimbursement for newly approved drugs, and coverage may be more limited than the purposes for which the medicine is approved by the FDA, EMA or other comparable foreign regulatory authorities. Moreover, eligibility for reimbursement does not imply that any drug will be paid for in all cases or at a rate that covers our costs, including research, development, manufacture, sale, and distribution. Interim reimbursement levels for new drugs, if applicable, may also not be sufficient to cover our costs and may not be made permanent. Reimbursement rates may vary according to the use of the drug and the clinical setting in which it is used, may be based on reimbursement levels already set for lower cost drugs and may be incorporated into existing payments for other services. Net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement policies. Our inability to promptly obtain coverage and profitable payment rates from both government-funded and private payors for any approved products we may develop could have a material adverse effect on our operating results, our ability to raise capital needed to commercialize product candidates, and our overall financial condition.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:4pt"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5ae1cfc88aa4492caf56e9d4ac91e096_7">Table of Contents</a></span></div></div><div style="margin-top:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If any of our small molecule product candidates obtain regulatory approval, additional competitors could enter the market with generic versions of such drugs, which may result in a material decline in sales of affected products.</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Drug Price Competition and Patent Term Restoration Act of 1984 (the "Hatch-Waxman Act"), a pharmaceutical manufacturer may file an abbreviated new drug application ("ANDA") seeking approval of a generic copy of an approved, small molecule innovator product. Under the Hatch-Waxman Act, a manufacturer may also submit a new drug application ("NDA") under section&#160;505(b)(2) that references the FDA&#8217;s prior approval of the small molecule innovator product. A 505(b)(2) NDA product may be for a new or improved version of the original innovator product. The Hatch-Waxman Act also provides for certain periods of regulatory exclusivity, which preclude FDA approval (or in some circumstances, FDA filing and reviewing) of an ANDA or 505(b)(2) NDA. These include, subject to certain exceptions, the period during which an FDA-approved drug is subject to orphan drug exclusivity. In addition to the benefits of regulatory exclusivity, an innovator NDA holder may have patents claiming the active ingredient, product formulation or an approved use of the drug, which would be listed with the product in the FDA publication, &#8220;Approved Drug Products with Therapeutic Equivalence Evaluations,&#8221; known as the &#8220;Orange Book.&#8221; If there are patents listed in the Orange Book, a generic or 505(b)(2) applicant that seeks to market its product before expiration of the patents must include in the ANDA a &#8220;Paragraph IV certification,&#8221; challenging the validity or enforceability of, or claiming non-infringement of, the listed patent or patents. Notice of the certification must be given to the innovator, too, and if within 45 days of receiving notice the innovator sues to protect its patents, approval of the ANDA is stayed for 30 months, or as lengthened or shortened by the court.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accordingly, if any of our small molecule product candidates are approved, competitors could file ANDAs for generic versions of our small molecule drug products or 505(b)(2) NDAs that reference our small molecule drug products, respectively. If there are patents listed for our small molecule drug products in the Orange Book, those ANDAs and 505(b)(2) NDAs would be required to include a certification as to each listed patent indicating whether the ANDA applicant does or does not intend to challenge the patent. We cannot predict which, if any, patents in our current portfolio or patents we may obtain in the future will be eligible for listing in the Orange Book, how any generic competitor would address such patents, whether we would sue on any such patents, or the outcome of any such suit.</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not be successful in securing or maintaining proprietary patent protection for products and technologies we develop or license. Moreover, if any of our owned or in-licensed patents that are listed in the Orange Book are successfully challenged by way of a Paragraph IV certification and subsequent litigation, the affected product could immediately face generic competition and its sales would likely decline rapidly and materially. Should sales decline, we may have to write off a portion or all of the intangible assets associated with the affected product and our results of operations and cash flows could be materially and adversely affected. See &#8220;Risks Related to Our Intellectual Property.&#8221;</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:4pt"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5ae1cfc88aa4492caf56e9d4ac91e096_7">Table of Contents</a></span></div></div><div style="margin-top:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our biologic, or large molecule, product candidates for which we intend to seek approval may face competition sooner than anticipated.</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we are successful in achieving regulatory approval to commercialize a product candidate faster than our competitors, our large molecule product candidates may face competition from biosimilar products. In the United States, our large molecule product candidates are regulated by the FDA as biologic products and we intend to seek approval for these product candidates pursuant to the biologics license application ("BLA"), pathway. The Biologics Price Competition and Innovation Act of 2009 (the "BPCIA"), created an abbreviated pathway for the approval of biosimilar and interchangeable biologic products. The abbreviated regulatory pathway establishes legal authority for the FDA to review and approve biosimilar biologics, including the possible designation of a biosimilar as &#8220;interchangeable&#8221; based on its similarity to an existing brand product. Under the BPCIA, an application for a biosimilar product cannot be approved by the FDA until 12 years after the original branded product was approved under a BLA. The law is complex and is still being interpreted and implemented by the FDA. As a result, its ultimate impact, implementation, and meaning are subject to uncertainty. While it is uncertain when such processes intended to implement BPCIA may be fully adopted by the FDA, any such processes could have a material adverse effect on the future commercial prospects for our large molecule product candidates.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that any of our large molecule product candidates approved as a biologic product under a BLA should qualify for the 12-year period of exclusivity. However, there is a risk that this exclusivity could be shortened due to congressional action or otherwise, or that the FDA will not consider our product candidates to be reference products for competing products, potentially creating the opportunity for generic competition sooner than anticipated. Moreover, the extent to which a biosimilar product, once approved, will be substituted for any one of our reference products in a way that is similar to traditional generic substitution for non-biologic products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing. In addition, a competitor could decide to forego the biosimilar approval path and submit a full BLA after completing its own preclinical studies and clinical trials. In such cases, any exclusivity to which we may be eligible under the BPCIA would not prevent the competitor from marketing its product as soon as it is approved.</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In Europe, the European Commission has granted marketing authorizations for several biosimilar products pursuant to a set of general and product class-specific guidelines for biosimilar approvals issued over the past few years. In Europe, a competitor may reference data supporting approval of an innovative biological product, but will not be able to get it on the market until 10 years after the time of approval of the innovative product. This 10-year marketing exclusivity period will be extended to 11 years if, during the first eight of those 10 years, the marketing authorization holder obtains an approval for one or more new therapeutic indications that bring significant clinical benefits compared with existing therapies. In addition, companies may be developing biosimilar products in other countries that could compete with our products, if approved.</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If competitors are able to obtain marketing approval for biosimilars referencing our large molecule product candidates, if approved, such products may become subject to competition from such biosimilars, with the attendant competitive pressure and potential adverse consequences. Such competitive products may be able to immediately compete with us in each indication for which our product candidates may have received approval.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:4pt"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5ae1cfc88aa4492caf56e9d4ac91e096_7">Table of Contents</a></span></div></div><div style="margin-top:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our product candidates.</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face an inherent risk of product liability as a result of the clinical testing of our product candidates and will face an even greater risk when and if we commercialize any products. For example, we may be sued if our product candidates cause or are perceived to cause injury or are found to be otherwise unsuitable during clinical testing, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability or a breach of warranties. Claims could also be asserted under state consumer protection acts. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit testing and commercialization of our product candidates. Even successful defense would require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in:</span></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">decreased or interrupted demand for our products;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">injury to our reputation;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">withdrawal of clinical trial participants and inability to continue clinical trials;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">initiation of investigations by regulators;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">costs to defend the related litigation;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">a diversion of management&#8217;s time and our resources;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">substantial monetary awards to trial participants or patients;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">product recalls, withdrawals or labeling, marketing or promotional restrictions;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">loss of revenue;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">exhaustion of any available insurance and our capital resources;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the inability to commercialize any product candidate; and</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">a decline in our share price.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our inability to obtain sufficient product liability insurance at an acceptable cost to protect against potential product liability claims could prevent or inhibit the commercialization of products we develop, alone or with collaborators. Our insurance policies may have various exclusions, and we may be subject to a product liability claim for which we have no coverage. We may have to pay any amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts. Even if our agreements with any future corporate collaborators entitle us to indemnification against losses, such indemnification may not be available or adequate should any claim arise.</span></div><div id="i5ae1cfc88aa4492caf56e9d4ac91e096_118"></div><div style="margin-top:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Regulatory Approval and Other Legal Compliance Matters</span></div><div style="margin-top:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The regulatory approval processes of the FDA, EMA and comparable foreign regulatory authorities are lengthy, time consuming, and inherently unpredictable. If we are ultimately unable to obtain regulatory approval for our product candidates, we will be unable to generate product revenue and our business will be substantially harmed.</span></div><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:4pt"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5ae1cfc88aa4492caf56e9d4ac91e096_7">Table of Contents</a></span></div></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The time required to obtain approval by the FDA, EMA and comparable foreign regulatory authorities is unpredictable, typically takes many years following the commencement of clinical trials, and depends upon numerous factors, including the type, complexity and novelty of the product candidates involved. In addition, approval policies, regulations, or the type and amount of clinical data necessary to gain approval may change during the course of a product candidate&#8217;s clinical development and may vary among jurisdictions, which may cause delays in the approval or the decision not to approve an application. Regulatory authorities have substantial discretion in the approval process and may refuse to accept any application or may decide that our data are insufficient for approval and require additional preclinical, clinical or other studies. Moreover, the FDA, EMA or other regulatory authorities may fail to approve companion diagnostics that we contemplate using with our therapeutic product candidates. We have not submitted for, or obtained regulatory approval for any product candidate, and it is possible that none of our existing product candidates or any product candidates we may seek to develop in the future will ever obtain regulatory approval.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Applications for our product candidates could fail to receive regulatory approval in an initial or subsequent indication for many reasons, including but not limited to the following:</span></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the FDA, EMA or comparable foreign regulatory authorities may disagree with the design, implementation or results of our clinical trials;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the FDA, EMA or comparable foreign regulatory authorities may determine that our product candidates are not safe and effective, only moderately effective or have undesirable or unintended side effects, toxicities or other characteristics that preclude our obtaining marketing approval or prevent or limit commercial use;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the population studied in the clinical program may not be sufficiently broad or representative to assure efficacy or potency and safety in the full population for which we seek approval;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">we may be unable to demonstrate to the FDA or comparable foreign regulatory authorities that a product candidate&#8217;s risk-benefit ratio when compared to the standard of care is acceptable;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the FDA, EMA or comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the data collected from clinical trials of our product candidates may not be sufficient to support the submission of an NDA, BLA, or other submission or to obtain regulatory approval in the United States or elsewhere;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">we may be unable to demonstrate to the FDA, EMA or comparable foreign regulatory authorities that a product candidate&#8217;s risk-benefit ratio for its proposed indication is acceptable;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the FDA, EMA or comparable foreign regulatory authorities may fail to approve the manufacturing processes, test procedures and specifications, or facilities of third-party manufacturers with which we contract for clinical and commercial supplies; and</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the approval policies or regulations of the FDA, EMA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval.</span></div><div style="padding-left:36pt;text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This lengthy approval process, as well as the unpredictability of the results of clinical trials, may result in our failing to obtain regulatory approval to market any of our product candidates, which would significantly harm our business, results of operations, and prospects.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:4pt"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5ae1cfc88aa4492caf56e9d4ac91e096_7">Table of Contents</a></span></div></div><div style="margin-top:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our product candidates may cause undesirable side effects or have other properties that could halt their clinical development, prevent their regulatory approval, limit their commercial potential, or result in significant negative consequences.</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adverse events or other undesirable side effects caused by our product candidates could cause us or regulatory authorities to interrupt, delay, or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA, EMA or other comparable foreign regulatory authorities.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our most advanced product candidates, DNL151 (BIIB122), DNL343, DNL310, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DNL758 (SAR443122) and DNL788 (SAR443820)</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are currently our only clinical stage product candidates. In our completed Phase 1b clinical trial of former product candidate DNL201 in patients with Parkinson&#8217;s disease, there was one SAE considered unrelated to drug, and at the high dose, there was one severe AE (headache) leading to dose reduction and one study withdrawal (headache and nausea).</span><span style="background-color:#ffffff;color:#ee2724;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adverse events and other side effects may result from higher dosing, repeated dosing and/or longer-term exposure to DNL151 (BIIB122), DNL343 and/or DNL310 and could lead to delays and/or termination of the development of these product candidates.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2016, we initiated a Phase 1 clinical trial in a former RIPK1 inhibitor product candidate, DNL104, which we subsequently discontinued based on liver function test abnormalities in some clinical trial healthy volunteer participants. In 2020, we paused clinical studies with DNL747 in our RIPK1 program. Chronic toxicity studies with DNL747 in cynomolgus monkeys showed dose- and duration-dependent adverse preclinical findings at exposures higher than those tested in the clinic. These findings, which are considered off-target and molecule-specific, may impact the ability to increase the dose of DNL747 and achieve higher levels of target inhibition without time consuming additional clinical safety studies in patients to evaluate the long-term safety and tolerability.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drug-related side effects could affect patient recruitment, the ability of enrolled patients to complete the trial, and/or result in potential product liability claims. We are required to maintain product liability insurance pursuant to certain of our license agreements. We may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to liability. A successful product liability claim or series of claims brought against us could cause our stock price to decline and, if judgments exceed our insurance coverage, could adversely affect our results of operations and business. In addition, regardless of merit or eventual outcome, product liability claims may result in impairment of our business reputation, withdrawal of clinical trial participants, costs due to related litigation, distraction of management&#8217;s attention from our primary business, initiation of investigations by regulators, substantial monetary awards to patients or other claimants, the inability to commercialize our product candidates, and decreased demand for our product candidates, if approved for commercial sale.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, if one or more of our product candidates receives marketing approval, and we or others later identify undesirable side effects or adverse events caused by such products, a number of potentially significant negative consequences could result, including but not limited to:</span></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">regulatory authorities may withdraw approvals of such product and cause us to recall our product;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">regulatory authorities may require additional warnings on the label;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">we may be required to change the way the product is administered or conduct additional clinical trials or post-approval studies;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">we may be required to create a Risk Evaluation and Mitigation Strategy plan, which could include a medication guide outlining the risks of such side effects for distribution to patients, a communication plan for healthcare providers, and/or other elements, such as boxed warning on the packaging, to assure safe use;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we could be sued and held liable for harm caused to patients; and</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:4pt"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5ae1cfc88aa4492caf56e9d4ac91e096_7">Table of Contents</a></span></div></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">our reputation may suffer.</span></div><div style="padding-left:36pt;text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of these events could prevent us from achieving or maintaining market acceptance of the particular product candidate, if approved, and could significantly harm our business, financial condition, results of operations, and growth prospects. We cannot predict whether our product candidates will cause toxicities in humans that would preclude or lead to the revocation of regulatory approval based on nonclinical studies or early-stage clinical trials.</span></div><div style="margin-top:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may in the future conduct clinical trials for our product candidates outside the United&#160;States, and the FDA, EMA and applicable foreign regulatory authorities may not accept data from such trials.</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may in the future choose to conduct one or more of our clinical trials outside the United States, including in Europe. The acceptance of data from clinical trials conducted outside the United States or another jurisdiction by the FDA, EMA or applicable foreign regulatory authority may be subject to certain conditions. In cases where data from foreign clinical trials are intended to serve as the basis for marketing approval in the United States, the FDA will generally not approve the application on the basis of foreign data alone unless (i)&#160;the data are applicable to the United States population and United States medical practice; and (ii)&#160;the trials were performed by clinical investigators of recognized competence and pursuant to cGCP regulations. Additionally, the FDA&#8217;s clinical trial requirements, including sufficient size of patient populations and statistical powering, must be met. Many foreign regulatory bodies have similar approval requirements. In addition, such foreign trials would be subject to the applicable local laws of the foreign jurisdictions where the trials are conducted. There can be no assurance that the FDA, EMA or any applicable foreign regulatory authority will accept data from trials conducted outside of the United States or the applicable jurisdiction. If the FDA, EMA or any applicable foreign regulatory authority does not accept such data, it would result in the need for additional trials, which would be costly and time-consuming and delay aspects of our business plan, and which may result in our product candidates not receiving approval or clearance for commercialization in the applicable jurisdiction.</span></div><div style="margin-top:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of our product candidates in other jurisdictions.</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not guarantee that we will be able to obtain or maintain regulatory approval in any other jurisdiction, but a failure or delay in obtaining regulatory approval in one jurisdiction may have a negative effect on the regulatory approval process in others. For example, even if the FDA or EMA grants marketing approval of a product candidate, comparable regulatory authorities in foreign jurisdictions must also approve the manufacturing, marketing and promotion of the product candidate in those countries. Approval procedures vary among jurisdictions and can involve requirements and administrative review periods different from those in the United States, including additional preclinical studies or clinical trials as clinical trials conducted in one jurisdiction may not be accepted by regulatory authorities in other jurisdictions. In many jurisdictions outside the United States, a product candidate must be approved for reimbursement before it can be approved for sale in that jurisdiction. In some cases, the price that we intend to charge for our products is also subject to approval.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Obtaining foreign regulatory approvals and compliance with foreign regulatory requirements could result in significant delays, difficulties and costs for us and could delay or prevent the introduction of our products in certain countries. If we or any partner we work with fail to comply with the regulatory requirements in international markets or fail to receive applicable marketing approvals, our target market will be reduced and our ability to realize the full market potential of our product candidates will be harmed.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:4pt"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5ae1cfc88aa4492caf56e9d4ac91e096_7">Table of Contents</a></span></div></div><div style="margin-top:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if we obtain regulatory approval for a product candidate, our products will remain subject to extensive regulatory scrutiny.</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of our product candidates are approved, they will be subject to ongoing regulatory requirements for manufacturing, labeling, packaging, storage, advertising, promotion, sampling, record-keeping, conduct of post-marketing studies, and submission of safety, efficacy or potency, and other post-market information, including both federal and state requirements in the United States and requirements of comparable foreign regulatory authorities. </span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While healthcare professionals are free to use and prescribe drug products for off-label uses, FDA strictly regulates manufacturers&#8217; promotional claims of drug products. In particular, a product may not be promoted for uses that are not approved by the FDA as reflected in the FDA-approved labeling. The FDA, the Department of Justice, the Inspector General of the Department of Health and Human Services, among other government agencies, actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant liability, including large civil and criminal fines, penalties, and enforcement actions. If we cannot successfully manage the promotion of our approved product candidates, we could become subject to significant liability, which would materially adversely affect our business and financial condition.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Manufacturers and manufacturers&#8217; facilities are required to comply with extensive requirements imposed by the FDA, EMA and comparable foreign regulatory authorities, including ensuring that quality control and manufacturing procedures conform to cGMP regulations. As such, we and our contract manufacturers will be subject to continual review and inspections to assess compliance with cGMP and adherence to commitments made in any NDA, BLA or marketing authorization application ("MAA"). Accordingly, we and others with whom we work must continue to expend time, money, and effort in all areas of regulatory compliance, including manufacturing, production and quality control.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any regulatory approvals that we receive for our product candidates will be subject to limitations on the approved indicated uses for which the product may be marketed and promoted or to the conditions of approval (including the requirement to implement a Risk Evaluation and Mitigation Strategy) or contain requirements for potentially costly post-marketing testing. We will be required to report certain adverse reactions and production problems, if any, to the FDA, EMA and comparable foreign regulatory authorities. Any new legislation addressing drug safety issues could result in delays in product development or commercialization, or increased costs to assure compliance. The FDA and other agencies, including the Department of Justice, closely regulate and monitor the post-approval marketing and promotion of products to ensure that they are manufactured, marketed and distributed only for the approved indications and in accordance with the provisions of the approved labeling. We will have to comply with requirements concerning advertising and promotion for our products. Promotional communications with respect to prescription drugs are subject to a variety of legal and regulatory restrictions and must be consistent with the information in the product&#8217;s approved label. As such, we may not promote our products for indications or uses for which they do not have approval. The holder of an approved NDA, BLA, or MAA must submit new or supplemental applications and obtain approval for certain changes to the approved product, product labeling, or manufacturing process. We could also be asked to conduct post-marketing clinical trials to verify the safety and efficacy of our non-biologic products or safety, purity, and potency for our biologic products, in general or in specific patient subsets. If original marketing approval was obtained via the accelerated approval pathway, we could be required to conduct a successful post-marketing clinical trial to confirm clinical benefit for our products. An unsuccessful post-marketing study or failure to complete such a study could result in the withdrawal of marketing approval.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a regulatory agency discovers previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the facility where the product is manufactured, or disagrees with the promotion, marketing or labeling of a product, such regulatory agency may impose restrictions on that product or us, including requiring withdrawal of the product from the market. If we fail to comply with applicable regulatory requirements, a regulatory agency or enforcement authority may, among other things:</span></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:4pt"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5ae1cfc88aa4492caf56e9d4ac91e096_7">Table of Contents</a></span></div></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">issue warning letters that would result in adverse publicity;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">impose civil or criminal penalties;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">suspend or withdraw regulatory approvals;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">suspend any of our ongoing clinical trials;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">refuse to approve pending applications or supplements to approved applications submitted by us;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">impose restrictions on our operations, including closing our contract manufacturers&#8217; facilities;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">seize or detain products; and/or</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">require a product recall.</span></div><div style="padding-left:36pt;text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any government investigation of alleged violations of law could require us to expend significant time and resources in response, and could generate negative publicity. Any failure to comply with ongoing regulatory requirements may significantly and adversely affect our ability to commercialize and generate revenue from our products. If regulatory sanctions are applied or if regulatory approval is withdrawn, the value of our company and our operating results will be adversely affected.</span></div><div style="margin-top:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We plan to seek orphan drug designation for some product candidates, but we may be unable to obtain such designations or to maintain the benefits associated with orphan drug status, including market exclusivity, which may cause our revenue, if any, to be reduced.</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Orphan Drug Act, the FDA may grant orphan designation to a drug or biologic intended to treat a rare disease or condition, defined as a disease or condition with a patient population of fewer than 200,000 in the United States, or a patient population greater than 200,000 in the United States when there is no reasonable expectation that the cost of developing and making available the drug or biologic in the United States will be recovered from sales in the United States for that drug or biologic. Orphan drug designation must be requested before submitting an NDA or BLA. In the United States, orphan drug designation entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages, and user-fee waivers. After the FDA grants orphan drug designation, the generic identity of the drug and its potential orphan use are disclosed publicly by the FDA. Orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process. In February 2019, the FDA granted orphan drug designation for our DNL310 program in Hunter syndrome. We plan to seek orphan drug designations for some other product candidates and may be unable to obtain such designations.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a product that has orphan drug designation subsequently receives the first FDA approval for a particular active ingredient for the disease for which it has such designation, the product is entitled to orphan product exclusivity, which means that the FDA may not approve any other NDA or BLA applications to market the same drug or biologic for the same indication for seven years, except in limited circumstances such as a showing of clinical superiority to the product with orphan exclusivity or if FDA finds that the holder of the orphan exclusivity has not shown that it can assure the availability of sufficient quantities of the orphan product to meet the needs of patients with the disease or condition for which the drug was designated. As a result, even though DNL310 has been granted orphan drug designation and even if one of our product candidates receives orphan exclusivity, the FDA can still approve other drugs that have a different active ingredient for use in treating the same indication or disease. Furthermore, the FDA can waive orphan exclusivity if we are unable to manufacture sufficient supply of our product.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:4pt"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5ae1cfc88aa4492caf56e9d4ac91e096_7">Table of Contents</a></span></div></div><div style="margin-top:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Healthcare legislative measures aimed at reducing healthcare costs may have a material adverse effect on our business and results of operations.</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may face difficulties from changes to current regulations and future legislation. Current and future legislation may increase the difficulty and cost for us to commercialize our drugs, if approved, and affect the prices we may obtain, including changes in coverage and reimbursement policies in certain market segments for our product candidates, which could make it difficult for us to sell our product candidates, if approved, profitably. Third-party payors, whether domestic or foreign, or governmental or commercial, are developing increasingly sophisticated methods of controlling healthcare costs. In both the United States and certain foreign jurisdictions, there have been a number of legislative and regulatory changes to the health care system that could impact our ability to sell our products profitably. In particular, in 2010, the Affordable Care Act ("ACA"), was enacted, which, among other things, subjected biologic products to potential competition by lower-cost biosimilars, addressed a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected, increased the minimum Medicaid rebates owed by most manufacturers under the Medicaid Drug Rebate Program, extended the Medicaid Drug Rebate Program to utilization of prescriptions of individuals&#160;enrolled in Medicaid managed care organizations, subjected manufacturers to new annual fees and taxes for certain branded prescription drugs, and provided incentives to programs that increase the federal government&#8217;s comparative effectiveness research. Recent changes in the U.S. administration could lead to repeal of or changes in some or all of the ACA, and complying with any new legislation or reversing changes implemented under the ACA could be time-intensive and expensive, resulting in a material adverse effect on our business. Until the ACA is fully implemented or there is more certainty concerning the future of the ACA, it will be difficult to predict its full impact and influence on our business.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, other legislative changes have been proposed and adopted in the United States since the ACA was enacted. In August&#160;2011, the Budget Control Act of 2011, among other things, created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, was unable to reach required goals, thereby triggering the legislation&#8217;s automatic reduction to several government programs. This includes aggregate reductions of Medicare payments to providers of 2%&#160;per fiscal year, which went into effect in&#160;2013, and will remain in effect through 2030, with the exception of a temporary suspension implemented under various COVID-19 relief legislation from May 1, 2020 through </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 31, 2021, unless additional Congressional action is taken. </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The American Taxpayer Relief Act of 2012 further reduced Medicare payments to several providers, including hospitals and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been, and likely will continue to be, legislative and regulatory proposals at the foreign, federal and state levels directed at containing or lowering the cost of healthcare. We cannot predict the initiatives that may be adopted in the future. The continuing efforts of the government, insurance companies, managed care organizations and other payors of healthcare services to contain or reduce costs of healthcare and/or impose price controls may adversely affect:</span></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the demand for our product candidates, if we obtain regulatory approval;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">our ability to receive or set a price that we believe is fair for our products;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">our ability to generate revenue and achieve or maintain profitability;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the level of taxes that we are required to pay; and</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the availability of capital.</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:4pt"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5ae1cfc88aa4492caf56e9d4ac91e096_7">Table of Contents</a></span></div></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that the ACA, as well as other healthcare reform measures that may be adopted in the future, may result in additional reductions in Medicare and other healthcare funding, more rigorous coverage criteria, lower reimbursement, and new payment methodologies. This could lower the price that we receive for any approved product. Any denial in coverage or reduction in reimbursement from Medicare or other government-funded programs may result in a similar denial or reduction in payments from private payors, which may prevent us from being able to generate sufficient revenue, attain profitability or commercialize our product candidates, if approved.</span></div><div style="margin-top:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our employees, independent contractors, consultants, commercial partners and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to the risk of fraud, misconduct or other illegal activity by our employees, independent contractors, consultants, commercial partners and vendors. Misconduct by these parties could include intentional, reckless and negligent conduct that fails to: comply with the laws of the FDA, EMA and other comparable foreign regulatory authorities; provide true, complete and accurate information to the FDA, EMA and other comparable foreign regulatory authorities; comply with manufacturing standards we have established; comply with healthcare fraud and abuse laws in the United States and similar foreign fraudulent misconduct laws; or report financial information or data accurately or to disclose unauthorized activities to us. If we obtain FDA approval of any of our product candidates and begin commercializing those products in the United States, our potential exposure under such laws will increase significantly, and our costs associated with compliance with such laws are also likely to increase. In particular, research, sales, marketing, education and other business arrangements in the healthcare industry are subject to extensive laws designed to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, educating, marketing and promotion, sales and commission, certain customer incentive programs and other business arrangements generally. Activities subject to these laws also involve the improper use of information obtained in the course of patient recruitment for clinical trials, which could result in regulatory sanctions and cause serious harm to our reputation. We have adopted a code of business conduct and ethics, but it is not always possible to identify and deter misconduct by employees and third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant fines or other sanctions.</span></div><div style="margin-top:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with healthcare laws, we could face substantial penalties and our business, operations and financial conditions could be adversely affected.</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we obtain FDA approval for any of our product candidates and begin commercializing those products in the United States, our operations will be subject to various federal and state fraud and abuse laws. The laws that may impact our operations include:</span></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the federal Anti-Kickback Statute, which prohibits, among other things, persons from knowingly and willfully soliciting, receiving, offering or paying any remuneration (including any kickback, bribe, or rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce, or in return for, either the referral of an individual, or the purchase, lease, order or recommendation of any good, facility, item or service for which payment may be made, in whole or in part, under a federal healthcare program, such as the Medicare and Medicaid programs. The intent standard under the federal Anti-Kickback Statute was amended by the ACA to eliminate the need to prove specific intent and actual knowledge to establish an Anti-Kickback Statute violation. In addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:4pt"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5ae1cfc88aa4492caf56e9d4ac91e096_7">Table of Contents</a></span></div></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">federal civil and criminal false claims laws, including the False Claims Act, which can be enforced through civil &#8220;qui tam&#8221; or &#8220;whistleblower&#8221; actions, and civil monetary penalty laws generally prohibit individuals or entities, among other things, from knowingly presenting, or causing to be presented, claims for payment or approval from Medicare, Medicaid, or other third-party payors that are false or fraudulent or knowingly making a false statement to improperly avoid, decrease or conceal an obligation to pay money to the federal government. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of these statutes or specific intent to violate them in order to have committed a violation;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the federal Health Insurance Portability and Accountability Act of 1996 ("HIPAA"), which created new federal criminal statutes that prohibit knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations, or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, regardless of the payor (e.g., public or private) and knowingly and willfully falsifying, concealing or covering up by any trick or device a material fact or making any materially false statements in connection with the delivery of, or payment for, healthcare benefits, items or services relating to healthcare matters;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 ("HITECH"), and their respective implementing regulations, which impose requirements on certain covered healthcare providers, health plans, and healthcare clearinghouses as well as their respective business associates that perform services for them that involve the use, or disclosure of, individually identifiable health information, relating to the privacy, security and transmission of individually identifiable health information without appropriate authorization;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the federal Physician Payment Sunshine Act, created under the ACA, and its implementing regulations, which require manufacturers of drugs, devices, biologicals and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program to report annually to the U.S. Department of Health and Human Services under the Open Payments Program, information related to payments or other transfers of value made to physicians, as defined by law, and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members. Effective January 1, 2022, these reporting and transparency requirements will extend to include payments and transfers of value made during the previous year to certain non-physician covered recipients, including physician assistants, nurse practitioners and other mid-level practitioners;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers; and</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">analogous state and foreign laws and regulations, such as state and foreign anti-kickback, false claims, consumer protection and unfair competition laws which may apply to pharmaceutical business practices, including but not limited to, research, distribution, sales and marketing arrangements as well as submitting claims involving healthcare items or services reimbursed by any third-party payer, including commercial insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government that otherwise restricts payments that may be made to healthcare providers and other potential referral sources; state laws that require drug manufacturers to file reports with states regarding pricing and marketing information, such as the tracking and reporting of gifts, compensations and other remuneration and items of value provided to healthcare professionals and entities; and state and foreign laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:4pt"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5ae1cfc88aa4492caf56e9d4ac91e096_7">Table of Contents</a></span></div></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available, it is possible that some of our business activities could, despite our efforts to comply, be subject to challenge under one or more of such laws. Efforts to ensure that our business arrangements will comply with applicable healthcare laws may involve substantial costs. It is possible that governmental and enforcement authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law interpreting applicable fraud and abuse or other healthcare laws and regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of civil, criminal and administrative penalties, damages, disgorgement, monetary fines, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of our operations, any of which could adversely affect our ability to operate our business and our results of operations. In addition, the approval and commercialization of any of our product candidates outside the United States will also likely subject us to foreign equivalents of the healthcare laws mentioned above, among other foreign laws.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business is subject to complex and evolving U.S. and foreign laws and regulations, information security policies and contractual obligations relating to privacy and data protection, including the use, processing, and cross-border transfer of personal information. These laws and regulations are subject to change and uncertain interpretation, and could result in claims, changes to our business practices, or monetary penalties, and otherwise may harm our business.</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We receive, generate and store significant and increasing volumes of sensitive information and business-critical information, including employee and personal data (including protected health information), research and development information, commercial information, and business and financial information. We heavily rely on external security and infrastructure vendors to manage our information technology systems and data centers. We face a number of risks relative to protecting this critical information, including loss of access risk, inappropriate use or disclosure, inappropriate modification, and the risk of our being unable to adequately monitor, audit and modify our controls over our critical information. This risk extends to the third-party vendors and subcontractors we use to manage this sensitive data.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:4pt"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5ae1cfc88aa4492caf56e9d4ac91e096_7">Table of Contents</a></span></div></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A wide variety of provincial, state, national, and international laws, and regulations apply to the collection, use, retention, protection, disclosure, transfer and other processing of personal data. These data protection and privacy-related laws and regulations are evolving and may result in ever-increasing regulatory and public scrutiny and escalating levels of enforcement and sanctions. For example, the collection and use of personal data in the EU are governed by the EU General Data Protection Regulation ("GDPR"), which became fully effective on May 25, 2018. The GDPR imposes stringent data protection requirements, including, for example, more robust disclosures to individuals and a strengthened individual data rights regime, shortened timelines for data breach notifications, limitations on retention of information, increased requirements pertaining to special categories of data, such as health data, and additional obligations when we contract with third-party processors in connection with the processing of the personal data. The GDPR also imposes strict rules on the transfer of personal data out of the EU to the United States and other third countries and in the context of clinical trials, we currently rely on patient informed consent as the legal basis for such transfers. In addition, the GDPR provides that EU member states may make their own further laws and regulations limiting the processing of personal data, including genetic, biometric or health data. The GDPR provides for penalties for noncompliance of up to the greater of &#8364;20 million or four percent of worldwide annual revenues. The GDPR applies extraterritorially, and we may be subject to the GDPR because of our data processing activities that involve the personal data of individuals located in the EU, such as in connection with any EU clinical trials. GDPR regulations may impose additional responsibility and liability in relation to the personal data that we process and we may be required to put in place additional mechanisms to ensure compliance with the new data protection rules. Beginning in 2021, the UK will be a &#8220;third country&#8221; under the GDPR. We may, however, incur liabilities, expenses, costs, and other operational losses under GDPR as well as applicable EU Member States and the United Kingdom privacy laws. This may be onerous and may interrupt or delay our development activities, and adversely affect our business, financial condition, results of operations and prospects.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, various states, such as California and Massachusetts, have implemented similar privacy laws and regulations that impose restrictive requirements regulating the use and disclosure of health information and other personally identifiable information. These laws and regulations are not necessarily preempted by HIPAA, particularly if a state affords greater protection to individuals than HIPAA. Where state laws are more protective, we have to comply with the stricter provisions. In addition to fines and penalties imposed upon violators, some of these state laws also afford private rights of action to individuals who believe their personal information has been misused. For example, California recently enacted legislation, the California Consumer Privacy Act ("CCPA"), that will, among other things, require covered companies to provide new disclosures to California consumers, and afford such consumers new abilities to opt-out of certain sales of personal information, that became effective on January 1, 2020. The CCPA was amended several times throughout 2018 and 2019, and it is unclear whether further modifications will be made to this legislation or how it will be interpreted. In addition, the CCPA, as amended and expanded by the California Privacy Rights Act ("CPRA"), requires covered companies to provide new disclosures to individuals and consumers in California, and afford such individuals and consumers new data protection rights, including the ability to opt-out of certain sales of personal information. The GDPR, CCPA, CPRA and many other federal, state, and foreign laws and regulations relating to privacy and data protection are still being tested in courts, and they are subject to new and differing interpretations by courts and regulatory officials. Additionally, the interplay of federal and state laws may be subject to varying interpretations by courts and government agencies, creating complex compliance issues for us and data we receive, use and share, potentially exposing us to additional expense, adverse publicity and liability. We are working to comply with the GDPR, CCPA and other privacy and data protection laws and regulations that apply to us, and we anticipate needing to devote significant additional resources to complying with these laws and regulations. These and future laws and regulations may increase our compliance costs and potential liability.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:4pt"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5ae1cfc88aa4492caf56e9d4ac91e096_7">Table of Contents</a></span></div></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is possible that the GDPR, CCPA or other laws and regulations relating to privacy and data protection may be interpreted and applied in a manner that is inconsistent from jurisdiction to jurisdiction or inconsistent with our current policies and practices and compliance with such laws and regulations could require us to change our business practices and compliance procedures in a manner adverse to our business. We cannot guarantee that we are in compliance with all such applicable data protection laws and regulations and we cannot be sure how these regulations will be interpreted, enforced or applied to our operations. Furthermore, other jurisdictions outside the EU are similarly introducing or enhancing privacy and data security laws, rules, and regulations, which could increase our compliance costs and the risks associated with noncompliance. It is possible that these laws may be interpreted and applied in a manner that is inconsistent with our practices and our efforts to comply with the evolving data protection rules may be unsuccessful. We cannot guarantee that we or our vendors may be in compliance with all applicable international laws and regulations as they are enforced now or as they evolve. For example, our privacy policies may be insufficient to protect any personal information we collect, or may not comply with applicable laws. Our non-compliance could result in government-imposed fines or orders requiring that we change our practices, which could adversely affect our business. In addition to the risks associated with enforcement activities and potential contractual liabilities, our ongoing efforts to comply with evolving laws and regulations at the federal and state level may be costly and require ongoing modifications to our policies, procedures and systems. In addition, if we are unable to properly protect the privacy and security of protected health information, we could be found to have breached our contracts.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our actual or perceived failure to adequately comply with applicable laws and regulations relating to privacy and data protection, or to protect personal data and other data we process or maintain, could result in regulatory enforcement actions against us, including fines, imprisonment of company officials and public censure, claims for damages by affected individuals, other lawsuits or reputational and damage, all of which could materially affect our business, financial condition, results of operations and growth prospects.</span></div><div style="margin-top:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we or any contract manufacturers and suppliers we engage fail to comply with environmental, health, and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business.</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and any contract manufacturers and suppliers we engage are subject to numerous federal, state, and local environmental, health, and safety laws, regulations, and permitting requirements, including those governing laboratory procedures; the generation, handling, use, storage, treatment, and disposal of hazardous and regulated materials and wastes; the emission and discharge of hazardous materials into the ground, air, and water; and employee health and safety. Our operations involve the use of hazardous and flammable materials, including chemicals and biological and radioactive materials. Our operations also produce hazardous waste. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. Under certain environmental laws, we could be held responsible for costs relating to any contamination at our current or past facilities and at third-party facilities. We also could incur significant costs associated with civil or criminal fines and penalties.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:4pt"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5ae1cfc88aa4492caf56e9d4ac91e096_7">Table of Contents</a></span></div></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compliance with applicable environmental laws and regulations may be expensive, and current or future environmental laws and regulations may impair our research, product development and manufacturing efforts. In addition, we cannot entirely eliminate the risk of accidental injury or contamination from these materials or wastes. Although we maintain workers&#8217; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not carry specific biological or hazardous waste insurance coverage, and our property, casualty, and general liability insurance policies specifically exclude coverage for damages and fines arising from biological or hazardous waste exposure or contamination. Accordingly, in the event of contamination or injury, we could be held liable for damages or be penalized with fines in an amount exceeding our resources, and our clinical trials or regulatory approvals could be suspended, which could have a material adverse effect on our business, financial condition, results of operations and growth prospects.</span></div><div style="margin-top:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business activities may be subject to the Foreign Corrupt Practices Act and similar anti-bribery and anti-corruption laws, as well as U.S. and certain foreign export controls, trade sanctions, and import laws and regulations.</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business activities may be subject to the Foreign Corrupt Practices Act of 1977, as amended (the "FCPA"), and similar anti-bribery or anti-corruption laws, regulations or rules of other countries in which we operate, including the U.K. Bribery Act. The FCPA generally prohibits offering, promising, giving, or authorizing others to give anything of value, either directly or indirectly, to a non-U.S. government official in order to influence official action, or otherwise obtain or retain business. The FCPA also requires public companies to make and keep books and records that accurately and fairly reflect the transactions of the corporation and to devise and maintain an adequate system of internal accounting controls. Our business is heavily regulated and therefore involves significant interaction with public officials, including officials of non-U.S. governments. Additionally, in many other countries, the health care providers who prescribe pharmaceuticals are employed by their government, and the purchasers of pharmaceuticals are government entities; therefore, our dealings with these prescribers and purchasers are subject to regulation under the FCPA. Recently the Securities and Exchange Commission (the "SEC"), and Department of Justice have increased their FCPA enforcement activities with respect to biotechnology and pharmaceutical companies. There is no certainty that all of our employees, agents, contractors, or collaborators, or those of our affiliates, will comply with all applicable laws and regulations, particularly given the high level of complexity of these laws. Violations of these laws and regulations could result in fines, criminal sanctions against us, our officers, or our employees, the closing down of our facilities, requirements to obtain export licenses, cessation of business activities in sanctioned countries, implementation of compliance programs, and prohibitions on the conduct of our business. Any such violations could include prohibitions on our ability to offer our products in one or more countries and could materially damage our reputation, our brand, our international expansion efforts, our ability to attract and retain employees, and our business, prospects, operating results, and financial condition.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in the future once we enter a commercialization phase, our products may be subject to U.S. and foreign export controls, trade sanctions and import laws and regulations. Governmental regulation of the import or export of our products, or our failure to obtain any required import or export authorization for our products, when applicable, could harm our international sales and adversely affect our revenue. Compliance with applicable regulatory requirements regarding the export of our products may create delays in the introduction of our products in international markets or, in some cases, prevent the export of our products to some countries altogether. Furthermore, U.S. export control laws and economic sanctions prohibit the shipment of certain products and services to countries, governments, and persons targeted by U.S. sanctions. If we fail to comply with export and import regulations and such economic sanctions, we may be fined or other penalties could be imposed, including a denial of certain export privileges. Moreover, any new export or import restrictions, new legislation or shifting approaches in the enforcement or scope of existing regulations, or in the countries, persons, or technologies targeted by such regulations, could result in decreased use of our products by, or in our decreased ability to export our products to existing or potential customers with international operations. Any limitation on our ability to export or sell access to our products would likely adversely affect our business.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:4pt"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5ae1cfc88aa4492caf56e9d4ac91e096_7">Table of Contents</a></span></div></div><div style="margin-top:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inadequate funding for the FDA, the SEC and other government agencies could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business.</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of the SEC and other government agencies on which our operations may rely, including those that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable. Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years, including from December 22, 2018 until January 25, 2019, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA and the SEC, have had to furlough critical FDA, SEC and other government employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Further, in our operations as a public company, future government shutdowns could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations.</span></div><div id="i5ae1cfc88aa4492caf56e9d4ac91e096_121"></div><div style="margin-top:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Reliance on Third Parties</span></div><div style="margin-top:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We expect to depend on collaborations with third parties for the research, development and commercialization of certain of the product candidates we may develop. If any such collaborations are not successful, we may not be able to realize the market potential of those product candidates.</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate seeking third-party collaborators for the research, development, and commercialization of certain of the product candidates we may develop. For example, we have collaborations with F-star, Takeda, Sanofi, Biogen and others, to further our development of product candidates and to enhance our research efforts directed to better understanding neurodegenerative diseases. Our likely collaborators for any other collaboration arrangements include large and mid-size pharmaceutical companies, regional and national pharmaceutical companies, biotechnology companies and academic institutions. If we enter into any such arrangements with any third parties, we will likely have shared or limited control over the amount and timing of resources that our collaborators dedicate to the development or potential commercialization of any product candidates we may seek to develop with them. Our ability to generate revenue from these arrangements with commercial entities will depend on our collaborators&#8217; abilities to successfully perform the functions assigned to them in these arrangements. We cannot predict the success of any collaboration that we enter into.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaborations involving our research programs, or any product candidates we may develop, pose the following risks to us:</span></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">collaborators generally have significant discretion in determining the efforts and resources that they will apply to these collaborations;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">collaborators may not properly obtain, maintain, enforce, or defend intellectual property or proprietary rights relating to our product candidates or research programs or may use our proprietary information in such a way as to expose us to potential litigation or other intellectual property related proceedings, including proceedings challenging the scope, ownership, validity and enforceability of our intellectual property;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:4pt"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5ae1cfc88aa4492caf56e9d4ac91e096_7">Table of Contents</a></span></div></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">collaborators may own or co-own intellectual property covering our product candidates or research programs that results from our collaboration with them, and in such cases, we may not have the exclusive right to commercialize such intellectual property or such product candidates or research programs;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">we may need the cooperation of our collaborators to enforce or defend any intellectual property we contribute to or that arises out of our collaborations, which may not be provided to us;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">collaborators may control certain interactions with regulatory authorities, which may impact on our ability to obtain and maintain regulatory approval of our products candidates;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">disputes may arise between the collaborators and us that result in the delay or termination of the research, development, or commercialization of our product candidates or research programs or that result in costly litigation or arbitration that diverts management attention and resources;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">collaborators may decide to not pursue development and commercialization of any product candidates we develop or may elect not to continue or renew development or commercialization programs based on clinical trial results, changes in the collaborator&#8217;s strategic focus or available funding or external factors such as an acquisition that diverts resources or creates competing priorities;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials, or require a new formulation of a product candidate for clinical testing;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our product candidates or research programs if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">collaborators may restrict us from researching, developing or commercializing certain products or technologies without their involvement;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">collaborators with marketing and distribution rights to one or more product candidates may not commit sufficient resources to the marketing and distribution of such product candidates;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">we may lose certain valuable rights under circumstances identified in our collaborations, including if we undergo a change of control;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">collaborators may grant sublicenses to our technology or product candidates or undergo a change of control and the sublicensees or new owners may decide to take the collaboration in a direction which is not in our best interest;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">collaborators may become bankrupt, which may significantly delay our research or development programs, or may cause us to lose access to valuable technology, know-how or intellectual property of the collaborator relating to our products, product candidates or research programs;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">key personnel at our collaborators may leave, which could negatively impact our ability to productively work with our collaborators;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">collaborations may require us to incur short and long-term expenditures, issue securities that dilute our stockholders, or disrupt our management and business;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:4pt"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5ae1cfc88aa4492caf56e9d4ac91e096_7">Table of Contents</a></span></div></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">if our collaborators do not satisfy their obligations under our agreements with them, or if they terminate our collaborations with them, we may not be able to develop or commercialize product candidates as planned;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">collaborations may require us to share in development and commercialization costs pursuant to budgets that we do not fully control and our failure to share in such costs could have a detrimental impact on the collaboration or our ability to share in revenue generated under the collaboration;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">collaborations may be terminated in their entirety or with respect to certain product candidates or technologies and, if so terminated, may result in a need for additional capital to pursue further development or commercialization of the applicable product candidates or technologies, including our BBB platform technology;&#160;and</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">collaboration agreements may not lead to development or commercialization of product candidates in the most efficient manner or at all. If a present or future collaborator of ours were to be involved in a business combination, the continued pursuit and emphasis on our development or commercialization program under such collaboration could be delayed, diminished, or terminated.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may face significant competition in seeking appropriate collaborations. Recent business combinations among biotechnology and pharmaceutical companies have resulted in a reduced number of potential collaborators. In addition, the negotiation process is time-consuming and complex, and we may not be able to negotiate collaborations on a timely basis, on acceptable terms, or at all. If we are unable to do so, we may have to curtail the development of the product candidate for which we are seeking to collaborate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to increase our expenditures to fund development or commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we may not be able to further develop product candidates or bring them to market and generate product revenue.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we enter into collaborations to develop and potentially commercialize any product candidates, we may not be able to realize the benefit of such transactions if we or our collaborator elects not to exercise the rights granted under the agreement or if we or our collaborator are unable to successfully integrate a product candidate into existing operations and company culture. The failure to develop and commercialize a product candidate pursuant to our agreements with our current or future collaborators could prevent us from receiving future payments under such agreements, which could negatively impact our revenues. In addition, if our agreement with any of our collaborators terminates, our access to technology and intellectual property licensed to us by that collaborator may be restricted or terminate entirely, which may delay our continued development of our product candidates utilizing the collaborator&#8217;s technology or intellectual property or require us to stop development of those product candidates completely. We may also find it more difficult to find a suitable replacement collaborator or attract new collaborators, and our development programs may be delayed or the perception of us in the business and financial communities could be adversely affected. Many of the risks relating to product development, regulatory approval, and commercialization described in this &#8220;Risk Factors&#8221; section also apply to the activities of our collaborators and any negative impact on our collaborators may adversely affect us.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We expect to rely on third parties to conduct our clinical trials and some aspects of our research and preclinical testing, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials, research, or testing.</span></div><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:4pt"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5ae1cfc88aa4492caf56e9d4ac91e096_7">Table of Contents</a></span></div></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently rely and expect to continue to rely on third parties, such as CROs, clinical data management organizations, medical institutions, and clinical investigators, to conduct some aspects of our research and preclinical testing and our clinical trials. Any of these third parties may terminate their engagements with us or be unable to fulfill their contractual obligations. If we need to enter into alternative arrangements, it would delay our product development activities.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our reliance on these third parties for research and development activities reduces our control over these activities but does not relieve us of our responsibilities. For example, we remain responsible for ensuring that each of our clinical trials is conducted in accordance with the general investigational plan and protocols for the trial. Moreover, the FDA requires us to comply with cGCPs for conducting, recording, and reporting the results of clinical trials to assure that data and reported results are credible, reproducible and accurate and that the rights, integrity, and confidentiality of trial participants are protected. We also are required to register ongoing clinical trials and post the results of completed clinical trials on a government-sponsored database within certain time frames. Failure to do so can result in fines, adverse publicity, and civil and criminal sanctions.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our third-party service providers are not our employees, and we are therefore unable to directly monitor whether or not they devote sufficient time and resources to our clinical and nonclinical programs. These third-party service providers may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical trials or other drug development activities that could harm our competitive position. If these third parties do not successfully carry out their contractual duties, meet expected deadlines, or conduct our clinical trials in accordance with regulatory requirements or our stated protocols, we will not be able to obtain, or may be delayed in obtaining, marketing approvals for any product candidates we may develop and will not be able to, or may be delayed in our efforts to, successfully commercialize our medicines.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also expect to rely on other third parties to store and distribute drug supplies for our clinical trials. Any performance failure on the part of our distributors, including with the shipment of any drug supplies, could delay clinical development or marketing approval of any product candidates we may develop or commercialization of our medicines, producing additional losses and depriving us of potential product revenue.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We currently contract with third parties for the manufacture of materials for our research programs, preclinical studies and clinical trials and expect to continue to do so for commercialization of some or all product candidates that we may develop. This reliance on third parties may increase the risk that we will not have sufficient quantities of such materials, product candidates, or any medicines that we may develop and commercialize, or that such supply will not be available to us at an acceptable cost, which could delay, prevent, or impair our development or commercialization efforts.</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have any manufacturing facilities. We currently rely on third-party manufacturers for the manufacture of our materials for preclinical studies and clinical trials and expect to continue to do so for preclinical studies, clinical trials and for commercial supply of any product candidates that we may develop.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may be unable to establish any further agreements with third-party manufacturers or to do so on acceptable terms. Even if we are able to establish agreements with third-party manufacturers, reliance on third-party manufacturers entails additional risks, including:</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the possible breach of the manufacturing agreement by the third party;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the possible termination or nonrenewal of the agreement by the third party at a time that is costly or inconvenient for us;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">reliance on the third party for regulatory compliance, quality assurance, safety, and pharmacovigilance and related reporting; and</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:4pt"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5ae1cfc88aa4492caf56e9d4ac91e096_7">Table of Contents</a></span></div></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the inability to produce required volume in a timely manner and to quality standards.</span></div><div style="padding-left:36pt;text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third-party manufacturers may not be able to comply with cGMP regulations or similar regulatory requirements outside the United States. Our failure, or the failure of our third-party manufacturers, to comply with applicable regulations could result in clinical holds on our trials, sanctions being imposed on us, including fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocations, seizures or recalls of product candidates or medicines, operating restrictions, and criminal prosecutions, any of which could significantly and adversely affect supplies of our medicines and harm our business, financial condition, results of operations and growth prospects.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any medicines that we may develop may compete with other product candidates and products for access to manufacturing facilities. There are a limited number of manufacturers that operate under cGMP regulations and that might be capable of manufacturing for us.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any performance failure on the part of our existing or future manufacturers could delay clinical development or marketing approval. We do not currently have arrangements in place for redundant supply for any of our product candidates. If any one of our current contract manufacturers cannot perform as agreed, we may be required to replace that manufacturer and may incur added costs and delays in identifying and qualifying any such replacement. Furthermore, securing and reserving production capacity with contract manufacturers may result in significant costs.</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current and anticipated future dependence upon others for the manufacture of any product candidates we may develop or medicines may adversely affect our future profit margins and our ability to commercialize any medicines that receive marketing approval on a timely and competitive basis.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We depend on third-party suppliers for key raw materials used in our manufacturing processes, and the loss of these third-party suppliers or their inability to supply us with adequate raw materials could harm our business.</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on third-party suppliers for the raw materials required for the production of our product candidates. Our dependence on these third-party suppliers and the challenges we may face in obtaining adequate supplies of raw materials involve several risks, including limited control over pricing, availability, quality and delivery schedules. As a small company, our negotiation leverage is limited and we are likely to get lower priority than our competitors who are larger than we are. We cannot be certain that our suppliers will continue to provide us with the quantities of these raw materials that we require or satisfy our anticipated specifications and quality requirements. Any supply interruption in limited or sole sourced raw materials could materially harm our ability to manufacture our product candidates until a new source of supply, if any, could be identified and qualified. We may be unable to find a sufficient alternative supply channel in a reasonable time or on commercially reasonable terms. Any performance failure on the part of our suppliers could delay the development and potential commercialization of our product candidates, including limiting supplies necessary for clinical trials and regulatory approvals, which would have a material adverse effect on our business.</span></div><div id="i5ae1cfc88aa4492caf56e9d4ac91e096_124"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Intellectual Property</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to obtain and maintain patent protection for any product candidates we develop or for our BBB platform technology, our competitors could develop and commercialize products or technology similar or identical to ours, and our ability to successfully commercialize any product candidates we may develop, and our technology may be adversely affected.</span></div><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:4pt"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5ae1cfc88aa4492caf56e9d4ac91e096_7">Table of Contents</a></span></div></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success depends in large part on our ability to obtain and maintain patent protection in the United States and other countries with respect to our BBB platform technology and any proprietary product candidates and other technologies we may develop. We seek to protect our proprietary position by in-licensing intellectual property and filing patent applications in the United States and abroad relating to our BBB platform technology, programs and product candidates, as well as other technologies that are important to our business. Given that the development of our technology and product candidates is at an early stage, our intellectual property portfolio with respect to certain aspects of our technology and product candidates is also at an early stage. In addition, we cannot be certain that any patents we own or in-license in the United States adequately cover the Fc domain portion of our BBB platform technology that binds to transferrin receptor, or adequately cover the antibodies, enzymes or proteins being developed in our ATV:TREM2, ETV:IDS or PTV:PGRN programs.&#160;We have filed or intend to file patent applications on these aspects of our technology and product candidates; however, there can be no assurance that any such patent applications will issue as granted patents.&#160;Furthermore, in some cases, we have only filed provisional patent applications on certain aspects of our technology and product candidates and each of these provisional patent applications is not eligible to become an issued patent until, among other things, we file a non-provisional patent application within 12 months of the filing date of the applicable provisional patent application. Any failure to file a non-provisional patent application within this timeline could cause us to lose the ability to obtain patent protection for the inventions disclosed in the associated provisional patent applications. Furthermore, in some cases, we may not be able to obtain issued claims covering compositions relating to our BBB platform technology, programs and product candidates, as well as other technologies that are important to our business, and instead may need to rely on filing patent applications with claims covering a method of use and/or method of manufacture for protection of such BBB platform technology, programs, product candidates and other technologies. There can be no assurance that any such patent applications will issue as granted patents, and even if they do issue, such patent claims may be insufficient to prevent third parties, such as our competitors, from utilizing our technology.&#160;Any failure to obtain or maintain patent protection with respect to our BBB platform technology, programs and product candidates could have a material adverse effect on our business, financial condition, results of operations and growth prospects.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If any of our owned or in-licensed patent applications do not issue as patents in any jurisdiction, we may not be able to compete effectively.</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in either the patent laws or their interpretation in the United States and other countries may diminish our ability to protect our inventions, obtain, maintain, and enforce our intellectual property rights and, more generally, could affect the value of our intellectual property or narrow the scope of our owned and licensed patents. With respect to both in-licensed and owned intellectual property, we cannot predict whether the patent applications we and our licensors are currently pursuing will issue as patents in any particular jurisdiction or whether the claims of any issued patents will provide sufficient protection from competitors or other third parties.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent prosecution process is expensive, time-consuming, and complex, and we may not be able to file, prosecute, maintain, enforce, or license all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development output in time to obtain patent protection. Although we enter into nondisclosure and confidentiality agreements with parties who have access to confidential or patentable aspects of our research and development output, such as our employees, corporate collaborators, outside scientific collaborators, CROs, contract manufacturers, consultants, advisors, and other third parties, any of these parties may breach the agreements and disclose such output before a patent application is filed, thereby jeopardizing our ability to seek patent protection. In addition, our ability to obtain and maintain valid and enforceable patents depends on whether the differences between our inventions and the prior art allow our inventions to be patentable over the prior art. Furthermore, publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18&#160;months after filing, or in some cases not at all. Therefore, we cannot be certain that we or our licensors were the first to make the inventions claimed in any of our owned or licensed patents or pending patent applications, or that we or our licensors were the first to file for patent protection of such inventions.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:4pt"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5ae1cfc88aa4492caf56e9d4ac91e096_7">Table of Contents</a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If the scope of any patent protection we obtain is not sufficiently broad, or if we lose any of our patent protection, our ability to prevent our competitors from commercializing similar or identical technology and product candidates would be adversely affected.</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions, and has been the subject of much litigation in recent years. As a result, the issuance, scope, validity, enforceability, and commercial value of our patent rights are highly uncertain. Our owned or in-licensed pending and future patent applications may not result in patents being issued which protect our BBB platform technology, product candidates or other technologies or which effectively prevent others from commercializing competitive technologies and product candidates.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, the coverage claimed in a patent application can be significantly reduced before the patent is issued, and its scope can be reinterpreted after issuance. Even if patent applications we license or own currently or in the future issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors or other third parties from competing with us, or otherwise provide us with any competitive advantage. Any patents that we own or in-license may be challenged, narrowed, circumvented, or invalidated by third parties. Consequently, we do not know whether our BBB platform technology, product candidates or other technologies will be protectable or remain protected by valid and enforceable patents. Our competitors or other third parties may be able to circumvent our patents by developing similar or alternative technologies or products in a non-infringing manner which could materially adversely affect our business, financial condition, results of operations and growth prospects.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The issuance of a patent is not conclusive as to its inventorship, scope, validity, or enforceability, and our patents may be challenged in the courts or patent offices in the United States and abroad. We or our licensors may be subject to a third-party preissuance submission of prior art to the USPTO, or become involved in opposition, derivation, revocation, reexamination, post-grant and&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;review, or interference proceedings or other similar proceedings challenging our owned or licensed patent rights. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate or render unenforceable, our owned or in-licensed patent rights, allow third parties to commercialize our BBB platform technology, product candidates or other technologies and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing third-party patent rights. Moreover, we, or one of our licensors, may have to participate in interference proceedings declared by the USPTO to determine priority of invention or in post-grant challenge proceedings, such as oppositions in a foreign patent office, that challenge our or our licensor&#8217;s priority of invention or other features of patentability with respect to our owned or in-licensed patents and patent applications. Such challenges may result in loss of patent rights, loss of exclusivity, or in patent claims being narrowed, invalidated, or held unenforceable, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our BBB platform technology, product candidates and other technologies. Such proceedings also may result in substantial cost and require significant time from our scientists and management, even if the eventual outcome is favorable to us. If we or our collaborators are unsuccessful in any such proceeding or other priority or inventorship dispute, we may be required to obtain and maintain licenses from third parties, including parties involved in any such interference proceedings or other priority or inventorship disputes. Such licenses may not be available on commercially reasonable terms or at all, or may be non-exclusive. If we are unable to obtain and maintain such licenses, we may need to cease the development, manufacture, and commercialization of one or more of the product candidates we may develop. The loss of exclusivity or the narrowing of our owned and licensed patent claims could limit our ability to stop others from using or commercializing similar or identical technology and products.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, given the amount of time required for the development, testing, and regulatory review of new product candidates, patents protecting such product candidates might expire before or shortly after such product candidates are commercialized. As a result, our intellectual property may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.</span></div><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">89</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:4pt"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5ae1cfc88aa4492caf56e9d4ac91e096_7">Table of Contents</a></span></div></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of our owned and in-licensed patents and patent applications are, and may in the future be, co-owned with third parties. For example, we may currently, and may in the future, co-own certain patents and patent applications relating to our BBB platform technology with F-star. In addition, certain of our licensors co-own the patents and patent applications we in-license with other third parties with whom we do not have a direct relationship. Our exclusive rights to certain of these patents and patent applications are dependent, in part, on inter-institutional or other operating agreements between the joint owners of such patents and patent applications, who are not parties to our license agreements. If our licensors do not have exclusive control of the grant of licenses under any such third-party co-owners&#8217; interest in such patents or patent applications or we are otherwise unable to secure such exclusive rights, such co-owners may be able to license their rights to other third parties, including our competitors, and our competitors could market competing products and technology. In addition, we may need the cooperation of any such co-owners of our patents in order to enforce such patents against third parties, and such cooperation may not be provided to us. Any of the foregoing could have a material adverse effect on our competitive position, business, financial conditions, results of operations and growth prospects.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our rights to develop and commercialize our BBB platform technology and product candidates are subject, in part, to the terms and conditions of licenses granted to us by others or licenses granted by us to others.</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are heavily reliant upon licenses to certain patent rights and proprietary technology from third parties that are important or necessary to the development of our BBB platform technology and product candidates. For example, in June 2016, we entered into a license agreement with Genentech pursuant to which we received an exclusive license to certain of Genentech&#8217;s intellectual property relating to our LRRK2 program, including our DNL151 (BIIB122) product candidate. </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our agreements with F-star and other license agreements may not provide exclusive rights to use certain licensed intellectual property and technology in all relevant fields of use and in all territories in which we may wish to develop or commercialize our technology and products in the future. For example, F-star retains the right to use itself, and to license to others, its modular antibody technology for any purpose other than the targets which we have agreed with F-star would or may be exclusively available to us. As a result, we may not be able to prevent competitors or other third parties from developing and commercializing competitive products that also utilizes technology that we have in-licensed.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, subject to the terms of any such license agreements, we do not have the right to control the preparation, filing, prosecution and maintenance, and we may not have the right to control the enforcement, and defense of patents and patent applications covering the technology that we license from third parties. For example, under our agreements with F-star and Genentech, the licensors control prosecution and, in the case of F-star and in specified circumstances, enforcement of certain of the patents and patent applications licensed to us. Also, under our agreements with Takeda, Sanofi and Biogen, they control prosecution, and in specified circumstances, enforcement of certain of the patents and patent applications licensed to them. We cannot be certain that our in-licensed or out-licensed patents and patent applications that are controlled by our licensors or licensees will be prepared, filed, prosecuted, maintained, enforced, and defended in a manner consistent with the best interests of our business. If our licensors or licensees fail to prosecute, maintain, enforce, and defend such patents, or lose rights to those patents or patent applications, the rights we have licensed may be reduced or eliminated, our right to develop and commercialize our BBB platform technology and any of our product candidates that are subject of such licensed rights could be adversely affected, and we may not be able to prevent competitors from making, using and selling competing products. In addition, even where we have the right to control patent prosecution of patents and patent applications we have licensed to and from third parties, we may still be adversely affected or prejudiced by actions or inactions of our licensees, our licensors and their counsel that took place prior to the date upon which we assumed control over patent prosecution.</span></div><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:4pt"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5ae1cfc88aa4492caf56e9d4ac91e096_7">Table of Contents</a></span></div></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, our owned and in-licensed patents may be subject to a reservation of rights by one or more third parties. For example, our license to certain intellectual property owned by Genentech is subject to certain research rights Genentech granted to third parties prior to our license agreement. In addition, certain of our in-licensed intellectual property relating to RIPK1 was funded in part by the U.S. government. As a result, the U.S. government may have certain rights to such intellectual property. When new technologies are developed with U.S. government funding, the U.S. government generally obtains certain rights in any resulting patents, including a non-exclusive license authorizing the U.S. government to use the invention or to have others use the invention on its behalf. The U.S. government&#8217;s rights may also permit it to disclose the funded inventions and technology to third parties and to exercise march-in rights to use or allow third parties to use the technology we have licensed that was developed using U.S. government funding. The U.S. government may exercise its march-in rights if it determines that action is necessary because we fail to achieve practical application of the government-funded technology, or because action is necessary to alleviate health or safety needs, to meet requirements of federal regulations, or to give preference to U.S. industry. In addition, our rights in such inventions may be subject to certain requirements to manufacture products embodying such inventions in the United States in certain circumstances and if this requirement is not waived. Any exercise by the U.S. government of such rights or by any third party of its reserved rights could have a material adverse effect on our competitive position, business, financial condition, results of operations and growth prospects.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with our obligations in the agreements under which we license intellectual property rights from third parties or otherwise experience disruptions to our business relationships with our licensors, we could lose license rights that are important to our business.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into license agreements with third parties and may need to obtain additional licenses from others to advance our research or allow commercialization of product candidates we may develop or our BBB platform technology. It is possible that we may be unable to obtain additional licenses at a reasonable cost or on reasonable terms, if at all. In that event, we may be required to expend significant time and resources to redesign our technology, product candidates, or the methods for manufacturing them or to develop or license replacement technology, all of which may not be feasible on a technical or commercial basis. If we are unable to do so, we may be unable to develop or commercialize the affected product candidates or continue to utilize our existing BBB platform technology, which could harm our business, financial condition, results of operations and growth prospects significantly. We cannot provide any assurances that third-party patents do not exist which might be enforced against our current technology, including our BBB platform technology, manufacturing methods, product candidates, or future methods or products resulting in either an injunction prohibiting our manufacture or future sales, or, with respect to our future sales, an obligation on our part to pay royalties and/or other forms of compensation to third parties, which could be significant.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, each of our license agreements, and we expect our future agreements, will impose various development, diligence, commercialization, and other obligations on us. Certain of our license agreements also require us to meet development timelines, or to exercise commercially reasonable efforts to develop and commercialize licensed products, in order to maintain the licenses. In spite of our efforts, our licensors might conclude that we have materially breached our obligations under such license agreements and might therefore terminate the license agreements, thereby removing or limiting our ability to develop and commercialize products and technology covered by these license agreements. If these in-licenses are terminated, or if the underlying patents fail to provide the intended exclusivity, competitors or other third parties would have the freedom to seek regulatory approval of, and to market, products identical to ours and we may be required to cease our development and commercialization of certain of our product candidates or of our current BBB platform technology. Any of the foregoing could have a material adverse effect on our competitive position, business, financial conditions, results of operations and growth prospects.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:4pt"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5ae1cfc88aa4492caf56e9d4ac91e096_7">Table of Contents</a></span></div></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, disputes may arise regarding intellectual property subject to a licensing agreement, including:</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the scope of rights granted under the license agreement and other interpretation-related issues;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the sublicensing of patent and other rights under our collaborative development relationships;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">our diligence obligations under the license agreement and what activities satisfy those diligence obligations;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the inventorship and ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our partners; and</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the priority of invention of patented technology.</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the agreements under which we currently license intellectual property or technology from third parties are complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations and growth prospects. Moreover, if disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on commercially acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates, which could have a material adverse effect on our business, financial conditions, results of operations and growth prospects.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to protect our intellectual property and proprietary rights throughout the world.</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Filing, prosecuting, and defending patents on our BBB platform technology, product candidates and other technologies in all countries throughout the world would be prohibitively expensive, and the laws of foreign countries may not protect our rights to the same extent as the laws of the United States. Further, our ability to pursue patents throughout the world may be delayed or affected due to the COVID-19 global pandemic. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we have patent protection but enforcement is not as strong as that in the United States. These products may compete with our products, and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:4pt"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5ae1cfc88aa4492caf56e9d4ac91e096_7">Table of Contents</a></span></div></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets, and other intellectual property protection, particularly those relating to biotechnology products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our intellectual property and proprietary rights generally. Proceedings to enforce our intellectual property and proprietary rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly, could put our patent applications at risk of not issuing, and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property and proprietary rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If we or any of our licensors is forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired, and our business, financial condition, results of operations, and growth prospects may be adversely affected.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment, and other requirements imposed by government patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Periodic maintenance fees, renewal fees, annuity fees, and various other government fees on patents and applications will be due to be paid to the USPTO and various government patent agencies outside of the United States over the lifetime of our owned or licensed patents and applications. In certain circumstances, we rely on our licensing partners to pay these fees due to U.S. and non-U.S. patent agencies. The USPTO and various non-U.S. government agencies require compliance with several procedural, documentary, fee payment, and other similar provisions during the patent application process. We are also dependent on our licensors to take the necessary action to comply with these requirements with respect to our licensed intellectual property. In some cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. There are situations, however, in which non-compliance can result in abandonment or lapse of the patent or patent application, resulting in a partial or complete loss of patent rights in the relevant jurisdiction. In such an event, potential competitors might be able to enter the market with similar or identical products or technology, which could have a material adverse effect on our business, financial condition, results of operations and growth prospects.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">93</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:4pt"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5ae1cfc88aa4492caf56e9d4ac91e096_7">Table of Contents</a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our products.</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in either the patent laws or interpretation of the patent laws in the United States could increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents. Assuming that other requirements for patentability are met, prior to March 2013, in the United States, the first to invent the claimed invention was entitled to the patent, while outside the United States, the first to file&#160;a patent application was entitled to the patent. After March 2013, under the Leahy-Smith America Invents Act (the "America Invents Act"), enacted in September 2011, the United States transitioned to a first inventor to file system in which, assuming that other requirements for patentability are met, the first inventor to file&#160;a patent application will be entitled to the patent on an invention regardless of whether a third party was the first to invent the claimed invention. A third party that files a patent application in the USPTO after March 2013, but before us could therefore be awarded a patent covering an invention of ours even if we had made the invention before it was made by such third party. This will require us to be cognizant going forward of the time from invention to filing of a patent application. Since patent applications in the United States and most other countries are confidential for a period of time after filing or until issuance, we cannot be certain that we or our licensors were the first to either (i)&#160;file any patent application related to our BBB platform technology, product candidates or other technologies or (ii)&#160;invent any of the inventions claimed in our or our licensor&#8217;s patents or patent applications.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The America Invents Act also includes a number of significant changes that affect the way patent applications will be prosecuted and also may affect patent litigation. These include allowing third-party submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a patent by USPTO administered post-grant proceedings, including post-grant review,&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;review, and derivation proceedin</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">gs. Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in United States federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Accordingly, a third party may attempt to use the USPTO procedures to invalidate our patent claims that would not have been invalidated if first challenged by the third party as a defendant in a district court action. Therefore, the America Invents Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our owned or in-licensed patent applications and the enforcement or defense of our owned or in-licensed issued patents, all of which could have a material adverse effect on our business, financial condition, results of operations and growth prospects.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the patent positions of companies in the development and commercialization of biologics and pharmaceuticals are particularly uncertain. Recent U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. This combination of events has created uncertainty with respect to the validity and enforceability of patents, once obtained. Depending on future actions by the U.S. Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that could have a material adverse effect on our existing patent portfolio and our ability to protect and enforce our intellectual property in the future.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">94</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:4pt"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5ae1cfc88aa4492caf56e9d4ac91e096_7">Table of Contents</a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Issued patents covering our BBB platform technology, product candidates and other technologies could be found invalid or unenforceable if challenged in court or before administrative bodies in the United States or abroad.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or one of our licensors initiated legal proceedings against a third party to enforce a patent covering our BBB platform technology, product candidates or other technologies, the defendant could counterclaim that such patent is invalid or unenforceable or raise a defense to infringement. In patent litigation in the United States, defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of subject matter eligibility for patenting, novelty, obviousness, or non-enablement. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO, or made a misleading statement, during prosecution. Grounds for defenses to infringement include statutory exemptions to patent infringement for uses related to submitting information to regulatory authorities to seek certain regulatory approvals. Third parties may raise claims challenging the validity or enforceability of our owned or in-licensed patents before administrative bodies in the United States or abroad, even outside the context of litigation. Such mechanisms include re-examination, post-grant review,&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;review, interference proceedings, derivation proceedings, and equivalent proceedings in foreign jurisdictions (e.g., opposition proceedings). Such proceedings could result in the revocation of, cancellation of, or amendment to our patents in such a way that they no longer cover our BBB platform technology, product candidates or other technologies. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity question, for example, a judge or jury could find that our patent claims laws of nature or are otherwise ineligible for patenting, and we cannot be certain that there is no invalidating prior art, of which we or our licensing partners and the patent examiner were unaware during prosecution. If a third party were to prevail on a legal assertion of invalidity or unenforceability, we would lose at least part, and perhaps all, of the patent protection on our BBB platform technology, product candidates or other technologies. Such a loss of patent protection would have a material adverse impact on our business, financial condition, results of operations and growth prospects.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we do not obtain patent term extension and data exclusivity for any product candidates we may develop, our business may be materially harmed.</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depending upon the timing, duration and specifics of any FDA marketing approval of any product candidates we may develop, one or more of our owned or in-licensed U.S. patents may be eligible for limited patent term extension under the Hatch-Waxman Act. The Hatch-Waxman Act permit a patent term extension of up to five years as compensation for patent term lost during the FDA regulatory review process. A patent term extension cannot extend the remaining term of a patent beyond a total of 14&#160;years from the date of product approval, only one patent may be extended and only those claims covering the approved drug, a method for using it, or a method for manufacturing it may be extended. Similar extensions as compensation for patent term lost during regulatory review processes are also available in certain foreign countries and territories, such as in Europe under a Supplementary Patent Certificate. However, we may not be granted an extension in the United States and/or foreign countries and territories because of, for example, failing to exercise due diligence during the testing phase or regulatory review process, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents, or otherwise failing to satisfy applicable requirements. Moreover, the applicable time period or the scope of patent protection afforded could be less than we request. If we are unable to obtain patent term extension or the term of any such extension is shorter than what we request, our competitors may obtain approval of competing products following our patent expiration, and our business, financial condition, results of operations and growth prospects could be materially harmed.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">95</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:4pt"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5ae1cfc88aa4492caf56e9d4ac91e096_7">Table of Contents</a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to claims challenging the inventorship of our patents and other intellectual property.</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We or our licensors may be subject to claims that former employees, collaborators or other third parties have an interest in our owned or in-licensed patents, trade secrets, or other intellectual property as an inventor or co-inventor. For example, we or our licensors may have inventorship disputes arise from conflicting obligations of employees, consultants or others who are involved in developing our BBB platform technology, product candidates or other technologies. Litigation may be necessary to defend against these and other claims challenging inventorship or our or our licensors&#8217; ownership of our owned or in-licensed patents, trade secrets or other intellectual property. If we or our licensors fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, intellectual property that is important to our BBB platform technology, product candidates and other technologies. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and growth prospects.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to seeking patents for our BBB platform technology, product candidates and other technologies, we also rely on trade secrets and confidentiality agreements to protect our unpatented know-how, technology, and other proprietary information and to maintain our competitive position. Trade secrets and know-how can be difficult to protect. We expect our trade secrets and know-how to over time be disseminated within the industry through independent development, the publication of journal articles describing the methodology, and the movement of personnel from academic to industry scientific positions.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We seek to protect these trade secrets and other proprietary technology, in part, by entering into nondisclosure and confidentiality agreements with parties who have access to them, such as our employees, corporate collaborators, outside scientific collaborators, CROs, contract manufacturers, consultants, advisors, and other third parties. We also enter into confidentiality and invention or patent assignment agreements with our employees and consultants as well as train our employees not to bring or use proprietary information or technology from former employers to us or in their work, and remind former employees when they leave their employment of their confidentiality obligations. We cannot guarantee that we have entered into such agreements with each party that may have or have had access to our trade secrets or proprietary technology and processes. Despite our efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive, and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor or other third party, we would have no right to prevent them from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor or other third party, our competitive position would be materially and adversely harmed.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">96</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:4pt"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5ae1cfc88aa4492caf56e9d4ac91e096_7">Table of Contents</a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be successful in obtaining, through acquisitions, in-licenses or otherwise, necessary rights to our BBB platform technology, product candidates or other technologies.</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have rights to intellectual property, through licenses from third parties, to identify and develop our BBB platform technology and product candidates. Many pharmaceutical companies, biotechnology companies, and academic institutions are competing with us in the field of neurodegeneration and BBB technology and may have patents and have filed and are likely filing patent applications potentially relevant to our business. In order to avoid infringing these third-party patents, we may find it necessary or prudent to obtain licenses to such patents from such third-party intellectual property holders. We may also require licenses from third parties for certain BBB technologies that we are evaluating for use with our current or future product candidates. In addition, with respect to any patents we co-own with third parties, we may require licenses to such co-owners&#8217; interest to such patents. However, we may be unable to secure such licenses or otherwise acquire or in-license any compositions, methods of use, processes, or other intellectual property rights from third parties that we identify as necessary for our current or future product candidates and our BBB platform technology. The licensing or acquisition of third-party intellectual property rights is a competitive area, and several more established companies may pursue strategies to license or acquire third-party intellectual property rights that we may consider attractive or necessary. These established companies may have a competitive advantage over us due to their size, capital resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment or at all. If we are unable to successfully obtain rights to required third-party intellectual property rights or maintain the existing intellectual property rights we have, we may have to abandon development of the relevant program or product candidate, which could have a material adverse effect on our business, financial condition, results of operations and growth prospects.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to claims that our employees, consultants, or advisors have wrongfully used or disclosed alleged trade secrets of their current or former employers or claims asserting ownership of what we regard as our own intellectual property.</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our employees, consultants, and advisors are currently or were previously employed at universities or other biotechnology or pharmaceutical companies, including our licensors, competitors and potential competitors. Although we try to ensure that our employees, consultants, and advisors do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or these individuals have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such individual&#8217;s current or former employer. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, while it is our policy to require our employees and contractors who may be involved in the conception or development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops intellectual property that we regard as our own. The assignment of intellectual property rights may not be self-executing, or the assignment agreements may be breached, and we may be forced to bring claims against third parties, or defend claims that they may bring against us, to determine the ownership of what we regard as our intellectual property. Such claims could have a material adverse effect on our business, financial condition, results of operations and growth prospects.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">97</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:4pt"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5ae1cfc88aa4492caf56e9d4ac91e096_7">Table of Contents</a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Third-party claims of intellectual property infringement, misappropriation or other violation against us, our licensors or our collaborators may prevent or delay the development and commercialization of our BBB platform technology, product candidates and other technologies.</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The field of discovering treatments for neurodegenerative diseases, especially using BBB technology, is highly competitive and dynamic. Due to the focused research and development that is taking place by several companies, including us and our competitors, in this field, the intellectual property landscape is in flux, and it may remain uncertain in the future. As such, there may be significant intellectual property litigation and proceedings relating to our owned and in-licensed, and other third-party intellectual property and proprietary rights in the future.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial success depends in part on our, our licensors&#8217; and our collaborators&#8217; ability to avoid infringing, misappropriating and otherwise violating the patents and other intellectual property rights of third parties. There is a substantial amount of complex litigation involving patents and other intellectual property rights in the biotechnology and pharmaceutical industries, as well as administrative proceedings for challenging patents, including interference, derivation and reexamination proceedings before the USPTO or oppositions and other comparable proceedings in foreign jurisdictions. As discussed above, recently, due to changes in U.S. law referred to as patent reform, new procedures including </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">partes</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> review and post-grant review have been implemented. As stated above, this reform adds uncertainty to the possibility of challenge to our patents in the future.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Numerous U.S. and foreign issued patents and pending patent applications owned by third parties exist relating to BBB technology and in the fields in which we are developing our product candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our BBB platform technology, product candidates and other technologies may give rise to claims of infringement of the patent rights of others. We cannot assure you that our BBB platform technology, product candidates and other technologies that we have developed, are developing or may develop in the future will not infringe existing or future patents owned by third parties. We may not be aware of patents that have already been issued and that a third party, for example, a competitor in the fields in which we are developing our BBB platform technology, product candidates, and other technologies might assert are infringed by our current or future BBB platform technology, product candidates or other technologies, including claims to compositions, formulations, methods of manufacture or methods of use or treatment that cover our BBB platform technology, product candidates or other technologies. It is also possible that patents owned by third parties of which we are aware, but which we do not believe are relevant to our BBB platform technology, product candidates or other technologies, could be found to be infringed by our BBB platform technology, product candidates or other technologies. In addition, because patent applications can take many years to issue, there may be currently pending patent applications that may later result in issued patents that our BBB platform technology, product candidates or other technologies may infringe.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third parties may have patents or obtain patents in the future and claim that the manufacture, use or sale of our BBB platform technology, product candidates or other technologies infringes upon these patents. In the event that any third-party claims that we infringe their patents or that we are otherwise employing their proprietary technology without authorization and initiates litigation against us, even if we believe such claims are without merit, a court of competent jurisdiction could hold that such patents are valid, enforceable and infringed by our BBB platform technology, product candidates or other technologies. In this case, the holders of such patents may be able to block our ability to commercialize the applicable product candidate or technology unless we obtain a license under the applicable patents, or until such patents expire or are finally determined to be held invalid or unenforceable. Such a license may not be available on commercially reasonable terms or at all. Even if we are able to obtain a license, the license would likely obligate us to pay license fees or royalties or both, and the rights granted to us might be nonexclusive, which could result in our competitors gaining access to the same intellectual property. If we are unable to obtain a necessary license to a third-party patent on commercially reasonable terms, we may be unable to commercialize our BBB platform technology, product candidates or other technologies, or such commercialization efforts may be significantly delayed, which could in turn significantly harm our business.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">98</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:4pt"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5ae1cfc88aa4492caf56e9d4ac91e096_7">Table of Contents</a></span></div></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Defense of infringement claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of management and other employee resources from our business, and may impact our reputation. In the event of a successful claim of infringement against us, we may be enjoined from further developing or commercializing our infringing BBB platform technology, product candidates or other technologies. In addition, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, obtain one or more licenses from third parties, pay royalties and/or redesign our infringing product candidates or technologies, which may be impossible or require substantial time and monetary expenditure. In that event, we would be unable to further develop and commercialize our BBB platform technology, product candidates or other technologies, which could harm our business significantly.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Engaging in litigation to defend against third parties alleging that we have infringed, misappropriated or otherwise violated their patents or other intellectual property rights is very expensive, particularly for a company of our size, and time-consuming. Some of our competitors may be able to sustain the costs of litigation or administrative proceedings more effectively than we can because of greater financial resources. Patent litigation and other proceedings may also absorb significant management time. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings against us could impair our ability to compete in the marketplace. The occurrence of any of the foregoing could have a material adverse effect on our business, financial condition or results of operations or growth prospects.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may become involved in lawsuits to protect or enforce our patents and other intellectual property rights, which could be expensive, time consuming, and unsuccessful.</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Competitors may infringe our patents or the patents of our licensing partners, or we may be required to defend against claims of infringement. In addition, our patents or the patents of our licensing partners also may become involved in inventorship, priority or validity disputes. To counter or defend against such claims can be expensive and time consuming. In an infringement proceeding, a court may decide that a patent in which we have an interest is invalid or unenforceable, the other party&#8217;s use of our patented technology falls under the safe harbor to patent infringement under 35 U.S.C. &#167;271(e)(1), or may refuse to stop the other party from using the technology at issue on the grounds that our owned and in-licensed patents do not cover the technology in question. An adverse result in any litigation proceeding could put one or more of our owned or in-licensed patents at risk of being invalidated or interpreted narrowly. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses and could distract our personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions, or other interim proceedings or developments, and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing, or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual property portfolios. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:4pt"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5ae1cfc88aa4492caf56e9d4ac91e096_7">Table of Contents</a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our registered or unregistered trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition among potential partners or customers in our markets of interest. At times, competitors or other third parties may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners of other registered trademarks or trademarks that incorporate variations of our registered or unregistered trademarks or trade names. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively and our business may be adversely affected. Our efforts to enforce or protect our proprietary rights related to trademarks, trade secrets, domain names, copyrights or other intellectual property may be ineffective and could result in substantial costs and diversion of resources and could adversely affect our business, financial condition, results of operations and growth prospects.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intellectual property rights do not necessarily address all potential threats.</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations and may not adequately protect our business or permit us to maintain our competitive advantage. For example:</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">others may be able to make products that are similar to our product candidates or utilize similar technology but that are not covered by the claims of the patents that we license or may own;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">we, or our current or future licensors or collaborators, might not have been the first to make the inventions covered by the issued patent or pending patent application that we license or own now or in the future;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">we, or our current or future licensors or collaborators, might not have been the first to file patent applications covering certain of our or their inventions;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our owned or licensed intellectual property rights;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">it is possible that our current or future pending owned or licensed patent applications will not lead to issued patents;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">issued patents that we hold rights to may be held invalid or unenforceable, including as a result of legal challenges by our competitors or other third parties;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">our competitors or other third parties might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">we may not develop additional proprietary technologies that are patentable;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the patents of others may harm our business; and</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">we may choose not to file&#160;a patent in order to maintain certain trade secrets or know-how, and a third party may subsequently file&#160;a patent covering such intellectual property.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Should any of these events occur, they could have a material adverse effect on our business, financial condition, results of operations and growth prospects.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100</span></div></div></div><div id="i5ae1cfc88aa4492caf56e9d4ac91e096_127"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:4pt"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5ae1cfc88aa4492caf56e9d4ac91e096_7">Table of Contents</a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Operations</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are highly dependent on our key personnel, and if we are not successful in attracting, motivating and retaining highly qualified personnel, we may not be able to successfully implement our business strategy.</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to compete in the highly competitive biotechnology and pharmaceutical industries depends upon our ability to attract, motivate and retain highly qualified managerial, scientific and medical personnel. We are highly dependent on our management, particularly our Chief Executive Officer, Dr.&#160;Ryan Watts, and our scientific and medical personnel. The loss of the services provided by any of our executive officers, other key employees, and other scientific and medical advisors, and our inability to find suitable replacements, could result in delays in the development of our product candidates and harm our business.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conduct our operations at our facility in South San Francisco, California, in a region that is headquarters to many other biopharmaceutical companies and many academic and research institutions. Competition for skilled personnel is intense and the turnover rate can be high, which may limit our ability to hire and retain highly qualified personnel on acceptable terms or at all. We expect that we may need to recruit talent from outside of our region, and doing so may be costly and difficult.</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To induce valuable employees to remain at our company, in addition to salary and cash incentives, we have provided restricted stock and stock option grants that vest over time. The value to employees of these equity grants that vest over time may be significantly affected by movements in our stock price that are beyond our control, and may at any time be insufficient to counteract more lucrative offers from other companies. Although we have employment agreements with our key employees, these employment agreements provide for at-will employment, which means that any of our employees could leave our employment at any time, with or without notice. We do not maintain &#8220;key man&#8221; insurance policies on the lives of all of these individuals or the lives of any of our other employees. If we are unable to attract and incentivize quality personnel on acceptable terms, or at all, it may cause our business and operating results to suffer.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will need to grow the size and capabilities of our organization, and we may experience difficulties in managing this growth.</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2021, we had 311</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> emplo</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">yees, all of whom were full-time. As our development plans and strategies develop, we must add a significant number of additional managerial, operational, financial, and other personnel. Future growth will impose significant added responsibilities on members of management, including:</span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:49.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">identifying, recruiting, integrating, retaining, and motivating additional employees;</span></div><div style="padding-left:49.5pt;text-indent:-9pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">managing our internal development efforts effectively, including the clinical and FDA review process for our current and future product candidates, while complying with our contractual obligations to contractors and other third parties;</span></div><div style="padding-left:49.5pt;text-indent:-9pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">expanding our operational, financial and management controls, reporting systems, and procedures; and</span></div><div style="padding-left:49.5pt;text-indent:-9pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">managing increasing operational and managerial complexity.</span></div><div style="padding-left:36pt;text-indent:27pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:4pt"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5ae1cfc88aa4492caf56e9d4ac91e096_7">Table of Contents</a></span></div></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future financial performance and our ability to continue to develop and, if approved, commercialize our product candidates will depend, in part, on our ability to effectively manage any future growth. Our management may also have to divert a disproportionate amount of its attention away from day-to-day activities in order to manage these growth activities. Our ability to successfully manage our expected growth is uncertain given the fact that all of our executive officers have joined us since February&#160;2015. This lack of long-term experience working together as a company may adversely impact our senior management team&#8217;s ability to effectively manage our business and growth.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently rely, and for the foreseeable future will continue to rely, in substantial part on certain independent organizations, advisors and consultants to provide certain services. There can be no assurance that the services of these independent organizations, advisors and consultants will continue to be available to us on a timely basis when needed, or that we can find qualified replacements. In addition, if we are unable to effectively manage our outsourced activities or if the quality or accuracy of the services provided by consultants is compromised for any reason, our clinical trials may be extended, delayed, or terminated, and we may not be able to obtain regulatory approval of our product candidates or otherwise advance our business. There can be no assurance that we will be able to manage our existing consultants or find other competent outside contractors and consultants on economically reasonable terms, if at all.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are not able to effectively expand our organization by hiring new employees and expanding our groups of consultants and contractors, we may not be able to successfully implement the tasks necessary to further develop our product candidates and, accordingly, may not achieve our research, development, and commercialization goals.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have engaged in and may in the future engage in acquisitions or strategic partnerships, which may increase our capital requirements, dilute our stockholders, cause us to incur debt or assume contingent liabilities, and subject us to other risks.</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have in the past engaged in acquisitions and strategic partnerships, and we may engage in various acquisitions and strategic partnerships in the future, including licensing or acquiring complementary products, intellectual property rights, technologies, or businesses. For instance, in January 2018 we entered into the Takeda Collaboration Agreement, as amended in February 2019, and in connection therewith we issued and sold to Takeda 4,214,559 shares of our common stock for an aggregate purchase price of $110.0 million in February 2018. On May&#160;30, 2018, we exercised our buy-out option in connection with the F-star Collaboration Agreement and entered into a Purchase Agreement pursuant to which we acquired all of the outstanding shares of F-star Gamma. Further, on October&#160;29, 2018, we entered into the Sanofi Collaboration Agreement. In August 2020, we entered into the Provisional Biogen Collaboration Agreement, and in connection therewith we sold 13,310,243 shares of our common stock to Biogen in September 2020 for an aggregate purchase price of $465.0 million. Any acquisition or strategic partnership may entail numerous risks, including:</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">increased operating expenses and cash requirements;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the assumption of indebtedness or contingent liabilities;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the issuance of our equity securities which would result in dilution to our stockholders;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">assimilation of operations, intellectual property, products and product candidates of an acquired company, including difficulties associated with integrating new personnel;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the diversion of our management&#8217;s attention from our existing product programs and initiatives in pursuing such an acquisition or strategic partnership;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">retention of key employees, the loss of key personnel, and uncertainties in our ability to maintain key business relationships;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">102</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:4pt"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5ae1cfc88aa4492caf56e9d4ac91e096_7">Table of Contents</a></span></div></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">risks and uncertainties associated with the other party to such a transaction, including the prospects of that party and their existing products or product candidates and regulatory approvals; and</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">our inability to generate revenue from acquired intellectual property, technology and/or products sufficient to meet our objectives or even to offset the associated transaction and maintenance costs.</span></div><div style="padding-left:36pt;text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, if we undertake such a transaction, we may issue dilutive securities, assume or incur debt obligations, incur large one-time expenses and acquire intangible assets that could result in significant future amortization expense.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our internal computer systems, or those used by our third-party research institution collaborators, CROs or other contractors or consultants, may fail or suffer other breakdowns, cyberattacks or information security breaches</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">that could compromise the confidentiality, integrity, and availability of such systems and data, expose us to liability, and affect our reputation.</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are increasingly dependent upon information technology systems, infrastructure, and data to operate our business. We also rely on third-party vendors and their information technology systems. Despite the implementation of security measures, our internal computer systems and those of our CROs and other contractors and consultants may be vulnerable to damage from computer viruses or unauthorized access, or breached due to operator error, malfeasance or other system disruptions. As the cyber-threat landscape evolves, these attacks are growing in frequency, sophistication and intensity, and are becoming increasingly difficult to detect. These threats can come from a variety of sources, ranging in sophistication from an individual hacker to a state-sponsored attack. Cyber threats may be generic, or they may be custom-crafted against our information systems. Over the past few years, cyber-attacks have become more prevalent, intense, sophisticated and much harder to detect and defend against. Such attacks could include the use of key loggers or other harmful and virulent malware, including ransomware or other denials of service, and can be deployed through malicious websites, the use of social engineering and/or other means. We and our third-party vendors may not be able to anticipate all types of security threats, and we may not be able to implement preventive measures effective against all such security threats. The techniques used by cyber criminals change frequently, may not be recognized until launched, and can originate from a wide variety of sources. Although to our knowledge we and our vendors have not experienced any such material system failure or security breach to date, if a breakdown, cyberattack or other information security breach were to occur and cause interruptions in our operations, it could result in a material disruption of our development programs and our business operations , whether due to a loss of trade secrets or other proprietary information or other similar disruption and we could incur liability and reputational damage. For example, the loss of clinical trial data from completed, ongoing or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. Likewise, we rely on our third-party research institution collaborators for research and development of our product candidates and other third parties for the manufacture of our product candidates and to conduct clinical trials, and similar events relating to their computer systems could also have a material adverse effect on our business. </span></div><div style="text-indent:27pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">103</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:4pt"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5ae1cfc88aa4492caf56e9d4ac91e096_7">Table of Contents</a></span></div></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cyber-attacks, breaches, interruptions or other data security incidents could result in legal claims or proceedings, liability under federal or state laws that protect the privacy of personal information, regulatory penal-ties, significant remediation costs, disrupt key business operations and divert attention of management and key information technology resources. In the United States, notice of breaches must be made to affected individuals, the U.S. Secretary of the Department of Health and Human Services ("HHS"), and for extensive breaches, notice may need to be made to the media or U.S. state attorneys general. Such a notice could harm our reputation and our ability to compete. The HHS has the discretion to impose penalties without attempting to resolve violations through informal means. In addition, U.S. state attorneys general are authorized to bring civil actions seeking either injunctions or damages in response to violations that threaten the privacy of state residents. There can be no assurance that we, our collaborators, CROs, vendors, and any other business counterparties will be successful in efforts to detect, prevent, protect against or fully recover systems or data from all break-downs, service interruptions, attacks or breaches of systems. In addition, we do not maintain standalone cyber-security insurance and have limited insurance coverage in the event of any breach or disruption of our or our collaborators&#8217;, CROs&#8217;, or vendors&#8217; systems, including any unauthorized access or loss of any personal data that we may collect, store or otherwise process. The costs related to significant security breaches or disruptions could be material and exceed the limits of any insurance coverage we may have. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or systems, or inappropriate disclosure of confidential or proprietary information, including data related to our personnel, we could incur liability and the further development and commercialization of our product candidates could be delayed and our business and operations could be adversely affected and/or could result in the loss or disclosure of critical or sensitive data, which could result in financial, legal, business or reputational harm to us.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business disruptions could seriously harm our future revenue and financial condition and increase our costs and expenses.</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations, and those of our third-party research institution collaborators, CROs, CDMOs, suppliers, and other contractors and consultants, could be subject to earthquakes, power shortages, telecommunications failures, water shortages, floods, hurricanes, typhoons, fires, extreme weather conditions, medical epidemics such as COVID-19, and other natural or man-made disasters or business interruptions, for which we are partly uninsured. In addition, we rely on our third-party research institution collaborators for conducting research and development of our product candidates, and they may be affected by government shutdowns or withdrawn funding. The occurrence of any of these business disruptions could seriously harm our operations and financial condition and increase our costs and expenses. We rely on third-party manufacturers to produce and process our product candidates. Our ability to obtain clinical supplies of our product candidates could be disrupted if the operations of these suppliers are affected by a man-made or natural disaster or other business interruption.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of our operations including our corporate headquarters are located in a single facility in South San Francisco, California. Damage or extended periods of interruption to our corporate, development or research facilities due to fire, natural disaster, power loss, communications failure, unauthorized entry or other events could cause us to cease or delay development of some or all of our product candidates. Although we maintain property damage and business interruption insurance coverage on these facilities, our insurance might not cover all losses under such circumstances and our business may be seriously harmed by such delays and interruption.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business is subject to economic, political, regulatory and other risks associated with international operations.</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business is subject to risks associated with conducting business internationally. Some of our suppliers and collaborative relationships are located outside the United States. Accordingly, our future results could be harmed by a variety of factors, including:</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">economic weakness, including inflation, or political instability in particular non-U.S. economies and markets;</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">104</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:4pt"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5ae1cfc88aa4492caf56e9d4ac91e096_7">Table of Contents</a></span></div></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">differing and changing regulatory requirements in non-U.S. countries;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">challenges enforcing our contractual and intellectual property rights, especially in those foreign countries that do not respect and protect intellectual property rights to the same extent as the United States;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">difficulties in compliance with non-U.S. laws and regulations;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">changes in non-U.S. regulations and customs, tariffs and trade barriers;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">changes in non-U.S. currency exchange rates and currency controls;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">changes in a specific country&#8217;s or region&#8217;s political or economic environment;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">trade protection measures, import or export licensing requirements or other restrictive actions by U.S. or non-U.S. governments;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">negative consequences from changes in tax laws;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">workforce uncertainty in countries where labor unrest is more common than in the United States;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">difficulties associated with staffing and managing international operations, including differing labor relations;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">potential liability under the FCPA, UK Bribery Act or comparable foreign laws;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">business interruptions resulting from geo-political actions, including war and terrorism, natural disasters including earthquakes, typhoons, floods and fires, or health epidemics such as COVID-19; and</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">cyberattacks, which are growing in frequency, sophistication and intensity, and are becoming increasingly difficult to detect.</span></div><div style="padding-left:36pt;text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These and other risks associated with our planned international operations may materially adversely affect our ability to attain profitable operations.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">105</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:4pt"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5ae1cfc88aa4492caf56e9d4ac91e096_7">Table of Contents</a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, we had federal net operating loss carryforwards of approximately $212.7 million, federal research and development tax credit carryforwards of approximately $20.4 million, and orphan tax credit carryforwards of approximately $3.3 million, some of which will begin to expire in 2035. Under Sections 382 and 383 of the United States Internal Revenue Code of 1986, as amended, (the "Code"), if a corporation undergoes an &#8220;ownership change&#8221; (generally defined as a greater than 50-percentage-point cumulative change (by value) in the equity ownership of certain stockholders over a rolling three-year period), the corporation&#8217;s ability to use its pre-change net operating loss carryforwards and other pre-change tax attributes to offset its post-change taxable income or taxes may be limited. As a result of our IPO in December 2017, our follow-on offering in January 2020, and private placements and other transactions that have occurred since our incorporation, we may have experienced such an ownership change. We may also experience ownership changes in the future as a result of subsequent shifts in our stock ownership, some of which are outside our control. As a result, our ability to use our pre-change net operating loss carryforwards and other pre-change tax attributes to offset post-change taxable income or taxes may be subject to limitation.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to adverse legislative or regulatory tax changes that could negatively impact our financial condition.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The rules dealing with U.S. federal, state and local income taxation are constantly under review by persons involved in the legislative process and by the IRS and the U.S. Treasury Department. Changes to tax laws (which changes may have retroactive application) could adversely affect our stockholders or us. In recent years, many such changes have been made and changes are likely to continue to occur in the future. For example, in December 2017, Congress passed the Tax Cuts and Jobs Act, which made broad and complex changes to the tax laws. We cannot predict whether, when, in what form, or with what effective dates, tax laws, regulations and rulings may be enacted, promulgated or decided, which could result in an increase in our, or our stockholders&#8217;, tax liability or require changes in the manner in which we operate in order to minimize increases in our tax liability.</span></div><div id="i5ae1cfc88aa4492caf56e9d4ac91e096_130"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Ownership of Our Common Stock</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The market price of our common stock has been and may continue to be volatile, which could result in substantial losses for investors.</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading price of our common stock has been and may continue to be highly volatile and could be subject to wide fluctuations in response to various factors, some of which are beyond our control. In addition to the factors discussed in this "Risk Factors" section and elsewhere in this report, these factors include:&#160;</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the success of existing or new competitive products or technologies;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the timing and results of clinical trials for our current product candidates and any future product candidates that we may develop;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:10pt">commencement or termination of collaborations for our product development and research programs;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">failure to achieve development, regulatory or commercialization milestones under our collaborations;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">failure or discontinuation of any of our product development and research programs;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">failure to develop our BBB platform technology;</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">106</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:4pt"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5ae1cfc88aa4492caf56e9d4ac91e096_7">Table of Contents</a></span></div></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">results of preclinical studies, clinical trials, or regulatory approvals of product candidates of our competitors, or announcements about new research programs or product candidates of our competitors;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">regulatory or legal developments in the United States and other countries;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">developments or disputes concerning patent applications, issued patents, or other proprietary rights;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the recruitment or departure of key personnel;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the level of expenses related to any of our research programs, clinical development programs, or product candidates that we may develop;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the results of our efforts to develop additional product candidates or products;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">actual or anticipated changes in estimates as to financial results, development timelines, or recommendations by securities analysts;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">announcement or expectation of additional financing efforts;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">sales of our common stock by us, our insiders, or other stockholders;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">variations in our financial results or those of companies that are perceived to be similar to us;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">changes in estimates or recommendations by securities analysts, if any, that cover our stock;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">changes in the structure of healthcare payment systems;</span></div><div style="padding-left:13.5pt;text-indent:4.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">adoption of new accounting standards or changes in accounting standards;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">ineffectiveness of our internal controls; </span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">significant lawsuits, including patent or stockholder litigation; </span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">market conditions in the pharmaceutical and biotechnology sectors; and</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">general economic, industry, and market conditions, including those caused by the COVID-19 pandemic.</span></div><div style="padding-left:36pt;text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In recent years, the stock market in general, and the market for pharmaceutical and biotechnology companies in particular, has experienced significant price and volume fluctuations that have often been unrelated or disproportionate to changes in the operating performance of the companies whose stock is experiencing those price and volume fluctuations. Broad market and industry factors may seriously affect the market price of our common stock, regardless of our actual operating performance. In the past, when the market price of a stock has been volatile, holders of that stock have instituted securities class action litigation against the company that issued the stock. If any of our stockholders were to bring a lawsuit against us, the defense and disposition of any such lawsuits could be costly and divert the time and attention of our management and harm our operating results, regardless of the merits of such a claim.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">107</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:4pt"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5ae1cfc88aa4492caf56e9d4ac91e096_7">Table of Contents</a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If securities analysts do not publish research or reports about our business or if they publish negative evaluations of our stock, the price of our stock and trading volume could decline.</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading market for our common stock relies in part on the research and reports that industry or financial analysts publish about us or our business. If one or more of the analysts covering our business downgrade their evaluations of our stock, the price of our stock could decline. If one or more of these analysts cease to cover our stock, we could lose visibility in the market for our stock, which in turn could cause our stock price or trading volume to decline.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sales of substantial amounts of our common stock in the public markets, or the perception that such sales might occur, could cause the market price of our common stock to decline significantly, even if our business is doing well.</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of a substantial number of shares of our common stock in the public market or the perception that these sales might occur, could depress the market price of our common stock and could impair our ability to raise capital through the sale of additional equity securities. We are unable to predict the effect that sales may have on the prevailing market price of our common stock.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of our common stock by current stockholders may make it more difficult for us to sell equity or equity-related securities in the future at a time and price that we deem reasonable or appropriate, and make it more difficult for you to sell shares of our common stock. </span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain holders of shares of our common stock have rights, subject to conditions, to require us to file registration statements covering their shares or to include their shares in registration statements that we may file for ourselves or other stockholders. Registration of these shares under the Securities Act would result in the shares becoming freely tradeable in the public market, subject to the restrictions of Rule 144 in the case of our affiliates. Any sales of securities by these stockholders could have a material adverse effect on the market price for our common stock.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have registered on Form S-8 all shares of common stock that are issuable under our 2017 Equity Incentive Plan and 2017 Employee Stock Purchase Plan. As a consequence, these shares can be freely sold in the public market upon issuance, subject to volume limitations applicable to affiliates.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Raising additional capital may cause dilution to our existing stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates.</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may seek additional capital through a combination of public and private equity offerings, debt financings, strategic partnerships and alliances and licensing arrangements. For example, in August 2020, we entered into the Provisional Biogen Collaboration Agreement, and in connection therewith issued and sold 13,310,243 shares of our common stock to Biogen in September 2020 for an aggregate purchase price of $465 million. We, and indirectly, our stockholders, will bear the cost of issuing and servicing all such securities. </span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because our decision to issue debt or equity securities in any future offering will depend on market conditions and other factors beyond our control, we cannot predict or estimate the amount, timing or nature of any future offerings. To the extent that we raise additional capital through the sale of equity or debt securities, your ownership interest will be diluted, and the terms may include liquidation or other preferences that adversely affect your rights as a stockholder. The incurrence of indebtedness would result in increased fixed payment obligations and could involve restrictive covenants, such as limitations on our ability to incur additional debt, limitations on our ability to acquire, sell or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">108</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:4pt"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5ae1cfc88aa4492caf56e9d4ac91e096_7">Table of Contents</a></span></div></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 12, 2019, we filed a shelf registration statement on Form S-3 (File No. 333-230232) with the Securities and Exchange Commission, which became effective upon filing. In January 2020, we sold 9.0 million shares of common stock in a follow-on offering pursuant to this registration statement. The shelf registration continues to allow us to sell, from time to time, an unspecified number of shares of common stock; shares of preferred stock; debt securities; warrants to purchase shares of common stock, preferred stock, or other securities; purchase contracts; and units representing two or more of the foregoing securities. Additionally, collaborations we enter into with third parties may provide capital in the near term but limit our potential cash flow and revenue in the future. If we raise additional funds through strategic partnerships and alliances and licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies or product candidates, or grant licenses on terms unfavorable to us.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our principal stockholders and management own a significant percentage of our stock and will be able to exercise significant influence over matters subject to stockholder approval.</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2021, our directors, executive officers, holders of more than 5% of our outstanding stock and their respective affiliates beneficially own shares representing more than 50.0% of our outstanding common stock. As a result, these stockholders, if they act together, may significantly influence all matters requiring stockholder approval, including the election of directors and approval of significant corporate transactions. This concentration of ownership may have the effect of delaying or preventing a change in control of our company that our other stockholders may believe is in their best interests. This in turn could have a material adverse effect on our stock price and may prevent attempts by our stockholders to replace or remove the board of directors or management.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to maintain effective internal controls, our business, financial position and results of operations and growth prospects could be adversely affected.</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a public company, we are subject to reporting and other obligations under the Securities Exchange Act of 1934, as amended, (the "Exchange Act"), including the requirements of Section 404 of the Sarbanes-Oxley Act, which require annual management assessments of the effectiveness of our internal control over financial reporting. </span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The rules governing the standards that must be met for management and our auditors to assess our internal control over financial reporting are complex and require significant documentation, testing and possible remediation to meet the detailed standards under the rules. During the course of its testing, our management or auditors may identify material weaknesses or deficiencies which may not be remedied in time to meet the deadline imposed by the Sarbanes-Oxley Act. These reporting and other obligations place significant demands on our management and administrative and operational resources, including accounting resources.</span></div><div style="margin-top:1pt;text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management is responsible for establishing and maintaining adequate internal control over financial reporting. Our internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with U.S. GAAP. Any failure to maintain effective internal controls could have an adverse effect on our business, financial position, results of operations and growth prospects.</span></div><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">109</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:4pt"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5ae1cfc88aa4492caf56e9d4ac91e096_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to the periodic reporting requirements of the Exchange Act. We designed our disclosure controls and procedures to reasonably assure that information we must disclose in reports we file or submit under the Exchange Act is accumulated and communicated to management, and recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC. We believe that any disclosure controls and procedures or internal controls and procedures, no matter how well-conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements due to error or fraud may occur and not be detected.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have not paid and do not expect to pay any dividends for the foreseeable future. Any return on investment may be limited to the value of our common stock. Investors may never obtain a return on their investment.</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have never paid cash dividends on our common stock and do not anticipate that we will pay any dividends in the foreseeable future. We currently intend to retain our future earnings, if any, to maintain and expand our existing operations. If we do not pay dividends, our common stock may be less valuable because a return on your investment will only occur if our stock price appreciates, which may never occur.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Delaware law and provisions in our charter documents might discourage, delay, or prevent a change in control of our company or changes in our management and, therefore, depress the trading price of our common stock.</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions in our amended and restated certificate of incorporation and amended and restated bylaws may discourage, delay, or prevent a merger, acquisition, or other change in control that stockholders may consider favorable, including transactions in which you might otherwise receive a premium for your shares of our common stock. These provisions may also prevent or frustrate attempts by our stockholders to replace or remove our management. Therefore, these provisions could adversely affect the price of our common stock.&#160;Among other things, our charter documents:</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">establish that our board of directors is divided into three classes, Class I, Class II and Class III, with each class serving staggered three-year terms;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">provide that vacancies on our board of directors may be filled only by a majority of directors then in office, even though less than a quorum;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">provide that our directors may only be removed for cause;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">eliminate cumulative voting in the election of directors;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">authorize our board of directors to issues shares of preferred stock and determine the price and other terms of those shares, including preferences and voting rights, without stockholder approval;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">provide our board of directors with the exclusive right to elect a director to fill a vacancy or newly created directorship;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">permit stockholders to only take actions at a duly called annual or special meeting and not by written consent;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">110</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:4pt"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5ae1cfc88aa4492caf56e9d4ac91e096_7">Table of Contents</a></span></div></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">prohibit stockholders from calling a special meeting of stockholders;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">require that stockholders give advance notice to nominate directors or submit proposals for consideration at stockholder meetings;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">authorize our board of directors, by a majority vote, to amend the bylaws; and</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">require the affirmative vote of at least 66 2/3% or more of the outstanding shares of common stock to amend many of the provisions described above.</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, Section&#160;203 of the General Corporation Law of the State of Delaware, (the "DGCL"), prohibits a publicly-held Delaware corporation from engaging in a business combination with an interested stockholder, generally a person which together with its affiliates owns, or within the last three years has owned, 15.0% of our voting stock, for a period of three years after the date of the transaction in which the person became an interested stockholder, unless the business combination is approved in a prescribed manner.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any provision of our amended and restated certificate of incorporation, amended and restated bylaws, or Delaware law that has the effect of delaying or preventing a change in control could limit the opportunity for our stockholders to receive a premium for their shares of our capital stock and could also affect the price that some investors are willing to pay for our common stock.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware and the federal district courts of the United States of America will be the exclusive forums for substantially all disputes between us and our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers, or employees.</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware is the exclusive forum for:</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">any derivative action or proceeding brought on our behalf;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">any action asserting a claim of breach of fiduciary duty;</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">any action asserting a claim against us arising under the DGCL, our amended and restated certificate of incorporation, or our amended and restated bylaws; and</span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">any action asserting a claim against us that is governed by the internal-affairs doctrine.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our amended and restated certificate of incorporation further provides that the federal district courts of the United States of America will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These exclusive-forum provisions may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers, or other employees, which may discourage lawsuits against us and our directors, officers, and other employees. If a court were to find either exclusive-forum provision in our amended and restated certificate of incorporation to be inapplicable or unenforceable in an action or we do not enforce such provision, we may incur additional costs associated with resolving the dispute in other jurisdictions, which could seriously harm our business.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">111</span></div></div></div><div id="i5ae1cfc88aa4492caf56e9d4ac91e096_133"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:4pt"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5ae1cfc88aa4492caf56e9d4ac91e096_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2.&#160;&#160;&#160;&#160; UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Sales of Unregistered Securities</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 22, 2020, we issued and sold 13,310,243 shares of our common stock to Biogen for an aggregate purchase price of $465.0 million pursuant to the terms of a common stock purchase agreement with Biogen and in connection with the Biogen Collaboration Agreement. No underwriters were involved in the sale and the book entry position representing the securities sold and issued contain legends restricting transfer of the securities without registration under the Securities Act or an applicable exemption from registration.</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The offer, sale and issuance of the securities described above was exempt from registration under the Securities Act under Section 4(a)(2) of the Securities Act as a transaction by an issuer not involving a public offering. The recipient of securities in this transaction acquired the securities for investment only and not with a view to or for sale in connection with any distribution thereof and appropriate legends were affixed to the securities issued in this transaction. The recipient of securities in this transaction was an accredited person and had adequate access, through employment, business or other relationships, to information about the registrant.</span></div><div style="margin-bottom:10pt;margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Proceeds from Registered Securities</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 28, 2020, we sold 9.0 million shares of common stock (inclusive of shares sold pursuant to an overallotment option granted to the underwriters in connection with the offering) through an underwritten public offering at a price of $23.00 per share for aggregate net proceeds of $193.9 million. There has been no material change in the planned use of the net proceeds from the follow-on public offering as described in our final prospectus supplement filed with the SEC on January 29, 2020. We invested the funds received in short-term, interest-bearing investment-grade securities and government securities.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Issuer Purchases of Equity Securities</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable. </span></div><div id="i5ae1cfc88aa4492caf56e9d4ac91e096_136"></div><div style="margin-top:18pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3.&#160;&#160;&#160;&#160; DEFAULTS UPON SENIOR SECURITIES</span></div><div style="margin-top:10pt;text-indent:25pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i5ae1cfc88aa4492caf56e9d4ac91e096_139"></div><div style="margin-top:18pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4.  MINE SAFETY DISCLOSURES</span></div><div style="margin-top:10pt;text-indent:25pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i5ae1cfc88aa4492caf56e9d4ac91e096_142"></div><div style="margin-top:18pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 5.  OTHER INFORMATION</span></div><div style="margin-top:10pt;text-indent:25pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">112</span></div></div></div><div id="i5ae1cfc88aa4492caf56e9d4ac91e096_145"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:4pt"><span><br/></span></div><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5ae1cfc88aa4492caf56e9d4ac91e096_7">Table of Contents</a></span></div></div><div style="-sec-extract:summary;margin-top:2pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 6.&#160;&#160;&#160;&#160; EXHIBITS</span></div><div style="margin-top:2pt"><span><br/></span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT INDEX</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:8.049%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.535%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.160%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.617%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.728%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.301%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Incorporated by Reference</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Form</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">File No.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Filing Date</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.1+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex101amendandrestoutsidedi.htm">Amended and Restated Outside Director Compensation Policy</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Filed herewith</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.2+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1714899/000171489920000118/exhibit106q32020.htm">Amended and Restated Key Executive Change in Control and Severance Plan.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-38311</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.6</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11/5/20</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit311q12021.htm">Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Filed herewith</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit312q12021.htm">Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Filed herewith</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit321q12021.htm">Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Furnished herewith</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32.2*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit322q12021.htm">Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Furnished herewith</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Incline XBRL document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Furnished herewith</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Furnished herewith</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Furnished herewith</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Furnished herewith</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Furnished herewith</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Furnished herewith</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">The cover page from the Company's Quarterly Report on Form 10-Q for the three months ended March 31, 2021, formatted in Inline XBRL (contained in Exhibit 101)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Furnished herewith</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.490%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.421%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.421%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.421%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.421%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.422%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">*</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The certifications attached as Exhibits 32.1 and 32.2 that accompany this Quarterly Report on Form 10-Q are not deemed filed with the Securities and Exchange Commission and are not to be incorporated by reference into any filing of Denali Therapeutics Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Form 10-Q, irrespective of any general incorporation language contained in such filing. </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 10pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Indicates management contract or compensatory plan.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center;text-indent:27pt"><span><br/></span></div><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">113</span></div></div></div><div id="i5ae1cfc88aa4492caf56e9d4ac91e096_148"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:4pt"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5ae1cfc88aa4492caf56e9d4ac91e096_7">Table of Contents</a></span></div></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:9pt;text-indent:30pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. </span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.150%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.098%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.617%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.088%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">DENALI THERAPEUTICS INC.</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 5, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/ Ryan J. Watts</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ryan J. Watts, Ph.D.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">President and Chief Executive Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(Principal Executive Officer)</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 5, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/ Steve E. Krognes</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Steve E. Krognes</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Chief Financial Officer and Treasurer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(Principal Financial and Accounting Officer)</span></div></td></tr></table></div><div><span><br/></span></div><div style="padding-left:261pt;text-indent:27pt"><span><br/></span></div><div style="padding-left:261pt;text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">114</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>ex101amendandrestoutsidedi.htm
<DESCRIPTION>EX-10.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i52d46b9bb272409bbf03c1e75c819d06_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">  Exhibit 10.1</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DENALI THERAPEUTICS INC.</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OUTSIDE DIRECTOR COMPENSATION POLICY</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Initially adopted and approved November 10, 2017&#59; most recently amended and restated April&#160;16, 2021 (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restatement Date</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;)</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Denali Therapeutics Inc. (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Company</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;)&#160;believes that granting equity and cash compensation to members of its Board of Directors (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Board</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,&#8221; and members of the Board, the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Directors</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;)&#160;represents an effective tool to attract, retain, and reward Directors who are not employees of the Company (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Outside Directors</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;).  This Outside Director Compensation Policy as amended and restated (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Policy</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;)&#160; formalizes the Company&#8217;s policy regarding cash compensation and grants of equity to its Outside Directors.  Unless otherwise defined in this Policy, any capitalized terms used in this Policy will have the meaning given such term in the Company&#8217;s 2017 Equity Incentive Plan, as amended from time to time (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Plan</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), or if the Plan is no longer in use at the time of an equity award, the meaning given such term or any similar term in the equity plan then in place under which such equity award is granted.  Each Outside Director will be solely responsible for any tax obligations incurred by such Outside Director as a result of the equity and cash payments such Outside Director receives under this Policy.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This amended and restated Policy will be effective as of the Restatement Date.</font></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:9.67pt;text-decoration:underline">CASH COMPENSATION</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Annual Cash Retainer</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each Outside Director will be paid an annual cash retainer of $40,000.  There are no per-meeting attendance fees for attending Board meetings or meetings of any committee of the Board.  </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Non-Executive Chair, Committee Chair and Committee Member Annual Cash Retainer</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective beginning for calendar year 2021, each Outside Director who serves as the non-executive Chair of the Board, chair of a committee of the Board, or member of a committee of the Board will be eligible to earn additional annual cash retainers as follows&#58; </font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.861%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.959%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-Executive Chair of the Board</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$35,000</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chair of Audit Committee&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$20,000</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Member of Audit Committee&#58;                        (excluding Committee Chair)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$10,000</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chair of Compensation Committee&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$15,000</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Member of Compensation Committee&#58;           (excluding Committee Chair)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$7,500</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chair of Nominating and Governance Committee&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$10,000</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Member of Nominating and Governance Committee&#58;                                                         (excluding Committee Chair)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$5,000</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chair of Science and Technology Committee&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$15,000</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Member of Science and Technology Committee&#58;        (excluding Committee Chair)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$7,500</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:justify"><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Payment&#160;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each annual cash retainer under this Policy will be paid quarterly in arrears on a prorated basis to each Outside Director who has served in the relevant capacity at any point during the immediately preceding fiscal quarter, and such payment shall be made no later than thirty (30) days following the end of such immediately preceding fiscal quarter. For the avoidance of doubt, cash retainers payable for the fiscal quarter containing the Restatement Date will be paid at the rates in effect on the Restatement Date. For purposes of clarification, an Outside Director who has served as an Outside Director, as non-executive Chair of the Board or as a member of an applicable committee (or chair thereof), as applicable, during only a portion of the relevant Company fiscal quarter will receive a pro-rated payment of the quarterly payment of the applicable annual cash retainer(s), calculated based on the number of days during such fiscal quarter such Outside Director has served in the relevant capacities.</font></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:9.67pt;text-decoration:underline">EQUITY COMPENSATION</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside Directors may receive any Awards (except Incentive Stock Options)&#160;under the Plan (or the applicable equity plan in place at the time of grant), including discretionary Awards not covered under this Policy.  All grants of Awards to Outside Directors under this Section&#160;2 will be automatic and nondiscretionary, except as otherwise provided herein, and will be made in accordance with the following provisions and all other provisions of the Plan that are not inconsistent with this Policy&#58;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.78pt;text-decoration:underline">Initial Awards</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:31.01pt;text-decoration:underline">Initial Stock Options</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Subject to Section 11 of the Plan, each person who first becomes an Outside Director on or following the Restatement Date automatically will be granted a Nonstatutory Stock Option (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Initial Option</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) covering the number of Shares equal to (x) the Initial Award Base Number </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">multiplied by </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(y) sixty percent (60%)&#59; provided, however, that the number of Shares covered by an Initial Option will be rounded down to the nearest whole Share.  The Initial Option grant will be effective on the date on which such person first becomes an Outside Director on or following the Restatement Date, whether through election by the stockholders of the Company or appointment by the Board to fill a vacancy.  Notwithstanding the foregoing, a Director who was an Employee (an &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inside Director</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) who ceases to be an Inside Director, but who remains a Director, will not receive an Initial Option. Subject to Section&#160;5 below and Section&#160;14 of the Plan, each Initial Option will vest and become exercisable as to twenty-five percent (25%) of the Shares subject to the Initial Option on the one (1)-year anniversary of the date of grant and as to one-forty-eighth (1&#47;48</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) of the Shares subject to the Initial Option on each monthly anniversary of the date of grant thereafter (and if there is no corresponding day, on the last day of the month), in each case, provided that the Outside Director continues to serve as an Outside Director through the applicable vesting date.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.79pt;text-decoration:underline">Initial Restricted Stock Unit Awards</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Subject to Section 11 of the Plan, each person who first becomes an Outside Director on or following the Restatement Date automatically will be granted a Restricted Stock Unit Award (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Initial RSU</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) covering the number of Shares determined by </font></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">taking the product of (x) the Initial Award Base Number </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">multiplied by </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(y) forty percent (40%)&#59; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">and</font></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">dividing such product by two (2) (representing a conversion to the Initial RSU Share number based on a 2&#58;1 option to RSU ratio)&#59;</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">provided, however, that the number of Shares covered by an Initial RSU will be rounded down to the nearest whole Share.  The Initial RSU will be effective on the date on which such person first becomes an Outside Director on or following the Restatement Date, whether through election by the stockholders of the Company or appointment by the Board to fill a vacancy&#59;.  Notwithstanding the foregoing, an Inside Director who ceases to be an Inside Director, but who remains a Director, will not receive an Initial RSU. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - 2 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:justify"><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to Section&#160;5 below and Section&#160;14 of the Plan, each Initial RSU will vest as to twenty-five percent (25%) of the Shares subject to the Initial RSU on each of the one (1)-year, two (2)-year and three (3)-year anniversaries of the date of grant (and if there is no corresponding day, on the last day of the month), and as to twenty-five percent (25%) of the Shares subject to the Initial RSU on the earlier of the four (4)-year anniversary of the grant date (and if there is no corresponding day, on the last day of the month) or the day prior to the Company&#8217;s next Annual Meeting occurring after the three (3)-year anniversary of the date of grant, in each case, provided that the Outside Director continues to serve as an Outside Director through the applicable vesting date.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:49.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.28pt;text-decoration:underline">Initial Award Base Number</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  For purposes of this Policy, &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Initial Award Base Number</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the number of Shares that would be subject to an Option with a Value of $600,000 if such Option was granted under the Plan on the date on which such person first becomes an Outside Director on or following the Restatement Date.</font></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-22.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.84pt;text-decoration:underline">Annual Awards</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:31.01pt;text-decoration:underline">Annual Stock Options</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Subject to Section&#160;11 of the Plan and to the following sentence, on the date of each annual meeting of stockholders of the Company (each, an &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Annual Meeting</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), beginning with the first Annual Meeting following the Restatement Date, each Outside Director automatically will be granted a Nonstatutory Stock Option (an&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Annual Option</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) covering the number of Shares equal to (x) the Annual Award Base Number </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">multiplied by </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(y) sixty percent (60%)&#59; provided that the number of Shares covered by each Annual Option will be rounded down to the nearest whole Share. Each Annual Option will be effective on the date of the applicable Annual Meeting, if, as of such Annual Meeting date, the applicable Outside Director will have served on the Board as a Director for at least the preceding six (6) months&#59; provided that any Outside Director who is not continuing as a Director following the applicable Annual Meeting will not receive an Annual Option with respect to such Annual Meeting.  Subject to Section&#160;5 below and Section&#160;14 of the Plan, each Annual Option will vest and become exercisable as to one hundred percent (100%) of the Shares subject thereto upon the earlier of the one (1) year anniversary of the grant date or the day prior to the Company&#8217;s next Annual Meeting occurring after the grant date, in each case, provided that the Outside Director continues to serve as an Outside Director through the applicable vesting date.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.79pt;text-decoration:underline">Annual Restricted Stock Unit Awards</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Subject to Section&#160;11 of the Plan and to the following sentence, on the date of each Annual Meeting, beginning with the first Annual Meeting following the Restatement Date, each Outside Director automatically will be granted a Restricted Stock Unit Award (an&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Annual RSU</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; and, together with the Annual Options, the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Annual Awards</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) covering the number of Shares determined by&#58;</font></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">taking the product of (x) the Annual Award Base Number </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">multiplied by </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(y) forty percent (40%)&#59; and</font></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">dividing such product by two (2) (representing a conversion to the Annual RSU Share number based on a 2&#58;1 option to RSU ratio)&#59;</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">provided that the number of Shares covered by each Annual RSU will be rounded down to the nearest whole Share.  Each Annual RSU will be effective on the date of the applicable Annual Meeting, if, as of such Annual Meeting date, the applicable Outside Director will have served on the Board as a Director for at least the preceding six (6) months&#59; provided that any Outside Director who is not continuing as a Director following the applicable Annual Meeting will not receive an Annual RSU with respect to such Annual Meeting.  Subject to Section&#160;5 below and Section&#160;14 of the Plan, each Annual RSU will vest as to one hundred percent (100%) of the Shares subject thereto upon the earlier of the one (1) year anniversary of the grant date or the day prior to the Company&#8217;s next Annual Meeting occurring after the grant date, in each case, provided that the Outside Director continues to serve as an Outside Director through the applicable vesting date.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - 3 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:justify"><font><br></font></div></div><div style="margin-top:12pt;text-align:justify;text-indent:49.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.28pt;text-decoration:underline">Annual Award Base Number</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  For purposes of this Policy, &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Annual Award Base Number</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the number of Shares that would be subject to an Option with a Value of $350,000 if such Option was granted under the Plan on the date of the applicable Annual Meeting.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:49.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.28pt;text-decoration:underline">Value</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  For purposes of this Policy, &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Value</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means, with respect to a stock option, its grant date value calculated in accordance with the Black-Scholes option valuation methodology utilized by the Company for equity grants to Company executives, or such other methodology the Board or Compensation Committee may determine prior to the grant of the stock option becoming effective, as applicable, consistent, as determined by the Board or Compensation Committee, with the general methodology used to value equity grants to Company executives.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </font></div><div style="margin-top:12pt;text-align:justify;text-indent:49.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.07pt;text-decoration:underline">No Discretion</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  No person will have any discretion to select which Outside Directors will be granted any Awards under this Policy or to determine the number of Shares to be covered by such Awards, as applicable (except as provided in Section&#160;6 below).</font></div><div style="margin-top:12pt;text-align:justify;text-indent:49.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(g)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.28pt;text-decoration:underline">Terms Applicable to all Options Granted Under this Policy</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The per Share exercise price for an Option granted under this Policy will be one hundred percent (100%) of the Fair Market Value on the grant date.  The maximum term to expiration of an Option granted under this Policy will be ten (10) years, subject to earlier termination as provided in the Plan.</font></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:9.67pt;text-decoration:underline">EXPENSES</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each Outside Director&#8217;s reasonable, customary, and properly documented expenses in connection with service on the Board or any committee of the Board will be reimbursed by the Company. </font></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:9.67pt;text-decoration:underline">OUTSIDE DIRECTOR COMPENSATION LIMITS</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Until at least the date of the Annual Meeting held in 2025 (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2025 Annual Meeting</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), neither the cash retainers nor the Value of equity compensation payable under this Policy to Outside Directors will be raised to a level that is in excess of the 75</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> percentile of the cash retainers or value of equity award compensation, respectively, paid by the then-applicable Peer Group to their non-employee directors.  For purposes of this Policy, &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Peer Group</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the peer group of the Company as approved by the Compensation Committee of the Board (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Compensation Committee</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) or the Board from time to time.  </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notwithstanding the foregoing, newly elected or appointed Outside Directors may receive total cash and equity compensation in connection with their initial appointment or election to the Board having an aggregate value (with value of equity compensation calculated as the Value of such equity compensation under the Policy) of up to two times (2x) the total of (x) the aggregate amount of annual cash retainers (for the avoidance of doubt, including all cash retainers for serving as an Outside Director, including cash retainers for serving as non-executive Chair of the Board or as a chair or member of an applicable committee) that could be provided to any incumbent Outside Director under the terms of the Policy as then in effect, and (y) the Value of Annual Awards that could be provided to any incumbent Outside Director under the terms of the Policy as then in effect.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company will assess and determine its Peer Group annually based on such factors as the Compensation Committee or the Board, as applicable, deems relevant after discussion with the Compensation Committee&#8217; compensation consultant, and shall consider, among other companies as determined appropriate by the Compensation Committee or the Board, as applicable, for selection as Peer Group companies those companies which are&#58; (a) operating in the same industries as the Company (by reference to Global Industry Classification Standard code or similar reasonable identifiers, which may change from time to time), and (b) similar in size to the Company based on market capitalization (or, during volatile market conditions, revenue, if so determined by the Compensation Committee or the Board, as applicable).</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - 4 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:justify"><font><br></font></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notwithstanding anything in the foregoing to the contrary, all determinations related to the foregoing, including but not limited to the determination of the Peer Group, the cash retainers and value of equity award compensation paid by the Peer Group and&#47;or under the Policy to incumbent Outside Directors, the determination of what constitutes the 75</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> percentile of such amounts, and the date or dates as of which such 75</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> percentile is to be assessed will be determined in the good faith of the Compensation Committee or the Board after consideration of the advice of the Compensation Committee&#8217;s compensation consultant as contemplated above.</font></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:9.67pt;text-decoration:underline">ADDITIONAL PROVISIONS</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All provisions of the Plan and form of award agreement approved for use under the Plan not inconsistent with this Policy will apply to Awards granted to Outside Directors.</font></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:9.67pt;text-decoration:underline">SECTION 409A</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is the intent of this Policy that this Policy and all payments hereunder be exempt from or otherwise comply with the requirements of Section&#160;409A (as defined below) so that none of the compensation to be provided hereunder will be subject to the additional tax imposed under 409A of the Internal Revenue Code of 1986, as amended, and the final regulations and guidance thereunder, as may be amended from time to time (together, &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section&#160;409A</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), and any ambiguities or ambiguous terms herein will be interpreted to be so exempt or comply.  In no event will cash compensation or expense reimbursement payments under this Policy be paid after the later of (i)&#160;15th day of the 3rd month following the end of the Company&#8217;s fiscal year in which the compensation is earned or expenses are incurred, as applicable, or (ii)&#160;15th day of the 3rd month following the end of the calendar year in which the compensation is earned or expenses are incurred, as applicable.  As such, all payments under this Policy are intended to fall within the &#8220;short-term deferral&#8221; exception under Section 409A.  In no event will the Company be obligated to reimburse an Outside Director for any taxes imposed or other costs incurred as a result of Section&#160;409A or otherwise because of the receipt of compensation under this Policy.</font></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:9.67pt;text-decoration:underline">REVISIONS</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except as provided herein, he Board or any committee designated by the Board (a &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Designated Committee</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), may amend, suspend or terminate this Policy at any time and for any reason.  Unless determined otherwise by the Board, the Compensation Committee is a Designated Committee under this Policy. This includes, that the Board or a Designated Committee in its discretion may at any time change and otherwise revise the terms of the cash compensation granted under this Policy, including, without limitation, the amount of cash and timing of unearned compensation to be paid on or after the date the Board or a Designated Committee, as applicable determines to make any such change or revision.  Any amendment to the terms of any cash compensation granted under the Policy will be effective no earlier than the date such amendment is made. Further, except as provide herein, the Board or a Designated Committee in its discretion may at any time change and otherwise revise the terms of Awards granted under this Policy, including, without limitation, the number of Shares subject thereto, the vesting schedule of Awards, and the type of Awards to be granted on or after the date the Board or a Designated Committee, as applicable, determines to make any such change or revision.  If, on the date of an Award grant under this Policy, an equity incentive plan other than the Plan is the primary equity incentive plan used by the Company, all references to the Plan in this Policy shall, with respect to such Award, be deemed to refer to the Company&#8217;s primary equity incentive plan in use at the time of such Award grant, including that references to Section&#160;11 of the Plan shall be deemed to refer to the section(s) of such primary equity incentive plan relating to the per person limits on the number or value of Shares that an Outside Director may receive under such plan during the period specified therein, and references to Section&#160;14 of the Plan shall be deemed to refer to the section(s) of such primary equity incentive plan relating to adjustments to the Shares, dissolution or liquidation or the Company, and&#47;or merger or Change in Control (or similar transactions) of the Company.  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - 5 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:justify"><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notwithstanding the foregoing, no amendment, alteration, suspension or termination of this Policy will materially impair the rights of an Outside Director with respect to compensation that already has been paid or awarded, unless otherwise mutually agreed between the Outside Director and the Company.  Further, and notwithstanding the foregoing, until at least the date of the 2025 Annual Meeting, this Policy shall not be amended in a manner inconsistent with the terms of the derivative settlement entered into by the Company on January 13, 2021 and referenced in the Form 8-K dated February 5, 2021.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Termination of this Policy will not affect the Board&#8217;s or the Compensation Committee&#8217;s ability to exercise the powers granted to it under the Plan with respect to Awards granted under the Plan pursuant to this Policy prior to the date of such termination.   </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - 6 -</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>exhibit311q12021.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i9a9a2b3722e24c92a8951850e94867a4_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF PERIODIC REPORT UNDER SECTION 302 OF </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-bottom:9pt;margin-top:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Ryan J. Watts, Ph.D., certify that&#58;</font></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">I have reviewed this Quarterly Report on Form 10-Q of Denali Therapeutics Inc.&#59;</font></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;  </font></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:76.5pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:76.5pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:76.5pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.23pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:76.5pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; </font></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:76.5pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:76.5pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div style="margin-bottom:10pt;margin-top:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; May&#160;5, 2021</font></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.201%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.932%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.567%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3pt;padding-right:3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Ryan J. Watts</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3pt;padding-right:3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ryan J. Watts, Ph.D.</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3pt;padding-right:3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></div></td></tr></table></div><div><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>exhibit312q12021.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i3933eff738ca41bbb2edad5d0157dbef_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF PERIODIC REPORT UNDER SECTION 302 OF</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">THE SARBANES-OXLEY ACT OF 2002</font></div><div><font><br></font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Steve E. Krognes, certify that&#58;</font></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">I have reviewed this Quarterly Report on Form 10-Q of Denali Therapeutics Inc.&#59;</font></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;  </font></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.23pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; </font></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:10pt;margin-top:9pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting. </font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; May&#160;5, 2021</font></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.198%"><tr><td style="width:1.0%"></td><td style="width:32.502%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.194%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.004%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:3pt;padding-right:3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Steve E. Krognes</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3pt;padding-right:3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Steve E. Krognes</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3pt;padding-right:3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer and Treasurer</font></div></td></tr></table></div><div><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>exhibit321q12021.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i92e511222ce745089837c6c09fe15a97_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF EXECUTIVE OFFICER </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, (the &#8220;Exchange Act&#8221;) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. &#167;1350), I, Ryan J. Watts, Ph.D., President and Chief Executive Officer of Denali Therapeutics Inc. (the &#8220;Company&#8221;), hereby certify that&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">The Company&#8217;s Quarterly Report on Form 10-Q for the fiscal period ended March 31, 2021, to which this Certification is attached as Exhibit 32.1 (the &#8220;Periodic Report&#8221;), fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act&#59; and</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">The information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;margin-top:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%">Date&#58; May&#160;5, 2021</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:7.888%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.152%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.660%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Ryan J. Watts</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ryan J. Watts, Ph.D.</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>6
<FILENAME>exhibit322q12021.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i56be003a88f74f9790cdb2f0a2419e38_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.2</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div><font><br></font></div><div style="text-indent:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, (the &#8220;Exchange Act&#8221;) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. &#167;1350), I, Steve E. Krognes, Chief Financial Officer and Treasurer of Denali Therapeutics Inc. (the &#8220;Company&#8221;), hereby certify that&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">The Company&#8217;s Quarterly Report on Form 10-Q for the fiscal period ended March 31, 2021, to which this Certification is attached as Exhibit 32.2 (the &#8220;Periodic Report&#8221;), fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act&#59; and</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">The information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;margin-top:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%">Date&#58; May&#160;5, 2021</font></div><div style="margin-bottom:12pt;margin-top:10pt"><font><br></font></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:7.888%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.152%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.660%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Steve E. Krognes</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Steve E. Krognes</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer and Treasurer</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="margin-top:12pt;text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>dnli-20210331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:be7bc6f9-6af9-45b5-b822-49fcbbf3ecfb,g:6a95e0ad-15c9-4fb8-a5d1-2bfd737ebde3-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dnli="http://www.denalitherapeutics.com/20210331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.denalitherapeutics.com/20210331">
  <xs:import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2020-01-31" schemaLocation="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="dnli-20210331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="dnli-20210331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="dnli-20210331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="dnli-20210331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="DocumentandEntityInformation" roleURI="http://www.denalitherapeutics.com/role/DocumentandEntityInformation">
        <link:definition>0001001 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheets" roleURI="http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheets">
        <link:definition>1001002 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" roleURI="http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss">
        <link:definition>1003004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofOperationsandComprehensiveLossParenthetical" roleURI="http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossParenthetical">
        <link:definition>1004005 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofStockholdersEquity" roleURI="http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquity">
        <link:definition>1005006 - Statement - Condensed Consolidated Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofStockholdersEquityParenthetical" roleURI="http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical">
        <link:definition>1006007 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlows" roleURI="http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofCashFlows">
        <link:definition>1007008 - Statement - Condensed Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingPolicies" roleURI="http://www.denalitherapeutics.com/role/SignificantAccountingPolicies">
        <link:definition>2101101 - Disclosure - Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingPoliciesPolicies" roleURI="http://www.denalitherapeutics.com/role/SignificantAccountingPoliciesPolicies">
        <link:definition>2202201 - Disclosure - Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingPoliciesNarrativeDetails" roleURI="http://www.denalitherapeutics.com/role/SignificantAccountingPoliciesNarrativeDetails">
        <link:definition>2403401 - Disclosure - Significant Accounting Policies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.denalitherapeutics.com/role/FairValueMeasurements">
        <link:definition>2104102 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.denalitherapeutics.com/role/FairValueMeasurementsTables">
        <link:definition>2305301 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsScheduleofAssetsandLiabilitiesDetails" roleURI="http://www.denalitherapeutics.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesDetails">
        <link:definition>2406402 - Disclosure - Fair Value Measurements - Schedule of Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecurities" roleURI="http://www.denalitherapeutics.com/role/MarketableSecurities">
        <link:definition>2107103 - Disclosure - Marketable Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesTables" roleURI="http://www.denalitherapeutics.com/role/MarketableSecuritiesTables">
        <link:definition>2308302 - Disclosure - Marketable Securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesSummaryofAvailableforSaleSecuritiesDetails" roleURI="http://www.denalitherapeutics.com/role/MarketableSecuritiesSummaryofAvailableforSaleSecuritiesDetails">
        <link:definition>2409403 - Disclosure - Marketable Securities - Summary of Available for Sale Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesNarrativeDetails" roleURI="http://www.denalitherapeutics.com/role/MarketableSecuritiesNarrativeDetails">
        <link:definition>2410404 - Disclosure - Marketable Securities - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeFinancialInstruments" roleURI="http://www.denalitherapeutics.com/role/DerivativeFinancialInstruments">
        <link:definition>2111104 - Disclosure - Derivative Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeFinancialInstrumentsTables" roleURI="http://www.denalitherapeutics.com/role/DerivativeFinancialInstrumentsTables">
        <link:definition>2312303 - Disclosure - Derivative Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeFinancialInstrumentsSummaryofForwardForeignCurrencyExchangeContractsOutstandingDetails" roleURI="http://www.denalitherapeutics.com/role/DerivativeFinancialInstrumentsSummaryofForwardForeignCurrencyExchangeContractsOutstandingDetails">
        <link:definition>2413405 - Disclosure - Derivative Financial Instruments - Summary of Forward Foreign Currency Exchange Contracts Outstanding (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeFinancialInstrumentsNarrativeDetails" roleURI="http://www.denalitherapeutics.com/role/DerivativeFinancialInstrumentsNarrativeDetails">
        <link:definition>2414406 - Disclosure - Derivative Financial Instruments - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreements" roleURI="http://www.denalitherapeutics.com/role/CollaborationAgreements">
        <link:definition>2115105 - Disclosure - Collaboration Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsTables" roleURI="http://www.denalitherapeutics.com/role/CollaborationAgreementsTables">
        <link:definition>2316304 - Disclosure - Collaboration Agreements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsBiogenDetails" roleURI="http://www.denalitherapeutics.com/role/CollaborationAgreementsBiogenDetails">
        <link:definition>2417407 - Disclosure - Collaboration Agreements - Biogen (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsSanofiDetails" roleURI="http://www.denalitherapeutics.com/role/CollaborationAgreementsSanofiDetails">
        <link:definition>2418408 - Disclosure - Collaboration Agreements - Sanofi (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsSanofiPerformanceObligationDetails" roleURI="http://www.denalitherapeutics.com/role/CollaborationAgreementsSanofiPerformanceObligationDetails">
        <link:definition>2419409 - Disclosure - Collaboration Agreements - Sanofi Performance Obligation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsTakedaDetails" roleURI="http://www.denalitherapeutics.com/role/CollaborationAgreementsTakedaDetails">
        <link:definition>2420410 - Disclosure - Collaboration Agreements - Takeda (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsSummaryofCollaborationRevenueDetails" roleURI="http://www.denalitherapeutics.com/role/CollaborationAgreementsSummaryofCollaborationRevenueDetails">
        <link:definition>2421411 - Disclosure - Collaboration Agreements - Summary of Collaboration Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseAgreements" roleURI="http://www.denalitherapeutics.com/role/LicenseAgreements">
        <link:definition>2122106 - Disclosure - License Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseAgreementsNarrativeDetails" roleURI="http://www.denalitherapeutics.com/role/LicenseAgreementsNarrativeDetails">
        <link:definition>2423412 - Disclosure - License Agreements - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.denalitherapeutics.com/role/CommitmentsandContingencies">
        <link:definition>2124107 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesTables" roleURI="http://www.denalitherapeutics.com/role/CommitmentsandContingenciesTables">
        <link:definition>2325305 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesNarrativeDetails" roleURI="http://www.denalitherapeutics.com/role/CommitmentsandContingenciesNarrativeDetails">
        <link:definition>2426413 - Disclosure - Commitments and Contingencies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesSummaryofCompanysFutureMinimumLeaseCommitmentsDetails" roleURI="http://www.denalitherapeutics.com/role/CommitmentsandContingenciesSummaryofCompanysFutureMinimumLeaseCommitmentsDetails">
        <link:definition>2427414 - Disclosure - Commitments and Contingencies - Summary of Company's Future Minimum Lease Commitments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesSummaryofCompanysFutureMinimumLeaseCommitmentsDetails_1" roleURI="http://www.denalitherapeutics.com/role/CommitmentsandContingenciesSummaryofCompanysFutureMinimumLeaseCommitmentsDetails_1">
        <link:definition>2427414 - Disclosure - Commitments and Contingencies - Summary of Company's Future Minimum Lease Commitments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesSummaryofCompanysFutureMinimumLeaseReceivablesDetails" roleURI="http://www.denalitherapeutics.com/role/CommitmentsandContingenciesSummaryofCompanysFutureMinimumLeaseReceivablesDetails">
        <link:definition>2428415 - Disclosure - Commitments and Contingencies - Summary of Company's Future Minimum Lease Receivables (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedAwards" roleURI="http://www.denalitherapeutics.com/role/StockBasedAwards">
        <link:definition>2129108 - Disclosure - Stock-Based Awards</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedAwardsTables" roleURI="http://www.denalitherapeutics.com/role/StockBasedAwardsTables">
        <link:definition>2330306 - Disclosure - Stock-Based Awards (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedAwardsSummaryofStockOptionActivityDetails" roleURI="http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofStockOptionActivityDetails">
        <link:definition>2431416 - Disclosure - Stock-Based Awards - Summary of Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedAwardsSummaryofAssumptionsUsedforEstimatingtheFairValueofStockOptionsGrantedDetails" roleURI="http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofAssumptionsUsedforEstimatingtheFairValueofStockOptionsGrantedDetails">
        <link:definition>2432417 - Disclosure - Stock-Based Awards - Summary of Assumptions Used for Estimating the Fair Value of Stock Options Granted (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedAwardsSummaryofRestrictedStockActivityDetails" roleURI="http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofRestrictedStockActivityDetails">
        <link:definition>2433418 - Disclosure - Stock-Based Awards - Summary of Restricted Stock Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedAwardsSummaryofStockBasedCompensationExpenseDetails" roleURI="http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofStockBasedCompensationExpenseDetails">
        <link:definition>2434419 - Disclosure - Stock-Based Awards - Summary of Stock-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShare" roleURI="http://www.denalitherapeutics.com/role/NetLossPerShare">
        <link:definition>2135109 - Disclosure - Net Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareTables" roleURI="http://www.denalitherapeutics.com/role/NetLossPerShareTables">
        <link:definition>2336307 - Disclosure - Net Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareScheduleofDilutiveSecuritiesNotIncludedinDilutedPerShareCalculationsDetails" roleURI="http://www.denalitherapeutics.com/role/NetLossPerShareScheduleofDilutiveSecuritiesNotIncludedinDilutedPerShareCalculationsDetails">
        <link:definition>2437420 - Disclosure - Net Loss Per Share - Schedule of Dilutive Securities Not Included in Diluted Per Share Calculations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactions" roleURI="http://www.denalitherapeutics.com/role/RelatedPartyTransactions">
        <link:definition>2138110 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="dnli_LongTermInvestmentsMember" abstract="true" name="LongTermInvestmentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="dnli_AggregateClinicalRegulatoryAndSalesMilestonePayment" abstract="false" name="AggregateClinicalRegulatoryAndSalesMilestonePayment" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dnli_CommercialMember" abstract="true" name="CommercialMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="dnli_CollaborativeRevenueAbstract" abstract="true" name="CollaborativeRevenueAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="dnli_OptionFeesPerProgram" abstract="false" name="OptionFeesPerProgram" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dnli_RegulatoryMember" abstract="true" name="RegulatoryMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="dnli_CollaborativeArrangementNumberOfMilestonesAchieved" abstract="false" name="CollaborativeArrangementNumberOfMilestonesAchieved" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="dnli_CollaborativeArrangementNumberOfAdditionalProgramsIfCircumstancesMet" abstract="false" name="CollaborativeArrangementNumberOfAdditionalProgramsIfCircumstancesMet" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="dnli_VariableConsiderationFutureConsideration" abstract="false" name="VariableConsiderationFutureConsideration" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dnli_IncreaseDecreaseInContractWithCustomerLiabilityRelatedParties" abstract="false" name="IncreaseDecreaseInContractWithCustomerLiabilityRelatedParties" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dnli_OrganizationAndDescriptionOfBusinessPolicyPolicyTextBlock" abstract="false" name="OrganizationAndDescriptionOfBusinessPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="dnli_DevelopmentMilestonePayments" abstract="false" name="DevelopmentMilestonePayments" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dnli_UpfrontFeesPaid" abstract="false" name="UpfrontFeesPaid" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dnli_LongTermMarketableSecuritiesMember" abstract="true" name="LongTermMarketableSecuritiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="dnli_CollaborativeArrangementNumberOfAdditionalProgramsNoThirdPartyAgreementExecutedIfCircumstancesMet" abstract="false" name="CollaborativeArrangementNumberOfAdditionalProgramsNoThirdPartyAgreementExecutedIfCircumstancesMet" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="dnli_CollaborativeAgreementAgreedShareOfCommercialProfitLoss" abstract="false" name="CollaborativeAgreementAgreedShareOfCommercialProfitLoss" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="dnli_AggregateOptionExerciseFee" abstract="false" name="AggregateOptionExerciseFee" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dnli_OtherAccruedManufacturingCostsCurrent" abstract="false" name="OtherAccruedManufacturingCostsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dnli_CollaborativeArrangementUpfrontPaymentToBeReceived" abstract="false" name="CollaborativeArrangementUpfrontPaymentToBeReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dnli_ShortTermMarketableSecuritiesMember" abstract="true" name="ShortTermMarketableSecuritiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="dnli_SanofiMember" abstract="true" name="SanofiMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="dnli_TargetOptionPeriod" abstract="false" name="TargetOptionPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="dnli_OptionServicesMember" abstract="true" name="OptionServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="dnli_CollaborativeArrangementFirstCommercialSaleMilestonePaymentsToBeReceived" abstract="false" name="CollaborativeArrangementFirstCommercialSaleMilestonePaymentsToBeReceived" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dnli_PreclinicalMilestonePaymentPerProgram" abstract="false" name="PreclinicalMilestonePaymentPerProgram" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dnli_CommercialMilestonePayments" abstract="false" name="CommercialMilestonePayments" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dnli_RevenueNumberOfPerformanceObligations" abstract="false" name="RevenueNumberOfPerformanceObligations" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="dnli_ConstrainedVariableConsideration" abstract="false" name="ConstrainedVariableConsideration" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dnli_ContractWithCustomerLiabilityFromRelatedPartiesNoncurrent" abstract="false" name="ContractWithCustomerLiabilityFromRelatedPartiesNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dnli_BiogenMember" abstract="true" name="BiogenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="dnli_StockIssuedDuringPeriodValueEquityIncentivePlan" abstract="false" name="StockIssuedDuringPeriodValueEquityIncentivePlan" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dnli_ForeignExchangeForwardEurosMember" abstract="true" name="ForeignExchangeForwardEurosMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="dnli_PurchaseOrderExecuted" abstract="false" name="PurchaseOrderExecuted" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dnli_LandlordFundedTenantImprovementsMember" abstract="true" name="LandlordFundedTenantImprovementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="dnli_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueExpectedToVest" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueExpectedToVest" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:perShareItemType"/>
  <xs:element id="dnli_ROFNAndOptionAgreementCollaborativeArrangementMember" abstract="true" name="ROFNAndOptionAgreementCollaborativeArrangementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="dnli_CNSProductMember" abstract="true" name="CNSProductMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="dnli_ContractWithCustomerLiabilityFromRelatedPartiesCurrent" abstract="false" name="ContractWithCustomerLiabilityFromRelatedPartiesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dnli_IncreaseDecreaseInNonCashOperatingLeaseExpense" abstract="false" name="IncreaseDecreaseInNonCashOperatingLeaseExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dnli_OperatingLeasesSubleaseNetRentableArea" abstract="false" name="OperatingLeasesSubleaseNetRentableArea" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:areaItemType"/>
  <xs:element id="dnli_MilestoneTriggeredMember" abstract="true" name="MilestoneTriggeredMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="dnli_LicenseAgreementMilestonePaymentObligationResponsibilityPercentage" abstract="false" name="LicenseAgreementMilestonePaymentObligationResponsibilityPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="dnli_TransportVehicleTechnologyProgramRightOfFirstNegotiationProgramsMember" abstract="true" name="TransportVehicleTechnologyProgramRightOfFirstNegotiationProgramsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="dnli_SaleOfStockConsiderationPremiumReceivedOnTransaction" abstract="false" name="SaleOfStockConsiderationPremiumReceivedOnTransaction" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dnli_TransportVehicleTechnologyPlatformPreclinicalProgramsMember" abstract="true" name="TransportVehicleTechnologyPlatformPreclinicalProgramsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="dnli_NumberOfPrograms" abstract="false" name="NumberOfPrograms" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="dnli_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="dnli_LicenseAgreementMember" abstract="true" name="LicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="dnli_CollaborativeArrangementOptionExerciseAndDevelopmentMilestonePaymentsToBeReceived" abstract="false" name="CollaborativeArrangementOptionExerciseAndDevelopmentMilestonePaymentsToBeReceived" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dnli_RestrictedSharesSubjectToFutureVestingMember" abstract="true" name="RestrictedSharesSubjectToFutureVestingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="dnli_TakedaCollaborationAgreementMember" abstract="true" name="TakedaCollaborationAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="dnli_CollaborativeAgreementFundedPercentage" abstract="false" name="CollaborativeAgreementFundedPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="dnli_BiogenCollaborativeArrangementMember" abstract="true" name="BiogenCollaborativeArrangementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="dnli_AccruedClinicalCostsCurrent" abstract="false" name="AccruedClinicalCostsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dnli_SanofiCollaborationAgreementMember" abstract="true" name="SanofiCollaborationAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="dnli_NumberOfIndications" abstract="false" name="NumberOfIndications" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="dnli_RegulatoryMilestonePayment" abstract="false" name="RegulatoryMilestonePayment" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dnli_TakedaPharmaceuticalCompanyLimitedMember" abstract="true" name="TakedaPharmaceuticalCompanyLimitedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="dnli_TransportVehicleTechnologyPlatformRightOfFirstNegotiationProgramsMember" abstract="true" name="TransportVehicleTechnologyPlatformRightOfFirstNegotiationProgramsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="dnli_SharePurchaseAgreementMember" abstract="true" name="SharePurchaseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="dnli_AggregateDevelopmentFirstCommercialSaleAndNetSalesBasedMilestonePayments" abstract="false" name="AggregateDevelopmentFirstCommercialSaleAndNetSalesBasedMilestonePayments" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dnli_LesseeOperatingLeaseRenewalNoticePeriod" abstract="false" name="LesseeOperatingLeaseRenewalNoticePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="dnli_PreclinicalMilestonePaymentReceived" abstract="false" name="PreclinicalMilestonePaymentReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dnli_ClinicalMilestonePayment" abstract="false" name="ClinicalMilestonePayment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dnli_CollaborativeArrangementNetSalesBasedMilestonePaymentsToBeReceived" abstract="false" name="CollaborativeArrangementNetSalesBasedMilestonePaymentsToBeReceived" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dnli_OperatingLeasesAreaUnderLease" abstract="false" name="OperatingLeasesAreaUnderLease" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:areaItemType"/>
  <xs:element id="dnli_CollaborativeArrangementATVTREM2Member" abstract="true" name="CollaborativeArrangementATVTREM2Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="dnli_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" abstract="false" name="LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dnli_LicenseAgreementMilestonePaymentUponAchievementOfClinicalAndRegulatoryMilestones" abstract="false" name="LicenseAgreementMilestonePaymentUponAchievementOfClinicalAndRegulatoryMilestones" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dnli_CollaborationAgreementTransactionPriceIncrease" abstract="false" name="CollaborationAgreementTransactionPriceIncrease" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dnli_PaymentsForManufacturingCost" abstract="false" name="PaymentsForManufacturingCost" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dnli_NewPremisesSubleaseAgreementMember" abstract="true" name="NewPremisesSubleaseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="dnli_EmployeeAndNonEmployeeStockOptionMember" abstract="true" name="EmployeeAndNonEmployeeStockOptionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="dnli_NumberOfTargets" abstract="false" name="NumberOfTargets" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="dnli_AlzheimersDiseaseServicesMember" abstract="true" name="AlzheimersDiseaseServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="dnli_AggregateDevelopmentMilestonePayment" abstract="false" name="AggregateDevelopmentMilestonePayment" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dnli_HeadquartersLeaseMember" abstract="true" name="HeadquartersLeaseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="dnli_FirstCommercialSaleMilestonePayments" abstract="false" name="FirstCommercialSaleMilestonePayments" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dnli_AggregatePreclinicalMilestonePayment" abstract="false" name="AggregatePreclinicalMilestonePayment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dnli_RetainedActivitiesMember" abstract="true" name="RetainedActivitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="dnli_StockIssuedDuringPeriodSharesEquityIncentivePlan" abstract="false" name="StockIssuedDuringPeriodSharesEquityIncentivePlan" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="dnli_CollaborativeArrangementPTVPGRNMember" abstract="true" name="CollaborativeArrangementPTVPGRNMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="dnli_NetSalesBasedMilestonePayments" abstract="false" name="NetSalesBasedMilestonePayments" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dnli_DMSAMember" abstract="true" name="DMSAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="dnli_MilestoneTriggeredAndRetainedActivitiesMember" abstract="true" name="MilestoneTriggeredAndRetainedActivitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="dnli_CommercialMilestonesPerProgram" abstract="false" name="CommercialMilestonesPerProgram" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dnli_AggregateCommercialMilestones" abstract="false" name="AggregateCommercialMilestones" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dnli_ClinicalMember" abstract="true" name="ClinicalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="dnli_TenantImprovementAllowanceRepayableAsRent" abstract="false" name="TenantImprovementAllowanceRepayableAsRent" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dnli_CollaborativeArrangementRightOfFirstNegotiationPeriodTermAdditionalProgramCriteria" abstract="false" name="CollaborativeArrangementRightOfFirstNegotiationPeriodTermAdditionalProgramCriteria" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="dnli_PeripheralProductMember" abstract="true" name="PeripheralProductMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="dnli_ResearchAndDevelopmentExpenseOffsetFromRelatedPartyCostReimbursement" abstract="false" name="ResearchAndDevelopmentExpenseOffsetFromRelatedPartyCostReimbursement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dnli_GenentechIncMember" abstract="true" name="GenentechIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="dnli_ProvisionalCollaborativeArrangementMember" abstract="true" name="ProvisionalCollaborativeArrangementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="dnli_ForeignExchangeForwardBritishPoundsMember" abstract="true" name="ForeignExchangeForwardBritishPoundsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="dnli_CollaborativeArrangementNumberOfPrograms" abstract="false" name="CollaborativeArrangementNumberOfPrograms" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="dnli_CollaborativeArrangementTermNumberOfBusinessDaysIfEffectiveDateCriteriaMet" abstract="false" name="CollaborativeArrangementTermNumberOfBusinessDaysIfEffectiveDateCriteriaMet" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="dnli_CollaborationAgreementTransactionPriceIncreaseDecrease" abstract="false" name="CollaborationAgreementTransactionPriceIncreaseDecrease" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dnli_LicenseAgreementTextBlock" abstract="false" name="LicenseAgreementTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="dnli_TransportVehicleTechnologyPlatformUnnamedProgramMember" abstract="true" name="TransportVehicleTechnologyPlatformUnnamedProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="dnli_OptionResearchServicesMember" abstract="true" name="OptionResearchServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="dnli_CollaborativeArrangementRightOfFirstNegotiationTermPeriodAfterEffectiveDateOfAgreementIfCircumstancesMet" abstract="false" name="CollaborativeArrangementRightOfFirstNegotiationTermPeriodAfterEffectiveDateOfAgreementIfCircumstancesMet" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="dnli_PreclinicalMilestonePaymentEarnedNotYetReceived" abstract="false" name="PreclinicalMilestonePaymentEarnedNotYetReceived" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dnli_UpfrontPayments" abstract="false" name="UpfrontPayments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>dnli-20210331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:be7bc6f9-6af9-45b5-b822-49fcbbf3ecfb,g:6a95e0ad-15c9-4fb8-a5d1-2bfd737ebde3-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/DocumentandEntityInformation" xlink:type="simple" xlink:href="dnli-20210331.xsd#DocumentandEntityInformation"/>
  <link:calculationLink xlink:role="http://www.denalitherapeutics.com/role/DocumentandEntityInformation" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="dnli-20210331.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_64f1bd9e-beed-4605-bb00-1e5183a1eb9e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_2331098a-78e8-4643-93d3-b538cd15c749" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_64f1bd9e-beed-4605-bb00-1e5183a1eb9e" xlink:to="loc_us-gaap_LiabilitiesCurrent_2331098a-78e8-4643-93d3-b538cd15c749" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_ContractWithCustomerLiabilityFromRelatedPartiesNoncurrent_dcd43252-49bb-4f58-beab-de9a19185307" xlink:href="dnli-20210331.xsd#dnli_ContractWithCustomerLiabilityFromRelatedPartiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_64f1bd9e-beed-4605-bb00-1e5183a1eb9e" xlink:to="loc_dnli_ContractWithCustomerLiabilityFromRelatedPartiesNoncurrent_dcd43252-49bb-4f58-beab-de9a19185307" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_40e0cffc-3b19-4e56-bfde-1444f6ab0d9e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_64f1bd9e-beed-4605-bb00-1e5183a1eb9e" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_40e0cffc-3b19-4e56-bfde-1444f6ab0d9e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_45210b8a-e5fe-447c-a359-9a72201b5d55" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_64f1bd9e-beed-4605-bb00-1e5183a1eb9e" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_45210b8a-e5fe-447c-a359-9a72201b5d55" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_02db314f-d410-450d-9184-9bd74f65838b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_64f1bd9e-beed-4605-bb00-1e5183a1eb9e" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_02db314f-d410-450d-9184-9bd74f65838b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_ae8c8881-faae-4fe2-91bd-85e6e3b328eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_af6746bb-68d3-4172-9f31-6efe7016f270" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_ae8c8881-faae-4fe2-91bd-85e6e3b328eb" xlink:to="loc_us-gaap_PreferredStockValue_af6746bb-68d3-4172-9f31-6efe7016f270" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_6b269d03-99b6-497e-a41f-3421bb24ffa1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_ae8c8881-faae-4fe2-91bd-85e6e3b328eb" xlink:to="loc_us-gaap_CommonStockValue_6b269d03-99b6-497e-a41f-3421bb24ffa1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_179243b6-5b70-4353-b865-56d2bbefadfd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_ae8c8881-faae-4fe2-91bd-85e6e3b328eb" xlink:to="loc_us-gaap_AdditionalPaidInCapital_179243b6-5b70-4353-b865-56d2bbefadfd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_5012096e-cb2c-45e1-b8f7-00525bd4933d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_ae8c8881-faae-4fe2-91bd-85e6e3b328eb" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_5012096e-cb2c-45e1-b8f7-00525bd4933d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_482e1378-e966-46d7-8285-5da002a0d2bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_ae8c8881-faae-4fe2-91bd-85e6e3b328eb" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_482e1378-e966-46d7-8285-5da002a0d2bf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_a7d40f92-d0ad-4c63-9898-7ab822dbed61" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_525f49a6-3cbd-490c-8e50-5c56620e8caf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_a7d40f92-d0ad-4c63-9898-7ab822dbed61" xlink:to="loc_us-gaap_AssetsCurrent_525f49a6-3cbd-490c-8e50-5c56620e8caf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_b9931639-9cee-4ba5-9d86-482f36f797ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_a7d40f92-d0ad-4c63-9898-7ab822dbed61" xlink:to="loc_us-gaap_MarketableSecuritiesNoncurrent_b9931639-9cee-4ba5-9d86-482f36f797ae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_a0bdea09-4f38-4ac2-bcd6-9da677152ee7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_a7d40f92-d0ad-4c63-9898-7ab822dbed61" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_a0bdea09-4f38-4ac2-bcd6-9da677152ee7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_ecc79e60-b5e0-49a5-abf0-abee3f27ad0d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_a7d40f92-d0ad-4c63-9898-7ab822dbed61" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_ecc79e60-b5e0-49a5-abf0-abee3f27ad0d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_e5649927-94bc-4368-be17-f65ce91f470d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_a7d40f92-d0ad-4c63-9898-7ab822dbed61" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_e5649927-94bc-4368-be17-f65ce91f470d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_0b80e2e0-c4a0-491b-be5e-b1b3d677f72f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_830d47ba-b04c-4bb2-a4e0-7ac648017aa3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0b80e2e0-c4a0-491b-be5e-b1b3d677f72f" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_830d47ba-b04c-4bb2-a4e0-7ac648017aa3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_009f1649-ba00-4829-ad65-bc863e275ee3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0b80e2e0-c4a0-491b-be5e-b1b3d677f72f" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_009f1649-ba00-4829-ad65-bc863e275ee3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueFromRelatedPartiesCurrent_734401cd-895e-4d64-a785-b0644d4c9b28" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueFromRelatedPartiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0b80e2e0-c4a0-491b-be5e-b1b3d677f72f" xlink:to="loc_us-gaap_DueFromRelatedPartiesCurrent_734401cd-895e-4d64-a785-b0644d4c9b28" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_d19ef75e-1a00-48d4-9526-397cdeadbe2e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0b80e2e0-c4a0-491b-be5e-b1b3d677f72f" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_d19ef75e-1a00-48d4-9526-397cdeadbe2e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_db8c34e4-1714-4ae5-99cd-bb8ec65677d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_c539af6f-5395-4802-9560-bc1c79570b47" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_db8c34e4-1714-4ae5-99cd-bb8ec65677d6" xlink:to="loc_us-gaap_Liabilities_c539af6f-5395-4802-9560-bc1c79570b47" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_f345d7a9-8d91-48c7-a64c-45d500964515" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_db8c34e4-1714-4ae5-99cd-bb8ec65677d6" xlink:to="loc_us-gaap_CommitmentsAndContingencies_f345d7a9-8d91-48c7-a64c-45d500964515" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_e2de0b94-e535-4930-aeba-604d58a63d60" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_db8c34e4-1714-4ae5-99cd-bb8ec65677d6" xlink:to="loc_us-gaap_StockholdersEquity_e2de0b94-e535-4930-aeba-604d58a63d60" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_d6628e3c-e02a-4c4b-98e2-d1b6cf366b26" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_0c669e9e-daa4-49eb-b65c-2aae7d2e8557" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_d6628e3c-e02a-4c4b-98e2-d1b6cf366b26" xlink:to="loc_us-gaap_AccountsPayableCurrent_0c669e9e-daa4-49eb-b65c-2aae7d2e8557" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_bab6279a-7ab0-4bd5-896c-3e9ba81623a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_d6628e3c-e02a-4c4b-98e2-d1b6cf366b26" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_bab6279a-7ab0-4bd5-896c-3e9ba81623a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_AccruedClinicalCostsCurrent_959b4681-6840-4a22-90fa-fee3b0f4dfbd" xlink:href="dnli-20210331.xsd#dnli_AccruedClinicalCostsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_d6628e3c-e02a-4c4b-98e2-d1b6cf366b26" xlink:to="loc_dnli_AccruedClinicalCostsCurrent_959b4681-6840-4a22-90fa-fee3b0f4dfbd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_OtherAccruedManufacturingCostsCurrent_78a328e6-80ce-41cf-a672-a6b6037f39fb" xlink:href="dnli-20210331.xsd#dnli_OtherAccruedManufacturingCostsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_d6628e3c-e02a-4c4b-98e2-d1b6cf366b26" xlink:to="loc_dnli_OtherAccruedManufacturingCostsCurrent_78a328e6-80ce-41cf-a672-a6b6037f39fb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_8181e3eb-3719-475e-adaa-c84ba996268e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_d6628e3c-e02a-4c4b-98e2-d1b6cf366b26" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_8181e3eb-3719-475e-adaa-c84ba996268e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_4f29e2bb-dca1-4da4-bfb8-828fc5097737" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_d6628e3c-e02a-4c4b-98e2-d1b6cf366b26" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_4f29e2bb-dca1-4da4-bfb8-828fc5097737" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_ContractWithCustomerLiabilityFromRelatedPartiesCurrent_3bd8645e-6003-46e8-ac0b-009a5657af52" xlink:href="dnli-20210331.xsd#dnli_ContractWithCustomerLiabilityFromRelatedPartiesCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_d6628e3c-e02a-4c4b-98e2-d1b6cf366b26" xlink:to="loc_dnli_ContractWithCustomerLiabilityFromRelatedPartiesCurrent_3bd8645e-6003-46e8-ac0b-009a5657af52" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_a7adda9e-5dfb-4b1a-8336-766e7ab9eb14" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_d6628e3c-e02a-4c4b-98e2-d1b6cf366b26" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_a7adda9e-5dfb-4b1a-8336-766e7ab9eb14" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="dnli-20210331.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:calculationLink xlink:role="http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="dnli-20210331.xsd#CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"/>
  <link:calculationLink xlink:role="http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent_4321d55a-47e2-4e6f-b8b4-9d126d02505c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_26951da3-ed5a-4bf6-9940-809dc3d6a15f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossAttributableToParent_4321d55a-47e2-4e6f-b8b4-9d126d02505c" xlink:to="loc_us-gaap_OperatingIncomeLoss_26951da3-ed5a-4bf6-9940-809dc3d6a15f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_0a7caf6a-7ddd-489d-8b39-4580020e0136" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossAttributableToParent_4321d55a-47e2-4e6f-b8b4-9d126d02505c" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_0a7caf6a-7ddd-489d-8b39-4580020e0136" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_ad50cb59-de5d-4e09-8b98-eb14681c174f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e60a2464-0b88-437d-9a6c-d1cad47ec477" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_ad50cb59-de5d-4e09-8b98-eb14681c174f" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e60a2464-0b88-437d-9a6c-d1cad47ec477" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_fb010f03-86f6-49b4-a3d9-9f5b2ed331d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_ad50cb59-de5d-4e09-8b98-eb14681c174f" xlink:to="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_fb010f03-86f6-49b4-a3d9-9f5b2ed331d0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_a843a880-7bdb-4cc5-8b29-c0935711ace2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_b05525b5-43e2-4ded-a201-6e2a483fb8b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_a843a880-7bdb-4cc5-8b29-c0935711ace2" xlink:to="loc_us-gaap_NetIncomeLoss_b05525b5-43e2-4ded-a201-6e2a483fb8b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax_e77d22f3-6f9a-42dd-8849-993bf1248b37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_a843a880-7bdb-4cc5-8b29-c0935711ace2" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax_e77d22f3-6f9a-42dd-8849-993bf1248b37" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_59effbf0-66e5-48b0-b12f-5de97bba6681" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent_8fea67a3-a54f-441c-a9e8-78e4e9925eba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_59effbf0-66e5-48b0-b12f-5de97bba6681" xlink:to="loc_us-gaap_IncomeLossAttributableToParent_8fea67a3-a54f-441c-a9e8-78e4e9925eba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_fd0950d9-f402-4902-b4fe-eede30594880" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_59effbf0-66e5-48b0-b12f-5de97bba6681" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_fd0950d9-f402-4902-b4fe-eede30594880" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_599e79f8-2663-4d37-a4a2-baa53aff1a86" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_1c5b254e-7313-4668-be6c-88b88b09d3f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_599e79f8-2663-4d37-a4a2-baa53aff1a86" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_1c5b254e-7313-4668-be6c-88b88b09d3f1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_36828342-f092-48d7-abcb-b54fd1bb72d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_599e79f8-2663-4d37-a4a2-baa53aff1a86" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_36828342-f092-48d7-abcb-b54fd1bb72d0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_1416cdc4-61c0-4743-8d7c-1b0fa1e2ad49" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_ad5299f0-1598-4e1c-8931-652906623bfe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_1416cdc4-61c0-4743-8d7c-1b0fa1e2ad49" xlink:to="loc_us-gaap_Revenues_ad5299f0-1598-4e1c-8931-652906623bfe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_52699d38-9f8e-482a-8c0d-7171fd8f2596" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_1416cdc4-61c0-4743-8d7c-1b0fa1e2ad49" xlink:to="loc_us-gaap_OperatingExpenses_52699d38-9f8e-482a-8c0d-7171fd8f2596" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossParenthetical" xlink:type="simple" xlink:href="dnli-20210331.xsd#CondensedConsolidatedStatementsofOperationsandComprehensiveLossParenthetical"/>
  <link:calculationLink xlink:role="http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="dnli-20210331.xsd#CondensedConsolidatedStatementsofStockholdersEquity"/>
  <link:calculationLink xlink:role="http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical" xlink:type="simple" xlink:href="dnli-20210331.xsd#CondensedConsolidatedStatementsofStockholdersEquityParenthetical"/>
  <link:calculationLink xlink:role="http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="dnli-20210331.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_4d0aa4bd-820d-4d19-b2a7-57341cdeb064" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_24eb4328-f221-4698-9d25-aab9077709f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_4d0aa4bd-820d-4d19-b2a7-57341cdeb064" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_24eb4328-f221-4698-9d25-aab9077709f9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f3cd6e40-12f8-4c09-832f-9b894787d7dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_4d0aa4bd-820d-4d19-b2a7-57341cdeb064" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f3cd6e40-12f8-4c09-832f-9b894787d7dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8b93f718-006d-4c22-bf9b-5f05be134ae5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_4d0aa4bd-820d-4d19-b2a7-57341cdeb064" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8b93f718-006d-4c22-bf9b-5f05be134ae5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3c395292-cfdf-45ad-a0c3-549b6c2c8d0f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_29562694-e7e9-4114-b41a-0c42ff2d067d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3c395292-cfdf-45ad-a0c3-549b6c2c8d0f" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_29562694-e7e9-4114-b41a-0c42ff2d067d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_8298d859-24ad-49b9-a950-a1cf9b269c34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3c395292-cfdf-45ad-a0c3-549b6c2c8d0f" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_8298d859-24ad-49b9-a950-a1cf9b269c34" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_40371058-6b03-4e44-902b-8589b8ee5df7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_5f5b1224-96bc-431e-be75-a15e06e54fb4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_40371058-6b03-4e44-902b-8589b8ee5df7" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_5f5b1224-96bc-431e-be75-a15e06e54fb4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_31911c93-0c0f-48ef-8bf2-209d8399edbb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_40371058-6b03-4e44-902b-8589b8ee5df7" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_31911c93-0c0f-48ef-8bf2-209d8399edbb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_ab1aa5b2-4bce-4236-8a51-9eea5e2a0739" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_40371058-6b03-4e44-902b-8589b8ee5df7" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_ab1aa5b2-4bce-4236-8a51-9eea5e2a0739" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_eae944ec-40a6-458d-94fa-4ba0be29436e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_9893c5fb-f1f9-4a43-8f68-146fb6222c5e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_eae944ec-40a6-458d-94fa-4ba0be29436e" xlink:to="loc_us-gaap_NetIncomeLoss_9893c5fb-f1f9-4a43-8f68-146fb6222c5e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_db0c532e-7be8-438f-9173-ead5c827d9ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_eae944ec-40a6-458d-94fa-4ba0be29436e" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_db0c532e-7be8-438f-9173-ead5c827d9ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_bbe3802f-0e18-4ab1-846a-39c563146a66" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_eae944ec-40a6-458d-94fa-4ba0be29436e" xlink:to="loc_us-gaap_ShareBasedCompensation_bbe3802f-0e18-4ab1-846a-39c563146a66" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_39c88fff-96bf-49d8-ab9f-e59723ffc6f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_eae944ec-40a6-458d-94fa-4ba0be29436e" xlink:to="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_39c88fff-96bf-49d8-ab9f-e59723ffc6f8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_IncreaseDecreaseInNonCashOperatingLeaseExpense_76d1e959-d224-4dea-8828-573d019220f7" xlink:href="dnli-20210331.xsd#dnli_IncreaseDecreaseInNonCashOperatingLeaseExpense"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_eae944ec-40a6-458d-94fa-4ba0be29436e" xlink:to="loc_dnli_IncreaseDecreaseInNonCashOperatingLeaseExpense_76d1e959-d224-4dea-8828-573d019220f7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_4db76b74-f78e-4435-a351-36d5936f27cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_eae944ec-40a6-458d-94fa-4ba0be29436e" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_4db76b74-f78e-4435-a351-36d5936f27cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_ef87c2f9-01d3-4a1f-9698-20557a3078ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_eae944ec-40a6-458d-94fa-4ba0be29436e" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_ef87c2f9-01d3-4a1f-9698-20557a3078ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_b9b6a379-1eb2-4b39-82cd-8e131f7fc24f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_eae944ec-40a6-458d-94fa-4ba0be29436e" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_b9b6a379-1eb2-4b39-82cd-8e131f7fc24f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_b95fb5ab-6318-4f1b-8d7a-0dd3e725f3a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_eae944ec-40a6-458d-94fa-4ba0be29436e" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_b95fb5ab-6318-4f1b-8d7a-0dd3e725f3a8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_a7a1dfee-c331-4d80-94c0-ad1b7dfb54a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_eae944ec-40a6-458d-94fa-4ba0be29436e" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_a7a1dfee-c331-4d80-94c0-ad1b7dfb54a7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_IncreaseDecreaseInContractWithCustomerLiabilityRelatedParties_d7dabe6a-59da-4be7-99d9-95c6e4e09a7f" xlink:href="dnli-20210331.xsd#dnli_IncreaseDecreaseInContractWithCustomerLiabilityRelatedParties"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_eae944ec-40a6-458d-94fa-4ba0be29436e" xlink:to="loc_dnli_IncreaseDecreaseInContractWithCustomerLiabilityRelatedParties_d7dabe6a-59da-4be7-99d9-95c6e4e09a7f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/SignificantAccountingPolicies" xlink:type="simple" xlink:href="dnli-20210331.xsd#SignificantAccountingPolicies"/>
  <link:calculationLink xlink:role="http://www.denalitherapeutics.com/role/SignificantAccountingPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/SignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="dnli-20210331.xsd#SignificantAccountingPoliciesPolicies"/>
  <link:calculationLink xlink:role="http://www.denalitherapeutics.com/role/SignificantAccountingPoliciesPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/SignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="dnli-20210331.xsd#SignificantAccountingPoliciesNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.denalitherapeutics.com/role/SignificantAccountingPoliciesNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="dnli-20210331.xsd#FairValueMeasurements"/>
  <link:calculationLink xlink:role="http://www.denalitherapeutics.com/role/FairValueMeasurements" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="dnli-20210331.xsd#FairValueMeasurementsTables"/>
  <link:calculationLink xlink:role="http://www.denalitherapeutics.com/role/FairValueMeasurementsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="dnli-20210331.xsd#FairValueMeasurementsScheduleofAssetsandLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.denalitherapeutics.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_2bb6c9ba-648e-45e0-a9cf-ae80e65382ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_746c62a4-4e0d-4eb6-ba3c-81abc899dfe1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_2bb6c9ba-648e-45e0-a9cf-ae80e65382ea" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_746c62a4-4e0d-4eb6-ba3c-81abc899dfe1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_bc074b64-13dc-4a8b-b8c4-7fc2e14d6056" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_2bb6c9ba-648e-45e0-a9cf-ae80e65382ea" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_bc074b64-13dc-4a8b-b8c4-7fc2e14d6056" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_469f65aa-0903-4b19-b964-c5d8e03d88cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_2bb6c9ba-648e-45e0-a9cf-ae80e65382ea" xlink:to="loc_us-gaap_DerivativeAssets_469f65aa-0903-4b19-b964-c5d8e03d88cb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_61fec9aa-b3e5-4573-b45b-d4c7fd5d18c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_3519fcfc-619a-40b1-9607-2f8691017218" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_61fec9aa-b3e5-4573-b45b-d4c7fd5d18c1" xlink:to="loc_us-gaap_DerivativeLiabilities_3519fcfc-619a-40b1-9607-2f8691017218" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/MarketableSecurities" xlink:type="simple" xlink:href="dnli-20210331.xsd#MarketableSecurities"/>
  <link:calculationLink xlink:role="http://www.denalitherapeutics.com/role/MarketableSecurities" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/MarketableSecuritiesTables" xlink:type="simple" xlink:href="dnli-20210331.xsd#MarketableSecuritiesTables"/>
  <link:calculationLink xlink:role="http://www.denalitherapeutics.com/role/MarketableSecuritiesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/MarketableSecuritiesSummaryofAvailableforSaleSecuritiesDetails" xlink:type="simple" xlink:href="dnli-20210331.xsd#MarketableSecuritiesSummaryofAvailableforSaleSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://www.denalitherapeutics.com/role/MarketableSecuritiesSummaryofAvailableforSaleSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_4083dd2c-c298-4bd2-834d-ea6736c36502" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_23ab7c66-1022-477c-939e-9491722bb1c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_4083dd2c-c298-4bd2-834d-ea6736c36502" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_23ab7c66-1022-477c-939e-9491722bb1c9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_649971d6-6c01-4bfc-a374-d32488363d64" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_4083dd2c-c298-4bd2-834d-ea6736c36502" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_649971d6-6c01-4bfc-a374-d32488363d64" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_787afbe1-2cbe-43c0-ad17-8067e61f8037" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_4083dd2c-c298-4bd2-834d-ea6736c36502" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_787afbe1-2cbe-43c0-ad17-8067e61f8037" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/MarketableSecuritiesNarrativeDetails" xlink:type="simple" xlink:href="dnli-20210331.xsd#MarketableSecuritiesNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.denalitherapeutics.com/role/MarketableSecuritiesNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/DerivativeFinancialInstruments" xlink:type="simple" xlink:href="dnli-20210331.xsd#DerivativeFinancialInstruments"/>
  <link:calculationLink xlink:role="http://www.denalitherapeutics.com/role/DerivativeFinancialInstruments" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/DerivativeFinancialInstrumentsTables" xlink:type="simple" xlink:href="dnli-20210331.xsd#DerivativeFinancialInstrumentsTables"/>
  <link:calculationLink xlink:role="http://www.denalitherapeutics.com/role/DerivativeFinancialInstrumentsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/DerivativeFinancialInstrumentsSummaryofForwardForeignCurrencyExchangeContractsOutstandingDetails" xlink:type="simple" xlink:href="dnli-20210331.xsd#DerivativeFinancialInstrumentsSummaryofForwardForeignCurrencyExchangeContractsOutstandingDetails"/>
  <link:calculationLink xlink:role="http://www.denalitherapeutics.com/role/DerivativeFinancialInstrumentsSummaryofForwardForeignCurrencyExchangeContractsOutstandingDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/DerivativeFinancialInstrumentsNarrativeDetails" xlink:type="simple" xlink:href="dnli-20210331.xsd#DerivativeFinancialInstrumentsNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.denalitherapeutics.com/role/DerivativeFinancialInstrumentsNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/CollaborationAgreements" xlink:type="simple" xlink:href="dnli-20210331.xsd#CollaborationAgreements"/>
  <link:calculationLink xlink:role="http://www.denalitherapeutics.com/role/CollaborationAgreements" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/CollaborationAgreementsTables" xlink:type="simple" xlink:href="dnli-20210331.xsd#CollaborationAgreementsTables"/>
  <link:calculationLink xlink:role="http://www.denalitherapeutics.com/role/CollaborationAgreementsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/CollaborationAgreementsBiogenDetails" xlink:type="simple" xlink:href="dnli-20210331.xsd#CollaborationAgreementsBiogenDetails"/>
  <link:calculationLink xlink:role="http://www.denalitherapeutics.com/role/CollaborationAgreementsBiogenDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/CollaborationAgreementsSanofiDetails" xlink:type="simple" xlink:href="dnli-20210331.xsd#CollaborationAgreementsSanofiDetails"/>
  <link:calculationLink xlink:role="http://www.denalitherapeutics.com/role/CollaborationAgreementsSanofiDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/CollaborationAgreementsSanofiPerformanceObligationDetails" xlink:type="simple" xlink:href="dnli-20210331.xsd#CollaborationAgreementsSanofiPerformanceObligationDetails"/>
  <link:calculationLink xlink:role="http://www.denalitherapeutics.com/role/CollaborationAgreementsSanofiPerformanceObligationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/CollaborationAgreementsTakedaDetails" xlink:type="simple" xlink:href="dnli-20210331.xsd#CollaborationAgreementsTakedaDetails"/>
  <link:calculationLink xlink:role="http://www.denalitherapeutics.com/role/CollaborationAgreementsTakedaDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/CollaborationAgreementsSummaryofCollaborationRevenueDetails" xlink:type="simple" xlink:href="dnli-20210331.xsd#CollaborationAgreementsSummaryofCollaborationRevenueDetails"/>
  <link:calculationLink xlink:role="http://www.denalitherapeutics.com/role/CollaborationAgreementsSummaryofCollaborationRevenueDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/LicenseAgreements" xlink:type="simple" xlink:href="dnli-20210331.xsd#LicenseAgreements"/>
  <link:calculationLink xlink:role="http://www.denalitherapeutics.com/role/LicenseAgreements" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/LicenseAgreementsNarrativeDetails" xlink:type="simple" xlink:href="dnli-20210331.xsd#LicenseAgreementsNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.denalitherapeutics.com/role/LicenseAgreementsNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="dnli-20210331.xsd#CommitmentsandContingencies"/>
  <link:calculationLink xlink:role="http://www.denalitherapeutics.com/role/CommitmentsandContingencies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/CommitmentsandContingenciesTables" xlink:type="simple" xlink:href="dnli-20210331.xsd#CommitmentsandContingenciesTables"/>
  <link:calculationLink xlink:role="http://www.denalitherapeutics.com/role/CommitmentsandContingenciesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="simple" xlink:href="dnli-20210331.xsd#CommitmentsandContingenciesNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.denalitherapeutics.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/CommitmentsandContingenciesSummaryofCompanysFutureMinimumLeaseCommitmentsDetails" xlink:type="simple" xlink:href="dnli-20210331.xsd#CommitmentsandContingenciesSummaryofCompanysFutureMinimumLeaseCommitmentsDetails"/>
  <link:calculationLink xlink:role="http://www.denalitherapeutics.com/role/CommitmentsandContingenciesSummaryofCompanysFutureMinimumLeaseCommitmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e2b6b5c1-29eb-472c-bf5f-8ca445acdd15" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_97532253-1baf-45bf-9475-572fa0daa361" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e2b6b5c1-29eb-472c-bf5f-8ca445acdd15" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_97532253-1baf-45bf-9475-572fa0daa361" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_07093323-bdd6-42bf-980e-57321025844c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e2b6b5c1-29eb-472c-bf5f-8ca445acdd15" xlink:to="loc_us-gaap_OperatingLeaseLiability_07093323-bdd6-42bf-980e-57321025844c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/CommitmentsandContingenciesSummaryofCompanysFutureMinimumLeaseCommitmentsDetails_1" xlink:type="simple" xlink:href="dnli-20210331.xsd#CommitmentsandContingenciesSummaryofCompanysFutureMinimumLeaseCommitmentsDetails_1"/>
  <link:calculationLink xlink:role="http://www.denalitherapeutics.com/role/CommitmentsandContingenciesSummaryofCompanysFutureMinimumLeaseCommitmentsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e7273d93-57ad-4f74-8ab0-62642a58991b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_c2704222-fe2d-4b5d-a0a2-5f5537afc7ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e7273d93-57ad-4f74-8ab0-62642a58991b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_c2704222-fe2d-4b5d-a0a2-5f5537afc7ea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_0b552dfb-21f7-48e5-a1f3-6b4efc4945c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e7273d93-57ad-4f74-8ab0-62642a58991b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_0b552dfb-21f7-48e5-a1f3-6b4efc4945c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_de52781f-f98c-4eb5-b069-a944f73a164e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e7273d93-57ad-4f74-8ab0-62642a58991b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_de52781f-f98c-4eb5-b069-a944f73a164e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_61d14c11-855a-4e4a-9734-50a5bc804077" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e7273d93-57ad-4f74-8ab0-62642a58991b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_61d14c11-855a-4e4a-9734-50a5bc804077" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_71397be6-db3a-445c-9ff8-723f580c5b72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e7273d93-57ad-4f74-8ab0-62642a58991b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_71397be6-db3a-445c-9ff8-723f580c5b72" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_0e88b7f9-8cb7-43e1-81d4-bfc5dd6a9e1b" xlink:href="dnli-20210331.xsd#dnli_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e7273d93-57ad-4f74-8ab0-62642a58991b" xlink:to="loc_dnli_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_0e88b7f9-8cb7-43e1-81d4-bfc5dd6a9e1b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/CommitmentsandContingenciesSummaryofCompanysFutureMinimumLeaseReceivablesDetails" xlink:type="simple" xlink:href="dnli-20210331.xsd#CommitmentsandContingenciesSummaryofCompanysFutureMinimumLeaseReceivablesDetails"/>
  <link:calculationLink xlink:role="http://www.denalitherapeutics.com/role/CommitmentsandContingenciesSummaryofCompanysFutureMinimumLeaseReceivablesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_2fe0ace3-1b07-475c-8518-e6b0debcefd1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceived"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear_264c611e-e062-4460-8b84-ef94a7b9c1ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_2fe0ace3-1b07-475c-8518-e6b0debcefd1" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear_264c611e-e062-4460-8b84-ef94a7b9c1ee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths_49ca1522-0488-4f9c-a542-67e4ee6ce904" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_2fe0ace3-1b07-475c-8518-e6b0debcefd1" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths_49ca1522-0488-4f9c-a542-67e4ee6ce904" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears_cac0a5c8-db95-4df4-baa9-7ae63e99e94b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_2fe0ace3-1b07-475c-8518-e6b0debcefd1" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears_cac0a5c8-db95-4df4-baa9-7ae63e99e94b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears_e68472b1-df82-442c-8be1-ba017b766450" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_2fe0ace3-1b07-475c-8518-e6b0debcefd1" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears_e68472b1-df82-442c-8be1-ba017b766450" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/StockBasedAwards" xlink:type="simple" xlink:href="dnli-20210331.xsd#StockBasedAwards"/>
  <link:calculationLink xlink:role="http://www.denalitherapeutics.com/role/StockBasedAwards" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/StockBasedAwardsTables" xlink:type="simple" xlink:href="dnli-20210331.xsd#StockBasedAwardsTables"/>
  <link:calculationLink xlink:role="http://www.denalitherapeutics.com/role/StockBasedAwardsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofStockOptionActivityDetails" xlink:type="simple" xlink:href="dnli-20210331.xsd#StockBasedAwardsSummaryofStockOptionActivityDetails"/>
  <link:calculationLink xlink:role="http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofStockOptionActivityDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofAssumptionsUsedforEstimatingtheFairValueofStockOptionsGrantedDetails" xlink:type="simple" xlink:href="dnli-20210331.xsd#StockBasedAwardsSummaryofAssumptionsUsedforEstimatingtheFairValueofStockOptionsGrantedDetails"/>
  <link:calculationLink xlink:role="http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofAssumptionsUsedforEstimatingtheFairValueofStockOptionsGrantedDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofRestrictedStockActivityDetails" xlink:type="simple" xlink:href="dnli-20210331.xsd#StockBasedAwardsSummaryofRestrictedStockActivityDetails"/>
  <link:calculationLink xlink:role="http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofRestrictedStockActivityDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="dnli-20210331.xsd#StockBasedAwardsSummaryofStockBasedCompensationExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofStockBasedCompensationExpenseDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/NetLossPerShare" xlink:type="simple" xlink:href="dnli-20210331.xsd#NetLossPerShare"/>
  <link:calculationLink xlink:role="http://www.denalitherapeutics.com/role/NetLossPerShare" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/NetLossPerShareTables" xlink:type="simple" xlink:href="dnli-20210331.xsd#NetLossPerShareTables"/>
  <link:calculationLink xlink:role="http://www.denalitherapeutics.com/role/NetLossPerShareTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/NetLossPerShareScheduleofDilutiveSecuritiesNotIncludedinDilutedPerShareCalculationsDetails" xlink:type="simple" xlink:href="dnli-20210331.xsd#NetLossPerShareScheduleofDilutiveSecuritiesNotIncludedinDilutedPerShareCalculationsDetails"/>
  <link:calculationLink xlink:role="http://www.denalitherapeutics.com/role/NetLossPerShareScheduleofDilutiveSecuritiesNotIncludedinDilutedPerShareCalculationsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="dnli-20210331.xsd#RelatedPartyTransactions"/>
  <link:calculationLink xlink:role="http://www.denalitherapeutics.com/role/RelatedPartyTransactions" xlink:type="extended"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>dnli-20210331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:be7bc6f9-6af9-45b5-b822-49fcbbf3ecfb,g:6a95e0ad-15c9-4fb8-a5d1-2bfd737ebde3-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/DocumentandEntityInformation" xlink:type="simple" xlink:href="dnli-20210331.xsd#DocumentandEntityInformation"/>
  <link:definitionLink xlink:role="http://www.denalitherapeutics.com/role/DocumentandEntityInformation" xlink:type="extended" id="if577ab05fa4d4926a3a09a9c45384e88_DocumentandEntityInformation"/>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="dnli-20210331.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:definitionLink xlink:role="http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended" id="i89480eba3bc8429994f868ec34b50b9d_CondensedConsolidatedBalanceSheets"/>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="dnli-20210331.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:definitionLink xlink:role="http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended" id="ic3c89fab37bd495f944abf2bce2d555f_CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="dnli-20210331.xsd#CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"/>
  <link:definitionLink xlink:role="http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="extended" id="ia10cea887c1042be83bf13459d68b17b_CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"/>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossParenthetical" xlink:type="simple" xlink:href="dnli-20210331.xsd#CondensedConsolidatedStatementsofOperationsandComprehensiveLossParenthetical"/>
  <link:definitionLink xlink:role="http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossParenthetical" xlink:type="extended" id="i73bc02cdb8a24b079ba45a2f29269dfe_CondensedConsolidatedStatementsofOperationsandComprehensiveLossParenthetical"/>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="dnli-20210331.xsd#CondensedConsolidatedStatementsofStockholdersEquity"/>
  <link:definitionLink xlink:role="http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="extended" id="i5b439b375b82449c845d38fe00f779ad_CondensedConsolidatedStatementsofStockholdersEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_0256e61b-a17d-4eb0-af66-df0854cfd11e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_889b5f2f-4442-4a13-81ed-55faae35dc12" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0256e61b-a17d-4eb0-af66-df0854cfd11e" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_889b5f2f-4442-4a13-81ed-55faae35dc12" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_90574ecb-f177-46ec-88e8-a8df5cb9375d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_889b5f2f-4442-4a13-81ed-55faae35dc12" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_90574ecb-f177-46ec-88e8-a8df5cb9375d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_a4e9552a-285c-4cd1-bbd3-0dbc67c9a6b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_889b5f2f-4442-4a13-81ed-55faae35dc12" xlink:to="loc_us-gaap_StockholdersEquity_a4e9552a-285c-4cd1-bbd3-0dbc67c9a6b9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_faae1019-6f2c-4184-9aaf-8be1595cc3b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_889b5f2f-4442-4a13-81ed-55faae35dc12" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_faae1019-6f2c-4184-9aaf-8be1595cc3b0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_de87471d-8d05-4e34-9121-3a73fd5819b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_889b5f2f-4442-4a13-81ed-55faae35dc12" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_de87471d-8d05-4e34-9121-3a73fd5819b2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_StockIssuedDuringPeriodSharesEquityIncentivePlan_401d4c71-868b-4bc1-bec3-12a3afff13c2" xlink:href="dnli-20210331.xsd#dnli_StockIssuedDuringPeriodSharesEquityIncentivePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_889b5f2f-4442-4a13-81ed-55faae35dc12" xlink:to="loc_dnli_StockIssuedDuringPeriodSharesEquityIncentivePlan_401d4c71-868b-4bc1-bec3-12a3afff13c2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_StockIssuedDuringPeriodValueEquityIncentivePlan_fe7ddd74-4359-4cf2-85cf-af2d3c8f0ebc" xlink:href="dnli-20210331.xsd#dnli_StockIssuedDuringPeriodValueEquityIncentivePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_889b5f2f-4442-4a13-81ed-55faae35dc12" xlink:to="loc_dnli_StockIssuedDuringPeriodValueEquityIncentivePlan_fe7ddd74-4359-4cf2-85cf-af2d3c8f0ebc" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_a2a48af0-d94d-442b-bbe4-c4218597a838" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_889b5f2f-4442-4a13-81ed-55faae35dc12" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_a2a48af0-d94d-442b-bbe4-c4218597a838" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_bc93a820-5c70-416a-abea-53068c852ad2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_889b5f2f-4442-4a13-81ed-55faae35dc12" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_bc93a820-5c70-416a-abea-53068c852ad2" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_7777618f-dd0f-4aa9-b1fd-d3b4d73b4cb7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_889b5f2f-4442-4a13-81ed-55faae35dc12" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_7777618f-dd0f-4aa9-b1fd-d3b4d73b4cb7" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_45dd2dde-8f4e-4c9d-93f2-0a8296ae2007" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_889b5f2f-4442-4a13-81ed-55faae35dc12" xlink:to="loc_us-gaap_NetIncomeLoss_45dd2dde-8f4e-4c9d-93f2-0a8296ae2007" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_23a72123-832b-4cb8-9250-a8569a3c4fea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_889b5f2f-4442-4a13-81ed-55faae35dc12" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_23a72123-832b-4cb8-9250-a8569a3c4fea" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_4a580326-5d10-4298-a017-1f8299a613a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_14e53f27-d2f2-44af-80cf-91e9fb2367e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_4ed9b480-7e28-46d9-8541-fd0fa8029977" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0256e61b-a17d-4eb0-af66-df0854cfd11e" xlink:to="loc_us-gaap_StatementTable_4ed9b480-7e28-46d9-8541-fd0fa8029977" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_f941b367-57ac-41b9-bd4a-e74ce5c1ceae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_4ed9b480-7e28-46d9-8541-fd0fa8029977" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_f941b367-57ac-41b9-bd4a-e74ce5c1ceae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_f941b367-57ac-41b9-bd4a-e74ce5c1ceae_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f941b367-57ac-41b9-bd4a-e74ce5c1ceae" xlink:to="loc_us-gaap_EquityComponentDomain_f941b367-57ac-41b9-bd4a-e74ce5c1ceae_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_de899a38-d740-4003-99f6-27b8d6f336b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f941b367-57ac-41b9-bd4a-e74ce5c1ceae" xlink:to="loc_us-gaap_EquityComponentDomain_de899a38-d740-4003-99f6-27b8d6f336b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_6375f451-315f-4566-ac6b-7ce8bb1332cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_de899a38-d740-4003-99f6-27b8d6f336b1" xlink:to="loc_us-gaap_CommonStockMember_6375f451-315f-4566-ac6b-7ce8bb1332cc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_7b5b710f-e402-4b4f-be27-fc9da99f0041" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_de899a38-d740-4003-99f6-27b8d6f336b1" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_7b5b710f-e402-4b4f-be27-fc9da99f0041" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_e107df8d-4285-46f7-84e9-a5af490be39b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_de899a38-d740-4003-99f6-27b8d6f336b1" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_e107df8d-4285-46f7-84e9-a5af490be39b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_95d06cdc-a62c-4aa7-85c4-0d9bbf02d77c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_de899a38-d740-4003-99f6-27b8d6f336b1" xlink:to="loc_us-gaap_RetainedEarningsMember_95d06cdc-a62c-4aa7-85c4-0d9bbf02d77c" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical" xlink:type="simple" xlink:href="dnli-20210331.xsd#CondensedConsolidatedStatementsofStockholdersEquityParenthetical"/>
  <link:definitionLink xlink:role="http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical" xlink:type="extended" id="i2b92ae0bc2264c96bc27cb825b9930ff_CondensedConsolidatedStatementsofStockholdersEquityParenthetical">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_3418545f-6299-4f2c-bfae-edb695b917a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_3d3854db-9598-4d98-958b-4f8810a8d585" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3418545f-6299-4f2c-bfae-edb695b917a7" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_3d3854db-9598-4d98-958b-4f8810a8d585" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_ab007735-cd2b-4586-ac5d-9b76b951fca4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_3418545f-6299-4f2c-bfae-edb695b917a7" xlink:to="loc_us-gaap_StatementTable_ab007735-cd2b-4586-ac5d-9b76b951fca4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_d451c8f5-1057-4c04-ac43-1e3d45fe1dd9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_ab007735-cd2b-4586-ac5d-9b76b951fca4" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_d451c8f5-1057-4c04-ac43-1e3d45fe1dd9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_d451c8f5-1057-4c04-ac43-1e3d45fe1dd9_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_d451c8f5-1057-4c04-ac43-1e3d45fe1dd9" xlink:to="loc_us-gaap_EquityComponentDomain_d451c8f5-1057-4c04-ac43-1e3d45fe1dd9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_4f809b71-d7ba-464b-b38d-4b94f33eebe9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_d451c8f5-1057-4c04-ac43-1e3d45fe1dd9" xlink:to="loc_us-gaap_EquityComponentDomain_4f809b71-d7ba-464b-b38d-4b94f33eebe9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_d9f359f1-0875-4d1f-bd36-4673023a5ede" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_4f809b71-d7ba-464b-b38d-4b94f33eebe9" xlink:to="loc_us-gaap_CommonStockMember_d9f359f1-0875-4d1f-bd36-4673023a5ede" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="dnli-20210331.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:definitionLink xlink:role="http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended" id="i8e2557b987004feb9831738b03c48cef_CondensedConsolidatedStatementsofCashFlows"/>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/SignificantAccountingPolicies" xlink:type="simple" xlink:href="dnli-20210331.xsd#SignificantAccountingPolicies"/>
  <link:definitionLink xlink:role="http://www.denalitherapeutics.com/role/SignificantAccountingPolicies" xlink:type="extended" id="i9c0cee17baa949d9b607d5dabe86febc_SignificantAccountingPolicies"/>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/SignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="dnli-20210331.xsd#SignificantAccountingPoliciesPolicies"/>
  <link:definitionLink xlink:role="http://www.denalitherapeutics.com/role/SignificantAccountingPoliciesPolicies" xlink:type="extended" id="i04873f68588c40e6bee44875f027b1e8_SignificantAccountingPoliciesPolicies"/>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/SignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="dnli-20210331.xsd#SignificantAccountingPoliciesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.denalitherapeutics.com/role/SignificantAccountingPoliciesNarrativeDetails" xlink:type="extended" id="i2c519df8dfbb4e43bd0c2e0fca266b61_SignificantAccountingPoliciesNarrativeDetails"/>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="dnli-20210331.xsd#FairValueMeasurements"/>
  <link:definitionLink xlink:role="http://www.denalitherapeutics.com/role/FairValueMeasurements" xlink:type="extended" id="id1427b2d0ae84126a289e0f30f0d0c31_FairValueMeasurements"/>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="dnli-20210331.xsd#FairValueMeasurementsTables"/>
  <link:definitionLink xlink:role="http://www.denalitherapeutics.com/role/FairValueMeasurementsTables" xlink:type="extended" id="ifc69e98c44ae4b4c9ddfeaebf5d604ba_FairValueMeasurementsTables"/>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="dnli-20210331.xsd#FairValueMeasurementsScheduleofAssetsandLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.denalitherapeutics.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesDetails" xlink:type="extended" id="i3b0dedac880642ff956659224918060e_FairValueMeasurementsScheduleofAssetsandLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_487143d0-814a-4dc1-a7b0-a692d32063fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_a21cbe4a-d0da-4f42-9703-b3183eb1b256" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_487143d0-814a-4dc1-a7b0-a692d32063fb" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_a21cbe4a-d0da-4f42-9703-b3183eb1b256" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_780c6734-f903-4f35-90f1-4bb2cb2b85d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_a21cbe4a-d0da-4f42-9703-b3183eb1b256" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_780c6734-f903-4f35-90f1-4bb2cb2b85d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_bf9ac4bf-9639-400c-9231-94f5e1f811dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_a21cbe4a-d0da-4f42-9703-b3183eb1b256" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_bf9ac4bf-9639-400c-9231-94f5e1f811dd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_33417d71-2bab-44e5-9304-396ab3db7e4d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_a21cbe4a-d0da-4f42-9703-b3183eb1b256" xlink:to="loc_us-gaap_DerivativeAssets_33417d71-2bab-44e5-9304-396ab3db7e4d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_686b3862-cb29-4072-a960-a8e0009091a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_a21cbe4a-d0da-4f42-9703-b3183eb1b256" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_686b3862-cb29-4072-a960-a8e0009091a0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_d79d0787-4587-4a0a-a747-4859d3ce9895" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_487143d0-814a-4dc1-a7b0-a692d32063fb" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_d79d0787-4587-4a0a-a747-4859d3ce9895" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_ddbd060b-fcc6-4805-9115-99127a724642" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_d79d0787-4587-4a0a-a747-4859d3ce9895" xlink:to="loc_us-gaap_DerivativeLiabilities_ddbd060b-fcc6-4805-9115-99127a724642" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_606d54c8-668e-4154-b5e3-c6ad56b3fdff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_d79d0787-4587-4a0a-a747-4859d3ce9895" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_606d54c8-668e-4154-b5e3-c6ad56b3fdff" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2545578b-ad36-4410-a2fa-2272fc38812d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_487143d0-814a-4dc1-a7b0-a692d32063fb" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2545578b-ad36-4410-a2fa-2272fc38812d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_234dca52-14bd-43c9-bdd5-0f6f566985ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2545578b-ad36-4410-a2fa-2272fc38812d" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_234dca52-14bd-43c9-bdd5-0f6f566985ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_234dca52-14bd-43c9-bdd5-0f6f566985ec_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_234dca52-14bd-43c9-bdd5-0f6f566985ec" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_234dca52-14bd-43c9-bdd5-0f6f566985ec_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_71058fb5-394e-4ce5-91d0-ac4e9cd9c796" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_234dca52-14bd-43c9-bdd5-0f6f566985ec" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_71058fb5-394e-4ce5-91d0-ac4e9cd9c796" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_68342994-163b-420b-9eab-2aea6dc26dfc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_71058fb5-394e-4ce5-91d0-ac4e9cd9c796" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_68342994-163b-420b-9eab-2aea6dc26dfc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_54fd5cb5-2949-4011-9dbc-d4168299c240" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_71058fb5-394e-4ce5-91d0-ac4e9cd9c796" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_54fd5cb5-2949-4011-9dbc-d4168299c240" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_ccd665d5-d628-4e6b-a67e-98bfdb65be26" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_71058fb5-394e-4ce5-91d0-ac4e9cd9c796" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_ccd665d5-d628-4e6b-a67e-98bfdb65be26" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_3295dabe-deb4-4355-8036-62b01e9dff7e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2545578b-ad36-4410-a2fa-2272fc38812d" xlink:to="loc_us-gaap_InvestmentTypeAxis_3295dabe-deb4-4355-8036-62b01e9dff7e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_3295dabe-deb4-4355-8036-62b01e9dff7e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_3295dabe-deb4-4355-8036-62b01e9dff7e" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_3295dabe-deb4-4355-8036-62b01e9dff7e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_82bbbce4-6229-45a5-ac35-7b7fc2e20e75" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_3295dabe-deb4-4355-8036-62b01e9dff7e" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_82bbbce4-6229-45a5-ac35-7b7fc2e20e75" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_9267763b-d51e-4a20-9d10-68284a6811c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_82bbbce4-6229-45a5-ac35-7b7fc2e20e75" xlink:to="loc_us-gaap_ShortTermInvestmentsMember_9267763b-d51e-4a20-9d10-68284a6811c8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_LongTermInvestmentsMember_61963fb5-72e3-4a95-ab55-30484535c0cd" xlink:href="dnli-20210331.xsd#dnli_LongTermInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_82bbbce4-6229-45a5-ac35-7b7fc2e20e75" xlink:to="loc_dnli_LongTermInvestmentsMember_61963fb5-72e3-4a95-ab55-30484535c0cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_f841257f-c62f-4d64-bc20-c404b75b7139" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2545578b-ad36-4410-a2fa-2272fc38812d" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_f841257f-c62f-4d64-bc20-c404b75b7139" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_f841257f-c62f-4d64-bc20-c404b75b7139_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_f841257f-c62f-4d64-bc20-c404b75b7139" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_f841257f-c62f-4d64-bc20-c404b75b7139_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_f1b45fd4-699b-4dec-9974-6eb6a717dc14" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_f841257f-c62f-4d64-bc20-c404b75b7139" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_f1b45fd4-699b-4dec-9974-6eb6a717dc14" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_eabfc9ca-2bd9-46f6-82a1-7036efe30a30" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_f1b45fd4-699b-4dec-9974-6eb6a717dc14" xlink:to="loc_us-gaap_MoneyMarketFundsMember_eabfc9ca-2bd9-46f6-82a1-7036efe30a30" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_a75c05da-83f5-4f61-a2f2-eaa68252912a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_f1b45fd4-699b-4dec-9974-6eb6a717dc14" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_a75c05da-83f5-4f61-a2f2-eaa68252912a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_1df95bf0-a422-44a3-92f3-73821294a7db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_f1b45fd4-699b-4dec-9974-6eb6a717dc14" xlink:to="loc_us-gaap_CommercialPaperMember_1df95bf0-a422-44a3-92f3-73821294a7db" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_94e4848b-3885-488d-b336-bae93ec8ce9b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2545578b-ad36-4410-a2fa-2272fc38812d" xlink:to="loc_us-gaap_FinancialInstrumentAxis_94e4848b-3885-488d-b336-bae93ec8ce9b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_94e4848b-3885-488d-b336-bae93ec8ce9b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_94e4848b-3885-488d-b336-bae93ec8ce9b" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_94e4848b-3885-488d-b336-bae93ec8ce9b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_404a0724-9f09-452f-a382-2b277fac77d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_94e4848b-3885-488d-b336-bae93ec8ce9b" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_404a0724-9f09-452f-a382-2b277fac77d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_9b7efa1e-45f1-4c11-be8c-b0116a10eaa8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_404a0724-9f09-452f-a382-2b277fac77d5" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_9b7efa1e-45f1-4c11-be8c-b0116a10eaa8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_71084d88-8a4e-46e9-b6c2-89e0acdae499" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_404a0724-9f09-452f-a382-2b277fac77d5" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_71084d88-8a4e-46e9-b6c2-89e0acdae499" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_b793c66a-8e44-446e-8be4-82e59fb89aa7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_404a0724-9f09-452f-a382-2b277fac77d5" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_b793c66a-8e44-446e-8be4-82e59fb89aa7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_7bbeca91-6f6e-4031-8d8b-53ea44fd2338" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_404a0724-9f09-452f-a382-2b277fac77d5" xlink:to="loc_us-gaap_CommercialPaperMember_7bbeca91-6f6e-4031-8d8b-53ea44fd2338" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/MarketableSecurities" xlink:type="simple" xlink:href="dnli-20210331.xsd#MarketableSecurities"/>
  <link:definitionLink xlink:role="http://www.denalitherapeutics.com/role/MarketableSecurities" xlink:type="extended" id="i5da79a3a9c5946afaf7cd1697c3957e7_MarketableSecurities"/>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/MarketableSecuritiesTables" xlink:type="simple" xlink:href="dnli-20210331.xsd#MarketableSecuritiesTables"/>
  <link:definitionLink xlink:role="http://www.denalitherapeutics.com/role/MarketableSecuritiesTables" xlink:type="extended" id="i392e0d32d17949e5acebb0f8dd8e2057_MarketableSecuritiesTables"/>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/MarketableSecuritiesSummaryofAvailableforSaleSecuritiesDetails" xlink:type="simple" xlink:href="dnli-20210331.xsd#MarketableSecuritiesSummaryofAvailableforSaleSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.denalitherapeutics.com/role/MarketableSecuritiesSummaryofAvailableforSaleSecuritiesDetails" xlink:type="extended" id="i2129b6bc81544f49ad9d296a626e51e9_MarketableSecuritiesSummaryofAvailableforSaleSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_542008ee-1e41-4c12-91c2-e4722007d1b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_421a2c27-4476-46c3-b0b5-bd5dd8b95edb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_542008ee-1e41-4c12-91c2-e4722007d1b5" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_421a2c27-4476-46c3-b0b5-bd5dd8b95edb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_276e7c9c-58d9-4c5f-8ec2-50784ad45ebf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_542008ee-1e41-4c12-91c2-e4722007d1b5" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_276e7c9c-58d9-4c5f-8ec2-50784ad45ebf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_2523e922-0847-4b1d-9c03-fd706f2cd81e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_542008ee-1e41-4c12-91c2-e4722007d1b5" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_2523e922-0847-4b1d-9c03-fd706f2cd81e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_fb509074-4097-4f58-a1d8-5e8dba4d642e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_542008ee-1e41-4c12-91c2-e4722007d1b5" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_fb509074-4097-4f58-a1d8-5e8dba4d642e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_110cc1ce-f7cf-4a8e-8241-98ebd0e29a69" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_542008ee-1e41-4c12-91c2-e4722007d1b5" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_110cc1ce-f7cf-4a8e-8241-98ebd0e29a69" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_92889ee6-fda6-4d7d-a3f2-568b290b65e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_542008ee-1e41-4c12-91c2-e4722007d1b5" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_92889ee6-fda6-4d7d-a3f2-568b290b65e0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_84be667e-8b04-496e-9c86-94fd2282131f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_542008ee-1e41-4c12-91c2-e4722007d1b5" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_84be667e-8b04-496e-9c86-94fd2282131f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_54e12291-7676-43af-9e5a-63a368dbac38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_84be667e-8b04-496e-9c86-94fd2282131f" xlink:to="loc_us-gaap_InvestmentTypeAxis_54e12291-7676-43af-9e5a-63a368dbac38" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_54e12291-7676-43af-9e5a-63a368dbac38_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_54e12291-7676-43af-9e5a-63a368dbac38" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_54e12291-7676-43af-9e5a-63a368dbac38_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_d08f6bf8-ba2e-49da-b6af-b22c0edf0cc7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_54e12291-7676-43af-9e5a-63a368dbac38" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_d08f6bf8-ba2e-49da-b6af-b22c0edf0cc7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_ShortTermMarketableSecuritiesMember_57c7479e-e492-4aef-b9d4-83570742060c" xlink:href="dnli-20210331.xsd#dnli_ShortTermMarketableSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_d08f6bf8-ba2e-49da-b6af-b22c0edf0cc7" xlink:to="loc_dnli_ShortTermMarketableSecuritiesMember_57c7479e-e492-4aef-b9d4-83570742060c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_LongTermMarketableSecuritiesMember_8bd9b0aa-6989-4412-b99e-50ab014d9b4a" xlink:href="dnli-20210331.xsd#dnli_LongTermMarketableSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_d08f6bf8-ba2e-49da-b6af-b22c0edf0cc7" xlink:to="loc_dnli_LongTermMarketableSecuritiesMember_8bd9b0aa-6989-4412-b99e-50ab014d9b4a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_284412df-56a9-4334-8dda-0cf73a112402" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_84be667e-8b04-496e-9c86-94fd2282131f" xlink:to="loc_us-gaap_FinancialInstrumentAxis_284412df-56a9-4334-8dda-0cf73a112402" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_284412df-56a9-4334-8dda-0cf73a112402_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_284412df-56a9-4334-8dda-0cf73a112402" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_284412df-56a9-4334-8dda-0cf73a112402_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_480eb44d-e512-4c47-887d-7db3716fe83d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_284412df-56a9-4334-8dda-0cf73a112402" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_480eb44d-e512-4c47-887d-7db3716fe83d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_bc5c2112-a2a0-44ba-b3be-7cdfcaf7d5ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_480eb44d-e512-4c47-887d-7db3716fe83d" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_bc5c2112-a2a0-44ba-b3be-7cdfcaf7d5ad" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_881963b3-f886-49a2-ac20-76006030dd67" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_480eb44d-e512-4c47-887d-7db3716fe83d" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_881963b3-f886-49a2-ac20-76006030dd67" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_a08517a7-42f5-477c-aede-c7d64addd66d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_480eb44d-e512-4c47-887d-7db3716fe83d" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_a08517a7-42f5-477c-aede-c7d64addd66d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_0da34d4d-7615-4788-a6a9-18e32992b1de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_480eb44d-e512-4c47-887d-7db3716fe83d" xlink:to="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_0da34d4d-7615-4788-a6a9-18e32992b1de" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/MarketableSecuritiesNarrativeDetails" xlink:type="simple" xlink:href="dnli-20210331.xsd#MarketableSecuritiesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.denalitherapeutics.com/role/MarketableSecuritiesNarrativeDetails" xlink:type="extended" id="i158db1bf5a0443b0981f511cb46f464d_MarketableSecuritiesNarrativeDetails"/>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/DerivativeFinancialInstruments" xlink:type="simple" xlink:href="dnli-20210331.xsd#DerivativeFinancialInstruments"/>
  <link:definitionLink xlink:role="http://www.denalitherapeutics.com/role/DerivativeFinancialInstruments" xlink:type="extended" id="ieaee5dbcaf904bc1b6b5740cc912b094_DerivativeFinancialInstruments"/>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/DerivativeFinancialInstrumentsTables" xlink:type="simple" xlink:href="dnli-20210331.xsd#DerivativeFinancialInstrumentsTables"/>
  <link:definitionLink xlink:role="http://www.denalitherapeutics.com/role/DerivativeFinancialInstrumentsTables" xlink:type="extended" id="ia0efd1196e7b465ebd29b63d59e66a87_DerivativeFinancialInstrumentsTables"/>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/DerivativeFinancialInstrumentsSummaryofForwardForeignCurrencyExchangeContractsOutstandingDetails" xlink:type="simple" xlink:href="dnli-20210331.xsd#DerivativeFinancialInstrumentsSummaryofForwardForeignCurrencyExchangeContractsOutstandingDetails"/>
  <link:definitionLink xlink:role="http://www.denalitherapeutics.com/role/DerivativeFinancialInstrumentsSummaryofForwardForeignCurrencyExchangeContractsOutstandingDetails" xlink:type="extended" id="i70759f0297934f3d99941d2908009abf_DerivativeFinancialInstrumentsSummaryofForwardForeignCurrencyExchangeContractsOutstandingDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_3fe3be21-bcc2-4b77-8373-20e8bffacee7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNumberOfInstrumentsHeld_070c601d-9881-4eff-bd62-8131a2874935" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeNumberOfInstrumentsHeld"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_3fe3be21-bcc2-4b77-8373-20e8bffacee7" xlink:to="loc_us-gaap_DerivativeNumberOfInstrumentsHeld_070c601d-9881-4eff-bd62-8131a2874935" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_049c6b2c-531b-42f2-9f4f-65dc0f00ef4d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_3fe3be21-bcc2-4b77-8373-20e8bffacee7" xlink:to="loc_us-gaap_DerivativeNotionalAmount_049c6b2c-531b-42f2-9f4f-65dc0f00ef4d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_0c26b376-1b90-4515-9f2a-ae3bf6cd4f81" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_3fe3be21-bcc2-4b77-8373-20e8bffacee7" xlink:to="loc_us-gaap_DerivativeTable_0c26b376-1b90-4515-9f2a-ae3bf6cd4f81" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_93fffd0b-289e-4c4b-bc8e-64ad3817b96e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_0c26b376-1b90-4515-9f2a-ae3bf6cd4f81" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_93fffd0b-289e-4c4b-bc8e-64ad3817b96e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_93fffd0b-289e-4c4b-bc8e-64ad3817b96e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_93fffd0b-289e-4c4b-bc8e-64ad3817b96e" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_93fffd0b-289e-4c4b-bc8e-64ad3817b96e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_d75e7556-b0a8-424d-aaf1-6fd05e8a3d1f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_93fffd0b-289e-4c4b-bc8e-64ad3817b96e" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_d75e7556-b0a8-424d-aaf1-6fd05e8a3d1f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_ForeignExchangeForwardEurosMember_f12ef76a-b8b8-4ac3-80e7-dd4118a4f42a" xlink:href="dnli-20210331.xsd#dnli_ForeignExchangeForwardEurosMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_d75e7556-b0a8-424d-aaf1-6fd05e8a3d1f" xlink:to="loc_dnli_ForeignExchangeForwardEurosMember_f12ef76a-b8b8-4ac3-80e7-dd4118a4f42a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_ForeignExchangeForwardBritishPoundsMember_1677bcb2-1133-471b-92e7-f4794855fec2" xlink:href="dnli-20210331.xsd#dnli_ForeignExchangeForwardBritishPoundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_d75e7556-b0a8-424d-aaf1-6fd05e8a3d1f" xlink:to="loc_dnli_ForeignExchangeForwardBritishPoundsMember_1677bcb2-1133-471b-92e7-f4794855fec2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_f5de6020-57c7-40a4-99d6-f5034da39a02" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_d75e7556-b0a8-424d-aaf1-6fd05e8a3d1f" xlink:to="loc_us-gaap_ForeignExchangeContractMember_f5de6020-57c7-40a4-99d6-f5034da39a02" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_6b919dc7-6e8f-42a1-9702-98541c2973d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_0c26b376-1b90-4515-9f2a-ae3bf6cd4f81" xlink:to="loc_us-gaap_HedgingDesignationAxis_6b919dc7-6e8f-42a1-9702-98541c2973d9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_6b919dc7-6e8f-42a1-9702-98541c2973d9_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_6b919dc7-6e8f-42a1-9702-98541c2973d9" xlink:to="loc_us-gaap_HedgingDesignationDomain_6b919dc7-6e8f-42a1-9702-98541c2973d9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_215cde8c-a920-49c2-a16c-e96b8b173406" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_6b919dc7-6e8f-42a1-9702-98541c2973d9" xlink:to="loc_us-gaap_HedgingDesignationDomain_215cde8c-a920-49c2-a16c-e96b8b173406" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_99e9e739-c1b6-4cf9-aa76-d8428b226473" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_215cde8c-a920-49c2-a16c-e96b8b173406" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_99e9e739-c1b6-4cf9-aa76-d8428b226473" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/DerivativeFinancialInstrumentsNarrativeDetails" xlink:type="simple" xlink:href="dnli-20210331.xsd#DerivativeFinancialInstrumentsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.denalitherapeutics.com/role/DerivativeFinancialInstrumentsNarrativeDetails" xlink:type="extended" id="i5419783c62564d0e9a89e8a788fefb79_DerivativeFinancialInstrumentsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_fbb46b8b-02de-4ed0-981f-bdd1cc85829a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_090e87b1-8665-4163-985f-cded6e9a0fe4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_fbb46b8b-02de-4ed0-981f-bdd1cc85829a" xlink:to="loc_us-gaap_DerivativeLiabilities_090e87b1-8665-4163-985f-cded6e9a0fe4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_2c5cd6e3-24bd-43d2-b456-9dc3e8aec57f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_fbb46b8b-02de-4ed0-981f-bdd1cc85829a" xlink:to="loc_us-gaap_DerivativeAssets_2c5cd6e3-24bd-43d2-b456-9dc3e8aec57f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_8e2a2ea2-0d9f-4cc2-a508-0ee05e203de8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_fbb46b8b-02de-4ed0-981f-bdd1cc85829a" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_8e2a2ea2-0d9f-4cc2-a508-0ee05e203de8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_36fb0810-dd2b-478c-921f-41edacbb62cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_fbb46b8b-02de-4ed0-981f-bdd1cc85829a" xlink:to="loc_us-gaap_DerivativeTable_36fb0810-dd2b-478c-921f-41edacbb62cb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_23f845b5-2a33-40c4-8fbc-673679ec8355" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_36fb0810-dd2b-478c-921f-41edacbb62cb" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_23f845b5-2a33-40c4-8fbc-673679ec8355" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_23f845b5-2a33-40c4-8fbc-673679ec8355_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_23f845b5-2a33-40c4-8fbc-673679ec8355" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_23f845b5-2a33-40c4-8fbc-673679ec8355_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_c70ef412-207c-4a0d-82ad-d6a5fbdbb74f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_23f845b5-2a33-40c4-8fbc-673679ec8355" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_c70ef412-207c-4a0d-82ad-d6a5fbdbb74f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_44b19829-a20a-49b7-8bb4-8b8ec9eee8ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_c70ef412-207c-4a0d-82ad-d6a5fbdbb74f" xlink:to="loc_us-gaap_ForeignExchangeContractMember_44b19829-a20a-49b7-8bb4-8b8ec9eee8ca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_7cfa8c51-866b-475d-8385-84ac29cefd7e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_36fb0810-dd2b-478c-921f-41edacbb62cb" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_7cfa8c51-866b-475d-8385-84ac29cefd7e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_7cfa8c51-866b-475d-8385-84ac29cefd7e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_7cfa8c51-866b-475d-8385-84ac29cefd7e" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_7cfa8c51-866b-475d-8385-84ac29cefd7e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_027e0c28-8a85-4f58-82d1-55b701fee73d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_7cfa8c51-866b-475d-8385-84ac29cefd7e" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_027e0c28-8a85-4f58-82d1-55b701fee73d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_4606a4ea-2eca-47b9-8694-f107839502ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_027e0c28-8a85-4f58-82d1-55b701fee73d" xlink:to="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_4606a4ea-2eca-47b9-8694-f107839502ff" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/CollaborationAgreements" xlink:type="simple" xlink:href="dnli-20210331.xsd#CollaborationAgreements"/>
  <link:definitionLink xlink:role="http://www.denalitherapeutics.com/role/CollaborationAgreements" xlink:type="extended" id="id5d5bd63600443c993ad13f263e1c3e0_CollaborationAgreements"/>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/CollaborationAgreementsTables" xlink:type="simple" xlink:href="dnli-20210331.xsd#CollaborationAgreementsTables"/>
  <link:definitionLink xlink:role="http://www.denalitherapeutics.com/role/CollaborationAgreementsTables" xlink:type="extended" id="i067923ac1ffe46ff8a883f7d153335f9_CollaborationAgreementsTables"/>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/CollaborationAgreementsBiogenDetails" xlink:type="simple" xlink:href="dnli-20210331.xsd#CollaborationAgreementsBiogenDetails"/>
  <link:definitionLink xlink:role="http://www.denalitherapeutics.com/role/CollaborationAgreementsBiogenDetails" xlink:type="extended" id="i304f60a5ac3341dd846d0d3c3b69c221_CollaborationAgreementsBiogenDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a8c4441e-4d10-4239-9330-25c3d05dbb4d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_CollaborativeArrangementNumberOfPrograms_2431d990-9397-4057-98ba-460503c9490c" xlink:href="dnli-20210331.xsd#dnli_CollaborativeArrangementNumberOfPrograms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a8c4441e-4d10-4239-9330-25c3d05dbb4d" xlink:to="loc_dnli_CollaborativeArrangementNumberOfPrograms_2431d990-9397-4057-98ba-460503c9490c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_CollaborativeArrangementNumberOfAdditionalProgramsIfCircumstancesMet_87358e02-e60e-40a7-8ce7-6ed46c82cc46" xlink:href="dnli-20210331.xsd#dnli_CollaborativeArrangementNumberOfAdditionalProgramsIfCircumstancesMet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a8c4441e-4d10-4239-9330-25c3d05dbb4d" xlink:to="loc_dnli_CollaborativeArrangementNumberOfAdditionalProgramsIfCircumstancesMet_87358e02-e60e-40a7-8ce7-6ed46c82cc46" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_CollaborativeArrangementUpfrontPaymentToBeReceived_b7820646-980e-480a-81b9-55187136f18c" xlink:href="dnli-20210331.xsd#dnli_CollaborativeArrangementUpfrontPaymentToBeReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a8c4441e-4d10-4239-9330-25c3d05dbb4d" xlink:to="loc_dnli_CollaborativeArrangementUpfrontPaymentToBeReceived_b7820646-980e-480a-81b9-55187136f18c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_AggregateDevelopmentFirstCommercialSaleAndNetSalesBasedMilestonePayments_937d188a-7287-4792-8a5f-036dbec2a524" xlink:href="dnli-20210331.xsd#dnli_AggregateDevelopmentFirstCommercialSaleAndNetSalesBasedMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a8c4441e-4d10-4239-9330-25c3d05dbb4d" xlink:to="loc_dnli_AggregateDevelopmentFirstCommercialSaleAndNetSalesBasedMilestonePayments_937d188a-7287-4792-8a5f-036dbec2a524" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_DevelopmentMilestonePayments_2efe4f40-62fe-4e58-bb1b-3cbb685c6355" xlink:href="dnli-20210331.xsd#dnli_DevelopmentMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a8c4441e-4d10-4239-9330-25c3d05dbb4d" xlink:to="loc_dnli_DevelopmentMilestonePayments_2efe4f40-62fe-4e58-bb1b-3cbb685c6355" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_FirstCommercialSaleMilestonePayments_09583a79-c1ac-46bb-bb56-bc8353c97f8b" xlink:href="dnli-20210331.xsd#dnli_FirstCommercialSaleMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a8c4441e-4d10-4239-9330-25c3d05dbb4d" xlink:to="loc_dnli_FirstCommercialSaleMilestonePayments_09583a79-c1ac-46bb-bb56-bc8353c97f8b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_NetSalesBasedMilestonePayments_1de25547-f3a8-440d-b6ff-2ba2a8c29468" xlink:href="dnli-20210331.xsd#dnli_NetSalesBasedMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a8c4441e-4d10-4239-9330-25c3d05dbb4d" xlink:to="loc_dnli_NetSalesBasedMilestonePayments_1de25547-f3a8-440d-b6ff-2ba2a8c29468" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_CollaborativeAgreementAgreedShareOfCommercialProfitLoss_86a67419-4438-47f8-84e9-934a0775d848" xlink:href="dnli-20210331.xsd#dnli_CollaborativeAgreementAgreedShareOfCommercialProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a8c4441e-4d10-4239-9330-25c3d05dbb4d" xlink:to="loc_dnli_CollaborativeAgreementAgreedShareOfCommercialProfitLoss_86a67419-4438-47f8-84e9-934a0775d848" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_CollaborativeAgreementFundedPercentage_41d46469-897e-465e-96a7-43575a1b1fa3" xlink:href="dnli-20210331.xsd#dnli_CollaborativeAgreementFundedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a8c4441e-4d10-4239-9330-25c3d05dbb4d" xlink:to="loc_dnli_CollaborativeAgreementFundedPercentage_41d46469-897e-465e-96a7-43575a1b1fa3" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_CollaborativeArrangementTermNumberOfBusinessDaysIfEffectiveDateCriteriaMet_9a459918-37af-4d2f-b234-ba56e81c9657" xlink:href="dnli-20210331.xsd#dnli_CollaborativeArrangementTermNumberOfBusinessDaysIfEffectiveDateCriteriaMet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a8c4441e-4d10-4239-9330-25c3d05dbb4d" xlink:to="loc_dnli_CollaborativeArrangementTermNumberOfBusinessDaysIfEffectiveDateCriteriaMet_9a459918-37af-4d2f-b234-ba56e81c9657" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_CollaborativeArrangementRightOfFirstNegotiationTermPeriodAfterEffectiveDateOfAgreementIfCircumstancesMet_5496d8f1-c948-4a46-82c4-7385e2e99252" xlink:href="dnli-20210331.xsd#dnli_CollaborativeArrangementRightOfFirstNegotiationTermPeriodAfterEffectiveDateOfAgreementIfCircumstancesMet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a8c4441e-4d10-4239-9330-25c3d05dbb4d" xlink:to="loc_dnli_CollaborativeArrangementRightOfFirstNegotiationTermPeriodAfterEffectiveDateOfAgreementIfCircumstancesMet_5496d8f1-c948-4a46-82c4-7385e2e99252" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_CollaborativeArrangementRightOfFirstNegotiationPeriodTermAdditionalProgramCriteria_b574b14f-a9a8-4170-bf49-2dde9f72594a" xlink:href="dnli-20210331.xsd#dnli_CollaborativeArrangementRightOfFirstNegotiationPeriodTermAdditionalProgramCriteria"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a8c4441e-4d10-4239-9330-25c3d05dbb4d" xlink:to="loc_dnli_CollaborativeArrangementRightOfFirstNegotiationPeriodTermAdditionalProgramCriteria_b574b14f-a9a8-4170-bf49-2dde9f72594a" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_CollaborativeArrangementNumberOfAdditionalProgramsNoThirdPartyAgreementExecutedIfCircumstancesMet_d1e871eb-4596-422b-929c-47b5dffcc83e" xlink:href="dnli-20210331.xsd#dnli_CollaborativeArrangementNumberOfAdditionalProgramsNoThirdPartyAgreementExecutedIfCircumstancesMet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a8c4441e-4d10-4239-9330-25c3d05dbb4d" xlink:to="loc_dnli_CollaborativeArrangementNumberOfAdditionalProgramsNoThirdPartyAgreementExecutedIfCircumstancesMet_d1e871eb-4596-422b-929c-47b5dffcc83e" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_eeb7f723-797c-48cc-9d98-a734616a5fde" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a8c4441e-4d10-4239-9330-25c3d05dbb4d" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_eeb7f723-797c-48cc-9d98-a734616a5fde" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_80c9d798-b502-4615-9302-a74540259fca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a8c4441e-4d10-4239-9330-25c3d05dbb4d" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_80c9d798-b502-4615-9302-a74540259fca" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStocksIncludingAdditionalPaidInCapital_29766ce9-2f27-4bb4-b431-13086259a2c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStocksIncludingAdditionalPaidInCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a8c4441e-4d10-4239-9330-25c3d05dbb4d" xlink:to="loc_us-gaap_CommonStocksIncludingAdditionalPaidInCapital_29766ce9-2f27-4bb4-b431-13086259a2c1" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_bef8e3e4-a26d-49e8-81d0-38294c8ad493" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a8c4441e-4d10-4239-9330-25c3d05dbb4d" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_bef8e3e4-a26d-49e8-81d0-38294c8ad493" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_SaleOfStockConsiderationPremiumReceivedOnTransaction_a6103375-3f64-450d-9cf9-0c32ffc46104" xlink:href="dnli-20210331.xsd#dnli_SaleOfStockConsiderationPremiumReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a8c4441e-4d10-4239-9330-25c3d05dbb4d" xlink:to="loc_dnli_SaleOfStockConsiderationPremiumReceivedOnTransaction_a6103375-3f64-450d-9cf9-0c32ffc46104" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_CollaborativeArrangementOptionExerciseAndDevelopmentMilestonePaymentsToBeReceived_9b039b98-64c9-4ab2-9373-b669ba1c8fd7" xlink:href="dnli-20210331.xsd#dnli_CollaborativeArrangementOptionExerciseAndDevelopmentMilestonePaymentsToBeReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a8c4441e-4d10-4239-9330-25c3d05dbb4d" xlink:to="loc_dnli_CollaborativeArrangementOptionExerciseAndDevelopmentMilestonePaymentsToBeReceived_9b039b98-64c9-4ab2-9373-b669ba1c8fd7" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_CollaborativeArrangementFirstCommercialSaleMilestonePaymentsToBeReceived_38163ed8-2a2b-4f6c-b893-d5320db718b9" xlink:href="dnli-20210331.xsd#dnli_CollaborativeArrangementFirstCommercialSaleMilestonePaymentsToBeReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a8c4441e-4d10-4239-9330-25c3d05dbb4d" xlink:to="loc_dnli_CollaborativeArrangementFirstCommercialSaleMilestonePaymentsToBeReceived_38163ed8-2a2b-4f6c-b893-d5320db718b9" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_CollaborativeArrangementNetSalesBasedMilestonePaymentsToBeReceived_cae72c77-763c-4701-9af9-fbc616d221d5" xlink:href="dnli-20210331.xsd#dnli_CollaborativeArrangementNetSalesBasedMilestonePaymentsToBeReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a8c4441e-4d10-4239-9330-25c3d05dbb4d" xlink:to="loc_dnli_CollaborativeArrangementNetSalesBasedMilestonePaymentsToBeReceived_cae72c77-763c-4701-9af9-fbc616d221d5" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_UpfrontPayments_86c5c164-8f5a-49e2-91e0-8f786b19589b" xlink:href="dnli-20210331.xsd#dnli_UpfrontPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a8c4441e-4d10-4239-9330-25c3d05dbb4d" xlink:to="loc_dnli_UpfrontPayments_86c5c164-8f5a-49e2-91e0-8f786b19589b" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_CollaborationAgreementTransactionPriceIncreaseDecrease_3017b61e-f973-438a-8661-768074e5f37d" xlink:href="dnli-20210331.xsd#dnli_CollaborationAgreementTransactionPriceIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a8c4441e-4d10-4239-9330-25c3d05dbb4d" xlink:to="loc_dnli_CollaborationAgreementTransactionPriceIncreaseDecrease_3017b61e-f973-438a-8661-768074e5f37d" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_f6f9aeee-fc26-4d4f-8556-46b1f41c6810" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a8c4441e-4d10-4239-9330-25c3d05dbb4d" xlink:to="loc_us-gaap_ContractWithCustomerLiability_f6f9aeee-fc26-4d4f-8556-46b1f41c6810" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_ResearchAndDevelopmentExpenseOffsetFromRelatedPartyCostReimbursement_14cc2781-159c-498c-9b22-8d27e920e8d3" xlink:href="dnli-20210331.xsd#dnli_ResearchAndDevelopmentExpenseOffsetFromRelatedPartyCostReimbursement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a8c4441e-4d10-4239-9330-25c3d05dbb4d" xlink:to="loc_dnli_ResearchAndDevelopmentExpenseOffsetFromRelatedPartyCostReimbursement_14cc2781-159c-498c-9b22-8d27e920e8d3" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueFromRelatedPartiesCurrent_e88a59aa-bb06-4ca6-a0c0-c5c0de90ca73" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueFromRelatedPartiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a8c4441e-4d10-4239-9330-25c3d05dbb4d" xlink:to="loc_us-gaap_DueFromRelatedPartiesCurrent_e88a59aa-bb06-4ca6-a0c0-c5c0de90ca73" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_CollaborativeArrangementNumberOfMilestonesAchieved_47f604ed-a6d5-4d9f-92e7-a40dd036bb9b" xlink:href="dnli-20210331.xsd#dnli_CollaborativeArrangementNumberOfMilestonesAchieved"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a8c4441e-4d10-4239-9330-25c3d05dbb4d" xlink:to="loc_dnli_CollaborativeArrangementNumberOfMilestonesAchieved_47f604ed-a6d5-4d9f-92e7-a40dd036bb9b" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7a5fa7b9-eef0-4f39-ad9c-a683dda9b070" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a8c4441e-4d10-4239-9330-25c3d05dbb4d" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7a5fa7b9-eef0-4f39-ad9c-a683dda9b070" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_66c3aba5-f74e-4547-bc5e-774846e9cd9a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7a5fa7b9-eef0-4f39-ad9c-a683dda9b070" xlink:to="loc_us-gaap_TypeOfArrangementAxis_66c3aba5-f74e-4547-bc5e-774846e9cd9a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_66c3aba5-f74e-4547-bc5e-774846e9cd9a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_66c3aba5-f74e-4547-bc5e-774846e9cd9a" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_66c3aba5-f74e-4547-bc5e-774846e9cd9a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_188d3bf5-8193-4511-aa62-bf59a709907b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_66c3aba5-f74e-4547-bc5e-774846e9cd9a" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_188d3bf5-8193-4511-aa62-bf59a709907b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_ProvisionalCollaborativeArrangementMember_58d402e8-9fea-4fe1-9c92-28c34f50ae70" xlink:href="dnli-20210331.xsd#dnli_ProvisionalCollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_188d3bf5-8193-4511-aa62-bf59a709907b" xlink:to="loc_dnli_ProvisionalCollaborativeArrangementMember_58d402e8-9fea-4fe1-9c92-28c34f50ae70" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_ROFNAndOptionAgreementCollaborativeArrangementMember_306666a0-5949-4d42-8adc-b972cce5eba2" xlink:href="dnli-20210331.xsd#dnli_ROFNAndOptionAgreementCollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_188d3bf5-8193-4511-aa62-bf59a709907b" xlink:to="loc_dnli_ROFNAndOptionAgreementCollaborativeArrangementMember_306666a0-5949-4d42-8adc-b972cce5eba2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_BiogenCollaborativeArrangementMember_80fd9c82-9b3c-46d5-b35a-8e0be66f6ba1" xlink:href="dnli-20210331.xsd#dnli_BiogenCollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_188d3bf5-8193-4511-aa62-bf59a709907b" xlink:to="loc_dnli_BiogenCollaborativeArrangementMember_80fd9c82-9b3c-46d5-b35a-8e0be66f6ba1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_0c8dd07e-58bb-4b7f-8fdc-765859545aa9" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7a5fa7b9-eef0-4f39-ad9c-a683dda9b070" xlink:to="loc_srt_CounterpartyNameAxis_0c8dd07e-58bb-4b7f-8fdc-765859545aa9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0c8dd07e-58bb-4b7f-8fdc-765859545aa9_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_0c8dd07e-58bb-4b7f-8fdc-765859545aa9" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0c8dd07e-58bb-4b7f-8fdc-765859545aa9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_98bd595b-fc79-4c6d-b848-f897777a9e33" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_0c8dd07e-58bb-4b7f-8fdc-765859545aa9" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_98bd595b-fc79-4c6d-b848-f897777a9e33" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_BiogenMember_def87e74-cae8-4e9d-8b2d-8fd534e24b43" xlink:href="dnli-20210331.xsd#dnli_BiogenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_98bd595b-fc79-4c6d-b848-f897777a9e33" xlink:to="loc_dnli_BiogenMember_def87e74-cae8-4e9d-8b2d-8fd534e24b43" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_5d09a4aa-b82c-4687-b694-85e2c3793f6a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7a5fa7b9-eef0-4f39-ad9c-a683dda9b070" xlink:to="loc_srt_ProductOrServiceAxis_5d09a4aa-b82c-4687-b694-85e2c3793f6a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_5d09a4aa-b82c-4687-b694-85e2c3793f6a_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_5d09a4aa-b82c-4687-b694-85e2c3793f6a" xlink:to="loc_srt_ProductsAndServicesDomain_5d09a4aa-b82c-4687-b694-85e2c3793f6a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_346c4849-1b65-44d7-97e8-e698fecaf8da" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_5d09a4aa-b82c-4687-b694-85e2c3793f6a" xlink:to="loc_srt_ProductsAndServicesDomain_346c4849-1b65-44d7-97e8-e698fecaf8da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_TransportVehicleTechnologyPlatformUnnamedProgramMember_b06da69c-0b6e-4d35-a90a-a031fce3fd13" xlink:href="dnli-20210331.xsd#dnli_TransportVehicleTechnologyPlatformUnnamedProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_346c4849-1b65-44d7-97e8-e698fecaf8da" xlink:to="loc_dnli_TransportVehicleTechnologyPlatformUnnamedProgramMember_b06da69c-0b6e-4d35-a90a-a031fce3fd13" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_TransportVehicleTechnologyProgramRightOfFirstNegotiationProgramsMember_dc90edb3-b67d-4426-9d2b-1eb9cacf3abc" xlink:href="dnli-20210331.xsd#dnli_TransportVehicleTechnologyProgramRightOfFirstNegotiationProgramsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_346c4849-1b65-44d7-97e8-e698fecaf8da" xlink:to="loc_dnli_TransportVehicleTechnologyProgramRightOfFirstNegotiationProgramsMember_dc90edb3-b67d-4426-9d2b-1eb9cacf3abc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_TransportVehicleTechnologyPlatformPreclinicalProgramsMember_7b8bb976-ab46-4cc6-8fd6-67fa258ffc65" xlink:href="dnli-20210331.xsd#dnli_TransportVehicleTechnologyPlatformPreclinicalProgramsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_346c4849-1b65-44d7-97e8-e698fecaf8da" xlink:to="loc_dnli_TransportVehicleTechnologyPlatformPreclinicalProgramsMember_7b8bb976-ab46-4cc6-8fd6-67fa258ffc65" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_TransportVehicleTechnologyPlatformRightOfFirstNegotiationProgramsMember_1d19fa75-16f5-4e82-ba77-c6608635ceed" xlink:href="dnli-20210331.xsd#dnli_TransportVehicleTechnologyPlatformRightOfFirstNegotiationProgramsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_346c4849-1b65-44d7-97e8-e698fecaf8da" xlink:to="loc_dnli_TransportVehicleTechnologyPlatformRightOfFirstNegotiationProgramsMember_1d19fa75-16f5-4e82-ba77-c6608635ceed" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_OptionResearchServicesMember_2bbe310a-23d8-4271-9428-ec552080d33d" xlink:href="dnli-20210331.xsd#dnli_OptionResearchServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_346c4849-1b65-44d7-97e8-e698fecaf8da" xlink:to="loc_dnli_OptionResearchServicesMember_2bbe310a-23d8-4271-9428-ec552080d33d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_9f57ca4f-3615-4883-9fe3-a91d46fa9e44" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7a5fa7b9-eef0-4f39-ad9c-a683dda9b070" xlink:to="loc_dei_LegalEntityAxis_9f57ca4f-3615-4883-9fe3-a91d46fa9e44" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_9f57ca4f-3615-4883-9fe3-a91d46fa9e44_default" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_9f57ca4f-3615-4883-9fe3-a91d46fa9e44" xlink:to="loc_dei_EntityDomain_9f57ca4f-3615-4883-9fe3-a91d46fa9e44_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_13a10a60-c1ed-46b7-a219-3653b20b6bbb" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_9f57ca4f-3615-4883-9fe3-a91d46fa9e44" xlink:to="loc_dei_EntityDomain_13a10a60-c1ed-46b7-a219-3653b20b6bbb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_BiogenMember_602b34ac-2ecc-4ef7-be43-c55a54aa5c02" xlink:href="dnli-20210331.xsd#dnli_BiogenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_13a10a60-c1ed-46b7-a219-3653b20b6bbb" xlink:to="loc_dnli_BiogenMember_602b34ac-2ecc-4ef7-be43-c55a54aa5c02" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_c7381bd6-884f-42a0-9908-68bb30822448" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7a5fa7b9-eef0-4f39-ad9c-a683dda9b070" xlink:to="loc_srt_StatementGeographicalAxis_c7381bd6-884f-42a0-9908-68bb30822448" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_c7381bd6-884f-42a0-9908-68bb30822448_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_c7381bd6-884f-42a0-9908-68bb30822448" xlink:to="loc_srt_SegmentGeographicalDomain_c7381bd6-884f-42a0-9908-68bb30822448_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_1cd4f766-feef-4b13-8b94-7e5551102efc" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_c7381bd6-884f-42a0-9908-68bb30822448" xlink:to="loc_srt_SegmentGeographicalDomain_1cd4f766-feef-4b13-8b94-7e5551102efc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_6ca681e5-7b71-4bed-93dc-ebc2402876f8" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_1cd4f766-feef-4b13-8b94-7e5551102efc" xlink:to="loc_country_US_6ca681e5-7b71-4bed-93dc-ebc2402876f8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CN_18918321-29a1-44e7-9559-e9c1d64791cf" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_CN"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_1cd4f766-feef-4b13-8b94-7e5551102efc" xlink:to="loc_country_CN_18918321-29a1-44e7-9559-e9c1d64791cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_df72851b-bc4d-4b77-a27a-72623cbeb8eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7a5fa7b9-eef0-4f39-ad9c-a683dda9b070" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_df72851b-bc4d-4b77-a27a-72623cbeb8eb" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_df72851b-bc4d-4b77-a27a-72623cbeb8eb_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_df72851b-bc4d-4b77-a27a-72623cbeb8eb" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_df72851b-bc4d-4b77-a27a-72623cbeb8eb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_c4d594db-0378-4822-bcf1-13341bae6271" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_df72851b-bc4d-4b77-a27a-72623cbeb8eb" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_c4d594db-0378-4822-bcf1-13341bae6271" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_SharePurchaseAgreementMember_deb6442f-e4c4-4b34-bf8c-5cae2a518b56" xlink:href="dnli-20210331.xsd#dnli_SharePurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_c4d594db-0378-4822-bcf1-13341bae6271" xlink:to="loc_dnli_SharePurchaseAgreementMember_deb6442f-e4c4-4b34-bf8c-5cae2a518b56" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_12aeaec0-20a5-43a6-89b6-604e52eb9da3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7a5fa7b9-eef0-4f39-ad9c-a683dda9b070" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_12aeaec0-20a5-43a6-89b6-604e52eb9da3" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_12aeaec0-20a5-43a6-89b6-604e52eb9da3_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_12aeaec0-20a5-43a6-89b6-604e52eb9da3" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_12aeaec0-20a5-43a6-89b6-604e52eb9da3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_65dfd509-e7e6-4ad8-b40a-b931ed36ee09" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_12aeaec0-20a5-43a6-89b6-604e52eb9da3" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_65dfd509-e7e6-4ad8-b40a-b931ed36ee09" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_09c35134-d5eb-4fe4-8254-82905ead54e8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_AffiliatedEntityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_65dfd509-e7e6-4ad8-b40a-b931ed36ee09" xlink:to="loc_srt_AffiliatedEntityMember_09c35134-d5eb-4fe4-8254-82905ead54e8" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/CollaborationAgreementsSanofiDetails" xlink:type="simple" xlink:href="dnli-20210331.xsd#CollaborationAgreementsSanofiDetails"/>
  <link:definitionLink xlink:role="http://www.denalitherapeutics.com/role/CollaborationAgreementsSanofiDetails" xlink:type="extended" id="i0c5fbd90abac4c0788d3785971145c5f_CollaborationAgreementsSanofiDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_24e2a97e-b29c-4ab2-a985-afdf1376941a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_UpfrontPayments_b5af3398-8dc0-4ed1-9ce6-454922b6f004" xlink:href="dnli-20210331.xsd#dnli_UpfrontPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_24e2a97e-b29c-4ab2-a985-afdf1376941a" xlink:to="loc_dnli_UpfrontPayments_b5af3398-8dc0-4ed1-9ce6-454922b6f004" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_AggregateClinicalRegulatoryAndSalesMilestonePayment_bdf5450d-f37d-4834-800d-0134eae3c7cb" xlink:href="dnli-20210331.xsd#dnli_AggregateClinicalRegulatoryAndSalesMilestonePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_24e2a97e-b29c-4ab2-a985-afdf1376941a" xlink:to="loc_dnli_AggregateClinicalRegulatoryAndSalesMilestonePayment_bdf5450d-f37d-4834-800d-0134eae3c7cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_ClinicalMilestonePayment_e9a1bdf7-5a93-4ba2-bce9-7bdde9b13a44" xlink:href="dnli-20210331.xsd#dnli_ClinicalMilestonePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_24e2a97e-b29c-4ab2-a985-afdf1376941a" xlink:to="loc_dnli_ClinicalMilestonePayment_e9a1bdf7-5a93-4ba2-bce9-7bdde9b13a44" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_RegulatoryMilestonePayment_4e406ee4-f13e-4bb0-8511-c7f4492b775f" xlink:href="dnli-20210331.xsd#dnli_RegulatoryMilestonePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_24e2a97e-b29c-4ab2-a985-afdf1376941a" xlink:to="loc_dnli_RegulatoryMilestonePayment_4e406ee4-f13e-4bb0-8511-c7f4492b775f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_NumberOfIndications_3e4d9b2e-e403-4695-a1e3-ca7d228ed2b5" xlink:href="dnli-20210331.xsd#dnli_NumberOfIndications"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_24e2a97e-b29c-4ab2-a985-afdf1376941a" xlink:to="loc_dnli_NumberOfIndications_3e4d9b2e-e403-4695-a1e3-ca7d228ed2b5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_CommercialMilestonePayments_aec46339-8572-4c00-bb8a-66952c607764" xlink:href="dnli-20210331.xsd#dnli_CommercialMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_24e2a97e-b29c-4ab2-a985-afdf1376941a" xlink:to="loc_dnli_CommercialMilestonePayments_aec46339-8572-4c00-bb8a-66952c607764" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_CollaborativeAgreementFundedPercentage_633e9992-a8d9-4279-a760-d2dd99206dcd" xlink:href="dnli-20210331.xsd#dnli_CollaborativeAgreementFundedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_24e2a97e-b29c-4ab2-a985-afdf1376941a" xlink:to="loc_dnli_CollaborativeAgreementFundedPercentage_633e9992-a8d9-4279-a760-d2dd99206dcd" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_CollaborationAgreementTransactionPriceIncrease_859a0a1c-0a88-4c7c-be03-98769def2339" xlink:href="dnli-20210331.xsd#dnli_CollaborationAgreementTransactionPriceIncrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_24e2a97e-b29c-4ab2-a985-afdf1376941a" xlink:to="loc_dnli_CollaborationAgreementTransactionPriceIncrease_859a0a1c-0a88-4c7c-be03-98769def2339" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNet_d9e31921-e9d8-4493-9344-101d554d103d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_24e2a97e-b29c-4ab2-a985-afdf1376941a" xlink:to="loc_us-gaap_AccountsReceivableNet_d9e31921-e9d8-4493-9344-101d554d103d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_936437ac-73dd-4595-b323-28a25eac5f2f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_24e2a97e-b29c-4ab2-a985-afdf1376941a" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_936437ac-73dd-4595-b323-28a25eac5f2f" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5df6515a-7f85-41c8-84e0-106555776c5a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_24e2a97e-b29c-4ab2-a985-afdf1376941a" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5df6515a-7f85-41c8-84e0-106555776c5a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_dc184731-471a-4764-a607-2d728b810725" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5df6515a-7f85-41c8-84e0-106555776c5a" xlink:to="loc_srt_CounterpartyNameAxis_dc184731-471a-4764-a607-2d728b810725" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_dc184731-471a-4764-a607-2d728b810725_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_dc184731-471a-4764-a607-2d728b810725" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_dc184731-471a-4764-a607-2d728b810725_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6a77c624-a0a4-4329-8ca3-e39ba51cc278" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_dc184731-471a-4764-a607-2d728b810725" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6a77c624-a0a4-4329-8ca3-e39ba51cc278" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_SanofiMember_da6b49a9-7a1b-44a3-9c6d-1a6ab04a7fc2" xlink:href="dnli-20210331.xsd#dnli_SanofiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6a77c624-a0a4-4329-8ca3-e39ba51cc278" xlink:to="loc_dnli_SanofiMember_da6b49a9-7a1b-44a3-9c6d-1a6ab04a7fc2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_71bdf881-5655-4071-90ed-a8c87dd68182" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5df6515a-7f85-41c8-84e0-106555776c5a" xlink:to="loc_dei_LegalEntityAxis_71bdf881-5655-4071-90ed-a8c87dd68182" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_71bdf881-5655-4071-90ed-a8c87dd68182_default" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_71bdf881-5655-4071-90ed-a8c87dd68182" xlink:to="loc_dei_EntityDomain_71bdf881-5655-4071-90ed-a8c87dd68182_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_49f5398f-ed8c-4445-aa89-9ffb4192f3f9" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_71bdf881-5655-4071-90ed-a8c87dd68182" xlink:to="loc_dei_EntityDomain_49f5398f-ed8c-4445-aa89-9ffb4192f3f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_SanofiMember_8e2f62eb-f250-4ab8-b35d-5d861a88e7b4" xlink:href="dnli-20210331.xsd#dnli_SanofiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_49f5398f-ed8c-4445-aa89-9ffb4192f3f9" xlink:to="loc_dnli_SanofiMember_8e2f62eb-f250-4ab8-b35d-5d861a88e7b4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_8aa87840-2211-405e-8eaa-6fc67d431fd2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5df6515a-7f85-41c8-84e0-106555776c5a" xlink:to="loc_us-gaap_TypeOfArrangementAxis_8aa87840-2211-405e-8eaa-6fc67d431fd2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8aa87840-2211-405e-8eaa-6fc67d431fd2_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_8aa87840-2211-405e-8eaa-6fc67d431fd2" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8aa87840-2211-405e-8eaa-6fc67d431fd2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_97b6e5a6-15c9-42d3-9fb4-633964a1f96e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_8aa87840-2211-405e-8eaa-6fc67d431fd2" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_97b6e5a6-15c9-42d3-9fb4-633964a1f96e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_1e58d245-0b84-492b-ad35-c02fc44902d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_97b6e5a6-15c9-42d3-9fb4-633964a1f96e" xlink:to="loc_us-gaap_CollaborativeArrangementMember_1e58d245-0b84-492b-ad35-c02fc44902d7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_ed35a890-1288-42b3-a12c-c4aa0e9263c0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5df6515a-7f85-41c8-84e0-106555776c5a" xlink:to="loc_srt_ProductOrServiceAxis_ed35a890-1288-42b3-a12c-c4aa0e9263c0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ed35a890-1288-42b3-a12c-c4aa0e9263c0_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_ed35a890-1288-42b3-a12c-c4aa0e9263c0" xlink:to="loc_srt_ProductsAndServicesDomain_ed35a890-1288-42b3-a12c-c4aa0e9263c0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_5f38b809-02b4-493a-b692-ffd6042f97c5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_ed35a890-1288-42b3-a12c-c4aa0e9263c0" xlink:to="loc_srt_ProductsAndServicesDomain_5f38b809-02b4-493a-b692-ffd6042f97c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_CNSProductMember_aaa7bb0b-5b3f-48e9-abec-bec157ac2168" xlink:href="dnli-20210331.xsd#dnli_CNSProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5f38b809-02b4-493a-b692-ffd6042f97c5" xlink:to="loc_dnli_CNSProductMember_aaa7bb0b-5b3f-48e9-abec-bec157ac2168" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_PeripheralProductMember_9abe512f-d6d6-4c25-85c6-bac741d01574" xlink:href="dnli-20210331.xsd#dnli_PeripheralProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5f38b809-02b4-493a-b692-ffd6042f97c5" xlink:to="loc_dnli_PeripheralProductMember_9abe512f-d6d6-4c25-85c6-bac741d01574" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_RetainedActivitiesMember_887d3383-be00-4686-9eb5-140005d3a437" xlink:href="dnli-20210331.xsd#dnli_RetainedActivitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5f38b809-02b4-493a-b692-ffd6042f97c5" xlink:to="loc_dnli_RetainedActivitiesMember_887d3383-be00-4686-9eb5-140005d3a437" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_MilestoneTriggeredMember_85c69163-b831-4e50-83a0-bf67b8832c89" xlink:href="dnli-20210331.xsd#dnli_MilestoneTriggeredMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5f38b809-02b4-493a-b692-ffd6042f97c5" xlink:to="loc_dnli_MilestoneTriggeredMember_85c69163-b831-4e50-83a0-bf67b8832c89" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_MilestoneTriggeredAndRetainedActivitiesMember_1a19f30e-8277-4525-8c62-5a3194dbbf56" xlink:href="dnli-20210331.xsd#dnli_MilestoneTriggeredAndRetainedActivitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5f38b809-02b4-493a-b692-ffd6042f97c5" xlink:to="loc_dnli_MilestoneTriggeredAndRetainedActivitiesMember_1a19f30e-8277-4525-8c62-5a3194dbbf56" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_00ba110a-61b3-4286-bba3-c9fe39496715" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5f38b809-02b4-493a-b692-ffd6042f97c5" xlink:to="loc_us-gaap_ProductMember_00ba110a-61b3-4286-bba3-c9fe39496715" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/CollaborationAgreementsSanofiPerformanceObligationDetails" xlink:type="simple" xlink:href="dnli-20210331.xsd#CollaborationAgreementsSanofiPerformanceObligationDetails"/>
  <link:definitionLink xlink:role="http://www.denalitherapeutics.com/role/CollaborationAgreementsSanofiPerformanceObligationDetails" xlink:type="extended" id="i7836bd9db1b447839b49ac0608cfa5cc_CollaborationAgreementsSanofiPerformanceObligationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_4583598b-2a12-4aab-a31d-697d21d29396" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_40a2fba5-7b4d-4965-875a-7a78db4f6589" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_4583598b-2a12-4aab-a31d-697d21d29396" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_40a2fba5-7b4d-4965-875a-7a78db4f6589" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_bce9ba03-692b-485a-b90b-31c5f97346dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_4583598b-2a12-4aab-a31d-697d21d29396" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_bce9ba03-692b-485a-b90b-31c5f97346dd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_9dac8314-458a-4623-98c0-eaad8106d236" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_bce9ba03-692b-485a-b90b-31c5f97346dd" xlink:to="loc_srt_ProductOrServiceAxis_9dac8314-458a-4623-98c0-eaad8106d236" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_9dac8314-458a-4623-98c0-eaad8106d236_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_9dac8314-458a-4623-98c0-eaad8106d236" xlink:to="loc_srt_ProductsAndServicesDomain_9dac8314-458a-4623-98c0-eaad8106d236_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ea1722ff-2a24-409f-982c-cb847f7230b3" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_9dac8314-458a-4623-98c0-eaad8106d236" xlink:to="loc_srt_ProductsAndServicesDomain_ea1722ff-2a24-409f-982c-cb847f7230b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_AlzheimersDiseaseServicesMember_12860c82-7ae7-46a8-ae29-5e20e1289c99" xlink:href="dnli-20210331.xsd#dnli_AlzheimersDiseaseServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ea1722ff-2a24-409f-982c-cb847f7230b3" xlink:to="loc_dnli_AlzheimersDiseaseServicesMember_12860c82-7ae7-46a8-ae29-5e20e1289c99" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/CollaborationAgreementsTakedaDetails" xlink:type="simple" xlink:href="dnli-20210331.xsd#CollaborationAgreementsTakedaDetails"/>
  <link:definitionLink xlink:role="http://www.denalitherapeutics.com/role/CollaborationAgreementsTakedaDetails" xlink:type="extended" id="iea2844d0865f463f9ff19a1c9b8f8fd9_CollaborationAgreementsTakedaDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5fc3dbe2-7df3-4bf0-84d2-2be9b8e156f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_UpfrontPayments_10d0ce90-a719-47ac-99b0-9db492941c15" xlink:href="dnli-20210331.xsd#dnli_UpfrontPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5fc3dbe2-7df3-4bf0-84d2-2be9b8e156f3" xlink:to="loc_dnli_UpfrontPayments_10d0ce90-a719-47ac-99b0-9db492941c15" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_PreclinicalMilestonePaymentPerProgram_a7dc04e5-ecf3-4523-853d-843be52d537b" xlink:href="dnli-20210331.xsd#dnli_PreclinicalMilestonePaymentPerProgram"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5fc3dbe2-7df3-4bf0-84d2-2be9b8e156f3" xlink:to="loc_dnli_PreclinicalMilestonePaymentPerProgram_a7dc04e5-ecf3-4523-853d-843be52d537b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_NumberOfPrograms_48285ff9-e1ce-46bc-8365-6c4174ba2533" xlink:href="dnli-20210331.xsd#dnli_NumberOfPrograms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5fc3dbe2-7df3-4bf0-84d2-2be9b8e156f3" xlink:to="loc_dnli_NumberOfPrograms_48285ff9-e1ce-46bc-8365-6c4174ba2533" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_AggregatePreclinicalMilestonePayment_4ab151b0-4ee1-461e-83c6-a12d2bf005ef" xlink:href="dnli-20210331.xsd#dnli_AggregatePreclinicalMilestonePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5fc3dbe2-7df3-4bf0-84d2-2be9b8e156f3" xlink:to="loc_dnli_AggregatePreclinicalMilestonePayment_4ab151b0-4ee1-461e-83c6-a12d2bf005ef" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_PreclinicalMilestonePaymentReceived_2926171d-4330-4951-b629-23b3811afe8c" xlink:href="dnli-20210331.xsd#dnli_PreclinicalMilestonePaymentReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5fc3dbe2-7df3-4bf0-84d2-2be9b8e156f3" xlink:to="loc_dnli_PreclinicalMilestonePaymentReceived_2926171d-4330-4951-b629-23b3811afe8c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_NumberOfTargets_6e511b5a-ce72-48f1-8631-90f6b63b0448" xlink:href="dnli-20210331.xsd#dnli_NumberOfTargets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5fc3dbe2-7df3-4bf0-84d2-2be9b8e156f3" xlink:to="loc_dnli_NumberOfTargets_6e511b5a-ce72-48f1-8631-90f6b63b0448" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_TargetOptionPeriod_314159f0-1aaf-4df1-bc50-d4986d870084" xlink:href="dnli-20210331.xsd#dnli_TargetOptionPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5fc3dbe2-7df3-4bf0-84d2-2be9b8e156f3" xlink:to="loc_dnli_TargetOptionPeriod_314159f0-1aaf-4df1-bc50-d4986d870084" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_OptionFeesPerProgram_4c01997e-641b-4b85-a727-5961215b3c6b" xlink:href="dnli-20210331.xsd#dnli_OptionFeesPerProgram"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5fc3dbe2-7df3-4bf0-84d2-2be9b8e156f3" xlink:to="loc_dnli_OptionFeesPerProgram_4c01997e-641b-4b85-a727-5961215b3c6b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_AggregateOptionExerciseFee_1e0aa7e7-0177-4226-8414-c3cdae3657aa" xlink:href="dnli-20210331.xsd#dnli_AggregateOptionExerciseFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5fc3dbe2-7df3-4bf0-84d2-2be9b8e156f3" xlink:to="loc_dnli_AggregateOptionExerciseFee_1e0aa7e7-0177-4226-8414-c3cdae3657aa" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_AggregateDevelopmentMilestonePayment_d621f8b1-4696-47de-8f26-50ac90007547" xlink:href="dnli-20210331.xsd#dnli_AggregateDevelopmentMilestonePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5fc3dbe2-7df3-4bf0-84d2-2be9b8e156f3" xlink:to="loc_dnli_AggregateDevelopmentMilestonePayment_d621f8b1-4696-47de-8f26-50ac90007547" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_RegulatoryMilestonePayment_9b837c74-e7e2-48d6-ad67-048b31d35da9" xlink:href="dnli-20210331.xsd#dnli_RegulatoryMilestonePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5fc3dbe2-7df3-4bf0-84d2-2be9b8e156f3" xlink:to="loc_dnli_RegulatoryMilestonePayment_9b837c74-e7e2-48d6-ad67-048b31d35da9" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_CommercialMilestonesPerProgram_785fa309-1d51-4fa1-840b-885239d96396" xlink:href="dnli-20210331.xsd#dnli_CommercialMilestonesPerProgram"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5fc3dbe2-7df3-4bf0-84d2-2be9b8e156f3" xlink:to="loc_dnli_CommercialMilestonesPerProgram_785fa309-1d51-4fa1-840b-885239d96396" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_AggregateCommercialMilestones_3bfbe470-9ff6-4599-9d3d-cbef729e8a84" xlink:href="dnli-20210331.xsd#dnli_AggregateCommercialMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5fc3dbe2-7df3-4bf0-84d2-2be9b8e156f3" xlink:to="loc_dnli_AggregateCommercialMilestones_3bfbe470-9ff6-4599-9d3d-cbef729e8a84" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_d91deb75-671c-4395-8835-e07f21fa06c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5fc3dbe2-7df3-4bf0-84d2-2be9b8e156f3" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_d91deb75-671c-4395-8835-e07f21fa06c1" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_8969b4bd-6199-4221-97ae-7a2b8b0231ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5fc3dbe2-7df3-4bf0-84d2-2be9b8e156f3" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_8969b4bd-6199-4221-97ae-7a2b8b0231ce" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStocksIncludingAdditionalPaidInCapital_192ccb67-e131-4b1b-9c04-7b37d1b07d0a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStocksIncludingAdditionalPaidInCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5fc3dbe2-7df3-4bf0-84d2-2be9b8e156f3" xlink:to="loc_us-gaap_CommonStocksIncludingAdditionalPaidInCapital_192ccb67-e131-4b1b-9c04-7b37d1b07d0a" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_cf57ef6a-e308-4a8d-a891-d7158a98cc09" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5fc3dbe2-7df3-4bf0-84d2-2be9b8e156f3" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_cf57ef6a-e308-4a8d-a891-d7158a98cc09" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_SaleOfStockConsiderationPremiumReceivedOnTransaction_77bc03e1-ee8a-4aa3-aa7f-657877d910a6" xlink:href="dnli-20210331.xsd#dnli_SaleOfStockConsiderationPremiumReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5fc3dbe2-7df3-4bf0-84d2-2be9b8e156f3" xlink:to="loc_dnli_SaleOfStockConsiderationPremiumReceivedOnTransaction_77bc03e1-ee8a-4aa3-aa7f-657877d910a6" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_VariableConsiderationFutureConsideration_3f951bcb-69c9-4a85-b27e-607755de64aa" xlink:href="dnli-20210331.xsd#dnli_VariableConsiderationFutureConsideration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5fc3dbe2-7df3-4bf0-84d2-2be9b8e156f3" xlink:to="loc_dnli_VariableConsiderationFutureConsideration_3f951bcb-69c9-4a85-b27e-607755de64aa" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_ConstrainedVariableConsideration_6c62a5bd-5817-4ae8-8d3e-2764b3beb16a" xlink:href="dnli-20210331.xsd#dnli_ConstrainedVariableConsideration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5fc3dbe2-7df3-4bf0-84d2-2be9b8e156f3" xlink:to="loc_dnli_ConstrainedVariableConsideration_6c62a5bd-5817-4ae8-8d3e-2764b3beb16a" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_CollaborationAgreementTransactionPriceIncreaseDecrease_ba45debc-0873-4539-8950-8e5f106bd357" xlink:href="dnli-20210331.xsd#dnli_CollaborationAgreementTransactionPriceIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5fc3dbe2-7df3-4bf0-84d2-2be9b8e156f3" xlink:to="loc_dnli_CollaborationAgreementTransactionPriceIncreaseDecrease_ba45debc-0873-4539-8950-8e5f106bd357" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_RevenueNumberOfPerformanceObligations_3c761dc1-6d6d-4d83-b615-a9f03594fa0b" xlink:href="dnli-20210331.xsd#dnli_RevenueNumberOfPerformanceObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5fc3dbe2-7df3-4bf0-84d2-2be9b8e156f3" xlink:to="loc_dnli_RevenueNumberOfPerformanceObligations_3c761dc1-6d6d-4d83-b615-a9f03594fa0b" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_4bf7624f-eb38-48c1-83c9-2fab344736df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5fc3dbe2-7df3-4bf0-84d2-2be9b8e156f3" xlink:to="loc_us-gaap_ContractWithCustomerLiability_4bf7624f-eb38-48c1-83c9-2fab344736df" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_PreclinicalMilestonePaymentEarnedNotYetReceived_fa017fd0-9010-46c8-8145-8bfd7a0cb203" xlink:href="dnli-20210331.xsd#dnli_PreclinicalMilestonePaymentEarnedNotYetReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5fc3dbe2-7df3-4bf0-84d2-2be9b8e156f3" xlink:to="loc_dnli_PreclinicalMilestonePaymentEarnedNotYetReceived_fa017fd0-9010-46c8-8145-8bfd7a0cb203" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d89285a4-8df0-4f60-b648-33025c4d8d16" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5fc3dbe2-7df3-4bf0-84d2-2be9b8e156f3" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d89285a4-8df0-4f60-b648-33025c4d8d16" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e490c3e3-ed0f-46a9-86d7-ab4f04c98ae6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5fc3dbe2-7df3-4bf0-84d2-2be9b8e156f3" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e490c3e3-ed0f-46a9-86d7-ab4f04c98ae6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_31090bce-f8dd-470c-903b-9f91ca54bf1f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e490c3e3-ed0f-46a9-86d7-ab4f04c98ae6" xlink:to="loc_us-gaap_TypeOfArrangementAxis_31090bce-f8dd-470c-903b-9f91ca54bf1f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_31090bce-f8dd-470c-903b-9f91ca54bf1f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_31090bce-f8dd-470c-903b-9f91ca54bf1f" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_31090bce-f8dd-470c-903b-9f91ca54bf1f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d39ade25-14cc-4144-af91-cd16cbb9ad03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_31090bce-f8dd-470c-903b-9f91ca54bf1f" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d39ade25-14cc-4144-af91-cd16cbb9ad03" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_f9d9cc3a-0c25-404c-b3b0-6ae1cba1ab90" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d39ade25-14cc-4144-af91-cd16cbb9ad03" xlink:to="loc_us-gaap_CollaborativeArrangementMember_f9d9cc3a-0c25-404c-b3b0-6ae1cba1ab90" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_CollaborativeArrangementPTVPGRNMember_60111018-4a53-4a31-b514-469832b909ce" xlink:href="dnli-20210331.xsd#dnli_CollaborativeArrangementPTVPGRNMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d39ade25-14cc-4144-af91-cd16cbb9ad03" xlink:to="loc_dnli_CollaborativeArrangementPTVPGRNMember_60111018-4a53-4a31-b514-469832b909ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_CollaborativeArrangementATVTREM2Member_b8179270-599f-4bf5-b073-e10a1b31327f" xlink:href="dnli-20210331.xsd#dnli_CollaborativeArrangementATVTREM2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d39ade25-14cc-4144-af91-cd16cbb9ad03" xlink:to="loc_dnli_CollaborativeArrangementATVTREM2Member_b8179270-599f-4bf5-b073-e10a1b31327f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_c68ffa5e-ad2a-493a-bbca-a72a4e48b622" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e490c3e3-ed0f-46a9-86d7-ab4f04c98ae6" xlink:to="loc_srt_RangeAxis_c68ffa5e-ad2a-493a-bbca-a72a4e48b622" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c68ffa5e-ad2a-493a-bbca-a72a4e48b622_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_c68ffa5e-ad2a-493a-bbca-a72a4e48b622" xlink:to="loc_srt_RangeMember_c68ffa5e-ad2a-493a-bbca-a72a4e48b622_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_be886749-013a-477d-ba5a-35847d43818f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_c68ffa5e-ad2a-493a-bbca-a72a4e48b622" xlink:to="loc_srt_RangeMember_be886749-013a-477d-ba5a-35847d43818f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_a9853d49-9b2b-48fe-90f4-e9874decf1e2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_be886749-013a-477d-ba5a-35847d43818f" xlink:to="loc_srt_MaximumMember_a9853d49-9b2b-48fe-90f4-e9874decf1e2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_cb828194-177b-4162-a253-16029d3f173b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e490c3e3-ed0f-46a9-86d7-ab4f04c98ae6" xlink:to="loc_srt_CounterpartyNameAxis_cb828194-177b-4162-a253-16029d3f173b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cb828194-177b-4162-a253-16029d3f173b_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_cb828194-177b-4162-a253-16029d3f173b" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cb828194-177b-4162-a253-16029d3f173b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6e16f168-f293-4169-a26a-ad0ae9882241" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_cb828194-177b-4162-a253-16029d3f173b" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6e16f168-f293-4169-a26a-ad0ae9882241" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_TakedaPharmaceuticalCompanyLimitedMember_3d0745c5-83eb-44c9-a201-49f42333a716" xlink:href="dnli-20210331.xsd#dnli_TakedaPharmaceuticalCompanyLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6e16f168-f293-4169-a26a-ad0ae9882241" xlink:to="loc_dnli_TakedaPharmaceuticalCompanyLimitedMember_3d0745c5-83eb-44c9-a201-49f42333a716" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_a3ea2a4f-62b4-43ec-8116-f70057241313" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e490c3e3-ed0f-46a9-86d7-ab4f04c98ae6" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_a3ea2a4f-62b4-43ec-8116-f70057241313" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_a3ea2a4f-62b4-43ec-8116-f70057241313_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_a3ea2a4f-62b4-43ec-8116-f70057241313" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_a3ea2a4f-62b4-43ec-8116-f70057241313_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_8bad6753-5059-41b9-ada7-d02f79d42ad8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_a3ea2a4f-62b4-43ec-8116-f70057241313" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_8bad6753-5059-41b9-ada7-d02f79d42ad8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_SharePurchaseAgreementMember_fb049074-a878-42ab-af54-a7852bea285c" xlink:href="dnli-20210331.xsd#dnli_SharePurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_8bad6753-5059-41b9-ada7-d02f79d42ad8" xlink:to="loc_dnli_SharePurchaseAgreementMember_fb049074-a878-42ab-af54-a7852bea285c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_e0617753-2972-4f0c-94cc-f58b277f2129" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e490c3e3-ed0f-46a9-86d7-ab4f04c98ae6" xlink:to="loc_srt_ProductOrServiceAxis_e0617753-2972-4f0c-94cc-f58b277f2129" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e0617753-2972-4f0c-94cc-f58b277f2129_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_e0617753-2972-4f0c-94cc-f58b277f2129" xlink:to="loc_srt_ProductsAndServicesDomain_e0617753-2972-4f0c-94cc-f58b277f2129_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_9ff5beed-ac0d-41ea-9c37-4d54f8231930" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_e0617753-2972-4f0c-94cc-f58b277f2129" xlink:to="loc_srt_ProductsAndServicesDomain_9ff5beed-ac0d-41ea-9c37-4d54f8231930" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_5a686c33-4469-42c9-becb-2e220c2bfd8c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_9ff5beed-ac0d-41ea-9c37-4d54f8231930" xlink:to="loc_us-gaap_ProductMember_5a686c33-4469-42c9-becb-2e220c2bfd8c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_MilestoneTriggeredMember_03b51fb3-7a69-43ad-914c-f417c26aaa50" xlink:href="dnli-20210331.xsd#dnli_MilestoneTriggeredMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_9ff5beed-ac0d-41ea-9c37-4d54f8231930" xlink:to="loc_dnli_MilestoneTriggeredMember_03b51fb3-7a69-43ad-914c-f417c26aaa50" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/CollaborationAgreementsSummaryofCollaborationRevenueDetails" xlink:type="simple" xlink:href="dnli-20210331.xsd#CollaborationAgreementsSummaryofCollaborationRevenueDetails"/>
  <link:definitionLink xlink:role="http://www.denalitherapeutics.com/role/CollaborationAgreementsSummaryofCollaborationRevenueDetails" xlink:type="extended" id="ia4292cb8357149b1a769cb130cebfce4_CollaborationAgreementsSummaryofCollaborationRevenueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_94d6847e-d7de-4f88-8a5b-30b1339d0964" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5f928103-7b12-4ac2-894f-50c938d7a5dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_94d6847e-d7de-4f88-8a5b-30b1339d0964" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5f928103-7b12-4ac2-894f-50c938d7a5dc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_6d86ce17-36be-4227-b66c-449bdb0caa03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_94d6847e-d7de-4f88-8a5b-30b1339d0964" xlink:to="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_6d86ce17-36be-4227-b66c-449bdb0caa03" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_5404d939-1639-428c-b2f8-59ffd4dfc30a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_94d6847e-d7de-4f88-8a5b-30b1339d0964" xlink:to="loc_us-gaap_Revenues_5404d939-1639-428c-b2f8-59ffd4dfc30a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_76a4dc90-157c-4079-94ab-a3c1ff3f4e8d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_94d6847e-d7de-4f88-8a5b-30b1339d0964" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_76a4dc90-157c-4079-94ab-a3c1ff3f4e8d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_171f787f-1d85-4435-94a0-6bfceba154d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_94d6847e-d7de-4f88-8a5b-30b1339d0964" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_171f787f-1d85-4435-94a0-6bfceba154d0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_d7a0ce31-2566-4034-88a5-de9cfb8f4b17" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_171f787f-1d85-4435-94a0-6bfceba154d0" xlink:to="loc_us-gaap_TypeOfArrangementAxis_d7a0ce31-2566-4034-88a5-de9cfb8f4b17" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d7a0ce31-2566-4034-88a5-de9cfb8f4b17_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_d7a0ce31-2566-4034-88a5-de9cfb8f4b17" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d7a0ce31-2566-4034-88a5-de9cfb8f4b17_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_59f84070-e9ec-4259-9fdf-5108f5364e56" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_d7a0ce31-2566-4034-88a5-de9cfb8f4b17" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_59f84070-e9ec-4259-9fdf-5108f5364e56" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_TakedaCollaborationAgreementMember_c634d28f-8b15-4e35-880a-64bac7d03096" xlink:href="dnli-20210331.xsd#dnli_TakedaCollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_59f84070-e9ec-4259-9fdf-5108f5364e56" xlink:to="loc_dnli_TakedaCollaborationAgreementMember_c634d28f-8b15-4e35-880a-64bac7d03096" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_SanofiCollaborationAgreementMember_a2f5ed8c-b363-472f-9ab5-d97bf2f7c57f" xlink:href="dnli-20210331.xsd#dnli_SanofiCollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_59f84070-e9ec-4259-9fdf-5108f5364e56" xlink:to="loc_dnli_SanofiCollaborationAgreementMember_a2f5ed8c-b363-472f-9ab5-d97bf2f7c57f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_BiogenMember_cf24dba4-c3de-4e20-bef9-e7b7b532c2e4" xlink:href="dnli-20210331.xsd#dnli_BiogenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_59f84070-e9ec-4259-9fdf-5108f5364e56" xlink:to="loc_dnli_BiogenMember_cf24dba4-c3de-4e20-bef9-e7b7b532c2e4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_02256e0d-6d1c-4dff-bc6b-9b0ca1ea2d76" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_171f787f-1d85-4435-94a0-6bfceba154d0" xlink:to="loc_srt_ProductOrServiceAxis_02256e0d-6d1c-4dff-bc6b-9b0ca1ea2d76" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_02256e0d-6d1c-4dff-bc6b-9b0ca1ea2d76_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_02256e0d-6d1c-4dff-bc6b-9b0ca1ea2d76" xlink:to="loc_srt_ProductsAndServicesDomain_02256e0d-6d1c-4dff-bc6b-9b0ca1ea2d76_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_013cbb65-0fa4-443d-af03-704c71685307" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_02256e0d-6d1c-4dff-bc6b-9b0ca1ea2d76" xlink:to="loc_srt_ProductsAndServicesDomain_013cbb65-0fa4-443d-af03-704c71685307" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_RetainedActivitiesMember_dd954f46-ab59-4c6d-8c1a-5c9d71ac3077" xlink:href="dnli-20210331.xsd#dnli_RetainedActivitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_013cbb65-0fa4-443d-af03-704c71685307" xlink:to="loc_dnli_RetainedActivitiesMember_dd954f46-ab59-4c6d-8c1a-5c9d71ac3077" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_AlzheimersDiseaseServicesMember_b1441496-b406-4e06-adc8-ce5f578c6d45" xlink:href="dnli-20210331.xsd#dnli_AlzheimersDiseaseServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_013cbb65-0fa4-443d-af03-704c71685307" xlink:to="loc_dnli_AlzheimersDiseaseServicesMember_b1441496-b406-4e06-adc8-ce5f578c6d45" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_OptionServicesMember_a0f82e51-c2c8-4b43-83c4-102adbf48c38" xlink:href="dnli-20210331.xsd#dnli_OptionServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_013cbb65-0fa4-443d-af03-704c71685307" xlink:to="loc_dnli_OptionServicesMember_a0f82e51-c2c8-4b43-83c4-102adbf48c38" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/LicenseAgreements" xlink:type="simple" xlink:href="dnli-20210331.xsd#LicenseAgreements"/>
  <link:definitionLink xlink:role="http://www.denalitherapeutics.com/role/LicenseAgreements" xlink:type="extended" id="if2018064afa94cfaa41501d16ffad3b3_LicenseAgreements"/>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/LicenseAgreementsNarrativeDetails" xlink:type="simple" xlink:href="dnli-20210331.xsd#LicenseAgreementsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.denalitherapeutics.com/role/LicenseAgreementsNarrativeDetails" xlink:type="extended" id="i2e4c345051804a99ab34ec4f6e9b4c17_LicenseAgreementsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c5f8ff2a-ab30-43dc-b5fb-dc813a03b1f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_LicenseAgreementMilestonePaymentUponAchievementOfClinicalAndRegulatoryMilestones_b40a70af-f284-4d19-8b29-9d110677a53c" xlink:href="dnli-20210331.xsd#dnli_LicenseAgreementMilestonePaymentUponAchievementOfClinicalAndRegulatoryMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c5f8ff2a-ab30-43dc-b5fb-dc813a03b1f2" xlink:to="loc_dnli_LicenseAgreementMilestonePaymentUponAchievementOfClinicalAndRegulatoryMilestones_b40a70af-f284-4d19-8b29-9d110677a53c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_LicenseAgreementMilestonePaymentObligationResponsibilityPercentage_f35bf991-075b-4ec3-8a39-a15f62c9fa06" xlink:href="dnli-20210331.xsd#dnli_LicenseAgreementMilestonePaymentObligationResponsibilityPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c5f8ff2a-ab30-43dc-b5fb-dc813a03b1f2" xlink:to="loc_dnli_LicenseAgreementMilestonePaymentObligationResponsibilityPercentage_f35bf991-075b-4ec3-8a39-a15f62c9fa06" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_UpfrontFeesPaid_9c682408-3a3f-4933-a561-5c69db9b35b9" xlink:href="dnli-20210331.xsd#dnli_UpfrontFeesPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c5f8ff2a-ab30-43dc-b5fb-dc813a03b1f2" xlink:to="loc_dnli_UpfrontFeesPaid_9c682408-3a3f-4933-a561-5c69db9b35b9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_14fa6293-4588-40a0-8f1a-201d66a8e1c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c5f8ff2a-ab30-43dc-b5fb-dc813a03b1f2" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_14fa6293-4588-40a0-8f1a-201d66a8e1c3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_050d053b-1db2-486c-8446-d0d06f126538" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_14fa6293-4588-40a0-8f1a-201d66a8e1c3" xlink:to="loc_srt_CounterpartyNameAxis_050d053b-1db2-486c-8446-d0d06f126538" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_050d053b-1db2-486c-8446-d0d06f126538_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_050d053b-1db2-486c-8446-d0d06f126538" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_050d053b-1db2-486c-8446-d0d06f126538_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a5117ad7-b4f7-4492-b3fe-745cf512379a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_050d053b-1db2-486c-8446-d0d06f126538" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a5117ad7-b4f7-4492-b3fe-745cf512379a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_GenentechIncMember_ea7e8a8c-bed4-4adb-b21a-a5c98ab91b85" xlink:href="dnli-20210331.xsd#dnli_GenentechIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a5117ad7-b4f7-4492-b3fe-745cf512379a" xlink:to="loc_dnli_GenentechIncMember_ea7e8a8c-bed4-4adb-b21a-a5c98ab91b85" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_aa498011-f876-49ef-8433-8b20b6a26899" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_14fa6293-4588-40a0-8f1a-201d66a8e1c3" xlink:to="loc_srt_RangeAxis_aa498011-f876-49ef-8433-8b20b6a26899" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_aa498011-f876-49ef-8433-8b20b6a26899_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_aa498011-f876-49ef-8433-8b20b6a26899" xlink:to="loc_srt_RangeMember_aa498011-f876-49ef-8433-8b20b6a26899_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e1659ba9-775e-4ec8-905c-38a9e4fa1043" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_aa498011-f876-49ef-8433-8b20b6a26899" xlink:to="loc_srt_RangeMember_e1659ba9-775e-4ec8-905c-38a9e4fa1043" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_299da197-183c-40b8-aeb6-f0b777016b4a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_e1659ba9-775e-4ec8-905c-38a9e4fa1043" xlink:to="loc_srt_MaximumMember_299da197-183c-40b8-aeb6-f0b777016b4a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_10ee89e7-93db-4dcf-ba0b-d9de3e755e72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_14fa6293-4588-40a0-8f1a-201d66a8e1c3" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_10ee89e7-93db-4dcf-ba0b-d9de3e755e72" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_10ee89e7-93db-4dcf-ba0b-d9de3e755e72_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_10ee89e7-93db-4dcf-ba0b-d9de3e755e72" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_10ee89e7-93db-4dcf-ba0b-d9de3e755e72_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_326bbbbe-ac47-45d5-b123-77bb75cd050e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_10ee89e7-93db-4dcf-ba0b-d9de3e755e72" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_326bbbbe-ac47-45d5-b123-77bb75cd050e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_ClinicalMember_1c1ad4d6-2593-48f0-a715-da45ae141ad3" xlink:href="dnli-20210331.xsd#dnli_ClinicalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_326bbbbe-ac47-45d5-b123-77bb75cd050e" xlink:to="loc_dnli_ClinicalMember_1c1ad4d6-2593-48f0-a715-da45ae141ad3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_RegulatoryMember_bcf1f77a-2878-496b-beb6-9fea170e651a" xlink:href="dnli-20210331.xsd#dnli_RegulatoryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_326bbbbe-ac47-45d5-b123-77bb75cd050e" xlink:to="loc_dnli_RegulatoryMember_bcf1f77a-2878-496b-beb6-9fea170e651a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_CommercialMember_e442e1f5-3780-4fb6-98c8-4f58d397e1ee" xlink:href="dnli-20210331.xsd#dnli_CommercialMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_326bbbbe-ac47-45d5-b123-77bb75cd050e" xlink:to="loc_dnli_CommercialMember_e442e1f5-3780-4fb6-98c8-4f58d397e1ee" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_26c80ac7-3f6a-4ce2-bff1-b73421f9f9e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_14fa6293-4588-40a0-8f1a-201d66a8e1c3" xlink:to="loc_us-gaap_TypeOfArrangementAxis_26c80ac7-3f6a-4ce2-bff1-b73421f9f9e8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_26c80ac7-3f6a-4ce2-bff1-b73421f9f9e8_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_26c80ac7-3f6a-4ce2-bff1-b73421f9f9e8" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_26c80ac7-3f6a-4ce2-bff1-b73421f9f9e8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3126b02a-ba3c-4f5c-ac55-3b9554e13833" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_26c80ac7-3f6a-4ce2-bff1-b73421f9f9e8" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3126b02a-ba3c-4f5c-ac55-3b9554e13833" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_LicenseAgreementMember_0d5fc568-74cc-4d88-ba7d-30078f372b53" xlink:href="dnli-20210331.xsd#dnli_LicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3126b02a-ba3c-4f5c-ac55-3b9554e13833" xlink:to="loc_dnli_LicenseAgreementMember_0d5fc568-74cc-4d88-ba7d-30078f372b53" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_5837bf79-984b-4758-8b14-fe33647fc579" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_14fa6293-4588-40a0-8f1a-201d66a8e1c3" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_5837bf79-984b-4758-8b14-fe33647fc579" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_5837bf79-984b-4758-8b14-fe33647fc579_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_5837bf79-984b-4758-8b14-fe33647fc579" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_5837bf79-984b-4758-8b14-fe33647fc579_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_7674cc62-65fd-433f-8569-4f1f822fec02" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_5837bf79-984b-4758-8b14-fe33647fc579" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_7674cc62-65fd-433f-8569-4f1f822fec02" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_b6405f4d-1988-4c16-b90b-042735cb46ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_7674cc62-65fd-433f-8569-4f1f822fec02" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_b6405f4d-1988-4c16-b90b-042735cb46ce" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_1efedf40-6d35-4629-92c0-4deb7f32e99f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_14fa6293-4588-40a0-8f1a-201d66a8e1c3" xlink:to="loc_dei_LegalEntityAxis_1efedf40-6d35-4629-92c0-4deb7f32e99f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_1efedf40-6d35-4629-92c0-4deb7f32e99f_default" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1efedf40-6d35-4629-92c0-4deb7f32e99f" xlink:to="loc_dei_EntityDomain_1efedf40-6d35-4629-92c0-4deb7f32e99f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_59e57337-7f25-4de9-89cc-359a988bf507" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1efedf40-6d35-4629-92c0-4deb7f32e99f" xlink:to="loc_dei_EntityDomain_59e57337-7f25-4de9-89cc-359a988bf507" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_BiogenMember_0b971cc6-b782-45d0-b545-4b5f00d13818" xlink:href="dnli-20210331.xsd#dnli_BiogenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_59e57337-7f25-4de9-89cc-359a988bf507" xlink:to="loc_dnli_BiogenMember_0b971cc6-b782-45d0-b545-4b5f00d13818" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="dnli-20210331.xsd#CommitmentsandContingencies"/>
  <link:definitionLink xlink:role="http://www.denalitherapeutics.com/role/CommitmentsandContingencies" xlink:type="extended" id="i3469680a0cd6483abaabe8856fe16e92_CommitmentsandContingencies"/>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/CommitmentsandContingenciesTables" xlink:type="simple" xlink:href="dnli-20210331.xsd#CommitmentsandContingenciesTables"/>
  <link:definitionLink xlink:role="http://www.denalitherapeutics.com/role/CommitmentsandContingenciesTables" xlink:type="extended" id="i83380b3fa08d4754a114ae130fb66c96_CommitmentsandContingenciesTables"/>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="simple" xlink:href="dnli-20210331.xsd#CommitmentsandContingenciesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.denalitherapeutics.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="extended" id="i4ae9b44c83594fa1b581426c17444701_CommitmentsandContingenciesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_a849c7ac-1b71-4300-a423-9d201ba4372a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_OperatingLeasesAreaUnderLease_4f6f623e-570e-4de9-b83a-16c7476ec21d" xlink:href="dnli-20210331.xsd#dnli_OperatingLeasesAreaUnderLease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_a849c7ac-1b71-4300-a423-9d201ba4372a" xlink:to="loc_dnli_OperatingLeasesAreaUnderLease_4f6f623e-570e-4de9-b83a-16c7476ec21d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_e2d38600-c1d8-4aef-8a08-b97b654d616e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_a849c7ac-1b71-4300-a423-9d201ba4372a" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_e2d38600-c1d8-4aef-8a08-b97b654d616e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_aaa8499d-1f3c-4996-bb8e-29dbe4786ead" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_a849c7ac-1b71-4300-a423-9d201ba4372a" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_aaa8499d-1f3c-4996-bb8e-29dbe4786ead" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_LesseeOperatingLeaseRenewalNoticePeriod_28c8a566-1a93-48b1-99cc-d6de189ededd" xlink:href="dnli-20210331.xsd#dnli_LesseeOperatingLeaseRenewalNoticePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_a849c7ac-1b71-4300-a423-9d201ba4372a" xlink:to="loc_dnli_LesseeOperatingLeaseRenewalNoticePeriod_28c8a566-1a93-48b1-99cc-d6de189ededd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_e07d376b-66e4-4b7b-aae2-a69adfd0484e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_a849c7ac-1b71-4300-a423-9d201ba4372a" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_e07d376b-66e4-4b7b-aae2-a69adfd0484e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsGross_ebfef3d3-4027-432f-b625-a823e1991a34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_a849c7ac-1b71-4300-a423-9d201ba4372a" xlink:to="loc_us-gaap_LeaseholdImprovementsGross_ebfef3d3-4027-432f-b625-a823e1991a34" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_TenantImprovementAllowanceRepayableAsRent_0095bbac-d446-4c75-bcac-6117c1b2ad15" xlink:href="dnli-20210331.xsd#dnli_TenantImprovementAllowanceRepayableAsRent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_a849c7ac-1b71-4300-a423-9d201ba4372a" xlink:to="loc_dnli_TenantImprovementAllowanceRepayableAsRent_0095bbac-d446-4c75-bcac-6117c1b2ad15" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseDiscountRate_727dd0ec-da72-4621-a469-61f86df4adfd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_a849c7ac-1b71-4300-a423-9d201ba4372a" xlink:to="loc_us-gaap_LesseeOperatingLeaseDiscountRate_727dd0ec-da72-4621-a469-61f86df4adfd" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_3287b2bd-e028-40cc-bff7-1e0ba0053f9f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_a849c7ac-1b71-4300-a423-9d201ba4372a" xlink:to="loc_us-gaap_LeaseCost_3287b2bd-e028-40cc-bff7-1e0ba0053f9f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_64e3e793-1b81-4d3b-8f0b-51664657dd42" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_a849c7ac-1b71-4300-a423-9d201ba4372a" xlink:to="loc_us-gaap_OperatingLeasePayments_64e3e793-1b81-4d3b-8f0b-51664657dd42" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_OperatingLeasesSubleaseNetRentableArea_954cd4f0-44fa-4e47-8d68-15fb4bacd66a" xlink:href="dnli-20210331.xsd#dnli_OperatingLeasesSubleaseNetRentableArea"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_a849c7ac-1b71-4300-a423-9d201ba4372a" xlink:to="loc_dnli_OperatingLeasesSubleaseNetRentableArea_954cd4f0-44fa-4e47-8d68-15fb4bacd66a" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeaseTermOfContract_dd60c621-efb1-499b-b16b-2786eb6cff3d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LessorOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_a849c7ac-1b71-4300-a423-9d201ba4372a" xlink:to="loc_us-gaap_LessorOperatingLeaseTermOfContract_dd60c621-efb1-499b-b16b-2786eb6cff3d" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome_107d916f-ac5c-4bb5-bda5-70e11ea9c750" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubleaseIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_a849c7ac-1b71-4300-a423-9d201ba4372a" xlink:to="loc_us-gaap_SubleaseIncome_107d916f-ac5c-4bb5-bda5-70e11ea9c750" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_PurchaseOrderExecuted_db7c01bb-a27a-4eb4-981b-c17125b0c4f3" xlink:href="dnli-20210331.xsd#dnli_PurchaseOrderExecuted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_a849c7ac-1b71-4300-a423-9d201ba4372a" xlink:to="loc_dnli_PurchaseOrderExecuted_db7c01bb-a27a-4eb4-981b-c17125b0c4f3" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligation_7df980af-1605-4dc2-9f21-eabe400e4e11" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PurchaseObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_a849c7ac-1b71-4300-a423-9d201ba4372a" xlink:to="loc_us-gaap_PurchaseObligation_7df980af-1605-4dc2-9f21-eabe400e4e11" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsIncurredDevelopmentCosts_2e604e80-ec1a-44fb-bd9e-baac0f8ccadb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsIncurredDevelopmentCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_a849c7ac-1b71-4300-a423-9d201ba4372a" xlink:to="loc_us-gaap_CostsIncurredDevelopmentCosts_2e604e80-ec1a-44fb-bd9e-baac0f8ccadb" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_PaymentsForManufacturingCost_be6fc048-907b-486d-964f-c81516e19170" xlink:href="dnli-20210331.xsd#dnli_PaymentsForManufacturingCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_a849c7ac-1b71-4300-a423-9d201ba4372a" xlink:to="loc_dnli_PaymentsForManufacturingCost_be6fc048-907b-486d-964f-c81516e19170" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_12f2ab78-3a75-4511-a6ff-6e6009617e0c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_a849c7ac-1b71-4300-a423-9d201ba4372a" xlink:to="loc_us-gaap_LossContingenciesTable_12f2ab78-3a75-4511-a6ff-6e6009617e0c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermAxis_a9799a55-8660-4cba-9e73-db45c888cde7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseContractualTermAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_12f2ab78-3a75-4511-a6ff-6e6009617e0c" xlink:to="loc_us-gaap_LeaseContractualTermAxis_a9799a55-8660-4cba-9e73-db45c888cde7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain_a9799a55-8660-4cba-9e73-db45c888cde7_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LeaseContractualTermAxis_a9799a55-8660-4cba-9e73-db45c888cde7" xlink:to="loc_us-gaap_LeaseContractualTermDomain_a9799a55-8660-4cba-9e73-db45c888cde7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain_ad68f132-8208-4fac-917c-8c85476a3ac0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LeaseContractualTermAxis_a9799a55-8660-4cba-9e73-db45c888cde7" xlink:to="loc_us-gaap_LeaseContractualTermDomain_ad68f132-8208-4fac-917c-8c85476a3ac0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_HeadquartersLeaseMember_7d71b90b-f3d2-4a8b-84eb-fa9a76fb079d" xlink:href="dnli-20210331.xsd#dnli_HeadquartersLeaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseContractualTermDomain_ad68f132-8208-4fac-917c-8c85476a3ac0" xlink:to="loc_dnli_HeadquartersLeaseMember_7d71b90b-f3d2-4a8b-84eb-fa9a76fb079d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_NewPremisesSubleaseAgreementMember_81cdab0c-cb65-4156-9a0f-24023b6ff80c" xlink:href="dnli-20210331.xsd#dnli_NewPremisesSubleaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseContractualTermDomain_ad68f132-8208-4fac-917c-8c85476a3ac0" xlink:to="loc_dnli_NewPremisesSubleaseAgreementMember_81cdab0c-cb65-4156-9a0f-24023b6ff80c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_801c08df-400b-4796-8b6f-fdc56d6bab35" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_12f2ab78-3a75-4511-a6ff-6e6009617e0c" xlink:to="loc_srt_RangeAxis_801c08df-400b-4796-8b6f-fdc56d6bab35" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_801c08df-400b-4796-8b6f-fdc56d6bab35_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_801c08df-400b-4796-8b6f-fdc56d6bab35" xlink:to="loc_srt_RangeMember_801c08df-400b-4796-8b6f-fdc56d6bab35_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_11f0828e-6a15-4f22-bf64-ae59fee5f17a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_801c08df-400b-4796-8b6f-fdc56d6bab35" xlink:to="loc_srt_RangeMember_11f0828e-6a15-4f22-bf64-ae59fee5f17a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_32de7471-86da-4c41-8895-31227f595853" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_11f0828e-6a15-4f22-bf64-ae59fee5f17a" xlink:to="loc_srt_MinimumMember_32de7471-86da-4c41-8895-31227f595853" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_97dd8f36-c63e-4933-9cd9-8810ffbbeddb" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_11f0828e-6a15-4f22-bf64-ae59fee5f17a" xlink:to="loc_srt_MaximumMember_97dd8f36-c63e-4933-9cd9-8810ffbbeddb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c4c52bc7-9631-4ca6-a998-d67e3784a045" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_12f2ab78-3a75-4511-a6ff-6e6009617e0c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c4c52bc7-9631-4ca6-a998-d67e3784a045" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c4c52bc7-9631-4ca6-a998-d67e3784a045_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c4c52bc7-9631-4ca6-a998-d67e3784a045" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c4c52bc7-9631-4ca6-a998-d67e3784a045_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_66e16210-3ffb-4a7d-82c3-e0aca5e22b21" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c4c52bc7-9631-4ca6-a998-d67e3784a045" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_66e16210-3ffb-4a7d-82c3-e0aca5e22b21" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_LandlordFundedTenantImprovementsMember_0e08d0f8-b0f6-4648-b973-fca829e605b4" xlink:href="dnli-20210331.xsd#dnli_LandlordFundedTenantImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_66e16210-3ffb-4a7d-82c3-e0aca5e22b21" xlink:to="loc_dnli_LandlordFundedTenantImprovementsMember_0e08d0f8-b0f6-4648-b973-fca829e605b4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_abbafd63-c76a-4b8b-9c13-a2da42332911" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_12f2ab78-3a75-4511-a6ff-6e6009617e0c" xlink:to="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_abbafd63-c76a-4b8b-9c13-a2da42332911" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_abbafd63-c76a-4b8b-9c13-a2da42332911_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_abbafd63-c76a-4b8b-9c13-a2da42332911" xlink:to="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_abbafd63-c76a-4b8b-9c13-a2da42332911_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_f8487b66-6ce7-4c6d-a77a-dd76f907ca3c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_abbafd63-c76a-4b8b-9c13-a2da42332911" xlink:to="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_f8487b66-6ce7-4c6d-a77a-dd76f907ca3c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_DMSAMember_75c15c7e-4b5f-41db-bb56-19b3749e5067" xlink:href="dnli-20210331.xsd#dnli_DMSAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_f8487b66-6ce7-4c6d-a77a-dd76f907ca3c" xlink:to="loc_dnli_DMSAMember_75c15c7e-4b5f-41db-bb56-19b3749e5067" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/CommitmentsandContingenciesSummaryofCompanysFutureMinimumLeaseCommitmentsDetails" xlink:type="simple" xlink:href="dnli-20210331.xsd#CommitmentsandContingenciesSummaryofCompanysFutureMinimumLeaseCommitmentsDetails"/>
  <link:definitionLink xlink:role="http://www.denalitherapeutics.com/role/CommitmentsandContingenciesSummaryofCompanysFutureMinimumLeaseCommitmentsDetails" xlink:type="extended" id="i5b183a6f548e49489b32a037ede393e1_CommitmentsandContingenciesSummaryofCompanysFutureMinimumLeaseCommitmentsDetails"/>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/CommitmentsandContingenciesSummaryofCompanysFutureMinimumLeaseReceivablesDetails" xlink:type="simple" xlink:href="dnli-20210331.xsd#CommitmentsandContingenciesSummaryofCompanysFutureMinimumLeaseReceivablesDetails"/>
  <link:definitionLink xlink:role="http://www.denalitherapeutics.com/role/CommitmentsandContingenciesSummaryofCompanysFutureMinimumLeaseReceivablesDetails" xlink:type="extended" id="i76bba87a231e48a58c511ba202e50c07_CommitmentsandContingenciesSummaryofCompanysFutureMinimumLeaseReceivablesDetails"/>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/StockBasedAwards" xlink:type="simple" xlink:href="dnli-20210331.xsd#StockBasedAwards"/>
  <link:definitionLink xlink:role="http://www.denalitherapeutics.com/role/StockBasedAwards" xlink:type="extended" id="i53bd003b735d4404bba3c99187f50046_StockBasedAwards"/>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/StockBasedAwardsTables" xlink:type="simple" xlink:href="dnli-20210331.xsd#StockBasedAwardsTables"/>
  <link:definitionLink xlink:role="http://www.denalitherapeutics.com/role/StockBasedAwardsTables" xlink:type="extended" id="i53c0519207b848a78f5b5f4cda10fcc1_StockBasedAwardsTables"/>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofStockOptionActivityDetails" xlink:type="simple" xlink:href="dnli-20210331.xsd#StockBasedAwardsSummaryofStockOptionActivityDetails"/>
  <link:definitionLink xlink:role="http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofStockOptionActivityDetails" xlink:type="extended" id="i1ce5f304b2654118af6736e5c11e392f_StockBasedAwardsSummaryofStockOptionActivityDetails"/>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofAssumptionsUsedforEstimatingtheFairValueofStockOptionsGrantedDetails" xlink:type="simple" xlink:href="dnli-20210331.xsd#StockBasedAwardsSummaryofAssumptionsUsedforEstimatingtheFairValueofStockOptionsGrantedDetails"/>
  <link:definitionLink xlink:role="http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofAssumptionsUsedforEstimatingtheFairValueofStockOptionsGrantedDetails" xlink:type="extended" id="i187ae7d0e5674cf1bf829da68b8c7594_StockBasedAwardsSummaryofAssumptionsUsedforEstimatingtheFairValueofStockOptionsGrantedDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_78fc2590-14b7-441a-b446-d8101716adf4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_226229c8-71b6-408e-93e7-a67d820a226c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_78fc2590-14b7-441a-b446-d8101716adf4" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_226229c8-71b6-408e-93e7-a67d820a226c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_6b935e98-6392-47a9-b14a-b336cfec18a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_78fc2590-14b7-441a-b446-d8101716adf4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_6b935e98-6392-47a9-b14a-b336cfec18a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_873e1398-49da-49aa-983d-3e4fb5d517cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_78fc2590-14b7-441a-b446-d8101716adf4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_873e1398-49da-49aa-983d-3e4fb5d517cb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_2d265f30-5016-47a2-90b3-07a6ec26aa8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_78fc2590-14b7-441a-b446-d8101716adf4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_2d265f30-5016-47a2-90b3-07a6ec26aa8b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_8f251502-0644-42bc-8006-d5e4c62bec62" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_78fc2590-14b7-441a-b446-d8101716adf4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_8f251502-0644-42bc-8006-d5e4c62bec62" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_9b3bfae2-f220-4030-903e-a98739a6a659" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_78fc2590-14b7-441a-b446-d8101716adf4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_9b3bfae2-f220-4030-903e-a98739a6a659" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bd78090c-ffda-4ce8-a0ad-d97dca192c9f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_78fc2590-14b7-441a-b446-d8101716adf4" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bd78090c-ffda-4ce8-a0ad-d97dca192c9f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_4bc58b03-f564-43d8-b3e5-b5e18f14fa1a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bd78090c-ffda-4ce8-a0ad-d97dca192c9f" xlink:to="loc_us-gaap_AwardTypeAxis_4bc58b03-f564-43d8-b3e5-b5e18f14fa1a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4bc58b03-f564-43d8-b3e5-b5e18f14fa1a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_4bc58b03-f564-43d8-b3e5-b5e18f14fa1a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4bc58b03-f564-43d8-b3e5-b5e18f14fa1a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b10edc60-ed80-46e6-aa31-4089dcb84ab5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_4bc58b03-f564-43d8-b3e5-b5e18f14fa1a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b10edc60-ed80-46e6-aa31-4089dcb84ab5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1b71529e-fad3-4799-bf00-0f38e64f6142" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b10edc60-ed80-46e6-aa31-4089dcb84ab5" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1b71529e-fad3-4799-bf00-0f38e64f6142" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofRestrictedStockActivityDetails" xlink:type="simple" xlink:href="dnli-20210331.xsd#StockBasedAwardsSummaryofRestrictedStockActivityDetails"/>
  <link:definitionLink xlink:role="http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofRestrictedStockActivityDetails" xlink:type="extended" id="ife4f7c64684b4491b9b42d19f812a0cd_StockBasedAwardsSummaryofRestrictedStockActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_230a85c1-2ec4-4e09-b50f-93d7acf4dda1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_b5f69219-e58d-4448-9752-b9044e420fb7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_230a85c1-2ec4-4e09-b50f-93d7acf4dda1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_b5f69219-e58d-4448-9752-b9044e420fb7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_d71c6f0a-385b-4f0d-8315-4534898161fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_b5f69219-e58d-4448-9752-b9044e420fb7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_d71c6f0a-385b-4f0d-8315-4534898161fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_ec1a6c97-6fe7-44a1-bf32-93b37793cea3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_b5f69219-e58d-4448-9752-b9044e420fb7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_ec1a6c97-6fe7-44a1-bf32-93b37793cea3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_6f7ea3ae-3e8c-4718-bdba-521973bdafc2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_b5f69219-e58d-4448-9752-b9044e420fb7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_6f7ea3ae-3e8c-4718-bdba-521973bdafc2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_715551e1-0399-4f09-9281-5d1b689456fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_b5f69219-e58d-4448-9752-b9044e420fb7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_715551e1-0399-4f09-9281-5d1b689456fe" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_945ca609-b15a-4258-b9fc-acfe552798fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber_7ed26a7b-5a95-4cee-a0c9-dc4a56b6d17b" xlink:href="dnli-20210331.xsd#dnli_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_230a85c1-2ec4-4e09-b50f-93d7acf4dda1" xlink:to="loc_dnli_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber_7ed26a7b-5a95-4cee-a0c9-dc4a56b6d17b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_2b88cdf2-c94d-4992-80b3-6b7f9d43e6b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_230a85c1-2ec4-4e09-b50f-93d7acf4dda1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_2b88cdf2-c94d-4992-80b3-6b7f9d43e6b5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_152cdb89-f35f-47ee-bdb6-dfe1db4fb148" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_2b88cdf2-c94d-4992-80b3-6b7f9d43e6b5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_152cdb89-f35f-47ee-bdb6-dfe1db4fb148" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c689c2ea-0b88-4c5b-817f-69efba1d5826" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_2b88cdf2-c94d-4992-80b3-6b7f9d43e6b5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c689c2ea-0b88-4c5b-817f-69efba1d5826" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_5cef4c37-f37e-42bd-965a-71fec3316405" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_2b88cdf2-c94d-4992-80b3-6b7f9d43e6b5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_5cef4c37-f37e-42bd-965a-71fec3316405" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_79d14a67-0013-48b7-9600-3272855208ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_2b88cdf2-c94d-4992-80b3-6b7f9d43e6b5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_79d14a67-0013-48b7-9600-3272855208ea" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6ef9ebd7-b0ed-4ef7-bcbb-ffb516ae0404" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueExpectedToVest_98abfc43-973c-4110-9b7f-7be80d5dc812" xlink:href="dnli-20210331.xsd#dnli_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueExpectedToVest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_230a85c1-2ec4-4e09-b50f-93d7acf4dda1" xlink:to="loc_dnli_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueExpectedToVest_98abfc43-973c-4110-9b7f-7be80d5dc812" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8afc7aff-f73e-45e6-8bec-3572a02d02c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_230a85c1-2ec4-4e09-b50f-93d7acf4dda1" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8afc7aff-f73e-45e6-8bec-3572a02d02c0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_071bf4dd-2f83-4c79-a5c9-5d8a1fb9caf3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8afc7aff-f73e-45e6-8bec-3572a02d02c0" xlink:to="loc_us-gaap_AwardTypeAxis_071bf4dd-2f83-4c79-a5c9-5d8a1fb9caf3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_071bf4dd-2f83-4c79-a5c9-5d8a1fb9caf3_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_071bf4dd-2f83-4c79-a5c9-5d8a1fb9caf3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_071bf4dd-2f83-4c79-a5c9-5d8a1fb9caf3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ffbd28b3-0db3-429b-bab8-48b7a14c188d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_071bf4dd-2f83-4c79-a5c9-5d8a1fb9caf3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ffbd28b3-0db3-429b-bab8-48b7a14c188d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_b95f2709-18a1-46ed-825c-421e5a8d0fe5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ffbd28b3-0db3-429b-bab8-48b7a14c188d" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_b95f2709-18a1-46ed-825c-421e5a8d0fe5" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="dnli-20210331.xsd#StockBasedAwardsSummaryofStockBasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofStockBasedCompensationExpenseDetails" xlink:type="extended" id="id172cf0488784782a3a02559809ae8af_StockBasedAwardsSummaryofStockBasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3a2a11a1-b134-40b7-a2a3-c95984bafced" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_52082f3c-e7fa-4305-b92b-90df6e16fd9f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3a2a11a1-b134-40b7-a2a3-c95984bafced" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_52082f3c-e7fa-4305-b92b-90df6e16fd9f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fddfa29c-0775-40bf-8b4e-2df4a683b07d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3a2a11a1-b134-40b7-a2a3-c95984bafced" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fddfa29c-0775-40bf-8b4e-2df4a683b07d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_df299a14-6f69-4035-9e99-cb927f1e84e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fddfa29c-0775-40bf-8b4e-2df4a683b07d" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_df299a14-6f69-4035-9e99-cb927f1e84e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_df299a14-6f69-4035-9e99-cb927f1e84e3_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_df299a14-6f69-4035-9e99-cb927f1e84e3" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_df299a14-6f69-4035-9e99-cb927f1e84e3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_88f9cfe9-071b-45e1-8008-dd888eae8ae6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_df299a14-6f69-4035-9e99-cb927f1e84e3" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_88f9cfe9-071b-45e1-8008-dd888eae8ae6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_d3a0ab22-e761-4e4e-809f-98deda8cadde" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_88f9cfe9-071b-45e1-8008-dd888eae8ae6" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_d3a0ab22-e761-4e4e-809f-98deda8cadde" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_7c4eb145-80d3-497f-837d-d10bc2874bf6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_88f9cfe9-071b-45e1-8008-dd888eae8ae6" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_7c4eb145-80d3-497f-837d-d10bc2874bf6" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/NetLossPerShare" xlink:type="simple" xlink:href="dnli-20210331.xsd#NetLossPerShare"/>
  <link:definitionLink xlink:role="http://www.denalitherapeutics.com/role/NetLossPerShare" xlink:type="extended" id="i29b56db30ea44773a18f84cbfa5cf345_NetLossPerShare"/>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/NetLossPerShareTables" xlink:type="simple" xlink:href="dnli-20210331.xsd#NetLossPerShareTables"/>
  <link:definitionLink xlink:role="http://www.denalitherapeutics.com/role/NetLossPerShareTables" xlink:type="extended" id="i78569026d2d74b3d8c5e80c4e8e466cf_NetLossPerShareTables"/>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/NetLossPerShareScheduleofDilutiveSecuritiesNotIncludedinDilutedPerShareCalculationsDetails" xlink:type="simple" xlink:href="dnli-20210331.xsd#NetLossPerShareScheduleofDilutiveSecuritiesNotIncludedinDilutedPerShareCalculationsDetails"/>
  <link:definitionLink xlink:role="http://www.denalitherapeutics.com/role/NetLossPerShareScheduleofDilutiveSecuritiesNotIncludedinDilutedPerShareCalculationsDetails" xlink:type="extended" id="i2a4d8c419c8447bc9426ae258150d054_NetLossPerShareScheduleofDilutiveSecuritiesNotIncludedinDilutedPerShareCalculationsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_00afa340-3523-449c-b100-84294ec31ec0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_6e3a4137-c42d-48b0-b23c-272b9e88dc73" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_00afa340-3523-449c-b100-84294ec31ec0" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_6e3a4137-c42d-48b0-b23c-272b9e88dc73" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_84412d1c-4d85-4b2b-82a2-e74eca0ee959" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_00afa340-3523-449c-b100-84294ec31ec0" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_84412d1c-4d85-4b2b-82a2-e74eca0ee959" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c57499f6-db11-4b42-b49c-49896c12c0ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_84412d1c-4d85-4b2b-82a2-e74eca0ee959" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c57499f6-db11-4b42-b49c-49896c12c0ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_c57499f6-db11-4b42-b49c-49896c12c0ca_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c57499f6-db11-4b42-b49c-49896c12c0ca" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_c57499f6-db11-4b42-b49c-49896c12c0ca_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_22dfb981-5bd3-4aa7-b2eb-142ecff4430d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c57499f6-db11-4b42-b49c-49896c12c0ca" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_22dfb981-5bd3-4aa7-b2eb-142ecff4430d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_EmployeeAndNonEmployeeStockOptionMember_1383ac5e-cd64-4b96-a281-2f82b7963586" xlink:href="dnli-20210331.xsd#dnli_EmployeeAndNonEmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_22dfb981-5bd3-4aa7-b2eb-142ecff4430d" xlink:to="loc_dnli_EmployeeAndNonEmployeeStockOptionMember_1383ac5e-cd64-4b96-a281-2f82b7963586" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_RestrictedSharesSubjectToFutureVestingMember_a8b7479c-7915-4bb4-a283-47e662cec0a8" xlink:href="dnli-20210331.xsd#dnli_RestrictedSharesSubjectToFutureVestingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_22dfb981-5bd3-4aa7-b2eb-142ecff4430d" xlink:to="loc_dnli_RestrictedSharesSubjectToFutureVestingMember_a8b7479c-7915-4bb4-a283-47e662cec0a8" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="dnli-20210331.xsd#RelatedPartyTransactions"/>
  <link:definitionLink xlink:role="http://www.denalitherapeutics.com/role/RelatedPartyTransactions" xlink:type="extended" id="ibaca5e4da7f14e41b5c9c5bae533b73a_RelatedPartyTransactions"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>dnli-20210331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:be7bc6f9-6af9-45b5-b822-49fcbbf3ecfb,g:6a95e0ad-15c9-4fb8-a5d1-2bfd737ebde3-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_9173e308-61f7-405a-9b4b-68f5c2332a3b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_1e7ded09-22e9-4de9-a3e3-87fc2512ed30_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_8bdfa3e4-5648-4ff3-a9b0-de46a704cdd5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_e081a27a-e81b-4478-85dc-1fec6f089f4c_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_9dfd393f-f265-4ebb-b7cf-0b6f0c062f58_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and released (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_country_CN_eea7b619-dffe-44f5-ba28-48e442ae8648_terseLabel_en-US" xlink:label="lab_country_CN" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">China</link:label>
    <link:label id="lab_country_CN_label_en-US" xlink:label="lab_country_CN" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CHINA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_CN" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_CN"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_CN" xlink:to="lab_country_CN" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_d9f75038-28eb-4c3d-a38e-ce3e8f285c2f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_54cb9209-00bb-4585-8adc-6fbe1906bd80_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_6471cfc5-edc9-4b18-b909-f38cfe9799d0_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturities and sales of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_UpfrontPayments_342cbc11-b116-4b3d-9f1c-10754df02709_terseLabel_en-US" xlink:label="lab_dnli_UpfrontPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront payment</link:label>
    <link:label id="lab_dnli_UpfrontPayments_label_en-US" xlink:label="lab_dnli_UpfrontPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront Payments</link:label>
    <link:label id="lab_dnli_UpfrontPayments_documentation_en-US" xlink:label="lab_dnli_UpfrontPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront payments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_UpfrontPayments" xlink:href="dnli-20210331.xsd#dnli_UpfrontPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_UpfrontPayments" xlink:to="lab_dnli_UpfrontPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssets_1f667943-613c-43e3-94f6-2ef790e22476_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency derivative contracts</link:label>
    <link:label id="lab_us-gaap_DerivativeAssets_cda8f9be-380e-49ee-b88d-2eab405ddeaf_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative asset</link:label>
    <link:label id="lab_us-gaap_DerivativeAssets_label_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssets" xlink:to="lab_us-gaap_DerivativeAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_CollaborativeAgreementAgreedShareOfCommercialProfitLoss_795f0883-3192-4345-b907-cfbbb9df90c6_terseLabel_en-US" xlink:label="lab_dnli_CollaborativeAgreementAgreedShareOfCommercialProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreed share of commercial profit (loss) percentage</link:label>
    <link:label id="lab_dnli_CollaborativeAgreementAgreedShareOfCommercialProfitLoss_label_en-US" xlink:label="lab_dnli_CollaborativeAgreementAgreedShareOfCommercialProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Agreed Share Of Commercial Profit (Loss)</link:label>
    <link:label id="lab_dnli_CollaborativeAgreementAgreedShareOfCommercialProfitLoss_documentation_en-US" xlink:label="lab_dnli_CollaborativeAgreementAgreedShareOfCommercialProfitLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Agreed Share Of Commercial Profit (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_CollaborativeAgreementAgreedShareOfCommercialProfitLoss" xlink:href="dnli-20210331.xsd#dnli_CollaborativeAgreementAgreedShareOfCommercialProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_CollaborativeAgreementAgreedShareOfCommercialProfitLoss" xlink:to="lab_dnli_CollaborativeAgreementAgreedShareOfCommercialProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_5176fc84-a461-4e80-8c61-24b0478136f6_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_45f728f7-0b2d-4f97-adc9-843a897d41c5_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and stockholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b002e65c-b950-425c-9ba2-f4d95d35ed12_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_fb67d6f4-8ecf-4085-8a6d-f9a87db2eb07_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Financial Instruments</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_2980137e-081c-4862-a065-61bef1691400_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_4a1f9a3d-bf9a-43bf-b0a3-b92e2b859845_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_f7205731-6ccf-4f25-a88b-52e26c77c184_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_CollaborativeArrangementNumberOfAdditionalProgramsNoThirdPartyAgreementExecutedIfCircumstancesMet_e43cb85d-9cb7-45bf-a026-9c9d7aacf0a2_terseLabel_en-US" xlink:label="lab_dnli_CollaborativeArrangementNumberOfAdditionalProgramsNoThirdPartyAgreementExecutedIfCircumstancesMet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of additional programs, no third party agreement executed, if circumstances met</link:label>
    <link:label id="lab_dnli_CollaborativeArrangementNumberOfAdditionalProgramsNoThirdPartyAgreementExecutedIfCircumstancesMet_label_en-US" xlink:label="lab_dnli_CollaborativeArrangementNumberOfAdditionalProgramsNoThirdPartyAgreementExecutedIfCircumstancesMet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Number Of Additional Programs, No Third Party Agreement Executed, If Circumstances Met</link:label>
    <link:label id="lab_dnli_CollaborativeArrangementNumberOfAdditionalProgramsNoThirdPartyAgreementExecutedIfCircumstancesMet_documentation_en-US" xlink:label="lab_dnli_CollaborativeArrangementNumberOfAdditionalProgramsNoThirdPartyAgreementExecutedIfCircumstancesMet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Number Of Additional Programs, No Third Party Agreement Executed, If Circumstances Met</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_CollaborativeArrangementNumberOfAdditionalProgramsNoThirdPartyAgreementExecutedIfCircumstancesMet" xlink:href="dnli-20210331.xsd#dnli_CollaborativeArrangementNumberOfAdditionalProgramsNoThirdPartyAgreementExecutedIfCircumstancesMet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_CollaborativeArrangementNumberOfAdditionalProgramsNoThirdPartyAgreementExecutedIfCircumstancesMet" xlink:to="lab_dnli_CollaborativeArrangementNumberOfAdditionalProgramsNoThirdPartyAgreementExecutedIfCircumstancesMet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_a9175ab7-ef04-45d7-bd5f-717952e68196_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_27b4ec80-b2d0-4b77-8564-75aba7787699_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0f093b78-9b6f-4d17-9cf6-53eca246c432_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_LicenseAgreementMember_69e942f8-7bac-43f0-8fe4-0602833b25e9_terseLabel_en-US" xlink:label="lab_dnli_LicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement</link:label>
    <link:label id="lab_dnli_LicenseAgreementMember_label_en-US" xlink:label="lab_dnli_LicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement [Member]</link:label>
    <link:label id="lab_dnli_LicenseAgreementMember_documentation_en-US" xlink:label="lab_dnli_LicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_LicenseAgreementMember" xlink:href="dnli-20210331.xsd#dnli_LicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_LicenseAgreementMember" xlink:to="lab_dnli_LicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_d5c567fc-8fb4-4e1f-b899-af02f8bb1812_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies (Note 7)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_5fac1983-bd16-43fa-b167-787706eee996_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting of restricted stock units</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_589e5f17-ca61-47e6-bf8a-a1848406ca30_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_f0ccb7f4-cd10-47ac-9092-988f4b2a20d5_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_ad8aa4fc-e64f-4b20-acd6-833721d82057_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_7662f1a4-9008-4e9d-88e6-6eb4c23ecc54_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and released (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_d7c16ad5-151a-453c-b6cf-a1a9c395f806_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_997ad461-c2f7-4255-8d0e-cc30524875cb_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubleaseIncome_8310d9af-bffa-4b8b-92eb-0b449a31e391_terseLabel_en-US" xlink:label="lab_us-gaap_SubleaseIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease income</link:label>
    <link:label id="lab_us-gaap_SubleaseIncome_label_en-US" xlink:label="lab_us-gaap_SubleaseIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubleaseIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubleaseIncome" xlink:to="lab_us-gaap_SubleaseIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_a63ef082-f437-40a9-a745-5736455df17c_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear_5ae96d66-a56c-43a1-9f5e-a0530357c1f9_terseLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 (nine months)</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Payment to be Received, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear" xlink:to="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_cb7cacba-328f-47df-8b32-b5b0edaad2a3_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use asset</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_TakedaPharmaceuticalCompanyLimitedMember_90bbf810-0164-4c73-ab86-e94288c17f9e_terseLabel_en-US" xlink:label="lab_dnli_TakedaPharmaceuticalCompanyLimitedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Takeda Pharmaceutical Company Limited</link:label>
    <link:label id="lab_dnli_TakedaPharmaceuticalCompanyLimitedMember_label_en-US" xlink:label="lab_dnli_TakedaPharmaceuticalCompanyLimitedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Takeda Pharmaceutical Company Limited [Member]</link:label>
    <link:label id="lab_dnli_TakedaPharmaceuticalCompanyLimitedMember_documentation_en-US" xlink:label="lab_dnli_TakedaPharmaceuticalCompanyLimitedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Takeda pharmaceutical company limited.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_TakedaPharmaceuticalCompanyLimitedMember" xlink:href="dnli-20210331.xsd#dnli_TakedaPharmaceuticalCompanyLimitedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_TakedaPharmaceuticalCompanyLimitedMember" xlink:to="lab_dnli_TakedaPharmaceuticalCompanyLimitedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_0a27ccb7-9f46-442b-9749-bba987d2f4e4_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_RetainedActivitiesMember_e363208b-6e05-42b1-9c2f-38218a36c72f_terseLabel_en-US" xlink:label="lab_dnli_RetainedActivitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Activities</link:label>
    <link:label id="lab_dnli_RetainedActivitiesMember_label_en-US" xlink:label="lab_dnli_RetainedActivitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Activities [Member]</link:label>
    <link:label id="lab_dnli_RetainedActivitiesMember_documentation_en-US" xlink:label="lab_dnli_RetainedActivitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_RetainedActivitiesMember" xlink:href="dnli-20210331.xsd#dnli_RetainedActivitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_RetainedActivitiesMember" xlink:to="lab_dnli_RetainedActivitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_04181f56-b780-4926-a15c-89446a460d28_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2ff521f5-4269-44df-8361-47dc043a9a99_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_cc6e4c25-26fa-4d39-8d4a-772f670825dd_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_CollaborativeArrangementPTVPGRNMember_e2b10267-6cdb-4f21-9974-a297f78b5d41_terseLabel_en-US" xlink:label="lab_dnli_CollaborativeArrangementPTVPGRNMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, PTV:PGRN</link:label>
    <link:label id="lab_dnli_CollaborativeArrangementPTVPGRNMember_label_en-US" xlink:label="lab_dnli_CollaborativeArrangementPTVPGRNMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, PTV:PGRN [Member]</link:label>
    <link:label id="lab_dnli_CollaborativeArrangementPTVPGRNMember_documentation_en-US" xlink:label="lab_dnli_CollaborativeArrangementPTVPGRNMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, PTV:PGRN</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_CollaborativeArrangementPTVPGRNMember" xlink:href="dnli-20210331.xsd#dnli_CollaborativeArrangementPTVPGRNMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_CollaborativeArrangementPTVPGRNMember" xlink:to="lab_dnli_CollaborativeArrangementPTVPGRNMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_16fd9093-7140-455c-8277-63e6270648c5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Assets and Liabilities Measured at Fair Value</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_OperatingLeasesAreaUnderLease_3e27922c-5ed1-4f19-acea-e2ab4be03b9c_terseLabel_en-US" xlink:label="lab_dnli_OperatingLeasesAreaUnderLease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area under lease</link:label>
    <link:label id="lab_dnli_OperatingLeasesAreaUnderLease_label_en-US" xlink:label="lab_dnli_OperatingLeasesAreaUnderLease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases Area Under Lease</link:label>
    <link:label id="lab_dnli_OperatingLeasesAreaUnderLease_documentation_en-US" xlink:label="lab_dnli_OperatingLeasesAreaUnderLease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating leases area under lease.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_OperatingLeasesAreaUnderLease" xlink:href="dnli-20210331.xsd#dnli_OperatingLeasesAreaUnderLease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_OperatingLeasesAreaUnderLease" xlink:to="lab_dnli_OperatingLeasesAreaUnderLease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_ae746be8-1aa1-4b23-aad6-57f9745c50fd_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible preferred stock, $0.01 par value; 40,000,000 shares authorized as of March 31, 2021 and December 31, 2020; 0 shares issued and outstanding as of March 31, 2021 and December 31, 2020</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_b639e7d0-936c-4cdb-9f0b-30fdaaeca42a_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationDomain" xlink:to="lab_us-gaap_HedgingDesignationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_735946dd-9340-4c2e-b7be-4b65e65eac42_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease costs</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_8b2ce18b-0745-47a3-b3cb-a49041d818c9_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_a5618635-d848-4fae-a1b6-a2fa4fed0e0d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_11530f2e-c5f7-4403-8f45-62f25f9df668_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (usd per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_2aa5f101-d17f-4f1a-be8d-bc09d949d75b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_ea95f2a8-0226-497e-83ca-937a454fd837_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term marketable securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesCurrent" xlink:to="lab_us-gaap_MarketableSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_7f8ea9b7-1ea4-46a8-af15-773deb6dc1cc_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_065b64f3-4fd1-4c24-bd75-e267845de044_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration revenue from customers</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_809735e6-9d5d-43c3-8315-0430f9e3c250_netLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative revenue, revenue from contract with customer</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_CollaborativeArrangementRightOfFirstNegotiationTermPeriodAfterEffectiveDateOfAgreementIfCircumstancesMet_30fc9f6f-f517-40fc-a2a0-9a77bdc50144_terseLabel_en-US" xlink:label="lab_dnli_CollaborativeArrangementRightOfFirstNegotiationTermPeriodAfterEffectiveDateOfAgreementIfCircumstancesMet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right of first negotiation (ROFN) term, period of time after effective date of agreement, if circumstances met</link:label>
    <link:label id="lab_dnli_CollaborativeArrangementRightOfFirstNegotiationTermPeriodAfterEffectiveDateOfAgreementIfCircumstancesMet_label_en-US" xlink:label="lab_dnli_CollaborativeArrangementRightOfFirstNegotiationTermPeriodAfterEffectiveDateOfAgreementIfCircumstancesMet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Right Of First Negotiation Term, Period After Effective Date Of Agreement, If Circumstances Met</link:label>
    <link:label id="lab_dnli_CollaborativeArrangementRightOfFirstNegotiationTermPeriodAfterEffectiveDateOfAgreementIfCircumstancesMet_documentation_en-US" xlink:label="lab_dnli_CollaborativeArrangementRightOfFirstNegotiationTermPeriodAfterEffectiveDateOfAgreementIfCircumstancesMet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Right Of First Negotiation Term, Period After Effective Date Of Agreement, If Circumstances Met</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_CollaborativeArrangementRightOfFirstNegotiationTermPeriodAfterEffectiveDateOfAgreementIfCircumstancesMet" xlink:href="dnli-20210331.xsd#dnli_CollaborativeArrangementRightOfFirstNegotiationTermPeriodAfterEffectiveDateOfAgreementIfCircumstancesMet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_CollaborativeArrangementRightOfFirstNegotiationTermPeriodAfterEffectiveDateOfAgreementIfCircumstancesMet" xlink:to="lab_dnli_CollaborativeArrangementRightOfFirstNegotiationTermPeriodAfterEffectiveDateOfAgreementIfCircumstancesMet" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_OptionResearchServicesMember_0568d0f6-94d4-45a3-be9e-f61e05dec7be_terseLabel_en-US" xlink:label="lab_dnli_OptionResearchServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option Research Services</link:label>
    <link:label id="lab_dnli_OptionResearchServicesMember_label_en-US" xlink:label="lab_dnli_OptionResearchServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option Research Services [Member]</link:label>
    <link:label id="lab_dnli_OptionResearchServicesMember_documentation_en-US" xlink:label="lab_dnli_OptionResearchServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option Research Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_OptionResearchServicesMember" xlink:href="dnli-20210331.xsd#dnli_OptionResearchServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_OptionResearchServicesMember" xlink:to="lab_dnli_OptionResearchServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_790dec8d-efca-4bd1-93da-258df4c1ab48_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_1c083868-fb98-48c9-9fff-4f873b7fbb02_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_1f01eac3-a6f7-4fd0-ae92-f95ba8508012_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Dilutive Securities Not Included in Diluted Per Share Calculations</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_aba1272e-7979-4d88-9455-4ba9de7dca2e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_66faebc0-502b-4160-bae7-de3d8c3ceac5_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_StockIssuedDuringPeriodSharesEquityIncentivePlan_21c3bba6-e75e-4399-a780-9f7f01fe2e69_terseLabel_en-US" xlink:label="lab_dnli_StockIssuedDuringPeriodSharesEquityIncentivePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuances under equity incentive plans (in shares)</link:label>
    <link:label id="lab_dnli_StockIssuedDuringPeriodSharesEquityIncentivePlan_label_en-US" xlink:label="lab_dnli_StockIssuedDuringPeriodSharesEquityIncentivePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Equity Incentive Plan</link:label>
    <link:label id="lab_dnli_StockIssuedDuringPeriodSharesEquityIncentivePlan_documentation_en-US" xlink:label="lab_dnli_StockIssuedDuringPeriodSharesEquityIncentivePlan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Equity Incentive Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_StockIssuedDuringPeriodSharesEquityIncentivePlan" xlink:href="dnli-20210331.xsd#dnli_StockIssuedDuringPeriodSharesEquityIncentivePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_StockIssuedDuringPeriodSharesEquityIncentivePlan" xlink:to="lab_dnli_StockIssuedDuringPeriodSharesEquityIncentivePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_PeripheralProductMember_ad1c708e-4139-4912-be1f-a0bf88070b37_terseLabel_en-US" xlink:label="lab_dnli_PeripheralProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Peripheral Program License</link:label>
    <link:label id="lab_dnli_PeripheralProductMember_label_en-US" xlink:label="lab_dnli_PeripheralProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Peripheral Product [Member]</link:label>
    <link:label id="lab_dnli_PeripheralProductMember_documentation_en-US" xlink:label="lab_dnli_PeripheralProductMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Peripheral Product</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_PeripheralProductMember" xlink:href="dnli-20210331.xsd#dnli_PeripheralProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_PeripheralProductMember" xlink:to="lab_dnli_PeripheralProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_ac79a448-0322-4039-8b80-e5ce0663a413_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_e08df7e8-cc4f-4198-b170-2d7627372042_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_60495f68-a37a-4a91-b60c-60a9f98f1fe1_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived_01d6b8a7-4e29-4f5b-82a1-d65543f42cf0_totalLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total undiscounted sublease receipts</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Payments to be Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:to="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_f0b1ed48-fdf3-4a50-afd5-c86b7f467c82_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_bf5d8d95-b69d-40fe-bd72-b71b9585869a_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. government agency securities</link:label>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government Agencies Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTerm_fb79d01b-e456-42b4-94cb-e7d21c49719e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective maturity (less than)</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTerm_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_25432060-40f6-4beb-9aac-a8fa90322e9a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Volatility, minimum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_CollaborativeArrangementFirstCommercialSaleMilestonePaymentsToBeReceived_76147959-fda4-4430-8e59-c2abc6cb9fe2_terseLabel_en-US" xlink:label="lab_dnli_CollaborativeArrangementFirstCommercialSaleMilestonePaymentsToBeReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">First commercial sale milestone payments, to be received</link:label>
    <link:label id="lab_dnli_CollaborativeArrangementFirstCommercialSaleMilestonePaymentsToBeReceived_label_en-US" xlink:label="lab_dnli_CollaborativeArrangementFirstCommercialSaleMilestonePaymentsToBeReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, First Commercial Sale Milestone Payments, To Be Received</link:label>
    <link:label id="lab_dnli_CollaborativeArrangementFirstCommercialSaleMilestonePaymentsToBeReceived_documentation_en-US" xlink:label="lab_dnli_CollaborativeArrangementFirstCommercialSaleMilestonePaymentsToBeReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, First Commercial Sale Milestone Payments, To Be Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_CollaborativeArrangementFirstCommercialSaleMilestonePaymentsToBeReceived" xlink:href="dnli-20210331.xsd#dnli_CollaborativeArrangementFirstCommercialSaleMilestonePaymentsToBeReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_CollaborativeArrangementFirstCommercialSaleMilestonePaymentsToBeReceived" xlink:to="lab_dnli_CollaborativeArrangementFirstCommercialSaleMilestonePaymentsToBeReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_24c1a495-823a-453c-8296-2103b0a89132_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesPolicy" xlink:to="lab_us-gaap_MarketableSecuritiesPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_3340c90d-a7ab-4e0e-900e-1107d0d60ad3_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_3740cfb0-0a77-4a1e-b6f8-f883deb8563a_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_1d3c8429-d2e4-49f6-b060-367746dbe40e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease Liabilities, Payments Due [Abstract]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payment, Due [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d27fc718-fa12-4c70-9fe1-df97b60581dd_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_ResearchAndDevelopmentExpenseOffsetFromRelatedPartyCostReimbursement_8b7eb762-59ea-41eb-8714-0520ebacbf72_terseLabel_en-US" xlink:label="lab_dnli_ResearchAndDevelopmentExpenseOffsetFromRelatedPartyCostReimbursement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Offset to research and development expense, related party cost reimbursement</link:label>
    <link:label id="lab_dnli_ResearchAndDevelopmentExpenseOffsetFromRelatedPartyCostReimbursement_label_en-US" xlink:label="lab_dnli_ResearchAndDevelopmentExpenseOffsetFromRelatedPartyCostReimbursement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Expense, Offset From Related Party Cost Reimbursement</link:label>
    <link:label id="lab_dnli_ResearchAndDevelopmentExpenseOffsetFromRelatedPartyCostReimbursement_documentation_en-US" xlink:label="lab_dnli_ResearchAndDevelopmentExpenseOffsetFromRelatedPartyCostReimbursement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Expense, Offset From Related Party Cost Reimbursement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_ResearchAndDevelopmentExpenseOffsetFromRelatedPartyCostReimbursement" xlink:href="dnli-20210331.xsd#dnli_ResearchAndDevelopmentExpenseOffsetFromRelatedPartyCostReimbursement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_ResearchAndDevelopmentExpenseOffsetFromRelatedPartyCostReimbursement" xlink:to="lab_dnli_ResearchAndDevelopmentExpenseOffsetFromRelatedPartyCostReimbursement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_dfd223db-4c2d-438d-9751-e747b431db99_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a7e540d2-805c-4a64-a312-d8ca4cbbb642_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_d032ea7d-ba97-4779-abce-6df2daa4d852_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementMember" xlink:to="lab_us-gaap_CollaborativeArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_1ed2f7d7-d942-4aa2-a663-f6ba945bba10_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from public offering of common stock, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeNumberOfInstrumentsHeld_52011266-e90c-4294-aeb9-26e6a717675d_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeNumberOfInstrumentsHeld" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Contracts</link:label>
    <link:label id="lab_us-gaap_DerivativeNumberOfInstrumentsHeld_label_en-US" xlink:label="lab_us-gaap_DerivativeNumberOfInstrumentsHeld" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Number of Instruments Held</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNumberOfInstrumentsHeld" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeNumberOfInstrumentsHeld"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeNumberOfInstrumentsHeld" xlink:to="lab_us-gaap_DerivativeNumberOfInstrumentsHeld" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_961b3b45-6ead-48b9-b9c0-aa5d779369b9_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_AlzheimersDiseaseServicesMember_f9dbb5a4-f29a-4db2-8751-e59bc8b9b206_terseLabel_en-US" xlink:label="lab_dnli_AlzheimersDiseaseServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alzheimer's Disease Services</link:label>
    <link:label id="lab_dnli_AlzheimersDiseaseServicesMember_label_en-US" xlink:label="lab_dnli_AlzheimersDiseaseServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alzheimer's Disease Services [Member]</link:label>
    <link:label id="lab_dnli_AlzheimersDiseaseServicesMember_documentation_en-US" xlink:label="lab_dnli_AlzheimersDiseaseServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alzheimer's Disease Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_AlzheimersDiseaseServicesMember" xlink:href="dnli-20210331.xsd#dnli_AlzheimersDiseaseServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_AlzheimersDiseaseServicesMember" xlink:to="lab_dnli_AlzheimersDiseaseServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContingentConsiderationTypeDomain_91cef977-4955-439d-9b90-bc093ac76489_terseLabel_en-US" xlink:label="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ContingentConsiderationTypeDomain_label_en-US" xlink:label="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain" xlink:to="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_CommercialMilestonesPerProgram_f070ad05-7580-41ae-90b0-4da9753fdd01_terseLabel_en-US" xlink:label="lab_dnli_CommercialMilestonesPerProgram" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payments per biologic product upon achievement of a certain sales-based milestone</link:label>
    <link:label id="lab_dnli_CommercialMilestonesPerProgram_label_en-US" xlink:label="lab_dnli_CommercialMilestonesPerProgram" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Milestones Per Program</link:label>
    <link:label id="lab_dnli_CommercialMilestonesPerProgram_documentation_en-US" xlink:label="lab_dnli_CommercialMilestonesPerProgram" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial milestones per program.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_CommercialMilestonesPerProgram" xlink:href="dnli-20210331.xsd#dnli_CommercialMilestonesPerProgram"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_CommercialMilestonesPerProgram" xlink:to="lab_dnli_CommercialMilestonesPerProgram" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_fdc9a76e-81ca-4f96-a322-5f68a7afdd8b_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_CollaborativeArrangementRightOfFirstNegotiationPeriodTermAdditionalProgramCriteria_d20553dd-9065-44fc-9623-9091449ee656_terseLabel_en-US" xlink:label="lab_dnli_CollaborativeArrangementRightOfFirstNegotiationPeriodTermAdditionalProgramCriteria" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right of first negotiation (ROFN) term, additional program criteria</link:label>
    <link:label id="lab_dnli_CollaborativeArrangementRightOfFirstNegotiationPeriodTermAdditionalProgramCriteria_label_en-US" xlink:label="lab_dnli_CollaborativeArrangementRightOfFirstNegotiationPeriodTermAdditionalProgramCriteria" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Right Of First Negotiation, Period Term, Additional Program Criteria</link:label>
    <link:label id="lab_dnli_CollaborativeArrangementRightOfFirstNegotiationPeriodTermAdditionalProgramCriteria_documentation_en-US" xlink:label="lab_dnli_CollaborativeArrangementRightOfFirstNegotiationPeriodTermAdditionalProgramCriteria" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Right Of First Negotiation, Period Term, Additional Program Criteria</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_CollaborativeArrangementRightOfFirstNegotiationPeriodTermAdditionalProgramCriteria" xlink:href="dnli-20210331.xsd#dnli_CollaborativeArrangementRightOfFirstNegotiationPeriodTermAdditionalProgramCriteria"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_CollaborativeArrangementRightOfFirstNegotiationPeriodTermAdditionalProgramCriteria" xlink:to="lab_dnli_CollaborativeArrangementRightOfFirstNegotiationPeriodTermAdditionalProgramCriteria" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_8e03df36-6744-48be-bb56-af044f78ea94_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_3638f15e-0310-4ee1-93b5-0f71fd9bcc18_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper, Not Included with Cash and Cash Equivalents [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_1ee430bd-fbff-4dd4-a767-9956162e998b_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e33f61df-1a7d-48e2-9632-fd07cef5a209_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeGainLossOnDerivativeNet_ccb5f1e6-7227-443e-b556-09b4786e013f_negatedLabel_en-US" xlink:label="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss on derivative instruments</link:label>
    <link:label id="lab_us-gaap_DerivativeGainLossOnDerivativeNet_label_en-US" xlink:label="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Gain (Loss) on Derivative, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:to="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_ClinicalMember_4b569003-552f-483d-a641-7f53c151a261_terseLabel_en-US" xlink:label="lab_dnli_ClinicalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical</link:label>
    <link:label id="lab_dnli_ClinicalMember_label_en-US" xlink:label="lab_dnli_ClinicalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical [Member]</link:label>
    <link:label id="lab_dnli_ClinicalMember_documentation_en-US" xlink:label="lab_dnli_ClinicalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_ClinicalMember" xlink:href="dnli-20210331.xsd#dnli_ClinicalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_ClinicalMember" xlink:to="lab_dnli_ClinicalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_ContractWithCustomerLiabilityFromRelatedPartiesNoncurrent_466280af-882f-4561-8e75-98c036a5bdbc_terseLabel_en-US" xlink:label="lab_dnli_ContractWithCustomerLiabilityFromRelatedPartiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related party contract liability, less current portion</link:label>
    <link:label id="lab_dnli_ContractWithCustomerLiabilityFromRelatedPartiesNoncurrent_label_en-US" xlink:label="lab_dnli_ContractWithCustomerLiabilityFromRelatedPartiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability, From Related Parties, Noncurrent</link:label>
    <link:label id="lab_dnli_ContractWithCustomerLiabilityFromRelatedPartiesNoncurrent_documentation_en-US" xlink:label="lab_dnli_ContractWithCustomerLiabilityFromRelatedPartiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability, From Related Parties, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_ContractWithCustomerLiabilityFromRelatedPartiesNoncurrent" xlink:href="dnli-20210331.xsd#dnli_ContractWithCustomerLiabilityFromRelatedPartiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_ContractWithCustomerLiabilityFromRelatedPartiesNoncurrent" xlink:to="lab_dnli_ContractWithCustomerLiabilityFromRelatedPartiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_PreclinicalMilestonePaymentReceived_df56e84f-27c5-44d9-85d2-692da2151419_terseLabel_en-US" xlink:label="lab_dnli_PreclinicalMilestonePaymentReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preclinical milestone payment received</link:label>
    <link:label id="lab_dnli_PreclinicalMilestonePaymentReceived_label_en-US" xlink:label="lab_dnli_PreclinicalMilestonePaymentReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preclinical Milestone Payment Received</link:label>
    <link:label id="lab_dnli_PreclinicalMilestonePaymentReceived_documentation_en-US" xlink:label="lab_dnli_PreclinicalMilestonePaymentReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preclinical milestone payment received.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_PreclinicalMilestonePaymentReceived" xlink:href="dnli-20210331.xsd#dnli_PreclinicalMilestonePaymentReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_PreclinicalMilestonePaymentReceived" xlink:to="lab_dnli_PreclinicalMilestonePaymentReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_53e67e96-cf1d-4c74-87e5-f0a81f172313_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives and Hedging Activities</link:label>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesPolicyTextBlock" xlink:to="lab_us-gaap_DerivativesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_2dd69ded-d597-4032-9259-4c84b026af5d_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_DevelopmentMilestonePayments_a8955446-64c7-44ea-ab98-dc3880c30ce7_terseLabel_en-US" xlink:label="lab_dnli_DevelopmentMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development milestone payments</link:label>
    <link:label id="lab_dnli_DevelopmentMilestonePayments_label_en-US" xlink:label="lab_dnli_DevelopmentMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development Milestone Payments</link:label>
    <link:label id="lab_dnli_DevelopmentMilestonePayments_documentation_en-US" xlink:label="lab_dnli_DevelopmentMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_DevelopmentMilestonePayments" xlink:href="dnli-20210331.xsd#dnli_DevelopmentMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_DevelopmentMilestonePayments" xlink:to="lab_dnli_DevelopmentMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_dafacf0a-a381-4fe0-8d23-b5e0b513ee09_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_fefaeace-ac67-4121-9623-17fd84ddc6fc_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease renewal option term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_c6e9f524-a5c5-42b0-90a5-63956763c73d_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Holding Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_0021900a-e55a-4ac9-ab00-490185e29bbe_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossAttributableToParent_fe541aeb-e316-48ff-befc-15896a1ce933_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossAttributableToParent_label_en-US" xlink:label="lab_us-gaap_IncomeLossAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) Attributable to Parent, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossAttributableToParent" xlink:to="lab_us-gaap_IncomeLossAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b01f8fa9-bbdc-4843-890d-5b84913c8f38_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_ae039074-17d6-43dc-8f19-b00f6e07b0f0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Restricted Stock Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_7b89ad55-5b07-4b04-ba51-3f5433d3fb8a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_CollaborationAgreementTransactionPriceIncrease_1760a68e-5944-4d4e-a2fa-3dfbd923dd4a_terseLabel_en-US" xlink:label="lab_dnli_CollaborationAgreementTransactionPriceIncrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction price increase</link:label>
    <link:label id="lab_dnli_CollaborationAgreementTransactionPriceIncrease_label_en-US" xlink:label="lab_dnli_CollaborationAgreementTransactionPriceIncrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Transaction Price, Increase</link:label>
    <link:label id="lab_dnli_CollaborationAgreementTransactionPriceIncrease_documentation_en-US" xlink:label="lab_dnli_CollaborationAgreementTransactionPriceIncrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Transaction Price, Increase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_CollaborationAgreementTransactionPriceIncrease" xlink:href="dnli-20210331.xsd#dnli_CollaborationAgreementTransactionPriceIncrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_CollaborationAgreementTransactionPriceIncrease" xlink:to="lab_dnli_CollaborationAgreementTransactionPriceIncrease" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_def0f759-919a-4391-9838-1a4252f37732_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding (shares)</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_ea6a11d5-aed0-45b4-8c7a-d0365a50b93d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_c5033f32-b62b-447b-8b85-ac70c85591af_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_34752750-1de9-4bf0-bf6d-319b861dce88_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Available for Sale Securities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesPolicyTextBlock_72617379-8825-43f6-9ff5-ad21149bc66f_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_ReceivablesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ReceivablesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesPolicyTextBlock" xlink:to="lab_us-gaap_ReceivablesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_5c84d377-d742-4ac2-84b9-979488e4401c_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Notional Amount in Foreign Currency</link:label>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_label_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Notional Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeNotionalAmount" xlink:to="lab_us-gaap_DerivativeNotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_afae3473-a80f-486a-af0a-839f239452e5_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Exchange Contracts</link:label>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_label_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Exchange Contract [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignExchangeContractMember" xlink:to="lab_us-gaap_ForeignExchangeContractMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_PurchaseOrderExecuted_30bdeaae-12bb-43f7-b9ba-ab3cbcdda6c1_terseLabel_en-US" xlink:label="lab_dnli_PurchaseOrderExecuted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase order executed</link:label>
    <link:label id="lab_dnli_PurchaseOrderExecuted_label_en-US" xlink:label="lab_dnli_PurchaseOrderExecuted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Order Executed</link:label>
    <link:label id="lab_dnli_PurchaseOrderExecuted_documentation_en-US" xlink:label="lab_dnli_PurchaseOrderExecuted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase order executed.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_PurchaseOrderExecuted" xlink:href="dnli-20210331.xsd#dnli_PurchaseOrderExecuted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_PurchaseOrderExecuted" xlink:to="lab_dnli_PurchaseOrderExecuted" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_OptionFeesPerProgram_1a094a33-5a76-4c8c-ac32-43220280496f_terseLabel_en-US" xlink:label="lab_dnli_OptionFeesPerProgram" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option fee</link:label>
    <link:label id="lab_dnli_OptionFeesPerProgram_label_en-US" xlink:label="lab_dnli_OptionFeesPerProgram" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option Fees Per Program</link:label>
    <link:label id="lab_dnli_OptionFeesPerProgram_documentation_en-US" xlink:label="lab_dnli_OptionFeesPerProgram" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option fees per program.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_OptionFeesPerProgram" xlink:href="dnli-20210331.xsd#dnli_OptionFeesPerProgram"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_OptionFeesPerProgram" xlink:to="lab_dnli_OptionFeesPerProgram" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_0a4e0f4c-c7c0-4af7-94c5-14fa02002d8f_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_06df46b5-06d3-48e2-bae9-c5d49baa7a21_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_NumberOfPrograms_8a41ef8a-7355-44cc-80ed-20d3dd3e7e3e_terseLabel_en-US" xlink:label="lab_dnli_NumberOfPrograms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of programs</link:label>
    <link:label id="lab_dnli_NumberOfPrograms_label_en-US" xlink:label="lab_dnli_NumberOfPrograms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Programs</link:label>
    <link:label id="lab_dnli_NumberOfPrograms_documentation_en-US" xlink:label="lab_dnli_NumberOfPrograms" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Programs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_NumberOfPrograms" xlink:href="dnli-20210331.xsd#dnli_NumberOfPrograms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_NumberOfPrograms" xlink:to="lab_dnli_NumberOfPrograms" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_661c9e93-538b-4e76-90b7-663e4eafd289_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock in follow-on offering, net of issuance costs of $632</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_a7f99cdf-f223-49a5-a358-5dc6cab7ad4b_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_06c33acf-1407-4da8-b68e-f05d05d2c4ac_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting of restricted stock units (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesNoncurrent_bebb068d-cc1b-4583-bcf7-80a75c77c684_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term marketable securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesNoncurrent" xlink:to="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_CommercialMilestonePayments_bff28d29-b904-4364-b14b-a5f68845cfef_terseLabel_en-US" xlink:label="lab_dnli_CommercialMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial milestone payments</link:label>
    <link:label id="lab_dnli_CommercialMilestonePayments_label_en-US" xlink:label="lab_dnli_CommercialMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Milestone Payments</link:label>
    <link:label id="lab_dnli_CommercialMilestonePayments_documentation_en-US" xlink:label="lab_dnli_CommercialMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_CommercialMilestonePayments" xlink:href="dnli-20210331.xsd#dnli_CommercialMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_CommercialMilestonePayments" xlink:to="lab_dnli_CommercialMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_8094ece6-6f2a-44c3-9f55-7e68e71298e4_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_cc8af537-b90b-41d3-a9b3-84c17ed95c8c_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax_522d9449-f8d6-4f73-9da7-93432aec9923_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized gain on marketable securities, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_MilestoneTriggeredMember_fc6a729d-b949-445e-b17b-d28771dfccbc_terseLabel_en-US" xlink:label="lab_dnli_MilestoneTriggeredMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Triggered</link:label>
    <link:label id="lab_dnli_MilestoneTriggeredMember_label_en-US" xlink:label="lab_dnli_MilestoneTriggeredMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Triggered [Member]</link:label>
    <link:label id="lab_dnli_MilestoneTriggeredMember_documentation_en-US" xlink:label="lab_dnli_MilestoneTriggeredMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Triggered</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_MilestoneTriggeredMember" xlink:href="dnli-20210331.xsd#dnli_MilestoneTriggeredMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_MilestoneTriggeredMember" xlink:to="lab_dnli_MilestoneTriggeredMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3ca917e4-a29d-4aba-9b36-988b1965ddbd_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2888e78f-a489-4b67-9349-07ff1aaf5360_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_50a05272-2755-4198-8a93-8dc84654b240_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_795e1bbe-f9d2-4ae0-a4c1-6e460135f021_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_CollaborativeRevenueAbstract_348211d5-b725-451a-8ac9-e773487e1c2d_terseLabel_en-US" xlink:label="lab_dnli_CollaborativeRevenueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration revenue:</link:label>
    <link:label id="lab_dnli_CollaborativeRevenueAbstract_label_en-US" xlink:label="lab_dnli_CollaborativeRevenueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Revenue [Abstract]</link:label>
    <link:label id="lab_dnli_CollaborativeRevenueAbstract_documentation_en-US" xlink:label="lab_dnli_CollaborativeRevenueAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_CollaborativeRevenueAbstract" xlink:href="dnli-20210331.xsd#dnli_CollaborativeRevenueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_CollaborativeRevenueAbstract" xlink:to="lab_dnli_CollaborativeRevenueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_0eda5a38-a194-46a3-b399-92158a8377df_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax charge in other comprehensive income</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears_354362cf-9118-4643-b8ef-c6ae9d41a950_terseLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Payment to be Received, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears" xlink:to="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_16af538d-231b-4ee4-8c68-feae2b68ae50_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration of Credit Risk and Other Risks and Uncertainties</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_ContractWithCustomerLiabilityFromRelatedPartiesCurrent_a756a7f9-8a91-44db-9e7e-4a6456c718a6_terseLabel_en-US" xlink:label="lab_dnli_ContractWithCustomerLiabilityFromRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related party contract liability, current</link:label>
    <link:label id="lab_dnli_ContractWithCustomerLiabilityFromRelatedPartiesCurrent_label_en-US" xlink:label="lab_dnli_ContractWithCustomerLiabilityFromRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, From Related Parties, Current</link:label>
    <link:label id="lab_dnli_ContractWithCustomerLiabilityFromRelatedPartiesCurrent_documentation_en-US" xlink:label="lab_dnli_ContractWithCustomerLiabilityFromRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, From Related Parties, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_ContractWithCustomerLiabilityFromRelatedPartiesCurrent" xlink:href="dnli-20210331.xsd#dnli_ContractWithCustomerLiabilityFromRelatedPartiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_ContractWithCustomerLiabilityFromRelatedPartiesCurrent" xlink:to="lab_dnli_ContractWithCustomerLiabilityFromRelatedPartiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_AggregateOptionExerciseFee_54e84019-5964-43dd-a9b4-c4f32373e30a_terseLabel_en-US" xlink:label="lab_dnli_AggregateOptionExerciseFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregated option exercise fee</link:label>
    <link:label id="lab_dnli_AggregateOptionExerciseFee_label_en-US" xlink:label="lab_dnli_AggregateOptionExerciseFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Option Exercise Fee</link:label>
    <link:label id="lab_dnli_AggregateOptionExerciseFee_documentation_en-US" xlink:label="lab_dnli_AggregateOptionExerciseFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate option exercise fee.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_AggregateOptionExerciseFee" xlink:href="dnli-20210331.xsd#dnli_AggregateOptionExerciseFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_AggregateOptionExerciseFee" xlink:to="lab_dnli_AggregateOptionExerciseFee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_b11d17db-4e66-4560-a331-a9ceedfc518a_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase price</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_335d54f4-9816-40e2-a252-ac1750b13bcc_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestmentsMember_a85bbbdb-e5ee-44b5-a7cd-dd7719d695c3_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term marketable securities</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestmentsMember_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Investments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestmentsMember" xlink:to="lab_us-gaap_ShortTermInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_61142315-32c7-4f97-8cf0-e0603ae4c938_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_7f0b11a7-b918-4b4b-9dbb-7a46aff29813_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_0d0a2f26-42a6-4e45-94a9-f38b764890cb_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis" xlink:to="lab_us-gaap_InvestmentTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_a1a10f27-e911-4a83-8c5d-9e49f08db2d6_negatedLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net amortization of discounts on marketable securities</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Net, Amortization of Discount and Premium</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:to="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_997378a3-526d-4a39-a8ab-432f4f70d349_negatedLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value adjustment</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_b5c90815-1d2e-4d86-bb26-a72199dd8616_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate fair value, unrealized holding loss position</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_NumberOfIndications_cf7ea926-0446-476d-a57d-ab7d71eacf9a_terseLabel_en-US" xlink:label="lab_dnli_NumberOfIndications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of indications</link:label>
    <link:label id="lab_dnli_NumberOfIndications_label_en-US" xlink:label="lab_dnli_NumberOfIndications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Indications</link:label>
    <link:label id="lab_dnli_NumberOfIndications_documentation_en-US" xlink:label="lab_dnli_NumberOfIndications" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Indications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_NumberOfIndications" xlink:href="dnli-20210331.xsd#dnli_NumberOfIndications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_NumberOfIndications" xlink:to="lab_dnli_NumberOfIndications" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_LongTermMarketableSecuritiesMember_4927bafd-b162-4781-9932-df1711c6bf52_terseLabel_en-US" xlink:label="lab_dnli_LongTermMarketableSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term marketable securities</link:label>
    <link:label id="lab_dnli_LongTermMarketableSecuritiesMember_label_en-US" xlink:label="lab_dnli_LongTermMarketableSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Marketable Securities [Member]</link:label>
    <link:label id="lab_dnli_LongTermMarketableSecuritiesMember_documentation_en-US" xlink:label="lab_dnli_LongTermMarketableSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long term marketable securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_LongTermMarketableSecuritiesMember" xlink:href="dnli-20210331.xsd#dnli_LongTermMarketableSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_LongTermMarketableSecuritiesMember" xlink:to="lab_dnli_LongTermMarketableSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_9ee1f434-9d64-470a-a432-3cb4f3a6e1eb_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue recognized included in the contract liability balance at the beginning of the year</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_PreclinicalMilestonePaymentPerProgram_46230fd1-5dea-4286-9b44-5291f9b50ef1_terseLabel_en-US" xlink:label="lab_dnli_PreclinicalMilestonePaymentPerProgram" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preclinical milestone payments per program</link:label>
    <link:label id="lab_dnli_PreclinicalMilestonePaymentPerProgram_label_en-US" xlink:label="lab_dnli_PreclinicalMilestonePaymentPerProgram" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preclinical Milestone Payment Per Program</link:label>
    <link:label id="lab_dnli_PreclinicalMilestonePaymentPerProgram_documentation_en-US" xlink:label="lab_dnli_PreclinicalMilestonePaymentPerProgram" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments due upon achievement of certain preclinical milestone events per program.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_PreclinicalMilestonePaymentPerProgram" xlink:href="dnli-20210331.xsd#dnli_PreclinicalMilestonePaymentPerProgram"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_PreclinicalMilestonePaymentPerProgram" xlink:to="lab_dnli_PreclinicalMilestonePaymentPerProgram" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsIncurredDevelopmentCosts_61479bc9-f8b6-4731-a800-5e47592f1e74_terseLabel_en-US" xlink:label="lab_us-gaap_CostsIncurredDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs incurred</link:label>
    <link:label id="lab_us-gaap_CostsIncurredDevelopmentCosts_label_en-US" xlink:label="lab_us-gaap_CostsIncurredDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs Incurred, Development Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsIncurredDevelopmentCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsIncurredDevelopmentCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsIncurredDevelopmentCosts" xlink:to="lab_us-gaap_CostsIncurredDevelopmentCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_4c2d6560-72c8-4ef3-880b-fe87abb51940_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b5dcc028-d9d8-43b7-8b4e-eb5551de6d35_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_c1680c1a-07bc-4466-9dc9-1086d593ba32_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_edb19995-df52-458d-ba82-7cb08b072920_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_CollaborativeArrangementNumberOfAdditionalProgramsIfCircumstancesMet_1e7136a7-fe46-4d58-878c-69aa98d60633_terseLabel_en-US" xlink:label="lab_dnli_CollaborativeArrangementNumberOfAdditionalProgramsIfCircumstancesMet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of additional programs, if circumstances met</link:label>
    <link:label id="lab_dnli_CollaborativeArrangementNumberOfAdditionalProgramsIfCircumstancesMet_label_en-US" xlink:label="lab_dnli_CollaborativeArrangementNumberOfAdditionalProgramsIfCircumstancesMet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Number Of Additional Programs, If Circumstances Met</link:label>
    <link:label id="lab_dnli_CollaborativeArrangementNumberOfAdditionalProgramsIfCircumstancesMet_documentation_en-US" xlink:label="lab_dnli_CollaborativeArrangementNumberOfAdditionalProgramsIfCircumstancesMet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Number Of Additional Programs, If Circumstances Met</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_CollaborativeArrangementNumberOfAdditionalProgramsIfCircumstancesMet" xlink:href="dnli-20210331.xsd#dnli_CollaborativeArrangementNumberOfAdditionalProgramsIfCircumstancesMet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_CollaborativeArrangementNumberOfAdditionalProgramsIfCircumstancesMet" xlink:to="lab_dnli_CollaborativeArrangementNumberOfAdditionalProgramsIfCircumstancesMet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_6aa3e9bc-7022-4f06-9ffe-2a19cd6de534_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Commitment, Excluding Long-term Commitment [Domain]</link:label>
    <link:label id="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_label_en-US" xlink:label="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Commitment, Excluding Long-term Commitment [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:to="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_1e978a63-ac4d-432c-904b-e6cd715189e4_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_973b073a-9ae5-4690-b1ac-cd4c5602ee0e_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_TransportVehicleTechnologyProgramRightOfFirstNegotiationProgramsMember_d7459fe1-9844-44f8-a55e-81bd7240e894_terseLabel_en-US" xlink:label="lab_dnli_TransportVehicleTechnologyProgramRightOfFirstNegotiationProgramsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transport Vehicle (TV) Technology Program, Unnamed Program, Right Of First Negotiation Programs (ROFN)</link:label>
    <link:label id="lab_dnli_TransportVehicleTechnologyProgramRightOfFirstNegotiationProgramsMember_label_en-US" xlink:label="lab_dnli_TransportVehicleTechnologyProgramRightOfFirstNegotiationProgramsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transport Vehicle Technology Program, Right Of First Negotiation Programs [Member]</link:label>
    <link:label id="lab_dnli_TransportVehicleTechnologyProgramRightOfFirstNegotiationProgramsMember_documentation_en-US" xlink:label="lab_dnli_TransportVehicleTechnologyProgramRightOfFirstNegotiationProgramsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transport Vehicle Technology Program, Unnamed Program, Right Of First Negotiation Programs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_TransportVehicleTechnologyProgramRightOfFirstNegotiationProgramsMember" xlink:href="dnli-20210331.xsd#dnli_TransportVehicleTechnologyProgramRightOfFirstNegotiationProgramsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_TransportVehicleTechnologyProgramRightOfFirstNegotiationProgramsMember" xlink:to="lab_dnli_TransportVehicleTechnologyProgramRightOfFirstNegotiationProgramsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContingentConsiderationByTypeAxis_eb505ea9-89c2-4181-838d-3977df33a1f6_terseLabel_en-US" xlink:label="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration by Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ContingentConsiderationByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration by Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis" xlink:to="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilities_46e50c9c-40dd-4fd5-a3b0-f2725353b2b6_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency derivative contracts</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilities_808fa70c-0822-486d-a234-7ddab8652276_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative liability</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilities_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilities" xlink:to="lab_us-gaap_DerivativeLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3334294f-2a5f-4f73-b881-4f8b9e903810_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_003894a4-4181-4aec-bebf-835da077b4d4_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_f47f4b26-37da-4a54-b858-c01d09366ea6_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_76ce47a5-21cb-4aaa-99f6-c204297362a2_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_AggregateCommercialMilestones_5afd96b1-8e84-4a88-bbaa-ce441f336bd9_terseLabel_en-US" xlink:label="lab_dnli_AggregateCommercialMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payments upon achievement of biologic product from each program</link:label>
    <link:label id="lab_dnli_AggregateCommercialMilestones_label_en-US" xlink:label="lab_dnli_AggregateCommercialMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Commercial Milestones</link:label>
    <link:label id="lab_dnli_AggregateCommercialMilestones_documentation_en-US" xlink:label="lab_dnli_AggregateCommercialMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate commercial milestones if one biologic product from each program achieves the milestone.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_AggregateCommercialMilestones" xlink:href="dnli-20210331.xsd#dnli_AggregateCommercialMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_AggregateCommercialMilestones" xlink:to="lab_dnli_AggregateCommercialMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_GenentechIncMember_da022ad6-82b0-4824-824a-83b89b0eddda_terseLabel_en-US" xlink:label="lab_dnli_GenentechIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Genentech Inc</link:label>
    <link:label id="lab_dnli_GenentechIncMember_label_en-US" xlink:label="lab_dnli_GenentechIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Genentech Inc [Member]</link:label>
    <link:label id="lab_dnli_GenentechIncMember_documentation_en-US" xlink:label="lab_dnli_GenentechIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Genentech Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_GenentechIncMember" xlink:href="dnli-20210331.xsd#dnli_GenentechIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_GenentechIncMember" xlink:to="lab_dnli_GenentechIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_34d35e91-39a6-4536-97d3-a4fc837300eb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_dd2eabcb-8966-4f2b-b39b-c170de77f43e_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueExpectedToVest_254b5609-9294-40f0-88b1-5de3afdf4631_terseLabel_en-US" xlink:label="lab_dnli_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueExpectedToVest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected to vest (usd per share)</link:label>
    <link:label id="lab_dnli_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueExpectedToVest_label_en-US" xlink:label="lab_dnli_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueExpectedToVest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value Expected To Vest</link:label>
    <link:label id="lab_dnli_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueExpectedToVest_documentation_en-US" xlink:label="lab_dnli_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueExpectedToVest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based compensation arrangement by share based payment award equity instruments other than options nonvested weighted average grant date fair value expected to vest.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueExpectedToVest" xlink:href="dnli-20210331.xsd#dnli_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueExpectedToVest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueExpectedToVest" xlink:to="lab_dnli_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueExpectedToVest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_b7ab3e62-2002-4135-a11c-0f9359cf9b38_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2dffcfb2-4bce-496d-96b6-291919c3ae99_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_044342bc-993d-4b06-bacd-28aac8c88328_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_e75ec7bf-7561-46bc-9f2a-2e464a8b0cf4_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_c939c528-b1bf-40e7-9b7c-933ab6b7c1d4_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ed63479e-31d9-4445-a941-86d7a1ccdd72_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ccde81e1-6770-4c5f-829f-bf67a90448dc_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_OperatingLeasesSubleaseNetRentableArea_be103caf-4f68-45be-b680-fe6ab5ac8306_terseLabel_en-US" xlink:label="lab_dnli_OperatingLeasesSubleaseNetRentableArea" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rentable square feet</link:label>
    <link:label id="lab_dnli_OperatingLeasesSubleaseNetRentableArea_label_en-US" xlink:label="lab_dnli_OperatingLeasesSubleaseNetRentableArea" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Sublease, Net Rentable Area</link:label>
    <link:label id="lab_dnli_OperatingLeasesSubleaseNetRentableArea_documentation_en-US" xlink:label="lab_dnli_OperatingLeasesSubleaseNetRentableArea" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Sublease, Net Rentable Area</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_OperatingLeasesSubleaseNetRentableArea" xlink:href="dnli-20210331.xsd#dnli_OperatingLeasesSubleaseNetRentableArea"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_OperatingLeasesSubleaseNetRentableArea" xlink:to="lab_dnli_OperatingLeasesSubleaseNetRentableArea" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_OptionServicesMember_c822f0e4-6d41-46a3-bdd9-61e39e721dcc_terseLabel_en-US" xlink:label="lab_dnli_OptionServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option Research Services</link:label>
    <link:label id="lab_dnli_OptionServicesMember_label_en-US" xlink:label="lab_dnli_OptionServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option Services [Member]</link:label>
    <link:label id="lab_dnli_OptionServicesMember_documentation_en-US" xlink:label="lab_dnli_OptionServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_OptionServicesMember" xlink:href="dnli-20210331.xsd#dnli_OptionServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_OptionServicesMember" xlink:to="lab_dnli_OptionServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_ForeignExchangeForwardBritishPoundsMember_19604418-b46a-4215-a082-d73fba092b2f_terseLabel_en-US" xlink:label="lab_dnli_ForeignExchangeForwardBritishPoundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">British Pounds</link:label>
    <link:label id="lab_dnli_ForeignExchangeForwardBritishPoundsMember_label_en-US" xlink:label="lab_dnli_ForeignExchangeForwardBritishPoundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Exchange Forward - British Pounds [Member]</link:label>
    <link:label id="lab_dnli_ForeignExchangeForwardBritishPoundsMember_documentation_en-US" xlink:label="lab_dnli_ForeignExchangeForwardBritishPoundsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Exchange Forward - British Pounds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_ForeignExchangeForwardBritishPoundsMember" xlink:href="dnli-20210331.xsd#dnli_ForeignExchangeForwardBritishPoundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_ForeignExchangeForwardBritishPoundsMember" xlink:to="lab_dnli_ForeignExchangeForwardBritishPoundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_b9b9f059-44cd-44f1-a3fa-6f4d9ef0d397_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liability, less current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_4ba0722e-6439-4357-b0fe-c9a77828c3bd_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_NetSalesBasedMilestonePayments_70b209ce-f72b-44ed-b523-f31ee310ceaa_terseLabel_en-US" xlink:label="lab_dnli_NetSalesBasedMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net sales-based milestone payments</link:label>
    <link:label id="lab_dnli_NetSalesBasedMilestonePayments_label_en-US" xlink:label="lab_dnli_NetSalesBasedMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Sales Based Milestone Payments</link:label>
    <link:label id="lab_dnli_NetSalesBasedMilestonePayments_documentation_en-US" xlink:label="lab_dnli_NetSalesBasedMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Sales Based Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_NetSalesBasedMilestonePayments" xlink:href="dnli-20210331.xsd#dnli_NetSalesBasedMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_NetSalesBasedMilestonePayments" xlink:to="lab_dnli_NetSalesBasedMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_PaymentsForManufacturingCost_85dbca4e-1058-4993-9614-4ea457366198_terseLabel_en-US" xlink:label="lab_dnli_PaymentsForManufacturingCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for development and manufacturing services</link:label>
    <link:label id="lab_dnli_PaymentsForManufacturingCost_label_en-US" xlink:label="lab_dnli_PaymentsForManufacturingCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Manufacturing Cost</link:label>
    <link:label id="lab_dnli_PaymentsForManufacturingCost_documentation_en-US" xlink:label="lab_dnli_PaymentsForManufacturingCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for manufacturing cost.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_PaymentsForManufacturingCost" xlink:href="dnli-20210331.xsd#dnli_PaymentsForManufacturingCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_PaymentsForManufacturingCost" xlink:to="lab_dnli_PaymentsForManufacturingCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_8539aeec-2220-4160-9eeb-0e5a899ddbce_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_8ea63015-807a-4ffc-8e75-60ab32d4e402_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_AggregateDevelopmentMilestonePayment_68b4bb99-53ec-411f-9593-a27ea49b1d49_terseLabel_en-US" xlink:label="lab_dnli_AggregateDevelopmentMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total aggregate payments due upon achievement of certain clinical and regulatory milestone events</link:label>
    <link:label id="lab_dnli_AggregateDevelopmentMilestonePayment_label_en-US" xlink:label="lab_dnli_AggregateDevelopmentMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Development Milestone Payment</link:label>
    <link:label id="lab_dnli_AggregateDevelopmentMilestonePayment_documentation_en-US" xlink:label="lab_dnli_AggregateDevelopmentMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate development milestone payment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_AggregateDevelopmentMilestonePayment" xlink:href="dnli-20210331.xsd#dnli_AggregateDevelopmentMilestonePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_AggregateDevelopmentMilestonePayment" xlink:to="lab_dnli_AggregateDevelopmentMilestonePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_TakedaCollaborationAgreementMember_470cffac-0334-4007-912d-c3407b863f34_terseLabel_en-US" xlink:label="lab_dnli_TakedaCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Takeda Collaboration Agreement</link:label>
    <link:label id="lab_dnli_TakedaCollaborationAgreementMember_label_en-US" xlink:label="lab_dnli_TakedaCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Takeda Collaboration Agreement [Member]</link:label>
    <link:label id="lab_dnli_TakedaCollaborationAgreementMember_documentation_en-US" xlink:label="lab_dnli_TakedaCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Takeda Collaboration Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_TakedaCollaborationAgreementMember" xlink:href="dnli-20210331.xsd#dnli_TakedaCollaborationAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_TakedaCollaborationAgreementMember" xlink:to="lab_dnli_TakedaCollaborationAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_dae0e607-0312-418c-96d3-a0ed6e218f45_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_LongTermInvestmentsMember_d5ee837f-37cd-465d-944e-6cd3aeacce3b_terseLabel_en-US" xlink:label="lab_dnli_LongTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term marketable securities</link:label>
    <link:label id="lab_dnli_LongTermInvestmentsMember_label_en-US" xlink:label="lab_dnli_LongTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Investments [Member]</link:label>
    <link:label id="lab_dnli_LongTermInvestmentsMember_documentation_en-US" xlink:label="lab_dnli_LongTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long term investments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_LongTermInvestmentsMember" xlink:href="dnli-20210331.xsd#dnli_LongTermInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_LongTermInvestmentsMember" xlink:to="lab_dnli_LongTermInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_5c9d3f9f-29a1-4ee0-bbe0-369a46a5a5d6_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_42580d55-265c-4e93-b000-edcfb3f55503_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_065f56cd-c970-48a5-b574-d5b2e27bdc88_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible preferred stock, par value (usd per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_3baa7ce2-ff46-48e8-a9f0-d99e172b5a9a_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_16a65405-abb2-4c39-9d0f-7d1e639fc754_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_cab2d56a-33be-4cc6-b3c0-f8d830b28e4e_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_7a369a96-e1ba-4b9f-9ec8-aac1edb4c55e_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_18a290fa-38b3-4b72-9a9e-74459d0815e1_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_85ad2a02-b7db-4b42-bc5f-5e41330f7806_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_BiogenMember_2edc6139-416e-4a23-8eb6-40426face6ec_terseLabel_en-US" xlink:label="lab_dnli_BiogenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biogen Collaboration Agreement</link:label>
    <link:label id="lab_dnli_BiogenMember_52ad649b-0560-4dbe-8469-976b3805ab41_verboseLabel_en-US" xlink:label="lab_dnli_BiogenMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biogen</link:label>
    <link:label id="lab_dnli_BiogenMember_label_en-US" xlink:label="lab_dnli_BiogenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biogen [Member]</link:label>
    <link:label id="lab_dnli_BiogenMember_documentation_en-US" xlink:label="lab_dnli_BiogenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biogen</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_BiogenMember" xlink:href="dnli-20210331.xsd#dnli_BiogenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_BiogenMember" xlink:to="lab_dnli_BiogenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DueFromRelatedPartiesCurrent_c9ab1d02-e1cd-4e55-be1c-51c60ee75b74_terseLabel_en-US" xlink:label="lab_us-gaap_DueFromRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost sharing reimbursements due from related party</link:label>
    <link:label id="lab_us-gaap_DueFromRelatedPartiesCurrent_label_en-US" xlink:label="lab_us-gaap_DueFromRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due from Related Parties, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueFromRelatedPartiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueFromRelatedPartiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueFromRelatedPartiesCurrent" xlink:to="lab_us-gaap_DueFromRelatedPartiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_d087b1a9-66bd-4ec1-9412-b2dcac5b6eaf_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for credit losses</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_66c3766a-bf6d-4de9-9bb4-facb1826485a_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Collaboration Revenue</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_79f7e0e9-5572-4e4f-8d86-0dde9aaa2d2e_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease period</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_9f9ffaa7-dda7-48af-9c26-3b77bb11de92_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationAxis" xlink:to="lab_us-gaap_HedgingDesignationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_d517374a-37a0-46f7-8c7d-1a0097b73cf0_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase (decrease) in cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_OtherAccruedManufacturingCostsCurrent_462e2be1-f182-4470-a7af-e1918d186c12_terseLabel_en-US" xlink:label="lab_dnli_OtherAccruedManufacturingCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued manufacturing costs</link:label>
    <link:label id="lab_dnli_OtherAccruedManufacturingCostsCurrent_label_en-US" xlink:label="lab_dnli_OtherAccruedManufacturingCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Manufacturing Costs, Current</link:label>
    <link:label id="lab_dnli_OtherAccruedManufacturingCostsCurrent_documentation_en-US" xlink:label="lab_dnli_OtherAccruedManufacturingCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Manufacturing Costs, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_OtherAccruedManufacturingCostsCurrent" xlink:href="dnli-20210331.xsd#dnli_OtherAccruedManufacturingCostsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_OtherAccruedManufacturingCostsCurrent" xlink:to="lab_dnli_OtherAccruedManufacturingCostsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_c849e829-2555-4ebc-aeee-8e67750ff57a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock&#8211;based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_fd74353c-d675-4ef1-8242-e2a988acad1c_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_LicenseAgreementTextBlock_d053903d-2476-465d-ad9a-54343bbefd5e_terseLabel_en-US" xlink:label="lab_dnli_LicenseAgreementTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreements</link:label>
    <link:label id="lab_dnli_LicenseAgreementTextBlock_label_en-US" xlink:label="lab_dnli_LicenseAgreementTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement [Text Block]</link:label>
    <link:label id="lab_dnli_LicenseAgreementTextBlock_documentation_en-US" xlink:label="lab_dnli_LicenseAgreementTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_LicenseAgreementTextBlock" xlink:href="dnli-20210331.xsd#dnli_LicenseAgreementTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_LicenseAgreementTextBlock" xlink:to="lab_dnli_LicenseAgreementTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_623dfc55-6b57-4bb5-81a7-92aa2f3aeae9_terseLabel_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as Hedging Instrument</link:label>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_label_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:to="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_AggregateClinicalRegulatoryAndSalesMilestonePayment_d305f052-628d-41f5-82c4-065881c8103c_terseLabel_en-US" xlink:label="lab_dnli_AggregateClinicalRegulatoryAndSalesMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payments upon achievement of certain clinical, regulatory and sales milestone events</link:label>
    <link:label id="lab_dnli_AggregateClinicalRegulatoryAndSalesMilestonePayment_label_en-US" xlink:label="lab_dnli_AggregateClinicalRegulatoryAndSalesMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Clinical Regulatory And Sales Milestone Payment</link:label>
    <link:label id="lab_dnli_AggregateClinicalRegulatoryAndSalesMilestonePayment_documentation_en-US" xlink:label="lab_dnli_AggregateClinicalRegulatoryAndSalesMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Clinical Regulatory And Sales Milestone Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_AggregateClinicalRegulatoryAndSalesMilestonePayment" xlink:href="dnli-20210331.xsd#dnli_AggregateClinicalRegulatoryAndSalesMilestonePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_AggregateClinicalRegulatoryAndSalesMilestonePayment" xlink:to="lab_dnli_AggregateClinicalRegulatoryAndSalesMilestonePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_5e6b3cd2-1371-4446-bd07-f723b67a8850_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_CollaborativeArrangementOptionExerciseAndDevelopmentMilestonePaymentsToBeReceived_4f0e59d9-1ef3-453d-ad36-d4431b921261_terseLabel_en-US" xlink:label="lab_dnli_CollaborativeArrangementOptionExerciseAndDevelopmentMilestonePaymentsToBeReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate option exercise and development milestone payments, to be received</link:label>
    <link:label id="lab_dnli_CollaborativeArrangementOptionExerciseAndDevelopmentMilestonePaymentsToBeReceived_label_en-US" xlink:label="lab_dnli_CollaborativeArrangementOptionExerciseAndDevelopmentMilestonePaymentsToBeReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Option Exercise And Development Milestone Payments, To Be Received</link:label>
    <link:label id="lab_dnli_CollaborativeArrangementOptionExerciseAndDevelopmentMilestonePaymentsToBeReceived_documentation_en-US" xlink:label="lab_dnli_CollaborativeArrangementOptionExerciseAndDevelopmentMilestonePaymentsToBeReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Option Exercise And Development Milestone Payments, To Be Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_CollaborativeArrangementOptionExerciseAndDevelopmentMilestonePaymentsToBeReceived" xlink:href="dnli-20210331.xsd#dnli_CollaborativeArrangementOptionExerciseAndDevelopmentMilestonePaymentsToBeReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_CollaborativeArrangementOptionExerciseAndDevelopmentMilestonePaymentsToBeReceived" xlink:to="lab_dnli_CollaborativeArrangementOptionExerciseAndDevelopmentMilestonePaymentsToBeReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_AffiliatedEntityMember_99505259-bf53-4044-a60d-7d5c55456483_terseLabel_en-US" xlink:label="lab_srt_AffiliatedEntityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party</link:label>
    <link:label id="lab_srt_AffiliatedEntityMember_label_en-US" xlink:label="lab_srt_AffiliatedEntityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliated Entity [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_AffiliatedEntityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_AffiliatedEntityMember" xlink:to="lab_srt_AffiliatedEntityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_5195fc17-81aa-4046-aeb9-d29ecc908a2f_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_TenantImprovementAllowanceRepayableAsRent_137ad4eb-edc4-42f4-a32e-e06ddbf5888c_terseLabel_en-US" xlink:label="lab_dnli_TenantImprovementAllowanceRepayableAsRent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tenant improvement allowance repayable in rent</link:label>
    <link:label id="lab_dnli_TenantImprovementAllowanceRepayableAsRent_label_en-US" xlink:label="lab_dnli_TenantImprovementAllowanceRepayableAsRent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tenant Improvement Allowance Repayable As Rent</link:label>
    <link:label id="lab_dnli_TenantImprovementAllowanceRepayableAsRent_documentation_en-US" xlink:label="lab_dnli_TenantImprovementAllowanceRepayableAsRent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion of tenant improvement allowance repayable to landlord in future rent.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_TenantImprovementAllowanceRepayableAsRent" xlink:href="dnli-20210331.xsd#dnli_TenantImprovementAllowanceRepayableAsRent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_TenantImprovementAllowanceRepayableAsRent" xlink:to="lab_dnli_TenantImprovementAllowanceRepayableAsRent" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_CNSProductMember_3ad23ac1-bac6-4361-9b85-4545fb5f6d54_terseLabel_en-US" xlink:label="lab_dnli_CNSProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CNS Product</link:label>
    <link:label id="lab_dnli_CNSProductMember_label_en-US" xlink:label="lab_dnli_CNSProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CNS Product [Member]</link:label>
    <link:label id="lab_dnli_CNSProductMember_documentation_en-US" xlink:label="lab_dnli_CNSProductMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CNS Product</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_CNSProductMember" xlink:href="dnli-20210331.xsd#dnli_CNSProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_CNSProductMember" xlink:to="lab_dnli_CNSProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_d909d20f-0f9d-4fa1-8eff-515b9c9b55e5_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_811c6aa4-f2d2-4c68-a2a1-b1b7050b0d43_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_48e81b28-15ab-4f33-8b0d-4db55fdc6adf_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_IncreaseDecreaseInContractWithCustomerLiabilityRelatedParties_66c271fa-a0a4-4843-86dc-61befd5f3c45_terseLabel_en-US" xlink:label="lab_dnli_IncreaseDecreaseInContractWithCustomerLiabilityRelatedParties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related party contract liability</link:label>
    <link:label id="lab_dnli_IncreaseDecreaseInContractWithCustomerLiabilityRelatedParties_label_en-US" xlink:label="lab_dnli_IncreaseDecreaseInContractWithCustomerLiabilityRelatedParties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability, Related Parties</link:label>
    <link:label id="lab_dnli_IncreaseDecreaseInContractWithCustomerLiabilityRelatedParties_documentation_en-US" xlink:label="lab_dnli_IncreaseDecreaseInContractWithCustomerLiabilityRelatedParties" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability, Related Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_IncreaseDecreaseInContractWithCustomerLiabilityRelatedParties" xlink:href="dnli-20210331.xsd#dnli_IncreaseDecreaseInContractWithCustomerLiabilityRelatedParties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_IncreaseDecreaseInContractWithCustomerLiabilityRelatedParties" xlink:to="lab_dnli_IncreaseDecreaseInContractWithCustomerLiabilityRelatedParties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5ba5acee-af0e-429e-9dca-0e66ec7db5ad_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_bee021ff-0062-404f-b0a6-6864eb023570_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_53229351-da94-4c77-bcdc-b47986d198ef_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_NumberOfTargets_e2be8bb8-e0e4-42ff-8b1b-f5450b774c4d_terseLabel_en-US" xlink:label="lab_dnli_NumberOfTargets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of targets</link:label>
    <link:label id="lab_dnli_NumberOfTargets_label_en-US" xlink:label="lab_dnli_NumberOfTargets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Targets</link:label>
    <link:label id="lab_dnli_NumberOfTargets_documentation_en-US" xlink:label="lab_dnli_NumberOfTargets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Targets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_NumberOfTargets" xlink:href="dnli-20210331.xsd#dnli_NumberOfTargets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_NumberOfTargets" xlink:to="lab_dnli_NumberOfTargets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_eedbff7e-8b51-4263-a48a-6c4831ebb042_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liability, current</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_ForeignExchangeForwardEurosMember_95439be2-4b87-45f0-93d2-7492358255f7_terseLabel_en-US" xlink:label="lab_dnli_ForeignExchangeForwardEurosMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Euros</link:label>
    <link:label id="lab_dnli_ForeignExchangeForwardEurosMember_label_en-US" xlink:label="lab_dnli_ForeignExchangeForwardEurosMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Exchange Forward - Euros [Member]</link:label>
    <link:label id="lab_dnli_ForeignExchangeForwardEurosMember_documentation_en-US" xlink:label="lab_dnli_ForeignExchangeForwardEurosMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Exchange Forward - Euros [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_ForeignExchangeForwardEurosMember" xlink:href="dnli-20210331.xsd#dnli_ForeignExchangeForwardEurosMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_ForeignExchangeForwardEurosMember" xlink:to="lab_dnli_ForeignExchangeForwardEurosMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_78a1b7df-4e04-46ab-8ead-216f4906d7f8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_438c5bb3-ea8b-4b9f-bef1-c7e6d4d9e51e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Assumptions Used for Estimating the Fair Value of Stock Granted</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_31ec6376-3068-4b69-9d9c-0dcb30bafed0_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_38b7504c-27da-4662-9d12-89bc43473855_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_68d4215c-f28f-46a0-9414-ec1de6fccf3a_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_7b1ff48a-5190-4fb1-9608-b3b9553eaaae_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_ce90e2be-971e-43dc-a4a9-87b22c20364e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseObligation_eddd22a8-b155-4d20-8d81-59f0bfc8adb0_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-refundable purchase commitments</link:label>
    <link:label id="lab_us-gaap_PurchaseObligation_label_en-US" xlink:label="lab_us-gaap_PurchaseObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PurchaseObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseObligation" xlink:to="lab_us-gaap_PurchaseObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_d25080a9-0e84-4346-b847-878ff5e84b61_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeTable_e18217c1-d8d3-4029-9df0-4ca0f81efbc4_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeTable_label_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeTable" xlink:to="lab_us-gaap_DerivativeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_dd1e9e4f-105c-4b37-876d-be6dfb4cc7d2_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_744ded85-396d-4e85-899e-a4fa0aa86e3e_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_LandlordFundedTenantImprovementsMember_2353db3c-dc2d-4d8e-8ac3-16c62ad78d46_terseLabel_en-US" xlink:label="lab_dnli_LandlordFundedTenantImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Landlord Funded Tenant Improvements</link:label>
    <link:label id="lab_dnli_LandlordFundedTenantImprovementsMember_label_en-US" xlink:label="lab_dnli_LandlordFundedTenantImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Landlord Funded Tenant Improvements [Member]</link:label>
    <link:label id="lab_dnli_LandlordFundedTenantImprovementsMember_documentation_en-US" xlink:label="lab_dnli_LandlordFundedTenantImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Landlord funded tenant improvements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_LandlordFundedTenantImprovementsMember" xlink:href="dnli-20210331.xsd#dnli_LandlordFundedTenantImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_LandlordFundedTenantImprovementsMember" xlink:to="lab_dnli_LandlordFundedTenantImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_41604b2e-7790-4bb0-b127-3d4f96829dc6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of RSU shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_CollaborativeArrangementNetSalesBasedMilestonePaymentsToBeReceived_a1b8243a-99db-4d4e-b465-9e5f58f3f50f_terseLabel_en-US" xlink:label="lab_dnli_CollaborativeArrangementNetSalesBasedMilestonePaymentsToBeReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net sales-based milestone payments, to be received</link:label>
    <link:label id="lab_dnli_CollaborativeArrangementNetSalesBasedMilestonePaymentsToBeReceived_label_en-US" xlink:label="lab_dnli_CollaborativeArrangementNetSalesBasedMilestonePaymentsToBeReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Net Sales-Based Milestone Payments, To Be Received</link:label>
    <link:label id="lab_dnli_CollaborativeArrangementNetSalesBasedMilestonePaymentsToBeReceived_documentation_en-US" xlink:label="lab_dnli_CollaborativeArrangementNetSalesBasedMilestonePaymentsToBeReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Net Sales-Based Milestone Payments, To Be Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_CollaborativeArrangementNetSalesBasedMilestonePaymentsToBeReceived" xlink:href="dnli-20210331.xsd#dnli_CollaborativeArrangementNetSalesBasedMilestonePaymentsToBeReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_CollaborativeArrangementNetSalesBasedMilestonePaymentsToBeReceived" xlink:to="lab_dnli_CollaborativeArrangementNetSalesBasedMilestonePaymentsToBeReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_122496bb-2117-44c4-821e-bb4828358414_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Exercise&#160;Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_CollaborativeArrangementATVTREM2Member_b0174f69-fdf1-4d8b-bb0c-1c01e196a0ad_terseLabel_en-US" xlink:label="lab_dnli_CollaborativeArrangementATVTREM2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, ATV:TREM2</link:label>
    <link:label id="lab_dnli_CollaborativeArrangementATVTREM2Member_label_en-US" xlink:label="lab_dnli_CollaborativeArrangementATVTREM2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, ATV:TREM2 [Member]</link:label>
    <link:label id="lab_dnli_CollaborativeArrangementATVTREM2Member_documentation_en-US" xlink:label="lab_dnli_CollaborativeArrangementATVTREM2Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, ATV:TREM2</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_CollaborativeArrangementATVTREM2Member" xlink:href="dnli-20210331.xsd#dnli_CollaborativeArrangementATVTREM2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_CollaborativeArrangementATVTREM2Member" xlink:to="lab_dnli_CollaborativeArrangementATVTREM2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_SharePurchaseAgreementMember_df0bc51f-e3ed-4e4b-bb78-6725755d5354_terseLabel_en-US" xlink:label="lab_dnli_SharePurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Purchase Agreement</link:label>
    <link:label id="lab_dnli_SharePurchaseAgreementMember_label_en-US" xlink:label="lab_dnli_SharePurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Purchase Agreement [Member]</link:label>
    <link:label id="lab_dnli_SharePurchaseAgreementMember_documentation_en-US" xlink:label="lab_dnli_SharePurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share purchase agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_SharePurchaseAgreementMember" xlink:href="dnli-20210331.xsd#dnli_SharePurchaseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_SharePurchaseAgreementMember" xlink:to="lab_dnli_SharePurchaseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_RestrictedSharesSubjectToFutureVestingMember_bd613073-8fce-404d-8da3-ec0b38beca75_terseLabel_en-US" xlink:label="lab_dnli_RestrictedSharesSubjectToFutureVestingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted shares subject to future vesting</link:label>
    <link:label id="lab_dnli_RestrictedSharesSubjectToFutureVestingMember_label_en-US" xlink:label="lab_dnli_RestrictedSharesSubjectToFutureVestingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted shares subject to future vesting [Member]</link:label>
    <link:label id="lab_dnli_RestrictedSharesSubjectToFutureVestingMember_documentation_en-US" xlink:label="lab_dnli_RestrictedSharesSubjectToFutureVestingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted shares subject to future vesting.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_RestrictedSharesSubjectToFutureVestingMember" xlink:href="dnli-20210331.xsd#dnli_RestrictedSharesSubjectToFutureVestingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_RestrictedSharesSubjectToFutureVestingMember" xlink:to="lab_dnli_RestrictedSharesSubjectToFutureVestingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_d4bf989e-8abf-478b-93fe-ca6957e3e0b5_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_fa8edfcc-ca25-4681-8471-7170d017aa80_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_CollaborativeArrangementNumberOfPrograms_df328b93-49af-4fa1-ad81-e93bdaaafc2c_terseLabel_en-US" xlink:label="lab_dnli_CollaborativeArrangementNumberOfPrograms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of programs</link:label>
    <link:label id="lab_dnli_CollaborativeArrangementNumberOfPrograms_label_en-US" xlink:label="lab_dnli_CollaborativeArrangementNumberOfPrograms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Number Of Programs</link:label>
    <link:label id="lab_dnli_CollaborativeArrangementNumberOfPrograms_documentation_en-US" xlink:label="lab_dnli_CollaborativeArrangementNumberOfPrograms" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Number Of Programs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_CollaborativeArrangementNumberOfPrograms" xlink:href="dnli-20210331.xsd#dnli_CollaborativeArrangementNumberOfPrograms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_CollaborativeArrangementNumberOfPrograms" xlink:to="lab_dnli_CollaborativeArrangementNumberOfPrograms" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_cec27057-cc23-47a8-b07c-daa33c3ee0bd_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total undiscounted lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_32b212c4-66a9-48c7-b385-983a9f0d2c5d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate, minimum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_MilestoneTriggeredAndRetainedActivitiesMember_43bcac7c-6e35-4d2f-9c0e-17d64e5d887c_terseLabel_en-US" xlink:label="lab_dnli_MilestoneTriggeredAndRetainedActivitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Triggered and Retained Activities</link:label>
    <link:label id="lab_dnli_MilestoneTriggeredAndRetainedActivitiesMember_label_en-US" xlink:label="lab_dnli_MilestoneTriggeredAndRetainedActivitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Triggered And Retained Activities [Member]</link:label>
    <link:label id="lab_dnli_MilestoneTriggeredAndRetainedActivitiesMember_documentation_en-US" xlink:label="lab_dnli_MilestoneTriggeredAndRetainedActivitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Triggered And Retained Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_MilestoneTriggeredAndRetainedActivitiesMember" xlink:href="dnli-20210331.xsd#dnli_MilestoneTriggeredAndRetainedActivitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_MilestoneTriggeredAndRetainedActivitiesMember" xlink:to="lab_dnli_MilestoneTriggeredAndRetainedActivitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_IncreaseDecreaseInNonCashOperatingLeaseExpense_af8bc1b0-4369-4d29-a304-6437d0ca4150_negatedLabel_en-US" xlink:label="lab_dnli_IncreaseDecreaseInNonCashOperatingLeaseExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash adjustment to operating lease expense</link:label>
    <link:label id="lab_dnli_IncreaseDecreaseInNonCashOperatingLeaseExpense_label_en-US" xlink:label="lab_dnli_IncreaseDecreaseInNonCashOperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Non-Cash Operating Lease Expense</link:label>
    <link:label id="lab_dnli_IncreaseDecreaseInNonCashOperatingLeaseExpense_documentation_en-US" xlink:label="lab_dnli_IncreaseDecreaseInNonCashOperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Non-Cash Operating Lease Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_IncreaseDecreaseInNonCashOperatingLeaseExpense" xlink:href="dnli-20210331.xsd#dnli_IncreaseDecreaseInNonCashOperatingLeaseExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_IncreaseDecreaseInNonCashOperatingLeaseExpense" xlink:to="lab_dnli_IncreaseDecreaseInNonCashOperatingLeaseExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_539705d7-a9df-4ba3-8eca-eda4642fc813_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Holding Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_HeadquartersLeaseMember_453e925a-3c81-43c2-8490-f9f38de5075b_terseLabel_en-US" xlink:label="lab_dnli_HeadquartersLeaseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Headquarters Lease</link:label>
    <link:label id="lab_dnli_HeadquartersLeaseMember_label_en-US" xlink:label="lab_dnli_HeadquartersLeaseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Headquarters Lease [Member]</link:label>
    <link:label id="lab_dnli_HeadquartersLeaseMember_documentation_en-US" xlink:label="lab_dnli_HeadquartersLeaseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Headquarters lease.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_HeadquartersLeaseMember" xlink:href="dnli-20210331.xsd#dnli_HeadquartersLeaseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_HeadquartersLeaseMember" xlink:to="lab_dnli_HeadquartersLeaseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_8a929fb4-57a7-4784-8ce0-72ff19963966_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_BiogenCollaborativeArrangementMember_dc100b97-af79-4777-ab85-d0444798f1a0_terseLabel_en-US" xlink:label="lab_dnli_BiogenCollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biogen Collaborative Arrangement</link:label>
    <link:label id="lab_dnli_BiogenCollaborativeArrangementMember_label_en-US" xlink:label="lab_dnli_BiogenCollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biogen Collaborative Arrangement [Member]</link:label>
    <link:label id="lab_dnli_BiogenCollaborativeArrangementMember_documentation_en-US" xlink:label="lab_dnli_BiogenCollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biogen Collaborative Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_BiogenCollaborativeArrangementMember" xlink:href="dnli-20210331.xsd#dnli_BiogenCollaborativeArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_BiogenCollaborativeArrangementMember" xlink:to="lab_dnli_BiogenCollaborativeArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_VariableConsiderationFutureConsideration_49069273-7b00-404d-a2ab-305fd35a379b_terseLabel_en-US" xlink:label="lab_dnli_VariableConsiderationFutureConsideration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable consideration relating to future milestones</link:label>
    <link:label id="lab_dnli_VariableConsiderationFutureConsideration_label_en-US" xlink:label="lab_dnli_VariableConsiderationFutureConsideration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Consideration Future Consideration</link:label>
    <link:label id="lab_dnli_VariableConsiderationFutureConsideration_documentation_en-US" xlink:label="lab_dnli_VariableConsiderationFutureConsideration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable consideration relating to future milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_VariableConsiderationFutureConsideration" xlink:href="dnli-20210331.xsd#dnli_VariableConsiderationFutureConsideration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_VariableConsiderationFutureConsideration" xlink:to="lab_dnli_VariableConsiderationFutureConsideration" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_RegulatoryMember_0810a67f-2c30-439d-a2e9-f17f81cfb202_terseLabel_en-US" xlink:label="lab_dnli_RegulatoryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulatory</link:label>
    <link:label id="lab_dnli_RegulatoryMember_label_en-US" xlink:label="lab_dnli_RegulatoryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulatory [Member]</link:label>
    <link:label id="lab_dnli_RegulatoryMember_documentation_en-US" xlink:label="lab_dnli_RegulatoryMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulatory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_RegulatoryMember" xlink:href="dnli-20210331.xsd#dnli_RegulatoryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_RegulatoryMember" xlink:to="lab_dnli_RegulatoryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_cf158bdc-411d-4a6c-a7e8-f0a239294956_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_70f09ba1-bfa4-48c2-a665-143fc727781e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_eff82fff-5802-4734-9535-5654c8379bfc_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0445fd88-058b-4ee7-93cd-63081117e73e_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_NewPremisesSubleaseAgreementMember_34dd2e1f-843b-4b8f-9e5a-0e5eae91876f_terseLabel_en-US" xlink:label="lab_dnli_NewPremisesSubleaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Premises Sublease Agreement</link:label>
    <link:label id="lab_dnli_NewPremisesSubleaseAgreementMember_label_en-US" xlink:label="lab_dnli_NewPremisesSubleaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Premises Sublease Agreement [Member]</link:label>
    <link:label id="lab_dnli_NewPremisesSubleaseAgreementMember_documentation_en-US" xlink:label="lab_dnli_NewPremisesSubleaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Premises Sublease Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_NewPremisesSubleaseAgreementMember" xlink:href="dnli-20210331.xsd#dnli_NewPremisesSubleaseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_NewPremisesSubleaseAgreementMember" xlink:to="lab_dnli_NewPremisesSubleaseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_cd48a864-e5fa-4405-a586-71f79038b9a9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_a40efd5e-ad64-49a4-95d6-a5a44b34bd26_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_d2a3eab1-e12d-404f-b86f-98e28712ebc4_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_9471a52c-32fe-4b6c-90bf-3ff5b3914e70_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_53d2a40e-ee01-40be-a0f6-7eadd9c1ecc7_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_LicenseAgreementMilestonePaymentUponAchievementOfClinicalAndRegulatoryMilestones_475a6d72-5f10-4916-84a7-956b5a54977e_terseLabel_en-US" xlink:label="lab_dnli_LicenseAgreementMilestonePaymentUponAchievementOfClinicalAndRegulatoryMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payments upon achievement of specified clinical and regulatory milestones</link:label>
    <link:label id="lab_dnli_LicenseAgreementMilestonePaymentUponAchievementOfClinicalAndRegulatoryMilestones_label_en-US" xlink:label="lab_dnli_LicenseAgreementMilestonePaymentUponAchievementOfClinicalAndRegulatoryMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement Milestone Payment Upon Achievement Of Clinical And Regulatory Milestones</link:label>
    <link:label id="lab_dnli_LicenseAgreementMilestonePaymentUponAchievementOfClinicalAndRegulatoryMilestones_documentation_en-US" xlink:label="lab_dnli_LicenseAgreementMilestonePaymentUponAchievementOfClinicalAndRegulatoryMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License agreement milestone payment upon achievement of clinical and regulatory milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_LicenseAgreementMilestonePaymentUponAchievementOfClinicalAndRegulatoryMilestones" xlink:href="dnli-20210331.xsd#dnli_LicenseAgreementMilestonePaymentUponAchievementOfClinicalAndRegulatoryMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_LicenseAgreementMilestonePaymentUponAchievementOfClinicalAndRegulatoryMilestones" xlink:to="lab_dnli_LicenseAgreementMilestonePaymentUponAchievementOfClinicalAndRegulatoryMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_5b705f0a-3a7c-4d3a-ad58-1980a6082204_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_f69733b1-677f-4116-aca0-cdf3d35b22b3_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock issuance costs</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_7a98fb94-010d-4b4c-9b25-d46accae8c1f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_AggregatePreclinicalMilestonePayment_70038464-273c-4bc6-a066-a28b1c701d62_terseLabel_en-US" xlink:label="lab_dnli_AggregatePreclinicalMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total aggregate payments due upon achievement of certain preclinical milestone events</link:label>
    <link:label id="lab_dnli_AggregatePreclinicalMilestonePayment_label_en-US" xlink:label="lab_dnli_AggregatePreclinicalMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Preclinical Milestone Payment</link:label>
    <link:label id="lab_dnli_AggregatePreclinicalMilestonePayment_documentation_en-US" xlink:label="lab_dnli_AggregatePreclinicalMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total aggregate payments due upon achievement of certain preclinical milestone events.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_AggregatePreclinicalMilestonePayment" xlink:href="dnli-20210331.xsd#dnli_AggregatePreclinicalMilestonePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_AggregatePreclinicalMilestonePayment" xlink:to="lab_dnli_AggregatePreclinicalMilestonePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_16be9b43-2f66-4f4f-9432-fa4315cf4e44_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract liabilities, current</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_9e9785cc-9673-4ca5-888f-f615b06aa1a5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_0a6342f2-2c24-42e4-a3c6-03b5f94dc1e4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_b21de8fc-cd21-4bb7-9f81-0874e086cd93_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain" xlink:to="lab_us-gaap_DerivativeContractTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_618f369c-b0dc-4021-a843-8b1dd12eb587_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average number of shares outstanding, diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_ab78bc16-22c4-4afd-8e9d-dbeae24d2191_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share, basic (usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_2c4a9cbe-3d2a-46b2-b506-3577ad56caa2_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_e5f08bc4-8dd3-4f85-9ae2-366a249f08ca_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_39e718ca-7e33-4f10-bfde-6566fb8d3a79_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_ae36ad0c-49f0-4c0f-bdec-ea8c23f09bf7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_013fa54f-dbb5-48b4-9b74-876feeb3aecd_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining lease term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_d06725f5-31c1-4395-84b0-3d0a78fab427_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other collaboration revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_fcee3813-c30e-4ad2-a144-040ff6d70c3d_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative revenue, excluding revenue from contract with customer</link:label>
    <link:label id="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_label_en-US" xlink:label="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:to="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_961f8695-ac64-452c-80e9-1c45a50b24b9_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_CollaborationAgreementTransactionPriceIncreaseDecrease_4cbee7c0-054c-46c9-a814-81da0c27fa91_terseLabel_en-US" xlink:label="lab_dnli_CollaborationAgreementTransactionPriceIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction price, change</link:label>
    <link:label id="lab_dnli_CollaborationAgreementTransactionPriceIncreaseDecrease_label_en-US" xlink:label="lab_dnli_CollaborationAgreementTransactionPriceIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Transaction Price, Increase (Decrease)</link:label>
    <link:label id="lab_dnli_CollaborationAgreementTransactionPriceIncreaseDecrease_documentation_en-US" xlink:label="lab_dnli_CollaborationAgreementTransactionPriceIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Transaction Price, Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_CollaborationAgreementTransactionPriceIncreaseDecrease" xlink:href="dnli-20210331.xsd#dnli_CollaborationAgreementTransactionPriceIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_CollaborationAgreementTransactionPriceIncreaseDecrease" xlink:to="lab_dnli_CollaborationAgreementTransactionPriceIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_8166422a-de27-429e-955c-3198ff200fdd_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_020449eb-cc6a-40ae-b68a-f2f1202c4e3c_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance obligation</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_57925294-6b94-483c-b0e4-5010c7d3f15f_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_0be87c27-9330-4b66-864f-92ead1bf03fc_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_7a403004-f6d2-4a7d-b0c4-c2477119baf7_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_adca740c-e793-4013-815b-0b035429a27c_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.01 par value; 400,000,000 shares authorized as of March 31, 2021 and December 31, 2020; 121,147,432 shares and 120,531,333 shares issued and outstanding as of March 31, 2021 and December 31, 2020, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_9b3dcb92-fda1-4767-97d5-e42c96a0ba69_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_SaleOfStockConsiderationPremiumReceivedOnTransaction_f4fe9446-0065-4c95-a52f-cb5242ec9ebd_terseLabel_en-US" xlink:label="lab_dnli_SaleOfStockConsiderationPremiumReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premium on sale of common stock</link:label>
    <link:label id="lab_dnli_SaleOfStockConsiderationPremiumReceivedOnTransaction_label_en-US" xlink:label="lab_dnli_SaleOfStockConsiderationPremiumReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Consideration, Premium Received On Transaction</link:label>
    <link:label id="lab_dnli_SaleOfStockConsiderationPremiumReceivedOnTransaction_documentation_en-US" xlink:label="lab_dnli_SaleOfStockConsiderationPremiumReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock consideration premium received on transaction.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_SaleOfStockConsiderationPremiumReceivedOnTransaction" xlink:href="dnli-20210331.xsd#dnli_SaleOfStockConsiderationPremiumReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_SaleOfStockConsiderationPremiumReceivedOnTransaction" xlink:to="lab_dnli_SaleOfStockConsiderationPremiumReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_12125cfe-099e-4f1e-abe9-c242ea5d0f2a_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_LesseeOperatingLeaseRenewalNoticePeriod_0a28d98c-da3e-461a-80bf-1bbc1d782b2e_terseLabel_en-US" xlink:label="lab_dnli_LesseeOperatingLeaseRenewalNoticePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease renewal notice period</link:label>
    <link:label id="lab_dnli_LesseeOperatingLeaseRenewalNoticePeriod_label_en-US" xlink:label="lab_dnli_LesseeOperatingLeaseRenewalNoticePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Renewal Notice Period</link:label>
    <link:label id="lab_dnli_LesseeOperatingLeaseRenewalNoticePeriod_documentation_en-US" xlink:label="lab_dnli_LesseeOperatingLeaseRenewalNoticePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Renewal Notice Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_LesseeOperatingLeaseRenewalNoticePeriod" xlink:href="dnli-20210331.xsd#dnli_LesseeOperatingLeaseRenewalNoticePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_LesseeOperatingLeaseRenewalNoticePeriod" xlink:to="lab_dnli_LesseeOperatingLeaseRenewalNoticePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_4de38a8a-f74e-4172-b8db-1a862b89cf87_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_EmployeeAndNonEmployeeStockOptionMember_04b1cf46-be3c-429b-875d-83af294bbe69_terseLabel_en-US" xlink:label="lab_dnli_EmployeeAndNonEmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options issued and outstanding and ESPP shares issuable</link:label>
    <link:label id="lab_dnli_EmployeeAndNonEmployeeStockOptionMember_label_en-US" xlink:label="lab_dnli_EmployeeAndNonEmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee And Non Employee Stock Option [Member]</link:label>
    <link:label id="lab_dnli_EmployeeAndNonEmployeeStockOptionMember_documentation_en-US" xlink:label="lab_dnli_EmployeeAndNonEmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee And Non Employee Stock Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_EmployeeAndNonEmployeeStockOptionMember" xlink:href="dnli-20210331.xsd#dnli_EmployeeAndNonEmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_EmployeeAndNonEmployeeStockOptionMember" xlink:to="lab_dnli_EmployeeAndNonEmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_6b286918-b1eb-4679-80b5-1320b8eadc87_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_fc3795a8-8209-4329-862d-966b4666aada_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Closing stock price (usd per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_92969188-24bb-4f9b-a818-adf9a18408d3_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_dc6cab6a-1b4c-4286-94a3-aa41b1f48421_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_ef8026c5-3dcf-4871-a9a1-db4349c8b402_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_ShortTermMarketableSecuritiesMember_41e10d15-9636-451c-b907-8f2b8ec1cfd4_terseLabel_en-US" xlink:label="lab_dnli_ShortTermMarketableSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term marketable securities</link:label>
    <link:label id="lab_dnli_ShortTermMarketableSecuritiesMember_label_en-US" xlink:label="lab_dnli_ShortTermMarketableSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short Term Marketable Securities [Member]</link:label>
    <link:label id="lab_dnli_ShortTermMarketableSecuritiesMember_documentation_en-US" xlink:label="lab_dnli_ShortTermMarketableSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short term marketable securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_ShortTermMarketableSecuritiesMember" xlink:href="dnli-20210331.xsd#dnli_ShortTermMarketableSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_ShortTermMarketableSecuritiesMember" xlink:to="lab_dnli_ShortTermMarketableSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_e444a0a5-1ca7-4cce-9050-0083208a5f1c_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_5ad720f4-562b-4634-9fef-ac751fb56325_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_0f6d3abf-1793-4315-8713-cc64a8e8ead3_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_TransportVehicleTechnologyPlatformRightOfFirstNegotiationProgramsMember_2db2330b-6e1d-43cd-9ab0-b12b6433b06c_terseLabel_en-US" xlink:label="lab_dnli_TransportVehicleTechnologyPlatformRightOfFirstNegotiationProgramsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transport Vehicle Technology Platform, Right Of First Negotiation Programs</link:label>
    <link:label id="lab_dnli_TransportVehicleTechnologyPlatformRightOfFirstNegotiationProgramsMember_label_en-US" xlink:label="lab_dnli_TransportVehicleTechnologyPlatformRightOfFirstNegotiationProgramsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transport Vehicle Technology Platform, Right Of First Negotiation Programs [Member]</link:label>
    <link:label id="lab_dnli_TransportVehicleTechnologyPlatformRightOfFirstNegotiationProgramsMember_documentation_en-US" xlink:label="lab_dnli_TransportVehicleTechnologyPlatformRightOfFirstNegotiationProgramsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transport Vehicle Technology Platform, Right Of First Negotiation Programs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_TransportVehicleTechnologyPlatformRightOfFirstNegotiationProgramsMember" xlink:href="dnli-20210331.xsd#dnli_TransportVehicleTechnologyPlatformRightOfFirstNegotiationProgramsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_TransportVehicleTechnologyPlatformRightOfFirstNegotiationProgramsMember" xlink:to="lab_dnli_TransportVehicleTechnologyPlatformRightOfFirstNegotiationProgramsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_458625ac-06f3-4d1f-a9ea-fc7289ebf23b_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_f1f6ffca-4da7-4233-b146-d1a9df2aa826_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Marketable Securities [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:to="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNet_325adbb9-9179-4741-9a20-0a10de8aa8e6_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNet_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNet" xlink:to="lab_us-gaap_AccountsReceivableNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_ecaaaca2-1abb-49e1-9a41-d2ce383cf1ea_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Commitment, Excluding Long-term Commitment [Axis]</link:label>
    <link:label id="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_label_en-US" xlink:label="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Commitment, Excluding Long-term Commitment [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xlink:to="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_e39a64c6-72b5-4e32-9fa8-2236c9a5bfd9_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_aa33f84f-2dc4-4510-82b0-bbd0c7803ae1_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_09fe035b-90c0-41e7-b50c-f7834c925b93_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_9c4f16be-597a-4703-9c4c-0f10a699573e_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_fe1568cf-a3de-46ba-bc81-8871633305ed_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_c6138569-f5bc-4b17-a1bd-c789ecb8edef_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_65dc26b9-0c50-4853-8b3f-8233e3eec930_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_304bdaf0-010d-43c3-90c3-e4606badc76c_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_32d5a230-4ff2-4c17-9679-540174a866a5_terseLabel_en-US" xlink:label="lab_dnli_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_dnli_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_label_en-US" xlink:label="lab_dnli_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, To Be Paid, After Year Four</link:label>
    <link:label id="lab_dnli_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_documentation_en-US" xlink:label="lab_dnli_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, To Be Paid, After Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:href="dnli-20210331.xsd#dnli_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:to="lab_dnli_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_11ed9229-3629-4575-a7a4-768cb614d081_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_58b77b48-2669-49e7-b04f-839b1f0a02e0_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs)</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_TargetOptionPeriod_77307548-6ae1-4011-8074-c13a599342de_terseLabel_en-US" xlink:label="lab_dnli_TargetOptionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Target option period</link:label>
    <link:label id="lab_dnli_TargetOptionPeriod_label_en-US" xlink:label="lab_dnli_TargetOptionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Target Option Period</link:label>
    <link:label id="lab_dnli_TargetOptionPeriod_documentation_en-US" xlink:label="lab_dnli_TargetOptionPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Target Option Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_TargetOptionPeriod" xlink:href="dnli-20210331.xsd#dnli_TargetOptionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_TargetOptionPeriod" xlink:to="lab_dnli_TargetOptionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_b1890212-835d-4af1-9ab0-650ba14bebbf_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_CommercialMember_14bc2906-e6c3-4b3e-8ed3-c07772a6d03e_terseLabel_en-US" xlink:label="lab_dnli_CommercialMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial</link:label>
    <link:label id="lab_dnli_CommercialMember_label_en-US" xlink:label="lab_dnli_CommercialMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial [Member]</link:label>
    <link:label id="lab_dnli_CommercialMember_documentation_en-US" xlink:label="lab_dnli_CommercialMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_CommercialMember" xlink:href="dnli-20210331.xsd#dnli_CommercialMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_CommercialMember" xlink:to="lab_dnli_CommercialMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_bf9b5bb1-ff4a-481a-a581-3bde40bfb05a_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_092babbb-5970-4130-b272-253f0854dd70_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_12e1e755-1db4-40ef-aa24-212a23071855_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_1055ace1-6d04-4cac-9ee9-f207a0463231_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-cash items</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_6a35843a-874b-4dc6-be49-880252d5d13d_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_TransportVehicleTechnologyPlatformPreclinicalProgramsMember_725fe8c1-9505-4dc6-9a0b-4e1ed23bdcef_terseLabel_en-US" xlink:label="lab_dnli_TransportVehicleTechnologyPlatformPreclinicalProgramsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transport Vehicle (TV)Technology Platform, Preclinical Programs</link:label>
    <link:label id="lab_dnli_TransportVehicleTechnologyPlatformPreclinicalProgramsMember_label_en-US" xlink:label="lab_dnli_TransportVehicleTechnologyPlatformPreclinicalProgramsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transport Vehicle Technology Platform, Preclinical Programs [Member]</link:label>
    <link:label id="lab_dnli_TransportVehicleTechnologyPlatformPreclinicalProgramsMember_documentation_en-US" xlink:label="lab_dnli_TransportVehicleTechnologyPlatformPreclinicalProgramsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transport Vehicle Technology Platform, Preclinical Programs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_TransportVehicleTechnologyPlatformPreclinicalProgramsMember" xlink:href="dnli-20210331.xsd#dnli_TransportVehicleTechnologyPlatformPreclinicalProgramsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_TransportVehicleTechnologyPlatformPreclinicalProgramsMember" xlink:to="lab_dnli_TransportVehicleTechnologyPlatformPreclinicalProgramsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_21786f80-7727-48bb-9f0c-a3dd86b8c30e_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_b184046a-8275-4351-8b17-d6cd7eef3215_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_8b922a55-00b1-470c-8647-07d6f0ec7d45_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Awards</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_c3fe86cf-17fa-41bf-8529-846c9975a47a_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_be932895-15e4-4af2-ab1c-f76f2a3b5074_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_8f4ccffe-d7b1-49a3-b9c1-981a68bd7871_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c6623712-5bf5-4b86-83cc-89970efa6870_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_PreclinicalMilestonePaymentEarnedNotYetReceived_5405189e-048f-49f2-aa26-a2fbec0dcab9_terseLabel_en-US" xlink:label="lab_dnli_PreclinicalMilestonePaymentEarnedNotYetReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preclinical milestone payment earned not yet received</link:label>
    <link:label id="lab_dnli_PreclinicalMilestonePaymentEarnedNotYetReceived_label_en-US" xlink:label="lab_dnli_PreclinicalMilestonePaymentEarnedNotYetReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preclinical Milestone Payment Earned Not Yet Received</link:label>
    <link:label id="lab_dnli_PreclinicalMilestonePaymentEarnedNotYetReceived_documentation_en-US" xlink:label="lab_dnli_PreclinicalMilestonePaymentEarnedNotYetReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preclinical Milestone Payment Earned Not Yet Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_PreclinicalMilestonePaymentEarnedNotYetReceived" xlink:href="dnli-20210331.xsd#dnli_PreclinicalMilestonePaymentEarnedNotYetReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_PreclinicalMilestonePaymentEarnedNotYetReceived" xlink:to="lab_dnli_PreclinicalMilestonePaymentEarnedNotYetReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_8d606aee-801b-4c6f-bdbb-47f23af1c077_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 (nine months)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsGross_395fe180-801f-4722-ab8e-b5692c3bb60e_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsGross_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsGross" xlink:to="lab_us-gaap_LeaseholdImprovementsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_AggregateDevelopmentFirstCommercialSaleAndNetSalesBasedMilestonePayments_050a5f0f-a235-480f-a98e-83389ac80610_terseLabel_en-US" xlink:label="lab_dnli_AggregateDevelopmentFirstCommercialSaleAndNetSalesBasedMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payments upon achievement of certain development and sales milestones</link:label>
    <link:label id="lab_dnli_AggregateDevelopmentFirstCommercialSaleAndNetSalesBasedMilestonePayments_label_en-US" xlink:label="lab_dnli_AggregateDevelopmentFirstCommercialSaleAndNetSalesBasedMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Development, First Commercial Sale, And Net Sales Based Milestone Payments</link:label>
    <link:label id="lab_dnli_AggregateDevelopmentFirstCommercialSaleAndNetSalesBasedMilestonePayments_documentation_en-US" xlink:label="lab_dnli_AggregateDevelopmentFirstCommercialSaleAndNetSalesBasedMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Development, First Commercial Sale, And Net Sales Based Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_AggregateDevelopmentFirstCommercialSaleAndNetSalesBasedMilestonePayments" xlink:href="dnli-20210331.xsd#dnli_AggregateDevelopmentFirstCommercialSaleAndNetSalesBasedMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_AggregateDevelopmentFirstCommercialSaleAndNetSalesBasedMilestonePayments" xlink:to="lab_dnli_AggregateDevelopmentFirstCommercialSaleAndNetSalesBasedMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_RegulatoryMilestonePayment_56b21448-4c5c-4f38-88ab-5922dd9911d8_terseLabel_en-US" xlink:label="lab_dnli_RegulatoryMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulatory milestone payment</link:label>
    <link:label id="lab_dnli_RegulatoryMilestonePayment_label_en-US" xlink:label="lab_dnli_RegulatoryMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulatory Milestone Payment</link:label>
    <link:label id="lab_dnli_RegulatoryMilestonePayment_documentation_en-US" xlink:label="lab_dnli_RegulatoryMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulatory Milestone Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_RegulatoryMilestonePayment" xlink:href="dnli-20210331.xsd#dnli_RegulatoryMilestonePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_RegulatoryMilestonePayment" xlink:to="lab_dnli_RegulatoryMilestonePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_5d713cba-cb5a-4f9b-9537-e9769ee823f1_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_2351d860-657e-4b77-8f1c-8e10b6434ea2_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_0539b2d2-9c20-4dd6-957c-fed4fa0b2991_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_FirstCommercialSaleMilestonePayments_7d769051-9511-4a84-9485-7b51874b0242_terseLabel_en-US" xlink:label="lab_dnli_FirstCommercialSaleMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">First commercial sale milestone payments</link:label>
    <link:label id="lab_dnli_FirstCommercialSaleMilestonePayments_label_en-US" xlink:label="lab_dnli_FirstCommercialSaleMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">First Commercial Sale Milestone Payments</link:label>
    <link:label id="lab_dnli_FirstCommercialSaleMilestonePayments_documentation_en-US" xlink:label="lab_dnli_FirstCommercialSaleMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">First Commercial Sale Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_FirstCommercialSaleMilestonePayments" xlink:href="dnli-20210331.xsd#dnli_FirstCommercialSaleMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_FirstCommercialSaleMilestonePayments" xlink:to="lab_dnli_FirstCommercialSaleMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_39d5dc53-1fc7-4742-8fd6-e06213bb7838_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_505356c4-bc52-4f8e-831c-c4692da67cb4_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9ebc511b-c64d-4728-8ebc-7d5d2b9154e9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_902b4e42-270e-47e5-a453-4945a63d64b6_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_OrganizationAndDescriptionOfBusinessPolicyPolicyTextBlock_692a4fa7-51cc-48d1-8463-ef7de4efcc18_terseLabel_en-US" xlink:label="lab_dnli_OrganizationAndDescriptionOfBusinessPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and Description of Business</link:label>
    <link:label id="lab_dnli_OrganizationAndDescriptionOfBusinessPolicyPolicyTextBlock_label_en-US" xlink:label="lab_dnli_OrganizationAndDescriptionOfBusinessPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and Description of Business, Policy [Policy Text Block]</link:label>
    <link:label id="lab_dnli_OrganizationAndDescriptionOfBusinessPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_dnli_OrganizationAndDescriptionOfBusinessPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and description of business, policy.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_OrganizationAndDescriptionOfBusinessPolicyPolicyTextBlock" xlink:href="dnli-20210331.xsd#dnli_OrganizationAndDescriptionOfBusinessPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_OrganizationAndDescriptionOfBusinessPolicyPolicyTextBlock" xlink:to="lab_dnli_OrganizationAndDescriptionOfBusinessPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_1d36934a-8b59-45f6-b10e-8e81fb66fa4a_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract liabilities, less current portion</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalariesWagesAndOfficersCompensationAbstract_label_en-US" xlink:label="lab_us-gaap_SalariesWagesAndOfficersCompensationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Salary and Wage, Excluding Cost of Good and Service Sold [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalariesWagesAndOfficersCompensationAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalariesWagesAndOfficersCompensationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalariesWagesAndOfficersCompensationAbstract" xlink:to="lab_us-gaap_SalariesWagesAndOfficersCompensationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_ProvisionalCollaborativeArrangementMember_48dc1dc0-8885-4b27-897a-3b6e040f6407_terseLabel_en-US" xlink:label="lab_dnli_ProvisionalCollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provisional Collaboration Agreement</link:label>
    <link:label id="lab_dnli_ProvisionalCollaborativeArrangementMember_label_en-US" xlink:label="lab_dnli_ProvisionalCollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provisional Collaborative Arrangement [Member]</link:label>
    <link:label id="lab_dnli_ProvisionalCollaborativeArrangementMember_documentation_en-US" xlink:label="lab_dnli_ProvisionalCollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provisional Collaborative Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_ProvisionalCollaborativeArrangementMember" xlink:href="dnli-20210331.xsd#dnli_ProvisionalCollaborativeArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_ProvisionalCollaborativeArrangementMember" xlink:to="lab_dnli_ProvisionalCollaborativeArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeaseTermOfContract_1d419c21-1708-44ec-a782-a39d6c61c538_terseLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease term</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeaseTermOfContract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LessorOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LessorOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_SanofiCollaborationAgreementMember_ab680322-8a69-4f84-90a7-986fe5b20d09_terseLabel_en-US" xlink:label="lab_dnli_SanofiCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Collaboration Agreement</link:label>
    <link:label id="lab_dnli_SanofiCollaborationAgreementMember_label_en-US" xlink:label="lab_dnli_SanofiCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Collaboration Agreement [Member]</link:label>
    <link:label id="lab_dnli_SanofiCollaborationAgreementMember_documentation_en-US" xlink:label="lab_dnli_SanofiCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Collaboration Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_SanofiCollaborationAgreementMember" xlink:href="dnli-20210331.xsd#dnli_SanofiCollaborationAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_SanofiCollaborationAgreementMember" xlink:to="lab_dnli_SanofiCollaborationAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_RevenueNumberOfPerformanceObligations_3a4ea2f7-c07c-4b3c-9d10-c21e69bde293_terseLabel_en-US" xlink:label="lab_dnli_RevenueNumberOfPerformanceObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of performance obligations</link:label>
    <link:label id="lab_dnli_RevenueNumberOfPerformanceObligations_label_en-US" xlink:label="lab_dnli_RevenueNumberOfPerformanceObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Number Of Performance Obligations</link:label>
    <link:label id="lab_dnli_RevenueNumberOfPerformanceObligations_documentation_en-US" xlink:label="lab_dnli_RevenueNumberOfPerformanceObligations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Number Of Performance Obligations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_RevenueNumberOfPerformanceObligations" xlink:href="dnli-20210331.xsd#dnli_RevenueNumberOfPerformanceObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_RevenueNumberOfPerformanceObligations" xlink:to="lab_dnli_RevenueNumberOfPerformanceObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_301b6ee9-8a67-4ee1-8548-48465a3bdd7f_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_d740a0eb-aa6b-429f-a227-1dcd66913004_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Stock-Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_CollaborativeArrangementTermNumberOfBusinessDaysIfEffectiveDateCriteriaMet_bdf1f8be-e378-428a-9164-4c917d424061_terseLabel_en-US" xlink:label="lab_dnli_CollaborativeArrangementTermNumberOfBusinessDaysIfEffectiveDateCriteriaMet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term of agreement, number of business days after 5th anniversary date of the effective date of the agreement</link:label>
    <link:label id="lab_dnli_CollaborativeArrangementTermNumberOfBusinessDaysIfEffectiveDateCriteriaMet_label_en-US" xlink:label="lab_dnli_CollaborativeArrangementTermNumberOfBusinessDaysIfEffectiveDateCriteriaMet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Term, Number Of Business Days, If Effective Date Criteria Met</link:label>
    <link:label id="lab_dnli_CollaborativeArrangementTermNumberOfBusinessDaysIfEffectiveDateCriteriaMet_documentation_en-US" xlink:label="lab_dnli_CollaborativeArrangementTermNumberOfBusinessDaysIfEffectiveDateCriteriaMet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Term, Number Of Business Days, If Effective Date Criteria Met</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_CollaborativeArrangementTermNumberOfBusinessDaysIfEffectiveDateCriteriaMet" xlink:href="dnli-20210331.xsd#dnli_CollaborativeArrangementTermNumberOfBusinessDaysIfEffectiveDateCriteriaMet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_CollaborativeArrangementTermNumberOfBusinessDaysIfEffectiveDateCriteriaMet" xlink:to="lab_dnli_CollaborativeArrangementTermNumberOfBusinessDaysIfEffectiveDateCriteriaMet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_ef42ac8b-7a87-47eb-9328-930d8fdd243a_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_6609af7b-853f-446e-9049-4d078e35de7b_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_9e392846-45b6-4f96-a848-405ee250ab93_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_CollaborativeArrangementNumberOfMilestonesAchieved_0a470936-1947-4d64-ad03-c0f4ecf92adc_terseLabel_en-US" xlink:label="lab_dnli_CollaborativeArrangementNumberOfMilestonesAchieved" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of milestones achieved</link:label>
    <link:label id="lab_dnli_CollaborativeArrangementNumberOfMilestonesAchieved_label_en-US" xlink:label="lab_dnli_CollaborativeArrangementNumberOfMilestonesAchieved" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Number Of Milestones Achieved</link:label>
    <link:label id="lab_dnli_CollaborativeArrangementNumberOfMilestonesAchieved_documentation_en-US" xlink:label="lab_dnli_CollaborativeArrangementNumberOfMilestonesAchieved" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Number Of Milestones Achieved</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_CollaborativeArrangementNumberOfMilestonesAchieved" xlink:href="dnli-20210331.xsd#dnli_CollaborativeArrangementNumberOfMilestonesAchieved"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_CollaborativeArrangementNumberOfMilestonesAchieved" xlink:to="lab_dnli_CollaborativeArrangementNumberOfMilestonesAchieved" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseDiscountRate_9241322b-342e-4a60-ae7c-217d07eccbac_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount rate (as a percentage)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseDiscountRate_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:to="lab_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_aeb840aa-c5f9-48b1-9362-3ac89799af3b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate, maximum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_AccruedClinicalCostsCurrent_6affea2c-526a-44b4-9db2-edd39ced8828_terseLabel_en-US" xlink:label="lab_dnli_AccruedClinicalCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued clinical costs</link:label>
    <link:label id="lab_dnli_AccruedClinicalCostsCurrent_label_en-US" xlink:label="lab_dnli_AccruedClinicalCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Clinical Costs, Current</link:label>
    <link:label id="lab_dnli_AccruedClinicalCostsCurrent_documentation_en-US" xlink:label="lab_dnli_AccruedClinicalCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Clinical Costs, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_AccruedClinicalCostsCurrent" xlink:href="dnli-20210331.xsd#dnli_AccruedClinicalCostsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_AccruedClinicalCostsCurrent" xlink:to="lab_dnli_AccruedClinicalCostsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseContractualTermAxis_a04aec83-e427-48ed-9d53-933ee2e4345c_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseContractualTermAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contractual Term [Axis]</link:label>
    <link:label id="lab_us-gaap_LeaseContractualTermAxis_label_en-US" xlink:label="lab_us-gaap_LeaseContractualTermAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contractual Term [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseContractualTermAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseContractualTermAxis" xlink:to="lab_us-gaap_LeaseContractualTermAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths_cc31fcb8-c7b0-4ffc-8be7-f468131b37b2_terseLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Payment to be Received, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths" xlink:to="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_3bcfc9d7-6e7c-4310-8324-90c12e0e9126_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. government treasuries</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasurySecuritiesMember" xlink:to="lab_us-gaap_USTreasurySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStocksIncludingAdditionalPaidInCapital_b4e8d2ec-d835-4861-a636-c22f3ce45efd_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStocksIncludingAdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair market value of common stock</link:label>
    <link:label id="lab_us-gaap_CommonStocksIncludingAdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_CommonStocksIncludingAdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stocks, Including Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStocksIncludingAdditionalPaidInCapital" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStocksIncludingAdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStocksIncludingAdditionalPaidInCapital" xlink:to="lab_us-gaap_CommonStocksIncludingAdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_StockIssuedDuringPeriodValueEquityIncentivePlan_569df79e-e649-458a-929f-1752d7b1bb21_terseLabel_en-US" xlink:label="lab_dnli_StockIssuedDuringPeriodValueEquityIncentivePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuances under equity incentive plans</link:label>
    <link:label id="lab_dnli_StockIssuedDuringPeriodValueEquityIncentivePlan_label_en-US" xlink:label="lab_dnli_StockIssuedDuringPeriodValueEquityIncentivePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Equity Incentive Plan</link:label>
    <link:label id="lab_dnli_StockIssuedDuringPeriodValueEquityIncentivePlan_documentation_en-US" xlink:label="lab_dnli_StockIssuedDuringPeriodValueEquityIncentivePlan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Equity Incentive Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_StockIssuedDuringPeriodValueEquityIncentivePlan" xlink:href="dnli-20210331.xsd#dnli_StockIssuedDuringPeriodValueEquityIncentivePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_StockIssuedDuringPeriodValueEquityIncentivePlan" xlink:to="lab_dnli_StockIssuedDuringPeriodValueEquityIncentivePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_92796243-206c-4334-9f60-f087f0653ed8_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock in follow-on offering, net of issuance costs of $632 (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_4338cecd-ca74-401c-b994-b78b522dacef_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_85070870-5550-479e-8072-89534a2fcb02_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_CollaborativeAgreementFundedPercentage_0d2f25e2-ef0d-4f9d-8ad0-351a0c5c09a6_terseLabel_en-US" xlink:label="lab_dnli_CollaborativeAgreementFundedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funded percentage</link:label>
    <link:label id="lab_dnli_CollaborativeAgreementFundedPercentage_label_en-US" xlink:label="lab_dnli_CollaborativeAgreementFundedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Funded Percentage</link:label>
    <link:label id="lab_dnli_CollaborativeAgreementFundedPercentage_documentation_en-US" xlink:label="lab_dnli_CollaborativeAgreementFundedPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Funded Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_CollaborativeAgreementFundedPercentage" xlink:href="dnli-20210331.xsd#dnli_CollaborativeAgreementFundedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_CollaborativeAgreementFundedPercentage" xlink:to="lab_dnli_CollaborativeAgreementFundedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_58cc2764-4e26-42bc-8166-3c95fa9df583_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest and other income, net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_ROFNAndOptionAgreementCollaborativeArrangementMember_ad5e5fb1-298f-4b5e-b617-8d2a04f575b7_terseLabel_en-US" xlink:label="lab_dnli_ROFNAndOptionAgreementCollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ROFN and Option Agreement</link:label>
    <link:label id="lab_dnli_ROFNAndOptionAgreementCollaborativeArrangementMember_label_en-US" xlink:label="lab_dnli_ROFNAndOptionAgreementCollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ROFN And Option Agreement, Collaborative Arrangement [Member]</link:label>
    <link:label id="lab_dnli_ROFNAndOptionAgreementCollaborativeArrangementMember_documentation_en-US" xlink:label="lab_dnli_ROFNAndOptionAgreementCollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ROFN And Option Agreement, Collaborative Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_ROFNAndOptionAgreementCollaborativeArrangementMember" xlink:href="dnli-20210331.xsd#dnli_ROFNAndOptionAgreementCollaborativeArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_ROFNAndOptionAgreementCollaborativeArrangementMember" xlink:to="lab_dnli_ROFNAndOptionAgreementCollaborativeArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_545fafaa-53c4-4e70-b11e-58f453f41585_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Future Minimum Lease Commitments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_17a73114-e621-4bcf-a293-7dedbffd11e9_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_ed4eb3eb-b95b-42b5-a2c2-7aba366d1f57_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_891a2c79-41eb-466b-812e-2d485a9bff83_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average number of shares outstanding, basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c1989faf-0079-46f4-a0d8-dbb69eed69f6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_b74b8eb9-19ba-4a3b-a28f-a9a2907e7c1a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of securities held in unrealized holding loss position</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position, Number of Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_3b4430b8-d9f9-40a3-b861-85984d0c325a_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accruals and other current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_ConstrainedVariableConsideration_68ff2eaf-6745-4fbd-a0d4-27e6a7f88392_terseLabel_en-US" xlink:label="lab_dnli_ConstrainedVariableConsideration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining preclinical milestones, cost and profit sharing income, and the development and commercial milestones</link:label>
    <link:label id="lab_dnli_ConstrainedVariableConsideration_label_en-US" xlink:label="lab_dnli_ConstrainedVariableConsideration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Constrained Variable Consideration</link:label>
    <link:label id="lab_dnli_ConstrainedVariableConsideration_documentation_en-US" xlink:label="lab_dnli_ConstrainedVariableConsideration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Constrained variable consideration.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_ConstrainedVariableConsideration" xlink:href="dnli-20210331.xsd#dnli_ConstrainedVariableConsideration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_ConstrainedVariableConsideration" xlink:to="lab_dnli_ConstrainedVariableConsideration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_752c99b2-3a65-4ed2-8f00-cb8cee7ae4fa_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_96e15422-4dd8-4216-b06b-01aa64186c04_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Volatility, maximum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_0a1de491-cec6-4843-8a22-c454deaa1f07_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_66cd60ea-3e09-421f-9425-31fcc56a7007_totalLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total collaboration revenue</link:label>
    <link:label id="lab_us-gaap_Revenues_c9c419f3-cf7a-4851-a5a0-1fa428dfdb26_verboseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Collaboration Revenue</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_CollaborativeArrangementUpfrontPaymentToBeReceived_abc74f44-5992-45d7-9a8e-ff8e3e515cab_terseLabel_en-US" xlink:label="lab_dnli_CollaborativeArrangementUpfrontPaymentToBeReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront payment, to be received</link:label>
    <link:label id="lab_dnli_CollaborativeArrangementUpfrontPaymentToBeReceived_label_en-US" xlink:label="lab_dnli_CollaborativeArrangementUpfrontPaymentToBeReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Upfront Payment, To Be Received</link:label>
    <link:label id="lab_dnli_CollaborativeArrangementUpfrontPaymentToBeReceived_documentation_en-US" xlink:label="lab_dnli_CollaborativeArrangementUpfrontPaymentToBeReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Upfront Payment, To Be Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_CollaborativeArrangementUpfrontPaymentToBeReceived" xlink:href="dnli-20210331.xsd#dnli_CollaborativeArrangementUpfrontPaymentToBeReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_CollaborativeArrangementUpfrontPaymentToBeReceived" xlink:to="lab_dnli_CollaborativeArrangementUpfrontPaymentToBeReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock_85a912e7-9f69-4a3d-9de7-d6e05830da65_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Forward Foreign Currency Exchange Contracts Outstanding</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivative Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_dc5367a2-ee74-4ed0-b7dd-741a0f38db45_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax benefit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_a10fc2a1-5f51-42d1-96cc-4c38c8bf3c1c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax benefit (provision)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c433f277-116c-4ac2-8a0f-1ca958d5689c_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4dad905d-ef40-4c00-8a6c-f620f4edfbe0_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_970bccc9-ed04-4e64-834a-8e9f512fed26_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_445204a7-a5f3-40c4-933a-dd7bbd202d94_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_1ade528d-36a8-4abf-940e-7434ed7faf3d_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial and Nonfinancial Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_cdfedfae-b9d4-4274-8401-a68cdbd4d78a_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other accruals and other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_63a1775a-bc57-4aaf-9232-bd3379bfd3fb_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share, diluted (usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_62509cb9-fe0d-4d9f-ada8-cef8a477a097_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_3a39d4be-5574-41ae-8925-2fabfc1222b2_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLineItems_65578376-31fb-4354-83e5-27dab09bb968_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativeLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLineItems" xlink:to="lab_us-gaap_DerivativeLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_5e8010ed-226f-4ffd-aac2-cffb3412ec64_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_a209694b-292f-421b-b8ba-7b6a2437a408_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract liability</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_SanofiMember_75ebb3e4-7970-4251-84fe-ca24b66f00c2_terseLabel_en-US" xlink:label="lab_dnli_SanofiMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi</link:label>
    <link:label id="lab_dnli_SanofiMember_label_en-US" xlink:label="lab_dnli_SanofiMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi [Member]</link:label>
    <link:label id="lab_dnli_SanofiMember_documentation_en-US" xlink:label="lab_dnli_SanofiMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_SanofiMember" xlink:href="dnli-20210331.xsd#dnli_SanofiMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_SanofiMember" xlink:to="lab_dnli_SanofiMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_c2d55479-2440-4fcf-9f56-aa83ac9fac03_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_e4b6ee98-f0a4-42f1-929a-e31ec8548515_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_34f7b91c-d11e-4ae4-b10c-45641dc5bc78_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_TransportVehicleTechnologyPlatformUnnamedProgramMember_3c53a8b5-5cf6-465e-a2f6-15eaa27365f8_terseLabel_en-US" xlink:label="lab_dnli_TransportVehicleTechnologyPlatformUnnamedProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transport Vehicle (TV) Technology Platform, Unnamed Program</link:label>
    <link:label id="lab_dnli_TransportVehicleTechnologyPlatformUnnamedProgramMember_label_en-US" xlink:label="lab_dnli_TransportVehicleTechnologyPlatformUnnamedProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transport Vehicle Technology Platform, Unnamed Program [Member]</link:label>
    <link:label id="lab_dnli_TransportVehicleTechnologyPlatformUnnamedProgramMember_documentation_en-US" xlink:label="lab_dnli_TransportVehicleTechnologyPlatformUnnamedProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transport Vehicle Technology Platform, Unnamed Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_TransportVehicleTechnologyPlatformUnnamedProgramMember" xlink:href="dnli-20210331.xsd#dnli_TransportVehicleTechnologyPlatformUnnamedProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_TransportVehicleTechnologyPlatformUnnamedProgramMember" xlink:to="lab_dnli_TransportVehicleTechnologyPlatformUnnamedProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_2a411257-a758-4687-9906-ee49dd6d0741_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0421121f-0cfb-4eb1-804c-b7f0db79bc39_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Fair Value at Date of Grant per Share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_LicenseAgreementMilestonePaymentObligationResponsibilityPercentage_7fc54fe4-9d16-4691-8dea-f36265280f87_terseLabel_en-US" xlink:label="lab_dnli_LicenseAgreementMilestonePaymentObligationResponsibilityPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment obligation responsibility</link:label>
    <link:label id="lab_dnli_LicenseAgreementMilestonePaymentObligationResponsibilityPercentage_label_en-US" xlink:label="lab_dnli_LicenseAgreementMilestonePaymentObligationResponsibilityPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Milestone Payment Obligation Responsibility, Percentage</link:label>
    <link:label id="lab_dnli_LicenseAgreementMilestonePaymentObligationResponsibilityPercentage_documentation_en-US" xlink:label="lab_dnli_LicenseAgreementMilestonePaymentObligationResponsibilityPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Milestone Payment Obligation Responsibility, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_LicenseAgreementMilestonePaymentObligationResponsibilityPercentage" xlink:href="dnli-20210331.xsd#dnli_LicenseAgreementMilestonePaymentObligationResponsibilityPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_LicenseAgreementMilestonePaymentObligationResponsibilityPercentage" xlink:to="lab_dnli_LicenseAgreementMilestonePaymentObligationResponsibilityPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_4fd75ef4-f5a9-4dfb-bf81-a6ae896d86e2_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Assets and Other Current Assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_label_en-US" xlink:label="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expenses and Other Current Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:to="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseContractualTermDomain_9c97f23b-41cc-4581-abe0-b45647f54f84_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseContractualTermDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contractual Term [Domain]</link:label>
    <link:label id="lab_us-gaap_LeaseContractualTermDomain_label_en-US" xlink:label="lab_us-gaap_LeaseContractualTermDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contractual Term [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseContractualTermDomain" xlink:to="lab_us-gaap_LeaseContractualTermDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_fd80e187-fd42-440b-83c2-409bfd0a7b52_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_3e6384cf-a6c0-4224-a985-29fe4b18cd1c_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_fe78163f-1ee0-4601-9576-312473b1dc81_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_a23868bf-f174-4522-ae7c-62ed5ea61258_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_27f741c9-b62c-4ae9-b516-0036cced2b24_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_adbe95cc-62b3-40d8-a97b-b31ac6a71585_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_87600145-f8dc-4c46-9430-013da857e7d0_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_08058107-fba6-4662-9b6d-a9d5687eefc3_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cb3b7b7b-e606-41b4-b2b1-7b617e5c9b64_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears_760da97c-393c-4f37-b83b-9c7526606526_terseLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Payment to be Received, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears" xlink:to="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3b4f016a-c6df-49b8-992f-239eaefe5f9c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock_a61db784-6caa-418d-8cdc-1daeabe3eac2_terseLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Future Minimum Lease Receivables</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Payment to be Received, Fiscal Year Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock" xlink:to="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_3e4464fc-1bc5-47af-8488-b197c67ef4d9_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_15dd6926-1c0b-456c-87e0-14119dab8ef1_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_d488915a-c454-4d66-9497-424419ff76e8_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromRelatedParties_203a95ba-b9af-4a57-b5ab-10d70f59d39e_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromRelatedParties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration revenue from customers, related party</link:label>
    <link:label id="lab_us-gaap_RevenueFromRelatedParties_label_en-US" xlink:label="lab_us-gaap_RevenueFromRelatedParties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Related Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromRelatedParties" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromRelatedParties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromRelatedParties" xlink:to="lab_us-gaap_RevenueFromRelatedParties" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_DMSAMember_6ee99fa0-96b4-4724-916a-54ce6fcf28cd_terseLabel_en-US" xlink:label="lab_dnli_DMSAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DMSA</link:label>
    <link:label id="lab_dnli_DMSAMember_label_en-US" xlink:label="lab_dnli_DMSAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DMSA [Member]</link:label>
    <link:label id="lab_dnli_DMSAMember_documentation_en-US" xlink:label="lab_dnli_DMSAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DMSA.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_DMSAMember" xlink:href="dnli-20210331.xsd#dnli_DMSAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_DMSAMember" xlink:to="lab_dnli_DMSAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_65b50620-ad61-4c44-b31c-e48cece25ede_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from exercise of awards under equity incentive plans</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber_0a42dbbb-cfda-408c-93bd-fd6e332b9881_terseLabel_en-US" xlink:label="lab_dnli_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected to vest (in shares)</link:label>
    <link:label id="lab_dnli_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_dnli_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested And Expected To Vest Outstanding Number</link:label>
    <link:label id="lab_dnli_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber_documentation_en-US" xlink:label="lab_dnli_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based compensation arrangement by share based payment award equity instruments other than options vested and expected to vest outstanding number.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="dnli-20210331.xsd#dnli_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_dnli_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_b3f8f016-351b-4e06-9f12-bde2571e406b_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1b65f1a2-e9f8-4aa1-a333-1d2feec95327_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_5f0cb2c7-3e27-46d6-aebf-3bedc80b9410_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_0130accb-e8ea-4872-a432-95cb4300d3ad_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_4dcee866-dc55-4856-ae4f-c763f6255be5_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_c1bdaf77-cfe6-4e80-b9d1-e8e9e91d46f2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_b4e964d7-7a55-40cb-9e6a-da44d3d8308b_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_ClinicalMilestonePayment_60ead338-f3a3-4b5e-bb64-d951b4de6597_terseLabel_en-US" xlink:label="lab_dnli_ClinicalMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical milestone payment</link:label>
    <link:label id="lab_dnli_ClinicalMilestonePayment_label_en-US" xlink:label="lab_dnli_ClinicalMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Milestone Payment</link:label>
    <link:label id="lab_dnli_ClinicalMilestonePayment_documentation_en-US" xlink:label="lab_dnli_ClinicalMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Milestone Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_ClinicalMilestonePayment" xlink:href="dnli-20210331.xsd#dnli_ClinicalMilestonePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_ClinicalMilestonePayment" xlink:to="lab_dnli_ClinicalMilestonePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_fc25ca6e-52a6-4485-ac88-45767f58b620_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recently Adopted Accounting Pronouncement</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_cd8b72bd-d5e9-45ba-9db1-5fea1fa456dc_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_UpfrontFeesPaid_15038d21-10d8-408d-bf37-29f5a9bfc1aa_terseLabel_en-US" xlink:label="lab_dnli_UpfrontFeesPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront fee paid</link:label>
    <link:label id="lab_dnli_UpfrontFeesPaid_label_en-US" xlink:label="lab_dnli_UpfrontFeesPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront Fees Paid</link:label>
    <link:label id="lab_dnli_UpfrontFeesPaid_documentation_en-US" xlink:label="lab_dnli_UpfrontFeesPaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront fees paid.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_UpfrontFeesPaid" xlink:href="dnli-20210331.xsd#dnli_UpfrontFeesPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_UpfrontFeesPaid" xlink:to="lab_dnli_UpfrontFeesPaid" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>dnli-20210331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:be7bc6f9-6af9-45b5-b822-49fcbbf3ecfb,g:6a95e0ad-15c9-4fb8-a5d1-2bfd737ebde3-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/DocumentandEntityInformation" xlink:type="simple" xlink:href="dnli-20210331.xsd#DocumentandEntityInformation"/>
  <link:presentationLink xlink:role="http://www.denalitherapeutics.com/role/DocumentandEntityInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_3a570453-3d47-4e54-aada-524513c2e8a6" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_9ecec42b-f93e-4155-a9cf-72af63148c86" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3a570453-3d47-4e54-aada-524513c2e8a6" xlink:to="loc_dei_DocumentType_9ecec42b-f93e-4155-a9cf-72af63148c86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_95d8c690-baf7-4bac-b94e-ad1851832b85" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3a570453-3d47-4e54-aada-524513c2e8a6" xlink:to="loc_dei_DocumentQuarterlyReport_95d8c690-baf7-4bac-b94e-ad1851832b85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_c0f3d632-6c6e-49df-86a6-a7d82da9cf25" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3a570453-3d47-4e54-aada-524513c2e8a6" xlink:to="loc_dei_DocumentPeriodEndDate_c0f3d632-6c6e-49df-86a6-a7d82da9cf25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_45a7feea-4299-47ac-b3af-edfb256fba0b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3a570453-3d47-4e54-aada-524513c2e8a6" xlink:to="loc_dei_DocumentTransitionReport_45a7feea-4299-47ac-b3af-edfb256fba0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_081581d8-e970-4132-af4a-4543ec0198e8" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3a570453-3d47-4e54-aada-524513c2e8a6" xlink:to="loc_dei_EntityFileNumber_081581d8-e970-4132-af4a-4543ec0198e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_d4bc31b4-b8ec-4ff7-b565-49ba73d90f7a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3a570453-3d47-4e54-aada-524513c2e8a6" xlink:to="loc_dei_EntityRegistrantName_d4bc31b4-b8ec-4ff7-b565-49ba73d90f7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_03967010-1d7d-408e-acbb-2491b6884c0b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3a570453-3d47-4e54-aada-524513c2e8a6" xlink:to="loc_dei_EntityIncorporationStateCountryCode_03967010-1d7d-408e-acbb-2491b6884c0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_c24415eb-6430-4898-9298-e2940b552cc0" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3a570453-3d47-4e54-aada-524513c2e8a6" xlink:to="loc_dei_EntityTaxIdentificationNumber_c24415eb-6430-4898-9298-e2940b552cc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_141d36c5-c540-49b9-9d2f-c555e56d7a97" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3a570453-3d47-4e54-aada-524513c2e8a6" xlink:to="loc_dei_EntityAddressAddressLine1_141d36c5-c540-49b9-9d2f-c555e56d7a97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_d0b5c663-df92-4281-85f7-851b6f39fff4" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3a570453-3d47-4e54-aada-524513c2e8a6" xlink:to="loc_dei_EntityAddressCityOrTown_d0b5c663-df92-4281-85f7-851b6f39fff4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_2a7b070f-e100-4bcd-a27b-6a985fdd81cb" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3a570453-3d47-4e54-aada-524513c2e8a6" xlink:to="loc_dei_EntityAddressStateOrProvince_2a7b070f-e100-4bcd-a27b-6a985fdd81cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_f1f58e0f-56dd-4984-84f6-ae809189a796" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3a570453-3d47-4e54-aada-524513c2e8a6" xlink:to="loc_dei_EntityAddressPostalZipCode_f1f58e0f-56dd-4984-84f6-ae809189a796" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_d90231e7-ebe9-4866-a333-2275dfda8f3b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3a570453-3d47-4e54-aada-524513c2e8a6" xlink:to="loc_dei_CityAreaCode_d90231e7-ebe9-4866-a333-2275dfda8f3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_af474f51-1eae-4759-94f7-f34edefb5e65" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3a570453-3d47-4e54-aada-524513c2e8a6" xlink:to="loc_dei_LocalPhoneNumber_af474f51-1eae-4759-94f7-f34edefb5e65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_8eeb645a-7eee-47f4-9358-d025d96bd664" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3a570453-3d47-4e54-aada-524513c2e8a6" xlink:to="loc_dei_Security12bTitle_8eeb645a-7eee-47f4-9358-d025d96bd664" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_b80850a0-d31a-453b-9997-a0aa8f0da5f7" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3a570453-3d47-4e54-aada-524513c2e8a6" xlink:to="loc_dei_TradingSymbol_b80850a0-d31a-453b-9997-a0aa8f0da5f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_d1090f9f-43e7-42bf-94da-f2788c142dc1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3a570453-3d47-4e54-aada-524513c2e8a6" xlink:to="loc_dei_SecurityExchangeName_d1090f9f-43e7-42bf-94da-f2788c142dc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_19126064-2511-4586-8108-ecd583ad34f9" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3a570453-3d47-4e54-aada-524513c2e8a6" xlink:to="loc_dei_EntityCurrentReportingStatus_19126064-2511-4586-8108-ecd583ad34f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_f0ce05c3-11b8-4b07-aed2-738bbb05134a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3a570453-3d47-4e54-aada-524513c2e8a6" xlink:to="loc_dei_EntityInteractiveDataCurrent_f0ce05c3-11b8-4b07-aed2-738bbb05134a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_faaaaa4c-2927-452d-bcc4-a67e4de7a356" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3a570453-3d47-4e54-aada-524513c2e8a6" xlink:to="loc_dei_EntityFilerCategory_faaaaa4c-2927-452d-bcc4-a67e4de7a356" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_6eea8196-4010-49f3-971b-bf475dc231bd" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3a570453-3d47-4e54-aada-524513c2e8a6" xlink:to="loc_dei_EntitySmallBusiness_6eea8196-4010-49f3-971b-bf475dc231bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_33a2b0c0-ae66-44de-80b0-2269215b98e7" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3a570453-3d47-4e54-aada-524513c2e8a6" xlink:to="loc_dei_EntityEmergingGrowthCompany_33a2b0c0-ae66-44de-80b0-2269215b98e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_5c188b8e-274b-47df-abb3-e0d1b2b72453" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3a570453-3d47-4e54-aada-524513c2e8a6" xlink:to="loc_dei_EntityShellCompany_5c188b8e-274b-47df-abb3-e0d1b2b72453" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_5732bbb2-c08b-473b-b46d-abc2d7a5e21f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3a570453-3d47-4e54-aada-524513c2e8a6" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_5732bbb2-c08b-473b-b46d-abc2d7a5e21f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_371e3ff7-407a-4cc2-88e8-567f1e70e266" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3a570453-3d47-4e54-aada-524513c2e8a6" xlink:to="loc_dei_DocumentFiscalYearFocus_371e3ff7-407a-4cc2-88e8-567f1e70e266" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_78d555bb-6a2f-4789-b61a-d01928f5427b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3a570453-3d47-4e54-aada-524513c2e8a6" xlink:to="loc_dei_DocumentFiscalPeriodFocus_78d555bb-6a2f-4789-b61a-d01928f5427b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_fbf1140e-b1d5-4ab2-b342-22c507e46985" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3a570453-3d47-4e54-aada-524513c2e8a6" xlink:to="loc_dei_AmendmentFlag_fbf1140e-b1d5-4ab2-b342-22c507e46985" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_5d8a28b5-cd11-4189-9ce1-b9be40fc252d" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3a570453-3d47-4e54-aada-524513c2e8a6" xlink:to="loc_dei_EntityCentralIndexKey_5d8a28b5-cd11-4189-9ce1-b9be40fc252d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_918b35da-0c55-4c63-8ca6-79a1c7c70dc9" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3a570453-3d47-4e54-aada-524513c2e8a6" xlink:to="loc_dei_CurrentFiscalYearEndDate_918b35da-0c55-4c63-8ca6-79a1c7c70dc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="dnli-20210331.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_46a098c2-4f61-4933-85bd-e72da1730529" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_ca4c65ff-4b85-494e-a750-ee23072a323a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_46a098c2-4f61-4933-85bd-e72da1730529" xlink:to="loc_us-gaap_AssetsAbstract_ca4c65ff-4b85-494e-a750-ee23072a323a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_af41635f-ed5b-441c-b77e-eecb355a7b14" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_ca4c65ff-4b85-494e-a750-ee23072a323a" xlink:to="loc_us-gaap_AssetsCurrentAbstract_af41635f-ed5b-441c-b77e-eecb355a7b14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f4197a56-0e0b-451b-945d-cef8f26cbf93" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_af41635f-ed5b-441c-b77e-eecb355a7b14" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f4197a56-0e0b-451b-945d-cef8f26cbf93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_cf42ca3c-b3b6-4aa7-9682-807c3c4cbcc4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_af41635f-ed5b-441c-b77e-eecb355a7b14" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_cf42ca3c-b3b6-4aa7-9682-807c3c4cbcc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueFromRelatedPartiesCurrent_afd913cd-33c3-4c93-85c2-97c3e032abe6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueFromRelatedPartiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_af41635f-ed5b-441c-b77e-eecb355a7b14" xlink:to="loc_us-gaap_DueFromRelatedPartiesCurrent_afd913cd-33c3-4c93-85c2-97c3e032abe6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_3bb703f4-97e0-421c-a888-e7e381d04993" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_af41635f-ed5b-441c-b77e-eecb355a7b14" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_3bb703f4-97e0-421c-a888-e7e381d04993" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_a3f7e195-30f1-4035-94f1-5e8d8a517d01" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_af41635f-ed5b-441c-b77e-eecb355a7b14" xlink:to="loc_us-gaap_AssetsCurrent_a3f7e195-30f1-4035-94f1-5e8d8a517d01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_5d0f43c4-fa6a-4524-91e1-e3d8e0323487" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_ca4c65ff-4b85-494e-a750-ee23072a323a" xlink:to="loc_us-gaap_MarketableSecuritiesNoncurrent_5d0f43c4-fa6a-4524-91e1-e3d8e0323487" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_ff8519fe-0090-4ac3-964f-797d8d3a4a4b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_ca4c65ff-4b85-494e-a750-ee23072a323a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_ff8519fe-0090-4ac3-964f-797d8d3a4a4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_8e273f63-def0-4936-b4ed-1b7bcc70c538" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_ca4c65ff-4b85-494e-a750-ee23072a323a" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_8e273f63-def0-4936-b4ed-1b7bcc70c538" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_b26b174f-906f-4714-bbb3-5635d604a9af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_ca4c65ff-4b85-494e-a750-ee23072a323a" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_b26b174f-906f-4714-bbb3-5635d604a9af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_444db1e0-f55c-493d-b76b-10eb2708a890" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_ca4c65ff-4b85-494e-a750-ee23072a323a" xlink:to="loc_us-gaap_Assets_444db1e0-f55c-493d-b76b-10eb2708a890" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7c90b0ae-a791-43dd-bfd3-a9c02343d0fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_46a098c2-4f61-4933-85bd-e72da1730529" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7c90b0ae-a791-43dd-bfd3-a9c02343d0fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_4241213c-01e9-4d7d-b753-ee50555b6a5b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7c90b0ae-a791-43dd-bfd3-a9c02343d0fe" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_4241213c-01e9-4d7d-b753-ee50555b6a5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_daf1cf2f-0699-4a57-9858-ed65aa37ed58" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4241213c-01e9-4d7d-b753-ee50555b6a5b" xlink:to="loc_us-gaap_AccountsPayableCurrent_daf1cf2f-0699-4a57-9858-ed65aa37ed58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_e5a2f2bd-eae4-4a29-91c4-064aec6b3eb8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4241213c-01e9-4d7d-b753-ee50555b6a5b" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_e5a2f2bd-eae4-4a29-91c4-064aec6b3eb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_AccruedClinicalCostsCurrent_27b8b77d-0934-4eac-91ee-5b0e048a81d6" xlink:href="dnli-20210331.xsd#dnli_AccruedClinicalCostsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4241213c-01e9-4d7d-b753-ee50555b6a5b" xlink:to="loc_dnli_AccruedClinicalCostsCurrent_27b8b77d-0934-4eac-91ee-5b0e048a81d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_OtherAccruedManufacturingCostsCurrent_cd611b4c-738d-42b8-a0b8-e0fb26ce3bae" xlink:href="dnli-20210331.xsd#dnli_OtherAccruedManufacturingCostsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4241213c-01e9-4d7d-b753-ee50555b6a5b" xlink:to="loc_dnli_OtherAccruedManufacturingCostsCurrent_cd611b4c-738d-42b8-a0b8-e0fb26ce3bae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_2023694f-6344-4235-9850-84a259c6aa83" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4241213c-01e9-4d7d-b753-ee50555b6a5b" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_2023694f-6344-4235-9850-84a259c6aa83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_ac8e0312-475b-4ee7-99ff-864c069a1804" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4241213c-01e9-4d7d-b753-ee50555b6a5b" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_ac8e0312-475b-4ee7-99ff-864c069a1804" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_ContractWithCustomerLiabilityFromRelatedPartiesCurrent_f5996310-adba-435d-907e-3b354cb6ac2f" xlink:href="dnli-20210331.xsd#dnli_ContractWithCustomerLiabilityFromRelatedPartiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4241213c-01e9-4d7d-b753-ee50555b6a5b" xlink:to="loc_dnli_ContractWithCustomerLiabilityFromRelatedPartiesCurrent_f5996310-adba-435d-907e-3b354cb6ac2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_1af5811e-4dc1-4de0-9abd-2c317c293047" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4241213c-01e9-4d7d-b753-ee50555b6a5b" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_1af5811e-4dc1-4de0-9abd-2c317c293047" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_6a11a80d-9083-4528-a44e-0cc8180cf7fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4241213c-01e9-4d7d-b753-ee50555b6a5b" xlink:to="loc_us-gaap_LiabilitiesCurrent_6a11a80d-9083-4528-a44e-0cc8180cf7fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_ContractWithCustomerLiabilityFromRelatedPartiesNoncurrent_a5885cfe-e645-4274-94ab-7b4450aa28cf" xlink:href="dnli-20210331.xsd#dnli_ContractWithCustomerLiabilityFromRelatedPartiesNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7c90b0ae-a791-43dd-bfd3-a9c02343d0fe" xlink:to="loc_dnli_ContractWithCustomerLiabilityFromRelatedPartiesNoncurrent_a5885cfe-e645-4274-94ab-7b4450aa28cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_c0ab649c-df93-4016-8bed-557c8989e2be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7c90b0ae-a791-43dd-bfd3-a9c02343d0fe" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_c0ab649c-df93-4016-8bed-557c8989e2be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_c84db712-67e9-4a49-a211-9346558eeb32" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7c90b0ae-a791-43dd-bfd3-a9c02343d0fe" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_c84db712-67e9-4a49-a211-9346558eeb32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_c5608092-cf19-4b69-b65b-c92711938fea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7c90b0ae-a791-43dd-bfd3-a9c02343d0fe" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_c5608092-cf19-4b69-b65b-c92711938fea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_e3a54a79-4495-4ff0-9f6b-2a19f44f98ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7c90b0ae-a791-43dd-bfd3-a9c02343d0fe" xlink:to="loc_us-gaap_Liabilities_e3a54a79-4495-4ff0-9f6b-2a19f44f98ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_04f5a7ba-5a40-4e77-bc2e-fd5711864b14" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7c90b0ae-a791-43dd-bfd3-a9c02343d0fe" xlink:to="loc_us-gaap_CommitmentsAndContingencies_04f5a7ba-5a40-4e77-bc2e-fd5711864b14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_30904503-635b-4afc-be14-12b4967138fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7c90b0ae-a791-43dd-bfd3-a9c02343d0fe" xlink:to="loc_us-gaap_StockholdersEquityAbstract_30904503-635b-4afc-be14-12b4967138fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_8aadfc56-55cc-48e7-af23-bec2a7e4c9a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_30904503-635b-4afc-be14-12b4967138fb" xlink:to="loc_us-gaap_PreferredStockValue_8aadfc56-55cc-48e7-af23-bec2a7e4c9a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_495cfaf7-176c-4eb6-b88b-5da16f138493" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_30904503-635b-4afc-be14-12b4967138fb" xlink:to="loc_us-gaap_CommonStockValue_495cfaf7-176c-4eb6-b88b-5da16f138493" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_72ecb535-4da2-4d54-acd8-f9723e122bf6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_30904503-635b-4afc-be14-12b4967138fb" xlink:to="loc_us-gaap_AdditionalPaidInCapital_72ecb535-4da2-4d54-acd8-f9723e122bf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_3e8ffecb-2068-445f-83e5-a7467558328b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_30904503-635b-4afc-be14-12b4967138fb" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_3e8ffecb-2068-445f-83e5-a7467558328b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_9c6bbbce-b410-4dfb-8d5d-e0c96af62c57" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_30904503-635b-4afc-be14-12b4967138fb" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_9c6bbbce-b410-4dfb-8d5d-e0c96af62c57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_09316526-24e0-4b50-9358-ef492003abde" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_30904503-635b-4afc-be14-12b4967138fb" xlink:to="loc_us-gaap_StockholdersEquity_09316526-24e0-4b50-9358-ef492003abde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_9dd1f55d-5b09-4e99-b4bc-d81b68c7eb06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7c90b0ae-a791-43dd-bfd3-a9c02343d0fe" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_9dd1f55d-5b09-4e99-b4bc-d81b68c7eb06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="dnli-20210331.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_6d441537-5d70-44a8-9b0a-5f7e89e38406" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_fae9d712-32f4-4559-af47-7339b834c441" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_6d441537-5d70-44a8-9b0a-5f7e89e38406" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_fae9d712-32f4-4559-af47-7339b834c441" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_7ef80f79-a465-47e9-8600-7adb68e3b4c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_6d441537-5d70-44a8-9b0a-5f7e89e38406" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_7ef80f79-a465-47e9-8600-7adb68e3b4c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_846d9779-467d-4f1a-ab50-e3bb4e97f47e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_6d441537-5d70-44a8-9b0a-5f7e89e38406" xlink:to="loc_us-gaap_PreferredStockSharesIssued_846d9779-467d-4f1a-ab50-e3bb4e97f47e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_e8a745e3-3d93-418d-af91-43b71c56be60" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_6d441537-5d70-44a8-9b0a-5f7e89e38406" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_e8a745e3-3d93-418d-af91-43b71c56be60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_1143bdfc-f224-4746-8561-ffcffbbf8cba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_6d441537-5d70-44a8-9b0a-5f7e89e38406" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_1143bdfc-f224-4746-8561-ffcffbbf8cba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_a05427c2-e6ff-45a3-ae43-5062dac46c7e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_6d441537-5d70-44a8-9b0a-5f7e89e38406" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_a05427c2-e6ff-45a3-ae43-5062dac46c7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_d9d5bb36-7c40-4c75-ae2e-ac4b2cb40563" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_6d441537-5d70-44a8-9b0a-5f7e89e38406" xlink:to="loc_us-gaap_CommonStockSharesIssued_d9d5bb36-7c40-4c75-ae2e-ac4b2cb40563" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_4b2378c9-c681-4aa8-96ad-147fc9f7e8f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_6d441537-5d70-44a8-9b0a-5f7e89e38406" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_4b2378c9-c681-4aa8-96ad-147fc9f7e8f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="dnli-20210331.xsd#CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"/>
  <link:presentationLink xlink:role="http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_505bb610-bebc-4495-b1bd-629aa02702d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_CollaborativeRevenueAbstract_43d02444-27cd-4ae3-b3d1-7c04a854418c" xlink:href="dnli-20210331.xsd#dnli_CollaborativeRevenueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_505bb610-bebc-4495-b1bd-629aa02702d0" xlink:to="loc_dnli_CollaborativeRevenueAbstract_43d02444-27cd-4ae3-b3d1-7c04a854418c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a13299ba-3b9c-43eb-8fc1-9f341b6e4225" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dnli_CollaborativeRevenueAbstract_43d02444-27cd-4ae3-b3d1-7c04a854418c" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a13299ba-3b9c-43eb-8fc1-9f341b6e4225" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_3de6d8f2-cbb5-4138-81f9-a86929b4f94a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dnli_CollaborativeRevenueAbstract_43d02444-27cd-4ae3-b3d1-7c04a854418c" xlink:to="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_3de6d8f2-cbb5-4138-81f9-a86929b4f94a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_1c50058a-ddc3-49b5-a915-6c87d6fc27af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_505bb610-bebc-4495-b1bd-629aa02702d0" xlink:to="loc_us-gaap_Revenues_1c50058a-ddc3-49b5-a915-6c87d6fc27af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_3532b72a-8dd8-47c9-8848-d7fcb1306f95" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_505bb610-bebc-4495-b1bd-629aa02702d0" xlink:to="loc_us-gaap_OperatingExpensesAbstract_3532b72a-8dd8-47c9-8848-d7fcb1306f95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_7c19875e-ba7f-43ad-9832-f5949bca7f1a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_3532b72a-8dd8-47c9-8848-d7fcb1306f95" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_7c19875e-ba7f-43ad-9832-f5949bca7f1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_c50be6d0-8205-4e8b-b199-20797328107d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_3532b72a-8dd8-47c9-8848-d7fcb1306f95" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_c50be6d0-8205-4e8b-b199-20797328107d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_5b492025-5ac4-4cba-8e3b-73269d4d8e0e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_3532b72a-8dd8-47c9-8848-d7fcb1306f95" xlink:to="loc_us-gaap_OperatingExpenses_5b492025-5ac4-4cba-8e3b-73269d4d8e0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_fb83b724-f2eb-4d55-82b9-8249c9764e26" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_505bb610-bebc-4495-b1bd-629aa02702d0" xlink:to="loc_us-gaap_OperatingIncomeLoss_fb83b724-f2eb-4d55-82b9-8249c9764e26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_bfab9c1e-d6ed-44e6-a279-bffb132e9f2c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_505bb610-bebc-4495-b1bd-629aa02702d0" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_bfab9c1e-d6ed-44e6-a279-bffb132e9f2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent_52e9fe8a-2147-4ce5-99f0-5132bdf0c010" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_505bb610-bebc-4495-b1bd-629aa02702d0" xlink:to="loc_us-gaap_IncomeLossAttributableToParent_52e9fe8a-2147-4ce5-99f0-5132bdf0c010" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_2f98de18-2140-41b1-a732-dc14177fab63" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_505bb610-bebc-4495-b1bd-629aa02702d0" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_2f98de18-2140-41b1-a732-dc14177fab63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_6e9bc5af-b8ef-43f0-baec-a9c49f26b69c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_505bb610-bebc-4495-b1bd-629aa02702d0" xlink:to="loc_us-gaap_NetIncomeLoss_6e9bc5af-b8ef-43f0-baec-a9c49f26b69c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_130c91dd-5179-4eae-ac14-14e563593800" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTaxAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_505bb610-bebc-4495-b1bd-629aa02702d0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_130c91dd-5179-4eae-ac14-14e563593800" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax_72594d8b-9ee7-4a19-a958-7ee80d479b65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_130c91dd-5179-4eae-ac14-14e563593800" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax_72594d8b-9ee7-4a19-a958-7ee80d479b65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_80d8d7b7-63a0-47de-8617-0bbb53ba2030" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_505bb610-bebc-4495-b1bd-629aa02702d0" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_80d8d7b7-63a0-47de-8617-0bbb53ba2030" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_f1ab3d9d-1225-4249-b370-6c855fc381c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_505bb610-bebc-4495-b1bd-629aa02702d0" xlink:to="loc_us-gaap_EarningsPerShareBasic_f1ab3d9d-1225-4249-b370-6c855fc381c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_1432ee83-5e70-41f1-8076-2d57847bb820" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_505bb610-bebc-4495-b1bd-629aa02702d0" xlink:to="loc_us-gaap_EarningsPerShareDiluted_1432ee83-5e70-41f1-8076-2d57847bb820" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2878d61c-7628-45bb-a6fb-cb876d7b6fc8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_505bb610-bebc-4495-b1bd-629aa02702d0" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2878d61c-7628-45bb-a6fb-cb876d7b6fc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_a705e298-14b2-4434-8294-3e4e30cd01e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_505bb610-bebc-4495-b1bd-629aa02702d0" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_a705e298-14b2-4434-8294-3e4e30cd01e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossParenthetical" xlink:type="simple" xlink:href="dnli-20210331.xsd#CondensedConsolidatedStatementsofOperationsandComprehensiveLossParenthetical"/>
  <link:presentationLink xlink:role="http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_f39b2a2e-48d7-4a12-a91d-c2c1f33414fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromRelatedParties_e5a83547-3948-4e90-b6fc-9d5d5463570b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromRelatedParties"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_f39b2a2e-48d7-4a12-a91d-c2c1f33414fa" xlink:to="loc_us-gaap_RevenueFromRelatedParties_e5a83547-3948-4e90-b6fc-9d5d5463570b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_ResearchAndDevelopmentExpenseOffsetFromRelatedPartyCostReimbursement_ca5f1419-2496-4778-ab7f-f031f11095ec" xlink:href="dnli-20210331.xsd#dnli_ResearchAndDevelopmentExpenseOffsetFromRelatedPartyCostReimbursement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_f39b2a2e-48d7-4a12-a91d-c2c1f33414fa" xlink:to="loc_dnli_ResearchAndDevelopmentExpenseOffsetFromRelatedPartyCostReimbursement_ca5f1419-2496-4778-ab7f-f031f11095ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="dnli-20210331.xsd#CondensedConsolidatedStatementsofStockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_26136e67-e2b1-4951-93d7-56881a388870" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_4ed9b480-7e28-46d9-8541-fd0fa8029977" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_26136e67-e2b1-4951-93d7-56881a388870" xlink:to="loc_us-gaap_StatementTable_4ed9b480-7e28-46d9-8541-fd0fa8029977" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_f941b367-57ac-41b9-bd4a-e74ce5c1ceae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4ed9b480-7e28-46d9-8541-fd0fa8029977" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_f941b367-57ac-41b9-bd4a-e74ce5c1ceae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_de899a38-d740-4003-99f6-27b8d6f336b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f941b367-57ac-41b9-bd4a-e74ce5c1ceae" xlink:to="loc_us-gaap_EquityComponentDomain_de899a38-d740-4003-99f6-27b8d6f336b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_6375f451-315f-4566-ac6b-7ce8bb1332cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_de899a38-d740-4003-99f6-27b8d6f336b1" xlink:to="loc_us-gaap_CommonStockMember_6375f451-315f-4566-ac6b-7ce8bb1332cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_7b5b710f-e402-4b4f-be27-fc9da99f0041" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_de899a38-d740-4003-99f6-27b8d6f336b1" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_7b5b710f-e402-4b4f-be27-fc9da99f0041" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_e107df8d-4285-46f7-84e9-a5af490be39b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_de899a38-d740-4003-99f6-27b8d6f336b1" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_e107df8d-4285-46f7-84e9-a5af490be39b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_95d06cdc-a62c-4aa7-85c4-0d9bbf02d77c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_de899a38-d740-4003-99f6-27b8d6f336b1" xlink:to="loc_us-gaap_RetainedEarningsMember_95d06cdc-a62c-4aa7-85c4-0d9bbf02d77c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_0256e61b-a17d-4eb0-af66-df0854cfd11e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4ed9b480-7e28-46d9-8541-fd0fa8029977" xlink:to="loc_us-gaap_StatementLineItems_0256e61b-a17d-4eb0-af66-df0854cfd11e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_889b5f2f-4442-4a13-81ed-55faae35dc12" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0256e61b-a17d-4eb0-af66-df0854cfd11e" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_889b5f2f-4442-4a13-81ed-55faae35dc12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_90574ecb-f177-46ec-88e8-a8df5cb9375d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_889b5f2f-4442-4a13-81ed-55faae35dc12" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_90574ecb-f177-46ec-88e8-a8df5cb9375d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_a4e9552a-285c-4cd1-bbd3-0dbc67c9a6b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_889b5f2f-4442-4a13-81ed-55faae35dc12" xlink:to="loc_us-gaap_StockholdersEquity_a4e9552a-285c-4cd1-bbd3-0dbc67c9a6b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_faae1019-6f2c-4184-9aaf-8be1595cc3b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_889b5f2f-4442-4a13-81ed-55faae35dc12" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_faae1019-6f2c-4184-9aaf-8be1595cc3b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_de87471d-8d05-4e34-9121-3a73fd5819b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_889b5f2f-4442-4a13-81ed-55faae35dc12" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_de87471d-8d05-4e34-9121-3a73fd5819b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_StockIssuedDuringPeriodSharesEquityIncentivePlan_401d4c71-868b-4bc1-bec3-12a3afff13c2" xlink:href="dnli-20210331.xsd#dnli_StockIssuedDuringPeriodSharesEquityIncentivePlan"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_889b5f2f-4442-4a13-81ed-55faae35dc12" xlink:to="loc_dnli_StockIssuedDuringPeriodSharesEquityIncentivePlan_401d4c71-868b-4bc1-bec3-12a3afff13c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_StockIssuedDuringPeriodValueEquityIncentivePlan_fe7ddd74-4359-4cf2-85cf-af2d3c8f0ebc" xlink:href="dnli-20210331.xsd#dnli_StockIssuedDuringPeriodValueEquityIncentivePlan"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_889b5f2f-4442-4a13-81ed-55faae35dc12" xlink:to="loc_dnli_StockIssuedDuringPeriodValueEquityIncentivePlan_fe7ddd74-4359-4cf2-85cf-af2d3c8f0ebc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_a2a48af0-d94d-442b-bbe4-c4218597a838" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_889b5f2f-4442-4a13-81ed-55faae35dc12" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_a2a48af0-d94d-442b-bbe4-c4218597a838" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_bc93a820-5c70-416a-abea-53068c852ad2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_889b5f2f-4442-4a13-81ed-55faae35dc12" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_bc93a820-5c70-416a-abea-53068c852ad2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_7777618f-dd0f-4aa9-b1fd-d3b4d73b4cb7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_889b5f2f-4442-4a13-81ed-55faae35dc12" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_7777618f-dd0f-4aa9-b1fd-d3b4d73b4cb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_45dd2dde-8f4e-4c9d-93f2-0a8296ae2007" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_889b5f2f-4442-4a13-81ed-55faae35dc12" xlink:to="loc_us-gaap_NetIncomeLoss_45dd2dde-8f4e-4c9d-93f2-0a8296ae2007" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_23a72123-832b-4cb8-9250-a8569a3c4fea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_889b5f2f-4442-4a13-81ed-55faae35dc12" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_23a72123-832b-4cb8-9250-a8569a3c4fea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_4a580326-5d10-4298-a017-1f8299a613a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_889b5f2f-4442-4a13-81ed-55faae35dc12" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_4a580326-5d10-4298-a017-1f8299a613a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_14e53f27-d2f2-44af-80cf-91e9fb2367e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_889b5f2f-4442-4a13-81ed-55faae35dc12" xlink:to="loc_us-gaap_StockholdersEquity_14e53f27-d2f2-44af-80cf-91e9fb2367e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical" xlink:type="simple" xlink:href="dnli-20210331.xsd#CondensedConsolidatedStatementsofStockholdersEquityParenthetical"/>
  <link:presentationLink xlink:role="http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_6ad53f22-167e-47f4-b508-2a5aa6282b76" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_ab007735-cd2b-4586-ac5d-9b76b951fca4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_6ad53f22-167e-47f4-b508-2a5aa6282b76" xlink:to="loc_us-gaap_StatementTable_ab007735-cd2b-4586-ac5d-9b76b951fca4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_d451c8f5-1057-4c04-ac43-1e3d45fe1dd9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_ab007735-cd2b-4586-ac5d-9b76b951fca4" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_d451c8f5-1057-4c04-ac43-1e3d45fe1dd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_4f809b71-d7ba-464b-b38d-4b94f33eebe9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_d451c8f5-1057-4c04-ac43-1e3d45fe1dd9" xlink:to="loc_us-gaap_EquityComponentDomain_4f809b71-d7ba-464b-b38d-4b94f33eebe9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_d9f359f1-0875-4d1f-bd36-4673023a5ede" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_4f809b71-d7ba-464b-b38d-4b94f33eebe9" xlink:to="loc_us-gaap_CommonStockMember_d9f359f1-0875-4d1f-bd36-4673023a5ede" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_3418545f-6299-4f2c-bfae-edb695b917a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_ab007735-cd2b-4586-ac5d-9b76b951fca4" xlink:to="loc_us-gaap_StatementLineItems_3418545f-6299-4f2c-bfae-edb695b917a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_3d3854db-9598-4d98-958b-4f8810a8d585" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3418545f-6299-4f2c-bfae-edb695b917a7" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_3d3854db-9598-4d98-958b-4f8810a8d585" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="dnli-20210331.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_547dc7af-66de-4389-ac26-21c575235f5a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_cec0778c-ba51-4a5c-a5ea-ccde132bc3cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_547dc7af-66de-4389-ac26-21c575235f5a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_cec0778c-ba51-4a5c-a5ea-ccde132bc3cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_1cc96243-a791-4222-9b11-c5096199ae45" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_cec0778c-ba51-4a5c-a5ea-ccde132bc3cb" xlink:to="loc_us-gaap_NetIncomeLoss_1cc96243-a791-4222-9b11-c5096199ae45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6520c7cd-087b-418c-bb22-f9629a63e185" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_cec0778c-ba51-4a5c-a5ea-ccde132bc3cb" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6520c7cd-087b-418c-bb22-f9629a63e185" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_85e02abd-4569-4453-a6bc-cea9b088b2b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6520c7cd-087b-418c-bb22-f9629a63e185" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_85e02abd-4569-4453-a6bc-cea9b088b2b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_c169e056-24ef-4602-a378-f20e2321f19f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6520c7cd-087b-418c-bb22-f9629a63e185" xlink:to="loc_us-gaap_ShareBasedCompensation_c169e056-24ef-4602-a378-f20e2321f19f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_c3cb8038-07cd-436b-800d-5df0a8ebef6c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6520c7cd-087b-418c-bb22-f9629a63e185" xlink:to="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_c3cb8038-07cd-436b-800d-5df0a8ebef6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_IncreaseDecreaseInNonCashOperatingLeaseExpense_38be9039-4348-48fe-8bf3-1c5d0a358946" xlink:href="dnli-20210331.xsd#dnli_IncreaseDecreaseInNonCashOperatingLeaseExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6520c7cd-087b-418c-bb22-f9629a63e185" xlink:to="loc_dnli_IncreaseDecreaseInNonCashOperatingLeaseExpense_38be9039-4348-48fe-8bf3-1c5d0a358946" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_aa53e194-5657-4978-98a7-a6e88f91654a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6520c7cd-087b-418c-bb22-f9629a63e185" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_aa53e194-5657-4978-98a7-a6e88f91654a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d9426f8b-9c8a-4c46-bccc-3014e3bf6b9d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_cec0778c-ba51-4a5c-a5ea-ccde132bc3cb" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d9426f8b-9c8a-4c46-bccc-3014e3bf6b9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_0c338ff4-fb59-422a-b727-dc74449b12ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d9426f8b-9c8a-4c46-bccc-3014e3bf6b9d" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_0c338ff4-fb59-422a-b727-dc74449b12ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_636f4e40-0963-454f-8b23-785cab441017" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d9426f8b-9c8a-4c46-bccc-3014e3bf6b9d" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_636f4e40-0963-454f-8b23-785cab441017" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_1696d3cc-5b8e-4049-91fd-7805749a8587" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d9426f8b-9c8a-4c46-bccc-3014e3bf6b9d" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_1696d3cc-5b8e-4049-91fd-7805749a8587" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_233e9633-6dd7-4624-b481-e7fed5d10e31" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d9426f8b-9c8a-4c46-bccc-3014e3bf6b9d" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_233e9633-6dd7-4624-b481-e7fed5d10e31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_IncreaseDecreaseInContractWithCustomerLiabilityRelatedParties_9f65d0b6-2346-4017-9497-2453b2dd4895" xlink:href="dnli-20210331.xsd#dnli_IncreaseDecreaseInContractWithCustomerLiabilityRelatedParties"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d9426f8b-9c8a-4c46-bccc-3014e3bf6b9d" xlink:to="loc_dnli_IncreaseDecreaseInContractWithCustomerLiabilityRelatedParties_9f65d0b6-2346-4017-9497-2453b2dd4895" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ed40d724-57c0-45ce-94e9-68ce184b1e6d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_cec0778c-ba51-4a5c-a5ea-ccde132bc3cb" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ed40d724-57c0-45ce-94e9-68ce184b1e6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_8ff2e1a9-00f8-459d-8ad3-ea37944555f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_547dc7af-66de-4389-ac26-21c575235f5a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_8ff2e1a9-00f8-459d-8ad3-ea37944555f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_ac2df91a-e30a-42fc-b714-dddbcee680f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_8ff2e1a9-00f8-459d-8ad3-ea37944555f5" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_ac2df91a-e30a-42fc-b714-dddbcee680f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_f99ecc16-a157-4da2-b468-82162cc0b025" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_8ff2e1a9-00f8-459d-8ad3-ea37944555f5" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_f99ecc16-a157-4da2-b468-82162cc0b025" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_d043ecfd-ba8f-47a2-935d-50086740e09a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_8ff2e1a9-00f8-459d-8ad3-ea37944555f5" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_d043ecfd-ba8f-47a2-935d-50086740e09a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_92a3b316-7c9d-4df9-bfb3-10b1eee9d386" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_8ff2e1a9-00f8-459d-8ad3-ea37944555f5" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_92a3b316-7c9d-4df9-bfb3-10b1eee9d386" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_da101c9f-77c3-41fc-b49d-a3891a18b758" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_547dc7af-66de-4389-ac26-21c575235f5a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_da101c9f-77c3-41fc-b49d-a3891a18b758" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_94d05f68-638b-465f-b224-cd0b03d5724d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_da101c9f-77c3-41fc-b49d-a3891a18b758" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_94d05f68-638b-465f-b224-cd0b03d5724d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_164b6efc-57db-4c8b-ad2f-e544280b6337" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_da101c9f-77c3-41fc-b49d-a3891a18b758" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_164b6efc-57db-4c8b-ad2f-e544280b6337" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_df0b4f19-f578-4543-b853-c2c4bcc513e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_da101c9f-77c3-41fc-b49d-a3891a18b758" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_df0b4f19-f578-4543-b853-c2c4bcc513e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_e87f4afb-fb98-4df6-baf6-aa7e79e79dfd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_547dc7af-66de-4389-ac26-21c575235f5a" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_e87f4afb-fb98-4df6-baf6-aa7e79e79dfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2e070ac2-6e29-4339-8010-0894aae5c70e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_547dc7af-66de-4389-ac26-21c575235f5a" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2e070ac2-6e29-4339-8010-0894aae5c70e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c8018813-cc46-4b5c-9e03-97615350f4cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_547dc7af-66de-4389-ac26-21c575235f5a" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c8018813-cc46-4b5c-9e03-97615350f4cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/SignificantAccountingPolicies" xlink:type="simple" xlink:href="dnli-20210331.xsd#SignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.denalitherapeutics.com/role/SignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_e6e1d1c8-9714-43f0-a7b5-cb62eee64c6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_82eac5ff-7232-4ae4-a40a-7480f93591a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e6e1d1c8-9714-43f0-a7b5-cb62eee64c6a" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_82eac5ff-7232-4ae4-a40a-7480f93591a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/SignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="dnli-20210331.xsd#SignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.denalitherapeutics.com/role/SignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_9e205653-ab5a-4898-8869-c4961aa7a0f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_OrganizationAndDescriptionOfBusinessPolicyPolicyTextBlock_08b66f52-de69-41bb-b3d9-ef123879bf71" xlink:href="dnli-20210331.xsd#dnli_OrganizationAndDescriptionOfBusinessPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9e205653-ab5a-4898-8869-c4961aa7a0f6" xlink:to="loc_dnli_OrganizationAndDescriptionOfBusinessPolicyPolicyTextBlock_08b66f52-de69-41bb-b3d9-ef123879bf71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_8d75f166-832a-4510-a8ed-6a5c3f841498" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9e205653-ab5a-4898-8869-c4961aa7a0f6" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_8d75f166-832a-4510-a8ed-6a5c3f841498" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_28f09cbe-4652-481b-9214-dbce52e4da8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9e205653-ab5a-4898-8869-c4961aa7a0f6" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_28f09cbe-4652-481b-9214-dbce52e4da8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_ab4dfa03-b031-4b4d-bd65-90d49f6fc4b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9e205653-ab5a-4898-8869-c4961aa7a0f6" xlink:to="loc_us-gaap_UseOfEstimates_ab4dfa03-b031-4b4d-bd65-90d49f6fc4b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_639cd818-f63c-4beb-a8b1-969b2659129c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9e205653-ab5a-4898-8869-c4961aa7a0f6" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_639cd818-f63c-4beb-a8b1-969b2659129c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_10c48f47-315f-454c-a96f-3d2a71dda3ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9e205653-ab5a-4898-8869-c4961aa7a0f6" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_10c48f47-315f-454c-a96f-3d2a71dda3ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_c97f4c5b-e846-41a5-9c82-e4f5bc9d3670" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9e205653-ab5a-4898-8869-c4961aa7a0f6" xlink:to="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_c97f4c5b-e846-41a5-9c82-e4f5bc9d3670" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy_4af7f211-ec4d-4cb9-96da-6cb76d90df08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9e205653-ab5a-4898-8869-c4961aa7a0f6" xlink:to="loc_us-gaap_MarketableSecuritiesPolicy_4af7f211-ec4d-4cb9-96da-6cb76d90df08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesPolicyTextBlock_8a0ad900-2eef-4f66-9f80-8c74d069da02" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9e205653-ab5a-4898-8869-c4961aa7a0f6" xlink:to="loc_us-gaap_ReceivablesPolicyTextBlock_8a0ad900-2eef-4f66-9f80-8c74d069da02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_610f43cf-ced5-4616-b2d6-39376d4fe241" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9e205653-ab5a-4898-8869-c4961aa7a0f6" xlink:to="loc_us-gaap_DerivativesPolicyTextBlock_610f43cf-ced5-4616-b2d6-39376d4fe241" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_68734af5-6b00-4038-b3fc-036ff6a4d005" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9e205653-ab5a-4898-8869-c4961aa7a0f6" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_68734af5-6b00-4038-b3fc-036ff6a4d005" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_42e55bab-b49e-4599-840a-a1459a393930" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9e205653-ab5a-4898-8869-c4961aa7a0f6" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_42e55bab-b49e-4599-840a-a1459a393930" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_5be39cab-5d5e-43e6-bc2d-9f16020725e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9e205653-ab5a-4898-8869-c4961aa7a0f6" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_5be39cab-5d5e-43e6-bc2d-9f16020725e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_12fa552b-616a-4654-96ec-45222f941c92" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9e205653-ab5a-4898-8869-c4961aa7a0f6" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_12fa552b-616a-4654-96ec-45222f941c92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_323b0a4e-ebb6-422b-9ec3-69b18ebe8c2c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9e205653-ab5a-4898-8869-c4961aa7a0f6" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_323b0a4e-ebb6-422b-9ec3-69b18ebe8c2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/SignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="dnli-20210331.xsd#SignificantAccountingPoliciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.denalitherapeutics.com/role/SignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_12b33ce1-5f11-4983-896c-43ac95490c26" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_5572d53a-9c93-4db8-b1a6-768597a1f50e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_12b33ce1-5f11-4983-896c-43ac95490c26" xlink:to="loc_us-gaap_NumberOfOperatingSegments_5572d53a-9c93-4db8-b1a6-768597a1f50e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_2984b227-bea0-47e8-b318-f7bd2ca311bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_12b33ce1-5f11-4983-896c-43ac95490c26" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_2984b227-bea0-47e8-b318-f7bd2ca311bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="dnli-20210331.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.denalitherapeutics.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_f6d4eae3-5de2-4b6a-a9c8-cbb2c6371a3d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_3362f561-e882-4baf-a731-2505fa655482" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_f6d4eae3-5de2-4b6a-a9c8-cbb2c6371a3d" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_3362f561-e882-4baf-a731-2505fa655482" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="dnli-20210331.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.denalitherapeutics.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_b37d0fd0-d3a1-415b-9c18-72088d8b8551" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_a6827609-791d-44e2-b95f-04f6d0303da7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_b37d0fd0-d3a1-415b-9c18-72088d8b8551" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_a6827609-791d-44e2-b95f-04f6d0303da7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="dnli-20210331.xsd#FairValueMeasurementsScheduleofAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.denalitherapeutics.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_9cfc864a-9f82-4033-bbda-d87775dfdee9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2545578b-ad36-4410-a2fa-2272fc38812d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_9cfc864a-9f82-4033-bbda-d87775dfdee9" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2545578b-ad36-4410-a2fa-2272fc38812d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_234dca52-14bd-43c9-bdd5-0f6f566985ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2545578b-ad36-4410-a2fa-2272fc38812d" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_234dca52-14bd-43c9-bdd5-0f6f566985ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_71058fb5-394e-4ce5-91d0-ac4e9cd9c796" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_234dca52-14bd-43c9-bdd5-0f6f566985ec" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_71058fb5-394e-4ce5-91d0-ac4e9cd9c796" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_68342994-163b-420b-9eab-2aea6dc26dfc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_71058fb5-394e-4ce5-91d0-ac4e9cd9c796" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_68342994-163b-420b-9eab-2aea6dc26dfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_54fd5cb5-2949-4011-9dbc-d4168299c240" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_71058fb5-394e-4ce5-91d0-ac4e9cd9c796" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_54fd5cb5-2949-4011-9dbc-d4168299c240" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_ccd665d5-d628-4e6b-a67e-98bfdb65be26" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_71058fb5-394e-4ce5-91d0-ac4e9cd9c796" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_ccd665d5-d628-4e6b-a67e-98bfdb65be26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_3295dabe-deb4-4355-8036-62b01e9dff7e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2545578b-ad36-4410-a2fa-2272fc38812d" xlink:to="loc_us-gaap_InvestmentTypeAxis_3295dabe-deb4-4355-8036-62b01e9dff7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_82bbbce4-6229-45a5-ac35-7b7fc2e20e75" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_3295dabe-deb4-4355-8036-62b01e9dff7e" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_82bbbce4-6229-45a5-ac35-7b7fc2e20e75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_9267763b-d51e-4a20-9d10-68284a6811c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_82bbbce4-6229-45a5-ac35-7b7fc2e20e75" xlink:to="loc_us-gaap_ShortTermInvestmentsMember_9267763b-d51e-4a20-9d10-68284a6811c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_LongTermInvestmentsMember_61963fb5-72e3-4a95-ab55-30484535c0cd" xlink:href="dnli-20210331.xsd#dnli_LongTermInvestmentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_82bbbce4-6229-45a5-ac35-7b7fc2e20e75" xlink:to="loc_dnli_LongTermInvestmentsMember_61963fb5-72e3-4a95-ab55-30484535c0cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_f841257f-c62f-4d64-bc20-c404b75b7139" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2545578b-ad36-4410-a2fa-2272fc38812d" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_f841257f-c62f-4d64-bc20-c404b75b7139" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_f1b45fd4-699b-4dec-9974-6eb6a717dc14" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_f841257f-c62f-4d64-bc20-c404b75b7139" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_f1b45fd4-699b-4dec-9974-6eb6a717dc14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_eabfc9ca-2bd9-46f6-82a1-7036efe30a30" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_f1b45fd4-699b-4dec-9974-6eb6a717dc14" xlink:to="loc_us-gaap_MoneyMarketFundsMember_eabfc9ca-2bd9-46f6-82a1-7036efe30a30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_a75c05da-83f5-4f61-a2f2-eaa68252912a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_f1b45fd4-699b-4dec-9974-6eb6a717dc14" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_a75c05da-83f5-4f61-a2f2-eaa68252912a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_1df95bf0-a422-44a3-92f3-73821294a7db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_f1b45fd4-699b-4dec-9974-6eb6a717dc14" xlink:to="loc_us-gaap_CommercialPaperMember_1df95bf0-a422-44a3-92f3-73821294a7db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_94e4848b-3885-488d-b336-bae93ec8ce9b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2545578b-ad36-4410-a2fa-2272fc38812d" xlink:to="loc_us-gaap_FinancialInstrumentAxis_94e4848b-3885-488d-b336-bae93ec8ce9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_404a0724-9f09-452f-a382-2b277fac77d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_94e4848b-3885-488d-b336-bae93ec8ce9b" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_404a0724-9f09-452f-a382-2b277fac77d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_9b7efa1e-45f1-4c11-be8c-b0116a10eaa8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_404a0724-9f09-452f-a382-2b277fac77d5" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_9b7efa1e-45f1-4c11-be8c-b0116a10eaa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_71084d88-8a4e-46e9-b6c2-89e0acdae499" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_404a0724-9f09-452f-a382-2b277fac77d5" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_71084d88-8a4e-46e9-b6c2-89e0acdae499" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_b793c66a-8e44-446e-8be4-82e59fb89aa7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_404a0724-9f09-452f-a382-2b277fac77d5" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_b793c66a-8e44-446e-8be4-82e59fb89aa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_7bbeca91-6f6e-4031-8d8b-53ea44fd2338" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_404a0724-9f09-452f-a382-2b277fac77d5" xlink:to="loc_us-gaap_CommercialPaperMember_7bbeca91-6f6e-4031-8d8b-53ea44fd2338" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_487143d0-814a-4dc1-a7b0-a692d32063fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2545578b-ad36-4410-a2fa-2272fc38812d" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_487143d0-814a-4dc1-a7b0-a692d32063fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_a21cbe4a-d0da-4f42-9703-b3183eb1b256" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_487143d0-814a-4dc1-a7b0-a692d32063fb" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_a21cbe4a-d0da-4f42-9703-b3183eb1b256" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_780c6734-f903-4f35-90f1-4bb2cb2b85d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_a21cbe4a-d0da-4f42-9703-b3183eb1b256" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_780c6734-f903-4f35-90f1-4bb2cb2b85d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_bf9ac4bf-9639-400c-9231-94f5e1f811dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_a21cbe4a-d0da-4f42-9703-b3183eb1b256" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_bf9ac4bf-9639-400c-9231-94f5e1f811dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_33417d71-2bab-44e5-9304-396ab3db7e4d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_a21cbe4a-d0da-4f42-9703-b3183eb1b256" xlink:to="loc_us-gaap_DerivativeAssets_33417d71-2bab-44e5-9304-396ab3db7e4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_686b3862-cb29-4072-a960-a8e0009091a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_a21cbe4a-d0da-4f42-9703-b3183eb1b256" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_686b3862-cb29-4072-a960-a8e0009091a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_d79d0787-4587-4a0a-a747-4859d3ce9895" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_487143d0-814a-4dc1-a7b0-a692d32063fb" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_d79d0787-4587-4a0a-a747-4859d3ce9895" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_ddbd060b-fcc6-4805-9115-99127a724642" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_d79d0787-4587-4a0a-a747-4859d3ce9895" xlink:to="loc_us-gaap_DerivativeLiabilities_ddbd060b-fcc6-4805-9115-99127a724642" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_606d54c8-668e-4154-b5e3-c6ad56b3fdff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_d79d0787-4587-4a0a-a747-4859d3ce9895" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_606d54c8-668e-4154-b5e3-c6ad56b3fdff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/MarketableSecurities" xlink:type="simple" xlink:href="dnli-20210331.xsd#MarketableSecurities"/>
  <link:presentationLink xlink:role="http://www.denalitherapeutics.com/role/MarketableSecurities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_ba0d528f-a70e-43b3-a5cc-7e17571a28f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_83608a8e-1400-424f-bde5-830ac81eec43" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_ba0d528f-a70e-43b3-a5cc-7e17571a28f0" xlink:to="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_83608a8e-1400-424f-bde5-830ac81eec43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/MarketableSecuritiesTables" xlink:type="simple" xlink:href="dnli-20210331.xsd#MarketableSecuritiesTables"/>
  <link:presentationLink xlink:role="http://www.denalitherapeutics.com/role/MarketableSecuritiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_659eee2e-1650-4917-910b-1b8a4909d5d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_53282d3f-43cc-4b48-af0b-28078d2c0a37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_659eee2e-1650-4917-910b-1b8a4909d5d8" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_53282d3f-43cc-4b48-af0b-28078d2c0a37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/MarketableSecuritiesSummaryofAvailableforSaleSecuritiesDetails" xlink:type="simple" xlink:href="dnli-20210331.xsd#MarketableSecuritiesSummaryofAvailableforSaleSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.denalitherapeutics.com/role/MarketableSecuritiesSummaryofAvailableforSaleSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_d282d9a5-b20d-46c8-b06c-894ee728f25d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_84be667e-8b04-496e-9c86-94fd2282131f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_d282d9a5-b20d-46c8-b06c-894ee728f25d" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_84be667e-8b04-496e-9c86-94fd2282131f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_54e12291-7676-43af-9e5a-63a368dbac38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_84be667e-8b04-496e-9c86-94fd2282131f" xlink:to="loc_us-gaap_InvestmentTypeAxis_54e12291-7676-43af-9e5a-63a368dbac38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_d08f6bf8-ba2e-49da-b6af-b22c0edf0cc7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_54e12291-7676-43af-9e5a-63a368dbac38" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_d08f6bf8-ba2e-49da-b6af-b22c0edf0cc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_ShortTermMarketableSecuritiesMember_57c7479e-e492-4aef-b9d4-83570742060c" xlink:href="dnli-20210331.xsd#dnli_ShortTermMarketableSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_d08f6bf8-ba2e-49da-b6af-b22c0edf0cc7" xlink:to="loc_dnli_ShortTermMarketableSecuritiesMember_57c7479e-e492-4aef-b9d4-83570742060c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_LongTermMarketableSecuritiesMember_8bd9b0aa-6989-4412-b99e-50ab014d9b4a" xlink:href="dnli-20210331.xsd#dnli_LongTermMarketableSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_d08f6bf8-ba2e-49da-b6af-b22c0edf0cc7" xlink:to="loc_dnli_LongTermMarketableSecuritiesMember_8bd9b0aa-6989-4412-b99e-50ab014d9b4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_284412df-56a9-4334-8dda-0cf73a112402" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_84be667e-8b04-496e-9c86-94fd2282131f" xlink:to="loc_us-gaap_FinancialInstrumentAxis_284412df-56a9-4334-8dda-0cf73a112402" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_480eb44d-e512-4c47-887d-7db3716fe83d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_284412df-56a9-4334-8dda-0cf73a112402" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_480eb44d-e512-4c47-887d-7db3716fe83d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_bc5c2112-a2a0-44ba-b3be-7cdfcaf7d5ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_480eb44d-e512-4c47-887d-7db3716fe83d" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_bc5c2112-a2a0-44ba-b3be-7cdfcaf7d5ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_881963b3-f886-49a2-ac20-76006030dd67" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_480eb44d-e512-4c47-887d-7db3716fe83d" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_881963b3-f886-49a2-ac20-76006030dd67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_a08517a7-42f5-477c-aede-c7d64addd66d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_480eb44d-e512-4c47-887d-7db3716fe83d" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_a08517a7-42f5-477c-aede-c7d64addd66d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_0da34d4d-7615-4788-a6a9-18e32992b1de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_480eb44d-e512-4c47-887d-7db3716fe83d" xlink:to="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_0da34d4d-7615-4788-a6a9-18e32992b1de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_542008ee-1e41-4c12-91c2-e4722007d1b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_84be667e-8b04-496e-9c86-94fd2282131f" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_542008ee-1e41-4c12-91c2-e4722007d1b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_421a2c27-4476-46c3-b0b5-bd5dd8b95edb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_542008ee-1e41-4c12-91c2-e4722007d1b5" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_421a2c27-4476-46c3-b0b5-bd5dd8b95edb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_276e7c9c-58d9-4c5f-8ec2-50784ad45ebf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_542008ee-1e41-4c12-91c2-e4722007d1b5" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_276e7c9c-58d9-4c5f-8ec2-50784ad45ebf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_2523e922-0847-4b1d-9c03-fd706f2cd81e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_542008ee-1e41-4c12-91c2-e4722007d1b5" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_2523e922-0847-4b1d-9c03-fd706f2cd81e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_fb509074-4097-4f58-a1d8-5e8dba4d642e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_542008ee-1e41-4c12-91c2-e4722007d1b5" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_fb509074-4097-4f58-a1d8-5e8dba4d642e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_110cc1ce-f7cf-4a8e-8241-98ebd0e29a69" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_542008ee-1e41-4c12-91c2-e4722007d1b5" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_110cc1ce-f7cf-4a8e-8241-98ebd0e29a69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_92889ee6-fda6-4d7d-a3f2-568b290b65e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_542008ee-1e41-4c12-91c2-e4722007d1b5" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_92889ee6-fda6-4d7d-a3f2-568b290b65e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/MarketableSecuritiesNarrativeDetails" xlink:type="simple" xlink:href="dnli-20210331.xsd#MarketableSecuritiesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.denalitherapeutics.com/role/MarketableSecuritiesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_de925cb3-90b1-45fd-ad9d-4ee4c1dd7a8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_c1004788-cf35-4a07-934b-b0b2826f4795" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_de925cb3-90b1-45fd-ad9d-4ee4c1dd7a8b" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_c1004788-cf35-4a07-934b-b0b2826f4795" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_82158c19-7267-4ff1-882e-c02a08c77e6e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_de925cb3-90b1-45fd-ad9d-4ee4c1dd7a8b" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_82158c19-7267-4ff1-882e-c02a08c77e6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_dec207a0-56f6-4097-8fe6-a8e29af641bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_de925cb3-90b1-45fd-ad9d-4ee4c1dd7a8b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_dec207a0-56f6-4097-8fe6-a8e29af641bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTerm_69263898-0444-4b86-897e-dd9fe4c71ddd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTerm"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_de925cb3-90b1-45fd-ad9d-4ee4c1dd7a8b" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTerm_69263898-0444-4b86-897e-dd9fe4c71ddd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/DerivativeFinancialInstruments" xlink:type="simple" xlink:href="dnli-20210331.xsd#DerivativeFinancialInstruments"/>
  <link:presentationLink xlink:role="http://www.denalitherapeutics.com/role/DerivativeFinancialInstruments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_4c1e65c7-f32a-4eec-89b6-9abce4020c05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_e25bc7c9-54f5-4827-a639-d1320caef791" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_4c1e65c7-f32a-4eec-89b6-9abce4020c05" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_e25bc7c9-54f5-4827-a639-d1320caef791" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/DerivativeFinancialInstrumentsTables" xlink:type="simple" xlink:href="dnli-20210331.xsd#DerivativeFinancialInstrumentsTables"/>
  <link:presentationLink xlink:role="http://www.denalitherapeutics.com/role/DerivativeFinancialInstrumentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_cc93c636-e762-4ffd-95c4-65281435f6a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock_0cf2cfa8-26ed-4d1b-add5-11d88a8d6444" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_cc93c636-e762-4ffd-95c4-65281435f6a8" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock_0cf2cfa8-26ed-4d1b-add5-11d88a8d6444" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/DerivativeFinancialInstrumentsSummaryofForwardForeignCurrencyExchangeContractsOutstandingDetails" xlink:type="simple" xlink:href="dnli-20210331.xsd#DerivativeFinancialInstrumentsSummaryofForwardForeignCurrencyExchangeContractsOutstandingDetails"/>
  <link:presentationLink xlink:role="http://www.denalitherapeutics.com/role/DerivativeFinancialInstrumentsSummaryofForwardForeignCurrencyExchangeContractsOutstandingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_27cba057-cea3-4857-900e-9faf7722a6b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_0c26b376-1b90-4515-9f2a-ae3bf6cd4f81" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_27cba057-cea3-4857-900e-9faf7722a6b6" xlink:to="loc_us-gaap_DerivativeTable_0c26b376-1b90-4515-9f2a-ae3bf6cd4f81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_93fffd0b-289e-4c4b-bc8e-64ad3817b96e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_0c26b376-1b90-4515-9f2a-ae3bf6cd4f81" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_93fffd0b-289e-4c4b-bc8e-64ad3817b96e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_d75e7556-b0a8-424d-aaf1-6fd05e8a3d1f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_93fffd0b-289e-4c4b-bc8e-64ad3817b96e" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_d75e7556-b0a8-424d-aaf1-6fd05e8a3d1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_ForeignExchangeForwardEurosMember_f12ef76a-b8b8-4ac3-80e7-dd4118a4f42a" xlink:href="dnli-20210331.xsd#dnli_ForeignExchangeForwardEurosMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_d75e7556-b0a8-424d-aaf1-6fd05e8a3d1f" xlink:to="loc_dnli_ForeignExchangeForwardEurosMember_f12ef76a-b8b8-4ac3-80e7-dd4118a4f42a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_ForeignExchangeForwardBritishPoundsMember_1677bcb2-1133-471b-92e7-f4794855fec2" xlink:href="dnli-20210331.xsd#dnli_ForeignExchangeForwardBritishPoundsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_d75e7556-b0a8-424d-aaf1-6fd05e8a3d1f" xlink:to="loc_dnli_ForeignExchangeForwardBritishPoundsMember_1677bcb2-1133-471b-92e7-f4794855fec2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_f5de6020-57c7-40a4-99d6-f5034da39a02" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_d75e7556-b0a8-424d-aaf1-6fd05e8a3d1f" xlink:to="loc_us-gaap_ForeignExchangeContractMember_f5de6020-57c7-40a4-99d6-f5034da39a02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_6b919dc7-6e8f-42a1-9702-98541c2973d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_0c26b376-1b90-4515-9f2a-ae3bf6cd4f81" xlink:to="loc_us-gaap_HedgingDesignationAxis_6b919dc7-6e8f-42a1-9702-98541c2973d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_215cde8c-a920-49c2-a16c-e96b8b173406" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_6b919dc7-6e8f-42a1-9702-98541c2973d9" xlink:to="loc_us-gaap_HedgingDesignationDomain_215cde8c-a920-49c2-a16c-e96b8b173406" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_99e9e739-c1b6-4cf9-aa76-d8428b226473" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_215cde8c-a920-49c2-a16c-e96b8b173406" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_99e9e739-c1b6-4cf9-aa76-d8428b226473" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_3fe3be21-bcc2-4b77-8373-20e8bffacee7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_0c26b376-1b90-4515-9f2a-ae3bf6cd4f81" xlink:to="loc_us-gaap_DerivativeLineItems_3fe3be21-bcc2-4b77-8373-20e8bffacee7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNumberOfInstrumentsHeld_070c601d-9881-4eff-bd62-8131a2874935" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeNumberOfInstrumentsHeld"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_3fe3be21-bcc2-4b77-8373-20e8bffacee7" xlink:to="loc_us-gaap_DerivativeNumberOfInstrumentsHeld_070c601d-9881-4eff-bd62-8131a2874935" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_049c6b2c-531b-42f2-9f4f-65dc0f00ef4d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_3fe3be21-bcc2-4b77-8373-20e8bffacee7" xlink:to="loc_us-gaap_DerivativeNotionalAmount_049c6b2c-531b-42f2-9f4f-65dc0f00ef4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/DerivativeFinancialInstrumentsNarrativeDetails" xlink:type="simple" xlink:href="dnli-20210331.xsd#DerivativeFinancialInstrumentsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.denalitherapeutics.com/role/DerivativeFinancialInstrumentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_ebde734f-428e-4a08-88a4-137e7804b865" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_36fb0810-dd2b-478c-921f-41edacbb62cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_ebde734f-428e-4a08-88a4-137e7804b865" xlink:to="loc_us-gaap_DerivativeTable_36fb0810-dd2b-478c-921f-41edacbb62cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_23f845b5-2a33-40c4-8fbc-673679ec8355" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_36fb0810-dd2b-478c-921f-41edacbb62cb" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_23f845b5-2a33-40c4-8fbc-673679ec8355" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_c70ef412-207c-4a0d-82ad-d6a5fbdbb74f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_23f845b5-2a33-40c4-8fbc-673679ec8355" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_c70ef412-207c-4a0d-82ad-d6a5fbdbb74f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_44b19829-a20a-49b7-8bb4-8b8ec9eee8ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_c70ef412-207c-4a0d-82ad-d6a5fbdbb74f" xlink:to="loc_us-gaap_ForeignExchangeContractMember_44b19829-a20a-49b7-8bb4-8b8ec9eee8ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_7cfa8c51-866b-475d-8385-84ac29cefd7e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_36fb0810-dd2b-478c-921f-41edacbb62cb" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_7cfa8c51-866b-475d-8385-84ac29cefd7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_027e0c28-8a85-4f58-82d1-55b701fee73d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_7cfa8c51-866b-475d-8385-84ac29cefd7e" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_027e0c28-8a85-4f58-82d1-55b701fee73d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_4606a4ea-2eca-47b9-8694-f107839502ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_027e0c28-8a85-4f58-82d1-55b701fee73d" xlink:to="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_4606a4ea-2eca-47b9-8694-f107839502ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_fbb46b8b-02de-4ed0-981f-bdd1cc85829a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_36fb0810-dd2b-478c-921f-41edacbb62cb" xlink:to="loc_us-gaap_DerivativeLineItems_fbb46b8b-02de-4ed0-981f-bdd1cc85829a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_090e87b1-8665-4163-985f-cded6e9a0fe4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_fbb46b8b-02de-4ed0-981f-bdd1cc85829a" xlink:to="loc_us-gaap_DerivativeLiabilities_090e87b1-8665-4163-985f-cded6e9a0fe4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_2c5cd6e3-24bd-43d2-b456-9dc3e8aec57f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_fbb46b8b-02de-4ed0-981f-bdd1cc85829a" xlink:to="loc_us-gaap_DerivativeAssets_2c5cd6e3-24bd-43d2-b456-9dc3e8aec57f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_8e2a2ea2-0d9f-4cc2-a508-0ee05e203de8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_fbb46b8b-02de-4ed0-981f-bdd1cc85829a" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_8e2a2ea2-0d9f-4cc2-a508-0ee05e203de8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/CollaborationAgreements" xlink:type="simple" xlink:href="dnli-20210331.xsd#CollaborationAgreements"/>
  <link:presentationLink xlink:role="http://www.denalitherapeutics.com/role/CollaborationAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_584dfb6d-f377-447e-a872-c485f1dbe0aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_dd0edd82-fc9b-4aef-ada9-fa52e7a51cc7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_584dfb6d-f377-447e-a872-c485f1dbe0aa" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_dd0edd82-fc9b-4aef-ada9-fa52e7a51cc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/CollaborationAgreementsTables" xlink:type="simple" xlink:href="dnli-20210331.xsd#CollaborationAgreementsTables"/>
  <link:presentationLink xlink:role="http://www.denalitherapeutics.com/role/CollaborationAgreementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6023c70f-46db-46a8-b356-5f0310187e34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_fa804551-bc24-4fbb-8963-cd246dfc8717" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6023c70f-46db-46a8-b356-5f0310187e34" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_fa804551-bc24-4fbb-8963-cd246dfc8717" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/CollaborationAgreementsBiogenDetails" xlink:type="simple" xlink:href="dnli-20210331.xsd#CollaborationAgreementsBiogenDetails"/>
  <link:presentationLink xlink:role="http://www.denalitherapeutics.com/role/CollaborationAgreementsBiogenDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_aafe415d-7f94-4c07-a61f-dd1e830fc9e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7a5fa7b9-eef0-4f39-ad9c-a683dda9b070" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_aafe415d-7f94-4c07-a61f-dd1e830fc9e2" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7a5fa7b9-eef0-4f39-ad9c-a683dda9b070" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_66c3aba5-f74e-4547-bc5e-774846e9cd9a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7a5fa7b9-eef0-4f39-ad9c-a683dda9b070" xlink:to="loc_us-gaap_TypeOfArrangementAxis_66c3aba5-f74e-4547-bc5e-774846e9cd9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_188d3bf5-8193-4511-aa62-bf59a709907b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_66c3aba5-f74e-4547-bc5e-774846e9cd9a" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_188d3bf5-8193-4511-aa62-bf59a709907b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_ProvisionalCollaborativeArrangementMember_58d402e8-9fea-4fe1-9c92-28c34f50ae70" xlink:href="dnli-20210331.xsd#dnli_ProvisionalCollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_188d3bf5-8193-4511-aa62-bf59a709907b" xlink:to="loc_dnli_ProvisionalCollaborativeArrangementMember_58d402e8-9fea-4fe1-9c92-28c34f50ae70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_ROFNAndOptionAgreementCollaborativeArrangementMember_306666a0-5949-4d42-8adc-b972cce5eba2" xlink:href="dnli-20210331.xsd#dnli_ROFNAndOptionAgreementCollaborativeArrangementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_188d3bf5-8193-4511-aa62-bf59a709907b" xlink:to="loc_dnli_ROFNAndOptionAgreementCollaborativeArrangementMember_306666a0-5949-4d42-8adc-b972cce5eba2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_BiogenCollaborativeArrangementMember_80fd9c82-9b3c-46d5-b35a-8e0be66f6ba1" xlink:href="dnli-20210331.xsd#dnli_BiogenCollaborativeArrangementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_188d3bf5-8193-4511-aa62-bf59a709907b" xlink:to="loc_dnli_BiogenCollaborativeArrangementMember_80fd9c82-9b3c-46d5-b35a-8e0be66f6ba1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_0c8dd07e-58bb-4b7f-8fdc-765859545aa9" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7a5fa7b9-eef0-4f39-ad9c-a683dda9b070" xlink:to="loc_srt_CounterpartyNameAxis_0c8dd07e-58bb-4b7f-8fdc-765859545aa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_98bd595b-fc79-4c6d-b848-f897777a9e33" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_0c8dd07e-58bb-4b7f-8fdc-765859545aa9" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_98bd595b-fc79-4c6d-b848-f897777a9e33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_BiogenMember_def87e74-cae8-4e9d-8b2d-8fd534e24b43" xlink:href="dnli-20210331.xsd#dnli_BiogenMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_98bd595b-fc79-4c6d-b848-f897777a9e33" xlink:to="loc_dnli_BiogenMember_def87e74-cae8-4e9d-8b2d-8fd534e24b43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_5d09a4aa-b82c-4687-b694-85e2c3793f6a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7a5fa7b9-eef0-4f39-ad9c-a683dda9b070" xlink:to="loc_srt_ProductOrServiceAxis_5d09a4aa-b82c-4687-b694-85e2c3793f6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_346c4849-1b65-44d7-97e8-e698fecaf8da" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_5d09a4aa-b82c-4687-b694-85e2c3793f6a" xlink:to="loc_srt_ProductsAndServicesDomain_346c4849-1b65-44d7-97e8-e698fecaf8da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_TransportVehicleTechnologyPlatformUnnamedProgramMember_b06da69c-0b6e-4d35-a90a-a031fce3fd13" xlink:href="dnli-20210331.xsd#dnli_TransportVehicleTechnologyPlatformUnnamedProgramMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_346c4849-1b65-44d7-97e8-e698fecaf8da" xlink:to="loc_dnli_TransportVehicleTechnologyPlatformUnnamedProgramMember_b06da69c-0b6e-4d35-a90a-a031fce3fd13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_TransportVehicleTechnologyProgramRightOfFirstNegotiationProgramsMember_dc90edb3-b67d-4426-9d2b-1eb9cacf3abc" xlink:href="dnli-20210331.xsd#dnli_TransportVehicleTechnologyProgramRightOfFirstNegotiationProgramsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_346c4849-1b65-44d7-97e8-e698fecaf8da" xlink:to="loc_dnli_TransportVehicleTechnologyProgramRightOfFirstNegotiationProgramsMember_dc90edb3-b67d-4426-9d2b-1eb9cacf3abc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_TransportVehicleTechnologyPlatformPreclinicalProgramsMember_7b8bb976-ab46-4cc6-8fd6-67fa258ffc65" xlink:href="dnli-20210331.xsd#dnli_TransportVehicleTechnologyPlatformPreclinicalProgramsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_346c4849-1b65-44d7-97e8-e698fecaf8da" xlink:to="loc_dnli_TransportVehicleTechnologyPlatformPreclinicalProgramsMember_7b8bb976-ab46-4cc6-8fd6-67fa258ffc65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_TransportVehicleTechnologyPlatformRightOfFirstNegotiationProgramsMember_1d19fa75-16f5-4e82-ba77-c6608635ceed" xlink:href="dnli-20210331.xsd#dnli_TransportVehicleTechnologyPlatformRightOfFirstNegotiationProgramsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_346c4849-1b65-44d7-97e8-e698fecaf8da" xlink:to="loc_dnli_TransportVehicleTechnologyPlatformRightOfFirstNegotiationProgramsMember_1d19fa75-16f5-4e82-ba77-c6608635ceed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_OptionResearchServicesMember_2bbe310a-23d8-4271-9428-ec552080d33d" xlink:href="dnli-20210331.xsd#dnli_OptionResearchServicesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_346c4849-1b65-44d7-97e8-e698fecaf8da" xlink:to="loc_dnli_OptionResearchServicesMember_2bbe310a-23d8-4271-9428-ec552080d33d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_9f57ca4f-3615-4883-9fe3-a91d46fa9e44" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7a5fa7b9-eef0-4f39-ad9c-a683dda9b070" xlink:to="loc_dei_LegalEntityAxis_9f57ca4f-3615-4883-9fe3-a91d46fa9e44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_13a10a60-c1ed-46b7-a219-3653b20b6bbb" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_9f57ca4f-3615-4883-9fe3-a91d46fa9e44" xlink:to="loc_dei_EntityDomain_13a10a60-c1ed-46b7-a219-3653b20b6bbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_BiogenMember_602b34ac-2ecc-4ef7-be43-c55a54aa5c02" xlink:href="dnli-20210331.xsd#dnli_BiogenMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_13a10a60-c1ed-46b7-a219-3653b20b6bbb" xlink:to="loc_dnli_BiogenMember_602b34ac-2ecc-4ef7-be43-c55a54aa5c02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_c7381bd6-884f-42a0-9908-68bb30822448" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7a5fa7b9-eef0-4f39-ad9c-a683dda9b070" xlink:to="loc_srt_StatementGeographicalAxis_c7381bd6-884f-42a0-9908-68bb30822448" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_1cd4f766-feef-4b13-8b94-7e5551102efc" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_c7381bd6-884f-42a0-9908-68bb30822448" xlink:to="loc_srt_SegmentGeographicalDomain_1cd4f766-feef-4b13-8b94-7e5551102efc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_6ca681e5-7b71-4bed-93dc-ebc2402876f8" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_1cd4f766-feef-4b13-8b94-7e5551102efc" xlink:to="loc_country_US_6ca681e5-7b71-4bed-93dc-ebc2402876f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CN_18918321-29a1-44e7-9559-e9c1d64791cf" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_CN"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_1cd4f766-feef-4b13-8b94-7e5551102efc" xlink:to="loc_country_CN_18918321-29a1-44e7-9559-e9c1d64791cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_df72851b-bc4d-4b77-a27a-72623cbeb8eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7a5fa7b9-eef0-4f39-ad9c-a683dda9b070" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_df72851b-bc4d-4b77-a27a-72623cbeb8eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_c4d594db-0378-4822-bcf1-13341bae6271" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_df72851b-bc4d-4b77-a27a-72623cbeb8eb" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_c4d594db-0378-4822-bcf1-13341bae6271" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_SharePurchaseAgreementMember_deb6442f-e4c4-4b34-bf8c-5cae2a518b56" xlink:href="dnli-20210331.xsd#dnli_SharePurchaseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_c4d594db-0378-4822-bcf1-13341bae6271" xlink:to="loc_dnli_SharePurchaseAgreementMember_deb6442f-e4c4-4b34-bf8c-5cae2a518b56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_12aeaec0-20a5-43a6-89b6-604e52eb9da3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7a5fa7b9-eef0-4f39-ad9c-a683dda9b070" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_12aeaec0-20a5-43a6-89b6-604e52eb9da3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_65dfd509-e7e6-4ad8-b40a-b931ed36ee09" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_12aeaec0-20a5-43a6-89b6-604e52eb9da3" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_65dfd509-e7e6-4ad8-b40a-b931ed36ee09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_09c35134-d5eb-4fe4-8254-82905ead54e8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_AffiliatedEntityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_65dfd509-e7e6-4ad8-b40a-b931ed36ee09" xlink:to="loc_srt_AffiliatedEntityMember_09c35134-d5eb-4fe4-8254-82905ead54e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a8c4441e-4d10-4239-9330-25c3d05dbb4d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7a5fa7b9-eef0-4f39-ad9c-a683dda9b070" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a8c4441e-4d10-4239-9330-25c3d05dbb4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_CollaborativeArrangementNumberOfPrograms_2431d990-9397-4057-98ba-460503c9490c" xlink:href="dnli-20210331.xsd#dnli_CollaborativeArrangementNumberOfPrograms"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a8c4441e-4d10-4239-9330-25c3d05dbb4d" xlink:to="loc_dnli_CollaborativeArrangementNumberOfPrograms_2431d990-9397-4057-98ba-460503c9490c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_CollaborativeArrangementNumberOfAdditionalProgramsIfCircumstancesMet_87358e02-e60e-40a7-8ce7-6ed46c82cc46" xlink:href="dnli-20210331.xsd#dnli_CollaborativeArrangementNumberOfAdditionalProgramsIfCircumstancesMet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a8c4441e-4d10-4239-9330-25c3d05dbb4d" xlink:to="loc_dnli_CollaborativeArrangementNumberOfAdditionalProgramsIfCircumstancesMet_87358e02-e60e-40a7-8ce7-6ed46c82cc46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_CollaborativeArrangementUpfrontPaymentToBeReceived_b7820646-980e-480a-81b9-55187136f18c" xlink:href="dnli-20210331.xsd#dnli_CollaborativeArrangementUpfrontPaymentToBeReceived"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a8c4441e-4d10-4239-9330-25c3d05dbb4d" xlink:to="loc_dnli_CollaborativeArrangementUpfrontPaymentToBeReceived_b7820646-980e-480a-81b9-55187136f18c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_AggregateDevelopmentFirstCommercialSaleAndNetSalesBasedMilestonePayments_937d188a-7287-4792-8a5f-036dbec2a524" xlink:href="dnli-20210331.xsd#dnli_AggregateDevelopmentFirstCommercialSaleAndNetSalesBasedMilestonePayments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a8c4441e-4d10-4239-9330-25c3d05dbb4d" xlink:to="loc_dnli_AggregateDevelopmentFirstCommercialSaleAndNetSalesBasedMilestonePayments_937d188a-7287-4792-8a5f-036dbec2a524" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_DevelopmentMilestonePayments_2efe4f40-62fe-4e58-bb1b-3cbb685c6355" xlink:href="dnli-20210331.xsd#dnli_DevelopmentMilestonePayments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a8c4441e-4d10-4239-9330-25c3d05dbb4d" xlink:to="loc_dnli_DevelopmentMilestonePayments_2efe4f40-62fe-4e58-bb1b-3cbb685c6355" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_FirstCommercialSaleMilestonePayments_09583a79-c1ac-46bb-bb56-bc8353c97f8b" xlink:href="dnli-20210331.xsd#dnli_FirstCommercialSaleMilestonePayments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a8c4441e-4d10-4239-9330-25c3d05dbb4d" xlink:to="loc_dnli_FirstCommercialSaleMilestonePayments_09583a79-c1ac-46bb-bb56-bc8353c97f8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_NetSalesBasedMilestonePayments_1de25547-f3a8-440d-b6ff-2ba2a8c29468" xlink:href="dnli-20210331.xsd#dnli_NetSalesBasedMilestonePayments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a8c4441e-4d10-4239-9330-25c3d05dbb4d" xlink:to="loc_dnli_NetSalesBasedMilestonePayments_1de25547-f3a8-440d-b6ff-2ba2a8c29468" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_CollaborativeAgreementAgreedShareOfCommercialProfitLoss_86a67419-4438-47f8-84e9-934a0775d848" xlink:href="dnli-20210331.xsd#dnli_CollaborativeAgreementAgreedShareOfCommercialProfitLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a8c4441e-4d10-4239-9330-25c3d05dbb4d" xlink:to="loc_dnli_CollaborativeAgreementAgreedShareOfCommercialProfitLoss_86a67419-4438-47f8-84e9-934a0775d848" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_CollaborativeAgreementFundedPercentage_41d46469-897e-465e-96a7-43575a1b1fa3" xlink:href="dnli-20210331.xsd#dnli_CollaborativeAgreementFundedPercentage"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a8c4441e-4d10-4239-9330-25c3d05dbb4d" xlink:to="loc_dnli_CollaborativeAgreementFundedPercentage_41d46469-897e-465e-96a7-43575a1b1fa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_CollaborativeArrangementTermNumberOfBusinessDaysIfEffectiveDateCriteriaMet_9a459918-37af-4d2f-b234-ba56e81c9657" xlink:href="dnli-20210331.xsd#dnli_CollaborativeArrangementTermNumberOfBusinessDaysIfEffectiveDateCriteriaMet"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a8c4441e-4d10-4239-9330-25c3d05dbb4d" xlink:to="loc_dnli_CollaborativeArrangementTermNumberOfBusinessDaysIfEffectiveDateCriteriaMet_9a459918-37af-4d2f-b234-ba56e81c9657" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_CollaborativeArrangementRightOfFirstNegotiationTermPeriodAfterEffectiveDateOfAgreementIfCircumstancesMet_5496d8f1-c948-4a46-82c4-7385e2e99252" xlink:href="dnli-20210331.xsd#dnli_CollaborativeArrangementRightOfFirstNegotiationTermPeriodAfterEffectiveDateOfAgreementIfCircumstancesMet"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a8c4441e-4d10-4239-9330-25c3d05dbb4d" xlink:to="loc_dnli_CollaborativeArrangementRightOfFirstNegotiationTermPeriodAfterEffectiveDateOfAgreementIfCircumstancesMet_5496d8f1-c948-4a46-82c4-7385e2e99252" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_CollaborativeArrangementRightOfFirstNegotiationPeriodTermAdditionalProgramCriteria_b574b14f-a9a8-4170-bf49-2dde9f72594a" xlink:href="dnli-20210331.xsd#dnli_CollaborativeArrangementRightOfFirstNegotiationPeriodTermAdditionalProgramCriteria"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a8c4441e-4d10-4239-9330-25c3d05dbb4d" xlink:to="loc_dnli_CollaborativeArrangementRightOfFirstNegotiationPeriodTermAdditionalProgramCriteria_b574b14f-a9a8-4170-bf49-2dde9f72594a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_CollaborativeArrangementNumberOfAdditionalProgramsNoThirdPartyAgreementExecutedIfCircumstancesMet_d1e871eb-4596-422b-929c-47b5dffcc83e" xlink:href="dnli-20210331.xsd#dnli_CollaborativeArrangementNumberOfAdditionalProgramsNoThirdPartyAgreementExecutedIfCircumstancesMet"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a8c4441e-4d10-4239-9330-25c3d05dbb4d" xlink:to="loc_dnli_CollaborativeArrangementNumberOfAdditionalProgramsNoThirdPartyAgreementExecutedIfCircumstancesMet_d1e871eb-4596-422b-929c-47b5dffcc83e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_eeb7f723-797c-48cc-9d98-a734616a5fde" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a8c4441e-4d10-4239-9330-25c3d05dbb4d" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_eeb7f723-797c-48cc-9d98-a734616a5fde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_80c9d798-b502-4615-9302-a74540259fca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a8c4441e-4d10-4239-9330-25c3d05dbb4d" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_80c9d798-b502-4615-9302-a74540259fca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStocksIncludingAdditionalPaidInCapital_29766ce9-2f27-4bb4-b431-13086259a2c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStocksIncludingAdditionalPaidInCapital"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a8c4441e-4d10-4239-9330-25c3d05dbb4d" xlink:to="loc_us-gaap_CommonStocksIncludingAdditionalPaidInCapital_29766ce9-2f27-4bb4-b431-13086259a2c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_bef8e3e4-a26d-49e8-81d0-38294c8ad493" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a8c4441e-4d10-4239-9330-25c3d05dbb4d" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_bef8e3e4-a26d-49e8-81d0-38294c8ad493" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_SaleOfStockConsiderationPremiumReceivedOnTransaction_a6103375-3f64-450d-9cf9-0c32ffc46104" xlink:href="dnli-20210331.xsd#dnli_SaleOfStockConsiderationPremiumReceivedOnTransaction"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a8c4441e-4d10-4239-9330-25c3d05dbb4d" xlink:to="loc_dnli_SaleOfStockConsiderationPremiumReceivedOnTransaction_a6103375-3f64-450d-9cf9-0c32ffc46104" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_CollaborativeArrangementOptionExerciseAndDevelopmentMilestonePaymentsToBeReceived_9b039b98-64c9-4ab2-9373-b669ba1c8fd7" xlink:href="dnli-20210331.xsd#dnli_CollaborativeArrangementOptionExerciseAndDevelopmentMilestonePaymentsToBeReceived"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a8c4441e-4d10-4239-9330-25c3d05dbb4d" xlink:to="loc_dnli_CollaborativeArrangementOptionExerciseAndDevelopmentMilestonePaymentsToBeReceived_9b039b98-64c9-4ab2-9373-b669ba1c8fd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_CollaborativeArrangementFirstCommercialSaleMilestonePaymentsToBeReceived_38163ed8-2a2b-4f6c-b893-d5320db718b9" xlink:href="dnli-20210331.xsd#dnli_CollaborativeArrangementFirstCommercialSaleMilestonePaymentsToBeReceived"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a8c4441e-4d10-4239-9330-25c3d05dbb4d" xlink:to="loc_dnli_CollaborativeArrangementFirstCommercialSaleMilestonePaymentsToBeReceived_38163ed8-2a2b-4f6c-b893-d5320db718b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_CollaborativeArrangementNetSalesBasedMilestonePaymentsToBeReceived_cae72c77-763c-4701-9af9-fbc616d221d5" xlink:href="dnli-20210331.xsd#dnli_CollaborativeArrangementNetSalesBasedMilestonePaymentsToBeReceived"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a8c4441e-4d10-4239-9330-25c3d05dbb4d" xlink:to="loc_dnli_CollaborativeArrangementNetSalesBasedMilestonePaymentsToBeReceived_cae72c77-763c-4701-9af9-fbc616d221d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_UpfrontPayments_86c5c164-8f5a-49e2-91e0-8f786b19589b" xlink:href="dnli-20210331.xsd#dnli_UpfrontPayments"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a8c4441e-4d10-4239-9330-25c3d05dbb4d" xlink:to="loc_dnli_UpfrontPayments_86c5c164-8f5a-49e2-91e0-8f786b19589b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_CollaborationAgreementTransactionPriceIncreaseDecrease_3017b61e-f973-438a-8661-768074e5f37d" xlink:href="dnli-20210331.xsd#dnli_CollaborationAgreementTransactionPriceIncreaseDecrease"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a8c4441e-4d10-4239-9330-25c3d05dbb4d" xlink:to="loc_dnli_CollaborationAgreementTransactionPriceIncreaseDecrease_3017b61e-f973-438a-8661-768074e5f37d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_f6f9aeee-fc26-4d4f-8556-46b1f41c6810" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a8c4441e-4d10-4239-9330-25c3d05dbb4d" xlink:to="loc_us-gaap_ContractWithCustomerLiability_f6f9aeee-fc26-4d4f-8556-46b1f41c6810" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_ResearchAndDevelopmentExpenseOffsetFromRelatedPartyCostReimbursement_14cc2781-159c-498c-9b22-8d27e920e8d3" xlink:href="dnli-20210331.xsd#dnli_ResearchAndDevelopmentExpenseOffsetFromRelatedPartyCostReimbursement"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a8c4441e-4d10-4239-9330-25c3d05dbb4d" xlink:to="loc_dnli_ResearchAndDevelopmentExpenseOffsetFromRelatedPartyCostReimbursement_14cc2781-159c-498c-9b22-8d27e920e8d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueFromRelatedPartiesCurrent_e88a59aa-bb06-4ca6-a0c0-c5c0de90ca73" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueFromRelatedPartiesCurrent"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a8c4441e-4d10-4239-9330-25c3d05dbb4d" xlink:to="loc_us-gaap_DueFromRelatedPartiesCurrent_e88a59aa-bb06-4ca6-a0c0-c5c0de90ca73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_CollaborativeArrangementNumberOfMilestonesAchieved_47f604ed-a6d5-4d9f-92e7-a40dd036bb9b" xlink:href="dnli-20210331.xsd#dnli_CollaborativeArrangementNumberOfMilestonesAchieved"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a8c4441e-4d10-4239-9330-25c3d05dbb4d" xlink:to="loc_dnli_CollaborativeArrangementNumberOfMilestonesAchieved_47f604ed-a6d5-4d9f-92e7-a40dd036bb9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/CollaborationAgreementsSanofiDetails" xlink:type="simple" xlink:href="dnli-20210331.xsd#CollaborationAgreementsSanofiDetails"/>
  <link:presentationLink xlink:role="http://www.denalitherapeutics.com/role/CollaborationAgreementsSanofiDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_26429f12-6754-4eb3-a99f-17ca49984438" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5df6515a-7f85-41c8-84e0-106555776c5a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_26429f12-6754-4eb3-a99f-17ca49984438" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5df6515a-7f85-41c8-84e0-106555776c5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_dc184731-471a-4764-a607-2d728b810725" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5df6515a-7f85-41c8-84e0-106555776c5a" xlink:to="loc_srt_CounterpartyNameAxis_dc184731-471a-4764-a607-2d728b810725" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6a77c624-a0a4-4329-8ca3-e39ba51cc278" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_dc184731-471a-4764-a607-2d728b810725" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6a77c624-a0a4-4329-8ca3-e39ba51cc278" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_SanofiMember_da6b49a9-7a1b-44a3-9c6d-1a6ab04a7fc2" xlink:href="dnli-20210331.xsd#dnli_SanofiMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6a77c624-a0a4-4329-8ca3-e39ba51cc278" xlink:to="loc_dnli_SanofiMember_da6b49a9-7a1b-44a3-9c6d-1a6ab04a7fc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_71bdf881-5655-4071-90ed-a8c87dd68182" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5df6515a-7f85-41c8-84e0-106555776c5a" xlink:to="loc_dei_LegalEntityAxis_71bdf881-5655-4071-90ed-a8c87dd68182" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_49f5398f-ed8c-4445-aa89-9ffb4192f3f9" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_71bdf881-5655-4071-90ed-a8c87dd68182" xlink:to="loc_dei_EntityDomain_49f5398f-ed8c-4445-aa89-9ffb4192f3f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_SanofiMember_8e2f62eb-f250-4ab8-b35d-5d861a88e7b4" xlink:href="dnli-20210331.xsd#dnli_SanofiMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_49f5398f-ed8c-4445-aa89-9ffb4192f3f9" xlink:to="loc_dnli_SanofiMember_8e2f62eb-f250-4ab8-b35d-5d861a88e7b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_8aa87840-2211-405e-8eaa-6fc67d431fd2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5df6515a-7f85-41c8-84e0-106555776c5a" xlink:to="loc_us-gaap_TypeOfArrangementAxis_8aa87840-2211-405e-8eaa-6fc67d431fd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_97b6e5a6-15c9-42d3-9fb4-633964a1f96e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_8aa87840-2211-405e-8eaa-6fc67d431fd2" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_97b6e5a6-15c9-42d3-9fb4-633964a1f96e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_1e58d245-0b84-492b-ad35-c02fc44902d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_97b6e5a6-15c9-42d3-9fb4-633964a1f96e" xlink:to="loc_us-gaap_CollaborativeArrangementMember_1e58d245-0b84-492b-ad35-c02fc44902d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_ed35a890-1288-42b3-a12c-c4aa0e9263c0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5df6515a-7f85-41c8-84e0-106555776c5a" xlink:to="loc_srt_ProductOrServiceAxis_ed35a890-1288-42b3-a12c-c4aa0e9263c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_5f38b809-02b4-493a-b692-ffd6042f97c5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_ed35a890-1288-42b3-a12c-c4aa0e9263c0" xlink:to="loc_srt_ProductsAndServicesDomain_5f38b809-02b4-493a-b692-ffd6042f97c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_CNSProductMember_aaa7bb0b-5b3f-48e9-abec-bec157ac2168" xlink:href="dnli-20210331.xsd#dnli_CNSProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5f38b809-02b4-493a-b692-ffd6042f97c5" xlink:to="loc_dnli_CNSProductMember_aaa7bb0b-5b3f-48e9-abec-bec157ac2168" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_PeripheralProductMember_9abe512f-d6d6-4c25-85c6-bac741d01574" xlink:href="dnli-20210331.xsd#dnli_PeripheralProductMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5f38b809-02b4-493a-b692-ffd6042f97c5" xlink:to="loc_dnli_PeripheralProductMember_9abe512f-d6d6-4c25-85c6-bac741d01574" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_RetainedActivitiesMember_887d3383-be00-4686-9eb5-140005d3a437" xlink:href="dnli-20210331.xsd#dnli_RetainedActivitiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5f38b809-02b4-493a-b692-ffd6042f97c5" xlink:to="loc_dnli_RetainedActivitiesMember_887d3383-be00-4686-9eb5-140005d3a437" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_MilestoneTriggeredMember_85c69163-b831-4e50-83a0-bf67b8832c89" xlink:href="dnli-20210331.xsd#dnli_MilestoneTriggeredMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5f38b809-02b4-493a-b692-ffd6042f97c5" xlink:to="loc_dnli_MilestoneTriggeredMember_85c69163-b831-4e50-83a0-bf67b8832c89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_MilestoneTriggeredAndRetainedActivitiesMember_1a19f30e-8277-4525-8c62-5a3194dbbf56" xlink:href="dnli-20210331.xsd#dnli_MilestoneTriggeredAndRetainedActivitiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5f38b809-02b4-493a-b692-ffd6042f97c5" xlink:to="loc_dnli_MilestoneTriggeredAndRetainedActivitiesMember_1a19f30e-8277-4525-8c62-5a3194dbbf56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_00ba110a-61b3-4286-bba3-c9fe39496715" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5f38b809-02b4-493a-b692-ffd6042f97c5" xlink:to="loc_us-gaap_ProductMember_00ba110a-61b3-4286-bba3-c9fe39496715" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_24e2a97e-b29c-4ab2-a985-afdf1376941a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5df6515a-7f85-41c8-84e0-106555776c5a" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_24e2a97e-b29c-4ab2-a985-afdf1376941a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_UpfrontPayments_b5af3398-8dc0-4ed1-9ce6-454922b6f004" xlink:href="dnli-20210331.xsd#dnli_UpfrontPayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_24e2a97e-b29c-4ab2-a985-afdf1376941a" xlink:to="loc_dnli_UpfrontPayments_b5af3398-8dc0-4ed1-9ce6-454922b6f004" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_AggregateClinicalRegulatoryAndSalesMilestonePayment_bdf5450d-f37d-4834-800d-0134eae3c7cb" xlink:href="dnli-20210331.xsd#dnli_AggregateClinicalRegulatoryAndSalesMilestonePayment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_24e2a97e-b29c-4ab2-a985-afdf1376941a" xlink:to="loc_dnli_AggregateClinicalRegulatoryAndSalesMilestonePayment_bdf5450d-f37d-4834-800d-0134eae3c7cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_ClinicalMilestonePayment_e9a1bdf7-5a93-4ba2-bce9-7bdde9b13a44" xlink:href="dnli-20210331.xsd#dnli_ClinicalMilestonePayment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_24e2a97e-b29c-4ab2-a985-afdf1376941a" xlink:to="loc_dnli_ClinicalMilestonePayment_e9a1bdf7-5a93-4ba2-bce9-7bdde9b13a44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_RegulatoryMilestonePayment_4e406ee4-f13e-4bb0-8511-c7f4492b775f" xlink:href="dnli-20210331.xsd#dnli_RegulatoryMilestonePayment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_24e2a97e-b29c-4ab2-a985-afdf1376941a" xlink:to="loc_dnli_RegulatoryMilestonePayment_4e406ee4-f13e-4bb0-8511-c7f4492b775f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_NumberOfIndications_3e4d9b2e-e403-4695-a1e3-ca7d228ed2b5" xlink:href="dnli-20210331.xsd#dnli_NumberOfIndications"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_24e2a97e-b29c-4ab2-a985-afdf1376941a" xlink:to="loc_dnli_NumberOfIndications_3e4d9b2e-e403-4695-a1e3-ca7d228ed2b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_CommercialMilestonePayments_aec46339-8572-4c00-bb8a-66952c607764" xlink:href="dnli-20210331.xsd#dnli_CommercialMilestonePayments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_24e2a97e-b29c-4ab2-a985-afdf1376941a" xlink:to="loc_dnli_CommercialMilestonePayments_aec46339-8572-4c00-bb8a-66952c607764" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_CollaborativeAgreementFundedPercentage_633e9992-a8d9-4279-a760-d2dd99206dcd" xlink:href="dnli-20210331.xsd#dnli_CollaborativeAgreementFundedPercentage"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_24e2a97e-b29c-4ab2-a985-afdf1376941a" xlink:to="loc_dnli_CollaborativeAgreementFundedPercentage_633e9992-a8d9-4279-a760-d2dd99206dcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_CollaborationAgreementTransactionPriceIncrease_859a0a1c-0a88-4c7c-be03-98769def2339" xlink:href="dnli-20210331.xsd#dnli_CollaborationAgreementTransactionPriceIncrease"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_24e2a97e-b29c-4ab2-a985-afdf1376941a" xlink:to="loc_dnli_CollaborationAgreementTransactionPriceIncrease_859a0a1c-0a88-4c7c-be03-98769def2339" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNet_d9e31921-e9d8-4493-9344-101d554d103d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNet"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_24e2a97e-b29c-4ab2-a985-afdf1376941a" xlink:to="loc_us-gaap_AccountsReceivableNet_d9e31921-e9d8-4493-9344-101d554d103d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_936437ac-73dd-4595-b323-28a25eac5f2f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_24e2a97e-b29c-4ab2-a985-afdf1376941a" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_936437ac-73dd-4595-b323-28a25eac5f2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/CollaborationAgreementsSanofiPerformanceObligationDetails" xlink:type="simple" xlink:href="dnli-20210331.xsd#CollaborationAgreementsSanofiPerformanceObligationDetails"/>
  <link:presentationLink xlink:role="http://www.denalitherapeutics.com/role/CollaborationAgreementsSanofiPerformanceObligationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_02828659-2b71-4fa2-8370-4a65224f53f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_bce9ba03-692b-485a-b90b-31c5f97346dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_02828659-2b71-4fa2-8370-4a65224f53f5" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_bce9ba03-692b-485a-b90b-31c5f97346dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_9dac8314-458a-4623-98c0-eaad8106d236" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_bce9ba03-692b-485a-b90b-31c5f97346dd" xlink:to="loc_srt_ProductOrServiceAxis_9dac8314-458a-4623-98c0-eaad8106d236" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ea1722ff-2a24-409f-982c-cb847f7230b3" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_9dac8314-458a-4623-98c0-eaad8106d236" xlink:to="loc_srt_ProductsAndServicesDomain_ea1722ff-2a24-409f-982c-cb847f7230b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_AlzheimersDiseaseServicesMember_12860c82-7ae7-46a8-ae29-5e20e1289c99" xlink:href="dnli-20210331.xsd#dnli_AlzheimersDiseaseServicesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ea1722ff-2a24-409f-982c-cb847f7230b3" xlink:to="loc_dnli_AlzheimersDiseaseServicesMember_12860c82-7ae7-46a8-ae29-5e20e1289c99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_4583598b-2a12-4aab-a31d-697d21d29396" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_bce9ba03-692b-485a-b90b-31c5f97346dd" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_4583598b-2a12-4aab-a31d-697d21d29396" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_40a2fba5-7b4d-4965-875a-7a78db4f6589" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_4583598b-2a12-4aab-a31d-697d21d29396" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_40a2fba5-7b4d-4965-875a-7a78db4f6589" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/CollaborationAgreementsTakedaDetails" xlink:type="simple" xlink:href="dnli-20210331.xsd#CollaborationAgreementsTakedaDetails"/>
  <link:presentationLink xlink:role="http://www.denalitherapeutics.com/role/CollaborationAgreementsTakedaDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_845d950b-c322-4d49-b59f-3978c6b5833c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e490c3e3-ed0f-46a9-86d7-ab4f04c98ae6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_845d950b-c322-4d49-b59f-3978c6b5833c" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e490c3e3-ed0f-46a9-86d7-ab4f04c98ae6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_31090bce-f8dd-470c-903b-9f91ca54bf1f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e490c3e3-ed0f-46a9-86d7-ab4f04c98ae6" xlink:to="loc_us-gaap_TypeOfArrangementAxis_31090bce-f8dd-470c-903b-9f91ca54bf1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d39ade25-14cc-4144-af91-cd16cbb9ad03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_31090bce-f8dd-470c-903b-9f91ca54bf1f" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d39ade25-14cc-4144-af91-cd16cbb9ad03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_f9d9cc3a-0c25-404c-b3b0-6ae1cba1ab90" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d39ade25-14cc-4144-af91-cd16cbb9ad03" xlink:to="loc_us-gaap_CollaborativeArrangementMember_f9d9cc3a-0c25-404c-b3b0-6ae1cba1ab90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_CollaborativeArrangementPTVPGRNMember_60111018-4a53-4a31-b514-469832b909ce" xlink:href="dnli-20210331.xsd#dnli_CollaborativeArrangementPTVPGRNMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d39ade25-14cc-4144-af91-cd16cbb9ad03" xlink:to="loc_dnli_CollaborativeArrangementPTVPGRNMember_60111018-4a53-4a31-b514-469832b909ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_CollaborativeArrangementATVTREM2Member_b8179270-599f-4bf5-b073-e10a1b31327f" xlink:href="dnli-20210331.xsd#dnli_CollaborativeArrangementATVTREM2Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d39ade25-14cc-4144-af91-cd16cbb9ad03" xlink:to="loc_dnli_CollaborativeArrangementATVTREM2Member_b8179270-599f-4bf5-b073-e10a1b31327f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_c68ffa5e-ad2a-493a-bbca-a72a4e48b622" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e490c3e3-ed0f-46a9-86d7-ab4f04c98ae6" xlink:to="loc_srt_RangeAxis_c68ffa5e-ad2a-493a-bbca-a72a4e48b622" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_be886749-013a-477d-ba5a-35847d43818f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_c68ffa5e-ad2a-493a-bbca-a72a4e48b622" xlink:to="loc_srt_RangeMember_be886749-013a-477d-ba5a-35847d43818f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_a9853d49-9b2b-48fe-90f4-e9874decf1e2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_be886749-013a-477d-ba5a-35847d43818f" xlink:to="loc_srt_MaximumMember_a9853d49-9b2b-48fe-90f4-e9874decf1e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_cb828194-177b-4162-a253-16029d3f173b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e490c3e3-ed0f-46a9-86d7-ab4f04c98ae6" xlink:to="loc_srt_CounterpartyNameAxis_cb828194-177b-4162-a253-16029d3f173b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6e16f168-f293-4169-a26a-ad0ae9882241" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_cb828194-177b-4162-a253-16029d3f173b" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6e16f168-f293-4169-a26a-ad0ae9882241" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_TakedaPharmaceuticalCompanyLimitedMember_3d0745c5-83eb-44c9-a201-49f42333a716" xlink:href="dnli-20210331.xsd#dnli_TakedaPharmaceuticalCompanyLimitedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6e16f168-f293-4169-a26a-ad0ae9882241" xlink:to="loc_dnli_TakedaPharmaceuticalCompanyLimitedMember_3d0745c5-83eb-44c9-a201-49f42333a716" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_a3ea2a4f-62b4-43ec-8116-f70057241313" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e490c3e3-ed0f-46a9-86d7-ab4f04c98ae6" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_a3ea2a4f-62b4-43ec-8116-f70057241313" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_8bad6753-5059-41b9-ada7-d02f79d42ad8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_a3ea2a4f-62b4-43ec-8116-f70057241313" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_8bad6753-5059-41b9-ada7-d02f79d42ad8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_SharePurchaseAgreementMember_fb049074-a878-42ab-af54-a7852bea285c" xlink:href="dnli-20210331.xsd#dnli_SharePurchaseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_8bad6753-5059-41b9-ada7-d02f79d42ad8" xlink:to="loc_dnli_SharePurchaseAgreementMember_fb049074-a878-42ab-af54-a7852bea285c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_e0617753-2972-4f0c-94cc-f58b277f2129" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e490c3e3-ed0f-46a9-86d7-ab4f04c98ae6" xlink:to="loc_srt_ProductOrServiceAxis_e0617753-2972-4f0c-94cc-f58b277f2129" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_9ff5beed-ac0d-41ea-9c37-4d54f8231930" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_e0617753-2972-4f0c-94cc-f58b277f2129" xlink:to="loc_srt_ProductsAndServicesDomain_9ff5beed-ac0d-41ea-9c37-4d54f8231930" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_5a686c33-4469-42c9-becb-2e220c2bfd8c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_9ff5beed-ac0d-41ea-9c37-4d54f8231930" xlink:to="loc_us-gaap_ProductMember_5a686c33-4469-42c9-becb-2e220c2bfd8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_MilestoneTriggeredMember_03b51fb3-7a69-43ad-914c-f417c26aaa50" xlink:href="dnli-20210331.xsd#dnli_MilestoneTriggeredMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_9ff5beed-ac0d-41ea-9c37-4d54f8231930" xlink:to="loc_dnli_MilestoneTriggeredMember_03b51fb3-7a69-43ad-914c-f417c26aaa50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5fc3dbe2-7df3-4bf0-84d2-2be9b8e156f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e490c3e3-ed0f-46a9-86d7-ab4f04c98ae6" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5fc3dbe2-7df3-4bf0-84d2-2be9b8e156f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_UpfrontPayments_10d0ce90-a719-47ac-99b0-9db492941c15" xlink:href="dnli-20210331.xsd#dnli_UpfrontPayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5fc3dbe2-7df3-4bf0-84d2-2be9b8e156f3" xlink:to="loc_dnli_UpfrontPayments_10d0ce90-a719-47ac-99b0-9db492941c15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_PreclinicalMilestonePaymentPerProgram_a7dc04e5-ecf3-4523-853d-843be52d537b" xlink:href="dnli-20210331.xsd#dnli_PreclinicalMilestonePaymentPerProgram"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5fc3dbe2-7df3-4bf0-84d2-2be9b8e156f3" xlink:to="loc_dnli_PreclinicalMilestonePaymentPerProgram_a7dc04e5-ecf3-4523-853d-843be52d537b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_NumberOfPrograms_48285ff9-e1ce-46bc-8365-6c4174ba2533" xlink:href="dnli-20210331.xsd#dnli_NumberOfPrograms"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5fc3dbe2-7df3-4bf0-84d2-2be9b8e156f3" xlink:to="loc_dnli_NumberOfPrograms_48285ff9-e1ce-46bc-8365-6c4174ba2533" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_AggregatePreclinicalMilestonePayment_4ab151b0-4ee1-461e-83c6-a12d2bf005ef" xlink:href="dnli-20210331.xsd#dnli_AggregatePreclinicalMilestonePayment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5fc3dbe2-7df3-4bf0-84d2-2be9b8e156f3" xlink:to="loc_dnli_AggregatePreclinicalMilestonePayment_4ab151b0-4ee1-461e-83c6-a12d2bf005ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_PreclinicalMilestonePaymentReceived_2926171d-4330-4951-b629-23b3811afe8c" xlink:href="dnli-20210331.xsd#dnli_PreclinicalMilestonePaymentReceived"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5fc3dbe2-7df3-4bf0-84d2-2be9b8e156f3" xlink:to="loc_dnli_PreclinicalMilestonePaymentReceived_2926171d-4330-4951-b629-23b3811afe8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_NumberOfTargets_6e511b5a-ce72-48f1-8631-90f6b63b0448" xlink:href="dnli-20210331.xsd#dnli_NumberOfTargets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5fc3dbe2-7df3-4bf0-84d2-2be9b8e156f3" xlink:to="loc_dnli_NumberOfTargets_6e511b5a-ce72-48f1-8631-90f6b63b0448" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_TargetOptionPeriod_314159f0-1aaf-4df1-bc50-d4986d870084" xlink:href="dnli-20210331.xsd#dnli_TargetOptionPeriod"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5fc3dbe2-7df3-4bf0-84d2-2be9b8e156f3" xlink:to="loc_dnli_TargetOptionPeriod_314159f0-1aaf-4df1-bc50-d4986d870084" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_OptionFeesPerProgram_4c01997e-641b-4b85-a727-5961215b3c6b" xlink:href="dnli-20210331.xsd#dnli_OptionFeesPerProgram"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5fc3dbe2-7df3-4bf0-84d2-2be9b8e156f3" xlink:to="loc_dnli_OptionFeesPerProgram_4c01997e-641b-4b85-a727-5961215b3c6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_AggregateOptionExerciseFee_1e0aa7e7-0177-4226-8414-c3cdae3657aa" xlink:href="dnli-20210331.xsd#dnli_AggregateOptionExerciseFee"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5fc3dbe2-7df3-4bf0-84d2-2be9b8e156f3" xlink:to="loc_dnli_AggregateOptionExerciseFee_1e0aa7e7-0177-4226-8414-c3cdae3657aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_AggregateDevelopmentMilestonePayment_d621f8b1-4696-47de-8f26-50ac90007547" xlink:href="dnli-20210331.xsd#dnli_AggregateDevelopmentMilestonePayment"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5fc3dbe2-7df3-4bf0-84d2-2be9b8e156f3" xlink:to="loc_dnli_AggregateDevelopmentMilestonePayment_d621f8b1-4696-47de-8f26-50ac90007547" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_RegulatoryMilestonePayment_9b837c74-e7e2-48d6-ad67-048b31d35da9" xlink:href="dnli-20210331.xsd#dnli_RegulatoryMilestonePayment"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5fc3dbe2-7df3-4bf0-84d2-2be9b8e156f3" xlink:to="loc_dnli_RegulatoryMilestonePayment_9b837c74-e7e2-48d6-ad67-048b31d35da9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_CommercialMilestonesPerProgram_785fa309-1d51-4fa1-840b-885239d96396" xlink:href="dnli-20210331.xsd#dnli_CommercialMilestonesPerProgram"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5fc3dbe2-7df3-4bf0-84d2-2be9b8e156f3" xlink:to="loc_dnli_CommercialMilestonesPerProgram_785fa309-1d51-4fa1-840b-885239d96396" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_AggregateCommercialMilestones_3bfbe470-9ff6-4599-9d3d-cbef729e8a84" xlink:href="dnli-20210331.xsd#dnli_AggregateCommercialMilestones"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5fc3dbe2-7df3-4bf0-84d2-2be9b8e156f3" xlink:to="loc_dnli_AggregateCommercialMilestones_3bfbe470-9ff6-4599-9d3d-cbef729e8a84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_d91deb75-671c-4395-8835-e07f21fa06c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5fc3dbe2-7df3-4bf0-84d2-2be9b8e156f3" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_d91deb75-671c-4395-8835-e07f21fa06c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_8969b4bd-6199-4221-97ae-7a2b8b0231ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5fc3dbe2-7df3-4bf0-84d2-2be9b8e156f3" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_8969b4bd-6199-4221-97ae-7a2b8b0231ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStocksIncludingAdditionalPaidInCapital_192ccb67-e131-4b1b-9c04-7b37d1b07d0a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStocksIncludingAdditionalPaidInCapital"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5fc3dbe2-7df3-4bf0-84d2-2be9b8e156f3" xlink:to="loc_us-gaap_CommonStocksIncludingAdditionalPaidInCapital_192ccb67-e131-4b1b-9c04-7b37d1b07d0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_cf57ef6a-e308-4a8d-a891-d7158a98cc09" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5fc3dbe2-7df3-4bf0-84d2-2be9b8e156f3" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_cf57ef6a-e308-4a8d-a891-d7158a98cc09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_SaleOfStockConsiderationPremiumReceivedOnTransaction_77bc03e1-ee8a-4aa3-aa7f-657877d910a6" xlink:href="dnli-20210331.xsd#dnli_SaleOfStockConsiderationPremiumReceivedOnTransaction"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5fc3dbe2-7df3-4bf0-84d2-2be9b8e156f3" xlink:to="loc_dnli_SaleOfStockConsiderationPremiumReceivedOnTransaction_77bc03e1-ee8a-4aa3-aa7f-657877d910a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_VariableConsiderationFutureConsideration_3f951bcb-69c9-4a85-b27e-607755de64aa" xlink:href="dnli-20210331.xsd#dnli_VariableConsiderationFutureConsideration"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5fc3dbe2-7df3-4bf0-84d2-2be9b8e156f3" xlink:to="loc_dnli_VariableConsiderationFutureConsideration_3f951bcb-69c9-4a85-b27e-607755de64aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_ConstrainedVariableConsideration_6c62a5bd-5817-4ae8-8d3e-2764b3beb16a" xlink:href="dnli-20210331.xsd#dnli_ConstrainedVariableConsideration"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5fc3dbe2-7df3-4bf0-84d2-2be9b8e156f3" xlink:to="loc_dnli_ConstrainedVariableConsideration_6c62a5bd-5817-4ae8-8d3e-2764b3beb16a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_CollaborationAgreementTransactionPriceIncreaseDecrease_ba45debc-0873-4539-8950-8e5f106bd357" xlink:href="dnli-20210331.xsd#dnli_CollaborationAgreementTransactionPriceIncreaseDecrease"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5fc3dbe2-7df3-4bf0-84d2-2be9b8e156f3" xlink:to="loc_dnli_CollaborationAgreementTransactionPriceIncreaseDecrease_ba45debc-0873-4539-8950-8e5f106bd357" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_RevenueNumberOfPerformanceObligations_3c761dc1-6d6d-4d83-b615-a9f03594fa0b" xlink:href="dnli-20210331.xsd#dnli_RevenueNumberOfPerformanceObligations"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5fc3dbe2-7df3-4bf0-84d2-2be9b8e156f3" xlink:to="loc_dnli_RevenueNumberOfPerformanceObligations_3c761dc1-6d6d-4d83-b615-a9f03594fa0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_4bf7624f-eb38-48c1-83c9-2fab344736df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5fc3dbe2-7df3-4bf0-84d2-2be9b8e156f3" xlink:to="loc_us-gaap_ContractWithCustomerLiability_4bf7624f-eb38-48c1-83c9-2fab344736df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_PreclinicalMilestonePaymentEarnedNotYetReceived_fa017fd0-9010-46c8-8145-8bfd7a0cb203" xlink:href="dnli-20210331.xsd#dnli_PreclinicalMilestonePaymentEarnedNotYetReceived"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5fc3dbe2-7df3-4bf0-84d2-2be9b8e156f3" xlink:to="loc_dnli_PreclinicalMilestonePaymentEarnedNotYetReceived_fa017fd0-9010-46c8-8145-8bfd7a0cb203" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d89285a4-8df0-4f60-b648-33025c4d8d16" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5fc3dbe2-7df3-4bf0-84d2-2be9b8e156f3" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d89285a4-8df0-4f60-b648-33025c4d8d16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/CollaborationAgreementsSummaryofCollaborationRevenueDetails" xlink:type="simple" xlink:href="dnli-20210331.xsd#CollaborationAgreementsSummaryofCollaborationRevenueDetails"/>
  <link:presentationLink xlink:role="http://www.denalitherapeutics.com/role/CollaborationAgreementsSummaryofCollaborationRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_dac74415-c74e-43f9-b048-5544f7c6c65b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_171f787f-1d85-4435-94a0-6bfceba154d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_dac74415-c74e-43f9-b048-5544f7c6c65b" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_171f787f-1d85-4435-94a0-6bfceba154d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_d7a0ce31-2566-4034-88a5-de9cfb8f4b17" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_171f787f-1d85-4435-94a0-6bfceba154d0" xlink:to="loc_us-gaap_TypeOfArrangementAxis_d7a0ce31-2566-4034-88a5-de9cfb8f4b17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_59f84070-e9ec-4259-9fdf-5108f5364e56" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_d7a0ce31-2566-4034-88a5-de9cfb8f4b17" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_59f84070-e9ec-4259-9fdf-5108f5364e56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_TakedaCollaborationAgreementMember_c634d28f-8b15-4e35-880a-64bac7d03096" xlink:href="dnli-20210331.xsd#dnli_TakedaCollaborationAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_59f84070-e9ec-4259-9fdf-5108f5364e56" xlink:to="loc_dnli_TakedaCollaborationAgreementMember_c634d28f-8b15-4e35-880a-64bac7d03096" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_SanofiCollaborationAgreementMember_a2f5ed8c-b363-472f-9ab5-d97bf2f7c57f" xlink:href="dnli-20210331.xsd#dnli_SanofiCollaborationAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_59f84070-e9ec-4259-9fdf-5108f5364e56" xlink:to="loc_dnli_SanofiCollaborationAgreementMember_a2f5ed8c-b363-472f-9ab5-d97bf2f7c57f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_BiogenMember_cf24dba4-c3de-4e20-bef9-e7b7b532c2e4" xlink:href="dnli-20210331.xsd#dnli_BiogenMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_59f84070-e9ec-4259-9fdf-5108f5364e56" xlink:to="loc_dnli_BiogenMember_cf24dba4-c3de-4e20-bef9-e7b7b532c2e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_02256e0d-6d1c-4dff-bc6b-9b0ca1ea2d76" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_171f787f-1d85-4435-94a0-6bfceba154d0" xlink:to="loc_srt_ProductOrServiceAxis_02256e0d-6d1c-4dff-bc6b-9b0ca1ea2d76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_013cbb65-0fa4-443d-af03-704c71685307" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_02256e0d-6d1c-4dff-bc6b-9b0ca1ea2d76" xlink:to="loc_srt_ProductsAndServicesDomain_013cbb65-0fa4-443d-af03-704c71685307" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_RetainedActivitiesMember_dd954f46-ab59-4c6d-8c1a-5c9d71ac3077" xlink:href="dnli-20210331.xsd#dnli_RetainedActivitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_013cbb65-0fa4-443d-af03-704c71685307" xlink:to="loc_dnli_RetainedActivitiesMember_dd954f46-ab59-4c6d-8c1a-5c9d71ac3077" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_AlzheimersDiseaseServicesMember_b1441496-b406-4e06-adc8-ce5f578c6d45" xlink:href="dnli-20210331.xsd#dnli_AlzheimersDiseaseServicesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_013cbb65-0fa4-443d-af03-704c71685307" xlink:to="loc_dnli_AlzheimersDiseaseServicesMember_b1441496-b406-4e06-adc8-ce5f578c6d45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_OptionServicesMember_a0f82e51-c2c8-4b43-83c4-102adbf48c38" xlink:href="dnli-20210331.xsd#dnli_OptionServicesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_013cbb65-0fa4-443d-af03-704c71685307" xlink:to="loc_dnli_OptionServicesMember_a0f82e51-c2c8-4b43-83c4-102adbf48c38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_94d6847e-d7de-4f88-8a5b-30b1339d0964" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_171f787f-1d85-4435-94a0-6bfceba154d0" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_94d6847e-d7de-4f88-8a5b-30b1339d0964" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5f928103-7b12-4ac2-894f-50c938d7a5dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_94d6847e-d7de-4f88-8a5b-30b1339d0964" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5f928103-7b12-4ac2-894f-50c938d7a5dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_6d86ce17-36be-4227-b66c-449bdb0caa03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_94d6847e-d7de-4f88-8a5b-30b1339d0964" xlink:to="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_6d86ce17-36be-4227-b66c-449bdb0caa03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_5404d939-1639-428c-b2f8-59ffd4dfc30a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_94d6847e-d7de-4f88-8a5b-30b1339d0964" xlink:to="loc_us-gaap_Revenues_5404d939-1639-428c-b2f8-59ffd4dfc30a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_76a4dc90-157c-4079-94ab-a3c1ff3f4e8d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_94d6847e-d7de-4f88-8a5b-30b1339d0964" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_76a4dc90-157c-4079-94ab-a3c1ff3f4e8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/LicenseAgreements" xlink:type="simple" xlink:href="dnli-20210331.xsd#LicenseAgreements"/>
  <link:presentationLink xlink:role="http://www.denalitherapeutics.com/role/LicenseAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_28265322-86b1-427b-b540-5d4155253aa8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_LicenseAgreementTextBlock_bb33e921-e9d0-4b2c-adae-38b6e4a0eb1e" xlink:href="dnli-20210331.xsd#dnli_LicenseAgreementTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_28265322-86b1-427b-b540-5d4155253aa8" xlink:to="loc_dnli_LicenseAgreementTextBlock_bb33e921-e9d0-4b2c-adae-38b6e4a0eb1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/LicenseAgreementsNarrativeDetails" xlink:type="simple" xlink:href="dnli-20210331.xsd#LicenseAgreementsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.denalitherapeutics.com/role/LicenseAgreementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_dfc96624-06c7-4c99-8356-0db4166a32f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_14fa6293-4588-40a0-8f1a-201d66a8e1c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_dfc96624-06c7-4c99-8356-0db4166a32f8" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_14fa6293-4588-40a0-8f1a-201d66a8e1c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_050d053b-1db2-486c-8446-d0d06f126538" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_14fa6293-4588-40a0-8f1a-201d66a8e1c3" xlink:to="loc_srt_CounterpartyNameAxis_050d053b-1db2-486c-8446-d0d06f126538" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a5117ad7-b4f7-4492-b3fe-745cf512379a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_050d053b-1db2-486c-8446-d0d06f126538" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a5117ad7-b4f7-4492-b3fe-745cf512379a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_GenentechIncMember_ea7e8a8c-bed4-4adb-b21a-a5c98ab91b85" xlink:href="dnli-20210331.xsd#dnli_GenentechIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a5117ad7-b4f7-4492-b3fe-745cf512379a" xlink:to="loc_dnli_GenentechIncMember_ea7e8a8c-bed4-4adb-b21a-a5c98ab91b85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_aa498011-f876-49ef-8433-8b20b6a26899" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_14fa6293-4588-40a0-8f1a-201d66a8e1c3" xlink:to="loc_srt_RangeAxis_aa498011-f876-49ef-8433-8b20b6a26899" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e1659ba9-775e-4ec8-905c-38a9e4fa1043" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_aa498011-f876-49ef-8433-8b20b6a26899" xlink:to="loc_srt_RangeMember_e1659ba9-775e-4ec8-905c-38a9e4fa1043" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_299da197-183c-40b8-aeb6-f0b777016b4a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_e1659ba9-775e-4ec8-905c-38a9e4fa1043" xlink:to="loc_srt_MaximumMember_299da197-183c-40b8-aeb6-f0b777016b4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_10ee89e7-93db-4dcf-ba0b-d9de3e755e72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_14fa6293-4588-40a0-8f1a-201d66a8e1c3" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_10ee89e7-93db-4dcf-ba0b-d9de3e755e72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_326bbbbe-ac47-45d5-b123-77bb75cd050e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_10ee89e7-93db-4dcf-ba0b-d9de3e755e72" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_326bbbbe-ac47-45d5-b123-77bb75cd050e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_ClinicalMember_1c1ad4d6-2593-48f0-a715-da45ae141ad3" xlink:href="dnli-20210331.xsd#dnli_ClinicalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_326bbbbe-ac47-45d5-b123-77bb75cd050e" xlink:to="loc_dnli_ClinicalMember_1c1ad4d6-2593-48f0-a715-da45ae141ad3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_RegulatoryMember_bcf1f77a-2878-496b-beb6-9fea170e651a" xlink:href="dnli-20210331.xsd#dnli_RegulatoryMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_326bbbbe-ac47-45d5-b123-77bb75cd050e" xlink:to="loc_dnli_RegulatoryMember_bcf1f77a-2878-496b-beb6-9fea170e651a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_CommercialMember_e442e1f5-3780-4fb6-98c8-4f58d397e1ee" xlink:href="dnli-20210331.xsd#dnli_CommercialMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_326bbbbe-ac47-45d5-b123-77bb75cd050e" xlink:to="loc_dnli_CommercialMember_e442e1f5-3780-4fb6-98c8-4f58d397e1ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_26c80ac7-3f6a-4ce2-bff1-b73421f9f9e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_14fa6293-4588-40a0-8f1a-201d66a8e1c3" xlink:to="loc_us-gaap_TypeOfArrangementAxis_26c80ac7-3f6a-4ce2-bff1-b73421f9f9e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3126b02a-ba3c-4f5c-ac55-3b9554e13833" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_26c80ac7-3f6a-4ce2-bff1-b73421f9f9e8" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3126b02a-ba3c-4f5c-ac55-3b9554e13833" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_LicenseAgreementMember_0d5fc568-74cc-4d88-ba7d-30078f372b53" xlink:href="dnli-20210331.xsd#dnli_LicenseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3126b02a-ba3c-4f5c-ac55-3b9554e13833" xlink:to="loc_dnli_LicenseAgreementMember_0d5fc568-74cc-4d88-ba7d-30078f372b53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_5837bf79-984b-4758-8b14-fe33647fc579" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_14fa6293-4588-40a0-8f1a-201d66a8e1c3" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_5837bf79-984b-4758-8b14-fe33647fc579" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_7674cc62-65fd-433f-8569-4f1f822fec02" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_5837bf79-984b-4758-8b14-fe33647fc579" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_7674cc62-65fd-433f-8569-4f1f822fec02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_b6405f4d-1988-4c16-b90b-042735cb46ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_7674cc62-65fd-433f-8569-4f1f822fec02" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_b6405f4d-1988-4c16-b90b-042735cb46ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_1efedf40-6d35-4629-92c0-4deb7f32e99f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_14fa6293-4588-40a0-8f1a-201d66a8e1c3" xlink:to="loc_dei_LegalEntityAxis_1efedf40-6d35-4629-92c0-4deb7f32e99f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_59e57337-7f25-4de9-89cc-359a988bf507" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1efedf40-6d35-4629-92c0-4deb7f32e99f" xlink:to="loc_dei_EntityDomain_59e57337-7f25-4de9-89cc-359a988bf507" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_BiogenMember_0b971cc6-b782-45d0-b545-4b5f00d13818" xlink:href="dnli-20210331.xsd#dnli_BiogenMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_59e57337-7f25-4de9-89cc-359a988bf507" xlink:to="loc_dnli_BiogenMember_0b971cc6-b782-45d0-b545-4b5f00d13818" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c5f8ff2a-ab30-43dc-b5fb-dc813a03b1f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_14fa6293-4588-40a0-8f1a-201d66a8e1c3" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c5f8ff2a-ab30-43dc-b5fb-dc813a03b1f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_LicenseAgreementMilestonePaymentUponAchievementOfClinicalAndRegulatoryMilestones_b40a70af-f284-4d19-8b29-9d110677a53c" xlink:href="dnli-20210331.xsd#dnli_LicenseAgreementMilestonePaymentUponAchievementOfClinicalAndRegulatoryMilestones"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c5f8ff2a-ab30-43dc-b5fb-dc813a03b1f2" xlink:to="loc_dnli_LicenseAgreementMilestonePaymentUponAchievementOfClinicalAndRegulatoryMilestones_b40a70af-f284-4d19-8b29-9d110677a53c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_LicenseAgreementMilestonePaymentObligationResponsibilityPercentage_f35bf991-075b-4ec3-8a39-a15f62c9fa06" xlink:href="dnli-20210331.xsd#dnli_LicenseAgreementMilestonePaymentObligationResponsibilityPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c5f8ff2a-ab30-43dc-b5fb-dc813a03b1f2" xlink:to="loc_dnli_LicenseAgreementMilestonePaymentObligationResponsibilityPercentage_f35bf991-075b-4ec3-8a39-a15f62c9fa06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_UpfrontFeesPaid_9c682408-3a3f-4933-a561-5c69db9b35b9" xlink:href="dnli-20210331.xsd#dnli_UpfrontFeesPaid"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c5f8ff2a-ab30-43dc-b5fb-dc813a03b1f2" xlink:to="loc_dnli_UpfrontFeesPaid_9c682408-3a3f-4933-a561-5c69db9b35b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="dnli-20210331.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.denalitherapeutics.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1323c5a3-02a0-4e93-82cf-b9002e865e11" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_d818e9cc-19e1-44e1-a187-43ee6e4b2747" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1323c5a3-02a0-4e93-82cf-b9002e865e11" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_d818e9cc-19e1-44e1-a187-43ee6e4b2747" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/CommitmentsandContingenciesTables" xlink:type="simple" xlink:href="dnli-20210331.xsd#CommitmentsandContingenciesTables"/>
  <link:presentationLink xlink:role="http://www.denalitherapeutics.com/role/CommitmentsandContingenciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_cb5dc72a-a581-4def-a165-66899d368035" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_28e0663f-94fa-4483-ac0f-c870e5a005a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_cb5dc72a-a581-4def-a165-66899d368035" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_28e0663f-94fa-4483-ac0f-c870e5a005a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock_c6c77134-eb44-411d-a3d7-e42d1fd919d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_cb5dc72a-a581-4def-a165-66899d368035" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock_c6c77134-eb44-411d-a3d7-e42d1fd919d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="simple" xlink:href="dnli-20210331.xsd#CommitmentsandContingenciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.denalitherapeutics.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0e09a7dc-327f-40a8-8120-43110487ae4d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_12f2ab78-3a75-4511-a6ff-6e6009617e0c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0e09a7dc-327f-40a8-8120-43110487ae4d" xlink:to="loc_us-gaap_LossContingenciesTable_12f2ab78-3a75-4511-a6ff-6e6009617e0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermAxis_a9799a55-8660-4cba-9e73-db45c888cde7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseContractualTermAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_12f2ab78-3a75-4511-a6ff-6e6009617e0c" xlink:to="loc_us-gaap_LeaseContractualTermAxis_a9799a55-8660-4cba-9e73-db45c888cde7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain_ad68f132-8208-4fac-917c-8c85476a3ac0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermAxis_a9799a55-8660-4cba-9e73-db45c888cde7" xlink:to="loc_us-gaap_LeaseContractualTermDomain_ad68f132-8208-4fac-917c-8c85476a3ac0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_HeadquartersLeaseMember_7d71b90b-f3d2-4a8b-84eb-fa9a76fb079d" xlink:href="dnli-20210331.xsd#dnli_HeadquartersLeaseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermDomain_ad68f132-8208-4fac-917c-8c85476a3ac0" xlink:to="loc_dnli_HeadquartersLeaseMember_7d71b90b-f3d2-4a8b-84eb-fa9a76fb079d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_NewPremisesSubleaseAgreementMember_81cdab0c-cb65-4156-9a0f-24023b6ff80c" xlink:href="dnli-20210331.xsd#dnli_NewPremisesSubleaseAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermDomain_ad68f132-8208-4fac-917c-8c85476a3ac0" xlink:to="loc_dnli_NewPremisesSubleaseAgreementMember_81cdab0c-cb65-4156-9a0f-24023b6ff80c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_801c08df-400b-4796-8b6f-fdc56d6bab35" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_12f2ab78-3a75-4511-a6ff-6e6009617e0c" xlink:to="loc_srt_RangeAxis_801c08df-400b-4796-8b6f-fdc56d6bab35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_11f0828e-6a15-4f22-bf64-ae59fee5f17a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_801c08df-400b-4796-8b6f-fdc56d6bab35" xlink:to="loc_srt_RangeMember_11f0828e-6a15-4f22-bf64-ae59fee5f17a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_32de7471-86da-4c41-8895-31227f595853" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_11f0828e-6a15-4f22-bf64-ae59fee5f17a" xlink:to="loc_srt_MinimumMember_32de7471-86da-4c41-8895-31227f595853" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_97dd8f36-c63e-4933-9cd9-8810ffbbeddb" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_11f0828e-6a15-4f22-bf64-ae59fee5f17a" xlink:to="loc_srt_MaximumMember_97dd8f36-c63e-4933-9cd9-8810ffbbeddb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c4c52bc7-9631-4ca6-a998-d67e3784a045" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_12f2ab78-3a75-4511-a6ff-6e6009617e0c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c4c52bc7-9631-4ca6-a998-d67e3784a045" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_66e16210-3ffb-4a7d-82c3-e0aca5e22b21" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c4c52bc7-9631-4ca6-a998-d67e3784a045" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_66e16210-3ffb-4a7d-82c3-e0aca5e22b21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_LandlordFundedTenantImprovementsMember_0e08d0f8-b0f6-4648-b973-fca829e605b4" xlink:href="dnli-20210331.xsd#dnli_LandlordFundedTenantImprovementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_66e16210-3ffb-4a7d-82c3-e0aca5e22b21" xlink:to="loc_dnli_LandlordFundedTenantImprovementsMember_0e08d0f8-b0f6-4648-b973-fca829e605b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_abbafd63-c76a-4b8b-9c13-a2da42332911" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_12f2ab78-3a75-4511-a6ff-6e6009617e0c" xlink:to="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_abbafd63-c76a-4b8b-9c13-a2da42332911" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_f8487b66-6ce7-4c6d-a77a-dd76f907ca3c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_abbafd63-c76a-4b8b-9c13-a2da42332911" xlink:to="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_f8487b66-6ce7-4c6d-a77a-dd76f907ca3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_DMSAMember_75c15c7e-4b5f-41db-bb56-19b3749e5067" xlink:href="dnli-20210331.xsd#dnli_DMSAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_f8487b66-6ce7-4c6d-a77a-dd76f907ca3c" xlink:to="loc_dnli_DMSAMember_75c15c7e-4b5f-41db-bb56-19b3749e5067" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_a849c7ac-1b71-4300-a423-9d201ba4372a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_12f2ab78-3a75-4511-a6ff-6e6009617e0c" xlink:to="loc_us-gaap_LossContingenciesLineItems_a849c7ac-1b71-4300-a423-9d201ba4372a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_OperatingLeasesAreaUnderLease_4f6f623e-570e-4de9-b83a-16c7476ec21d" xlink:href="dnli-20210331.xsd#dnli_OperatingLeasesAreaUnderLease"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_a849c7ac-1b71-4300-a423-9d201ba4372a" xlink:to="loc_dnli_OperatingLeasesAreaUnderLease_4f6f623e-570e-4de9-b83a-16c7476ec21d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_e2d38600-c1d8-4aef-8a08-b97b654d616e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_a849c7ac-1b71-4300-a423-9d201ba4372a" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_e2d38600-c1d8-4aef-8a08-b97b654d616e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_aaa8499d-1f3c-4996-bb8e-29dbe4786ead" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_a849c7ac-1b71-4300-a423-9d201ba4372a" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_aaa8499d-1f3c-4996-bb8e-29dbe4786ead" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_LesseeOperatingLeaseRenewalNoticePeriod_28c8a566-1a93-48b1-99cc-d6de189ededd" xlink:href="dnli-20210331.xsd#dnli_LesseeOperatingLeaseRenewalNoticePeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_a849c7ac-1b71-4300-a423-9d201ba4372a" xlink:to="loc_dnli_LesseeOperatingLeaseRenewalNoticePeriod_28c8a566-1a93-48b1-99cc-d6de189ededd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_e07d376b-66e4-4b7b-aae2-a69adfd0484e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_a849c7ac-1b71-4300-a423-9d201ba4372a" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_e07d376b-66e4-4b7b-aae2-a69adfd0484e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsGross_ebfef3d3-4027-432f-b625-a823e1991a34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsGross"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_a849c7ac-1b71-4300-a423-9d201ba4372a" xlink:to="loc_us-gaap_LeaseholdImprovementsGross_ebfef3d3-4027-432f-b625-a823e1991a34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_TenantImprovementAllowanceRepayableAsRent_0095bbac-d446-4c75-bcac-6117c1b2ad15" xlink:href="dnli-20210331.xsd#dnli_TenantImprovementAllowanceRepayableAsRent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_a849c7ac-1b71-4300-a423-9d201ba4372a" xlink:to="loc_dnli_TenantImprovementAllowanceRepayableAsRent_0095bbac-d446-4c75-bcac-6117c1b2ad15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseDiscountRate_727dd0ec-da72-4621-a469-61f86df4adfd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseDiscountRate"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_a849c7ac-1b71-4300-a423-9d201ba4372a" xlink:to="loc_us-gaap_LesseeOperatingLeaseDiscountRate_727dd0ec-da72-4621-a469-61f86df4adfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_3287b2bd-e028-40cc-bff7-1e0ba0053f9f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_a849c7ac-1b71-4300-a423-9d201ba4372a" xlink:to="loc_us-gaap_LeaseCost_3287b2bd-e028-40cc-bff7-1e0ba0053f9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_64e3e793-1b81-4d3b-8f0b-51664657dd42" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_a849c7ac-1b71-4300-a423-9d201ba4372a" xlink:to="loc_us-gaap_OperatingLeasePayments_64e3e793-1b81-4d3b-8f0b-51664657dd42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_OperatingLeasesSubleaseNetRentableArea_954cd4f0-44fa-4e47-8d68-15fb4bacd66a" xlink:href="dnli-20210331.xsd#dnli_OperatingLeasesSubleaseNetRentableArea"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_a849c7ac-1b71-4300-a423-9d201ba4372a" xlink:to="loc_dnli_OperatingLeasesSubleaseNetRentableArea_954cd4f0-44fa-4e47-8d68-15fb4bacd66a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeaseTermOfContract_dd60c621-efb1-499b-b16b-2786eb6cff3d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LessorOperatingLeaseTermOfContract"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_a849c7ac-1b71-4300-a423-9d201ba4372a" xlink:to="loc_us-gaap_LessorOperatingLeaseTermOfContract_dd60c621-efb1-499b-b16b-2786eb6cff3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome_107d916f-ac5c-4bb5-bda5-70e11ea9c750" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubleaseIncome"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_a849c7ac-1b71-4300-a423-9d201ba4372a" xlink:to="loc_us-gaap_SubleaseIncome_107d916f-ac5c-4bb5-bda5-70e11ea9c750" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_PurchaseOrderExecuted_db7c01bb-a27a-4eb4-981b-c17125b0c4f3" xlink:href="dnli-20210331.xsd#dnli_PurchaseOrderExecuted"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_a849c7ac-1b71-4300-a423-9d201ba4372a" xlink:to="loc_dnli_PurchaseOrderExecuted_db7c01bb-a27a-4eb4-981b-c17125b0c4f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligation_7df980af-1605-4dc2-9f21-eabe400e4e11" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PurchaseObligation"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_a849c7ac-1b71-4300-a423-9d201ba4372a" xlink:to="loc_us-gaap_PurchaseObligation_7df980af-1605-4dc2-9f21-eabe400e4e11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsIncurredDevelopmentCosts_2e604e80-ec1a-44fb-bd9e-baac0f8ccadb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsIncurredDevelopmentCosts"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_a849c7ac-1b71-4300-a423-9d201ba4372a" xlink:to="loc_us-gaap_CostsIncurredDevelopmentCosts_2e604e80-ec1a-44fb-bd9e-baac0f8ccadb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_PaymentsForManufacturingCost_be6fc048-907b-486d-964f-c81516e19170" xlink:href="dnli-20210331.xsd#dnli_PaymentsForManufacturingCost"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_a849c7ac-1b71-4300-a423-9d201ba4372a" xlink:to="loc_dnli_PaymentsForManufacturingCost_be6fc048-907b-486d-964f-c81516e19170" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/CommitmentsandContingenciesSummaryofCompanysFutureMinimumLeaseCommitmentsDetails" xlink:type="simple" xlink:href="dnli-20210331.xsd#CommitmentsandContingenciesSummaryofCompanysFutureMinimumLeaseCommitmentsDetails"/>
  <link:presentationLink xlink:role="http://www.denalitherapeutics.com/role/CommitmentsandContingenciesSummaryofCompanysFutureMinimumLeaseCommitmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5fa69b91-8487-4385-993a-593b5a18d718" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_71f4076f-7410-4986-a919-d4996bc23e94" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5fa69b91-8487-4385-993a-593b5a18d718" xlink:to="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_71f4076f-7410-4986-a919-d4996bc23e94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_46524683-cfc2-40e8-861b-9e269a4c52c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_71f4076f-7410-4986-a919-d4996bc23e94" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_46524683-cfc2-40e8-861b-9e269a4c52c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_8c92d1ea-6285-4f1d-9fda-fb7714f07497" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_71f4076f-7410-4986-a919-d4996bc23e94" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_8c92d1ea-6285-4f1d-9fda-fb7714f07497" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_2b101699-e73c-46ff-9029-3cdb5ec4cbbe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_71f4076f-7410-4986-a919-d4996bc23e94" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_2b101699-e73c-46ff-9029-3cdb5ec4cbbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_d20485e2-095a-4daa-892b-f8626cc661eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_71f4076f-7410-4986-a919-d4996bc23e94" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_d20485e2-095a-4daa-892b-f8626cc661eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_4b1f625b-b2f2-4d12-a217-b6a4224a56c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_71f4076f-7410-4986-a919-d4996bc23e94" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_4b1f625b-b2f2-4d12-a217-b6a4224a56c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_8b40f598-9277-460d-8f92-912f3eb3bd39" xlink:href="dnli-20210331.xsd#dnli_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_71f4076f-7410-4986-a919-d4996bc23e94" xlink:to="loc_dnli_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_8b40f598-9277-460d-8f92-912f3eb3bd39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9ddabab6-0a3e-4ffd-abd7-588cd378745b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_71f4076f-7410-4986-a919-d4996bc23e94" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9ddabab6-0a3e-4ffd-abd7-588cd378745b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_5049f51e-fc41-4146-9dac-5d4450948b16" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_71f4076f-7410-4986-a919-d4996bc23e94" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_5049f51e-fc41-4146-9dac-5d4450948b16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_1ae9794d-6f6e-4038-a679-2b4b16223b1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_71f4076f-7410-4986-a919-d4996bc23e94" xlink:to="loc_us-gaap_OperatingLeaseLiability_1ae9794d-6f6e-4038-a679-2b4b16223b1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/CommitmentsandContingenciesSummaryofCompanysFutureMinimumLeaseCommitmentsDetails_1" xlink:type="simple" xlink:href="dnli-20210331.xsd#CommitmentsandContingenciesSummaryofCompanysFutureMinimumLeaseCommitmentsDetails_1"/>
  <link:presentationLink xlink:role="http://www.denalitherapeutics.com/role/CommitmentsandContingenciesSummaryofCompanysFutureMinimumLeaseCommitmentsDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/CommitmentsandContingenciesSummaryofCompanysFutureMinimumLeaseReceivablesDetails" xlink:type="simple" xlink:href="dnli-20210331.xsd#CommitmentsandContingenciesSummaryofCompanysFutureMinimumLeaseReceivablesDetails"/>
  <link:presentationLink xlink:role="http://www.denalitherapeutics.com/role/CommitmentsandContingenciesSummaryofCompanysFutureMinimumLeaseReceivablesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1d21832e-e4e6-4694-93ff-82aff410a9f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear_948c1f7f-d783-486e-9581-a9c3b7c117f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1d21832e-e4e6-4694-93ff-82aff410a9f7" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear_948c1f7f-d783-486e-9581-a9c3b7c117f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths_daa8df01-73d1-4812-96d9-40f6445a1e9b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1d21832e-e4e6-4694-93ff-82aff410a9f7" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths_daa8df01-73d1-4812-96d9-40f6445a1e9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears_db7268b0-74ba-4149-9406-1e95d42dacdb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1d21832e-e4e6-4694-93ff-82aff410a9f7" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears_db7268b0-74ba-4149-9406-1e95d42dacdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears_4d6e2a16-7469-4c9a-9e30-9fa932fc795e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1d21832e-e4e6-4694-93ff-82aff410a9f7" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears_4d6e2a16-7469-4c9a-9e30-9fa932fc795e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_e3966042-3b3d-4226-b346-b8803af8de01" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceived"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1d21832e-e4e6-4694-93ff-82aff410a9f7" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_e3966042-3b3d-4226-b346-b8803af8de01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/StockBasedAwards" xlink:type="simple" xlink:href="dnli-20210331.xsd#StockBasedAwards"/>
  <link:presentationLink xlink:role="http://www.denalitherapeutics.com/role/StockBasedAwards" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3b533acf-5b38-45f0-b5ed-51443121f231" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_b9afd3c1-6623-40a0-99f1-af75196dd640" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3b533acf-5b38-45f0-b5ed-51443121f231" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_b9afd3c1-6623-40a0-99f1-af75196dd640" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/StockBasedAwardsTables" xlink:type="simple" xlink:href="dnli-20210331.xsd#StockBasedAwardsTables"/>
  <link:presentationLink xlink:role="http://www.denalitherapeutics.com/role/StockBasedAwardsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3b6f1f5e-d2db-4e42-991d-c752cb871af9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_0239a876-9b9b-4ea3-b4be-9177c410ff39" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3b6f1f5e-d2db-4e42-991d-c752cb871af9" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_0239a876-9b9b-4ea3-b4be-9177c410ff39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_f04a4b03-2517-435d-a926-452e2d4446d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3b6f1f5e-d2db-4e42-991d-c752cb871af9" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_f04a4b03-2517-435d-a926-452e2d4446d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_877123ac-92d5-4aca-a3aa-add405a7bf85" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3b6f1f5e-d2db-4e42-991d-c752cb871af9" xlink:to="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_877123ac-92d5-4aca-a3aa-add405a7bf85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_88c07e24-11cd-4b23-a8b0-228f28d74708" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3b6f1f5e-d2db-4e42-991d-c752cb871af9" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_88c07e24-11cd-4b23-a8b0-228f28d74708" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofStockOptionActivityDetails" xlink:type="simple" xlink:href="dnli-20210331.xsd#StockBasedAwardsSummaryofStockOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ca6dd0dc-bc9b-45c0-98a4-62b698221173" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_2b394cbe-e48c-4729-98ca-9946f70db58a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ca6dd0dc-bc9b-45c0-98a4-62b698221173" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_2b394cbe-e48c-4729-98ca-9946f70db58a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_b0fff04d-4688-48cd-9c94-1d25adb7143b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_2b394cbe-e48c-4729-98ca-9946f70db58a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_b0fff04d-4688-48cd-9c94-1d25adb7143b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_712dd187-826b-4eca-844e-d87c1d7948ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_2b394cbe-e48c-4729-98ca-9946f70db58a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_712dd187-826b-4eca-844e-d87c1d7948ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_b8d0b13f-29f7-42ff-b2bf-56a1ac847e60" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_2b394cbe-e48c-4729-98ca-9946f70db58a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_b8d0b13f-29f7-42ff-b2bf-56a1ac847e60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_fd575f8a-cf52-4003-8fa4-f9dfc994db83" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_2b394cbe-e48c-4729-98ca-9946f70db58a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_fd575f8a-cf52-4003-8fa4-f9dfc994db83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9343d0c5-7d3f-4981-b620-403454d5cb72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_2b394cbe-e48c-4729-98ca-9946f70db58a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9343d0c5-7d3f-4981-b620-403454d5cb72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_5d24e540-ca61-44b6-b399-80774c715c09" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ca6dd0dc-bc9b-45c0-98a4-62b698221173" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_5d24e540-ca61-44b6-b399-80774c715c09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_cf339636-62fc-45a6-89c3-2bbba9db5e75" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ca6dd0dc-bc9b-45c0-98a4-62b698221173" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_cf339636-62fc-45a6-89c3-2bbba9db5e75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7be91164-0616-47f3-b25f-0162ec46dcc7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ca6dd0dc-bc9b-45c0-98a4-62b698221173" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7be91164-0616-47f3-b25f-0162ec46dcc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_510801b8-f6ed-4c99-b03c-e6f4aa213ccb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7be91164-0616-47f3-b25f-0162ec46dcc7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_510801b8-f6ed-4c99-b03c-e6f4aa213ccb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_ab353f3a-3f3a-4e96-aca6-4aad5c301c38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7be91164-0616-47f3-b25f-0162ec46dcc7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_ab353f3a-3f3a-4e96-aca6-4aad5c301c38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_08dcebb5-e8c4-4223-8807-1a19304d6a79" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7be91164-0616-47f3-b25f-0162ec46dcc7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_08dcebb5-e8c4-4223-8807-1a19304d6a79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_dbe55d21-fb2d-45e9-9438-df3c6d72923b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7be91164-0616-47f3-b25f-0162ec46dcc7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_dbe55d21-fb2d-45e9-9438-df3c6d72923b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_142c65af-c5f1-48cf-9f61-12f9ee5bd071" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7be91164-0616-47f3-b25f-0162ec46dcc7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_142c65af-c5f1-48cf-9f61-12f9ee5bd071" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_5a6178bd-1542-4c81-a85e-3d3f4c159589" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ca6dd0dc-bc9b-45c0-98a4-62b698221173" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_5a6178bd-1542-4c81-a85e-3d3f4c159589" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_6f3b9577-7705-4539-a075-cfbdd955f6f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ca6dd0dc-bc9b-45c0-98a4-62b698221173" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_6f3b9577-7705-4539-a075-cfbdd955f6f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofAssumptionsUsedforEstimatingtheFairValueofStockOptionsGrantedDetails" xlink:type="simple" xlink:href="dnli-20210331.xsd#StockBasedAwardsSummaryofAssumptionsUsedforEstimatingtheFairValueofStockOptionsGrantedDetails"/>
  <link:presentationLink xlink:role="http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofAssumptionsUsedforEstimatingtheFairValueofStockOptionsGrantedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_31c9769d-cc9e-47bf-b8af-16d694e39ba8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bd78090c-ffda-4ce8-a0ad-d97dca192c9f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_31c9769d-cc9e-47bf-b8af-16d694e39ba8" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bd78090c-ffda-4ce8-a0ad-d97dca192c9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_4bc58b03-f564-43d8-b3e5-b5e18f14fa1a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bd78090c-ffda-4ce8-a0ad-d97dca192c9f" xlink:to="loc_us-gaap_AwardTypeAxis_4bc58b03-f564-43d8-b3e5-b5e18f14fa1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b10edc60-ed80-46e6-aa31-4089dcb84ab5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_4bc58b03-f564-43d8-b3e5-b5e18f14fa1a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b10edc60-ed80-46e6-aa31-4089dcb84ab5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1b71529e-fad3-4799-bf00-0f38e64f6142" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b10edc60-ed80-46e6-aa31-4089dcb84ab5" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1b71529e-fad3-4799-bf00-0f38e64f6142" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_78fc2590-14b7-441a-b446-d8101716adf4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bd78090c-ffda-4ce8-a0ad-d97dca192c9f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_78fc2590-14b7-441a-b446-d8101716adf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_226229c8-71b6-408e-93e7-a67d820a226c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_78fc2590-14b7-441a-b446-d8101716adf4" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_226229c8-71b6-408e-93e7-a67d820a226c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_6b935e98-6392-47a9-b14a-b336cfec18a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_78fc2590-14b7-441a-b446-d8101716adf4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_6b935e98-6392-47a9-b14a-b336cfec18a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_873e1398-49da-49aa-983d-3e4fb5d517cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_78fc2590-14b7-441a-b446-d8101716adf4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_873e1398-49da-49aa-983d-3e4fb5d517cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_2d265f30-5016-47a2-90b3-07a6ec26aa8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_78fc2590-14b7-441a-b446-d8101716adf4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_2d265f30-5016-47a2-90b3-07a6ec26aa8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_8f251502-0644-42bc-8006-d5e4c62bec62" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_78fc2590-14b7-441a-b446-d8101716adf4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_8f251502-0644-42bc-8006-d5e4c62bec62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_9b3bfae2-f220-4030-903e-a98739a6a659" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_78fc2590-14b7-441a-b446-d8101716adf4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_9b3bfae2-f220-4030-903e-a98739a6a659" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofRestrictedStockActivityDetails" xlink:type="simple" xlink:href="dnli-20210331.xsd#StockBasedAwardsSummaryofRestrictedStockActivityDetails"/>
  <link:presentationLink xlink:role="http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofRestrictedStockActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_65e768e8-2907-46f1-8ccf-be339d3a655c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8afc7aff-f73e-45e6-8bec-3572a02d02c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_65e768e8-2907-46f1-8ccf-be339d3a655c" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8afc7aff-f73e-45e6-8bec-3572a02d02c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_071bf4dd-2f83-4c79-a5c9-5d8a1fb9caf3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8afc7aff-f73e-45e6-8bec-3572a02d02c0" xlink:to="loc_us-gaap_AwardTypeAxis_071bf4dd-2f83-4c79-a5c9-5d8a1fb9caf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ffbd28b3-0db3-429b-bab8-48b7a14c188d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_071bf4dd-2f83-4c79-a5c9-5d8a1fb9caf3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ffbd28b3-0db3-429b-bab8-48b7a14c188d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_b95f2709-18a1-46ed-825c-421e5a8d0fe5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ffbd28b3-0db3-429b-bab8-48b7a14c188d" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_b95f2709-18a1-46ed-825c-421e5a8d0fe5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_230a85c1-2ec4-4e09-b50f-93d7acf4dda1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8afc7aff-f73e-45e6-8bec-3572a02d02c0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_230a85c1-2ec4-4e09-b50f-93d7acf4dda1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_b5f69219-e58d-4448-9752-b9044e420fb7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_230a85c1-2ec4-4e09-b50f-93d7acf4dda1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_b5f69219-e58d-4448-9752-b9044e420fb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_d71c6f0a-385b-4f0d-8315-4534898161fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_b5f69219-e58d-4448-9752-b9044e420fb7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_d71c6f0a-385b-4f0d-8315-4534898161fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_ec1a6c97-6fe7-44a1-bf32-93b37793cea3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_b5f69219-e58d-4448-9752-b9044e420fb7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_ec1a6c97-6fe7-44a1-bf32-93b37793cea3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_6f7ea3ae-3e8c-4718-bdba-521973bdafc2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_b5f69219-e58d-4448-9752-b9044e420fb7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_6f7ea3ae-3e8c-4718-bdba-521973bdafc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_715551e1-0399-4f09-9281-5d1b689456fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_b5f69219-e58d-4448-9752-b9044e420fb7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_715551e1-0399-4f09-9281-5d1b689456fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_945ca609-b15a-4258-b9fc-acfe552798fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_b5f69219-e58d-4448-9752-b9044e420fb7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_945ca609-b15a-4258-b9fc-acfe552798fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber_7ed26a7b-5a95-4cee-a0c9-dc4a56b6d17b" xlink:href="dnli-20210331.xsd#dnli_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_230a85c1-2ec4-4e09-b50f-93d7acf4dda1" xlink:to="loc_dnli_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber_7ed26a7b-5a95-4cee-a0c9-dc4a56b6d17b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_2b88cdf2-c94d-4992-80b3-6b7f9d43e6b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_230a85c1-2ec4-4e09-b50f-93d7acf4dda1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_2b88cdf2-c94d-4992-80b3-6b7f9d43e6b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_152cdb89-f35f-47ee-bdb6-dfe1db4fb148" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_2b88cdf2-c94d-4992-80b3-6b7f9d43e6b5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_152cdb89-f35f-47ee-bdb6-dfe1db4fb148" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c689c2ea-0b88-4c5b-817f-69efba1d5826" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_2b88cdf2-c94d-4992-80b3-6b7f9d43e6b5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c689c2ea-0b88-4c5b-817f-69efba1d5826" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_5cef4c37-f37e-42bd-965a-71fec3316405" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_2b88cdf2-c94d-4992-80b3-6b7f9d43e6b5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_5cef4c37-f37e-42bd-965a-71fec3316405" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_79d14a67-0013-48b7-9600-3272855208ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_2b88cdf2-c94d-4992-80b3-6b7f9d43e6b5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_79d14a67-0013-48b7-9600-3272855208ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6ef9ebd7-b0ed-4ef7-bcbb-ffb516ae0404" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_2b88cdf2-c94d-4992-80b3-6b7f9d43e6b5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6ef9ebd7-b0ed-4ef7-bcbb-ffb516ae0404" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueExpectedToVest_98abfc43-973c-4110-9b7f-7be80d5dc812" xlink:href="dnli-20210331.xsd#dnli_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueExpectedToVest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_230a85c1-2ec4-4e09-b50f-93d7acf4dda1" xlink:to="loc_dnli_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueExpectedToVest_98abfc43-973c-4110-9b7f-7be80d5dc812" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="dnli-20210331.xsd#StockBasedAwardsSummaryofStockBasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofStockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalariesWagesAndOfficersCompensationAbstract_83f8ee64-7c7a-4cb8-84f3-c1ce7c46ffdd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalariesWagesAndOfficersCompensationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fddfa29c-0775-40bf-8b4e-2df4a683b07d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SalariesWagesAndOfficersCompensationAbstract_83f8ee64-7c7a-4cb8-84f3-c1ce7c46ffdd" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fddfa29c-0775-40bf-8b4e-2df4a683b07d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_df299a14-6f69-4035-9e99-cb927f1e84e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fddfa29c-0775-40bf-8b4e-2df4a683b07d" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_df299a14-6f69-4035-9e99-cb927f1e84e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_88f9cfe9-071b-45e1-8008-dd888eae8ae6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_df299a14-6f69-4035-9e99-cb927f1e84e3" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_88f9cfe9-071b-45e1-8008-dd888eae8ae6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_d3a0ab22-e761-4e4e-809f-98deda8cadde" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_88f9cfe9-071b-45e1-8008-dd888eae8ae6" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_d3a0ab22-e761-4e4e-809f-98deda8cadde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_7c4eb145-80d3-497f-837d-d10bc2874bf6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_88f9cfe9-071b-45e1-8008-dd888eae8ae6" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_7c4eb145-80d3-497f-837d-d10bc2874bf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3a2a11a1-b134-40b7-a2a3-c95984bafced" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fddfa29c-0775-40bf-8b4e-2df4a683b07d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3a2a11a1-b134-40b7-a2a3-c95984bafced" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_52082f3c-e7fa-4305-b92b-90df6e16fd9f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3a2a11a1-b134-40b7-a2a3-c95984bafced" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_52082f3c-e7fa-4305-b92b-90df6e16fd9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/NetLossPerShare" xlink:type="simple" xlink:href="dnli-20210331.xsd#NetLossPerShare"/>
  <link:presentationLink xlink:role="http://www.denalitherapeutics.com/role/NetLossPerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_23ed30e1-4109-46ee-bb21-99d82748c89d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_274adef2-81d1-4a8a-b3b0-b78bd30faba8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_23ed30e1-4109-46ee-bb21-99d82748c89d" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_274adef2-81d1-4a8a-b3b0-b78bd30faba8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/NetLossPerShareTables" xlink:type="simple" xlink:href="dnli-20210331.xsd#NetLossPerShareTables"/>
  <link:presentationLink xlink:role="http://www.denalitherapeutics.com/role/NetLossPerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_aef3a702-33f4-4e70-8780-c9951fbda8da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_ca4831bf-d877-4f02-99c7-f8af35ffa25c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_aef3a702-33f4-4e70-8780-c9951fbda8da" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_ca4831bf-d877-4f02-99c7-f8af35ffa25c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/NetLossPerShareScheduleofDilutiveSecuritiesNotIncludedinDilutedPerShareCalculationsDetails" xlink:type="simple" xlink:href="dnli-20210331.xsd#NetLossPerShareScheduleofDilutiveSecuritiesNotIncludedinDilutedPerShareCalculationsDetails"/>
  <link:presentationLink xlink:role="http://www.denalitherapeutics.com/role/NetLossPerShareScheduleofDilutiveSecuritiesNotIncludedinDilutedPerShareCalculationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_9f7d26b6-d6d8-422b-9b03-7ba2ad352c4b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_84412d1c-4d85-4b2b-82a2-e74eca0ee959" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_9f7d26b6-d6d8-422b-9b03-7ba2ad352c4b" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_84412d1c-4d85-4b2b-82a2-e74eca0ee959" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c57499f6-db11-4b42-b49c-49896c12c0ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_84412d1c-4d85-4b2b-82a2-e74eca0ee959" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c57499f6-db11-4b42-b49c-49896c12c0ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_22dfb981-5bd3-4aa7-b2eb-142ecff4430d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c57499f6-db11-4b42-b49c-49896c12c0ca" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_22dfb981-5bd3-4aa7-b2eb-142ecff4430d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_EmployeeAndNonEmployeeStockOptionMember_1383ac5e-cd64-4b96-a281-2f82b7963586" xlink:href="dnli-20210331.xsd#dnli_EmployeeAndNonEmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_22dfb981-5bd3-4aa7-b2eb-142ecff4430d" xlink:to="loc_dnli_EmployeeAndNonEmployeeStockOptionMember_1383ac5e-cd64-4b96-a281-2f82b7963586" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_RestrictedSharesSubjectToFutureVestingMember_a8b7479c-7915-4bb4-a283-47e662cec0a8" xlink:href="dnli-20210331.xsd#dnli_RestrictedSharesSubjectToFutureVestingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_22dfb981-5bd3-4aa7-b2eb-142ecff4430d" xlink:to="loc_dnli_RestrictedSharesSubjectToFutureVestingMember_a8b7479c-7915-4bb4-a283-47e662cec0a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_00afa340-3523-449c-b100-84294ec31ec0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_84412d1c-4d85-4b2b-82a2-e74eca0ee959" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_00afa340-3523-449c-b100-84294ec31ec0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_6e3a4137-c42d-48b0-b23c-272b9e88dc73" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_00afa340-3523-449c-b100-84294ec31ec0" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_6e3a4137-c42d-48b0-b23c-272b9e88dc73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="dnli-20210331.xsd#RelatedPartyTransactions"/>
  <link:presentationLink xlink:role="http://www.denalitherapeutics.com/role/RelatedPartyTransactions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_90672746-1cc8-4098-8a41-44eb49e28bc7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_241817bd-7325-45e4-b2ab-0993f8e3ae20" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_90672746-1cc8-4098-8a41-44eb49e28bc7" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_241817bd-7325-45e4-b2ab-0993f8e3ae20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>dnli-20210331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2020-01-31"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:dnli="http://www.denalitherapeutics.com/20210331"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2020-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="dnli-20210331.xsd" xlink:type="simple"/>
    <context id="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="id5f8b6da332f4721952346e234823fd7_I20210426">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
        </entity>
        <period>
            <instant>2021-04-26</instant>
        </period>
    </context>
    <context id="i9953f50a7fd74f7d8438f304f136a07b_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="idb7ca9f362da46eab3a29bbbecbda977_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia34dfea6b8734d64abf707c28256801c_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i6b1694c4d5a44ff2b0218864ff3535bb_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1182c403bed14f779ebd3c5cf55f280c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3e68706d6d7742388257b82fc7c16d8d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibe96d84e0a5e425bab91f9c7441e0d1d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3cc86f0bf14143f4ae8b3600808a8b8e_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i512d7365f8ba4cffa29eb6d1a746e90d_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i8f89be0032cd49c2b7c0a19693e48b5c_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i8017a7d7e9414d9cac2f173a2d4a39dc_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i6881ec9f4b804f8bb0b380a22e0d14bc_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="iab67b1cb96b04f5eae11176694e59a6b_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i8faf25a1f5264f7bbd65f096a2d9a464_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i2d9b04bba6cb45aab3777466d4b29061_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="if9deb2734a184a7cbde40db4324e7d19_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia3061e69973345b0a814850b46a1e70d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i7fc2ea20a15f4358958ac2de513cbedf_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4f05e20d565c4dec84e3cf8ab862dd61_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id36b0e599cb3498a8671e8c185763bc9_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia63b42181ffa4fb5aa0692f27bc204e4_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i481b7d29f5714b2c9591d38d45fb69a2_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="idc9c2fd3102f4601910401b0065ccdee_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i5462764077c54d46b830279d94f82af0_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i9e6a5f965fc64fdc84e37350364784a2_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i6acc176d0fde4b30bb04303aefe4c09c_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="if9160027ce4c429abb35b07016b25738_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i8288b3c6af7a4ceca6f0c97aa25994dc_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i29b65d7585ff41c5843594c6319bdb90_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i6c67df6d9d254626b9391157cc6763f4_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="iaa61d3a997f64111a4b23a96b7fe5b8a_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ida70779bab1a408eab2c0f807c7c2184_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i5a012763ca204bf7ac713bfc5a5fe5bb_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ia57c5b507b6a47618a967591bf368bff_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="if3f854bad0dd4fcab527216138601aaa_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i66e037a80d03458791ec3572ec41d1cb_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ie652e808c1f147618ebb4562358ce95a_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ie5f979a4d5d94f0ead845cf6e9d26c7e_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i8efa8793ba8f446f8ffd529b619bbbfd_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i78246248a32444d0b6f9cc3c2d85efd5_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="iaab08a4f99ff4ba2950d1437d42c90b2_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i6b542a8ed7164ce7a3f01a3325375861_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i588c2440f58644e8a6a0c3b8856f304b_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ic52a660c9ba0416c80ca6df7c8fb50dc_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="icf0336c48b2a4b5f93669576fb24b804_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i67d5388ca1f140b0b751939b213807d3_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ie9c36eef19a84e07bdddd763d415a7f7_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i1b241ffdc9c94e2082b8b85ebca483df_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i000addedaff44daba745c02655b81159_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i131f1b1eb6604026a5c42366001ad668_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dnli:LongTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i79306ba88f4140a183b8a8b4b6135daa_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dnli:LongTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ib0c77906277e4e39847898b3e7673e51_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dnli:LongTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ia06ecd5d4e7943cfb188e226606891fc_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dnli:LongTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i19b242abfd1e4002a024557986c6d987_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dnli:LongTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i99a26d4be72a42eb865297d52d41de8b_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dnli:LongTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i9dbd5d046d3244ef870fa23ff49cb036_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dnli:LongTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ie4aa0eddd0fb49eda4c41fc2a826b8c1_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dnli:LongTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i50be2f68d7ea46f1a2d7e733b2391ac5_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i0881221dc0304651bd4cc951315603f9_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i057152fc2b0d48c0969e0b03ae05f47f_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ie0489620584748b8a18511d5315c484d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iacef9d3f91dd40d0a87a4c4a0d2b6fb2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i216c3025b0124b688dd2fd43fb4468fb_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib663c99903ea42359657773d88880b3a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4680cafe26584c1f86d850c496eda36c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8a690a2144264f4f8dfff3d5dfce6fe6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i239e913cbb1a4a0389051b486d08f75a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if25b3a1f38994654bc19ed04aca9372f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="idc5b52a3db1b4f8baed84d10ed64492c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i86c3ea8f2f1f49c4a026b6bc52858668_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i908a382fdfd44406be1c76e156800e93_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i72798f9b723345d7b2945778149039ab_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i118d49e34100478aad6bb4134c3b2aaa_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i178051c344504d07985f78aa8cc32492_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id3593591cc6b4645bcbbae5e79b647d6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9286f708ff8349709d22f68a1a329272_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ided63883ce3647bc936cd798e72ea186_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0e93f92b75c548efb9c7fbf7491b4063_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="idb6cdf24410f45c282312f8166a766ff_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic16516c243df4551a83161ad3c5c0f09_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i25d88de0f197490fb779e1e3071f901e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3b60ffb67bd147c3a56d06666f6ff77c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibfac6e99e22f43c68f58fb5907948edb_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="idf6e2668dddb49d2ac374501483e7bf9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i215ae1ee50d14e92a7ea23ab3f943a5d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dnli:LongTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4026f6a97f4340d6a98d226ab3c04c12_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dnli:LongTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iec8ba588c80d4f4191cc54f76a956ff0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dnli:LongTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i57f0286f0cdd41afb93b20cd06df11c7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dnli:LongTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i480dc0971b7d403fad3d95c1932c7534_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dnli:LongTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifa86ad4908bc434aa3c51f66f9a60281_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dnli:LongTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic4170e2296ad4137872fb9951088b913_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dnli:LongTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6da17c1dcc0c448cbd20f8ec3a5656d1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dnli:LongTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0b67e7dddea84ea5bd2068d25930c3f0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i71c0a54ceaf448c7b9d4d9c1d534b5cc_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2db26540968047c2b760e6148893f1f0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5c991a09175c4907972778fd5a54038d_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dnli:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i58c971960b254076bc5ebc8a3a3a5a34_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dnli:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i5abb55cd5abc4ef4a6963ecc132bb1be_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dnli:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i382bf15544d0451c8ad0005fe504ecc1_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dnli:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i0c72ee3da1524776845e9b5ae9946eee_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dnli:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i89fb6181d11a43d88db96cf5f175becc_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dnli:LongTermMarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="iad80279b43b74b3fbb24392412ebf8d4_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dnli:LongTermMarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="id97fb3aa68ae491e9d798fe7cf3f01b6_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dnli:LongTermMarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ia965935f3dfc41e9898218d34d2db66f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dnli:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3607ed8ca137404691d4a18591291e6d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dnli:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0fd58d29aa7f4494bf30f6d59ca72c8c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dnli:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ieb9f9878977d4bee8003a43bbd55fbf7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dnli:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i86be035a34fe478ea00df2e76fba4dc9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dnli:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i74d3c7dbdd71495c8557f07cac6cd34d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dnli:LongTermMarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="icc4f3f2e913840ec946d6ab82f45dc71_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dnli:LongTermMarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iac0bb6ea773e4895b9939e783cbf93a7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dnli:LongTermMarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5e5ef3c57c01481ab32c18cba94f5fe4_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dnli:ForeignExchangeForwardEurosMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="id84a031bb1374baa8de940b07c3dff05_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dnli:ForeignExchangeForwardBritishPoundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ibf15d1cb21ae4c5b886c0aea82e7d1f3_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i8d51a225b0e74a329c75163f5353da38_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dnli:ForeignExchangeForwardEurosMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i83e8165a75164bcd89f57c0c00451316_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dnli:ForeignExchangeForwardBritishPoundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="idcf71a3762844d5ebc7aaa02a121c837_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3e3538bcdaba49b4bc9b8ff9d89ef4b8_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i2d55a3178b03487c9c5028f18060a482_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i67ac6e40ada9472996476ac5ea5bcbc7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i90752bb1d6844732a5f7754270148e69_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="id19e1b668ad54ff0a1bcaaf50d236bcd_I20200805">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:BiogenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dnli:TransportVehicleTechnologyPlatformUnnamedProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dnli:ProvisionalCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-05</instant>
        </period>
    </context>
    <context id="if6dd4f0c67444b1194ee0a12b060c2e7_I20200805">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:BiogenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dnli:TransportVehicleTechnologyProgramRightOfFirstNegotiationProgramsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dnli:ProvisionalCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-05</instant>
        </period>
    </context>
    <context id="i708f730074a74563a853bf7ef8f740fe_D20200805-20200805">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:BiogenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dnli:ProvisionalCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-05</startDate>
            <endDate>2020-08-05</endDate>
        </period>
    </context>
    <context id="i3bf8c8eaa53e41d5a068b18edae5519f_I20200805">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:BiogenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dnli:ProvisionalCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-05</instant>
        </period>
    </context>
    <context id="i19ba65d441e94cbda7c97a7dedf0b14c_I20200805">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dnli:ProvisionalCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-05</instant>
        </period>
    </context>
    <context id="id5c33ba7e2874d50a83a5008b6ae7852_I20200805">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dnli:ProvisionalCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-05</instant>
        </period>
    </context>
    <context id="id978123c42ea48179c72134ceea46ba2_I20200805">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dnli:ProvisionalCollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">dnli:BiogenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-05</instant>
        </period>
    </context>
    <context id="i8a30e11a54f94b2ebb02e2da6fe5446f_I20200805">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dnli:ProvisionalCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-05</instant>
        </period>
    </context>
    <context id="ib106d7ba52674677b8cb2ac5693422b7_I20200805">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:BiogenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dnli:TransportVehicleTechnologyPlatformPreclinicalProgramsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dnli:ProvisionalCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-05</instant>
        </period>
    </context>
    <context id="ia961be148e584fd4a2a57cc1b21dced2_D20200805-20200805">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:BiogenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dnli:TransportVehicleTechnologyPlatformPreclinicalProgramsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dnli:ProvisionalCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-05</startDate>
            <endDate>2020-08-05</endDate>
        </period>
    </context>
    <context id="i3df519c68317420e8222a86148ab6e41_I20200805">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:BiogenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dnli:TransportVehicleTechnologyPlatformRightOfFirstNegotiationProgramsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dnli:ProvisionalCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-05</instant>
        </period>
    </context>
    <context id="id16d8e434fba4f8ca86744e3c63d5d95_D20200805-20200805">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:BiogenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dnli:TransportVehicleTechnologyPlatformRightOfFirstNegotiationProgramsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dnli:ProvisionalCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-05</startDate>
            <endDate>2020-08-05</endDate>
        </period>
    </context>
    <context id="i3f469ca238db4f19ade2b0c2f5542d55_D20200922-20200922">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:BiogenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">dnli:SharePurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dnli:ProvisionalCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-22</startDate>
            <endDate>2020-09-22</endDate>
        </period>
    </context>
    <context id="i53d1846478874ac7a03801cbb5049533_I20200922">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:BiogenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">dnli:SharePurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dnli:ProvisionalCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-22</instant>
        </period>
    </context>
    <context id="i3d221276fee544dc91f74c0f2b96de94_I20201006">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:BiogenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dnli:ROFNAndOptionAgreementCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-06</instant>
        </period>
    </context>
    <context id="ia59d27ad521d4576896de358cda1e1a8_D20201006-20201031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:BiogenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dnli:BiogenCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-06</startDate>
            <endDate>2020-10-31</endDate>
        </period>
    </context>
    <context id="i22fa845ccdd543acb615ea629ab5344c_D20201006-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:BiogenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dnli:BiogenCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-06</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i2934421e8d7b4a55a318b2d3d6102fed_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:BiogenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i611b2655965e42dfbda911bc7c9ee9c8_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:BiogenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dnli:ROFNAndOptionAgreementCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i0f8d7006122c478b92ae9f39d8d1b0e5_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:BiogenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dnli:OptionResearchServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dnli:BiogenCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="if1065b142ae843249dfdfee04de24a66_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:BiogenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dnli:BiogenCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i5dd55e97d29845d79435cc613548f911_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:BiogenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dnli:BiogenCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i0013ce3d1a8247a08d873ceee1cdf67a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:BiogenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dnli:BiogenCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i37367f9356d64fd3928fdd776c7f31a8_D20181101-20181130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-11-01</startDate>
            <endDate>2018-11-30</endDate>
        </period>
    </context>
    <context id="ic6d24297d8d84d17b99d57fe8ee7d6f5_I20181130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-11-30</instant>
        </period>
    </context>
    <context id="i69a8709612b349b38ac7bf012d3e0fd3_I20181130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dnli:CNSProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-11-30</instant>
        </period>
    </context>
    <context id="i32ecdc0092f641bd9100243e5a27d217_I20181130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
        </entity>
        <period>
            <instant>2018-11-30</instant>
        </period>
    </context>
    <context id="iaa8b5535fbd846a4bd38c3e3b7f756a4_I20181130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dnli:PeripheralProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-11-30</instant>
        </period>
    </context>
    <context id="i6ea2228697dd4aaba41a39520dc51665_I20181130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">dnli:SanofiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-11-30</instant>
        </period>
    </context>
    <context id="iae801c2eda2b4f468e16600312d29411_I20181130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-11-30</instant>
        </period>
    </context>
    <context id="i46ab6c65582f4d8bab7e57d6dd6f7588_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dnli:MilestoneTriggeredAndRetainedActivitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i1c01d0c60cd542c4a229d6789938312a_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dnli:MilestoneTriggeredAndRetainedActivitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i71f6e4875572417586577b9989db412c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dnli:AlzheimersDiseaseServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i261cc6d074024d72a8c693a4ea9e24fa_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dnli:AlzheimersDiseaseServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i85da405a68d44147816b407c550dd77b_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ib2c5d3daea2b469eb42d1e130f45621f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8e78aebb6758499aa9b578b8b7365ab9_D20181001-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dnli:MilestoneTriggeredMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ieb8b43e946ab4a5e983647ccb9581dc3_D20181001-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="iaf62192d651f44fa9a8f0990d46c3286_D20180223-20180223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-02-23</startDate>
            <endDate>2018-02-23</endDate>
        </period>
    </context>
    <context id="i2e206bb2a68d468195031df47711679a_D20180223-20180223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-02-23</startDate>
            <endDate>2018-02-23</endDate>
        </period>
    </context>
    <context id="i629da488ba924dfc9f4eb9daeb937953_I20180223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-02-23</instant>
        </period>
    </context>
    <context id="idf9de44243d0448abccdf83151ea9bfa_I20180223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-02-23</instant>
        </period>
    </context>
    <context id="i9261bc8472184e6fa1082e8c5405a625_D20180223-20180223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">dnli:SharePurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-02-23</startDate>
            <endDate>2018-02-23</endDate>
        </period>
    </context>
    <context id="i9e0b33f51ccf452bae9b4c3f0109b86d_I20180223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">dnli:SharePurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-02-23</instant>
        </period>
    </context>
    <context id="i8319328706f24bcdb7bf7f3fc0782056_D20180223-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-02-23</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i8fd4f33cc0454770bb9522977f4298cc_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i1b343adcffb94181bcbdfcb6161d5aba_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6a890b5264394316bc209b1df064b85d_D20210301-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dnli:CollaborativeArrangementATVTREM2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="if1c8a3c07b01480bb07bf6e10da36189_D20210101-20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dnli:CollaborativeArrangementPTVPGRNMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="i82572c2ba407421ab1eeaea4cc017b83_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dnli:CollaborativeArrangementPTVPGRNMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if1fffa1219a047f0a51060aeafb58951_D20180101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dnli:MilestoneTriggeredMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i98a0ba98854b4bb8ac86be212e357b16_D20180101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i643ec7e1d2a3451c9d8905efbcdbf48c_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dnli:TakedaCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="iff0f9b13d274493e8564765eb94360ae_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dnli:TakedaCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ie9ccfab524d04954920c80a3c7ac6796_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dnli:RetainedActivitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dnli:SanofiCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="if81ccf0b3968466bb8ad747c00401a8d_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dnli:RetainedActivitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dnli:SanofiCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ifcf20312d910402ab56471a2d6469134_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dnli:AlzheimersDiseaseServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dnli:SanofiCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="idc2536462b694f07b028b19e58c564fe_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dnli:AlzheimersDiseaseServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dnli:SanofiCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ieb7e2edd7c3c4ff1a01d715afc57516e_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dnli:SanofiCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i18c380c88187451c9ad16eccfc6df52c_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dnli:SanofiCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ic480049fe58042bdb36bf14a067dcfc0_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dnli:OptionServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dnli:BiogenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i1a7cd8e57f5f494c9a40a6b2b090b922_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dnli:OptionServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dnli:BiogenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ifedff44484c341d28f698f572ac47df9_D20160601-20160630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:GenentechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-06-01</startDate>
            <endDate>2016-06-30</endDate>
        </period>
    </context>
    <context id="i14b16f9e96df4c0a9e50dca2366b9336_D20160601-20160630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:GenentechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">dnli:ClinicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-06-01</startDate>
            <endDate>2016-06-30</endDate>
        </period>
    </context>
    <context id="i692ffa74a5584f1cbfe4713804c9f8bc_D20160601-20160630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:GenentechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">dnli:RegulatoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-06-01</startDate>
            <endDate>2016-06-30</endDate>
        </period>
    </context>
    <context id="i80495385ed674ae8925cf688501ec409_D20160601-20160630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:GenentechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">dnli:CommercialMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-06-01</startDate>
            <endDate>2016-06-30</endDate>
        </period>
    </context>
    <context id="id8ddb142f82e43fa84f4fd4d9e8cbf3d_I20201005">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:GenentechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">dnli:BiogenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-05</instant>
        </period>
    </context>
    <context id="id263c00fb24f43c9874f4e5f5bcb3bc4_D20160601-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:GenentechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dnli:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-06-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="iab3d75662fac47f5a5b91e0c391e1ad9_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:GenentechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dnli:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i90ec159768884d8a91ddd3533160d98c_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:GenentechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dnli:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i7fec5584f40f4e2589bf51cfb5be2fa0_D20180502-20180502">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">dnli:HeadquartersLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-02</startDate>
            <endDate>2018-05-02</endDate>
        </period>
    </context>
    <context id="ie37401f4fa5441f69f346d3a02b8b078_I20180502">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">dnli:HeadquartersLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-05-02</instant>
        </period>
    </context>
    <context id="i99207688a3a04bb6b263d1f44c4431cb_D20180502-20180502">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">dnli:HeadquartersLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-02</startDate>
            <endDate>2018-05-02</endDate>
        </period>
    </context>
    <context id="ic993dcf5385f4b81b82f62d1d7c425ad_D20180502-20180502">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">dnli:HeadquartersLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-02</startDate>
            <endDate>2018-05-02</endDate>
        </period>
    </context>
    <context id="i8bf8a6f92025417783902a1461338b26_I20180502">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-05-02</instant>
        </period>
    </context>
    <context id="i6456f8216b9a4588b93f1a1da733ca1d_D20180502-20180502">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">dnli:HeadquartersLeaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">dnli:LandlordFundedTenantImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-02</startDate>
            <endDate>2018-05-02</endDate>
        </period>
    </context>
    <context id="ib5b9d59cd718474d84fa120208dacc38_I20181031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">dnli:NewPremisesSubleaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-31</instant>
        </period>
    </context>
    <context id="i5883d19040b14361a685e33448d24167_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">dnli:DMSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i71996497ebce4b2c8c7d7e4cd228fb94_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">dnli:DMSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i450a57d93cb84950a947b2c09bd3ca2d_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">dnli:DMSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i8e1a3ef913c04a4dbb9618e565378ec6_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">dnli:DMSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i84ba3b58bcce4a4c9748d2ca212f024c_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i884b579d788c483eb3a9ee088d3e5d89_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="id3763ebb47a74e7aa55cdc9ec33e6ba1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if9c544fa84d346779359fdcd69c81fe6_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ifa1dc7a3953b414298ab33929383425a_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ic95a24eb031142ffb8fea378c4c16539_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ie9e73e4cbcdf45859b5ab6fdf05d2397_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="if224ee1d3e1d40cda888c5569a5ca491_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ie960cec998d6496380dc4b23cade2ada_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i1bfd917477b04985b275e7880a6800ee_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">dnli:EmployeeAndNonEmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ieb96c5c2a58b43ecb70f4570ae6501d5_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">dnli:EmployeeAndNonEmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i14d03db975fe42b1b25891a5de38963a_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">dnli:RestrictedSharesSubjectToFutureVestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="iaab0bf674ec742169a75f1ba80135e68_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">dnli:RestrictedSharesSubjectToFutureVestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="segment">
        <measure>dnli:Segment</measure>
    </unit>
    <unit id="security">
        <measure>dnli:security</measure>
    </unit>
    <unit id="derivative_instrument">
        <measure>dnli:derivative_instrument</measure>
    </unit>
    <unit id="eur">
        <measure>iso4217:EUR</measure>
    </unit>
    <unit id="gbp">
        <measure>iso4217:GBP</measure>
    </unit>
    <unit id="program">
        <measure>dnli:program</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="milestone">
        <measure>dnli:milestone</measure>
    </unit>
    <unit id="indication">
        <measure>dnli:indication</measure>
    </unit>
    <unit id="target">
        <measure>dnli:target</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <dei:DocumentFiscalYearFocus
      contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80L2ZyYWc6ZDMyN2EyZDg2ZGRiNDdkOGIwZjY5YmE4ODk3NjEzYjYvdGFibGU6NmIxMGVlNDA4ZmRiNDFkZGIwZWU2YmY0ZTQ3M2JmMjAvdGFibGVyYW5nZTo2YjEwZWU0MDhmZGI0MWRkYjBlZTZiZjRlNDczYmYyMF8xMi0xLTEtMS0w_c285fbf9-ff4b-49da-b295-07899dd0cdbc">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80L2ZyYWc6ZDMyN2EyZDg2ZGRiNDdkOGIwZjY5YmE4ODk3NjEzYjYvdGFibGU6NmIxMGVlNDA4ZmRiNDFkZGIwZWU2YmY0ZTQ3M2JmMjAvdGFibGVyYW5nZTo2YjEwZWU0MDhmZGI0MWRkYjBlZTZiZjRlNDczYmYyMF8xMy0xLTEtMS0w_f9ce3166-90bf-4e5e-9ea9-64386b6fb57e">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80L2ZyYWc6ZDMyN2EyZDg2ZGRiNDdkOGIwZjY5YmE4ODk3NjEzYjYvdGFibGU6NmIxMGVlNDA4ZmRiNDFkZGIwZWU2YmY0ZTQ3M2JmMjAvdGFibGVyYW5nZTo2YjEwZWU0MDhmZGI0MWRkYjBlZTZiZjRlNDczYmYyMF8xNC0xLTEtMS0w_1b290a87-e9e7-445d-aa9b-dc3518eb779d">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80L2ZyYWc6ZDMyN2EyZDg2ZGRiNDdkOGIwZjY5YmE4ODk3NjEzYjYvdGV4dHJlZ2lvbjpkMzI3YTJkODZkZGI0N2Q4YjBmNjliYTg4OTc2MTNiNl84MQ_84cc81af-1c0f-407e-9626-f5fe6d308354">0001714899</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80L2ZyYWc6ZDMyN2EyZDg2ZGRiNDdkOGIwZjY5YmE4ODk3NjEzYjYvdGV4dHJlZ2lvbjpkMzI3YTJkODZkZGI0N2Q4YjBmNjliYTg4OTc2MTNiNl84Mg_73a2e1e3-8d7e-48bf-99e0-c77e73d8a361">--12-31</dei:CurrentFiscalYearEndDate>
    <us-gaap:DerivativeLiabilities
      contextRef="i67ac6e40ada9472996476ac5ea5bcbc7_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xMDgwL2ZyYWc6NTBhMGUzMzE1YWQ3NGZjMThhODBjOTMxNzY4MmM0YTkvdGV4dHJlZ2lvbjo1MGEwZTMzMTVhZDc0ZmMxOGE4MGM5MzE3NjgyYzRhOV80Mzk4MDQ2NTExOTg5_cff67f9f-587c-43b7-a204-854bdbcc49fb"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeAssets
      contextRef="i90752bb1d6844732a5f7754270148e69_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xMDgwL2ZyYWc6NTBhMGUzMzE1YWQ3NGZjMThhODBjOTMxNzY4MmM0YTkvdGV4dHJlZ2lvbjo1MGEwZTMzMTVhZDc0ZmMxOGE4MGM5MzE3NjgyYzRhOV80Mzk4MDQ2NTExOTky_4eca0241-284f-4f69-a9d1-7ce710d6bb81"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <dnli:CollaborativeArrangementTermNumberOfBusinessDaysIfEffectiveDateCriteriaMet
      contextRef="ia961be148e584fd4a2a57cc1b21dced2_D20200805-20200805"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfNTMxNA_6ca82b29-adf5-4704-b8b5-513bcd955ad5">P30D</dnli:CollaborativeArrangementTermNumberOfBusinessDaysIfEffectiveDateCriteriaMet>
    <dei:DocumentType
      contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xL2ZyYWc6NTljZGFhMGY5N2ZkNDFhNDg5MDgwNDc2MDljYTRlYmEvdGV4dHJlZ2lvbjo1OWNkYWEwZjk3ZmQ0MWE0ODkwODA0NzYwOWNhNGViYV84Nw_dda14b06-9f53-4057-8539-5c2dda4ead20">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xL2ZyYWc6NTljZGFhMGY5N2ZkNDFhNDg5MDgwNDc2MDljYTRlYmEvdGFibGU6M2EyNGNkM2M0MTZjNDk3YTg2YWNlMGY3M2I5MzE3ZTEvdGFibGVyYW5nZTozYTI0Y2QzYzQxNmM0OTdhODZhY2UwZjczYjkzMTdlMV8wLTAtMS0xLTA_7d28d03b-7fa6-4758-b7d7-b5eb110d483b">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xL2ZyYWc6NTljZGFhMGY5N2ZkNDFhNDg5MDgwNDc2MDljYTRlYmEvdGV4dHJlZ2lvbjo1OWNkYWEwZjk3ZmQ0MWE0ODkwODA0NzYwOWNhNGViYV8xMzY_295c6713-8359-4632-bfe0-d779bac6d035">2021-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xL2ZyYWc6NTljZGFhMGY5N2ZkNDFhNDg5MDgwNDc2MDljYTRlYmEvdGFibGU6NzYwOWMwYTg4N2NmNGZhYmFiNDQ4ZGZkNzBjYjM0YmEvdGFibGVyYW5nZTo3NjA5YzBhODg3Y2Y0ZmFiYWI0NDhkZmQ3MGNiMzRiYV8wLTAtMS0xLTA_901ba6f0-b175-4ec4-b296-0769683d6f74">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xL2ZyYWc6NTljZGFhMGY5N2ZkNDFhNDg5MDgwNDc2MDljYTRlYmEvdGV4dHJlZ2lvbjo1OWNkYWEwZjk3ZmQ0MWE0ODkwODA0NzYwOWNhNGViYV8yNDU_118f9ef8-4041-4a4f-bc5b-c004223b41d2">001-38311</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xL2ZyYWc6NTljZGFhMGY5N2ZkNDFhNDg5MDgwNDc2MDljYTRlYmEvdGV4dHJlZ2lvbjo1OWNkYWEwZjk3ZmQ0MWE0ODkwODA0NzYwOWNhNGViYV8yNTA_6d459f57-666a-4376-8994-ae00298ddc09">Denali Therapeutics Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xL2ZyYWc6NTljZGFhMGY5N2ZkNDFhNDg5MDgwNDc2MDljYTRlYmEvdGFibGU6Y2Y5OTU0NmMxYjIyNDhmZGFiMzE2YmI5MTFkOTkwNTYvdGFibGVyYW5nZTpjZjk5NTQ2YzFiMjI0OGZkYWIzMTZiYjkxMWQ5OTA1Nl8wLTAtMS0xLTA_8bb26ff5-2fc8-4093-85ad-898e19054255">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xL2ZyYWc6NTljZGFhMGY5N2ZkNDFhNDg5MDgwNDc2MDljYTRlYmEvdGFibGU6Y2Y5OTU0NmMxYjIyNDhmZGFiMzE2YmI5MTFkOTkwNTYvdGFibGVyYW5nZTpjZjk5NTQ2YzFiMjI0OGZkYWIzMTZiYjkxMWQ5OTA1Nl8wLTItMS0xLTA_fd890157-9459-478b-a9b3-842c4e3a89d6">46-3872213</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xL2ZyYWc6NTljZGFhMGY5N2ZkNDFhNDg5MDgwNDc2MDljYTRlYmEvdGFibGU6Y2Y5OTU0NmMxYjIyNDhmZGFiMzE2YmI5MTFkOTkwNTYvdGFibGVyYW5nZTpjZjk5NTQ2YzFiMjI0OGZkYWIzMTZiYjkxMWQ5OTA1Nl8zLTAtMS0xLTAvdGV4dHJlZ2lvbjphNzZkZjNlMTdjYzU0NGI3YTQzYTIyZjM5YmE3NzM4MV81_6bb06cfa-d3d1-431e-bc64-94ce78cc6581">161 Oyster Point Blvd</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xL2ZyYWc6NTljZGFhMGY5N2ZkNDFhNDg5MDgwNDc2MDljYTRlYmEvdGFibGU6Y2Y5OTU0NmMxYjIyNDhmZGFiMzE2YmI5MTFkOTkwNTYvdGFibGVyYW5nZTpjZjk5NTQ2YzFiMjI0OGZkYWIzMTZiYjkxMWQ5OTA1Nl8zLTAtMS0xLTAvdGV4dHJlZ2lvbjphNzZkZjNlMTdjYzU0NGI3YTQzYTIyZjM5YmE3NzM4MV85_8ca787dc-0dde-4e23-b460-00394677530f">South San Francisco</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xL2ZyYWc6NTljZGFhMGY5N2ZkNDFhNDg5MDgwNDc2MDljYTRlYmEvdGFibGU6Y2Y5OTU0NmMxYjIyNDhmZGFiMzE2YmI5MTFkOTkwNTYvdGFibGVyYW5nZTpjZjk5NTQ2YzFiMjI0OGZkYWIzMTZiYjkxMWQ5OTA1Nl8zLTAtMS0xLTAvdGV4dHJlZ2lvbjphNzZkZjNlMTdjYzU0NGI3YTQzYTIyZjM5YmE3NzM4MV8xMw_e356a33e-1d1b-4ce7-8aa4-0ff7bae8c354">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xL2ZyYWc6NTljZGFhMGY5N2ZkNDFhNDg5MDgwNDc2MDljYTRlYmEvdGFibGU6Y2Y5OTU0NmMxYjIyNDhmZGFiMzE2YmI5MTFkOTkwNTYvdGFibGVyYW5nZTpjZjk5NTQ2YzFiMjI0OGZkYWIzMTZiYjkxMWQ5OTA1Nl8zLTAtMS0xLTAvdGV4dHJlZ2lvbjphNzZkZjNlMTdjYzU0NGI3YTQzYTIyZjM5YmE3NzM4MV8xNw_fe1a224e-9f98-4a11-bb0b-ba79aeb62682">94080</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xL2ZyYWc6NTljZGFhMGY5N2ZkNDFhNDg5MDgwNDc2MDljYTRlYmEvdGV4dHJlZ2lvbjo1OWNkYWEwZjk3ZmQ0MWE0ODkwODA0NzYwOWNhNGViYV8zMTQ_9f22157e-5422-4209-bd16-627e334337e8">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xL2ZyYWc6NTljZGFhMGY5N2ZkNDFhNDg5MDgwNDc2MDljYTRlYmEvdGV4dHJlZ2lvbjo1OWNkYWEwZjk3ZmQ0MWE0ODkwODA0NzYwOWNhNGViYV8zMTg_789e8b4a-1c69-48f0-aafa-70f223a3720d">866-8548</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xL2ZyYWc6NTljZGFhMGY5N2ZkNDFhNDg5MDgwNDc2MDljYTRlYmEvdGFibGU6NGM2YzEwZWUyZmEwNGMwNjk4MTRlMGNkYTg0OWYxMzIvdGFibGVyYW5nZTo0YzZjMTBlZTJmYTA0YzA2OTgxNGUwY2RhODQ5ZjEzMl8xLTAtMS0xLTA_738252b8-9e65-4e9e-a8af-53b15fc6ac9b">Common Stock, par value $0.01 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xL2ZyYWc6NTljZGFhMGY5N2ZkNDFhNDg5MDgwNDc2MDljYTRlYmEvdGFibGU6NGM2YzEwZWUyZmEwNGMwNjk4MTRlMGNkYTg0OWYxMzIvdGFibGVyYW5nZTo0YzZjMTBlZTJmYTA0YzA2OTgxNGUwY2RhODQ5ZjEzMl8xLTEtMS0xLTA_f722b37a-b755-4d4c-848b-3a389d2ea4c5">DNLI</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xL2ZyYWc6NTljZGFhMGY5N2ZkNDFhNDg5MDgwNDc2MDljYTRlYmEvdGFibGU6NGM2YzEwZWUyZmEwNGMwNjk4MTRlMGNkYTg0OWYxMzIvdGFibGVyYW5nZTo0YzZjMTBlZTJmYTA0YzA2OTgxNGUwY2RhODQ5ZjEzMl8xLTItMS0xLTA_f1926460-3056-46a3-a812-5ea7095cc322">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xL2ZyYWc6NTljZGFhMGY5N2ZkNDFhNDg5MDgwNDc2MDljYTRlYmEvdGV4dHJlZ2lvbjo1OWNkYWEwZjk3ZmQ0MWE0ODkwODA0NzYwOWNhNGViYV84MjQ_bd14d090-58b9-47f4-a61a-1fb355a01aa5">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityShellCompany
      contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xL2ZyYWc6NTljZGFhMGY5N2ZkNDFhNDg5MDgwNDc2MDljYTRlYmEvdGV4dHJlZ2lvbjo1OWNkYWEwZjk3ZmQ0MWE0ODkwODA0NzYwOWNhNGViYV84Mjg_e65f2035-c37f-4947-9679-44d6dd34c861">false</dei:EntityShellCompany>
    <dei:EntityInteractiveDataCurrent
      contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xL2ZyYWc6NTljZGFhMGY5N2ZkNDFhNDg5MDgwNDc2MDljYTRlYmEvdGV4dHJlZ2lvbjo1OWNkYWEwZjk3ZmQ0MWE0ODkwODA0NzYwOWNhNGViYV8xMTUz_bed8d6fd-3bb9-4aa2-9861-0598020aaf81">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityShellCompany
      contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xL2ZyYWc6NTljZGFhMGY5N2ZkNDFhNDg5MDgwNDc2MDljYTRlYmEvdGV4dHJlZ2lvbjo1OWNkYWEwZjk3ZmQ0MWE0ODkwODA0NzYwOWNhNGViYV8xMTU3_e65f2035-c37f-4947-9679-44d6dd34c861">false</dei:EntityShellCompany>
    <dei:EntityFilerCategory
      contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xL2ZyYWc6NTljZGFhMGY5N2ZkNDFhNDg5MDgwNDc2MDljYTRlYmEvdGFibGU6YzNhNzM0YzBkMmNmNDMwNjkzYTU3MjNkNWRjYzBjZTMvdGFibGVyYW5nZTpjM2E3MzRjMGQyY2Y0MzA2OTNhNTcyM2Q1ZGNjMGNlM18xLTAtMS0xLTA_6e4a08c1-b51c-481c-b437-fa799d3f948f">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xL2ZyYWc6NTljZGFhMGY5N2ZkNDFhNDg5MDgwNDc2MDljYTRlYmEvdGFibGU6YzNhNzM0YzBkMmNmNDMwNjkzYTU3MjNkNWRjYzBjZTMvdGFibGVyYW5nZTpjM2E3MzRjMGQyY2Y0MzA2OTNhNTcyM2Q1ZGNjMGNlM18zLTMtMS0xLTA_abc7b0a9-11f9-4aec-993b-c581e6b0caad">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xL2ZyYWc6NTljZGFhMGY5N2ZkNDFhNDg5MDgwNDc2MDljYTRlYmEvdGFibGU6YzNhNzM0YzBkMmNmNDMwNjkzYTU3MjNkNWRjYzBjZTMvdGFibGVyYW5nZTpjM2E3MzRjMGQyY2Y0MzA2OTNhNTcyM2Q1ZGNjMGNlM181LTMtMS0xLTA_4e84023e-c0a1-4fda-81f9-417389b6cf55">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xL2ZyYWc6NTljZGFhMGY5N2ZkNDFhNDg5MDgwNDc2MDljYTRlYmEvdGV4dHJlZ2lvbjo1OWNkYWEwZjk3ZmQ0MWE0ODkwODA0NzYwOWNhNGViYV8xOTA0_e65f2035-c37f-4947-9679-44d6dd34c861">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="id5f8b6da332f4721952346e234823fd7_I20210426"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xL2ZyYWc6NTljZGFhMGY5N2ZkNDFhNDg5MDgwNDc2MDljYTRlYmEvdGV4dHJlZ2lvbjo1OWNkYWEwZjk3ZmQ0MWE0ODkwODA0NzYwOWNhNGViYV8xOTg2_e3a4da4a-bc1e-4657-ba35-922abec33ec4"
      unitRef="shares">121192210</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i9953f50a7fd74f7d8438f304f136a07b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfMy0xLTEtMS0w_cf2c1560-21db-46b4-af90-2524a9ab29e3"
      unitRef="usd">435321000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="idb7ca9f362da46eab3a29bbbecbda977_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfMy0zLTEtMS0w_2bc400f5-57ae-47d3-956e-8f06773f1d89"
      unitRef="usd">507144000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i9953f50a7fd74f7d8438f304f136a07b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfNC0xLTEtMS0w_7ec45a3e-9913-449e-968b-3c423abeda05"
      unitRef="usd">977827000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="idb7ca9f362da46eab3a29bbbecbda977_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfNC0zLTEtMS0w_69bbc470-32dd-4049-aa61-33a4e170cc57"
      unitRef="usd">962553000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:DueFromRelatedPartiesCurrent
      contextRef="i9953f50a7fd74f7d8438f304f136a07b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfNS0xLTEtMS0yOQ_dfb839e4-93d4-417d-936e-c44609276613"
      unitRef="usd">2511000</us-gaap:DueFromRelatedPartiesCurrent>
    <us-gaap:DueFromRelatedPartiesCurrent
      contextRef="idb7ca9f362da46eab3a29bbbecbda977_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfNS0zLTEtMS0zMg_46bf291d-2875-4296-8ded-7e94e1131b4f"
      unitRef="usd">5674000</us-gaap:DueFromRelatedPartiesCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i9953f50a7fd74f7d8438f304f136a07b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfNS0xLTEtMS0w_b189563b-6713-4be9-b698-541f36fd346e"
      unitRef="usd">15963000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="idb7ca9f362da46eab3a29bbbecbda977_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfNS0zLTEtMS0w_8c03cf21-ad6c-4ceb-b53d-8f6be09c6f3e"
      unitRef="usd">20284000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i9953f50a7fd74f7d8438f304f136a07b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfNi0xLTEtMS0w_c0465fd8-4553-4d41-beb7-c2c9269f7d61"
      unitRef="usd">1431622000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="idb7ca9f362da46eab3a29bbbecbda977_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfNi0zLTEtMS0w_ee1aede5-77b6-4466-a75a-f23c60366525"
      unitRef="usd">1495655000</us-gaap:AssetsCurrent>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="i9953f50a7fd74f7d8438f304f136a07b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfNy0xLTEtMS0w_b42339a2-7c5d-46ff-9f49-889d14d52f0e"
      unitRef="usd">38885000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="idb7ca9f362da46eab3a29bbbecbda977_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfNy0zLTEtMS0w_c8b152b4-7c0a-47ef-8f80-fa0eba55ae2e"
      unitRef="usd">32699000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i9953f50a7fd74f7d8438f304f136a07b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfOC0xLTEtMS0w_4f253388-f359-4d0d-8fbe-5be1b40dec27"
      unitRef="usd">41376000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="idb7ca9f362da46eab3a29bbbecbda977_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfOC0zLTEtMS0w_4b345a88-d882-4e32-bb3a-954354529ec9"
      unitRef="usd">40846000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i9953f50a7fd74f7d8438f304f136a07b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfOS0xLTEtMS0w_6118d93f-40c5-41d9-8ff4-5d2073899e64"
      unitRef="usd">32236000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="idb7ca9f362da46eab3a29bbbecbda977_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfOS0zLTEtMS0w_ad728fde-e0fd-4b3a-a9a6-6ee612157613"
      unitRef="usd">32618000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i9953f50a7fd74f7d8438f304f136a07b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfMTAtMS0xLTEtMA_51ad5d9a-a38b-43f5-bb34-4c4b2c6f73a5"
      unitRef="usd">3739000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="idb7ca9f362da46eab3a29bbbecbda977_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfMTAtMy0xLTEtMA_3d524367-c6a0-48b2-b17c-8a664b18f4af"
      unitRef="usd">2462000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i9953f50a7fd74f7d8438f304f136a07b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfMTEtMS0xLTEtMA_f3485074-bbe3-4f49-8966-a0143a353639"
      unitRef="usd">1547858000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="idb7ca9f362da46eab3a29bbbecbda977_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfMTEtMy0xLTEtMA_2653eab9-9f25-492e-92e3-c995cbec6fd5"
      unitRef="usd">1604280000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i9953f50a7fd74f7d8438f304f136a07b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfMTQtMS0xLTEtMA_afaef670-96b8-46d6-915f-c91fa6ab6527"
      unitRef="usd">1626000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="idb7ca9f362da46eab3a29bbbecbda977_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfMTQtMy0xLTEtMA_50829d99-05da-4043-901f-aea46d786674"
      unitRef="usd">1071000</us-gaap:AccountsPayableCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i9953f50a7fd74f7d8438f304f136a07b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfMTUtMS0xLTEtMA_ea0a9aec-0893-49f2-b9b9-54c8034971b3"
      unitRef="usd">4963000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="idb7ca9f362da46eab3a29bbbecbda977_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfMTUtMy0xLTEtMA_a45fad14-8703-4461-afbf-c41cea76f6f4"
      unitRef="usd">20503000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <dnli:AccruedClinicalCostsCurrent
      contextRef="i9953f50a7fd74f7d8438f304f136a07b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfMTYtMS0xLTEtMA_cd5a6ff5-9746-447d-b7a2-b9d9371285f8"
      unitRef="usd">5049000</dnli:AccruedClinicalCostsCurrent>
    <dnli:AccruedClinicalCostsCurrent
      contextRef="idb7ca9f362da46eab3a29bbbecbda977_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfMTYtMy0xLTEtMA_4374a1f4-b914-4c25-9fbd-f7dc8fa12cd6"
      unitRef="usd">6497000</dnli:AccruedClinicalCostsCurrent>
    <dnli:OtherAccruedManufacturingCostsCurrent
      contextRef="i9953f50a7fd74f7d8438f304f136a07b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfMTgtMS0xLTEtNDI5MA_75387d3c-50b3-48a0-a3fe-0cb57b5ab4a1"
      unitRef="usd">13342000</dnli:OtherAccruedManufacturingCostsCurrent>
    <dnli:OtherAccruedManufacturingCostsCurrent
      contextRef="idb7ca9f362da46eab3a29bbbecbda977_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfMTgtMy0xLTEtNDI5NQ_b334af1d-7fc5-4e18-bba0-9a35686bc876"
      unitRef="usd">7140000</dnli:OtherAccruedManufacturingCostsCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i9953f50a7fd74f7d8438f304f136a07b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfMTctMS0xLTEtMA_c76e12d5-b3a4-462d-b936-fc0916602058"
      unitRef="usd">8299000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="idb7ca9f362da46eab3a29bbbecbda977_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfMTctMy0xLTEtMA_e0f51f21-7d02-4e13-a5ff-88e55615ad4c"
      unitRef="usd">8315000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i9953f50a7fd74f7d8438f304f136a07b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfMTgtMS0xLTEtMA_888da52f-004e-452f-8eaa-d54e3b38fd0d"
      unitRef="usd">4876000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="idb7ca9f362da46eab3a29bbbecbda977_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfMTgtMy0xLTEtMA_d4099fe6-77e8-4c88-a82b-acca3aa88070"
      unitRef="usd">4690000</us-gaap:OperatingLeaseLiabilityCurrent>
    <dnli:ContractWithCustomerLiabilityFromRelatedPartiesCurrent
      contextRef="i9953f50a7fd74f7d8438f304f136a07b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfMTktMS0xLTEtMA_502bdc51-5159-4e07-beff-afca67ffec04"
      unitRef="usd">3569000</dnli:ContractWithCustomerLiabilityFromRelatedPartiesCurrent>
    <dnli:ContractWithCustomerLiabilityFromRelatedPartiesCurrent
      contextRef="idb7ca9f362da46eab3a29bbbecbda977_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfMTktMy0xLTEtMA_7cb426f6-72d5-4645-b309-4ad8006d1976"
      unitRef="usd">3569000</dnli:ContractWithCustomerLiabilityFromRelatedPartiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i9953f50a7fd74f7d8438f304f136a07b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfMjAtMS0xLTEtMA_402647a5-7184-4860-ab27-fc580bc33acd"
      unitRef="usd">12886000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="idb7ca9f362da46eab3a29bbbecbda977_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfMjAtMy0xLTEtMA_a19229a2-24c5-4745-abb4-6b4e7b656078"
      unitRef="usd">19914000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i9953f50a7fd74f7d8438f304f136a07b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfMjEtMS0xLTEtMA_215ecb06-716e-44ac-8d82-2f445907589d"
      unitRef="usd">54610000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="idb7ca9f362da46eab3a29bbbecbda977_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfMjEtMy0xLTEtMA_9ccd6d19-8260-4bf5-be06-f63da7fe0abd"
      unitRef="usd">71699000</us-gaap:LiabilitiesCurrent>
    <dnli:ContractWithCustomerLiabilityFromRelatedPartiesNoncurrent
      contextRef="i9953f50a7fd74f7d8438f304f136a07b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfMjMtMS0xLTEtMTg3_7bca2cee-ced0-4a39-b8de-ea7bdf8e7f1f"
      unitRef="usd">292956000</dnli:ContractWithCustomerLiabilityFromRelatedPartiesNoncurrent>
    <dnli:ContractWithCustomerLiabilityFromRelatedPartiesNoncurrent
      contextRef="idb7ca9f362da46eab3a29bbbecbda977_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfMjMtMy0xLTEtMTkw_ea80a8c6-6408-45d4-b0fc-860fe734567c"
      unitRef="usd">293849000</dnli:ContractWithCustomerLiabilityFromRelatedPartiesNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i9953f50a7fd74f7d8438f304f136a07b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfMjItMS0xLTEtMA_91c6b1f3-abdb-4871-91a5-7b50ab7ca582"
      unitRef="usd">31322000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="idb7ca9f362da46eab3a29bbbecbda977_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfMjItMy0xLTEtMA_e53d01bd-80c5-44a5-85b6-cd1bd2869a83"
      unitRef="usd">23325000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i9953f50a7fd74f7d8438f304f136a07b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfMjMtMS0xLTEtMA_344e1538-c378-483b-9479-7a8ff5442ea9"
      unitRef="usd">62916000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="idb7ca9f362da46eab3a29bbbecbda977_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfMjMtMy0xLTEtMA_99809f63-4f2f-4edc-8d93-825ee48742c4"
      unitRef="usd">64175000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i9953f50a7fd74f7d8438f304f136a07b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfMjQtMS0xLTEtMA_b883eb70-6861-44e5-85ed-e0e9616d307b"
      unitRef="usd">701000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="idb7ca9f362da46eab3a29bbbecbda977_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfMjQtMy0xLTEtMA_78290355-244a-40f9-ba48-cece21349431"
      unitRef="usd">701000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i9953f50a7fd74f7d8438f304f136a07b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfMjUtMS0xLTEtMA_769851a8-860c-492e-955c-80ad73b86329"
      unitRef="usd">442505000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="idb7ca9f362da46eab3a29bbbecbda977_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfMjUtMy0xLTEtMA_8629e210-d1cd-4405-9218-c131db9fe813"
      unitRef="usd">453749000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i9953f50a7fd74f7d8438f304f136a07b_I20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfMjYtMS0xLTEtMA_966d8431-1811-4510-a067-b740c5f0c9af"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="idb7ca9f362da46eab3a29bbbecbda977_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfMjYtMy0xLTEtMA_85cb7e15-484b-418f-b012-caacc107e788"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="idb7ca9f362da46eab3a29bbbecbda977_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfMjgtMC0xLTEtMC90ZXh0cmVnaW9uOjBiNTgyZDk3ZTM1NDRlYzI4YWFhYThlZDA1NGIyYzJmXzM0_0de80b99-b915-4170-be94-842d700d7cf7"
      unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i9953f50a7fd74f7d8438f304f136a07b_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfMjgtMC0xLTEtMC90ZXh0cmVnaW9uOjBiNTgyZDk3ZTM1NDRlYzI4YWFhYThlZDA1NGIyYzJmXzM0_52fab557-3428-4853-8885-678739d9b64a"
      unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i9953f50a7fd74f7d8438f304f136a07b_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfMjgtMC0xLTEtMC90ZXh0cmVnaW9uOjBiNTgyZDk3ZTM1NDRlYzI4YWFhYThlZDA1NGIyYzJmXzQ4_3b7b92d2-7209-4a89-b9fa-fd9e3dadceaf"
      unitRef="shares">40000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="idb7ca9f362da46eab3a29bbbecbda977_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfMjgtMC0xLTEtMC90ZXh0cmVnaW9uOjBiNTgyZDk3ZTM1NDRlYzI4YWFhYThlZDA1NGIyYzJmXzQ4_6cf3240e-7f83-4936-8e8b-31a977baa77a"
      unitRef="shares">40000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="idb7ca9f362da46eab3a29bbbecbda977_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfMjgtMC0xLTEtMC90ZXh0cmVnaW9uOjBiNTgyZDk3ZTM1NDRlYzI4YWFhYThlZDA1NGIyYzJmXzg2_1db05b09-2ed6-4abe-99af-ce315f9e14dc"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i9953f50a7fd74f7d8438f304f136a07b_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfMjgtMC0xLTEtMC90ZXh0cmVnaW9uOjBiNTgyZDk3ZTM1NDRlYzI4YWFhYThlZDA1NGIyYzJmXzg2_3d303cfc-a517-4f5c-b3c3-95ef14ee40f5"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="idb7ca9f362da46eab3a29bbbecbda977_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfMjgtMC0xLTEtMC90ZXh0cmVnaW9uOjBiNTgyZDk3ZTM1NDRlYzI4YWFhYThlZDA1NGIyYzJmXzg2_78ea2491-810a-4e4c-94d7-0f6c56a8ed88"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i9953f50a7fd74f7d8438f304f136a07b_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfMjgtMC0xLTEtMC90ZXh0cmVnaW9uOjBiNTgyZDk3ZTM1NDRlYzI4YWFhYThlZDA1NGIyYzJmXzg2_da5352cf-ea6a-4c5d-8f37-c40c6661814e"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="i9953f50a7fd74f7d8438f304f136a07b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfMjgtMS0xLTEtMA_8660419c-27ed-4964-8744-30298c8c9243"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="idb7ca9f362da46eab3a29bbbecbda977_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfMjgtMy0xLTEtMA_e9e129b4-1f14-4555-858f-35489f61c8f8"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i9953f50a7fd74f7d8438f304f136a07b_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfMjktMC0xLTEtMC90ZXh0cmVnaW9uOjA1YWQxNDc2NTMxYjQxNGI5YWRiODFkY2E3ZDA2ZjdlXzE4_c6b744d0-0f7c-47b5-af59-55cc091119ba"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="idb7ca9f362da46eab3a29bbbecbda977_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfMjktMC0xLTEtMC90ZXh0cmVnaW9uOjA1YWQxNDc2NTMxYjQxNGI5YWRiODFkY2E3ZDA2ZjdlXzE4_ead3099c-ce64-4346-b649-3227dd69b40b"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i9953f50a7fd74f7d8438f304f136a07b_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfMjktMC0xLTEtMC90ZXh0cmVnaW9uOjA1YWQxNDc2NTMxYjQxNGI5YWRiODFkY2E3ZDA2ZjdlXzMy_a584d5b6-fc12-4301-a196-3708adbf459d"
      unitRef="shares">400000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="idb7ca9f362da46eab3a29bbbecbda977_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfMjktMC0xLTEtMC90ZXh0cmVnaW9uOjA1YWQxNDc2NTMxYjQxNGI5YWRiODFkY2E3ZDA2ZjdlXzMy_c3a276ff-b81f-4eb7-a1cb-1d684df1d243"
      unitRef="shares">400000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i9953f50a7fd74f7d8438f304f136a07b_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfMjktMC0xLTEtMC90ZXh0cmVnaW9uOjA1YWQxNDc2NTMxYjQxNGI5YWRiODFkY2E3ZDA2ZjdlXzcw_2c20251f-19e7-4a9a-93b1-8180cd471426"
      unitRef="shares">121147432</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i9953f50a7fd74f7d8438f304f136a07b_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfMjktMC0xLTEtMC90ZXh0cmVnaW9uOjA1YWQxNDc2NTMxYjQxNGI5YWRiODFkY2E3ZDA2ZjdlXzcw_958a8067-a014-40ea-916a-ff88d2100daa"
      unitRef="shares">121147432</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="idb7ca9f362da46eab3a29bbbecbda977_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfMjktMC0xLTEtMC90ZXh0cmVnaW9uOjA1YWQxNDc2NTMxYjQxNGI5YWRiODFkY2E3ZDA2ZjdlXzg0_1531b96d-4511-4f2b-84fc-0a2d2228f650"
      unitRef="shares">120531333</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="idb7ca9f362da46eab3a29bbbecbda977_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfMjktMC0xLTEtMC90ZXh0cmVnaW9uOjA1YWQxNDc2NTMxYjQxNGI5YWRiODFkY2E3ZDA2ZjdlXzg0_90e808c3-66f6-4de7-91b7-8dcd1c4edbea"
      unitRef="shares">120531333</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="i9953f50a7fd74f7d8438f304f136a07b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfMjktMS0xLTEtMA_536cd9a9-ae3b-41c9-b346-d35fe7041294"
      unitRef="usd">1537000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="idb7ca9f362da46eab3a29bbbecbda977_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfMjktMy0xLTEtMA_cdb8ab95-2880-4804-906a-5a3412a69f07"
      unitRef="usd">1531000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i9953f50a7fd74f7d8438f304f136a07b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfMzAtMS0xLTEtMA_1205d558-077a-49a9-ae2f-dacf40a49e5e"
      unitRef="usd">1528504000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="idb7ca9f362da46eab3a29bbbecbda977_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfMzAtMy0xLTEtMA_7662ee9e-168c-4656-8566-ea5ac6635dfb"
      unitRef="usd">1503660000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i9953f50a7fd74f7d8438f304f136a07b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfMzEtMS0xLTEtMA_94fa2d18-0246-4338-923a-c933028b31ba"
      unitRef="usd">-232000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="idb7ca9f362da46eab3a29bbbecbda977_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfMzEtMy0xLTEtMA_8cf25565-e3e9-4d02-907e-a1d91d768900"
      unitRef="usd">-245000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i9953f50a7fd74f7d8438f304f136a07b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfMzItMS0xLTEtMA_fc03c30b-7641-4497-b3b6-3850e0e54ec5"
      unitRef="usd">-424456000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="idb7ca9f362da46eab3a29bbbecbda977_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfMzItMy0xLTEtMA_80ef1818-2be4-43cb-984a-8136dd1a153d"
      unitRef="usd">-354415000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i9953f50a7fd74f7d8438f304f136a07b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfMzMtMS0xLTEtMA_fb858ec3-7669-439a-96a8-3fda49aa5003"
      unitRef="usd">1105353000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="idb7ca9f362da46eab3a29bbbecbda977_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfMzMtMy0xLTEtMA_3c92eba2-b0a0-41f2-875e-7517e3c7292f"
      unitRef="usd">1150531000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i9953f50a7fd74f7d8438f304f136a07b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfMzQtMS0xLTEtMA_75953f67-c8fd-462c-884a-336c6884f19a"
      unitRef="usd">1547858000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="idb7ca9f362da46eab3a29bbbecbda977_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xNi9mcmFnOjk2M2U0NzdiZDU1YjRhOWU5Yzk0MGVjNjhhMGJkYzdkL3RhYmxlOmZkMmM5OWE5ODg3ODQ4YmRhZTc0YzM5Y2I2MDM0MTFhL3RhYmxlcmFuZ2U6ZmQyYzk5YTk4ODc4NDhiZGFlNzRjMzljYjYwMzQxMWFfMzQtMy0xLTEtMA_9426620e-7a07-4f70-a3a9-912b1ef87bed"
      unitRef="usd">1604280000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xOS9mcmFnOjU2Y2EwZjE3OWFiNTQ3M2VhZGFlZDM5NjQxYjQ1NzhkL3RhYmxlOmRhMmJiMjEyNGYyZDQyODY4OTE3MTc5NWI4YmJmOThmL3RhYmxlcmFuZ2U6ZGEyYmIyMTI0ZjJkNDI4Njg5MTcxNzk1YjhiYmY5OGZfMy0xLTEtMS0w_3e600fff-1d7a-4a97-8ad7-909f7d61a045"
      unitRef="usd">7922000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia34dfea6b8734d64abf707c28256801c_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xOS9mcmFnOjU2Y2EwZjE3OWFiNTQ3M2VhZGFlZDM5NjQxYjQ1NzhkL3RhYmxlOmRhMmJiMjEyNGYyZDQyODY4OTE3MTc5NWI4YmJmOThmL3RhYmxlcmFuZ2U6ZGEyYmIyMTI0ZjJkNDI4Njg5MTcxNzk1YjhiYmY5OGZfMy0zLTEtMS0w_2085c283-6abe-41cb-87a7-f1af23aba47a"
      unitRef="usd">3552000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xOS9mcmFnOjU2Y2EwZjE3OWFiNTQ3M2VhZGFlZDM5NjQxYjQ1NzhkL3RhYmxlOmRhMmJiMjEyNGYyZDQyODY4OTE3MTc5NWI4YmJmOThmL3RhYmxlcmFuZ2U6ZGEyYmIyMTI0ZjJkNDI4Njg5MTcxNzk1YjhiYmY5OGZfNC0xLTEtMS0w_6002fe5d-5bf8-40f0-96e0-21910e296057"
      unitRef="usd">1000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="ia34dfea6b8734d64abf707c28256801c_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xOS9mcmFnOjU2Y2EwZjE3OWFiNTQ3M2VhZGFlZDM5NjQxYjQ1NzhkL3RhYmxlOmRhMmJiMjEyNGYyZDQyODY4OTE3MTc5NWI4YmJmOThmL3RhYmxlcmFuZ2U6ZGEyYmIyMTI0ZjJkNDI4Njg5MTcxNzk1YjhiYmY5OGZfNC0zLTEtMS0w_74f4c8f7-1de4-42e4-8be5-2fe3f3cd424a"
      unitRef="usd">52000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:Revenues
      contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xOS9mcmFnOjU2Y2EwZjE3OWFiNTQ3M2VhZGFlZDM5NjQxYjQ1NzhkL3RhYmxlOmRhMmJiMjEyNGYyZDQyODY4OTE3MTc5NWI4YmJmOThmL3RhYmxlcmFuZ2U6ZGEyYmIyMTI0ZjJkNDI4Njg5MTcxNzk1YjhiYmY5OGZfNS0xLTEtMS0w_fe256c91-bf8c-445a-af17-dec1b46f116e"
      unitRef="usd">7923000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia34dfea6b8734d64abf707c28256801c_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xOS9mcmFnOjU2Y2EwZjE3OWFiNTQ3M2VhZGFlZDM5NjQxYjQ1NzhkL3RhYmxlOmRhMmJiMjEyNGYyZDQyODY4OTE3MTc5NWI4YmJmOThmL3RhYmxlcmFuZ2U6ZGEyYmIyMTI0ZjJkNDI4Njg5MTcxNzk1YjhiYmY5OGZfNS0zLTEtMS0w_27e5d189-1e49-4a97-b56a-d4557f58e3a4"
      unitRef="usd">3604000</us-gaap:Revenues>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xOS9mcmFnOjU2Y2EwZjE3OWFiNTQ3M2VhZGFlZDM5NjQxYjQ1NzhkL3RhYmxlOmRhMmJiMjEyNGYyZDQyODY4OTE3MTc5NWI4YmJmOThmL3RhYmxlcmFuZ2U6ZGEyYmIyMTI0ZjJkNDI4Njg5MTcxNzk1YjhiYmY5OGZfNy0xLTEtMS0w_ff2936cd-371c-41a6-961e-a0ff4d0036c6"
      unitRef="usd">60207000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ia34dfea6b8734d64abf707c28256801c_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xOS9mcmFnOjU2Y2EwZjE3OWFiNTQ3M2VhZGFlZDM5NjQxYjQ1NzhkL3RhYmxlOmRhMmJiMjEyNGYyZDQyODY4OTE3MTc5NWI4YmJmOThmL3RhYmxlcmFuZ2U6ZGEyYmIyMTI0ZjJkNDI4Njg5MTcxNzk1YjhiYmY5OGZfNy0zLTEtMS0w_c27c224f-10c1-4e6b-a179-07afb5d152de"
      unitRef="usd">51016000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xOS9mcmFnOjU2Y2EwZjE3OWFiNTQ3M2VhZGFlZDM5NjQxYjQ1NzhkL3RhYmxlOmRhMmJiMjEyNGYyZDQyODY4OTE3MTc5NWI4YmJmOThmL3RhYmxlcmFuZ2U6ZGEyYmIyMTI0ZjJkNDI4Njg5MTcxNzk1YjhiYmY5OGZfOC0xLTEtMS0w_a14038a1-5245-4bcf-b692-b36663e277ee"
      unitRef="usd">18936000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ia34dfea6b8734d64abf707c28256801c_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xOS9mcmFnOjU2Y2EwZjE3OWFiNTQ3M2VhZGFlZDM5NjQxYjQ1NzhkL3RhYmxlOmRhMmJiMjEyNGYyZDQyODY4OTE3MTc5NWI4YmJmOThmL3RhYmxlcmFuZ2U6ZGEyYmIyMTI0ZjJkNDI4Njg5MTcxNzk1YjhiYmY5OGZfOC0zLTEtMS0w_18cfc9ef-460f-4db6-835d-18140332c88a"
      unitRef="usd">12555000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xOS9mcmFnOjU2Y2EwZjE3OWFiNTQ3M2VhZGFlZDM5NjQxYjQ1NzhkL3RhYmxlOmRhMmJiMjEyNGYyZDQyODY4OTE3MTc5NWI4YmJmOThmL3RhYmxlcmFuZ2U6ZGEyYmIyMTI0ZjJkNDI4Njg5MTcxNzk1YjhiYmY5OGZfOS0xLTEtMS0w_68fe63c2-ecbc-442b-bb5e-ed250b39c11e"
      unitRef="usd">79143000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="ia34dfea6b8734d64abf707c28256801c_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xOS9mcmFnOjU2Y2EwZjE3OWFiNTQ3M2VhZGFlZDM5NjQxYjQ1NzhkL3RhYmxlOmRhMmJiMjEyNGYyZDQyODY4OTE3MTc5NWI4YmJmOThmL3RhYmxlcmFuZ2U6ZGEyYmIyMTI0ZjJkNDI4Njg5MTcxNzk1YjhiYmY5OGZfOS0zLTEtMS0w_cd636a98-a2c0-4181-9c15-65cc79134649"
      unitRef="usd">63571000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xOS9mcmFnOjU2Y2EwZjE3OWFiNTQ3M2VhZGFlZDM5NjQxYjQ1NzhkL3RhYmxlOmRhMmJiMjEyNGYyZDQyODY4OTE3MTc5NWI4YmJmOThmL3RhYmxlcmFuZ2U6ZGEyYmIyMTI0ZjJkNDI4Njg5MTcxNzk1YjhiYmY5OGZfMTAtMS0xLTEtMA_a686a84b-0be9-441e-a313-0aa0445e342c"
      unitRef="usd">-71220000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ia34dfea6b8734d64abf707c28256801c_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xOS9mcmFnOjU2Y2EwZjE3OWFiNTQ3M2VhZGFlZDM5NjQxYjQ1NzhkL3RhYmxlOmRhMmJiMjEyNGYyZDQyODY4OTE3MTc5NWI4YmJmOThmL3RhYmxlcmFuZ2U6ZGEyYmIyMTI0ZjJkNDI4Njg5MTcxNzk1YjhiYmY5OGZfMTAtMy0xLTEtMA_ea306577-d562-4247-8b37-345d41ad5f52"
      unitRef="usd">-59967000</us-gaap:OperatingIncomeLoss>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xOS9mcmFnOjU2Y2EwZjE3OWFiNTQ3M2VhZGFlZDM5NjQxYjQ1NzhkL3RhYmxlOmRhMmJiMjEyNGYyZDQyODY4OTE3MTc5NWI4YmJmOThmL3RhYmxlcmFuZ2U6ZGEyYmIyMTI0ZjJkNDI4Njg5MTcxNzk1YjhiYmY5OGZfMTEtMS0xLTEtMA_9b23a34f-69e8-42cd-bddb-8e12a8e694a2"
      unitRef="usd">1179000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="ia34dfea6b8734d64abf707c28256801c_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xOS9mcmFnOjU2Y2EwZjE3OWFiNTQ3M2VhZGFlZDM5NjQxYjQ1NzhkL3RhYmxlOmRhMmJiMjEyNGYyZDQyODY4OTE3MTc5NWI4YmJmOThmL3RhYmxlcmFuZ2U6ZGEyYmIyMTI0ZjJkNDI4Njg5MTcxNzk1YjhiYmY5OGZfMTEtMy0xLTEtMA_5a94b413-9e43-4d2b-ae6c-3a12ff99ee5c"
      unitRef="usd">3069000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossAttributableToParent
      contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xOS9mcmFnOjU2Y2EwZjE3OWFiNTQ3M2VhZGFlZDM5NjQxYjQ1NzhkL3RhYmxlOmRhMmJiMjEyNGYyZDQyODY4OTE3MTc5NWI4YmJmOThmL3RhYmxlcmFuZ2U6ZGEyYmIyMTI0ZjJkNDI4Njg5MTcxNzk1YjhiYmY5OGZfMTItMS0xLTEtMA_c46605d8-080e-4c4a-b534-3915bc7973d9"
      unitRef="usd">-70041000</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:IncomeLossAttributableToParent
      contextRef="ia34dfea6b8734d64abf707c28256801c_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xOS9mcmFnOjU2Y2EwZjE3OWFiNTQ3M2VhZGFlZDM5NjQxYjQ1NzhkL3RhYmxlOmRhMmJiMjEyNGYyZDQyODY4OTE3MTc5NWI4YmJmOThmL3RhYmxlcmFuZ2U6ZGEyYmIyMTI0ZjJkNDI4Njg5MTcxNzk1YjhiYmY5OGZfMTItMy0xLTEtMA_4ce84b76-9908-43f7-b079-d1f4bc916888"
      unitRef="usd">-56898000</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xOS9mcmFnOjU2Y2EwZjE3OWFiNTQ3M2VhZGFlZDM5NjQxYjQ1NzhkL3RhYmxlOmRhMmJiMjEyNGYyZDQyODY4OTE3MTc5NWI4YmJmOThmL3RhYmxlcmFuZ2U6ZGEyYmIyMTI0ZjJkNDI4Njg5MTcxNzk1YjhiYmY5OGZfMTMtMS0xLTEtMA_15c3de78-bcae-43df-9cb7-3fe47321b9eb"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ia34dfea6b8734d64abf707c28256801c_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xOS9mcmFnOjU2Y2EwZjE3OWFiNTQ3M2VhZGFlZDM5NjQxYjQ1NzhkL3RhYmxlOmRhMmJiMjEyNGYyZDQyODY4OTE3MTc5NWI4YmJmOThmL3RhYmxlcmFuZ2U6ZGEyYmIyMTI0ZjJkNDI4Njg5MTcxNzk1YjhiYmY5OGZfMTMtMy0xLTEtMA_a6e8bc46-0a48-41a0-b960-43b58cd50555"
      unitRef="usd">-135000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xOS9mcmFnOjU2Y2EwZjE3OWFiNTQ3M2VhZGFlZDM5NjQxYjQ1NzhkL3RhYmxlOmRhMmJiMjEyNGYyZDQyODY4OTE3MTc5NWI4YmJmOThmL3RhYmxlcmFuZ2U6ZGEyYmIyMTI0ZjJkNDI4Njg5MTcxNzk1YjhiYmY5OGZfMTQtMS0xLTEtMA_925af861-1450-4332-a251-593607c17747"
      unitRef="usd">-70041000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ia34dfea6b8734d64abf707c28256801c_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xOS9mcmFnOjU2Y2EwZjE3OWFiNTQ3M2VhZGFlZDM5NjQxYjQ1NzhkL3RhYmxlOmRhMmJiMjEyNGYyZDQyODY4OTE3MTc5NWI4YmJmOThmL3RhYmxlcmFuZ2U6ZGEyYmIyMTI0ZjJkNDI4Njg5MTcxNzk1YjhiYmY5OGZfMTQtMy0xLTEtMA_d4610458-faa9-4bc5-8b64-8acc566f5d80"
      unitRef="usd">-56763000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
      contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xOS9mcmFnOjU2Y2EwZjE3OWFiNTQ3M2VhZGFlZDM5NjQxYjQ1NzhkL3RhYmxlOmRhMmJiMjEyNGYyZDQyODY4OTE3MTc5NWI4YmJmOThmL3RhYmxlcmFuZ2U6ZGEyYmIyMTI0ZjJkNDI4Njg5MTcxNzk1YjhiYmY5OGZfMTYtMS0xLTEtMA_a5ddb717-ea6a-42a0-ae1f-cb558de7f4a5"
      unitRef="usd">13000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
      contextRef="ia34dfea6b8734d64abf707c28256801c_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xOS9mcmFnOjU2Y2EwZjE3OWFiNTQ3M2VhZGFlZDM5NjQxYjQ1NzhkL3RhYmxlOmRhMmJiMjEyNGYyZDQyODY4OTE3MTc5NWI4YmJmOThmL3RhYmxlcmFuZ2U6ZGEyYmIyMTI0ZjJkNDI4Njg5MTcxNzk1YjhiYmY5OGZfMTYtMy0xLTEtMA_15a85b23-bd9d-4075-a833-991696e4f166"
      unitRef="usd">485000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xOS9mcmFnOjU2Y2EwZjE3OWFiNTQ3M2VhZGFlZDM5NjQxYjQ1NzhkL3RhYmxlOmRhMmJiMjEyNGYyZDQyODY4OTE3MTc5NWI4YmJmOThmL3RhYmxlcmFuZ2U6ZGEyYmIyMTI0ZjJkNDI4Njg5MTcxNzk1YjhiYmY5OGZfMTctMS0xLTEtMA_76cbf43a-4ba4-4ebe-9e1c-b469e5eee71a"
      unitRef="usd">-70028000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ia34dfea6b8734d64abf707c28256801c_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xOS9mcmFnOjU2Y2EwZjE3OWFiNTQ3M2VhZGFlZDM5NjQxYjQ1NzhkL3RhYmxlOmRhMmJiMjEyNGYyZDQyODY4OTE3MTc5NWI4YmJmOThmL3RhYmxlcmFuZ2U6ZGEyYmIyMTI0ZjJkNDI4Njg5MTcxNzk1YjhiYmY5OGZfMTctMy0xLTEtMA_46534ffc-c202-4d48-bc05-f3488f2689bc"
      unitRef="usd">-56278000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasic
      contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xOS9mcmFnOjU2Y2EwZjE3OWFiNTQ3M2VhZGFlZDM5NjQxYjQ1NzhkL3RhYmxlOmRhMmJiMjEyNGYyZDQyODY4OTE3MTc5NWI4YmJmOThmL3RhYmxlcmFuZ2U6ZGEyYmIyMTI0ZjJkNDI4Njg5MTcxNzk1YjhiYmY5OGZfMTgtMS0xLTEtMA_286d7405-7acb-44ad-94db-dd208f2207f0"
      unitRef="usdPerShare">-0.58</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xOS9mcmFnOjU2Y2EwZjE3OWFiNTQ3M2VhZGFlZDM5NjQxYjQ1NzhkL3RhYmxlOmRhMmJiMjEyNGYyZDQyODY4OTE3MTc5NWI4YmJmOThmL3RhYmxlcmFuZ2U6ZGEyYmIyMTI0ZjJkNDI4Njg5MTcxNzk1YjhiYmY5OGZfMTgtMS0xLTEtMA_abf84322-713d-4b1e-b7a1-75fa05c608e1"
      unitRef="usdPerShare">-0.58</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="ia34dfea6b8734d64abf707c28256801c_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xOS9mcmFnOjU2Y2EwZjE3OWFiNTQ3M2VhZGFlZDM5NjQxYjQ1NzhkL3RhYmxlOmRhMmJiMjEyNGYyZDQyODY4OTE3MTc5NWI4YmJmOThmL3RhYmxlcmFuZ2U6ZGEyYmIyMTI0ZjJkNDI4Njg5MTcxNzk1YjhiYmY5OGZfMTgtMy0xLTEtMA_70df80d6-01e9-4040-911c-1a0f05e2ce26"
      unitRef="usdPerShare">-0.55</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ia34dfea6b8734d64abf707c28256801c_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xOS9mcmFnOjU2Y2EwZjE3OWFiNTQ3M2VhZGFlZDM5NjQxYjQ1NzhkL3RhYmxlOmRhMmJiMjEyNGYyZDQyODY4OTE3MTc5NWI4YmJmOThmL3RhYmxlcmFuZ2U6ZGEyYmIyMTI0ZjJkNDI4Njg5MTcxNzk1YjhiYmY5OGZfMTgtMy0xLTEtMA_dc268d5b-0f05-402e-98db-5b05b75d01a9"
      unitRef="usdPerShare">-0.55</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xOS9mcmFnOjU2Y2EwZjE3OWFiNTQ3M2VhZGFlZDM5NjQxYjQ1NzhkL3RhYmxlOmRhMmJiMjEyNGYyZDQyODY4OTE3MTc5NWI4YmJmOThmL3RhYmxlcmFuZ2U6ZGEyYmIyMTI0ZjJkNDI4Njg5MTcxNzk1YjhiYmY5OGZfMTktMS0xLTEtMA_3f570753-c7b7-490a-8f0b-cc526cba4531"
      unitRef="shares">120884665</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xOS9mcmFnOjU2Y2EwZjE3OWFiNTQ3M2VhZGFlZDM5NjQxYjQ1NzhkL3RhYmxlOmRhMmJiMjEyNGYyZDQyODY4OTE3MTc5NWI4YmJmOThmL3RhYmxlcmFuZ2U6ZGEyYmIyMTI0ZjJkNDI4Njg5MTcxNzk1YjhiYmY5OGZfMTktMS0xLTEtMA_75e87f16-ec01-4604-a3eb-b793f78036d7"
      unitRef="shares">120884665</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ia34dfea6b8734d64abf707c28256801c_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xOS9mcmFnOjU2Y2EwZjE3OWFiNTQ3M2VhZGFlZDM5NjQxYjQ1NzhkL3RhYmxlOmRhMmJiMjEyNGYyZDQyODY4OTE3MTc5NWI4YmJmOThmL3RhYmxlcmFuZ2U6ZGEyYmIyMTI0ZjJkNDI4Njg5MTcxNzk1YjhiYmY5OGZfMTktMy0xLTEtMA_60e45f11-b1b1-447f-82a1-2f62e5730233"
      unitRef="shares">102419718</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ia34dfea6b8734d64abf707c28256801c_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xOS9mcmFnOjU2Y2EwZjE3OWFiNTQ3M2VhZGFlZDM5NjQxYjQ1NzhkL3RhYmxlOmRhMmJiMjEyNGYyZDQyODY4OTE3MTc5NWI4YmJmOThmL3RhYmxlcmFuZ2U6ZGEyYmIyMTI0ZjJkNDI4Njg5MTcxNzk1YjhiYmY5OGZfMTktMy0xLTEtMA_e71a2566-eeac-462d-9166-3e90685e0b2d"
      unitRef="shares">102419718</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:RevenueFromRelatedParties
      contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xOS9mcmFnOjU2Y2EwZjE3OWFiNTQ3M2VhZGFlZDM5NjQxYjQ1NzhkL3RleHRyZWdpb246NTZjYTBmMTc5YWI1NDczZWFkYWVkMzk2NDFiNDU3OGRfMTA5OTUxMTYyODI0OA_dc54ec58-a372-45cb-be75-971226cedec6"
      unitRef="usd">900000</us-gaap:RevenueFromRelatedParties>
    <dnli:ResearchAndDevelopmentExpenseOffsetFromRelatedPartyCostReimbursement
      contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xOS9mcmFnOjU2Y2EwZjE3OWFiNTQ3M2VhZGFlZDM5NjQxYjQ1NzhkL3RleHRyZWdpb246NTZjYTBmMTc5YWI1NDczZWFkYWVkMzk2NDFiNDU3OGRfMTA5OTUxMTYyODI2MA_dbb3c119-6678-4bf7-9532-ca97b065d2a9"
      unitRef="usd">2500000</dnli:ResearchAndDevelopmentExpenseOffsetFromRelatedPartyCostReimbursement>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i6b1694c4d5a44ff2b0218864ff3535bb_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yMi9mcmFnOjY1NDQ3MWYzNDY0OTRiYmRiMTQ3ZWJmZjQ0ZjE5NDAzL3RhYmxlOjFlNDMxNWRlMDJjZDRjYTE5OGYyZjc0Y2RiYTlkOGJlL3RhYmxlcmFuZ2U6MWU0MzE1ZGUwMmNkNGNhMTk4ZjJmNzRjZGJhOWQ4YmVfMi02LTEtMS0w_29248d0a-8ef0-4c9a-8a9e-83a5070f137c"
      unitRef="shares">120531333</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i6b1694c4d5a44ff2b0218864ff3535bb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yMi9mcmFnOjY1NDQ3MWYzNDY0OTRiYmRiMTQ3ZWJmZjQ0ZjE5NDAzL3RhYmxlOjFlNDMxNWRlMDJjZDRjYTE5OGYyZjc0Y2RiYTlkOGJlL3RhYmxlcmFuZ2U6MWU0MzE1ZGUwMmNkNGNhMTk4ZjJmNzRjZGJhOWQ4YmVfMi04LTEtMS0w_ccd89bfd-c35a-4106-bbec-1c2d39c4a05e"
      unitRef="usd">1531000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1182c403bed14f779ebd3c5cf55f280c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yMi9mcmFnOjY1NDQ3MWYzNDY0OTRiYmRiMTQ3ZWJmZjQ0ZjE5NDAzL3RhYmxlOjFlNDMxNWRlMDJjZDRjYTE5OGYyZjc0Y2RiYTlkOGJlL3RhYmxlcmFuZ2U6MWU0MzE1ZGUwMmNkNGNhMTk4ZjJmNzRjZGJhOWQ4YmVfMi0xMC0xLTEtMA_f36d8d23-65c7-41d5-ac64-15ec81a366fb"
      unitRef="usd">1503660000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3e68706d6d7742388257b82fc7c16d8d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yMi9mcmFnOjY1NDQ3MWYzNDY0OTRiYmRiMTQ3ZWJmZjQ0ZjE5NDAzL3RhYmxlOjFlNDMxNWRlMDJjZDRjYTE5OGYyZjc0Y2RiYTlkOGJlL3RhYmxlcmFuZ2U6MWU0MzE1ZGUwMmNkNGNhMTk4ZjJmNzRjZGJhOWQ4YmVfMi0xMi0xLTEtMA_6facecc0-e60b-4203-ae8f-161f1f03a340"
      unitRef="usd">-245000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ibe96d84e0a5e425bab91f9c7441e0d1d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yMi9mcmFnOjY1NDQ3MWYzNDY0OTRiYmRiMTQ3ZWJmZjQ0ZjE5NDAzL3RhYmxlOjFlNDMxNWRlMDJjZDRjYTE5OGYyZjc0Y2RiYTlkOGJlL3RhYmxlcmFuZ2U6MWU0MzE1ZGUwMmNkNGNhMTk4ZjJmNzRjZGJhOWQ4YmVfMi0xNC0xLTEtMA_b8f6176c-98bf-4290-ad16-085106a238e6"
      unitRef="usd">-354415000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="idb7ca9f362da46eab3a29bbbecbda977_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yMi9mcmFnOjY1NDQ3MWYzNDY0OTRiYmRiMTQ3ZWJmZjQ0ZjE5NDAzL3RhYmxlOjFlNDMxNWRlMDJjZDRjYTE5OGYyZjc0Y2RiYTlkOGJlL3RhYmxlcmFuZ2U6MWU0MzE1ZGUwMmNkNGNhMTk4ZjJmNzRjZGJhOWQ4YmVfMi0xNi0xLTEtMA_9f66c4a8-1655-4c37-851a-107f26938f1e"
      unitRef="usd">1150531000</us-gaap:StockholdersEquity>
    <dnli:StockIssuedDuringPeriodSharesEquityIncentivePlan
      contextRef="i3cc86f0bf14143f4ae8b3600808a8b8e_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yMi9mcmFnOjY1NDQ3MWYzNDY0OTRiYmRiMTQ3ZWJmZjQ0ZjE5NDAzL3RhYmxlOjFlNDMxNWRlMDJjZDRjYTE5OGYyZjc0Y2RiYTlkOGJlL3RhYmxlcmFuZ2U6MWU0MzE1ZGUwMmNkNGNhMTk4ZjJmNzRjZGJhOWQ4YmVfNS02LTEtMS0w_bfa9de0b-d9e6-4e34-811e-c3ab3cce402b"
      unitRef="shares">334634</dnli:StockIssuedDuringPeriodSharesEquityIncentivePlan>
    <dnli:StockIssuedDuringPeriodValueEquityIncentivePlan
      contextRef="i3cc86f0bf14143f4ae8b3600808a8b8e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yMi9mcmFnOjY1NDQ3MWYzNDY0OTRiYmRiMTQ3ZWJmZjQ0ZjE5NDAzL3RhYmxlOjFlNDMxNWRlMDJjZDRjYTE5OGYyZjc0Y2RiYTlkOGJlL3RhYmxlcmFuZ2U6MWU0MzE1ZGUwMmNkNGNhMTk4ZjJmNzRjZGJhOWQ4YmVfNS04LTEtMS0w_4b81b4ed-5514-4d4d-bb7f-b87d7ae9ef29"
      unitRef="usd">3000</dnli:StockIssuedDuringPeriodValueEquityIncentivePlan>
    <dnli:StockIssuedDuringPeriodValueEquityIncentivePlan
      contextRef="i512d7365f8ba4cffa29eb6d1a746e90d_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yMi9mcmFnOjY1NDQ3MWYzNDY0OTRiYmRiMTQ3ZWJmZjQ0ZjE5NDAzL3RhYmxlOjFlNDMxNWRlMDJjZDRjYTE5OGYyZjc0Y2RiYTlkOGJlL3RhYmxlcmFuZ2U6MWU0MzE1ZGUwMmNkNGNhMTk4ZjJmNzRjZGJhOWQ4YmVfNS0xMC0xLTEtMA_9165fba1-9803-4e07-8372-a7af6db5879a"
      unitRef="usd">3819000</dnli:StockIssuedDuringPeriodValueEquityIncentivePlan>
    <dnli:StockIssuedDuringPeriodValueEquityIncentivePlan
      contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yMi9mcmFnOjY1NDQ3MWYzNDY0OTRiYmRiMTQ3ZWJmZjQ0ZjE5NDAzL3RhYmxlOjFlNDMxNWRlMDJjZDRjYTE5OGYyZjc0Y2RiYTlkOGJlL3RhYmxlcmFuZ2U6MWU0MzE1ZGUwMmNkNGNhMTk4ZjJmNzRjZGJhOWQ4YmVfNS0xNi0xLTEtMA_32042ec5-5bd9-4391-b078-0aa72070b021"
      unitRef="usd">3822000</dnli:StockIssuedDuringPeriodValueEquityIncentivePlan>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="i3cc86f0bf14143f4ae8b3600808a8b8e_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yMi9mcmFnOjY1NDQ3MWYzNDY0OTRiYmRiMTQ3ZWJmZjQ0ZjE5NDAzL3RhYmxlOjFlNDMxNWRlMDJjZDRjYTE5OGYyZjc0Y2RiYTlkOGJlL3RhYmxlcmFuZ2U6MWU0MzE1ZGUwMmNkNGNhMTk4ZjJmNzRjZGJhOWQ4YmVfNi02LTEtMS0w_067a147e-cd9e-44b3-b13b-356e1a7e2239"
      unitRef="shares">281465</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i3cc86f0bf14143f4ae8b3600808a8b8e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yMi9mcmFnOjY1NDQ3MWYzNDY0OTRiYmRiMTQ3ZWJmZjQ0ZjE5NDAzL3RhYmxlOjFlNDMxNWRlMDJjZDRjYTE5OGYyZjc0Y2RiYTlkOGJlL3RhYmxlcmFuZ2U6MWU0MzE1ZGUwMmNkNGNhMTk4ZjJmNzRjZGJhOWQ4YmVfNi04LTEtMS0w_87754892-d034-4068-90d8-e2a06160d9d3"
      unitRef="usd">3000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i512d7365f8ba4cffa29eb6d1a746e90d_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yMi9mcmFnOjY1NDQ3MWYzNDY0OTRiYmRiMTQ3ZWJmZjQ0ZjE5NDAzL3RhYmxlOjFlNDMxNWRlMDJjZDRjYTE5OGYyZjc0Y2RiYTlkOGJlL3RhYmxlcmFuZ2U6MWU0MzE1ZGUwMmNkNGNhMTk4ZjJmNzRjZGJhOWQ4YmVfNi0xMC0xLTEtMA_a26a767f-18aa-4b91-bf43-fc854f8ca96b"
      unitRef="usd">-3000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yMi9mcmFnOjY1NDQ3MWYzNDY0OTRiYmRiMTQ3ZWJmZjQ0ZjE5NDAzL3RhYmxlOjFlNDMxNWRlMDJjZDRjYTE5OGYyZjc0Y2RiYTlkOGJlL3RhYmxlcmFuZ2U6MWU0MzE1ZGUwMmNkNGNhMTk4ZjJmNzRjZGJhOWQ4YmVfNi0xNi0xLTEtMA_d5c50f63-8fd9-4215-b0ff-004b302c1e76"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i512d7365f8ba4cffa29eb6d1a746e90d_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yMi9mcmFnOjY1NDQ3MWYzNDY0OTRiYmRiMTQ3ZWJmZjQ0ZjE5NDAzL3RhYmxlOjFlNDMxNWRlMDJjZDRjYTE5OGYyZjc0Y2RiYTlkOGJlL3RhYmxlcmFuZ2U6MWU0MzE1ZGUwMmNkNGNhMTk4ZjJmNzRjZGJhOWQ4YmVfNy0xMC0xLTEtMA_562891cf-9f89-4c15-9182-69cd5e3deb23"
      unitRef="usd">21028000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yMi9mcmFnOjY1NDQ3MWYzNDY0OTRiYmRiMTQ3ZWJmZjQ0ZjE5NDAzL3RhYmxlOjFlNDMxNWRlMDJjZDRjYTE5OGYyZjc0Y2RiYTlkOGJlL3RhYmxlcmFuZ2U6MWU0MzE1ZGUwMmNkNGNhMTk4ZjJmNzRjZGJhOWQ4YmVfNy0xNi0xLTEtMA_ffe52130-b5da-46dd-a2d5-7833a69c6435"
      unitRef="usd">21028000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="i8f89be0032cd49c2b7c0a19693e48b5c_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yMi9mcmFnOjY1NDQ3MWYzNDY0OTRiYmRiMTQ3ZWJmZjQ0ZjE5NDAzL3RhYmxlOjFlNDMxNWRlMDJjZDRjYTE5OGYyZjc0Y2RiYTlkOGJlL3RhYmxlcmFuZ2U6MWU0MzE1ZGUwMmNkNGNhMTk4ZjJmNzRjZGJhOWQ4YmVfOC0xNC0xLTEtMA_0ec6960f-4f01-4a43-8e9f-56b053631b96"
      unitRef="usd">-70041000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yMi9mcmFnOjY1NDQ3MWYzNDY0OTRiYmRiMTQ3ZWJmZjQ0ZjE5NDAzL3RhYmxlOjFlNDMxNWRlMDJjZDRjYTE5OGYyZjc0Y2RiYTlkOGJlL3RhYmxlcmFuZ2U6MWU0MzE1ZGUwMmNkNGNhMTk4ZjJmNzRjZGJhOWQ4YmVfOC0xNi0xLTEtMA_45e86b11-6b09-47c5-b7f4-cb3cde0f5f6b"
      unitRef="usd">-70041000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i8017a7d7e9414d9cac2f173a2d4a39dc_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yMi9mcmFnOjY1NDQ3MWYzNDY0OTRiYmRiMTQ3ZWJmZjQ0ZjE5NDAzL3RhYmxlOjFlNDMxNWRlMDJjZDRjYTE5OGYyZjc0Y2RiYTlkOGJlL3RhYmxlcmFuZ2U6MWU0MzE1ZGUwMmNkNGNhMTk4ZjJmNzRjZGJhOWQ4YmVfOS0xMi0xLTEtMA_4b217e53-0425-4fe0-8e4c-9a059e41c569"
      unitRef="usd">13000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yMi9mcmFnOjY1NDQ3MWYzNDY0OTRiYmRiMTQ3ZWJmZjQ0ZjE5NDAzL3RhYmxlOjFlNDMxNWRlMDJjZDRjYTE5OGYyZjc0Y2RiYTlkOGJlL3RhYmxlcmFuZ2U6MWU0MzE1ZGUwMmNkNGNhMTk4ZjJmNzRjZGJhOWQ4YmVfOS0xNi0xLTEtMA_893039b3-684d-4c9a-b7fe-7e854b0eec5e"
      unitRef="usd">13000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i6881ec9f4b804f8bb0b380a22e0d14bc_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yMi9mcmFnOjY1NDQ3MWYzNDY0OTRiYmRiMTQ3ZWJmZjQ0ZjE5NDAzL3RhYmxlOjFlNDMxNWRlMDJjZDRjYTE5OGYyZjc0Y2RiYTlkOGJlL3RhYmxlcmFuZ2U6MWU0MzE1ZGUwMmNkNGNhMTk4ZjJmNzRjZGJhOWQ4YmVfMTAtNi0xLTEtMA_e5fcf46c-c85b-4efb-96e8-101e262ef6f7"
      unitRef="shares">121147432</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i6881ec9f4b804f8bb0b380a22e0d14bc_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yMi9mcmFnOjY1NDQ3MWYzNDY0OTRiYmRiMTQ3ZWJmZjQ0ZjE5NDAzL3RhYmxlOjFlNDMxNWRlMDJjZDRjYTE5OGYyZjc0Y2RiYTlkOGJlL3RhYmxlcmFuZ2U6MWU0MzE1ZGUwMmNkNGNhMTk4ZjJmNzRjZGJhOWQ4YmVfMTAtOC0xLTEtMA_1bb9ec45-a6ad-4df1-ad78-610bd957170f"
      unitRef="usd">1537000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iab67b1cb96b04f5eae11176694e59a6b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yMi9mcmFnOjY1NDQ3MWYzNDY0OTRiYmRiMTQ3ZWJmZjQ0ZjE5NDAzL3RhYmxlOjFlNDMxNWRlMDJjZDRjYTE5OGYyZjc0Y2RiYTlkOGJlL3RhYmxlcmFuZ2U6MWU0MzE1ZGUwMmNkNGNhMTk4ZjJmNzRjZGJhOWQ4YmVfMTAtMTAtMS0xLTA_0c263fb2-00ff-4fa1-83f4-852165509dbe"
      unitRef="usd">1528504000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8faf25a1f5264f7bbd65f096a2d9a464_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yMi9mcmFnOjY1NDQ3MWYzNDY0OTRiYmRiMTQ3ZWJmZjQ0ZjE5NDAzL3RhYmxlOjFlNDMxNWRlMDJjZDRjYTE5OGYyZjc0Y2RiYTlkOGJlL3RhYmxlcmFuZ2U6MWU0MzE1ZGUwMmNkNGNhMTk4ZjJmNzRjZGJhOWQ4YmVfMTAtMTItMS0xLTA_cbf83a62-bb9c-4f5b-a37f-f77f29b0845b"
      unitRef="usd">-232000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2d9b04bba6cb45aab3777466d4b29061_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yMi9mcmFnOjY1NDQ3MWYzNDY0OTRiYmRiMTQ3ZWJmZjQ0ZjE5NDAzL3RhYmxlOjFlNDMxNWRlMDJjZDRjYTE5OGYyZjc0Y2RiYTlkOGJlL3RhYmxlcmFuZ2U6MWU0MzE1ZGUwMmNkNGNhMTk4ZjJmNzRjZGJhOWQ4YmVfMTAtMTQtMS0xLTA_ca464809-6370-46a1-a996-51d4ff062d60"
      unitRef="usd">-424456000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9953f50a7fd74f7d8438f304f136a07b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yMi9mcmFnOjY1NDQ3MWYzNDY0OTRiYmRiMTQ3ZWJmZjQ0ZjE5NDAzL3RhYmxlOjFlNDMxNWRlMDJjZDRjYTE5OGYyZjc0Y2RiYTlkOGJlL3RhYmxlcmFuZ2U6MWU0MzE1ZGUwMmNkNGNhMTk4ZjJmNzRjZGJhOWQ4YmVfMTAtMTYtMS0xLTA_618de84b-219d-47a8-ac92-f085bc1b721c"
      unitRef="usd">1105353000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="if9deb2734a184a7cbde40db4324e7d19_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yMi9mcmFnOjY1NDQ3MWYzNDY0OTRiYmRiMTQ3ZWJmZjQ0ZjE5NDAzL3RhYmxlOjFlNDMxNWRlMDJjZDRjYTE5OGYyZjc0Y2RiYTlkOGJlL3RhYmxlcmFuZ2U6MWU0MzE1ZGUwMmNkNGNhMTk4ZjJmNzRjZGJhOWQ4YmVfMjEtNi0xLTEtMA_b22abb3b-ea23-40c8-8618-d24b4b08ceff"
      unitRef="shares">96189935</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="if9deb2734a184a7cbde40db4324e7d19_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yMi9mcmFnOjY1NDQ3MWYzNDY0OTRiYmRiMTQ3ZWJmZjQ0ZjE5NDAzL3RhYmxlOjFlNDMxNWRlMDJjZDRjYTE5OGYyZjc0Y2RiYTlkOGJlL3RhYmxlcmFuZ2U6MWU0MzE1ZGUwMmNkNGNhMTk4ZjJmNzRjZGJhOWQ4YmVfMjEtOC0xLTEtMA_1dd51a71-88ba-4042-83d9-cbda382a0017"
      unitRef="usd">1288000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia3061e69973345b0a814850b46a1e70d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yMi9mcmFnOjY1NDQ3MWYzNDY0OTRiYmRiMTQ3ZWJmZjQ0ZjE5NDAzL3RhYmxlOjFlNDMxNWRlMDJjZDRjYTE5OGYyZjc0Y2RiYTlkOGJlL3RhYmxlcmFuZ2U6MWU0MzE1ZGUwMmNkNGNhMTk4ZjJmNzRjZGJhOWQ4YmVfMjEtMTAtMS0xLTA_de9f6877-4b44-4c9b-9747-8b49777c4c75"
      unitRef="usd">818803000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7fc2ea20a15f4358958ac2de513cbedf_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yMi9mcmFnOjY1NDQ3MWYzNDY0OTRiYmRiMTQ3ZWJmZjQ0ZjE5NDAzL3RhYmxlOjFlNDMxNWRlMDJjZDRjYTE5OGYyZjc0Y2RiYTlkOGJlL3RhYmxlcmFuZ2U6MWU0MzE1ZGUwMmNkNGNhMTk4ZjJmNzRjZGJhOWQ4YmVfMjEtMTItMS0xLTA_613a03e7-db8a-43bd-b8a6-d256d7fafeff"
      unitRef="usd">350000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4f05e20d565c4dec84e3cf8ab862dd61_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yMi9mcmFnOjY1NDQ3MWYzNDY0OTRiYmRiMTQ3ZWJmZjQ0ZjE5NDAzL3RhYmxlOjFlNDMxNWRlMDJjZDRjYTE5OGYyZjc0Y2RiYTlkOGJlL3RhYmxlcmFuZ2U6MWU0MzE1ZGUwMmNkNGNhMTk4ZjJmNzRjZGJhOWQ4YmVfMjEtMTQtMS0xLTA_5a54e031-d00b-418c-ad60-d570923c3b31"
      unitRef="usd">-425551000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id36b0e599cb3498a8671e8c185763bc9_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yMi9mcmFnOjY1NDQ3MWYzNDY0OTRiYmRiMTQ3ZWJmZjQ0ZjE5NDAzL3RhYmxlOjFlNDMxNWRlMDJjZDRjYTE5OGYyZjc0Y2RiYTlkOGJlL3RhYmxlcmFuZ2U6MWU0MzE1ZGUwMmNkNGNhMTk4ZjJmNzRjZGJhOWQ4YmVfMjEtMTYtMS0xLTA_8bf3624f-9f66-4ded-acc4-cf9fc504472b"
      unitRef="usd">394890000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="ia63b42181ffa4fb5aa0692f27bc204e4_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yMi9mcmFnOjY1NDQ3MWYzNDY0OTRiYmRiMTQ3ZWJmZjQ0ZjE5NDAzL3RhYmxlOjFlNDMxNWRlMDJjZDRjYTE5OGYyZjc0Y2RiYTlkOGJlL3RhYmxlcmFuZ2U6MWU0MzE1ZGUwMmNkNGNhMTk4ZjJmNzRjZGJhOWQ4YmVfMTItMC0xLTEtOTYvdGV4dHJlZ2lvbjphMTNmZDhmYjMwOWM0YjY5YmMxZTAzYmUyMzU3MGFiNF8xMDk5NTExNjI3ODYw_e3299929-72b3-42c9-977f-f368290ddb79"
      unitRef="usd">632000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ia63b42181ffa4fb5aa0692f27bc204e4_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yMi9mcmFnOjY1NDQ3MWYzNDY0OTRiYmRiMTQ3ZWJmZjQ0ZjE5NDAzL3RhYmxlOjFlNDMxNWRlMDJjZDRjYTE5OGYyZjc0Y2RiYTlkOGJlL3RhYmxlcmFuZ2U6MWU0MzE1ZGUwMmNkNGNhMTk4ZjJmNzRjZGJhOWQ4YmVfMTItNi0xLTEtOTA_7014afcd-d930-462f-8f65-7b5150501fe6"
      unitRef="shares">9000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ia63b42181ffa4fb5aa0692f27bc204e4_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yMi9mcmFnOjY1NDQ3MWYzNDY0OTRiYmRiMTQ3ZWJmZjQ0ZjE5NDAzL3RhYmxlOjFlNDMxNWRlMDJjZDRjYTE5OGYyZjc0Y2RiYTlkOGJlL3RhYmxlcmFuZ2U6MWU0MzE1ZGUwMmNkNGNhMTk4ZjJmNzRjZGJhOWQ4YmVfMTItOC0xLTEtOTk_bce0cddf-296e-42ee-b40d-f20c5df924bd"
      unitRef="usd">90000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i481b7d29f5714b2c9591d38d45fb69a2_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yMi9mcmFnOjY1NDQ3MWYzNDY0OTRiYmRiMTQ3ZWJmZjQ0ZjE5NDAzL3RhYmxlOjFlNDMxNWRlMDJjZDRjYTE5OGYyZjc0Y2RiYTlkOGJlL3RhYmxlcmFuZ2U6MWU0MzE1ZGUwMmNkNGNhMTk4ZjJmNzRjZGJhOWQ4YmVfMTItMTAtMS0xLTEwMw_27ee5563-fdbd-4d16-b76a-3eff1adeed83"
      unitRef="usd">193858000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ia34dfea6b8734d64abf707c28256801c_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yMi9mcmFnOjY1NDQ3MWYzNDY0OTRiYmRiMTQ3ZWJmZjQ0ZjE5NDAzL3RhYmxlOjFlNDMxNWRlMDJjZDRjYTE5OGYyZjc0Y2RiYTlkOGJlL3RhYmxlcmFuZ2U6MWU0MzE1ZGUwMmNkNGNhMTk4ZjJmNzRjZGJhOWQ4YmVfMTItMTYtMS0xLTExNg_e6cab4cc-4f62-460e-94a7-5c604b536e3a"
      unitRef="usd">193948000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <dnli:StockIssuedDuringPeriodSharesEquityIncentivePlan
      contextRef="ia63b42181ffa4fb5aa0692f27bc204e4_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yMi9mcmFnOjY1NDQ3MWYzNDY0OTRiYmRiMTQ3ZWJmZjQ0ZjE5NDAzL3RhYmxlOjFlNDMxNWRlMDJjZDRjYTE5OGYyZjc0Y2RiYTlkOGJlL3RhYmxlcmFuZ2U6MWU0MzE1ZGUwMmNkNGNhMTk4ZjJmNzRjZGJhOWQ4YmVfMjItNi0xLTEtMA_12b466d1-02ac-4cd2-9471-1347e5de26a0"
      unitRef="shares">259569</dnli:StockIssuedDuringPeriodSharesEquityIncentivePlan>
    <dnli:StockIssuedDuringPeriodValueEquityIncentivePlan
      contextRef="ia63b42181ffa4fb5aa0692f27bc204e4_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yMi9mcmFnOjY1NDQ3MWYzNDY0OTRiYmRiMTQ3ZWJmZjQ0ZjE5NDAzL3RhYmxlOjFlNDMxNWRlMDJjZDRjYTE5OGYyZjc0Y2RiYTlkOGJlL3RhYmxlcmFuZ2U6MWU0MzE1ZGUwMmNkNGNhMTk4ZjJmNzRjZGJhOWQ4YmVfMjItOC0xLTEtMA_abc9de20-4327-4cc6-9464-16003f71f938"
      unitRef="usd">3000</dnli:StockIssuedDuringPeriodValueEquityIncentivePlan>
    <dnli:StockIssuedDuringPeriodValueEquityIncentivePlan
      contextRef="i481b7d29f5714b2c9591d38d45fb69a2_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yMi9mcmFnOjY1NDQ3MWYzNDY0OTRiYmRiMTQ3ZWJmZjQ0ZjE5NDAzL3RhYmxlOjFlNDMxNWRlMDJjZDRjYTE5OGYyZjc0Y2RiYTlkOGJlL3RhYmxlcmFuZ2U6MWU0MzE1ZGUwMmNkNGNhMTk4ZjJmNzRjZGJhOWQ4YmVfMjItMTAtMS0xLTA_bf2af1b7-384d-4f8e-b9dd-4fa6bb11daca"
      unitRef="usd">1963000</dnli:StockIssuedDuringPeriodValueEquityIncentivePlan>
    <dnli:StockIssuedDuringPeriodValueEquityIncentivePlan
      contextRef="ia34dfea6b8734d64abf707c28256801c_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yMi9mcmFnOjY1NDQ3MWYzNDY0OTRiYmRiMTQ3ZWJmZjQ0ZjE5NDAzL3RhYmxlOjFlNDMxNWRlMDJjZDRjYTE5OGYyZjc0Y2RiYTlkOGJlL3RhYmxlcmFuZ2U6MWU0MzE1ZGUwMmNkNGNhMTk4ZjJmNzRjZGJhOWQ4YmVfMjItMTYtMS0xLTA_a64a45ff-ab25-40c4-b9d1-283e0536929a"
      unitRef="usd">1966000</dnli:StockIssuedDuringPeriodValueEquityIncentivePlan>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="ia63b42181ffa4fb5aa0692f27bc204e4_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yMi9mcmFnOjY1NDQ3MWYzNDY0OTRiYmRiMTQ3ZWJmZjQ0ZjE5NDAzL3RhYmxlOjFlNDMxNWRlMDJjZDRjYTE5OGYyZjc0Y2RiYTlkOGJlL3RhYmxlcmFuZ2U6MWU0MzE1ZGUwMmNkNGNhMTk4ZjJmNzRjZGJhOWQ4YmVfMjQtNi0xLTEtMA_99f809a2-9254-429b-8b7e-5b8b24d0f316"
      unitRef="shares">91839</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="ia63b42181ffa4fb5aa0692f27bc204e4_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yMi9mcmFnOjY1NDQ3MWYzNDY0OTRiYmRiMTQ3ZWJmZjQ0ZjE5NDAzL3RhYmxlOjFlNDMxNWRlMDJjZDRjYTE5OGYyZjc0Y2RiYTlkOGJlL3RhYmxlcmFuZ2U6MWU0MzE1ZGUwMmNkNGNhMTk4ZjJmNzRjZGJhOWQ4YmVfMjQtOC0xLTEtMA_1461024e-26f9-4825-ac7b-e37753bafee4"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i481b7d29f5714b2c9591d38d45fb69a2_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yMi9mcmFnOjY1NDQ3MWYzNDY0OTRiYmRiMTQ3ZWJmZjQ0ZjE5NDAzL3RhYmxlOjFlNDMxNWRlMDJjZDRjYTE5OGYyZjc0Y2RiYTlkOGJlL3RhYmxlcmFuZ2U6MWU0MzE1ZGUwMmNkNGNhMTk4ZjJmNzRjZGJhOWQ4YmVfMjQtMTAtMS0xLTA_dd804ac5-dc37-4773-b072-8023c6d86a92"
      unitRef="usd">-1000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="ia34dfea6b8734d64abf707c28256801c_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yMi9mcmFnOjY1NDQ3MWYzNDY0OTRiYmRiMTQ3ZWJmZjQ0ZjE5NDAzL3RhYmxlOjFlNDMxNWRlMDJjZDRjYTE5OGYyZjc0Y2RiYTlkOGJlL3RhYmxlcmFuZ2U6MWU0MzE1ZGUwMmNkNGNhMTk4ZjJmNzRjZGJhOWQ4YmVfMjQtMTYtMS0xLTA_a88dabe0-d28b-4d5c-839e-ec348164d7a1"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i481b7d29f5714b2c9591d38d45fb69a2_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yMi9mcmFnOjY1NDQ3MWYzNDY0OTRiYmRiMTQ3ZWJmZjQ0ZjE5NDAzL3RhYmxlOjFlNDMxNWRlMDJjZDRjYTE5OGYyZjc0Y2RiYTlkOGJlL3RhYmxlcmFuZ2U6MWU0MzE1ZGUwMmNkNGNhMTk4ZjJmNzRjZGJhOWQ4YmVfMjUtMTAtMS0xLTA_3e9b02fd-61ac-4af5-b836-fc3011ba6777"
      unitRef="usd">10785000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ia34dfea6b8734d64abf707c28256801c_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yMi9mcmFnOjY1NDQ3MWYzNDY0OTRiYmRiMTQ3ZWJmZjQ0ZjE5NDAzL3RhYmxlOjFlNDMxNWRlMDJjZDRjYTE5OGYyZjc0Y2RiYTlkOGJlL3RhYmxlcmFuZ2U6MWU0MzE1ZGUwMmNkNGNhMTk4ZjJmNzRjZGJhOWQ4YmVfMjUtMTYtMS0xLTA_e6b943bf-1622-456b-9275-b8b65e430886"
      unitRef="usd">10785000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="idc9c2fd3102f4601910401b0065ccdee_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yMi9mcmFnOjY1NDQ3MWYzNDY0OTRiYmRiMTQ3ZWJmZjQ0ZjE5NDAzL3RhYmxlOjFlNDMxNWRlMDJjZDRjYTE5OGYyZjc0Y2RiYTlkOGJlL3RhYmxlcmFuZ2U6MWU0MzE1ZGUwMmNkNGNhMTk4ZjJmNzRjZGJhOWQ4YmVfMjYtMTQtMS0xLTA_83dccb88-bbac-46ac-a99a-395247c15806"
      unitRef="usd">-56763000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ia34dfea6b8734d64abf707c28256801c_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yMi9mcmFnOjY1NDQ3MWYzNDY0OTRiYmRiMTQ3ZWJmZjQ0ZjE5NDAzL3RhYmxlOjFlNDMxNWRlMDJjZDRjYTE5OGYyZjc0Y2RiYTlkOGJlL3RhYmxlcmFuZ2U6MWU0MzE1ZGUwMmNkNGNhMTk4ZjJmNzRjZGJhOWQ4YmVfMjYtMTYtMS0xLTA_5e2be81f-d640-4b8b-8c9d-5967fc9d36d8"
      unitRef="usd">-56763000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i5462764077c54d46b830279d94f82af0_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yMi9mcmFnOjY1NDQ3MWYzNDY0OTRiYmRiMTQ3ZWJmZjQ0ZjE5NDAzL3RhYmxlOjFlNDMxNWRlMDJjZDRjYTE5OGYyZjc0Y2RiYTlkOGJlL3RhYmxlcmFuZ2U6MWU0MzE1ZGUwMmNkNGNhMTk4ZjJmNzRjZGJhOWQ4YmVfMjctMTItMS0xLTA_57344729-b204-4f57-8894-4950cae9a27b"
      unitRef="usd">485000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ia34dfea6b8734d64abf707c28256801c_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yMi9mcmFnOjY1NDQ3MWYzNDY0OTRiYmRiMTQ3ZWJmZjQ0ZjE5NDAzL3RhYmxlOjFlNDMxNWRlMDJjZDRjYTE5OGYyZjc0Y2RiYTlkOGJlL3RhYmxlcmFuZ2U6MWU0MzE1ZGUwMmNkNGNhMTk4ZjJmNzRjZGJhOWQ4YmVfMjctMTYtMS0xLTA_56649749-e264-4478-9438-7f4d9d61e585"
      unitRef="usd">485000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i9e6a5f965fc64fdc84e37350364784a2_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yMi9mcmFnOjY1NDQ3MWYzNDY0OTRiYmRiMTQ3ZWJmZjQ0ZjE5NDAzL3RhYmxlOjFlNDMxNWRlMDJjZDRjYTE5OGYyZjc0Y2RiYTlkOGJlL3RhYmxlcmFuZ2U6MWU0MzE1ZGUwMmNkNGNhMTk4ZjJmNzRjZGJhOWQ4YmVfMjgtNi0xLTEtMA_9709761b-c127-460b-a982-57471be7fbe7"
      unitRef="shares">105541343</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i9e6a5f965fc64fdc84e37350364784a2_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yMi9mcmFnOjY1NDQ3MWYzNDY0OTRiYmRiMTQ3ZWJmZjQ0ZjE5NDAzL3RhYmxlOjFlNDMxNWRlMDJjZDRjYTE5OGYyZjc0Y2RiYTlkOGJlL3RhYmxlcmFuZ2U6MWU0MzE1ZGUwMmNkNGNhMTk4ZjJmNzRjZGJhOWQ4YmVfMjgtOC0xLTEtMA_0d6bb11a-352c-41a1-8517-665b66c9b9b2"
      unitRef="usd">1382000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6acc176d0fde4b30bb04303aefe4c09c_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yMi9mcmFnOjY1NDQ3MWYzNDY0OTRiYmRiMTQ3ZWJmZjQ0ZjE5NDAzL3RhYmxlOjFlNDMxNWRlMDJjZDRjYTE5OGYyZjc0Y2RiYTlkOGJlL3RhYmxlcmFuZ2U6MWU0MzE1ZGUwMmNkNGNhMTk4ZjJmNzRjZGJhOWQ4YmVfMjgtMTAtMS0xLTA_4b2f283a-9bcf-4e9a-8246-7f7fba7c794e"
      unitRef="usd">1025408000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if9160027ce4c429abb35b07016b25738_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yMi9mcmFnOjY1NDQ3MWYzNDY0OTRiYmRiMTQ3ZWJmZjQ0ZjE5NDAzL3RhYmxlOjFlNDMxNWRlMDJjZDRjYTE5OGYyZjc0Y2RiYTlkOGJlL3RhYmxlcmFuZ2U6MWU0MzE1ZGUwMmNkNGNhMTk4ZjJmNzRjZGJhOWQ4YmVfMjgtMTItMS0xLTA_4fe4ee48-261a-4d59-b9bb-f933bf2da640"
      unitRef="usd">835000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8288b3c6af7a4ceca6f0c97aa25994dc_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yMi9mcmFnOjY1NDQ3MWYzNDY0OTRiYmRiMTQ3ZWJmZjQ0ZjE5NDAzL3RhYmxlOjFlNDMxNWRlMDJjZDRjYTE5OGYyZjc0Y2RiYTlkOGJlL3RhYmxlcmFuZ2U6MWU0MzE1ZGUwMmNkNGNhMTk4ZjJmNzRjZGJhOWQ4YmVfMjgtMTQtMS0xLTA_b5a8b40d-b3d9-421f-a67a-64b4d3d5cfaa"
      unitRef="usd">-482314000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i29b65d7585ff41c5843594c6319bdb90_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yMi9mcmFnOjY1NDQ3MWYzNDY0OTRiYmRiMTQ3ZWJmZjQ0ZjE5NDAzL3RhYmxlOjFlNDMxNWRlMDJjZDRjYTE5OGYyZjc0Y2RiYTlkOGJlL3RhYmxlcmFuZ2U6MWU0MzE1ZGUwMmNkNGNhMTk4ZjJmNzRjZGJhOWQ4YmVfMjgtMTYtMS0xLTA_9ed75f2d-0b38-414e-952a-9b879dc3817d"
      unitRef="usd">545311000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yNS9mcmFnOjYzZmYxMmI2NTFjMTRhMTRhNWZkYmE3ODczNzg3M2U5L3RhYmxlOmFiYWYwYmNlMzAxMjRmNTk4ZTE0MzdlNTRjMDY4NzZiL3RhYmxlcmFuZ2U6YWJhZjBiY2UzMDEyNGY1OThlMTQzN2U1NGMwNjg3NmJfMy0xLTEtMS0w_c003414c-99e6-4a43-ba1c-b6500d9fb0a6"
      unitRef="usd">-70041000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ia34dfea6b8734d64abf707c28256801c_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yNS9mcmFnOjYzZmYxMmI2NTFjMTRhMTRhNWZkYmE3ODczNzg3M2U5L3RhYmxlOmFiYWYwYmNlMzAxMjRmNTk4ZTE0MzdlNTRjMDY4NzZiL3RhYmxlcmFuZ2U6YWJhZjBiY2UzMDEyNGY1OThlMTQzN2U1NGMwNjg3NmJfMy0zLTEtMS0w_b7ef8aee-2b36-4581-9646-0a25cb652c1b"
      unitRef="usd">-56763000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yNS9mcmFnOjYzZmYxMmI2NTFjMTRhMTRhNWZkYmE3ODczNzg3M2U5L3RhYmxlOmFiYWYwYmNlMzAxMjRmNTk4ZTE0MzdlNTRjMDY4NzZiL3RhYmxlcmFuZ2U6YWJhZjBiY2UzMDEyNGY1OThlMTQzN2U1NGMwNjg3NmJfNS0xLTEtMS0w_56d9cbee-e344-46d9-aee6-395011e1ceda"
      unitRef="usd">2108000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ia34dfea6b8734d64abf707c28256801c_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yNS9mcmFnOjYzZmYxMmI2NTFjMTRhMTRhNWZkYmE3ODczNzg3M2U5L3RhYmxlOmFiYWYwYmNlMzAxMjRmNTk4ZTE0MzdlNTRjMDY4NzZiL3RhYmxlcmFuZ2U6YWJhZjBiY2UzMDEyNGY1OThlMTQzN2U1NGMwNjg3NmJfNS0zLTEtMS0w_2489ca1f-bacb-49f3-b162-6ea80e633290"
      unitRef="usd">2109000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yNS9mcmFnOjYzZmYxMmI2NTFjMTRhMTRhNWZkYmE3ODczNzg3M2U5L3RhYmxlOmFiYWYwYmNlMzAxMjRmNTk4ZTE0MzdlNTRjMDY4NzZiL3RhYmxlcmFuZ2U6YWJhZjBiY2UzMDEyNGY1OThlMTQzN2U1NGMwNjg3NmJfNi0xLTEtMS0w_80dd0011-a8ae-4f28-af66-98cc2d1ccd28"
      unitRef="usd">21028000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ia34dfea6b8734d64abf707c28256801c_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yNS9mcmFnOjYzZmYxMmI2NTFjMTRhMTRhNWZkYmE3ODczNzg3M2U5L3RhYmxlOmFiYWYwYmNlMzAxMjRmNTk4ZTE0MzdlNTRjMDY4NzZiL3RhYmxlcmFuZ2U6YWJhZjBiY2UzMDEyNGY1OThlMTQzN2U1NGMwNjg3NmJfNi0zLTEtMS0w_f010e005-2a39-4458-86df-96fdc8a56b9d"
      unitRef="usd">10785000</us-gaap:ShareBasedCompensation>
    <us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium
      contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yNS9mcmFnOjYzZmYxMmI2NTFjMTRhMTRhNWZkYmE3ODczNzg3M2U5L3RhYmxlOmFiYWYwYmNlMzAxMjRmNTk4ZTE0MzdlNTRjMDY4NzZiL3RhYmxlcmFuZ2U6YWJhZjBiY2UzMDEyNGY1OThlMTQzN2U1NGMwNjg3NmJfNy0xLTEtMS0w_4520b146-a55e-47b8-8d13-ae11d9f5ad3a"
      unitRef="usd">-1161000</us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium>
    <us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium
      contextRef="ia34dfea6b8734d64abf707c28256801c_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yNS9mcmFnOjYzZmYxMmI2NTFjMTRhMTRhNWZkYmE3ODczNzg3M2U5L3RhYmxlOmFiYWYwYmNlMzAxMjRmNTk4ZTE0MzdlNTRjMDY4NzZiL3RhYmxlcmFuZ2U6YWJhZjBiY2UzMDEyNGY1OThlMTQzN2U1NGMwNjg3NmJfNy0zLTEtMS0w_6d04180c-cffc-48a2-8e24-24a561658362"
      unitRef="usd">607000</us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium>
    <dnli:IncreaseDecreaseInNonCashOperatingLeaseExpense
      contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yNS9mcmFnOjYzZmYxMmI2NTFjMTRhMTRhNWZkYmE3ODczNzg3M2U5L3RhYmxlOmFiYWYwYmNlMzAxMjRmNTk4ZTE0MzdlNTRjMDY4NzZiL3RhYmxlcmFuZ2U6YWJhZjBiY2UzMDEyNGY1OThlMTQzN2U1NGMwNjg3NmJfOC0xLTEtMS0w_2f3f83bf-e6a6-4128-b118-df1ac32ccb6b"
      unitRef="usd">691000</dnli:IncreaseDecreaseInNonCashOperatingLeaseExpense>
    <dnli:IncreaseDecreaseInNonCashOperatingLeaseExpense
      contextRef="ia34dfea6b8734d64abf707c28256801c_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yNS9mcmFnOjYzZmYxMmI2NTFjMTRhMTRhNWZkYmE3ODczNzg3M2U5L3RhYmxlOmFiYWYwYmNlMzAxMjRmNTk4ZTE0MzdlNTRjMDY4NzZiL3RhYmxlcmFuZ2U6YWJhZjBiY2UzMDEyNGY1OThlMTQzN2U1NGMwNjg3NmJfOC0zLTEtMS0w_d8bd4c81-1fd2-441c-9139-210d08f06fb5"
      unitRef="usd">321000</dnli:IncreaseDecreaseInNonCashOperatingLeaseExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yNS9mcmFnOjYzZmYxMmI2NTFjMTRhMTRhNWZkYmE3ODczNzg3M2U5L3RhYmxlOmFiYWYwYmNlMzAxMjRmNTk4ZTE0MzdlNTRjMDY4NzZiL3RhYmxlcmFuZ2U6YWJhZjBiY2UzMDEyNGY1OThlMTQzN2U1NGMwNjg3NmJfMTAtMS0xLTEtMA_67cb7910-ed93-483c-b21a-ea38d0fb0b94"
      unitRef="usd">2000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="ia34dfea6b8734d64abf707c28256801c_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yNS9mcmFnOjYzZmYxMmI2NTFjMTRhMTRhNWZkYmE3ODczNzg3M2U5L3RhYmxlOmFiYWYwYmNlMzAxMjRmNTk4ZTE0MzdlNTRjMDY4NzZiL3RhYmxlcmFuZ2U6YWJhZjBiY2UzMDEyNGY1OThlMTQzN2U1NGMwNjg3NmJfMTAtMy0xLTEtMA_f1243fbf-2160-4163-85a3-b3aa55d866ec"
      unitRef="usd">53000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yNS9mcmFnOjYzZmYxMmI2NTFjMTRhMTRhNWZkYmE3ODczNzg3M2U5L3RhYmxlOmFiYWYwYmNlMzAxMjRmNTk4ZTE0MzdlNTRjMDY4NzZiL3RhYmxlcmFuZ2U6YWJhZjBiY2UzMDEyNGY1OThlMTQzN2U1NGMwNjg3NmJfMTItMS0xLTEtMA_5515a98c-e033-4308-b76c-f606d649b411"
      unitRef="usd">-6301000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="ia34dfea6b8734d64abf707c28256801c_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yNS9mcmFnOjYzZmYxMmI2NTFjMTRhMTRhNWZkYmE3ODczNzg3M2U5L3RhYmxlOmFiYWYwYmNlMzAxMjRmNTk4ZTE0MzdlNTRjMDY4NzZiL3RhYmxlcmFuZ2U6YWJhZjBiY2UzMDEyNGY1OThlMTQzN2U1NGMwNjg3NmJfMTItMy0xLTEtMA_f22aa879-d579-4ed4-b034-e53191557066"
      unitRef="usd">2454000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yNS9mcmFnOjYzZmYxMmI2NTFjMTRhMTRhNWZkYmE3ODczNzg3M2U5L3RhYmxlOmFiYWYwYmNlMzAxMjRmNTk4ZTE0MzdlNTRjMDY4NzZiL3RhYmxlcmFuZ2U6YWJhZjBiY2UzMDEyNGY1OThlMTQzN2U1NGMwNjg3NmJfMTMtMS0xLTEtMA_22a0d43c-19ba-4b0c-8317-30e496f31bfc"
      unitRef="usd">623000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="ia34dfea6b8734d64abf707c28256801c_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yNS9mcmFnOjYzZmYxMmI2NTFjMTRhMTRhNWZkYmE3ODczNzg3M2U5L3RhYmxlOmFiYWYwYmNlMzAxMjRmNTk4ZTE0MzdlNTRjMDY4NzZiL3RhYmxlcmFuZ2U6YWJhZjBiY2UzMDEyNGY1OThlMTQzN2U1NGMwNjg3NmJfMTMtMy0xLTEtMA_679e7037-f054-49aa-b036-e8e12cb75e84"
      unitRef="usd">-292000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yNS9mcmFnOjYzZmYxMmI2NTFjMTRhMTRhNWZkYmE3ODczNzg3M2U5L3RhYmxlOmFiYWYwYmNlMzAxMjRmNTk4ZTE0MzdlNTRjMDY4NzZiL3RhYmxlcmFuZ2U6YWJhZjBiY2UzMDEyNGY1OThlMTQzN2U1NGMwNjg3NmJfMTQtMS0xLTEtMA_e55b43d4-5dfe-43aa-ac3e-1204290eaa5b"
      unitRef="usd">-10804000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="ia34dfea6b8734d64abf707c28256801c_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yNS9mcmFnOjYzZmYxMmI2NTFjMTRhMTRhNWZkYmE3ODczNzg3M2U5L3RhYmxlOmFiYWYwYmNlMzAxMjRmNTk4ZTE0MzdlNTRjMDY4NzZiL3RhYmxlcmFuZ2U6YWJhZjBiY2UzMDEyNGY1OThlMTQzN2U1NGMwNjg3NmJfMTQtMy0xLTEtMA_f66c39bf-c953-45e0-ba33-2c81c9aa0eb0"
      unitRef="usd">-3827000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yNS9mcmFnOjYzZmYxMmI2NTFjMTRhMTRhNWZkYmE3ODczNzg3M2U5L3RhYmxlOmFiYWYwYmNlMzAxMjRmNTk4ZTE0MzdlNTRjMDY4NzZiL3RhYmxlcmFuZ2U6YWJhZjBiY2UzMDEyNGY1OThlMTQzN2U1NGMwNjg3NmJfMTUtMS0xLTEtMA_4a6fe491-0091-4adb-9e25-df2302d287fe"
      unitRef="usd">969000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="ia34dfea6b8734d64abf707c28256801c_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yNS9mcmFnOjYzZmYxMmI2NTFjMTRhMTRhNWZkYmE3ODczNzg3M2U5L3RhYmxlOmFiYWYwYmNlMzAxMjRmNTk4ZTE0MzdlNTRjMDY4NzZiL3RhYmxlcmFuZ2U6YWJhZjBiY2UzMDEyNGY1OThlMTQzN2U1NGMwNjg3NmJfMTUtMy0xLTEtMA_721a68ae-5562-4616-8f39-4b30479e464d"
      unitRef="usd">-3069000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <dnli:IncreaseDecreaseInContractWithCustomerLiabilityRelatedParties
      contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yNS9mcmFnOjYzZmYxMmI2NTFjMTRhMTRhNWZkYmE3ODczNzg3M2U5L3RhYmxlOmFiYWYwYmNlMzAxMjRmNTk4ZTE0MzdlNTRjMDY4NzZiL3RhYmxlcmFuZ2U6YWJhZjBiY2UzMDEyNGY1OThlMTQzN2U1NGMwNjg3NmJfMTYtMS0xLTEtMA_03dc03e6-43bd-4f14-adf7-e359a54117a6"
      unitRef="usd">-892000</dnli:IncreaseDecreaseInContractWithCustomerLiabilityRelatedParties>
    <dnli:IncreaseDecreaseInContractWithCustomerLiabilityRelatedParties
      contextRef="ia34dfea6b8734d64abf707c28256801c_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yNS9mcmFnOjYzZmYxMmI2NTFjMTRhMTRhNWZkYmE3ODczNzg3M2U5L3RhYmxlOmFiYWYwYmNlMzAxMjRmNTk4ZTE0MzdlNTRjMDY4NzZiL3RhYmxlcmFuZ2U6YWJhZjBiY2UzMDEyNGY1OThlMTQzN2U1NGMwNjg3NmJfMTYtMy0xLTEtMA_c7ed04d0-b19b-4d98-ac0d-377b46dde9a2"
      unitRef="usd">0</dnli:IncreaseDecreaseInContractWithCustomerLiabilityRelatedParties>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yNS9mcmFnOjYzZmYxMmI2NTFjMTRhMTRhNWZkYmE3ODczNzg3M2U5L3RhYmxlOmFiYWYwYmNlMzAxMjRmNTk4ZTE0MzdlNTRjMDY4NzZiL3RhYmxlcmFuZ2U6YWJhZjBiY2UzMDEyNGY1OThlMTQzN2U1NGMwNjg3NmJfMTktMS0xLTEtMA_1e9588b9-8b97-4bbe-ad23-361e76c60fff"
      unitRef="usd">-50240000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ia34dfea6b8734d64abf707c28256801c_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yNS9mcmFnOjYzZmYxMmI2NTFjMTRhMTRhNWZkYmE3ODczNzg3M2U5L3RhYmxlOmFiYWYwYmNlMzAxMjRmNTk4ZTE0MzdlNTRjMDY4NzZiL3RhYmxlcmFuZ2U6YWJhZjBiY2UzMDEyNGY1OThlMTQzN2U1NGMwNjg3NmJfMTktMy0xLTEtMA_0ddbae32-1e3f-4253-a3c7-ba689d8dbf47"
      unitRef="usd">-54492000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yNS9mcmFnOjYzZmYxMmI2NTFjMTRhMTRhNWZkYmE3ODczNzg3M2U5L3RhYmxlOmFiYWYwYmNlMzAxMjRmNTk4ZTE0MzdlNTRjMDY4NzZiL3RhYmxlcmFuZ2U6YWJhZjBiY2UzMDEyNGY1OThlMTQzN2U1NGMwNjg3NmJfMjEtMS0xLTEtMA_f310c4d4-0f42-4992-8278-a8b94dc2d843"
      unitRef="usd">463105000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="ia34dfea6b8734d64abf707c28256801c_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yNS9mcmFnOjYzZmYxMmI2NTFjMTRhMTRhNWZkYmE3ODczNzg3M2U5L3RhYmxlOmFiYWYwYmNlMzAxMjRmNTk4ZTE0MzdlNTRjMDY4NzZiL3RhYmxlcmFuZ2U6YWJhZjBiY2UzMDEyNGY1OThlMTQzN2U1NGMwNjg3NmJfMjEtMy0xLTEtMA_5a75f9fe-fcb3-4eec-825d-25360c7ab4e7"
      unitRef="usd">153155000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yNS9mcmFnOjYzZmYxMmI2NTFjMTRhMTRhNWZkYmE3ODczNzg3M2U5L3RhYmxlOmFiYWYwYmNlMzAxMjRmNTk4ZTE0MzdlNTRjMDY4NzZiL3RhYmxlcmFuZ2U6YWJhZjBiY2UzMDEyNGY1OThlMTQzN2U1NGMwNjg3NmJfMjItMS0xLTEtMA_b4384297-5983-46d6-b5d1-4a7f38cf9a42"
      unitRef="usd">2800000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ia34dfea6b8734d64abf707c28256801c_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yNS9mcmFnOjYzZmYxMmI2NTFjMTRhMTRhNWZkYmE3ODczNzg3M2U5L3RhYmxlOmFiYWYwYmNlMzAxMjRmNTk4ZTE0MzdlNTRjMDY4NzZiL3RhYmxlcmFuZ2U6YWJhZjBiY2UzMDEyNGY1OThlMTQzN2U1NGMwNjg3NmJfMjItMy0xLTEtMA_63d441b3-07d9-4eff-a8bc-3f3f734050f3"
      unitRef="usd">879000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yNS9mcmFnOjYzZmYxMmI2NTFjMTRhMTRhNWZkYmE3ODczNzg3M2U5L3RhYmxlOmFiYWYwYmNlMzAxMjRmNTk4ZTE0MzdlNTRjMDY4NzZiL3RhYmxlcmFuZ2U6YWJhZjBiY2UzMDEyNGY1OThlMTQzN2U1NGMwNjg3NmJfMjMtMS0xLTEtMA_262aece3-4f2f-46c9-afe0-192a72e51f25"
      unitRef="usd">440500000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="ia34dfea6b8734d64abf707c28256801c_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yNS9mcmFnOjYzZmYxMmI2NTFjMTRhMTRhNWZkYmE3ODczNzg3M2U5L3RhYmxlOmFiYWYwYmNlMzAxMjRmNTk4ZTE0MzdlNTRjMDY4NzZiL3RhYmxlcmFuZ2U6YWJhZjBiY2UzMDEyNGY1OThlMTQzN2U1NGMwNjg3NmJfMjMtMy0xLTEtMA_e0d3853c-69dc-47b4-be95-080a853c4b43"
      unitRef="usd">140701000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yNS9mcmFnOjYzZmYxMmI2NTFjMTRhMTRhNWZkYmE3ODczNzg3M2U5L3RhYmxlOmFiYWYwYmNlMzAxMjRmNTk4ZTE0MzdlNTRjMDY4NzZiL3RhYmxlcmFuZ2U6YWJhZjBiY2UzMDEyNGY1OThlMTQzN2U1NGMwNjg3NmJfMjQtMS0xLTEtMA_d3256b20-18ed-47d9-88ed-43e6e09e17a9"
      unitRef="usd">-25405000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ia34dfea6b8734d64abf707c28256801c_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yNS9mcmFnOjYzZmYxMmI2NTFjMTRhMTRhNWZkYmE3ODczNzg3M2U5L3RhYmxlOmFiYWYwYmNlMzAxMjRmNTk4ZTE0MzdlNTRjMDY4NzZiL3RhYmxlcmFuZ2U6YWJhZjBiY2UzMDEyNGY1OThlMTQzN2U1NGMwNjg3NmJfMjQtMy0xLTEtMA_7bcc352b-6d9e-4752-97da-81f1fa9992ed"
      unitRef="usd">-13333000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yNS9mcmFnOjYzZmYxMmI2NTFjMTRhMTRhNWZkYmE3ODczNzg3M2U5L3RhYmxlOmFiYWYwYmNlMzAxMjRmNTk4ZTE0MzdlNTRjMDY4NzZiL3RhYmxlcmFuZ2U6YWJhZjBiY2UzMDEyNGY1OThlMTQzN2U1NGMwNjg3NmJfMjctMS0xLTEtMA_e19876e2-fd80-46c7-b1b1-84c97aa47beb"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="ia34dfea6b8734d64abf707c28256801c_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yNS9mcmFnOjYzZmYxMmI2NTFjMTRhMTRhNWZkYmE3ODczNzg3M2U5L3RhYmxlOmFiYWYwYmNlMzAxMjRmNTk4ZTE0MzdlNTRjMDY4NzZiL3RhYmxlcmFuZ2U6YWJhZjBiY2UzMDEyNGY1OThlMTQzN2U1NGMwNjg3NmJfMjctMy0xLTEtMA_24b36591-d040-4523-a3a7-aea60d7f7465"
      unitRef="usd">193948000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yNS9mcmFnOjYzZmYxMmI2NTFjMTRhMTRhNWZkYmE3ODczNzg3M2U5L3RhYmxlOmFiYWYwYmNlMzAxMjRmNTk4ZTE0MzdlNTRjMDY4NzZiL3RhYmxlcmFuZ2U6YWJhZjBiY2UzMDEyNGY1OThlMTQzN2U1NGMwNjg3NmJfMjktMS0xLTEtMA_3a7c6b6e-3989-4056-9e5c-0ba651f46d2a"
      unitRef="usd">3822000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="ia34dfea6b8734d64abf707c28256801c_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yNS9mcmFnOjYzZmYxMmI2NTFjMTRhMTRhNWZkYmE3ODczNzg3M2U5L3RhYmxlOmFiYWYwYmNlMzAxMjRmNTk4ZTE0MzdlNTRjMDY4NzZiL3RhYmxlcmFuZ2U6YWJhZjBiY2UzMDEyNGY1OThlMTQzN2U1NGMwNjg3NmJfMjktMy0xLTEtMA_b2e4eae4-28ae-41ce-abbc-9fcf63f6c33e"
      unitRef="usd">1965000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yNS9mcmFnOjYzZmYxMmI2NTFjMTRhMTRhNWZkYmE3ODczNzg3M2U5L3RhYmxlOmFiYWYwYmNlMzAxMjRmNTk4ZTE0MzdlNTRjMDY4NzZiL3RhYmxlcmFuZ2U6YWJhZjBiY2UzMDEyNGY1OThlMTQzN2U1NGMwNjg3NmJfMzAtMS0xLTEtMA_96558033-18e5-436a-9c0d-1e6433a025c3"
      unitRef="usd">3822000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ia34dfea6b8734d64abf707c28256801c_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yNS9mcmFnOjYzZmYxMmI2NTFjMTRhMTRhNWZkYmE3ODczNzg3M2U5L3RhYmxlOmFiYWYwYmNlMzAxMjRmNTk4ZTE0MzdlNTRjMDY4NzZiL3RhYmxlcmFuZ2U6YWJhZjBiY2UzMDEyNGY1OThlMTQzN2U1NGMwNjg3NmJfMzAtMy0xLTEtMA_e89bdc6d-f33f-4302-b631-fcbc1da35c66"
      unitRef="usd">195913000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yNS9mcmFnOjYzZmYxMmI2NTFjMTRhMTRhNWZkYmE3ODczNzg3M2U5L3RhYmxlOmFiYWYwYmNlMzAxMjRmNTk4ZTE0MzdlNTRjMDY4NzZiL3RhYmxlcmFuZ2U6YWJhZjBiY2UzMDEyNGY1OThlMTQzN2U1NGMwNjg3NmJfMzEtMS0xLTEtMA_c872649c-5c78-43f9-a10e-293c5df6140d"
      unitRef="usd">-71823000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="ia34dfea6b8734d64abf707c28256801c_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yNS9mcmFnOjYzZmYxMmI2NTFjMTRhMTRhNWZkYmE3ODczNzg3M2U5L3RhYmxlOmFiYWYwYmNlMzAxMjRmNTk4ZTE0MzdlNTRjMDY4NzZiL3RhYmxlcmFuZ2U6YWJhZjBiY2UzMDEyNGY1OThlMTQzN2U1NGMwNjg3NmJfMzEtMy0xLTEtMA_0ea1dcd8-795d-4a05-a868-b65c13908e56"
      unitRef="usd">128088000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="idb7ca9f362da46eab3a29bbbecbda977_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yNS9mcmFnOjYzZmYxMmI2NTFjMTRhMTRhNWZkYmE3ODczNzg3M2U5L3RhYmxlOmFiYWYwYmNlMzAxMjRmNTk4ZTE0MzdlNTRjMDY4NzZiL3RhYmxlcmFuZ2U6YWJhZjBiY2UzMDEyNGY1OThlMTQzN2U1NGMwNjg3NmJfMzItMS0xLTEtMA_df0eb480-d1de-42d9-ac1f-5504f325b467"
      unitRef="usd">508644000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="id36b0e599cb3498a8671e8c185763bc9_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yNS9mcmFnOjYzZmYxMmI2NTFjMTRhMTRhNWZkYmE3ODczNzg3M2U5L3RhYmxlOmFiYWYwYmNlMzAxMjRmNTk4ZTE0MzdlNTRjMDY4NzZiL3RhYmxlcmFuZ2U6YWJhZjBiY2UzMDEyNGY1OThlMTQzN2U1NGMwNjg3NmJfMzItMy0xLTEtMA_aa5eb411-b790-40ca-ab86-7e76aa487d72"
      unitRef="usd">80949000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i9953f50a7fd74f7d8438f304f136a07b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yNS9mcmFnOjYzZmYxMmI2NTFjMTRhMTRhNWZkYmE3ODczNzg3M2U5L3RhYmxlOmFiYWYwYmNlMzAxMjRmNTk4ZTE0MzdlNTRjMDY4NzZiL3RhYmxlcmFuZ2U6YWJhZjBiY2UzMDEyNGY1OThlMTQzN2U1NGMwNjg3NmJfMzMtMS0xLTEtMA_a7489d21-6f99-43c5-8793-cf7cef681011"
      unitRef="usd">436821000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i29b65d7585ff41c5843594c6319bdb90_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8yNS9mcmFnOjYzZmYxMmI2NTFjMTRhMTRhNWZkYmE3ODczNzg3M2U5L3RhYmxlOmFiYWYwYmNlMzAxMjRmNTk4ZTE0MzdlNTRjMDY4NzZiL3RhYmxlcmFuZ2U6YWJhZjBiY2UzMDEyNGY1OThlMTQzN2U1NGMwNjg3NmJfMzMtMy0xLTEtMA_d1e708a6-bc5e-4292-98c0-bd157d061502"
      unitRef="usd">209037000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zMS9mcmFnOjcwYWY3MzdmZGVkYjQzOWFhZjJiY2E2NmEyMGIyYjViL3RleHRyZWdpb246NzBhZjczN2ZkZWRiNDM5YWFmMmJjYTY2YTIwYjJiNWJfMjExNzI_4a372001-274d-4e69-86fb-761ca02d9ebe">Significant Accounting Policies&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Organization and Description of Business&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Denali Therapeutics Inc. ("Denali" or the &#x201c;Company&#x201d;) is a biopharmaceutical company, incorporated in Delaware, that discovers and develops therapeutics to defeat neurodegenerative diseases. The Company is headquartered in South San Francisco, California.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) for interim financial information and the instructions to Form 10-Q and Article 10 of SEC Regulation S-X for interim financial information. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These unaudited condensed consolidated financial statements and notes should be read in conjunction with the audited consolidated financial statements and notes thereto contained in the Annual Report on Form 10-K for the year ended December 31, 2020, as filed with the Securities and Exchange Commission on February&#160;26, 2021 (the "2020 Annual Report on Form 10-K"). The Condensed Consolidated Balance Sheet as of December 31, 2020 was derived from the audited annual consolidated financial statements as of and for the period then ended. Certain information and footnote disclosures typically included in the Company's annual consolidated financial statements have been condensed or omitted. The accompanying unaudited condensed consolidated financial statements reflect all adjustments that, in the opinion of management, are necessary for a fair statement of the results of the interim periods presented. All such adjustments are of a normal recurring nature except for the impacts of adopting new accounting standards, if any, discussed below. These interim financial results are not necessarily indicative of results expected for the full fiscal year or for any subsequent interim period.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended&#160;March 31, 2021, except as discussed below in the section titled "Recently Adopted Accounting Pronouncement," there were no material changes to the Company's significant accounting and financial reporting policies from those reflected in the 2020 Annual Report on Form 10-K. For further information with regard to the Company&#x2019;s Significant Accounting Policies, please refer to Note 1, "Significant Accounting Policies," to the Company&#x2019;s Consolidated Financial Statements included in the 2020 Annual Report on Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. All intercompany balances and transactions have been eliminated in consolidation.&#160;For the Company and its subsidiary, the functional currency has been determined to be U.S. dollars. Monetary assets and liabilities denominated in foreign currency are remeasured at period-end exchange rates. Non-monetary assets and liabilities denominated in foreign currencies are remeasured at historical rates. Foreign currency transaction gains and losses resulting from remeasurement are recognized in interest and other income, net in the Condensed Consolidated Statements of Operations and Comprehensive Loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with U.S. GAAP requires the Company to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, as well as the reported amounts of expenses during the reporting period. Actual results could differ from those estimates, and such differences could be material to the Condensed Consolidated Balance Sheets and Statements of Operations and Comprehensive Loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentration of Credit Risk and Other Risks and Uncertainties&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents, marketable securities and forward foreign currency exchange contracts. Substantially all of the Company&#x2019;s cash and cash equivalents are deposited in accounts with financial institutions that management believes are of high credit quality. Such deposits have and will continue to exceed federally insured limits. The Company maintains its cash with accredited financial institutions and accordingly, such funds are subject to minimal credit risk. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s investment policy limits investments to certain types of securities issued by the U.S. government, its agencies and institutions with investment-grade credit ratings and places restrictions on maturities and concentration by type and issuer. The Company is exposed to credit risk in the event of a default by the financial institutions holding its cash, cash equivalents and marketable securities and issuers of marketable securities to the extent recorded on the Condensed Consolidated Balance Sheets. As of March 31, 2021 and December 31, 2020, the Company had no off balance sheet concentrations of credit risk. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is exposed to counterparty credit risk on all of its derivative financial instruments. The Company has established and maintains strict counterparty credit guidelines and enters into hedges only with financial institutions that are investment grade or better to minimize the Company&#x2019;s exposure to potential defaults. The Company does not require collateral to be pledged under these agreements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to a number of risks similar to other early-stage biopharmaceutical companies, including, but not limited to, the need to obtain adequate additional funding, possible failure of current or future preclinical testing or clinical trials, its reliance on third parties to conduct its clinical trials, the need to obtain regulatory and marketing approvals for its product candidates, competitors developing new technological innovations, the need to successfully commercialize and gain market acceptance of the Company&#x2019;s product candidates, its right to develop and commercialize its product candidates pursuant to the terms and conditions of the licenses granted to the Company, protection of proprietary technology, the ability to make milestone, royalty or other payments due under any license or collaboration agreements, and the need to secure and maintain adequate manufacturing arrangements with third parties. If the Company does not successfully commercialize or partner any of its product candidates, it will be unable to generate product revenue or achieve profitability.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The COVID-19 pandemic has caused increased risk and uncertainty for the Company. Credit risk associated with investments in securities may increase if any institution with which the Company has an investment is significantly impacted by the COVID-19 pandemic. As of March 31, 2021, the Company has not realized any losses on its cash deposits or investments. COVID-19 may impact the timelines and progress of the Company's preclinical activities and clinical trials, and may impact its ability to raise capital in the near term. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Segments&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has one operating segment. The Company&#x2019;s chief operating decision maker, its Chief Executive Officer, manages the Company&#x2019;s operations on a consolidated basis for the purposes of allocating resources.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash, Cash Equivalents and Restricted Cash&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers all highly liquid investments with original maturities of 90 days or less at the date of purchase to be cash and cash equivalents. Cash equivalents are reported at fair value.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash, cash equivalents, and restricted cash reported within the Condensed Consolidated Statements of Cash Flows is composed of Cash and Cash equivalents reported in the Condensed Consolidated Balance Sheets and $1.5 million of restricted cash for the letter of credit for the Company&#x2019;s headquarters building lease, which is included&#160;within other&#160;non-current&#160;assets&#160;in the Condensed Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Marketable Securities&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company generally invests its excess cash in money market funds and investment grade short to intermediate-term fixed income securities. Such investments are included in cash and cash equivalents, short-term marketable securities, or long-term marketable securities on the Condensed Consolidated Balance Sheets, are considered available-for-sale, and reported at fair value with net unrealized gains and losses included as a component of stockholders&#x2019; equity. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company classifies investments in securities with remaining maturities of less than one year, or where its intent is to use the investments to fund current operations or to make them available for current operations, as short-term investments. The Company classifies investments in securities with remaining maturities of over one year as long-term investments. The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity, which is included in interest and other income, net in the Condensed Consolidated Statements of Operations and Comprehensive Loss. Realized gains and losses and declines in value determined to be due to credit losses on marketable securities, if any, are included in interest and other income, net.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company periodically evaluates the need for an allowance for credit losses. This evaluation includes consideration of several qualitative and quantitative factors, including whether it has plans to sell the security, whether it is more likely than not it will be required to sell any marketable securities before recovery of its amortized cost basis, and if the entity has the ability and intent to hold the security to maturity, and the portion of any unrealized loss that is the result of a credit loss. Factors considered in making these evaluations include quoted market prices, recent financial results and operating trends, implied values from any recent transactions or offers of investee securities, credit quality of debt instrument issuers, expected cash flows from securities, other publicly available information that may affect the value of the marketable security, duration and severity of the decline in value, and the Company's strategy and intentions for holding the marketable security.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounts Receivable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts receivable are included within prepaid expenses and other current assets on the Condensed Consolidated Balance Sheets. The accounts receivable balance represents amounts receivable from the Company's collaboration partners, net of an allowance for credit losses, if required. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Derivatives and Hedging Activities&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company measures its derivative instruments at fair value, and accounts for them as either assets or liabilities included within Prepaid expenses and other current assets and Other accruals and other current liabilities, respectively, on the Condensed Consolidated Balance Sheets. Derivatives are adjusted to fair value through interest and other income, net in the Condensed Consolidated Statements of Operations and Comprehensive Loss. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company leases real estate, and certain equipment for use in its operations. A determination is made as to whether an arrangement is a lease at inception. A right-of-use (&#x201c;ROU&#x201d;) asset an&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;d operating lease liability is recognized for identified operating leases in the Condensed Consolidated Balance Sheets. The changes in operating lease ROU assets and operating lease liabilities are presented net within non-cash adjustment to operating lease expense in the Condensed Consolidated Statements of Cash Flows. Certain amounts for the three months ended March 31, 2020 were reclassified to conform to the current period presentation.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ROU assets represent the Company&#x2019;s right to use the underlying asset for the lease term and lease liabilities represent the Company&#x2019;s obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the lease commencement date based on the present value of lease payments due over the lease term, with the ROU assets adjusted for lease incentives received. When determining the present value of lease payments, the Company uses its incremental borrowing rate on the date of lease commencement, or the rate implicit in the lease, if known. The Company does not assume renewals in its determination of the lease term unless the renewals are deemed by management to be reasonably certain at lease inception.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Leases with an initial term of 12 months or less are not recorded on the balance sheet, unless they include an option to purchase the underlying asset that the Company is reasonably certain to exercise. The Company recognizes lease expenses on a straight-line basis over the lease term. The Company has leases with lease and non-lease components, which the Company has elected to account for as a single lease component. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;License and Collaboration Revenue&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company analyzes its collaboration arrangements to assess whether they are within the scope of ASC&#160;808,&#160;Collaborative Arrangements&#160;(&#x201c;ASC&#160;808&#x201d;) to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities.&#160;This assessment is performed throughout the life of the arrangement based on changes in the responsibilities of all parties in the arrangement.&#160;For collaboration arrangements within the scope of ASC&#160;808&#160;that contain multiple elements, the Company first determines which elements of the collaboration are deemed to be within the scope of ASC&#160;808&#160;and those that are more reflective of a vendor-customer relationship and, therefore, within the scope of Topic 606. For elements of collaboration arrangements that are accounted for pursuant to ASC&#160;808, an appropriate recognition method is determined and applied consistently, generally by analogy to Topic 606.&#160;The accounting treatment pursuant to Topic 606 is outlined below. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The terms of licensing and collaboration agreements entered into typically include payment of one or more of the following: non-refundable, up-front license fees; development, regulatory and commercial milestone payments; payments for manufacturing supply and research and development services and royalties on net sales of licensed products. Each of these payments results in license, collaboration and other revenue, except for revenues from royalties on net sales of licensed products, which are classified as royalty revenue. The core principle of Topic 606 is to recognize revenue when promised goods or services are transferred to customers in an amount that reflects the consideration that is expected to be received in exchange for those goods or services. The Company may also receive reimbursement or make payments to a collaboration partner to satisfy cost sharing requirements. These payments are accounted for pursuant to ASC 808 and are recorded as an offset or increase to research and development expenses, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under each of its agreements, the Company performs the following steps: (i)&#160;identification of the promised goods or services in the contract; (ii)&#160;determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii)&#160;measurement of the transaction price, including the constraint on variable consideration; (iv)&#160;allocation of the transaction price to the performance obligations based on estimated selling prices; and (v)&#160;recognition of revenue when (or as) the Company satisfies each performance obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts received prior to satisfying the revenue recognition criteria are recorded as contract liabilities in the Company&#x2019;s Condensed Consolidated Balance Sheets. If the related performance obligation is expected to be satisfied within the next twelve months this will be classified in current liabilities. Amounts recognized as revenue prior to the Company having an unconditional right (other than a right that is conditioned only on the passage of time) to receipt are recorded as contract assets in the Company's Condensed Consolidated Balance Sheets. If the Company expects to have an unconditional right to receive the consideration in the next twelve months, this will be classified in current assets. A net contract asset or liability is presented for each contract with a customer. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At contract inception, the Company assesses the goods or services promised in a contract with a customer and identifies those distinct goods and services that represent a performance obligation. A promised good or service may not be identified as a performance obligation if it is immaterial in the context of the contract with the customer, if it is not separately identifiable from other promises in the contract (either because it is not capable of being separated or because it is not separable in the context of the contract), or if the promised good or service does not provide the customer with a material right. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers the terms of the contract to determine the transaction price. The transaction price is the amount of consideration to which the Company expects to be entitled in exchange for transferring promised goods or services to a customer. The consideration promised in a contract with a customer may include fixed amounts, variable amounts, or both. Variable consideration will only be included in the transaction price when it is not considered constrained, which is when it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If it is determined that multiple performance obligations exist, the transaction price is allocated at the inception of the agreement to all identified performance obligations based on the relative standalone selling prices ("SSP").&#160;The relative SSP for each deliverable is estimated using external sourced evidence if it is available. If external sourced evidence is not available, the Company uses its best estimate of the SSP for the deliverable. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue is recognized when, or as, the Company satisfies a performance obligation by transferring a promised good or service to a customer. An asset is transferred when, or as, the customer obtains control of that asset, which for a service is considered to be as the services are received and used. The Company recognizes revenue over time by measuring the progress toward complete satisfaction of the relevant performance obligation using an appropriate input or output method based on the nature of the service promised to the customer. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;After contract inception, the transaction price is reassessed at every period end and updated for changes such as resolution of uncertain events. Any change in the transaction price is allocated to the performance obligations on the same basis as at contract inception, or to a single performance obligation as applicable. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Management may be required to exercise considerable judgment in estimating revenue to be recognized. Judgment is required in identifying performance obligations, estimating the transaction price, estimating the SSP of identified performance obligations, which may include forecasted revenue, development timelines, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success, and estimating the progress towards satisfaction of performance obligations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Comprehensive Loss&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Comprehensive loss is composed of net loss and certain changes in stockholders&#x2019; equity that are excluded from net loss, primarily unrealized gains or losses on the Company&#x2019;s marketable securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Loss per Share&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding during the period, without consideration for common stock equivalents. Diluted net loss per share is the same as basic net loss per share, since the effects of potentially dilutive securities are antidilutive given the net loss for each period presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Pronouncement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, the Financial Accounting Standards Board ("FASB") issued ASU No. 2019-12&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;, Income Taxes (Topic 740) Simplifying the Accounting for Income Taxes. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASU No. 2019-12 modifies ASC 740 to simplify several aspects of accounting for income taxes, including eliminating certain exceptions to the guidance in ASC 740 related to the approach for intraperiod tax allocation. The guidance is effective for fiscal years beginning after December 15, 2020 and interim periods within those fiscal years, with early adoption permitted, and is required to be adopted prospectively, with the exception of certain specific amendments, which were not applicable to the Company. The Company adopted this standard as of January 1, 2021 using a prospective approach. Adoption of the standard did not have a material impact on its Condensed Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <dnli:OrganizationAndDescriptionOfBusinessPolicyPolicyTextBlock
      contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zMS9mcmFnOjcwYWY3MzdmZGVkYjQzOWFhZjJiY2E2NmEyMGIyYjViL3RleHRyZWdpb246NzBhZjczN2ZkZWRiNDM5YWFmMmJjYTY2YTIwYjJiNWJfMjExODQ_718b0516-3973-49bc-be8c-e4e3b81d23ec">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Organization and Description of Business&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Denali Therapeutics Inc. ("Denali" or the &#x201c;Company&#x201d;) is a biopharmaceutical company, incorporated in Delaware, that discovers and develops therapeutics to defeat neurodegenerative diseases. The Company is headquartered in South San Francisco, California.&lt;/span&gt;&lt;/div&gt;</dnli:OrganizationAndDescriptionOfBusinessPolicyPolicyTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zMS9mcmFnOjcwYWY3MzdmZGVkYjQzOWFhZjJiY2E2NmEyMGIyYjViL3RleHRyZWdpb246NzBhZjczN2ZkZWRiNDM5YWFmMmJjYTY2YTIwYjJiNWJfMjExNzQ_1741a799-1835-4519-bd82-d7fa0eadd4be">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) for interim financial information and the instructions to Form 10-Q and Article 10 of SEC Regulation S-X for interim financial information. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These unaudited condensed consolidated financial statements and notes should be read in conjunction with the audited consolidated financial statements and notes thereto contained in the Annual Report on Form 10-K for the year ended December 31, 2020, as filed with the Securities and Exchange Commission on February&#160;26, 2021 (the "2020 Annual Report on Form 10-K"). The Condensed Consolidated Balance Sheet as of December 31, 2020 was derived from the audited annual consolidated financial statements as of and for the period then ended. Certain information and footnote disclosures typically included in the Company's annual consolidated financial statements have been condensed or omitted. The accompanying unaudited condensed consolidated financial statements reflect all adjustments that, in the opinion of management, are necessary for a fair statement of the results of the interim periods presented. All such adjustments are of a normal recurring nature except for the impacts of adopting new accounting standards, if any, discussed below. These interim financial results are not necessarily indicative of results expected for the full fiscal year or for any subsequent interim period.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zMS9mcmFnOjcwYWY3MzdmZGVkYjQzOWFhZjJiY2E2NmEyMGIyYjViL3RleHRyZWdpb246NzBhZjczN2ZkZWRiNDM5YWFmMmJjYTY2YTIwYjJiNWJfMjExNzk_88a5a3e2-749f-49e5-9b07-49f81e3bf379">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. All intercompany balances and transactions have been eliminated in consolidation.&#160;For the Company and its subsidiary, the functional currency has been determined to be U.S. dollars. Monetary assets and liabilities denominated in foreign currency are remeasured at period-end exchange rates. Non-monetary assets and liabilities denominated in foreign currencies are remeasured at historical rates. Foreign currency transaction gains and losses resulting from remeasurement are recognized in interest and other income, net in the Condensed Consolidated Statements of Operations and Comprehensive Loss.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zMS9mcmFnOjcwYWY3MzdmZGVkYjQzOWFhZjJiY2E2NmEyMGIyYjViL3RleHRyZWdpb246NzBhZjczN2ZkZWRiNDM5YWFmMmJjYTY2YTIwYjJiNWJfMjExODk_59fc7666-d667-41ef-a976-8d3b7a53dff4">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with U.S. GAAP requires the Company to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, as well as the reported amounts of expenses during the reporting period. Actual results could differ from those estimates, and such differences could be material to the Condensed Consolidated Balance Sheets and Statements of Operations and Comprehensive Loss.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zMS9mcmFnOjcwYWY3MzdmZGVkYjQzOWFhZjJiY2E2NmEyMGIyYjViL3RleHRyZWdpb246NzBhZjczN2ZkZWRiNDM5YWFmMmJjYTY2YTIwYjJiNWJfMjExNzU_7c446b49-6414-4000-b973-850bd8279ce2">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentration of Credit Risk and Other Risks and Uncertainties&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents, marketable securities and forward foreign currency exchange contracts. Substantially all of the Company&#x2019;s cash and cash equivalents are deposited in accounts with financial institutions that management believes are of high credit quality. Such deposits have and will continue to exceed federally insured limits. The Company maintains its cash with accredited financial institutions and accordingly, such funds are subject to minimal credit risk. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s investment policy limits investments to certain types of securities issued by the U.S. government, its agencies and institutions with investment-grade credit ratings and places restrictions on maturities and concentration by type and issuer. The Company is exposed to credit risk in the event of a default by the financial institutions holding its cash, cash equivalents and marketable securities and issuers of marketable securities to the extent recorded on the Condensed Consolidated Balance Sheets. As of March 31, 2021 and December 31, 2020, the Company had no off balance sheet concentrations of credit risk. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is exposed to counterparty credit risk on all of its derivative financial instruments. The Company has established and maintains strict counterparty credit guidelines and enters into hedges only with financial institutions that are investment grade or better to minimize the Company&#x2019;s exposure to potential defaults. The Company does not require collateral to be pledged under these agreements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to a number of risks similar to other early-stage biopharmaceutical companies, including, but not limited to, the need to obtain adequate additional funding, possible failure of current or future preclinical testing or clinical trials, its reliance on third parties to conduct its clinical trials, the need to obtain regulatory and marketing approvals for its product candidates, competitors developing new technological innovations, the need to successfully commercialize and gain market acceptance of the Company&#x2019;s product candidates, its right to develop and commercialize its product candidates pursuant to the terms and conditions of the licenses granted to the Company, protection of proprietary technology, the ability to make milestone, royalty or other payments due under any license or collaboration agreements, and the need to secure and maintain adequate manufacturing arrangements with third parties. If the Company does not successfully commercialize or partner any of its product candidates, it will be unable to generate product revenue or achieve profitability.&lt;/span&gt;&lt;/div&gt;The COVID-19 pandemic has caused increased risk and uncertainty for the Company. Credit risk associated with investments in securities may increase if any institution with which the Company has an investment is significantly impacted by the COVID-19 pandemic.</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zMS9mcmFnOjcwYWY3MzdmZGVkYjQzOWFhZjJiY2E2NmEyMGIyYjViL3RleHRyZWdpb246NzBhZjczN2ZkZWRiNDM5YWFmMmJjYTY2YTIwYjJiNWJfMjExNzY_b2e1a7d4-7bcb-4ecf-a47c-c342a16addfe">&lt;div style="margin-bottom:8pt;margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Segments&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has one operating segment. The Company&#x2019;s chief operating decision maker, its Chief Executive Officer, manages the Company&#x2019;s operations on a consolidated basis for the purposes of allocating resources.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zMS9mcmFnOjcwYWY3MzdmZGVkYjQzOWFhZjJiY2E2NmEyMGIyYjViL3RleHRyZWdpb246NzBhZjczN2ZkZWRiNDM5YWFmMmJjYTY2YTIwYjJiNWJfNzA1Nw_260e2b5a-e37b-4c53-ae40-d9063c93dcfb"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy
      contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zMS9mcmFnOjcwYWY3MzdmZGVkYjQzOWFhZjJiY2E2NmEyMGIyYjViL3RleHRyZWdpb246NzBhZjczN2ZkZWRiNDM5YWFmMmJjYTY2YTIwYjJiNWJfMjExNzc_210a644a-c2cd-4abf-b4b1-4118c47e0d3a">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash, Cash Equivalents and Restricted Cash&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers all highly liquid investments with original maturities of 90 days or less at the date of purchase to be cash and cash equivalents. Cash equivalents are reported at fair value.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash, cash equivalents, and restricted cash reported within the Condensed Consolidated Statements of Cash Flows is composed of Cash and Cash equivalents reported in the Condensed Consolidated Balance Sheets and $1.5 million of restricted cash for the letter of credit for the Company&#x2019;s headquarters building lease, which is included&#160;within other&#160;non-current&#160;assets&#160;in the Condensed Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="i29b65d7585ff41c5843594c6319bdb90_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zMS9mcmFnOjcwYWY3MzdmZGVkYjQzOWFhZjJiY2E2NmEyMGIyYjViL3RleHRyZWdpb246NzBhZjczN2ZkZWRiNDM5YWFmMmJjYTY2YTIwYjJiNWJfMTA5OTUxMTY0OTMzNA_76cae682-cf72-4a01-adb8-712b24110fb3"
      unitRef="usd">1500000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:MarketableSecuritiesPolicy
      contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zMS9mcmFnOjcwYWY3MzdmZGVkYjQzOWFhZjJiY2E2NmEyMGIyYjViL3RleHRyZWdpb246NzBhZjczN2ZkZWRiNDM5YWFmMmJjYTY2YTIwYjJiNWJfMjExOTM_cb415140-0d8b-494e-9aa5-75c05d5494e0">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Marketable Securities&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company generally invests its excess cash in money market funds and investment grade short to intermediate-term fixed income securities. Such investments are included in cash and cash equivalents, short-term marketable securities, or long-term marketable securities on the Condensed Consolidated Balance Sheets, are considered available-for-sale, and reported at fair value with net unrealized gains and losses included as a component of stockholders&#x2019; equity. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company classifies investments in securities with remaining maturities of less than one year, or where its intent is to use the investments to fund current operations or to make them available for current operations, as short-term investments. The Company classifies investments in securities with remaining maturities of over one year as long-term investments. The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity, which is included in interest and other income, net in the Condensed Consolidated Statements of Operations and Comprehensive Loss. Realized gains and losses and declines in value determined to be due to credit losses on marketable securities, if any, are included in interest and other income, net.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company periodically evaluates the need for an allowance for credit losses. This evaluation includes consideration of several qualitative and quantitative factors, including whether it has plans to sell the security, whether it is more likely than not it will be required to sell any marketable securities before recovery of its amortized cost basis, and if the entity has the ability and intent to hold the security to maturity, and the portion of any unrealized loss that is the result of a credit loss. Factors considered in making these evaluations include quoted market prices, recent financial results and operating trends, implied values from any recent transactions or offers of investee securities, credit quality of debt instrument issuers, expected cash flows from securities, other publicly available information that may affect the value of the marketable security, duration and severity of the decline in value, and the Company's strategy and intentions for holding the marketable security.&lt;/span&gt;&lt;/div&gt;</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:ReceivablesPolicyTextBlock
      contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zMS9mcmFnOjcwYWY3MzdmZGVkYjQzOWFhZjJiY2E2NmEyMGIyYjViL3RleHRyZWdpb246NzBhZjczN2ZkZWRiNDM5YWFmMmJjYTY2YTIwYjJiNWJfMjExODE_1319f765-a6e5-408f-965e-51affba14cf1">Accounts ReceivableAccounts receivable are included within prepaid expenses and other current assets on the Condensed Consolidated Balance Sheets. The accounts receivable balance represents amounts receivable from the Company's collaboration partners, net of an allowance for credit losses, if required.</us-gaap:ReceivablesPolicyTextBlock>
    <us-gaap:DerivativesPolicyTextBlock
      contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zMS9mcmFnOjcwYWY3MzdmZGVkYjQzOWFhZjJiY2E2NmEyMGIyYjViL3RleHRyZWdpb246NzBhZjczN2ZkZWRiNDM5YWFmMmJjYTY2YTIwYjJiNWJfMjExODI_5ea009d2-e7fe-4878-8d9b-9d64cdf8a461">Derivatives and Hedging ActivitiesThe Company measures its derivative instruments at fair value, and accounts for them as either assets or liabilities included within Prepaid expenses and other current assets and Other accruals and other current liabilities, respectively, on the Condensed Consolidated Balance Sheets. Derivatives are adjusted to fair value through interest and other income, net in the Condensed Consolidated Statements of Operations and Comprehensive Loss.</us-gaap:DerivativesPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zMS9mcmFnOjcwYWY3MzdmZGVkYjQzOWFhZjJiY2E2NmEyMGIyYjViL3RleHRyZWdpb246NzBhZjczN2ZkZWRiNDM5YWFmMmJjYTY2YTIwYjJiNWJfMjExOTQ_590956bd-ac26-442e-8ed1-e53bd8fd497a">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company leases real estate, and certain equipment for use in its operations. A determination is made as to whether an arrangement is a lease at inception. A right-of-use (&#x201c;ROU&#x201d;) asset an&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;d operating lease liability is recognized for identified operating leases in the Condensed Consolidated Balance Sheets. The changes in operating lease ROU assets and operating lease liabilities are presented net within non-cash adjustment to operating lease expense in the Condensed Consolidated Statements of Cash Flows. Certain amounts for the three months ended March 31, 2020 were reclassified to conform to the current period presentation.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ROU assets represent the Company&#x2019;s right to use the underlying asset for the lease term and lease liabilities represent the Company&#x2019;s obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the lease commencement date based on the present value of lease payments due over the lease term, with the ROU assets adjusted for lease incentives received. When determining the present value of lease payments, the Company uses its incremental borrowing rate on the date of lease commencement, or the rate implicit in the lease, if known. The Company does not assume renewals in its determination of the lease term unless the renewals are deemed by management to be reasonably certain at lease inception.&lt;/span&gt;&lt;/div&gt;Leases with an initial term of 12 months or less are not recorded on the balance sheet, unless they include an option to purchase the underlying asset that the Company is reasonably certain to exercise. The Company recognizes lease expenses on a straight-line basis over the lease term. The Company has leases with lease and non-lease components, which the Company has elected to account for as a single lease component.</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:RevenueRecognitionPolicyTextBlock
      contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zMS9mcmFnOjcwYWY3MzdmZGVkYjQzOWFhZjJiY2E2NmEyMGIyYjViL3RleHRyZWdpb246NzBhZjczN2ZkZWRiNDM5YWFmMmJjYTY2YTIwYjJiNWJfMjExODU_2be1adce-789d-46b0-b8f9-6490cf5fbcd4">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;License and Collaboration Revenue&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company analyzes its collaboration arrangements to assess whether they are within the scope of ASC&#160;808,&#160;Collaborative Arrangements&#160;(&#x201c;ASC&#160;808&#x201d;) to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities.&#160;This assessment is performed throughout the life of the arrangement based on changes in the responsibilities of all parties in the arrangement.&#160;For collaboration arrangements within the scope of ASC&#160;808&#160;that contain multiple elements, the Company first determines which elements of the collaboration are deemed to be within the scope of ASC&#160;808&#160;and those that are more reflective of a vendor-customer relationship and, therefore, within the scope of Topic 606. For elements of collaboration arrangements that are accounted for pursuant to ASC&#160;808, an appropriate recognition method is determined and applied consistently, generally by analogy to Topic 606.&#160;The accounting treatment pursuant to Topic 606 is outlined below. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The terms of licensing and collaboration agreements entered into typically include payment of one or more of the following: non-refundable, up-front license fees; development, regulatory and commercial milestone payments; payments for manufacturing supply and research and development services and royalties on net sales of licensed products. Each of these payments results in license, collaboration and other revenue, except for revenues from royalties on net sales of licensed products, which are classified as royalty revenue. The core principle of Topic 606 is to recognize revenue when promised goods or services are transferred to customers in an amount that reflects the consideration that is expected to be received in exchange for those goods or services. The Company may also receive reimbursement or make payments to a collaboration partner to satisfy cost sharing requirements. These payments are accounted for pursuant to ASC 808 and are recorded as an offset or increase to research and development expenses, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under each of its agreements, the Company performs the following steps: (i)&#160;identification of the promised goods or services in the contract; (ii)&#160;determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii)&#160;measurement of the transaction price, including the constraint on variable consideration; (iv)&#160;allocation of the transaction price to the performance obligations based on estimated selling prices; and (v)&#160;recognition of revenue when (or as) the Company satisfies each performance obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts received prior to satisfying the revenue recognition criteria are recorded as contract liabilities in the Company&#x2019;s Condensed Consolidated Balance Sheets. If the related performance obligation is expected to be satisfied within the next twelve months this will be classified in current liabilities. Amounts recognized as revenue prior to the Company having an unconditional right (other than a right that is conditioned only on the passage of time) to receipt are recorded as contract assets in the Company's Condensed Consolidated Balance Sheets. If the Company expects to have an unconditional right to receive the consideration in the next twelve months, this will be classified in current assets. A net contract asset or liability is presented for each contract with a customer. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At contract inception, the Company assesses the goods or services promised in a contract with a customer and identifies those distinct goods and services that represent a performance obligation. A promised good or service may not be identified as a performance obligation if it is immaterial in the context of the contract with the customer, if it is not separately identifiable from other promises in the contract (either because it is not capable of being separated or because it is not separable in the context of the contract), or if the promised good or service does not provide the customer with a material right. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers the terms of the contract to determine the transaction price. The transaction price is the amount of consideration to which the Company expects to be entitled in exchange for transferring promised goods or services to a customer. The consideration promised in a contract with a customer may include fixed amounts, variable amounts, or both. Variable consideration will only be included in the transaction price when it is not considered constrained, which is when it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If it is determined that multiple performance obligations exist, the transaction price is allocated at the inception of the agreement to all identified performance obligations based on the relative standalone selling prices ("SSP").&#160;The relative SSP for each deliverable is estimated using external sourced evidence if it is available. If external sourced evidence is not available, the Company uses its best estimate of the SSP for the deliverable. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue is recognized when, or as, the Company satisfies a performance obligation by transferring a promised good or service to a customer. An asset is transferred when, or as, the customer obtains control of that asset, which for a service is considered to be as the services are received and used. The Company recognizes revenue over time by measuring the progress toward complete satisfaction of the relevant performance obligation using an appropriate input or output method based on the nature of the service promised to the customer. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;After contract inception, the transaction price is reassessed at every period end and updated for changes such as resolution of uncertain events. Any change in the transaction price is allocated to the performance obligations on the same basis as at contract inception, or to a single performance obligation as applicable. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Management may be required to exercise considerable judgment in estimating revenue to be recognized. Judgment is required in identifying performance obligations, estimating the transaction price, estimating the SSP of identified performance obligations, which may include forecasted revenue, development timelines, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success, and estimating the progress towards satisfaction of performance obligations.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zMS9mcmFnOjcwYWY3MzdmZGVkYjQzOWFhZjJiY2E2NmEyMGIyYjViL3RleHRyZWdpb246NzBhZjczN2ZkZWRiNDM5YWFmMmJjYTY2YTIwYjJiNWJfMjExODY_f8762b42-bee9-49c3-a680-0b97417a9687">&lt;div style="margin-bottom:10pt;margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Comprehensive Loss&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Comprehensive loss is composed of net loss and certain changes in stockholders&#x2019; equity that are excluded from net loss, primarily unrealized gains or losses on the Company&#x2019;s marketable securities.&lt;/span&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zMS9mcmFnOjcwYWY3MzdmZGVkYjQzOWFhZjJiY2E2NmEyMGIyYjViL3RleHRyZWdpb246NzBhZjczN2ZkZWRiNDM5YWFmMmJjYTY2YTIwYjJiNWJfMjExODc_8656fc48-af86-429b-9892-2ea382d2a511">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Loss per Share&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding during the period, without consideration for common stock equivalents. Diluted net loss per share is the same as basic net loss per share, since the effects of potentially dilutive securities are antidilutive given the net loss for each period presented.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zMS9mcmFnOjcwYWY3MzdmZGVkYjQzOWFhZjJiY2E2NmEyMGIyYjViL3RleHRyZWdpb246NzBhZjczN2ZkZWRiNDM5YWFmMmJjYTY2YTIwYjJiNWJfMjExNzg_b0cbd047-97ba-4eb1-877f-cedb84b826f8">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Pronouncement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, the Financial Accounting Standards Board ("FASB") issued ASU No. 2019-12&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;, Income Taxes (Topic 740) Simplifying the Accounting for Income Taxes. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASU No. 2019-12 modifies ASC 740 to simplify several aspects of accounting for income taxes, including eliminating certain exceptions to the guidance in ASC 740 related to the approach for intraperiod tax allocation. The guidance is effective for fiscal years beginning after December 15, 2020 and interim periods within those fiscal years, with early adoption permitted, and is required to be adopted prospectively, with the exception of certain specific amendments, which were not applicable to the Company. The Company adopted this standard as of January 1, 2021 using a prospective approach. Adoption of the standard did not have a material impact on its Condensed Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RleHRyZWdpb246NDdjNjg5ZGVlNzBkNGM0Mjk2MTA5OWRlNzNkYTQwZjBfNzA2_2de11114-12e5-4036-99b1-b6d44d6fef7b">Fair Value Measurements&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets and liabilities measured at fair value at each balance sheet date are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.214%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.720%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.720%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.720%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.723%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;426,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;426,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Short-term marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;U.S. government treasuries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;870,756&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;870,756&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;U.S. government agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20,136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20,136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15,729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15,729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;71,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;71,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Long-term marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;U.S. government treasuries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;34,835&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;34,835&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign currency derivative contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,301,576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;141,951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,443,527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign currency derivative contracts&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.053%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.720%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.720%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.720%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.884%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;335,284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;335,284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;U.S. government treasuries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;149,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;149,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Short-term marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;U.S. government treasuries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;878,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;878,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;U.S. government agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27,180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27,180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;31,218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;31,218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Long-term marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;U.S. government treasuries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30,138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30,138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign currency derivative contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,366,780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;113,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,480,718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign currency derivative contracts&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts of prepaid expenses and other current assets, accounts payable and accrued liabilities approximate their fair values due to their short-term maturities.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s Level&#160;2 securities are valued using third-party pricing sources. The pricing services utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The company has not transferred any assets or liabilities between the fair value measurement levels.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RleHRyZWdpb246NDdjNjg5ZGVlNzBkNGM0Mjk2MTA5OWRlNzNkYTQwZjBfNzA3_4b1d70a0-4c0e-403a-8078-dcb5a3a4fcaf">&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets and liabilities measured at fair value at each balance sheet date are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.214%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.720%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.720%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.720%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.723%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;426,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;426,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Short-term marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;U.S. government treasuries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;870,756&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;870,756&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;U.S. government agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20,136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20,136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15,729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15,729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;71,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;71,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Long-term marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;U.S. government treasuries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;34,835&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;34,835&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign currency derivative contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,301,576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;141,951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,443,527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign currency derivative contracts&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.053%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.720%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.720%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.720%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.884%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;335,284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;335,284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;U.S. government treasuries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;149,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;149,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Short-term marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;U.S. government treasuries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;878,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;878,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;U.S. government agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27,180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27,180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;31,218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;31,218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Long-term marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;U.S. government treasuries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30,138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30,138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign currency derivative contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,366,780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;113,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,480,718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign currency derivative contracts&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i6c67df6d9d254626b9391157cc6763f4_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjg5MmUxMTZkYjQxODQxYjg5YjBhYjEzMzNjN2M5OTc1L3RhYmxlcmFuZ2U6ODkyZTExNmRiNDE4NDFiODliMGFiMTMzM2M3Yzk5NzVfNC0xLTEtMS0w_cfcb0398-c0de-4710-8c96-8c79d135e524"
      unitRef="usd">426770000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="iaa61d3a997f64111a4b23a96b7fe5b8a_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjg5MmUxMTZkYjQxODQxYjg5YjBhYjEzMzNjN2M5OTc1L3RhYmxlcmFuZ2U6ODkyZTExNmRiNDE4NDFiODliMGFiMTMzM2M3Yzk5NzVfNC0zLTEtMS0w_338069ed-a53c-4121-ad63-c6618767e348"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ida70779bab1a408eab2c0f807c7c2184_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjg5MmUxMTZkYjQxODQxYjg5YjBhYjEzMzNjN2M5OTc1L3RhYmxlcmFuZ2U6ODkyZTExNmRiNDE4NDFiODliMGFiMTMzM2M3Yzk5NzVfNC01LTEtMS0w_ac110731-2553-48c9-8040-d40a54c93f77"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i5a012763ca204bf7ac713bfc5a5fe5bb_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjg5MmUxMTZkYjQxODQxYjg5YjBhYjEzMzNjN2M5OTc1L3RhYmxlcmFuZ2U6ODkyZTExNmRiNDE4NDFiODliMGFiMTMzM2M3Yzk5NzVfNC03LTEtMS0w_e7434ae7-e217-435b-a0a4-4a45fd45efd0"
      unitRef="usd">426770000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia57c5b507b6a47618a967591bf368bff_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjg5MmUxMTZkYjQxODQxYjg5YjBhYjEzMzNjN2M5OTc1L3RhYmxlcmFuZ2U6ODkyZTExNmRiNDE4NDFiODliMGFiMTMzM2M3Yzk5NzVfOC0xLTEtMS0w_5d1008b7-f46e-4026-b75d-95b6ef79da2e"
      unitRef="usd">870756000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if3f854bad0dd4fcab527216138601aaa_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjg5MmUxMTZkYjQxODQxYjg5YjBhYjEzMzNjN2M5OTc1L3RhYmxlcmFuZ2U6ODkyZTExNmRiNDE4NDFiODliMGFiMTMzM2M3Yzk5NzVfOC0zLTEtMS0w_e509ff8e-fda7-40b1-8782-34781d4b5dc9"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i66e037a80d03458791ec3572ec41d1cb_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjg5MmUxMTZkYjQxODQxYjg5YjBhYjEzMzNjN2M5OTc1L3RhYmxlcmFuZ2U6ODkyZTExNmRiNDE4NDFiODliMGFiMTMzM2M3Yzk5NzVfOC01LTEtMS0w_d3d7c722-da83-45f5-baf9-f0f7874de141"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie652e808c1f147618ebb4562358ce95a_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjg5MmUxMTZkYjQxODQxYjg5YjBhYjEzMzNjN2M5OTc1L3RhYmxlcmFuZ2U6ODkyZTExNmRiNDE4NDFiODliMGFiMTMzM2M3Yzk5NzVfOC03LTEtMS0w_5fca6d31-9035-4cd8-8b0a-898aa2b418a2"
      unitRef="usd">870756000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie5f979a4d5d94f0ead845cf6e9d26c7e_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjg5MmUxMTZkYjQxODQxYjg5YjBhYjEzMzNjN2M5OTc1L3RhYmxlcmFuZ2U6ODkyZTExNmRiNDE4NDFiODliMGFiMTMzM2M3Yzk5NzVfOS0xLTEtMS0w_0e1ae674-dbc7-465f-89a9-de73542afae3"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8efa8793ba8f446f8ffd529b619bbbfd_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjg5MmUxMTZkYjQxODQxYjg5YjBhYjEzMzNjN2M5OTc1L3RhYmxlcmFuZ2U6ODkyZTExNmRiNDE4NDFiODliMGFiMTMzM2M3Yzk5NzVfOS0zLTEtMS0w_3c575f5a-6c80-4410-b542-bc1646e2e308"
      unitRef="usd">20136000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i78246248a32444d0b6f9cc3c2d85efd5_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjg5MmUxMTZkYjQxODQxYjg5YjBhYjEzMzNjN2M5OTc1L3RhYmxlcmFuZ2U6ODkyZTExNmRiNDE4NDFiODliMGFiMTMzM2M3Yzk5NzVfOS01LTEtMS0w_56ff84e3-8dfa-4296-9453-b1f5a3f8f947"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iaab08a4f99ff4ba2950d1437d42c90b2_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjg5MmUxMTZkYjQxODQxYjg5YjBhYjEzMzNjN2M5OTc1L3RhYmxlcmFuZ2U6ODkyZTExNmRiNDE4NDFiODliMGFiMTMzM2M3Yzk5NzVfOS03LTEtMS0w_46ae85f9-b271-46bb-8f1e-b0d1fe7fd9d9"
      unitRef="usd">20136000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6b542a8ed7164ce7a3f01a3325375861_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjg5MmUxMTZkYjQxODQxYjg5YjBhYjEzMzNjN2M5OTc1L3RhYmxlcmFuZ2U6ODkyZTExNmRiNDE4NDFiODliMGFiMTMzM2M3Yzk5NzVfMTAtMS0xLTEtMA_1d0bff01-9d19-47b4-85e3-97d7b43c47aa"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i588c2440f58644e8a6a0c3b8856f304b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjg5MmUxMTZkYjQxODQxYjg5YjBhYjEzMzNjN2M5OTc1L3RhYmxlcmFuZ2U6ODkyZTExNmRiNDE4NDFiODliMGFiMTMzM2M3Yzk5NzVfMTAtMy0xLTEtMA_18d785ee-e8ac-4108-a178-4f36d3b68c80"
      unitRef="usd">15729000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic52a660c9ba0416c80ca6df7c8fb50dc_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjg5MmUxMTZkYjQxODQxYjg5YjBhYjEzMzNjN2M5OTc1L3RhYmxlcmFuZ2U6ODkyZTExNmRiNDE4NDFiODliMGFiMTMzM2M3Yzk5NzVfMTAtNS0xLTEtMA_a12bc185-e5d7-4c35-82c4-b1dc4e7803dd"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="icf0336c48b2a4b5f93669576fb24b804_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjg5MmUxMTZkYjQxODQxYjg5YjBhYjEzMzNjN2M5OTc1L3RhYmxlcmFuZ2U6ODkyZTExNmRiNDE4NDFiODliMGFiMTMzM2M3Yzk5NzVfMTAtNy0xLTEtMA_9a319374-a0c5-4971-b6fd-6df27a496d61"
      unitRef="usd">15729000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i67d5388ca1f140b0b751939b213807d3_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjg5MmUxMTZkYjQxODQxYjg5YjBhYjEzMzNjN2M5OTc1L3RhYmxlcmFuZ2U6ODkyZTExNmRiNDE4NDFiODliMGFiMTMzM2M3Yzk5NzVfMTEtMS0xLTEtMA_0a35630f-638b-4a72-b1f9-95773163341e"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie9c36eef19a84e07bdddd763d415a7f7_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjg5MmUxMTZkYjQxODQxYjg5YjBhYjEzMzNjN2M5OTc1L3RhYmxlcmFuZ2U6ODkyZTExNmRiNDE4NDFiODliMGFiMTMzM2M3Yzk5NzVfMTEtMy0xLTEtMA_fa03f653-1159-46a1-a39a-1d59f726cd96"
      unitRef="usd">71206000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1b241ffdc9c94e2082b8b85ebca483df_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjg5MmUxMTZkYjQxODQxYjg5YjBhYjEzMzNjN2M5OTc1L3RhYmxlcmFuZ2U6ODkyZTExNmRiNDE4NDFiODliMGFiMTMzM2M3Yzk5NzVfMTEtNS0xLTEtMA_e28b401a-5137-453d-9ebe-006dfc03565e"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i000addedaff44daba745c02655b81159_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjg5MmUxMTZkYjQxODQxYjg5YjBhYjEzMzNjN2M5OTc1L3RhYmxlcmFuZ2U6ODkyZTExNmRiNDE4NDFiODliMGFiMTMzM2M3Yzk5NzVfMTEtNy0xLTEtMA_686431c4-1c4d-46f2-a0ce-fb2bf42ea9d4"
      unitRef="usd">71206000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i131f1b1eb6604026a5c42366001ad668_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjg5MmUxMTZkYjQxODQxYjg5YjBhYjEzMzNjN2M5OTc1L3RhYmxlcmFuZ2U6ODkyZTExNmRiNDE4NDFiODliMGFiMTMzM2M3Yzk5NzVfMTMtMS0xLTEtMA_8da36e13-50f5-4f33-9723-05575fee6115"
      unitRef="usd">4050000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i79306ba88f4140a183b8a8b4b6135daa_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjg5MmUxMTZkYjQxODQxYjg5YjBhYjEzMzNjN2M5OTc1L3RhYmxlcmFuZ2U6ODkyZTExNmRiNDE4NDFiODliMGFiMTMzM2M3Yzk5NzVfMTMtMy0xLTEtMA_d2084932-1a6f-4356-99f0-fef0f7f0fb13"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib0c77906277e4e39847898b3e7673e51_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjg5MmUxMTZkYjQxODQxYjg5YjBhYjEzMzNjN2M5OTc1L3RhYmxlcmFuZ2U6ODkyZTExNmRiNDE4NDFiODliMGFiMTMzM2M3Yzk5NzVfMTMtNS0xLTEtMA_d12b247b-5dfd-4817-8c1f-d3e109288255"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia06ecd5d4e7943cfb188e226606891fc_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjg5MmUxMTZkYjQxODQxYjg5YjBhYjEzMzNjN2M5OTc1L3RhYmxlcmFuZ2U6ODkyZTExNmRiNDE4NDFiODliMGFiMTMzM2M3Yzk5NzVfMTMtNy0xLTEtMA_70aa7c63-9033-48aa-b844-addd6f32e502"
      unitRef="usd">4050000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i19b242abfd1e4002a024557986c6d987_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjg5MmUxMTZkYjQxODQxYjg5YjBhYjEzMzNjN2M5OTc1L3RhYmxlcmFuZ2U6ODkyZTExNmRiNDE4NDFiODliMGFiMTMzM2M3Yzk5NzVfMTUtMS0xLTEtMA_948fec35-dc02-4aa1-8d1b-e3d9d02e7cb5"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i99a26d4be72a42eb865297d52d41de8b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjg5MmUxMTZkYjQxODQxYjg5YjBhYjEzMzNjN2M5OTc1L3RhYmxlcmFuZ2U6ODkyZTExNmRiNDE4NDFiODliMGFiMTMzM2M3Yzk5NzVfMTUtMy0xLTEtMA_cc4cb9b4-5e11-4726-9757-cee2267cb113"
      unitRef="usd">34835000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9dbd5d046d3244ef870fa23ff49cb036_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjg5MmUxMTZkYjQxODQxYjg5YjBhYjEzMzNjN2M5OTc1L3RhYmxlcmFuZ2U6ODkyZTExNmRiNDE4NDFiODliMGFiMTMzM2M3Yzk5NzVfMTUtNS0xLTEtMA_4a75baba-068d-44e0-874a-9144a2193463"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie4aa0eddd0fb49eda4c41fc2a826b8c1_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjg5MmUxMTZkYjQxODQxYjg5YjBhYjEzMzNjN2M5OTc1L3RhYmxlcmFuZ2U6ODkyZTExNmRiNDE4NDFiODliMGFiMTMzM2M3Yzk5NzVfMTUtNy0xLTEtMA_8fc2dbb4-a49d-493f-8ad3-a0208ff30552"
      unitRef="usd">34835000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DerivativeAssets
      contextRef="i50be2f68d7ea46f1a2d7e733b2391ac5_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjg5MmUxMTZkYjQxODQxYjg5YjBhYjEzMzNjN2M5OTc1L3RhYmxlcmFuZ2U6ODkyZTExNmRiNDE4NDFiODliMGFiMTMzM2M3Yzk5NzVfMTYtMS0xLTEtMA_d69c6b15-b09f-46cb-abf1-ed2cd144e043"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i0881221dc0304651bd4cc951315603f9_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjg5MmUxMTZkYjQxODQxYjg5YjBhYjEzMzNjN2M5OTc1L3RhYmxlcmFuZ2U6ODkyZTExNmRiNDE4NDFiODliMGFiMTMzM2M3Yzk5NzVfMTYtMy0xLTEtMA_7a9aa900-d923-4936-8764-1d3af8230965"
      unitRef="usd">45000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i057152fc2b0d48c0969e0b03ae05f47f_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjg5MmUxMTZkYjQxODQxYjg5YjBhYjEzMzNjN2M5OTc1L3RhYmxlcmFuZ2U6ODkyZTExNmRiNDE4NDFiODliMGFiMTMzM2M3Yzk5NzVfMTYtNS0xLTEtMA_d77d8de3-dbb5-4dde-8d9f-aeea75fc0d16"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i9953f50a7fd74f7d8438f304f136a07b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjg5MmUxMTZkYjQxODQxYjg5YjBhYjEzMzNjN2M5OTc1L3RhYmxlcmFuZ2U6ODkyZTExNmRiNDE4NDFiODliMGFiMTMzM2M3Yzk5NzVfMTYtNy0xLTEtMA_f4ff5d70-25b2-42ec-b798-b0956f08a963"
      unitRef="usd">45000</us-gaap:DerivativeAssets>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i50be2f68d7ea46f1a2d7e733b2391ac5_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjg5MmUxMTZkYjQxODQxYjg5YjBhYjEzMzNjN2M5OTc1L3RhYmxlcmFuZ2U6ODkyZTExNmRiNDE4NDFiODliMGFiMTMzM2M3Yzk5NzVfMTctMS0xLTEtMA_746fc484-e4c9-45e8-8a65-339b5795348e"
      unitRef="usd">1301576000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i0881221dc0304651bd4cc951315603f9_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjg5MmUxMTZkYjQxODQxYjg5YjBhYjEzMzNjN2M5OTc1L3RhYmxlcmFuZ2U6ODkyZTExNmRiNDE4NDFiODliMGFiMTMzM2M3Yzk5NzVfMTctMy0xLTEtMA_b279aced-4f17-42a6-b3ce-299fc03fb05e"
      unitRef="usd">141951000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i057152fc2b0d48c0969e0b03ae05f47f_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjg5MmUxMTZkYjQxODQxYjg5YjBhYjEzMzNjN2M5OTc1L3RhYmxlcmFuZ2U6ODkyZTExNmRiNDE4NDFiODliMGFiMTMzM2M3Yzk5NzVfMTctNS0xLTEtMA_2de0da63-61c6-4951-9867-58dfb17e278c"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i9953f50a7fd74f7d8438f304f136a07b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjg5MmUxMTZkYjQxODQxYjg5YjBhYjEzMzNjN2M5OTc1L3RhYmxlcmFuZ2U6ODkyZTExNmRiNDE4NDFiODliMGFiMTMzM2M3Yzk5NzVfMTctNy0xLTEtMA_46ba566e-23df-4c9c-a618-5041f4430c83"
      unitRef="usd">1443527000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:DerivativeLiabilities
      contextRef="i50be2f68d7ea46f1a2d7e733b2391ac5_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjg5MmUxMTZkYjQxODQxYjg5YjBhYjEzMzNjN2M5OTc1L3RhYmxlcmFuZ2U6ODkyZTExNmRiNDE4NDFiODliMGFiMTMzM2M3Yzk5NzVfMTktMS0xLTEtMA_8ae0959b-d949-4ecc-b2f5-819ade9efb96"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i0881221dc0304651bd4cc951315603f9_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjg5MmUxMTZkYjQxODQxYjg5YjBhYjEzMzNjN2M5OTc1L3RhYmxlcmFuZ2U6ODkyZTExNmRiNDE4NDFiODliMGFiMTMzM2M3Yzk5NzVfMTktMy0xLTEtMA_7fc819cd-a98b-4960-ba5d-f94ef96cf62e"
      unitRef="usd">176000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i057152fc2b0d48c0969e0b03ae05f47f_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjg5MmUxMTZkYjQxODQxYjg5YjBhYjEzMzNjN2M5OTc1L3RhYmxlcmFuZ2U6ODkyZTExNmRiNDE4NDFiODliMGFiMTMzM2M3Yzk5NzVfMTktNS0xLTEtMA_9d1e2954-9f0f-45bf-baf7-f5920d888e1a"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i9953f50a7fd74f7d8438f304f136a07b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjg5MmUxMTZkYjQxODQxYjg5YjBhYjEzMzNjN2M5OTc1L3RhYmxlcmFuZ2U6ODkyZTExNmRiNDE4NDFiODliMGFiMTMzM2M3Yzk5NzVfMTktNy0xLTEtMA_b8014c3f-7f56-41f6-bfd8-e78b534d99fb"
      unitRef="usd">176000</us-gaap:DerivativeLiabilities>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i50be2f68d7ea46f1a2d7e733b2391ac5_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjg5MmUxMTZkYjQxODQxYjg5YjBhYjEzMzNjN2M5OTc1L3RhYmxlcmFuZ2U6ODkyZTExNmRiNDE4NDFiODliMGFiMTMzM2M3Yzk5NzVfMjAtMS0xLTEtMA_46b9de95-0a02-4c82-82b1-09dbf9a04910"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i0881221dc0304651bd4cc951315603f9_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjg5MmUxMTZkYjQxODQxYjg5YjBhYjEzMzNjN2M5OTc1L3RhYmxlcmFuZ2U6ODkyZTExNmRiNDE4NDFiODliMGFiMTMzM2M3Yzk5NzVfMjAtMy0xLTEtMA_db802700-3009-4797-be5f-54cb783567f9"
      unitRef="usd">176000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i057152fc2b0d48c0969e0b03ae05f47f_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjg5MmUxMTZkYjQxODQxYjg5YjBhYjEzMzNjN2M5OTc1L3RhYmxlcmFuZ2U6ODkyZTExNmRiNDE4NDFiODliMGFiMTMzM2M3Yzk5NzVfMjAtNS0xLTEtMA_fda7ec28-bdf7-4c97-8a79-fb9d69d1e01b"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i9953f50a7fd74f7d8438f304f136a07b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjg5MmUxMTZkYjQxODQxYjg5YjBhYjEzMzNjN2M5OTc1L3RhYmxlcmFuZ2U6ODkyZTExNmRiNDE4NDFiODliMGFiMTMzM2M3Yzk5NzVfMjAtNy0xLTEtMA_14195799-6b8a-43ed-8efa-7e9af96cd5b4"
      unitRef="usd">176000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ie0489620584748b8a18511d5315c484d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjIwYmEwMjk4ZDEyNDQ3MTRiMjk2NjkyNzRhNDZjOWQ2L3RhYmxlcmFuZ2U6MjBiYTAyOThkMTI0NDcxNGIyOTY2OTI3NGE0NmM5ZDZfNC0xLTEtMS0w_8df3c7a9-f289-4bfd-803a-b64d7b76165b"
      unitRef="usd">335284000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="iacef9d3f91dd40d0a87a4c4a0d2b6fb2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjIwYmEwMjk4ZDEyNDQ3MTRiMjk2NjkyNzRhNDZjOWQ2L3RhYmxlcmFuZ2U6MjBiYTAyOThkMTI0NDcxNGIyOTY2OTI3NGE0NmM5ZDZfNC0zLTEtMS0w_d4d3d2a4-d84e-40cc-a00c-b84038d451a1"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i216c3025b0124b688dd2fd43fb4468fb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjIwYmEwMjk4ZDEyNDQ3MTRiMjk2NjkyNzRhNDZjOWQ2L3RhYmxlcmFuZ2U6MjBiYTAyOThkMTI0NDcxNGIyOTY2OTI3NGE0NmM5ZDZfNC01LTEtMS0w_9595e233-c039-4911-a91a-0b74d4f103ff"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ib663c99903ea42359657773d88880b3a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjIwYmEwMjk4ZDEyNDQ3MTRiMjk2NjkyNzRhNDZjOWQ2L3RhYmxlcmFuZ2U6MjBiYTAyOThkMTI0NDcxNGIyOTY2OTI3NGE0NmM5ZDZfNC03LTEtMS0w_028b7cb6-30c1-47d6-83a2-6c38b05685a1"
      unitRef="usd">335284000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i4680cafe26584c1f86d850c496eda36c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjIwYmEwMjk4ZDEyNDQ3MTRiMjk2NjkyNzRhNDZjOWQ2L3RhYmxlcmFuZ2U6MjBiYTAyOThkMTI0NDcxNGIyOTY2OTI3NGE0NmM5ZDZfNS0xLTEtMS0w_55a1521e-2348-404a-b45f-e681cbfd5715"
      unitRef="usd">149997000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i8a690a2144264f4f8dfff3d5dfce6fe6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjIwYmEwMjk4ZDEyNDQ3MTRiMjk2NjkyNzRhNDZjOWQ2L3RhYmxlcmFuZ2U6MjBiYTAyOThkMTI0NDcxNGIyOTY2OTI3NGE0NmM5ZDZfNS0zLTEtMS0w_a9ef62ff-b505-4a82-9f27-8271d48bb5b8"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i239e913cbb1a4a0389051b486d08f75a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjIwYmEwMjk4ZDEyNDQ3MTRiMjk2NjkyNzRhNDZjOWQ2L3RhYmxlcmFuZ2U6MjBiYTAyOThkMTI0NDcxNGIyOTY2OTI3NGE0NmM5ZDZfNS01LTEtMS0w_3166aecf-10fd-47e2-a1ce-bc96b2c3240b"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="if25b3a1f38994654bc19ed04aca9372f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjIwYmEwMjk4ZDEyNDQ3MTRiMjk2NjkyNzRhNDZjOWQ2L3RhYmxlcmFuZ2U6MjBiYTAyOThkMTI0NDcxNGIyOTY2OTI3NGE0NmM5ZDZfNS03LTEtMS0w_ebb4c3ac-2787-4e55-b248-c1d4dc38ca4b"
      unitRef="usd">149997000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="idc5b52a3db1b4f8baed84d10ed64492c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjIwYmEwMjk4ZDEyNDQ3MTRiMjk2NjkyNzRhNDZjOWQ2L3RhYmxlcmFuZ2U6MjBiYTAyOThkMTI0NDcxNGIyOTY2OTI3NGE0NmM5ZDZfNy0xLTEtMS0w_96b36df7-0b78-4100-98d0-ea97fe2f83f9"
      unitRef="usd">878938000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i86c3ea8f2f1f49c4a026b6bc52858668_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjIwYmEwMjk4ZDEyNDQ3MTRiMjk2NjkyNzRhNDZjOWQ2L3RhYmxlcmFuZ2U6MjBiYTAyOThkMTI0NDcxNGIyOTY2OTI3NGE0NmM5ZDZfNy0zLTEtMS0w_4b6aa9b7-4e53-4a83-ac22-c8cecca32f35"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i908a382fdfd44406be1c76e156800e93_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjIwYmEwMjk4ZDEyNDQ3MTRiMjk2NjkyNzRhNDZjOWQ2L3RhYmxlcmFuZ2U6MjBiYTAyOThkMTI0NDcxNGIyOTY2OTI3NGE0NmM5ZDZfNy01LTEtMS0w_40b2e6f7-50cb-46d6-9cbd-10619343c7c7"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i72798f9b723345d7b2945778149039ab_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjIwYmEwMjk4ZDEyNDQ3MTRiMjk2NjkyNzRhNDZjOWQ2L3RhYmxlcmFuZ2U6MjBiYTAyOThkMTI0NDcxNGIyOTY2OTI3NGE0NmM5ZDZfNy03LTEtMS0w_6c8a643b-a124-4dc8-bab4-4b4c6cbd96f9"
      unitRef="usd">878938000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i118d49e34100478aad6bb4134c3b2aaa_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjIwYmEwMjk4ZDEyNDQ3MTRiMjk2NjkyNzRhNDZjOWQ2L3RhYmxlcmFuZ2U6MjBiYTAyOThkMTI0NDcxNGIyOTY2OTI3NGE0NmM5ZDZfOC0xLTEtMS0w_e81c639b-6617-4294-9de5-9c5ba06c739f"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i178051c344504d07985f78aa8cc32492_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjIwYmEwMjk4ZDEyNDQ3MTRiMjk2NjkyNzRhNDZjOWQ2L3RhYmxlcmFuZ2U6MjBiYTAyOThkMTI0NDcxNGIyOTY2OTI3NGE0NmM5ZDZfOC0zLTEtMS0w_a18c8097-c484-4eec-8420-f369d6297428"
      unitRef="usd">25217000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id3593591cc6b4645bcbbae5e79b647d6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjIwYmEwMjk4ZDEyNDQ3MTRiMjk2NjkyNzRhNDZjOWQ2L3RhYmxlcmFuZ2U6MjBiYTAyOThkMTI0NDcxNGIyOTY2OTI3NGE0NmM5ZDZfOC01LTEtMS0w_c95173a1-b335-4c64-bef4-2c0dc8a19db2"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9286f708ff8349709d22f68a1a329272_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjIwYmEwMjk4ZDEyNDQ3MTRiMjk2NjkyNzRhNDZjOWQ2L3RhYmxlcmFuZ2U6MjBiYTAyOThkMTI0NDcxNGIyOTY2OTI3NGE0NmM5ZDZfOC03LTEtMS0w_128b4016-c3bc-466c-9545-1c06e30d1cf5"
      unitRef="usd">25217000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ided63883ce3647bc936cd798e72ea186_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjIwYmEwMjk4ZDEyNDQ3MTRiMjk2NjkyNzRhNDZjOWQ2L3RhYmxlcmFuZ2U6MjBiYTAyOThkMTI0NDcxNGIyOTY2OTI3NGE0NmM5ZDZfOS0xLTEtMS0w_6b06e93a-fa30-4ed0-89c6-5956679aa0c2"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0e93f92b75c548efb9c7fbf7491b4063_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjIwYmEwMjk4ZDEyNDQ3MTRiMjk2NjkyNzRhNDZjOWQ2L3RhYmxlcmFuZ2U6MjBiYTAyOThkMTI0NDcxNGIyOTY2OTI3NGE0NmM5ZDZfOS0zLTEtMS0w_46eb873f-0f99-4449-826a-6f75fd4167b0"
      unitRef="usd">27180000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="idb6cdf24410f45c282312f8166a766ff_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjIwYmEwMjk4ZDEyNDQ3MTRiMjk2NjkyNzRhNDZjOWQ2L3RhYmxlcmFuZ2U6MjBiYTAyOThkMTI0NDcxNGIyOTY2OTI3NGE0NmM5ZDZfOS01LTEtMS0w_8f50b06d-3a50-431b-a940-b900f72b159c"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic16516c243df4551a83161ad3c5c0f09_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjIwYmEwMjk4ZDEyNDQ3MTRiMjk2NjkyNzRhNDZjOWQ2L3RhYmxlcmFuZ2U6MjBiYTAyOThkMTI0NDcxNGIyOTY2OTI3NGE0NmM5ZDZfOS03LTEtMS0w_71da31fb-acf8-4246-b267-ca37e257aa56"
      unitRef="usd">27180000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i25d88de0f197490fb779e1e3071f901e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjIwYmEwMjk4ZDEyNDQ3MTRiMjk2NjkyNzRhNDZjOWQ2L3RhYmxlcmFuZ2U6MjBiYTAyOThkMTI0NDcxNGIyOTY2OTI3NGE0NmM5ZDZfMTAtMS0xLTEtMA_0fd322aa-06fd-4f75-94a8-9ac8ec1c9d3a"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3b60ffb67bd147c3a56d06666f6ff77c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjIwYmEwMjk4ZDEyNDQ3MTRiMjk2NjkyNzRhNDZjOWQ2L3RhYmxlcmFuZ2U6MjBiYTAyOThkMTI0NDcxNGIyOTY2OTI3NGE0NmM5ZDZfMTAtMy0xLTEtMA_56b3f254-e093-4404-a1f4-38e20aa66f82"
      unitRef="usd">31218000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ibfac6e99e22f43c68f58fb5907948edb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjIwYmEwMjk4ZDEyNDQ3MTRiMjk2NjkyNzRhNDZjOWQ2L3RhYmxlcmFuZ2U6MjBiYTAyOThkMTI0NDcxNGIyOTY2OTI3NGE0NmM5ZDZfMTAtNS0xLTEtMA_b9f421f6-f2f1-413a-9035-2e473189fee4"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="idf6e2668dddb49d2ac374501483e7bf9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjIwYmEwMjk4ZDEyNDQ3MTRiMjk2NjkyNzRhNDZjOWQ2L3RhYmxlcmFuZ2U6MjBiYTAyOThkMTI0NDcxNGIyOTY2OTI3NGE0NmM5ZDZfMTAtNy0xLTEtMA_8cba09fe-5555-4834-a994-a6d64c3495fe"
      unitRef="usd">31218000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i215ae1ee50d14e92a7ea23ab3f943a5d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjIwYmEwMjk4ZDEyNDQ3MTRiMjk2NjkyNzRhNDZjOWQ2L3RhYmxlcmFuZ2U6MjBiYTAyOThkMTI0NDcxNGIyOTY2OTI3NGE0NmM5ZDZfMTItMS0xLTEtMA_5a7f0dae-fbb5-4bb0-992a-6adc0c14ec84"
      unitRef="usd">2561000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4026f6a97f4340d6a98d226ab3c04c12_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjIwYmEwMjk4ZDEyNDQ3MTRiMjk2NjkyNzRhNDZjOWQ2L3RhYmxlcmFuZ2U6MjBiYTAyOThkMTI0NDcxNGIyOTY2OTI3NGE0NmM5ZDZfMTItMy0xLTEtMA_efa70157-85f0-40dc-8c4e-1cb0f3a4dad3"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iec8ba588c80d4f4191cc54f76a956ff0_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjIwYmEwMjk4ZDEyNDQ3MTRiMjk2NjkyNzRhNDZjOWQ2L3RhYmxlcmFuZ2U6MjBiYTAyOThkMTI0NDcxNGIyOTY2OTI3NGE0NmM5ZDZfMTItNS0xLTEtMA_80fc19de-37fb-4706-bb6f-0311e33886d7"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i57f0286f0cdd41afb93b20cd06df11c7_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjIwYmEwMjk4ZDEyNDQ3MTRiMjk2NjkyNzRhNDZjOWQ2L3RhYmxlcmFuZ2U6MjBiYTAyOThkMTI0NDcxNGIyOTY2OTI3NGE0NmM5ZDZfMTItNy0xLTEtMA_68d1d7db-4d36-44fe-8c3b-2200fd39e0a3"
      unitRef="usd">2561000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i480dc0971b7d403fad3d95c1932c7534_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjIwYmEwMjk4ZDEyNDQ3MTRiMjk2NjkyNzRhNDZjOWQ2L3RhYmxlcmFuZ2U6MjBiYTAyOThkMTI0NDcxNGIyOTY2OTI3NGE0NmM5ZDZfMTMtMS0xLTEtMA_6828a0e3-3f5b-403c-b730-0da9d39d6dd7"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ifa86ad4908bc434aa3c51f66f9a60281_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjIwYmEwMjk4ZDEyNDQ3MTRiMjk2NjkyNzRhNDZjOWQ2L3RhYmxlcmFuZ2U6MjBiYTAyOThkMTI0NDcxNGIyOTY2OTI3NGE0NmM5ZDZfMTMtMy0xLTEtMA_c2fac36f-5123-484d-9d86-f19aaaad3d64"
      unitRef="usd">30138000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic4170e2296ad4137872fb9951088b913_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjIwYmEwMjk4ZDEyNDQ3MTRiMjk2NjkyNzRhNDZjOWQ2L3RhYmxlcmFuZ2U6MjBiYTAyOThkMTI0NDcxNGIyOTY2OTI3NGE0NmM5ZDZfMTMtNS0xLTEtMA_8dd39fe9-0e24-4451-ba38-0f86b579d736"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6da17c1dcc0c448cbd20f8ec3a5656d1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjIwYmEwMjk4ZDEyNDQ3MTRiMjk2NjkyNzRhNDZjOWQ2L3RhYmxlcmFuZ2U6MjBiYTAyOThkMTI0NDcxNGIyOTY2OTI3NGE0NmM5ZDZfMTMtNy0xLTEtMA_b09a0e18-0e51-4f0d-a6f6-267b99c75594"
      unitRef="usd">30138000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DerivativeAssets
      contextRef="i0b67e7dddea84ea5bd2068d25930c3f0_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjIwYmEwMjk4ZDEyNDQ3MTRiMjk2NjkyNzRhNDZjOWQ2L3RhYmxlcmFuZ2U6MjBiYTAyOThkMTI0NDcxNGIyOTY2OTI3NGE0NmM5ZDZfMTQtMS0xLTEtMA_18bb0888-2521-4ddc-afad-59633f6d9d2c"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i71c0a54ceaf448c7b9d4d9c1d534b5cc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjIwYmEwMjk4ZDEyNDQ3MTRiMjk2NjkyNzRhNDZjOWQ2L3RhYmxlcmFuZ2U6MjBiYTAyOThkMTI0NDcxNGIyOTY2OTI3NGE0NmM5ZDZfMTQtMy0xLTEtMA_c26cf1e4-8146-4579-b4ba-dcf0816dd115"
      unitRef="usd">185000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i2db26540968047c2b760e6148893f1f0_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjIwYmEwMjk4ZDEyNDQ3MTRiMjk2NjkyNzRhNDZjOWQ2L3RhYmxlcmFuZ2U6MjBiYTAyOThkMTI0NDcxNGIyOTY2OTI3NGE0NmM5ZDZfMTQtNS0xLTEtMA_7abfd15e-3d72-4f41-a6b4-de76a178aaaa"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="idb7ca9f362da46eab3a29bbbecbda977_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjIwYmEwMjk4ZDEyNDQ3MTRiMjk2NjkyNzRhNDZjOWQ2L3RhYmxlcmFuZ2U6MjBiYTAyOThkMTI0NDcxNGIyOTY2OTI3NGE0NmM5ZDZfMTQtNy0xLTEtMA_ea59584f-af8f-40eb-b19e-64593506ec4d"
      unitRef="usd">185000</us-gaap:DerivativeAssets>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i0b67e7dddea84ea5bd2068d25930c3f0_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjIwYmEwMjk4ZDEyNDQ3MTRiMjk2NjkyNzRhNDZjOWQ2L3RhYmxlcmFuZ2U6MjBiYTAyOThkMTI0NDcxNGIyOTY2OTI3NGE0NmM5ZDZfMTUtMS0xLTEtMA_f9796c26-96f9-49e6-a32f-4297dc1e16bc"
      unitRef="usd">1366780000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i71c0a54ceaf448c7b9d4d9c1d534b5cc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjIwYmEwMjk4ZDEyNDQ3MTRiMjk2NjkyNzRhNDZjOWQ2L3RhYmxlcmFuZ2U6MjBiYTAyOThkMTI0NDcxNGIyOTY2OTI3NGE0NmM5ZDZfMTUtMy0xLTEtMA_57b98d1c-9d16-4f3a-94b0-6c0c1908ed6f"
      unitRef="usd">113938000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i2db26540968047c2b760e6148893f1f0_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjIwYmEwMjk4ZDEyNDQ3MTRiMjk2NjkyNzRhNDZjOWQ2L3RhYmxlcmFuZ2U6MjBiYTAyOThkMTI0NDcxNGIyOTY2OTI3NGE0NmM5ZDZfMTUtNS0xLTEtMA_bbcd8ae6-8dd6-460f-9a55-cb1bb6a43a95"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="idb7ca9f362da46eab3a29bbbecbda977_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjIwYmEwMjk4ZDEyNDQ3MTRiMjk2NjkyNzRhNDZjOWQ2L3RhYmxlcmFuZ2U6MjBiYTAyOThkMTI0NDcxNGIyOTY2OTI3NGE0NmM5ZDZfMTUtNy0xLTEtMA_66665f51-1c08-4cbe-88c4-7e1a3431969a"
      unitRef="usd">1480718000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:DerivativeLiabilities
      contextRef="i0b67e7dddea84ea5bd2068d25930c3f0_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjIwYmEwMjk4ZDEyNDQ3MTRiMjk2NjkyNzRhNDZjOWQ2L3RhYmxlcmFuZ2U6MjBiYTAyOThkMTI0NDcxNGIyOTY2OTI3NGE0NmM5ZDZfMTctMS0xLTEtMA_1e1e226f-47fd-4471-b265-1f483d73cb1d"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i71c0a54ceaf448c7b9d4d9c1d534b5cc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjIwYmEwMjk4ZDEyNDQ3MTRiMjk2NjkyNzRhNDZjOWQ2L3RhYmxlcmFuZ2U6MjBiYTAyOThkMTI0NDcxNGIyOTY2OTI3NGE0NmM5ZDZfMTctMy0xLTEtMA_70360605-57d2-495a-8234-1e001bbca4fb"
      unitRef="usd">11000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i2db26540968047c2b760e6148893f1f0_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjIwYmEwMjk4ZDEyNDQ3MTRiMjk2NjkyNzRhNDZjOWQ2L3RhYmxlcmFuZ2U6MjBiYTAyOThkMTI0NDcxNGIyOTY2OTI3NGE0NmM5ZDZfMTctNS0xLTEtMA_a577d26e-248d-4ada-9466-b1c4ce4532b8"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="idb7ca9f362da46eab3a29bbbecbda977_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjIwYmEwMjk4ZDEyNDQ3MTRiMjk2NjkyNzRhNDZjOWQ2L3RhYmxlcmFuZ2U6MjBiYTAyOThkMTI0NDcxNGIyOTY2OTI3NGE0NmM5ZDZfMTctNy0xLTEtMA_30748d42-b37c-4157-9c7e-22f759f7524b"
      unitRef="usd">11000</us-gaap:DerivativeLiabilities>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i0b67e7dddea84ea5bd2068d25930c3f0_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjIwYmEwMjk4ZDEyNDQ3MTRiMjk2NjkyNzRhNDZjOWQ2L3RhYmxlcmFuZ2U6MjBiYTAyOThkMTI0NDcxNGIyOTY2OTI3NGE0NmM5ZDZfMTgtMS0xLTEtMA_223fa935-25c6-4792-ba49-450885f135c5"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i71c0a54ceaf448c7b9d4d9c1d534b5cc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjIwYmEwMjk4ZDEyNDQ3MTRiMjk2NjkyNzRhNDZjOWQ2L3RhYmxlcmFuZ2U6MjBiYTAyOThkMTI0NDcxNGIyOTY2OTI3NGE0NmM5ZDZfMTgtMy0xLTEtMA_06689b59-a98b-4b38-8afd-52cdde0f3809"
      unitRef="usd">11000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i2db26540968047c2b760e6148893f1f0_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjIwYmEwMjk4ZDEyNDQ3MTRiMjk2NjkyNzRhNDZjOWQ2L3RhYmxlcmFuZ2U6MjBiYTAyOThkMTI0NDcxNGIyOTY2OTI3NGE0NmM5ZDZfMTgtNS0xLTEtMA_f9df74b8-0b97-4a3b-8eda-a27da5a6247a"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="idb7ca9f362da46eab3a29bbbecbda977_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNC9mcmFnOjQ3YzY4OWRlZTcwZDRjNDI5NjEwOTlkZTczZGE0MGYwL3RhYmxlOjIwYmEwMjk4ZDEyNDQ3MTRiMjk2NjkyNzRhNDZjOWQ2L3RhYmxlcmFuZ2U6MjBiYTAyOThkMTI0NDcxNGIyOTY2OTI3NGE0NmM5ZDZfMTgtNy0xLTEtMA_8e80dc48-f93b-46e0-8ab6-6f4357d5627b"
      unitRef="usd">11000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock
      contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RleHRyZWdpb246MjFlN2QzYmNkYTljNDAwMzgwZjEzZmJmZjY4YzA4NTRfMjczNQ_0201c45f-8bf2-4b07-bb51-db9a7ed160a8">Marketable SecuritiesAll marketable securities were considered&#160;available-for-sale&#160;at March 31, 2021 and December 31, 2020. On a recurring basis, the Company records its marketable securities at fair value using Level 1 or Level 2 inputs as discussed in Note 2, "Fair Value Measurements". The amortized cost, gross unrealized holding gains or losses, and fair value of the Company&#x2019;s marketable securities by major security type at each balance sheet date are summarized in the tables below (in thousands):&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.085%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.002%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.002%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.002%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.006%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Holding Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Holding Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Short-term marketable securities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;U.S. government treasuries&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;870,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;870,756&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;U.S. government agency securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20,136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15,684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15,729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;71,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;71,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total short-term marketable securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;977,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;977,827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Long-term marketable securities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;U.S. government treasuries&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;34,854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;34,835&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total long-term marketable securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;38,903&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;38,885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,016,593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(30)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,016,712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:120%"&gt;__________________________________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10.69pt"&gt;Unrealized holding losses on 3 securities with an aggregate fair value of $126.4 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10.69pt"&gt;Unrealized holding losses on 4 securities with an aggregate fair value of $7.1 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:120%"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10.69pt"&gt;Unrealized holding losses on 4 securities with an aggregate fair value of $34.8 million.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.085%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.002%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.002%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.002%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.006%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Holding Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Holding Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Short-term marketable securities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;U.S. government treasuries&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;878,906&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;878,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;U.S. government agency securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27,180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;31,218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;31,218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total short-term marketable securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;962,439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;962,553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Long-term marketable securities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;U.S. government treasuries&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30,147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30,138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total long-term marketable securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;32,708&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;32,699&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;995,147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;995,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:120%"&gt;__________________________________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10.69pt"&gt;Unrealized holding losses on 19 securities with an aggregate fair value of $369.9 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10.69pt"&gt;Unrealized holding losses on 2 securities with an aggregate fair value of $10.1 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:120%"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10.69pt"&gt;Unrealized holding losses on 1 security with an aggregate fair value of $20.1 million.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; As of March 31, 2021 and December 31, 2020, some of the Company's marketable securities were in an unrealized loss position. The Company has not recognized an allowance for credit losses as of March 31, 2021 or December 31, 2020. The Company determined that it had the ability and intent to hold all marketable securities that have been in a continuous loss position until maturity or recovery. Further, these marketable securities were initially, and continue to be, held with investment grade, high credit quality institutions. All marketable securities with unrealized losses as of each balance sheet date have been in a loss position for less than twelve months or the loss is not material.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded unrealized gains on marketable securities in other comprehensive income for the three months ended March 31, 2020. As a result, the Company recorded a tax benefit of $0.1&#160;million for the three months ended March 31, 2020 on the Condensed Consolidated Statements of Operations and Comprehensive Loss and a corresponding tax charge in other comprehensive income. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All of the Company&#x2019;s marketable securities have an effective maturity of less than two years.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock>
    <us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock
      contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RleHRyZWdpb246MjFlN2QzYmNkYTljNDAwMzgwZjEzZmJmZjY4YzA4NTRfMjczMQ_cc4ceb8b-581c-499a-bfc1-b88b30c73ab8">The amortized cost, gross unrealized holding gains or losses, and fair value of the Company&#x2019;s marketable securities by major security type at each balance sheet date are summarized in the tables below (in thousands):&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.085%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.002%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.002%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.002%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.006%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Holding Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Holding Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Short-term marketable securities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;U.S. government treasuries&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;870,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;870,756&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;U.S. government agency securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20,136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15,684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15,729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;71,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;71,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total short-term marketable securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;977,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;977,827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Long-term marketable securities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;U.S. government treasuries&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;34,854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;34,835&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total long-term marketable securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;38,903&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;38,885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,016,593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(30)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,016,712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:120%"&gt;__________________________________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10.69pt"&gt;Unrealized holding losses on 3 securities with an aggregate fair value of $126.4 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10.69pt"&gt;Unrealized holding losses on 4 securities with an aggregate fair value of $7.1 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:120%"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10.69pt"&gt;Unrealized holding losses on 4 securities with an aggregate fair value of $34.8 million.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.085%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.002%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.002%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.002%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.006%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Holding Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Holding Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Short-term marketable securities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;U.S. government treasuries&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;878,906&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;878,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;U.S. government agency securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27,180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;31,218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;31,218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total short-term marketable securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;962,439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;962,553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Long-term marketable securities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;U.S. government treasuries&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30,147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30,138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total long-term marketable securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;32,708&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;32,699&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;995,147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;995,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:120%"&gt;__________________________________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10.69pt"&gt;Unrealized holding losses on 19 securities with an aggregate fair value of $369.9 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10.69pt"&gt;Unrealized holding losses on 2 securities with an aggregate fair value of $10.1 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:120%"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10.69pt"&gt;Unrealized holding losses on 1 security with an aggregate fair value of $20.1 million.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i5c991a09175c4907972778fd5a54038d_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RhYmxlOjhjMjY2ZGU1NDdhOTQ2ODM4YmIxZGYzMjdjMTY2YmU3L3RhYmxlcmFuZ2U6OGMyNjZkZTU0N2E5NDY4MzhiYjFkZjMyN2MxNjZiZTdfMy0xLTEtMS0w_24b67c7b-3724-4d7c-bd9c-606e1fd9e184"
      unitRef="usd">870674000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i5c991a09175c4907972778fd5a54038d_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RhYmxlOjhjMjY2ZGU1NDdhOTQ2ODM4YmIxZGYzMjdjMTY2YmU3L3RhYmxlcmFuZ2U6OGMyNjZkZTU0N2E5NDY4MzhiYjFkZjMyN2MxNjZiZTdfMy0zLTEtMS0w_5a600c62-ccd4-4f10-bbef-5fbceb38484e"
      unitRef="usd">90000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i5c991a09175c4907972778fd5a54038d_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RhYmxlOjhjMjY2ZGU1NDdhOTQ2ODM4YmIxZGYzMjdjMTY2YmU3L3RhYmxlcmFuZ2U6OGMyNjZkZTU0N2E5NDY4MzhiYjFkZjMyN2MxNjZiZTdfMy01LTEtMS0w_142fcb05-8627-4c8c-a9c5-5bb10a3e79bd"
      unitRef="usd">8000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5c991a09175c4907972778fd5a54038d_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RhYmxlOjhjMjY2ZGU1NDdhOTQ2ODM4YmIxZGYzMjdjMTY2YmU3L3RhYmxlcmFuZ2U6OGMyNjZkZTU0N2E5NDY4MzhiYjFkZjMyN2MxNjZiZTdfMy03LTEtMS0w_03c1da61-0207-40ea-93b8-58c0d6c2049b"
      unitRef="usd">870756000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i58c971960b254076bc5ebc8a3a3a5a34_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RhYmxlOjhjMjY2ZGU1NDdhOTQ2ODM4YmIxZGYzMjdjMTY2YmU3L3RhYmxlcmFuZ2U6OGMyNjZkZTU0N2E5NDY4MzhiYjFkZjMyN2MxNjZiZTdfNC0xLTEtMS0w_278cc404-49ab-43dd-9139-5df8d868ae01"
      unitRef="usd">20126000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i58c971960b254076bc5ebc8a3a3a5a34_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RhYmxlOjhjMjY2ZGU1NDdhOTQ2ODM4YmIxZGYzMjdjMTY2YmU3L3RhYmxlcmFuZ2U6OGMyNjZkZTU0N2E5NDY4MzhiYjFkZjMyN2MxNjZiZTdfNC0zLTEtMS0w_62f6e81a-4f9f-4215-ba7a-872c4d6cc5bb"
      unitRef="usd">10000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i58c971960b254076bc5ebc8a3a3a5a34_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RhYmxlOjhjMjY2ZGU1NDdhOTQ2ODM4YmIxZGYzMjdjMTY2YmU3L3RhYmxlcmFuZ2U6OGMyNjZkZTU0N2E5NDY4MzhiYjFkZjMyN2MxNjZiZTdfNC01LTEtMS0w_58a3ddcc-0427-4393-b881-95ace9665d92"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i58c971960b254076bc5ebc8a3a3a5a34_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RhYmxlOjhjMjY2ZGU1NDdhOTQ2ODM4YmIxZGYzMjdjMTY2YmU3L3RhYmxlcmFuZ2U6OGMyNjZkZTU0N2E5NDY4MzhiYjFkZjMyN2MxNjZiZTdfNC03LTEtMS0w_5c94fef5-2505-4751-adc4-0a683c618977"
      unitRef="usd">20136000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i5abb55cd5abc4ef4a6963ecc132bb1be_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RhYmxlOjhjMjY2ZGU1NDdhOTQ2ODM4YmIxZGYzMjdjMTY2YmU3L3RhYmxlcmFuZ2U6OGMyNjZkZTU0N2E5NDY4MzhiYjFkZjMyN2MxNjZiZTdfNS0xLTEtMS0w_7765d5a6-baef-4bdc-84dd-0e375dcc48d4"
      unitRef="usd">15684000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i5abb55cd5abc4ef4a6963ecc132bb1be_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RhYmxlOjhjMjY2ZGU1NDdhOTQ2ODM4YmIxZGYzMjdjMTY2YmU3L3RhYmxlcmFuZ2U6OGMyNjZkZTU0N2E5NDY4MzhiYjFkZjMyN2MxNjZiZTdfNS0zLTEtMS0w_7a8d57f3-0ed6-402d-ac4d-f5289e457966"
      unitRef="usd">48000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i5abb55cd5abc4ef4a6963ecc132bb1be_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RhYmxlOjhjMjY2ZGU1NDdhOTQ2ODM4YmIxZGYzMjdjMTY2YmU3L3RhYmxlcmFuZ2U6OGMyNjZkZTU0N2E5NDY4MzhiYjFkZjMyN2MxNjZiZTdfNS01LTEtMS0w_3e29f035-b2e4-48b9-bf61-a3a4359cdf9f"
      unitRef="usd">3000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5abb55cd5abc4ef4a6963ecc132bb1be_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RhYmxlOjhjMjY2ZGU1NDdhOTQ2ODM4YmIxZGYzMjdjMTY2YmU3L3RhYmxlcmFuZ2U6OGMyNjZkZTU0N2E5NDY4MzhiYjFkZjMyN2MxNjZiZTdfNS03LTEtMS0w_9135baef-3040-4310-83c1-0b6739cc6554"
      unitRef="usd">15729000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i382bf15544d0451c8ad0005fe504ecc1_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RhYmxlOjhjMjY2ZGU1NDdhOTQ2ODM4YmIxZGYzMjdjMTY2YmU3L3RhYmxlcmFuZ2U6OGMyNjZkZTU0N2E5NDY4MzhiYjFkZjMyN2MxNjZiZTdfNi0xLTEtMS0w_605ea546-6a09-4b50-af0b-27852b28c9eb"
      unitRef="usd">71206000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i382bf15544d0451c8ad0005fe504ecc1_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RhYmxlOjhjMjY2ZGU1NDdhOTQ2ODM4YmIxZGYzMjdjMTY2YmU3L3RhYmxlcmFuZ2U6OGMyNjZkZTU0N2E5NDY4MzhiYjFkZjMyN2MxNjZiZTdfNi0zLTEtMS0w_f39965c3-80f6-40c5-aeaa-7b7cad5f6d85"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i382bf15544d0451c8ad0005fe504ecc1_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RhYmxlOjhjMjY2ZGU1NDdhOTQ2ODM4YmIxZGYzMjdjMTY2YmU3L3RhYmxlcmFuZ2U6OGMyNjZkZTU0N2E5NDY4MzhiYjFkZjMyN2MxNjZiZTdfNi01LTEtMS0w_e9e2c23d-ad3e-45bb-b850-ab4c125593b6"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i382bf15544d0451c8ad0005fe504ecc1_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RhYmxlOjhjMjY2ZGU1NDdhOTQ2ODM4YmIxZGYzMjdjMTY2YmU3L3RhYmxlcmFuZ2U6OGMyNjZkZTU0N2E5NDY4MzhiYjFkZjMyN2MxNjZiZTdfNi03LTEtMS0w_54ce129a-c6de-4f42-b982-7b2fad6005d9"
      unitRef="usd">71206000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i0c72ee3da1524776845e9b5ae9946eee_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RhYmxlOjhjMjY2ZGU1NDdhOTQ2ODM4YmIxZGYzMjdjMTY2YmU3L3RhYmxlcmFuZ2U6OGMyNjZkZTU0N2E5NDY4MzhiYjFkZjMyN2MxNjZiZTdfNy0xLTEtMS0w_7ebc8885-71b5-4967-aad0-8e07c87a55df"
      unitRef="usd">977690000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i0c72ee3da1524776845e9b5ae9946eee_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RhYmxlOjhjMjY2ZGU1NDdhOTQ2ODM4YmIxZGYzMjdjMTY2YmU3L3RhYmxlcmFuZ2U6OGMyNjZkZTU0N2E5NDY4MzhiYjFkZjMyN2MxNjZiZTdfNy0zLTEtMS0w_71927f3e-1cee-43d8-ae6e-7a7a251a5ce1"
      unitRef="usd">148000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i0c72ee3da1524776845e9b5ae9946eee_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RhYmxlOjhjMjY2ZGU1NDdhOTQ2ODM4YmIxZGYzMjdjMTY2YmU3L3RhYmxlcmFuZ2U6OGMyNjZkZTU0N2E5NDY4MzhiYjFkZjMyN2MxNjZiZTdfNy01LTEtMS0w_6a0bdf0b-8eda-4cba-a62d-6eefcfa51b9f"
      unitRef="usd">11000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0c72ee3da1524776845e9b5ae9946eee_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RhYmxlOjhjMjY2ZGU1NDdhOTQ2ODM4YmIxZGYzMjdjMTY2YmU3L3RhYmxlcmFuZ2U6OGMyNjZkZTU0N2E5NDY4MzhiYjFkZjMyN2MxNjZiZTdfNy03LTEtMS0w_68526601-ba8a-4ba0-922a-642ba1e10374"
      unitRef="usd">977827000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i89fb6181d11a43d88db96cf5f175becc_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RhYmxlOjhjMjY2ZGU1NDdhOTQ2ODM4YmIxZGYzMjdjMTY2YmU3L3RhYmxlcmFuZ2U6OGMyNjZkZTU0N2E5NDY4MzhiYjFkZjMyN2MxNjZiZTdfOS0xLTEtMS0w_5ff8e70c-3f83-4071-9fc6-04a17b6a042d"
      unitRef="usd">4049000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i89fb6181d11a43d88db96cf5f175becc_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RhYmxlOjhjMjY2ZGU1NDdhOTQ2ODM4YmIxZGYzMjdjMTY2YmU3L3RhYmxlcmFuZ2U6OGMyNjZkZTU0N2E5NDY4MzhiYjFkZjMyN2MxNjZiZTdfOS0zLTEtMS0w_ed299bf1-2623-4400-8dff-5c533bb94566"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i89fb6181d11a43d88db96cf5f175becc_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RhYmxlOjhjMjY2ZGU1NDdhOTQ2ODM4YmIxZGYzMjdjMTY2YmU3L3RhYmxlcmFuZ2U6OGMyNjZkZTU0N2E5NDY4MzhiYjFkZjMyN2MxNjZiZTdfOS01LTEtMS0w_3097c93f-0d3f-476f-bea1-60fd75e8ba35"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i89fb6181d11a43d88db96cf5f175becc_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RhYmxlOjhjMjY2ZGU1NDdhOTQ2ODM4YmIxZGYzMjdjMTY2YmU3L3RhYmxlcmFuZ2U6OGMyNjZkZTU0N2E5NDY4MzhiYjFkZjMyN2MxNjZiZTdfOS03LTEtMS0w_eec4817b-931e-44e5-9a19-aef9fd61ac60"
      unitRef="usd">4050000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="iad80279b43b74b3fbb24392412ebf8d4_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RhYmxlOjhjMjY2ZGU1NDdhOTQ2ODM4YmIxZGYzMjdjMTY2YmU3L3RhYmxlcmFuZ2U6OGMyNjZkZTU0N2E5NDY4MzhiYjFkZjMyN2MxNjZiZTdfMTEtMS0xLTEtMA_5d3ae2ec-9b83-4b89-a2fc-e7a3c9de2820"
      unitRef="usd">34854000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="iad80279b43b74b3fbb24392412ebf8d4_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RhYmxlOjhjMjY2ZGU1NDdhOTQ2ODM4YmIxZGYzMjdjMTY2YmU3L3RhYmxlcmFuZ2U6OGMyNjZkZTU0N2E5NDY4MzhiYjFkZjMyN2MxNjZiZTdfMTEtMy0xLTEtMA_dbb3994b-aeb5-4643-8e51-5be15ec3e7c0"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="iad80279b43b74b3fbb24392412ebf8d4_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RhYmxlOjhjMjY2ZGU1NDdhOTQ2ODM4YmIxZGYzMjdjMTY2YmU3L3RhYmxlcmFuZ2U6OGMyNjZkZTU0N2E5NDY4MzhiYjFkZjMyN2MxNjZiZTdfMTEtNS0xLTEtMA_7afbac0b-aae5-4c65-84fa-07725617d817"
      unitRef="usd">19000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iad80279b43b74b3fbb24392412ebf8d4_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RhYmxlOjhjMjY2ZGU1NDdhOTQ2ODM4YmIxZGYzMjdjMTY2YmU3L3RhYmxlcmFuZ2U6OGMyNjZkZTU0N2E5NDY4MzhiYjFkZjMyN2MxNjZiZTdfMTEtNy0xLTEtMA_f8d4e75c-5541-4d18-97b2-a512317d774a"
      unitRef="usd">34835000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="id97fb3aa68ae491e9d798fe7cf3f01b6_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RhYmxlOjhjMjY2ZGU1NDdhOTQ2ODM4YmIxZGYzMjdjMTY2YmU3L3RhYmxlcmFuZ2U6OGMyNjZkZTU0N2E5NDY4MzhiYjFkZjMyN2MxNjZiZTdfMTItMS0xLTEtMA_5ac2c7ff-e496-4c9d-b6c5-a67f9d8e10cb"
      unitRef="usd">38903000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="id97fb3aa68ae491e9d798fe7cf3f01b6_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RhYmxlOjhjMjY2ZGU1NDdhOTQ2ODM4YmIxZGYzMjdjMTY2YmU3L3RhYmxlcmFuZ2U6OGMyNjZkZTU0N2E5NDY4MzhiYjFkZjMyN2MxNjZiZTdfMTItMy0xLTEtMA_6deaa75a-da2c-41cc-842e-538068f9e1b2"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="id97fb3aa68ae491e9d798fe7cf3f01b6_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RhYmxlOjhjMjY2ZGU1NDdhOTQ2ODM4YmIxZGYzMjdjMTY2YmU3L3RhYmxlcmFuZ2U6OGMyNjZkZTU0N2E5NDY4MzhiYjFkZjMyN2MxNjZiZTdfMTItNS0xLTEtMA_80b4f6ef-826a-45df-9220-77f0bc436761"
      unitRef="usd">19000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id97fb3aa68ae491e9d798fe7cf3f01b6_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RhYmxlOjhjMjY2ZGU1NDdhOTQ2ODM4YmIxZGYzMjdjMTY2YmU3L3RhYmxlcmFuZ2U6OGMyNjZkZTU0N2E5NDY4MzhiYjFkZjMyN2MxNjZiZTdfMTItNy0xLTEtMA_4920cf81-8df7-41f6-bd30-b647a083f8ad"
      unitRef="usd">38885000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i9953f50a7fd74f7d8438f304f136a07b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RhYmxlOjhjMjY2ZGU1NDdhOTQ2ODM4YmIxZGYzMjdjMTY2YmU3L3RhYmxlcmFuZ2U6OGMyNjZkZTU0N2E5NDY4MzhiYjFkZjMyN2MxNjZiZTdfMTMtMS0xLTEtMA_b63bea75-fa2c-48fd-b3f5-20415950beda"
      unitRef="usd">1016593000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i9953f50a7fd74f7d8438f304f136a07b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RhYmxlOjhjMjY2ZGU1NDdhOTQ2ODM4YmIxZGYzMjdjMTY2YmU3L3RhYmxlcmFuZ2U6OGMyNjZkZTU0N2E5NDY4MzhiYjFkZjMyN2MxNjZiZTdfMTMtMy0xLTEtMA_11c07772-b694-448d-81c9-da3668994bf5"
      unitRef="usd">149000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i9953f50a7fd74f7d8438f304f136a07b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RhYmxlOjhjMjY2ZGU1NDdhOTQ2ODM4YmIxZGYzMjdjMTY2YmU3L3RhYmxlcmFuZ2U6OGMyNjZkZTU0N2E5NDY4MzhiYjFkZjMyN2MxNjZiZTdfMTMtNS0xLTEtMA_9cfce900-4301-4797-a5ee-d9e142b5735d"
      unitRef="usd">30000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9953f50a7fd74f7d8438f304f136a07b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RhYmxlOjhjMjY2ZGU1NDdhOTQ2ODM4YmIxZGYzMjdjMTY2YmU3L3RhYmxlcmFuZ2U6OGMyNjZkZTU0N2E5NDY4MzhiYjFkZjMyN2MxNjZiZTdfMTMtNy0xLTEtMA_107ed197-f7a5-464b-a3c4-59f55d3acd5a"
      unitRef="usd">1016712000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="i5c991a09175c4907972778fd5a54038d_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RleHRyZWdpb246MjFlN2QzYmNkYTljNDAwMzgwZjEzZmJmZjY4YzA4NTRfODk2_83a2bc83-67b6-454c-a6c7-af8e614c1460"
      unitRef="security">3</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i5c991a09175c4907972778fd5a54038d_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RleHRyZWdpb246MjFlN2QzYmNkYTljNDAwMzgwZjEzZmJmZjY4YzA4NTRfOTQy_a798ff3f-1c38-43c0-a94b-f9c7fc2c4c8d"
      unitRef="usd">126400000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="i5abb55cd5abc4ef4a6963ecc132bb1be_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RleHRyZWdpb246MjFlN2QzYmNkYTljNDAwMzgwZjEzZmJmZjY4YzA4NTRfMTA5OTUxMTYzMzU5OA_3d1315f5-2abb-405b-90de-d44d66ce3f54"
      unitRef="security">4</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i5abb55cd5abc4ef4a6963ecc132bb1be_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RleHRyZWdpb246MjFlN2QzYmNkYTljNDAwMzgwZjEzZmJmZjY4YzA4NTRfMTA5OTUxMTYzMzU4OA_47abea4c-7f44-436f-88e5-8fb9db1290eb"
      unitRef="usd">7100000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="iad80279b43b74b3fbb24392412ebf8d4_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RleHRyZWdpb246MjFlN2QzYmNkYTljNDAwMzgwZjEzZmJmZjY4YzA4NTRfMTA5OTUxMTYzMzc1Ng_f2ebcbd2-832e-4a0c-acde-da2f983445ac"
      unitRef="security">4</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="iad80279b43b74b3fbb24392412ebf8d4_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RleHRyZWdpb246MjFlN2QzYmNkYTljNDAwMzgwZjEzZmJmZjY4YzA4NTRfMTA5OTUxMTYzMzc0Ng_ddd50aa4-0abf-424b-b06d-19afbc62d20b"
      unitRef="usd">34800000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ia965935f3dfc41e9898218d34d2db66f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RhYmxlOmEwMWVjYjY1YzA5MzQyODJiZTVkZmMzNTdjNTU0MjM3L3RhYmxlcmFuZ2U6YTAxZWNiNjVjMDkzNDI4MmJlNWRmYzM1N2M1NTQyMzdfMy0xLTEtMS0w_0f8469b1-6739-4915-afb2-0a1ced612ae3"
      unitRef="usd">878906000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ia965935f3dfc41e9898218d34d2db66f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RhYmxlOmEwMWVjYjY1YzA5MzQyODJiZTVkZmMzNTdjNTU0MjM3L3RhYmxlcmFuZ2U6YTAxZWNiNjVjMDkzNDI4MmJlNWRmYzM1N2M1NTQyMzdfMy0zLTEtMS0w_520f65bd-6226-4c0e-a306-4b7f9821a213"
      unitRef="usd">44000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ia965935f3dfc41e9898218d34d2db66f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RhYmxlOmEwMWVjYjY1YzA5MzQyODJiZTVkZmMzNTdjNTU0MjM3L3RhYmxlcmFuZ2U6YTAxZWNiNjVjMDkzNDI4MmJlNWRmYzM1N2M1NTQyMzdfMy01LTEtMS0w_4d92535d-a201-4b4b-bd13-fb32f4ea3442"
      unitRef="usd">12000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia965935f3dfc41e9898218d34d2db66f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RhYmxlOmEwMWVjYjY1YzA5MzQyODJiZTVkZmMzNTdjNTU0MjM3L3RhYmxlcmFuZ2U6YTAxZWNiNjVjMDkzNDI4MmJlNWRmYzM1N2M1NTQyMzdfMy03LTEtMS0w_e91879cc-7985-41f1-b0ba-144800f08221"
      unitRef="usd">878938000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i3607ed8ca137404691d4a18591291e6d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RhYmxlOmEwMWVjYjY1YzA5MzQyODJiZTVkZmMzNTdjNTU0MjM3L3RhYmxlcmFuZ2U6YTAxZWNiNjVjMDkzNDI4MmJlNWRmYzM1N2M1NTQyMzdfNC0xLTEtMS0w_04d30223-057d-4f94-a4df-3624f01662b1"
      unitRef="usd">25214000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i3607ed8ca137404691d4a18591291e6d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RhYmxlOmEwMWVjYjY1YzA5MzQyODJiZTVkZmMzNTdjNTU0MjM3L3RhYmxlcmFuZ2U6YTAxZWNiNjVjMDkzNDI4MmJlNWRmYzM1N2M1NTQyMzdfNC0zLTEtMS0w_22735b54-96e4-4de0-8238-be68c65f0ffa"
      unitRef="usd">5000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i3607ed8ca137404691d4a18591291e6d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RhYmxlOmEwMWVjYjY1YzA5MzQyODJiZTVkZmMzNTdjNTU0MjM3L3RhYmxlcmFuZ2U6YTAxZWNiNjVjMDkzNDI4MmJlNWRmYzM1N2M1NTQyMzdfNC01LTEtMS0w_a1dcb1b4-0e5b-4499-964c-534f20746340"
      unitRef="usd">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3607ed8ca137404691d4a18591291e6d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RhYmxlOmEwMWVjYjY1YzA5MzQyODJiZTVkZmMzNTdjNTU0MjM3L3RhYmxlcmFuZ2U6YTAxZWNiNjVjMDkzNDI4MmJlNWRmYzM1N2M1NTQyMzdfNC03LTEtMS0w_c8c1cad6-9361-4aa8-8e8e-da0381fec05c"
      unitRef="usd">25217000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i0fd58d29aa7f4494bf30f6d59ca72c8c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RhYmxlOmEwMWVjYjY1YzA5MzQyODJiZTVkZmMzNTdjNTU0MjM3L3RhYmxlcmFuZ2U6YTAxZWNiNjVjMDkzNDI4MmJlNWRmYzM1N2M1NTQyMzdfNS0xLTEtMS0w_a77790da-537f-4e06-a818-0f4c0c90190a"
      unitRef="usd">27101000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i0fd58d29aa7f4494bf30f6d59ca72c8c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RhYmxlOmEwMWVjYjY1YzA5MzQyODJiZTVkZmMzNTdjNTU0MjM3L3RhYmxlcmFuZ2U6YTAxZWNiNjVjMDkzNDI4MmJlNWRmYzM1N2M1NTQyMzdfNS0zLTEtMS0w_cc2d4aff-7138-43f0-b928-5fb38afdb903"
      unitRef="usd">79000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i0fd58d29aa7f4494bf30f6d59ca72c8c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RhYmxlOmEwMWVjYjY1YzA5MzQyODJiZTVkZmMzNTdjNTU0MjM3L3RhYmxlcmFuZ2U6YTAxZWNiNjVjMDkzNDI4MmJlNWRmYzM1N2M1NTQyMzdfNS01LTEtMS0w_f0f51293-818d-4fb6-be50-3b231a765da5"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0fd58d29aa7f4494bf30f6d59ca72c8c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RhYmxlOmEwMWVjYjY1YzA5MzQyODJiZTVkZmMzNTdjNTU0MjM3L3RhYmxlcmFuZ2U6YTAxZWNiNjVjMDkzNDI4MmJlNWRmYzM1N2M1NTQyMzdfNS03LTEtMS0w_51bd8a1c-cb4b-43cd-8703-f7794e680f1f"
      unitRef="usd">27180000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ieb9f9878977d4bee8003a43bbd55fbf7_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RhYmxlOmEwMWVjYjY1YzA5MzQyODJiZTVkZmMzNTdjNTU0MjM3L3RhYmxlcmFuZ2U6YTAxZWNiNjVjMDkzNDI4MmJlNWRmYzM1N2M1NTQyMzdfNi0xLTEtMS0w_97e7f8b1-2d14-41e6-8bcb-0bb8774d6cb8"
      unitRef="usd">31218000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ieb9f9878977d4bee8003a43bbd55fbf7_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RhYmxlOmEwMWVjYjY1YzA5MzQyODJiZTVkZmMzNTdjNTU0MjM3L3RhYmxlcmFuZ2U6YTAxZWNiNjVjMDkzNDI4MmJlNWRmYzM1N2M1NTQyMzdfNi0zLTEtMS0w_6f633f50-65cc-4582-a70d-6a14a6447191"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ieb9f9878977d4bee8003a43bbd55fbf7_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RhYmxlOmEwMWVjYjY1YzA5MzQyODJiZTVkZmMzNTdjNTU0MjM3L3RhYmxlcmFuZ2U6YTAxZWNiNjVjMDkzNDI4MmJlNWRmYzM1N2M1NTQyMzdfNi01LTEtMS0w_d1778b8e-71fa-42a6-926f-b58f34b4ba68"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ieb9f9878977d4bee8003a43bbd55fbf7_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RhYmxlOmEwMWVjYjY1YzA5MzQyODJiZTVkZmMzNTdjNTU0MjM3L3RhYmxlcmFuZ2U6YTAxZWNiNjVjMDkzNDI4MmJlNWRmYzM1N2M1NTQyMzdfNi03LTEtMS0w_503cc52a-3b01-4106-a89b-a06ec3a8f8b3"
      unitRef="usd">31218000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i86be035a34fe478ea00df2e76fba4dc9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RhYmxlOmEwMWVjYjY1YzA5MzQyODJiZTVkZmMzNTdjNTU0MjM3L3RhYmxlcmFuZ2U6YTAxZWNiNjVjMDkzNDI4MmJlNWRmYzM1N2M1NTQyMzdfNy0xLTEtMS0w_3dcf7ecc-1005-4346-8524-485d3ec45689"
      unitRef="usd">962439000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i86be035a34fe478ea00df2e76fba4dc9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RhYmxlOmEwMWVjYjY1YzA5MzQyODJiZTVkZmMzNTdjNTU0MjM3L3RhYmxlcmFuZ2U6YTAxZWNiNjVjMDkzNDI4MmJlNWRmYzM1N2M1NTQyMzdfNy0zLTEtMS0w_00f708b1-ee71-4d44-9d91-2e7404e9225e"
      unitRef="usd">128000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i86be035a34fe478ea00df2e76fba4dc9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RhYmxlOmEwMWVjYjY1YzA5MzQyODJiZTVkZmMzNTdjNTU0MjM3L3RhYmxlcmFuZ2U6YTAxZWNiNjVjMDkzNDI4MmJlNWRmYzM1N2M1NTQyMzdfNy01LTEtMS0w_9e253df8-a07a-463a-93f3-2f2a15cca77d"
      unitRef="usd">14000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i86be035a34fe478ea00df2e76fba4dc9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RhYmxlOmEwMWVjYjY1YzA5MzQyODJiZTVkZmMzNTdjNTU0MjM3L3RhYmxlcmFuZ2U6YTAxZWNiNjVjMDkzNDI4MmJlNWRmYzM1N2M1NTQyMzdfNy03LTEtMS0w_32e180d9-99e6-4264-ad01-7d68774cc624"
      unitRef="usd">962553000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i74d3c7dbdd71495c8557f07cac6cd34d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RhYmxlOmEwMWVjYjY1YzA5MzQyODJiZTVkZmMzNTdjNTU0MjM3L3RhYmxlcmFuZ2U6YTAxZWNiNjVjMDkzNDI4MmJlNWRmYzM1N2M1NTQyMzdfOS0xLTEtMS0w_ea7058ee-fb3d-4c97-87c6-0ea80a3e2194"
      unitRef="usd">2561000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i74d3c7dbdd71495c8557f07cac6cd34d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RhYmxlOmEwMWVjYjY1YzA5MzQyODJiZTVkZmMzNTdjNTU0MjM3L3RhYmxlcmFuZ2U6YTAxZWNiNjVjMDkzNDI4MmJlNWRmYzM1N2M1NTQyMzdfOS0zLTEtMS0w_31f311de-fd42-41ae-b0a8-1fa172d82c78"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i74d3c7dbdd71495c8557f07cac6cd34d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RhYmxlOmEwMWVjYjY1YzA5MzQyODJiZTVkZmMzNTdjNTU0MjM3L3RhYmxlcmFuZ2U6YTAxZWNiNjVjMDkzNDI4MmJlNWRmYzM1N2M1NTQyMzdfOS01LTEtMS0w_d1ce3487-9bd4-4cf7-ac22-26bbe0a5323c"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i74d3c7dbdd71495c8557f07cac6cd34d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RhYmxlOmEwMWVjYjY1YzA5MzQyODJiZTVkZmMzNTdjNTU0MjM3L3RhYmxlcmFuZ2U6YTAxZWNiNjVjMDkzNDI4MmJlNWRmYzM1N2M1NTQyMzdfOS03LTEtMS0w_f38d8907-0013-4538-8847-a1f27199d8d8"
      unitRef="usd">2561000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="icc4f3f2e913840ec946d6ab82f45dc71_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RhYmxlOmEwMWVjYjY1YzA5MzQyODJiZTVkZmMzNTdjNTU0MjM3L3RhYmxlcmFuZ2U6YTAxZWNiNjVjMDkzNDI4MmJlNWRmYzM1N2M1NTQyMzdfMTEtMS0xLTEtMA_ea437638-cefb-43f9-a951-edd653017fe3"
      unitRef="usd">30147000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="icc4f3f2e913840ec946d6ab82f45dc71_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RhYmxlOmEwMWVjYjY1YzA5MzQyODJiZTVkZmMzNTdjNTU0MjM3L3RhYmxlcmFuZ2U6YTAxZWNiNjVjMDkzNDI4MmJlNWRmYzM1N2M1NTQyMzdfMTEtMy0xLTEtMA_703f8c1f-1a73-49a2-a603-de1103c8fe9c"
      unitRef="usd">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="icc4f3f2e913840ec946d6ab82f45dc71_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RhYmxlOmEwMWVjYjY1YzA5MzQyODJiZTVkZmMzNTdjNTU0MjM3L3RhYmxlcmFuZ2U6YTAxZWNiNjVjMDkzNDI4MmJlNWRmYzM1N2M1NTQyMzdfMTEtNS0xLTEtMA_93572e91-67d2-49d8-ac52-01029837f279"
      unitRef="usd">11000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="icc4f3f2e913840ec946d6ab82f45dc71_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RhYmxlOmEwMWVjYjY1YzA5MzQyODJiZTVkZmMzNTdjNTU0MjM3L3RhYmxlcmFuZ2U6YTAxZWNiNjVjMDkzNDI4MmJlNWRmYzM1N2M1NTQyMzdfMTEtNy0xLTEtMA_d53f687f-9f95-42a4-a30b-37b4a752ba6f"
      unitRef="usd">30138000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="iac0bb6ea773e4895b9939e783cbf93a7_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RhYmxlOmEwMWVjYjY1YzA5MzQyODJiZTVkZmMzNTdjNTU0MjM3L3RhYmxlcmFuZ2U6YTAxZWNiNjVjMDkzNDI4MmJlNWRmYzM1N2M1NTQyMzdfMTItMS0xLTEtMA_0da1b19b-7f39-4289-af29-238a3a7c684e"
      unitRef="usd">32708000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="iac0bb6ea773e4895b9939e783cbf93a7_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RhYmxlOmEwMWVjYjY1YzA5MzQyODJiZTVkZmMzNTdjNTU0MjM3L3RhYmxlcmFuZ2U6YTAxZWNiNjVjMDkzNDI4MmJlNWRmYzM1N2M1NTQyMzdfMTItMy0xLTEtMA_68bfef65-caaf-41cf-9c5d-a21f018b762a"
      unitRef="usd">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="iac0bb6ea773e4895b9939e783cbf93a7_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RhYmxlOmEwMWVjYjY1YzA5MzQyODJiZTVkZmMzNTdjNTU0MjM3L3RhYmxlcmFuZ2U6YTAxZWNiNjVjMDkzNDI4MmJlNWRmYzM1N2M1NTQyMzdfMTItNS0xLTEtMA_a63ccd6e-e8f5-4d1c-a3ba-0c6c232b3db3"
      unitRef="usd">11000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iac0bb6ea773e4895b9939e783cbf93a7_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RhYmxlOmEwMWVjYjY1YzA5MzQyODJiZTVkZmMzNTdjNTU0MjM3L3RhYmxlcmFuZ2U6YTAxZWNiNjVjMDkzNDI4MmJlNWRmYzM1N2M1NTQyMzdfMTItNy0xLTEtMA_5e2e4925-2789-44d7-815f-5e54547667f3"
      unitRef="usd">32699000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="idb7ca9f362da46eab3a29bbbecbda977_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RhYmxlOmEwMWVjYjY1YzA5MzQyODJiZTVkZmMzNTdjNTU0MjM3L3RhYmxlcmFuZ2U6YTAxZWNiNjVjMDkzNDI4MmJlNWRmYzM1N2M1NTQyMzdfMTMtMS0xLTEtMA_119ffa24-a1cd-42a1-a879-f1e4897356b1"
      unitRef="usd">995147000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="idb7ca9f362da46eab3a29bbbecbda977_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RhYmxlOmEwMWVjYjY1YzA5MzQyODJiZTVkZmMzNTdjNTU0MjM3L3RhYmxlcmFuZ2U6YTAxZWNiNjVjMDkzNDI4MmJlNWRmYzM1N2M1NTQyMzdfMTMtMy0xLTEtMA_d7ee7b48-5210-4660-8ce5-2f78bc721921"
      unitRef="usd">130000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="idb7ca9f362da46eab3a29bbbecbda977_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RhYmxlOmEwMWVjYjY1YzA5MzQyODJiZTVkZmMzNTdjNTU0MjM3L3RhYmxlcmFuZ2U6YTAxZWNiNjVjMDkzNDI4MmJlNWRmYzM1N2M1NTQyMzdfMTMtNS0xLTEtMA_1d0007b0-416f-4cbe-88af-2c0563fbc6e0"
      unitRef="usd">25000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="idb7ca9f362da46eab3a29bbbecbda977_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RhYmxlOmEwMWVjYjY1YzA5MzQyODJiZTVkZmMzNTdjNTU0MjM3L3RhYmxlcmFuZ2U6YTAxZWNiNjVjMDkzNDI4MmJlNWRmYzM1N2M1NTQyMzdfMTMtNy0xLTEtMA_c797fd9e-269c-4775-bd22-b3bd3232147b"
      unitRef="usd">995252000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="ia965935f3dfc41e9898218d34d2db66f_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RleHRyZWdpb246MjFlN2QzYmNkYTljNDAwMzgwZjEzZmJmZjY4YzA4NTRfMTA5OTUxMTYzMTIzNQ_c7d1f524-8af1-454f-bead-effd656944f2"
      unitRef="security">19</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="ia965935f3dfc41e9898218d34d2db66f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RleHRyZWdpb246MjFlN2QzYmNkYTljNDAwMzgwZjEzZmJmZjY4YzA4NTRfMTA5OTUxMTYzMTI1OQ_a9563279-1c15-4ca4-a3a9-0b081249f300"
      unitRef="usd">369900000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="i3607ed8ca137404691d4a18591291e6d_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RleHRyZWdpb246MjFlN2QzYmNkYTljNDAwMzgwZjEzZmJmZjY4YzA4NTRfMTA5OTUxMTYzMTI2OQ_3516e64f-e74e-46b3-8c59-7370d7c7e744"
      unitRef="security">2</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i3607ed8ca137404691d4a18591291e6d_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RleHRyZWdpb246MjFlN2QzYmNkYTljNDAwMzgwZjEzZmJmZjY4YzA4NTRfMTA5OTUxMTYzMTI5Mw_f58f4889-901f-422a-9642-5750537fcb0f"
      unitRef="usd">10100000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="icc4f3f2e913840ec946d6ab82f45dc71_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RleHRyZWdpb246MjFlN2QzYmNkYTljNDAwMzgwZjEzZmJmZjY4YzA4NTRfMTA5OTUxMTYzMTMwNg_3749bc50-bf21-4070-92a1-9580ed5cf601"
      unitRef="security">1</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="icc4f3f2e913840ec946d6ab82f45dc71_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RleHRyZWdpb246MjFlN2QzYmNkYTljNDAwMzgwZjEzZmJmZjY4YzA4NTRfMTA5OTUxMTYzMTMzMA_48f7c94a-44e5-408e-bfe8-42a5136336d5"
      unitRef="usd">20100000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="idb7ca9f362da46eab3a29bbbecbda977_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RleHRyZWdpb246MjFlN2QzYmNkYTljNDAwMzgwZjEzZmJmZjY4YzA4NTRfMTYyOA_1b2cff37-4c0d-4cfe-b884-86e6d2493515"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="i9953f50a7fd74f7d8438f304f136a07b_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RleHRyZWdpb246MjFlN2QzYmNkYTljNDAwMzgwZjEzZmJmZjY4YzA4NTRfMTYyOA_a28060ef-e17c-4ccd-a94c-10a1a16e3e4e"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
      contextRef="ia34dfea6b8734d64abf707c28256801c_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RleHRyZWdpb246MjFlN2QzYmNkYTljNDAwMzgwZjEzZmJmZjY4YzA4NTRfMjM1NA_090b023e-02f0-4365-804a-f9cd097d2a0c"
      unitRef="usd">-100000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ia34dfea6b8734d64abf707c28256801c_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RleHRyZWdpb246MjFlN2QzYmNkYTljNDAwMzgwZjEzZmJmZjY4YzA4NTRfMjM1NA_6f8a118a-2172-49e3-a8e0-b6212117bda3"
      unitRef="usd">-100000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:DebtSecuritiesAvailableForSaleTerm
      contextRef="i9953f50a7fd74f7d8438f304f136a07b_I20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8zNy9mcmFnOjIxZTdkM2JjZGE5YzQwMDM4MGYxM2ZiZmY2OGMwODU0L3RleHRyZWdpb246MjFlN2QzYmNkYTljNDAwMzgwZjEzZmJmZjY4YzA4NTRfMjcyNw_7ef42a61-e760-4ad7-97d2-22a03be7f1ed">P2Y</us-gaap:DebtSecuritiesAvailableForSaleTerm>
    <us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock
      contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80MC9mcmFnOmM4NDBhMmRhOTM0YzQ4YjBhNzkzOTczMWU0YTVkMzQ0L3RleHRyZWdpb246Yzg0MGEyZGE5MzRjNDhiMGE3OTM5NzMxZTRhNWQzNDRfMTQxNg_b2c276a9-222e-4622-9891-537bc926b275">Derivative Financial Instruments&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Foreign Currency Exchange Rate Exposure&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses forward foreign currency exchange contracts to hedge certain operational exposures resulting from potential changes in foreign currency exchange rates. Such exposures result from portions of the Company&#x2019;s forecasted cash flows being denominated in currencies other than the U.S. dollar, primarily the Euro and British Pound. The derivative instruments the Company uses to hedge this exposure are not designated as cash flow hedges, and as a result, changes in their fair value are recorded in interest and other income, net, on the Company's Condensed Consolidated Statements of Operations and Comprehensive Loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair values of forward foreign currency exchange contracts are estimated using current exchange rates and interest rates and take into consideration the current creditworthiness of the counterparties. Information regarding the specific instruments used by the Company to hedge its exposure to foreign currency exchange rate fluctuations is provided below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s forward foreign currency exchange contracts outstanding as of March 31, 2021 and December 31, 2020, respectively (notional amounts in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:27.265%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.252%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.778%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.902%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Foreign Exchange Contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of Contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate Notional&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount in Foreign Currency&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Maturity&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Euros &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Apr 2021- Mar 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;British Pounds &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Apr 2021- Nov 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total at March 31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Euros &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Jan 2021 - Nov 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;British Pounds &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,658&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Jan 2021 - Nov 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total at December 31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:120%"&gt;_________________________________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;padding-left:11.65pt;position:relative;top:-2.8pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;The notional amount represents the net amount of foreign currency that will be received upon maturity of the forward contracts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A derivative liability balance of $0.2 million is recorded on the Condensed Consolidated Balance Sheets as of March 31, 2021 and an immaterial derivative liability balance is recorded on the Condensed Consolidated Balance Sheets as of December 31, 2020. An immaterial derivative asset balance is recorded in prepaid expenses and other current assets on the Condensed Consolidated Balance Sheets as of March 31, 2021 and a derivative asset balance of $0.2 million is recorded in prepaid expenses and other current assets on the Condensed Consolidated Balance Sheets as of December 31, 2020. A net loss of $0.2 million associated with the Company's derivative instruments is recognized in interest and other income, net on the Condensed Consolidated Statements of Operations and Comprehensive Loss for each of the three months ended March 31, 2021 and March 31, 2020.&lt;/span&gt;&lt;/div&gt;</us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfDerivativeInstrumentsTextBlock
      contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80MC9mcmFnOmM4NDBhMmRhOTM0YzQ4YjBhNzkzOTczMWU0YTVkMzQ0L3RleHRyZWdpb246Yzg0MGEyZGE5MzRjNDhiMGE3OTM5NzMxZTRhNWQzNDRfMTQxOA_c1a7dde2-8d48-4b6b-8515-4a9075d24f85">&lt;div style="margin-bottom:10pt;margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s forward foreign currency exchange contracts outstanding as of March 31, 2021 and December 31, 2020, respectively (notional amounts in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:27.265%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.252%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.778%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.902%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Foreign Exchange Contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of Contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate Notional&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount in Foreign Currency&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Maturity&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Euros &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Apr 2021- Mar 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;British Pounds &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Apr 2021- Nov 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total at March 31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Euros &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Jan 2021 - Nov 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;British Pounds &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,658&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Jan 2021 - Nov 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total at December 31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:120%"&gt;_________________________________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;padding-left:11.65pt;position:relative;top:-2.8pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;The notional amount represents the net amount of foreign currency that will be received upon maturity of the forward contracts.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsTextBlock>
    <us-gaap:DerivativeNumberOfInstrumentsHeld
      contextRef="i5e5ef3c57c01481ab32c18cba94f5fe4_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80MC9mcmFnOmM4NDBhMmRhOTM0YzQ4YjBhNzkzOTczMWU0YTVkMzQ0L3RhYmxlOjA4MDUwZTQ1N2VjYzQ3NjBiODQ0MzhhNDNjNTViNzEzL3RhYmxlcmFuZ2U6MDgwNTBlNDU3ZWNjNDc2MGI4NDQzOGE0M2M1NWI3MTNfMS0yLTEtMS0w_564f2b01-d4c7-4bda-a7d5-cbd5d0674661"
      unitRef="derivative_instrument">26</us-gaap:DerivativeNumberOfInstrumentsHeld>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i5e5ef3c57c01481ab32c18cba94f5fe4_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80MC9mcmFnOmM4NDBhMmRhOTM0YzQ4YjBhNzkzOTczMWU0YTVkMzQ0L3RhYmxlOjA4MDUwZTQ1N2VjYzQ3NjBiODQ0MzhhNDNjNTViNzEzL3RhYmxlcmFuZ2U6MDgwNTBlNDU3ZWNjNDc2MGI4NDQzOGE0M2M1NWI3MTNfMS00LTEtMS0w_31cad5bb-720c-471c-bc97-e528be6032c7"
      unitRef="eur">4305000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNumberOfInstrumentsHeld
      contextRef="id84a031bb1374baa8de940b07c3dff05_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80MC9mcmFnOmM4NDBhMmRhOTM0YzQ4YjBhNzkzOTczMWU0YTVkMzQ0L3RhYmxlOjA4MDUwZTQ1N2VjYzQ3NjBiODQ0MzhhNDNjNTViNzEzL3RhYmxlcmFuZ2U6MDgwNTBlNDU3ZWNjNDc2MGI4NDQzOGE0M2M1NWI3MTNfMi0yLTEtMS0w_55a8c5ae-e61b-4293-b0b5-b0d152dc7b45"
      unitRef="derivative_instrument">11</us-gaap:DerivativeNumberOfInstrumentsHeld>
    <us-gaap:DerivativeNotionalAmount
      contextRef="id84a031bb1374baa8de940b07c3dff05_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80MC9mcmFnOmM4NDBhMmRhOTM0YzQ4YjBhNzkzOTczMWU0YTVkMzQ0L3RhYmxlOjA4MDUwZTQ1N2VjYzQ3NjBiODQ0MzhhNDNjNTViNzEzL3RhYmxlcmFuZ2U6MDgwNTBlNDU3ZWNjNDc2MGI4NDQzOGE0M2M1NWI3MTNfMi00LTEtMS0w_4e96f6f9-df1e-4585-90f8-36c0dddfddce"
      unitRef="gbp">963000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNumberOfInstrumentsHeld
      contextRef="ibf15d1cb21ae4c5b886c0aea82e7d1f3_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80MC9mcmFnOmM4NDBhMmRhOTM0YzQ4YjBhNzkzOTczMWU0YTVkMzQ0L3RhYmxlOjA4MDUwZTQ1N2VjYzQ3NjBiODQ0MzhhNDNjNTViNzEzL3RhYmxlcmFuZ2U6MDgwNTBlNDU3ZWNjNDc2MGI4NDQzOGE0M2M1NWI3MTNfNC0yLTEtMS0w_9b396e25-980c-4124-8c88-67ebd9044f78"
      unitRef="derivative_instrument">37</us-gaap:DerivativeNumberOfInstrumentsHeld>
    <us-gaap:DerivativeNumberOfInstrumentsHeld
      contextRef="i8d51a225b0e74a329c75163f5353da38_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80MC9mcmFnOmM4NDBhMmRhOTM0YzQ4YjBhNzkzOTczMWU0YTVkMzQ0L3RhYmxlOjA4MDUwZTQ1N2VjYzQ3NjBiODQ0MzhhNDNjNTViNzEzL3RhYmxlcmFuZ2U6MDgwNTBlNDU3ZWNjNDc2MGI4NDQzOGE0M2M1NWI3MTNfNS0yLTEtMS0w_de871a70-3192-4874-90b2-81b73639ec5a"
      unitRef="derivative_instrument">26</us-gaap:DerivativeNumberOfInstrumentsHeld>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i8d51a225b0e74a329c75163f5353da38_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80MC9mcmFnOmM4NDBhMmRhOTM0YzQ4YjBhNzkzOTczMWU0YTVkMzQ0L3RhYmxlOjA4MDUwZTQ1N2VjYzQ3NjBiODQ0MzhhNDNjNTViNzEzL3RhYmxlcmFuZ2U6MDgwNTBlNDU3ZWNjNDc2MGI4NDQzOGE0M2M1NWI3MTNfNS00LTEtMS0w_715bfb02-4c58-40a5-b286-2ace8ccf487c"
      unitRef="eur">3855000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNumberOfInstrumentsHeld
      contextRef="i83e8165a75164bcd89f57c0c00451316_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80MC9mcmFnOmM4NDBhMmRhOTM0YzQ4YjBhNzkzOTczMWU0YTVkMzQ0L3RhYmxlOjA4MDUwZTQ1N2VjYzQ3NjBiODQ0MzhhNDNjNTViNzEzL3RhYmxlcmFuZ2U6MDgwNTBlNDU3ZWNjNDc2MGI4NDQzOGE0M2M1NWI3MTNfNi0yLTEtMS0w_c67cd388-c335-463f-9655-5b59eb69fe32"
      unitRef="derivative_instrument">21</us-gaap:DerivativeNumberOfInstrumentsHeld>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i83e8165a75164bcd89f57c0c00451316_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80MC9mcmFnOmM4NDBhMmRhOTM0YzQ4YjBhNzkzOTczMWU0YTVkMzQ0L3RhYmxlOjA4MDUwZTQ1N2VjYzQ3NjBiODQ0MzhhNDNjNTViNzEzL3RhYmxlcmFuZ2U6MDgwNTBlNDU3ZWNjNDc2MGI4NDQzOGE0M2M1NWI3MTNfNi00LTEtMS0w_c9df10d8-a2bd-4edb-8b98-24e566f1ecb3"
      unitRef="gbp">2658000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNumberOfInstrumentsHeld
      contextRef="idcf71a3762844d5ebc7aaa02a121c837_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80MC9mcmFnOmM4NDBhMmRhOTM0YzQ4YjBhNzkzOTczMWU0YTVkMzQ0L3RhYmxlOjA4MDUwZTQ1N2VjYzQ3NjBiODQ0MzhhNDNjNTViNzEzL3RhYmxlcmFuZ2U6MDgwNTBlNDU3ZWNjNDc2MGI4NDQzOGE0M2M1NWI3MTNfOC0yLTEtMS0w_a8bd1382-6142-4f75-a1e2-0799ffd2b032"
      unitRef="derivative_instrument">47</us-gaap:DerivativeNumberOfInstrumentsHeld>
    <us-gaap:DerivativeLiabilities
      contextRef="i3e3538bcdaba49b4bc9b8ff9d89ef4b8_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80MC9mcmFnOmM4NDBhMmRhOTM0YzQ4YjBhNzkzOTczMWU0YTVkMzQ0L3RleHRyZWdpb246Yzg0MGEyZGE5MzRjNDhiMGE3OTM5NzMxZTRhNWQzNDRfMTA5OTUxMTYzMTM2Ng_ab5dc2e7-df30-40b7-ac21-f4c6b591a994"
      unitRef="usd">200000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeAssets
      contextRef="i2d55a3178b03487c9c5028f18060a482_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80MC9mcmFnOmM4NDBhMmRhOTM0YzQ4YjBhNzkzOTczMWU0YTVkMzQ0L3RleHRyZWdpb246Yzg0MGEyZGE5MzRjNDhiMGE3OTM5NzMxZTRhNWQzNDRfMTA5OTUxMTYzMTMwMA_9d74a06f-4349-4b7f-9247-ca26bc4a340d"
      unitRef="usd">200000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80MC9mcmFnOmM4NDBhMmRhOTM0YzQ4YjBhNzkzOTczMWU0YTVkMzQ0L3RleHRyZWdpb246Yzg0MGEyZGE5MzRjNDhiMGE3OTM5NzMxZTRhNWQzNDRfMTA5OTUxMTYzMTEwOA_1556ac27-b6b9-4437-81fb-095edb3c4cfc"
      unitRef="usd">-200000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="ia34dfea6b8734d64abf707c28256801c_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80MC9mcmFnOmM4NDBhMmRhOTM0YzQ4YjBhNzkzOTczMWU0YTVkMzQ0L3RleHRyZWdpb246Yzg0MGEyZGE5MzRjNDhiMGE3OTM5NzMxZTRhNWQzNDRfMTA5OTUxMTYzMTEwOA_21f2f906-649c-4bb6-9cc6-01766ccee4be"
      unitRef="usd">-200000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMjkyNjk_9230ab11-45f7-4493-970c-c8dc1c1d2c31">Collaboration Agreements&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Biogen&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Provisional Biogen Collaboration Agreement and Common Stock Purchase Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August&#160;5, 2020, the Company entered into a binding Provisional Collaboration and License Agreement (&#x201c;Provisional Biogen Collaboration Agreement&#x201d;) with Biogen Inc.&#x2019;s subsidiaries, Biogen MA Inc. (&#x201c;BIMA&#x201d;) and Biogen International GmbH (&#x201c;BIG&#x201d;) (BIMA and BIG, collectively, &#x201c;Biogen&#x201d;) pursuant to which the Company granted Biogen a license to co-develop and co-commercialize Denali&#x2019;s small molecule LRRK2 inhibitor program (the &#x201c;LRRK2 Program&#x201d;), an option in respect of each of (i) the Company&#x2019;s amyloid beta program utilizing the Company's Transport Vehicle ("TV") technology platform to cross the blood-brain barrier ("BBB") and (ii) one other unnamed program also utilizing the Company's TV technology platform (the &#x201c;Option Programs&#x201d;), and a right of first negotiation with respect to two additional unnamed programs for indications within Alzheimer&#x2019;s disease, Parkinson&#x2019;s disease, amyotrophic lateral sclerosis ("ALS") or multiple sclerosis utilizing the Company's TV technology platform (the &#x201c;ROFN Programs&#x201d;) should the Company decide to seek a collaboration with a third party for such programs. The Provisional Biogen Collaboration Agreement was a binding agreement, which became effective on the closing of the Common Stock Purchase Agreement ("SPA"), as described further below. The Provisional Biogen Collaboration Agreement expired in October 2020 upon the execution of a Definitive LRRK2 Collaboration and License Agreement (&#x201c;LRRK2 Agreement&#x201d;) with Biogen on October&#160;4, 2020 and a Right of First Negotiation, Option and License Agreement (the &#x201c;ROFN and Option Agreement&#x201d;) on October&#160;6, 2020 (collectively, the "Biogen Collaboration Agreement").&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the Provisional Biogen Collaboration Agreement, Biogen was obligated to pay the Company a $560.0 million upfront payment, payable upon execution of the Biogen Collaboration Agreement, which occurred in October 2020. With respect to the LRRK2 Program, Biogen is required to make milestone payments up to approximately $1.125 billion upon achievement of certain development and sales milestone events. Such milestone payments include $375.0&#160;million in development, $375.0&#160;million upon first commercial sale, and $375.0&#160;million in net sales-based milestones. The Company will share 50% of the profits and losses with Biogen for LRRK2 Products in the United States, and 40% of such profits and losses in China. The Company will be entitled to receive royalties in the high teens to low twenties percentages on net sales for LRRK2 Products outside of the United States and China.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the Provisional Biogen Collaboration Agreement, Denali conducted and controlled LRRK2 clinical development through the effective date of the Biogen Collaboration Agreement. Subsequently, the Company and Biogen are jointly developing LRRK2 Products pursuant to a clinical development plan set forth within the LRRK2 Agreement. The parties share responsibility and costs for global development of LRRK2 Products pursuant to a mutually agreed development plan and budget ("LRRK2 Development Activities"), with Biogen funding 60% and the Company funding 40% of such costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company may opt out of development cost sharing worldwide and upon such election, from any further profit-sharing from the LRRK2 Program. The Company also has the right to opt-out of the profit sharing arrangement for the LRRK2 Program or for only those LRRK2 Products that do not penetrate the BBB (&#x201c;Peripheral LRRK2 Products&#x201d;), in each of the United States and China. After such an opt out, the Company will no longer be obligated to share in the development and commercialization costs for, or be entitled to share in the applicable revenues from, such LRRK2 Program (or from the Peripheral LRRK2 Products) for such country, as applicable. If the Company chooses to exercise its opt out rights, the Company will be entitled to receive tiered royalties on net sales of the applicable LRRK2 Program in the relevant country (or countries). The royalty rates for the applicable LRRK2 Program will be a percentage in the high teens to low twenties, but may increase to the mid-twenties if the Company has met certain co-funding thresholds or there has been a first commercial sale at the time of the Company's election.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to the LRRK2 Program, Biogen received an exclusive option to license two preclinical programs enabled by the Company's TV technology platform, which platform aims to improve brain uptake of biotherapeutics, including its Antibody Transport Vehicle ("ATV"): Abeta program ("ATV-enabled anti-amyloid beta program") and a second program utilizing the Company's TV technology for an unnamed target ("TV program"), excluding small molecules, Adeno-associated viruses ("AAV") and oligonucleotides. Biogen&#x2019;s option may be exercised up to initiation of investigational new drug ("IND")-enabling studies for each program and continues for each program until a specified period of time after delivery of an option data package, or &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfNTMxNA_6ca82b29-adf5-4704-b8b5-513bcd955ad5"&gt;thirty&lt;/span&gt; business days after the 5th anniversary of the effective date of the Provisional Biogen Collaboration Agreement, whichever is earlier.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Further, Biogen will have the right of first negotiation ("ROFN") on two additional TV-enabled therapeutics within Alzheimer&#x2019;s disease, Parkinson&#x2019;s disease, ALS or multiple sclerosis should the Company decide to seek a collaboration with a third party for such programs, but this does not include any of the Company&#x2019;s small molecule, AAV or oligonucleotide programs. The ROFN period continues until seven years after the effective date of the Provisional Biogen Collaboration Agreement or the date on which the Company has offered Biogen two ROFN Programs, and for which Biogen has agreed to trigger a ROFN for such program, whichever is earlier. However, if the Company does not execute an agreement with a third party with respect to a particular ROFN Program offered to Biogen within a specified amount of time, Biogen will have one additional right to exercise the ROFN again with respect to such ROFN Program.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the Provisional Biogen Collaboration Agreement, the Company entered into a common stock purchase agreement (the "Stock Purchase Agreement") with BIMA on August&#160;5, 2020, pursuant to which the Company agreed to issue and sell, and BIMA agreed to purchase, 13,310,243 shares of the Company&#x2019;s common stock (the &#x201c;Shares&#x201d;) for an aggregate purchase price of $465.0 million pursuant to the terms and conditions thereof. Since the shares of common stock owned by Biogen as of March 31, 2021 represent more than 10% of the voting interest of the Company, Biogen is considered a related party as defined in ASC 850. Management determined that it was appropriate to account for the Provisional Biogen Collaboration Agreement and the SPA as one arrangement because they were entered into at the same time with interrelated financial terms.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September&#160;22, 2020, the Company closed the sale of the Shares to BIMA pursuant to the Stock Purchase Agreement. The estimated fair market value of the Shares issued to BIMA was $420.1&#160;million, based on the closing stock price of $35.87 on the date of issuance adjusted by a discount for lack of marketability due to certain holding period restrictions, which was valued using an option pricing model. This stock issuance resulted in a $44.9&#160;million premium paid to the Company above the estimated fair value of the Company's common stock (the "Stock Premium"), which forms part of the transaction price for the Biogen Collaboration Agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Biogen Collaboration Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company entered into the LRRK2 Agreement with Biogen on October&#160;4, 2020 and the ROFN and Option Agreement on October&#160;6, 2020. Collectively these are known as the Biogen Collaboration Agreement, the material terms of which are consistent with, and supersede, the Provisional Biogen Collaboration Agreement discussed above. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the ROFN and Option Agreement, with respect to the options granted by the Company to Biogen, Biogen is obligated to pay to the Company an aggregate of up to $270.0&#160;million in option exercise and development milestone payments, up to $325.0&#160;million upon first commercial sale, and up to $290.0&#160;million of net sales-based milestone payments, following the achievement of certain prespecified milestone events and if Biogen exercises both of its options. Furthermore, Biogen is obligated to pay to the Company royalties in the mid-single digit to mid-teens percentages, depending on the program for which Biogen exercises its option and upon the achievement of certain sales thresholds.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2020, the Company received upfront payments totaling $560.0&#160;million pursuant to the Biogen Collaboration Agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Biogen Collaboration Agreement is considered a contract modification to the Provisional Biogen Collaboration Agreement and was accounted for as a termination of the provisional agreement and commencement of a new contract.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company identified the following distinct performance obligations associated with the Biogen Collaboration Agreement that had not yet been delivered under the original contract: the LRRK2 Program license, the research services for the ATV:Abeta and TV programs (&#x201c;Option Research Services&#x201d;) which include option joint steering committee ("JSC") participation, and a material right for an option under the ROFN and Option Agreement. Further, the LRRK2 Development Activities which includes LRRK2 JSC and joint development committee (&#x201c;JDC&#x201d;) participation was identified as a unit of account under ASC 808. The LRRK2 Development Activities, JSC and JDC participation are considered to be a single unit of account since the development activities are highly interrelated with the JSC and JDC involvement and these are not distinct in the context of the contract. Further, the same was considered to be true for the option research services and option JSC participation performance obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company believes that the Biogen Collaboration Agreement is a collaboration arrangement as defined in ASC 808, Collaborative Arrangements. The Company also believes that Biogen meets the definition of a customer as defined in ASC 606, Revenue From Contracts With Customers for all of the performance obligations identified at inception except for the LRRK2 Development Activities. Since ASC 808 does not address recognition and measurement, the Company looked to other accounting literature for guidance where the performance obligation does not fall under ASC 606, and determined that for the interim LRRK2 development activities subject to cost sharing provisions, the guidance in ASC 730, Research and Development should be applied.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The transaction price at inception included fixed consideration consisting of the upfront fee of $560.0&#160;million and the $44.9&#160;million premium on the sale of common stock. All potential future milestones and other payments were considered constrained at the inception of the Biogen Collaboration Agreement since the Company could not conclude it was probable that a significant reversal in the amount recognized would not occur. From inception of the Biogen Collaboration Agreement through March 31, 2021, there was no change to the transaction price.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The respective standalone value for each of the performance obligations was determined by applying the SSP method and the transaction price was allocated based on the relative SSP method with revenue recognition timing to be determined either by delivery, resolution of an option, or the provision of services.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company used an adjusted market assessment approach to estimate the selling price for the LRRK2 Program license, an expected cost plus margin approach for estimating the Option Research Services and estimated the intrinsic value of the material right for the option, taking into account the likelihood that an option would be exercised. The LRRK2 Program license was delivered on or around the effective date of the Biogen Collaboration Agreement and the revenue allocated to this performance obligation was recognized during the year ended December 31, 2020. The Option Research Services are expected to be delivered over time as the services are performed, with revenue being recognized over time based on costs incurred to perform the services, since the level of costs incurred over time is thought to best reflect the transfer of services to Biogen. Revenue allocated to the material right for an option under the ROFN and Option Agreement is deferred as a contract liability until the option opt in period ends, expiration or ROFN and Option Agreement termination. The LRRK2 Development Activities cost sharing reimbursements or expenses will be recognized over time as earned or incurred, since this is believed to directly correlate to the value of the services performed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A related party contract liability of $296.5 million was recorded on the Consolidated Balance Sheet as of March 31, 2021. Approximately $288.9&#160;million of this contract liability relates to the revenue allocated to the material right for an option under the ROFN and Option Agreement which is being deferred until resolution of the option which is expected to be several years from the balance sheet date, and $7.6&#160;million of this contract liability relates to the portion of the Option Research Services performance obligation yet to be satisfied, with such amount to be recognized over the estimated period of the services, which is expected to be several years. The Company recorded $2.5&#160;million of cost sharing reimbursements for LRRK2 Development Activities as an offset to research and development expenses in the Consolidated Statement of Operations and Comprehensive Income for the three months ended March 31, 2021. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;cost sharing reimbursements due from Biogen&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; on the Condensed Consolidated Balance Sheet as of March 31, 2021 and December 31, 2020 of $2.5 million and $5.7&#160;million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In assessing the Biogen Collaboration Agreement, management exercised considerable judgment in estimating revenue to be recognized, specifically related to estimating the discount for lack of marketability associated with the stock issuance, determining the separate performance obligations under the Biogen Collaboration Agreement, and estimating the standalone selling price of those performance obligations. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March 31, 2021, the Company had not achieved any milestones or recorded any product sales under the Biogen Collaboration Agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Sanofi &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2018, the Company entered into a Collaboration and License Agreement ("Sanofi Collaboration Agreement") with Genzyme Corporation, a wholly owned subsidiary of Sanofi S.A. ("Sanofi") pursuant to which certain small molecule CNS and peripheral &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;receptor interacting serine/threonine protein kinase 1 ("&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;RIPK1") inhibitors contributed by Sanofi and by the Company will be developed and commercialized. The Sanofi Collaboration Agreement became effective in November 2018 at which time Sanofi paid the Company an upfront payment of $125.0 million. Under the Sanofi Collaboration Agreement, the Company is eligible to receive milestone payments from Sanofi up to approximately $1.1 billion upon achievement of certain clinical, regulatory and sales milestone events. Such milestone payments include $215.0 million in clinical milestone payments and $385.0 million in regulatory milestone payments for CNS Products, as defined, that are developed and approved in the United States, by the European Medicines Agency ("EMA") and in Japan for three indications, including Alzheimer's disease. These milestones also include $120.0 million in clinical milestone payments, $175.0 million in regulatory milestone payments and $200.0 million in commercial milestone payments for Peripheral Products, as defined, that are developed and approved in the United States, by the EMA and Japan for three indications. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company will share profits and losses equally with Sanofi for CNS Products sold in the United States and China, and receive variable royalties on net sales for CNS Products sold outside of the United States and China and for Peripheral Products sold worldwide.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company and Sanofi will jointly develop CNS Products pursuant to a global development plan. The Company will be responsible, at its own cost, for conducting Phase 1 and Phase 2 trials for CNS Products in Alzheimer&#x2019;s disease and any activities required to support such clinical trials and specific for Alzheimer's disease ("Denali CNS Development Activities"). The Company conducted, at Sanofi&#x2019;s cost, a Phase 1b trial for the initial lead CNS penetrant RIPK1 inhibitor, DNL747 (SAR443060), in ALS. In June 2020, the Company announced that clinical activities on DNL747 would be paused and efforts focused on the development of the backup preclinical candidate, DNL788 (SAR443820). Other than with the Denali CNS Development Activities, Sanofi is responsible, at its cost, for all other Phase 1 and Phase 2 trials for CNS Products, including for ALS and multiple sclerosis. Sanofi will lead the conduct of all Phase 3 and later stage development trials for CNS Products, with Sanofi and the Company funding 70% and 30% of such costs, respectively. Sanofi will also lead the commercialization activities globally for CNS Products, subject to certain options that the Company has to conduct co-commercialization activities with respect to each CNS Product in the United States and China. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sanofi will be responsible, at its cost, for conducting activities relating to the development and commercialization of all Peripheral Products. Denali will be entitled to receive tiered royalties in the low- to mid- teen percentages on net sales of Peripheral Products.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company identified the following distinct performance obligations associated with the Sanofi Collaboration Agreement upon inception: the CNS program license, the Peripheral program license, the Phase 1 and Phase 2 trials for CNS Products for Alzheimer&#x2019;s disease ("Alzheimer's Disease Services"), and the Phase 1b trial for DNL747 for ALS and associated activities ("Retained Activities"). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company believes that the Sanofi Collaboration Agreement is a collaboration arrangement as defined in ASC 808, Collaborative Arrangements. The Company also believes that Sanofi meets the definition of a customer as defined in ASC 606, Revenue From Contracts With Customers for three of the performance obligations identified at inception, but does not meet the definition of a customer for the Alzheimer's Disease Services. Further, Sanofi does not meet the definition of a customer for all Phase 3 and later stage development trials for CNS Products led by Sanofi for which the Company will fund 30% of total costs. Since ASC 808 does not address recognition and measurement, the Company looked to other accounting literature for guidance where the performance obligation does not fall under ASC 606, and determined that for the Alzheimer's Disease Services, the guidance in ASC 606 should be analogized for the recognition, measurement and reporting of this performance obligation, and for the cost sharing provisions, the Company determined that the guidance in ASC 730, Research and Development should be applied. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The transaction price at inception included upfront fixed consideration of $125.0 million. All potential future milestones and other payments were considered constrained at the inception of the Sanofi Collaboration Agreement since the Company could not conclude it was probable that a significant reversal in the amount recognized would not occur. The transaction price did not increase in the three months ended March 31, 2021, and increased by $0.5 million for the three months ended March 31, 2020 related to costs incurred for Retained Activities that were no longer constrained. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The respective standalone value for each of the performance obligations was determined by applying the SSP method and the transaction price allocated based on the relative SSP method with revenue recognition timing to be determined either by delivery or the provision of services.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company used an adjusted market assessment approach to estimate the selling price for the program licenses, and an expected cost plus margin approach for estimating the Alzheimer&#x2019;s Disease Services and the Retained Activities. The program licenses and existing know-how were delivered on the effective date of the Sanofi Collaboration Agreement. The Alzheimer&#x2019;s Disease Services and the Retained Activities were expected to be delivered over time as the services are performed. For the Alzheimer's Disease Services, revenue is being recognized over time using the input method, based on costs incurred to perform the services, since the level of costs incurred over time is thought to best reflect the transfer of services to Sanofi. For the Retained Activities, revenue is being recognized over time using the output method, based on amounts invoiced to Sanofi, since this is believed to directly correlate to the value of the services performed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A contract liability of $3.4 million was recorded on the Condensed Consolidated Balance Sheets as of March 31, 2021 and December 31, 2020. This contract liability relates to the portion of the Alzheimer's Disease Services performance obligation yet to&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; be satisfied, with such amounts to be recognized over the estimated period of the services, which is expected to be several years. The Company recorded no receivable associated with the Sanofi Collaboration Agreement on the Condensed Consolidated Balance Sheets as of March 31, 2021, and a receivable of $44,303 as of December 31, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In assessing the Sanofi Collaboration Agreement, management is required to exercise considerable judgment in estimating revenue to be recognized. Managem&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ent applies judgment in determining the separate performance obligations, in estimating the selling price, in determining when control was transferred to Sanofi for the licenses, and in estimating total future costs when using the input method.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Through March 31, 2021, the Company has received milestone payments of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$10.0 million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and has not recorded any product sales under the Sanofi Collaboration Agreement.&lt;/span&gt;&lt;span style="color:#ee2724;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Takeda &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2018, the Company entered into a Collaboration and Option Agreement ("Takeda Collaboration Agreement") with Takeda Pharmaceutical Company Limited ("Takeda"), pursuant to which the Company granted Takeda an option to develop and commercialize, jointly with the Company, certain biologic products that are enabled by the Company's BBB delivery technology and intended for the treatment of neurodegenerative disorders. The programs were the Company&#x2019;s ATV:BACE1/Tau and ATV:TREM2 and PTV:PGRN programs. The Takeda Collaboration Agreement became effective in February 2018, at which time Takeda paid the Company an upfront payment of $40.0 million. Takeda may pay up to an aggregate of $25.0 million with respect to each of the three programs directed to a target and based upon the achievement of certain preclinical milestone events, up to $75.0 million in total, $5.0 million of which was paid upon the Takeda Collaboration Agreement becoming effective. In February 2019, the agreement was amended to replace the ATV:BACE1/Tau program with the ATV:Tau program. The amendment did not have a material impact to the condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the Takeda Collaboration Agreement and unless otherwise agreed jointly between both parties, the Company will be responsible, at its cost, for conducting activities relating to pre-IND&#160;development of biologic products directed to the three identified targets and enabled by its BBB delivery technology targeting TfR during the applicable research period. The period through which the option can be exercised continues for each target until the first biologic product directed to the relevant target is&#160;IND-ready&#160;or approximately five years after selection of the target, whichever is earlier.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If Takeda exercises its option with respect to a particular target, then Takeda will have the right to develop and commercialize, jointly with the Company, a specified number of biologic products enabled by its BBB delivery technology that were developed during the research period and which are directed to the relevant target. The Company will grant to Takeda a&#160;co-exclusive&#160;license under the intellectual property the Company controls related to those biologic products.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Takeda is obligated to pay the Company a $5.0 million option fee for each target for which Takeda exercises its option, up to $15.0 million in total.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, if Takeda exercises its option for all three collaboration programs, Takeda may be obligated to pay the Company up to an aggregate of $407.5 million upon achievement of certain clinical milestone events and up to an aggregate of $300.0 million in regulatory milestone events relating to receipt of regulatory approval in the United States, certain European countries and Japan. Takeda may also be obligated to pay the Company up to $75.0 million per biologic product upon achievement of a certain sales-based milestone, or an aggregate of $225.0 million if one biologic product from each program achieves this milestone.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If Takeda exercises its option for a particular target, the Company and Takeda will share equally in the development and commercialization costs, and, if applicable, the profits, for each collaboration program.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the terms of the Takeda Collaboration Agreement, the Company entered into a common stock purchase agreement (the "Stock Purchase Agreement") with Takeda on January&#160;3, 2018, pursuant to which Takeda purchased 4,214,559 shares of the Company's common stock (the "Shares") for an aggregate purchase price of $110.0 million. The sale of the Shares closed on February&#160;23, 2018. The fair market value of the common stock sold to Takeda was $94.4 million, based on the closing stock price of $22.40 on the date of issuance, resulting in&#160;a $15.6 million premium paid to the Company above the fair value of the Company's common stock which was credited to contract liability in the Company's Condensed Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company believes that the Takeda Collaboration Agreement is a collaboration arrangement as defined in ASC&#160;808, Collaborative Arrangements.&#160;Further, during the research period, the Company believes that the arrangement is a contract with a customer as defined in ASC 606,&#160;Revenue From Contracts With Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Takeda Collaboration Agreement and the Stock Purchase Agreement are being accounted for as one arrangement because they were entered into at the same time with interrelated financial terms.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company identified performance obligations during the research period consisting of the license, the development options, and joint steering committee ("JSC") participation together with the research services for each collaboration program. The license rights, JSC involvement, option and research services are considered to be a single performance obligation for each program since the research services are highly interrelated with the option and JSC involvement and will significantly modify the license. The performance obligations under each of the three programs are separate since the activities and risks under the programs are distinct. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determined that all other goods or services which are contingent upon Takeda exercising its option for each program were not considered performance obligations at the inception of the Takeda Collaboration Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The transaction price at inception included fixed consideration consisting of the upfront fee of $40.0 million, the $15.6 million premium on the sale of common stock, and the &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;first preclinical milestone payment of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$5.0 million. It also included variable consideration of $26.0 million relating to future milestones that were not constrained, and have since all been met and received. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The remaining $44.0 million of preclinical milestones were considered constrained at the inception of the Takeda Collaboration Agreement since the Company could not conclude it is probable that a significant reversal in the amount recognized will not occur. Additionally, cost and profit-sharing income, and the development and commercial milestones as outlined above, have not been considered given Takeda has not exercised its options for the development and commercial phases for any program. No change in the transaction price has been recorded since inception. This will be reassessed at each reporting period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The transaction price has been ascribed in its entirety to the three performance obligations identified in the research term of the Takeda Collaboration Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue is recognized when, or as, the Company satisfies its performance obligations by transferring the promised services to Takeda. Revenue is being recognized over time using the input method, based on costs incurred to perform the research services, since the level of costs incurred over time is thought to best reflect the transfer of services to Takeda. There were no material changes in estimates during the three months ended March 31, 2021 or March 31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A contract liability of $40.8 million and $39.8 million was recorded on the Condensed Consolidated Balance Sheets as of March 31, 2021 and December 31, 2020, respectively. This contract liability relates to the three performance obligations identified, with such amounts to be recognized over the estimated period of the pre-IND research services, which is expected to be several years. In December 2020 and January 2021, GLP toxicology studies were initiated for PTV:PGRN and ATV:TREM2, respectively, triggering the second preclinical milestone payments of $8.0 million for each program, which were received in January and March 2021, respectively. There was no receivable as of March 31, 2021 and a receivable of $8.0 million for the PTV:PGRN milestone as of December 31, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In assessing the Takeda Collaboration Agreement, management is required to exercise considerable judgment in estimating revenue to be recognized. Management applies judgment in determining the separate performance obligations in the research period and estimating total future costs when using the input method. There is some increase in the judgment required in estimating the timing of future costs due to the COVID-19 pandemic. This is because it is challenging to predict the duration and extent of the impact of the COVID-19 pandemic on the third-party service providers assisting with the Company's ATV:Tau, ATV:TREM2 and PTV:PGRN programs. This may impact the split between current and non-current contract liability on the Condensed Consolidated Balance Sheets in the future. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Through March 31, 2021, the Company had received $31.0 million in preclinical milestone payments from Takeda which are included in the transaction price described above, and had not recorded any product sales under the Takeda Collaboration Agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Collaboration Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue disaggregated by collaboration agreement and performance obligation is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.432%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.073%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.921%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.074%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Takeda Collaboration Agreement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,030&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Sanofi Collaboration Agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Retained Activities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Alzheimer's Disease Services&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total Sanofi Collaboration Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen Collaboration Agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Option Research Services&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total Collaboration Revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:120%"&gt;_________________________________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10.69pt"&gt;$5.7&#160;million of revenue for the three months ended March 31, 2021 and all of revenue for the three months ended March 31, 2020 was included in the contract liability balance at the beginning of the period. &lt;/span&gt;&lt;/div&gt;(2)Revenue for the three months ended March 31, 2021 and March 31, 2020, where applicable, represent amounts that were included in the contract liability balance at the beginning of the respective period.</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <dnli:CollaborativeArrangementNumberOfPrograms
      contextRef="id19e1b668ad54ff0a1bcaaf50d236bcd_I20200805"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfNzM0_8c081a07-3db8-4840-8288-c1a6d3713aaf"
      unitRef="program">1</dnli:CollaborativeArrangementNumberOfPrograms>
    <dnli:CollaborativeArrangementNumberOfAdditionalProgramsIfCircumstancesMet
      contextRef="if6dd4f0c67444b1194ee0a12b060c2e7_I20200805"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfODg1_9759b9a2-1fa4-4b06-8c28-c2fbb7e61a32"
      unitRef="program">2</dnli:CollaborativeArrangementNumberOfAdditionalProgramsIfCircumstancesMet>
    <dnli:CollaborativeArrangementUpfrontPaymentToBeReceived
      contextRef="i708f730074a74563a853bf7ef8f740fe_D20200805-20200805"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMTg0Nw_d7d9154c-df56-4928-86fb-32608f7db76f"
      unitRef="usd">560000000.0</dnli:CollaborativeArrangementUpfrontPaymentToBeReceived>
    <dnli:AggregateDevelopmentFirstCommercialSaleAndNetSalesBasedMilestonePayments
      contextRef="i3bf8c8eaa53e41d5a068b18edae5519f_I20200805"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMjA2Mw_bbe8bb1a-b743-4cb7-b592-ad56f6881522"
      unitRef="usd">1125000000</dnli:AggregateDevelopmentFirstCommercialSaleAndNetSalesBasedMilestonePayments>
    <dnli:DevelopmentMilestonePayments
      contextRef="i3bf8c8eaa53e41d5a068b18edae5519f_I20200805"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMjE2MQ_8cc50dec-9c24-42d8-b0f6-b94d91b15ee6"
      unitRef="usd">375000000.0</dnli:DevelopmentMilestonePayments>
    <dnli:FirstCommercialSaleMilestonePayments
      contextRef="i3bf8c8eaa53e41d5a068b18edae5519f_I20200805"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMjE4MA_de3fdff6-53e5-48ec-9da8-87f8d1270c0c"
      unitRef="usd">375000000.0</dnli:FirstCommercialSaleMilestonePayments>
    <dnli:NetSalesBasedMilestonePayments
      contextRef="i3bf8c8eaa53e41d5a068b18edae5519f_I20200805"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMjIxNQ_4656a46f-7c1f-435e-b90a-0ace5afddc1e"
      unitRef="usd">375000000.0</dnli:NetSalesBasedMilestonePayments>
    <dnli:CollaborativeAgreementAgreedShareOfCommercialProfitLoss
      contextRef="i19ba65d441e94cbda7c97a7dedf0b14c_I20200805"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMTA5OTUxMTcwMjcyOQ_b09efb0d-9365-461b-b68e-a1bcac36950d"
      unitRef="number">0.50</dnli:CollaborativeAgreementAgreedShareOfCommercialProfitLoss>
    <dnli:CollaborativeAgreementAgreedShareOfCommercialProfitLoss
      contextRef="id5c33ba7e2874d50a83a5008b6ae7852_I20200805"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMjM1OA_17c03de2-34d9-4730-b254-f2d89235b9d5"
      unitRef="number">0.40</dnli:CollaborativeAgreementAgreedShareOfCommercialProfitLoss>
    <dnli:CollaborativeAgreementFundedPercentage
      contextRef="id978123c42ea48179c72134ceea46ba2_I20200805"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMzA5NA_fc009065-b01d-42f2-9259-997fbecb83e2"
      unitRef="number">0.60</dnli:CollaborativeAgreementFundedPercentage>
    <dnli:CollaborativeAgreementFundedPercentage
      contextRef="i8a30e11a54f94b2ebb02e2da6fe5446f_I20200805"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMzEyMQ_2ffb4be0-e5af-4f46-b9cf-7f5a84f6617d"
      unitRef="number">0.40</dnli:CollaborativeAgreementFundedPercentage>
    <dnli:CollaborativeArrangementNumberOfPrograms
      contextRef="ib106d7ba52674677b8cb2ac5693422b7_I20200805"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfNDY2Mw_89b10637-642e-4e11-bfc7-7ea3abeae7b9"
      unitRef="program">2</dnli:CollaborativeArrangementNumberOfPrograms>
    <dnli:CollaborativeArrangementNumberOfAdditionalProgramsIfCircumstancesMet
      contextRef="i3df519c68317420e8222a86148ab6e41_I20200805"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfNTUyMQ_a962cc6c-85a4-499f-a60f-9dcde6ca4b2a"
      unitRef="program">2</dnli:CollaborativeArrangementNumberOfAdditionalProgramsIfCircumstancesMet>
    <dnli:CollaborativeArrangementRightOfFirstNegotiationTermPeriodAfterEffectiveDateOfAgreementIfCircumstancesMet
      contextRef="id16d8e434fba4f8ca86744e3c63d5d95_D20200805-20200805"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfNTg1Mg_bdc38ba6-ddfa-4cec-a3f0-9975ffa48c8b">P7Y</dnli:CollaborativeArrangementRightOfFirstNegotiationTermPeriodAfterEffectiveDateOfAgreementIfCircumstancesMet>
    <dnli:CollaborativeArrangementRightOfFirstNegotiationPeriodTermAdditionalProgramCriteria
      contextRef="i3df519c68317420e8222a86148ab6e41_I20200805"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfNTk4Mg_8ecb7806-7f37-476c-905f-b47001931bae"
      unitRef="program">2</dnli:CollaborativeArrangementRightOfFirstNegotiationPeriodTermAdditionalProgramCriteria>
    <dnli:CollaborativeArrangementNumberOfAdditionalProgramsNoThirdPartyAgreementExecutedIfCircumstancesMet
      contextRef="i3df519c68317420e8222a86148ab6e41_I20200805"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfNjIwNw_b744b707-394a-47f1-88ac-7ed079ece811"
      unitRef="program">1</dnli:CollaborativeArrangementNumberOfAdditionalProgramsNoThirdPartyAgreementExecutedIfCircumstancesMet>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i3f469ca238db4f19ade2b0c2f5542d55_D20200922-20200922"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfNjU1MA_265734d2-834c-42b9-8e23-6153ab21eb73"
      unitRef="shares">13310243</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i3f469ca238db4f19ade2b0c2f5542d55_D20200922-20200922"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfNjY0MA_3fdba689-a8a9-498a-bc7f-695785769f6c"
      unitRef="usd">465000000.0</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:CommonStocksIncludingAdditionalPaidInCapital
      contextRef="i53d1846478874ac7a03801cbb5049533_I20200922"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfNzI1Ng_8a7157a4-90e1-44a7-adc5-5fa30e5729cc"
      unitRef="usd">420100000</us-gaap:CommonStocksIncludingAdditionalPaidInCapital>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i53d1846478874ac7a03801cbb5049533_I20200922"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfNzI5Ng_1de955ee-4888-4cce-8a60-18efd3a69f82"
      unitRef="usdPerShare">35.87</us-gaap:SaleOfStockPricePerShare>
    <dnli:SaleOfStockConsiderationPremiumReceivedOnTransaction
      contextRef="i3f469ca238db4f19ade2b0c2f5542d55_D20200922-20200922"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfNzQ5OA_3ce619e8-0db7-4a21-9411-f51f1fa2a39f"
      unitRef="usd">44900000</dnli:SaleOfStockConsiderationPremiumReceivedOnTransaction>
    <dnli:CollaborativeArrangementOptionExerciseAndDevelopmentMilestonePaymentsToBeReceived
      contextRef="i3d221276fee544dc91f74c0f2b96de94_I20201006"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMTE4NDU_bc529328-792e-41b5-ad4e-465055c21251"
      unitRef="usd">270000000.0</dnli:CollaborativeArrangementOptionExerciseAndDevelopmentMilestonePaymentsToBeReceived>
    <dnli:CollaborativeArrangementFirstCommercialSaleMilestonePaymentsToBeReceived
      contextRef="i3d221276fee544dc91f74c0f2b96de94_I20201006"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMTE5MDk_2f7c1e35-8324-485e-837c-f3fafb9acb6d"
      unitRef="usd">325000000.0</dnli:CollaborativeArrangementFirstCommercialSaleMilestonePaymentsToBeReceived>
    <dnli:CollaborativeArrangementNetSalesBasedMilestonePaymentsToBeReceived
      contextRef="i3d221276fee544dc91f74c0f2b96de94_I20201006"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMTE5NTA_46911fa5-5e2d-4ac5-9208-cf4c187a6138"
      unitRef="usd">290000000.0</dnli:CollaborativeArrangementNetSalesBasedMilestonePaymentsToBeReceived>
    <dnli:UpfrontPayments
      contextRef="ia59d27ad521d4576896de358cda1e1a8_D20201006-20201031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMTI0MDA_482d71c3-d373-4175-890b-77877f155f80"
      unitRef="usd">560000000.0</dnli:UpfrontPayments>
    <dnli:UpfrontPayments
      contextRef="ia59d27ad521d4576896de358cda1e1a8_D20201006-20201031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMTY0OTI2NzQ4MjgzOA_11beab15-ae94-4654-b610-103ad279428d"
      unitRef="usd">560000000.0</dnli:UpfrontPayments>
    <dnli:SaleOfStockConsiderationPremiumReceivedOnTransaction
      contextRef="i3f469ca238db4f19ade2b0c2f5542d55_D20200922-20200922"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMTY0OTI2NzQ4Mjg1NA_96e9daf0-3fcb-4ede-ba0e-78a1cc1b1e0f"
      unitRef="usd">44900000</dnli:SaleOfStockConsiderationPremiumReceivedOnTransaction>
    <dnli:CollaborationAgreementTransactionPriceIncreaseDecrease
      contextRef="i22fa845ccdd543acb615ea629ab5344c_D20201006-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMTY0OTI2NzQ4Mjg4OA_2977e961-2cc5-4e16-a203-80c6d60bd024"
      unitRef="usd">0</dnli:CollaborationAgreementTransactionPriceIncreaseDecrease>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i2934421e8d7b4a55a318b2d3d6102fed_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMTY0OTI2NzQ4MjkyNQ_f7a6bb5b-1036-4d5d-9c12-a068a5f1f715"
      unitRef="usd">296500000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i611b2655965e42dfbda911bc7c9ee9c8_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMTY0OTI2NzQ4Mjk0NQ_56a23032-f5f1-42bf-9f03-bdfbd65f680f"
      unitRef="usd">288900000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i0f8d7006122c478b92ae9f39d8d1b0e5_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMTY0OTI2NzQ4Mjk5OQ_98b1fb1d-9961-4887-804b-6d5e9564c713"
      unitRef="usd">7600000</us-gaap:ContractWithCustomerLiability>
    <dnli:ResearchAndDevelopmentExpenseOffsetFromRelatedPartyCostReimbursement
      contextRef="if1065b142ae843249dfdfee04de24a66_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMTY0OTI2NzQ4MzA1Nw_8815c5a8-7431-4fb4-b758-d7f29c8a81a4"
      unitRef="usd">2500000</dnli:ResearchAndDevelopmentExpenseOffsetFromRelatedPartyCostReimbursement>
    <us-gaap:DueFromRelatedPartiesCurrent
      contextRef="i5dd55e97d29845d79435cc613548f911_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMjc0ODc3OTEzNzMxNg_a1d93721-0f41-438e-813a-7166a947cb28"
      unitRef="usd">2500000</us-gaap:DueFromRelatedPartiesCurrent>
    <us-gaap:DueFromRelatedPartiesCurrent
      contextRef="i0013ce3d1a8247a08d873ceee1cdf67a_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMjc0ODc3OTE0MTU5Mg_b8d851a6-0126-400c-8266-32dd81c1c941"
      unitRef="usd">5700000</us-gaap:DueFromRelatedPartiesCurrent>
    <dnli:CollaborativeArrangementNumberOfMilestonesAchieved
      contextRef="i5dd55e97d29845d79435cc613548f911_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMTY0OTI2NzQ3Njc3MA_ad3c8e2a-8c61-4977-b2d2-c4984aa3e516"
      unitRef="milestone">0</dnli:CollaborativeArrangementNumberOfMilestonesAchieved>
    <dnli:UpfrontPayments
      contextRef="i37367f9356d64fd3928fdd776c7f31a8_D20181101-20181130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMTMxODI_efb028c8-9f1b-4ff2-b565-579b4906f5d4"
      unitRef="usd">125000000.0</dnli:UpfrontPayments>
    <dnli:AggregateClinicalRegulatoryAndSalesMilestonePayment
      contextRef="ic6d24297d8d84d17b99d57fe8ee7d6f5_I20181130"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMTMzMTQ_1f43aee6-d0ef-44a0-a176-3eb88f78bc7a"
      unitRef="usd">1100000000</dnli:AggregateClinicalRegulatoryAndSalesMilestonePayment>
    <dnli:ClinicalMilestonePayment
      contextRef="i69a8709612b349b38ac7bf012d3e0fd3_I20181130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMTM0MjY_92cae6b0-e305-4f1a-88da-ce1fedba5e1a"
      unitRef="usd">215000000.0</dnli:ClinicalMilestonePayment>
    <dnli:RegulatoryMilestonePayment
      contextRef="i69a8709612b349b38ac7bf012d3e0fd3_I20181130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMTM0NjQ_e2c528a0-26b3-48ff-b173-8419aed2cb16"
      unitRef="usd">385000000.0</dnli:RegulatoryMilestonePayment>
    <dnli:NumberOfIndications
      contextRef="i32ecdc0092f641bd9100243e5a27d217_I20181130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMTM2NDI_485544c9-9aa4-407f-9bd6-707c01dc9f3c"
      unitRef="indication">3</dnli:NumberOfIndications>
    <dnli:ClinicalMilestonePayment
      contextRef="iaa8b5535fbd846a4bd38c3e3b7f756a4_I20181130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMTM3MTk_9a6f05d1-c4be-4032-9b04-c1ec9ea7bbab"
      unitRef="usd">120000000.0</dnli:ClinicalMilestonePayment>
    <dnli:RegulatoryMilestonePayment
      contextRef="iaa8b5535fbd846a4bd38c3e3b7f756a4_I20181130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMTM3NTQ_4c828007-05ab-4473-9185-a285b1f2ef20"
      unitRef="usd">175000000.0</dnli:RegulatoryMilestonePayment>
    <dnli:CommercialMilestonePayments
      contextRef="iaa8b5535fbd846a4bd38c3e3b7f756a4_I20181130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMTM3OTQ_625693ee-964e-45df-a526-b24dc46ef509"
      unitRef="usd">200000000.0</dnli:CommercialMilestonePayments>
    <dnli:NumberOfIndications
      contextRef="i32ecdc0092f641bd9100243e5a27d217_I20181130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMTM5NDY_b7ad2622-d35e-410e-9fea-f31ac4bcf05f"
      unitRef="indication">3</dnli:NumberOfIndications>
    <dnli:CollaborativeAgreementFundedPercentage
      contextRef="i6ea2228697dd4aaba41a39520dc51665_I20181130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMTUxMjU_09e8dd58-eb79-4bb4-b936-5a6dbfb64d7e"
      unitRef="number">0.70</dnli:CollaborativeAgreementFundedPercentage>
    <dnli:CollaborativeAgreementFundedPercentage
      contextRef="iae801c2eda2b4f468e16600312d29411_I20181130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMTUxMzI_90913293-d0d6-4f51-b189-8126d5f0478e"
      unitRef="number">0.30</dnli:CollaborativeAgreementFundedPercentage>
    <dnli:CollaborativeAgreementFundedPercentage
      contextRef="iae801c2eda2b4f468e16600312d29411_I20181130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMTY2NDE_90913293-d0d6-4f51-b189-8126d5f0478e"
      unitRef="number">0.30</dnli:CollaborativeAgreementFundedPercentage>
    <dnli:UpfrontPayments
      contextRef="i37367f9356d64fd3928fdd776c7f31a8_D20181101-20181130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMTcyMzc_efb028c8-9f1b-4ff2-b565-579b4906f5d4"
      unitRef="usd">125000000.0</dnli:UpfrontPayments>
    <dnli:CollaborationAgreementTransactionPriceIncrease
      contextRef="i46ab6c65582f4d8bab7e57d6dd6f7588_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfNDM5ODA0NjU4NDg5NQ_d354a7fd-d25f-40e6-9eba-8fe52942a0cd"
      unitRef="usd">0</dnli:CollaborationAgreementTransactionPriceIncrease>
    <dnli:CollaborationAgreementTransactionPriceIncrease
      contextRef="i1c01d0c60cd542c4a229d6789938312a_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMTY0OTI2NzQ4MzY4Mg_a9aca8f9-dce0-4f77-b575-c550b54486d2"
      unitRef="usd">500000</dnli:CollaborationAgreementTransactionPriceIncrease>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="i71f6e4875572417586577b9989db412c_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMTk0MjA_6c59c130-eab2-48ce-aa2e-c3c9a7edf738"
      unitRef="usd">3400000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="i261cc6d074024d72a8c693a4ea9e24fa_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMTk0MjA_ac70b266-b13e-42f1-b970-adf6fd2c20e1"
      unitRef="usd">3400000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:AccountsReceivableNet
      contextRef="i85da405a68d44147816b407c550dd77b_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfNDM5ODA0NjU4NDkwMw_2e0883eb-a50f-4dce-9fc2-eb5aa80660fb"
      unitRef="usd">0</us-gaap:AccountsReceivableNet>
    <us-gaap:AccountsReceivableNet
      contextRef="ib2c5d3daea2b469eb42d1e130f45621f_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMjc0ODc3OTE0MTkyMw_66db8f95-6834-4431-af9d-239bb457239c"
      unitRef="usd">44303</us-gaap:AccountsReceivableNet>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8e78aebb6758499aa9b578b8b7365ab9_D20181001-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMjAzOTY_23662527-52aa-4997-827d-495bcc45f7aa"
      unitRef="usd">10000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ieb8b43e946ab4a5e983647ccb9581dc3_D20181001-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMjA0MDc_b5335f63-36c8-4f97-9c64-c383c703eefb"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <dnli:UpfrontPayments
      contextRef="iaf62192d651f44fa9a8f0990d46c3286_D20180223-20180223"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMjExNDE_d219599e-ab85-4a3d-86d9-b9b4b5dc9313"
      unitRef="usd">40000000.0</dnli:UpfrontPayments>
    <dnli:PreclinicalMilestonePaymentPerProgram
      contextRef="i2e206bb2a68d468195031df47711679a_D20180223-20180223"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMjExODI_be7141f9-1c70-4fde-aaaa-5247f01d2abe"
      unitRef="usd">25000000.0</dnli:PreclinicalMilestonePaymentPerProgram>
    <dnli:NumberOfPrograms
      contextRef="i629da488ba924dfc9f4eb9daeb937953_I20180223"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMjEyMTM_f7a4cdc2-e358-4ed1-8773-130ad3625087"
      unitRef="program">3</dnli:NumberOfPrograms>
    <dnli:AggregatePreclinicalMilestonePayment
      contextRef="i2e206bb2a68d468195031df47711679a_D20180223-20180223"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMjEzMjQ_3d5fa34b-b408-4957-a328-4ed57e6642e7"
      unitRef="usd">75000000.0</dnli:AggregatePreclinicalMilestonePayment>
    <dnli:PreclinicalMilestonePaymentReceived
      contextRef="iaf62192d651f44fa9a8f0990d46c3286_D20180223-20180223"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMjEzMzc_b370c370-0522-492f-ba37-9b54d94736f9"
      unitRef="usd">5000000.0</dnli:PreclinicalMilestonePaymentReceived>
    <dnli:NumberOfTargets
      contextRef="i629da488ba924dfc9f4eb9daeb937953_I20180223"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMjE4ODA_df16c7b6-d1a2-4c53-9ded-dd7de2c7559d"
      unitRef="target">3</dnli:NumberOfTargets>
    <dnli:TargetOptionPeriod
      contextRef="iaf62192d651f44fa9a8f0990d46c3286_D20180223-20180223"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMjIxNzI_caa9e489-8485-4ebe-9edf-320de5a035f6">P5Y</dnli:TargetOptionPeriod>
    <dnli:OptionFeesPerProgram
      contextRef="i629da488ba924dfc9f4eb9daeb937953_I20180223"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMjI3NDM_2e8392be-f4fc-45d3-b96f-5e2d212947d8"
      unitRef="usd">5000000.0</dnli:OptionFeesPerProgram>
    <dnli:AggregateOptionExerciseFee
      contextRef="idf9de44243d0448abccdf83151ea9bfa_I20180223"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMjI4MTg_c15ca5c0-a42b-4b8c-acc9-bb6f4f52d2ce"
      unitRef="usd">15000000.0</dnli:AggregateOptionExerciseFee>
    <dnli:NumberOfPrograms
      contextRef="i629da488ba924dfc9f4eb9daeb937953_I20180223"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMjI4ODM_c2622e74-4dce-4212-ae93-1e51800f25b8"
      unitRef="program">3</dnli:NumberOfPrograms>
    <dnli:AggregateDevelopmentMilestonePayment
      contextRef="idf9de44243d0448abccdf83151ea9bfa_I20180223"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMjI5NzU_e651b80a-01bd-4d11-8bbd-107277751a52"
      unitRef="usd">407500000</dnli:AggregateDevelopmentMilestonePayment>
    <dnli:RegulatoryMilestonePayment
      contextRef="idf9de44243d0448abccdf83151ea9bfa_I20180223"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMjMwNTg_5d3cb8b0-ae27-4ab0-94e9-055b37f0eee4"
      unitRef="usd">300000000.0</dnli:RegulatoryMilestonePayment>
    <dnli:CommercialMilestonesPerProgram
      contextRef="idf9de44243d0448abccdf83151ea9bfa_I20180223"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMjMyNDk_7d849092-a96f-4e95-9aea-7936e91402c6"
      unitRef="usd">75000000.0</dnli:CommercialMilestonesPerProgram>
    <dnli:AggregateCommercialMilestones
      contextRef="idf9de44243d0448abccdf83151ea9bfa_I20180223"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMjMzNDU_d1adac58-d4da-4bbc-a063-19a68cb7cf38"
      unitRef="usd">225000000.0</dnli:AggregateCommercialMilestones>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i9261bc8472184e6fa1082e8c5405a625_D20180223-20180223"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMjM4MzM_6a79ac7f-6c42-4213-9d63-0d77c7914304"
      unitRef="shares">4214559</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i9261bc8472184e6fa1082e8c5405a625_D20180223-20180223"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMjM5MjM_ec977466-879b-4c69-94f1-7da092d78f67"
      unitRef="usd">110000000.0</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:CommonStocksIncludingAdditionalPaidInCapital
      contextRef="i9e0b33f51ccf452bae9b4c3f0109b86d_I20180223"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMjQwMjU_77a85470-3320-46af-aeda-746dd094967f"
      unitRef="usd">94400000</us-gaap:CommonStocksIncludingAdditionalPaidInCapital>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i9e0b33f51ccf452bae9b4c3f0109b86d_I20180223"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMjQwNjU_944408c1-4b71-494a-bccf-7c5c98b715ab"
      unitRef="usdPerShare">22.40</us-gaap:SaleOfStockPricePerShare>
    <dnli:SaleOfStockConsiderationPremiumReceivedOnTransaction
      contextRef="i9261bc8472184e6fa1082e8c5405a625_D20180223-20180223"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMjQxMDg_f79aad69-1963-45c0-8a5d-bf5c3cb1e1a5"
      unitRef="usd">15600000</dnli:SaleOfStockConsiderationPremiumReceivedOnTransaction>
    <dnli:NumberOfPrograms
      contextRef="i629da488ba924dfc9f4eb9daeb937953_I20180223"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfNDM5ODA0NjU4NDkxOQ_e868046d-5115-40f5-a981-a9e01dce3a57"
      unitRef="program">3</dnli:NumberOfPrograms>
    <dnli:UpfrontPayments
      contextRef="iaf62192d651f44fa9a8f0990d46c3286_D20180223-20180223"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMjU3NDA_d219599e-ab85-4a3d-86d9-b9b4b5dc9313"
      unitRef="usd">40000000.0</dnli:UpfrontPayments>
    <dnli:SaleOfStockConsiderationPremiumReceivedOnTransaction
      contextRef="i9261bc8472184e6fa1082e8c5405a625_D20180223-20180223"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMjU3NDg_f79aad69-1963-45c0-8a5d-bf5c3cb1e1a5"
      unitRef="usd">15600000</dnli:SaleOfStockConsiderationPremiumReceivedOnTransaction>
    <dnli:PreclinicalMilestonePaymentReceived
      contextRef="iaf62192d651f44fa9a8f0990d46c3286_D20180223-20180223"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMjU4MzU_b370c370-0522-492f-ba37-9b54d94736f9"
      unitRef="usd">5000000.0</dnli:PreclinicalMilestonePaymentReceived>
    <dnli:VariableConsiderationFutureConsideration
      contextRef="iaf62192d651f44fa9a8f0990d46c3286_D20180223-20180223"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMjU4ODI_a62399d7-c0c5-4c4f-ad7d-34f0aab2b100"
      unitRef="usd">26000000.0</dnli:VariableConsiderationFutureConsideration>
    <dnli:ConstrainedVariableConsideration
      contextRef="i629da488ba924dfc9f4eb9daeb937953_I20180223"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMjYwNDQ_84edd3f0-f9f7-4992-ad24-31739e9bb22a"
      unitRef="usd">44000000.0</dnli:ConstrainedVariableConsideration>
    <dnli:CollaborationAgreementTransactionPriceIncreaseDecrease
      contextRef="i8319328706f24bcdb7bf7f3fc0782056_D20180223-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMjY1MTU_8b571d16-0eba-4a7c-ad52-5652c37c2260"
      unitRef="usd">0</dnli:CollaborationAgreementTransactionPriceIncreaseDecrease>
    <dnli:RevenueNumberOfPerformanceObligations
      contextRef="i629da488ba924dfc9f4eb9daeb937953_I20180223"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMjY2OTk_6e69572c-e35a-4cad-8cef-000d1cada667"
      unitRef="program">3</dnli:RevenueNumberOfPerformanceObligations>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i8fd4f33cc0454770bb9522977f4298cc_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMjcyNTA_30d92d1f-e5a2-4f2b-b690-481a9f487acb"
      unitRef="usd">40800000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i1b343adcffb94181bcbdfcb6161d5aba_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMjcyNTc_c83d1492-e1fe-4090-b9a3-2437ce971bc2"
      unitRef="usd">39800000</us-gaap:ContractWithCustomerLiability>
    <dnli:RevenueNumberOfPerformanceObligations
      contextRef="i629da488ba924dfc9f4eb9daeb937953_I20180223"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMjczODg_6e69572c-e35a-4cad-8cef-000d1cada667"
      unitRef="program">3</dnli:RevenueNumberOfPerformanceObligations>
    <dnli:PreclinicalMilestonePaymentReceived
      contextRef="i6a890b5264394316bc209b1df064b85d_D20210301-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMTY0OTI2NzQ4Njg0Nw_44989ff8-a2d8-4bc6-a840-cef1495503a6"
      unitRef="usd">8000000.0</dnli:PreclinicalMilestonePaymentReceived>
    <dnli:PreclinicalMilestonePaymentReceived
      contextRef="if1c8a3c07b01480bb07bf6e10da36189_D20210101-20210131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMTY0OTI2NzQ4Njg0Nw_97340907-c24a-4744-83d1-7ab9fc81aa7a"
      unitRef="usd">8000000.0</dnli:PreclinicalMilestonePaymentReceived>
    <dnli:PreclinicalMilestonePaymentEarnedNotYetReceived
      contextRef="i8fd4f33cc0454770bb9522977f4298cc_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMTA5OTUxMTY5OTgxMg_739a8546-e787-420f-965a-8dbc6077b36f"
      unitRef="usd">0</dnli:PreclinicalMilestonePaymentEarnedNotYetReceived>
    <dnli:PreclinicalMilestonePaymentEarnedNotYetReceived
      contextRef="i82572c2ba407421ab1eeaea4cc017b83_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMTA5OTUxMTY5OTc4NA_abbce44a-742a-4357-9391-a4e7bdb78322"
      unitRef="usd">8000000.0</dnli:PreclinicalMilestonePaymentEarnedNotYetReceived>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if1fffa1219a047f0a51060aeafb58951_D20180101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMjg4MTk_a8fb3cc8-1e27-4c32-8278-fb3a9e3005e8"
      unitRef="usd">31000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i98a0ba98854b4bb8ac86be212e357b16_D20180101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMjg4NzY_4549cf22-bc37-4e6f-a2bb-33e5a3bf66e1"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMjkyNzI_42c87e89-f77a-4909-a099-244724dc0def">&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue disaggregated by collaboration agreement and performance obligation is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.432%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.073%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.921%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.074%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Takeda Collaboration Agreement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,030&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Sanofi Collaboration Agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Retained Activities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Alzheimer's Disease Services&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total Sanofi Collaboration Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen Collaboration Agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Option Research Services&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total Collaboration Revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:120%"&gt;_________________________________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10.69pt"&gt;$5.7&#160;million of revenue for the three months ended March 31, 2021 and all of revenue for the three months ended March 31, 2020 was included in the contract liability balance at the beginning of the period. &lt;/span&gt;&lt;/div&gt;(2)Revenue for the three months ended March 31, 2021 and March 31, 2020, where applicable, represent amounts that were included in the contract liability balance at the beginning of the respective period.</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i643ec7e1d2a3451c9d8905efbcdbf48c_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RhYmxlOmJhNWVhZTk2NGVkODRkNjg4MTRmOGU2NTNiZDUxNDY4L3RhYmxlcmFuZ2U6YmE1ZWFlOTY0ZWQ4NGQ2ODgxNGY4ZTY1M2JkNTE0NjhfMi0xLTEtMS0w_44f95404-6768-4319-b4f0-82805ccf0a70"
      unitRef="usd">7030000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iff0f9b13d274493e8564765eb94360ae_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RhYmxlOmJhNWVhZTk2NGVkODRkNjg4MTRmOGU2NTNiZDUxNDY4L3RhYmxlcmFuZ2U6YmE1ZWFlOTY0ZWQ4NGQ2ODgxNGY4ZTY1M2JkNTE0NjhfMi0zLTEtMS0w_9335c3c3-7538-43a0-a10e-98cad965912c"
      unitRef="usd">3018000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie9ccfab524d04954920c80a3c7ac6796_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RhYmxlOmJhNWVhZTk2NGVkODRkNjg4MTRmOGU2NTNiZDUxNDY4L3RhYmxlcmFuZ2U6YmE1ZWFlOTY0ZWQ4NGQ2ODgxNGY4ZTY1M2JkNTE0NjhfNi0xLTEtMS0w_16cc4a9d-e072-467d-a951-bb1871b51404"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if81ccf0b3968466bb8ad747c00401a8d_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RhYmxlOmJhNWVhZTk2NGVkODRkNjg4MTRmOGU2NTNiZDUxNDY4L3RhYmxlcmFuZ2U6YmE1ZWFlOTY0ZWQ4NGQ2ODgxNGY4ZTY1M2JkNTE0NjhfNi0zLTEtMS0w_ea0cc034-7d2d-4069-a84e-b76c95e41e0e"
      unitRef="usd">534000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="ifcf20312d910402ab56471a2d6469134_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RhYmxlOmJhNWVhZTk2NGVkODRkNjg4MTRmOGU2NTNiZDUxNDY4L3RhYmxlcmFuZ2U6YmE1ZWFlOTY0ZWQ4NGQ2ODgxNGY4ZTY1M2JkNTE0NjhfNy0xLTEtMS0w_33ad5500-10d7-40d3-81a0-c1daa5bb15ed"
      unitRef="usd">1000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="idc2536462b694f07b028b19e58c564fe_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RhYmxlOmJhNWVhZTk2NGVkODRkNjg4MTRmOGU2NTNiZDUxNDY4L3RhYmxlcmFuZ2U6YmE1ZWFlOTY0ZWQ4NGQ2ODgxNGY4ZTY1M2JkNTE0NjhfNy0zLTEtMS0w_eaa6f727-3e90-4ca2-aaf5-92aa6a5a73cd"
      unitRef="usd">52000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:Revenues
      contextRef="ieb7e2edd7c3c4ff1a01d715afc57516e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RhYmxlOmJhNWVhZTk2NGVkODRkNjg4MTRmOGU2NTNiZDUxNDY4L3RhYmxlcmFuZ2U6YmE1ZWFlOTY0ZWQ4NGQ2ODgxNGY4ZTY1M2JkNTE0NjhfOC0xLTEtMS0w_f3886546-f1ba-4b58-b35b-e1e915070c0f"
      unitRef="usd">1000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i18c380c88187451c9ad16eccfc6df52c_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RhYmxlOmJhNWVhZTk2NGVkODRkNjg4MTRmOGU2NTNiZDUxNDY4L3RhYmxlcmFuZ2U6YmE1ZWFlOTY0ZWQ4NGQ2ODgxNGY4ZTY1M2JkNTE0NjhfOC0zLTEtMS0w_f66e1f59-9ebd-491b-ade7-d02d4cb9541a"
      unitRef="usd">586000</us-gaap:Revenues>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic480049fe58042bdb36bf14a067dcfc0_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RhYmxlOmJhNWVhZTk2NGVkODRkNjg4MTRmOGU2NTNiZDUxNDY4L3RhYmxlcmFuZ2U6YmE1ZWFlOTY0ZWQ4NGQ2ODgxNGY4ZTY1M2JkNTE0NjhfMTItMS0xLTEtMA_c1b90fd6-a239-4e2c-be96-94b5bdda9f19"
      unitRef="usd">892000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1a7cd8e57f5f494c9a40a6b2b090b922_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RhYmxlOmJhNWVhZTk2NGVkODRkNjg4MTRmOGU2NTNiZDUxNDY4L3RhYmxlcmFuZ2U6YmE1ZWFlOTY0ZWQ4NGQ2ODgxNGY4ZTY1M2JkNTE0NjhfMTItMy0xLTEtMA_87fc787b-99b4-4d67-a705-92de9955ba41"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:Revenues
      contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RhYmxlOmJhNWVhZTk2NGVkODRkNjg4MTRmOGU2NTNiZDUxNDY4L3RhYmxlcmFuZ2U6YmE1ZWFlOTY0ZWQ4NGQ2ODgxNGY4ZTY1M2JkNTE0NjhfMTQtMS0xLTEtMA_826e519d-3ef8-4da1-a8e7-0a100576bf9f"
      unitRef="usd">7923000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia34dfea6b8734d64abf707c28256801c_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RhYmxlOmJhNWVhZTk2NGVkODRkNjg4MTRmOGU2NTNiZDUxNDY4L3RhYmxlcmFuZ2U6YmE1ZWFlOTY0ZWQ4NGQ2ODgxNGY4ZTY1M2JkNTE0NjhfMTQtMy0xLTEtMA_e7438866-4b62-4a5e-beac-befa5a06c847"
      unitRef="usd">3604000</us-gaap:Revenues>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="i643ec7e1d2a3451c9d8905efbcdbf48c_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfMTY0OTI2NzQ5MTY4MA_1fef7022-14b7-43c5-ab13-4d5c76695935"
      unitRef="usd">5700000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <dnli:LicenseAgreementTextBlock
      contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81Mi9mcmFnOjczMGQxNTRlYTk5YzRhNmRhY2I4ZGE4ZTFhMDAxMWNjL3RleHRyZWdpb246NzMwZDE1NGVhOTljNGE2ZGFjYjhkYThlMWEwMDExY2NfMTUxMw_af315cdd-4b49-45b2-8725-1f98b0c44afc">License Agreements&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Genentech&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the Company entered into an Exclusive License Agreement with Genentech, Inc. (&#x201c;Genentech&#x201d;). The agreement gives the Company access to Genentech&#x2019;s LRRK2 inhibitor small molecule program for Parkinson&#x2019;s disease. Under the agreement, Genentech granted the Company (i)&#160;an exclusive, worldwide, sublicensable license under Genentech&#x2019;s rights to certain patents and patent applications directed to small molecule compounds which bind to and inhibit LRRK2 and (ii)&#160;a&#160;non-exclusive,&#160;worldwide, sublicensable license to certain related&#160;know-how,&#160;in each case, to develop and commercialize certain compounds and licensed products incorporating any such compound. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company may owe Genentech milestone payments upon the achievement of certain development, regulatory, and commercial milestones, up to a maximum of $315.0 million in the aggregate. These milestones include up to $37.5 million in clinical milestone payments, $102.5 million in regulatory milestone payments and $175.0 million in commercial milestone payments. In addition, the Company may owe royalties on net sales of licensed products ranging from low to high single-digit percentages. Under the terms of our LRRK2 Agreement with Biogen, Biogen is responsible for 50% of any payment obligation to Genentech under this agreement accruing after October&#160;4, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To date, the Company has paid Genentech $12.5&#160;million in the aggregate, including an upfront fee, a technology transfer fee and a clinical milestone payment, all of which was recorded as research and development expense as incurred. No expenses were recorded in the three months ended March 31, 2021 or 2020.&lt;/span&gt;&lt;/div&gt;</dnli:LicenseAgreementTextBlock>
    <dnli:LicenseAgreementMilestonePaymentUponAchievementOfClinicalAndRegulatoryMilestones
      contextRef="ifedff44484c341d28f698f572ac47df9_D20160601-20160630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81Mi9mcmFnOjczMGQxNTRlYTk5YzRhNmRhY2I4ZGE4ZTFhMDAxMWNjL3RleHRyZWdpb246NzMwZDE1NGVhOTljNGE2ZGFjYjhkYThlMWEwMDExY2NfODUx_0b918179-567b-458a-ae71-7e5fd070aa19"
      unitRef="usd">315000000.0</dnli:LicenseAgreementMilestonePaymentUponAchievementOfClinicalAndRegulatoryMilestones>
    <dnli:LicenseAgreementMilestonePaymentUponAchievementOfClinicalAndRegulatoryMilestones
      contextRef="i14b16f9e96df4c0a9e50dca2366b9336_D20160601-20160630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81Mi9mcmFnOjczMGQxNTRlYTk5YzRhNmRhY2I4ZGE4ZTFhMDAxMWNjL3RleHRyZWdpb246NzMwZDE1NGVhOTljNGE2ZGFjYjhkYThlMWEwMDExY2NfOTAz_8957a5ae-9975-494f-9d08-a9d185acf16d"
      unitRef="usd">37500000</dnli:LicenseAgreementMilestonePaymentUponAchievementOfClinicalAndRegulatoryMilestones>
    <dnli:LicenseAgreementMilestonePaymentUponAchievementOfClinicalAndRegulatoryMilestones
      contextRef="i692ffa74a5584f1cbfe4713804c9f8bc_D20160601-20160630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81Mi9mcmFnOjczMGQxNTRlYTk5YzRhNmRhY2I4ZGE4ZTFhMDAxMWNjL3RleHRyZWdpb246NzMwZDE1NGVhOTljNGE2ZGFjYjhkYThlMWEwMDExY2NfOTM4_6a9470b9-e516-40fe-82ca-77ea9f499400"
      unitRef="usd">102500000</dnli:LicenseAgreementMilestonePaymentUponAchievementOfClinicalAndRegulatoryMilestones>
    <dnli:LicenseAgreementMilestonePaymentUponAchievementOfClinicalAndRegulatoryMilestones
      contextRef="i80495385ed674ae8925cf688501ec409_D20160601-20160630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81Mi9mcmFnOjczMGQxNTRlYTk5YzRhNmRhY2I4ZGE4ZTFhMDAxMWNjL3RleHRyZWdpb246NzMwZDE1NGVhOTljNGE2ZGFjYjhkYThlMWEwMDExY2NfOTc4_7f748972-2685-4382-b166-57b80733fe1e"
      unitRef="usd">175000000.0</dnli:LicenseAgreementMilestonePaymentUponAchievementOfClinicalAndRegulatoryMilestones>
    <dnli:LicenseAgreementMilestonePaymentObligationResponsibilityPercentage
      contextRef="id8ddb142f82e43fa84f4fd4d9e8cbf3d_I20201005"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81Mi9mcmFnOjczMGQxNTRlYTk5YzRhNmRhY2I4ZGE4ZTFhMDAxMWNjL3RleHRyZWdpb246NzMwZDE1NGVhOTljNGE2ZGFjYjhkYThlMWEwMDExY2NfMTE4Mw_d2ce3eb5-ea36-4512-83ab-d2831dea2833"
      unitRef="number">0.50</dnli:LicenseAgreementMilestonePaymentObligationResponsibilityPercentage>
    <dnli:UpfrontFeesPaid
      contextRef="id263c00fb24f43c9874f4e5f5bcb3bc4_D20160601-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81Mi9mcmFnOjczMGQxNTRlYTk5YzRhNmRhY2I4ZGE4ZTFhMDAxMWNjL3RleHRyZWdpb246NzMwZDE1NGVhOTljNGE2ZGFjYjhkYThlMWEwMDExY2NfMTI4Nw_aa855c32-522e-4bf0-babf-a548eb0ccc39"
      unitRef="usd">12500000</dnli:UpfrontFeesPaid>
    <dnli:UpfrontFeesPaid
      contextRef="iab3d75662fac47f5a5b91e0c391e1ad9_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81Mi9mcmFnOjczMGQxNTRlYTk5YzRhNmRhY2I4ZGE4ZTFhMDAxMWNjL3RleHRyZWdpb246NzMwZDE1NGVhOTljNGE2ZGFjYjhkYThlMWEwMDExY2NfMTQ2OQ_a75cadbe-1ac1-42af-b09d-00e4c8c53b4d"
      unitRef="usd">0</dnli:UpfrontFeesPaid>
    <dnli:UpfrontFeesPaid
      contextRef="i90ec159768884d8a91ddd3533160d98c_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81Mi9mcmFnOjczMGQxNTRlYTk5YzRhNmRhY2I4ZGE4ZTFhMDAxMWNjL3RleHRyZWdpb246NzMwZDE1NGVhOTljNGE2ZGFjYjhkYThlMWEwMDExY2NfMTQ2OQ_df627736-1d66-4ee6-b41c-d0c4eee90faa"
      unitRef="usd">0</dnli:UpfrontFeesPaid>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81NS9mcmFnOjFlY2VlN2YxM2M0ZTQ0NWQ4ZjMwODVkYjQ4NzdkZmUxL3RleHRyZWdpb246MWVjZWU3ZjEzYzRlNDQ1ZDhmMzA4NWRiNDg3N2RmZTFfNzk1Nw_864bcc9a-7453-44c4-b02b-dfd3c62b9c52">Commitments and Contingencies &lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Lease Obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2018, the Company entered into an amendment to its operating lease for its former corporate headquarters in South San Francisco (the "Headquarters Lease Amendment") to relocate and expand its headquarters to 148,020 rentable square feet in a building in South San Francisco, California (the "New Premises"). The Headquarters Lease Amendment has a contractual term of ten years from the legal commencement date, which was April&#160;1, 2019, when the building was ready for occupancy. For accounting purposes, the lease commencement date was determined to be August&#160;1, 2018, which was the date at which the Company was deemed to have obtained control over the property. The Company has an option to extend the lease term for a period of ten years by giving the landlord written notice of the election to exercise the option at least nine months, but not more than twelve months, prior to the expiration of the Headquarters Lease Amendment lease term. The Company determined that this renewal was not reasonably certain at lease inception. The remaining lease term was 8.1 years at March 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Headquarters Lease Amendment provides for monthly base rent amounts escalating over the term of the lease. In addition, the Headquarters Lease Amendment provided a tenant improvement allowance ("TIA") of up to $25.9 million, which was fully utilized, of which $4.4 million will be repaid to the landlord in the form of additional monthly rent. This is recorded as leasehold improvement assets and an offset to the lease ROU asset on the Condensed Consolidated Balance Sheets as of March 31, 2021 and December 31, 2020. The Company is also required to pay the operating expenses for the New Premises, such as taxes and insurance, which are treated as variable lease payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Management exercised judgment in applying the requirements of ASC 842, including the determination as to whether certain contracts contain a lease and for the Headquarters Lease Amendment, the discount rate used to determine the measurement of the lease liability. As the implicit rate of the Headquarters Lease Amendment was not known, the Company estimated a 9.0% discount rate, which was management&#x2019;s estimate of the Company&#x2019;s incremental borrowing rate. To estimate the incremental borrowing rate, management considered observable debt yields of comparable market instruments, as well as benchmarks within the Headquarters Lease Amendment that may be indicative of the rate implicit in the lease. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total operating lease costs, including variable and short-term lease costs, were $2.8 million and $2.6 million for the three months ended March 31, 2021 and 2020, respectively. Cash paid for amounts included in the measurement of lease liabilities for the three months ended&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; March 31, 2021 and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;March 31, 2020&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; of $2.5 million and $2.2 million, respectively, was included in net cash used in operating activities in the Company's Condensed Consolidated Statements of Cash Flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table reconciles the undiscounted cash flows for the next five years and total of the remaining years to the operating lease liabilities recorded in the Condensed Consolidated Balance Sheet as of March 31, 2021 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.867%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.162%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021 (nine months)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11,083&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11,447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;42,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total undiscounted lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;95,190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Present value adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(27,398)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;67,792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2018, the Company entered into a sublease agreement ("Sublease Agreement") to sublease approximately 36,835 rentable square feet of space in its New Premises. The Sublease Agreement has a term of five years from the commencement date of April&#160;12, 2019 and provides for the Company to receive monthly base rent amounts escalating over the term of the lease. The Company also passes through a portion of the operating expenses, such as taxes and insurance for the New Premises to the sublessee, which are treated as variable sublease income. Total sublease income, including rent and variable sublease cost reimbursements, was $0.9 million for both the three months ended March 31, 2021 and 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table details the future undiscounted cash inflows relating to the Sublease Agreement as of March 31, 2021 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.867%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.162%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021 (nine months)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,096&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total undiscounted sublease receipts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Indemnification&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the ordinary course of business, the Company may provide indemnifications of varying scope and terms to vendors, lessors, business partners, board members, officers, and other parties with respect to certain matters, including, but not limited to, losses arising out of breach of such agreements, services to be provided by the Company, negligence or willful misconduct of the Company, violations of law by the Company, or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with directors and certain officers and employees that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors, officers or employees. No demands have been made upon the Company to provide indemnification under such agreements, and thus, there are no claims that the Company is aware of that could have a material effect on the Company&#x2019;s Condensed Consolidated Balance Sheets, Condensed Consolidated Statements of Operations and Comprehensive Loss, or Condensed Consolidated Statements of Cash Flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Commitments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective September 2017, the Company entered into a Development and Manufacturing Services Agreement as amended (&#x201c;DMSA&#x201d;) with Lonza Sales AG (&#x201c;Lonza&#x201d;) for the development and manufacture of biologic products. Under the DMSA, the Company will execute purchase orders based on project plans authorizing Lonza to provide development and manufacturing services with respect to certain of the Company's antibody and enzyme products, and will pay for the services provided and batches delivered in accordance with the DMSA and project plan. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unless earlier terminated, the DMSA will expire on September&#160;6, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March 31, 2021 and December 31, 2020, the Company had open purchase orders for biological product development and manufacturing costs totaling $33.4 million and $33.0 million, respectively. The activities under these purchase orders are expected to be completed by February 2028. As of March 31, 2021 and December 31, 2020, the Company had total non-cancellable purchase commitments under the DMSA of $28.5 million and $27.1 million, respectively, under the DMSA.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March 31, 2021 and 2020, the Company incurred costs of $5.2 million and $1.0&#160;million, respectively, and made payments of $0.7 million and $3.2 million, respectively, for the development and manufacturing services rendered under the DMSA. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contingencies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, the Company may be involved in lawsuits, arbitration, claims, investigations and proceedings consisting of intellectual property, employment and other matters which arise in the ordinary course of business. The Company records accruals for loss contingencies to the extent that the Company concludes that it is probable that a liability has been incurred and the amount of the related loss can be reasonably estimated. &lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 10, 2020, the Company and all Directors were named in a shareholder derivative action filed in the Delaware Court of Chancery challenging the compensation paid to the Company's Directors since the &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;initial public offering ("IPO")&lt;/span&gt; in December 2017. On January&#160;13, 2021, the parties to the derivative action entered into a settlement agreement, the terms of which were disclosed in a Form 8-K filed on February&#160;5, 2021. The settlement agreement was approved by the Court on April 16, 2021. Amounts owed by the Company pursuant to the settlement agreement are not material to the Company.</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <dnli:OperatingLeasesAreaUnderLease
      contextRef="i7fec5584f40f4e2589bf51cfb5be2fa0_D20180502-20180502"
      decimals="-1"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81NS9mcmFnOjFlY2VlN2YxM2M0ZTQ0NWQ4ZjMwODVkYjQ4NzdkZmUxL3RleHRyZWdpb246MWVjZWU3ZjEzYzRlNDQ1ZDhmMzA4NWRiNDg3N2RmZTFfMjY2_ba4b0b7b-eb05-49d4-9873-3df792de18ee"
      unitRef="sqft">148020</dnli:OperatingLeasesAreaUnderLease>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="ie37401f4fa5441f69f346d3a02b8b078_I20180502"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81NS9mcmFnOjFlY2VlN2YxM2M0ZTQ0NWQ4ZjMwODVkYjQ4NzdkZmUxL3RleHRyZWdpb246MWVjZWU3ZjEzYzRlNDQ1ZDhmMzA4NWRiNDg3N2RmZTFfNDIw_c767fa9c-e45f-46a8-8267-f87f76cafd0f">P10Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="ie37401f4fa5441f69f346d3a02b8b078_I20180502"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81NS9mcmFnOjFlY2VlN2YxM2M0ZTQ0NWQ4ZjMwODVkYjQ4NzdkZmUxL3RleHRyZWdpb246MWVjZWU3ZjEzYzRlNDQ1ZDhmMzA4NWRiNDg3N2RmZTFfNzU0_75c7dee2-5fc0-4a1c-bddb-0c4177a2ee32">P10Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <dnli:LesseeOperatingLeaseRenewalNoticePeriod
      contextRef="i99207688a3a04bb6b263d1f44c4431cb_D20180502-20180502"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81NS9mcmFnOjFlY2VlN2YxM2M0ZTQ0NWQ4ZjMwODVkYjQ4NzdkZmUxL3RleHRyZWdpb246MWVjZWU3ZjEzYzRlNDQ1ZDhmMzA4NWRiNDg3N2RmZTFfODQz_cc7ea482-f59f-4145-8275-06645a30f285">P9M</dnli:LesseeOperatingLeaseRenewalNoticePeriod>
    <dnli:LesseeOperatingLeaseRenewalNoticePeriod
      contextRef="ic993dcf5385f4b81b82f62d1d7c425ad_D20180502-20180502"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81NS9mcmFnOjFlY2VlN2YxM2M0ZTQ0NWQ4ZjMwODVkYjQ4NzdkZmUxL3RleHRyZWdpb246MWVjZWU3ZjEzYzRlNDQ1ZDhmMzA4NWRiNDg3N2RmZTFfNzk1OQ_b38427ce-3704-41b8-b101-898e0ecf2e97">P12M</dnli:LesseeOperatingLeaseRenewalNoticePeriod>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i9953f50a7fd74f7d8438f304f136a07b_I20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81NS9mcmFnOjFlY2VlN2YxM2M0ZTQ0NWQ4ZjMwODVkYjQ4NzdkZmUxL3RleHRyZWdpb246MWVjZWU3ZjEzYzRlNDQ1ZDhmMzA4NWRiNDg3N2RmZTFfMjc0ODc3OTA4MTU3OQ_619833fc-898b-4fdb-824e-77ee86ec2274">P8Y1M6D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:LeaseholdImprovementsGross
      contextRef="i8bf8a6f92025417783902a1461338b26_I20180502"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81NS9mcmFnOjFlY2VlN2YxM2M0ZTQ0NWQ4ZjMwODVkYjQ4NzdkZmUxL3RleHRyZWdpb246MWVjZWU3ZjEzYzRlNDQ1ZDhmMzA4NWRiNDg3N2RmZTFfMTI0Mw_a38b80f0-d5a0-4558-8afd-485f4f15e12b"
      unitRef="usd">25900000</us-gaap:LeaseholdImprovementsGross>
    <dnli:TenantImprovementAllowanceRepayableAsRent
      contextRef="i6456f8216b9a4588b93f1a1da733ca1d_D20180502-20180502"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81NS9mcmFnOjFlY2VlN2YxM2M0ZTQ0NWQ4ZjMwODVkYjQ4NzdkZmUxL3RleHRyZWdpb246MWVjZWU3ZjEzYzRlNDQ1ZDhmMzA4NWRiNDg3N2RmZTFfMTI4Mg_6098e8c2-f6a0-4195-9fc9-a532a68dc79a"
      unitRef="usd">4400000</dnli:TenantImprovementAllowanceRepayableAsRent>
    <us-gaap:LesseeOperatingLeaseDiscountRate
      contextRef="i9953f50a7fd74f7d8438f304f136a07b_I20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81NS9mcmFnOjFlY2VlN2YxM2M0ZTQ0NWQ4ZjMwODVkYjQ4NzdkZmUxL3RleHRyZWdpb246MWVjZWU3ZjEzYzRlNDQ1ZDhmMzA4NWRiNDg3N2RmZTFfMjAyMQ_5281cd4e-7da6-4cc1-96ac-4302794b1cbd"
      unitRef="number">0.090</us-gaap:LesseeOperatingLeaseDiscountRate>
    <us-gaap:LeaseCost
      contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81NS9mcmFnOjFlY2VlN2YxM2M0ZTQ0NWQ4ZjMwODVkYjQ4NzdkZmUxL3RleHRyZWdpb246MWVjZWU3ZjEzYzRlNDQ1ZDhmMzA4NWRiNDg3N2RmZTFfMjQ0MQ_11749fea-2646-44fc-944a-45a540f0e27b"
      unitRef="usd">2800000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="ia34dfea6b8734d64abf707c28256801c_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81NS9mcmFnOjFlY2VlN2YxM2M0ZTQ0NWQ4ZjMwODVkYjQ4NzdkZmUxL3RleHRyZWdpb246MWVjZWU3ZjEzYzRlNDQ1ZDhmMzA4NWRiNDg3N2RmZTFfMjQ4NA_b065956b-05b3-4a9e-86e6-719ac041acae"
      unitRef="usd">2600000</us-gaap:LeaseCost>
    <us-gaap:OperatingLeasePayments
      contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81NS9mcmFnOjFlY2VlN2YxM2M0ZTQ0NWQ4ZjMwODVkYjQ4NzdkZmUxL3RleHRyZWdpb246MWVjZWU3ZjEzYzRlNDQ1ZDhmMzA4NWRiNDg3N2RmZTFfMzA3MQ_57758fdf-c18d-4a98-be4f-457edad93ff8"
      unitRef="usd">2500000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="ia34dfea6b8734d64abf707c28256801c_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81NS9mcmFnOjFlY2VlN2YxM2M0ZTQ0NWQ4ZjMwODVkYjQ4NzdkZmUxL3RleHRyZWdpb246MWVjZWU3ZjEzYzRlNDQ1ZDhmMzA4NWRiNDg3N2RmZTFfMzA3OA_d4f19a75-db32-462f-8c79-8e769ed35246"
      unitRef="usd">2200000</us-gaap:OperatingLeasePayments>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81NS9mcmFnOjFlY2VlN2YxM2M0ZTQ0NWQ4ZjMwODVkYjQ4NzdkZmUxL3RleHRyZWdpb246MWVjZWU3ZjEzYzRlNDQ1ZDhmMzA4NWRiNDg3N2RmZTFfNzk2MQ_7c382dea-6e7d-40c0-ad3f-da1c474c2243">&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table reconciles the undiscounted cash flows for the next five years and total of the remaining years to the operating lease liabilities recorded in the Condensed Consolidated Balance Sheet as of March 31, 2021 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.867%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.162%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021 (nine months)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11,083&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11,447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;42,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total undiscounted lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;95,190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Present value adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(27,398)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;67,792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="i9953f50a7fd74f7d8438f304f136a07b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81NS9mcmFnOjFlY2VlN2YxM2M0ZTQ0NWQ4ZjMwODVkYjQ4NzdkZmUxL3RhYmxlOjVkYTNlZTI3NTBjYzRjNWE4NzQ4Mjc3OTE2MGFlNTlmL3RhYmxlcmFuZ2U6NWRhM2VlMjc1MGNjNGM1YTg3NDgyNzc5MTYwYWU1OWZfMS0yLTEtMS0w_b123fa54-549c-47c8-a0a8-d6c6d87b0425"
      unitRef="usd">7855000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i9953f50a7fd74f7d8438f304f136a07b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81NS9mcmFnOjFlY2VlN2YxM2M0ZTQ0NWQ4ZjMwODVkYjQ4NzdkZmUxL3RhYmxlOjVkYTNlZTI3NTBjYzRjNWE4NzQ4Mjc3OTE2MGFlNTlmL3RhYmxlcmFuZ2U6NWRhM2VlMjc1MGNjNGM1YTg3NDgyNzc5MTYwYWU1OWZfMi0yLTEtMS0w_6f172162-ef83-4974-93bd-d1af6efc240d"
      unitRef="usd">10731000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i9953f50a7fd74f7d8438f304f136a07b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81NS9mcmFnOjFlY2VlN2YxM2M0ZTQ0NWQ4ZjMwODVkYjQ4NzdkZmUxL3RhYmxlOjVkYTNlZTI3NTBjYzRjNWE4NzQ4Mjc3OTE2MGFlNTlmL3RhYmxlcmFuZ2U6NWRhM2VlMjc1MGNjNGM1YTg3NDgyNzc5MTYwYWU1OWZfMy0yLTEtMS0w_e393d73b-439a-4060-b33b-696c3070839c"
      unitRef="usd">11083000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="i9953f50a7fd74f7d8438f304f136a07b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81NS9mcmFnOjFlY2VlN2YxM2M0ZTQ0NWQ4ZjMwODVkYjQ4NzdkZmUxL3RhYmxlOjVkYTNlZTI3NTBjYzRjNWE4NzQ4Mjc3OTE2MGFlNTlmL3RhYmxlcmFuZ2U6NWRhM2VlMjc1MGNjNGM1YTg3NDgyNzc5MTYwYWU1OWZfNC0yLTEtMS0w_ff7d8556-defd-4c61-a3a1-56f6ad7d1025"
      unitRef="usd">11447000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="i9953f50a7fd74f7d8438f304f136a07b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81NS9mcmFnOjFlY2VlN2YxM2M0ZTQ0NWQ4ZjMwODVkYjQ4NzdkZmUxL3RhYmxlOjVkYTNlZTI3NTBjYzRjNWE4NzQ4Mjc3OTE2MGFlNTlmL3RhYmxlcmFuZ2U6NWRhM2VlMjc1MGNjNGM1YTg3NDgyNzc5MTYwYWU1OWZfNS0yLTEtMS0w_5da1812f-f103-4df2-af14-7250282d4730"
      unitRef="usd">11824000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <dnli:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour
      contextRef="i9953f50a7fd74f7d8438f304f136a07b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81NS9mcmFnOjFlY2VlN2YxM2M0ZTQ0NWQ4ZjMwODVkYjQ4NzdkZmUxL3RhYmxlOjVkYTNlZTI3NTBjYzRjNWE4NzQ4Mjc3OTE2MGFlNTlmL3RhYmxlcmFuZ2U6NWRhM2VlMjc1MGNjNGM1YTg3NDgyNzc5MTYwYWU1OWZfNi0yLTEtMS0w_8e3928eb-87c2-47b7-ab40-487bfa6ad412"
      unitRef="usd">42250000</dnli:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i9953f50a7fd74f7d8438f304f136a07b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81NS9mcmFnOjFlY2VlN2YxM2M0ZTQ0NWQ4ZjMwODVkYjQ4NzdkZmUxL3RhYmxlOjVkYTNlZTI3NTBjYzRjNWE4NzQ4Mjc3OTE2MGFlNTlmL3RhYmxlcmFuZ2U6NWRhM2VlMjc1MGNjNGM1YTg3NDgyNzc5MTYwYWU1OWZfNy0yLTEtMS0w_f4db27ee-31fa-479f-9fab-40d92fbfe810"
      unitRef="usd">95190000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i9953f50a7fd74f7d8438f304f136a07b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81NS9mcmFnOjFlY2VlN2YxM2M0ZTQ0NWQ4ZjMwODVkYjQ4NzdkZmUxL3RhYmxlOjVkYTNlZTI3NTBjYzRjNWE4NzQ4Mjc3OTE2MGFlNTlmL3RhYmxlcmFuZ2U6NWRhM2VlMjc1MGNjNGM1YTg3NDgyNzc5MTYwYWU1OWZfOC0yLTEtMS0w_14072796-c03e-49ff-b15c-541435938e90"
      unitRef="usd">27398000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="i9953f50a7fd74f7d8438f304f136a07b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81NS9mcmFnOjFlY2VlN2YxM2M0ZTQ0NWQ4ZjMwODVkYjQ4NzdkZmUxL3RhYmxlOjVkYTNlZTI3NTBjYzRjNWE4NzQ4Mjc3OTE2MGFlNTlmL3RhYmxlcmFuZ2U6NWRhM2VlMjc1MGNjNGM1YTg3NDgyNzc5MTYwYWU1OWZfOS0yLTEtMS0w_01882ac7-385d-4b65-826b-6ba410c6161b"
      unitRef="usd">67792000</us-gaap:OperatingLeaseLiability>
    <dnli:OperatingLeasesSubleaseNetRentableArea
      contextRef="ib5b9d59cd718474d84fa120208dacc38_I20181031"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81NS9mcmFnOjFlY2VlN2YxM2M0ZTQ0NWQ4ZjMwODVkYjQ4NzdkZmUxL3RleHRyZWdpb246MWVjZWU3ZjEzYzRlNDQ1ZDhmMzA4NWRiNDg3N2RmZTFfMzU1MA_723c5f46-a9d7-471d-945d-0ad137829c4d"
      unitRef="sqft">36835</dnli:OperatingLeasesSubleaseNetRentableArea>
    <us-gaap:LessorOperatingLeaseTermOfContract
      contextRef="ib5b9d59cd718474d84fa120208dacc38_I20181031"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81NS9mcmFnOjFlY2VlN2YxM2M0ZTQ0NWQ4ZjMwODVkYjQ4NzdkZmUxL3RleHRyZWdpb246MWVjZWU3ZjEzYzRlNDQ1ZDhmMzA4NWRiNDg3N2RmZTFfMzY0MQ_eb03f648-89dc-429a-8115-359988796ba6">P5Y</us-gaap:LessorOperatingLeaseTermOfContract>
    <us-gaap:SubleaseIncome
      contextRef="ia34dfea6b8734d64abf707c28256801c_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81NS9mcmFnOjFlY2VlN2YxM2M0ZTQ0NWQ4ZjMwODVkYjQ4NzdkZmUxL3RleHRyZWdpb246MWVjZWU3ZjEzYzRlNDQ1ZDhmMzA4NWRiNDg3N2RmZTFfNDA5NA_0349fec2-786a-43c6-a03d-b914d40718d4"
      unitRef="usd">900000</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome
      contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81NS9mcmFnOjFlY2VlN2YxM2M0ZTQ0NWQ4ZjMwODVkYjQ4NzdkZmUxL3RleHRyZWdpb246MWVjZWU3ZjEzYzRlNDQ1ZDhmMzA4NWRiNDg3N2RmZTFfNDA5NA_cebf51e7-7a42-4846-b0aa-0249eed3a07c"
      unitRef="usd">900000</us-gaap:SubleaseIncome>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock
      contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81NS9mcmFnOjFlY2VlN2YxM2M0ZTQ0NWQ4ZjMwODVkYjQ4NzdkZmUxL3RleHRyZWdpb246MWVjZWU3ZjEzYzRlNDQ1ZDhmMzA4NWRiNDg3N2RmZTFfNzk1Ng_0554304d-1caa-4fc6-807a-7672ee2eea76">&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table details the future undiscounted cash inflows relating to the Sublease Agreement as of March 31, 2021 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.867%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.162%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021 (nine months)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,096&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total undiscounted sublease receipts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear
      contextRef="i9953f50a7fd74f7d8438f304f136a07b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81NS9mcmFnOjFlY2VlN2YxM2M0ZTQ0NWQ4ZjMwODVkYjQ4NzdkZmUxL3RhYmxlOjg3MzhjNWJkNzlmZDQ0ZDE5ZGE4MjYyOGEwNTgyZmZiL3RhYmxlcmFuZ2U6ODczOGM1YmQ3OWZkNDRkMTlkYTgyNjI4YTA1ODJmZmJfMS0yLTEtMS0w_33e8b20a-fac0-4dfc-aac8-4d7a82b6f774"
      unitRef="usd">2209000</us-gaap:LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths
      contextRef="i9953f50a7fd74f7d8438f304f136a07b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81NS9mcmFnOjFlY2VlN2YxM2M0ZTQ0NWQ4ZjMwODVkYjQ4NzdkZmUxL3RhYmxlOjg3MzhjNWJkNzlmZDQ0ZDE5ZGE4MjYyOGEwNTgyZmZiL3RhYmxlcmFuZ2U6ODczOGM1YmQ3OWZkNDRkMTlkYTgyNjI4YTA1ODJmZmJfMi0yLTEtMS0w_c1fbf029-1188-44f7-8e21-41cc4f4b8a70"
      unitRef="usd">3009000</us-gaap:LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceivedTwoYears
      contextRef="i9953f50a7fd74f7d8438f304f136a07b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81NS9mcmFnOjFlY2VlN2YxM2M0ZTQ0NWQ4ZjMwODVkYjQ4NzdkZmUxL3RhYmxlOjg3MzhjNWJkNzlmZDQ0ZDE5ZGE4MjYyOGEwNTgyZmZiL3RhYmxlcmFuZ2U6ODczOGM1YmQ3OWZkNDRkMTlkYTgyNjI4YTA1ODJmZmJfMy0yLTEtMS0w_3276d202-4177-43a7-b2a8-213b9cab5b7f"
      unitRef="usd">3096000</us-gaap:LessorOperatingLeasePaymentsToBeReceivedTwoYears>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceivedThreeYears
      contextRef="i9953f50a7fd74f7d8438f304f136a07b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81NS9mcmFnOjFlY2VlN2YxM2M0ZTQ0NWQ4ZjMwODVkYjQ4NzdkZmUxL3RhYmxlOjg3MzhjNWJkNzlmZDQ0ZDE5ZGE4MjYyOGEwNTgyZmZiL3RhYmxlcmFuZ2U6ODczOGM1YmQ3OWZkNDRkMTlkYTgyNjI4YTA1ODJmZmJfNC0yLTEtMS0w_917e5b0e-e809-4b20-be17-211d1a8dcaa1"
      unitRef="usd">876000</us-gaap:LessorOperatingLeasePaymentsToBeReceivedThreeYears>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceived
      contextRef="i9953f50a7fd74f7d8438f304f136a07b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81NS9mcmFnOjFlY2VlN2YxM2M0ZTQ0NWQ4ZjMwODVkYjQ4NzdkZmUxL3RhYmxlOjg3MzhjNWJkNzlmZDQ0ZDE5ZGE4MjYyOGEwNTgyZmZiL3RhYmxlcmFuZ2U6ODczOGM1YmQ3OWZkNDRkMTlkYTgyNjI4YTA1ODJmZmJfNy0yLTEtMS0w_39f8adc9-e85e-43d4-97f9-a5e05be06a66"
      unitRef="usd">9190000</us-gaap:LessorOperatingLeasePaymentsToBeReceived>
    <dnli:PurchaseOrderExecuted
      contextRef="i5883d19040b14361a685e33448d24167_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81NS9mcmFnOjFlY2VlN2YxM2M0ZTQ0NWQ4ZjMwODVkYjQ4NzdkZmUxL3RleHRyZWdpb246MWVjZWU3ZjEzYzRlNDQ1ZDhmMzA4NWRiNDg3N2RmZTFfNjE3Mg_85c2640c-9164-4563-9f98-23e1db68deb8"
      unitRef="usd">33400000</dnli:PurchaseOrderExecuted>
    <dnli:PurchaseOrderExecuted
      contextRef="i71996497ebce4b2c8c7d7e4cd228fb94_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81NS9mcmFnOjFlY2VlN2YxM2M0ZTQ0NWQ4ZjMwODVkYjQ4NzdkZmUxL3RleHRyZWdpb246MWVjZWU3ZjEzYzRlNDQ1ZDhmMzA4NWRiNDg3N2RmZTFfNjE3OQ_3e09d178-3892-4e10-816c-51bd3a0f8f87"
      unitRef="usd">33000000.0</dnli:PurchaseOrderExecuted>
    <us-gaap:PurchaseObligation
      contextRef="i5883d19040b14361a685e33448d24167_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81NS9mcmFnOjFlY2VlN2YxM2M0ZTQ0NWQ4ZjMwODVkYjQ4NzdkZmUxL3RleHRyZWdpb246MWVjZWU3ZjEzYzRlNDQ1ZDhmMzA4NWRiNDg3N2RmZTFfNjM3MA_75de225a-685d-4efb-b3fe-7386107ec861"
      unitRef="usd">28500000</us-gaap:PurchaseObligation>
    <us-gaap:PurchaseObligation
      contextRef="i71996497ebce4b2c8c7d7e4cd228fb94_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81NS9mcmFnOjFlY2VlN2YxM2M0ZTQ0NWQ4ZjMwODVkYjQ4NzdkZmUxL3RleHRyZWdpb246MWVjZWU3ZjEzYzRlNDQ1ZDhmMzA4NWRiNDg3N2RmZTFfNjM3Nw_9d1a90c5-751d-46c8-9022-8394b6ca8009"
      unitRef="usd">27100000</us-gaap:PurchaseObligation>
    <us-gaap:CostsIncurredDevelopmentCosts
      contextRef="i450a57d93cb84950a947b2c09bd3ca2d_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81NS9mcmFnOjFlY2VlN2YxM2M0ZTQ0NWQ4ZjMwODVkYjQ4NzdkZmUxL3RleHRyZWdpb246MWVjZWU3ZjEzYzRlNDQ1ZDhmMzA4NWRiNDg3N2RmZTFfNjQ1MA_5874e967-f59a-4995-b434-cddfaba5add3"
      unitRef="usd">5200000</us-gaap:CostsIncurredDevelopmentCosts>
    <us-gaap:CostsIncurredDevelopmentCosts
      contextRef="i8e1a3ef913c04a4dbb9618e565378ec6_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81NS9mcmFnOjFlY2VlN2YxM2M0ZTQ0NWQ4ZjMwODVkYjQ4NzdkZmUxL3RleHRyZWdpb246MWVjZWU3ZjEzYzRlNDQ1ZDhmMzA4NWRiNDg3N2RmZTFfNjQ1Nw_a4607852-35ca-4048-84ed-59f99398a237"
      unitRef="usd">1000000.0</us-gaap:CostsIncurredDevelopmentCosts>
    <dnli:PaymentsForManufacturingCost
      contextRef="i450a57d93cb84950a947b2c09bd3ca2d_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81NS9mcmFnOjFlY2VlN2YxM2M0ZTQ0NWQ4ZjMwODVkYjQ4NzdkZmUxL3RleHRyZWdpb246MWVjZWU3ZjEzYzRlNDQ1ZDhmMzA4NWRiNDg3N2RmZTFfNjQ5Ng_ee1e2a72-0fd6-4fab-9dba-6fbded72cf3e"
      unitRef="usd">700000</dnli:PaymentsForManufacturingCost>
    <dnli:PaymentsForManufacturingCost
      contextRef="i8e1a3ef913c04a4dbb9618e565378ec6_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81NS9mcmFnOjFlY2VlN2YxM2M0ZTQ0NWQ4ZjMwODVkYjQ4NzdkZmUxL3RleHRyZWdpb246MWVjZWU3ZjEzYzRlNDQ1ZDhmMzA4NWRiNDg3N2RmZTFfNjUwMw_f91b47b2-ab0d-42f7-adff-3782d5d742bf"
      unitRef="usd">3200000</dnli:PaymentsForManufacturingCost>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81OC9mcmFnOjdiZjczNTljOWJmNTQ1Yjg4ODEzMGFlMmU4YzMwMjA2L3RleHRyZWdpb246N2JmNzM1OWM5YmY1NDViODg4MTMwYWUyZThjMzAyMDZfODY1_1ab153d3-d32a-4984-9221-bb5fde041dbc">Stock-Based Awards&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has issued stock-based awards from various equity incentive and stock purchase plans, as more fully described in Note 10, "Stock-Based Awards" to the consolidated financial statements in the Company's 2020 Annual Report on Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Option Activity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes stock option activity for the three months ended March 31, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.226%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.335%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.338%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of Options&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Exercise&#160;Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12,959,926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,639,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;75.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(334,634)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(34,056)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26.77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,230,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;text-indent:-12pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest at March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13,357,914&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24.69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Exercisable at March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,013,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair value of stock options granted to employees were calculated using the Black-Scholes option-pricing model using the following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.226%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.335%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.338%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.08&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.08&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Volatility&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;62.2% - 63.4%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;65.2% - 65.6%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.5% - 1.0%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.7% - 1.7%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Stock Activity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes restricted stock unit ("RSU") activity for the three months ended March 31, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.226%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.335%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.338%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of RSU shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average Fair Value at Date of Grant per Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unvested at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,301,679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;696,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;76.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vested and released&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(281,465)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22.73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(17,377)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;61.97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unvested at March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,699,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expected to vest at March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,699,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s results of operations include expenses relating to stock-based compensation as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.778%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.061%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12,314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,054&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21,028&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81OC9mcmFnOjdiZjczNTljOWJmNTQ1Yjg4ODEzMGFlMmU4YzMwMjA2L3RleHRyZWdpb246N2JmNzM1OWM5YmY1NDViODg4MTMwYWUyZThjMzAyMDZfODYw_fc346972-ad63-46bb-8297-14f5f37b94e1">&lt;div style="margin-bottom:10pt;margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes stock option activity for the three months ended March 31, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.226%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.335%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.338%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of Options&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Exercise&#160;Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12,959,926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,639,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;75.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(334,634)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(34,056)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26.77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,230,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;text-indent:-12pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest at March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13,357,914&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24.69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Exercisable at March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,013,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="idb7ca9f362da46eab3a29bbbecbda977_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81OC9mcmFnOjdiZjczNTljOWJmNTQ1Yjg4ODEzMGFlMmU4YzMwMjA2L3RhYmxlOjE3ZTA3ZTI3OTg3NDQwZjc4OTBhMjgyOWFjNGUwYmI1L3RhYmxlcmFuZ2U6MTdlMDdlMjc5ODc0NDBmNzg5MGEyODI5YWM0ZTBiYjVfMS0xLTEtMS0w_c974e1d6-f2bd-491d-a369-dd4ce5f25121"
      unitRef="shares">12959926</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="idb7ca9f362da46eab3a29bbbecbda977_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81OC9mcmFnOjdiZjczNTljOWJmNTQ1Yjg4ODEzMGFlMmU4YzMwMjA2L3RhYmxlOjE3ZTA3ZTI3OTg3NDQwZjc4OTBhMjgyOWFjNGUwYmI1L3RhYmxlcmFuZ2U6MTdlMDdlMjc5ODc0NDBmNzg5MGEyODI5YWM0ZTBiYjVfMS0zLTEtMS0w_6b5c5f16-0c4d-4f52-a416-ffb13aafce55"
      unitRef="usdPerShare">16.31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81OC9mcmFnOjdiZjczNTljOWJmNTQ1Yjg4ODEzMGFlMmU4YzMwMjA2L3RhYmxlOjE3ZTA3ZTI3OTg3NDQwZjc4OTBhMjgyOWFjNGUwYmI1L3RhYmxlcmFuZ2U6MTdlMDdlMjc5ODc0NDBmNzg5MGEyODI5YWM0ZTBiYjVfMi0xLTEtMS0w_a06cf805-6f08-4b2b-84a9-3369d36f8e03"
      unitRef="shares">1639041</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81OC9mcmFnOjdiZjczNTljOWJmNTQ1Yjg4ODEzMGFlMmU4YzMwMjA2L3RhYmxlOjE3ZTA3ZTI3OTg3NDQwZjc4OTBhMjgyOWFjNGUwYmI1L3RhYmxlcmFuZ2U6MTdlMDdlMjc5ODc0NDBmNzg5MGEyODI5YWM0ZTBiYjVfMi0zLTEtMS0w_ce922683-eb0f-474a-a7c0-17c282ba4106"
      unitRef="usdPerShare">75.52</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81OC9mcmFnOjdiZjczNTljOWJmNTQ1Yjg4ODEzMGFlMmU4YzMwMjA2L3RhYmxlOjE3ZTA3ZTI3OTg3NDQwZjc4OTBhMjgyOWFjNGUwYmI1L3RhYmxlcmFuZ2U6MTdlMDdlMjc5ODc0NDBmNzg5MGEyODI5YWM0ZTBiYjVfMy0xLTEtMS0w_81712c26-dc9d-4bf6-8d25-284f9d7c3871"
      unitRef="shares">334634</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81OC9mcmFnOjdiZjczNTljOWJmNTQ1Yjg4ODEzMGFlMmU4YzMwMjA2L3RhYmxlOjE3ZTA3ZTI3OTg3NDQwZjc4OTBhMjgyOWFjNGUwYmI1L3RhYmxlcmFuZ2U6MTdlMDdlMjc5ODc0NDBmNzg5MGEyODI5YWM0ZTBiYjVfMy0zLTEtMS0w_f3ce35c0-f5f2-45e1-af8c-2ec1e7423061"
      unitRef="usdPerShare">11.42</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81OC9mcmFnOjdiZjczNTljOWJmNTQ1Yjg4ODEzMGFlMmU4YzMwMjA2L3RhYmxlOjE3ZTA3ZTI3OTg3NDQwZjc4OTBhMjgyOWFjNGUwYmI1L3RhYmxlcmFuZ2U6MTdlMDdlMjc5ODc0NDBmNzg5MGEyODI5YWM0ZTBiYjVfNC0xLTEtMS0w_5436917f-b152-4d03-a3f6-04d35beb39fc"
      unitRef="shares">34056</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81OC9mcmFnOjdiZjczNTljOWJmNTQ1Yjg4ODEzMGFlMmU4YzMwMjA2L3RhYmxlOjE3ZTA3ZTI3OTg3NDQwZjc4OTBhMjgyOWFjNGUwYmI1L3RhYmxlcmFuZ2U6MTdlMDdlMjc5ODc0NDBmNzg5MGEyODI5YWM0ZTBiYjVfNC0zLTEtMS0w_dbee7aad-c490-4eef-a39c-66a2b871a896"
      unitRef="usdPerShare">26.77</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i9953f50a7fd74f7d8438f304f136a07b_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81OC9mcmFnOjdiZjczNTljOWJmNTQ1Yjg4ODEzMGFlMmU4YzMwMjA2L3RhYmxlOjE3ZTA3ZTI3OTg3NDQwZjc4OTBhMjgyOWFjNGUwYmI1L3RhYmxlcmFuZ2U6MTdlMDdlMjc5ODc0NDBmNzg5MGEyODI5YWM0ZTBiYjVfNS0xLTEtMS0w_fe706335-b987-4dea-800a-b4d8f6e6dab1"
      unitRef="shares">14230277</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i9953f50a7fd74f7d8438f304f136a07b_I20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81OC9mcmFnOjdiZjczNTljOWJmNTQ1Yjg4ODEzMGFlMmU4YzMwMjA2L3RhYmxlOjE3ZTA3ZTI3OTg3NDQwZjc4OTBhMjgyOWFjNGUwYmI1L3RhYmxlcmFuZ2U6MTdlMDdlMjc5ODc0NDBmNzg5MGEyODI5YWM0ZTBiYjVfNS0zLTEtMS0w_fa0ad58b-4946-4d28-b546-33e8d8b20bbc"
      unitRef="usdPerShare">23.22</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="i9953f50a7fd74f7d8438f304f136a07b_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81OC9mcmFnOjdiZjczNTljOWJmNTQ1Yjg4ODEzMGFlMmU4YzMwMjA2L3RhYmxlOjE3ZTA3ZTI3OTg3NDQwZjc4OTBhMjgyOWFjNGUwYmI1L3RhYmxlcmFuZ2U6MTdlMDdlMjc5ODc0NDBmNzg5MGEyODI5YWM0ZTBiYjVfNi0xLTEtMS0w_7bd5a38f-32a8-426b-8baf-c6d18efe9238"
      unitRef="shares">13357914</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="i9953f50a7fd74f7d8438f304f136a07b_I20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81OC9mcmFnOjdiZjczNTljOWJmNTQ1Yjg4ODEzMGFlMmU4YzMwMjA2L3RhYmxlOjE3ZTA3ZTI3OTg3NDQwZjc4OTBhMjgyOWFjNGUwYmI1L3RhYmxlcmFuZ2U6MTdlMDdlMjc5ODc0NDBmNzg5MGEyODI5YWM0ZTBiYjVfNi0zLTEtMS0w_05d77876-18e4-4891-b3c9-bb6aec770fd6"
      unitRef="usdPerShare">24.69</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i9953f50a7fd74f7d8438f304f136a07b_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81OC9mcmFnOjdiZjczNTljOWJmNTQ1Yjg4ODEzMGFlMmU4YzMwMjA2L3RhYmxlOjE3ZTA3ZTI3OTg3NDQwZjc4OTBhMjgyOWFjNGUwYmI1L3RhYmxlcmFuZ2U6MTdlMDdlMjc5ODc0NDBmNzg5MGEyODI5YWM0ZTBiYjVfNy0xLTEtMS0w_62caa6d6-4402-43d7-b50c-ad8b5679a5bf"
      unitRef="shares">7013040</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="i9953f50a7fd74f7d8438f304f136a07b_I20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81OC9mcmFnOjdiZjczNTljOWJmNTQ1Yjg4ODEzMGFlMmU4YzMwMjA2L3RhYmxlOjE3ZTA3ZTI3OTg3NDQwZjc4OTBhMjgyOWFjNGUwYmI1L3RhYmxlcmFuZ2U6MTdlMDdlMjc5ODc0NDBmNzg5MGEyODI5YWM0ZTBiYjVfNy0zLTEtMS0w_620a1a84-3830-4344-a882-acd18617532c"
      unitRef="usdPerShare">14.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81OC9mcmFnOjdiZjczNTljOWJmNTQ1Yjg4ODEzMGFlMmU4YzMwMjA2L3RleHRyZWdpb246N2JmNzM1OWM5YmY1NDViODg4MTMwYWUyZThjMzAyMDZfODYy_0f9f464e-50a4-42bf-93b4-ecddc304a6cd">&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair value of stock options granted to employees were calculated using the Black-Scholes option-pricing model using the following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.226%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.335%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.338%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.08&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.08&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Volatility&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;62.2% - 63.4%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;65.2% - 65.6%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.5% - 1.0%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.7% - 1.7%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i84ba3b58bcce4a4c9748d2ca212f024c_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81OC9mcmFnOjdiZjczNTljOWJmNTQ1Yjg4ODEzMGFlMmU4YzMwMjA2L3RhYmxlOjdlNDk0MjEzNGU4NDRkMjlhMjMzNWM4NzM5OWJjZjUzL3RhYmxlcmFuZ2U6N2U0OTQyMTM0ZTg0NGQyOWEyMzM1Yzg3Mzk5YmNmNTNfMi0xLTEtMS0wL3RleHRyZWdpb246NjU1MDZjNTIxYjZmNGRmNDg1NTYwYTc3NTA4MzdhZDhfMTA5OTUxMTYyNzgwNg_4a2a0861-4f2f-46da-97fb-ad557cc7f380">P6Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i884b579d788c483eb3a9ee088d3e5d89_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81OC9mcmFnOjdiZjczNTljOWJmNTQ1Yjg4ODEzMGFlMmU4YzMwMjA2L3RhYmxlOjdlNDk0MjEzNGU4NDRkMjlhMjMzNWM4NzM5OWJjZjUzL3RhYmxlcmFuZ2U6N2U0OTQyMTM0ZTg0NGQyOWEyMzM1Yzg3Mzk5YmNmNTNfMi0zLTEtMS0wL3RleHRyZWdpb246MTZhNWU3MWJiYTQ5NGQxNTllMTRjOTg1NTRjODJhMDhfMTA5OTUxMTYyNzgxNA_cae915fa-e553-4ff7-a4ab-73448ab73546">P6Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="i84ba3b58bcce4a4c9748d2ca212f024c_D20210101-20210331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81OC9mcmFnOjdiZjczNTljOWJmNTQ1Yjg4ODEzMGFlMmU4YzMwMjA2L3RhYmxlOjdlNDk0MjEzNGU4NDRkMjlhMjMzNWM4NzM5OWJjZjUzL3RhYmxlcmFuZ2U6N2U0OTQyMTM0ZTg0NGQyOWEyMzM1Yzg3Mzk5YmNmNTNfMy0xLTEtMS0wL3RleHRyZWdpb246ODFkOWU1MTU0NmZhNDBkNGJkM2VlNjBiNWVkYjZiYTNfNA_0e2ca703-51e8-43e9-89aa-0dead8f563bf"
      unitRef="number">0.622</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="i84ba3b58bcce4a4c9748d2ca212f024c_D20210101-20210331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81OC9mcmFnOjdiZjczNTljOWJmNTQ1Yjg4ODEzMGFlMmU4YzMwMjA2L3RhYmxlOjdlNDk0MjEzNGU4NDRkMjlhMjMzNWM4NzM5OWJjZjUzL3RhYmxlcmFuZ2U6N2U0OTQyMTM0ZTg0NGQyOWEyMzM1Yzg3Mzk5YmNmNTNfMy0xLTEtMS0wL3RleHRyZWdpb246ODFkOWU1MTU0NmZhNDBkNGJkM2VlNjBiNWVkYjZiYTNfOQ_13a8d433-41af-4aed-9d43-9cadcea36e7e"
      unitRef="number">0.634</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="i884b579d788c483eb3a9ee088d3e5d89_D20200101-20200331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81OC9mcmFnOjdiZjczNTljOWJmNTQ1Yjg4ODEzMGFlMmU4YzMwMjA2L3RhYmxlOjdlNDk0MjEzNGU4NDRkMjlhMjMzNWM4NzM5OWJjZjUzL3RhYmxlcmFuZ2U6N2U0OTQyMTM0ZTg0NGQyOWEyMzM1Yzg3Mzk5YmNmNTNfMy0zLTEtMS0wL3RleHRyZWdpb246NDExMDE3ZTMxMTJiNGExZmIxYzA4YTZjZDA3NWNjNjdfNA_da5e755f-ab70-4231-ab99-df55c7c0ac6e"
      unitRef="number">0.652</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="i884b579d788c483eb3a9ee088d3e5d89_D20200101-20200331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81OC9mcmFnOjdiZjczNTljOWJmNTQ1Yjg4ODEzMGFlMmU4YzMwMjA2L3RhYmxlOjdlNDk0MjEzNGU4NDRkMjlhMjMzNWM4NzM5OWJjZjUzL3RhYmxlcmFuZ2U6N2U0OTQyMTM0ZTg0NGQyOWEyMzM1Yzg3Mzk5YmNmNTNfMy0zLTEtMS0wL3RleHRyZWdpb246NDExMDE3ZTMxMTJiNGExZmIxYzA4YTZjZDA3NWNjNjdfOQ_2f9afb32-f6e9-4a4b-ada3-79b1b7f455e5"
      unitRef="number">0.656</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="i84ba3b58bcce4a4c9748d2ca212f024c_D20210101-20210331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81OC9mcmFnOjdiZjczNTljOWJmNTQ1Yjg4ODEzMGFlMmU4YzMwMjA2L3RhYmxlOjdlNDk0MjEzNGU4NDRkMjlhMjMzNWM4NzM5OWJjZjUzL3RhYmxlcmFuZ2U6N2U0OTQyMTM0ZTg0NGQyOWEyMzM1Yzg3Mzk5YmNmNTNfNC0xLTEtMS0wL3RleHRyZWdpb246ZWRmOThhMTZkOWNkNGY5NWE2YjIwMDQzNDU5MTI5ZDFfNA_e563eb64-a01b-495b-8a1d-8ab44840247d"
      unitRef="number">0.005</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="i84ba3b58bcce4a4c9748d2ca212f024c_D20210101-20210331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81OC9mcmFnOjdiZjczNTljOWJmNTQ1Yjg4ODEzMGFlMmU4YzMwMjA2L3RhYmxlOjdlNDk0MjEzNGU4NDRkMjlhMjMzNWM4NzM5OWJjZjUzL3RhYmxlcmFuZ2U6N2U0OTQyMTM0ZTg0NGQyOWEyMzM1Yzg3Mzk5YmNmNTNfNC0xLTEtMS0wL3RleHRyZWdpb246ZWRmOThhMTZkOWNkNGY5NWE2YjIwMDQzNDU5MTI5ZDFfOQ_b6af21a4-f98e-4faa-a342-12258919d39b"
      unitRef="number">0.010</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="i884b579d788c483eb3a9ee088d3e5d89_D20200101-20200331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81OC9mcmFnOjdiZjczNTljOWJmNTQ1Yjg4ODEzMGFlMmU4YzMwMjA2L3RhYmxlOjdlNDk0MjEzNGU4NDRkMjlhMjMzNWM4NzM5OWJjZjUzL3RhYmxlcmFuZ2U6N2U0OTQyMTM0ZTg0NGQyOWEyMzM1Yzg3Mzk5YmNmNTNfNC0zLTEtMS0wL3RleHRyZWdpb246YjkxOGVjNWQ4ZTI2NGQ2YzlmN2M0OTRhMmMzMjc5YTRfNA_0be29516-8b58-4d0a-a274-ab7b050fc801"
      unitRef="number">0.007</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="i884b579d788c483eb3a9ee088d3e5d89_D20200101-20200331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81OC9mcmFnOjdiZjczNTljOWJmNTQ1Yjg4ODEzMGFlMmU4YzMwMjA2L3RhYmxlOjdlNDk0MjEzNGU4NDRkMjlhMjMzNWM4NzM5OWJjZjUzL3RhYmxlcmFuZ2U6N2U0OTQyMTM0ZTg0NGQyOWEyMzM1Yzg3Mzk5YmNmNTNfNC0zLTEtMS0wL3RleHRyZWdpb246YjkxOGVjNWQ4ZTI2NGQ2YzlmN2M0OTRhMmMzMjc5YTRfOQ_be97122a-45eb-4f5c-8dfe-aa61fd042439"
      unitRef="number">0.017</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i84ba3b58bcce4a4c9748d2ca212f024c_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81OC9mcmFnOjdiZjczNTljOWJmNTQ1Yjg4ODEzMGFlMmU4YzMwMjA2L3RhYmxlOjdlNDk0MjEzNGU4NDRkMjlhMjMzNWM4NzM5OWJjZjUzL3RhYmxlcmFuZ2U6N2U0OTQyMTM0ZTg0NGQyOWEyMzM1Yzg3Mzk5YmNmNTNfNS0xLTEtMS0w_e03868cf-eb5f-4a64-8149-10d8af24aa9d"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i884b579d788c483eb3a9ee088d3e5d89_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81OC9mcmFnOjdiZjczNTljOWJmNTQ1Yjg4ODEzMGFlMmU4YzMwMjA2L3RhYmxlOjdlNDk0MjEzNGU4NDRkMjlhMjMzNWM4NzM5OWJjZjUzL3RhYmxlcmFuZ2U6N2U0OTQyMTM0ZTg0NGQyOWEyMzM1Yzg3Mzk5YmNmNTNfNS0zLTEtMS0w_b2a77764-45f3-4f98-8ebf-b1b6042bd329"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock
      contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81OC9mcmFnOjdiZjczNTljOWJmNTQ1Yjg4ODEzMGFlMmU4YzMwMjA2L3RleHRyZWdpb246N2JmNzM1OWM5YmY1NDViODg4MTMwYWUyZThjMzAyMDZfODYz_26ec0b5d-8adc-4fd5-908d-30959bb27284">&lt;div style="margin-bottom:10pt;margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes restricted stock unit ("RSU") activity for the three months ended March 31, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.226%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.335%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.338%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of RSU shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average Fair Value at Date of Grant per Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unvested at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,301,679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;696,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;76.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vested and released&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(281,465)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22.73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(17,377)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;61.97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unvested at March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,699,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expected to vest at March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,699,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="id3763ebb47a74e7aa55cdc9ec33e6ba1_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81OC9mcmFnOjdiZjczNTljOWJmNTQ1Yjg4ODEzMGFlMmU4YzMwMjA2L3RhYmxlOmRkNTgxOWU1NDVhODQ1NzM5Njc0Y2U2Y2ExODkzNjdlL3RhYmxlcmFuZ2U6ZGQ1ODE5ZTU0NWE4NDU3Mzk2NzRjZTZjYTE4OTM2N2VfMS0xLTEtMS0w_481e1fb5-a1d7-4a6d-811d-aa6c204c678d"
      unitRef="shares">2301679</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="id3763ebb47a74e7aa55cdc9ec33e6ba1_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81OC9mcmFnOjdiZjczNTljOWJmNTQ1Yjg4ODEzMGFlMmU4YzMwMjA2L3RhYmxlOmRkNTgxOWU1NDVhODQ1NzM5Njc0Y2U2Y2ExODkzNjdlL3RhYmxlcmFuZ2U6ZGQ1ODE5ZTU0NWE4NDU3Mzk2NzRjZTZjYTE4OTM2N2VfMS0zLTEtMS0w_c13a8a32-4808-4c8b-8c5d-147419d0e4ee"
      unitRef="usdPerShare">27.08</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="if9c544fa84d346779359fdcd69c81fe6_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81OC9mcmFnOjdiZjczNTljOWJmNTQ1Yjg4ODEzMGFlMmU4YzMwMjA2L3RhYmxlOmRkNTgxOWU1NDVhODQ1NzM5Njc0Y2U2Y2ExODkzNjdlL3RhYmxlcmFuZ2U6ZGQ1ODE5ZTU0NWE4NDU3Mzk2NzRjZTZjYTE4OTM2N2VfMi0xLTEtMS0w_28c1f0a7-f9fc-446a-8dcb-64423bf1c311"
      unitRef="shares">696270</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="if9c544fa84d346779359fdcd69c81fe6_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81OC9mcmFnOjdiZjczNTljOWJmNTQ1Yjg4ODEzMGFlMmU4YzMwMjA2L3RhYmxlOmRkNTgxOWU1NDVhODQ1NzM5Njc0Y2U2Y2ExODkzNjdlL3RhYmxlcmFuZ2U6ZGQ1ODE5ZTU0NWE4NDU3Mzk2NzRjZTZjYTE4OTM2N2VfMi0zLTEtMS0w_767bae70-c366-4411-8640-4ce9881ec839"
      unitRef="usdPerShare">76.33</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="if9c544fa84d346779359fdcd69c81fe6_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81OC9mcmFnOjdiZjczNTljOWJmNTQ1Yjg4ODEzMGFlMmU4YzMwMjA2L3RhYmxlOmRkNTgxOWU1NDVhODQ1NzM5Njc0Y2U2Y2ExODkzNjdlL3RhYmxlcmFuZ2U6ZGQ1ODE5ZTU0NWE4NDU3Mzk2NzRjZTZjYTE4OTM2N2VfMy0xLTEtMS0w_20aaeef1-b8d5-41e4-a8f8-9fb5f78bdc38"
      unitRef="shares">281465</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="if9c544fa84d346779359fdcd69c81fe6_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81OC9mcmFnOjdiZjczNTljOWJmNTQ1Yjg4ODEzMGFlMmU4YzMwMjA2L3RhYmxlOmRkNTgxOWU1NDVhODQ1NzM5Njc0Y2U2Y2ExODkzNjdlL3RhYmxlcmFuZ2U6ZGQ1ODE5ZTU0NWE4NDU3Mzk2NzRjZTZjYTE4OTM2N2VfMy0zLTEtMS0w_b9660d2c-0363-4224-8368-ddcadba1711f"
      unitRef="usdPerShare">22.73</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="if9c544fa84d346779359fdcd69c81fe6_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81OC9mcmFnOjdiZjczNTljOWJmNTQ1Yjg4ODEzMGFlMmU4YzMwMjA2L3RhYmxlOmRkNTgxOWU1NDVhODQ1NzM5Njc0Y2U2Y2ExODkzNjdlL3RhYmxlcmFuZ2U6ZGQ1ODE5ZTU0NWE4NDU3Mzk2NzRjZTZjYTE4OTM2N2VfNC0xLTEtMS0w_610835c8-850c-4353-b236-74a51f68ca7c"
      unitRef="shares">17377</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="if9c544fa84d346779359fdcd69c81fe6_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81OC9mcmFnOjdiZjczNTljOWJmNTQ1Yjg4ODEzMGFlMmU4YzMwMjA2L3RhYmxlOmRkNTgxOWU1NDVhODQ1NzM5Njc0Y2U2Y2ExODkzNjdlL3RhYmxlcmFuZ2U6ZGQ1ODE5ZTU0NWE4NDU3Mzk2NzRjZTZjYTE4OTM2N2VfNC0zLTEtMS0w_b0f82f9d-272d-45e2-b3b6-8f3551d996cf"
      unitRef="usdPerShare">61.97</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ifa1dc7a3953b414298ab33929383425a_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81OC9mcmFnOjdiZjczNTljOWJmNTQ1Yjg4ODEzMGFlMmU4YzMwMjA2L3RhYmxlOmRkNTgxOWU1NDVhODQ1NzM5Njc0Y2U2Y2ExODkzNjdlL3RhYmxlcmFuZ2U6ZGQ1ODE5ZTU0NWE4NDU3Mzk2NzRjZTZjYTE4OTM2N2VfNS0xLTEtMS0w_32728e3d-2dd9-4e9b-8e4e-32aa45abc90b"
      unitRef="shares">2699107</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="ifa1dc7a3953b414298ab33929383425a_I20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81OC9mcmFnOjdiZjczNTljOWJmNTQ1Yjg4ODEzMGFlMmU4YzMwMjA2L3RhYmxlOmRkNTgxOWU1NDVhODQ1NzM5Njc0Y2U2Y2ExODkzNjdlL3RhYmxlcmFuZ2U6ZGQ1ODE5ZTU0NWE4NDU3Mzk2NzRjZTZjYTE4OTM2N2VfNS0zLTEtMS0w_66a23e32-b5d2-4bdd-8f61-ebb35eacbeb8"
      unitRef="usdPerShare">40.24</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <dnli:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="ifa1dc7a3953b414298ab33929383425a_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81OC9mcmFnOjdiZjczNTljOWJmNTQ1Yjg4ODEzMGFlMmU4YzMwMjA2L3RhYmxlOmRkNTgxOWU1NDVhODQ1NzM5Njc0Y2U2Y2ExODkzNjdlL3RhYmxlcmFuZ2U6ZGQ1ODE5ZTU0NWE4NDU3Mzk2NzRjZTZjYTE4OTM2N2VfNi0xLTEtMS0w_85b64720-fd78-42b8-8019-b58f1f7a16dc"
      unitRef="shares">2699107</dnli:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber>
    <dnli:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueExpectedToVest
      contextRef="ifa1dc7a3953b414298ab33929383425a_I20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81OC9mcmFnOjdiZjczNTljOWJmNTQ1Yjg4ODEzMGFlMmU4YzMwMjA2L3RhYmxlOmRkNTgxOWU1NDVhODQ1NzM5Njc0Y2U2Y2ExODkzNjdlL3RhYmxlcmFuZ2U6ZGQ1ODE5ZTU0NWE4NDU3Mzk2NzRjZTZjYTE4OTM2N2VfNi0zLTEtMS0w_d6165589-e9c2-4b7d-9ca5-1f8c4995407f"
      unitRef="usdPerShare">40.24</dnli:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueExpectedToVest>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81OC9mcmFnOjdiZjczNTljOWJmNTQ1Yjg4ODEzMGFlMmU4YzMwMjA2L3RleHRyZWdpb246N2JmNzM1OWM5YmY1NDViODg4MTMwYWUyZThjMzAyMDZfODY0_a139acf5-537a-48bb-a907-04bed518ce21">&lt;div style="margin-bottom:10pt;margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s results of operations include expenses relating to stock-based compensation as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.778%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.061%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12,314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,054&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21,028&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic95a24eb031142ffb8fea378c4c16539_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81OC9mcmFnOjdiZjczNTljOWJmNTQ1Yjg4ODEzMGFlMmU4YzMwMjA2L3RhYmxlOjUzOGYwY2E5MjYxMTRiNGFhYTk4YzE3ODQxNTY1MjAwL3RhYmxlcmFuZ2U6NTM4ZjBjYTkyNjExNGI0YWFhOThjMTc4NDE1NjUyMDBfMi0xLTEtMS0w_ed0758ae-0b8b-4627-b38e-19dcd21fc24a"
      unitRef="usd">12314000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie9e73e4cbcdf45859b5ab6fdf05d2397_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81OC9mcmFnOjdiZjczNTljOWJmNTQ1Yjg4ODEzMGFlMmU4YzMwMjA2L3RhYmxlOjUzOGYwY2E5MjYxMTRiNGFhYTk4YzE3ODQxNTY1MjAwL3RhYmxlcmFuZ2U6NTM4ZjBjYTkyNjExNGI0YWFhOThjMTc4NDE1NjUyMDBfMi0zLTEtMS0w_0d73ef83-b4a7-4336-b2a5-90bdbf9442a6"
      unitRef="usd">6054000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if224ee1d3e1d40cda888c5569a5ca491_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81OC9mcmFnOjdiZjczNTljOWJmNTQ1Yjg4ODEzMGFlMmU4YzMwMjA2L3RhYmxlOjUzOGYwY2E5MjYxMTRiNGFhYTk4YzE3ODQxNTY1MjAwL3RhYmxlcmFuZ2U6NTM4ZjBjYTkyNjExNGI0YWFhOThjMTc4NDE1NjUyMDBfMy0xLTEtMS0w_b3ae7855-a0ce-4966-a423-8f850fcb9fb0"
      unitRef="usd">8714000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie960cec998d6496380dc4b23cade2ada_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81OC9mcmFnOjdiZjczNTljOWJmNTQ1Yjg4ODEzMGFlMmU4YzMwMjA2L3RhYmxlOjUzOGYwY2E5MjYxMTRiNGFhYTk4YzE3ODQxNTY1MjAwL3RhYmxlcmFuZ2U6NTM4ZjBjYTkyNjExNGI0YWFhOThjMTc4NDE1NjUyMDBfMy0zLTEtMS0w_c3dc7388-0572-4cd3-ae42-8b3260dc254b"
      unitRef="usd">4731000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81OC9mcmFnOjdiZjczNTljOWJmNTQ1Yjg4ODEzMGFlMmU4YzMwMjA2L3RhYmxlOjUzOGYwY2E5MjYxMTRiNGFhYTk4YzE3ODQxNTY1MjAwL3RhYmxlcmFuZ2U6NTM4ZjBjYTkyNjExNGI0YWFhOThjMTc4NDE1NjUyMDBfNC0xLTEtMS0w_bfe9ec00-9ee3-45cb-af1e-224fc5a8633a"
      unitRef="usd">21028000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ia34dfea6b8734d64abf707c28256801c_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl81OC9mcmFnOjdiZjczNTljOWJmNTQ1Yjg4ODEzMGFlMmU4YzMwMjA2L3RhYmxlOjUzOGYwY2E5MjYxMTRiNGFhYTk4YzE3ODQxNTY1MjAwL3RhYmxlcmFuZ2U6NTM4ZjBjYTkyNjExNGI0YWFhOThjMTc4NDE1NjUyMDBfNC0zLTEtMS0w_2d1152b2-4466-45e2-9011-784adbacbe4a"
      unitRef="usd">10785000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl82MS9mcmFnOjZkNzY2NWQ3YTZlZTRlOGNiZTEyZDlhYjE3ZDg1ODRjL3RleHRyZWdpb246NmQ3NjY1ZDdhNmVlNGU4Y2JlMTJkOWFiMTdkODU4NGNfNDI5_542bf52c-d513-41d7-8bf0-7ff5da753633">Net Loss Per Share&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Since the Company was in a loss position for all periods presented, basic net loss per share is the same as diluted net loss per share for all periods as the inclusion of all potential shares of common stock outstanding would have been anti-dilutive. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:25pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Potentially dilutive securities that were not included in the diluted per share calculations because they would be anti-dilutive were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.778%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.061%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Options issued and outstanding and ESPP shares issuable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,323,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,530,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restricted shares subject to future vesting&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,699,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,637,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17,022,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16,168,362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl82MS9mcmFnOjZkNzY2NWQ3YTZlZTRlOGNiZTEyZDlhYjE3ZDg1ODRjL3RleHRyZWdpb246NmQ3NjY1ZDdhNmVlNGU4Y2JlMTJkOWFiMTdkODU4NGNfNDI4_806b40ca-5b5c-4551-80d7-4b8e04d3df0f">&lt;div style="margin-bottom:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Potentially dilutive securities that were not included in the diluted per share calculations because they would be anti-dilutive were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.778%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.061%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Options issued and outstanding and ESPP shares issuable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,323,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,530,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restricted shares subject to future vesting&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,699,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,637,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17,022,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16,168,362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i1bfd917477b04985b275e7880a6800ee_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl82MS9mcmFnOjZkNzY2NWQ3YTZlZTRlOGNiZTEyZDlhYjE3ZDg1ODRjL3RhYmxlOjQ3NDk0ZTQyZGRhNTRmOGVhZmU5MDMwYzdjZTg0NjU1L3RhYmxlcmFuZ2U6NDc0OTRlNDJkZGE1NGY4ZWFmZTkwMzBjN2NlODQ2NTVfMi0xLTEtMS0w_1d3d2ca3-d726-49d1-b540-a6f29553edb2"
      unitRef="shares">14323256</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ieb96c5c2a58b43ecb70f4570ae6501d5_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl82MS9mcmFnOjZkNzY2NWQ3YTZlZTRlOGNiZTEyZDlhYjE3ZDg1ODRjL3RhYmxlOjQ3NDk0ZTQyZGRhNTRmOGVhZmU5MDMwYzdjZTg0NjU1L3RhYmxlcmFuZ2U6NDc0OTRlNDJkZGE1NGY4ZWFmZTkwMzBjN2NlODQ2NTVfMi0zLTEtMS0w_7c1623a7-336e-4a42-8253-2ff7781a4452"
      unitRef="shares">14530378</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i14d03db975fe42b1b25891a5de38963a_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl82MS9mcmFnOjZkNzY2NWQ3YTZlZTRlOGNiZTEyZDlhYjE3ZDg1ODRjL3RhYmxlOjQ3NDk0ZTQyZGRhNTRmOGVhZmU5MDMwYzdjZTg0NjU1L3RhYmxlcmFuZ2U6NDc0OTRlNDJkZGE1NGY4ZWFmZTkwMzBjN2NlODQ2NTVfMy0xLTEtMS0w_07a6b5a0-d676-468e-9100-146701d987ba"
      unitRef="shares">2699107</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="iaab0bf674ec742169a75f1ba80135e68_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl82MS9mcmFnOjZkNzY2NWQ3YTZlZTRlOGNiZTEyZDlhYjE3ZDg1ODRjL3RhYmxlOjQ3NDk0ZTQyZGRhNTRmOGVhZmU5MDMwYzdjZTg0NjU1L3RhYmxlcmFuZ2U6NDc0OTRlNDJkZGE1NGY4ZWFmZTkwMzBjN2NlODQ2NTVfMy0zLTEtMS0w_3688ce7b-24bb-40c1-a203-16ee6c70b11f"
      unitRef="shares">1637984</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl82MS9mcmFnOjZkNzY2NWQ3YTZlZTRlOGNiZTEyZDlhYjE3ZDg1ODRjL3RhYmxlOjQ3NDk0ZTQyZGRhNTRmOGVhZmU5MDMwYzdjZTg0NjU1L3RhYmxlcmFuZ2U6NDc0OTRlNDJkZGE1NGY4ZWFmZTkwMzBjN2NlODQ2NTVfNS0xLTEtMS0w_5e4f87dc-d8c4-4d28-a1f3-c54fa9f55f69"
      unitRef="shares">17022363</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ia34dfea6b8734d64abf707c28256801c_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl82MS9mcmFnOjZkNzY2NWQ3YTZlZTRlOGNiZTEyZDlhYjE3ZDg1ODRjL3RhYmxlOjQ3NDk0ZTQyZGRhNTRmOGVhZmU5MDMwYzdjZTg0NjU1L3RhYmxlcmFuZ2U6NDc0OTRlNDJkZGE1NGY4ZWFmZTkwMzBjN2NlODQ2NTVfNS0zLTEtMS0w_9f259a15-1c13-4148-9ac2-781a8da27642"
      unitRef="shares">16168362</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl82NC9mcmFnOjRhNWM3YTAyYTcxZDQxNGRhODRhMTk3ZTZmODJhNmNhL3RleHRyZWdpb246NGE1YzdhMDJhNzFkNDE0ZGE4NGExOTdlNmY4MmE2Y2FfMjYw_06cc89d6-42c3-4235-9290-a61c984e0605">Related Party TransactionsOn September 22, 2020, upon becoming an owner of record of more than 10% of the voting interest in the Company, Biogen became a related party under ASC 850. Refer to Note 5, "Collaboration Agreements" for further information.</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xOS9mcmFnOjU2Y2EwZjE3OWFiNTQ3M2VhZGFlZDM5NjQxYjQ1NzhkL3RhYmxlOmRhMmJiMjEyNGYyZDQyODY4OTE3MTc5NWI4YmJmOThmL3RhYmxlcmFuZ2U6ZGEyYmIyMTI0ZjJkNDI4Njg5MTcxNzk1YjhiYmY5OGZfNy0xLTEtMS0w_ff2936cd-371c-41a6-961e-a0ff4d0036c6"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xOS9mcmFnOjU2Y2EwZjE3OWFiNTQ3M2VhZGFlZDM5NjQxYjQ1NzhkL3RhYmxlOmRhMmJiMjEyNGYyZDQyODY4OTE3MTc5NWI4YmJmOThmL3RhYmxlcmFuZ2U6ZGEyYmIyMTI0ZjJkNDI4Njg5MTcxNzk1YjhiYmY5OGZfNy0xLTEtMS0w_ff2936cd-371c-41a6-961e-a0ff4d0036c6"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xOS9mcmFnOjU2Y2EwZjE3OWFiNTQ3M2VhZGFlZDM5NjQxYjQ1NzhkL3RleHRyZWdpb246NTZjYTBmMTc5YWI1NDczZWFkYWVkMzk2NDFiNDU3OGRfNDM5ODA0NjUxMTg1Ng_76fefc42-6d2b-4030-95d8-128d6d256c4f" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xOS9mcmFnOjU2Y2EwZjE3OWFiNTQ3M2VhZGFlZDM5NjQxYjQ1NzhkL3RleHRyZWdpb246NTZjYTBmMTc5YWI1NDczZWFkYWVkMzk2NDFiNDU3OGRfNDM5ODA0NjUxMTg1Ng_76fefc42-6d2b-4030-95d8-128d6d256c4f" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Includes an offset to expense from related party cost reimbursement of $2.5&#160;million for the three months ended March 31, 2021.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xOS9mcmFnOjU2Y2EwZjE3OWFiNTQ3M2VhZGFlZDM5NjQxYjQ1NzhkL3RhYmxlOmRhMmJiMjEyNGYyZDQyODY4OTE3MTc5NWI4YmJmOThmL3RhYmxlcmFuZ2U6ZGEyYmIyMTI0ZjJkNDI4Njg5MTcxNzk1YjhiYmY5OGZfNy0xLTEtMS0w_ff2936cd-371c-41a6-961e-a0ff4d0036c6"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xOS9mcmFnOjU2Y2EwZjE3OWFiNTQ3M2VhZGFlZDM5NjQxYjQ1NzhkL3RleHRyZWdpb246NTZjYTBmMTc5YWI1NDczZWFkYWVkMzk2NDFiNDU3OGRfNDM5ODA0NjUxMTg1Ng_76fefc42-6d2b-4030-95d8-128d6d256c4f"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xOS9mcmFnOjU2Y2EwZjE3OWFiNTQ3M2VhZGFlZDM5NjQxYjQ1NzhkL3RhYmxlOmRhMmJiMjEyNGYyZDQyODY4OTE3MTc5NWI4YmJmOThmL3RhYmxlcmFuZ2U6ZGEyYmIyMTI0ZjJkNDI4Njg5MTcxNzk1YjhiYmY5OGZfMy0xLTEtMS0w_3e600fff-1d7a-4a97-8ad7-909f7d61a045"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xOS9mcmFnOjU2Y2EwZjE3OWFiNTQ3M2VhZGFlZDM5NjQxYjQ1NzhkL3RhYmxlOmRhMmJiMjEyNGYyZDQyODY4OTE3MTc5NWI4YmJmOThmL3RhYmxlcmFuZ2U6ZGEyYmIyMTI0ZjJkNDI4Njg5MTcxNzk1YjhiYmY5OGZfMy0xLTEtMS0w_3e600fff-1d7a-4a97-8ad7-909f7d61a045"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xOS9mcmFnOjU2Y2EwZjE3OWFiNTQ3M2VhZGFlZDM5NjQxYjQ1NzhkL3RleHRyZWdpb246NTZjYTBmMTc5YWI1NDczZWFkYWVkMzk2NDFiNDU3OGRfNDM5ODA0NjUxMTg1NQ_863ec15a-a62e-4021-bc98-1a2980c27a3f" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xOS9mcmFnOjU2Y2EwZjE3OWFiNTQ3M2VhZGFlZDM5NjQxYjQ1NzhkL3RleHRyZWdpb246NTZjYTBmMTc5YWI1NDczZWFkYWVkMzk2NDFiNDU3OGRfNDM5ODA0NjUxMTg1NQ_863ec15a-a62e-4021-bc98-1a2980c27a3f" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Includes related party collaboration revenue from customer of $0.9&#160;million for the three months ended March 31, 2021.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xOS9mcmFnOjU2Y2EwZjE3OWFiNTQ3M2VhZGFlZDM5NjQxYjQ1NzhkL3RhYmxlOmRhMmJiMjEyNGYyZDQyODY4OTE3MTc5NWI4YmJmOThmL3RhYmxlcmFuZ2U6ZGEyYmIyMTI0ZjJkNDI4Njg5MTcxNzk1YjhiYmY5OGZfMy0xLTEtMS0w_3e600fff-1d7a-4a97-8ad7-909f7d61a045"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl8xOS9mcmFnOjU2Y2EwZjE3OWFiNTQ3M2VhZGFlZDM5NjQxYjQ1NzhkL3RleHRyZWdpb246NTZjYTBmMTc5YWI1NDczZWFkYWVkMzk2NDFiNDU3OGRfNDM5ODA0NjUxMTg1NQ_863ec15a-a62e-4021-bc98-1a2980c27a3f"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140237894355576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Apr. 26, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38311<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Denali Therapeutics Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">46-3872213<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">161 Oyster Point Blvd<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">South San Francisco<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">866-8548<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.01 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">DNLI<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">121,192,210<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001714899<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140237894118488">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 435,321<span></span>
</td>
<td class="nump">$ 507,144<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Short-term marketable securities</a></td>
<td class="nump">977,827<span></span>
</td>
<td class="nump">962,553<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueFromRelatedPartiesCurrent', window );">Cost sharing reimbursements due from related party</a></td>
<td class="nump">2,511<span></span>
</td>
<td class="nump">5,674<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">15,963<span></span>
</td>
<td class="nump">20,284<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">1,431,622<span></span>
</td>
<td class="nump">1,495,655<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Long-term marketable securities</a></td>
<td class="nump">38,885<span></span>
</td>
<td class="nump">32,699<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">41,376<span></span>
</td>
<td class="nump">40,846<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="nump">32,236<span></span>
</td>
<td class="nump">32,618<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other non-current assets</a></td>
<td class="nump">3,739<span></span>
</td>
<td class="nump">2,462<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">1,547,858<span></span>
</td>
<td class="nump">1,604,280<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,626<span></span>
</td>
<td class="nump">1,071<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation</a></td>
<td class="nump">4,963<span></span>
</td>
<td class="nump">20,503<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_AccruedClinicalCostsCurrent', window );">Accrued clinical costs</a></td>
<td class="nump">5,049<span></span>
</td>
<td class="nump">6,497<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_OtherAccruedManufacturingCostsCurrent', window );">Accrued manufacturing costs</a></td>
<td class="nump">13,342<span></span>
</td>
<td class="nump">7,140<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Other accruals and other current liabilities</a></td>
<td class="nump">8,299<span></span>
</td>
<td class="nump">8,315<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability, current</a></td>
<td class="nump">4,876<span></span>
</td>
<td class="nump">4,690<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_ContractWithCustomerLiabilityFromRelatedPartiesCurrent', window );">Related party contract liability, current</a></td>
<td class="nump">3,569<span></span>
</td>
<td class="nump">3,569<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Contract liabilities, current</a></td>
<td class="nump">12,886<span></span>
</td>
<td class="nump">19,914<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">54,610<span></span>
</td>
<td class="nump">71,699<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_ContractWithCustomerLiabilityFromRelatedPartiesNoncurrent', window );">Related party contract liability, less current portion</a></td>
<td class="nump">292,956<span></span>
</td>
<td class="nump">293,849<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Contract liabilities, less current portion</a></td>
<td class="nump">31,322<span></span>
</td>
<td class="nump">23,325<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, less current portion</a></td>
<td class="nump">62,916<span></span>
</td>
<td class="nump">64,175<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other non-current liabilities</a></td>
<td class="nump">701<span></span>
</td>
<td class="nump">701<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">442,505<span></span>
</td>
<td class="nump">453,749<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 7)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Convertible preferred stock, $0.01 par value; 40,000,000 shares authorized as of March 31, 2021 and December 31, 2020; 0 shares issued and outstanding as of March 31, 2021 and December 31, 2020</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.01 par value; 400,000,000 shares authorized as of March 31, 2021 and December 31, 2020; 121,147,432 shares and 120,531,333 shares issued and outstanding as of March 31, 2021 and December 31, 2020, respectively</a></td>
<td class="nump">1,537<span></span>
</td>
<td class="nump">1,531<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">1,528,504<span></span>
</td>
<td class="nump">1,503,660<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(232)<span></span>
</td>
<td class="num">(245)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(424,456)<span></span>
</td>
<td class="num">(354,415)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">1,105,353<span></span>
</td>
<td class="nump">1,150,531<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 1,547,858<span></span>
</td>
<td class="nump">$ 1,604,280<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dnli_AccruedClinicalCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Clinical Costs, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dnli_AccruedClinicalCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dnli_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dnli_ContractWithCustomerLiabilityFromRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract with Customer, Liability, From Related Parties, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dnli_ContractWithCustomerLiabilityFromRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dnli_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dnli_ContractWithCustomerLiabilityFromRelatedPartiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Liability, From Related Parties, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dnli_ContractWithCustomerLiabilityFromRelatedPartiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dnli_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dnli_OtherAccruedManufacturingCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Accrued Manufacturing Costs, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dnli_OtherAccruedManufacturingCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dnli_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueFromRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of receivables to be collected from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth, at the financial statement date. which are usually due within one year (or one business cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueFromRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140237975709752">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Convertible preferred stock, par value (usd per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Convertible preferred stock, shares authorized (in shares)</a></td>
<td class="nump">40,000,000<span></span>
</td>
<td class="nump">40,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Convertible preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Convertible preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (usd per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">400,000,000<span></span>
</td>
<td class="nump">400,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">121,147,432<span></span>
</td>
<td class="nump">120,531,333<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">121,147,432<span></span>
</td>
<td class="nump">120,531,333<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140237966444760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
</tr>
<tr>
<th class="th" colspan="2"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_CollaborativeRevenueAbstract', window );"><strong>Collaboration revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue from customers</a></td>
<td class="nump">$ 7,922<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 3,552<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Other collaboration revenue</a></td>
<td class="nump">1<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">52<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total collaboration revenue</a></td>
<td class="nump">7,923<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">3,604<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">60,207<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">51,016<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">18,936<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">12,555<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">79,143<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">63,571<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(71,220)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(59,967)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Interest and other income, net</a></td>
<td class="nump">1,179<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">3,069<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossAttributableToParent', window );">Loss before income taxes</a></td>
<td class="num">(70,041)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(56,898)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit</a></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">135<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(70,041)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(56,763)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTaxAbstract', window );"><strong>Other comprehensive income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax', window );">Net unrealized gain on marketable securities, net of tax</a></td>
<td class="nump">13<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">485<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (70,028)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (56,278)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic (usd per share)</a></td>
<td class="num">$ (0.58)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (0.55)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted (usd per share)</a></td>
<td class="num">$ (0.58)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (0.55)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of shares outstanding, basic (in shares)</a></td>
<td class="nump">120,884,665<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">102,419,718<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average number of shares outstanding, diluted (in shares)</a></td>
<td class="nump">120,884,665<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">102,419,718<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Includes related party collaboration revenue from customer of $0.9&#160;million for the three months ended March 31, 2021.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Includes an offset to expense from related party cost reimbursement of $2.5&#160;million for the three months ended March 31, 2021.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dnli_CollaborativeRevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Revenue</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dnli_CollaborativeRevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dnli_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of income (loss) attributable to parent. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=118644919&amp;loc=SL5834089-161433<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140237889501016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations and Comprehensive Loss (Parenthetical)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromRelatedParties', window );">Collaboration revenue from customers, related party</a></td>
<td class="nump">$ 0.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_ResearchAndDevelopmentExpenseOffsetFromRelatedPartyCostReimbursement', window );">Offset to research and development expense, related party cost reimbursement</a></td>
<td class="nump">$ 2.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dnli_ResearchAndDevelopmentExpenseOffsetFromRelatedPartyCostReimbursement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research And Development Expense, Offset From Related Party Cost Reimbursement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dnli_ResearchAndDevelopmentExpenseOffsetFromRelatedPartyCostReimbursement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dnli_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07.1(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401555&amp;loc=SL114874292-224272<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140237890399496">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Stockholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96,189,935<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2019</a></td>
<td class="nump">$ 394,890<span></span>
</td>
<td class="nump">$ 1,288<span></span>
</td>
<td class="nump">$ 818,803<span></span>
</td>
<td class="nump">$ 350<span></span>
</td>
<td class="num">$ (425,551)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock in follow-on offering, net of issuance costs of $632 (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock in follow-on offering, net of issuance costs of $632</a></td>
<td class="nump">193,948<span></span>
</td>
<td class="nump">$ 90<span></span>
</td>
<td class="nump">193,858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_StockIssuedDuringPeriodSharesEquityIncentivePlan', window );">Issuances under equity incentive plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">259,569<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_StockIssuedDuringPeriodValueEquityIncentivePlan', window );">Issuances under equity incentive plans</a></td>
<td class="nump">1,966<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">1,963<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Vesting of restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91,839<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Vesting of restricted stock units</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">10,785<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,785<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(56,763)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(56,763)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income</a></td>
<td class="nump">485<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">485<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105,541,343<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2020</a></td>
<td class="nump">$ 545,311<span></span>
</td>
<td class="nump">$ 1,382<span></span>
</td>
<td class="nump">1,025,408<span></span>
</td>
<td class="nump">835<span></span>
</td>
<td class="num">(482,314)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="nump">120,531,333<span></span>
</td>
<td class="nump">120,531,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">$ 1,150,531<span></span>
</td>
<td class="nump">$ 1,531<span></span>
</td>
<td class="nump">1,503,660<span></span>
</td>
<td class="num">(245)<span></span>
</td>
<td class="num">(354,415)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_StockIssuedDuringPeriodSharesEquityIncentivePlan', window );">Issuances under equity incentive plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">334,634<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_StockIssuedDuringPeriodValueEquityIncentivePlan', window );">Issuances under equity incentive plans</a></td>
<td class="nump">3,822<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">3,819<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Vesting of restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">281,465<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Vesting of restricted stock units</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">21,028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(70,041)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(70,041)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income</a></td>
<td class="nump">$ 13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2021</a></td>
<td class="nump">121,147,432<span></span>
</td>
<td class="nump">121,147,432<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2021</a></td>
<td class="nump">$ 1,105,353<span></span>
</td>
<td class="nump">$ 1,537<span></span>
</td>
<td class="nump">$ 1,528,504<span></span>
</td>
<td class="num">$ (232)<span></span>
</td>
<td class="num">$ (424,456)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dnli_StockIssuedDuringPeriodSharesEquityIncentivePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Equity Incentive Plan</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dnli_StockIssuedDuringPeriodSharesEquityIncentivePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dnli_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dnli_StockIssuedDuringPeriodValueEquityIncentivePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Value, Equity Incentive Plan</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dnli_StockIssuedDuringPeriodValueEquityIncentivePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dnli_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326096&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140237887848680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Stockholders' Equity (Parenthetical)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Common stock issuance costs</a></td>
<td class="nump">$ 632<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140237894650840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (70,041)<span></span>
</td>
<td class="num">$ (56,763)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">2,108<span></span>
</td>
<td class="nump">2,109<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock&#8211;based compensation expense</a></td>
<td class="nump">21,028<span></span>
</td>
<td class="nump">10,785<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium', window );">Net amortization of discounts on marketable securities</a></td>
<td class="nump">1,161<span></span>
</td>
<td class="num">(607)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_IncreaseDecreaseInNonCashOperatingLeaseExpense', window );">Non-cash adjustment to operating lease expense</a></td>
<td class="num">(691)<span></span>
</td>
<td class="num">(321)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other non-cash items</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(53)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="nump">6,301<span></span>
</td>
<td class="num">(2,454)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">623<span></span>
</td>
<td class="num">(292)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accruals and other current liabilities</a></td>
<td class="num">(10,804)<span></span>
</td>
<td class="num">(3,827)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Contract liabilities</a></td>
<td class="nump">969<span></span>
</td>
<td class="num">(3,069)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_IncreaseDecreaseInContractWithCustomerLiabilityRelatedParties', window );">Related party contract liability</a></td>
<td class="num">(892)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(50,240)<span></span>
</td>
<td class="num">(54,492)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract', window );"><strong>Investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of marketable securities</a></td>
<td class="num">(463,105)<span></span>
</td>
<td class="num">(153,155)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(2,800)<span></span>
</td>
<td class="num">(879)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Maturities and sales of marketable securities</a></td>
<td class="nump">440,500<span></span>
</td>
<td class="nump">140,701<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(25,405)<span></span>
</td>
<td class="num">(13,333)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from public offering of common stock, net of issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">193,948<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions', window );">Proceeds from exercise of awards under equity incentive plans</a></td>
<td class="nump">3,822<span></span>
</td>
<td class="nump">1,965<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">3,822<span></span>
</td>
<td class="nump">195,913<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net increase (decrease) in cash, cash equivalents and restricted cash</a></td>
<td class="num">(71,823)<span></span>
</td>
<td class="nump">128,088<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at beginning of period</a></td>
<td class="nump">508,644<span></span>
</td>
<td class="nump">80,949<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at end of period</a></td>
<td class="nump">$ 436,821<span></span>
</td>
<td class="nump">$ 209,037<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dnli_IncreaseDecreaseInContractWithCustomerLiabilityRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) in Contract with Customer, Liability, Related Parties</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dnli_IncreaseDecreaseInContractWithCustomerLiabilityRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dnli_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dnli_IncreaseDecreaseInNonCashOperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Non-Cash Operating Lease Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dnli_IncreaseDecreaseInNonCashOperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dnli_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140237889511784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Significant Accounting Policies</a></td>
<td class="text">Significant Accounting Policies<div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Organization and Description of Business</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Denali Therapeutics Inc. ("Denali" or the &#8220;Company&#8221;) is a biopharmaceutical company, incorporated in Delaware, that discovers and develops therapeutics to defeat neurodegenerative diseases. The Company is headquartered in South San Francisco, California.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) for interim financial information and the instructions to Form 10-Q and Article 10 of SEC Regulation S-X for interim financial information. </span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These unaudited condensed consolidated financial statements and notes should be read in conjunction with the audited consolidated financial statements and notes thereto contained in the Annual Report on Form 10-K for the year ended December 31, 2020, as filed with the Securities and Exchange Commission on February&#160;26, 2021 (the "2020 Annual Report on Form 10-K"). The Condensed Consolidated Balance Sheet as of December 31, 2020 was derived from the audited annual consolidated financial statements as of and for the period then ended. Certain information and footnote disclosures typically included in the Company's annual consolidated financial statements have been condensed or omitted. The accompanying unaudited condensed consolidated financial statements reflect all adjustments that, in the opinion of management, are necessary for a fair statement of the results of the interim periods presented. All such adjustments are of a normal recurring nature except for the impacts of adopting new accounting standards, if any, discussed below. These interim financial results are not necessarily indicative of results expected for the full fiscal year or for any subsequent interim period.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended&#160;March 31, 2021, except as discussed below in the section titled "Recently Adopted Accounting Pronouncement," there were no material changes to the Company's significant accounting and financial reporting policies from those reflected in the 2020 Annual Report on Form 10-K. For further information with regard to the Company&#8217;s Significant Accounting Policies, please refer to Note 1, "Significant Accounting Policies," to the Company&#8217;s Consolidated Financial Statements included in the 2020 Annual Report on Form 10-K.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. All intercompany balances and transactions have been eliminated in consolidation.&#160;For the Company and its subsidiary, the functional currency has been determined to be U.S. dollars. Monetary assets and liabilities denominated in foreign currency are remeasured at period-end exchange rates. Non-monetary assets and liabilities denominated in foreign currencies are remeasured at historical rates. Foreign currency transaction gains and losses resulting from remeasurement are recognized in interest and other income, net in the Condensed Consolidated Statements of Operations and Comprehensive Loss.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires the Company to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, as well as the reported amounts of expenses during the reporting period. Actual results could differ from those estimates, and such differences could be material to the Condensed Consolidated Balance Sheets and Statements of Operations and Comprehensive Loss.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk and Other Risks and Uncertainties</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents, marketable securities and forward foreign currency exchange contracts. Substantially all of the Company&#8217;s cash and cash equivalents are deposited in accounts with financial institutions that management believes are of high credit quality. Such deposits have and will continue to exceed federally insured limits. The Company maintains its cash with accredited financial institutions and accordingly, such funds are subject to minimal credit risk. </span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s investment policy limits investments to certain types of securities issued by the U.S. government, its agencies and institutions with investment-grade credit ratings and places restrictions on maturities and concentration by type and issuer. The Company is exposed to credit risk in the event of a default by the financial institutions holding its cash, cash equivalents and marketable securities and issuers of marketable securities to the extent recorded on the Condensed Consolidated Balance Sheets. As of March 31, 2021 and December 31, 2020, the Company had no off balance sheet concentrations of credit risk. </span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is exposed to counterparty credit risk on all of its derivative financial instruments. The Company has established and maintains strict counterparty credit guidelines and enters into hedges only with financial institutions that are investment grade or better to minimize the Company&#8217;s exposure to potential defaults. The Company does not require collateral to be pledged under these agreements.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to a number of risks similar to other early-stage biopharmaceutical companies, including, but not limited to, the need to obtain adequate additional funding, possible failure of current or future preclinical testing or clinical trials, its reliance on third parties to conduct its clinical trials, the need to obtain regulatory and marketing approvals for its product candidates, competitors developing new technological innovations, the need to successfully commercialize and gain market acceptance of the Company&#8217;s product candidates, its right to develop and commercialize its product candidates pursuant to the terms and conditions of the licenses granted to the Company, protection of proprietary technology, the ability to make milestone, royalty or other payments due under any license or collaboration agreements, and the need to secure and maintain adequate manufacturing arrangements with third parties. If the Company does not successfully commercialize or partner any of its product candidates, it will be unable to generate product revenue or achieve profitability.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic has caused increased risk and uncertainty for the Company. Credit risk associated with investments in securities may increase if any institution with which the Company has an investment is significantly impacted by the COVID-19 pandemic. As of March 31, 2021, the Company has not realized any losses on its cash deposits or investments. COVID-19 may impact the timelines and progress of the Company's preclinical activities and clinical trials, and may impact its ability to raise capital in the near term. </span></div><div style="margin-bottom:8pt;margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segments</span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has one operating segment. The Company&#8217;s chief operating decision maker, its Chief Executive Officer, manages the Company&#8217;s operations on a consolidated basis for the purposes of allocating resources.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents and Restricted Cash</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly liquid investments with original maturities of 90 days or less at the date of purchase to be cash and cash equivalents. Cash equivalents are reported at fair value.</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents, and restricted cash reported within the Condensed Consolidated Statements of Cash Flows is composed of Cash and Cash equivalents reported in the Condensed Consolidated Balance Sheets and $1.5 million of restricted cash for the letter of credit for the Company&#8217;s headquarters building lease, which is included&#160;within other&#160;non-current&#160;assets&#160;in the Condensed Consolidated Balance Sheets.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Marketable Securities</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company generally invests its excess cash in money market funds and investment grade short to intermediate-term fixed income securities. Such investments are included in cash and cash equivalents, short-term marketable securities, or long-term marketable securities on the Condensed Consolidated Balance Sheets, are considered available-for-sale, and reported at fair value with net unrealized gains and losses included as a component of stockholders&#8217; equity. </span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company classifies investments in securities with remaining maturities of less than one year, or where its intent is to use the investments to fund current operations or to make them available for current operations, as short-term investments. The Company classifies investments in securities with remaining maturities of over one year as long-term investments. The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity, which is included in interest and other income, net in the Condensed Consolidated Statements of Operations and Comprehensive Loss. Realized gains and losses and declines in value determined to be due to credit losses on marketable securities, if any, are included in interest and other income, net.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company periodically evaluates the need for an allowance for credit losses. This evaluation includes consideration of several qualitative and quantitative factors, including whether it has plans to sell the security, whether it is more likely than not it will be required to sell any marketable securities before recovery of its amortized cost basis, and if the entity has the ability and intent to hold the security to maturity, and the portion of any unrealized loss that is the result of a credit loss. Factors considered in making these evaluations include quoted market prices, recent financial results and operating trends, implied values from any recent transactions or offers of investee securities, credit quality of debt instrument issuers, expected cash flows from securities, other publicly available information that may affect the value of the marketable security, duration and severity of the decline in value, and the Company's strategy and intentions for holding the marketable security.</span></div><div style="margin-bottom:10pt;margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable</span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable are included within prepaid expenses and other current assets on the Condensed Consolidated Balance Sheets. The accounts receivable balance represents amounts receivable from the Company's collaboration partners, net of an allowance for credit losses, if required. </span></div><div style="margin-bottom:10pt;margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Derivatives and Hedging Activities</span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures its derivative instruments at fair value, and accounts for them as either assets or liabilities included within Prepaid expenses and other current assets and Other accruals and other current liabilities, respectively, on the Condensed Consolidated Balance Sheets. Derivatives are adjusted to fair value through interest and other income, net in the Condensed Consolidated Statements of Operations and Comprehensive Loss. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases real estate, and certain equipment for use in its operations. A determination is made as to whether an arrangement is a lease at inception. A right-of-use (&#8220;ROU&#8221;) asset an</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d operating lease liability is recognized for identified operating leases in the Condensed Consolidated Balance Sheets. The changes in operating lease ROU assets and operating lease liabilities are presented net within non-cash adjustment to operating lease expense in the Condensed Consolidated Statements of Cash Flows. Certain amounts for the three months ended March 31, 2020 were reclassified to conform to the current period presentation.</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ROU assets represent the Company&#8217;s right to use the underlying asset for the lease term and lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the lease commencement date based on the present value of lease payments due over the lease term, with the ROU assets adjusted for lease incentives received. When determining the present value of lease payments, the Company uses its incremental borrowing rate on the date of lease commencement, or the rate implicit in the lease, if known. The Company does not assume renewals in its determination of the lease term unless the renewals are deemed by management to be reasonably certain at lease inception.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leases with an initial term of 12 months or less are not recorded on the balance sheet, unless they include an option to purchase the underlying asset that the Company is reasonably certain to exercise. The Company recognizes lease expenses on a straight-line basis over the lease term. The Company has leases with lease and non-lease components, which the Company has elected to account for as a single lease component. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License and Collaboration Revenue</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company analyzes its collaboration arrangements to assess whether they are within the scope of ASC&#160;808,&#160;Collaborative Arrangements&#160;(&#8220;ASC&#160;808&#8221;) to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities.&#160;This assessment is performed throughout the life of the arrangement based on changes in the responsibilities of all parties in the arrangement.&#160;For collaboration arrangements within the scope of ASC&#160;808&#160;that contain multiple elements, the Company first determines which elements of the collaboration are deemed to be within the scope of ASC&#160;808&#160;and those that are more reflective of a vendor-customer relationship and, therefore, within the scope of Topic 606. For elements of collaboration arrangements that are accounted for pursuant to ASC&#160;808, an appropriate recognition method is determined and applied consistently, generally by analogy to Topic 606.&#160;The accounting treatment pursuant to Topic 606 is outlined below. </span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The terms of licensing and collaboration agreements entered into typically include payment of one or more of the following: non-refundable, up-front license fees; development, regulatory and commercial milestone payments; payments for manufacturing supply and research and development services and royalties on net sales of licensed products. Each of these payments results in license, collaboration and other revenue, except for revenues from royalties on net sales of licensed products, which are classified as royalty revenue. The core principle of Topic 606 is to recognize revenue when promised goods or services are transferred to customers in an amount that reflects the consideration that is expected to be received in exchange for those goods or services. The Company may also receive reimbursement or make payments to a collaboration partner to satisfy cost sharing requirements. These payments are accounted for pursuant to ASC 808 and are recorded as an offset or increase to research and development expenses, respectively.</span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under each of its agreements, the Company performs the following steps: (i)&#160;identification of the promised goods or services in the contract; (ii)&#160;determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii)&#160;measurement of the transaction price, including the constraint on variable consideration; (iv)&#160;allocation of the transaction price to the performance obligations based on estimated selling prices; and (v)&#160;recognition of revenue when (or as) the Company satisfies each performance obligation.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts received prior to satisfying the revenue recognition criteria are recorded as contract liabilities in the Company&#8217;s Condensed Consolidated Balance Sheets. If the related performance obligation is expected to be satisfied within the next twelve months this will be classified in current liabilities. Amounts recognized as revenue prior to the Company having an unconditional right (other than a right that is conditioned only on the passage of time) to receipt are recorded as contract assets in the Company's Condensed Consolidated Balance Sheets. If the Company expects to have an unconditional right to receive the consideration in the next twelve months, this will be classified in current assets. A net contract asset or liability is presented for each contract with a customer. </span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At contract inception, the Company assesses the goods or services promised in a contract with a customer and identifies those distinct goods and services that represent a performance obligation. A promised good or service may not be identified as a performance obligation if it is immaterial in the context of the contract with the customer, if it is not separately identifiable from other promises in the contract (either because it is not capable of being separated or because it is not separable in the context of the contract), or if the promised good or service does not provide the customer with a material right. </span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers the terms of the contract to determine the transaction price. The transaction price is the amount of consideration to which the Company expects to be entitled in exchange for transferring promised goods or services to a customer. The consideration promised in a contract with a customer may include fixed amounts, variable amounts, or both. Variable consideration will only be included in the transaction price when it is not considered constrained, which is when it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur. </span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If it is determined that multiple performance obligations exist, the transaction price is allocated at the inception of the agreement to all identified performance obligations based on the relative standalone selling prices ("SSP").&#160;The relative SSP for each deliverable is estimated using external sourced evidence if it is available. If external sourced evidence is not available, the Company uses its best estimate of the SSP for the deliverable. </span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue is recognized when, or as, the Company satisfies a performance obligation by transferring a promised good or service to a customer. An asset is transferred when, or as, the customer obtains control of that asset, which for a service is considered to be as the services are received and used. The Company recognizes revenue over time by measuring the progress toward complete satisfaction of the relevant performance obligation using an appropriate input or output method based on the nature of the service promised to the customer. </span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After contract inception, the transaction price is reassessed at every period end and updated for changes such as resolution of uncertain events. Any change in the transaction price is allocated to the performance obligations on the same basis as at contract inception, or to a single performance obligation as applicable. </span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management may be required to exercise considerable judgment in estimating revenue to be recognized. Judgment is required in identifying performance obligations, estimating the transaction price, estimating the SSP of identified performance obligations, which may include forecasted revenue, development timelines, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success, and estimating the progress towards satisfaction of performance obligations.</span></div><div style="margin-bottom:10pt;margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Loss</span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss is composed of net loss and certain changes in stockholders&#8217; equity that are excluded from net loss, primarily unrealized gains or losses on the Company&#8217;s marketable securities.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss per Share</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding during the period, without consideration for common stock equivalents. Diluted net loss per share is the same as basic net loss per share, since the effects of potentially dilutive securities are antidilutive given the net loss for each period presented.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncement</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the Financial Accounting Standards Board ("FASB") issued ASU No. 2019-12</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">, Income Taxes (Topic 740) Simplifying the Accounting for Income Taxes. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASU No. 2019-12 modifies ASC 740 to simplify several aspects of accounting for income taxes, including eliminating certain exceptions to the guidance in ASC 740 related to the approach for intraperiod tax allocation. The guidance is effective for fiscal years beginning after December 15, 2020 and interim periods within those fiscal years, with early adoption permitted, and is required to be adopted prospectively, with the exception of certain specific amendments, which were not applicable to the Company. The Company adopted this standard as of January 1, 2021 using a prospective approach. Adoption of the standard did not have a material impact on its Condensed Consolidated Financial Statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140237890015368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">Fair Value Measurements<div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities measured at fair value at each balance sheet date are as follows (in thousands):</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.214%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.720%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.720%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.720%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.723%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">426,770&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">426,770&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Short-term marketable securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. government treasuries</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">870,756&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">870,756&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. government agency securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,136&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,136&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,729&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,729&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">71,206&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">71,206&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. government treasuries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,050&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,050&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34,835&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34,835&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency derivative contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,301,576&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">141,951&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,443,527&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency derivative contracts</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">176&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">176&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">176&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">176&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.053%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.720%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.720%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.720%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.884%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">335,284&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">335,284&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. government treasuries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">149,997&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">149,997&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Short-term marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. government treasuries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">878,938&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">878,938&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. government agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25,217&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25,217&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27,180&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27,180&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31,218&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31,218&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term marketable securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. government treasuries</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,561&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,561&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30,138&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30,138&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency derivative contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,366,780&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">113,938&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,480,718&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liabilities:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency derivative contracts</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of prepaid expenses and other current assets, accounts payable and accrued liabilities approximate their fair values due to their short-term maturities.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s Level&#160;2 securities are valued using third-party pricing sources. The pricing services utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company has not transferred any assets or liabilities between the fair value measurement levels.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140237887915880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock', window );">Marketable Securities</a></td>
<td class="text">Marketable SecuritiesAll marketable securities were considered&#160;available-for-sale&#160;at March 31, 2021 and December 31, 2020. On a recurring basis, the Company records its marketable securities at fair value using Level 1 or Level 2 inputs as discussed in Note 2, "Fair Value Measurements". The amortized cost, gross unrealized holding gains or losses, and fair value of the Company&#8217;s marketable securities by major security type at each balance sheet date are summarized in the tables below (in thousands):<div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.085%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.002%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.002%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.002%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.006%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Holding Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Holding Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Short-term marketable securities:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. government treasuries</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">870,674&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">870,756&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. government agency securities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,126&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,136&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,684&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,729&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">71,206&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">71,206&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total short-term marketable securities</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">977,690&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">148&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">977,827&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term marketable securities:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. government treasuries</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,049&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,050&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34,854&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34,835&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total long-term marketable securities</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38,903&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38,885&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,016,593&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,016,712&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:120%">__________________________________________________</span></div><div style="margin-top:4pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10.69pt">Unrealized holding losses on 3 securities with an aggregate fair value of $126.4 million.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10.69pt">Unrealized holding losses on 4 securities with an aggregate fair value of $7.1 million.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10.69pt">Unrealized holding losses on 4 securities with an aggregate fair value of $34.8 million.</span></div><div><span><br/></span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.085%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.002%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.002%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.002%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.006%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Holding Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Holding Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Short-term marketable securities:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. government treasuries</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">878,906&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">878,938&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. government agency securities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25,214&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25,217&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27,101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27,180&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31,218&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31,218&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total short-term marketable securities</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">962,439&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">128&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">962,553&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term marketable securities:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. government treasuries</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,561&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,561&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30,147&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30,138&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total long-term marketable securities</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32,708&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32,699&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">995,147&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">995,252&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:120%">__________________________________________________</span></div><div style="margin-top:4pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10.69pt">Unrealized holding losses on 19 securities with an aggregate fair value of $369.9 million.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10.69pt">Unrealized holding losses on 2 securities with an aggregate fair value of $10.1 million.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10.69pt">Unrealized holding losses on 1 security with an aggregate fair value of $20.1 million.</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> As of March 31, 2021 and December 31, 2020, some of the Company's marketable securities were in an unrealized loss position. The Company has not recognized an allowance for credit losses as of March 31, 2021 or December 31, 2020. The Company determined that it had the ability and intent to hold all marketable securities that have been in a continuous loss position until maturity or recovery. Further, these marketable securities were initially, and continue to be, held with investment grade, high credit quality institutions. All marketable securities with unrealized losses as of each balance sheet date have been in a loss position for less than twelve months or the loss is not material.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded unrealized gains on marketable securities in other comprehensive income for the three months ended March 31, 2020. As a result, the Company recorded a tax benefit of $0.1&#160;million for the three months ended March 31, 2020 on the Condensed Consolidated Statements of Operations and Comprehensive Loss and a corresponding tax charge in other comprehensive income. </span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of the Company&#8217;s marketable securities have an effective maturity of less than two years.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140237887949768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock', window );">Derivative Financial Instruments</a></td>
<td class="text">Derivative Financial Instruments<div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foreign Currency Exchange Rate Exposure</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses forward foreign currency exchange contracts to hedge certain operational exposures resulting from potential changes in foreign currency exchange rates. Such exposures result from portions of the Company&#8217;s forecasted cash flows being denominated in currencies other than the U.S. dollar, primarily the Euro and British Pound. The derivative instruments the Company uses to hedge this exposure are not designated as cash flow hedges, and as a result, changes in their fair value are recorded in interest and other income, net, on the Company's Condensed Consolidated Statements of Operations and Comprehensive Loss.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of forward foreign currency exchange contracts are estimated using current exchange rates and interest rates and take into consideration the current creditworthiness of the counterparties. Information regarding the specific instruments used by the Company to hedge its exposure to foreign currency exchange rate fluctuations is provided below.</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s forward foreign currency exchange contracts outstanding as of March 31, 2021 and December 31, 2020, respectively (notional amounts in thousands):</span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:27.265%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.252%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.778%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.902%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign Exchange Contracts</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Contracts</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Notional</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount in Foreign Currency</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maturity</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Euros </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,305&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Apr 2021- Mar 2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">British Pounds </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">963&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Apr 2021- Nov 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total at March 31, 2021</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Euros </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,855&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Jan 2021 - Nov 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">British Pounds </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,658&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Jan 2021 - Nov 2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total at December 31, 2020</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:120%">_________________________________________________</span></div><div style="margin-top:4pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;padding-left:11.65pt;position:relative;top:-2.8pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The notional amount represents the net amount of foreign currency that will be received upon maturity of the forward contracts.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A derivative liability balance of $0.2 million is recorded on the Condensed Consolidated Balance Sheets as of March 31, 2021 and an immaterial derivative liability balance is recorded on the Condensed Consolidated Balance Sheets as of December 31, 2020. An immaterial derivative asset balance is recorded in prepaid expenses and other current assets on the Condensed Consolidated Balance Sheets as of March 31, 2021 and a derivative asset balance of $0.2 million is recorded in prepaid expenses and other current assets on the Condensed Consolidated Balance Sheets as of December 31, 2020. A net loss of $0.2 million associated with the Company's derivative instruments is recognized in interest and other income, net on the Condensed Consolidated Statements of Operations and Comprehensive Loss for each of the three months ended March 31, 2021 and March 31, 2020.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -URI http://asc.fasb.org/topic&amp;trid=2229140<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140237990773208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaboration Agreements</a></td>
<td class="text">Collaboration Agreements<div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Biogen</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Provisional Biogen Collaboration Agreement and Common Stock Purchase Agreement</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August&#160;5, 2020, the Company entered into a binding Provisional Collaboration and License Agreement (&#8220;Provisional Biogen Collaboration Agreement&#8221;) with Biogen Inc.&#8217;s subsidiaries, Biogen MA Inc. (&#8220;BIMA&#8221;) and Biogen International GmbH (&#8220;BIG&#8221;) (BIMA and BIG, collectively, &#8220;Biogen&#8221;) pursuant to which the Company granted Biogen a license to co-develop and co-commercialize Denali&#8217;s small molecule LRRK2 inhibitor program (the &#8220;LRRK2 Program&#8221;), an option in respect of each of (i) the Company&#8217;s amyloid beta program utilizing the Company's Transport Vehicle ("TV") technology platform to cross the blood-brain barrier ("BBB") and (ii) one other unnamed program also utilizing the Company's TV technology platform (the &#8220;Option Programs&#8221;), and a right of first negotiation with respect to two additional unnamed programs for indications within Alzheimer&#8217;s disease, Parkinson&#8217;s disease, amyotrophic lateral sclerosis ("ALS") or multiple sclerosis utilizing the Company's TV technology platform (the &#8220;ROFN Programs&#8221;) should the Company decide to seek a collaboration with a third party for such programs. The Provisional Biogen Collaboration Agreement was a binding agreement, which became effective on the closing of the Common Stock Purchase Agreement ("SPA"), as described further below. The Provisional Biogen Collaboration Agreement expired in October 2020 upon the execution of a Definitive LRRK2 Collaboration and License Agreement (&#8220;LRRK2 Agreement&#8221;) with Biogen on October&#160;4, 2020 and a Right of First Negotiation, Option and License Agreement (the &#8220;ROFN and Option Agreement&#8221;) on October&#160;6, 2020 (collectively, the "Biogen Collaboration Agreement").</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Provisional Biogen Collaboration Agreement, Biogen was obligated to pay the Company a $560.0 million upfront payment, payable upon execution of the Biogen Collaboration Agreement, which occurred in October 2020. With respect to the LRRK2 Program, Biogen is required to make milestone payments up to approximately $1.125 billion upon achievement of certain development and sales milestone events. Such milestone payments include $375.0&#160;million in development, $375.0&#160;million upon first commercial sale, and $375.0&#160;million in net sales-based milestones. The Company will share 50% of the profits and losses with Biogen for LRRK2 Products in the United States, and 40% of such profits and losses in China. The Company will be entitled to receive royalties in the high teens to low twenties percentages on net sales for LRRK2 Products outside of the United States and China.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Provisional Biogen Collaboration Agreement, Denali conducted and controlled LRRK2 clinical development through the effective date of the Biogen Collaboration Agreement. Subsequently, the Company and Biogen are jointly developing LRRK2 Products pursuant to a clinical development plan set forth within the LRRK2 Agreement. The parties share responsibility and costs for global development of LRRK2 Products pursuant to a mutually agreed development plan and budget ("LRRK2 Development Activities"), with Biogen funding 60% and the Company funding 40% of such costs.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may opt out of development cost sharing worldwide and upon such election, from any further profit-sharing from the LRRK2 Program. The Company also has the right to opt-out of the profit sharing arrangement for the LRRK2 Program or for only those LRRK2 Products that do not penetrate the BBB (&#8220;Peripheral LRRK2 Products&#8221;), in each of the United States and China. After such an opt out, the Company will no longer be obligated to share in the development and commercialization costs for, or be entitled to share in the applicable revenues from, such LRRK2 Program (or from the Peripheral LRRK2 Products) for such country, as applicable. If the Company chooses to exercise its opt out rights, the Company will be entitled to receive tiered royalties on net sales of the applicable LRRK2 Program in the relevant country (or countries). The royalty rates for the applicable LRRK2 Program will be a percentage in the high teens to low twenties, but may increase to the mid-twenties if the Company has met certain co-funding thresholds or there has been a first commercial sale at the time of the Company's election.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the LRRK2 Program, Biogen received an exclusive option to license two preclinical programs enabled by the Company's TV technology platform, which platform aims to improve brain uptake of biotherapeutics, including its Antibody Transport Vehicle ("ATV"): Abeta program ("ATV-enabled anti-amyloid beta program") and a second program utilizing the Company's TV technology for an unnamed target ("TV program"), excluding small molecules, Adeno-associated viruses ("AAV") and oligonucleotides. Biogen&#8217;s option may be exercised up to initiation of investigational new drug ("IND")-enabling studies for each program and continues for each program until a specified period of time after delivery of an option data package, or <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjVhZTFjZmM4OGFhNDQ5MmNhZjU2ZTlkNGFjOTFlMDk2L3NlYzo1YWUxY2ZjODhhYTQ0OTJjYWY1NmU5ZDRhYzkxZTA5Nl80Ni9mcmFnOmEyYmRhODMwNDU4YTRkNmQ4YWE1Y2RkNGQzY2ExOTE2L3RleHRyZWdpb246YTJiZGE4MzA0NThhNGQ2ZDhhYTVjZGQ0ZDNjYTE5MTZfNTMxNA_6ca82b29-adf5-4704-b8b5-513bcd955ad5">thirty</span> business days after the 5th anniversary of the effective date of the Provisional Biogen Collaboration Agreement, whichever is earlier.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, Biogen will have the right of first negotiation ("ROFN") on two additional TV-enabled therapeutics within Alzheimer&#8217;s disease, Parkinson&#8217;s disease, ALS or multiple sclerosis should the Company decide to seek a collaboration with a third party for such programs, but this does not include any of the Company&#8217;s small molecule, AAV or oligonucleotide programs. The ROFN period continues until seven years after the effective date of the Provisional Biogen Collaboration Agreement or the date on which the Company has offered Biogen two ROFN Programs, and for which Biogen has agreed to trigger a ROFN for such program, whichever is earlier. However, if the Company does not execute an agreement with a third party with respect to a particular ROFN Program offered to Biogen within a specified amount of time, Biogen will have one additional right to exercise the ROFN again with respect to such ROFN Program.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Provisional Biogen Collaboration Agreement, the Company entered into a common stock purchase agreement (the "Stock Purchase Agreement") with BIMA on August&#160;5, 2020, pursuant to which the Company agreed to issue and sell, and BIMA agreed to purchase, 13,310,243 shares of the Company&#8217;s common stock (the &#8220;Shares&#8221;) for an aggregate purchase price of $465.0 million pursuant to the terms and conditions thereof. Since the shares of common stock owned by Biogen as of March 31, 2021 represent more than 10% of the voting interest of the Company, Biogen is considered a related party as defined in ASC 850. Management determined that it was appropriate to account for the Provisional Biogen Collaboration Agreement and the SPA as one arrangement because they were entered into at the same time with interrelated financial terms.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September&#160;22, 2020, the Company closed the sale of the Shares to BIMA pursuant to the Stock Purchase Agreement. The estimated fair market value of the Shares issued to BIMA was $420.1&#160;million, based on the closing stock price of $35.87 on the date of issuance adjusted by a discount for lack of marketability due to certain holding period restrictions, which was valued using an option pricing model. This stock issuance resulted in a $44.9&#160;million premium paid to the Company above the estimated fair value of the Company's common stock (the "Stock Premium"), which forms part of the transaction price for the Biogen Collaboration Agreement. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Biogen Collaboration Agreement</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company entered into the LRRK2 Agreement with Biogen on October&#160;4, 2020 and the ROFN and Option Agreement on October&#160;6, 2020. Collectively these are known as the Biogen Collaboration Agreement, the material terms of which are consistent with, and supersede, the Provisional Biogen Collaboration Agreement discussed above. </span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the ROFN and Option Agreement, with respect to the options granted by the Company to Biogen, Biogen is obligated to pay to the Company an aggregate of up to $270.0&#160;million in option exercise and development milestone payments, up to $325.0&#160;million upon first commercial sale, and up to $290.0&#160;million of net sales-based milestone payments, following the achievement of certain prespecified milestone events and if Biogen exercises both of its options. Furthermore, Biogen is obligated to pay to the Company royalties in the mid-single digit to mid-teens percentages, depending on the program for which Biogen exercises its option and upon the achievement of certain sales thresholds.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, the Company received upfront payments totaling $560.0&#160;million pursuant to the Biogen Collaboration Agreement. </span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Biogen Collaboration Agreement is considered a contract modification to the Provisional Biogen Collaboration Agreement and was accounted for as a termination of the provisional agreement and commencement of a new contract.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company identified the following distinct performance obligations associated with the Biogen Collaboration Agreement that had not yet been delivered under the original contract: the LRRK2 Program license, the research services for the ATV:Abeta and TV programs (&#8220;Option Research Services&#8221;) which include option joint steering committee ("JSC") participation, and a material right for an option under the ROFN and Option Agreement. Further, the LRRK2 Development Activities which includes LRRK2 JSC and joint development committee (&#8220;JDC&#8221;) participation was identified as a unit of account under ASC 808. The LRRK2 Development Activities, JSC and JDC participation are considered to be a single unit of account since the development activities are highly interrelated with the JSC and JDC involvement and these are not distinct in the context of the contract. Further, the same was considered to be true for the option research services and option JSC participation performance obligation.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes that the Biogen Collaboration Agreement is a collaboration arrangement as defined in ASC 808, Collaborative Arrangements. The Company also believes that Biogen meets the definition of a customer as defined in ASC 606, Revenue From Contracts With Customers for all of the performance obligations identified at inception except for the LRRK2 Development Activities. Since ASC 808 does not address recognition and measurement, the Company looked to other accounting literature for guidance where the performance obligation does not fall under ASC 606, and determined that for the interim LRRK2 development activities subject to cost sharing provisions, the guidance in ASC 730, Research and Development should be applied.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The transaction price at inception included fixed consideration consisting of the upfront fee of $560.0&#160;million and the $44.9&#160;million premium on the sale of common stock. All potential future milestones and other payments were considered constrained at the inception of the Biogen Collaboration Agreement since the Company could not conclude it was probable that a significant reversal in the amount recognized would not occur. From inception of the Biogen Collaboration Agreement through March 31, 2021, there was no change to the transaction price.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The respective standalone value for each of the performance obligations was determined by applying the SSP method and the transaction price was allocated based on the relative SSP method with revenue recognition timing to be determined either by delivery, resolution of an option, or the provision of services.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company used an adjusted market assessment approach to estimate the selling price for the LRRK2 Program license, an expected cost plus margin approach for estimating the Option Research Services and estimated the intrinsic value of the material right for the option, taking into account the likelihood that an option would be exercised. The LRRK2 Program license was delivered on or around the effective date of the Biogen Collaboration Agreement and the revenue allocated to this performance obligation was recognized during the year ended December 31, 2020. The Option Research Services are expected to be delivered over time as the services are performed, with revenue being recognized over time based on costs incurred to perform the services, since the level of costs incurred over time is thought to best reflect the transfer of services to Biogen. Revenue allocated to the material right for an option under the ROFN and Option Agreement is deferred as a contract liability until the option opt in period ends, expiration or ROFN and Option Agreement termination. The LRRK2 Development Activities cost sharing reimbursements or expenses will be recognized over time as earned or incurred, since this is believed to directly correlate to the value of the services performed.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A related party contract liability of $296.5 million was recorded on the Consolidated Balance Sheet as of March 31, 2021. Approximately $288.9&#160;million of this contract liability relates to the revenue allocated to the material right for an option under the ROFN and Option Agreement which is being deferred until resolution of the option which is expected to be several years from the balance sheet date, and $7.6&#160;million of this contract liability relates to the portion of the Option Research Services performance obligation yet to be satisfied, with such amount to be recognized over the estimated period of the services, which is expected to be several years. The Company recorded $2.5&#160;million of cost sharing reimbursements for LRRK2 Development Activities as an offset to research and development expenses in the Consolidated Statement of Operations and Comprehensive Income for the three months ended March 31, 2021. </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">cost sharing reimbursements due from Biogen</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the Condensed Consolidated Balance Sheet as of March 31, 2021 and December 31, 2020 of $2.5 million and $5.7&#160;million, respectively.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In assessing the Biogen Collaboration Agreement, management exercised considerable judgment in estimating revenue to be recognized, specifically related to estimating the discount for lack of marketability associated with the stock issuance, determining the separate performance obligations under the Biogen Collaboration Agreement, and estimating the standalone selling price of those performance obligations. </span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2021, the Company had not achieved any milestones or recorded any product sales under the Biogen Collaboration Agreement. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sanofi </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, the Company entered into a Collaboration and License Agreement ("Sanofi Collaboration Agreement") with Genzyme Corporation, a wholly owned subsidiary of Sanofi S.A. ("Sanofi") pursuant to which certain small molecule CNS and peripheral </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">receptor interacting serine/threonine protein kinase 1 ("</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RIPK1") inhibitors contributed by Sanofi and by the Company will be developed and commercialized. The Sanofi Collaboration Agreement became effective in November 2018 at which time Sanofi paid the Company an upfront payment of $125.0 million. Under the Sanofi Collaboration Agreement, the Company is eligible to receive milestone payments from Sanofi up to approximately $1.1 billion upon achievement of certain clinical, regulatory and sales milestone events. Such milestone payments include $215.0 million in clinical milestone payments and $385.0 million in regulatory milestone payments for CNS Products, as defined, that are developed and approved in the United States, by the European Medicines Agency ("EMA") and in Japan for three indications, including Alzheimer's disease. These milestones also include $120.0 million in clinical milestone payments, $175.0 million in regulatory milestone payments and $200.0 million in commercial milestone payments for Peripheral Products, as defined, that are developed and approved in the United States, by the EMA and Japan for three indications. </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company will share profits and losses equally with Sanofi for CNS Products sold in the United States and China, and receive variable royalties on net sales for CNS Products sold outside of the United States and China and for Peripheral Products sold worldwide.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and Sanofi will jointly develop CNS Products pursuant to a global development plan. The Company will be responsible, at its own cost, for conducting Phase 1 and Phase 2 trials for CNS Products in Alzheimer&#8217;s disease and any activities required to support such clinical trials and specific for Alzheimer's disease ("Denali CNS Development Activities"). The Company conducted, at Sanofi&#8217;s cost, a Phase 1b trial for the initial lead CNS penetrant RIPK1 inhibitor, DNL747 (SAR443060), in ALS. In June 2020, the Company announced that clinical activities on DNL747 would be paused and efforts focused on the development of the backup preclinical candidate, DNL788 (SAR443820). Other than with the Denali CNS Development Activities, Sanofi is responsible, at its cost, for all other Phase 1 and Phase 2 trials for CNS Products, including for ALS and multiple sclerosis. Sanofi will lead the conduct of all Phase 3 and later stage development trials for CNS Products, with Sanofi and the Company funding 70% and 30% of such costs, respectively. Sanofi will also lead the commercialization activities globally for CNS Products, subject to certain options that the Company has to conduct co-commercialization activities with respect to each CNS Product in the United States and China. </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sanofi will be responsible, at its cost, for conducting activities relating to the development and commercialization of all Peripheral Products. Denali will be entitled to receive tiered royalties in the low- to mid- teen percentages on net sales of Peripheral Products.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company identified the following distinct performance obligations associated with the Sanofi Collaboration Agreement upon inception: the CNS program license, the Peripheral program license, the Phase 1 and Phase 2 trials for CNS Products for Alzheimer&#8217;s disease ("Alzheimer's Disease Services"), and the Phase 1b trial for DNL747 for ALS and associated activities ("Retained Activities"). </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes that the Sanofi Collaboration Agreement is a collaboration arrangement as defined in ASC 808, Collaborative Arrangements. The Company also believes that Sanofi meets the definition of a customer as defined in ASC 606, Revenue From Contracts With Customers for three of the performance obligations identified at inception, but does not meet the definition of a customer for the Alzheimer's Disease Services. Further, Sanofi does not meet the definition of a customer for all Phase 3 and later stage development trials for CNS Products led by Sanofi for which the Company will fund 30% of total costs. Since ASC 808 does not address recognition and measurement, the Company looked to other accounting literature for guidance where the performance obligation does not fall under ASC 606, and determined that for the Alzheimer's Disease Services, the guidance in ASC 606 should be analogized for the recognition, measurement and reporting of this performance obligation, and for the cost sharing provisions, the Company determined that the guidance in ASC 730, Research and Development should be applied. </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The transaction price at inception included upfront fixed consideration of $125.0 million. All potential future milestones and other payments were considered constrained at the inception of the Sanofi Collaboration Agreement since the Company could not conclude it was probable that a significant reversal in the amount recognized would not occur. The transaction price did not increase in the three months ended March 31, 2021, and increased by $0.5 million for the three months ended March 31, 2020 related to costs incurred for Retained Activities that were no longer constrained. </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The respective standalone value for each of the performance obligations was determined by applying the SSP method and the transaction price allocated based on the relative SSP method with revenue recognition timing to be determined either by delivery or the provision of services.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company used an adjusted market assessment approach to estimate the selling price for the program licenses, and an expected cost plus margin approach for estimating the Alzheimer&#8217;s Disease Services and the Retained Activities. The program licenses and existing know-how were delivered on the effective date of the Sanofi Collaboration Agreement. The Alzheimer&#8217;s Disease Services and the Retained Activities were expected to be delivered over time as the services are performed. For the Alzheimer's Disease Services, revenue is being recognized over time using the input method, based on costs incurred to perform the services, since the level of costs incurred over time is thought to best reflect the transfer of services to Sanofi. For the Retained Activities, revenue is being recognized over time using the output method, based on amounts invoiced to Sanofi, since this is believed to directly correlate to the value of the services performed.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A contract liability of $3.4 million was recorded on the Condensed Consolidated Balance Sheets as of March 31, 2021 and December 31, 2020. This contract liability relates to the portion of the Alzheimer's Disease Services performance obligation yet to</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> be satisfied, with such amounts to be recognized over the estimated period of the services, which is expected to be several years. The Company recorded no receivable associated with the Sanofi Collaboration Agreement on the Condensed Consolidated Balance Sheets as of March 31, 2021, and a receivable of $44,303 as of December 31, 2020. </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In assessing the Sanofi Collaboration Agreement, management is required to exercise considerable judgment in estimating revenue to be recognized. Managem</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ent applies judgment in determining the separate performance obligations, in estimating the selling price, in determining when control was transferred to Sanofi for the licenses, and in estimating total future costs when using the input method.  </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through March 31, 2021, the Company has received milestone payments of </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$10.0 million</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and has not recorded any product sales under the Sanofi Collaboration Agreement.</span><span style="color:#ee2724;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Takeda </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2018, the Company entered into a Collaboration and Option Agreement ("Takeda Collaboration Agreement") with Takeda Pharmaceutical Company Limited ("Takeda"), pursuant to which the Company granted Takeda an option to develop and commercialize, jointly with the Company, certain biologic products that are enabled by the Company's BBB delivery technology and intended for the treatment of neurodegenerative disorders. The programs were the Company&#8217;s ATV:BACE1/Tau and ATV:TREM2 and PTV:PGRN programs. The Takeda Collaboration Agreement became effective in February 2018, at which time Takeda paid the Company an upfront payment of $40.0 million. Takeda may pay up to an aggregate of $25.0 million with respect to each of the three programs directed to a target and based upon the achievement of certain preclinical milestone events, up to $75.0 million in total, $5.0 million of which was paid upon the Takeda Collaboration Agreement becoming effective. In February 2019, the agreement was amended to replace the ATV:BACE1/Tau program with the ATV:Tau program. The amendment did not have a material impact to the condensed consolidated financial statements.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Takeda Collaboration Agreement and unless otherwise agreed jointly between both parties, the Company will be responsible, at its cost, for conducting activities relating to pre-IND&#160;development of biologic products directed to the three identified targets and enabled by its BBB delivery technology targeting TfR during the applicable research period. The period through which the option can be exercised continues for each target until the first biologic product directed to the relevant target is&#160;IND-ready&#160;or approximately five years after selection of the target, whichever is earlier.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If Takeda exercises its option with respect to a particular target, then Takeda will have the right to develop and commercialize, jointly with the Company, a specified number of biologic products enabled by its BBB delivery technology that were developed during the research period and which are directed to the relevant target. The Company will grant to Takeda a&#160;co-exclusive&#160;license under the intellectual property the Company controls related to those biologic products.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Takeda is obligated to pay the Company a $5.0 million option fee for each target for which Takeda exercises its option, up to $15.0 million in total.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, if Takeda exercises its option for all three collaboration programs, Takeda may be obligated to pay the Company up to an aggregate of $407.5 million upon achievement of certain clinical milestone events and up to an aggregate of $300.0 million in regulatory milestone events relating to receipt of regulatory approval in the United States, certain European countries and Japan. Takeda may also be obligated to pay the Company up to $75.0 million per biologic product upon achievement of a certain sales-based milestone, or an aggregate of $225.0 million if one biologic product from each program achieves this milestone.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If Takeda exercises its option for a particular target, the Company and Takeda will share equally in the development and commercialization costs, and, if applicable, the profits, for each collaboration program.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the terms of the Takeda Collaboration Agreement, the Company entered into a common stock purchase agreement (the "Stock Purchase Agreement") with Takeda on January&#160;3, 2018, pursuant to which Takeda purchased 4,214,559 shares of the Company's common stock (the "Shares") for an aggregate purchase price of $110.0 million. The sale of the Shares closed on February&#160;23, 2018. The fair market value of the common stock sold to Takeda was $94.4 million, based on the closing stock price of $22.40 on the date of issuance, resulting in&#160;a $15.6 million premium paid to the Company above the fair value of the Company's common stock which was credited to contract liability in the Company's Condensed Consolidated Balance Sheets.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes that the Takeda Collaboration Agreement is a collaboration arrangement as defined in ASC&#160;808, Collaborative Arrangements.&#160;Further, during the research period, the Company believes that the arrangement is a contract with a customer as defined in ASC 606,&#160;Revenue From Contracts With Customers</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Takeda Collaboration Agreement and the Stock Purchase Agreement are being accounted for as one arrangement because they were entered into at the same time with interrelated financial terms.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company identified performance obligations during the research period consisting of the license, the development options, and joint steering committee ("JSC") participation together with the research services for each collaboration program. The license rights, JSC involvement, option and research services are considered to be a single performance obligation for each program since the research services are highly interrelated with the option and JSC involvement and will significantly modify the license. The performance obligations under each of the three programs are separate since the activities and risks under the programs are distinct. </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that all other goods or services which are contingent upon Takeda exercising its option for each program were not considered performance obligations at the inception of the Takeda Collaboration Agreement.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The transaction price at inception included fixed consideration consisting of the upfront fee of $40.0 million, the $15.6 million premium on the sale of common stock, and the </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">first preclinical milestone payment of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$5.0 million. It also included variable consideration of $26.0 million relating to future milestones that were not constrained, and have since all been met and received. </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The remaining $44.0 million of preclinical milestones were considered constrained at the inception of the Takeda Collaboration Agreement since the Company could not conclude it is probable that a significant reversal in the amount recognized will not occur. Additionally, cost and profit-sharing income, and the development and commercial milestones as outlined above, have not been considered given Takeda has not exercised its options for the development and commercial phases for any program. No change in the transaction price has been recorded since inception. This will be reassessed at each reporting period. </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The transaction price has been ascribed in its entirety to the three performance obligations identified in the research term of the Takeda Collaboration Agreement.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue is recognized when, or as, the Company satisfies its performance obligations by transferring the promised services to Takeda. Revenue is being recognized over time using the input method, based on costs incurred to perform the research services, since the level of costs incurred over time is thought to best reflect the transfer of services to Takeda. There were no material changes in estimates during the three months ended March 31, 2021 or March 31, 2020.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A contract liability of $40.8 million and $39.8 million was recorded on the Condensed Consolidated Balance Sheets as of March 31, 2021 and December 31, 2020, respectively. This contract liability relates to the three performance obligations identified, with such amounts to be recognized over the estimated period of the pre-IND research services, which is expected to be several years. In December 2020 and January 2021, GLP toxicology studies were initiated for PTV:PGRN and ATV:TREM2, respectively, triggering the second preclinical milestone payments of $8.0 million for each program, which were received in January and March 2021, respectively. There was no receivable as of March 31, 2021 and a receivable of $8.0 million for the PTV:PGRN milestone as of December 31, 2020. </span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In assessing the Takeda Collaboration Agreement, management is required to exercise considerable judgment in estimating revenue to be recognized. Management applies judgment in determining the separate performance obligations in the research period and estimating total future costs when using the input method. There is some increase in the judgment required in estimating the timing of future costs due to the COVID-19 pandemic. This is because it is challenging to predict the duration and extent of the impact of the COVID-19 pandemic on the third-party service providers assisting with the Company's ATV:Tau, ATV:TREM2 and PTV:PGRN programs. This may impact the split between current and non-current contract liability on the Condensed Consolidated Balance Sheets in the future. </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through March 31, 2021, the Company had received $31.0 million in preclinical milestone payments from Takeda which are included in the transaction price described above, and had not recorded any product sales under the Takeda Collaboration Agreement. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration Revenue</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue disaggregated by collaboration agreement and performance obligation is as follows (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.432%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.073%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.921%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.074%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Takeda Collaboration Agreement</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,030&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,018&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sanofi Collaboration Agreement</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Retained Activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">534&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Alzheimer's Disease Services</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Sanofi Collaboration Revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">586&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen Collaboration Agreement</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Option Research Services</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">892&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Collaboration Revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,923&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,604&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:120%">_________________________________________________</span></div><div style="margin-top:4pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10.69pt">$5.7&#160;million of revenue for the three months ended March 31, 2021 and all of revenue for the three months ended March 31, 2020 was included in the contract liability balance at the beginning of the period. </span></div>(2)Revenue for the three months ended March 31, 2021 and March 31, 2020, where applicable, represent amounts that were included in the contract liability balance at the beginning of the respective period.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140237889524424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License Agreements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_LicenseAgreementTextBlock', window );">License Agreements</a></td>
<td class="text">License Agreements<div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Genentech</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Company entered into an Exclusive License Agreement with Genentech, Inc. (&#8220;Genentech&#8221;). The agreement gives the Company access to Genentech&#8217;s LRRK2 inhibitor small molecule program for Parkinson&#8217;s disease. Under the agreement, Genentech granted the Company (i)&#160;an exclusive, worldwide, sublicensable license under Genentech&#8217;s rights to certain patents and patent applications directed to small molecule compounds which bind to and inhibit LRRK2 and (ii)&#160;a&#160;non-exclusive,&#160;worldwide, sublicensable license to certain related&#160;know-how,&#160;in each case, to develop and commercialize certain compounds and licensed products incorporating any such compound. </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may owe Genentech milestone payments upon the achievement of certain development, regulatory, and commercial milestones, up to a maximum of $315.0 million in the aggregate. These milestones include up to $37.5 million in clinical milestone payments, $102.5 million in regulatory milestone payments and $175.0 million in commercial milestone payments. In addition, the Company may owe royalties on net sales of licensed products ranging from low to high single-digit percentages. Under the terms of our LRRK2 Agreement with Biogen, Biogen is responsible for 50% of any payment obligation to Genentech under this agreement accruing after October&#160;4, 2020.</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, the Company has paid Genentech $12.5&#160;million in the aggregate, including an upfront fee, a technology transfer fee and a clinical milestone payment, all of which was recorded as research and development expense as incurred. No expenses were recorded in the three months ended March 31, 2021 or 2020.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dnli_LicenseAgreementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dnli_LicenseAgreementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dnli_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140237889554328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies <div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lease Obligations</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2018, the Company entered into an amendment to its operating lease for its former corporate headquarters in South San Francisco (the "Headquarters Lease Amendment") to relocate and expand its headquarters to 148,020 rentable square feet in a building in South San Francisco, California (the "New Premises"). The Headquarters Lease Amendment has a contractual term of ten years from the legal commencement date, which was April&#160;1, 2019, when the building was ready for occupancy. For accounting purposes, the lease commencement date was determined to be August&#160;1, 2018, which was the date at which the Company was deemed to have obtained control over the property. The Company has an option to extend the lease term for a period of ten years by giving the landlord written notice of the election to exercise the option at least nine months, but not more than twelve months, prior to the expiration of the Headquarters Lease Amendment lease term. The Company determined that this renewal was not reasonably certain at lease inception. The remaining lease term was 8.1 years at March 31, 2021.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Headquarters Lease Amendment provides for monthly base rent amounts escalating over the term of the lease. In addition, the Headquarters Lease Amendment provided a tenant improvement allowance ("TIA") of up to $25.9 million, which was fully utilized, of which $4.4 million will be repaid to the landlord in the form of additional monthly rent. This is recorded as leasehold improvement assets and an offset to the lease ROU asset on the Condensed Consolidated Balance Sheets as of March 31, 2021 and December 31, 2020. The Company is also required to pay the operating expenses for the New Premises, such as taxes and insurance, which are treated as variable lease payments.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management exercised judgment in applying the requirements of ASC 842, including the determination as to whether certain contracts contain a lease and for the Headquarters Lease Amendment, the discount rate used to determine the measurement of the lease liability. As the implicit rate of the Headquarters Lease Amendment was not known, the Company estimated a 9.0% discount rate, which was management&#8217;s estimate of the Company&#8217;s incremental borrowing rate. To estimate the incremental borrowing rate, management considered observable debt yields of comparable market instruments, as well as benchmarks within the Headquarters Lease Amendment that may be indicative of the rate implicit in the lease. </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total operating lease costs, including variable and short-term lease costs, were $2.8 million and $2.6 million for the three months ended March 31, 2021 and 2020, respectively. Cash paid for amounts included in the measurement of lease liabilities for the three months ended</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> March 31, 2021 and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 31, 2020</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of $2.5 million and $2.2 million, respectively, was included in net cash used in operating activities in the Company's Condensed Consolidated Statements of Cash Flows.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles the undiscounted cash flows for the next five years and total of the remaining years to the operating lease liabilities recorded in the Condensed Consolidated Balance Sheet as of March 31, 2021 (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.867%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:38.162%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.671%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021 (nine months)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,855&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,731&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,083&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,447&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,824&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total undiscounted lease payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">95,190&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Present value adjustment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(27,398)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">67,792&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, the Company entered into a sublease agreement ("Sublease Agreement") to sublease approximately 36,835 rentable square feet of space in its New Premises. The Sublease Agreement has a term of five years from the commencement date of April&#160;12, 2019 and provides for the Company to receive monthly base rent amounts escalating over the term of the lease. The Company also passes through a portion of the operating expenses, such as taxes and insurance for the New Premises to the sublessee, which are treated as variable sublease income. Total sublease income, including rent and variable sublease cost reimbursements, was $0.9 million for both the three months ended March 31, 2021 and 2020.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table details the future undiscounted cash inflows relating to the Sublease Agreement as of March 31, 2021 (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.867%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:38.162%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.671%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021 (nine months)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,209&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,009&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,096&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">876&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total undiscounted sublease receipts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,190&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Indemnification</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, the Company may provide indemnifications of varying scope and terms to vendors, lessors, business partners, board members, officers, and other parties with respect to certain matters, including, but not limited to, losses arising out of breach of such agreements, services to be provided by the Company, negligence or willful misconduct of the Company, violations of law by the Company, or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with directors and certain officers and employees that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors, officers or employees. No demands have been made upon the Company to provide indemnification under such agreements, and thus, there are no claims that the Company is aware of that could have a material effect on the Company&#8217;s Condensed Consolidated Balance Sheets, Condensed Consolidated Statements of Operations and Comprehensive Loss, or Condensed Consolidated Statements of Cash Flows.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Commitments</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective September 2017, the Company entered into a Development and Manufacturing Services Agreement as amended (&#8220;DMSA&#8221;) with Lonza Sales AG (&#8220;Lonza&#8221;) for the development and manufacture of biologic products. Under the DMSA, the Company will execute purchase orders based on project plans authorizing Lonza to provide development and manufacturing services with respect to certain of the Company's antibody and enzyme products, and will pay for the services provided and batches delivered in accordance with the DMSA and project plan. </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier terminated, the DMSA will expire on September&#160;6, 2022.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2021 and December 31, 2020, the Company had open purchase orders for biological product development and manufacturing costs totaling $33.4 million and $33.0 million, respectively. The activities under these purchase orders are expected to be completed by February 2028. As of March 31, 2021 and December 31, 2020, the Company had total non-cancellable purchase commitments under the DMSA of $28.5 million and $27.1 million, respectively, under the DMSA.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2021 and 2020, the Company incurred costs of $5.2 million and $1.0&#160;million, respectively, and made payments of $0.7 million and $3.2 million, respectively, for the development and manufacturing services rendered under the DMSA. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingencies</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company may be involved in lawsuits, arbitration, claims, investigations and proceedings consisting of intellectual property, employment and other matters which arise in the ordinary course of business. The Company records accruals for loss contingencies to the extent that the Company concludes that it is probable that a liability has been incurred and the amount of the related loss can be reasonably estimated. </span></div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 10, 2020, the Company and all Directors were named in a shareholder derivative action filed in the Delaware Court of Chancery challenging the compensation paid to the Company's Directors since the </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">initial public offering ("IPO")</span> in December 2017. On January&#160;13, 2021, the parties to the derivative action entered into a settlement agreement, the terms of which were disclosed in a Form 8-K filed on February&#160;5, 2021. The settlement agreement was approved by the Court on April 16, 2021. Amounts owed by the Company pursuant to the settlement agreement are not material to the Company.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140237889518616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Awards<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Awards</a></td>
<td class="text">Stock-Based Awards<div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has issued stock-based awards from various equity incentive and stock purchase plans, as more fully described in Note 10, "Stock-Based Awards" to the consolidated financial statements in the Company's 2020 Annual Report on Form 10-K.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Option Activity</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity for the three months ended March 31, 2021:</span></div><div style="margin-bottom:10pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.226%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.335%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.338%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Options</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercise&#160;Price</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,959,926&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.31&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,639,041&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">75.52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercised</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(334,634)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(34,056)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26.77&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at March 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,230,277&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;text-indent:-12pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested and expected to vest at March 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,357,914&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24.69&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercisable at March 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,013,040&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.01&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of stock options granted to employees were calculated using the Black-Scholes option-pricing model using the following assumptions:</span></div><div style="margin-top:18pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.226%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.335%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.338%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected term (in years)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.08</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.08</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Volatility</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62.2% - 63.4%</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">65.2% - 65.6%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Risk-free interest rate</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.5% - 1.0%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.7% - 1.7%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividend yield</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td></tr></table></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Activity</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes restricted stock unit ("RSU") activity for the three months ended March 31, 2021:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.226%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.335%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.338%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of RSU shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Fair Value at Date of Grant per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unvested at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,301,679&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27.08&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">696,270&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">76.33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested and released</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(281,465)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22.73&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(17,377)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">61.97&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unvested at March 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,699,107&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40.24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected to vest at March 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,699,107&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40.24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:27pt"><span><br/></span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation Expense</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s results of operations include expenses relating to stock-based compensation as follows (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.778%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.061%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,314&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,054&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">General and administrative</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,714&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,731&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21,028&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,785&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140237977163656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text">Net Loss Per Share<div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since the Company was in a loss position for all periods presented, basic net loss per share is the same as diluted net loss per share for all periods as the inclusion of all potential shares of common stock outstanding would have been anti-dilutive. </span></div><div style="text-indent:25pt"><span><br/></span></div><div style="margin-bottom:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potentially dilutive securities that were not included in the diluted per share calculations because they would be anti-dilutive were as follows:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.778%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.061%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Options issued and outstanding and ESPP shares issuable</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,323,256&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,530,378&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted shares subject to future vesting</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,699,107&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,637,984&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,022,363&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,168,362&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140237890026040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text">Related Party TransactionsOn September 22, 2020, upon becoming an owner of record of more than 10% of the voting interest in the Company, Biogen became a related party under ASC 850. Refer to Note 5, "Collaboration Agreements" for further information.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140237977486952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_OrganizationAndDescriptionOfBusinessPolicyPolicyTextBlock', window );">Organization and Description of Business</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Organization and Description of Business</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Denali Therapeutics Inc. ("Denali" or the &#8220;Company&#8221;) is a biopharmaceutical company, incorporated in Delaware, that discovers and develops therapeutics to defeat neurodegenerative diseases. The Company is headquartered in South San Francisco, California.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) for interim financial information and the instructions to Form 10-Q and Article 10 of SEC Regulation S-X for interim financial information. </span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These unaudited condensed consolidated financial statements and notes should be read in conjunction with the audited consolidated financial statements and notes thereto contained in the Annual Report on Form 10-K for the year ended December 31, 2020, as filed with the Securities and Exchange Commission on February&#160;26, 2021 (the "2020 Annual Report on Form 10-K"). The Condensed Consolidated Balance Sheet as of December 31, 2020 was derived from the audited annual consolidated financial statements as of and for the period then ended. Certain information and footnote disclosures typically included in the Company's annual consolidated financial statements have been condensed or omitted. The accompanying unaudited condensed consolidated financial statements reflect all adjustments that, in the opinion of management, are necessary for a fair statement of the results of the interim periods presented. All such adjustments are of a normal recurring nature except for the impacts of adopting new accounting standards, if any, discussed below. These interim financial results are not necessarily indicative of results expected for the full fiscal year or for any subsequent interim period.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. All intercompany balances and transactions have been eliminated in consolidation.&#160;For the Company and its subsidiary, the functional currency has been determined to be U.S. dollars. Monetary assets and liabilities denominated in foreign currency are remeasured at period-end exchange rates. Non-monetary assets and liabilities denominated in foreign currencies are remeasured at historical rates. Foreign currency transaction gains and losses resulting from remeasurement are recognized in interest and other income, net in the Condensed Consolidated Statements of Operations and Comprehensive Loss.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires the Company to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, as well as the reported amounts of expenses during the reporting period. Actual results could differ from those estimates, and such differences could be material to the Condensed Consolidated Balance Sheets and Statements of Operations and Comprehensive Loss.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk and Other Risks and Uncertainties</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk and Other Risks and Uncertainties</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents, marketable securities and forward foreign currency exchange contracts. Substantially all of the Company&#8217;s cash and cash equivalents are deposited in accounts with financial institutions that management believes are of high credit quality. Such deposits have and will continue to exceed federally insured limits. The Company maintains its cash with accredited financial institutions and accordingly, such funds are subject to minimal credit risk. </span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s investment policy limits investments to certain types of securities issued by the U.S. government, its agencies and institutions with investment-grade credit ratings and places restrictions on maturities and concentration by type and issuer. The Company is exposed to credit risk in the event of a default by the financial institutions holding its cash, cash equivalents and marketable securities and issuers of marketable securities to the extent recorded on the Condensed Consolidated Balance Sheets. As of March 31, 2021 and December 31, 2020, the Company had no off balance sheet concentrations of credit risk. </span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is exposed to counterparty credit risk on all of its derivative financial instruments. The Company has established and maintains strict counterparty credit guidelines and enters into hedges only with financial institutions that are investment grade or better to minimize the Company&#8217;s exposure to potential defaults. The Company does not require collateral to be pledged under these agreements.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to a number of risks similar to other early-stage biopharmaceutical companies, including, but not limited to, the need to obtain adequate additional funding, possible failure of current or future preclinical testing or clinical trials, its reliance on third parties to conduct its clinical trials, the need to obtain regulatory and marketing approvals for its product candidates, competitors developing new technological innovations, the need to successfully commercialize and gain market acceptance of the Company&#8217;s product candidates, its right to develop and commercialize its product candidates pursuant to the terms and conditions of the licenses granted to the Company, protection of proprietary technology, the ability to make milestone, royalty or other payments due under any license or collaboration agreements, and the need to secure and maintain adequate manufacturing arrangements with third parties. If the Company does not successfully commercialize or partner any of its product candidates, it will be unable to generate product revenue or achieve profitability.</span></div>The COVID-19 pandemic has caused increased risk and uncertainty for the Company. Credit risk associated with investments in securities may increase if any institution with which the Company has an investment is significantly impacted by the COVID-19 pandemic.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segments</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segments</span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has one operating segment. The Company&#8217;s chief operating decision maker, its Chief Executive Officer, manages the Company&#8217;s operations on a consolidated basis for the purposes of allocating resources.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Cash, Cash Equivalents and Restricted Cash</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents and Restricted Cash</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly liquid investments with original maturities of 90 days or less at the date of purchase to be cash and cash equivalents. Cash equivalents are reported at fair value.</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents, and restricted cash reported within the Condensed Consolidated Statements of Cash Flows is composed of Cash and Cash equivalents reported in the Condensed Consolidated Balance Sheets and $1.5 million of restricted cash for the letter of credit for the Company&#8217;s headquarters building lease, which is included&#160;within other&#160;non-current&#160;assets&#160;in the Condensed Consolidated Balance Sheets.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Marketable Securities</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Marketable Securities</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company generally invests its excess cash in money market funds and investment grade short to intermediate-term fixed income securities. Such investments are included in cash and cash equivalents, short-term marketable securities, or long-term marketable securities on the Condensed Consolidated Balance Sheets, are considered available-for-sale, and reported at fair value with net unrealized gains and losses included as a component of stockholders&#8217; equity. </span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company classifies investments in securities with remaining maturities of less than one year, or where its intent is to use the investments to fund current operations or to make them available for current operations, as short-term investments. The Company classifies investments in securities with remaining maturities of over one year as long-term investments. The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity, which is included in interest and other income, net in the Condensed Consolidated Statements of Operations and Comprehensive Loss. Realized gains and losses and declines in value determined to be due to credit losses on marketable securities, if any, are included in interest and other income, net.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company periodically evaluates the need for an allowance for credit losses. This evaluation includes consideration of several qualitative and quantitative factors, including whether it has plans to sell the security, whether it is more likely than not it will be required to sell any marketable securities before recovery of its amortized cost basis, and if the entity has the ability and intent to hold the security to maturity, and the portion of any unrealized loss that is the result of a credit loss. Factors considered in making these evaluations include quoted market prices, recent financial results and operating trends, implied values from any recent transactions or offers of investee securities, credit quality of debt instrument issuers, expected cash flows from securities, other publicly available information that may affect the value of the marketable security, duration and severity of the decline in value, and the Company's strategy and intentions for holding the marketable security.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesPolicyTextBlock', window );">Accounts Receivable</a></td>
<td class="text">Accounts ReceivableAccounts receivable are included within prepaid expenses and other current assets on the Condensed Consolidated Balance Sheets. The accounts receivable balance represents amounts receivable from the Company's collaboration partners, net of an allowance for credit losses, if required.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Derivatives and Hedging Activities</a></td>
<td class="text">Derivatives and Hedging ActivitiesThe Company measures its derivative instruments at fair value, and accounts for them as either assets or liabilities included within Prepaid expenses and other current assets and Other accruals and other current liabilities, respectively, on the Condensed Consolidated Balance Sheets. Derivatives are adjusted to fair value through interest and other income, net in the Condensed Consolidated Statements of Operations and Comprehensive Loss.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases real estate, and certain equipment for use in its operations. A determination is made as to whether an arrangement is a lease at inception. A right-of-use (&#8220;ROU&#8221;) asset an</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d operating lease liability is recognized for identified operating leases in the Condensed Consolidated Balance Sheets. The changes in operating lease ROU assets and operating lease liabilities are presented net within non-cash adjustment to operating lease expense in the Condensed Consolidated Statements of Cash Flows. Certain amounts for the three months ended March 31, 2020 were reclassified to conform to the current period presentation.</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ROU assets represent the Company&#8217;s right to use the underlying asset for the lease term and lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the lease commencement date based on the present value of lease payments due over the lease term, with the ROU assets adjusted for lease incentives received. When determining the present value of lease payments, the Company uses its incremental borrowing rate on the date of lease commencement, or the rate implicit in the lease, if known. The Company does not assume renewals in its determination of the lease term unless the renewals are deemed by management to be reasonably certain at lease inception.</span></div>Leases with an initial term of 12 months or less are not recorded on the balance sheet, unless they include an option to purchase the underlying asset that the Company is reasonably certain to exercise. The Company recognizes lease expenses on a straight-line basis over the lease term. The Company has leases with lease and non-lease components, which the Company has elected to account for as a single lease component.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License and Collaboration Revenue</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company analyzes its collaboration arrangements to assess whether they are within the scope of ASC&#160;808,&#160;Collaborative Arrangements&#160;(&#8220;ASC&#160;808&#8221;) to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities.&#160;This assessment is performed throughout the life of the arrangement based on changes in the responsibilities of all parties in the arrangement.&#160;For collaboration arrangements within the scope of ASC&#160;808&#160;that contain multiple elements, the Company first determines which elements of the collaboration are deemed to be within the scope of ASC&#160;808&#160;and those that are more reflective of a vendor-customer relationship and, therefore, within the scope of Topic 606. For elements of collaboration arrangements that are accounted for pursuant to ASC&#160;808, an appropriate recognition method is determined and applied consistently, generally by analogy to Topic 606.&#160;The accounting treatment pursuant to Topic 606 is outlined below. </span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The terms of licensing and collaboration agreements entered into typically include payment of one or more of the following: non-refundable, up-front license fees; development, regulatory and commercial milestone payments; payments for manufacturing supply and research and development services and royalties on net sales of licensed products. Each of these payments results in license, collaboration and other revenue, except for revenues from royalties on net sales of licensed products, which are classified as royalty revenue. The core principle of Topic 606 is to recognize revenue when promised goods or services are transferred to customers in an amount that reflects the consideration that is expected to be received in exchange for those goods or services. The Company may also receive reimbursement or make payments to a collaboration partner to satisfy cost sharing requirements. These payments are accounted for pursuant to ASC 808 and are recorded as an offset or increase to research and development expenses, respectively.</span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under each of its agreements, the Company performs the following steps: (i)&#160;identification of the promised goods or services in the contract; (ii)&#160;determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii)&#160;measurement of the transaction price, including the constraint on variable consideration; (iv)&#160;allocation of the transaction price to the performance obligations based on estimated selling prices; and (v)&#160;recognition of revenue when (or as) the Company satisfies each performance obligation.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts received prior to satisfying the revenue recognition criteria are recorded as contract liabilities in the Company&#8217;s Condensed Consolidated Balance Sheets. If the related performance obligation is expected to be satisfied within the next twelve months this will be classified in current liabilities. Amounts recognized as revenue prior to the Company having an unconditional right (other than a right that is conditioned only on the passage of time) to receipt are recorded as contract assets in the Company's Condensed Consolidated Balance Sheets. If the Company expects to have an unconditional right to receive the consideration in the next twelve months, this will be classified in current assets. A net contract asset or liability is presented for each contract with a customer. </span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At contract inception, the Company assesses the goods or services promised in a contract with a customer and identifies those distinct goods and services that represent a performance obligation. A promised good or service may not be identified as a performance obligation if it is immaterial in the context of the contract with the customer, if it is not separately identifiable from other promises in the contract (either because it is not capable of being separated or because it is not separable in the context of the contract), or if the promised good or service does not provide the customer with a material right. </span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers the terms of the contract to determine the transaction price. The transaction price is the amount of consideration to which the Company expects to be entitled in exchange for transferring promised goods or services to a customer. The consideration promised in a contract with a customer may include fixed amounts, variable amounts, or both. Variable consideration will only be included in the transaction price when it is not considered constrained, which is when it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur. </span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If it is determined that multiple performance obligations exist, the transaction price is allocated at the inception of the agreement to all identified performance obligations based on the relative standalone selling prices ("SSP").&#160;The relative SSP for each deliverable is estimated using external sourced evidence if it is available. If external sourced evidence is not available, the Company uses its best estimate of the SSP for the deliverable. </span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue is recognized when, or as, the Company satisfies a performance obligation by transferring a promised good or service to a customer. An asset is transferred when, or as, the customer obtains control of that asset, which for a service is considered to be as the services are received and used. The Company recognizes revenue over time by measuring the progress toward complete satisfaction of the relevant performance obligation using an appropriate input or output method based on the nature of the service promised to the customer. </span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After contract inception, the transaction price is reassessed at every period end and updated for changes such as resolution of uncertain events. Any change in the transaction price is allocated to the performance obligations on the same basis as at contract inception, or to a single performance obligation as applicable. </span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management may be required to exercise considerable judgment in estimating revenue to be recognized. Judgment is required in identifying performance obligations, estimating the transaction price, estimating the SSP of identified performance obligations, which may include forecasted revenue, development timelines, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success, and estimating the progress towards satisfaction of performance obligations.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text"><div style="margin-bottom:10pt;margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Loss</span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss is composed of net loss and certain changes in stockholders&#8217; equity that are excluded from net loss, primarily unrealized gains or losses on the Company&#8217;s marketable securities.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss per Share</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss per Share</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding during the period, without consideration for common stock equivalents. Diluted net loss per share is the same as basic net loss per share, since the effects of potentially dilutive securities are antidilutive given the net loss for each period presented.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Pronouncement</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncement</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the Financial Accounting Standards Board ("FASB") issued ASU No. 2019-12</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">, Income Taxes (Topic 740) Simplifying the Accounting for Income Taxes. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASU No. 2019-12 modifies ASC 740 to simplify several aspects of accounting for income taxes, including eliminating certain exceptions to the guidance in ASC 740 related to the approach for intraperiod tax allocation. The guidance is effective for fiscal years beginning after December 15, 2020 and interim periods within those fiscal years, with early adoption permitted, and is required to be adopted prospectively, with the exception of certain specific amendments, which were not applicable to the Company. The Company adopted this standard as of January 1, 2021 using a prospective approach. Adoption of the standard did not have a material impact on its Condensed Consolidated Financial Statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dnli_OrganizationAndDescriptionOfBusinessPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Organization and description of business, policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dnli_OrganizationAndDescriptionOfBusinessPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dnli_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108315417&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=d3e41620-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=d3e41638-113959<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5579245-113959<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=d3e41675-113959<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(n))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5579240-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120252992&amp;loc=d3e62652-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=d3e5033-111524<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10178-111534<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10149-111534<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140237889826040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Assets and Liabilities Measured at Fair Value</a></td>
<td class="text"><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities measured at fair value at each balance sheet date are as follows (in thousands):</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.214%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.720%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.720%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.720%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.723%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">426,770&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">426,770&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Short-term marketable securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. government treasuries</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">870,756&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">870,756&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. government agency securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,136&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,136&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,729&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,729&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">71,206&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">71,206&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. government treasuries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,050&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,050&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34,835&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34,835&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency derivative contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,301,576&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">141,951&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,443,527&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency derivative contracts</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">176&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">176&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">176&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">176&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.053%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.720%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.720%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.720%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.884%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">335,284&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">335,284&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. government treasuries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">149,997&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">149,997&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Short-term marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. government treasuries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">878,938&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">878,938&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. government agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25,217&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25,217&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27,180&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27,180&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31,218&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31,218&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term marketable securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. government treasuries</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,561&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,561&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30,138&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30,138&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency derivative contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,366,780&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">113,938&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,480,718&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liabilities:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency derivative contracts</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140237997683272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock', window );">Summary of Available for Sale Securities</a></td>
<td class="text">The amortized cost, gross unrealized holding gains or losses, and fair value of the Company&#8217;s marketable securities by major security type at each balance sheet date are summarized in the tables below (in thousands):<div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.085%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.002%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.002%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.002%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.006%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Holding Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Holding Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Short-term marketable securities:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. government treasuries</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">870,674&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">870,756&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. government agency securities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,126&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,136&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,684&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,729&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">71,206&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">71,206&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total short-term marketable securities</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">977,690&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">148&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">977,827&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term marketable securities:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. government treasuries</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,049&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,050&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34,854&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34,835&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total long-term marketable securities</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38,903&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38,885&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,016,593&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,016,712&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:120%">__________________________________________________</span></div><div style="margin-top:4pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10.69pt">Unrealized holding losses on 3 securities with an aggregate fair value of $126.4 million.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10.69pt">Unrealized holding losses on 4 securities with an aggregate fair value of $7.1 million.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10.69pt">Unrealized holding losses on 4 securities with an aggregate fair value of $34.8 million.</span></div><div><span><br/></span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.085%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.002%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.002%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.002%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.006%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Holding Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Holding Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Short-term marketable securities:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. government treasuries</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">878,906&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">878,938&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. government agency securities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25,214&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25,217&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27,101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27,180&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31,218&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31,218&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total short-term marketable securities</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">962,439&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">128&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">962,553&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term marketable securities:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. government treasuries</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,561&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,561&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30,147&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30,138&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total long-term marketable securities</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32,708&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32,699&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">995,147&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">995,252&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:120%">__________________________________________________</span></div><div style="margin-top:4pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10.69pt">Unrealized holding losses on 19 securities with an aggregate fair value of $369.9 million.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10.69pt">Unrealized holding losses on 2 securities with an aggregate fair value of $10.1 million.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10.69pt">Unrealized holding losses on 1 security with an aggregate fair value of $20.1 million.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140237889826040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock', window );">Summary of Forward Foreign Currency Exchange Contracts Outstanding</a></td>
<td class="text"><div style="margin-bottom:10pt;margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s forward foreign currency exchange contracts outstanding as of March 31, 2021 and December 31, 2020, respectively (notional amounts in thousands):</span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:27.265%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.252%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.778%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.902%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign Exchange Contracts</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Contracts</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Notional</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount in Foreign Currency</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maturity</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Euros </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,305&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Apr 2021- Mar 2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">British Pounds </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">963&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Apr 2021- Nov 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total at March 31, 2021</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Euros </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,855&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Jan 2021 - Nov 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">British Pounds </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,658&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Jan 2021 - Nov 2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total at December 31, 2020</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:120%">_________________________________________________</span></div><div style="margin-top:4pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;padding-left:11.65pt;position:relative;top:-2.8pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The notional amount represents the net amount of foreign currency that will be received upon maturity of the forward contracts.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of pertinent information about a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624163-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5580258-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=d3e41620-113959<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5579245-113959<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=d3e41638-113959<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=d3e41678-113959<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=d3e41641-113959<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624171-113959<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5579240-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140237887890920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Summary of Collaboration Revenue</a></td>
<td class="text"><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue disaggregated by collaboration agreement and performance obligation is as follows (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.432%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.073%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.921%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.074%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Takeda Collaboration Agreement</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,030&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,018&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sanofi Collaboration Agreement</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Retained Activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">534&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Alzheimer's Disease Services</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Sanofi Collaboration Revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">586&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen Collaboration Agreement</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Option Research Services</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">892&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Collaboration Revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,923&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,604&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:120%">_________________________________________________</span></div><div style="margin-top:4pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10.69pt">$5.7&#160;million of revenue for the three months ended March 31, 2021 and all of revenue for the three months ended March 31, 2020 was included in the contract liability balance at the beginning of the period. </span></div>(2)Revenue for the three months ended March 31, 2021 and March 31, 2020, where applicable, represent amounts that were included in the contract liability balance at the beginning of the respective period.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140237889216712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Summary of Future Minimum Lease Commitments</a></td>
<td class="text"><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles the undiscounted cash flows for the next five years and total of the remaining years to the operating lease liabilities recorded in the Condensed Consolidated Balance Sheet as of March 31, 2021 (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.867%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:38.162%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.671%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021 (nine months)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,855&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,731&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,083&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,447&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,824&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total undiscounted lease payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">95,190&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Present value adjustment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(27,398)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">67,792&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock', window );">Summary of Future Minimum Lease Receivables</a></td>
<td class="text"><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table details the future undiscounted cash inflows relating to the Sublease Agreement as of March 31, 2021 (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.867%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:38.162%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.671%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021 (nine months)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,209&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,009&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,096&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">876&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total undiscounted sublease receipts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,190&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity of undiscounted cash flows to be received by lessor on annual basis for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121576215&amp;loc=SL77919396-209981<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140237887718664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Awards (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity</a></td>
<td class="text"><div style="margin-bottom:10pt;margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity for the three months ended March 31, 2021:</span></div><div style="margin-bottom:10pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.226%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.335%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.338%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Options</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercise&#160;Price</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,959,926&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.31&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,639,041&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">75.52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercised</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(334,634)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(34,056)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26.77&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at March 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,230,277&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;text-indent:-12pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested and expected to vest at March 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,357,914&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24.69&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercisable at March 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,013,040&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.01&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Summary of Assumptions Used for Estimating the Fair Value of Stock Granted</a></td>
<td class="text"><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of stock options granted to employees were calculated using the Black-Scholes option-pricing model using the following assumptions:</span></div><div style="margin-top:18pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.226%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.335%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.338%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected term (in years)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.08</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.08</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Volatility</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62.2% - 63.4%</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">65.2% - 65.6%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Risk-free interest rate</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.5% - 1.0%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.7% - 1.7%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividend yield</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock', window );">Summary of Restricted Stock Activity</a></td>
<td class="text"><div style="margin-bottom:10pt;margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes restricted stock unit ("RSU") activity for the three months ended March 31, 2021:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.226%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.335%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.338%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of RSU shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Fair Value at Date of Grant per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unvested at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,301,679&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27.08&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">696,270&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">76.33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested and released</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(281,465)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22.73&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(17,377)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">61.97&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unvested at March 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,699,107&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40.24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected to vest at March 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,699,107&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40.24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Summary of Stock-Based Compensation Expense</a></td>
<td class="text"><div style="margin-bottom:10pt;margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s results of operations include expenses relating to stock-based compensation as follows (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.778%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.061%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,314&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,054&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">General and administrative</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,714&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,731&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21,028&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,785&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140237890120808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Dilutive Securities Not Included in Diluted Per Share Calculations</a></td>
<td class="text"><div style="margin-bottom:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potentially dilutive securities that were not included in the diluted per share calculations because they would be anti-dilutive were as follows:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.778%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.061%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Options issued and outstanding and ESPP shares issuable</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,323,256&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,530,378&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted shares subject to future vesting</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,699,107&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,637,984&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,022,363&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,168,362&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140237972949880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>Segment</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | Segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Restricted cash | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6812-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140237893738312">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">$ 1,016,712<span></span>
</td>
<td class="nump">$ 995,252<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Foreign currency derivative contracts</a></td>
<td class="nump">45<span></span>
</td>
<td class="nump">185<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">1,443,527<span></span>
</td>
<td class="nump">1,480,718<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Foreign currency derivative contracts</a></td>
<td class="nump">176<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">176<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">426,770<span></span>
</td>
<td class="nump">335,284<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. government treasuries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">149,997<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember', window );">Short-term marketable securities | U.S. government treasuries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">870,756<span></span>
</td>
<td class="nump">878,938<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember', window );">Short-term marketable securities | U.S. government agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">20,136<span></span>
</td>
<td class="nump">25,217<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember', window );">Short-term marketable securities | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">15,729<span></span>
</td>
<td class="nump">27,180<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember', window );">Short-term marketable securities | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">71,206<span></span>
</td>
<td class="nump">31,218<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=dnli_LongTermInvestmentsMember', window );">Long-term marketable securities | U.S. government treasuries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">4,050<span></span>
</td>
<td class="nump">2,561<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=dnli_LongTermInvestmentsMember', window );">Long-term marketable securities | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">34,835<span></span>
</td>
<td class="nump">30,138<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Foreign currency derivative contracts</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">1,301,576<span></span>
</td>
<td class="nump">1,366,780<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Foreign currency derivative contracts</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">426,770<span></span>
</td>
<td class="nump">335,284<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | U.S. government treasuries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">149,997<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Short-term marketable securities | U.S. government treasuries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">870,756<span></span>
</td>
<td class="nump">878,938<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Short-term marketable securities | U.S. government agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Short-term marketable securities | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Short-term marketable securities | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Long-term marketable securities | U.S. government treasuries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">4,050<span></span>
</td>
<td class="nump">2,561<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Long-term marketable securities | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Foreign currency derivative contracts</a></td>
<td class="nump">45<span></span>
</td>
<td class="nump">185<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">141,951<span></span>
</td>
<td class="nump">113,938<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Foreign currency derivative contracts</a></td>
<td class="nump">176<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">176<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | U.S. government treasuries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Short-term marketable securities | U.S. government treasuries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Short-term marketable securities | U.S. government agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">20,136<span></span>
</td>
<td class="nump">25,217<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Short-term marketable securities | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">15,729<span></span>
</td>
<td class="nump">27,180<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Short-term marketable securities | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">71,206<span></span>
</td>
<td class="nump">31,218<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Long-term marketable securities | U.S. government treasuries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Long-term marketable securities | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">34,835<span></span>
</td>
<td class="nump">30,138<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Foreign currency derivative contracts</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Foreign currency derivative contracts</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | U.S. government treasuries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Short-term marketable securities | U.S. government treasuries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Short-term marketable securities | U.S. government agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Short-term marketable securities | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Short-term marketable securities | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Long-term marketable securities | U.S. government treasuries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Long-term marketable securities | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13433-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13433-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=dnli_LongTermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=dnli_LongTermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140237894763640">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Marketable Securities - Summary of Available for Sale Securities (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($) </div>
<div>security</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>security</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 1,016,593<span></span>
</td>
<td class="nump">$ 995,147<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Holding Gains</a></td>
<td class="nump">149<span></span>
</td>
<td class="nump">130<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Holding Losses</a></td>
<td class="num">(30)<span></span>
</td>
<td class="num">(25)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Aggregate Fair Value</a></td>
<td class="nump">1,016,712<span></span>
</td>
<td class="nump">995,252<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=dnli_ShortTermMarketableSecuritiesMember', window );">Short-term marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">977,690<span></span>
</td>
<td class="nump">962,439<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Holding Gains</a></td>
<td class="nump">148<span></span>
</td>
<td class="nump">128<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Holding Losses</a></td>
<td class="num">(11)<span></span>
</td>
<td class="num">(14)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Aggregate Fair Value</a></td>
<td class="nump">977,827<span></span>
</td>
<td class="nump">962,553<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=dnli_ShortTermMarketableSecuritiesMember', window );">Short-term marketable securities | U.S. government treasuries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">870,674<span></span>
</td>
<td class="nump">878,906<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Holding Gains</a></td>
<td class="nump">90<span></span>
</td>
<td class="nump">44<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Holding Losses</a></td>
<td class="num">(8)<span></span>
</td>
<td class="num">(12)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Aggregate Fair Value</a></td>
<td class="nump">$ 870,756<span></span>
</td>
<td class="nump">$ 878,938<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions', window );">Number of securities held in unrealized holding loss position | security</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Aggregate fair value, unrealized holding loss position</a></td>
<td class="nump">$ 126,400<span></span>
</td>
<td class="nump">$ 369,900<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=dnli_ShortTermMarketableSecuritiesMember', window );">Short-term marketable securities | U.S. government agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">20,126<span></span>
</td>
<td class="nump">25,214<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Holding Gains</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Holding Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Aggregate Fair Value</a></td>
<td class="nump">20,136<span></span>
</td>
<td class="nump">$ 25,217<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions', window );">Number of securities held in unrealized holding loss position | security</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Aggregate fair value, unrealized holding loss position</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=dnli_ShortTermMarketableSecuritiesMember', window );">Short-term marketable securities | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">15,684<span></span>
</td>
<td class="nump">27,101<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Holding Gains</a></td>
<td class="nump">48<span></span>
</td>
<td class="nump">79<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Holding Losses</a></td>
<td class="num">(3)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Aggregate Fair Value</a></td>
<td class="nump">$ 15,729<span></span>
</td>
<td class="nump">27,180<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions', window );">Number of securities held in unrealized holding loss position | security</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Aggregate fair value, unrealized holding loss position</a></td>
<td class="nump">$ 7,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=dnli_ShortTermMarketableSecuritiesMember', window );">Short-term marketable securities | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">71,206<span></span>
</td>
<td class="nump">31,218<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Holding Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Holding Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Aggregate Fair Value</a></td>
<td class="nump">71,206<span></span>
</td>
<td class="nump">31,218<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=dnli_LongTermMarketableSecuritiesMember', window );">Long-term marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">38,903<span></span>
</td>
<td class="nump">32,708<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Holding Gains</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Holding Losses</a></td>
<td class="num">(19)<span></span>
</td>
<td class="num">(11)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Aggregate Fair Value</a></td>
<td class="nump">38,885<span></span>
</td>
<td class="nump">32,699<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=dnli_LongTermMarketableSecuritiesMember', window );">Long-term marketable securities | U.S. government treasuries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">4,049<span></span>
</td>
<td class="nump">2,561<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Holding Gains</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Holding Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Aggregate Fair Value</a></td>
<td class="nump">4,050<span></span>
</td>
<td class="nump">2,561<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=dnli_LongTermMarketableSecuritiesMember', window );">Long-term marketable securities | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">34,854<span></span>
</td>
<td class="nump">30,147<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Holding Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Holding Losses</a></td>
<td class="num">(19)<span></span>
</td>
<td class="num">(11)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Aggregate Fair Value</a></td>
<td class="nump">$ 34,835<span></span>
</td>
<td class="nump">$ 30,138<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions', window );">Number of securities held in unrealized holding loss position | security</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Aggregate fair value, unrealized holding loss position</a></td>
<td class="nump">$ 34,800<span></span>
</td>
<td class="nump">$ 20,100<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121582814&amp;loc=SL82922888-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121582814&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=dnli_ShortTermMarketableSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=dnli_ShortTermMarketableSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=dnli_LongTermMarketableSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=dnli_LongTermMarketableSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140237890743256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss', window );">Allowance for credit losses</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Tax benefit (provision)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 135,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax', window );">Tax charge in other comprehensive income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTerm', window );">Effective maturity (less than)</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121582814&amp;loc=SL82922900-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121582814&amp;loc=SL82922900-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and maturity of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before adjustment, of tax expense (benefit) for unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e640-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140237894947976">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Derivative Financial Instruments - Summary of Forward Foreign Currency Exchange Contracts Outstanding (Details) - Designated as Hedging Instrument<br> &#8364; in Thousands, &#163; in Thousands</strong></div></th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>EUR (&#8364;) </div>
<div>derivative_instrument</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>GBP (&#163;) </div>
<div>derivative_instrument</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>EUR (&#8364;) </div>
<div>derivative_instrument</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>GBP (&#163;) </div>
<div>derivative_instrument</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=dnli_ForeignExchangeForwardEurosMember', window );">Euros</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNumberOfInstrumentsHeld', window );">Number of Contracts</a></td>
<td class="nump">26<span></span>
</td>
<td class="nump">26<span></span>
</td>
<td class="nump">26<span></span>
</td>
<td class="nump">26<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Aggregate Notional Amount in Foreign Currency | &#8364;</a></td>
<td class="nump">&#8364; 4,305<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 3,855<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=dnli_ForeignExchangeForwardBritishPoundsMember', window );">British Pounds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNumberOfInstrumentsHeld', window );">Number of Contracts</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Aggregate Notional Amount in Foreign Currency | &#163;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 963<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 2,658<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign Exchange Contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNumberOfInstrumentsHeld', window );">Number of Contracts</a></td>
<td class="nump">37<span></span>
</td>
<td class="nump">37<span></span>
</td>
<td class="nump">47<span></span>
</td>
<td class="nump">47<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payment on derivative.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5580258-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNumberOfInstrumentsHeld">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of derivative instruments of a particular group held by the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5579245-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5580258-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNumberOfInstrumentsHeld</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=dnli_ForeignExchangeForwardEurosMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=dnli_ForeignExchangeForwardEurosMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=dnli_ForeignExchangeForwardBritishPoundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=dnli_ForeignExchangeForwardBritishPoundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140237890946552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Financial Instruments - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liability</a></td>
<td class="nump">$ 176<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative asset</a></td>
<td class="nump">45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">185<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Net loss on derivative instruments</a></td>
<td class="nump">200<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember', window );">Prepaid Assets and Other Current Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative asset</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign Exchange Contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liability</a></td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13433-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13433-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140237893921688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements - Biogen (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 22, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 05, 2020 </div>
<div>USD ($) </div>
<div>program</div>
</th>
<th class="th">
<div>Oct. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($) </div>
<div>milestone</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($) </div>
<div>milestone</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 06, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_ResearchAndDevelopmentExpenseOffsetFromRelatedPartyCostReimbursement', window );">Offset to research and development expense, related party cost reimbursement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueFromRelatedPartiesCurrent', window );">Cost sharing reimbursements due from related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,511,000<span></span>
</td>
<td class="nump">$ 2,511,000<span></span>
</td>
<td class="nump">$ 5,674,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=dnli_BiogenMember', window );">Biogen | Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">296,500,000<span></span>
</td>
<td class="nump">296,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=dnli_ProvisionalCollaborativeArrangementMember', window );">Provisional Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_CollaborativeAgreementFundedPercentage', window );">Funded percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=dnli_ProvisionalCollaborativeArrangementMember', window );">Provisional Collaboration Agreement | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_CollaborativeAgreementAgreedShareOfCommercialProfitLoss', window );">Agreed share of commercial profit (loss) percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=dnli_ProvisionalCollaborativeArrangementMember', window );">Provisional Collaboration Agreement | China</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_CollaborativeAgreementAgreedShareOfCommercialProfitLoss', window );">Agreed share of commercial profit (loss) percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=dnli_ProvisionalCollaborativeArrangementMember', window );">Provisional Collaboration Agreement | Biogen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_CollaborativeAgreementFundedPercentage', window );">Funded percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=dnli_ProvisionalCollaborativeArrangementMember', window );">Provisional Collaboration Agreement | Biogen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_CollaborativeArrangementUpfrontPaymentToBeReceived', window );">Upfront payment, to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 560,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_AggregateDevelopmentFirstCommercialSaleAndNetSalesBasedMilestonePayments', window );">Milestone payments upon achievement of certain development and sales milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,125,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_DevelopmentMilestonePayments', window );">Development milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">375,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_FirstCommercialSaleMilestonePayments', window );">First commercial sale milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">375,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_NetSalesBasedMilestonePayments', window );">Net sales-based milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 375,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=dnli_ProvisionalCollaborativeArrangementMember', window );">Provisional Collaboration Agreement | Biogen | Stock Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of common stock (in shares) | shares</a></td>
<td class="nump">13,310,243<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Purchase price</a></td>
<td class="nump">$ 465,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStocksIncludingAdditionalPaidInCapital', window );">Fair market value of common stock</a></td>
<td class="nump">$ 420,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Closing stock price (usd per share) | $ / shares</a></td>
<td class="nump">$ 35.87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_SaleOfStockConsiderationPremiumReceivedOnTransaction', window );">Premium on sale of common stock</a></td>
<td class="nump">$ 44,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=dnli_ProvisionalCollaborativeArrangementMember', window );">Provisional Collaboration Agreement | Biogen | Transport Vehicle (TV) Technology Platform, Unnamed Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_CollaborativeArrangementNumberOfPrograms', window );">Number of programs | program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=dnli_ProvisionalCollaborativeArrangementMember', window );">Provisional Collaboration Agreement | Biogen | Transport Vehicle (TV) Technology Program, Unnamed Program, Right Of First Negotiation Programs (ROFN)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_CollaborativeArrangementNumberOfAdditionalProgramsIfCircumstancesMet', window );">Number of additional programs, if circumstances met | program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=dnli_ProvisionalCollaborativeArrangementMember', window );">Provisional Collaboration Agreement | Biogen | Transport Vehicle (TV)Technology Platform, Preclinical Programs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_CollaborativeArrangementNumberOfPrograms', window );">Number of programs | program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_CollaborativeArrangementTermNumberOfBusinessDaysIfEffectiveDateCriteriaMet', window );">Term of agreement, number of business days after 5th anniversary date of the effective date of the agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=dnli_ProvisionalCollaborativeArrangementMember', window );">Provisional Collaboration Agreement | Biogen | Transport Vehicle Technology Platform, Right Of First Negotiation Programs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_CollaborativeArrangementNumberOfAdditionalProgramsIfCircumstancesMet', window );">Number of additional programs, if circumstances met | program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_CollaborativeArrangementRightOfFirstNegotiationTermPeriodAfterEffectiveDateOfAgreementIfCircumstancesMet', window );">Right of first negotiation (ROFN) term, period of time after effective date of agreement, if circumstances met</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_CollaborativeArrangementRightOfFirstNegotiationPeriodTermAdditionalProgramCriteria', window );">Right of first negotiation (ROFN) term, additional program criteria | program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_CollaborativeArrangementNumberOfAdditionalProgramsNoThirdPartyAgreementExecutedIfCircumstancesMet', window );">Number of additional programs, no third party agreement executed, if circumstances met | program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=dnli_ROFNAndOptionAgreementCollaborativeArrangementMember', window );">ROFN and Option Agreement | Biogen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_CollaborativeArrangementOptionExerciseAndDevelopmentMilestonePaymentsToBeReceived', window );">Aggregate option exercise and development milestone payments, to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 270,000,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_CollaborativeArrangementFirstCommercialSaleMilestonePaymentsToBeReceived', window );">First commercial sale milestone payments, to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">325,000,000.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_CollaborativeArrangementNetSalesBasedMilestonePaymentsToBeReceived', window );">Net sales-based milestone payments, to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 290,000,000.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=dnli_ROFNAndOptionAgreementCollaborativeArrangementMember', window );">ROFN and Option Agreement | Biogen | Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">288,900,000<span></span>
</td>
<td class="nump">288,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=dnli_BiogenCollaborativeArrangementMember', window );">Biogen Collaborative Arrangement | Biogen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_UpfrontPayments', window );">Upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 560,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_CollaborationAgreementTransactionPriceIncreaseDecrease', window );">Transaction price, change</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_ResearchAndDevelopmentExpenseOffsetFromRelatedPartyCostReimbursement', window );">Offset to research and development expense, related party cost reimbursement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueFromRelatedPartiesCurrent', window );">Cost sharing reimbursements due from related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="nump">$ 5,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_CollaborativeArrangementNumberOfMilestonesAchieved', window );">Number of milestones achieved | milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=dnli_BiogenCollaborativeArrangementMember', window );">Biogen Collaborative Arrangement | Biogen | Option Research Services | Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,600,000<span></span>
</td>
<td class="nump">$ 7,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dnli_AggregateDevelopmentFirstCommercialSaleAndNetSalesBasedMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate Development, First Commercial Sale, And Net Sales Based Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dnli_AggregateDevelopmentFirstCommercialSaleAndNetSalesBasedMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dnli_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dnli_CollaborationAgreementTransactionPriceIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Transaction Price, Increase (Decrease)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dnli_CollaborationAgreementTransactionPriceIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dnli_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dnli_CollaborativeAgreementAgreedShareOfCommercialProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Agreed Share Of Commercial Profit (Loss)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dnli_CollaborativeAgreementAgreedShareOfCommercialProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dnli_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dnli_CollaborativeAgreementFundedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Funded Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dnli_CollaborativeAgreementFundedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dnli_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dnli_CollaborativeArrangementFirstCommercialSaleMilestonePaymentsToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, First Commercial Sale Milestone Payments, To Be Received</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dnli_CollaborativeArrangementFirstCommercialSaleMilestonePaymentsToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dnli_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dnli_CollaborativeArrangementNetSalesBasedMilestonePaymentsToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Net Sales-Based Milestone Payments, To Be Received</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dnli_CollaborativeArrangementNetSalesBasedMilestonePaymentsToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dnli_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dnli_CollaborativeArrangementNumberOfAdditionalProgramsIfCircumstancesMet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Number Of Additional Programs, If Circumstances Met</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dnli_CollaborativeArrangementNumberOfAdditionalProgramsIfCircumstancesMet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dnli_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dnli_CollaborativeArrangementNumberOfAdditionalProgramsNoThirdPartyAgreementExecutedIfCircumstancesMet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Number Of Additional Programs, No Third Party Agreement Executed, If Circumstances Met</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dnli_CollaborativeArrangementNumberOfAdditionalProgramsNoThirdPartyAgreementExecutedIfCircumstancesMet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dnli_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dnli_CollaborativeArrangementNumberOfMilestonesAchieved">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Number Of Milestones Achieved</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dnli_CollaborativeArrangementNumberOfMilestonesAchieved</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dnli_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dnli_CollaborativeArrangementNumberOfPrograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Number Of Programs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dnli_CollaborativeArrangementNumberOfPrograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dnli_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dnli_CollaborativeArrangementOptionExerciseAndDevelopmentMilestonePaymentsToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Option Exercise And Development Milestone Payments, To Be Received</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dnli_CollaborativeArrangementOptionExerciseAndDevelopmentMilestonePaymentsToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dnli_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dnli_CollaborativeArrangementRightOfFirstNegotiationPeriodTermAdditionalProgramCriteria">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Right Of First Negotiation, Period Term, Additional Program Criteria</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dnli_CollaborativeArrangementRightOfFirstNegotiationPeriodTermAdditionalProgramCriteria</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dnli_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dnli_CollaborativeArrangementRightOfFirstNegotiationTermPeriodAfterEffectiveDateOfAgreementIfCircumstancesMet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Right Of First Negotiation Term, Period After Effective Date Of Agreement, If Circumstances Met</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dnli_CollaborativeArrangementRightOfFirstNegotiationTermPeriodAfterEffectiveDateOfAgreementIfCircumstancesMet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dnli_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dnli_CollaborativeArrangementTermNumberOfBusinessDaysIfEffectiveDateCriteriaMet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Term, Number Of Business Days, If Effective Date Criteria Met</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dnli_CollaborativeArrangementTermNumberOfBusinessDaysIfEffectiveDateCriteriaMet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dnli_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dnli_CollaborativeArrangementUpfrontPaymentToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Upfront Payment, To Be Received</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dnli_CollaborativeArrangementUpfrontPaymentToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dnli_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dnli_DevelopmentMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Development Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dnli_DevelopmentMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dnli_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dnli_FirstCommercialSaleMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>First Commercial Sale Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dnli_FirstCommercialSaleMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dnli_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dnli_NetSalesBasedMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net Sales Based Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dnli_NetSalesBasedMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dnli_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dnli_ResearchAndDevelopmentExpenseOffsetFromRelatedPartyCostReimbursement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research And Development Expense, Offset From Related Party Cost Reimbursement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dnli_ResearchAndDevelopmentExpenseOffsetFromRelatedPartyCostReimbursement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dnli_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dnli_SaleOfStockConsiderationPremiumReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale of stock consideration premium received on transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dnli_SaleOfStockConsiderationPremiumReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dnli_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dnli_UpfrontPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dnli_UpfrontPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dnli_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStocksIncludingAdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of par value plus amounts in excess of par value or issuance value for common stock issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStocksIncludingAdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueFromRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of receivables to be collected from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth, at the financial statement date. which are usually due within one year (or one business cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueFromRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=dnli_BiogenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=dnli_BiogenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=srt_AffiliatedEntityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=srt_AffiliatedEntityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=dnli_ProvisionalCollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=dnli_ProvisionalCollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CN">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CN</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=dnli_BiogenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=dnli_BiogenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=dnli_SharePurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=dnli_SharePurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=dnli_TransportVehicleTechnologyPlatformUnnamedProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=dnli_TransportVehicleTechnologyPlatformUnnamedProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=dnli_TransportVehicleTechnologyProgramRightOfFirstNegotiationProgramsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=dnli_TransportVehicleTechnologyProgramRightOfFirstNegotiationProgramsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=dnli_TransportVehicleTechnologyPlatformPreclinicalProgramsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=dnli_TransportVehicleTechnologyPlatformPreclinicalProgramsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=dnli_TransportVehicleTechnologyPlatformRightOfFirstNegotiationProgramsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=dnli_TransportVehicleTechnologyPlatformRightOfFirstNegotiationProgramsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=dnli_ROFNAndOptionAgreementCollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=dnli_ROFNAndOptionAgreementCollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=dnli_BiogenCollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=dnli_BiogenCollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=dnli_OptionResearchServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=dnli_OptionResearchServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140237895887128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements - Sanofi (Details)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="1">30 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Nov. 30, 2018 </div>
<div>USD ($) </div>
<div>indication</div>
</th>
<th class="th" colspan="2">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_NumberOfIndications', window );">Number of indications | indication</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue from customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,922,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 3,552,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_CollaborativeAgreementFundedPercentage', window );">Funded percentage</a></td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=dnli_SanofiMember', window );">Sanofi | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_CollaborativeAgreementFundedPercentage', window );">Funded percentage</a></td>
<td class="nump">70.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=dnli_SanofiMember', window );">Sanofi | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_UpfrontPayments', window );">Upfront payment</a></td>
<td class="nump">$ 125,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_AggregateClinicalRegulatoryAndSalesMilestonePayment', window );">Milestone payments upon achievement of certain clinical, regulatory and sales milestone events</a></td>
<td class="nump">1,100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNet', window );">Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 44,303<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=dnli_SanofiMember', window );">Sanofi | Collaborative Arrangement | CNS Product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_ClinicalMilestonePayment', window );">Clinical milestone payment</a></td>
<td class="nump">215,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_RegulatoryMilestonePayment', window );">Regulatory milestone payment</a></td>
<td class="nump">385,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=dnli_SanofiMember', window );">Sanofi | Collaborative Arrangement | Peripheral Program License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_ClinicalMilestonePayment', window );">Clinical milestone payment</a></td>
<td class="nump">120,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_RegulatoryMilestonePayment', window );">Regulatory milestone payment</a></td>
<td class="nump">175,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_CommercialMilestonePayments', window );">Commercial milestone payments</a></td>
<td class="nump">$ 200,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=dnli_SanofiMember', window );">Sanofi | Collaborative Arrangement | Milestone Triggered</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue from customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=dnli_SanofiMember', window );">Sanofi | Collaborative Arrangement | Milestone Triggered and Retained Activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_CollaborationAgreementTransactionPriceIncrease', window );">Transaction price increase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=dnli_SanofiMember', window );">Sanofi | Collaborative Arrangement | Product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue from customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="7"></td></tr>
<tr><td colspan="7"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Includes related party collaboration revenue from customer of $0.9&#160;million for the three months ended March 31, 2021.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dnli_AggregateClinicalRegulatoryAndSalesMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate Clinical Regulatory And Sales Milestone Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dnli_AggregateClinicalRegulatoryAndSalesMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dnli_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dnli_ClinicalMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Clinical Milestone Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dnli_ClinicalMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dnli_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dnli_CollaborationAgreementTransactionPriceIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Transaction Price, Increase</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dnli_CollaborationAgreementTransactionPriceIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dnli_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dnli_CollaborativeAgreementFundedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Funded Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dnli_CollaborativeAgreementFundedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dnli_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dnli_CommercialMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commercial Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dnli_CommercialMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dnli_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dnli_NumberOfIndications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Indications</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dnli_NumberOfIndications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dnli_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dnli_RegulatoryMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Regulatory Milestone Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dnli_RegulatoryMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dnli_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dnli_UpfrontPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dnli_UpfrontPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dnli_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=dnli_SanofiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=dnli_SanofiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=dnli_SanofiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=dnli_SanofiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=dnli_CNSProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=dnli_CNSProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=dnli_PeripheralProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=dnli_PeripheralProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=dnli_MilestoneTriggeredMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=dnli_MilestoneTriggeredMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=dnli_MilestoneTriggeredAndRetainedActivitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=dnli_MilestoneTriggeredAndRetainedActivitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140237889515496">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Collaboration Agreements - Sanofi Performance Obligation (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=dnli_AlzheimersDiseaseServicesMember', window );">Alzheimer's Disease Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Performance obligation</a></td>
<td class="nump">$ 3.4<span></span>
</td>
<td class="nump">$ 3.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=dnli_AlzheimersDiseaseServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=dnli_AlzheimersDiseaseServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140237885882200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements - Takeda (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="1">37 Months Ended</th>
<th class="th" colspan="1">39 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Feb. 23, 2018 </div>
<div>USD ($) </div>
<div>program </div>
<div>target </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th" colspan="2">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue from customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,922,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 3,552,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement | Takeda Pharmaceutical Company Limited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_UpfrontPayments', window );">Upfront payment</a></td>
<td class="nump">$ 40,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_NumberOfPrograms', window );">Number of programs | program</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_PreclinicalMilestonePaymentReceived', window );">Preclinical milestone payment received</a></td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_NumberOfTargets', window );">Number of targets | target</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_TargetOptionPeriod', window );">Target option period</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_OptionFeesPerProgram', window );">Option fee</a></td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_VariableConsiderationFutureConsideration', window );">Variable consideration relating to future milestones</a></td>
<td class="nump">26,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_ConstrainedVariableConsideration', window );">Remaining preclinical milestones, cost and profit sharing income, and the development and commercial milestones</a></td>
<td class="nump">$ 44,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_CollaborationAgreementTransactionPriceIncreaseDecrease', window );">Transaction price, change</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_RevenueNumberOfPerformanceObligations', window );">Number of performance obligations | program</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,800,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,800,000<span></span>
</td>
<td class="nump">$ 40,800,000<span></span>
</td>
<td class="nump">$ 39,800,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_PreclinicalMilestonePaymentEarnedNotYetReceived', window );">Preclinical milestone payment earned not yet received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement | Takeda Pharmaceutical Company Limited | Product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue from customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement | Takeda Pharmaceutical Company Limited | Milestone Triggered</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue from customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement | Takeda Pharmaceutical Company Limited | Stock Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of common stock (in shares) | shares</a></td>
<td class="nump">4,214,559<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Purchase price</a></td>
<td class="nump">$ 110,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStocksIncludingAdditionalPaidInCapital', window );">Fair market value of common stock</a></td>
<td class="nump">$ 94,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Closing stock price (usd per share) | $ / shares</a></td>
<td class="nump">$ 22.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_SaleOfStockConsiderationPremiumReceivedOnTransaction', window );">Premium on sale of common stock</a></td>
<td class="nump">$ 15,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement | Maximum | Takeda Pharmaceutical Company Limited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_PreclinicalMilestonePaymentPerProgram', window );">Preclinical milestone payments per program</a></td>
<td class="nump">25,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_AggregatePreclinicalMilestonePayment', window );">Total aggregate payments due upon achievement of certain preclinical milestone events</a></td>
<td class="nump">75,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_AggregateOptionExerciseFee', window );">Aggregated option exercise fee</a></td>
<td class="nump">15,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_AggregateDevelopmentMilestonePayment', window );">Total aggregate payments due upon achievement of certain clinical and regulatory milestone events</a></td>
<td class="nump">407,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_RegulatoryMilestonePayment', window );">Regulatory milestone payment</a></td>
<td class="nump">300,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_CommercialMilestonesPerProgram', window );">Milestone payments per biologic product upon achievement of a certain sales-based milestone</a></td>
<td class="nump">75,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_AggregateCommercialMilestones', window );">Milestone payments upon achievement of biologic product from each program</a></td>
<td class="nump">$ 225,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=dnli_CollaborativeArrangementPTVPGRNMember', window );">Collaborative Arrangement, PTV:PGRN | Takeda Pharmaceutical Company Limited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_PreclinicalMilestonePaymentReceived', window );">Preclinical milestone payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_PreclinicalMilestonePaymentEarnedNotYetReceived', window );">Preclinical milestone payment earned not yet received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,000,000.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=dnli_CollaborativeArrangementATVTREM2Member', window );">Collaborative Arrangement, ATV:TREM2 | Takeda Pharmaceutical Company Limited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_PreclinicalMilestonePaymentReceived', window );">Preclinical milestone payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="10"></td></tr>
<tr><td colspan="10"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Includes related party collaboration revenue from customer of $0.9&#160;million for the three months ended March 31, 2021.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dnli_AggregateCommercialMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate commercial milestones if one biologic product from each program achieves the milestone.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dnli_AggregateCommercialMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dnli_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dnli_AggregateDevelopmentMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate development milestone payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dnli_AggregateDevelopmentMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dnli_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dnli_AggregateOptionExerciseFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate option exercise fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dnli_AggregateOptionExerciseFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dnli_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dnli_AggregatePreclinicalMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total aggregate payments due upon achievement of certain preclinical milestone events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dnli_AggregatePreclinicalMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dnli_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dnli_CollaborationAgreementTransactionPriceIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Transaction Price, Increase (Decrease)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dnli_CollaborationAgreementTransactionPriceIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dnli_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dnli_CommercialMilestonesPerProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commercial milestones per program.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dnli_CommercialMilestonesPerProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dnli_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dnli_ConstrainedVariableConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Constrained variable consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dnli_ConstrainedVariableConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dnli_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dnli_NumberOfPrograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Programs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dnli_NumberOfPrograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dnli_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dnli_NumberOfTargets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Targets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dnli_NumberOfTargets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dnli_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dnli_OptionFeesPerProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Option fees per program.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dnli_OptionFeesPerProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dnli_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dnli_PreclinicalMilestonePaymentEarnedNotYetReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Preclinical Milestone Payment Earned Not Yet Received</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dnli_PreclinicalMilestonePaymentEarnedNotYetReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dnli_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dnli_PreclinicalMilestonePaymentPerProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments due upon achievement of certain preclinical milestone events per program.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dnli_PreclinicalMilestonePaymentPerProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dnli_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dnli_PreclinicalMilestonePaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Preclinical milestone payment received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dnli_PreclinicalMilestonePaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dnli_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dnli_RegulatoryMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Regulatory Milestone Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dnli_RegulatoryMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dnli_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dnli_RevenueNumberOfPerformanceObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue, Number Of Performance Obligations</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dnli_RevenueNumberOfPerformanceObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dnli_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dnli_SaleOfStockConsiderationPremiumReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale of stock consideration premium received on transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dnli_SaleOfStockConsiderationPremiumReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dnli_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dnli_TargetOptionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Target Option Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dnli_TargetOptionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dnli_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dnli_UpfrontPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dnli_UpfrontPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dnli_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dnli_VariableConsiderationFutureConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Variable consideration relating to future milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dnli_VariableConsiderationFutureConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dnli_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStocksIncludingAdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of par value plus amounts in excess of par value or issuance value for common stock issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStocksIncludingAdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=dnli_TakedaPharmaceuticalCompanyLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=dnli_TakedaPharmaceuticalCompanyLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=dnli_MilestoneTriggeredMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=dnli_MilestoneTriggeredMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=dnli_SharePurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=dnli_SharePurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=dnli_CollaborativeArrangementPTVPGRNMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=dnli_CollaborativeArrangementPTVPGRNMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=dnli_CollaborativeArrangementATVTREM2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=dnli_CollaborativeArrangementATVTREM2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140237890341528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements - Summary of Collaboration Revenue (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
</tr>
<tr>
<th class="th" colspan="2"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaborative revenue, revenue from contract with customer</a></td>
<td class="nump">$ 7,922<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 3,552<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Collaborative revenue, excluding revenue from contract with customer</a></td>
<td class="nump">1<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">52<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total Collaboration Revenue</a></td>
<td class="nump">7,923<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">3,604<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=dnli_TakedaCollaborationAgreementMember', window );">Takeda Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaborative revenue, revenue from contract with customer</a></td>
<td class="nump">7,030<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">3,018<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized included in the contract liability balance at the beginning of the year</a></td>
<td class="nump">5,700<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=dnli_SanofiCollaborationAgreementMember', window );">Sanofi Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total Collaboration Revenue</a></td>
<td class="nump">1<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">586<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=dnli_SanofiCollaborationAgreementMember', window );">Sanofi Collaboration Agreement | Retained Activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaborative revenue, revenue from contract with customer</a></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">534<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=dnli_SanofiCollaborationAgreementMember', window );">Sanofi Collaboration Agreement | Alzheimer's Disease Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Collaborative revenue, excluding revenue from contract with customer</a></td>
<td class="nump">1<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">52<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=dnli_BiogenMember', window );">Biogen Collaboration Agreement | Option Research Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaborative revenue, revenue from contract with customer</a></td>
<td class="nump">$ 892<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Includes related party collaboration revenue from customer of $0.9&#160;million for the three months ended March 31, 2021.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=118644919&amp;loc=SL5834089-161433<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=dnli_TakedaCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=dnli_TakedaCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=dnli_SanofiCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=dnli_SanofiCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=dnli_RetainedActivitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=dnli_RetainedActivitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=dnli_AlzheimersDiseaseServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=dnli_AlzheimersDiseaseServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=dnli_BiogenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=dnli_BiogenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=dnli_OptionServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=dnli_OptionServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140237894605704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License Agreements - Narrative (Details) - Genentech Inc - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">58 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Oct. 05, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=dnli_GenentechIncMember', window );">Biogen Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_LicenseAgreementMilestonePaymentObligationResponsibilityPercentage', window );">Payment obligation responsibility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=dnli_GenentechIncMember', window );">License Agreement | Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_UpfrontFeesPaid', window );">Upfront fee paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 12,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=dnli_GenentechIncMember', window );">Clinical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_LicenseAgreementMilestonePaymentUponAchievementOfClinicalAndRegulatoryMilestones', window );">Milestone payments upon achievement of specified clinical and regulatory milestones</a></td>
<td class="nump">$ 37,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=dnli_GenentechIncMember', window );">Regulatory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_LicenseAgreementMilestonePaymentUponAchievementOfClinicalAndRegulatoryMilestones', window );">Milestone payments upon achievement of specified clinical and regulatory milestones</a></td>
<td class="nump">102,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=dnli_GenentechIncMember', window );">Commercial</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_LicenseAgreementMilestonePaymentUponAchievementOfClinicalAndRegulatoryMilestones', window );">Milestone payments upon achievement of specified clinical and regulatory milestones</a></td>
<td class="nump">175,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=dnli_GenentechIncMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_LicenseAgreementMilestonePaymentUponAchievementOfClinicalAndRegulatoryMilestones', window );">Milestone payments upon achievement of specified clinical and regulatory milestones</a></td>
<td class="nump">$ 315,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dnli_LicenseAgreementMilestonePaymentObligationResponsibilityPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Milestone Payment Obligation Responsibility, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dnli_LicenseAgreementMilestonePaymentObligationResponsibilityPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dnli_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dnli_LicenseAgreementMilestonePaymentUponAchievementOfClinicalAndRegulatoryMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License agreement milestone payment upon achievement of clinical and regulatory milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dnli_LicenseAgreementMilestonePaymentUponAchievementOfClinicalAndRegulatoryMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dnli_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dnli_UpfrontFeesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront fees paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dnli_UpfrontFeesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dnli_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=dnli_GenentechIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=dnli_GenentechIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=dnli_BiogenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=dnli_BiogenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=dnli_LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=dnli_LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=dnli_ClinicalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=dnli_ClinicalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=dnli_RegulatoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=dnli_RegulatoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=dnli_CommercialMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=dnli_CommercialMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140237966723736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>May 02, 2018 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2018 </div>
<div>ft&#178;</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDiscountRate', window );">Discount rate (as a percentage)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Operating lease costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.8<span></span>
</td>
<td class="nump">$ 2.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.5<span></span>
</td>
<td class="nump">2.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Sublease income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.9<span></span>
</td>
<td class="nump">0.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis=dnli_DMSAMember', window );">DMSA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_PurchaseOrderExecuted', window );">Purchase order executed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseObligation', window );">Non-refundable purchase commitments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsIncurredDevelopmentCosts', window );">Costs incurred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.2<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_PaymentsForManufacturingCost', window );">Payments for development and manufacturing services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.7<span></span>
</td>
<td class="nump">$ 3.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseholdImprovementsGross', window );">Leasehold improvements</a></td>
<td class="nump">$ 25.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=dnli_HeadquartersLeaseMember', window );">Headquarters Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_OperatingLeasesAreaUnderLease', window );">Area under lease | ft&#178;</a></td>
<td class="nump">148,020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lease renewal option term</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=dnli_HeadquartersLeaseMember', window );">Headquarters Lease | Landlord Funded Tenant Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_TenantImprovementAllowanceRepayableAsRent', window );">Tenant improvement allowance repayable in rent</a></td>
<td class="nump">$ 4.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=dnli_HeadquartersLeaseMember', window );">Headquarters Lease | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_LesseeOperatingLeaseRenewalNoticePeriod', window );">Lease renewal notice period</a></td>
<td class="text">9 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=dnli_HeadquartersLeaseMember', window );">Headquarters Lease | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_LesseeOperatingLeaseRenewalNoticePeriod', window );">Lease renewal notice period</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=dnli_NewPremisesSubleaseAgreementMember', window );">New Premises Sublease Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_OperatingLeasesSubleaseNetRentableArea', window );">Rentable square feet | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,835<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LessorOperatingLeaseTermOfContract', window );">Sublease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dnli_LesseeOperatingLeaseRenewalNoticePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Renewal Notice Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dnli_LesseeOperatingLeaseRenewalNoticePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dnli_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dnli_OperatingLeasesAreaUnderLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating leases area under lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dnli_OperatingLeasesAreaUnderLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dnli_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dnli_OperatingLeasesSubleaseNetRentableArea">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Leases, Sublease, Net Rentable Area</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dnli_OperatingLeasesSubleaseNetRentableArea</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dnli_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dnli_PaymentsForManufacturingCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments for manufacturing cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dnli_PaymentsForManufacturingCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dnli_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dnli_PurchaseOrderExecuted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase order executed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dnli_PurchaseOrderExecuted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dnli_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dnli_TenantImprovementAllowanceRepayableAsRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Portion of tenant improvement allowance repayable to landlord in future rent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dnli_TenantImprovementAllowanceRepayableAsRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dnli_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsIncurredDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Development costs incurred, including capitalized costs and costs charged to expense, in oil and gas activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 932<br> -SubTopic 235<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=68064819&amp;loc=d3e62014-109447<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsIncurredDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseholdImprovementsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6812-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseholdImprovementsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Discount rate used by lessee to determine present value of operating lease payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessor's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121576215&amp;loc=SL77919359-209981<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis=dnli_DMSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis=dnli_DMSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=dnli_HeadquartersLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=dnli_HeadquartersLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=dnli_LandlordFundedTenantImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=dnli_LandlordFundedTenantImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=dnli_NewPremisesSubleaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=dnli_NewPremisesSubleaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140237889460488">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Summary of Company's Future Minimum Lease Commitments (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Operating Lease Liabilities, Payments Due [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2021 (nine months)</a></td>
<td class="nump">$ 7,855<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2022</a></td>
<td class="nump">10,731<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2023</a></td>
<td class="nump">11,083<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2024</a></td>
<td class="nump">11,447<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2025</a></td>
<td class="nump">11,824<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour', window );">Thereafter</a></td>
<td class="nump">42,250<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total undiscounted lease payments</a></td>
<td class="nump">95,190<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Present value adjustment</a></td>
<td class="num">(27,398)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Net operating lease liabilities</a></td>
<td class="nump">$ 67,792<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dnli_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, To Be Paid, After Year Four</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dnli_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dnli_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140237887715784">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Summary of Company's Future Minimum Lease Receivables (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear', window );">2021 (nine months)</a></td>
<td class="nump">$ 2,209<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths', window );">2022</a></td>
<td class="nump">3,009<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears', window );">2023</a></td>
<td class="nump">3,096<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears', window );">2024</a></td>
<td class="nump">876<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceived', window );">Total undiscounted sublease receipts</a></td>
<td class="nump">$ 9,190<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payments to be received by lessor for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121576215&amp;loc=SL77919396-209981<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payment to be received by lessor for operating lease in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121576215&amp;loc=SL77919396-209981<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payment to be received by lessor for operating lease in remainder of current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121576215&amp;loc=SL77919396-209981<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payment to be received by lessor for operating lease in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121576215&amp;loc=SL77919396-209981<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payment to be received by lessor for operating lease in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121576215&amp;loc=SL77919396-209981<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140237895898936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Awards - Summary of Stock Option Activity (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning balance (in shares) | shares</a></td>
<td class="nump">12,959,926<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares) | shares</a></td>
<td class="nump">1,639,041<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares) | shares</a></td>
<td class="num">(334,634)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited (in shares) | shares</a></td>
<td class="num">(34,056)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending balance (in shares) | shares</a></td>
<td class="nump">14,230,277<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and expected to vest (in shares) | shares</a></td>
<td class="nump">13,357,914<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable (in shares) | shares</a></td>
<td class="nump">7,013,040<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted-Average Exercise&#160;Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning balance (usd per share) | $ / shares</a></td>
<td class="nump">$ 16.31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (usd per share) | $ / shares</a></td>
<td class="nump">75.52<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (usd per share) | $ / shares</a></td>
<td class="nump">11.42<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited (usd per share) | $ / shares</a></td>
<td class="nump">26.77<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending balance (usd per share) | $ / shares</a></td>
<td class="nump">23.22<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested and expected to vest (usd per share) | $ / shares</a></td>
<td class="nump">24.69<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Exercisable (usd per share) | $ / shares</a></td>
<td class="nump">$ 14.01<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140237887975992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Awards - Summary of Assumptions Used for Estimating the Fair Value of Stock Options Granted (Details) - Stock Options<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years 29 days<span></span>
</td>
<td class="text">6 years 29 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Volatility, minimum</a></td>
<td class="nump">62.20%<span></span>
</td>
<td class="nump">65.20%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Volatility, maximum</a></td>
<td class="nump">63.40%<span></span>
</td>
<td class="nump">65.60%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="nump">0.70%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.70%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140237894410344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Awards - Summary of Restricted Stock Activity (Details) - Restricted Stock Units (RSUs)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward', window );"><strong>Number of RSU shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning balance (in shares) | shares</a></td>
<td class="nump">2,301,679<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares) | shares</a></td>
<td class="nump">696,270<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested and released (in shares) | shares</a></td>
<td class="num">(281,465)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares) | shares</a></td>
<td class="num">(17,377)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending balance (in shares) | shares</a></td>
<td class="nump">2,699,107<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber', window );">Expected to vest (in shares) | shares</a></td>
<td class="nump">2,699,107<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-Average Fair Value at Date of Grant per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning balance (usd per share) | $ / shares</a></td>
<td class="nump">$ 27.08<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (usd per share) | $ / shares</a></td>
<td class="nump">76.33<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested and released (usd per share) | $ / shares</a></td>
<td class="nump">22.73<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (usd per share) | $ / shares</a></td>
<td class="nump">61.97<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending balance (usd per share) | $ / shares</a></td>
<td class="nump">40.24<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueExpectedToVest', window );">Expected to vest (usd per share) | $ / shares</a></td>
<td class="nump">$ 40.24<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dnli_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueExpectedToVest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award equity instruments other than options nonvested weighted average grant date fair value expected to vest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dnli_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueExpectedToVest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dnli_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dnli_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award equity instruments other than options vested and expected to vest outstanding number.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dnli_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dnli_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140237887975864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Awards - Summary of Stock-Based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total</a></td>
<td class="nump">$ 21,028<span></span>
</td>
<td class="nump">$ 10,785<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total</a></td>
<td class="nump">12,314<span></span>
</td>
<td class="nump">6,054<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total</a></td>
<td class="nump">$ 8,714<span></span>
</td>
<td class="nump">$ 4,731<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140237889796168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Schedule of Dilutive Securities Not Included in Diluted Per Share Calculations (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total (in shares)</a></td>
<td class="nump">17,022,363<span></span>
</td>
<td class="nump">16,168,362<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=dnli_EmployeeAndNonEmployeeStockOptionMember', window );">Options issued and outstanding and ESPP shares issuable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total (in shares)</a></td>
<td class="nump">14,323,256<span></span>
</td>
<td class="nump">14,530,378<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=dnli_RestrictedSharesSubjectToFutureVestingMember', window );">Restricted shares subject to future vesting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total (in shares)</a></td>
<td class="nump">2,699,107<span></span>
</td>
<td class="nump">1,637,984<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=dnli_EmployeeAndNonEmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=dnli_EmployeeAndNonEmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=dnli_RestrictedSharesSubjectToFutureVestingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=dnli_RestrictedSharesSubjectToFutureVestingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>59
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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M:W-H965T<R]S:&5E=#@N>&ULE5AM4]LX$/XKFESGIIUI&DE^B<T!,Y!>I_U
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M"_-='C[SUJ'(VLMDH>O_Z-#(+N,9RO;:R+)5!@2EJ)I?]M &XD@![+@5:*M
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M57,3V3P8N:LO\];2&%G6PRUGT$ZL +S?2&F>'NP"W7WP^?]02P,$%     @
MZ$.E4B 4_TK@&P  ;%<  !@   !X;"]W;W)K<VAE971S+W-H965T.2YX;6R]
M7&F3VSB2_2N,VHT=.T(EEZN/Z>DKHNRV=WJV#Z^K/;,1&_L!(B$);8I0$V25
MU;]^\V4F#DI4V9Z9F"]VB0>02.3Q\@"_OO?]V["U=JC>[=HN?'.Q'8;]ET^>
MA'IK=R8L_=YV=&?M^YT9Z&>_>1+VO34-O[1KGUQ?77W^9&=<=_'MUWSM5?_M
MUWX<6M?95WT5QMW.](=GMO7WWUP\O8@77KO-=L"%)]]^O3<;>VN'-_M7/?UZ
MDD9IW,YVP?FNZNWZFXN;IU\^^Q3/\P-_=?8^%']76,G*^[?X\7WSS<45"+*M
MK0>,8.B_._O<MBT&(C)^TS$OTI1XL?P[COZ2UTYK69E@G_OV;ZX9MM]<?'%1
M-79MQG9X[>__;'4]GV&\VK>!_ZWNY=E/KB^J>@R#W^G+1,'.=?*_>:=\*%[X
MXNK,"]?ZPC73+1,QE=^9P7S[=>_OJQY/TVCX@Y?*;Q-QKL.FW X]W77TWO#M
MK=MT;NUJTPW535W[L1M<MZE>^=;5SH:OGPPT"1Y]4NN SV3 ZS,#?E+]Z+MA
M&ZH776.;Z?M/B+A$X76D\-GU@P/^:/IE]<G3175]=?WT@?$^22O^A,?[Y,QX
M,ZNL_O=F%8:>).3_'IC@TS3!ISS!I_\\EOY# U8_]QO3N=^-B'G75-_94/=N
MS[_]NGHV!AHQ!+K>F=95OVQM;_9V'%P=JN^[>ED]NI!;%Y7OJV%KJ__XMR^N
MKZ^^>NYW>],=^-?3KQY7+E2F6CF_WQK2B)J',&U5RV.+RG6U[_>^-X-MZ =-
MV)I[T]L%#6J&JG&A]G>V#TQE8^_()NP#)LST#!Y*9>GISHZ];^S&=G0;NHOW
M+6E@6&()E1('HK9DCGX;33_87B:^)?NSK6Y-5[WL35=CWD7UG%9(9JQS9ED]
M,X'>(^:\ZFVPW2#,P["FUN6 QV-GQL9A-;4G>>Z"_!6(]0TO<NTZC$],"#2&
M)7,U$#F&B%U9VU5D*/=&:<+ ?4-/6])QHL[DK=SWQ#FW;VDS9;EM>\!]NU=&
M8D_>=$S(+>9ATF]VMB?^5X]TM]XL;Y?5?][<O$K[1:NEMXDK;E=0ZCHQYE%<
M,+CK2 %&MI2\!S!YU=.KR__F)VYZVIO6T@7,>_OB>?7:;L96AKB]_)_W3\1;
M%NS?R5#0T'DL.VS]V#;$W HN"*RAMW\=.['QS%<LIYCD@X>&&%I:.KTSD#?+
MC+_INI%>>FU)LH>*IHG,^2]>-QXY6--7%A:/9+ZVNY7MH\VZ6E0FT-PMW4OT
MW=IZ[-T [04!+][56]-M6*9W+K#'PSQVU9-4'ZKKS\7\58_P\@5&?8"JB\=1
M02*'GY=L>&9:%L);=OJ&1>F$Z.J>;C2TGW=@7.]W$[8:F?L#N,NC8XF14WL:
MT[/,=<*P9?7<]F#XB5RNO1^P-6PW6A_&'KMTV,/FD'Z0RK1CD[=)[<$?PH>3
MEQ4U2R/1Z7=N&$#9/\D>$-  "JF([,HTOY)7E^LPBHM(OM^[3@WVSG0$B/ ,
MR4YOR1+69+XA"."BJ=;&]7E\O($!B#L$14+\&=51&!Y@BF#HL*P;HB.,]79"
M#";"7I$VT":T-!R):(]%=V8@UE?V'>Q1VDA'3*EE.M/X/=NQCE!88=:(Q*XQ
M?1-HD9 "\A#8RC& ;2L PF@63FU'7 VOWP^)!XYWOB$98)= L\<G[;L],=EF
M45N/M,XU34C#L8+2=68@.8TPKH+];03[IHQ:5M^-O&J,,&Q[:ZN= !I1;X(C
MQ+B(1Q:1*]"6Z=+BO@;%GX,;8 (N7M-"NH%6<0.NT972I?>^H[]KV?L+,4G5
MO64>D%B 4 @V&PNVTU/!#P52*/:!E:G@+"P&NYV((%3!?;!15K-:O<?8+/$G
ML;H'K1,59F/7VPT)P!&E\$]/__A5J-Z#;!85N40C1-'@-,A/, ?$]8OWO7EQ
M;LJ)*7R9F'*;M?78KKR7 :^R]R9QS!,HHOB[O9X2(I97UIBT.X(?;*VCR_=;
M3S;QTM_#;T&X7>/(8(BNLX2K%:,8ALV_.!X"O5TPZO:S-;2MHU@CHKBZ7)'L
M]QP)>=:%JI]X90@L61+;U0>:(L@,C262=NQE::/(G3-X:6@1IB=\1S&$'6#P
M#"F4>NG6F95KQ6D2#WU!(0D=A5]=G@=6HR<V&C@-\E>#:O<E*3%45KPM<"I-
M]I/O+G?_T(3LQT^FW#H*WWI&R#K3RV,Z"_Y7&_*!.K$G(H(:-H@UZV<:G(V^
M3%=[4H/?A2;>91L&'L*K.M*N$_JFM64O.0L*"ODG"?MYSY#;*SW8Z=YN$8J3
MA/Q U"VK-X&-[XLPN!T#4OA*@;LF!AYGI!H"!3/AAH,8B01<:46_C:X7,)8$
M;(#I>VNK6G&"C7,NJE_'9I-Q'.W=N-LKAD7 8=9K^%WQCM!<;,PN*=*9O>;@
M)$$./ A(2/O ?#_SCLP"9D85_0A59XAX;P$/PEEJX=\ZR$63'51AR]5[W=3#
M6+C/FN%RX]8PH(69+WB(I3 :D*<L&X<ZPNSD=)(]?3^H%/9\M$C1@'"-67Z>
MDR*YH7KMPEM^Z6<6:OR40=YT*A*\!2^+N /!3,98Y.@&^N$8-I*9^C4*12%A
MI>NL2T*8^EHHZ4$)=I,T&T';3O ('C!AN^!_*XCPG6EE7^F)MV185BT#@1+S
MDP;<PS6>V*YDGB!U2$H0:V[)MA*8TB4 1T[]0')O3 &&/R:%#49#XA+<D.-1
MEBW6P?6$>VX8"S7*>!30QE'<GN#BUFVVD3L4@9,V'$ MI$GF4K<"DNY=VZHJ
MC18\!W:"1MA&0UZ:FHTGW,]P%.8CPSBPB<2@O+P81O/T$]6:K(%- P??I"@M
M>2>6=G)/C2PC281'ALT!_!;[/:$B\=EUQ 1&SH*B#DIS<8/Q6;19%+8(/"BD
M@ *]$6CQ(.$]C. &Z9%.D#]&([:K=X&3+1?%:\^376YZ0U ATFU@$^2M?6MJ
M<28#^2*5Z YZ74KC1.29)")89@65_4G*A:R1#^*]2^50+T,B(H&)B2G2N,PS
M>T3P!;N3]O94EYB8\^HD9 8)G^8>4OMEW\$4L.OL ?+\@VYQ:M;(NO($TQA
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M6SNN,4"7>S%)S_F9%^](!A@M_+RF+<-- ?]AUK[Y'-1!D:>![HI+;"GO/_;
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M/+V.&IB2>-HY>ESJG11@%P7%J:48X_M]E.V<_9M3)X9ZY0ZR+3U9$7<[H+
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M(#AD3UB:^-XHB?$U]O'O(-T(D^'HCC9V_&JZ[CHS]+T@'+' 9\[KX<].$HW
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MZ@\-#SV!H\D.@5DC,(MVUXJBE1<ZZ--C[S;*RVJ@R4MT-4K#.&,E*%?!8]9
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MM5S<$N\<O7'<54P9,B'L3*)@'%>$G X(7A1!Z%P4A!(_69?@PB""T+83_!9
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MY QD!]3-^E*%8:DKM@ZK6;96H%VI-#W@>CM]M \WGKMG5W<.?^B+DO!A_^G
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ML)_W;2T!/$ECR^D([FYH;9_2#E;PVD<$#7?<X#N-0)0'(;'K_]N*BM$@&"M
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M69*]>T.PDVO-O$>9WTV>B \7LLS&7H(E,D'\X[Y@?J&E9/Z8HT^Z&L0;=M-
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MF$Y&)\>#M@5O)M'5Z>FS<!$/J30L\7)E+QOP?>E<W$S$0?\6OO@74$L#!!0
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M04E(T"R(KL!G#>H(?B>)MC!,%2C ZX0&RHG<NMIB@Q(; ,)OC72@YT%.7 ,
M-N(:--\Y";Y\;L4A73WZOK\S\GK173LZHHL=H"(GHB2;NJGI#UTZN /[IB>+
M;#*;8'\5Y-(HA#3>@DD",_ @Q;+1IB#N'^8H$Y?2:,A2:=ER]R-PY)-3I?;*
MCX[&XF<L/L6QV$C8 (JHV%D::02VE<*N\+<2MTKBS,K9DO5NU!H;<I@/ME)\
MOH"@F=AM=+X1.]"ZJ)TV@AU^>DXO0(6.)E%H$\'O+1O#YGD#!>6W8P&4 LCE
MMF%G$'4#VT"*K+V9V+YW,U,K%+$,'RM(JTM(UZR!/"T3BSYW1(K/R="N]MTI
M$@-U)K216R7L,DBFS!H"O-DM_(8.U8Z<*]Q&'7<D6)T5_(XQ&U34#?18]&1@
M]9+H4N"\ML50U\M;L=9;4@ ?@>\8ZPJQ<SK0ILH&G2L^@M<I.?!%RL$K%+]H
M[X>4=&D0%600)4-;!E,$HH//CG:#W;!39KO? !."/]#D.VYJ[3@0NUN?]*>]
MD$/%](VT 5]AH\D/*K6#1Y'BB2/XA;<58N%6Y-"MU$D$A1#(%4L5Z<+'\7H?
MV:Q6HK,83UM5XBC@%S;N\/<9X0"K;G6A&"&B/L +I4V.4@ ,N:<7RN?21&!)
M#I'BIC/UF(!+%H4FKK.OJZZ]NX!GP-02*[JDM>CNTJ  0:0H<3CZ^?T%H 9W
M-369Z6!V.CY'=C6&+]J[^ZHQ8+\)VN@OJLCH1'QY<#(^Z0X@8QM#8>-4+771
MV3VYGHX!3)!)!#J!8+9./Z0:TBTLRD8%K+(8/NIA8TTQ%,5[U4(_Q<IJA8_I
M6E;*3Q]_B;N$K=H014*NO.)DX:W1%,6%> LKD$JNJ8#P=",X'!J=K[E2 (TE
M#-6N3H;.":ZE\83<OS7:Q?"OD7%B*'4I!)% +$3?H%=]L,U0%^)6PAAYHZ)P
MND(J)OXZFQ"Z!SAYB-K92J<9^*/0N)%SXA@25*@H65==6!?BUZ98\Q)%15V;
MVPXD6JYC/H7\%]>78G$RRRAD3%-TV[H(C+$L.04!GO'*I6CK\H#G)XZ_ECF2
MIY/[*2^.?EY0>D*D"$ZNC8\J31C >TH<;"+;@[ 1!DJ!QQ*T7D3(AO,8G>N6
MW'-@J$.4SY7=57>*!A]T&4T@SL>3OPZ9[8=/F<SPM[\L9M.S;WTZW#'1$DWO
MH?(H$L)C:1WJ+%(_$8;'V?UQENK1O5GO:K*$!RR06]JE5V[++E.H91"W6IF"
M;9X3'X[?H#GYS 4$ZK^&G2(C:P/B#?U=(H%N: ^6-%"X^KHR&;!+Q,.2F"XT
MBAN]32I@FR0+M?1: /S9DG!WJ[#<>F)J[YXI$,C+_,:Z\ VCZ6#[#BH U(T7
M";AH-Q9>I(7.0</&J2Z=H4@D,'H % @',D2/KQ7W5@8.=RG]1C ,<HINX3YR
MJA(6WG'=H=OJ'D(\CY'!TH0H0JK3NV+.]@C?YSEC5^US6,'Z.<G!<:>KGOZY
MB8PLZJKOP'_WCT'L=<"?A"VLGW?(1#XBZ,I26F*(80,2^*,X-2H&;E-UP44E
M%)U=T=FDGPKED5B1,[4IFTJEZ#.M<Z4T'S>T6>*N1_5UG_*/?G[J>#AS'#(%
MVWBPY8]>BG^#A=@9]A/*RW9SK\8Z$@?B+%N<GM*KF9A.LK/YE)[G8CK-)HLY
M/9_0\\G)&3V?TO,"2] I\L,*WB^ X+/321M" T4.TX4X/\VFYQ/*1)X<<BM-
M@T@J?D4-S!YZ.#O+YN>+(^2K\*3F#L2+L^SL?$9UR\<\6)+O:TT7TMZRS1!K
MIV)('(ZNN\6+;C&V1OO--<J!&\9"%!#S%]EB?OIP(P2S^%KFA#S<1?63;O3!
M^Y>U74U7D?4<++4R]UL)RIRQ>9G%[H6]<5 0]M7 C5ZN=%<W_Y$ZL5^+<"%2
M4_%#(>1LL]Y0JP!,[)7@]XN2)^N/!RN6+I;8)KCNJU5*,A[ QI8)W>\L]W$]
MZ@*<W*=!H([WNEPVSJLV31&2'4SVM2SSO;1A\SM1_6%L0ODAM8G M&H"34GN
MXY.N(D*AB8\*;K7T@)/]^9B!B)^<1\R89Y/X.*?'\Q<1,19G+QX"A*15]L@Z
M4"B?,RB\Q\UEI5><LZ'0]Q$3 9 H!!W:+$OJ)SF6C0<SW@^#G;)^&P*4^ONT
M6'H8ENM0L%+']$WNS;ZUA8FL SWR+G[HKH![NU I7K(2+4;)>O'4H( Z/Q$I
MR[4I;29THFJERWQ$OZM9@2&!CR2_V[>X1I<Z</$)-BS'%#S1<SPVC"U+.#KL
M1RC#\=-9EP(*M1:X\>U4(;5GR]N^BC(DL;71-+TBO7(WA;X++@R=5$63ASNU
M8B:VVIJ]"HW<W2,).HQ4P%B4;2H.9KJ) _FHHWE9+ ^-U"75JK 0D]%0:*NS
M!SK0_J!B@.1WK-O31-1\@18#.:%-TIWR.X/%61>*0'NK&+AHP$)]9=N<#,4#
M/)(%V+Q4@J[)Z_8LL#)*<""IB$UW]5-5*DG)G"QXG!VTNM9.>-0MC2=-MG:D
M>$U"[%V-=B3&Q^)':E-*"MXX %HJ547E-K6M[F: 1T*#HE.Y^Q[%\;%I8HQ!
M*82TE>U,V,Y%AFWICO:P4)):@0:M-/,ER>\54-4(M5I12 RY2QW)LSKG['G5
MW\>8=LAQX]P63;W:T%<<X.@'2^ !;?[N0K(_#_Z.A2%ZUZH.$2^1C,^>K$&N
M%"IA6Y==ND'_W*QHG$EA D)M' ^@FV?%('%(FII-OKWZ<'W!C]-OCZ+'_V"K
M+U)<2RIF+_Z1-O)RVMEEUN(."V5B(:(K0MZN=4X>0Y@ J7]A'Z&S=/50/@X=
MM/YY@\*D;I!A"-VIK*41H23=PMR@]2M9OH8I(5"#O./T%Q(YLMYST,?98_3N
M-/08Q@X1[.]D_J"7MKB-<5]]02F:1(M^SB+0$*734+ID/^?"MJ4,^4;1W-7
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M_94!&[<V0%&\B91<VX"46XLBJ6$GSD/1AQ4YDA9><IG=I63UZSN[I&4ZL8T
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MO=P1K(]<X@#'53"8-YH<HQ/ ++1(ZJ2RG12J1Y<;)^UHYLE#SD3>".:R9>C
MG#7&9_;0"]GB<P4=-SG=*4'-S)S#7:D1GU4_4.WFY5"\[B>&KW5W!C>FH1!R
M^\RVFU]OUNMCBEP8VPJ$9!QF:1:FDZD;3K(XS&9SN$6J7)X[+SW --O?U.7
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MBZ@/=0V=1CCXQ8'G5?4:0 H_+4T?^'L*M7^94/N7)U'TC988;@I_?]K( Y=
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M<Z;5\_DT>M&/$Q>AFA<*8&&$RDA2;\RP29D7I^,OW!XR!#X&$G=3QNO_N@I
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M4(M(9YGKKK\-%DH17!U%>35$D+B!'4S4P2%Z"<+W9+:XK+[9MH9F8?GW4O[
M1L(THP(L@D&4/UC[Q,+HL?R/<\;)RN345,SHS7*Q76 3XS=>?>02)?8<%A1G
M(D6>;&_9Z1&RV;NRE"7J'$+F0^E!'\'@<J,(:T&@F'&Q6(9D&/)YYQX1=!CV
M>E7*#7,)ZA@3GT=6/PF\KC+PNCH)F*YCJO\=G14!#5IA$G8]>);TE4M?C2U:
M *%<RC1-KKIEZ[:'2A^6CXU-,_LTQ"0K+2NM*#[5_HJG4J]1/JIQ:B($_UX\
M#BON*6O*5CU:I9,GEUM6+Y^>Y/EW*7\K//N+;E80EVNT-Q_'S__HI*/"B]3J
M_7X^N:RRC?#@+%5<F.$AG-D =FC#9Q[/VHVJOOM"\_:3A287!X$V!F0)#Y\M
MEH+M\S JM \4A!XF="/V(3L5L1"P84;%_=K98;7^?]/-<)G;F"]/=QO_P"VX
MDX+U*0-'&*65K^#KN+30!_%([0>D+5NV]Y"3@?NS6-(R3IY7UPEN!9!"X "1
MF6(@$5$#E#,G :63F9>'>!++]5;:?JXE_WINE^=8+[:TOOOY?6IF9;G"A*4C
ME+FB&''.O^A;X;1T ].^A)?<&_; <)M9*&5@'KE/!-%:ROXQ&F,W3^K'8XD+
MZL4I 8Y"4V<>)^+WY@K:]R YS8F6W'$9[6_,;I!Z$"38R)4!:6<=U=4NJCLM
MD"U&/Z'NQ?X\YK*C<H=6SVW183TON90<P61F)>7C8\3':>N6VS!%%'*RAG-?
M")PX1#A@]^F%+,&35< B(524*5+27#GC4Z-46G$>5?^8!.R?>"&8(8$GPSB_
M38+&I\TY/5QR26702'L"17O4(<CA6'+,BUGN-B[I*F-$>=APM9,MI_AAM(C^
M?5VTT44L]!%*QN75P0?W1/-+5QE9&_+B9/DX\\NYRVZ4QSQDQRS>C.#'&>W6
M)MGGD&8C!_^ALW?=D5HB]TR!^YV^@Q<*MFQLO6)Y)HO2T(7$1#%4^C6(,NX0
M*%HP)-PD@^HM*@V[9$KIH#.7Q=:=<@?Y%L3EZ?L+[T+5XIW(U+'6TH?/4OT0
M:D+BS$KD%9\NN4PL:'>_AY/>JR&5Q1\48 ''?/(,](]T4A898U^3I>.K#3>O
MJN<7SV<E!>1.K\LIHX\(SR8_P26\D A(JTF[<SF<(B#;TIR_6I,S0+ M"7#!
M@,&NR6FG FJLB2\L=[HP8?QC;8@E.8E;3,3U]]PG4/8UN=0YY31ZCR"86YC>
MKH_JD>M?L2[&H3_O**T1L@;"Y.AK\P8"\+%#,#QFF>*KTC\GPU/XN1#\;A'>
M)GLF99S$E+CE/)5T\IZ0B!/'+CP.]S"J#=I4MQ0:Z%9/V)FE<83CTHG[D+B*
M#^=>Q3$E29%%=4]1(\&C93<4SGXCF0MNZP]MZ*HB[6BL.Y<K@R1S3LL-&;\V
M7$V>R1439#UFDPO^8K>FKIY=/!/FE5LXI5J1J(#N@W$OJ]))G0#'ME)4AD%U
MA=YO2%$L>G;*-!H'#5O),80>.UH3\#QG\Q=B!>R*<RS%'HI ,.0L5.C.*DA+
MSV/E<&>UO!P0JNGP#FR86$6YM#Y=KY8^%\[! ([LWQ:)SHH3L!U7??DL@Y0L
M+2))6N,KAF)T6(0Z$)?.JF%[3OZ?8Q8QD$NM_8O8+2#.:J]3HE#<5)Q/WO)%
M]N XKG'AW _$]%VLM&G&8,7E/=Z!U^[6Q%9[J?B'(@, )0H$!=MT$PO>9"E>
M*YI.=EP"B9AJ(K$,@V;[;$[14JB:S\I;(>&[D AZ $4QV<P5CXPL*9*(C0QA
MZH#!+</G<"UBI#BA2)"05JKNWZWY-I[=&"R\LK@10R1G'J)!"=FRI78A?1GU
MF!FB(E@6=0NJ[V,;=)&5C3G#E"&+V$"@%29+W:2"8&%9#BC:;[1$AZFW<1KZ
MWVP6I$;A!I 3W)J.DON=)O,F['_H&[_<28+5KY634CSG2'+188R /\&\B+4(
M0-?%LA*PU1)PG:\(UDZ'0O51N8ZIA7%"8%Y]?PA(2UL6CH>+NG+FB?$)=8^[
M[I=#NS1M*]@E1P$^-,CHH"72\YG[8<HI@H/U8^-1D97<^J^J1^9Q"C_K$<X\
M(8DF.GUI-'Y!L] T!VBU@%$?D^M I#1%%=L\+ <D3-88])?5?4F-ON^S,RV(
M(^K*JR/AD?+N"2>WR_)#U!IZR C.N24AY/S?2)DP_^WCU#"2^7<P>XP]C^TU
M 9MX+:#A\D2X?%O#DD,.']%JI5,LI(DMR"-4;_SCD0R(-L'0L<1,4S"OKD>Y
M3K9^QI;JF&\\R((E';4S?$GA0+WB2>PE[28#W4],<WP?KQ.V_//T?B8L7.3#
MJ >D@]3T=QI(.^05>N#46"\JS+WIIM*"(\85BARYE+A8'LE:W0I.(%5./7@H
MIG!.X9$-P@ZC'O,,P6JGIUE:<(\@!.%$)MI"(7]FHQ\'+Z/-MC]^)OM-'3&A
M_;"#B)L2=K-M#^W[D[OKLY,X=$Y'3V7V*<<B^T&RKI,VZ6*;9>*8TW YOP5W
MP:J11L@E@>1A:<9BNA0ICTVM1#:AE'IHZ)(--*$3;7(EJ?;$C* /SC=9.YE6
M2DIAWN#N8^I#'=?OL1DNB&/OC4P$,;;(1G+/Q3'M6H9ZJ]FDZTFG37'.]L2]
MSO(LW%(I%]=0N(U$Y()+J-3)!@Y\4/4HU @6NE:<#DZSUFK+LQ U"RV=B+),
M(RWB^\_+SU(#/+6=QYSY,1/>LF1LRO&@#]F$RZSIK,/9)P:R?LR/-.?U9:@Q
MVOPHGS#I?$*@<N"30N4X(Y,]I&@#[CVBY8M0ZVZG4&/$JN+!COI_ 8))SWXY
ML B?J#<0X1A"28-5R!W/LNM.W^#D2:+FU=\FO;I8&;:NBW&CQ;1K9\];B%RN
MLR<,H9NB8:5XGG:WD,Y?#I+'F1=4C7U6K.*8A@V_W.+VP!G_KL.5*1!B:S*,
M;*9EL;+]A(O:,7%Q#)3H>S(\LR.[-C[BGIPO3J8QY6XB+N6#QF7L;%\^"H62
ME\=&Y:Y^BPAU#(RJ1V<W-V_C.R72\_1=-NRX9X)&%-9K7V"L@>-UW.]Q\%#2
M[-M4&LH*NI*%2KT!S,\3 T).-SY^).>\0&TODA&9%4F6%H%$\3PE-L?%(X@1
MR[+: _T9\!VUWXO=6$/5<1NVIZ'77?"G,!Y%0'I 35)-N:418(<-MQ!5<,M1
M+>3%$7%-,^I6$5,3@J-1Y)"P*EPB,;<96\_$K S'I!!!"(D3Y!P6Y.J!)6E%
M2MWR)4NT&[:D,H&?JBX%F^1,WRHI(DTQ> B)H%$(:+KMP$#$#CW^"BFMD<"'
MEUF$92)#TNFD$E8ZCR4:@8^!DTFU18C+6(7U5G-S4ZB%X04!S,MMN"J-'&E(
MM4I"E],PMATB,X8N565O)32_AM\23W#49(Z,QT="H\ 8KS8Z-.TK;AZ8VK-
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MHZ 'LNG FXD6*]OUSH7&'MH.E_C1PJ79@.L+(?1N8@QTGT&3OP!02P,$%
M  @ Z$.E4F3*^,=$ P  9@<  !D   !X;"]W;W)K<VAE971S+W-H965T,C(N
M>&ULE55M3]LP$/XKITR:0.I(F[2E8VVE%IA@$@P!VSY,T^0FU\3"L3/;H;!?
MO[/S0L?;M'YH_'+WW'.OGFZ4OC$YHH6[0D@S"W)KRX,P-$F.!3-[JD1)-VNE
M"V9IJ[/0E!I9ZI4*$4;]_C@L&)?!?.K/+O1\JBHKN,0+#:8J"J;OERC49A8,
M@O;@DF>Y=0?A?%JR#*_0?BDO-.W"#B7E!4K#E02-ZUFP&!PLAT[>"WSEN#%;
M:W">K)2Z<9O3=!;T'2$4F%B'P.ASBX<HA ,B&K\:S* SZ12WURWZ1^\[^;)B
M!@^5^,93F\^"20 IKEDE[*7:G&#CS\CA)4H8_P^;6G9,PDEEK"H:96)0<%E_
MV5T3ARV%2?\%A:A1B#SOVI!G><0LFT^UVH!VTH3F%MY5KTWDN'1)N;*:;CGI
MV?D1:G[+7&3@(Y=,)IP).)7&ZHI";PWL7+.50+,[#2V9<TIATD O:^CH!>@8
MSI2TN8%CF6+ZMWY(-#NN4<MU&;T*>,;T'L2#'D3]:/ *7MSY'GN\^-^^;WO,
M9 HGF&9<9K!P1<,M1P-'W"1"F4HC?%^L2)P*ZL<K+(8=BZ%G,7R!Q57=#J#6
M0'6V83IU7ZHF"8>5UBB3>SB^2W(F,X1#BJ@S;.!S98TEJL3RN=2\;O,Z1U@K
M01WIG+0NPTU;\M_DJLV=I:)D\O[MFTDTV/]@2+SFMFZX)2TW;+DE'3?UP V8
M<9Y1ZI*\RYT/\1$F6*Q0MZ?]'C6Y*=&WJ;B'':E<WU(YLD)5+C%<$C-5&=(V
MNP==E)X)SGGED<GPP]DBRS1FS"*<M\ [@UU8>'"'_23J9\Q6FEL*?Z65@6@,
MPU[<'\&BU-Z-=\XMMXI@27+<Y'!!8*F!P0#>C^,MP7-U6WM^K:SSR#Z.2+S_
M8"7N348C^,1D?;6E_<@,G42]\6CRK&QGZ4F@8;@//__WYX/EZN916BAI]!H8
MWSFN;B0]),T-A?])M=B<&&VX$+!"4DV0DIU"5=* +MIPDY[U!5I77%=7>\]U
M6[@U^PK4F9_PAI2(03T&N]/N$5G4L_-!O'Z!*"74] 8$KDFUO[<_"D#74[W>
M6%7Z2;I2EN:R7^;T$*)V G2_5LJV&V>@>UKG?P!02P,$%     @ Z$.E4N&G
M"A0[ P  < <  !D   !X;"]W;W)K<VAE971S+W-H965T,C,N>&ULG55M3]LP
M$/XKIVS:0$)-FK106%NIA:'M P)1MGV8ILE)KHF%8V>V2X%?O[.39E1JT;9*
MC=_NGGONQ>?Q6NE[4R):>*R$-).@M+8^"T.3E5@QTU,U2CI9*ETQ2TM=A*;6
MR'*O5(DPCJ+CL&)<!M.QW[O1T[%:6<$EWF@PJZIB^FF.0JTG03_8;-SRHK1N
M(YR.:U;@ NV7^D;3*NQ0<EZA-%Q)T+B<!+/^V7S@Y+W 5XYK\V(.SI-4J7NW
M^)Q/@L@10H&9=0B,A@<\1R$<$-'XU6(&G4FG^'*^0;_TOI,O*3-XKL0WGMMR
M$HP"R'')5L+>JO4G;/T9.KQ,">._L&YEHP"RE;&J:I6)0<5E,[+'-@Y_HQ"W
M"K'GW1CR+"^89=.Q5FO03IK0W,2[ZK6)')<N*0NKZ923GIV2-X*E2C,?HUFA
M$2GDUL#!'4L%FL-Q:,F,$PZS%G+>0,9[(!.X4M*6!C[*'/-M_9#H=1SC#<=Y
M_"K@%=,]2/I'$$=Q_Q6\I/,Y\7C)'KQK73#)G[W+1W"NI%&"YTT$F,SA1J.A
M&#0;:@F77#*9<29@09MM?+[/4F,U%=6/5Q@-.D8#SVBPA]&BN1+.V'9";O$!
MY0IW)>%51'>7STS-,IP$M7-'/V P;=$@YX85E.J"O,DA?8)LRRC;5(&/1HW:
MWWV9(:A4\*(1X@:8@24IJC55"Y=@2[4RI&$.S^"N)(BM.@#*8E9V:72?".[8
M/>8,]A0A'/0/X2V<'$5)1&-R%/5'L&!2+?E>E5NTU(G(W,Q==VXY&GCW9A3W
MXP\P3 8P$\\E4E?1[PU<<(-TH6%!T>$9"1[$A]"'80QWRKIL[S*UB2')C8YA
MSE6!<B^;Z[K5(4/.^RU+H].XH]88W&W)1> T3GP$CJ,!_/S77Q/'8>^$&H@0
M;5'K%IUR2YE#^KN,54W&<%?&7#$P(?Y'.8(U%0N7F5BY,U\L2%4G_0T"P5G*
M!;=/U&"%+S1FO42*!9>2R\(9=1M4C%SE/=AUY\(779 27/A>;\C*2MJF(7:[
MW7,R:[KH'_'F+2+R9-B P"6I1KV380"ZZ>_-PJK:]]146>K0?EK2DXC:"=#Y
M4BF[63@#W2,[_0U02P,$%     @ Z$.E4G"QLUAT P  ,0@  !D   !X;"]W
M;W)K<VAE971S+W-H965T,C0N>&ULK59=;^LV#/TKA'$?6B"H'3MI/I $Z,<N
M-F =BJ;;, Q[4&PZUJXL99+<M/]^I)1XN5@;#-M>8DHB#P^I(RF+O;%?7(/H
MX;55VBV3QOO=/$U=V6 KW)79H::5VMA6>!K:;>IV%D45@EJ5YEEVG;9"ZF2U
M"'./=K4PG5=2XZ,%U[6ML&^WJ,Q^F0R3X\23W#:>)]+58B>VN$;_X^[1TBCM
M42K9HG;2:+!8+Y.;X?QVS/[!X2>)>W=B U>R,>8+#[ZKEDG&A%!AZ1E!T.<%
M[U I!B(:?QPPDSXE!Y[:1_3/H7:J92,<WAGULZQ\LTRF"518BT[Y)[/_%@_U
M!(*E42[\PC[ZCO,$RLYYTQZ"B4$K=?R*UT,?3@*FV0<!^2$@#[QCHL#R7GBQ
M6EBS!\O>A,9&*#5$$SFI>5/6WM*JI#B_NC-M*SUUV3L0NH([H[W46]2E1 <7
MSV*CT%TN4D^Y."(M#[BW$3?_ +> !T)J''RC*ZR^CD^)8T\T/Q*]S<\"/@A[
M!<5P 'F6#\_@%7WA1< K_E7A]]*5RKC.(OQZLW'>DGI^.Y-UU&<=A:RC#[*N
MH_;!U/"Y\PS_(+5LNQ:^1](6G+!ZK^=GP?G\SMU.E+A,Z( ZM"^8K)X;A-HH
M.GQ4'7C>3SI,I:$Z:6?!TW*G*RK7=-IC!:5P#=3D[BC,AG6-KQYJ.CSPAL+&
M=GGCA>(RV,$B'W_&CP[>A&FZ.:S@IH(*Q2DI-E))SPUF"I:4 5('7VI_14<=
MPT8XHV0EF,VM4$*7".MP00G'&4D)9=-+ 2X"@ND<T7*7<_B%*$35P3V6V&[0
MDO/\X$PL$=H@S4OX!)/!=#SFI1R&V6!2#-DN8#@<9-."[1';H]&$[3';4YJB
MGM(%6'M"'N6#?)S!<VC'5XV,->_$6]38;#P8SC)XY(W1'EZ$ZA!$]3L=<7:
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M")@[BD?NB"5P D'BA0%\H@00' 1N$HY</PH@C;V8]; YG(5A1!^C<P@"+V)
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M6?E@(<>."= M&:#;]J;3%#NKTDP 7TDHOA+ 5X+CRZ?23&PZ.2M-1QQ6:2:
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MO'W35JO-MW8?JK:M%IN7<Y7K*J0+T']_JJIV_Z;[(O#AF]^W_P%02P,$%
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MR-]7G(M?7ZIWT=IW#Z?_ U!+ P04    " #H0Z52*><2S\$"  !<!P  &0
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M9'2?"I]3Z XD2LD40-9Q%]"B;/W*@>*SHK>YYPHZI>(Q@7:9"!T [Z><J\5
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MB4AC /-S(?2F8Q8H7U^C?U!+ P04    " #H0Z52=226L34(  "++@  &0
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MS_ HL$9!@7[_%42C7R3)Q!\6Q?Q*,5\K%G39NU@(X [) *(%P3Q>:842\@2
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MGX.GN,#\!7Z2FGWDBB"R6!!]K+KS+6XO[$J;[.KYCE[;YNY:C_\_)JG6Q!V
M8#;M#6<%!\99@>&L8"AG[0FZ@B:I=26Z(;7 3FI%G$#'A8Y37HM303 (LAOB
M";4=98G.79J1,NF;B5W;+VWVM5IE5W""7@CFUF0Q/!?8SQ&&&MN,%XHYA=\H
M[HG0='"$# ,&_XH!<P9H0OGVO+ * "+?2;R1)/E'F=;R,M5QNF9(,K23I'*P
MWI.?UF_OAX6&V,(#([;0$%MH)[:K)9B\U#NE< &$B,<47BQ?'P8WFQ8#FF<?
MPF;SS)M8FV>A(<30SCA#VSV#]&QVR7Q[DRPT;!;:V:R__3-(PY:SZ#.[)VO'
MS/;&6?\^>,,9=&C8*#RP4^C0<%"XCW/HL.5X>3I]]:)>'$0/&KJKK.&0T,XA
M98@ZW3D(S0SXAP=V)AT9/(_L>/ZJN]]V72IJML5ZNOF1P?G(WA:K&5?TH$Y0
MO%*FMUV1*F75$Z)+ 8/FD1W-_^L[/5'+:XWM,D5DL#RR8_E^KO5$_9>.2N</
M'/B^96 XL5EL6"'J886JAC+G-]MSGP1VK.U"W,]1\Q2E8:)MR*[.AB>B0?>1
M^H$&'DHJ>=@FXB/A3U15>F^XS52[SG1@3!(9)HGVP22ED'J>3:+6S.T?6"@Z
MKEV:5=>T/V*^I&!@2A8PTSF=0*AY<?.Y^"#96M^CG3,I6:8?5P0GA*L!\/N"
M,;G]H*[F5O?/+_\&4$L#!!0    ( .A#I5+O#!J(0@4  *P9   9    >&PO
M=V]R:W-H965T<R]S:&5E=#,T+GAM;,U96T\;.13^*U:VNVJEEAG;N0 ;(G$+
MBU00@K+[4/7!3$Z246?&J<<)1>J/WV/'C!,R<;*E*P4)F(O/YW/S=XX]W4>I
MOI9C $V^YUE1'C7&6D\.HZA,QI"+<D].H, W0ZERH?%6C:)RHD ,K%">12R.
MVU$NTJ+1Z]IG-ZK7E5.=I07<*%).\URHIQ/(Y.-1@S:>']RFH[$V#Z)>=R)&
M< ?Z?G*C\"ZJ4 9I#D69RH(H&!XUCNGA!6\; 3OB[Q0>RX5K8DQYD/*KN;D<
M'#5BHQ%DD&@#(?#?#$XARPP2ZO'-@3:J.8W@XO4S>M\:C\8\B!).9?9/.M#C
MH\9^@PQ@**:9OI6/?X$SJ&7P$IF5]B]Y=&/C!DFFI9:Y$T8-\K28_Q??G2.V
M$6!.@+T08'2- '<"_(4 Y6L$FDZ@N>T,+2?0VE:@[03:VPITG$#'!FON71N:
M,Z%%KZOD(U%F-**9"QM?*XT120N3BG=:X=L4Y70/0YB)!ZF$38SCD0+ 1-,E
M^4#N1"&'*7E[!EJD6?FN&VF<T(A%B0,_F8.S->"47,E"CTMR7@Q@4"-_&I;G
MF^3[&^3C $"$GJK<Q9[==<*"B-=RMD=X_)ZPF.[?WYV1MV_>I<4@3:S_ZBP,
MXUT)A7C4X#'J\&I0SK='B=>C]'^)+A=AE#-(-NBRY'A>Y2FWL'QSGLZ '"LE
MBI'+5%$,R+4L/B3KAI!/>%D*RWTE^?P1H<FEAKS\$E"L62G6M(HUUV7$-'\
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ML+W[&MOA,>3KB(GE:[V0:>WN8<6'+IB>4M39TBMLZ37:<B\-Y=4'M@IB[P2
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M-[] 8U!B^5)9:/=/-LW>*"#I6AM9-F#4H.2B?K*GQA$[ #H\ (@;0/P:D!P
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M#;U$;^H$^9?<@0:FL!Y8MV7PB-=4]4Z,1JVXT7'%Z*15[,3KAX=JJ;!VD"4
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M0:KN+NN)D97KAA;28&_EABOLR$'9#?A^*:5YGE@!;8\__0]02P,$%     @
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M,C+_ )C?:)%D'ZR>A-8BRBZW4%),&@/X?2V$?KTQW\#*S[#3_P%02P,$%
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M6CMJ$?6PH)Z,QA^@_8W6[F7B^T37Y=,_4$L#!!0    ( .A#I5++NWTI> ,
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MVIUF%?5.4[/2U#RIZ1$5,ADE0'>(/LP559R%<>!$NJV*NO4Y_&]7@MH?\[^
M->O.!J'?V/%_/ZKE-1N'[>]4DCHG)7U#CI)EUGT64^5)E9;,U-P3^5Y7Y->?
MXP!\[ZT.>A\[@A)7O]V=]MX1'(AJM$-_YPS<6J'.4<YM_U(0B277136K5JL>
M.;"=86=]:'JG;0!O-$7CI5HU3[F"#&=$Z5VUZ5K(HI<5$RT6MAU,A:;F8H<)
M]7^4)H#V9T+H[<2\H/I'T?\'4$L#!!0    ( .A#I5(I*ZTN!P,  .D(   9
M    >&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;,U676_:,!3]*U:>6FEKOB"!
M"I *[;1*:X?*/AZF/9CD!KPZ-K,=Z/[]KIV04@9H4E_Z0OQQS_&Y]P3?##92
M/>HE@"%/)1=ZZ"V-65WZOLZ64%)](5<@<*>0JJ0&IVKAZY4"FCM0R?TH"!*_
MI$QXHX%;FZK10%:&,P%31715EE3]&0.7FZ$7>MN%![98&KO@CP8KNH 9F*^K
MJ<*9W[+DK 2AF11$03'TKL++21A8@(OXQF"C=\;$IC*7\M%.;O.A%UA%P"$S
MEH+B8PT3X-PRH8[?#:G7GFF!N^,M^P>7/"8SIQHFDG]GN5D.O9Y'<BAHQ<V#
MW'R$)J&NY<LDU^Z7;)K8P"-9I8TL&S J*)FHG_2I*<0. 'D. Z(&$.T#.D<
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M!A<IJE)U7ZTG1JY<:YI+@XW.#9?X+0+*!N!^(:793NP![=?-Z"]02P,$%
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MJMZ#.^^C</V>"MO_^XU^ U!+ P04    " #H0Z52EXJ[',     3 @  "P
M %]R96QS+RYR96QSG9*Y;L,P#$!_Q=">, ?0(8@S9?$6!/D!5J(/V!(%BD6=
MOZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C]$%)I6M6X 4BV)8]ISI%"KM0L'C6'
MTD!$VV-#L%HL/D N&6:WO606IW.D5XA<UYVE/=LO3T%O@*\Z3'%":4A+,P[P
MS=)_,O?S##5%Y4HCE5L:>-/E_G;@2=&A(E@6FD7)TZ(=I7\=Q_:0T^FO8R*T
M>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L#!!0    ( .A#I5*'$\9/V ,
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M4$L! A0#%     @ Z$.E4@=!36*!    L0   !               ( !
M &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " #H0Z52V[3L?NT    K @
M$0              @ &O    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4
M" #H0Z52F5R<(Q &  "<)P  $P              @ '+ 0  >&PO=&AE;64O
M=&AE;64Q+GAM;%!+ 0(4 Q0    ( .A#I5(\X1C[3@4  ),5   8
M      " @0P(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4
M" #H0Z52+^BZ!+\&  !$'   &               @(&0#0  >&PO=V]R:W-H
M965T<R]S:&5E=#(N>&UL4$L! A0#%     @ Z$.E4M.A2:[; @  Z0D  !@
M             ("!A10  'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4
M Q0    ( .A#I5)P/@B6504  !T4   8              " @987  !X;"]W
M;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4    " #H0Z52YMU7UG8"  !?
M!0  &               @($A'0  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL
M4$L! A0#%     @ Z$.E4AG\.G*:!0  OQ@  !@              ("!S1\
M 'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    ( .A#I5+0!8ZO
M'0(  'D$   8              " @9TE  !X;"]W;W)K<VAE971S+W-H965T
M-RYX;6Q02P$"% ,4    " #H0Z528HMBY]X%   ;%@  &
M@('P)P  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @ Z$.E
M4B 4_TK@&P  ;%<  !@              ("!!"X  'AL+W=O<FMS:&5E=',O
M<VAE970Y+GAM;%!+ 0(4 Q0    ( .A#I5*J_-2NQP0  #$-   9
M      " @1I*  !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%
M  @ Z$.E4BQ)*@UG!@  KQ(  !D              ("!&$\  'AL+W=O<FMS
M:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4    " #H0Z52_)@U:%$%  #+#@
M&0              @(&V50  >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+
M 0(4 Q0    ( .A#I5+XH*G1$2$  (^!   9              " @3Y;  !X
M;"]W;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#%     @ Z$.E4KIF, 7*
M!   %PL  !D              ("!AGP  'AL+W=O<FMS:&5E=',O<VAE970Q
M-"YX;6Q02P$"% ,4    " #H0Z52!S%:=L ,  "7(@  &0
M@(&'@0  >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( .A#
MI5)6;RP*/P4  ',+   9              " @7Z.  !X;"]W;W)K<VAE971S
M+W-H965T,38N>&UL4$L! A0#%     @ Z$.E4C4%SNLC P  R 8  !D
M         ("!]),  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4
M    " #H0Z52; Z@NF0"  !5!0  &0              @(%.EP  >&PO=V]R
M:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( .A#I5(>DVJZ2AL  $M9
M   9              " @>F9  !X;"]W;W)K<VAE971S+W-H965T,3DN>&UL
M4$L! A0#%     @ Z$.E4N-=A6S< P  +@L  !D              ("!:K4
M 'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"% ,4    " #H0Z52E*U3
M%W<$   2#0  &0              @(%]N0  >&PO=V]R:W-H965T<R]S:&5E
M=#(Q+GAM;%!+ 0(4 Q0    ( .A#I5)DROC'1 ,  &8'   9
M  " @2N^  !X;"]W;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#%     @
MZ$.E4N&G"A0[ P  < <  !D              ("!IL$  'AL+W=O<FMS:&5E
M=',O<VAE970R,RYX;6Q02P$"% ,4    " #H0Z52<+&S6'0#   Q"   &0
M            @($8Q0  >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4
M Q0    ( .A#I5*FGOD2#04  %$,   9              " @</(  !X;"]W
M;W)K<VAE971S+W-H965T,C4N>&UL4$L! A0#%     @ Z$.E4A3#.1K@ @
M_P4  !D              ("!!\X  'AL+W=O<FMS:&5E=',O<VAE970R-BYX
M;6Q02P$"% ,4    " #H0Z52YQ]1]%0"  !R!0  &0              @($>
MT0  >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( .A#I5+(
MB)+YAP@   4^   9              " @:G3  !X;"]W;W)K<VAE971S+W-H
M965T,C@N>&UL4$L! A0#%     @ Z$.E4L>7)O>[!@  AR@  !D
M     ("!9]P  'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( .A#I5+O#!J(0@4  *P9   9              "
M@7#U  !X;"]W;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#%     @ Z$.E
M4ODCALE& @  (04  !D              ("!Z?H  'AL+W=O<FMS:&5E=',O
M<VAE970S-2YX;6Q02P$"% ,4    " #H0Z52>)/FA44'   8)   &0
M        @(%F_0  >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0
M   ( .A#I5(GA*!A8 0  )$2   9              " @>($ 0!X;"]W;W)K
M<VAE971S+W-H965T,S<N>&UL4$L! A0#%     @ Z$.E4M:R!NV_ P  [P\
M !D              ("!>0D! 'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q0
M2P$"% ,4    " #H0Z52Q4QO5C\%  "2%0  &0              @(%O#0$
M>&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    ( .A#I5+]*TF;
MX@(  .4'   9              " @>42 0!X;"]W;W)K<VAE971S+W-H965T
M-# N>&UL4$L! A0#%     @ Z$.E4J'TO2YO @  \04  !D
M ("!_A4! 'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6Q02P$"% ,4    " #H
M0Z52R[M]*7@#  !;#   &0              @(&D& $ >&PO=V]R:W-H965T
M<R]S:&5E=#0R+GAM;%!+ 0(4 Q0    ( .A#I5*'V638!@,  *T)   9
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M;',O+G)E;'-02P$"% ,4    " #H0Z52AQ/&3]@#   W'P  #P
M    @ &\+0$ >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ Z$.E4OTLU:6N
M 0  P1L  !H              ( !P3$! 'AL+U]R96QS+W=O<FMB;V]K+GAM
M;"YR96QS4$L! A0#%     @ Z$.E4B;ZAZ>U 0  W!L  !,
M ( !IS,! %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     #8 -@"Q#@  C34!
#

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>217</ContextCount>
  <ElementCount>352</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>71</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>14</UnitCount>
  <MyReports>
    <Report instance="dnli-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.denalitherapeutics.com/role/DocumentandEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="dnli-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="dnli-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="dnli-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss</Role>
      <ShortName>Condensed Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="dnli-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossParenthetical</Role>
      <ShortName>Condensed Consolidated Statements of Operations and Comprehensive Loss (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="dnli-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - Condensed Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquity</Role>
      <ShortName>Condensed Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="dnli-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1006007 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical</Role>
      <ShortName>Condensed Consolidated Statements of Stockholders' Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="dnli-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>1007008 - Statement - Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="dnli-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.denalitherapeutics.com/role/SignificantAccountingPolicies</Role>
      <ShortName>Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="dnli-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2104102 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.denalitherapeutics.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="dnli-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2107103 - Disclosure - Marketable Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.denalitherapeutics.com/role/MarketableSecurities</Role>
      <ShortName>Marketable Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="dnli-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2111104 - Disclosure - Derivative Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.denalitherapeutics.com/role/DerivativeFinancialInstruments</Role>
      <ShortName>Derivative Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="dnli-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2115105 - Disclosure - Collaboration Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.denalitherapeutics.com/role/CollaborationAgreements</Role>
      <ShortName>Collaboration Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="dnli-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2122106 - Disclosure - License Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.denalitherapeutics.com/role/LicenseAgreements</Role>
      <ShortName>License Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="dnli-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2124107 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.denalitherapeutics.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="dnli-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2129108 - Disclosure - Stock-Based Awards</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.denalitherapeutics.com/role/StockBasedAwards</Role>
      <ShortName>Stock-Based Awards</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="dnli-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2135109 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.denalitherapeutics.com/role/NetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="dnli-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2138110 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.denalitherapeutics.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="dnli-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2202201 - Disclosure - Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.denalitherapeutics.com/role/SignificantAccountingPoliciesPolicies</Role>
      <ShortName>Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.denalitherapeutics.com/role/SignificantAccountingPolicies</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="dnli-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.denalitherapeutics.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.denalitherapeutics.com/role/FairValueMeasurements</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="dnli-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2308302 - Disclosure - Marketable Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.denalitherapeutics.com/role/MarketableSecuritiesTables</Role>
      <ShortName>Marketable Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.denalitherapeutics.com/role/MarketableSecurities</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="dnli-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2312303 - Disclosure - Derivative Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.denalitherapeutics.com/role/DerivativeFinancialInstrumentsTables</Role>
      <ShortName>Derivative Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.denalitherapeutics.com/role/DerivativeFinancialInstruments</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="dnli-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2316304 - Disclosure - Collaboration Agreements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.denalitherapeutics.com/role/CollaborationAgreementsTables</Role>
      <ShortName>Collaboration Agreements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.denalitherapeutics.com/role/CollaborationAgreements</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="dnli-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2325305 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.denalitherapeutics.com/role/CommitmentsandContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.denalitherapeutics.com/role/CommitmentsandContingencies</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="dnli-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2330306 - Disclosure - Stock-Based Awards (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.denalitherapeutics.com/role/StockBasedAwardsTables</Role>
      <ShortName>Stock-Based Awards (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.denalitherapeutics.com/role/StockBasedAwards</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="dnli-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2336307 - Disclosure - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.denalitherapeutics.com/role/NetLossPerShareTables</Role>
      <ShortName>Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.denalitherapeutics.com/role/NetLossPerShare</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="dnli-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2403401 - Disclosure - Significant Accounting Policies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.denalitherapeutics.com/role/SignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>Significant Accounting Policies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="dnli-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Fair Value Measurements - Schedule of Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.denalitherapeutics.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesDetails</Role>
      <ShortName>Fair Value Measurements - Schedule of Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="dnli-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2409403 - Disclosure - Marketable Securities - Summary of Available for Sale Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.denalitherapeutics.com/role/MarketableSecuritiesSummaryofAvailableforSaleSecuritiesDetails</Role>
      <ShortName>Marketable Securities - Summary of Available for Sale Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="dnli-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2410404 - Disclosure - Marketable Securities - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.denalitherapeutics.com/role/MarketableSecuritiesNarrativeDetails</Role>
      <ShortName>Marketable Securities - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="dnli-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2413405 - Disclosure - Derivative Financial Instruments - Summary of Forward Foreign Currency Exchange Contracts Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.denalitherapeutics.com/role/DerivativeFinancialInstrumentsSummaryofForwardForeignCurrencyExchangeContractsOutstandingDetails</Role>
      <ShortName>Derivative Financial Instruments - Summary of Forward Foreign Currency Exchange Contracts Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="dnli-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2414406 - Disclosure - Derivative Financial Instruments - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.denalitherapeutics.com/role/DerivativeFinancialInstrumentsNarrativeDetails</Role>
      <ShortName>Derivative Financial Instruments - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="dnli-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2417407 - Disclosure - Collaboration Agreements - Biogen (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.denalitherapeutics.com/role/CollaborationAgreementsBiogenDetails</Role>
      <ShortName>Collaboration Agreements - Biogen (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="dnli-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2418408 - Disclosure - Collaboration Agreements - Sanofi (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.denalitherapeutics.com/role/CollaborationAgreementsSanofiDetails</Role>
      <ShortName>Collaboration Agreements - Sanofi (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="dnli-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2419409 - Disclosure - Collaboration Agreements - Sanofi Performance Obligation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.denalitherapeutics.com/role/CollaborationAgreementsSanofiPerformanceObligationDetails</Role>
      <ShortName>Collaboration Agreements - Sanofi Performance Obligation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="dnli-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2420410 - Disclosure - Collaboration Agreements - Takeda (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.denalitherapeutics.com/role/CollaborationAgreementsTakedaDetails</Role>
      <ShortName>Collaboration Agreements - Takeda (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="dnli-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2421411 - Disclosure - Collaboration Agreements - Summary of Collaboration Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.denalitherapeutics.com/role/CollaborationAgreementsSummaryofCollaborationRevenueDetails</Role>
      <ShortName>Collaboration Agreements - Summary of Collaboration Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="dnli-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2423412 - Disclosure - License Agreements - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.denalitherapeutics.com/role/LicenseAgreementsNarrativeDetails</Role>
      <ShortName>License Agreements - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="dnli-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2426413 - Disclosure - Commitments and Contingencies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.denalitherapeutics.com/role/CommitmentsandContingenciesNarrativeDetails</Role>
      <ShortName>Commitments and Contingencies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="dnli-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2427414 - Disclosure - Commitments and Contingencies - Summary of Company's Future Minimum Lease Commitments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.denalitherapeutics.com/role/CommitmentsandContingenciesSummaryofCompanysFutureMinimumLeaseCommitmentsDetails</Role>
      <ShortName>Commitments and Contingencies - Summary of Company's Future Minimum Lease Commitments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="dnli-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2428415 - Disclosure - Commitments and Contingencies - Summary of Company's Future Minimum Lease Receivables (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.denalitherapeutics.com/role/CommitmentsandContingenciesSummaryofCompanysFutureMinimumLeaseReceivablesDetails</Role>
      <ShortName>Commitments and Contingencies - Summary of Company's Future Minimum Lease Receivables (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="dnli-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2431416 - Disclosure - Stock-Based Awards - Summary of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofStockOptionActivityDetails</Role>
      <ShortName>Stock-Based Awards - Summary of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="dnli-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2432417 - Disclosure - Stock-Based Awards - Summary of Assumptions Used for Estimating the Fair Value of Stock Options Granted (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofAssumptionsUsedforEstimatingtheFairValueofStockOptionsGrantedDetails</Role>
      <ShortName>Stock-Based Awards - Summary of Assumptions Used for Estimating the Fair Value of Stock Options Granted (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="dnli-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2433418 - Disclosure - Stock-Based Awards - Summary of Restricted Stock Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofRestrictedStockActivityDetails</Role>
      <ShortName>Stock-Based Awards - Summary of Restricted Stock Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="dnli-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2434419 - Disclosure - Stock-Based Awards - Summary of Stock-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofStockBasedCompensationExpenseDetails</Role>
      <ShortName>Stock-Based Awards - Summary of Stock-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="dnli-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2437420 - Disclosure - Net Loss Per Share - Schedule of Dilutive Securities Not Included in Diluted Per Share Calculations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.denalitherapeutics.com/role/NetLossPerShareScheduleofDilutiveSecuritiesNotIncludedinDilutedPerShareCalculationsDetails</Role>
      <ShortName>Net Loss Per Share - Schedule of Dilutive Securities Not Included in Diluted Per Share Calculations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="dnli-20210331.htm">dnli-20210331.htm</File>
    <File>dnli-20210331.xsd</File>
    <File>dnli-20210331_cal.xml</File>
    <File>dnli-20210331_def.xml</File>
    <File>dnli-20210331_lab.xml</File>
    <File>dnli-20210331_pre.xml</File>
    <File>ex101amendandrestoutsidedi.htm</File>
    <File>exhibit311q12021.htm</File>
    <File>exhibit312q12021.htm</File>
    <File>exhibit321q12021.htm</File>
    <File>exhibit322q12021.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/country/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>65
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "dnli-20210331.htm": {
   "axisCustom": 0,
   "axisStandard": 23,
   "contextCount": 217,
   "dts": {
    "calculationLink": {
     "local": [
      "dnli-20210331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "dnli-20210331_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "dnli-20210331.htm"
     ]
    },
    "labelLink": {
     "local": [
      "dnli-20210331_lab.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml",
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "dnli-20210331_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml",
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "dnli-20210331.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 452,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2020-01-31": 2,
    "http://www.denalitherapeutics.com/20210331": 1,
    "http://xbrl.sec.gov/dei/2020-01-31": 5,
    "total": 8
   },
   "keyCustom": 64,
   "keyStandard": 288,
   "memberCustom": 39,
   "memberStandard": 28,
   "nsprefix": "dnli",
   "nsuri": "http://www.denalitherapeutics.com/20210331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dnli-20210331.htm",
      "contextRef": "i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Document and Entity Information",
     "role": "http://www.denalitherapeutics.com/role/DocumentandEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dnli-20210331.htm",
      "contextRef": "i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dnli-20210331.htm",
      "contextRef": "i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2104102 - Disclosure - Fair Value Measurements",
     "role": "http://www.denalitherapeutics.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dnli-20210331.htm",
      "contextRef": "i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dnli-20210331.htm",
      "contextRef": "i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2107103 - Disclosure - Marketable Securities",
     "role": "http://www.denalitherapeutics.com/role/MarketableSecurities",
     "shortName": "Marketable Securities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dnli-20210331.htm",
      "contextRef": "i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dnli-20210331.htm",
      "contextRef": "i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2111104 - Disclosure - Derivative Financial Instruments",
     "role": "http://www.denalitherapeutics.com/role/DerivativeFinancialInstruments",
     "shortName": "Derivative Financial Instruments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dnli-20210331.htm",
      "contextRef": "i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dnli-20210331.htm",
      "contextRef": "i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2115105 - Disclosure - Collaboration Agreements",
     "role": "http://www.denalitherapeutics.com/role/CollaborationAgreements",
     "shortName": "Collaboration Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dnli-20210331.htm",
      "contextRef": "i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dnli-20210331.htm",
      "contextRef": "i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dnli:LicenseAgreementTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2122106 - Disclosure - License Agreements",
     "role": "http://www.denalitherapeutics.com/role/LicenseAgreements",
     "shortName": "License Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dnli-20210331.htm",
      "contextRef": "i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dnli:LicenseAgreementTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dnli-20210331.htm",
      "contextRef": "i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2124107 - Disclosure - Commitments and Contingencies",
     "role": "http://www.denalitherapeutics.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dnli-20210331.htm",
      "contextRef": "i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dnli-20210331.htm",
      "contextRef": "i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2129108 - Disclosure - Stock-Based Awards",
     "role": "http://www.denalitherapeutics.com/role/StockBasedAwards",
     "shortName": "Stock-Based Awards",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dnli-20210331.htm",
      "contextRef": "i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dnli-20210331.htm",
      "contextRef": "i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2135109 - Disclosure - Net Loss Per Share",
     "role": "http://www.denalitherapeutics.com/role/NetLossPerShare",
     "shortName": "Net Loss Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dnli-20210331.htm",
      "contextRef": "i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dnli-20210331.htm",
      "contextRef": "i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2138110 - Disclosure - Related Party Transactions",
     "role": "http://www.denalitherapeutics.com/role/RelatedPartyTransactions",
     "shortName": "Related Party Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dnli-20210331.htm",
      "contextRef": "i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dnli-20210331.htm",
      "contextRef": "i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dnli:OrganizationAndDescriptionOfBusinessPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2202201 - Disclosure - Significant Accounting Policies (Policies)",
     "role": "http://www.denalitherapeutics.com/role/SignificantAccountingPoliciesPolicies",
     "shortName": "Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dnli-20210331.htm",
      "contextRef": "i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dnli:OrganizationAndDescriptionOfBusinessPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dnli-20210331.htm",
      "contextRef": "i9953f50a7fd74f7d8438f304f136a07b_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - Condensed Consolidated Balance Sheets",
     "role": "http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dnli-20210331.htm",
      "contextRef": "i9953f50a7fd74f7d8438f304f136a07b_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dnli-20210331.htm",
      "contextRef": "i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2305301 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://www.denalitherapeutics.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dnli-20210331.htm",
      "contextRef": "i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dnli-20210331.htm",
      "contextRef": "i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2308302 - Disclosure - Marketable Securities (Tables)",
     "role": "http://www.denalitherapeutics.com/role/MarketableSecuritiesTables",
     "shortName": "Marketable Securities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dnli-20210331.htm",
      "contextRef": "i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dnli-20210331.htm",
      "contextRef": "i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2312303 - Disclosure - Derivative Financial Instruments (Tables)",
     "role": "http://www.denalitherapeutics.com/role/DerivativeFinancialInstrumentsTables",
     "shortName": "Derivative Financial Instruments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dnli-20210331.htm",
      "contextRef": "i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dnli-20210331.htm",
      "contextRef": "i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2316304 - Disclosure - Collaboration Agreements (Tables)",
     "role": "http://www.denalitherapeutics.com/role/CollaborationAgreementsTables",
     "shortName": "Collaboration Agreements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dnli-20210331.htm",
      "contextRef": "i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dnli-20210331.htm",
      "contextRef": "i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2325305 - Disclosure - Commitments and Contingencies (Tables)",
     "role": "http://www.denalitherapeutics.com/role/CommitmentsandContingenciesTables",
     "shortName": "Commitments and Contingencies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dnli-20210331.htm",
      "contextRef": "i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dnli-20210331.htm",
      "contextRef": "i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2330306 - Disclosure - Stock-Based Awards (Tables)",
     "role": "http://www.denalitherapeutics.com/role/StockBasedAwardsTables",
     "shortName": "Stock-Based Awards (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dnli-20210331.htm",
      "contextRef": "i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dnli-20210331.htm",
      "contextRef": "i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2336307 - Disclosure - Net Loss Per Share (Tables)",
     "role": "http://www.denalitherapeutics.com/role/NetLossPerShareTables",
     "shortName": "Net Loss Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dnli-20210331.htm",
      "contextRef": "i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dnli-20210331.htm",
      "contextRef": "i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2403401 - Disclosure - Significant Accounting Policies - Narrative (Details)",
     "role": "http://www.denalitherapeutics.com/role/SignificantAccountingPoliciesNarrativeDetails",
     "shortName": "Significant Accounting Policies - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dnli-20210331.htm",
      "contextRef": "i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dnli-20210331.htm",
      "contextRef": "i9953f50a7fd74f7d8438f304f136a07b_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - Fair Value Measurements - Schedule of Assets and Liabilities (Details)",
     "role": "http://www.denalitherapeutics.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesDetails",
     "shortName": "Fair Value Measurements - Schedule of Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dnli-20210331.htm",
      "contextRef": "i9953f50a7fd74f7d8438f304f136a07b_I20210331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dnli-20210331.htm",
      "contextRef": "i9953f50a7fd74f7d8438f304f136a07b_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409403 - Disclosure - Marketable Securities - Summary of Available for Sale Securities (Details)",
     "role": "http://www.denalitherapeutics.com/role/MarketableSecuritiesSummaryofAvailableforSaleSecuritiesDetails",
     "shortName": "Marketable Securities - Summary of Available for Sale Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dnli-20210331.htm",
      "contextRef": "i9953f50a7fd74f7d8438f304f136a07b_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dnli-20210331.htm",
      "contextRef": "i9953f50a7fd74f7d8438f304f136a07b_I20210331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)",
     "role": "http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
     "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dnli-20210331.htm",
      "contextRef": "i9953f50a7fd74f7d8438f304f136a07b_I20210331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dnli-20210331.htm",
      "contextRef": "i9953f50a7fd74f7d8438f304f136a07b_I20210331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410404 - Disclosure - Marketable Securities - Narrative (Details)",
     "role": "http://www.denalitherapeutics.com/role/MarketableSecuritiesNarrativeDetails",
     "shortName": "Marketable Securities - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dnli-20210331.htm",
      "contextRef": "i9953f50a7fd74f7d8438f304f136a07b_I20210331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dnli-20210331.htm",
      "contextRef": "i5e5ef3c57c01481ab32c18cba94f5fe4_I20210331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeNumberOfInstrumentsHeld",
      "reportCount": 1,
      "unitRef": "derivative_instrument",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413405 - Disclosure - Derivative Financial Instruments - Summary of Forward Foreign Currency Exchange Contracts Outstanding (Details)",
     "role": "http://www.denalitherapeutics.com/role/DerivativeFinancialInstrumentsSummaryofForwardForeignCurrencyExchangeContractsOutstandingDetails",
     "shortName": "Derivative Financial Instruments - Summary of Forward Foreign Currency Exchange Contracts Outstanding (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dnli-20210331.htm",
      "contextRef": "i5e5ef3c57c01481ab32c18cba94f5fe4_I20210331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DerivativeNotionalAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "eur",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dnli-20210331.htm",
      "contextRef": "i9953f50a7fd74f7d8438f304f136a07b_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeLiabilities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414406 - Disclosure - Derivative Financial Instruments - Narrative (Details)",
     "role": "http://www.denalitherapeutics.com/role/DerivativeFinancialInstrumentsNarrativeDetails",
     "shortName": "Derivative Financial Instruments - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dnli-20210331.htm",
      "contextRef": "i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:DerivativeGainLossOnDerivativeNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "link:footnote",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dnli-20210331.htm",
      "contextRef": "i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "dnli:ResearchAndDevelopmentExpenseOffsetFromRelatedPartyCostReimbursement",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417407 - Disclosure - Collaboration Agreements - Biogen (Details)",
     "role": "http://www.denalitherapeutics.com/role/CollaborationAgreementsBiogenDetails",
     "shortName": "Collaboration Agreements - Biogen (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dnli-20210331.htm",
      "contextRef": "i8a30e11a54f94b2ebb02e2da6fe5446f_I20200805",
      "decimals": "INF",
      "lang": "en-US",
      "name": "dnli:CollaborativeAgreementFundedPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dnli-20210331.htm",
      "contextRef": "i32ecdc0092f641bd9100243e5a27d217_I20181130",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "dnli:NumberOfIndications",
      "reportCount": 1,
      "unique": true,
      "unitRef": "indication",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418408 - Disclosure - Collaboration Agreements - Sanofi (Details)",
     "role": "http://www.denalitherapeutics.com/role/CollaborationAgreementsSanofiDetails",
     "shortName": "Collaboration Agreements - Sanofi (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dnli-20210331.htm",
      "contextRef": "i32ecdc0092f641bd9100243e5a27d217_I20181130",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "dnli:NumberOfIndications",
      "reportCount": 1,
      "unique": true,
      "unitRef": "indication",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:RevenueRemainingPerformanceObligation",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dnli-20210331.htm",
      "contextRef": "i261cc6d074024d72a8c693a4ea9e24fa_I20210331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueRemainingPerformanceObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419409 - Disclosure - Collaboration Agreements - Sanofi Performance Obligation (Details)",
     "role": "http://www.denalitherapeutics.com/role/CollaborationAgreementsSanofiPerformanceObligationDetails",
     "shortName": "Collaboration Agreements - Sanofi Performance Obligation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:RevenueRemainingPerformanceObligation",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dnli-20210331.htm",
      "contextRef": "i261cc6d074024d72a8c693a4ea9e24fa_I20210331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueRemainingPerformanceObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dnli-20210331.htm",
      "contextRef": "i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420410 - Disclosure - Collaboration Agreements - Takeda (Details)",
     "role": "http://www.denalitherapeutics.com/role/CollaborationAgreementsTakedaDetails",
     "shortName": "Collaboration Agreements - Takeda (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dnli-20210331.htm",
      "contextRef": "iaf62192d651f44fa9a8f0990d46c3286_D20180223-20180223",
      "decimals": "-5",
      "lang": "en-US",
      "name": "dnli:UpfrontPayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dnli-20210331.htm",
      "contextRef": "i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421411 - Disclosure - Collaboration Agreements - Summary of Collaboration Revenue (Details)",
     "role": "http://www.denalitherapeutics.com/role/CollaborationAgreementsSummaryofCollaborationRevenueDetails",
     "shortName": "Collaboration Agreements - Summary of Collaboration Revenue (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dnli-20210331.htm",
      "contextRef": "i643ec7e1d2a3451c9d8905efbcdbf48c_D20210101-20210331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dnli-20210331.htm",
      "contextRef": "id8ddb142f82e43fa84f4fd4d9e8cbf3d_I20201005",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "dnli:LicenseAgreementMilestonePaymentObligationResponsibilityPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423412 - Disclosure - License Agreements - Narrative (Details)",
     "role": "http://www.denalitherapeutics.com/role/LicenseAgreementsNarrativeDetails",
     "shortName": "License Agreements - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dnli-20210331.htm",
      "contextRef": "id8ddb142f82e43fa84f4fd4d9e8cbf3d_I20201005",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "dnli:LicenseAgreementMilestonePaymentObligationResponsibilityPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dnli-20210331.htm",
      "contextRef": "i9953f50a7fd74f7d8438f304f136a07b_I20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2426413 - Disclosure - Commitments and Contingencies - Narrative (Details)",
     "role": "http://www.denalitherapeutics.com/role/CommitmentsandContingenciesNarrativeDetails",
     "shortName": "Commitments and Contingencies - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dnli-20210331.htm",
      "contextRef": "i9953f50a7fd74f7d8438f304f136a07b_I20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dnli-20210331.htm",
      "contextRef": "i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss",
     "role": "http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
     "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dnli-20210331.htm",
      "contextRef": "i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dnli-20210331.htm",
      "contextRef": "i9953f50a7fd74f7d8438f304f136a07b_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2427414 - Disclosure - Commitments and Contingencies - Summary of Company's Future Minimum Lease Commitments (Details)",
     "role": "http://www.denalitherapeutics.com/role/CommitmentsandContingenciesSummaryofCompanysFutureMinimumLeaseCommitmentsDetails",
     "shortName": "Commitments and Contingencies - Summary of Company's Future Minimum Lease Commitments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dnli-20210331.htm",
      "contextRef": "i9953f50a7fd74f7d8438f304f136a07b_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dnli-20210331.htm",
      "contextRef": "i9953f50a7fd74f7d8438f304f136a07b_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428415 - Disclosure - Commitments and Contingencies - Summary of Company's Future Minimum Lease Receivables (Details)",
     "role": "http://www.denalitherapeutics.com/role/CommitmentsandContingenciesSummaryofCompanysFutureMinimumLeaseReceivablesDetails",
     "shortName": "Commitments and Contingencies - Summary of Company's Future Minimum Lease Receivables (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dnli-20210331.htm",
      "contextRef": "i9953f50a7fd74f7d8438f304f136a07b_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dnli-20210331.htm",
      "contextRef": "idb7ca9f362da46eab3a29bbbecbda977_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2431416 - Disclosure - Stock-Based Awards - Summary of Stock Option Activity (Details)",
     "role": "http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofStockOptionActivityDetails",
     "shortName": "Stock-Based Awards - Summary of Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dnli-20210331.htm",
      "contextRef": "idb7ca9f362da46eab3a29bbbecbda977_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dnli-20210331.htm",
      "contextRef": "i84ba3b58bcce4a4c9748d2ca212f024c_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2432417 - Disclosure - Stock-Based Awards - Summary of Assumptions Used for Estimating the Fair Value of Stock Options Granted (Details)",
     "role": "http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofAssumptionsUsedforEstimatingtheFairValueofStockOptionsGrantedDetails",
     "shortName": "Stock-Based Awards - Summary of Assumptions Used for Estimating the Fair Value of Stock Options Granted (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dnli-20210331.htm",
      "contextRef": "i84ba3b58bcce4a4c9748d2ca212f024c_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dnli-20210331.htm",
      "contextRef": "id3763ebb47a74e7aa55cdc9ec33e6ba1_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2433418 - Disclosure - Stock-Based Awards - Summary of Restricted Stock Activity (Details)",
     "role": "http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofRestrictedStockActivityDetails",
     "shortName": "Stock-Based Awards - Summary of Restricted Stock Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dnli-20210331.htm",
      "contextRef": "id3763ebb47a74e7aa55cdc9ec33e6ba1_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dnli-20210331.htm",
      "contextRef": "i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434419 - Disclosure - Stock-Based Awards - Summary of Stock-Based Compensation Expense (Details)",
     "role": "http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofStockBasedCompensationExpenseDetails",
     "shortName": "Stock-Based Awards - Summary of Stock-Based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dnli-20210331.htm",
      "contextRef": "i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dnli-20210331.htm",
      "contextRef": "i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2437420 - Disclosure - Net Loss Per Share - Schedule of Dilutive Securities Not Included in Diluted Per Share Calculations (Details)",
     "role": "http://www.denalitherapeutics.com/role/NetLossPerShareScheduleofDilutiveSecuritiesNotIncludedinDilutedPerShareCalculationsDetails",
     "shortName": "Net Loss Per Share - Schedule of Dilutive Securities Not Included in Diluted Per Share Calculations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dnli-20210331.htm",
      "contextRef": "i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "link:footnote",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dnli-20210331.htm",
      "contextRef": "i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromRelatedParties",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Parenthetical)",
     "role": "http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossParenthetical",
     "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Loss (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "link:footnote",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dnli-20210331.htm",
      "contextRef": "i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromRelatedParties",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dnli-20210331.htm",
      "contextRef": "if9deb2734a184a7cbde40db4324e7d19_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - Condensed Consolidated Statements of Stockholders' Equity",
     "role": "http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
     "shortName": "Condensed Consolidated Statements of Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dnli-20210331.htm",
      "contextRef": "if9deb2734a184a7cbde40db4324e7d19_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dnli-20210331.htm",
      "contextRef": "ia63b42181ffa4fb5aa0692f27bc204e4_D20200101-20200331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006007 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Parenthetical)",
     "role": "http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical",
     "shortName": "Condensed Consolidated Statements of Stockholders' Equity (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dnli-20210331.htm",
      "contextRef": "ia63b42181ffa4fb5aa0692f27bc204e4_D20200101-20200331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dnli-20210331.htm",
      "contextRef": "i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1007008 - Statement - Condensed Consolidated Statements of Cash Flows",
     "role": "http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofCashFlows",
     "shortName": "Condensed Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dnli-20210331.htm",
      "contextRef": "i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dnli-20210331.htm",
      "contextRef": "i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Significant Accounting Policies",
     "role": "http://www.denalitherapeutics.com/role/SignificantAccountingPolicies",
     "shortName": "Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dnli-20210331.htm",
      "contextRef": "i3b486a82cc4746e8b0b491c5e7d46db6_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 71,
   "tag": {
    "country_CN": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CHINA",
        "terseLabel": "China"
       }
      }
     },
     "localname": "CN",
     "nsuri": "http://xbrl.sec.gov/country/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsBiogenDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "United States"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsBiogenDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding (shares)"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsBiogenDetails",
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsSanofiDetails",
      "http://www.denalitherapeutics.com/role/LicenseAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsBiogenDetails",
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsSanofiDetails",
      "http://www.denalitherapeutics.com/role/LicenseAgreementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r436"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dnli_AccruedClinicalCostsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Clinical Costs, Current",
        "label": "Accrued Clinical Costs, Current",
        "terseLabel": "Accrued clinical costs"
       }
      }
     },
     "localname": "AccruedClinicalCostsCurrent",
     "nsuri": "http://www.denalitherapeutics.com/20210331",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dnli_AggregateClinicalRegulatoryAndSalesMilestonePayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate Clinical Regulatory And Sales Milestone Payment",
        "label": "Aggregate Clinical Regulatory And Sales Milestone Payment",
        "terseLabel": "Milestone payments upon achievement of certain clinical, regulatory and sales milestone events"
       }
      }
     },
     "localname": "AggregateClinicalRegulatoryAndSalesMilestonePayment",
     "nsuri": "http://www.denalitherapeutics.com/20210331",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsSanofiDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dnli_AggregateCommercialMilestones": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate commercial milestones if one biologic product from each program achieves the milestone.",
        "label": "Aggregate Commercial Milestones",
        "terseLabel": "Milestone payments upon achievement of biologic product from each program"
       }
      }
     },
     "localname": "AggregateCommercialMilestones",
     "nsuri": "http://www.denalitherapeutics.com/20210331",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsTakedaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dnli_AggregateDevelopmentFirstCommercialSaleAndNetSalesBasedMilestonePayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate Development, First Commercial Sale, And Net Sales Based Milestone Payments",
        "label": "Aggregate Development, First Commercial Sale, And Net Sales Based Milestone Payments",
        "terseLabel": "Milestone payments upon achievement of certain development and sales milestones"
       }
      }
     },
     "localname": "AggregateDevelopmentFirstCommercialSaleAndNetSalesBasedMilestonePayments",
     "nsuri": "http://www.denalitherapeutics.com/20210331",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsBiogenDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dnli_AggregateDevelopmentMilestonePayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate development milestone payment.",
        "label": "Aggregate Development Milestone Payment",
        "terseLabel": "Total aggregate payments due upon achievement of certain clinical and regulatory milestone events"
       }
      }
     },
     "localname": "AggregateDevelopmentMilestonePayment",
     "nsuri": "http://www.denalitherapeutics.com/20210331",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsTakedaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dnli_AggregateOptionExerciseFee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate option exercise fee.",
        "label": "Aggregate Option Exercise Fee",
        "terseLabel": "Aggregated option exercise fee"
       }
      }
     },
     "localname": "AggregateOptionExerciseFee",
     "nsuri": "http://www.denalitherapeutics.com/20210331",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsTakedaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dnli_AggregatePreclinicalMilestonePayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total aggregate payments due upon achievement of certain preclinical milestone events.",
        "label": "Aggregate Preclinical Milestone Payment",
        "terseLabel": "Total aggregate payments due upon achievement of certain preclinical milestone events"
       }
      }
     },
     "localname": "AggregatePreclinicalMilestonePayment",
     "nsuri": "http://www.denalitherapeutics.com/20210331",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsTakedaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dnli_AlzheimersDiseaseServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Alzheimer's Disease Services",
        "label": "Alzheimer's Disease Services [Member]",
        "terseLabel": "Alzheimer's Disease Services"
       }
      }
     },
     "localname": "AlzheimersDiseaseServicesMember",
     "nsuri": "http://www.denalitherapeutics.com/20210331",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsSanofiPerformanceObligationDetails",
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsSummaryofCollaborationRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dnli_BiogenCollaborativeArrangementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Biogen Collaborative Arrangement",
        "label": "Biogen Collaborative Arrangement [Member]",
        "terseLabel": "Biogen Collaborative Arrangement"
       }
      }
     },
     "localname": "BiogenCollaborativeArrangementMember",
     "nsuri": "http://www.denalitherapeutics.com/20210331",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsBiogenDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dnli_BiogenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Biogen",
        "label": "Biogen [Member]",
        "terseLabel": "Biogen Collaboration Agreement",
        "verboseLabel": "Biogen"
       }
      }
     },
     "localname": "BiogenMember",
     "nsuri": "http://www.denalitherapeutics.com/20210331",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsBiogenDetails",
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsSummaryofCollaborationRevenueDetails",
      "http://www.denalitherapeutics.com/role/LicenseAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dnli_CNSProductMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CNS Product",
        "label": "CNS Product [Member]",
        "terseLabel": "CNS Product"
       }
      }
     },
     "localname": "CNSProductMember",
     "nsuri": "http://www.denalitherapeutics.com/20210331",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsSanofiDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dnli_ClinicalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Clinical",
        "label": "Clinical [Member]",
        "terseLabel": "Clinical"
       }
      }
     },
     "localname": "ClinicalMember",
     "nsuri": "http://www.denalitherapeutics.com/20210331",
     "presentation": [
      "http://www.denalitherapeutics.com/role/LicenseAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dnli_ClinicalMilestonePayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Clinical Milestone Payment",
        "label": "Clinical Milestone Payment",
        "terseLabel": "Clinical milestone payment"
       }
      }
     },
     "localname": "ClinicalMilestonePayment",
     "nsuri": "http://www.denalitherapeutics.com/20210331",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsSanofiDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dnli_CollaborationAgreementTransactionPriceIncrease": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreement, Transaction Price, Increase",
        "label": "Collaboration Agreement, Transaction Price, Increase",
        "terseLabel": "Transaction price increase"
       }
      }
     },
     "localname": "CollaborationAgreementTransactionPriceIncrease",
     "nsuri": "http://www.denalitherapeutics.com/20210331",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsSanofiDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dnli_CollaborationAgreementTransactionPriceIncreaseDecrease": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreement, Transaction Price, Increase (Decrease)",
        "label": "Collaboration Agreement, Transaction Price, Increase (Decrease)",
        "terseLabel": "Transaction price, change"
       }
      }
     },
     "localname": "CollaborationAgreementTransactionPriceIncreaseDecrease",
     "nsuri": "http://www.denalitherapeutics.com/20210331",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsBiogenDetails",
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsTakedaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dnli_CollaborativeAgreementAgreedShareOfCommercialProfitLoss": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Agreement, Agreed Share Of Commercial Profit (Loss)",
        "label": "Collaborative Agreement, Agreed Share Of Commercial Profit (Loss)",
        "terseLabel": "Agreed share of commercial profit (loss) percentage"
       }
      }
     },
     "localname": "CollaborativeAgreementAgreedShareOfCommercialProfitLoss",
     "nsuri": "http://www.denalitherapeutics.com/20210331",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsBiogenDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "dnli_CollaborativeAgreementFundedPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Agreement, Funded Percentage",
        "label": "Collaborative Agreement, Funded Percentage",
        "terseLabel": "Funded percentage"
       }
      }
     },
     "localname": "CollaborativeAgreementFundedPercentage",
     "nsuri": "http://www.denalitherapeutics.com/20210331",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsBiogenDetails",
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsSanofiDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "dnli_CollaborativeArrangementATVTREM2Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, ATV:TREM2",
        "label": "Collaborative Arrangement, ATV:TREM2 [Member]",
        "terseLabel": "Collaborative Arrangement, ATV:TREM2"
       }
      }
     },
     "localname": "CollaborativeArrangementATVTREM2Member",
     "nsuri": "http://www.denalitherapeutics.com/20210331",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsTakedaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dnli_CollaborativeArrangementFirstCommercialSaleMilestonePaymentsToBeReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, First Commercial Sale Milestone Payments, To Be Received",
        "label": "Collaborative Arrangement, First Commercial Sale Milestone Payments, To Be Received",
        "terseLabel": "First commercial sale milestone payments, to be received"
       }
      }
     },
     "localname": "CollaborativeArrangementFirstCommercialSaleMilestonePaymentsToBeReceived",
     "nsuri": "http://www.denalitherapeutics.com/20210331",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsBiogenDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dnli_CollaborativeArrangementNetSalesBasedMilestonePaymentsToBeReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Net Sales-Based Milestone Payments, To Be Received",
        "label": "Collaborative Arrangement, Net Sales-Based Milestone Payments, To Be Received",
        "terseLabel": "Net sales-based milestone payments, to be received"
       }
      }
     },
     "localname": "CollaborativeArrangementNetSalesBasedMilestonePaymentsToBeReceived",
     "nsuri": "http://www.denalitherapeutics.com/20210331",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsBiogenDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dnli_CollaborativeArrangementNumberOfAdditionalProgramsIfCircumstancesMet": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Number Of Additional Programs, If Circumstances Met",
        "label": "Collaborative Arrangement, Number Of Additional Programs, If Circumstances Met",
        "terseLabel": "Number of additional programs, if circumstances met"
       }
      }
     },
     "localname": "CollaborativeArrangementNumberOfAdditionalProgramsIfCircumstancesMet",
     "nsuri": "http://www.denalitherapeutics.com/20210331",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsBiogenDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "dnli_CollaborativeArrangementNumberOfAdditionalProgramsNoThirdPartyAgreementExecutedIfCircumstancesMet": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Number Of Additional Programs, No Third Party Agreement Executed, If Circumstances Met",
        "label": "Collaborative Arrangement, Number Of Additional Programs, No Third Party Agreement Executed, If Circumstances Met",
        "terseLabel": "Number of additional programs, no third party agreement executed, if circumstances met"
       }
      }
     },
     "localname": "CollaborativeArrangementNumberOfAdditionalProgramsNoThirdPartyAgreementExecutedIfCircumstancesMet",
     "nsuri": "http://www.denalitherapeutics.com/20210331",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsBiogenDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "dnli_CollaborativeArrangementNumberOfMilestonesAchieved": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Number Of Milestones Achieved",
        "label": "Collaborative Arrangement, Number Of Milestones Achieved",
        "terseLabel": "Number of milestones achieved"
       }
      }
     },
     "localname": "CollaborativeArrangementNumberOfMilestonesAchieved",
     "nsuri": "http://www.denalitherapeutics.com/20210331",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsBiogenDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "dnli_CollaborativeArrangementNumberOfPrograms": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Number Of Programs",
        "label": "Collaborative Arrangement, Number Of Programs",
        "terseLabel": "Number of programs"
       }
      }
     },
     "localname": "CollaborativeArrangementNumberOfPrograms",
     "nsuri": "http://www.denalitherapeutics.com/20210331",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsBiogenDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "dnli_CollaborativeArrangementOptionExerciseAndDevelopmentMilestonePaymentsToBeReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Option Exercise And Development Milestone Payments, To Be Received",
        "label": "Collaborative Arrangement, Option Exercise And Development Milestone Payments, To Be Received",
        "terseLabel": "Aggregate option exercise and development milestone payments, to be received"
       }
      }
     },
     "localname": "CollaborativeArrangementOptionExerciseAndDevelopmentMilestonePaymentsToBeReceived",
     "nsuri": "http://www.denalitherapeutics.com/20210331",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsBiogenDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dnli_CollaborativeArrangementPTVPGRNMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, PTV:PGRN",
        "label": "Collaborative Arrangement, PTV:PGRN [Member]",
        "terseLabel": "Collaborative Arrangement, PTV:PGRN"
       }
      }
     },
     "localname": "CollaborativeArrangementPTVPGRNMember",
     "nsuri": "http://www.denalitherapeutics.com/20210331",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsTakedaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dnli_CollaborativeArrangementRightOfFirstNegotiationPeriodTermAdditionalProgramCriteria": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Right Of First Negotiation, Period Term, Additional Program Criteria",
        "label": "Collaborative Arrangement, Right Of First Negotiation, Period Term, Additional Program Criteria",
        "terseLabel": "Right of first negotiation (ROFN) term, additional program criteria"
       }
      }
     },
     "localname": "CollaborativeArrangementRightOfFirstNegotiationPeriodTermAdditionalProgramCriteria",
     "nsuri": "http://www.denalitherapeutics.com/20210331",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsBiogenDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "dnli_CollaborativeArrangementRightOfFirstNegotiationTermPeriodAfterEffectiveDateOfAgreementIfCircumstancesMet": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Right Of First Negotiation Term, Period After Effective Date Of Agreement, If Circumstances Met",
        "label": "Collaborative Arrangement, Right Of First Negotiation Term, Period After Effective Date Of Agreement, If Circumstances Met",
        "terseLabel": "Right of first negotiation (ROFN) term, period of time after effective date of agreement, if circumstances met"
       }
      }
     },
     "localname": "CollaborativeArrangementRightOfFirstNegotiationTermPeriodAfterEffectiveDateOfAgreementIfCircumstancesMet",
     "nsuri": "http://www.denalitherapeutics.com/20210331",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsBiogenDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "dnli_CollaborativeArrangementTermNumberOfBusinessDaysIfEffectiveDateCriteriaMet": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Term, Number Of Business Days, If Effective Date Criteria Met",
        "label": "Collaborative Arrangement, Term, Number Of Business Days, If Effective Date Criteria Met",
        "terseLabel": "Term of agreement, number of business days after 5th anniversary date of the effective date of the agreement"
       }
      }
     },
     "localname": "CollaborativeArrangementTermNumberOfBusinessDaysIfEffectiveDateCriteriaMet",
     "nsuri": "http://www.denalitherapeutics.com/20210331",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsBiogenDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "dnli_CollaborativeArrangementUpfrontPaymentToBeReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Upfront Payment, To Be Received",
        "label": "Collaborative Arrangement, Upfront Payment, To Be Received",
        "terseLabel": "Upfront payment, to be received"
       }
      }
     },
     "localname": "CollaborativeArrangementUpfrontPaymentToBeReceived",
     "nsuri": "http://www.denalitherapeutics.com/20210331",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsBiogenDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dnli_CollaborativeRevenueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Revenue",
        "label": "Collaborative Revenue [Abstract]",
        "terseLabel": "Collaboration revenue:"
       }
      }
     },
     "localname": "CollaborativeRevenueAbstract",
     "nsuri": "http://www.denalitherapeutics.com/20210331",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "dnli_CommercialMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commercial",
        "label": "Commercial [Member]",
        "terseLabel": "Commercial"
       }
      }
     },
     "localname": "CommercialMember",
     "nsuri": "http://www.denalitherapeutics.com/20210331",
     "presentation": [
      "http://www.denalitherapeutics.com/role/LicenseAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dnli_CommercialMilestonePayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commercial Milestone Payments",
        "label": "Commercial Milestone Payments",
        "terseLabel": "Commercial milestone payments"
       }
      }
     },
     "localname": "CommercialMilestonePayments",
     "nsuri": "http://www.denalitherapeutics.com/20210331",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsSanofiDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dnli_CommercialMilestonesPerProgram": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commercial milestones per program.",
        "label": "Commercial Milestones Per Program",
        "terseLabel": "Milestone payments per biologic product upon achievement of a certain sales-based milestone"
       }
      }
     },
     "localname": "CommercialMilestonesPerProgram",
     "nsuri": "http://www.denalitherapeutics.com/20210331",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsTakedaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dnli_ConstrainedVariableConsideration": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Constrained variable consideration.",
        "label": "Constrained Variable Consideration",
        "terseLabel": "Remaining preclinical milestones, cost and profit sharing income, and the development and commercial milestones"
       }
      }
     },
     "localname": "ConstrainedVariableConsideration",
     "nsuri": "http://www.denalitherapeutics.com/20210331",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsTakedaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dnli_ContractWithCustomerLiabilityFromRelatedPartiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract with Customer, Liability, From Related Parties, Current",
        "label": "Contract with Customer, Liability, From Related Parties, Current",
        "terseLabel": "Related party contract liability, current"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityFromRelatedPartiesCurrent",
     "nsuri": "http://www.denalitherapeutics.com/20210331",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dnli_ContractWithCustomerLiabilityFromRelatedPartiesNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract With Customer, Liability, From Related Parties, Noncurrent",
        "label": "Contract With Customer, Liability, From Related Parties, Noncurrent",
        "terseLabel": "Related party contract liability, less current portion"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityFromRelatedPartiesNoncurrent",
     "nsuri": "http://www.denalitherapeutics.com/20210331",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dnli_DMSAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "DMSA.",
        "label": "DMSA [Member]",
        "terseLabel": "DMSA"
       }
      }
     },
     "localname": "DMSAMember",
     "nsuri": "http://www.denalitherapeutics.com/20210331",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dnli_DevelopmentMilestonePayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development Milestone Payments",
        "label": "Development Milestone Payments",
        "terseLabel": "Development milestone payments"
       }
      }
     },
     "localname": "DevelopmentMilestonePayments",
     "nsuri": "http://www.denalitherapeutics.com/20210331",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsBiogenDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dnli_EmployeeAndNonEmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee And Non Employee Stock Option [Member]",
        "label": "Employee And Non Employee Stock Option [Member]",
        "terseLabel": "Options issued and outstanding and ESPP shares issuable"
       }
      }
     },
     "localname": "EmployeeAndNonEmployeeStockOptionMember",
     "nsuri": "http://www.denalitherapeutics.com/20210331",
     "presentation": [
      "http://www.denalitherapeutics.com/role/NetLossPerShareScheduleofDilutiveSecuritiesNotIncludedinDilutedPerShareCalculationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dnli_FirstCommercialSaleMilestonePayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First Commercial Sale Milestone Payments",
        "label": "First Commercial Sale Milestone Payments",
        "terseLabel": "First commercial sale milestone payments"
       }
      }
     },
     "localname": "FirstCommercialSaleMilestonePayments",
     "nsuri": "http://www.denalitherapeutics.com/20210331",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsBiogenDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dnli_ForeignExchangeForwardBritishPoundsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Foreign Exchange Forward - British Pounds [Member]",
        "label": "Foreign Exchange Forward - British Pounds [Member]",
        "terseLabel": "British Pounds"
       }
      }
     },
     "localname": "ForeignExchangeForwardBritishPoundsMember",
     "nsuri": "http://www.denalitherapeutics.com/20210331",
     "presentation": [
      "http://www.denalitherapeutics.com/role/DerivativeFinancialInstrumentsSummaryofForwardForeignCurrencyExchangeContractsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dnli_ForeignExchangeForwardEurosMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Foreign Exchange Forward - Euros [Member]",
        "label": "Foreign Exchange Forward - Euros [Member]",
        "terseLabel": "Euros"
       }
      }
     },
     "localname": "ForeignExchangeForwardEurosMember",
     "nsuri": "http://www.denalitherapeutics.com/20210331",
     "presentation": [
      "http://www.denalitherapeutics.com/role/DerivativeFinancialInstrumentsSummaryofForwardForeignCurrencyExchangeContractsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dnli_GenentechIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Genentech Inc.",
        "label": "Genentech Inc [Member]",
        "terseLabel": "Genentech Inc"
       }
      }
     },
     "localname": "GenentechIncMember",
     "nsuri": "http://www.denalitherapeutics.com/20210331",
     "presentation": [
      "http://www.denalitherapeutics.com/role/LicenseAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dnli_HeadquartersLeaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Headquarters lease.",
        "label": "Headquarters Lease [Member]",
        "terseLabel": "Headquarters Lease"
       }
      }
     },
     "localname": "HeadquartersLeaseMember",
     "nsuri": "http://www.denalitherapeutics.com/20210331",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dnli_IncreaseDecreaseInContractWithCustomerLiabilityRelatedParties": {
     "auth_ref": [],
     "calculation": {
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) in Contract with Customer, Liability, Related Parties",
        "label": "Increase (Decrease) in Contract with Customer, Liability, Related Parties",
        "terseLabel": "Related party contract liability"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiabilityRelatedParties",
     "nsuri": "http://www.denalitherapeutics.com/20210331",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dnli_IncreaseDecreaseInNonCashOperatingLeaseExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Non-Cash Operating Lease Expense",
        "label": "Increase (Decrease) In Non-Cash Operating Lease Expense",
        "negatedLabel": "Non-cash adjustment to operating lease expense"
       }
      }
     },
     "localname": "IncreaseDecreaseInNonCashOperatingLeaseExpense",
     "nsuri": "http://www.denalitherapeutics.com/20210331",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dnli_LandlordFundedTenantImprovementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Landlord funded tenant improvements.",
        "label": "Landlord Funded Tenant Improvements [Member]",
        "terseLabel": "Landlord Funded Tenant Improvements"
       }
      }
     },
     "localname": "LandlordFundedTenantImprovementsMember",
     "nsuri": "http://www.denalitherapeutics.com/20210331",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dnli_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.denalitherapeutics.com/role/CommitmentsandContingenciesSummaryofCompanysFutureMinimumLeaseCommitmentsDetails_1": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, To Be Paid, After Year Four",
        "label": "Lessee, Operating Lease, Liability, To Be Paid, After Year Four",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityToBePaidAfterYearFour",
     "nsuri": "http://www.denalitherapeutics.com/20210331",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CommitmentsandContingenciesSummaryofCompanysFutureMinimumLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dnli_LesseeOperatingLeaseRenewalNoticePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Renewal Notice Period",
        "label": "Lessee, Operating Lease, Renewal Notice Period",
        "terseLabel": "Lease renewal notice period"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalNoticePeriod",
     "nsuri": "http://www.denalitherapeutics.com/20210331",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "dnli_LicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License agreement.",
        "label": "License Agreement [Member]",
        "terseLabel": "License Agreement"
       }
      }
     },
     "localname": "LicenseAgreementMember",
     "nsuri": "http://www.denalitherapeutics.com/20210331",
     "presentation": [
      "http://www.denalitherapeutics.com/role/LicenseAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dnli_LicenseAgreementMilestonePaymentObligationResponsibilityPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement, Milestone Payment Obligation Responsibility, Percentage",
        "label": "License Agreement, Milestone Payment Obligation Responsibility, Percentage",
        "terseLabel": "Payment obligation responsibility"
       }
      }
     },
     "localname": "LicenseAgreementMilestonePaymentObligationResponsibilityPercentage",
     "nsuri": "http://www.denalitherapeutics.com/20210331",
     "presentation": [
      "http://www.denalitherapeutics.com/role/LicenseAgreementsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "dnli_LicenseAgreementMilestonePaymentUponAchievementOfClinicalAndRegulatoryMilestones": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License agreement milestone payment upon achievement of clinical and regulatory milestones.",
        "label": "License Agreement Milestone Payment Upon Achievement Of Clinical And Regulatory Milestones",
        "terseLabel": "Milestone payments upon achievement of specified clinical and regulatory milestones"
       }
      }
     },
     "localname": "LicenseAgreementMilestonePaymentUponAchievementOfClinicalAndRegulatoryMilestones",
     "nsuri": "http://www.denalitherapeutics.com/20210331",
     "presentation": [
      "http://www.denalitherapeutics.com/role/LicenseAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dnli_LicenseAgreementTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement",
        "label": "License Agreement [Text Block]",
        "terseLabel": "License Agreements"
       }
      }
     },
     "localname": "LicenseAgreementTextBlock",
     "nsuri": "http://www.denalitherapeutics.com/20210331",
     "presentation": [
      "http://www.denalitherapeutics.com/role/LicenseAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dnli_LongTermInvestmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long term investments.",
        "label": "Long Term Investments [Member]",
        "terseLabel": "Long-term marketable securities"
       }
      }
     },
     "localname": "LongTermInvestmentsMember",
     "nsuri": "http://www.denalitherapeutics.com/20210331",
     "presentation": [
      "http://www.denalitherapeutics.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dnli_LongTermMarketableSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long term marketable securities.",
        "label": "Long Term Marketable Securities [Member]",
        "terseLabel": "Long-term marketable securities"
       }
      }
     },
     "localname": "LongTermMarketableSecuritiesMember",
     "nsuri": "http://www.denalitherapeutics.com/20210331",
     "presentation": [
      "http://www.denalitherapeutics.com/role/MarketableSecuritiesSummaryofAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dnli_MilestoneTriggeredAndRetainedActivitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Triggered And Retained Activities",
        "label": "Milestone Triggered And Retained Activities [Member]",
        "terseLabel": "Milestone Triggered and Retained Activities"
       }
      }
     },
     "localname": "MilestoneTriggeredAndRetainedActivitiesMember",
     "nsuri": "http://www.denalitherapeutics.com/20210331",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsSanofiDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dnli_MilestoneTriggeredMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Triggered",
        "label": "Milestone Triggered [Member]",
        "terseLabel": "Milestone Triggered"
       }
      }
     },
     "localname": "MilestoneTriggeredMember",
     "nsuri": "http://www.denalitherapeutics.com/20210331",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsSanofiDetails",
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsTakedaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dnli_NetSalesBasedMilestonePayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net Sales Based Milestone Payments",
        "label": "Net Sales Based Milestone Payments",
        "terseLabel": "Net sales-based milestone payments"
       }
      }
     },
     "localname": "NetSalesBasedMilestonePayments",
     "nsuri": "http://www.denalitherapeutics.com/20210331",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsBiogenDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dnli_NewPremisesSubleaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "New Premises Sublease Agreement [Member]",
        "label": "New Premises Sublease Agreement [Member]",
        "terseLabel": "New Premises Sublease Agreement"
       }
      }
     },
     "localname": "NewPremisesSubleaseAgreementMember",
     "nsuri": "http://www.denalitherapeutics.com/20210331",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dnli_NumberOfIndications": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Indications",
        "label": "Number Of Indications",
        "terseLabel": "Number of indications"
       }
      }
     },
     "localname": "NumberOfIndications",
     "nsuri": "http://www.denalitherapeutics.com/20210331",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsSanofiDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "dnli_NumberOfPrograms": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Programs",
        "label": "Number Of Programs",
        "terseLabel": "Number of programs"
       }
      }
     },
     "localname": "NumberOfPrograms",
     "nsuri": "http://www.denalitherapeutics.com/20210331",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsTakedaDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "dnli_NumberOfTargets": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Targets",
        "label": "Number Of Targets",
        "terseLabel": "Number of targets"
       }
      }
     },
     "localname": "NumberOfTargets",
     "nsuri": "http://www.denalitherapeutics.com/20210331",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsTakedaDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "dnli_OperatingLeasesAreaUnderLease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating leases area under lease.",
        "label": "Operating Leases Area Under Lease",
        "terseLabel": "Area under lease"
       }
      }
     },
     "localname": "OperatingLeasesAreaUnderLease",
     "nsuri": "http://www.denalitherapeutics.com/20210331",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "dnli_OperatingLeasesSubleaseNetRentableArea": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Leases, Sublease, Net Rentable Area",
        "label": "Operating Leases, Sublease, Net Rentable Area",
        "terseLabel": "Rentable square feet"
       }
      }
     },
     "localname": "OperatingLeasesSubleaseNetRentableArea",
     "nsuri": "http://www.denalitherapeutics.com/20210331",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "dnli_OptionFeesPerProgram": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Option fees per program.",
        "label": "Option Fees Per Program",
        "terseLabel": "Option fee"
       }
      }
     },
     "localname": "OptionFeesPerProgram",
     "nsuri": "http://www.denalitherapeutics.com/20210331",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsTakedaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dnli_OptionResearchServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Option Research Services",
        "label": "Option Research Services [Member]",
        "terseLabel": "Option Research Services"
       }
      }
     },
     "localname": "OptionResearchServicesMember",
     "nsuri": "http://www.denalitherapeutics.com/20210331",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsBiogenDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dnli_OptionServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Option Services",
        "label": "Option Services [Member]",
        "terseLabel": "Option Research Services"
       }
      }
     },
     "localname": "OptionServicesMember",
     "nsuri": "http://www.denalitherapeutics.com/20210331",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsSummaryofCollaborationRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dnli_OrganizationAndDescriptionOfBusinessPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization and description of business, policy.",
        "label": "Organization and Description of Business, Policy [Policy Text Block]",
        "terseLabel": "Organization and Description of Business"
       }
      }
     },
     "localname": "OrganizationAndDescriptionOfBusinessPolicyPolicyTextBlock",
     "nsuri": "http://www.denalitherapeutics.com/20210331",
     "presentation": [
      "http://www.denalitherapeutics.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dnli_OtherAccruedManufacturingCostsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Accrued Manufacturing Costs, Current",
        "label": "Other Accrued Manufacturing Costs, Current",
        "terseLabel": "Accrued manufacturing costs"
       }
      }
     },
     "localname": "OtherAccruedManufacturingCostsCurrent",
     "nsuri": "http://www.denalitherapeutics.com/20210331",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dnli_PaymentsForManufacturingCost": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments for manufacturing cost.",
        "label": "Payments for Manufacturing Cost",
        "terseLabel": "Payments for development and manufacturing services"
       }
      }
     },
     "localname": "PaymentsForManufacturingCost",
     "nsuri": "http://www.denalitherapeutics.com/20210331",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dnli_PeripheralProductMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Peripheral Product",
        "label": "Peripheral Product [Member]",
        "terseLabel": "Peripheral Program License"
       }
      }
     },
     "localname": "PeripheralProductMember",
     "nsuri": "http://www.denalitherapeutics.com/20210331",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsSanofiDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dnli_PreclinicalMilestonePaymentEarnedNotYetReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preclinical Milestone Payment Earned Not Yet Received",
        "label": "Preclinical Milestone Payment Earned Not Yet Received",
        "terseLabel": "Preclinical milestone payment earned not yet received"
       }
      }
     },
     "localname": "PreclinicalMilestonePaymentEarnedNotYetReceived",
     "nsuri": "http://www.denalitherapeutics.com/20210331",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsTakedaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dnli_PreclinicalMilestonePaymentPerProgram": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments due upon achievement of certain preclinical milestone events per program.",
        "label": "Preclinical Milestone Payment Per Program",
        "terseLabel": "Preclinical milestone payments per program"
       }
      }
     },
     "localname": "PreclinicalMilestonePaymentPerProgram",
     "nsuri": "http://www.denalitherapeutics.com/20210331",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsTakedaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dnli_PreclinicalMilestonePaymentReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preclinical milestone payment received.",
        "label": "Preclinical Milestone Payment Received",
        "terseLabel": "Preclinical milestone payment received"
       }
      }
     },
     "localname": "PreclinicalMilestonePaymentReceived",
     "nsuri": "http://www.denalitherapeutics.com/20210331",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsTakedaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dnli_ProvisionalCollaborativeArrangementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Provisional Collaborative Arrangement",
        "label": "Provisional Collaborative Arrangement [Member]",
        "terseLabel": "Provisional Collaboration Agreement"
       }
      }
     },
     "localname": "ProvisionalCollaborativeArrangementMember",
     "nsuri": "http://www.denalitherapeutics.com/20210331",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsBiogenDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dnli_PurchaseOrderExecuted": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase order executed.",
        "label": "Purchase Order Executed",
        "terseLabel": "Purchase order executed"
       }
      }
     },
     "localname": "PurchaseOrderExecuted",
     "nsuri": "http://www.denalitherapeutics.com/20210331",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dnli_ROFNAndOptionAgreementCollaborativeArrangementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ROFN And Option Agreement, Collaborative Arrangement",
        "label": "ROFN And Option Agreement, Collaborative Arrangement [Member]",
        "terseLabel": "ROFN and Option Agreement"
       }
      }
     },
     "localname": "ROFNAndOptionAgreementCollaborativeArrangementMember",
     "nsuri": "http://www.denalitherapeutics.com/20210331",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsBiogenDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dnli_RegulatoryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Regulatory",
        "label": "Regulatory [Member]",
        "terseLabel": "Regulatory"
       }
      }
     },
     "localname": "RegulatoryMember",
     "nsuri": "http://www.denalitherapeutics.com/20210331",
     "presentation": [
      "http://www.denalitherapeutics.com/role/LicenseAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dnli_RegulatoryMilestonePayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Regulatory Milestone Payment",
        "label": "Regulatory Milestone Payment",
        "terseLabel": "Regulatory milestone payment"
       }
      }
     },
     "localname": "RegulatoryMilestonePayment",
     "nsuri": "http://www.denalitherapeutics.com/20210331",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsSanofiDetails",
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsTakedaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dnli_ResearchAndDevelopmentExpenseOffsetFromRelatedPartyCostReimbursement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research And Development Expense, Offset From Related Party Cost Reimbursement",
        "label": "Research And Development Expense, Offset From Related Party Cost Reimbursement",
        "terseLabel": "Offset to research and development expense, related party cost reimbursement"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseOffsetFromRelatedPartyCostReimbursement",
     "nsuri": "http://www.denalitherapeutics.com/20210331",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsBiogenDetails",
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dnli_RestrictedSharesSubjectToFutureVestingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted shares subject to future vesting.",
        "label": "Restricted shares subject to future vesting [Member]",
        "terseLabel": "Restricted shares subject to future vesting"
       }
      }
     },
     "localname": "RestrictedSharesSubjectToFutureVestingMember",
     "nsuri": "http://www.denalitherapeutics.com/20210331",
     "presentation": [
      "http://www.denalitherapeutics.com/role/NetLossPerShareScheduleofDilutiveSecuritiesNotIncludedinDilutedPerShareCalculationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dnli_RetainedActivitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Retained Activities",
        "label": "Retained Activities [Member]",
        "terseLabel": "Retained Activities"
       }
      }
     },
     "localname": "RetainedActivitiesMember",
     "nsuri": "http://www.denalitherapeutics.com/20210331",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsSanofiDetails",
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsSummaryofCollaborationRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dnli_RevenueNumberOfPerformanceObligations": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue, Number Of Performance Obligations",
        "label": "Revenue, Number Of Performance Obligations",
        "terseLabel": "Number of performance obligations"
       }
      }
     },
     "localname": "RevenueNumberOfPerformanceObligations",
     "nsuri": "http://www.denalitherapeutics.com/20210331",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsTakedaDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "dnli_SaleOfStockConsiderationPremiumReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of stock consideration premium received on transaction.",
        "label": "Sale Of Stock, Consideration, Premium Received On Transaction",
        "terseLabel": "Premium on sale of common stock"
       }
      }
     },
     "localname": "SaleOfStockConsiderationPremiumReceivedOnTransaction",
     "nsuri": "http://www.denalitherapeutics.com/20210331",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsBiogenDetails",
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsTakedaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dnli_SanofiCollaborationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sanofi Collaboration Agreement",
        "label": "Sanofi Collaboration Agreement [Member]",
        "terseLabel": "Sanofi Collaboration Agreement"
       }
      }
     },
     "localname": "SanofiCollaborationAgreementMember",
     "nsuri": "http://www.denalitherapeutics.com/20210331",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsSummaryofCollaborationRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dnli_SanofiMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sanofi [Member]",
        "label": "Sanofi [Member]",
        "terseLabel": "Sanofi"
       }
      }
     },
     "localname": "SanofiMember",
     "nsuri": "http://www.denalitherapeutics.com/20210331",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsSanofiDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dnli_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueExpectedToVest": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options nonvested weighted average grant date fair value expected to vest.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value Expected To Vest",
        "terseLabel": "Expected to vest (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueExpectedToVest",
     "nsuri": "http://www.denalitherapeutics.com/20210331",
     "presentation": [
      "http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofRestrictedStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "dnli_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options vested and expected to vest outstanding number.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested And Expected To Vest Outstanding Number",
        "terseLabel": "Expected to vest (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://www.denalitherapeutics.com/20210331",
     "presentation": [
      "http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofRestrictedStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "dnli_SharePurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share purchase agreement.",
        "label": "Share Purchase Agreement [Member]",
        "terseLabel": "Stock Purchase Agreement"
       }
      }
     },
     "localname": "SharePurchaseAgreementMember",
     "nsuri": "http://www.denalitherapeutics.com/20210331",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsBiogenDetails",
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsTakedaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dnli_ShortTermMarketableSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short term marketable securities.",
        "label": "Short Term Marketable Securities [Member]",
        "terseLabel": "Short-term marketable securities"
       }
      }
     },
     "localname": "ShortTermMarketableSecuritiesMember",
     "nsuri": "http://www.denalitherapeutics.com/20210331",
     "presentation": [
      "http://www.denalitherapeutics.com/role/MarketableSecuritiesSummaryofAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dnli_StockIssuedDuringPeriodSharesEquityIncentivePlan": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Shares, Equity Incentive Plan",
        "label": "Stock Issued During Period, Shares, Equity Incentive Plan",
        "terseLabel": "Issuances under equity incentive plans (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEquityIncentivePlan",
     "nsuri": "http://www.denalitherapeutics.com/20210331",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "dnli_StockIssuedDuringPeriodValueEquityIncentivePlan": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Value, Equity Incentive Plan",
        "label": "Stock Issued During Period, Value, Equity Incentive Plan",
        "terseLabel": "Issuances under equity incentive plans"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEquityIncentivePlan",
     "nsuri": "http://www.denalitherapeutics.com/20210331",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dnli_TakedaCollaborationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Takeda Collaboration Agreement",
        "label": "Takeda Collaboration Agreement [Member]",
        "terseLabel": "Takeda Collaboration Agreement"
       }
      }
     },
     "localname": "TakedaCollaborationAgreementMember",
     "nsuri": "http://www.denalitherapeutics.com/20210331",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsSummaryofCollaborationRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dnli_TakedaPharmaceuticalCompanyLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Takeda pharmaceutical company limited.",
        "label": "Takeda Pharmaceutical Company Limited [Member]",
        "terseLabel": "Takeda Pharmaceutical Company Limited"
       }
      }
     },
     "localname": "TakedaPharmaceuticalCompanyLimitedMember",
     "nsuri": "http://www.denalitherapeutics.com/20210331",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsTakedaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dnli_TargetOptionPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Target Option Period",
        "label": "Target Option Period",
        "terseLabel": "Target option period"
       }
      }
     },
     "localname": "TargetOptionPeriod",
     "nsuri": "http://www.denalitherapeutics.com/20210331",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsTakedaDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "dnli_TenantImprovementAllowanceRepayableAsRent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Portion of tenant improvement allowance repayable to landlord in future rent.",
        "label": "Tenant Improvement Allowance Repayable As Rent",
        "terseLabel": "Tenant improvement allowance repayable in rent"
       }
      }
     },
     "localname": "TenantImprovementAllowanceRepayableAsRent",
     "nsuri": "http://www.denalitherapeutics.com/20210331",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dnli_TransportVehicleTechnologyPlatformPreclinicalProgramsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transport Vehicle Technology Platform, Preclinical Programs",
        "label": "Transport Vehicle Technology Platform, Preclinical Programs [Member]",
        "terseLabel": "Transport Vehicle (TV)Technology Platform, Preclinical Programs"
       }
      }
     },
     "localname": "TransportVehicleTechnologyPlatformPreclinicalProgramsMember",
     "nsuri": "http://www.denalitherapeutics.com/20210331",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsBiogenDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dnli_TransportVehicleTechnologyPlatformRightOfFirstNegotiationProgramsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transport Vehicle Technology Platform, Right Of First Negotiation Programs",
        "label": "Transport Vehicle Technology Platform, Right Of First Negotiation Programs [Member]",
        "terseLabel": "Transport Vehicle Technology Platform, Right Of First Negotiation Programs"
       }
      }
     },
     "localname": "TransportVehicleTechnologyPlatformRightOfFirstNegotiationProgramsMember",
     "nsuri": "http://www.denalitherapeutics.com/20210331",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsBiogenDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dnli_TransportVehicleTechnologyPlatformUnnamedProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transport Vehicle Technology Platform, Unnamed Program",
        "label": "Transport Vehicle Technology Platform, Unnamed Program [Member]",
        "terseLabel": "Transport Vehicle (TV) Technology Platform, Unnamed Program"
       }
      }
     },
     "localname": "TransportVehicleTechnologyPlatformUnnamedProgramMember",
     "nsuri": "http://www.denalitherapeutics.com/20210331",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsBiogenDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dnli_TransportVehicleTechnologyProgramRightOfFirstNegotiationProgramsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transport Vehicle Technology Program, Unnamed Program, Right Of First Negotiation Programs",
        "label": "Transport Vehicle Technology Program, Right Of First Negotiation Programs [Member]",
        "terseLabel": "Transport Vehicle (TV) Technology Program, Unnamed Program, Right Of First Negotiation Programs (ROFN)"
       }
      }
     },
     "localname": "TransportVehicleTechnologyProgramRightOfFirstNegotiationProgramsMember",
     "nsuri": "http://www.denalitherapeutics.com/20210331",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsBiogenDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dnli_UpfrontFeesPaid": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront fees paid.",
        "label": "Upfront Fees Paid",
        "terseLabel": "Upfront fee paid"
       }
      }
     },
     "localname": "UpfrontFeesPaid",
     "nsuri": "http://www.denalitherapeutics.com/20210331",
     "presentation": [
      "http://www.denalitherapeutics.com/role/LicenseAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dnli_UpfrontPayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront payments.",
        "label": "Upfront Payments",
        "terseLabel": "Upfront payment"
       }
      }
     },
     "localname": "UpfrontPayments",
     "nsuri": "http://www.denalitherapeutics.com/20210331",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsBiogenDetails",
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsSanofiDetails",
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsTakedaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dnli_VariableConsiderationFutureConsideration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Variable consideration relating to future milestones.",
        "label": "Variable Consideration Future Consideration",
        "terseLabel": "Variable consideration relating to future milestones"
       }
      }
     },
     "localname": "VariableConsiderationFutureConsideration",
     "nsuri": "http://www.denalitherapeutics.com/20210331",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsTakedaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "srt_AffiliatedEntityMember": {
     "auth_ref": [
      "r215",
      "r331",
      "r332",
      "r333",
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Affiliated Entity [Member]",
        "terseLabel": "Related Party"
       }
      }
     },
     "localname": "AffiliatedEntityMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsBiogenDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r41",
      "r82"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsBiogenDetails",
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsSanofiDetails",
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsTakedaDetails",
      "http://www.denalitherapeutics.com/role/LicenseAgreementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r217",
      "r218",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r366",
      "r395",
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsTakedaDetails",
      "http://www.denalitherapeutics.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.denalitherapeutics.com/role/LicenseAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r217",
      "r218",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r366",
      "r395",
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r142",
      "r202",
      "r205",
      "r367",
      "r394",
      "r396"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsBiogenDetails",
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsSanofiDetails",
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsSanofiPerformanceObligationDetails",
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsSummaryofCollaborationRevenueDetails",
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsTakedaDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r142",
      "r202",
      "r205",
      "r367",
      "r394",
      "r396"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsBiogenDetails",
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsSanofiDetails",
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsSanofiPerformanceObligationDetails",
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsSummaryofCollaborationRevenueDetails",
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsTakedaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r207",
      "r217",
      "r218",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r366",
      "r395",
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Range [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsTakedaDetails",
      "http://www.denalitherapeutics.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.denalitherapeutics.com/role/LicenseAgreementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r207",
      "r217",
      "r218",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r366",
      "r395",
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Range [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsTakedaDetails",
      "http://www.denalitherapeutics.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.denalitherapeutics.com/role/LicenseAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsBiogenDetails",
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsSanofiDetails",
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsTakedaDetails",
      "http://www.denalitherapeutics.com/role/LicenseAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r143",
      "r144",
      "r202",
      "r206",
      "r397",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsBiogenDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r143",
      "r144",
      "r202",
      "r206",
      "r397",
      "r422",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsBiogenDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNet": {
     "auth_ref": [
      "r17",
      "r382"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.",
        "label": "Accounts Receivable, after Allowance for Credit Loss",
        "terseLabel": "Receivable"
       }
      }
     },
     "localname": "AccountsReceivableNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsSanofiDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Other accruals and other current liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r20",
      "r45",
      "r47",
      "r48",
      "r385",
      "r403",
      "r404"
     ],
     "calculation": {
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r44",
      "r48",
      "r49",
      "r85",
      "r86",
      "r87",
      "r275",
      "r399",
      "r400"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r18",
      "r249"
     ],
     "calculation": {
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r85",
      "r86",
      "r87",
      "r246",
      "r247",
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r219",
      "r221",
      "r252",
      "r253"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "auth_ref": [
      "r196",
      "r197"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.",
        "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs",
        "terseLabel": "Common stock issuance costs"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r221",
      "r243",
      "r251"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "verboseLabel": "Total"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r105"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Total (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/NetLossPerShareScheduleofDilutiveSecuritiesNotIncludedinDilutedPerShareCalculationsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r105"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/NetLossPerShareScheduleofDilutiveSecuritiesNotIncludedinDilutedPerShareCalculationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/NetLossPerShareScheduleofDilutiveSecuritiesNotIncludedinDilutedPerShareCalculationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r105"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/NetLossPerShareScheduleofDilutiveSecuritiesNotIncludedinDilutedPerShareCalculationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Arrangements and Non-arrangement Transactions [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsBiogenDetails",
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsSanofiDetails",
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsSummaryofCollaborationRevenueDetails",
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsTakedaDetails",
      "http://www.denalitherapeutics.com/role/LicenseAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r79",
      "r125",
      "r134",
      "r140",
      "r163",
      "r271",
      "r276",
      "r306",
      "r370",
      "r383"
     ],
     "calculation": {
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r4",
      "r5",
      "r38",
      "r79",
      "r163",
      "r271",
      "r276",
      "r306"
     ],
     "calculation": {
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r299"
     ],
     "calculation": {
      "http://www.denalitherapeutics.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets:"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r156"
     ],
     "calculation": {
      "http://www.denalitherapeutics.com/role/MarketableSecuritiesSummaryofAvailableforSaleSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Unrealized Holding Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/MarketableSecuritiesSummaryofAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r157"
     ],
     "calculation": {
      "http://www.denalitherapeutics.com/role/MarketableSecuritiesSummaryofAvailableforSaleSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Unrealized Holding Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/MarketableSecuritiesSummaryofAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r153",
      "r170"
     ],
     "calculation": {
      "http://www.denalitherapeutics.com/role/MarketableSecuritiesSummaryofAvailableforSaleSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/MarketableSecuritiesSummaryofAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r151",
      "r154",
      "r170",
      "r373"
     ],
     "calculation": {
      "http://www.denalitherapeutics.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      },
      "http://www.denalitherapeutics.com/role/MarketableSecuritiesSummaryofAvailableforSaleSecuritiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Aggregate Fair Value",
        "verboseLabel": "Fair value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesDetails",
      "http://www.denalitherapeutics.com/role/MarketableSecuritiesSummaryofAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r222",
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofAssumptionsUsedforEstimatingtheFairValueofStockOptionsGrantedDetails",
      "http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofRestrictedStockActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/DerivativeFinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r284",
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/DerivativeFinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r1",
      "r26",
      "r73"
     ],
     "calculation": {
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash and Cash Equivalents [Axis]",
        "terseLabel": "Cash and Cash Equivalents [Axis]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.denalitherapeutics.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r8",
      "r74",
      "r76",
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash, Cash Equivalents and Restricted Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock": {
     "auth_ref": [
      "r162"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).",
        "label": "Cash, Cash Equivalents, and Marketable Securities [Text Block]",
        "terseLabel": "Marketable Securities"
       }
      }
     },
     "localname": "CashCashEquivalentsAndMarketableSecuritiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/MarketableSecurities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r68",
      "r73",
      "r75"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "auth_ref": [
      "r68",
      "r307"
     ],
     "calculation": {
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r264",
      "r265",
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "Collaboration Agreements"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementMember": {
     "auth_ref": [
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity.",
        "label": "Collaborative Arrangement [Member]",
        "terseLabel": "Collaborative Arrangement"
       }
      }
     },
     "localname": "CollaborativeArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsSanofiDetails",
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsTakedaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsBiogenDetails",
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsSanofiDetails",
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsSummaryofCollaborationRevenueDetails",
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsTakedaDetails",
      "http://www.denalitherapeutics.com/role/LicenseAgreementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r195"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember": {
     "auth_ref": [
      "r208",
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds that is excluded from cash and cash equivalents.",
        "label": "Commercial Paper, Not Included with Cash and Cash Equivalents [Member]",
        "terseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaperNotIncludedWithCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/MarketableSecuritiesSummaryofAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r36",
      "r185",
      "r374",
      "r389"
     ],
     "calculation": {
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 7)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r182",
      "r183",
      "r184",
      "r192"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r85",
      "r86"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (usd per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r15",
      "r196"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r15"
     ],
     "calculation": {
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.01 par value; 400,000,000 shares authorized as of March 31, 2021 and December 31, 2020; 121,147,432 shares and 120,531,333 shares issued and outstanding as of March 31, 2021 and December 31, 2020, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommonStocksIncludingAdditionalPaidInCapital": {
     "auth_ref": [
      "r15",
      "r18",
      "r197"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of par value plus amounts in excess of par value or issuance value for common stock issued.",
        "label": "Common Stocks, Including Additional Paid in Capital",
        "terseLabel": "Fair market value of common stock"
       }
      }
     },
     "localname": "CommonStocksIncludingAdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsBiogenDetails",
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsTakedaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r52",
      "r54",
      "r55",
      "r58",
      "r376",
      "r391"
     ],
     "calculation": {
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Comprehensive Loss"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r114",
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of Credit Risk and Other Risks and Uncertainties"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r76",
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContingentConsiderationByTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of contingent consideration.",
        "label": "Contingent Consideration by Type [Axis]",
        "terseLabel": "Contingent Consideration by Type [Axis]"
       }
      }
     },
     "localname": "ContingentConsiderationByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/LicenseAgreementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ContingentConsiderationTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of contingent payment arrangement.",
        "label": "Contingent Consideration Type [Domain]",
        "terseLabel": "Contingent Consideration Type [Domain]"
       }
      }
     },
     "localname": "ContingentConsiderationTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/LicenseAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r198",
      "r199",
      "r203"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "terseLabel": "Contract liability"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsBiogenDetails",
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsTakedaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r198",
      "r199",
      "r203"
     ],
     "calculation": {
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 8.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Contract liabilities, current"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r198",
      "r199",
      "r203"
     ],
     "calculation": {
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "terseLabel": "Contract liabilities, less current portion"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r204"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "verboseLabel": "Revenue recognized included in the contract liability balance at the beginning of the year"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsSummaryofCollaborationRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r208",
      "r216",
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate debt securities"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesDetails",
      "http://www.denalitherapeutics.com/role/MarketableSecuritiesSummaryofAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostsIncurredDevelopmentCosts": {
     "auth_ref": [
      "r368"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development costs incurred, including capitalized costs and costs charged to expense, in oil and gas activities.",
        "label": "Costs Incurred, Development Costs",
        "terseLabel": "Costs incurred"
       }
      }
     },
     "localname": "CostsIncurredDevelopmentCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss": {
     "auth_ref": [
      "r155",
      "r170",
      "r175",
      "r176"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Allowance for Credit Loss",
        "terseLabel": "Allowance for credit losses"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/MarketableSecuritiesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "auth_ref": [
      "r162"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale [Table]",
        "terseLabel": "Debt Securities, Available-for-sale [Table]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/MarketableSecuritiesSummaryofAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTerm": {
     "auth_ref": [
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period between issuance and maturity of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Debt Securities, Available-for-sale, Term",
        "terseLabel": "Effective maturity (less than)"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTerm",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/MarketableSecuritiesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": {
     "auth_ref": [
      "r160",
      "r171",
      "r178"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.",
        "label": "Debt Securities, Available-for-sale, Unrealized Loss Position",
        "terseLabel": "Aggregate fair value, unrealized holding loss position"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/MarketableSecuritiesSummaryofAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions": {
     "auth_ref": [
      "r161",
      "r172"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Unrealized Loss Position, Number of Positions",
        "terseLabel": "Number of securities held in unrealized holding loss position"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/MarketableSecuritiesSummaryofAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r71",
      "r123"
     ],
     "calculation": {
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssets": {
     "auth_ref": [
      "r39",
      "r40",
      "r305"
     ],
     "calculation": {
      "http://www.denalitherapeutics.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Asset",
        "terseLabel": "Foreign currency derivative contracts",
        "verboseLabel": "Derivative asset"
       }
      }
     },
     "localname": "DerivativeAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/DerivativeFinancialInstrumentsNarrativeDetails",
      "http://www.denalitherapeutics.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Contract [Domain]",
        "terseLabel": "Derivative Contract [Domain]"
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/DerivativeFinancialInstrumentsNarrativeDetails",
      "http://www.denalitherapeutics.com/role/DerivativeFinancialInstrumentsSummaryofForwardForeignCurrencyExchangeContractsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeGainLossOnDerivativeNet": {
     "auth_ref": [
      "r286"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.",
        "label": "Derivative, Gain (Loss) on Derivative, Net",
        "negatedLabel": "Net loss on derivative instruments"
       }
      }
     },
     "localname": "DerivativeGainLossOnDerivativeNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/DerivativeFinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r285",
      "r287",
      "r290",
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]",
        "terseLabel": "Derivative Instrument [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/DerivativeFinancialInstrumentsNarrativeDetails",
      "http://www.denalitherapeutics.com/role/DerivativeFinancialInstrumentsSummaryofForwardForeignCurrencyExchangeContractsOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": {
     "auth_ref": [
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.",
        "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]",
        "terseLabel": "Derivative Financial Instruments"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/DerivativeFinancialInstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DerivativeLiabilities": {
     "auth_ref": [
      "r39",
      "r40",
      "r305"
     ],
     "calculation": {
      "http://www.denalitherapeutics.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liability",
        "terseLabel": "Foreign currency derivative contracts",
        "verboseLabel": "Derivative liability"
       }
      }
     },
     "localname": "DerivativeLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/DerivativeFinancialInstrumentsNarrativeDetails",
      "http://www.denalitherapeutics.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivative [Line Items]",
        "terseLabel": "Derivative [Line Items]"
       }
      }
     },
     "localname": "DerivativeLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/DerivativeFinancialInstrumentsNarrativeDetails",
      "http://www.denalitherapeutics.com/role/DerivativeFinancialInstrumentsSummaryofForwardForeignCurrencyExchangeContractsOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeNotionalAmount": {
     "auth_ref": [
      "r279",
      "r281"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nominal or face amount used to calculate payment on derivative.",
        "label": "Derivative, Notional Amount",
        "terseLabel": "Aggregate Notional Amount in Foreign Currency"
       }
      }
     },
     "localname": "DerivativeNotionalAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/DerivativeFinancialInstrumentsSummaryofForwardForeignCurrencyExchangeContractsOutstandingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeNumberOfInstrumentsHeld": {
     "auth_ref": [
      "r279",
      "r281"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of derivative instruments of a particular group held by the entity.",
        "label": "Derivative, Number of Instruments Held",
        "terseLabel": "Number of Contracts"
       }
      }
     },
     "localname": "DerivativeNumberOfInstrumentsHeld",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/DerivativeFinancialInstrumentsSummaryofForwardForeignCurrencyExchangeContractsOutstandingDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DerivativeTable": {
     "auth_ref": [
      "r278",
      "r280",
      "r281",
      "r282",
      "r283",
      "r289",
      "r290",
      "r294",
      "r296",
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.",
        "label": "Derivative [Table]",
        "terseLabel": "Derivative [Table]"
       }
      }
     },
     "localname": "DerivativeTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/DerivativeFinancialInstrumentsNarrativeDetails",
      "http://www.denalitherapeutics.com/role/DerivativeFinancialInstrumentsSummaryofForwardForeignCurrencyExchangeContractsOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "auth_ref": [
      "r76",
      "r83",
      "r278",
      "r280",
      "r282",
      "r283",
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.",
        "label": "Derivatives, Policy [Policy Text Block]",
        "terseLabel": "Derivatives and Hedging Activities"
       }
      }
     },
     "localname": "DerivativesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DesignatedAsHedgingInstrumentMember": {
     "auth_ref": [
      "r282"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Designated as Hedging Instrument [Member]",
        "terseLabel": "Designated as Hedging Instrument"
       }
      }
     },
     "localname": "DesignatedAsHedgingInstrumentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/DerivativeFinancialInstrumentsSummaryofForwardForeignCurrencyExchangeContractsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r202"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Summary of Collaboration Revenue"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-Based Awards"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/StockBasedAwards"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]",
        "terseLabel": "Disclosure of Compensation Related Costs, Share-based Payments [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DueFromRelatedPartiesCurrent": {
     "auth_ref": [
      "r2",
      "r9",
      "r16",
      "r81",
      "r332"
     ],
     "calculation": {
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of receivables to be collected from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth, at the financial statement date. which are usually due within one year (or one business cycle).",
        "label": "Due from Related Parties, Current",
        "terseLabel": "Cost sharing reimbursements due from related party"
       }
      }
     },
     "localname": "DueFromRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsBiogenDetails",
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r59",
      "r90",
      "r91",
      "r92",
      "r93",
      "r94",
      "r98",
      "r100",
      "r102",
      "r103",
      "r104",
      "r108",
      "r109",
      "r377",
      "r392"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per share, basic (usd per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r59",
      "r90",
      "r91",
      "r92",
      "r93",
      "r94",
      "r100",
      "r102",
      "r103",
      "r104",
      "r108",
      "r109",
      "r377",
      "r392"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per share, diluted (usd per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r76",
      "r105",
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r105",
      "r106",
      "r107",
      "r110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/NetLossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued compensation"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "verboseLabel": "Stock Options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofAssumptionsUsedforEstimatingtheFairValueofStockOptionsGrantedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r85",
      "r86",
      "r87",
      "r89",
      "r95",
      "r97",
      "r111",
      "r164",
      "r196",
      "r197",
      "r246",
      "r247",
      "r248",
      "r259",
      "r260",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r399",
      "r400",
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r299",
      "r300",
      "r301",
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r216",
      "r300",
      "r339",
      "r340",
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r208",
      "r209",
      "r214",
      "r216",
      "r300",
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r208",
      "r209",
      "r214",
      "r216",
      "r300",
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r216",
      "r300",
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r216",
      "r339",
      "r340",
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r158",
      "r159",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r173",
      "r174",
      "r177",
      "r178",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesDetails",
      "http://www.denalitherapeutics.com/role/MarketableSecuritiesSummaryofAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ForeignExchangeContractMember": {
     "auth_ref": [
      "r208",
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates.",
        "label": "Foreign Exchange Contract [Member]",
        "terseLabel": "Foreign Exchange Contracts"
       }
      }
     },
     "localname": "ForeignExchangeContractMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/DerivativeFinancialInstrumentsNarrativeDetails",
      "http://www.denalitherapeutics.com/role/DerivativeFinancialInstrumentsSummaryofForwardForeignCurrencyExchangeContractsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r60"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_HedgingDesignationAxis": {
     "auth_ref": [
      "r282",
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Axis]",
        "terseLabel": "Hedging Designation [Axis]"
       }
      }
     },
     "localname": "HedgingDesignationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/DerivativeFinancialInstrumentsSummaryofForwardForeignCurrencyExchangeContractsOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HedgingDesignationDomain": {
     "auth_ref": [
      "r282"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Domain]",
        "terseLabel": "Hedging Designation [Domain]"
       }
      }
     },
     "localname": "HedgingDesignationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/DerivativeFinancialInstrumentsSummaryofForwardForeignCurrencyExchangeContractsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossAttributableToParent": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of income (loss) attributable to parent. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments.",
        "label": "Income (Loss) Attributable to Parent, before Tax",
        "totalLabel": "Loss before income taxes"
       }
      }
     },
     "localname": "IncomeLossAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r181"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/LicenseAgreementsNarrativeDetails",
      "http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/LicenseAgreementsNarrativeDetails",
      "http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r80",
      "r96",
      "r97",
      "r124",
      "r258",
      "r261",
      "r262",
      "r393"
     ],
     "calculation": {
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "Income tax benefit",
        "negatedTerseLabel": "Tax benefit (provision)"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.denalitherapeutics.com/role/MarketableSecuritiesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other.",
        "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities",
        "terseLabel": "Accruals and other current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Contract liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities.",
        "label": "Investment Income, Net, Amortization of Discount and Premium",
        "negatedLabel": "Net amortization of discounts on marketable securities"
       }
      }
     },
     "localname": "InvestmentIncomeNetAmortizationOfDiscountAndPremium",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type [Axis]"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesDetails",
      "http://www.denalitherapeutics.com/role/MarketableSecuritiesSummaryofAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investments [Domain]",
        "terseLabel": "Investments [Domain]"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesDetails",
      "http://www.denalitherapeutics.com/role/MarketableSecuritiesSummaryofAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseContractualTermAxis": {
     "auth_ref": [
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by contractual term of lease arrangement.",
        "label": "Lease Contractual Term [Axis]",
        "terseLabel": "Lease Contractual Term [Axis]"
       }
      }
     },
     "localname": "LeaseContractualTermAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseContractualTermDomain": {
     "auth_ref": [
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual term of lease arrangement.",
        "label": "Lease Contractual Term [Domain]",
        "terseLabel": "Lease Contractual Term [Domain]"
       }
      }
     },
     "localname": "LeaseContractualTermDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r324",
      "r326"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "terseLabel": "Operating lease costs"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseholdImprovementsGross": {
     "auth_ref": [
      "r7",
      "r179"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements, Gross",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseDiscountRate": {
     "auth_ref": [
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discount rate used by lessee to determine present value of operating lease payments.",
        "label": "Lessee, Operating Lease, Discount Rate",
        "terseLabel": "Discount rate (as a percentage)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseDiscountRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Summary of Future Minimum Lease Commitments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CommitmentsandContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r325"
     ],
     "calculation": {
      "http://www.denalitherapeutics.com/role/CommitmentsandContingenciesSummaryofCompanysFutureMinimumLeaseCommitmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.denalitherapeutics.com/role/CommitmentsandContingenciesSummaryofCompanysFutureMinimumLeaseCommitmentsDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total undiscounted lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CommitmentsandContingenciesSummaryofCompanysFutureMinimumLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r325"
     ],
     "calculation": {
      "http://www.denalitherapeutics.com/role/CommitmentsandContingenciesSummaryofCompanysFutureMinimumLeaseCommitmentsDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CommitmentsandContingenciesSummaryofCompanysFutureMinimumLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r325"
     ],
     "calculation": {
      "http://www.denalitherapeutics.com/role/CommitmentsandContingenciesSummaryofCompanysFutureMinimumLeaseCommitmentsDetails_1": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CommitmentsandContingenciesSummaryofCompanysFutureMinimumLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r325"
     ],
     "calculation": {
      "http://www.denalitherapeutics.com/role/CommitmentsandContingenciesSummaryofCompanysFutureMinimumLeaseCommitmentsDetails_1": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CommitmentsandContingenciesSummaryofCompanysFutureMinimumLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r325"
     ],
     "calculation": {
      "http://www.denalitherapeutics.com/role/CommitmentsandContingenciesSummaryofCompanysFutureMinimumLeaseCommitmentsDetails_1": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CommitmentsandContingenciesSummaryofCompanysFutureMinimumLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r325"
     ],
     "calculation": {
      "http://www.denalitherapeutics.com/role/CommitmentsandContingenciesSummaryofCompanysFutureMinimumLeaseCommitmentsDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "2021 (nine months)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CommitmentsandContingenciesSummaryofCompanysFutureMinimumLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r325"
     ],
     "calculation": {
      "http://www.denalitherapeutics.com/role/CommitmentsandContingenciesSummaryofCompanysFutureMinimumLeaseCommitmentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Present value adjustment"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CommitmentsandContingenciesSummaryofCompanysFutureMinimumLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Lease renewal option term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Lease period"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceived": {
     "auth_ref": [
      "r327"
     ],
     "calculation": {
      "http://www.denalitherapeutics.com/role/CommitmentsandContingenciesSummaryofCompanysFutureMinimumLeaseReceivablesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease payments to be received by lessor for operating lease.",
        "label": "Lessor, Operating Lease, Payments to be Received",
        "totalLabel": "Total undiscounted sublease receipts"
       }
      }
     },
     "localname": "LessorOperatingLeasePaymentsToBeReceived",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CommitmentsandContingenciesSummaryofCompanysFutureMinimumLeaseReceivablesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock": {
     "auth_ref": [
      "r327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturity of undiscounted cash flows to be received by lessor on annual basis for operating lease.",
        "label": "Lessor, Operating Lease, Payment to be Received, Fiscal Year Maturity [Table Text Block]",
        "terseLabel": "Summary of Future Minimum Lease Receivables"
       }
      }
     },
     "localname": "LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CommitmentsandContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths": {
     "auth_ref": [
      "r327"
     ],
     "calculation": {
      "http://www.denalitherapeutics.com/role/CommitmentsandContingenciesSummaryofCompanysFutureMinimumLeaseReceivablesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease payment to be received by lessor for operating lease in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessor, Operating Lease, Payment to be Received, Year One",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CommitmentsandContingenciesSummaryofCompanysFutureMinimumLeaseReceivablesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear": {
     "auth_ref": [
      "r327"
     ],
     "calculation": {
      "http://www.denalitherapeutics.com/role/CommitmentsandContingenciesSummaryofCompanysFutureMinimumLeaseReceivablesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease payment to be received by lessor for operating lease in remainder of current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessor, Operating Lease, Payment to be Received, Remainder of Fiscal Year",
        "terseLabel": "2021 (nine months)"
       }
      }
     },
     "localname": "LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CommitmentsandContingenciesSummaryofCompanysFutureMinimumLeaseReceivablesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears": {
     "auth_ref": [
      "r327"
     ],
     "calculation": {
      "http://www.denalitherapeutics.com/role/CommitmentsandContingenciesSummaryofCompanysFutureMinimumLeaseReceivablesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease payment to be received by lessor for operating lease in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessor, Operating Lease, Payment to be Received, Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LessorOperatingLeasePaymentsToBeReceivedThreeYears",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CommitmentsandContingenciesSummaryofCompanysFutureMinimumLeaseReceivablesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears": {
     "auth_ref": [
      "r327"
     ],
     "calculation": {
      "http://www.denalitherapeutics.com/role/CommitmentsandContingenciesSummaryofCompanysFutureMinimumLeaseReceivablesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease payment to be received by lessor for operating lease in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessor, Operating Lease, Payment to be Received, Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LessorOperatingLeasePaymentsToBeReceivedTwoYears",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CommitmentsandContingenciesSummaryofCompanysFutureMinimumLeaseReceivablesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LessorOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessor's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessor, Operating Lease, Term of Contract",
        "terseLabel": "Sublease term"
       }
      }
     },
     "localname": "LessorOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r31",
      "r79",
      "r135",
      "r163",
      "r272",
      "r276",
      "r277",
      "r306"
     ],
     "calculation": {
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r23",
      "r79",
      "r163",
      "r306",
      "r372",
      "r387"
     ],
     "calculation": {
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r34",
      "r79",
      "r163",
      "r272",
      "r276",
      "r277",
      "r306"
     ],
     "calculation": {
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "auth_ref": [
      "r299"
     ],
     "calculation": {
      "http://www.denalitherapeutics.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial and nonfinancial obligations.",
        "label": "Financial and Nonfinancial Liabilities, Fair Value Disclosure",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Fair Value Disclosure [Abstract]",
        "terseLabel": "Liabilities:"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r193",
      "r194"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]",
        "terseLabel": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "auth_ref": [
      "r3",
      "r32"
     ],
     "calculation": {
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as current.",
        "label": "Marketable Securities, Current",
        "terseLabel": "Short-term marketable securities"
       }
      }
     },
     "localname": "MarketableSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesNoncurrent": {
     "auth_ref": [
      "r27"
     ],
     "calculation": {
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as noncurrent.",
        "label": "Marketable Securities, Noncurrent",
        "terseLabel": "Long-term marketable securities"
       }
      }
     },
     "localname": "MarketableSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "auth_ref": [
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment classified as marketable security.",
        "label": "Marketable Securities, Policy [Policy Text Block]",
        "terseLabel": "Marketable Securities"
       }
      }
     },
     "localname": "MarketableSecuritiesPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r208"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]",
        "terseLabel": "Financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]",
        "terseLabel": "Investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r68",
      "r69",
      "r72"
     ],
     "calculation": {
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]",
        "terseLabel": "Operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r0",
      "r50",
      "r53",
      "r57",
      "r72",
      "r79",
      "r88",
      "r90",
      "r91",
      "r92",
      "r93",
      "r96",
      "r97",
      "r101",
      "r125",
      "r133",
      "r136",
      "r139",
      "r141",
      "r163",
      "r306",
      "r375",
      "r390"
     ],
     "calculation": {
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Adopted Accounting Pronouncement"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "terseLabel": "Interest and other income, net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r120"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r125",
      "r133",
      "r136",
      "r139",
      "r141"
     ],
     "calculation": {
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]",
        "terseLabel": "Operating Lease Liabilities, Payments Due [Abstract]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CommitmentsandContingenciesSummaryofCompanysFutureMinimumLeaseCommitmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r315"
     ],
     "calculation": {
      "http://www.denalitherapeutics.com/role/CommitmentsandContingenciesSummaryofCompanysFutureMinimumLeaseCommitmentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Net operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CommitmentsandContingenciesSummaryofCompanysFutureMinimumLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r315"
     ],
     "calculation": {
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liability, current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r315"
     ],
     "calculation": {
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liability, less current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r316",
      "r322"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Cash paid for lease liabilities"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r314"
     ],
     "calculation": {
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r323",
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average remaining lease term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other non-current assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax": {
     "auth_ref": [
      "r42",
      "r43"
     ],
     "calculation": {
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Net unrealized gain on marketable securities, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r51",
      "r54",
      "r269",
      "r270",
      "r274"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Other comprehensive income"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Tax [Abstract]",
        "terseLabel": "Other comprehensive income:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax": {
     "auth_ref": [
      "r43",
      "r46"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before adjustment, of tax expense (benefit) for unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax",
        "negatedLabel": "Tax charge in other comprehensive income"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/MarketableSecuritiesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other non-current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedLabel": "Other non-cash items"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "auth_ref": [
      "r152"
     ],
     "calculation": {
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for purchase of marketable security.",
        "label": "Payments to Acquire Marketable Securities",
        "negatedLabel": "Purchases of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Convertible preferred stock, par value (usd per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Convertible preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Convertible preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Convertible preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r14"
     ],
     "calculation": {
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Convertible preferred stock, $0.01 par value; 40,000,000 shares authorized as of March 31, 2021 and December 31, 2020; 0 shares issued and outstanding as of March 31, 2021 and December 31, 2020"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r4",
      "r24",
      "r25"
     ],
     "calculation": {
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing prepaid expenses and other current assets.",
        "label": "Prepaid Expenses and Other Current Assets [Member]",
        "terseLabel": "Prepaid Assets and Other Current Assets"
       }
      }
     },
     "localname": "PrepaidExpensesAndOtherCurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/DerivativeFinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from public offering of common stock, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": {
     "auth_ref": [
      "r67",
      "r245"
     ],
     "calculation": {
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.",
        "label": "Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised",
        "terseLabel": "Proceeds from exercise of awards under equity incentive plans"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.",
        "label": "Proceeds from Sale and Maturity of Marketable Securities",
        "terseLabel": "Maturities and sales of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r205"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "terseLabel": "Product"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsSanofiDetails",
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsTakedaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r28",
      "r180"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r10",
      "r11",
      "r180",
      "r388"
     ],
     "calculation": {
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r10",
      "r179"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Long-Lived Tangible Asset [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis": {
     "auth_ref": [
      "r13",
      "r371",
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by arrangement, in which the entity has agreed to expend funds to procure goods or services from one or more suppliers.",
        "label": "Purchase Commitment, Excluding Long-term Commitment [Axis]",
        "terseLabel": "Purchase Commitment, Excluding Long-term Commitment [Axis]"
       }
      }
     },
     "localname": "PurchaseCommitmentExcludingLongtermCommitmentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain": {
     "auth_ref": [
      "r13",
      "r371",
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item is intended to be populated, by the entity, with Members identifying each purchase commitment about which information required or determined to be disclosed is being provided. If only one such commitment exists, this item may be used to capture such information; if multiple commitments exist, this item is the dimensional default, which will aggregate such information, as appropriate.",
        "label": "Purchase Commitment, Excluding Long-term Commitment [Domain]",
        "terseLabel": "Purchase Commitment, Excluding Long-term Commitment [Domain]"
       }
      }
     },
     "localname": "PurchaseCommitmentExcludingLongtermCommitmentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PurchaseObligation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.",
        "label": "Purchase Obligation",
        "terseLabel": "Non-refundable purchase commitments"
       }
      }
     },
     "localname": "PurchaseObligation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReceivablesPolicyTextBlock": {
     "auth_ref": [
      "r76",
      "r146",
      "r148",
      "r149",
      "r150"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.",
        "label": "Receivable [Policy Text Block]",
        "terseLabel": "Accounts Receivable"
       }
      }
     },
     "localname": "ReceivablesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r215",
      "r331",
      "r332",
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]",
        "terseLabel": "Related Party Transaction [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsBiogenDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party.",
        "label": "Related Party Transaction [Domain]",
        "terseLabel": "Related Party Transaction [Domain]"
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsBiogenDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r329",
      "r330",
      "r332",
      "r334",
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related Party Transactions"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/RelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "auth_ref": [
      "r256",
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by form of arrangement related to research and development.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsBiogenDetails",
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsTakedaDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "auth_ref": [
      "r256",
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsBiogenDetails",
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsTakedaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r255",
      "r434"
     ],
     "calculation": {
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "verboseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/LicenseAgreementsNarrativeDetails",
      "http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]",
        "terseLabel": "Cash and Cash Equivalents [Domain]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsNoncurrent": {
     "auth_ref": [
      "r6",
      "r12",
      "r73",
      "r75",
      "r423"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents, Noncurrent",
        "verboseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Units (RSUs)"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofRestrictedStockActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r19",
      "r197",
      "r249",
      "r386",
      "r402",
      "r404"
     ],
     "calculation": {
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r85",
      "r86",
      "r87",
      "r89",
      "r95",
      "r97",
      "r164",
      "r246",
      "r247",
      "r248",
      "r259",
      "r260",
      "r399",
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer": {
     "auth_ref": [
      "r263",
      "r266"
     ],
     "calculation": {
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606.",
        "label": "Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer",
        "terseLabel": "Other collaboration revenue",
        "verboseLabel": "Collaborative revenue, excluding revenue from contract with customer"
       }
      }
     },
     "localname": "RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsSummaryofCollaborationRevenueDetails",
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r121",
      "r122",
      "r132",
      "r137",
      "r138",
      "r142",
      "r143",
      "r145",
      "r201",
      "r202",
      "r367"
     ],
     "calculation": {
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "netLabel": "Collaborative revenue, revenue from contract with customer",
        "terseLabel": "Collaboration revenue from customers"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsSanofiDetails",
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsSummaryofCollaborationRevenueDetails",
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsTakedaDetails",
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromRelatedParties": {
     "auth_ref": [
      "r61",
      "r406"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.",
        "label": "Revenue from Related Parties",
        "terseLabel": "Collaboration revenue from customers, related party"
       }
      }
     },
     "localname": "RevenueFromRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r77",
      "r78"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "auth_ref": [
      "r200"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.",
        "label": "Revenue, Remaining Performance Obligation, Amount",
        "terseLabel": "Performance obligation"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsSanofiPerformanceObligationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]",
        "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsSanofiPerformanceObligationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about expected timing for satisfying remaining performance obligation.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]",
        "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsSanofiPerformanceObligationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r56",
      "r79",
      "r121",
      "r122",
      "r132",
      "r137",
      "r138",
      "r142",
      "r143",
      "r145",
      "r163",
      "r306",
      "r378"
     ],
     "calculation": {
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "totalLabel": "Total collaboration revenue",
        "verboseLabel": "Total Collaboration Revenue"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsSummaryofCollaborationRevenueDetails",
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SalariesWagesAndOfficersCompensationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Salary and Wage, Excluding Cost of Good and Service Sold [Abstract]"
       }
      }
     },
     "localname": "SalariesWagesAndOfficersCompensationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Purchase price"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsBiogenDetails",
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsTakedaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Number of common stock (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsBiogenDetails",
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsTakedaDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Closing stock price (usd per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsBiogenDetails",
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsTakedaDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r105"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/NetLossPerShareScheduleofDilutiveSecuritiesNotIncludedinDilutedPerShareCalculationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r105"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Dilutive Securities Not Included in Diluted Per Share Calculations"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/NetLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/MarketableSecuritiesSummaryofAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.",
        "label": "Schedule of Available-for-sale Securities Reconciliation [Table Text Block]",
        "terseLabel": "Summary of Available for Sale Securities"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/MarketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsBiogenDetails",
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsSanofiDetails",
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsSummaryofCollaborationRevenueDetails",
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsTakedaDetails",
      "http://www.denalitherapeutics.com/role/LicenseAgreementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsTextBlock": {
     "auth_ref": [
      "r278",
      "r280",
      "r281",
      "r282",
      "r283",
      "r289",
      "r290",
      "r294",
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of pertinent information about a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.",
        "label": "Schedule of Derivative Instruments [Table Text Block]",
        "terseLabel": "Summary of Forward Foreign Currency Exchange Contracts Outstanding"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/DerivativeFinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r221",
      "r242",
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Summary of Stock-Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/StockBasedAwardsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r299",
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Assets and Liabilities Measured at Fair Value"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r222",
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofAssumptionsUsedforEstimatingtheFairValueofStockOptionsGrantedDetails",
      "http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofRestrictedStockActivityDetails",
      "http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r224",
      "r234",
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary of Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/StockBasedAwardsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Summary of Assumptions Used for Estimating the Fair Value of Stock Granted"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/StockBasedAwardsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Summary of Restricted Stock Activity"
       }
      }
     },
     "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/StockBasedAwardsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r76",
      "r126",
      "r127",
      "r128",
      "r129",
      "r130",
      "r131",
      "r143"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segments"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock\u2013based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedTerseLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofRestrictedStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Forfeited (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofRestrictedStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofRestrictedStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Granted (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofRestrictedStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r230"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofRestrictedStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r230"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Ending balance (usd per share)",
        "periodStartLabel": "Beginning balance (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofRestrictedStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted-Average Fair Value at Date of Grant per Share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofRestrictedStockActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r232"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Vested and released (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofRestrictedStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r232"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested and released (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofRestrictedStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofAssumptionsUsedforEstimatingtheFairValueofStockOptionsGrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "terseLabel": "Volatility, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofAssumptionsUsedforEstimatingtheFairValueofStockOptionsGrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "terseLabel": "Volatility, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofAssumptionsUsedforEstimatingtheFairValueofStockOptionsGrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "terseLabel": "Risk-free interest rate, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofAssumptionsUsedforEstimatingtheFairValueofStockOptionsGrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "terseLabel": "Risk-free interest rate, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofAssumptionsUsedforEstimatingtheFairValueofStockOptionsGrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofAssumptionsUsedforEstimatingtheFairValueofStockOptionsGrantedDetails",
      "http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofRestrictedStockActivityDetails",
      "http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]",
        "terseLabel": "Number of RSU shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofRestrictedStockActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r227"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Exercisable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r226",
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of Options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r225"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Ending balance (usd per share)",
        "periodStartLabel": "Beginning balance (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted-Average Exercise\u00a0Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r237"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Exercisable (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Vested and expected to vest (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Vested and expected to vest (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r220",
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Equity Award [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofAssumptionsUsedforEstimatingtheFairValueofStockOptionsGrantedDetails",
      "http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofRestrictedStockActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "verboseLabel": "Exercised (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Forfeited (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r239",
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofAssumptionsUsedforEstimatingtheFairValueofStockOptionsGrantedDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShortTermInvestmentsMember": {
     "auth_ref": [
      "r418",
      "r419",
      "r420",
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments which are not otherwise included in another category or item that the entity has the intent to sell or dispose of within one year from the date of the balance sheet.",
        "label": "Short-term Investments [Member]",
        "terseLabel": "Short-term marketable securities"
       }
      }
     },
     "localname": "ShortTermInvestmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r84"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/SignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r37",
      "r85",
      "r86",
      "r87",
      "r89",
      "r95",
      "r97",
      "r111",
      "r164",
      "r196",
      "r197",
      "r246",
      "r247",
      "r248",
      "r259",
      "r260",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r399",
      "r400",
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r85",
      "r86",
      "r87",
      "r111",
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r14",
      "r15",
      "r196",
      "r197"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "verboseLabel": "Issuance of common stock in follow-on offering, net of issuance costs of $632 (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r14",
      "r15",
      "r196",
      "r197"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures",
        "terseLabel": "Vesting of restricted stock units (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r14",
      "r15",
      "r196",
      "r197",
      "r228"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r14",
      "r15",
      "r196",
      "r197"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "verboseLabel": "Issuance of common stock in follow-on offering, net of issuance costs of $632"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r196",
      "r197"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures",
        "terseLabel": "Vesting of restricted stock units"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r15",
      "r21",
      "r22",
      "r79",
      "r147",
      "r163",
      "r306"
     ],
     "calculation": {
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "verboseLabel": "Stockholders' equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubleaseIncome": {
     "auth_ref": [
      "r321",
      "r326"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of sublease income excluding finance and operating lease expense.",
        "label": "Sublease Income",
        "terseLabel": "Sublease income"
       }
      }
     },
     "localname": "SubleaseIncome",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r158",
      "r159",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesDetails",
      "http://www.denalitherapeutics.com/role/MarketableSecuritiesSummaryofAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Type of Arrangement and Non-arrangement Transactions [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsBiogenDetails",
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsSanofiDetails",
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsSummaryofCollaborationRevenueDetails",
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsTakedaDetails",
      "http://www.denalitherapeutics.com/role/LicenseAgreementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "auth_ref": [
      "r208",
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).",
        "label": "US Government Agencies Debt Securities [Member]",
        "terseLabel": "U.S. government agency securities"
       }
      }
     },
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesDetails",
      "http://www.denalitherapeutics.com/role/MarketableSecuritiesSummaryofAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "auth_ref": [
      "r208",
      "r216",
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).",
        "label": "US Treasury Securities [Member]",
        "terseLabel": "U.S. government treasuries"
       }
      }
     },
     "localname": "USTreasurySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesDetails",
      "http://www.denalitherapeutics.com/role/MarketableSecuritiesSummaryofAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r112",
      "r113",
      "r115",
      "r116",
      "r117",
      "r118",
      "r119"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r99",
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted average number of shares outstanding, diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r98",
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted average number of shares outstanding, basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 14
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8672-108599"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(25))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5033-111524"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10149-111534"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10178-111534"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26610-111562"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26853-111562"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aaa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27232-111563"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL120269820-111563"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(a)(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27290-111563"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27290-111563"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919244-210447"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919253-210447"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919258-210447"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919230-210447"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121558606&loc=SL82898722-210454"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922895-210455"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922900-210455"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(i)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922900-210455"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922900-210455"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14394-108349"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14453-108349"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14472-108349"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=121555522&loc=d3e12021-110248"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=121555522&loc=d3e12053-110248"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130531-203044"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130532-203044"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=118644919&loc=SL5834089-161433"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5579240-113959"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5579245-113959"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5579245-113959"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5580258-113959"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41620-113959"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41638-113959"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624181-113959"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41641-113959"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41675-113959"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41678-113959"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "25",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "815",
   "URI": "http://asc.fasb.org/topic&trid=2229140"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13433-108611"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918666-209980"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.2)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121576215&loc=SL77919396-209981"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121576215&loc=SL77919359-209981"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62014-109447"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(17))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62557-112803"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62652-112803"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=108315417&loc=d3e61044-112788"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(5))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121641442&loc=d3e19393-158473"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07.1(c))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=SL120429264-123010"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=SL120429264-123010"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r435": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r436": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r437": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r438": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r439": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r440": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e640-108580"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6812-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1(e))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.20)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6812-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4273-108586"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(n))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(11))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1505-109256"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>66
<FILENAME>0001714899-21-000054-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001714899-21-000054-xbrl.zip
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M+/(8A*=(4<Y65A'H=(D92-<Y4NC=J-^_IBLWNGX=_(.71J3#+Y(:$G"@F?)
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M2B0=480+A;";V X3>8X6A 6NR7-T?WF.'B//K\V;L%AHYICGAK$8B05F5$K
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M.1'@J%OKP=)!6H"LU(8)MCQD>F8/<'8D \H 2UEKA+.,&V.I!.]=",]2UH[
M2T.RN7J LZ-/U#Y8(BDS6#$CG?6!(6\9)2Q(C_-%?*R7P$.?DU+">F;.N:'
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M3)Z7&6F881::8^ UDG1N@V(H.,V$%\8J$AGW3I8Y/@7T96=Y/!RR5@0C)0U
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M70V<U^%!@Y->?_@I-%NN'>K!-;N]=N_P[$/;#&.OW]GO=DTG^ ]C LYB.._
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M@DND%M$Q]Q'\;R<4Q9(1%!0AQ*A4:<Y8 :YZ*7>?&LV/BQ$N*K*?QJC'PJO
M*$N;R:)R %3)6*!.4,^]YJ4,+E%;='D<F=#.$*J\91%KXP.QR)'(.4M)(A.(
M:T*RZ8<2XL^W0#1]U]TP"*FRZ1I0/E4N[9WD+WSY-M/4B7KO0^@G!MKL]?.5
M^L%?9]_M,S7]\&$$O9E!6#OLAR?RXVZ"76>$W!/L5YL^ NR<>JR88%(IR8R3
M!E&%L+.6(Z8YG12^+S%>8GPV9LA5V#XFI=(3@HD4,:08DG<:1\D<BL1JD?8D
M3;*_$!)%A.WNSF8MI1&=Y,E&4](L,H(?BPL,T!"S"!%P[8DTGA/L&9=")3A0
MKIPW.&"CQKH[X2(;?UC<Q+,? 61,DR4#Q UE> T2/U:&T/0R_>T1RI"0:!3C
MSGG/&37."LR#$40;RREC[CIZ%CIML43//=%S(WGR,>C1@!&"@_+2,I,GDRM+
M//4"(Q)# 4K0[X9VVN[Q(9$M]S_!DKA(=TUT78NQU6ZE-N,EJ8)BY4GV#PB,
MTX$17 L>P$^,UAL-/SGI= C:%6"7Q]S)7]I"3PE(%$$2@:["A#CP[ZPF)NA(
MM5<>6Q0*L%G_6>31#V)R8Q!.G;#)]9G5KGEQ*OM)4!\Q$MQB!F!7C!*F??3@
M)2+F V%&B-R&PV#$X=*&6S1 7+/A !+I?_.UX3A8_CQHZ8D&1\!+S2BX P)3
MSE0$=;[X,O/%@>9I="?"U 7JL5&$28.45Q)^" $['X4TB[^[\"7C8#95O3JM
M=A@,>]UP^Y:XB\O3?NZ=+DTE%3)JRH47+'JJB8K>2RF<C'02I,(*CU54^D#1
MHJ'L)S3>,]U>;#VQ87194G!>:7=7]1-6&;ZG?AHWI6@&^LD)3Q@!_00"B7DL
MK=:>RQA4"-*+F-OT)6(6!S&70NDF"!X3:=!&2:3!L;.4:4N5<=)&T$:>!@3R
MY(6#X"=.W+O:WN1JB;:?J<!6U[?&6]YOUX&7UQ^N!$EPWJ65Y2@8MEYCA BC
M@1L"UC>6\P/Q<[&Q,<IR3GFT(,N%8=93Y6B@5D;)X7O)QC]BXP\PT2?-T,\3
M4$MNOK?N"(80H@28$)Z95) (&ZHY0=YQ+,0"&Q!/2Y^?/O[NS3CW@ONBT-^$
ME-Y#@C?$LLB$"D!UA"@8#T2S<8#C)=)_4>@#BL *)SA/1=^]LL;*P,&T]V#=
M2ZY4 <*7BZ =JE/GO-YO'1Z&?O!K7;\;AJ;5A8\.L#'3LO,+@\GGCZ!BA[!'
M3B#G.2..@;K17DC %E4@9<PD>W8"8%0"N 3PCS)B[PM@-#, 2QQ%8$IR+@G#
M(',%ERG.HK2W#),%/IGK)Y!::Y\W [3N#]9; W#3PCT7,)\Q%GL]OT9@YX1'
MDH&CZ"4QR@E-#0M&!\*B6=RUF84DS Q+;7-O&.)&J%0"A$F%A65(.LY1"FO;
MQ2;,2PY*SA $ECCNJ3<A.19"!\N(QP'\B,BX('B!CT5]\2"882'U()4)U@I0
MFTQK8[3E4EEE)17<6#U9V4(OW7MYYEC&@VW/IU]*0W-W5 + DM&@D\?-# ]:
M4<&D<U9SA;VC)587'*N7]7?O$_\M)$9-!-6IB1<<1P8FKC8J(JV19\)1HL08
MHX@0FDT_% RC=7,<O/G0-/V.<6$T3!4EWO4Z)Z9[]K[5:0U_*GN*IWEOP J1
MC-#[91%<:_J8G0J!(&$MR2UVH;#FB&(?F908"ZE-":O[#6 W@>0R&[EJ3EN=
MT:-K+)> _0ZP@FAP,96R1H/K'YV.+%CX"?ZB4O-)QD.)TR*@Z=JRR36 _&*2
M B#P,-QQW.;XVH.3$WS4/C!&&/6(I3H\SOFH*.8X@$LS#C65>'OI<G%62+Y^
M8@81V#K%),&*!1$-1HH$Y7@>82.\U,W/C91[/[Z(U1J>7]?K@"RED6/G(N/$
MFJ M<S0BC+15PI>RM\1]060Y6 P:W'2)1"3I7$DK;9211H>D(HA?=]\+&6(J
M.J;G)R%G&!52T;-(J7.(<?#9D;6:$Z*EC(QHY5QAU]M>()J>9"T.6\JH\2Y&
MJQE68$]:<)JMP"*=^V$7>/=:"9#Y')YHE$:6$\&H9A0+ZP@85]A'))A5W$^R
M#&EQUSZ>'2GCO29WP&2M_JF^NU$E3Y\ 2.>^9A&Q4X:"B6/3&8^@G.!3% $C
M;ZC 2M_,8,4EMF:*K0_U3Q^V=FL+E5N*9V3X$"Z) Y>0(<D(-A:'8()A8 EA
M:14M]5JQ$/4DNBWB&&,ZA5T;Q&1$AN-T@G,PT7*E.9XX707.H']VM+R\_)1G
M2*37RB!KM%*<66:M,DX)&P@F@7)IL2AQ7& <SSMWY1GP"[Y%<#)@3PQE'#OM
MP>?@(:8X6&3*%6 GTWV4YAC$5Q!TI4K=0ME@LS+O(XK@*E)/)&.:!L4%DX('
M"XYD4K,%V-^SX&1]EETO03L7C>6$^53XG6F"G$+@QTGCA-3+4C9MG!+Y2V1]
MK-7RX,U;Q10/*JW;(4NU4$R(9+=XR:1#B"%LE%\2\?"2</0L\BBZ2/)=Z1H#
M<@A()E SV! OF-"8LE(>/19'<]QU]OQBR3O"*4"'6*%93+%)HBS6@2L'P(K+
M8K6\0#@]C[5D92#!>^FH8S%B@["7F)OHN.18A%(Z%5)*8.6H KM7825SE]5X
M(";8,T[XR(DKI40AN=4Q!>:GCB#M$2/66RILQ,P@(3W0%A6 6^]5F'S^!<F7
M4@@8Z;P*7$8>F68@!!@RPA*+-+*:D ((@9>)EN?Q4X*/D3&FF*,,>Z*BT"IR
M28QCTL?QCF>!Q+B6+WQ8O,):/XG2;X4N]!-<<[OK9F%#_M+F@,=&P$6&Q#V+
M]>9-9U*L%S.+1=1!@_7 '#+@;B"?#A85PFI*18F-V^1(2@YN 43R-.$!#'YL
MH7R7&?QN<O[X,B)':!*CD>D4*<4B=C8&)C'8IJ".HK*N1,YCD+,;#D=M,^SU
M?W9>3"&QH_*#6Q4/7@" @M*$NRB4X@@'QU 1--*#14&OTPE]U_JI,)@C:@N)
M':^\3V?G1$4"H^DPQ,BB9UX'!3*(^HMC51?N4/<YBIN[*\'.[:C4BV/.'Y$G
MY8F@#J%H"1"9.JTD_!MXY-99:AV[)B<6URN>LXZ!KGJ=L#<$!DN#?-\;ES^_
MGM5Q^P:HC=,3Z"W,P]]Z#XY==W[[!.\OJV99&\52+[D0)"97*W+#K<8!.:K3
M2;]>%\1/+_'[[/A]GLB!1L%AKB689HIY933VWE,.,!7(ZT+D1Y7X70S\SBM.
M>E%R8_#O^'W!C=&P_S9=F-Y\[VH;,@:7.[H,@05"N-(V;?^.EML TAU-,EUY
MVFHY^;!HG# %Q?NT\CG=WCPR[7KH=Z[@XE_!^'^/@#JA/\B;/GWB)\\0N8\3
M<:/I8Q9'J60(@^-@.&,X"ATI$YX:1*RR2*K)!OZ2BO?>CGZ5,(\I+:()2NK&
M "V8M<*"!^!383G'&,7.%H#/;@L@M[JSK"[S_+1_?@YV6E/O8HHB1685MHI$
M03SVTC'"C2\H4&9;AJ@$RDI+V:B,B"!7"&=82D4U(@8S@2E5(%X65]3/<R7J
M282Y8%Q$1;"PVC"NE-4T8H.]D90Z^+< //I$G'3OYW[H]V#"AV<?VD #\!4V
M_CUJY9["=P'F]Z;KV[V^WQQU??#UT(4;MCLG_=[7W+Q_XARWY^%ML+ZUY]IY
MB163X*&RM*L2/&#EC7-T8L:!7[IP;ND]<54+WS[T0Z<U"(.]D6V'.188PF@V
M>UV![\&"TX@ABQD5V C% Z6,*4\8%G)Q*\%<\."DM%-:PFD-QVZZ:X]\JWOX
MOM<]!)[O7%ZZ0KSUZM[:DP;:9U>-16*M!=,R6!>8)4XYZ65@SA.B4H&6Q=VU
MOO!$FMVN<<:1X=)KZJQB&KYH)H%62%L/ZI3X D3C%I-:SY_0IP(V-$2-J4/,
M,&^M%E@%+CB5*CA1@(6" I#V66+HBEE#+5?6@6@US&F9-!_P*R81$5:$&/J4
MM&O?3-]?FIW3GS<Z)^W>60A[PYX['B=N+B6/ B6YU%XJY9BBP5*C0T!*>1JX
M5T58S%LX0CX+1WHJ!9#/,FDD"](8SIUW.CA*@[ &+[ZQ<P?]=L-@V&^Y8? Y
M!?>[K>%@=V^_(.9-U(ZG T04\Y0)*37E.GKGA78*QU"D[=W/39_G%Y;@AWLG
MT['=U#*<:GX:2ZDFZ835%)]=?*_ON6GX)'Z>T]P0%BRB.*701:MB,&!B.N8P
MV)K?%;Y;8/H\^2I[(?DNZ" I..[6^<BXXMIR8T7T$7%/J)8%,E(6GL#/LYF'
M /\&##8G]@PY;Q28HYP+;;@S3.-EX^"4H-,W;:#OFN^TNBV0OGD)K*7F88%<
M<%HK+Y@65"'OF"74&1^(\44XGKQ )'X6+L8V>HTED](BIA6W1/( CB4R0B$4
MBK0Y?PUZ\*WV*%%L+[A1/Z_W,H[Y!+_9[Z5PS\EHF!-^)VZ8?K?5/1Q\"/W\
MW(2_SF[OX$ID:.J6 D!JO>X+B38$JX7CCAB>'P'JK$RG%$MD@N (>UX@(;#\
M"'D>&<(\HMYJR6-@Q&*;LA*QX3Y0!5K#E#+DVGZZ"[<MW9%64X]".MUE<S0<
M]<,GN P]+J,@,<8B&X5DP:6"U& H F"P-0IARH-0I2!9-)@\O31IG;[MAW8^
M38-FZZ0"'E2_U[Y.SW3+ZU[_\$W"Q)M)BS?1N&$6>[UAMS<,*Y4(<[X;XB"/
MJGXZL^N]K^_)[M<&K8[\T<;7@RU]M'/TJ7E0WSPZZ%39SM9FL[;^D5<[M>;!
MT3XYJ+>/:UN;1SOUS79U_9B\I[5VX[R'&Y_W3QODX&AGO=ELU#^BG?K?1XW/
M#5SK[/.#]=UFX_SX]*"^QFMM=;JSISNNL]G=@?X:9./;P=$&W?F\V:K5/](J
M@6=O;;8/UJN\=O3QM''T$=?.F\?O*?31.6WO=':;U<[?K>K1QEEMJW%VL/[Q
M;&>]P7;J&[1:=[SV>9LU.G]W=NK-SO0>>-;H@.R+@ZV-LT9G^ZQ:WT8'1W\?
MU]:W6>WHD,-]I[7S8]PX:K8:G0;?V3J(M3-T^KZ^,:SNH6]?8B2:"N<S*K'+
M&#8BTP*'S* 80:0CN"96*NU6]WCWQS3)"9+:K52&O6)2H1W^M7MV\-F?6,)$
MK7YPU*C_U4DSW_B\C6OK[OS@\^9QX_.GX^KY,:FM0W_K^W1G:S?6H*^=]354
M.]H_K=8/<>WPBQ0Q1,=()CRQ&4,499I[E6$"?I0G7#@65RJ]O@_]/U>2C'MS
M@PU*OI@W7U2O\@4- @$+Q Q[:3)FM,Q28<Y,(QVE%]@@QDN^>"A??/RB!$V[
MN$QF! G %V!;6*>!+PS1"CDB#?T97XQ_&?1&?1<&XZ_-8'RN['SKZ^H?\-<D
MV\L$[*)3RAC&-'$F<A&T9\:EC8]:?,D?<''/8'B62 E>?]8,K</F\"WC)\/?
MO[7\L/D6(_2?*]?;F?XA-!WV3MZRD[2[9W!BNJM_V/X;Z'3\^:+O\<7IG:[7
M[O7?_@/L$H#8[Q$4819-I]4^>_O?:_V6:?_WJX'I#K(!*,S)Y4'K/, 08#3Y
MUV^3X2'T.T K3(>+"?K/WY-2S7QPDT)E;U,&9C^U@A&:9QY!I=D/\<^5?_R<
M,G)EM6YL.U1ZL9(R$E/2Z!]OS(V9_9YV8YK8WG#8Z[PE,-I\,*;=.NR^=2%M
MO/LQH1[6T3 ?XN06FZ,V<ZE,W,D@O)U^^-VW!B=M<_:VU<VG*K_I]Z^AG]?O
MGW0)*+H$VFLT!ML0(#WTT_XGEU_GE]X,_??7M'JMT=V7T6M\<>U-WG=_VF!"
M/IKC&.Z#L:>)^7.%KMQXO<F,X)-A9=!KMWPE!Q' 8'(]L</W%T^,3SDW;U$%
MYX^X',.;?#KNID#J3_R CA?#,^[XL-\#K&43<,?\S^]7H X#N3_4U0VHRUN@
MOK*Z7]NN;ZQ7]NIK]8V].]'TL\$_[1CW-M[M[V[7MS?V*FNU]<K&_[[[UUIM
M:Z/R;J=:W=[;V]ZI_?+ 9S[KY%YO]-F *N@>#GO=5Y7UU^]>5PCB3-\B=1>,
M02EY+1B]%X,^J%O\FN$GZ#:-ECV1.+E5(CQ<\MPN61[PR'L)H2MJX(I84HLK
MEC9W=JN5Y$%T>]W:J .=N,K$X=Y-&KA%+5/"*.(<DTP$99%E&CL>I&?"VUOS
M6RI=D\(LJ9S+>L^-4CPAI22L3!.9GL>H?4\.SAJ?'1BF[2,P8)O5K0:OD0,P
M]=.SP-1?/_P&1BJIKK?!<-UM-SH;7_W6)^;_]7?[@+2_VJ,>WOE< P,V&<3'
M]*#S$54_;Z"=]>-ON?%ZWO@&UYNUK4^MQB?%:M^^>&\PLPA<Y<@I&+$<G -.
M=<8=@4L,C%&"5E8QRC[FUNDE#6XS#$L1M3PBZGOCYXGDT],*&7TO&?-;U?2/
M*SO=\,][6M%WF7$+Q@'D-<5\YDC5_#53]^MV@M2?P82<G":@7)W2=HC#6^9D
M1M;F3YV_\7S/6NND\^[-$.Z&UQP$]];V>FUKVNW>T/9.;U-*'\=[']MGN^&D
MUQ\64C]MMNS6OJB2%/*J'5=)%57K!T>U]6/:J!^2QN=:&_JA5;+-J^<;]* ^
MO><3/(MW#^J]\T9]&S7(Q_/&^<?36J<*8_3-G?6#9H/L@YYSYXVCX_-JW;>K
MG]2W]_6U%/8ZA7^_2$^41]1F,AJ1,<E59J67F>7!8HP\4]2NK/[7/S10\/<[
M]=O/I=S<X?M3UR*'[\?]M=WZQN[[1F5WX\/.;KWR87]W;W^M5J_4=RK@2=7!
M7:I@6MG9K6#^F_]G96>S4O_71N72R?JO?V"!?K_PLM;>U5,;K"F[-COW]GY_
M%,5X7@VPV>M7ALU0^?>4X2KC-9Y*2+M^9V]_7I$$;WW*XH$>F]Z<G073#]W;
M1,&'?#P;XY6H0@J"7S943ZOGC2]$<R<DIIFB7&=,4)+9&%#FI=2 &0&,SE=6
MJREIL4+QJTJ:ZYL\75F8Z,#]4+FS6]HCI3VR0/9(O0_#;Z50>.$-DK&,J7X#
M(X352*U3VP*#HI-6?#ZR@RWHX_ROH\91%5W><V&0T-K1&F^<_P5&R"%MD 8Z
M@/L:G[=1;;UY#+*,5K=JK>KY;I)=UPP2C; U(J+,8LDS%AS++-$B0U)HH:@7
M4;*)0<*6T""I[Z[5]K9SL^-7+9+*;(R1VZ-@BV^>#"_X;VJ?I!7QL9DVG87G
M'NV/ENW&(YW_WXLR-],9&/86:UR+3+.?\#!;6*;-M^,/4JI=9;,%9A@(<AOZ
M;Y\RF+V1Y\*EIXT?5DC]_,M^PEEM??\+QBKJ$%7&$,,9,RQFUG&;I6-H"4F[
M)CU)B90XHXKB[UR$,JR]U&'M9UQY6_#E_R>72KOA,-^"U!VF6M$O33*!]2\\
MXSIRF0DA3,:H%)G2FF4F($2T\MXAO;*Z'KH CDJ]&?KF)(Q ? PJVUWW^J>"
MZF&1@>=7C[]MG!HWS&&24J/Z%_"HF$%E<!)<RFKWE5:WTAH.*JZ9!^:^7Z I
MY?,RR><Y+SL^*'6N($$VAE]S0F8.%,Q?,WJ_C+P'X4^_EDP]<?!N3*HG"W_\
M5-[-)WHW2-N!4V'2)%*O+R*,-7#:-=P_F;AX^>;A_ 2'_MF[GB^F0AZ'\AJD
MP7?J^ZC6J9XVCK;!#6AVH(]6]7R#-#K;O%K?/-ZI'W^KU1LW0GDG1Z"\>:W^
MD33.H?W1-MK9.@"EOGU>K1^T&D?'I]7/'Z'O-0QCO!;*4]82$2//2'3)U] T
M4]QXT.@J8(TX(YPG9=XVWTP_/"*6]P"Q]V*0?Q/8=7.Z/=D'-]X(7V#O=]Z0
MWKZ =/1*(PSVJ69IA4TJFQEM =>,.!:H4=J+E54FP'&6A&#Z0U _Q4K+TZ<A
M_]15RO'\6RX[*[U^I3<$,[UR-.JW!K[E\KAL+][3G+B54^?Y&JVKZB!_F_ZA
MZ;;.\^\W#.TG%U0%H/KVZ]W7>Z\KDVWP_:*0^;IDK-1ZKV^C[>W&/7^,<2_N
M89??E!!ZT;&R(!IOS?M^& PF_[R' >!2V_U,VYU?,>!N1'-.FK7S@^.#HUJ[
M6O='C7,8R]8VA7=.R6=G!T=5#N.EM?,JJWY2^(NP%@D73>:IQQFC.&36"0::
MTP6IG!-<X955+'!EYVP V*M\Z+6ZP\I?[:_^IM9\_?QR9+$P_0X^[O3KO6_=
M$M'S0C3_HIR12GJ7(>]#Q@*AF64"90A1G:J&<HKBRNI>;S1L5O8 <9M]TW6M
M@>O=Q/.KIU_?F@ EM\)V^A_ XP53IG1@YX:6T^JW+X%R82@-&?;89DGL96D'
M;(9BE-8$Y2AG*ZOOUIX/'A]Z@Z%I'[1.RNC&7,%1^_8E!FQ2/<5,1ZTR9C#.
M0&':S!JI3;"""$565C5#"OUX6>.1AN(31S_NZ3=,\)@6.4[Z(*E:)Z9=":?!
MY?5RX&>PS<.@8KJ^<MXZ@5?T5_:A/&AY<7%S(7Y[0JY/!L-:/YC"\ODO+RL"
M'W_\HB,AF,N0<49(Q@C2F?589(+(=!X0I3*HE57!OV.U?SZE*$XE*=L?FKWN
MB\Q$ <(<?I%*P[0QDV$G=,941)DQX#-(!!2CADJ"_,JJ$B)3G*E[K^_.F\'O
MES[PV^7R_G_]0Q$L?Q]4AJ$=3A($*MT< Z\J(/W&1Y94###L#5&W> O9-U_]
M]K3L+_?[\X!\MMM$>JN;XCAY-L?3:*_;"J" Q7]1SFVR0A_ZP5=.1OW!*"W5
M#WL5:)$'EC#YS?XS*;F4J+KFAF\+L%2O7X-XG/U2*72K[[[UEY=*Y6LM[[>P
M^Y/H^V3F4QSMYFK[S]?A[VUGC0$]3U.KWAJ.Z^P$XYH5US:#P3U6VI9V-OHF
M%[5[9QW;:\]D(OKC[I=HDFJ3]*,<,>'4-=/!L!409]^:+?CE4N8]9'6K^(B:
MTP:D2WMQHF?.,+$Y%Q?27ISL+-JJ@L,-=N+G_;.#SL8W^/ZM=G3,JM"NN@4V
M9/T0[7QNG%;/MV_N+$*-<W"GZW^U#^I_=QKU-?B^1G;JAZ>UK?UO#;+;W('W
M/#C:.*^F,5[=ZDP5X<2J3 >1=A;ID!EE8L:IQ3PZ89RVXXQT@'9>P/E5Y<3T
M*U]->Q0J_Q<T*$X[2BJ#YJ]E*_PPO;9DAP>SPT1VCT5WR0OWX(6-RSP&28BE
MTF16<N %SURFF+(9N%Q*>Q(,<RDUI_9^>_Y +[("?:9-J4DI?Y_1-M47&Q.5
M7=B<\GGSR95\'ZR)2&L\%'&1,6$HZ Q,,AZ,1)H[1PD! VEM;WWM8V6KW;.F
M#<Y>&]R]2JJ7$X;W20"ZD5"@OTLHT+^: OR0C9X/=ZKG'DK(O>WMKD]Y&J%B
MSRJN&=QQI9,J$WUKACS1*'G65_+D?\/_'&^5:YI!);;:X)B;=AM:I*W9R5__
M]ZB5O'5PTFV8-(".)P[[^%9,4^;/>+?MQ'>_XO)/N2OY\^ERVFU;\7 5W(K4
M]*0?7,B=#$PJ>0V+0>4WZ ]XN#(8@?T\:/92VOYTM^JP:88WW^*;N3[4-,[Q
MS9,7^>>K/#;^&[GRMA;$ 33*J\BGF_+V<&<:RJ2SM%]]D(\D'ZD9#"L:5;PY
M&[R^<\OA4R]-O1OU^S"L\>;YI-^'9C@:%%)N_7K9N>K1QR_6IV,V-,JXLBG7
M,++,"&PR'"WEW"!L#.CH1AC<E#%/2JZK55E2+81@NM&T!^%[0NXU0[N=3D4P
MW;,71[[#+^!D1((HSQR5,6.:R4P+"81D7GA/F5,"WUE9Z2[NJ_6>8LOV9V"S
M)*$&CQ+,%S49GBB&6P1UD^0NB-Q.:S@$29T; OU>-QF?[;-* $/TK+*=;%+C
M\G7-=3,TXXW/-Q3191]7P\B[(VC)$$]J9C<<CL9UTBM[6;UR&Q2>=%Y^2Q"4
MOQ-*7D]&-&RV\CUH)VD/VH4&G,?V_?N-^(ET\9A4%]HU#/[Y?+KS"K82M":J
M]&4)W]-J??_\BPU>>1%]1FU2GL:03(/ S1#7"A%D3$S9AZ7R7$SZT5)[OD3M
M"?K#5-KP6J%BG /MV3=)!2:IVD\.SJV_5H#PV:T7!AU0N_"4_M25  [.&2JY
M<] ;N#]I!@\K,"_?ALWIU=?@W85\:#[$5C<O)91G)J5%>P)O><< \\OX]VFS
MGS:X<WC3=LFC6[ECD"MITW=N#V!B,S+U2Z\ZH_?-FB[(GETL7E,E9KYBS.5K
M*O13K&\+,?LZ?N0U5@\Z\N.N&.V4;, \X<<;DN;5<K:[X98QR)L;!KDH22+U
ML-<_NVT'<W(G^N\F#0II.DQR>L_!)#BOHL;Y7\<PIDYM/0_WGC? /*@>U8YK
MGW>/X-K10;WZ74YOE6S0ZOGN477KXUDJ/EC-P[W07]V=5<E'?+!5@VNU=A5?
M7R(4@1FD',XL3^?C*?C+,BH!)5)K3Z-F*JZLOK]= 3Q],<+Y@_K"P"K^JZQ]
M3Z_BO]1-J_'):Y#,L6G1%4+M-KMT64%7T%?9&]O@8X?PPA ??YU8VLOPFL]7
M%7D2S4C3_-=H  ,;%',I9ZXVR?G[>O7")C'628N,SC".*9(57*8UM9GC"@=A
MD3/&WZ\@\@M3#$\SDH7E\8W; P6E^'J\^)I.[58^LT6.RLY5C.&K8HP%Q1"A
M(7/(X(Q%;S*5"S0LJ=)6N)B*0=U;C#U94LO3AD/C#^*.:>O/K='25KQMF3%?
M7 2SLMO+UP9'@W',$MYN?![++770>_W\6>VS]/!O+7AT"H9VP[<4$.V'KZU!
M;J9VT[9UTTX>;JI]EAH/AJ;K3=\/*JEX6LO?M;^%_F;^>6LLLE(I ]R3 /<@
M+>U<A*)_ U+F<>9Q'<\?AW3O7EILA,'U'_/)+N)"2+GH]AR+;COU-?2X1;=[
M,K8J"&/7F],MF8D1>Z-A+@)S69CR_P=3]NQ_OZ?3C;<0#-(6@E2H%UJNG?1;
M[3&W$3$]>&G.&1MYYL*$NS;S+ $8Y*C;&O/6^*U6KO.;YU%9X0VE)#))L.:$
M M_!7XK0Z.67[9S-&!$K(,1<"]R\P9\KV[7-ZUP'\^A[PTF#6S+^\OG*=USL
MY:/8N9QM,%+!\H3FZ,4QY"'Y$JAAWC"368=#Q@27F37 GYH08X.C-#BVLHH)
M?H4U>064F#+EE+ZWE$Y:N(6]I3K'_J[MUS^IHCQ]D[06>](;FVUO^R$E>'T-
MEU/\G]?KMTW>"EW>8BR\P6CX_2UWC^+JWZGOG,NX"=A%IU*]&J:),Y&+H#TS
M3N. M/@B5Z;W-/N7?N1AR&P_F./,1'CUMZ;]S9P-5MY<5P<@^:>E\Y+T?^A(
MG_.\^IMGD-V^S[^^]M?[C73PTKN=6GVC5M^[?YV":[J0\ M=^!/X/%D_BY<&
MH%XC>K]:[ _J%;UF<O:5N]5KK.^7LC#[F-8<BD+&.-L">C\Z8ND/\[P#J#3[
MR23ZQ\]%(T8KJQ_6=NN5[=>5S>W:6NW=]MK["AA%.[O5M71\VQ]OS&TUG&94
MN'J6X;G'$NT#:(3BA*"?N![SY/[)UD=RP_')TB_SK%6Y/0R34_'PZUF@\8=S
M\"0BY+9@\5Q%R ,'\  10E=6-R_B<'D1Q_%6K=_VNV;D6\/@_SDK*?)0I9!O
MSWT:G;#<!*5W4.SY57])S(<14Z0R$4ELIW@Y?,J]QCS'XR_3!J8-E;UF",-!
MR:(%HVK)HLM"3'TGBU[1IKU8V3D)X\>,BXNFX'\_-.&VM#WO?6]0\G#1R,Y*
M'EX.8J;*&O?BX7SEH-EKPR,&DT68RL:_1ZWA6<F\!:,W+YEW28C)[\F\[\R@
M6=EL][Z5FK9H]!4ELRX),57:K3 ,@Y3+=0?7WA:.*CFV8$26C^/8I8M\DS+R
MO6 HE6AEM6JZYC"7,/\]J*RW!FXT&*1<I>2@KW5-^VS0RDV'2Y&49-8XU36U
MV0V#4?NF>U_*JH*A@.A26%T35K045@L&4RU75C^F'/C6,$_4RJ4/_-">?D_"
MJ]T;C%*^Z)KMC:9502N[K<%Q*9$*1FKVR.6!I9-(K)1("P93Z"B/NPS[0()<
M''WH]USP20*5\J9HA&0_6<NXD4:%'W44]2+OSRUS&9\MEY%.DQFW7U=VZO_:
MV'UT)F.9<U?FW"VDQ!4KJ^_#H6F/=69>)[94FH4C(7OD&N+RB9JU4M8L'%#U
MRFJ* 50VC1OV^J68*1SU2C%3KJ4L.DXI&._[W2MGTNZ9]GCG^C@]ZNHQ-BE6
ML#_(SWF<F#^E4"H<L3$FI50J%TT6'*A@I*^':/(UVOV3=(!)Z+9Z_2O2J)0\
M12-H*7G*Q9'%!RK8[56X!^R@&,#\N;(\6TJ<HA&RE#@W)0XO)<ZB 961E=6=
MO!+@=G=<$0NZ*F5-T4A8RIJ;LD:4LF;A@,I75C=.FRW;*C/SBT<YC,O-YTM#
M3[6RN@<S:(:E:U%$VF'\P\2K>]8>YR?7*MWR&\J;R/M6Y;M:+?%)BD/^0KK4
MH\HFWEZ?ELRB+F4JOO9$A2EO4'E2O?C'))P)]]UK_IZ4_1X[@@?L_%A9K><%
M)WNQDO-@H8:>,F_OV!AYAZS("\^2ZX+^27GO]I*E/ZE7>%,PW9,7Z<J/7SS5
MK;[FX<CO/!PY,P_GGC.Q7=^H5O"==?8K5Z9HK[X&C6\O\'K/&1(_F:%\T,\+
MC?70A6=7ZLW0-R=A!-;'H++==3\]738-_ZZC9><W^GO6Z;KC59YW[->*_2WF
M"+>[E6&S-X(^_.!5)9RZD(IHIR+N%=-)AX<,'C[TXM<H%O0U4W3V9PJ+UXJI
M7^KVQ]<$^K4[?SA8_IJ+^PUV+@[NTQ?+O7D*P^TAM*KINV:%XNN'0#SY&66+
M\OKKP87\4(W)#*#;R@/?6<S_NWKNSH4 UN "G6!V^VNO#097]<S=)+SS%1]^
M4,$OSN%C^OC%TQ0>0O%)!?\%HOCM9]:]&_7[P',5DU/^[2^1_L:[_A)EGKJ/
M&;%L)?^7+B0E4X6JE![ITH?P[U'KJVF/O;SK-'W(*Z/*PB+W_S[JO7Z_&8%\
M_A>Z\\RCT<#?./!(:TXC1T9&+UF47C&J(D4L8BH,DG9RX%%^KMCE@4<9O<=Y
M1Z-!=FC,R=L$I[6N3_]L7&)I;?C.]/OI8+Y/ICT*%\<>T6<^]JC6TAW7V>SN
M'!V3*ME'M7/?.EC?QXVCW>;.YWT.;5%UZ]-1[:C9K&[]?=PX]\?O*?31.6WO
M= Z.JYTJW_F\P7?6#^G.^D?6Z.S">!UJG%=Y@VR3ZGH55>N;S>D]\*S1 =D7
M!YV/9] W;]2/V<ZZ8[7U9NM@:[-=2T=/GK>/&D>-;]7SCZ?5SYNQ>I:.F-Q(
M1TU^^^(B<9@+E!'L;<:$99F)&KYRPHPVENA TU9^_HHF\^O&<4G7#\3[%0:8
MRK(',,(LM74I@PHO@[R5SNA(!?&&B6 L-41;:X.SWF@Y/G0-85+*H,620><7
M,HA8!RB(/./2A(Q)3S/-1<A41$)*&K%7>F65(_D*IRW^"R.#9F2,+[ MM]?L
M]8<9>,*=_)S6, D<74D\O\-,)P^;A5M%:_%$T1S,H>H%&2[3_R>^4RF 'B"
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MP;EPSPSAQ@;+VSBP,-CPRO8Z,(_]&?&\K*53T&<A])GK.I@\9IYAAY3DN1N
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MTM)@+)?\<A KS5/O#K*V)Y#E7=+,2HJ >GF +# >+5,)):42-0YK+MS&%KW
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M.1.&>\F(<<$97&SGU8#%:<C;1! 7$$2$'=.($QZ1$32;TEJ9X)DF*FQL"2X
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M?HOY]SDEK+^9'Z$Q&EP>U&&TX3]#VP/64-_X77<X.&R\@XE]W<L<!.[;;+R
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M#7(+C&O7NU/U(L=LQH/NOJEF*8OC/)CUFKO?/9QD^>"U0I-^T?]O;#SFLB5
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M\?PR\._PV $6-?W6)K5C:;&45;VW*R-A*F4/KTS3>1TC.CVTD[K,017UTH:
M+[NH;D'K 0!UC;N-)VHR3UC(SH^4K=VJE$]3JZA:HVOV]=R(73[]+L47;D5+
M@LN!\?H>&-]Z 'SQP#@IDH(SR6/&A5'61I>XMDZZ$'4N8G;U?6XUWOO#9EY=
M]B%W>6(#V%52:ZT%%E"\<)0OMV-(IT=I>'14FY.MXW[:E R,C=ZLBQ.W%0*[
MEVA,F^DRG8#YB"?3%X,?AC\V*:S-09=?\@_?H*"&<\.K+O'],UQJ?JU+KN:.
MC7N;SFN&6Q>,[#SPY6R'A<$<AKGVII]UAP2[H-,;HAWA?(C=7E'-Y[K-IJH
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M\R*M0)(;!=))<,K1$]WK-7G]52OP@0U-*O-)/GZ;S?+!9G6UZ9+_+Q\)-&@
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M-DCJ?L]_)>U]?C31"N6%$U@Y:;F21%LCE3#$)2:U2VD%-'%G7@KLM_'D#=#
M-PO$>1G=K/VML,1[L,3779^]"+#NVBF4N,RQS%0BIT1 1C@9DS+!4M!S6N%-
M)62/6.*J(P^^3Q%.+&G!G0TXA!RV[@15E$C"M,3$V@?ZNXOT?AOI;=W=46"3
MDHXH!0LV'JZR>S5%C"M- G<B>+/&OJ;O7'JEC)@IJW'(]8&T,B1Z)A2-GI-
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MLL")L"JI0A]Z+,0M?4@6LR0%0X0(@[BT!%EF+")!F*2H],'(C6U%-BGNTU%
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M2GC!=4S.>)5<4MP04$ORCL=YA4,\@0AW3N1E=%JQA' R!G'.#=)46@3L4*3
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M*X:N ]J%L-R+L/BE0+I((J4R(:YR*6:N2"X"+Q!)7+.@&%AB88V#\ O@/'O
M67TP8(&6!T!+:PLIS"266""A D7<"(LT91R1B#%QSEN>7'94%U0IJ-([5'FL
MH,:"-5^/-1U'LA4*0$9&1+D&&F-#/A23$CGB03-PP:C3A<84P.DOX*P^.K-
MRP.@I:4Q#"O %$Z18\HCGFL'&J\ :6A2PL!_E/>-QJQ_=N/](C27_73U:"^Z
MZJYWHJ\?>JYR/IXWZGY;;U4'@<LYVT-!^:#KMJ*4)6MRNQ+A)>+* #Q;;A 7
M6&N1"!-^=8$#*Q27)\Z *0A9$/*)W&L%"U>+A2U!Q5)JXX1!UFB'N&,::9L"
M$M2'W":3:6Q605 +#!88_&YA\-OZ PLXKA0<][H)0"$I[C3"SBC$+7-(QV"1
MI2I8827E:N4ISP4A"T)^?PBY*@=FP<+58F&G6V#,=:NY1LD #,(:82"*3B*9
M.!,J"$G52CR9/8#!R@/Z4]5V;[MZG+Q5AZ-36SU/$]T)?\T?XMA.#H:C>C1X
MCDC#48BCV0NJ*FA<@<Q5E[Y1Z&CEW#R, V\GDW.8A8$]AJF=30?C-#B9Q!,+
MLQ0_G\31-$X'=A0&X]EAG#11=K.!K8*Z-P?6^_IK)_:\ZCV8/PHO3DYC&!RU
M$C:P)R>3\6<0QED<P)6&DT$"H1M\RE(W'813>'7<O#$]'$]F\Z:&LZ9VXM9R
MP&QG2J^9PNV_N<E/V_?]UN--_"_C8[C?><4(U,_3P>_Q4SRJ!8!V*N(/["36
MLQ0&I].\4+/#X22@$SN9G<-*#7U^;3H^G7B8I$&^\N+%./DTA%<'IS-8A2]Q
M (][.IU-SN$A89GL)%07KK;JX'@<XA$LZ'#DCTZS6 Q@HQ_F7\?']:K6#2:1
MLU,82K6<UA]&^ H0S\'9X= ?#NS1T6 *0C),(#"P2X:CD]-9_0ACEX>3M\CF
M( ZKO12&D^AG1^<#^#X,K?EM[1;:UPL].+33P6B<^Q;"!5,$.8)IA-=K4<J3
MT)47%V=G,8ZR2'0D97!<]3R,50/$H[QC+@K&90S*<U%IL-P5T">OM;6<&^IM
M$C*:P*TW)(+!\9ZIC5L@*ROS!C919E#5C"Z!&/J&<WPIJKZ:8[952\WEOQM2
ML7=Z#%?VRRR".:ZEU=1[KD!#:8<=-\2+J *7P<GW+X%%$ S_0]4/+-.)90+Q
M"QA8^;]?__=T"*L#3S_=&87=11_6MO#K/MSV[T=C__&IN<3YG$N\@M?"QUWZ
MKP_ &<3;+W^<[;[<Y< =/N_2=\-WQZ#C_[%[]OKE7QAXP5'\YY_G[_X;3ASE
MP M^.]JC?WQY>[SW\>W^$7"0G;/=+P=G[S[\^N7=\;^.WWUXR]]^V>%[^W^F
MW0_^R]X?[S,=\UPDI%VBB#NLD'."H.",53' 4EE=DSS8M3'L9",V4)(B-<DF
MR3DCU%H=B+6)<"&X$G9C$(&@G60!!UVSL=U.^^!-IYW(T@ZX-TCT&5K^=D'0
MFYUUZ[0M3S/ET:AD)"P1YU@29Q7S-!'#*674I8WM'<#T*WL+#\[BI JQGPZ!
M8,50RYR=UT)&H!;0%,2B>7TV@"4"'<'(YB!+5*537D8?CQWH@N95O#5X/1K8
MP23?95)I(3L=@HZ9M1HSOPF<;CH8 FI>/3*X60<S:[59Z=<!R3A;_T@7Z@GX
M!_#^TVE6;,/18&\,'(5N#C:R63"H[(+!;HN[TXVMP3=&EC>@6,/I47R=KB\M
M_2?,PLB#NJA6?S]_YGN&F=T_WOL<@N6T0T(3C[@Q%KGD"7):.X:]8M9=@AEB
MHB:)!<&QXB9X0"1 JH"9HB1&2R["3%;HP)3!(O@2LP=D.ML<@%$R!9(UFD1[
M5+U\.#ZJ&-2!'8YJQ0X?R$PI;_G.Q@2J/;N""5Z]I]TYO/$!+M:\=CZ8G9_$
MO-4C\#"0DR,[\O"-PQC! ,HT.].NZ>DQ7*X:U; F$]6%,[\X&I\-?JA>')\"
M$(7ICR\NX^5EBV:E"-H@FN"95XRGPWR/%Y-X5,45_7PV#+/#N8.@\ZW&TL/M
M5ZP#N^YT=OU7.E:=AR'&R:-B-6$72%KG[\/)? PG]B B![OH([()AOC"'IW9
M\^G&3\MT#+A8=]HN/O&USY72BI^KYGTAHW&U.5Z :1XG^5,P$OO$(Q@<3C(:
M_Y_;62^0W@H]LSC^DH%\E//%[/952W:ESKU=AU[]O5NQIUG/!@KF>[]R9\"L
M'MF3:7PQ_^%G4&$G1_;\Q7!4S5+UI8N^"^#P[7[9PO6>:>*WFNLW;V]5;UWP
MP-3O<?BF%M>^C;?(M>_==%G"8$#TJRY[\WL2?]TWRV"?;+#R3I>])?KP]NJL
MY-)GKS@HJ-7%8WK(KTX>7V;/2S[2ATY$Y_SF'@G^?9RDG04U^P6HV;5=)^[Y
MP-_!Q/W5LM=_-NSU'YF]EBE\R!3^7O'^,H=WE]^#@TD\R,9+:WO?!^J>38&0
MJT]!WW1//JXP E=;->1A.^V1"EV403[R(%=4,>0^$G:!J-0G"_FLX3$C$/[:
M>K,U.!C#,$?5Z<IL4KG\.DVI5S 4L47O,)@K7"%Y 1'=RH]R<2+M--8V]P_D
MQZOQH63M/?N@%^&-(18;HH3G!BNCJ%(Z!6$%QTR'*NBE\26OJ(OA<N_"!;/.
MQ/KOV2G?GPB9KW,W-Q$RAQ]V/\"=_O$7V7L9#E_O_T%?PW?>'L.U_O'VR^Z'
M\&%W_RU]>_P7NQ@A ]<ZW_OP[N.[_;_P'OU5[+U\RW>_' [??OCMX[L/\![=
M_0SO#V%,:1%&_0:?O:?<2>650TSEAJ1!>>2"\4AB&4D*)A+--[:UPIM2\1ZE
M^Y4DX@)'#X6C>V&.]Z?'IZ !8_A'/F-I+:QLF_X] K3%??NY -']@.C+ HB$
ME1A[29'W 8 H$8R<BPF)Y'QT3'/-@5>85;4K*!A4,.B6!_KA&8%0]NX4$/I*
M$"(+$"*<)N^P0%I2A;C7'EGC!1+.$6Q95,8%8$.7,.C' C]/+:UK!S_]MLCZ
MWU?^>6 /6V /9IX$*PG"%*O<%L\BPYQ&0GL<I*>8&U=;8DK('K&@)W"#]]))
M9P^JDK_33L3GC0[R[[,A)^QFHXB1V-$<:R*=%]%Y;1G\3UC&B_.HWY"U]TO7
M>:2T]QR#N6:L0YR%@ QA!HF0=-!2VXC)QC;%FX0^&+%*:]VUD>3B=WER&6[]
M+I(F&36QB">3>T02@9Q5%FE%/0?>X<'VV=@F#_:[%/E=&_F]4^NPXLAX?*EN
M'1D"UC$$[Q'FV9'!#,NI!P0987TT4HI@:.EZ7T2[^ -Z)L*M/T!XPU-,N=P?
M%H@K09 -GB-LI69>$FV4JLDUZQ.Y_EYC=GX93TYRZD<$B7*S*]P O0_9H=>$
M[-P)3._J+'Z&8&J=$\('^-?SF+B51K+H/6'4.>)B\5CT'%3?=#P62@'U$5:"
MC1/!VG'!(\U#0#@R)8 OY:K78.V(3:G7,-JE2/)72G+Q6#RY#+<>"V5U$"HQ
M$-K<0!G3@*SG 25!M8E<*+!O-K;YJAJ-%OGM3Y3%$PMP<4X\0(!;YP3+54$P
M$\C1R!'7SB"7))@WS'(FC _)I(UMME91%NLHNOTFT<4CL1JY;3T2AC!1\6:&
M.4:<$8PT\P3EAA+,>"^%J,FSHJ9'RO=[#5#X97Q\'"<>+C,XL2=Q4N(1K@ F
MIJE+!#8N#Y@+XK4-,""1HL \XU.Q[GL.4,..=2^QB%9PB:3%!JQ[@9%-V"&J
MM*".:F^BV]A69)/B/KE,RZ%'?R1YU>>9Q>9_@&2W-G]BQDCA&=(X99O?"V2C
MM4CE MQ!)!GTRGL?%=$NHEV\ =](M%MO0#21>LH"LH%%Q(5SR.FLN1WWA IA
MF)-%M(MH%\= ST2X$ZK ?2346.1E !%.N7&LT12T,TTV2%C/8'K(NY\@5.&Q
MV\4N-S"XHHS/PX_\[USG:4T0"WM%8V3!$D&Y4E)S$8T3-AK#98PE'J#OR-4M
M?Z%R7)S6 BGB!.)&*F1! R$=L?):62%"VM@V2FW*E:6>WZ<PVG,YLB@@<%<0
M*&Z%)Q?_3B@!,50E,#L(L(J<P*21C3(B996E@E@!O&9CFZPLEJ"(?D]%_SY1
M"$\M^\7O\ #9;_T.TF(7\NE U1N3>V>1E30@6,+DDQ7$Y2B$*SK#W3L,H4A]
M3Z6^WZR_^"E6(_*MGT)J0:7$!#FK0>2=Q<A0:I'DU%D28?D4K]F^INJYJ/SU
M+D/\^WAT\&VK$/>E/&ZYQAVN\;UF%]U>$;CD['2TM3;)2:))(,1FJTX'9Z1/
M(A$E7/2^^.CZK;5?=W-V1$HZ*NP12YHACA5!)GF),+=$.:#QG(:-;;Z)>9^B
M#DO<\-,*<O&S/;D(MWZV&*@Q+A%$)041AFV!=$@)"2\8<\YPD5-V'MR$O8CO
MVHAO"=SIJ5!WTGBP4=ZPA'" O[B2";EH"9(X!26B=I:M+B:OB/9:BG9QB#V!
M"+<.L1@]UT"BD6$D@EZ. AE+#+(QF10DL5[BBEJ+/M5=O\4),.\^"H.--\M\
M^>3R)[_?3*GG7KN%/:1VR_I&E]J@,57&<>84=RPY1SDSE!,:7=*A5)OMN;+:
MK155[0O:>2\"LY%&CXS+GB"G05/1Y%%4EGD3(M44U!7CFUH\N'I+B11?2UDN
M^5V]DNWSA6P'YY@QW 'WS)&8DC.DHR (C DBHF=1>5S20)Z5<-\GJ.KKI;OX
MA)Y>CO=:':UL@HV+08XM6)/<2X$T3Q9AI:B01 6P-S>VR>6CFKN'517I74O5
M7'Q!3R*ZK0K.2Q65\$@(3A /1".C'$56$,I <I7BMJ;73/1( W\/:5Q'-X=!
ME2RN^T)6,"HY9FUN4L(-B28HHQ.0S,02)DX6ST#?H>O5DF? >NI52@@64P+K
M, $YF8M$2)5,T)%@[P"Z]*;!E^O*]32PLT1U]Q@%BO>@!_+?4A<9HK5*6!0L
M]8@3G^LZTX@$TUCJ9")Q='4!)D7T>RKZ]_$X/+7L%X_#0V2_XW'0V/$D8T*:
M2HNX""EG=6"D5,+.<R:5) _T.!2Y[[?<]YOX%U_%JH2^5?C<4.R3)CF.5('"
M3Q*YP#"P?JXLUBQI&RK"K_6#?14EDVMECHRK'16W/6 S\_7 7S"8WC ^S1Z0
M^5 ?!F+/K8'YZF?E>4.Z,8(E@:U*0?&D@N9,)X9Y(DQ:K%SQY?0=VG>[OAPG
MF8M@S,%FRK:<3@$YEON@84Z$$=C%8('/;6(B-X5YL#MGY=+TQ&=1!4P+F#X)
MF!:76 ]@M&7(A'BLE*) B0U'G.N -/$&!<NDU#G4)HE<V^C!29,%0 N KCN
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M_:9N< RR(,4>X%/-];<S@Z5'F:T,AZ?<!3DQ0*WNRG^ZPTFTLV#YNW]6BQN
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M)'AG-/<$B(J2M3#Z+>I91A";QLB^-3%,9<TS.;3(X>#3VV-/+:<2) LM38'
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M[>$)2(;&%8]0V?%#4^2&J4<^:D HURSB/"9H1E45V>4TMK@)$'Q!%"@Q@<M
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MK(:Z%Z$&\=2 6S%8"I='+/+-./90@]Q00;G-EJ)9]+E%/]G_'H%_YC/75J/
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M-E_#CN,Y7@4C84\\ J67HU'YK]O7P@67@5+MLEAYC_9H,"S^YP_V=M$Z+R\
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M(^NIJ4-^YG7(=^H/O 6UR,^W*/3-=+C!FS.[WJ;,[FHO6@M /H94&N@M3,V
MUG9\?.7EL5PL_4M'$=:U9.$/-9!%@7W\5E3-R2NI*D\W:O6/5-GDM/6-%3;A
MO^(4_P6>6+WL$1_M3&JJEA= ;=OZ&UNR_K?ZN*(R4XE&=,5JBXC+?4NNNR@5
MG;XH&<Q<)(LNF>!/1F&,J* S&2C+Y79>!E:J=5NO0+/\E9Q@VT(5,^>.5Y5<
M_YKV :1RUR8_80&H\M%P^4_F"CTV71M^H[B:SHP#4/MO+Y_LL7.N!K Q?Z@L
MAB&^9NDU&Q=[?TPK9M#*]6F;?>.E[Q7'&WXOH0(B'LIBX=>BN)FB)/_#GG@$
M"NRR^'_W_BNQ&=?#./0\QBS+-T(6VP[W(XN%OLXUW_GN@A='!8B@#-_# W'O
M_L\?[.VB);M=X!]'H&;KZF^OSH278Y>@*7XF?=CNZ5CYS:_5T@H#<U?C@C7U
MEWF"Y:)P8S8<YDDP$D6=LBZ_*BZ=+_]< #AH$J;TK64_G,59<<HQZ&(X;S9H
M=E83\6F[8[6I^GA_QH9[-9X $(?+I=J]!1!D4"0%(0&4">4WH^W6?CN1J8*E
ML* @.H*48 ;=S*[R#)G"C27#/<ZB$+#[4%@Q-H5!IL=P&W9:+G8X;7@IVL/_
MC)(A7''-\D@!4XG&F3+^1GGY-)P.N-$//L1;AOR-T@CJ)@3U-ZOM52L+\C;A
MQU@S_7(*PM86CJ@UKG@Q),F2DG>97%*TOB5Q3PF]Z.Z\*,KK/G7_>?WIXVF'
M!K /_^B>'AY7@ J$!(D'TE3R8@S@V:.YYTG!)F2MY%DP D!8/K^1HLU(T9%<
M:S)COYDUR@?)65/78(JH^L%O;BT%N,%-FI(7>"S\N^ 3T4 R&Q@\Q@*4(;YU
M46)\-)5O\/'-VF]$@VAM:[$&R=;/.6A)ERBI Y;%=$ Q"Y.4N&OF7?MY'IU2
MRT3\,N=A,FVDB Z#YTB*(VF!6%%D>)5TR)3W)_\<':BZ#T8WYD,BT@#+EZ7"
M3LV,+&4!6?%1GVS=S*BJJ,$R-B"X9A)JJ*B!4"/2?(*WRG,0:AIH:\$T3?UF
MF#.8Y=OAP8UX "8-1BJ<9OD4W'W5I(#\1;R?A"L3?]U&L_+@X+R8P'/)7;,"
M,Y,[!8)H"FZ) LRO#H*DE)>D3*3#>GA_ =[UH-15\.5!YR_=UI57[XZ.WNF&
M\7N+EGR58 8.UFA+3OQ*VB24TVM0=%ZZ5D^9WA66MX]RO]#K1^"= [C.*7XQ
M>96%E$I/Q/6SPGB%Q#X^#=1ONC=+1Z<;$S6[19/X!)-S;U*K;9@VC%L\_M25
MJGB;9@)TZ!-L,&=B^K=I,FX((#W!1FM"5H\;";@I6C7AG.S!_6OP=('YJL)*
M].6MH:-9#'[/@%$C)1OR]MS%4I+R<[GL5:0H!M=<+!B,X H6H:A)SKSC$I)P
MB"/0B!J,Q9S/^V+P;[@O85$)H27L?3_%C+I_#O88KVI6?E,K[]SDY\_XI1.7
M.P%/&+9HR%NTIKBV1]TYC[2)R&QRI8S%*S6)F<S-?^L!@R0/0QO\V([D$1Y+
M\V)8TW&BZW%+&?#A4]#RWCPB02"NSS+RFAO,6Q$$XE-!DGIX81HV2C5?7AV)
M? @<OFP>S5F.I-390-KQ,HI?U'Z*(5W2*?*GH.Q7"$74&7ZW*SHQWTWS:01I
MKJ<G"8]V!UG1ZB'"^AWG[/A &0U %%(8** XU"OP&('9!.$P#T>YT%95? J1
M8LY[H)$040K!(2G,!6'^(*NU(J\>O;*<MV\]$%HF2O,6YPEHS><82V5[ 23A
M3XI)S/%QJ<P7CVI^+1[7XUUSN+-"+A2B[M]#]3QM%/R4Q["?8)\2=M'>' UY
M7S':\)X#=D[ F<I8W#>%<I 4X8B@O#B(!40_+A(*4G](!@#M8#"8FB/\,[KF
ME!>C=$B7G(#_2%"BD'4Q2[_[_^R]:7,;1](N^E<0BKGGVA$MCJC%R^LX-X):
M/*-W;$NOI!G'.=\:Z +1HT8WIA=2\*^_N59E]0)2,B5!8G^Q*1+HI2HKUR>?
MQ+J<5'Y_QK+SZ;V[_W/H[!Y1BB26CD^OP6F9TD46=DJ.>AT6N_*+_44NZF"8
MR-'E>$]_G/9$;@N2\OMI)"4^9)[][SM70_Y^N']GAE]^V?#+S^4;'33BO^3_
MZ?*,4H=@HYZD.S3_:*O Y*SZ78!'\#+OZ:.\YM? G?)O>J-H\<]L#WYWBW4G
M:5YCS$*(27&% (-6SF52%L??-"F+,!@1T-^<?28H9K>$Q<6BO\.R.N>1=^F>
M \_:K1SHYVQJ_%*J2<;&SI]*9%P2U]PY._EYPKK%?Z=EE]9[B=TO';9498L?
M#4(+\00L,]'2?$/I((JRX$_R(?KRKJN;+BU;P>14%YCV*RH&W%4[6A?*R0=+
M37KG$F(Y5S,R"\L)JS# "C^C._ M.B55=RX!HGP1U$Y_JQ8IQ)2<W&?$PX.3
M>_>P6,%/RQ[1.6S0.<2<E!#Q4C$$6Y_^^" D+FXJ7W7<I^FEV4?< )F=-I%%
M)^&A\6#^3/SE>SO<21.*<+5N!\=%RCSP9P<25;IPJ'1_/_V!B(/](_)T3Q8_
M=S4F.!(6>=H0DS!Y36<2=FQ%:"&_*[@I?C\^!R#D]%X0@2-:3U0R/[ME+;KO
M] <?\9 =0,',&Y1^UAV??N4>)O=/'R:/'OUX3(L63 %;NF ./K%&_+2*3\8G
M3BJ^(]HB>]S1/(JB%=7ZF4 KI_<?':T2^ W<D^T2%"HI 89 #DS2YUJWX]6=
M9]TY]DE@2D,AV9A=;^O\_)Q&HLJ04=01#I2HKF**J-7O'_VP^.;UV:N'#Q\@
M;G7Q4A"N,1X?;[-Q:=%N]HN+JNC 7P3O\&3Q^Z??B9YC<TQ[\>D78\V.2'#7
MJ*IG6SC0E(*;C9U!:D!?Z439LS!15MV\7H7E:[8D402U4V_-!XF+I6LO<;AN
MQV'FX^>_GBV^P2_>$0C+E)]WY]LD<O7^\O [HW/Q*+UVNU8UW?U[A]V=TP?)
M@]-[R?V'#PZ9_ 6$CR]6;:77[#W!H^] ?440\PB#?D2'*!\8RB%VX6H8$6BF
M?@!T"(__>4S*C\>)'[U*,#YZUO[S*Z+/M/1GGTD2X[66Y $.'6XV"?V7,)P7
MH)T4NSE9^*=0>$NX40:8/'RT6%Z5J#F<L?W4B=F?N[:K'<3X)>&K7N&[UZPH
M/DI^]B/W3U6+##1GR B552OPOY;B$H)^9=VJU:GSI#NSBCZ(>+(564S]RM@W
M%EU98&,G2@:"0@N\6;4D]%GMSKLB;7%V-67Q0(K(]RPS]D=KK$?#^]!UQ;+I
MY5?PJ1R?7AA:+OUSO2VK2W!U79DLP';FZV3A<G*$+G/L,%Z!2'Y5OLOOSFR%
M-D_CSWD)K[IH\O,R7X.[#L>NJ!!RZWT*^+]KG*.CNB;)]FNI5X1/R9?X@HP/
MHW9M_(QBM2>;S-+@1O*VZN,1W"Q\KEKSK>%QWH[)!3UT<E "ENX<E4PU(CM\
M%43 \W<;DZ8++WL \>X;MH:K,%QQ@V\?QU<VW6Y7U;[!'JP)C8,/E1 Z9ICZ
M;KKEOV5GTZ+P4("\>0N/LM]A$%;L;<9VN*Z+TET>.C7;=+^ R _5,C7YBE"4
MMC<@7X, =05N8\*=CW!G>E+X(]Q\WQCD8E?B":2^7MA"#!_2ENZ29A<0&&*6
M/EVO\:WPY9== Q+=R"O#4J[R':H2^A8\'AW:TL';P5HT+7X"MR@L\5IT\4@U
MPK )]-=WIE?Z(%# #S.]TM=6WS].=_>?ZBJ QC+^!2@!5$4YF1;O2JJKX6O$
MU@*DVJ,];CO01_ U8?=."'NFBL/D4K"I')2,6?NUF[QFHG52EOEZ 0\7F1G0
MTFL"VSFZIUR-7.F2BIH:YFB9%!\;/&QX?VF7@M]D;MG*9;#8_3F*TF?&S D
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M?:RI*1V\A%<==F6>/DCOGC[ZQGU+'SY]E,F_Y([/U"D\6[6<D;S.?;POP)Z
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M9M*?*/VM[(*3RYT> &[.0O6!0D7VKVJQS<"(D$@!>$[49X"\1L9C7M'L,(1
MB)0PB<)@.WEFH,B'"950?,*]_ 2K>7,_2NR$"'2'S;3D$MGT/O'[&""*;K=G
M.(!M5BU2N@[VR8ESA>=37'&TRN 8NR(+^,X&"4LUHI:M1IGJ1^$':#3F/?\3
M!]J50AX0[78&/L"^\=5E38VT^"@-Q4]&&5#4R^>>CC7G.F@ZUMC7O<Q@5PT&
M3S0^CZ9K46MX2G,BYR/^D;<;)S?D*R2=<,CE6U=%P3Q4V5]A VL<M$2=]MBF
MIT1>H\*@LXE# LVZB8'1C(NH1!2TW%.O&@H9YM$$4'>)$VC[4?8ADI19$CY$
M$EZ,'$D4C76:%VR$MQ6R$A"G"I85RC TN$G73AC:'(I/NCK@H_DIKE(]A]TF
MQ",J>[[:JMHQ+F7HO_E&ORC F&7AQK7".EW% 3=A ]M0MF!V<<JM<%><A-#4
MU,*X ?H\5OE1CI0O<&Q3E\P1UED,"-T HG [M ;EK"8S4T7=6L14AKRILR#<
MK" P&5TT-W;J4'/[MO )\3@+VC<9T>R#R!UL/@\W\M%D@F+$OL$[98X[8)5"
MKH4H<N8MO]$M?[[66G!7J@OG&F1X17H_RGL:XE>:MYKN F]>53.*5S"\"G9M
M%+B3UYGB@#VP?C1ZM$I>^*CZT2%ZA2@M&T>NXY[G7TMQ;58%-RX7N@7*D[A?
M%.EET^7"6[:$!X5K>%+&+NPP5\AL*-$?,<<-%A%O 7L$ V,_K82&6_Y5I%M?
M!8MY9MT@'H/Z"W6*/$'MF5.6[%=JO9]3JY_83([Y-<J3X5E&?GYZEBR>_7JF
M;BS.@*3BL%"!V8OP%'4^(-C30Z1O[&3GY<9)MK4K=T@7N"(*[I.%T=Y%JU1K
M09%72RI5C#WKNJJG'78I>B^M4= JF?^&%,IFQ?M10G3)G3.,P"=5!DF4KD6\
M/I/^E90]HX%"GDNE)X-$BK&ZC@RJH<8"V:[%N9XIET2ICLZWG[?^9K?^[RXM
MVLV*C_]YW@@GZM:E#;,!Y41RA$</I($)9/TW>((Y;MO[-0%.CPJ>M_?F4RY^
MU2$$,OS8-AIRV+>#FTLLGG;(![I?LEUT9G&3DJCU1FCU]_&8QJEAYXQ/9R+]
M'3;GK=C>T&$'-=\RRO,]_:QI;/VQ-E*-(CGAG^Q@P;*^H3CF)<<QM[X'X+M/
MQ\XP@_D_^ D^.J/#; 0^T+WC*A<GV1&404SX2-:\K!0[.,R>>+@30DR1ER<9
MH)-'0^=#<*7GW)9''EWO ;19.21I^ND;C0N$PSEJ*/,S BD.PMS@=:+W+U"P
M/K/\,)U]V9,46X0=J?(0.T-%#7H[Y;['SZE@"56:"]_C+F,-*3C5:V^H4B%$
MG MD%&BXY0^68M[H#]UH]=L.J8->NEZ=_L8'^'Y; RC2;F[3=IGW$V-)$2+U
MVCA"PWWWE/&^US/"S?MI14V'*7VL(2/?&;8-R>PGTC[AL:OK9?IF$;J>" 4+
M0UMWESEHFH[(,6N6DK<.>>TOS29T36C1C2;:A+0"MCX$XO]P01;+' L"!F9+
M?R>J#)ZIDSD0@M:96TYT>_^I'.]1Q!%(S5@4CJ.OES6&UR,3K+ZV;.UQ%+(D
M_\D%!QE2A[T].!K.A[<'4J$+^4N,ADT&!6]E!N!*=M\7<Z$5#$]'0-4V.:Q(
M2A5NIJ%<,2L,EK:3Z6X3<Z[BVZ S-RO/FY,G@SVN+DO&*$$4"LJ 1^N)*$E2
ME1UG&7Z4-TWG>(9.ZP<@PN7^#6JTP?P]D5:,>]0L60;P,/M0?R+C5N-G&HLK
M'I[/"<3[B$+HS;6+R*E$+AH<=UJ*!>AH.!D!VQJ&/?4^PP12>.CI,_-&_YFB
M2>\@B8[WU*_>#._$#,/^41$;QY_B5EY6=?%U( D^_188-FI*7(MR+%)E\C&D
M-,:"V3WZJH#]G\%BH<W)O,6A?BUEC^I[,&.JS;,O^@\&P.X2"X8=U:(O0&>2
M*>Q*AZ6'%3<\YVO/+_B5H'$^FQI;1C9F5:0Y=ESUR!N16JI$[U-F%4PJN7DO
M;BR>4&4E\^;6[+7SO.HPNS<C?I3:80=Y5&F]U*.$8>Y\2&[$UO=ZT);2L)"H
M:5^DJ_]T.5?6J%AZU[M@MN,@\;-#]L9C/ ABG0@7!QITWN8;UX4>=>ZVNZ+:
M.\2[('5E5R#>D%N3('3.&PS.*?UX65?E.5,847*KJ@V!+"K6<Y[<&,ZN)+=R
MG3--'4TT9\K?=G;7/QA IVGD_81C+AMML:6XWWQVJ]IG9D+92AL/N,-D0 SP
MGB=YW!GZ\K.1@:MS3D%^1)<A+IU2\J>E4@Z9IFW5$A,V-]J9+CMA+?D/' 4>
M20.[U>!(FLGJ:[A)0;2?PCH=N1W<Q74^.X(?;(C(A(#OG9[KJ.1L!*3)'Z"_
M&Y^#9NWQ#N0KTGFE(Z<]3/.V9312:D(15QN*..3/1U 0?8#869D.GHT=4_!S
M(HG!]YE;DL5".H6MDV[\<XK( Q1_EH@/3BN:44+;74>=T_NF==M&>*4JV@].
M\ T,5;)X\NJ%<1>UT$M_\EV8-*1QC2UP'M:'@*K51GOD.#3'!ZBK;2XUV%Y<
MDM"3GM?T(Y44+N#:FH#1^JL\>T#_$1"1R"%%JGP3R"PS'RPS$^!/H=QLFFJ5
MISI,4P5,&*,/H7*_*!_D4K2?D@0]8;[IUZC19I?D(W5T7D%LC@P<2V3@4+MF
MN5O V;BH$,-:>&X?UCN,&4=S%S5Z!4I$)C\_.,9EWKO#[F1C6<^1E+_U%<9=
MQRV:'M]#? T\YA<,3==S G$_UMPVJ=\LW3DW&(0)AQX,1H*1*'5PD!L6& *!
M0+",/BL(!SL8AAQ_WO /VO!7*3B-&!2$20'J"M*I)">/W$":ZL#Y*?<NYR$@
ML5,(8M'"QK$4&%9*DA)R*\6P([RK1'=UTTM\156 &99U@Q2'.J$):V-29[Z0
MF=)*K[+AD:!9M>JXGWJ+%T7DW@5!#LR\4S_+TFOV'0$7:OE,8Y!<?FQ8YG#.
M1*/%!#W,TZ,@YJW^4*\OW?)@5^FS:LD50E@V46VTM-P0LU7U3M#7@<C=O5L5
MH, OJ%NOV[)9S?(& PXTV>TE6NVN\>P[L0Z@CFK9XCRJNBHP"@*-BXI[4O_=
M93DQU=*MIO?[MG2Y?'\CDRY.[\^#+FYA;\SAL>"?<0#&QQI8\+E??#(N'5^*
MXQH"8!.!V_0M/%<;*'"(D(4==,D.2CDJ:N 55@">%,;I2*51Q#]?3&=O;F+D
MR6>:3RZ[B&.\: =UW^[25BZ6>;7#2GNZ<AUC:]4W8A#Z%5N8P%:MN%A8JA"(
M,:W3'5V2#?(AIDL>>(5?.RO^@(>';?=DMYZ:_B4$Z'G95&7_3SR-[9?7Q%A.
M0E.NPJ.*O_BI/1V<"[_'V9^/QN[\F40A$4+W:YZX<) QE+XN ?S)XOW)YC_]
M[@AEB)_^&#-ZQD,@@QY\N4%Y.TT6ITL,'4[_>G_0.*8X^5]>O?K'_63Q[/G/
M]Q_#_][\Z[^>/WW-0P&?O_S':2")CA89KM5R>G/LNA9JS2EQT7)C?8MO*DQ2
M\Z3FD>L;YM&,.(<O*K1?\6T3\8&=I;:*V%'&T/1')/&.2@6^^0O?U KY"J5<
M'I_Q$'6-T2 ?A]1T<E% 0+,,/#6$VZ3%F@M+W$B(K+PC5&"&US/ 9]94M^BS
M-8^P.)+_T6QH\M_0?C;\0J2OT2@VM"$I9A<;RU1^R-K9++LE-PQ3%_=T!JA5
M+=#/A?&,$1'=&A,G3,.#+9AUSMIXN6?S<X75$2H[Y#C,\ K*\D!,R-+N8>5Y
M[UI+PIG1 &[;464*OXCTI&'E5,P9?WPE"Y+T(42KF "0_JV)-[8WZ6/9<,FX
M/'7E>,4OP!L\[J%!7[:/]J%K:[TG\TDX]Y_>J/[E^WLG]Q9PN0(>[(BL ,G?
M9UB.1]^=_*#+X46YW:!S 2JKW2"9-":]CFBI?J4JR8-3G@G[F18.;GWOB-:$
MZ@0[WV6V.*/C%:^4N%EL@%:K;MMQ B%SV-#=?J;S^/#^PY-'1W@@IXWAAPT6
M/G:MCB7>GE8/0\_"U"9B(33\$N/L\%;CAZ[<0%80D11,H3;A.V_^Y8&>Y-^)
MSQ.(,SR9X72PQWXL#OJ">^WAR1L[EX F8Z=;=!A[CJBQ5.0$< =^0C3&X&TG
M.OB@P!7H?1<?$%-OS/9&]0+F6%S\"EX">GGLA9E[$%JHZ! ^VT8,WN 6TDO]
MI^-2$KRU_DBCR^&-\'?X?QF.Q[S;B#G,JPR<MKO\DQ!7YDW@8AT?MF[AB8OS
MJL(H-)/&V-Z+"E,(TDK<F@,3I&_H%]KC0T+0B  (+A .!.PGYAE<;8*EJUU)
MBO![[BE7C>4F)*,>?1B/<A?"Y11G<_S7%[;@/ '^>E7+AS]BM:Y7MWS %;Q;
M5[DDGCXOH0-BH$P'P1FU?5/+_#Y KWG/^GM&:3>"^I@B 8>G>Z]WAS93^Z0F
M[:PQU?-&'\-&:Z93N3UI1PUFR.QD$K;1@XV5\6F:]F3>YF/8YLNJ?LN5*@;C
M"!>8R?G6A-7B5&^WZ]&!R1 %(20_R'&3Q(T,B1D 01[UCGWEM'=U^(G2D;.X
M'(.X""",.A^S"$(X+CF4I1?6KGD'CV$'P75_.\;5/ZBZ,$W['Q)VS7K\N+>U
M-TTGL3O)#G5;YTO&].;END[AWQT3.AYB^.*-E]EJSB/Z1&;FK3^&K:<^P-K%
MO&&C(S?&NZ )9V]@V-.[>EM0F3_,W.,SOG)68I]2B1$B$:Z/O5PXW[VN]FG1
M[D- N4OWW*.0=8ZA3V2G5-U5MOF52N9^2MQLI8YA@]EU2#Q%:N)YCJ@+F#F^
M#I#H8<_9NBKRRI9OQC_J,5>:=5(AF67BN&1"Z"J2Q2:OG6&I&..FF'?L&'9,
MFH9LY.\Y"H9A!8;^!+R3U!(F^[/I$JVI\FE&>5>D)9[DX=0)MUY3%VJ45)J%
MY!B$). 6:0^)*TF&N"KXD6TZ\1?+A"AN%HG[2.?M/(;MW#K7RE"8T)LCAW<+
M_Z,*_=)1JH';OE>*J?T)/S9OXA%L8N;6.*)!J<XL[#Q,WA4^-.]S^TF\O1/Z
MGA2Z?W9KC[/V_X(6(D>Z;09(")N-(R"[E$+E3P1C8G1;-D3M<J]7.3%"T7;;
M2NO. @^B9&ZP@)/SP&R$(I\LGC,'?!B=[A$YE?]1B.X"QD.Q-IZ'=PE6^9+[
MUNB5 G'#&%N$Y>&(^3N83B"0.G#O-_&D7T'B<!C6_:G1VV>PH""!VWR5+-PN
MIY^8'K"E'!"N3$JI59KWT)G&*X(]I<WBR8M_/7]Z]_1'X6XB?)("O+$[&]:1
M=U[HF71L2;&?GM*P](V5/><IP.-6VF?Y<1#?'_>0O61SPA-(_6(W85%U+Y@\
M0K:HD<XD#A']CG"G29N>V_UIQC8(ES]&N<&GZVX7+_K)XC5^TS_58E>-C2B2
MRDG,(AJ8N'Q]+#%\D,K@INRD0LF B@7A=E*/Q_<+#9JA388;BQ 8Y]98QW<"
MMR.VT7SK*(<B@P4:N'2:Z2QI+[3RB6;3M5EU60H7F!FHSHC,B@@?LE2&#*Q=
MADC&9$$$!/0^186X@'-$\Y3H.2#PPTP QCV1?C;/=TH'Q#RB@]>MMN150!2/
MW3$(]NQ36=&)$@$X\1W'NG%T,(0BGM('+OH+$98PEPG_N^Q3R,.&72!#(N'4
M0('#_UMXXJK&;B2D>"4XI0(0N6BM(Z\H0 F_TEGSLL=)KVD,)(^R]7!D+E!9
M2LP5R8K*\K#D>K+X?9,7U-V;-\SA S8HQ^QGBFX<_))$ !M^&Y[F3<]7$0:U
M( )](I].V>G30^'7U@]1NG#]*;^)<L-II(=M2$;"P@%;5M@;NZHK;@Z*QTK+
MFOFA"5LZ9>LP/"$,B/)3B]OTK2M1!/&W0=JXTQJ#CEHW@P4RFH1.^M1E1%$E
M4B%4&DHXI&RO@HH1E5VZRWZ?H;(9*4I*N@W+\XJ,=/_#YAZB8-BOQOL-<,D&
MP4S=V#H L=@/A[1ASUN^TQ8V6F[J,Q?LY<JIE<B;#<+L\6_J$*I\#E$<ZRI^
M)!G:-S;7K6>S1*QB:1DQ4J0M^V[)EVBY?L9X]UV*':()]QD*E9D(\O!<D39N
MA:OE"2; JKK,4_2G7"U=^<+?@A\!TR2C8E"B06 3DM^<YS-4-6J,0,YBK .<
M_ M06@3MQ>Q+!(B74[^MFC9HQ L!DJ/<\979Q!0$OB<>2&%YVE)YN%ULJBTB
M?-[16/=U\'<4CXVOB)@A;ABVDLW.H^KH90X7RDBL-&U$:&/N"U F6LP3ZBAJ
M4ER.R?1I *5(LS>_^*"$>H*GA1-4"&,E.0'^*A$_W90Y#4\"\EY%CP,+3$Y&
MDZY=2Z$6>+^5MB'#NE7EW4:NI-R[81,8GE$G8EL1IN'%18\<H:XRC^&G7F2>
MH.AU(O465'2^L/Z/1TW.*OGD:[DYI\Y;[L^AT(+T!G?.4H2#)C!O^K,)Q"FC
MQ>/7["]U0GF[KB1:4._2#)6%!"OYCGG5+\F :6"#AJIL**.(!Z1KT%DPU*(Q
M 9WQ@ANV=EV)&LMEO#&PZ$Q"Y[>W8>X+;&07!H00F7E*#-+]K,+\3J",6"MH
MG 4S5"N:DCKQG)+E3'Q QQX-+_ JK8T/H#E5';DR&+$)=\<C?TY])^2&5CBL
M):<SRBO+G &8N*VPUXK:2P(B" 411*SM.+_+#Q4LZN*\ V.@!D0/#%ATGFX$
MSPKV IW$LB):X)H^&W6L&F;I]*+*N4%\H0>#)Z+)8I.W&[NI?OTQZ*20-3B%
M)XM;CUWX<<8NW&;LPO$[1F?-9%QA%+*<]Y3R>NS4%]72L'%8<H0Q1EE3A+"!
MGJ&TIK:[2=_4NKD1U\C A_=V>]B]-%,+_UENPU \BC@C,%U0UE51D"NDYDUY
M+?L[%'*AR(F!F=3"LW:0OU$QQ5,K-#O"SL'93A22!9@M);C-7 JVF0Q3B&<E
MY<F6;]W50KB^Y9F=G!SAP!"\6/%_X<]5O<PS\<JI+Y+F:\,9EP\J\3$]*#L%
MTSQ0PVK9+'Y_6OQBH0-3"1M#SA<1V),4C(B<S5[Y](LD=V,?QFPO"W28B=V_
MIJ@N2?KH)>9=_Y1*)[C;&+R%;)"-WOK? 4-2=QR%][^.)1-TU:M^6$1_AT@'
M?))Y?S_"J<:TE"3Q3)05F 32RW0?@@\?PJT/6'_)G]LK5PW5Y!I.Y6+LW8R<
M;,[W,H^9?(.WWL9ZAQ]C%I*;%Q+2]N(WXI*_=?O^QMF\E1:11O86R6IPA#N-
M91++0(FYU!<;N+J GF@E@^- :Q 58Q955GC.#\;V)L>=A-))*"$U/T7W8&H,
MD6Z.QLD)]K,)>?BJIZ+LR5N?Y7_4S0I'8>FD[@LRG*_>ZK=X7EJ3UR;VIXH<
MW(2<&_#0SN'5P.G?-9R@JG8%MYO%&=3P]G=US4AX[OW4;%R!Q6YDPBC2E:-?
MG_Y$"P?K@?5PS2S9BL]\@CZ:&643Z/*+F/P0E2O78FPWFBG+$&^%-"%3/4*Q
M@+/N^\2ZCPNRP]WT!<GF4,W(^\C#>B5E,>OSM/1]AEIW1OM'\R:0N1$ID_T
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M)Z(G//6NCAO8J&UB;. WIO!H*3YT</K18+^?T[E$Z9DP4MQ1@B'SI0MM@7I
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MZ(#4-<:3("V(XFRXFQ8.T1[+D@@-B5O9_:GQQ<J&Z@&4B^GI]0966P4@Z/C
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M!1D=.UUA*B.\W794(&!LJEH$'1Q3#>I'5M\EM'7R22D,2"W+$-GTF7ZL9TS
M>[S3?SY!<QE<4W9JG!*I=/,$][-B_EY>A&*#::$FY2)D4ZO-51->8E^GR&U,
M,^$<*Y\(3ZU-.,C9&H<H5SZ\M55E;)B+9S;^FE;L=+'#K-^6'!*LED]51N>/
MZS[L44[_#?6^C-+ >22H2-4C%0U0-"(RMFJR6O72=&IQ6,FK\E"_H>]HT!F>
MJ=Z*QK-&I&2O?KSB-8QORH>M9 E_CS U73V 4YG"K; OU94[V+%(D]KPMBO[
MOAJFO+JS[Z@YNF7QS4W97ZUVA_96K3X2]?K\4B9#:I%^D^N'UZK,8_L!*FX_
M*-:G1?Z4:@QA_D+ %8[VX"&&FP:?61R?)Y\5_/TY*WC."KXW64':S^L:!\,&
MA^Z!D#WF7Q5SOF4"IH@N#.!2YO(S$>VF2FQMW[:-LD63_C/K<'Y8XK%9)T]Z
MFG.'E.N]243 IPT_<U"6LA]T# 5@K[X]%X#2&9R;P-FYX9)6'<QL&(HRN@]+
MH)B'W:J,F+BD7$^NM*Z[U%,YL:8F4%1_I^N1]+ZX6(U\C5R]5P<GR_]]^6?@
M_L("O JFEY-F7]IWYM.MWW+<ZS*L+Y\__UPRK%^^?O4M+@D6?!0"D[RIW,DP
M+SXZ=N,.?X2.+>[-@>F9C!0_KK^Z6T]Z(P.=5A16[ZF0*+B'^! T%6AA0&\,
M/ *.&OTCV5!ZE *S4J)U@]Q)PHE8-J5,7JA7;R)[+4V56.$>;AA_2RJ891-+
M[^M.2K)Y3A@#7TARS&:8LZC3!>VPB3,PDM48S-)A]>+EZJXJ.^T/2A*N> [G
MA]V6#I#"^>1R%587S]&AO&5\+@ENO.79I0P(!US"7U]U(;X;I'9<JS1'\F 9
MCHN&*OQ0'T%0!=QB$;\IKC'\U:KD]JLN:P>45"IE.W^^HFR 0"KT#ZQCK*V%
M9,.(=1T[4X)DO1M/@&6OX>*7V_8Z?8'"!7EVO8?6NUVHZAJ*KE55WK(#]QJD
MIY$Z^IG2U0<A?Q>8D@1S#S#9NI9I74],CU_AE)ZC^?M[" 3J730J+UX^H]VC
M67G2]?3)]3^VMQ7"S$'1ZR7DHOE9AROH*MOG8^@2DX';4;IC*64N*F=(HXL&
M.5WXMNXK22.4@VUOTQT \&^;,J_Z46 IG)C+2LA9IZ0:163HI0!7=5!@. !U
M9&I\GVM[B&/D8O*Y3HTY^Q;>&?WLEOS3W [%S^%VHV;3L"@:PUW.O"I*L'22
M8 AK,\XX8KO2:L#Z1G8'M;^4R9Z>\@(&OJO"@!_".I'V[F4B=4[B7Q_*C2)D
M[:S;>3%CV+B!KX/T1IB"3%&D])DJ%>=&*T=X)ZH+[,U[L/-+SVDZ5S43P:5%
MLG78"'Q,L)'GG!D%Y+<-E\P4Q#:$DU/ ]1E3-[>3DFT$8)!MI=\$-N6WAIZT
M7-V8GH22PY"LX0U34U3^O>'J1?BS+XZ$/4]KD?[+Y\&RR,9[;!_#8'\]4N*"
MMQ7_')XJ^'O'&O8DG$G64^N1XNQ _:]CC@1I!+D%4]<Y\4E+0 _#:N;>U,/*
M>3-4^^G#VY"X/&&E]R,U?U/+/&XQLQAI%_4CN4TW,O?7(2Y8[8(3!\<%"TK?
M,5GT#+'0O1Z,7:EH[$G9WJJ9]4WT06.K!S<%>R67V'Y+E2 ]N*4&)Y[5\XEG
M!91YNYN4B]S-76D[K,D7S_E\B?/BMXJ<.I;2?AM=EA<OY.;UKM!B<41Y5]PI
MO9.2@3YIX5YBL@:TPLM9]3Y6:"5<\2W 5-$?7 G5\SW"?JWQ0!YQ;6;"JL_6
MP8'$H#G'?-UZHJ 4NX'$:D3+.+MBJ9 @ &I%?;K6?UY&U;2QI#BMQ_,^FXI=
M4CWS3>:G>^KCZ/:VWY2@ZUXG+!G/AQ%\3&)Y?,D]1>%RR:0:M2V;G%Z^ZD4!
M=.L%!\0;)X\)^7=@G7_$837##:<+34?))^&3]3-BM:&8%G>"2RXM.&:66Q=!
MFJT-^QF1^ODY]WS./;\WN>=OHZC@H58P##4HC'30D:5=A\>D,[DD#:F>]$:M
MO%8W&T(#4,11LIW2:ZB+;8T7L:Z/MH$Y-<HEF:X/ZBC[N>*L+_PZ"KVIG8'B
M[G9N(LJ8;C)<D04M%7L=R_)F%M'I'<%ULD=FM..[(K^DN*-I<V\D-;A8?4.@
MJ;<E15>%BX#@ ->+S\!<1!3I=I63S*&S$G^IF[^-W9U^8$?SH0JXFD (3BNM
M1NQ!\1?S0?"-6?*K(Q.BVO#%ZM)EOK)A!NJKUR7-J)/#H=HK#_@N>&P@H%O!
MU4CNY/[""5AR]4EV;60)3F(0QQ4HXPK!-)EU*=*;']]4^W!F5>!FDUZ@^(2<
M1^UP4(>+W4)JDUOG7O'#LW,(@.F::]C=8+G0GNH%TD2*'B$#*91<7>#9YZ1L
M A.@U^,:-XN#FAE8&L4'&@=RSN;L@JYJ;E5\N(U@(3U7Z,&#]PIQT<Y8[]?'
M?AJV5$TI4#]3]Z06NGW9;0^B)L@MD%W-N"N$]51^%WQ,,;^B#$I_%IX[RQZ$
MX0CN")@L!,T33'$W(DT?Z0Z2L.[,,?L89DW.*8HXD:>]'KG <YZ=QS [%,MN
MN_*6\U9I7E?8;^KP>%+=3GI/A?*ORK/!YXE]#!.KM*9\]C.S7ZU^V?HN5B$>
M]WR=3STF+(">.AQ*YHUD1$I$DC[J27PR<U6NPEC%3K?H&5O3':H%#OO*[O*C
MGKWS%O2AV)$TPD$#$D+)+2LD3@_+]CU13'PR4ZB!;U<%1^4@U01V?'H&CK+Z
M6)8 (7Z-5G "7B/H/*F/85(/;2]=?J!1/D_*8YB4ZNU5.?:&I23>&./) TUI
MJ8(5P/\*O<O[<10^F4ED $,2[-U+4W@6AWDLLU=ZPA&TG5XQ\5;]5$@ )T19
M@G9PK'#3-+RS3@.@,*SY0H8+3&NN4=QR^88S6*R-<'E!L6S(7%[5Z]I@;=-$
MO:?7$L!+L2H/ L8!^B",7K"H5)QM.^,%TZ=7OK (-K@IN[H=#9@*X@DG2I.*
M(I1+[Y*VSN#"36N48^CW]:V#4($G\W\4PF%RF!E477(G_ J,?OMVJ(6KCF%F
M@P"S =TAKHQ*S@HE-_/\:0J1I07.R-CP(;Y+ZT=EHL)#CUE(-27%Q!1^F>@!
M)2_$!,W\1E(ZD1)>N>^J2JG$ ;6\BZ!OX>-+YXVXANKAH*RCM(F.C>L:E35&
M7H[IY.0?\O2RGI[6"$0%Y QE$4QB6 K]G!6HM__UT?TU_1<O?O_1(ZK9GZS0
M3]H_?XC(VTL%.]&J^!Z8L3^CR82:9L*ZIWWT'0&-NOY]%V=R2C])OU;L8\CU
MH:6$^# *4FZ?9N&3(N/<%68.*=P21V(C5 "0O9+J*5U NT'PF0RB-O?P6:TG
M 9_=1D: >"W35(F1(&NOJ">J*D\IXKQ44#Q13?UB<. 307#][OD9P75&<#U6
MG_ G!6M[[(28&+,K.27SNYE"=* Y"Q?LX=TUE<:(<;E\ Y<L',2,XMX%7Z"]
M51 W/,%PZ@AE4EY4$[9D-)CT3#7;$"*%O#KI(LG;&\.MJT);]X")(AVJX!X=
M6"/2TVHYW)$(I&WSUA,[-L2[+%(!/FF>HIMR(Z:I:MB; *W?5'3HE%P1WB=C
M3[Z,2+HY=/L&"!KNRYP\KN75XTTBZ;3AZ)BV&13V?PL7[K>2Q?.\C;GT6]KC
MVHFLPJ9&;I\\+O*4I=DT[=V\\'Z&7QVB>!!SR42@W%7PX_([RN%LKQ!V+#T?
MW111B1+R6L.H]$9H.Q"YQ'2J8<Q9?,4YM3M/_,<]22)B%ZDQ7>]/$8<W\D9S
M.U#>XS7E,E_8*MS%71_\. K<OR5]@'+?A)B+FIFC?D9# B_DS:U&*-L9D-_W
M)<Q!G'ZV<&60]B=I(RL2UOPE1V,VW2&^#=J,K),8S]JXOK1(O3W#4;IP92,[
M4@D7I;N983VJ;JQ]8^[QGT:T?QGW07_",U3R,%EU@L"?G74R2XTI%;:=I^_)
MX/ZPZ(1+@D&))IBZBVB]F4( M^:9U3^#VLZU1<FT>J/Y<&<#YK[ND7>(S3$*
MI4V[Z9FA/S(M43;EC-KYX%:#JF/%\W^!U 0'8;EC5XV)"FJDPTC(Z-AN*Q:K
MB7^"=C(=H11&]'6G>::Q,5(%KS=.O)QO@[.AB&7IR@M!-.GZ=K4[V8V6%V1M
MILPRTY>&>JRE4?-N"**4?=2+^&SKF'3E6BF!V84TTCTS2-<L$)*R"JKO&A;E
MNFO++5LTD0'A-MM!-)6P"L.5-D#_(T4O ARTY)'H%S^*= [C\R3I[82[YU&O
MJR>S?&*U(J;UME4(ZZ#%6:F']<U7[V@ZN7YP(KBDAI]GTL.\0CJ%VW^\'AVX
MTW-!.6(@L"+2HUY$9^/TSW3$N/(DQ$A6UT,LSB)W,[P:[=DE>[3K C-'M3OF
M,&5AJ72R3G03SIYC+ 3).H*P'926Z'N#S1"_<T'L+(7+N;C/=/<42.84K-![
MI;J[Y]7U&%;7P\^T7V"8?LG!!O4_IM0A'<.M3W>\/\?9DUD__]BIE2=@F2K&
M=>G&(G&!!E/^?1M\;$Y-*^>/JP*$[UJK*A49HF2>5[H1D(2YV]#K+EDS))K6
MM)<5]O(0+GQ&FCVFY3>I#'%H9K6A";S@G9=I*A,L)2)1V&H:U!BHN*G\-&G!
M:;'PL9P;3U[TT]]F4_Z^9\M!0B6 C4G!J2#FA-LJ!,8B?N/JF:KW(BU(EDV<
ME"I3'32:$C(THIAZPF>)BC>.\G$6X>'$@M+%03"-!,Y1S#/,%TI@QA2<3YY\
MYW<OSM"-,W3CO<&T?;\<:7$AWZ>I?6+:\M@<45VS_D-&%'=5'@91XYW#%12>
MF;+NYDQ9H:0<?!%'^JN X2*69""4XN@U&O"GW&2<91\2E\^E4B3?5-(MQ].Q
M.&N85 /U+I9V9>Z]!S*)B=I('5$PWJ/@17$8)C$]^Y],@^)D/5O0PDLWV$W%
MS6,1)'(HD7@.8UYS6_W<6?=/T'Y_$K5]VNE'0M^7VQM"Y6YG'8*O_N?/+W[S
M8O7QE]]^^^6+ER\_P;]\^MFG_-\7SXO5K^TM?_3_A3O_[C>_7WW\X^4/GWWV
M*3T5UA/]\^_MGW__\ODG<X_V;QIM% =%A^O FPTE09>MA*;Y#,;FVRCH<  ;
M_.NKDGA(USFK1-@0) Q9S>QC&IR7SU_0-M/V68X37P>W,#CR)'(JJ8MMW1,7
MC-)P$XT]P6Y^O/S:R+%!XM1%^#<+30*<QCFWJ_#FJVT[O0I8<:M5N-;'5U6Y
M+3=7U2?!92ZWXL/2=\*NI(=7<05\;1BW=ZZS-'Z;L7=DG<I/+G[)?%?5R]^]
M_.R?/]^/:.UEAP(&E=.>_B1PL072L#2'%8G2]<";=]4URU?P/]!5_H.*Q2UQ
MB#VC\CA)9[:]<(PMV0W]'EL/=P[0(N <'8""\C$NNR=RG!Z'R/\T*_SQ-(QX
ML UA6_^V8'F46OI]2C41N87 *2LVXH=O7__IA?9,M3,V@XW_\\\*5[LUL-8!
ME1EEJME&L8X#\32L=F/#.QBYK7+=A'N6DKPR4>#TV<*./E#@?!.BN>!'D!5S
MC?\P@R^?OWR.5[UFKV52ZH%)HW/@L]]I@,RO*97OB]6KJZX-WU$4Q=W25S=W
M37ML#_O@\AS;YDT5EF1_U=[R^J^>,6AXY##B&:.' 8R5K>;K4#M*]#;[?H6F
M*]XBO6XO4/LSL30-55ZT5]%CO8;.!4Z3:(W;W>[90.3! LT5!F%C#N?, >N!
M,!PV-O#5#9-_\>9J&1$L P&3#FVB2A_X0-N/4T]\0UE!--DTANTX9+TJB2R\
MS1@#!G3T_;E$4IJL',S/1":&#8Q\"<*%X14[>8NGL=5)>/F9'KJI#\^-:*R*
M(L-((,QNK <.J_R4D^Q&TU');9N,N?H7C#;O$$F)%8X^^OUMF< $L[Q3; 90
MA<J3O:&>%5_%9E2=1*6:K!70FB(SBGF[4[RN=3>B9L. TMA[*BKE,9.I796N
M*77LLYY!51JQUR#Q=L?TN-3G"5V 3C+XTL8Z);--8BYT&0_MY@UW&?,1R3W(
M879 "/ZW<;OG_DC7TSE]_T(72J;M>(]:I.;[LK:%+J&A! 7E/ /E26[3N++(
M.-6=GNI)WUBDMO/L(O?0JA4KYG>2F9H2.Q5T@*$TLDPJ!$+T2)W.(7)]I*Z'
MF 9]."%8L;J'\,;V8PQ:::SX?>ZA#EA*Z7)[BQ(\SC,Z+E',JZJ-U8F(MO9)
M6-M+.[-$9MLK-BPC$@3ZWL^@+*U/6N>V7QW >ES3JY-.TJG46IGZ\#%MDV@
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M/+7-H<5YK+ZI$!$TX)9@?0+?+G*BHF!^,!FHA@E%I )^A[/*F>UMD:Y@ZRL
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M!OES&;.[L:E=A.U@_/!3+)78JR.P,F2=YED]L Y-'C1S;ZKJ>K5NVS>Z)3:
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M<O<_3$V9%V+\YFRKKY0/'M)GD+9CW$CJ\D"@)NW,QZPG<&>R4E^%1P ="TF
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MC=FM4QI/LOFRMHY510NK))EJQ](FF])#W!11'IN,8)GP4+^0]NRI%.!^<R[
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MY&0C)U.A>#OEG'Z[.E1[H=O:R5G\]Y$H]:Q/Y*HD'Z.2DWU<_PU!]&YUI).
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MMT/YAR$W^%[),GK(>E2]N*5Y&2?Y<R?9CH;1T.!^0">)! MYA)%NF9[BWB+
M?I$G[&@+ Q1>SWX?E\6N+(L*V8-Y?CRAA-_>;!,\;L[S"X";J+W<( T\3O$N
M3#$&(A+H]T2BP\;]4LI_%R1A+,+$!'_KO>8XY;LPY;Y2SC08(CA!_]*,-A2E
M :O>WGEQJ1*(7!>29L>9C2JD-M\0A+?_5.@ 1N'Z3:7(S,H:'N0%_&1<+3NR
M6@;8CN0P" KUPR'\K<[:[B1CMU=9/2OH]GIK45[1<\9<&%[APS6RB<B:1QRT
M6HL0<5"!5J)(X:U@&]M+M7QSDO'"^E?F<+%$_,FJ$"V='QOI^4,!/3P?\E%>
MB15R+CD/.C49XD!(Q2"(+11R@OU"U[%TC2%C%BLP1( \Z;T=)L)=ALHW=/<>
M>N[F*@;EFHDKQ7T;^2W%R98N?+"-P-W^D0JRT"K]S13%)90!DK1LYX)=)EPG
M%Y6S7I:@#\4@FA8[$HB>K&M=H>TK,@9:W,.IYRM*CNVRX6=/Q[UL5/YS (>O
M1;:&N@EU:ZS#9)0@EP-,@C ]ET69W4D"]]?M/BUA1*)N#UV"X*7S^;QQTG#I
M==#Z1M-3Y;NR+/8:*ADHT8PA,;:%(S8,!=:XP.WF.;2R5;)RP7]2!9?K0,J<
MLDQ7.@!:BWW72^_[\/:?VRAP0QT0;E//"2P GSUY\W]/7^X=/(^663%%X5"[
M,E;IK(?U>4M?24__)&,/I>@5HN?"Z1"UI,X 4(D=KB9=*60]0<I8DT2L$N2<
M&KA7SLB?+F3/'4J!-@Z\NJ]IP5LW5:OCEE=5**D3]L+ 2!'<QI.Q*59$5?RC
MCA(@>M%%/VLJ9?()+ IOK;!@BE#4]Y\605=Q^$#=9YC:]:([XCA?9)=E59<@
MSYLP)J,/[XC.2V7T) AEN?&8,U_T;1,HN['?BHA3:\[Q_2/0=$!MU*Q:?.MC
MC>O3:ER'8XUKK'%]ZQJ7J""0= MC.?'<0 R$AA-:PV'?;H5F61$EAJ[%5E.3
MYNY ;QT'R,:).C#5IJH- Z4$ZRW'6*SD.JW?(+]7/ +JHXQH0^K8=KNY:H^T
M\6X)9YOUE6P4&"@ ]K]+H%&A'X?RA+J3)A3-\88ZE"3X8+ /(05S"PR["\PY
M.=Y0RFY1=4(SKR@K3_@-SF?W,#R!R%]:9)XQ]::^L>N9F41O%2&MHG2Z\26'
MUH(C1Q]B&Q9M11L$U1JX1#W =<W)'(\9;DM1^DB);@6JC'I $R#1J3Z@ZA%)
M[2CICD*5_XQD [S@;GBMCIJH7%=$4I34*7Z[+"Z*#ZV&-"PA5Q6\+3/-"@P3
M@&DJ"((C&C!%W+\$/F^3*@63U/H6T$SBO>QYLDJ6VDF#MHDY)F<NDW*.--F8
M+XFUEQ"$Q5Z\91(=SZS]A)4!XZ%GYG/626+];G[<P.FV0>[<^LX($_.HZ\!@
M*<BP$W?QB=[MF84NF/E>H2_9[DMX0,UYUG T604@,9\3P<A)IP"=^ <FV)U(
M!Q@=9%" #B,DY=,<5:T.RR#=N H?Q?.>A_H@04<[;P#5MI- ;8:[.=2/)<]7
ME!7CZ UE\N24\*04ZH4XK;1"7USV1-ML.^BCD_NNM<RV(E50=.6*H\"7#%($
MUL_TX'GNJTX+7ANAG"BQ(I?C:W63Q(-@-[>=,&$F% >?FM^+^U'J0G9X#8&\
MW4PUO4'S(MZ.I!$E&.Z&?4HT%U/<*?:KX,P),AFA!T#MGX&K,FMPN6KUD(4Q
MHI:AG9*@KX[0S@A558M>#A_>$NW 4#^H@YGW4G.@*P*-KNV7H&VD'^4N9LK>
MVJ\5UN_0%$8P[)@MS<VE7?#TKR3/&S!!\J^YFT6:$]V2"@PL14AI&[)N,(,&
M)XA0^C@5OAN6#-%W&)Y7E]3I2VQY%>4L71CL!+I2Q;?]K&@Q>QLN8^+9@Q[J
M7!DSD3;(N5$+NB%HJ>"P\"MCQR7<"U86_J/U8MS/VQD*]_D^NR_0^_92K<P%
M=L+V[3?K9@SN,R49)-6HN6MYZE/R8RP1NF10V\*& ,?'&PY40>-3B_2R[_I-
M7.Y*]T)V]UMOH\KV)G^"_#L]Z9A:9= HX\MDR;IR0H) 98MV101[4/<+@&XX
M8-062R,%+B"E ='_"ZR$C!"$Q663\=R6-$+V!&KDW#@O+@U5@(3*I65WX+E\
M4)!,[4P5W+%;\J.'^BB]/$5QV#.4T*GJ.LS6&:36>J5F)$/GCE@=M=#08J4R
MES:]=8&A"$NCNERG-%5)?A<33]1D1PR]M&K[./E=/-<J%'[+VMV#S^(=C5F\
M,8NW:_[JR7F"$EK69ND#U@9S;";Z8Q;%V<T9']]K10%"3X.5+L0-2]/LOC>H
MQHQA$>HPH0)B&_K=.G'P0[W$%33H#LU!'6'L6;EF>$IN54V)&0_G:?21NK42
M2YP?"1*<I6;39+%HI]QZ#!QI=(>D[@LL%N[TE)E.J <W]D1$OV'?_>'^P5'<
M^]847"_2LD('A4J&^#,OBBS0*V![@;_6F>-^Y/OC\0;;<;B"&=P&&!E)(;)7
M;WGX1G944+M'OY9'S_QJDO/-WMD*#N?CE5UAL\2>^1<X6,=V]7\''WK4\YM'
MWP/I8H)%83M*9V9=F]747M7>X2#N62MU:1<QGGU,R<?O)@A'>4G.E#N'*2;F
MNT^<53^&[?ML&TR.9?H'%)OX<S7)U#.3&?*N1-4X"9A5+KEB?ZUE8Z<L^#*^
M-SQSU2^V+:N4(HO.;$.QEA6=&MFSOBT5?#;*BOJ+.Q;:X#TIT*J<JAV6A^=4
M0@]9G?AN*=$=X0>F6KB"W@M\YI0CQ[##&#-ORSS]%SBDU/UH+PA/*:;)2_#Y
MN]+$<KF@;Z FT5F*XG,]QF908W>%;!8XI3Z;Q_2J"W)B(:"&)!A04MG(V\EZ
MT53(,X'8:0UY;%;=)2Z5?@Y8+P+H ZM+PYKI;@VQ/?\N_9X6,VX?GS<+UHAT
M\]1;I69NH(M:P(WESKR:$]^WJI 42BM^JU3G5B+6>Y6FACQ G[7%V)H:Z'"O
MYPV:5$B[ZOP_G^C$MD,!$-81DKZ9#Y31F<V74B*B@,F7D-/>Z?D*3H,?B'AH
MVC*TUY&.E@Q##Y\K/HCGE)%L!I>'ZCJ9?1!?#A6V@ZUM;0K;O#FZ?53;57JS
M@<JLDJGTGV"YY5&#ND^#FDK@(NGM1[/ON:9VII;HX>WQ(R[P?R^^[ ,OK=?W
M,[/-42JGL';2'E%LF4L@][7O 4<'1 VX7 *Y;  )E/Z,'_QF<# (#QU+M@?L
M=DKGVA^H8 +CED_ Q5')IV0;KRN!#S$SE,MI/[2&,(E@I--D/B\R.,CQAO(H
M=&*#FO3R7$$)Y28.OICF(3A*O8GS4^#@IP-H#1Q5>2V\WW.[_ZQ!JVE,..$W
M^?I+."S7AB..UJZVWN4ZH*Q4 ^QLCU8K]R4&KE33&4VX>9$#F(*LF"ZINX%R
MVL].05L_4P*&GH F!*$?'$M*,2Z0-K8>.D$ LD@5E R]8ZW,?AN!VE4*[3>,
MX 8O%X9V+6JM'<L)WD$/I-,9(V>S$V!GR T!J-@[OA83RC1%%W'&#.W #I;,
M3(.Y7O*< WB16X>3Z)V!3">E=LZ:-81WT0GN@++)T%H3/I;%SL.VE&X1T&N]
M;"78O#3)!Y/SY80>TUV/U=_4%7QZGP,8.PI3*"SR^QO:C>=V8V.['?;?RU[K
M"LL'W@T\SR ^ "0/L4^3H,&3Z"5683"XR!US%,.-- WH29$O2]P"&#X$9Y='
MS: 5C#VN//%JPWA%JDYIG#UM0W)'882:W,X9E YPT"$33);R)MO54<^Y!5G:
M("5+"U?M[<G1J6';@L0)U8T>?(;_\9CA'S/\NY;A/PV.?9^(NJ5^'H<+62#Z
M3OQCS,TXNPL'QD)[;835+6NBML;4ED2<3)XP+>;JF.RTBB33LDBNB0KZYMRW
M#M2%6@(=4!>C+>>,:]:QE.#70J=;H22["<9;R47%[)R(#\WG$J&]*6K!<TAA
MUP"<-CC[]@=E ITRB7-5,2+P8&4LC'<2)@/E@N#!W"-52(.^5$#<E'IEU;/X
M9#9X6D6.K+.3Z)_HH%><='3?=2M6:?WD=!? /%EG"!P$(7#D7)W@2*Q'5#?(
MI*=3ZSIKDD$N!A& 1 JS@D@*857+E)_4)^(1 9S;6<Z Z:^87@#2A2%[A+TR
MV%Q*@QF\4-XS H@3#H!=\F9,-XK36ZP,K%GKW>?4K8:^5BN 4<XN_/K<("K;
M-3##(DP\TEHY1@A(GZ,+DU:922@4ASEF&DY.<BDMGN#%>"E5[;7D\FM^"LQ'
M"%&%H5M6K/X.@>E-I?.ZF(JK&0/BWP.YD3U/(BDY" (;:10]MWV'3I%\7 73
MA!":-@>O8EEU$B_JI=QU9:\('ZO/L:\L+*4K:H"3M;:4]'9]7O,,#,'*@.>:
M5MCY03-0FCU02&%G/AX3A==,%.*SB/!"D'3M2Q\N.>@ .V-7BPD3M<,=%-^9
MR7)B]^':@7S5U[[G60US>V'+!>&<+@JG9A'#T3*SH8+_ :PFN\/F(FO2TOPF
M,!2FVIESVD #0939$ LK1!=F*^'Z]0\U0@O:Q3P#:)L-@3CY3L>NLX@5<WWH
M"+)C/],JC,TFT9_;HM"_&U/1!EAHS:#$SL=\B<>CG1C)7R[2G*5-NGDRZ4^V
M^XF9J4.1>;NL\/3(3/OH8%[6@?(85B^IZ=2GW,CX<OTA]LFB=BTM0'-*\,O/
M3;L?F@(,\:]?HBQ/CV4_7;0KO*9TC<W0KH)4[ZW):LU5SV&/1<%++[!@7]8>
M-9!MQ9?"C(HISY,UN@]QZT!3R8]/Z($?6(9GM.1;Z$%UJ\NMX3T ;+YJ-F['
M IJ%DJ7E=AX>0N#;H(;^2DIA=B(239+L-9&O$GJ(0R$/;DU0[1R0A^OK3-C]
M7*5/<Z$B(I?_T4P \-G5$5F[=>:$@E^_/%8]A(HA^MI#JM34MCDO"HSFACZP
M;-)TTS_S'H[S2U+/SO?^3#ZN[. >SVHZ!-H_%>FK9.!ZH!B^)CB$W9,;DX"A
MJT*"?F]OZ=L9P!P4$AS&3OF#=-)[,/CQP*W98.,/.*-J5MQ3@A\-ZK=F4T#]
MUSYJ3?-R\)@<"WIFYX%3&<;+G<A4P@QE)'K'EW22WTPXCGF W'6QBL^J59;I
M8L!M439P\K D [O8Z$W7Y!?HWX1B#VGGSH U(:RS&YR;3<+@X#/\!,OWO2GN
M+KD(,<$[>H>8W1CT:%XUD!_E-9A WETJ1_;.;^GA0"8 T0>U=1U^$4A[2.PA
M7+. %'?+80A5 _(15SZFDQ$#ORSP1""6Y5YD)S4 71B>S%"MY-IP0OD\(0FW
MP9$-+@R%+,K60TG.P_WG-O)CL8/.IQV&T'Q<IZ679Y3P4HL1>R](74:X&75[
M@>Y&4I12K2X$!!P)_JB\LC0"':QS,_?Q-,+7K'.54PL,NH#]6C1;#S&^M=OJ
M(M>NED05538"I>X N!WCG?B>84N?T*A('ZPRX3W]X-Y)5JZHGXK/ZP'L;P%T
MXW>-D_:A%1B>C 6&L<"P:_[XGX[=3HL[]J>R O+5%CW%%70:=]'/_K,'=#HX
M5H1)ME$EI(#MJ5QLL(G4<TIO476A4)$(R:VMK1TR=$MBL,-G<@4+%,!J<C>#
MU >W)_]LB2'WH6U=OWRP"!R)(U%G,F%4OLA2(HT)))86X<#D<*@DFL *>+8*
MTDO,+XKL@DI-BO;EEB+X7WV%@N<S *Q1?<)5;Z@ITZ_OGLT1;HRR#]9;,:XW
M)"R^X2Q?,<F*@""<O 7SA7C^'N>(T-M@9X< 8+BE%T7;;"B!CB]3B#@G-R/U
MK:QA9WN8#<@[UUY&68\!KMR2M*$0@A9OH^Q(JZZ6YN?702?1*X_AQY95Q^_9
M&C9>$\'0J8+7]4AMID8P;;X-V,9/R;*M0.'VRRU((#W03%/HJPM AFLAKE]!
M56/:9E5GD1CCU677<)#1NYM5.@T- !3" AFS[<*I-]AL:$-81H^8!4(;1X,<
MSHTBAFZU(C:YX_(6NO<XU"!U#Z%9AW1!T*FC:=;@GEF>1.\[#^HHYKF?WM-[
M^>=$J@"E:=A]77<5L&A(Z #1*UZNJHRP='#L39X8B7A'S%<*/W 4!($8(F;#
M40K#A=]_V8> Y@)$'4(3U=Q4LS*=BIM'61TU?/A#^UR.4LV:%Z@I9W3@)[,$
MB4ZID,L/5B%J&I(D'D-YKQ"C?QHJ%H=6!: 1G>GM+K]0396+&=,-L00POQZD
MR.U6JF;VK$4DX_9]0;5](0^R?A0="WB.<45KY<]BA!9J;ZQ<@Y-J0H<U=L5C
M-9VM3YR\>T/N'!&M*^75,G3S8CB84E+-5I8AI(SZDTT##@2-0N>=<]U1JKJC
M*F@*8K:0<%B"MY6!=.YG HGN+$..UE(,@/\XY/.@!Z^4KC6B:NTU)3UL^&%,
M0(0@#3<9PZ2D)1">?8@97[J"\F$[CH FRIQJJYEA\<=4?B^[DG[6.=6\!ZYU
M@Y=-@OG)EM*GT?K>;4I^'$J4<%5MF"XNL"^$?T(+I%]U77M7#.V$4*D)T+RL
M6ZI%2WU'764"# 8)DU(6,-0=Y2UDI'.];^+:FL8]7)']M,U.!IPYZARSWJ)@
M-5163 4?$RN;Z$9&"H65\'"F"-\AIC%Z8HP*5FF%:3[[V'@*),'#@4/LSIRX
M0[%MCY$]7.HK5T6N516]6P</</!$(D,M/=;M)9WI^7"+-CI;F#B%%CO7Y"G_
MT)92CR\5C_-^#\S5D:<(PR;&?<<&C;O(G7R>BY]:2Q*5-^V+O75UF9FF?232
M94*FX@<5W/VJQ4<(T$4!=7-S_=?STPX+ZW/?;) )[K(G14MMAT+;-B9L*6'[
M=$S8C@G;70MK0SF,,%%1"']A[ *#9/9WDU:B#J)5K'7-+589,*^R<#OIMCL8
M"_^I]8_P9/"#TIN<\N/MAK<KA13CU]$W6VRXF9C99X<'6KRBUEA/(J1V#;O)
M?(-:W.*D5K] 4R\1&R2STKKA9 _3ZE$5D4\OUR64 C 8L&NFL4]CB#C(Q<_P
M]*V'=IZA+A'@#X"7@7ONP6%(/\"AP[00?6V3NB5XB/H471>HX6*].;DHTGFD
MA!TX-%.-^B[#RHX=XO;26FT$]%2;N0 ?R=/3=+<*/\_S[2D]^"[]J4QH2C:E
MIW7F; A1?FQ90>A5"JPA&/+4> )H&%2#N=F:F4(P9G&1D"@B >: FN3ZUE?@
M"6XCHP588K$'HAO,!A@L>1[=SLO)\-%7C<^/NR)(:X"[0(M0D<D E2%]H]?$
MD24DU*4W@Y$0XQ?.1E+Z S.AF(UV(<F5-18V$CWSYKBYW>[73?*26[O.Q+B:
M_8"]8(Y]KWQ:ZB. 8J>KEJ<P(5;*SP07TBZLA R(=$D@$LQ.EIV%M#HW<]4B
M"S/$XCH(6S=+AMC+R,N3E>;ZCR3C2 HI&)*4T,&.B70*0MVP"EW'\.-QXCQX
M14<@CGFXIE(*/RFPA?[+ $AZ#<<UZLTUI?3-+K&Y%>I#]@@&:WQU=["]$.%<
MNW39_DGQG>THS P\H",$"D( MQU4K$7Y$,4 JPZQ1J5:.EOI<R8((B"03=.4
M ,B3P@^.,@@)(U<HI+7#:->Z0^A":J>JI34>XN,LZP?>!")L;)[]*[+%F=_@
MV4N? \8N?6F]W?HM3ITXJX2+"H:?J$N#5< %'(]_*HMEF:PX)Q+N]!WE^]Q)
M9WBX(M_)<ZIT)"POSDC2^%Z"5!,MIX:S+SXFE[ZQ5C;+Y=V4[6YG_ I7-&;D
M.]AE70;VF"]@3I/\+!RI]P9,\9O*@ Q-"&<A:$;0&W5.>,$M")"5@=8YD).C
MJX 8B#4*H!-241N7.Z5#'Q@VV:"['*;_7.4\#I!WZ(KWT?U.HN.,Z60NH0#
M39Z8MK]R&09OS<!X86+9DF=V-2,85$)/! EE]ONTMS2P1P@Q4#.WE5TPZ;P!
M:@K<$]V-,!  ^1$<@"P,IEXU+M+?W_&@#>^L3T-RT*O+D?(MH1&X)*66ME,8
MA'M5J0LC&60933%QC@6!PF[VC7(8^HM%HBZ"E34G3>-!2@PH0*UBVI^M<W\
MTX* ;>"@"ZH6Z+D1LQ7NB8&OAKN[R<,50Q=V5P&GRTD>MTLY]JUPG4/E+J87
ML0:U4N]1;4/E]!U=%(BHHMS@('0%"BN3+?;<\\>"HNZO\/'K<YUE'E1KD-E
M)%>H@M<25VJ%J]*7/ \L)%;>J,JD=V!#*9VY 9?7+CNJK5Q]L ^ M\[\AMXU
MK^^A9/Q_'#/^8\9_UX*<]RJ 9?,P:$LU*4(<UH[Y7")GS.L$:F,6HD8E*Q5
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M]90J_MYH7=Y@G./!%8$8618KIW9-&BP<C'XDPRV06OHC5W)S10NZ 1<7?N8
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M!+3E_@L-&'4R.2[_*1%EA[K;:^IBCX^F),';02W!_-U06--S-Q>S#C,9WRL
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ME+N8"2"E$CHC6*;D@ ),"C>1XL6.T:PA6GK(O6/$J9+/: Y(^>)_R8"#Q@!
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MBE+8 S 1F&$QQWV:J0(R^R-R$#8L0F_/ 6BZ@J#-7?D\'=6%=F,!P/9O1;N
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M:$?CM@:()/3@;T*VXJ"@VU=6#ED9N2C+7?1MTE8L)G<JN>1J 60M=3@D>%/
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M5;=?]7H2#K=+Z^]\CZOVV6=:B&=760@4IOGW&Q_\7SMZOO(]O'>E6UVJR'I
MR0QL7U*)JU-%T*6+''#0V61]*5!@G<W(!2,5XNU>&,": 1@]![7Q>4?7-)0;
M??61A5>MC[=**XSC45N9+U(7T13@UZ&V1"G:$J!O6J!*\X+XL(M%]-+D=GQ1
MZS59F\:.> 60ZLD6W?!%=/#\Z"A&_6IBS(NCHO-1]ZS^.X_#[UR>&Y107H&P
MZM18)].@*#DHD^'5YJ!2B^U"=AC=D,516I8&-6%9BA?>:&ER$-U5+P^#D]DG
M:, [#OS4JK'>+0V!D@6]U0-\MSYZ$X.S_U7=CNL9E9LP<^ZF.3G-YV!'[+Y8
M);E=D-@5 8L2VA]@U<^$1[DH-RBH_(4R<+OUT2L6ICAP>8&]DENN_C ^>4/_
M>DAN?<#AOI8W_M5D.'MU";^U-N?1[6AS/GOTCQW2YMPU^<UO] 1?7&ESIP0D
M>^30=_$QST[_^?OQ^^MJ5C^7YV6;=[1_6\*D5Z9'\&G?JI9W<&!+\W>3EGC8
M5Z[O_2H7F;ZX3"MK^NRESJW+/&]L](!-D7-RADN*),C?K^S<V%]8=Q<"DJDY
M3[(%^/UP(5S>_ %PMDT#(0!>+VGJ\Z*T+S>?#"^&@1/DJXPFB;E>4PONZ<!2
MW;%,T9/)P9/;SQ0='DWVGW^:*.76RQY^LB[GMLL>39X\OOVK/K9S\NQZ8[";
M6I=//S64N4TYK:O-,FG_O?K]^-?3" 3HC]^^^N/]Z<E9=/K[R:2OIMCR' \.
MMZAK[6:4\H4B[:\[L]=+\(-"VD^W'VU__1?Y+=E$3ZA^^4TKPU__S7_>W(L)
M_*'Z(7JWL3?[STGT9U*#AWUSO,)N&8?^CWZJMN)N3%,P17'T]GSRLO<4V-GA
MOT];'S!]*?CJ6!488)L<9^?+S0Y>YJ>TMK>876.^OGM;IODL72=9=YJ^'WVI
MT9?:C1<9?:D[/H'@2YW5QAJ75Y/HO\IBF9O1G=K)F7HHL[3S$S'$:@J.U?O2
M)%53CJY4>W9N'0#]Z?Z4GSF8L>/9K&CR&C O'??*XY3ZRZO7*HORB.W!\/QT
M^-0-VK6+K[=^H4_[%@_GCX=?NKS[K2NYCX<KN3],B_G&_G%>K[)__']02P,$
M%     @ Z$.E4I6XI_T>$@  A\<  !$   !D;FQI+3(P,C$P,S,Q+GAS9.T=
M:W/B./+[_@H?7VZOZIA (,DDM9DK\MI+55Y%F-G;3UO"ED$W1F(E.PG[ZZ\E
MVV!C6WX 9^_"UM8$L+K54K?ZI9;\T[\^9H[QAKD@C%ZVNI\Z+0-3DUF$3BY;
M7T=W[<^M?WWYX8>?_M9N_^=J^&#<,-.;8>H:UQPC%UO&.W&GQB\6%M\-F[.9
M\0OCW\D;:K>_**!K-E]P,IFZQG'GN+O^E%^,\=G8/+7/VZ<(_NF?C$_:X\_'
MQ^W^N6V.QW8/F_;XGY.+4W1^@CO(:G=/3&AFCS^WT8G5;1^/;>NL=X;'%NXI
MI!_B0IA3/$,&#(R*BP]QV9JZ[OSBZ.C]_?W3>^\3XY.CXTZG>_2?QX=7U;05
MM'4(_1YK_3'F3MB^=R0?CY' 87.+.B36W,(4.3 =F*,Y]EQBBD\FFQW)@7=Z
MO6X()[$233^$"A=1<]D/991ZLW0 R^5'[F*.CZ!1&UIA3LPE7#Y0"(!<EY.Q
MY^([QF<WV$:>XUZV//J[!P.R";9 *APL^1YK$'GL(C[![A.:83%')BXU+U]^
M, S).#*;,^X:-('$1F*L*!?<E6"==J?;EA/JL_J!F<A5\ANT5R-- !UAQQ7R
M6WN%XM.'L%I'Q0GP1'N"T+P\$5% GY#@E_+$1.2X>WY^?O0A!3.3C*1\J?9M
M^;'=/2[7;9:@%N\;OK5#N&W0L%J4Y6@(X3:D(7W]%2$E"OGD TI:SB4MW=/-
M:*E&1U4B%"J!S4\3]G9D,H^Z?)&[0(0.,/Q2?FW$4%J8E*<C!)(?,OM'E#)7
M89&_!+_-YX3:S/\!?I(2=A&*V1#;H?9/6)F4M:S^7"!N<N;D+/RC.6=SS%V"
M1=1"*013CNW+EK13[5#9_N:@\2>@)&R2Z""^5N3C(P#!SL-J)"&L%)O+E@!F
M.-B?FR8/W$1.V8$#B.DYBL]_^N%;V"X[?  AE/PE1C_GN.SH 42 PU.%^Q)^
M!,\-8EVV0H\94>N6NL1=W(.6X#.%MV7(IE^']T7\)465%EM(14C'BH%?.N#Q
MPO]&>^7!1SX"-L-'9T3P_72TCF4-OR>P]4R_J,_KTQ4 !TTT@&N+K#!<7#I3
MP8(?0W9HF'3-*,PZ ,,'P1QBR=CF"CG237F=8NR*\JPJ@%/#L*YBV#%PZ14F
M%0<<6^(THDB- *OAHSWP+3+'+XC#\*88>(.<73 QWH&>HU*[5.&H\6.LEW_L
M.X>7$RB8_0QV0-$H0(M=LQD,=PH Y T_,+&M95NB0[T$]#J=?C$)6'5I,-M8
M=:J4=:Q;0_9[$(FB'-J%1JC:NUY8^IW.R4Z$Y:!/LMGWZC+S^Y0Y%N;B]G</
M?*(=R$A*)WI1..ET3JN(0K2COQM^5P=NZQBQ:_60UZ->#DX[G;-MR<%!"V1S
MZ1J)Z9W#WG?A0*QPZWE]UNE\KL)KB=]0'>P11U_)A!(;Y)BZ U/E#PF=O, ,
MF0178*(>G89OQ]U.M^L'VD28#A,>QY*)*WS&"J$18CPPRI^''3&L$...._!_
M6<:!#@T^[9/ZU$[V$^+2^WS#-]A%Q-DV+Q/H=3SM=WK]\CQM&\M.C!^#;O:)
MO7>(\&_(\? C1G+*E&4IS\9T-'K=V>^JG%>,71*/H1 944S[SI 1&CM5-*4.
MF8XYO<Y)+[F6,IAC_.ACW/ME(TM,+,_!S!X(@5V9$W@@:$R .Z!J*JO(#?K2
MZ\O3?N$%*#5IT*-T._T^5<8ATNM>*M!'Q+_#J&$!O&+3XVHBRO,X%8M>?9YU
M58(YQKT5&F.%9\^9455W:G#I5>?G7G)9I3)F'Q5GVJR^>K,9X@M096^@/>0S
MF_%7%&U267ENV)]>@9[W"RY!J3[]3I7V#+LUH%]#=AP3BH,251.Q>6Q1"*N6
MP^"DJCV<0AS>[T#B!G/RIH9_1RBB)D'./14N]RI&%#GXM+81_DNR;8706&(T
M(B@/O HFHJK!+(15:SJ[8#T3"C6/;_MH1?53O;1O=XR_(V[!'TPF]-KC'%-S
M<?MA3A&=X&M&78Y,5SQ[KJS2E0<!*NO:G5.DU].]OMH^+2<X,:,<4&8$I!DA
M;49(G+&DSHB0=]#U"69O;KA+XM>+1K^OME/+BL9^6_-KYH"'ROS2@L&$XZJ)
MP2Q$>OM]TDTNYQ@F8X7JP)6J!EN/3F^I3WM)#RN+0_MHH3/F]HJP"::5%6,A
MK'IU>-97507%&-<V?-0'';B:E%=$F4VVS<(X5CT+/_=5L4!1%OJH#RQ<G^P7
MS%7].S7Q\]@A$]5H-WS5=J5G]GF_<UZ>V9$.C56/!QF(6KGOV$+;9G<<JY:S
MQW(#M 1G?=0'%D;65AA5QIX/\1NF7O7@8Y/.] SO]KN)/57=4EX%I_%60:=[
M*0H/Q)1%<9N$)$D4VF#D^+B;#" #'/L9AB0F</.(/Q^E?FGU^MW$GEN21X>P
MGLUFQ%5SH0XLJ&(H3*N5X>F0Z5<4&+Z4&&2)+3C)$,%W8)&YP4YV/DIMK']\
MTDO+QFC8M9\!?^8D;ZX>RR#7*\K3?C>QPZ+GY4%G9LY]Q"><S1%=B#O/A2E]
MA,YGWNP!(X$CT+O@?C4*]")RUN^FI/;T(A+S514E?Q>&3XL1$&,H:F*8#N*T
M.3-_Z]8O4+]U#R+UIQ6I(38Q>5/VNB8-E4*!7IP^][LE'9(RXA0A9R_%29T?
MO(*9L 9R1[S*H8YU#/IPX+R;S&<K%&V%P_"1[#$'JCK^&7BTWGZOTTNF.Y+<
MV$<7?WTZEZI-/7B>JX2A"8XR<1?5#T15Z$2K+7O=?K<(0V,J4CTW_-Z,L+N#
M-HSR8R"$-U,3)+["4YOQ6^$2>9T2G0!KEZ<V8IP3/W-$76QM7SRV0HY>D.3N
M<5E!BI!E2+I4R?.*,@-(BYXY61,]800$'D0ORNLA%BXGICIK#DUVIW-R.M*+
M2Z_?+6#6X^*RZC"0@X/NR;0%ZH'T93$5BM#;#_EQ@[.X&W6G%X9^OYO8QBYD
MA(+GT8Z-H.>]E(DG[*J[A3!_G2*.RW-Y'8'6-^^==)/E!X#!OUH(<!@*R?[.
M?U77/!V-WC,_[26W39*\V$?/?&TV5X=C;XCCR<QUY  0<^^IZ7@6M@A5C[$5
MPEVOQE(]%[)#6O0J]JQ_G*@G21&/^$G>D*CH428@RPCI,@@U LHB.*+$[:46
M'F)'WL;S@KB[&(&+*I"I)J.\N&1BTNOES]UD\5" RE"XC"BROR9G?CJ*W\7M
M?X_=URUOZPY>9Z#X)J\*_NV!T<D(\]D]?0-W4Z4,'_%LC'G+0&.ASGA<MESN
M@7&5UXY?MC0 E#CJ*&<(H-[X<#''G#!KI.X-MCR_;*=E" ^P$]>3WW[FS)M?
MMOSFQ,6SEN%?,^R_ N+"8C-$Z#T\D%A6UY$G!C.83#B> -^O88;DW5Y#/)%,
M8'PQH)8\7"H>"?SC,HI?T$("1X=I(T<LQUD)5_X,^"\!<,-'8_^^4Z ?CXE;
M<%K\7V;0L0O>88%YD?E@S.7!#CUOD^UJ9VFDVNL-!\5>@X#X[&'H8+8^)/\7
M&:O128$1^='\'<;2++YP-N%HEBF%Z8T;*F:K%:(7LV2[9HG9@'-YR$VV>/(D
M@<_V<JF+@3DE(%)6)LNJH"K!T!*L(]3%$\RW,/R!92F;A)Q !L6]?4VXZ<W\
M5YJ "<C6I-M!7O<4?4.<R/[E!83$"BZ:]??,8C]E3D-Q!&56P_]S?8,?S.6N
MX WV_][3\!CH+^#077L@U6 ^PDMP%A%O3M749<S+AEB;.EG/?((H^<.OG*;6
M#18F)TJ;/]M7GB"P_OW[^1;^OR/\X5XYS/R>;0NJ8]R5?G7#+@I,R VH.H?-
MY8_KCE.V<.B!&FH'O\YM#B*LK#8BV98BT6X#68:U8^UN1*'3GW:+2+%P00?9
M>.N?M%!/;#0EW(]4ES75MQ\P--!-.[6-I7NNVW#&AQA2K#Y8*H/R;*_B#ABE
M35S_#0:%IJP$OFU/A!0Q@#:A]S*QJ>_2 \> 0(%A\>>'H"D@#55]SS*Q,S!-
MH,EZ1-2S852>#(RNF7"%?X]$]FHH"%U][+O5DEF+.=#S@=T:L:N@RJM"$*%#
MU51/Z'7*N%O->A0"K=U\^.=,<T82:U,[R2/UWE)?K[RH;C-%,:WICG(H(5#A
M+,HKYF_$S).B]+:U\R!KC=\1+MR5"9.IQH3ONY$2*=]!0ZW-"\=FD)U='T"!
MW%I!Z*:JU4BRMG XI85I*).#!&[H$:=>'Y ]XH+0]3O)\L(ET!O82LT3:3B:
M!]A<;TF3Y;GC;!;/]#PQ:N:XCQM@;.HD^5?.Z,U;O$WM9DU5*MT+ 3[\C7+>
M?:=!U33Z+^"YIS)F LOR G.8R<W2>!J;/0FNT0LOSPMNU[OU.,MQ7 H UL[N
M%X\#=0(_<U Y81XBV^:FMV[J\GM U'(8M^X\:F%KA"F0<#^;<_:&BVR5%X2N
MG8<J;9*H:8QXC%>+59/ 85!%BN$Z7%X6J"+X$4AK4+,,.E:6"6#K%Q#D*?P=
MO(%AFF!5RGP#RGA9BRWK&&6MZXA] X!LK=! 4G>46%+C*.(@/=\]#:@5'(<(
M$V)9SG_.UFPE7+4+\/73*_CKEF?F#"_9KG[2RSDM>2FTJNB:JH&3NX.P3N6;
MWH*7?=*).J@85$&7V&34HVFL+Q&G5[QZ0"1\>,+N4-:IP;<!#%!33U(,?!<J
M#;09*C#"960ZXF0"T1.V]&LZNWWM:WO])I_UH'L5@@ZQF,NPS5^G+_ZN AB?
M3$9N W6]&R*J)G/.N/L-3XGIX!$VIY0Y;+((4B]#:8:?;96M>L(3YA(UGG C
M3"\5V\)>NPS)[-RS?^HD%MB_<#PCWBS,T3W32(UKMO=4"5E3,V :'H.-DWF>
M2(IO8[')1UF[K"RS7 %AF7*0;%AW FQW?OTWY=2#4QMWVR/WUONS44/(49RT
MW;!'2+)%%4.FCWLS6M>^/K+BF/C^NJJMRBX[VFCK98.>&IN>7QZ+5=($+N5_
M099'S"]ME/(,<IQ7$%P&1^UBY-\^FWXW:HYY*0!9^_#2"VS\)%8!S[0H>+W>
MIY\TKY8D*09;.Q^#0IKP_$JA"APM3%-S!'YM197U6 2R=CZ&SMH]> 1FSG9G
M:MNZ?;O(>8^BIZ]T( TUA+YN?P$#-D.F.MDHUX^Z7>N!S !U3AZC.'SM$ID?
M)>TJ=B^'OO:)4NY,N.=55"=I86H?TK(H->*YIA04@6O[A%UU3%+%1<5K5+;7
M04,5Q0,6 N-X)G:(*7Y'SA-(LHES"O(*P]=?I:<IL<H-H0K!-C4U=9U!>;;7
MG G05*\K\^B"=E5N%#V70=W0Q;^V 2-W6[Y"9,35UZ+;-NM0VS<*Q;=KLG@U
M&'T;#6\?C_-.G!>#KMWLI2G=Y;ZJE#QY@FM@NYC_BA&_8UYV/K$*JJ8J@;QM
MJ*]S>4.C.N:LTE]VJ.? ?*?X^-E>P?8[:NP6;WHX&MF1>>$P&>&.=A$E6@A-
M8^<CU.]WC"<.!65[#UJ@QH[U";^KO;C(WGS!L*$(9.U:]'8V=]@"*^>=T?!;
MY!)._1@+@]<^T# /XQ^>R<_7+-O5G:L9.'],,8$X2]R *($0%3MBDPM6.T?2
MPLKREP%I@1OJ<OX;(^MW#W%P*(1R-O2LS&Q>.PN+G%O*9&$QX(:R<"E_FJ X
M7WBUP$V-I(?R0CV*K>#RV]PCH]GM:Y??C!,-_I[G%HY&:!#MZM*KH@4$67'>
MR^C;R\_#IVI!XAIP[?RMF/#\DZ8Q;QY?!WJ^15O4SIQDF:B*#,LIEY)(:A]T
MRGG/(K?.Y8$U5")75S:FT%_@HL=4J(:.=9DOUFO.M5:U"V3B$-3 <=B[G*\A
MGJ.%*D 70YTW4P)#8Z/\+(.6M:WI4XSY+'$=T#4'0CC)+OC?15=UQZB2R+F\
M0-@I=.@GLWGMJV&((5;FYC1>!Q@<0GFV;8'=M2,["YF_&D*D/?:XP#DE%-M
MWM@U]#.F\!V;4_!T]?Q/:UD[ZT$4WXA0ZZM:$5H)!+4/-OT<\Y6\QD=,7YA'
MK4H'H5,1U#[8O"O=<HOSBR.H6Q%G42KM1TAM>#/E#5J(>_O6MK&IWM K':[
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M^;33Q3L_02Y\ OP[WV'KV48Q]X?8LY;6S&]!95%$Z[(/P@1\<51V4OJ0>8C
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MKU&>[=3<7YS'$K?Y?0[?EZOWP^F?5W6V1,XYT4"X=:4=E@PH)@NDG,8(RTQ
MB[(M/QZ".MQ5^P[*7DF<'87>=(VXL</*:<Q-=;X.V%K>E:\#=YB[[WJJ7,F1
M2GK8-U>246"4TB10;W&ODXEXGTOYET056"]2J[2"?7-DPX7S82C21_RU(S:O
M';L;A^[:W7MQ.1E_KY',(1OM2; !T?DHB*5@2$J2,>MEEHO%R%>$[&T<ZI#6
MY*YJ&3>3:>THS>7H?BTGJ]-/[\9W"N0S;4R(@1/&A"#2H!WL.*+,TCAIE<H0
M^0Z:7S+DXV; KC)N$;1Y'^B-#&YHJA+HLG27J&(BJ9?$N:1)5E3(Y(7SC4(W
MUZ%Z!!RI+_T&=ZS_">EL?IPW18CS&.;Y+JB#8RXA( TVXWP](\Y0=(ZMDBQR
M9T1JDG6]',YC<#$J"'HOZK\F?!=<+1V+5< .XU344-Y&/NP@^09[QDI\G*F8
M2D5D[U!STD5./-.1@--HYS C)&W2Q7R_C-C@0NR3$'T$WL2GO ($Z=GT&N-W
MM^FF:+8#!T8X4BZ6T6G*#K='7">3E=P&SK4THHUKN1';_@V).HI\X%K6U<)*
M?Z-1,,SZB\@:83$]1]CC)7"O4!E<*)RQ(FJNM$P4G+<.#4QC;88<C-MPI?M@
MK/H7M#D$60A+*$] )"1*2CP/"2FQ&*VRW#7I6];T@O9.AZ !=12L"8Q8K161
M3(NR@&>"+V_2J!":H4E7R*5HCN/RK8_.5Y^*;2ODII>O5TVB!CSBXJQ!$"Y#
M(E(D3H)$AP^W<X'O'T1E&I^.7@%Y3/K>0K1-#\5+/<A2#.CMZ,Z%,,P&%KCG
MX#FAR:'95BX>O:*64 #T[CD5N&NWU?T*9(^)##6$W\ #7O3QA<Z!6D9)2CR4
MB.)(',?)2@;)QQ TCTW*#Q_1%7P=??<7YP]Q!<]%ME(%1;@O1[DT2F)SB$0;
MH8V#:(5J'+%UO%?PO93=YPJ^C]#W?:W:!=O3%?QVJNQSO[J-'O;-E6A*1!GC
MJ$L3B?0TE6;4B23M50XI!".?KN#;4:2/^/=^#2=E8 ZW5N(Y]42Z8(C%C1C_
ML1 = -C8Q*W^D:[A>BFPUS5<'^DW<$=_]>=^%.'#)X#9Z_+IFQ-E$[.W4<W=
MY+*E*IRQL(I8Z2-W$7(R32+^5@%Z#*9&%6$W<$66X;HF?A=D+8V,U= .8V+4
M46$'7NP@_P8[R!J$E!N@D9=>DJ4%;RGV;GEB1*E@*,L IDWYF7TS8X-AL6]B
M]!%[ T*\F\!G/TPOOGY&^4#)Y'Y;;BBN,KAF5^=O-SN<IMI+\(1#Q!W.!(>B
M<))D1HT53E&>F]B>W2'NW]BHI=CQ7K2R[SN[Y^-SI%PI#U&4<#8!V#I+>M6C
MJM["=<*[<-V65%(A::%IR4R/S@F?F,A<"V!1 !UT0%Y9OMMG0J]_X#YDW2'W
MF:(/QX6/+&>0.F=\OZS()C$EA%#9K9)XO:3G%0/\.AR?P6B'&^A.S]V'%M;,
M9+%-)I594Z]\%$*RE*S4B2811= N<LY6*>/^"+N6>;D=X@L\FTR*=S8?!-?-
M-^-17/'K>?D2=.!*&Y'O9]>XQTLI2_OVA,Z!Y,(1)P0E7$61J$(7L4WN9,U)
M[!3XO0K(;>N5R?ALXE%27 J6G*,HG](=B"I#G VX!VFJ**Z$TG6LT-QUQ/UO
M[P=CUKTP\28:J9TOL GDLY2&5YFS-W!?Y>=#=-\O2D6 6$I&S0;6"&6!<@*:
MEH[2WA ;H43#):FCY3%*78527= \T6U/FJR=K+1J G]\1I&/9N_\M[G4QK_B
MYA\!/Y,&P5A.M=3XOA2XEGIB&9K22C%KF-"9V=W6LM5C/]&LB98J'J_-X3X[
M0]OE;%[H[@N<CS\7<"^'D^GL>_&Q4J&[B!!FY:OIKWX*Z?<A?C4;C^!Z/B4_
M$$U5:STQW.(BC;8L>H@J$RIT"A"Y5UQVHEHM1*=*P(-H=&4-N2UI>0?[0V <
MT$/*DA+-<XG#4):$P (1Y7S;JJ@?A!JLH-JZ44Z5/M4D_Y 26W<EO,HJ?,CA
MAP"I4U9X4T*]?40#,00$6-+3RN4HFHHFV]")&EU&.U6*5-?$0ZILW4]P#G##
MPL82<*6D(5F4I$5)$PDZ9\*#YR@4[J2VG4CRM $MHT=%Z3\DAJYH0M^<VLR_
M2!\^^0F\S7>*KD[&>3@KH9D#J[TVDI6^,@(Q(W>)E5 $(CTU1B4KNS%F2P"G
M2J5]Z.LAQTP#CKV\+*>+[Q I?N//8" 9>HQ2.V*=0<%H!<3I4E):**,\"RQ[
ML0.E%L=[8E U;3PDC&WBUY>&5S>'$[]>3E$6T^EO_MOT57Z1,\1Y,A.:^<\G
MPQE,AKX<3S@OE7/,$F%\1EGQTEM+2!*\TF!9=%J9+4BU"Z8GXNU5JP_)Z9J0
M\_WP[-.L5#Y'4_ -G(UGP_E-2)D=OE;#<7J6$?^]*;W-M^_?DI,U)9U.-C,2
MG2Q%8:0FED=)C+ *.#C'5;=R*_M"_$3L(V+$DK/6-N?^*V9Y-<,RUP?'R#=O
M\J 4%@],9N)=,7R9H21DZ0A/"5PV7+F.W1_K8WOB\D&TO(2U;:X(5M]QO!E_
M_#2<I'=^,OMV^S*^^ KQ<@9IR4N9&%C#(!#<DC2*FI>*32Z6"!V5<H[HW6^,
M!]@/U"=.'P,'EE!\YWC@<KKP-G^8C>.?-Y.:.X/35]/I)2(>W9'H " 8?.T$
M,:Z$QML8B4O.$F^$U*S$Q[?I>-,'Y E2M;DNEQ!OZRN))6"?HP2&^-CYOG!S
MD_?V'EI+HTL&X05%.?J4I2J6P*^\D4I2W ARF\257BB?J-= FTNXM_7=QW>Q
M75R,1W.TTZLV4,/1V9VUW _Q97GN/P]G_GS G=$Z EH=F1LB2\).D((1)JC5
MB-7SV*1>>A^0)\R\9KI<0KRM;U*6O";O)L,(: 3/5^A!@&Q!@"2>ZT2D TLL
M2Y0(RYV,UB?IFA2W6@7HA E514=+R+/;;<NJ!?;=!"Z&EQ?+UUFOBZ-@%!%9
M2[0P:2*N5.RB47"T+7'AI=WB2+89_00IM!]-+>%6S5N6[X)Y^[E@0^=E$H?3
M$N2R+I[A7A26"U2X@!N\EM$1Z0-'X1E!@M8N>!9M3KN=G6\-[519>5@=+Z%L
MFWN>+N$4]V8A+-,"DB7<EQS?K",)U@F2E. T!<-L<#LQM2^B)X+N4:-+>-GF
MBF=]',<]_-&#X=$88K0HYT!HM#F/6T$.$?WRQ#E+W2+R=L?RQ,6]:'%)'/)N
M%R[WXZ-+"$=4D>E2XD25PA. 2S4#BM\:JP-SRKIND7P+#SY5?NPBWR7*KG9/
M<2=[[LZ,YUX,NL830-K^!E?_'0C*3- X^>QPTY;"^I*USI"OEAH)*@N3^BXS
M/<8_5>KL05M+&+;S-<%-)9MYL_1+7/9P.[ZIM/IMD'5V'@#11:Y1)#(36QI9
M2"1_EBQJRVB;([(UJ$Z08?6UM81+NR4CO(<IX.,^W?<TKJL8O,UY"K.7*-CW
M<%[JD,^OT9Z/I[/W,+P(EY/I7& #5BIX&LL(4^6JS)7"/(%S8A,WX$H7Q]0M
MWJ\&FA/DV6$TN82+.]\$_'8)"R"',+VNH3$ :[URWI,0:*EU[S7Q-%*"FSU-
MX&CTC3H.K %U@FRKKJLE1-HM1V)3F,"MJS!]%C\-H?@'TF1-)23B=5(H#9>O
MNG5Y25.B0H?0T23O/_8)4F@?6EK"JJV/_&_O(N(G2)?G\]#\G45X5=3.>)5]
M*0$$D%%\&<7G$ZZ]7EN1DG>!FB:V6OVI[*M\]<'9>R1L.);2V:56Y]M\9UI7
M;9%T%#YX13+Z0T26I*@0%1!CI)4:7$QM.H8L17.H"I:'9LBXMJ8:E+-[* R_
M?/[7U=.ZP&U9%K,GWL/4RJR@Z?'^U70$[&(6/9R0%;',B=+ND1'O-2?X(^<-
M=8Z:)JT@CH)5&^IL'IY4?;13NT3-N\GXRW Z#V):M9A?HU0V2<K!$I?!XQ(-
MC+CH..$V"ID5];!HTJWP)3H/N7\7HJGFQLW%7KN4UONW+]^4DI^?[QTC;P L
MJ,;_>4J4DZX<_)4B)"F2X R/$10$WRTM;)O1'S%EFBNC]M)R55EQ T!+,]IY
MEA,7R@UF<8"#4)Y8H &TSCIXUHDM749[Q.RH+NR*9:NFDQFZMY?HIDT^EP/:
M-_X"YILLC38E:H H&P*1P61B,[+3:&654U)YWZ4W-S[_CDF"WRV:(ZL G+@#
M544OE7GR'CY?3N(G/X4[2]Q]B#=EK3N [.$Q=2)19W3[]8_J*'*\+RU4W&CZ
M@74V) 052(X&=\.H$PE66I*M,_@_[T!TN6KY$:BRPNDY(%/Z"+^-*7*]"Z*(
MK0$C2?1H5DMPB=C 4YFO$A*X#++;O>[=I^[/M&@H]8<&Q18BJ^B$E*FBIY0N
MX^SMY -,O@SC%5M5HL[+<@]G>3%D+'KGI== *3,0A7$BZR['L)U>Y&4 G@R'
MW?52L0#E'3QE_M>(IM>O0!=0M0V%E6CV;QCLKJB'6J\DY<J&P&IP0NHH+7K
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ML^BN(YXJAYIH9 EO=CNH+E!FDWGF^U+  QTU]PKM/&690710VK8+(-QH&42
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MZ6@4( @DFDM2*AJ*.AGB@\Q41F<]-"'K4^?<W8]$#\N&0U<S6=_103#J:(A
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MZ/PX]4[Q3D8!K -#G,#]7J:82? TD.02"#!*@6ET\[4!V8GOR6TTV""U=P7
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MLU%Z\=^7P_EI_)V"XE%&Q4,TQ&G!D&1>$^^<)4D;$,9*3V47NZ?_E=AF;(_
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M@TK!KY]%3NY%1=?O22D^DBS_C<Q78H:YY"$.)91!'$$D*(4T81)Z5-$G\^)
M1NDTMF8M-9L:-]?B5^R1B[FH3+DWJX*#)Y'71OED]G)MWZ'7WNP=\,V8OOUO
MN!O<O'XM[V"-$VB JAT(H*$"&BM0@34!]V&H^9^$T^%<N;^&JS+4G(ZW,=U7
M0#N#@2U7BS)_F;W[,A.")#3V,>12"N7JR$@10I!"E J$ B+2&!FMU-M'3FV)
M?/>0+8C9(MC"I7OUZ:?MT.[$/SY]N;Z<60]UZ]B+;BZN*:WYQSZ;M1XX"HT<
M*K#^?H_\II^EO?D /RV>5F7Q63R+>?B+>*0BGW$LD\@+4QBD@D+$0@Y)F K(
M1"A2&:01"Z2-[=LQUM0^M4HV$-I9G%U8FMF CA :^//<6C]7H!;T"C2 @=]K
M:1TZ]P:8N+14NH8;U78PT'M_-3>YI1]-?!9%(<1G[985M\MYQEZV>UL18A0'
M'H:>I[QC%*413 EG,)94^-B+*4^-#HL-QIH>36@A[5BB"THSEG $T, L44NI
MF4'+"7ZO)06#;  :(.*2([J&&Y4C#/3>YPB36_IQQ&V^9$+PXJ,2\QN9B^L%
M_X64JUSY"3?R%Y+_(4I"Y^*;8/IGF2AF,4I\)ED$!=<Q_M1/(<6*2&28,BEP
M@C&W8@YK":;&)XVT>M-<;X052H<"+"5XW,@.BHWP=K1C/SMF9#0HY@-3U%KV
M.H]%2U_!OI9?([_5 'P[C[PU<?5&SR6=V0LQ*LGUQFB?^OH_R#*<;C'/9K\^
M*4T69;-G4LQ"%##*?!]2WX\5UREG"DN?0=]+(L2E%R0>-@JI._+PJ=%8(QYX
MJN4S#*P[AEHW!UV*Q<#TLH9A+=H%./ FYJS:GAL,CYU11GL]BI\<!!]V:%Y3
MI;Y"$Z#OA>L(PV/WC!-EV"'M)M*PZYI^!MI[D6?/:FZ?Q;6R =5;Y<LX3C *
M8>R'#"(=X8N1C&$@9((]$00HB6WLK_T!IL9+'Y>YR.X70/%[+A;*&>$;@8&:
MLC(GS/0K/8DIXR25F H8IIZ " L!:9IRA2FAR(LX%T3.GD5.EV.@VAYH.%RW
M$@*B1;P00C/#\Q)8!B;^%A[7G7A8VXNGE'9I#AZ,,:JU=TK#?6/NY'4];+5W
MR[GZ^S*O'W>?B^KHJ_H+KXZ_;J0.?Q$YR\A<69$R*S_K$-T$1])+TU AB /%
MGRC2_FL"F:248BZQQXSX\Q(AIL:QM<!UQ(9VH-A&9O!4"0W>S)78/^JX#J9M
MC7O3Q(M+9LK CAP!_Z&/S=H:@(T*5Z"9DTH+<"/!5@]PV\R)5L4PP.:BB; P
M9$>8D)$,WN$FQLY OA#13D.Z[[/',[@OU'[',+_T67:+5)&7LZ\Z(J,Y3(S\
M))8L19"@V(=(I!Y,F?I;@*B'DM0/8VFT[NP]=VI+224:^/W]\I%DB].G!9U0
M=1/_!0 ,S.7?-"<59<84%?PBB ZNK:+:SJ)AS @G=.^P)-4=+2M2_6O?@MQ_
MY"C?]@D]UI_KJ5_W/ ?-",WFU>;@]8)_*Y?LCX?E7-U?U %1U[2HO,@9BF02
MI#*!'@TX1!(GD.A#CA2%),4)1SZSRL(S'7AJWW!+[OI(HR7Y_P"BDMWR_-1T
M"LS<R"& '9@;]C%M0EQ_7XOJ\F#5$AVGIZRF8X][Y&J)R,'YJ^W](V=0?,X6
MXE,I'HL9];Q Q!%3/FWD012HOV%* B@1QQ$/(\']8)34AXU(4R.WB\/3P>]:
M-U I9VC@.)Q@,X(<=]J&-JO&F;'Q@O\/0)Y$U/Y6JK]&N/T!BL[BY ^??.G9
M32OF7BT@_Q#\/EO<7S/UJVI1.99]*FF<\%@BF HF(?*J"+V80XE)FG :".HE
M_<YY[(69&H>W]NH_9@NRJ#9?6FKU/<OH,4VVYQ[#@C_>&4D[-TO;LXTF8*O*
M\"G$+E =YA"FASRO=&#3'[G3ASL7/-.^!E83^?/RX3M[T,3^1;V_LP"GGA\F
M GJISR!*XP 2+XY@[%,A_1C[R#.NA75L@*D1XEI&L!82:"G-BV,=!?',^8L#
M:(8V'.U0L:J:U:7Z!=6SCCYVM"I:74JUJVEU7M?/5KIY$GIC?G'_:<&6CZ(Z
M=T+$5]9.R"%5?T 44@FI1T+EVP8BH&F$4Q3-RDW=V;.K\)$QK#[D$X5TG6X3
M*9GJR-9E+>QR86G-' /2S$BY$)Z!/^:-=* 6S]DIFX'Z+HV$8\.,NO9WZ+F_
MI'==>O%>_+LJH*N<R23PHB3T8<RTHR.#")(TI3!2'WG,DH3Y*;+YR@^'F-I'
M7I7*;@+:2C#?RMM[4WV-I?7V>0^$QMLHOP*->(/LC>^I/M N^'J4U]KOWM.R
M8V=[_\J+8[*V&RU?5OH8[T9><Y[I):TZ7K_/R6/Q97GWD.7\EN3ER^9(_L-W
M95_H0@3R79:SU6/=EZ/X190S@4*F5GX.,:.);D0BE6$?Q.J?F">$,.D1H_WM
M<<2=FIM0*Z8CO,A&-1WA5>EV!19+4&KUP)/6#Y"U@D T&EZ!3 +65A(\FD:.
MCO2"G'%:)C?M [/I7A335MDKT+P,-Q)L%0:WFY?ARQ)42H-*ZVT %/BP>1D^
M2;"C.OAE8B]#[\"U5WXI7B?$[15?CDM"X@:<*XO@N2&D>*TPNP$1[0C(&W+4
MOLG1XHED_,-W?7BD,P^K>DEUZ/K:XB;83R*B;!$A/:0,$IY RB,)$S_!RH.)
M4Q];I>,8C#DUJZ(165D)E<SU><"RJM>V]G&J#!/KY.?SZ)OY.XXQ'7C)7L/9
MB%NA65>_JR4>P"NR ,AM#O/Y84?.6C;&X3!/V?S6J=57_;)</%>5W\Z7Q0P2
MB@1+/4@#[D%$DP2F48R@YD"2)&D28SQ[VFL3^(IE-,U5LV& ?06'(X.WXCY;
M+/2N)R5SO:Q-M;ZJQ3OD20^'-$DAIK&$B/N)<M]E#*-0,!*@F*$P:-ZA=;N^
M_Z)OT/'&AR[?'S7"?ZV7QVS%GX*H$S(IQBO)NX'GOU(M7OLYGT1 GTN]_AHA
M@0/,Y'C%=WO(UF.+_G/&*@-U[3PW*5<Q%A@%,H4));JJA/1@*@6"7NP%:1C2
M(!+FE6Z.CS$UM[61<KMY9;%U>0)%@\WGR[$9_/QM#Y;SY4&-\;'8C[T<IY$V
M4==X;4Y+7%7&Z4:@<VORQ*WC[2=VR[ZS"7CF4N<=EV8\8E&<2*8(CB*(A"\A
M33&&1'J* "GU4[L4F8ZQID9Y^RU_V$[+GS=?ELHT2RR]@BZHS8QU1P .?I+6
MIP^5R[9(0QB77<--I>'1*5/,Y):>6VTZP^]34:P$?[_*U5/KA@B5\?55V6AY
MQI1]5EU5V79?1'DC/RYS*;)RI5ZZ620)\W$:0LIUX<!0$DC].(%)FB1>+(3
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M#NQ#C!,$28 3F:0TXL@HA-U\R*F16$>3/B7WW[3@#GHN[J)NL#7D',N!><P
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MLWG!TN(:\&&6%F=2OM+2XAKETTN+\Y$NW**H:2".)1&4>3#R @J1'WN0$I%
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M6(@_R5QGR,ZDD$2H%Q(2%BLST0_\NO*$GTB>(LY9+(W.H@W'FYJQ6,D'\EI
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MP)0*JZ;:'8--C6,WLE9]C'2N?"4N^'TML&4F7"?09B3J"KZ!N?$"Y.P[8AM
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MPP6" ]/&3L^:7?B&*,IX'(=A2C+NC?5*!1F/:WRZ'..)Z_MQ1?/V?_C.'G3
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M\%)@+/CL4H!&HK/M2U. )P744RVI*SKK0J&3S8[>.!Z9=<F]PV6=%XX0M*!
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M%*8$AS#E+$5QA&B C!JJ'WOXU)R_2BB]/^@';^B/ZVTFPV*J1]$[X_==B,G
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M;,>9O>28'FNJ22GT9_M<-=PFFU0Y^XP9^TDQ=)D& WJ\W!DACN3.M.(#VVJ
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MYA$.*0D#NP-)\\&G>!BYEATP);4=W5J@;L:GPR Y,&&V(-3BUB<<^B\MP:_
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MDY"E@1!90C.C\T,385/SXIKEKBHKTL'66A3/=*N$[ME;])RIG]>=<*M#%KL
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M=_WF&<FQI#E24QQPB"AB,*=1 CE*"6-$8!8:59\/H][4/'%KG=Z*=>WK,!:
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MHECWZ)592V/[,$*%BKT)1B_4(<?MPPANYBV);AV^!P,7IPPTK7^:'6AM/^@
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M\UB%1YS2'.9AED.4H1#F1,\."0,NL')XPLKAG94R-9>V5\ZR6]=9",T\U<W
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M:_7>_8,\BE+YRJ]2%DR]^P>[?<OC"(LA)_365&K7_9"TYK/FR+;B[%R5%;'
MWU9JTZ@_\%VL?RB;P'=-[S'(:84#AEX393;RQTU_.2!SDM1R&<.)T7/UHRC5
M8&3Q;K50/U[IHN ?HI,^:UK^J5TI"SD+(,98$Q1'&<1Y1F!,4Q&@0*8H,*)?
MLQ,[M8"@HSCH:*XSWX]K(2SOX9JC;[#]' 33@3W:!3A_B,.>'O;-+<V1M:+F
M' #AT4@Y#9#V1L)IB5,/_:;I:&,2;UI:>$2Y:?NT.]GF:GW(2_<@UL^Z64H=
MN:E]'@IS%H4PS (,$1(,D@Q'D,0Y3UD:LL2N\+%?Y-0\^O<M751TZ$K8LSUO
M9@^^9O&H7]0&]MFULF=X,+7&.@9M=?9+=&F&CV]"RQZIHQ-7FJ%PCJ#2\$F'
M&/([6:YD<1 -[8*A9I$E-,5!'$40DS37%7@(Y@')8(Y3*1(:!3PP)X+OES<Y
M'U-I["%@-(#:(%+T"^#@F]YKV+G$A@8@6@2%?L$<*1IT_$+:A8'FR%R-_PR&
M&2_P,[?I(.*S>,R)4>R'6&Y%73'W5=Z+M6Y83I0U7^FB>*S$E?.8:,(-F4$6
M9$QMX&,&<QX&4$5_(LTI%U$>6Y"+&8B<FAO>EQ2^[/4%J[W"5A1:)I@;.&/O
M2 [LCQM]9TUC8/!5@H[.X.N :%IQDWE&=32:LIO1M24MLP"JA[_,9*0QJ<PL
M+#MB-;-YTK5K^\=B(=;OR$8\KM:O\S@(:2I$KB/D#"(A0H@3S02)49J0F'*>
M2;M>[0?C3\T5URJ"2D?0*FG;EOT0P1Y?>SLN SM6.T@<^JZ?-?SF;NN'HX[<
M8_VL2:>=U<]_S/$XDCT)OEV(K_+#\\MB]2I$<]1VH0YY44U-5=CQ3;#5X[+X
M'\'KBL.J/W&GI"E# 0D$A82D%*(HUU3K409#SGB:YF$<!,CJGLA0FD[-F7S?
M/C_K@U$5V'7;L1]<3&A8;BPOD0PVUV9YP4G,X-#[^^L-W6?MS-7'VDTS0VW7
M#-P]K[95R_?J<MX@C=\'GP&O1^*#*3ON^?G0F)\<M@\NT&%3?^ED2.=MV\BT
MK11\3U[+3_*#E(+I3VN&OW?K0KG>@OPB-G/*92@Q%5#$F8HH(TQ@'J8((I:'
M&4<1"E(C4C[/>DUM&6G/+TB;F9F!Y2YCT!;6 JYL D0JA4"R>5).::DL6Y=Z
M_>&ZX8#Z[.9) -$:??!3XI#S]?A%,$A'O,WT#KS&7#SPK@^MNKOMUC:@C9N!
M3Q+L[*L(2D%K(5 FOLTL6J1!WF8V1\J5C#ZK=ID5_]A?3;]X%#=>CL8_1@>)
MG &&=RV[?WY>+:O-27/")"2*",,49@1KQBFU[<OC"*O_!1Q+SB,46Q;8'TF8
MVNI:*UAOT&R+Y8_!,]L]W03)X"O2'HW^,TR'0O<+IOLM:3\6,G+Q^@4;3\O4
M+WW0[F4NUQM=NL6W;*-+<IL]0OE^I1M[SM,TR(G,*,1)+"%"J8!Y@'*(>)!A
M$2=<9-3DA;XJ96HO=:/H0<7Y;[6JAB?RUT&]_J)[@VK@E]T))>-WW@B%*^^]
M>K[SSJM_';_OUP6,\LX;V=B^]V8?=EO(U;@O8KUYO5<3O%&#:_ZAJHO8@QJO
M^=+F(LXCC%*($IKJ;C4I)%@?Y02)$%$2$&IVT&XA<VI^X?-J^0@_ZW[QX$']
MO-#YN:K?B*5WL('=+"CP#.; GN,&'*UC!@MD?$81)F)'C2LL<#B.-&P>]9@2
M;+<R.WK=\JYN-\OG 4%9D,<I#'.DMAD\19#P((8LD$@PF4>$LYM3?Y?E3\TO
M[2N ]CUVV]Z\W$,VY\I,W)![\X/OV^78]GF8O07@;A34/>3*_*#_]CDQMUGP
MD_/JQ] IMW5EV+?/8?7;;)2K,AC&_7:0$(>7 MX7)=-GJM]TL[$\0F$<113&
M*!(0D32 1&0,1F&F]K2",4J,U@Y3@5-;+%K=P%IGB'\B:J70A:-,O\6/XB_V
M=X6NHFT6OOK$<.C8M5+US#VA':[?O#1\LX7&]Q6AJS)'OR!D@L"YZT%&SXU,
MJ_N1%.N_D\56J"W/]KEF:_Q6E/_\N!;BTU*Y .40M7Z_D#^*Y^WSG B*44 (
M9(G,(<(TA"KTC6!,&,ZS/"<R-DK!C:WXU!R?5A5*I2LH&F4K%S@#S[6^(S'Q
MVDZ_F0>=XJ0.[(D]L/5JXT%E/>B8/P,: * 1 "T$E5>?@5]ZOBKC4?@ZSMLD
M2'UM=?]ST/PZSH@WXE]7^0XIFSO&UENEH/I]P?1U_W+?F#LE4@H2,9A$*8$(
M401S3B,H.(]S)CC&D3GKYQ5!4UM>&E4!:W0%3"MKD0>X!JI!FL435 ,[[1:E
M5LV*XLF@$;H=7!;Y$4^PC90(<87/+M]A@,G5Q,:UY\?+8!A8<9"J,/F\:TY"
M^>J6DV!+%KI0Y^Z/HIR3 !'!< P%BC(5V@NN?&42J_@^%B(2*$:)92[BO*"I
M^<I*3]!1M&;9^$WK:GF&=A%;T\S#[8@-GG%P <LAT7 =";\)A@NR1DXL7+?X
M-*'0\WE_?$9M)\F'U<_BFV!"GY5^$7]L'GX7BQ_B%Z7#4SEG+ XEHQBRC 80
M2<D@IB*#$J4XC$,:9]2H7^^MBDS-NZ@O770[Y9'1%)BG-X<&=H2TYUEZI'9'
MO5D!*D!KR0S\ER!K\'7I.1-Z"XI#DR@9Z?+FU$HVB)D0+EF-Y^8@?_W^L%:B
MMNO7?2/&IF0VIDRRG&<PU4<X* X#B.-(TS"Q,!*!R,/(J/5,OZBI.;E?__K]
MK^!Q]4.LE_7[5^NM]+5S?5? -7-N?B ;V'W]^AVT6G:;P_HO4>Y'PZ<;NB)M
M5$?3;_6Q*S%XXN8[">6G94,D?<=YL:F8*>])P3\MF_NV<XH$YI%@D.,X4?NO
M-(0DC5/(HDC&3*!$2.YX7:%7^-0<2I4+?R;K?XH-^%&EQ%<2L+J@O[SI>D/_
M/)AYFJ'0'=CW="]%Z%M:K>9@KSK0NH-BV5X$'^3*A#%F ]VFZ)?_5A<MC)&Y
M<@?#? P7+DHMX5-9;@5_KYSE\K&^EEUE^^M>L4JZB@)4\*6+-.=)FG.9Y0**
M5-_52/35:$V\$69)Q#,:4AJ97XVV%#XUOZ8UUR1')=@N%=Q-JVCULC4Z@Q?U
M<9L\O>UD&.3N!X1XZ$/8ZJI7K3JH=6^:_,WJ@]59VW)Z9P'0)@R(MPW+Y7"X
MCT5YZ1M_2S),-P"O,V-:CCDB3::;M8><F8YC.!8IG9=6'2"77\3OU:_*>1YE
M>1JA6,U&JK?1L=I!RS2 ,L"9#-(D%AS/U5:3KHR+C(P$V[Q07?'#KQ;'P:\.
MSN1JL5C]#JN6=%)HHV9@*:H&-47[6'7HJW_RO](X C^II\K*9,NZ2L-Y,XN;
M_<_%&RXJM=8SH/2N/^&!,M(-**^E-&:2QRV$L4+CI(S%[FDW]_;+:BE>?ZGV
MK!]5=-<FKI0#PTPP#AG)$$1!R"#-<P1IAFD215Q]ZXQ8)Z^+F5J@6VG9[N"E
MUM/.YUP T\S'W [1P#ZE1J?6$%0J#I#]NXZ"3X=Q0=*H#N*ZM<<.H>?3 \0W
MU2^_UH5P'_X0:U:4@L]Q$F0JK E@DB0!1'J7C(,L@CA/8D0BR6@0S9?BD6P$
M]Q#KG%7"Z+W(Z_>BJ\IPK\=.M8%BEO-SX2%^<<?W3U.E_+4M2V[M*W4T6H,P
M4O!S%>71 J'S6DPG*+J*DE6 ='TD-U_Y32RT([DGZ\WK@_KNE815XUMV&>T;
M9D+O7J,JJ'0%764'Z1UJBHS/]Z57YJAOARD"Q^^"\7,WTPNT3)4Z!*G839M[
MC_. 1S)*1 2%#+BF-^$0$Q[ . E)P!(6Y,2HDL!"YM0V$+5^G<N@SI?8+Z)L
MD OWC]W@YWL'E]/W-*L-GO<#XNE,!. #U[>Y_.^"[RW7_?N0LKCB?W&HM[K6
MWV?;E:O\O8^Z!2E?5LM56U_V:<E6SZ(A2I\GF+$HT_S.(DHABBB#.$Q3&+,\
MD23G,L%6_%,7)4W-+>^N(&JBM=7F2:SUX:72M\H^V^W1+L-K%OQY 6U@?]S5
M$=1*@I\:-2]O::VCO5XH?(9YEX6-&M_UVGP<V/4_X-(8[NO'+[IY_,M!P[F>
MAMB$)R*1-(11CB5$-%&;[33,(.81"9!,LH2:-WIWT6!J;D7;4+F4V@JGQIU.
M,V$0 PZ-[]#[3@WMW1EH9W[;P3O!;]-N;N!I&*O[G,-T^.I#=P."U]O2N0P\
M8I>Z&^P^;%IWRT#^&*0^%X06BV+S^@O9Z&KEUZHYS[[Q48)4#"H)@4G,=(2:
M!9"&H8 )EBB))0H3G-Q**M6CP]36ET[[JH];I;  OQ1+33P V@N-S\_%IKH[
M<COG5-_\F$6W Z,^\*ISD9EJ9X+F+ZF-&+2[U TP#LUBU:?&FQ-;&>)DPG5E
M.I2;E]SUE-J?5#0!1IB1+ Y#!$4:A2K29KKA7Q[#C M.I>3*+^9VQ60794VO
M?JPN76I.;NS\VF5$S;R7%Y0&]E&];?&:$,U_:48O.CY=SV5AHSJ87IN/W4C_
M V[.XF=2%N57><<J\CU]UKE:%.RU_O]^E18<"1H+"FF>Z%:A-%&>@T4P(Y3$
M:<I#M4VWB:+,Q$XM<*JTUF'3O1JUW1W9N1)#O,W\BG\4!W8R.P#W*L] K2[X
MK?ESD,#'#BF?#L=0\JC>QPZ-8U=D^;2;7_J'*!Z?-H+?J>" /.Y:H]<U&%^W
MFW)#EOI*EU:&S7$>*G>4Y1"%RD>A-*40AY& $4<X(;F*;>Q.(*RD3\U+M<H#
M4FO?:2I95X^!U=Z"&:#:!O?:,KN),O-K@\$_L'O;(=\H#O;T_[7NX&L7^4I]
M?S[."36?KLY.@5$]GA,VQX[/;9"!.(S+2V23S0[GXVHM1:&S.^6G95W =J1_
M6[UVORZ8F+,PQ[DD$@:!]J.I1) $'$-.:9H+P=-<6O%UC&W U+QPH[XNV]V6
M5>E.[5]M2W?'_AZ8>>@IS^Z(&^5+9<.E:=UP!X9]Y? ,G"PD+1B@0F-$DN.!
MYG%4LF/?-DR+]'B@&;(F/QY*#[?U\[V@FSU_S=T/4BQTCE4I\9TLQ*_+M2"+
MXG\$_[PJR_M56=%"M MZ^^]R3C-$L: Y#'-*("(QA23"$I*<1'F0B8R%5DUS
MO6@UM95N'^26>_ZF)[&H:%.V.YO TVI1D:LLE''@I;'&;C7T,ZMF2]SH<S7P
MNJ7MZ3!LS<#.)"A7:U@JHV9@;Q;0=H'6D%EG*[,SSM\RY!5KGVN+'\5&73"\
M8GF\"O@=W,VU?UJR==4Q1M1_?EHV_-#ML9K6;,F_ZGK,_;G;_G?SF"(4!U3M
M;7+=MB4@,:2:8 PG.48\8'&46'GU6Q6:FD.OM">+LE/6RFJV;;#8:VWGN6^>
M-#.G/>94#.RO6U/ 3ZTQ?]$+:LLSWU&ZKA6LYJE386 P4]9^VA>\/EWTS3J-
MZIU](7CLF+V-ZW2/:ZDO@Q5+P?].UH5>$/2/"EZ)62WG*98R$D3"-$,)1))R
MG5M",,I$2C*)<9P;T6$;29N:-_TF=!M>_4J^K,6N!<F^'>RL8J:IWN&7]4H6
MFRI/I#_?WB70OU+S!KCX(1:KJK]O]3/-@J-W3 ?#6=UDZIFWZS[7^VP,[% [
MJH)65W"@K$_LK.Y_^<-PM)M?>RQ_M%BRKM)_]7;ERPR<GLM>/8.,><W+S)ZC
M"UZ&#SG6U:IH77=/4$Y'+)E:#:IZM'F61"S/J>YGF"JW+7@$L0P"R"AF0F1$
M(&D5)Y\7,S5_7>U[#]1L2C)MVY^<!]4LCKT=JH&=J0-*]M6J5T'P6I!Z7M*X
M-:=7K3TI*[W^Z0DT3M77R=A&.:S50@VCJUV[O3/S5(0)BB*(.,<016$*:9!2
M-3>$I"C$*0O0F[5.O:KZU/S57LDI]$N]/NN>#A??9"XG<*SHV#.UA0#L,?A3
M-$TUFKK)MDV]KOVTSA"]S\J@K5/--'!; B_U00A(R 7*0\@$2R'"*(:8J.6+
MH01Q04@H ZL"Z#])ZXE.(X07I2<LEH#U-$*P@M5L09A^)XDQ&D:,V!MB$FT@
M+#L^^&WNL.>_^B&6FM Y31E/ T%@+()<!ZP2YBA*H&[TQY*49(%V "LET<P!
MM -;O?&[X8?[)C]H&8#MK_&J$&1=ZVKWRN^08SE#82YCR&1&E.M,0D@2$L!0
M$A1A+CF-4KM;9R[8C7/)K$;OW0%ZWVY"S\Q#NB RL$ML5?+)XG=HI%^VOF;L
MD5GY#BTZ9=\[^OW-+'O[B.O7%Z7/<M,$6]TF@7-"688D0C#)<[5#3W@&<X(%
ME!*+6"1APM3@;HQ[)O*G%@0UFJH(Z+6^"EEWU%PWZCISQQG-A=$9S) (#WXJ
M<X'G8P9:W.];W!]6X.=])]-A<7?F[_.-_]MP^?F8AUNX_6Q0M.#Y,QKVK3C_
M;&R^PO]G-8QCHI@]";Y=B*_RO5@7/RJYG_01U;;N.+N[QZIOWX61R'33FEP7
MT'*8<_5/GHH@P7' 26K%OF(J>&I+2)=R9;76B0W]IR@>U3ZQ*JUBK^##'^Q)
MS]RNH?S!=3'+G*[I!!EF9 > ?>A\:J.RAGRO-.AH/2C3BBUB7M.8IK+'34):
M(G*20K1]WKFZ=/4L'L@?#1WBSV(I9+&9<Y;$:48B*(3N7"-X &G&.<Q02 (9
M8TY18M><XH(DHW=HU X4#5/GAORAPMY*1^O:S[.0DC"0+"(A3&020A3Q$.8I
M8Q"Q&#-,9<Q"UD+Z8%6.ZPG7AQ%6AH<]JN"GE_7J1U&J.,_REN EA,V\^RV
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MC74<8C])(@P)C1)I@F!I@@1A  D+PR0C@H5"*TSSS#A+XXO/?-?6D.MJJJX
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MA7%XJ+D[_DNQRW?/5XS)VZ)J_U/7]=<13SW?XPP&02P@$H)!K *6J1 D1'[
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M7R##TAB]UP*T:H"?;O_X&>R5 9TVJE]WK0]H%3)80)HX7QIK;>YGP3$I'TZ
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ML"#O- >/2D/3C'Z7=X&>4;68N75,ZIV>*]!IV<?:5JOCH;3[3>45Z-5K&_.
M7]H;PVJ)MAFFPFX% Y<"SUS_8 ;L#ZLGS#'H!"O779N=/^H>.U*=OB]TJ;X:
MU(SX_%1;4!Y& 2.$0"H8ALA+*<Q"PJ!@,0_#@&2I7MF[A>BSM+=<W]A]5P*U
M66)>EF8AP.IX&6\OY8)>A+6FX-UXY[IW;79)>]S+[)*3C>MN!XWK0 ,-D-B
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M?9"W<_X,J]7N6EX:EJ)2S?7RXDE^UZ8/26+K[WW/#SU,*8$\Y1BB- D@1F$
MLX@2%'H>"[%6Y(U=L99&/[WXMHOBF4Z7'E7-/PF.:>U,,;W]].PUJPW 5C>P
M5\X)&=K%>X92?*:2+:%,WT0T-4OX3;VZ>;;"+_*JN^>O]WRS40N5N'A>(T8Y
M3^,8,AI%DH0C9=<A 6D2AR(.HHAPK7+ZQR^_-#)M) 2UB*"543][X0A\9[8M
M+P;%]0*>"1Y&V0RGU;X@I>'(16?+:SBMT#"Y8>0H1R6(3FTM:&\@_,GSNWMU
MS'?)-'>\BXBZV>:4KZE/&!9) JG@,40\]2#)F*],MHQG/D.Q,"IK\;;J+(V.
M_AC9V/SIJ6) DG^S>VK89.B-[QH]4_'O<R_,$<MQIE3H:*7051>NL0*#6VH8
M'*2^7@T#-E:@ P>TZ/2QD*#&9\823K/,\ZS%GMQJM*RR4+/,GG$!J7FDFOA.
MYW=*GB_\L=SVW0B>FY^#G7?$LQBQ!"986>8>)3#C,88,(\1"EH9>:K3SKC7J
MTMZ0K="F/4NT -9\2]F&S?7+I)$7] *OFFXES^!;^[^;EB4F,%GE8JV!YZ5,
M$RP.F,WHY E1X>_E'W**-Y_RC62\LNAJ.:UCCV,6ABD4(0XA(I&T-4B,(,LB
MGR#&XRC3VJ$?'65I!-/)"1XZ0;L018-8UI.0GED>L 648TKI,>IE[,Q/&Q@9
M1.':P&JFV-@)F)F%IY[#8C1H].3)\X5RGI/_18#EV8.G;F3]->@)M2T+^9$V
M.^K'309!@XCBF,,H4,V;4!I!3-,4HBB)$Q&E) Z,=L%-!5@:>ZK2?\5N\PRN
M6/E8^Y*#'FE#=4QWK SG17=ORAW:SG>A_CJ);36/A3<5/;M[2H8RS+Q[- VA
MPWVBB=>9Z(YV842#T**;LLIKC[K;_:4L)4E &&01SR3?$0PS1GP8"8Y]@5$4
M,[.J]1J#+HWM>IE?1O!U8D\.O-2: $UOU3*LKIW5RQ$U]U0-(++JJ.J,.Z^?
M:H#$@9MJ<NX$+_7W1REOL?O(>76#<[;V(R],6>"K EZI2B1FD*A^0D$F(IP1
M07V,M9W35Q=?&L^TX@'!E3.:GZY-<!XV#0?T C <LT.'@Q(-W%P&A(&7>0$@
M,SF7@QNDJN\06SF/)U0?]25?GS.?"WE"VA>>XZEC3E'2$,C?Y*=__:/[1OY0
M6V__^L?_ U!+ P04    " #H0Z52UH[E66=]  !YV@4 %0   &1N;&DM,C R
M,3 S,S%?<')E+GAM;.R]6W=;N9(F^-Z_(B?[=7 2]TNMJNKEE)VGO-II>VQG
MG9YYX<(E(',.1;I)RFG7KY\ 2=U):9/<X(:<XY4I2Q3-'9</@8A (.)?_\>W
MB\E/7V&^&,^F__8S^QO]^2>8QED:3\__[><_/OU&[,__X]__VW_[U_^#D/_U
MZX<W/[V<Q<L+F"Y_.IN#7T+ZZ<_Q\O-/_TBP^.=/>3Z[^.D?L_D_QU\](?^^
M^D=GLR_?Y^/SS\N?..7L_F_G_Q+ A*BS(]KC%ZF"(L%R3J3+,80L(.;P?Y[_
MB_9. ?6),!7Q;3E8XE5BA(><C# 0$HC5AT[&TW_^2_D2_ )^0N:FB]6/__;S
MY^7RR[_\\LN??_[YMV]A/OG;;'[^"Z=4_'+U[I\W;__VX/U_BM6[F7/NE]5O
MK]^Z&&][(WXL^^5__?[F8_P,%YZ,IXNEG\;R@,7X7Q:K%]_,HE^N9/XD73_M
M?$?YB5R]C927".-$L+]]6Z2?__V__?336ASSV00^0/ZI_/W'A]=W'IE@ZB>H
M0IC[+W"Y',?%W^+LXI?RUE^N=.VGZ=5T.5Y^?SW-L_G%BF[D9?79R^]?X-]^
M7HPOODS@ZK7/<\C_]G.:3L:D*)V*-47__='/^^6&WB]S6)2WE=??X N;CRTT
M5: =OBUAFF ML"L2)K-XYTV3HJ[9_.I?3GR R>K548+QZ&R&*^A%6"SG/BY'
MPBM#I1)$)&F(!"6)]\D3Q:5B(G*P7M\55>%I@4RMM+N ^+?SV==?\(-1RYR6
M;XH<*:%LH]O__N"A:_$=1OV5J#[A>T<.(D3) \E. )%,*>)=S,1PG[5@TD;;
M!_&WGWF7]MO*?S&//\WF">9HF:X>ZN?Q 1#NKHK-.W[YXN?X021^'D_2U;\N
M)JH/O2UG/<AOK1PD]^>?D.L,\SFD-VO=[&1NQ=D2[36LWMF'WO^O2S_'3YQ\
M_P!?9O/ER*EDHW:4!)]1#L%'$IP$XA.SBEG!@U4]0N#>XSNA@;>/AF.DV@@P
MWL-\/$/SF5[B3C^*-(ND!2<Z:D2V2YE8[37Q)EF>"LAYG["X\_!.H!#M@^)P
MB38"B4]S/UV,B^ WL);*FPS@B>0.'3-38"U\)I!RX$KGX&GH<[^X]_Q.P)#M
M ^,HN0Z,C;5_]=MX F\O+P+,1]0R95FR!)RAN <BPGV6R(J2Z,]3YBS8'C!Q
M_[F=L*#:Q<)1<FP" Q_@?%R$,%V^]1<P2C)$P8+$B XB!FVX[P6E%5JZX(U(
MCF;C>\/!W6=WPH)N'0M'R+,)/+R>QMD<S=E*\!]1_G VNYPNY]_/9@E&5#AM
M**.$)9.(I!:=(8SY"9>.!6VMC+UL'1U(Z806TSI:^I-V$^#YY+^]Q@A_.<[C
M=:ID8Q4CEQA602!:"K2*UEGB.'X![B0-2O$8:6^PV4%$)\#8U@'3AX2;@,J+
ME% %B\U?;\938",F61(Z*A*5I,5$.N(2S_BC4J!T,MZ9WF"RA8!.$'&M0^18
MR;8$CS/\]MW\T^S/Z2@AC*/6@J3L.+K8EA&K<#O%2#SH+%S.6?8-CIO'=TMX
MT6>"C0/%VA(R5IOEN_G[^>SK>!IAQ+T)U%",MAA%A(>8B.<&[:%WR$]*EL7^
M/)/M-'3#2,-9T=X$W!)0WL\62S_Y?\9?5BY59EE90"[0Z*%+Y:PD5F9-/%CJ
MF'7>N#YRY;LIZ :2AI.E/0EW8(@4"_AB#GY%-X9A7# P! (X=)XTDBR$()P;
ME7+R-HL^;,?M9W:#0</IT8,%.+#BRR'NY/WGV?0J8^.S-#(K1AAX(-(H=(TD
M;H!92$B0@P+=1X[\_G.[ :#A-.A1@AP8!!\A7LX1P(R'3^/E!$86(&BI/#$
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MJ@4_J!<<]2?[%H!TX[S=LJF!Z\ ,PM]17>H!F"2A%*$IW/Z3IM([OZ5LJP<
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M%%EEL/6MG;8 ]V#;][3,1HN<@"X-H)3'@!VD((IJGGR4.M;9+!^A:>C\V>D
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ME^/))<8N(R8%1\LIB()2\\LR(Y8:37A2QDH3@N55;- .>KK!YUD5,O0A^08
M] \8GW]&NE]\A;D_A[>7%P'F[_*#8N_UZN#6V*19)$9S2R1*CWB= XG!&HT6
M5^=89>SK7E1V ]NS*H"HIZ5V(;A94 ^O'7A#%7!GT8,-' 4I)+'<22)  OJZ
MB3*HTCAL3SJ[P?!9G3;5U-0/?T&D3C>?0Y_?UM61^GV =BV'+%S@G@.1&#&4
MN).7,L1$(H\L"R&9S%5JKGJ^1[*E:/?NM*8R(=P*)0T13MK2/ LM &X$Q"65
ME-1"&5JEV>=.BMJ\<[(/'AZIF#Y"^$//*GVT..Y=S@M8WN/P>QD<_0'&%^$2
M*2CO'D6O,I/,$0R@-$;@QA(?3":9"O2(&74*NMU:ZH.:-JNH#T':, KZ ;;F
M+0T5:^S N_HVGG"C?8K3_OOJ/=(.DFLF-&A#@ =&T-<L,[(0[4I;R[RPUIHJ
M:8A.U!W??W;SD$\E"SZ2D%R0EA(#)>K2R1&K)",YT>PMY<Z9*F')73*:Z937
M$RH>MJ ]6.@-A+K7U*\E4OS@V;2LVQ??QHM1=I(%@7)1QL=2W>!(2-(3,*52
M)K((OE+WXD>H:@10!ZA[%W*.EGT#0+K'P\O9A1]/1PFL<[B 2#*E/ :?6\JK
M-.$FV*31J="A2DO%K=0T ISCM7T_\7NTZ!O SZV^'K]#R>*,M# J2U5TJTK7
M(:V)CSH0$\&&P(3@L4IMT@-*AL5-#]K=W4+E %$W@)4=TU$VS)B@@F$T$Y"4
M$QED)@&X(3FZY$MQ)ZW3./A1JH:-^/K'4'\J: %/3X\^V3 &Y3I4MHE(;A5N
M]]D0*\$1KWR6C@; $+H*MKI2..PEI HXJZ*:!C!W?_K)A@NG$M4Q1>(UCZ6#
M%7*AHB04W<R0*4_&5-GTMI,S[/6D_M'4@] ;@,ZU)_D&>7F-WRY&E"N,7UD@
MGI6&QA H\1EW\90IAB,Q)\;J!FK7I#32KKS'Z.PP*3> $S2/\S(P_B6L_WX]
M?9@"^3";3'Z;S?_T\S2RU@65.3J 4O*2_Q7$,DA$J>P]")7B34%,SR=/^]#9
M2!AW("P>WBNIIJ,&(/AHMT9'E9%E@EQFQN#JA$BL!4N\35G%X# HJ=(%X.CN
MF37/ .NA89]&FONHYF"8?8'Y>%:."N;+GO;%!P.:/'J 2G%/T"?$G3TF1D)(
M G?V$+6)SNO@ZNR+!XW+JGGD=S)@':F&MN"T;EK\\G*.J^+]^@&KQ?(6_ES]
M:C$J F&4.:)S<1Z9E<1YGXD-P)13,8I0Z42I"WF#MUXZ+>SZ55<3O71V\+5J
M_7_#%D9%1AJ6B$VK-BX"V6(<0>.-R$E9YD(5WZT3=8-WN1@:A$<H:U ,KJH[
M'EU8:_&AB%$1XZ_P?N*G(TE9DM$P8K4-1(:(UAZB((Q[X7/.3,1[6-Q1:K/O
MDP?OAE$=9_45,G2QUV,K:!MO&4Q*R4@BA7+H6F1><C<9(S">1+290NA6U[7G
M@P?OE#$HUGI11P/QZ:-+Z0,LEO-Q7&XF/+THDES=Z$.I9A@O+_$](\^]M#Y3
MDIPL76EX0-<6)(F2,ZN<\594N8!R-.6#]^@8>E.NI.1V4;U:M)WX#=$);Q%W
M*JZNC.DR'P\\48)J&RU&<NGDWF1OF*[9261H3-=1<0.0OG5#_]-LQ^'S:D$'
MORI%O2BUQRO-?P 4_&*\A(\P_SJ.L!;4!XBS\^GJ4U8R&QG\HYG-)"6:RQF0
M(X'E1)((,IDR9S14*9:LS=C@;5!.MB2:@D@#2^9N$R*I4N*I]!W($M Q<XDX
M@=X912/@M >DH J^]^_T5+7KP\G0>+CTF\@Z/=9GY:JKQ?O9?*6Z;7WUN/"&
M,XX"$^@LX<JPQ'%%B;=*.R^BS%#E%MN1= _?5>)D #VEAANPAH_/C?/*4L$U
M48FA,U0N"'O*#&$9EZ?SF@E?I2/P\2>1/\2)46^Z.?+LZ-6TGQZ+6T[ 2F\K
M-/B&))[+Q?-RXD!C)HZ!RX$+;: *P@X\B*S:C&+(D\A]]- KFEJZ:5C_XO]3
MSQS^#F+]"_[=KIYIGPH@.6$(/2)-EB0H:@GWRGO-+0^FDF$X_85$']#--4*1
MF(K+H&RY9J#0%48>@U,L1U^E@=CSNY"X#RJ>N)"XC] ;\-,>OR:5I&+19D48
M5:5=-Y5E;K0@# 3^*@-+J5(]SW.YD+B7NO>ZD+B/[!L TO;J<9DM15$PDDSP
M1&H92!#ETD!P,@L!$* *@)[=A<2]M-WI0N(^HF\ /P]OR267A7*9$6J-(C*Q
M3$(2&EDQ@F(XK"!5*;)_%A<2]]+NDQ<2]Q%U UC94A0N)+,*%TII8^:(+,5F
M(7L@D()V*CAF?-WF"V^:O)'1R_9TF)0;P$FG(XJ;D[WRU4\CE&8YR&L2R&L*
MQ"EG<4W@%Z=*/4^VEE%OD[)5NI<?0W0C.]R!@#GD@*D/[?T [8W._.+S;Y/9
MGXLJZ86;3S]U(F$'7_VG#*X?=-,G4YH4C4?HZH0QH; .32?7A+.HC.)"957E
M2.4QHGHXHRR?^7X^^SI&\?WZ_0^4_>OI]1"Y%W$Y_KIJX5^F>(^GE_C:3>/&
M:]%$B+BK6%S+7C$BO8H$701/8DQ0!CE%$:M<R^Z'_$:,Y+&8VW(">FK=-K#%
MWSWW93$ZS3%L\L8A\9QS]'08(U%1IYES'F25/?N 4_=:^!H"!H^>Q>^CDP8
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M<4! .DZD!V3%)8GQNS+42$XUC4^Y:%T?UA)6CE?NK**DAT;.57.D1]BQ(;E
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MJ:AA5&X6WOLY1/RGX^@G]_@T <,79S3Q099N?U$7/U,3;;+GRN8<[_>N.=@
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M9.@[V:Q\<>QQ1V% \4=C=6!.6=>M%/?>!W?#U@]^A':,L(<&RBT)WIHL>TM
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M*,&&2H0,&3Q7I#:*VR1,"$&S3L[.7F,9#CRM91<,#,?&"=B*05MQZ))DCBC
MYE+;@18&3F4!Y*SYZ)!K4YHD0 [>*[U9I[R).$VCHV-L*[G=OYNSS!)Z1K$'
M)ZVN[5^\CPQ\CLH+KWC:'C+QP_5*[R7>YWJE]^'UV#AY?X'I[/'FR!0NT[[S
M^2*<SX+-B2G4@*FR1@L)]8R8^",C:I&UM-VZHW=ZW0GU0]\94\/+96RDW73
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M<] L6TEP G <(%P6D@6G$X=ZLQ84$NU1LP)>9AM2M15A6G>G3ZXD:1_/X<
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M+#'PK)TPQV4)>G+@2-WQ'\H<M 3U<3< ZYF9?YEU.F%125HRIQ;K=<P,WN@
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MSNL=\_GU#KWD]5#YLY]?^_*62?^G%_)@U]\_'+X<#G>/=O?[\'O4W_,&XNC
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M]JR(;3@<PO[8*Q6H'U529IS(',/R3BR3-S1"*;!:P> JEB0(OH6^%$_)KUN
MX7@K,;PQ5:U!>7.2VQC16 53)0BHW.J<$YMS"Y!3#4GHY48LD 1L*QZK3+DY
MI?/[NJ5UY4'G\126Q"W1E1K4)XWK:D!%:0K@V?KR(TFT$=X!7XV.9(ZJ(@.L
MT2(+6B\D@DH[0!?K2A7@[1<&WN0G@S=J-SM=&O-@RK/2TQ2%5J8IRD$U15#L
M/67=JYV#3K1_9#>AW7![?Z7GP0I%4*8-]62L2_>P!YLD!GXC+:E83G^\N6'Q
MH@SWZT^&F8 _'FO4P<O!F]@6L@R17$<$;:^K6LVWW*E9'T&.E+YUDI2&(KZ2
M*V_9FVCK\(1.&F'%)C#Q5SBD86_6A%/ %51U1ZYR$]L@Z<\!Z(@@+V]\>1L\
M&7-[4TP0R7EX2^'9WX^^8N8Y=OM7,JL.!>[(U__&A 0POYQMU=Z6(/FQVRI_
M+"@6\*\OR8>X<!6.2QXB6#VBGEBK2N$41TWJM+$WR=L_@+')1#DGY3K'0RG6
M* RH12CXY-7? *X@4TMDC;]4$R_6E?RK5'#9KZ0R3_P!P=NG/%W> OK<EOW2
M:88J"U6? K)H@TI;W41)0*'*N#?[EIGD5Y1"0]7EDZBO%_WYY.(@YU$ J[88
MX7C@'M;B HI6WI#6/6"LZDL( U<H ^LA@UND;UM.@ %,CQ]&E13N/>QZ;';V
MT[WE^-J6O<PILG!JP!%U1%MZ0@->_"ER!:QZ2&LJG^IL*BFWY7Q4'8:;B@/E
MI,CT7*)U-M:!^/@MV )F?S/--W^8T2C4-!//&L<SS%(X+/J-SU_M1._:1WMU
M_Q[\GE>(SF_(*K]B+ =I&G OXX65O<7%$5)&D?%Y3^6^.Z]T-*4L@V*D>F&*
ML5;ON0\/F]'A ;WJ=@;_Q<)\]1:\Z=^"MYQ8;^MVFGOMSH/-[6;T8-OWS'8B
M.+3[Y&9WN\UV>S.S+3\3838PJ[;@^?M:M[90J-9!K\TB#Y:%O:<1[137)'RT
M\G:;%MS=  :JJGV'Q3IKI=C* _^10J_[?&#W7U.\VMG%7M#_KKUKOO/APD^+
M0[6L/!D4F!<ZE&.+"7EDD&#D=H2V+![;&H,7-LW]L9(I^WB3DRY6ROPA54:E
MD>:AN6]Y_G[DER2KGS,5.GS,U0N'T5.Y]H'3$OJ>.-I+%1X#_Z5;5WG0B5N_
MX?,L_Z'8R?\ 4$L#!!0    ( .A#I5*RVV2"&@4  +L5   4    97AH:6)I
M=#,R,7$Q,C R,2YH=&WE6&USVS8,_KY?@3JW-KVS7OUNN;ES9>7J71NGMK*T
MGW:T2$5<94FEZ#C>KQ](V76<-+UDZ[*LRP?%(@CP ?" (#5X-IKXX<?3 !*Y
M2.'T[/7;L0\UP[+.&[YEC<(1O G?O86F:3L0"I*57/(\(ZEE!2<UJ"52%GW+
M6JU6YJIAYN+""J>6,M6TTCPOF4DEK1T-U @^&:%'/PV>&0:,\FBY8)F$2# B
M&85ER;,+.*>L_ 2&L9GEY\5:\(M$@FN[#ISGXA._))5<<IFRHZV=@56]#RR]
MR&">T_71@/)+X/15C?=<UG(<UW4CUFFV[&ZOV^A$[<CNQ<QID5[G-P=!6CB]
MTBGE.F6O:@N>&0E3Z_<[;B&]%:<RZ3NV_7--SSL:Q'DF<3&!RM7/6S8DNY(&
M2?E%UM>>U"JEK3C*TUST#VS]YRF)$9,%3]?]%T/!2?JB7F+,C9()'E?BDO_!
M$ /"T:^K#3[43GG&MG@=5X$,KA(^YQ(:KNGL(_P6S@CCR<2C O6#:3@^'OO#
M<#PY@<DQ^&_&P3$$'P+_+!S_&N 02H,IW"?._P+^T[/I[&QX$D(X>:H0G2Z<
MF3/3-V$6^#K,3J-EUY\HVN$,AJ/):1B,X%ILGRC8;4![=EMQ-WP3P&PX?3T\
M"6;&Y,/;X",,_5!)7-MV;_GPP%WD]V4I>;SV]!#/*+K;=SO%/[6Q-+_.]Z4H
MEP17DSG(A(%@GY=<,+VCETQ"G N9 ,]@NDP9$HT83O-P_A+R6$^?L6@IL)&P
M$H*K*"'9!8-A))78Z36:=2 E$#1&&:W#H=)X?M!U7=N[/EL/.=Y+(!E5%E5?
MTIQ69OR$%$@#:#?46ZAZ V %;-8_R[CJ.3.)K:?$+D,9'.[JX_F!T^YXRM++
M.HSK,%V3#'XQX9Q(6=;A-#%')OX3K.0J^GI]/^$L1F?0,<DO&4SBF$>X/BXX
M8M@N.80)$Z1@*(Y*&&>1N>>8GR\*DJVW/M4!9[/Y&M"&RC:B)NAPJ^L]@"*U
M^S"K()1BYS52%LM^HXW9OTXLP^D^,K,<<POUL=;T]D+0,]NZF#!=<"TI3L<K
MX?V2""15NH8I*Y#A@(0[SL4"'-MXKSBOR17S,B(I%(@EIZ!)#.^(B!)H.'5]
MD*FKLEDE'(=DPI& .LD\(IK".(!$(U&">D05R*Z'[U'F5"_ HPV8'77B98H0
M(P2?J@I;<9G<+-)2$7-7,X<$2U/L!EJ']$NM[I=<J^<IOO_H+'2?$ MYALQ:
M5-R(T I!3:KV5I6=&R2 F'#%SP(W)Y7FNII'TA10GRF(2(*RP#2CI.)J1K)(
MC:-EJH_V>CO#6<NT8DF.1-:+EUM&;,K"_-XD6!!Q@2?N>2YEOL"@8-0V0S(O
M=!0?BP/-)G)@A"'36RY6[UKU!-MK5?7[  _^@N-?V'_C/"/)')O81F6>"\J$
M@1%(25&R_O:'1WE9I&3=YYGV2"MYEVJ#P4UI8Q+#N;G+]'IFM]%3UQF)^"3=
MFM_<=$Q]T[$DO2WKF-UN]TZI;3IWRKYEM8F*+??[F^V:[?;=XNMF+1V(*A@8
MU!*9_JK6J-W8J/IN<07.?J)4X=Z,=)72QZ*MOIB^7N^?$S8._R=]>7[0Q+ZK
MG_NGL =X9RO??ICLGN"Q^+[YW>P1>O,L$%^><@I;8$_?U:\=N_^W>=<WF!^G
ML.]U>?I;R;9TYWO IX)OM^CKGP&+O/H(VA<L)0KPK0^#NPK4'=W>J9 YEN%2
MWE:Y$\3>L_JLJ3^P'OT)4$L#!!0    ( .A#I5+I[PO.) 4  "86   4
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M+FAT;5!+ 0(4 Q0    ( .A#I5*5N*?]'A(  (?'   1              "
M <S_ @!D;FQI+3(P,C$P,S,Q+GAS9%!+ 0(4 Q0    ( .A#I5+:_)IQ$1H
M !$. 0 5              "  1D2 P!D;FQI+3(P,C$P,S,Q7V-A;"YX;6Q0
M2P$"% ,4    " #H0Z52!^&!-<Q4  ">P@, %0              @ %=+ ,
M9&YL:2TR,#(Q,#,S,5]D968N>&UL4$L! A0#%     @ Z$.E4I-B?-:TU
MR?\( !4              ( !7($# &1N;&DM,C R,3 S,S%?;&%B+GAM;%!+
M 0(4 Q0    ( .A#I5+6CN599WT  'G:!0 5              "  4-6! !D
M;FQI+3(P,C$P,S,Q7W!R92YX;6Q02P$"% ,4    " #H0Z52#AA@5& :   <
MOP  '@              @ '=TP0 97@Q,#%A;65N9&%N9')E<W1O=71S:61E
M9&DN:'1M4$L! A0#%     @ Z$.E4BLTJND7"   A28  !0
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64$L%!@     +  L W@(  *<)!0    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
